{"docstore/data": {"df68f982-117d-44fb-a91a-bcfb23d17447": {"__data__": {"id_": "df68f982-117d-44fb-a91a-bcfb23d17447", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 22 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n06-May -2021  \nMcKesson Corp.   (MCK ) \nQ4 2021 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 22 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n06-May -2021  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70020eb5-2224-4543-aef8-9b1b4fe4eba0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9b7bc89d950bb47df5b89154c9d6ae0e628e3bf7a41f862e8d0355c4a41d921f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5f7a822-4b25-43c8-925c-3fcc0f1286b9", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 22 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n06-May -2021  \nMcKesson Corp.   (MCK ) \nQ4 2021 Earnings Call    ", "original_text": "(MCK ) \nQ4 2021 Earnings Call    "}, "hash": "909bdec0a6d1aa04e24c73c1eeba59e4626606657869a9dc44cc76bdbba3b365", "class_name": "RelatedNodeInfo"}}, "text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 22 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n06-May -2021  \nMcKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 166, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5f7a822-4b25-43c8-925c-3fcc0f1286b9": {"__data__": {"id_": "a5f7a822-4b25-43c8-925c-3fcc0f1286b9", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 22 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n06-May -2021  \nMcKesson Corp.   (MCK ) \nQ4 2021 Earnings Call    ", "original_text": "(MCK ) \nQ4 2021 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70020eb5-2224-4543-aef8-9b1b4fe4eba0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9b7bc89d950bb47df5b89154c9d6ae0e628e3bf7a41f862e8d0355c4a41d921f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df68f982-117d-44fb-a91a-bcfb23d17447", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 22 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n06-May -2021  \nMcKesson Corp.   (MCK ) \nQ4 2021 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 22 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n06-May -2021  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "47ea468c4c745e317ce081d2b7ea01caaf137185d8a65a7585ac2c6b838051f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfb2ae1f-2076-4e7c-baee-61a8862bba9c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson \nCorp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  "}, "hash": "94c9724e393d04645e79d7b34ca12ae21ffe52c126f225c87c50fe8c587cf69e", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2021 Earnings Call    ", "start_char_idx": 166, "end_char_idx": 199, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bfb2ae1f-2076-4e7c-baee-61a8862bba9c": {"__data__": {"id_": "bfb2ae1f-2076-4e7c-baee-61a8862bba9c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson \nCorp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "78cda6f2-9cf3-42b7-afb0-13841559d1cb", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c18197a323c87eff2c36018ac2d773d2e6ba689271d9d828a9f023cc688a7b90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5f7a822-4b25-43c8-925c-3fcc0f1286b9", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 22 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n06-May -2021  \nMcKesson Corp.   (MCK ) \nQ4 2021 Earnings Call    ", "original_text": "(MCK ) \nQ4 2021 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6260ca9d536e8c57ff0aac560c0fb5d96b461c8bc3f911cc09cc969b86c1cded", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2df6c36c-4f4a-460d-a679-b39cbc4bb868", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson \nCorp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson \nCorp.  \n"}, "hash": "dd607b7ffb52132ea46dbce40bcbec5b88616ec80e23a09754dd4be7b22b4c90", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2df6c36c-4f4a-460d-a679-b39cbc4bb868": {"__data__": {"id_": "2df6c36c-4f4a-460d-a679-b39cbc4bb868", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson \nCorp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson \nCorp.  \n", "page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "78cda6f2-9cf3-42b7-afb0-13841559d1cb", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c18197a323c87eff2c36018ac2d773d2e6ba689271d9d828a9f023cc688a7b90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bfb2ae1f-2076-4e7c-baee-61a8862bba9c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson \nCorp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be861166aeae70b7bb4fd7dd179374c4ef0a7427b5d1b5cd316c2fe84c3ea3e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ab4f5f4-5b10-40ae-bc79-af33632e1362", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson \nCorp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "481d6c054c9ebec2921dc5f7fc4e18e030c473bd488162954bcd4c9fb1f33906", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson \nCorp.  \n", "start_char_idx": 16, "end_char_idx": 295, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ab4f5f4-5b10-40ae-bc79-af33632e1362": {"__data__": {"id_": "1ab4f5f4-5b10-40ae-bc79-af33632e1362", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson \nCorp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "78cda6f2-9cf3-42b7-afb0-13841559d1cb", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c18197a323c87eff2c36018ac2d773d2e6ba689271d9d828a9f023cc688a7b90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2df6c36c-4f4a-460d-a679-b39cbc4bb868", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson \nCorp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson \nCorp.  \n", "page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a66eb319e91aaea6c09da4e25af62af9d043cfc707c0fab0f6eef46c4d5e171a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1aa3b904-8c18-49bc-97de-f374134132db", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson \nCorp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n "}, "hash": "fac8b523cc1014dd99025dd81877f32370a5003d10ddcf1be0936d92bbf0929f", "class_name": "RelatedNodeInfo"}}, "text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 295, "end_char_idx": 367, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1aa3b904-8c18-49bc-97de-f374134132db": {"__data__": {"id_": "1aa3b904-8c18-49bc-97de-f374134132db", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson \nCorp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "78cda6f2-9cf3-42b7-afb0-13841559d1cb", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c18197a323c87eff2c36018ac2d773d2e6ba689271d9d828a9f023cc688a7b90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ab4f5f4-5b10-40ae-bc79-af33632e1362", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson \nCorp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cf263bb2538c210712b2940c7e4c7ea44aa5bcf9cb57dfdc3c91e04ab14b37d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ff117b0-5756-4ff3-ba1c-18b9d8d0d7c5", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson \nCorp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. "}, "hash": "bf19f4c4ab07bf8b1dfe9577679743ccc642e35f3af8ffe974f5e4dc6e501bc3", "class_name": "RelatedNodeInfo"}}, "text": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "start_char_idx": 367, "end_char_idx": 454, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ff117b0-5756-4ff3-ba1c-18b9d8d0d7c5": {"__data__": {"id_": "3ff117b0-5756-4ff3-ba1c-18b9d8d0d7c5", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson \nCorp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "78cda6f2-9cf3-42b7-afb0-13841559d1cb", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c18197a323c87eff2c36018ac2d773d2e6ba689271d9d828a9f023cc688a7b90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1aa3b904-8c18-49bc-97de-f374134132db", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson \nCorp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99f7b248d195c200a6ac7dc72819db7e1c3b950c8a97092457f4792e16d3d868", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "252a33a3-581a-4ab5-b953-420d28e71cd3", "node_type": "1", "metadata": {"window": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n"}, "hash": "e0bb4219bbae91923bdc7589455075de0129c5d7ffaef2f5c2ed2bc784a56612", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "start_char_idx": 454, "end_char_idx": 833, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "252a33a3-581a-4ab5-b953-420d28e71cd3": {"__data__": {"id_": "252a33a3-581a-4ab5-b953-420d28e71cd3", "embedding": null, "metadata": {"window": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "78cda6f2-9cf3-42b7-afb0-13841559d1cb", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c18197a323c87eff2c36018ac2d773d2e6ba689271d9d828a9f023cc688a7b90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ff117b0-5756-4ff3-ba1c-18b9d8d0d7c5", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson \nCorp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "011c6317c8ea471033b98b361a42cf4aaee8960cba4d2583f01800f7cac3f33b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "947bb482-9404-4616-8412-88bbea06c3da", "node_type": "1", "metadata": {"window": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nGeorge  Hill \nAnalyst, Deutsche Bank Securities, Inc.  \n", "original_text": "Eric Percher  \nAnalyst, Nephron Research LLC \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. "}, "hash": "192f9a0ff19175ce9f31256c174b52ac742c28e587c284d0b6542ac819a0fbe2", "class_name": "RelatedNodeInfo"}}, "text": "LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "start_char_idx": 833, "end_char_idx": 889, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "947bb482-9404-4616-8412-88bbea06c3da": {"__data__": {"id_": "947bb482-9404-4616-8412-88bbea06c3da", "embedding": null, "metadata": {"window": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nGeorge  Hill \nAnalyst, Deutsche Bank Securities, Inc.  \n", "original_text": "Eric Percher  \nAnalyst, Nephron Research LLC \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "78cda6f2-9cf3-42b7-afb0-13841559d1cb", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c18197a323c87eff2c36018ac2d773d2e6ba689271d9d828a9f023cc688a7b90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "252a33a3-581a-4ab5-b953-420d28e71cd3", "node_type": "1", "metadata": {"window": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e2fb7ce14cbc34e9a3b7eee8604ebbb32cf728e254d80fa2003aa99060b79a2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d1d3c3b-02d8-4731-8392-5f3d7b54597e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nGeorge  Hill \nAnalyst, Deutsche Bank Securities, Inc.  \n Jailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \n  ", "original_text": "LLC  Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n"}, "hash": "d0f033b03bdf9b3424b547949f6850214aa9bd535186bdb481c976f667ed2278", "class_name": "RelatedNodeInfo"}}, "text": "Eric Percher  \nAnalyst, Nephron Research LLC \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "start_char_idx": 889, "end_char_idx": 1019, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d1d3c3b-02d8-4731-8392-5f3d7b54597e": {"__data__": {"id_": "0d1d3c3b-02d8-4731-8392-5f3d7b54597e", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nGeorge  Hill \nAnalyst, Deutsche Bank Securities, Inc.  \n Jailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \n  ", "original_text": "LLC  Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "78cda6f2-9cf3-42b7-afb0-13841559d1cb", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c18197a323c87eff2c36018ac2d773d2e6ba689271d9d828a9f023cc688a7b90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "947bb482-9404-4616-8412-88bbea06c3da", "node_type": "1", "metadata": {"window": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nGeorge  Hill \nAnalyst, Deutsche Bank Securities, Inc.  \n", "original_text": "Eric Percher  \nAnalyst, Nephron Research LLC \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44dee6215097ed0454dc7a8b83012ae6de947af251de8b3954e31febc9ff459b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98666372-6af5-4092-bb4a-17551a9a62c2", "node_type": "1", "metadata": {"window": "LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nGeorge  Hill \nAnalyst, Deutsche Bank Securities, Inc.  \n Jailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \n  ", "original_text": "Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. "}, "hash": "8438ee1fa2badcc918c5bbfc9d4597e6ca2e5f5176d18acb1667241d6383badc", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "start_char_idx": 1019, "end_char_idx": 1141, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98666372-6af5-4092-bb4a-17551a9a62c2": {"__data__": {"id_": "98666372-6af5-4092-bb4a-17551a9a62c2", "embedding": null, "metadata": {"window": "LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nGeorge  Hill \nAnalyst, Deutsche Bank Securities, Inc.  \n Jailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \n  ", "original_text": "Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "78cda6f2-9cf3-42b7-afb0-13841559d1cb", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c18197a323c87eff2c36018ac2d773d2e6ba689271d9d828a9f023cc688a7b90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d1d3c3b-02d8-4731-8392-5f3d7b54597e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nGeorge  Hill \nAnalyst, Deutsche Bank Securities, Inc.  \n Jailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \n  ", "original_text": "LLC  Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "62109a57519e6075c89793da3fd4cb2c141ca46a8da1a170d0fda1f27be62dfc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39a88a04-d677-4a52-8e24-06ea81bf3fee", "node_type": "1", "metadata": {"window": "Eric Percher  \nAnalyst, Nephron Research LLC \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nGeorge  Hill \nAnalyst, Deutsche Bank Securities, Inc.  \n Jailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \n  ", "original_text": "LLC  \nGeorge  Hill \nAnalyst, Deutsche Bank Securities, Inc.  \n"}, "hash": "bd9082e44356b82ea63d239a366a6ff44073f5048e84a938fc8a558c315fd059", "class_name": "RelatedNodeInfo"}}, "text": "Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 1141, "end_char_idx": 1193, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39a88a04-d677-4a52-8e24-06ea81bf3fee": {"__data__": {"id_": "39a88a04-d677-4a52-8e24-06ea81bf3fee", "embedding": null, "metadata": {"window": "Eric Percher  \nAnalyst, Nephron Research LLC \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nGeorge  Hill \nAnalyst, Deutsche Bank Securities, Inc.  \n Jailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \n  ", "original_text": "LLC  \nGeorge  Hill \nAnalyst, Deutsche Bank Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "78cda6f2-9cf3-42b7-afb0-13841559d1cb", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c18197a323c87eff2c36018ac2d773d2e6ba689271d9d828a9f023cc688a7b90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98666372-6af5-4092-bb4a-17551a9a62c2", "node_type": "1", "metadata": {"window": "LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nGeorge  Hill \nAnalyst, Deutsche Bank Securities, Inc.  \n Jailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \n  ", "original_text": "Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "616006bcceb33e747fed86d3760634a705b046d10c91acc0d7a05ff2aebd82b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0742350f-efea-4952-9288-7335deefb584", "node_type": "1", "metadata": {"window": "LLC  Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nGeorge  Hill \nAnalyst, Deutsche Bank Securities, Inc.  \n Jailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \n  ", "original_text": "Jailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \n  "}, "hash": "1a8b0e68d0c17649b0a7dd575c09381a8586683c773e972d4ac701ee6e3c81b7", "class_name": "RelatedNodeInfo"}}, "text": "LLC  \nGeorge  Hill \nAnalyst, Deutsche Bank Securities, Inc.  \n", "start_char_idx": 1193, "end_char_idx": 1255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0742350f-efea-4952-9288-7335deefb584": {"__data__": {"id_": "0742350f-efea-4952-9288-7335deefb584", "embedding": null, "metadata": {"window": "LLC  Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nGeorge  Hill \nAnalyst, Deutsche Bank Securities, Inc.  \n Jailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \n  ", "original_text": "Jailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \n  ", "page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "78cda6f2-9cf3-42b7-afb0-13841559d1cb", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c18197a323c87eff2c36018ac2d773d2e6ba689271d9d828a9f023cc688a7b90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39a88a04-d677-4a52-8e24-06ea81bf3fee", "node_type": "1", "metadata": {"window": "Eric Percher  \nAnalyst, Nephron Research LLC \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nGeorge  Hill \nAnalyst, Deutsche Bank Securities, Inc.  \n Jailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \n  ", "original_text": "LLC  \nGeorge  Hill \nAnalyst, Deutsche Bank Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4537d8d75373dc7407413c67bfcd8deac2370673afb8a4089b5fedcceea51ab0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "046d6f12-1632-429b-a3f7-0d64d8bb59a4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd \nlike to turn the conference over to Holly Weiss. ", "original_text": "McKesson Corp.  "}, "hash": "80d3208858b3d0cb7c9867ec1400bde8efa90f6fc5a8eb90fdda43a6d15aa329", "class_name": "RelatedNodeInfo"}}, "text": "Jailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \n  ", "start_char_idx": 1255, "end_char_idx": 1368, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "046d6f12-1632-429b-a3f7-0d64d8bb59a4": {"__data__": {"id_": "046d6f12-1632-429b-a3f7-0d64d8bb59a4", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd \nlike to turn the conference over to Holly Weiss. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9690d5c831bd1337e1b3ddb7c243f812a921c0fd8ce3cd5a0126a1b04902ab32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0742350f-efea-4952-9288-7335deefb584", "node_type": "1", "metadata": {"window": "LLC  Steven Valiquette  \nAnalyst, Barclays Investment Bank  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nGeorge  Hill \nAnalyst, Deutsche Bank Securities, Inc.  \n Jailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \n  ", "original_text": "Jailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \n  ", "page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "923ccbef13f3f58817f4019e7396279d35a6a95c874d80daba7c7191f4fa626e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5750b52-ab4f-49fe-92ff-73db09976056", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd \nlike to turn the conference over to Holly Weiss.  Please go ahead.  \n ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson Q4 Earnings Call. "}, "hash": "5e313df6b069d480ede9b9a5c9bed2e8c08861ca0e986fe442763eab3eb19a61", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5750b52-ab4f-49fe-92ff-73db09976056": {"__data__": {"id_": "b5750b52-ab4f-49fe-92ff-73db09976056", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd \nlike to turn the conference over to Holly Weiss.  Please go ahead.  \n ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson Q4 Earnings Call. ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9690d5c831bd1337e1b3ddb7c243f812a921c0fd8ce3cd5a0126a1b04902ab32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "046d6f12-1632-429b-a3f7-0d64d8bb59a4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd \nlike to turn the conference over to Holly Weiss. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4910acc111d69cd87041c0654a95bc5689153b65b8ca5a3996cf3524727efe0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "886628b5-e9a3-4183-a9e5-80b14e8659b1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd \nlike to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "original_text": "Today's conference is being recorded. "}, "hash": "2fa01c3e6321690ab319fa72a4b55c2a3f140772e9d26672d5df84e5bdb837c6", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson Q4 Earnings Call. ", "start_char_idx": 16, "end_char_idx": 270, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "886628b5-e9a3-4183-a9e5-80b14e8659b1": {"__data__": {"id_": "886628b5-e9a3-4183-a9e5-80b14e8659b1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd \nlike to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "original_text": "Today's conference is being recorded. ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9690d5c831bd1337e1b3ddb7c243f812a921c0fd8ce3cd5a0126a1b04902ab32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5750b52-ab4f-49fe-92ff-73db09976056", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd \nlike to turn the conference over to Holly Weiss.  Please go ahead.  \n ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson Q4 Earnings Call. ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1013fe6c83d9f8bf976c1dd45d56056009a0870b9fcebc07e6ddc78648ce49d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47ea722d-01e4-438e-81b0-39daaffa86d5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd \nlike to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Stephanie. ", "original_text": "At this time, I'd \nlike to turn the conference over to Holly Weiss. "}, "hash": "e5dd337e24080137f661fe167754e763b4702dc36133d01d83dee2e82d70ca3d", "class_name": "RelatedNodeInfo"}}, "text": "Today's conference is being recorded. ", "start_char_idx": 270, "end_char_idx": 308, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47ea722d-01e4-438e-81b0-39daaffa86d5": {"__data__": {"id_": "47ea722d-01e4-438e-81b0-39daaffa86d5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd \nlike to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Stephanie. ", "original_text": "At this time, I'd \nlike to turn the conference over to Holly Weiss. ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9690d5c831bd1337e1b3ddb7c243f812a921c0fd8ce3cd5a0126a1b04902ab32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "886628b5-e9a3-4183-a9e5-80b14e8659b1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd \nlike to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "original_text": "Today's conference is being recorded. ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "30912c53e2fa39fe6d41100aaaacb9dca3018f3e93222467fa4e777463e294ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "531eec11-982b-4b38-951d-21bc222149a6", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd \nlike to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Stephanie.  Good afternoon and welcome everyone to McKesson's Fourth Quarter Fiscal 2021 \nEarnings Call. ", "original_text": "Please go ahead.  \n "}, "hash": "193381b23d44088bf57e80fb661ec29e612d536b30e132d83430a1baaae73fa1", "class_name": "RelatedNodeInfo"}}, "text": "At this time, I'd \nlike to turn the conference over to Holly Weiss. ", "start_char_idx": 308, "end_char_idx": 376, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "531eec11-982b-4b38-951d-21bc222149a6": {"__data__": {"id_": "531eec11-982b-4b38-951d-21bc222149a6", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd \nlike to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Stephanie.  Good afternoon and welcome everyone to McKesson's Fourth Quarter Fiscal 2021 \nEarnings Call. ", "original_text": "Please go ahead.  \n ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9690d5c831bd1337e1b3ddb7c243f812a921c0fd8ce3cd5a0126a1b04902ab32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47ea722d-01e4-438e-81b0-39daaffa86d5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd \nlike to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Stephanie. ", "original_text": "At this time, I'd \nlike to turn the conference over to Holly Weiss. ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b555df537496fec2a87a6581c79f8775de848efe8f99fa1701f8e64132c7dd27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae751d68-767b-460c-bfb2-10175e94e806", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.  At this time, I'd \nlike to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Stephanie.  Good afternoon and welcome everyone to McKesson's Fourth Quarter Fiscal 2021 \nEarnings Call.  Today, I'm joined by; Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial \nOfficer. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n"}, "hash": "c70796e294d9939942e4bef2ae32d61a0b1dd147c6b0e5cf2fc4dcd1377ef506", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 376, "end_char_idx": 396, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae751d68-767b-460c-bfb2-10175e94e806": {"__data__": {"id_": "ae751d68-767b-460c-bfb2-10175e94e806", "embedding": null, "metadata": {"window": "Today's conference is being recorded.  At this time, I'd \nlike to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Stephanie.  Good afternoon and welcome everyone to McKesson's Fourth Quarter Fiscal 2021 \nEarnings Call.  Today, I'm joined by; Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial \nOfficer. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9690d5c831bd1337e1b3ddb7c243f812a921c0fd8ce3cd5a0126a1b04902ab32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "531eec11-982b-4b38-951d-21bc222149a6", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd \nlike to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Stephanie.  Good afternoon and welcome everyone to McKesson's Fourth Quarter Fiscal 2021 \nEarnings Call. ", "original_text": "Please go ahead.  \n ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "70c6b3ae1d53a1098896cf9016a8b7cc31240b096ae73e334ead3ffa004404cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb1e1204-820d-43fa-8211-08284f889719", "node_type": "1", "metadata": {"window": "At this time, I'd \nlike to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Stephanie.  Good afternoon and welcome everyone to McKesson's Fourth Quarter Fiscal 2021 \nEarnings Call.  Today, I'm joined by; Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a question -and-answer session. ", "original_text": "Thank you, Stephanie. "}, "hash": "b59747d40853c426f3b1a5b99a215629311963d2b15ff263ba6c228c7ad9f7b4", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "start_char_idx": 396, "end_char_idx": 738, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb1e1204-820d-43fa-8211-08284f889719": {"__data__": {"id_": "bb1e1204-820d-43fa-8211-08284f889719", "embedding": null, "metadata": {"window": "At this time, I'd \nlike to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Stephanie.  Good afternoon and welcome everyone to McKesson's Fourth Quarter Fiscal 2021 \nEarnings Call.  Today, I'm joined by; Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a question -and-answer session. ", "original_text": "Thank you, Stephanie. ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9690d5c831bd1337e1b3ddb7c243f812a921c0fd8ce3cd5a0126a1b04902ab32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae751d68-767b-460c-bfb2-10175e94e806", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.  At this time, I'd \nlike to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Stephanie.  Good afternoon and welcome everyone to McKesson's Fourth Quarter Fiscal 2021 \nEarnings Call.  Today, I'm joined by; Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial \nOfficer. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56ba08014df18c9142798b1e8e76fc1f1b6d6de56698aa13ea4625895c1dae4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0ccf3ef-daf4-49d2-9701-e8a350c2d4b7", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Stephanie.  Good afternoon and welcome everyone to McKesson's Fourth Quarter Fiscal 2021 \nEarnings Call.  Today, I'm joined by; Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  Today's \ndiscussion will include forward -looking statements, such as forecasts about McKesson's operations and future \nresults.  \n \n", "original_text": "Good afternoon and welcome everyone to McKesson's Fourth Quarter Fiscal 2021 \nEarnings Call. "}, "hash": "89c26d9c6b00d467b0e13df4e34b0bd7677251afba7a510a0d759e7b4cc4f3d0", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Stephanie. ", "start_char_idx": 738, "end_char_idx": 760, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0ccf3ef-daf4-49d2-9701-e8a350c2d4b7": {"__data__": {"id_": "b0ccf3ef-daf4-49d2-9701-e8a350c2d4b7", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Stephanie.  Good afternoon and welcome everyone to McKesson's Fourth Quarter Fiscal 2021 \nEarnings Call.  Today, I'm joined by; Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  Today's \ndiscussion will include forward -looking statements, such as forecasts about McKesson's operations and future \nresults.  \n \n", "original_text": "Good afternoon and welcome everyone to McKesson's Fourth Quarter Fiscal 2021 \nEarnings Call. ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9690d5c831bd1337e1b3ddb7c243f812a921c0fd8ce3cd5a0126a1b04902ab32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb1e1204-820d-43fa-8211-08284f889719", "node_type": "1", "metadata": {"window": "At this time, I'd \nlike to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Stephanie.  Good afternoon and welcome everyone to McKesson's Fourth Quarter Fiscal 2021 \nEarnings Call.  Today, I'm joined by; Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a question -and-answer session. ", "original_text": "Thank you, Stephanie. ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a9716cf1f034cbaf9d2a046a15881894c6d11185cf434d94e278a36bd2e22405", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "742dce34-a795-4152-ba46-c7ef2aa2f9d7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Stephanie.  Good afternoon and welcome everyone to McKesson's Fourth Quarter Fiscal 2021 \nEarnings Call.  Today, I'm joined by; Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  Today's \ndiscussion will include forward -looking statements, such as forecasts about McKesson's operations and future \nresults.  \n \n Please refer to the cautionary statements in today's press release and our slide presentation and for the Risk \nFactors section of our periodic SEC filings for additional information concerning risk factors that could cause our \nactual results to materially differ from those in our forward -looking statements. ", "original_text": "Today, I'm joined by; Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial \nOfficer. "}, "hash": "bb85d6d423b0410704bfee8a75da0509ac295f407b1e2506018ae21f02056151", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon and welcome everyone to McKesson's Fourth Quarter Fiscal 2021 \nEarnings Call. ", "start_char_idx": 760, "end_char_idx": 853, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "742dce34-a795-4152-ba46-c7ef2aa2f9d7": {"__data__": {"id_": "742dce34-a795-4152-ba46-c7ef2aa2f9d7", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Stephanie.  Good afternoon and welcome everyone to McKesson's Fourth Quarter Fiscal 2021 \nEarnings Call.  Today, I'm joined by; Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  Today's \ndiscussion will include forward -looking statements, such as forecasts about McKesson's operations and future \nresults.  \n \n Please refer to the cautionary statements in today's press release and our slide presentation and for the Risk \nFactors section of our periodic SEC filings for additional information concerning risk factors that could cause our \nactual results to materially differ from those in our forward -looking statements. ", "original_text": "Today, I'm joined by; Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial \nOfficer. ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9690d5c831bd1337e1b3ddb7c243f812a921c0fd8ce3cd5a0126a1b04902ab32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0ccf3ef-daf4-49d2-9701-e8a350c2d4b7", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Stephanie.  Good afternoon and welcome everyone to McKesson's Fourth Quarter Fiscal 2021 \nEarnings Call.  Today, I'm joined by; Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  Today's \ndiscussion will include forward -looking statements, such as forecasts about McKesson's operations and future \nresults.  \n \n", "original_text": "Good afternoon and welcome everyone to McKesson's Fourth Quarter Fiscal 2021 \nEarnings Call. ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a1a6bf831217d2e4d12c00e061c0ee3b23fc73d236c429031bbf9b078c381a72", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49093942-6be4-4761-a1f4-3150419318fc", "node_type": "1", "metadata": {"window": "Thank you, Stephanie.  Good afternoon and welcome everyone to McKesson's Fourth Quarter Fiscal 2021 \nEarnings Call.  Today, I'm joined by; Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  Today's \ndiscussion will include forward -looking statements, such as forecasts about McKesson's operations and future \nresults.  \n \n Please refer to the cautionary statements in today's press release and our slide presentation and for the Risk \nFactors section of our periodic SEC filings for additional information concerning risk factors that could cause our \nactual results to materially differ from those in our forward -looking statements.  During this call, we will discuss \nnon-GAAP financial measu res. ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session. "}, "hash": "5512a4ee72be791d22f917c763a0b1f95225df507821bd4dd6b1f2f42e52783f", "class_name": "RelatedNodeInfo"}}, "text": "Today, I'm joined by; Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial \nOfficer. ", "start_char_idx": 853, "end_char_idx": 967, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49093942-6be4-4761-a1f4-3150419318fc": {"__data__": {"id_": "49093942-6be4-4761-a1f4-3150419318fc", "embedding": null, "metadata": {"window": "Thank you, Stephanie.  Good afternoon and welcome everyone to McKesson's Fourth Quarter Fiscal 2021 \nEarnings Call.  Today, I'm joined by; Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  Today's \ndiscussion will include forward -looking statements, such as forecasts about McKesson's operations and future \nresults.  \n \n Please refer to the cautionary statements in today's press release and our slide presentation and for the Risk \nFactors section of our periodic SEC filings for additional information concerning risk factors that could cause our \nactual results to materially differ from those in our forward -looking statements.  During this call, we will discuss \nnon-GAAP financial measu res. ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session. ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9690d5c831bd1337e1b3ddb7c243f812a921c0fd8ce3cd5a0126a1b04902ab32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "742dce34-a795-4152-ba46-c7ef2aa2f9d7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Stephanie.  Good afternoon and welcome everyone to McKesson's Fourth Quarter Fiscal 2021 \nEarnings Call.  Today, I'm joined by; Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  Today's \ndiscussion will include forward -looking statements, such as forecasts about McKesson's operations and future \nresults.  \n \n Please refer to the cautionary statements in today's press release and our slide presentation and for the Risk \nFactors section of our periodic SEC filings for additional information concerning risk factors that could cause our \nactual results to materially differ from those in our forward -looking statements. ", "original_text": "Today, I'm joined by; Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial \nOfficer. ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cc3aee520604f1b5c11a9657b0eebf7f91452cd0b8b9dc9bd620d6ce72c6632", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93f22f59-4782-4460-9bc4-6ddd2939cffb", "node_type": "1", "metadata": {"window": "Good afternoon and welcome everyone to McKesson's Fourth Quarter Fiscal 2021 \nEarnings Call.  Today, I'm joined by; Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  Today's \ndiscussion will include forward -looking statements, such as forecasts about McKesson's operations and future \nresults.  \n \n Please refer to the cautionary statements in today's press release and our slide presentation and for the Risk \nFactors section of our periodic SEC filings for additional information concerning risk factors that could cause our \nactual results to materially differ from those in our forward -looking statements.  During this call, we will discuss \nnon-GAAP financial measu res.  Additional information about our non -GAAP financial measures, including a \nreconciliation of those measures to GAAP results, is included in today's press release and presentation slides, \nwhich are available on our website at investor.mckesson.com.  \n \n", "original_text": "Today's \ndiscussion will include forward -looking statements, such as forecasts about McKesson's operations and future \nresults.  \n \n"}, "hash": "3242ee23f7ce8a22be6dc3373b37d8c11b58f045558010163aaa47af5403e0af", "class_name": "RelatedNodeInfo"}}, "text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session. ", "start_char_idx": 967, "end_char_idx": 1064, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93f22f59-4782-4460-9bc4-6ddd2939cffb": {"__data__": {"id_": "93f22f59-4782-4460-9bc4-6ddd2939cffb", "embedding": null, "metadata": {"window": "Good afternoon and welcome everyone to McKesson's Fourth Quarter Fiscal 2021 \nEarnings Call.  Today, I'm joined by; Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  Today's \ndiscussion will include forward -looking statements, such as forecasts about McKesson's operations and future \nresults.  \n \n Please refer to the cautionary statements in today's press release and our slide presentation and for the Risk \nFactors section of our periodic SEC filings for additional information concerning risk factors that could cause our \nactual results to materially differ from those in our forward -looking statements.  During this call, we will discuss \nnon-GAAP financial measu res.  Additional information about our non -GAAP financial measures, including a \nreconciliation of those measures to GAAP results, is included in today's press release and presentation slides, \nwhich are available on our website at investor.mckesson.com.  \n \n", "original_text": "Today's \ndiscussion will include forward -looking statements, such as forecasts about McKesson's operations and future \nresults.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9690d5c831bd1337e1b3ddb7c243f812a921c0fd8ce3cd5a0126a1b04902ab32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49093942-6be4-4761-a1f4-3150419318fc", "node_type": "1", "metadata": {"window": "Thank you, Stephanie.  Good afternoon and welcome everyone to McKesson's Fourth Quarter Fiscal 2021 \nEarnings Call.  Today, I'm joined by; Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  Today's \ndiscussion will include forward -looking statements, such as forecasts about McKesson's operations and future \nresults.  \n \n Please refer to the cautionary statements in today's press release and our slide presentation and for the Risk \nFactors section of our periodic SEC filings for additional information concerning risk factors that could cause our \nactual results to materially differ from those in our forward -looking statements.  During this call, we will discuss \nnon-GAAP financial measu res. ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session. ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82d2e36d224ae0f16ad9c26bfaa20fc165f474b9fba548bd43b3a1c1bfc99e38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a80ee28-ca18-4332-87e0-a25a56427d1f", "node_type": "1", "metadata": {"window": "Today, I'm joined by; Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  Today's \ndiscussion will include forward -looking statements, such as forecasts about McKesson's operations and future \nresults.  \n \n Please refer to the cautionary statements in today's press release and our slide presentation and for the Risk \nFactors section of our periodic SEC filings for additional information concerning risk factors that could cause our \nactual results to materially differ from those in our forward -looking statements.  During this call, we will discuss \nnon-GAAP financial measu res.  Additional information about our non -GAAP financial measures, including a \nreconciliation of those measures to GAAP results, is included in today's press release and presentation slides, \nwhich are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n ", "original_text": "Please refer to the cautionary statements in today's press release and our slide presentation and for the Risk \nFactors section of our periodic SEC filings for additional information concerning risk factors that could cause our \nactual results to materially differ from those in our forward -looking statements. "}, "hash": "19543bb76a2198aa09571234bc44abade795df13479be6dc5e9b81cb1aa89715", "class_name": "RelatedNodeInfo"}}, "text": "Today's \ndiscussion will include forward -looking statements, such as forecasts about McKesson's operations and future \nresults.  \n \n", "start_char_idx": 1064, "end_char_idx": 1197, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a80ee28-ca18-4332-87e0-a25a56427d1f": {"__data__": {"id_": "0a80ee28-ca18-4332-87e0-a25a56427d1f", "embedding": null, "metadata": {"window": "Today, I'm joined by; Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  Today's \ndiscussion will include forward -looking statements, such as forecasts about McKesson's operations and future \nresults.  \n \n Please refer to the cautionary statements in today's press release and our slide presentation and for the Risk \nFactors section of our periodic SEC filings for additional information concerning risk factors that could cause our \nactual results to materially differ from those in our forward -looking statements.  During this call, we will discuss \nnon-GAAP financial measu res.  Additional information about our non -GAAP financial measures, including a \nreconciliation of those measures to GAAP results, is included in today's press release and presentation slides, \nwhich are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n ", "original_text": "Please refer to the cautionary statements in today's press release and our slide presentation and for the Risk \nFactors section of our periodic SEC filings for additional information concerning risk factors that could cause our \nactual results to materially differ from those in our forward -looking statements. ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9690d5c831bd1337e1b3ddb7c243f812a921c0fd8ce3cd5a0126a1b04902ab32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93f22f59-4782-4460-9bc4-6ddd2939cffb", "node_type": "1", "metadata": {"window": "Good afternoon and welcome everyone to McKesson's Fourth Quarter Fiscal 2021 \nEarnings Call.  Today, I'm joined by; Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  Today's \ndiscussion will include forward -looking statements, such as forecasts about McKesson's operations and future \nresults.  \n \n Please refer to the cautionary statements in today's press release and our slide presentation and for the Risk \nFactors section of our periodic SEC filings for additional information concerning risk factors that could cause our \nactual results to materially differ from those in our forward -looking statements.  During this call, we will discuss \nnon-GAAP financial measu res.  Additional information about our non -GAAP financial measures, including a \nreconciliation of those measures to GAAP results, is included in today's press release and presentation slides, \nwhich are available on our website at investor.mckesson.com.  \n \n", "original_text": "Today's \ndiscussion will include forward -looking statements, such as forecasts about McKesson's operations and future \nresults.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5589c282b94e8fc5985e117de758cc3cc4124fc1f426b733ce0600c838a77773", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4fa1e4f9-e704-4798-b504-86c088fe22d0", "node_type": "1", "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  Today's \ndiscussion will include forward -looking statements, such as forecasts about McKesson's operations and future \nresults.  \n \n Please refer to the cautionary statements in today's press release and our slide presentation and for the Risk \nFactors section of our periodic SEC filings for additional information concerning risk factors that could cause our \nactual results to materially differ from those in our forward -looking statements.  During this call, we will discuss \nnon-GAAP financial measu res.  Additional information about our non -GAAP financial measures, including a \nreconciliation of those measures to GAAP results, is included in today's press release and presentation slides, \nwhich are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "During this call, we will discuss \nnon-GAAP financial measu res. "}, "hash": "fc6ddc6fb272c7a0da4003407c0140add09e4012ff087f1a394e9ebc1124be56", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the cautionary statements in today's press release and our slide presentation and for the Risk \nFactors section of our periodic SEC filings for additional information concerning risk factors that could cause our \nactual results to materially differ from those in our forward -looking statements. ", "start_char_idx": 1197, "end_char_idx": 1509, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4fa1e4f9-e704-4798-b504-86c088fe22d0": {"__data__": {"id_": "4fa1e4f9-e704-4798-b504-86c088fe22d0", "embedding": null, "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  Today's \ndiscussion will include forward -looking statements, such as forecasts about McKesson's operations and future \nresults.  \n \n Please refer to the cautionary statements in today's press release and our slide presentation and for the Risk \nFactors section of our periodic SEC filings for additional information concerning risk factors that could cause our \nactual results to materially differ from those in our forward -looking statements.  During this call, we will discuss \nnon-GAAP financial measu res.  Additional information about our non -GAAP financial measures, including a \nreconciliation of those measures to GAAP results, is included in today's press release and presentation slides, \nwhich are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "During this call, we will discuss \nnon-GAAP financial measu res. ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9690d5c831bd1337e1b3ddb7c243f812a921c0fd8ce3cd5a0126a1b04902ab32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a80ee28-ca18-4332-87e0-a25a56427d1f", "node_type": "1", "metadata": {"window": "Today, I'm joined by; Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial \nOfficer.  Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  Today's \ndiscussion will include forward -looking statements, such as forecasts about McKesson's operations and future \nresults.  \n \n Please refer to the cautionary statements in today's press release and our slide presentation and for the Risk \nFactors section of our periodic SEC filings for additional information concerning risk factors that could cause our \nactual results to materially differ from those in our forward -looking statements.  During this call, we will discuss \nnon-GAAP financial measu res.  Additional information about our non -GAAP financial measures, including a \nreconciliation of those measures to GAAP results, is included in today's press release and presentation slides, \nwhich are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n ", "original_text": "Please refer to the cautionary statements in today's press release and our slide presentation and for the Risk \nFactors section of our periodic SEC filings for additional information concerning risk factors that could cause our \nactual results to materially differ from those in our forward -looking statements. ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85036c0d3cf12c5ced76cb451b051d9ab2f355be40c8d42ced5366831c960fe8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3ccac06-64f7-4d68-aade-c86c93406b78", "node_type": "1", "metadata": {"window": "Today's \ndiscussion will include forward -looking statements, such as forecasts about McKesson's operations and future \nresults.  \n \n Please refer to the cautionary statements in today's press release and our slide presentation and for the Risk \nFactors section of our periodic SEC filings for additional information concerning risk factors that could cause our \nactual results to materially differ from those in our forward -looking statements.  During this call, we will discuss \nnon-GAAP financial measu res.  Additional information about our non -GAAP financial measures, including a \nreconciliation of those measures to GAAP results, is included in today's press release and presentation slides, \nwhich are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody. ", "original_text": "Additional information about our non -GAAP financial measures, including a \nreconciliation of those measures to GAAP results, is included in today's press release and presentation slides, \nwhich are available on our website at investor.mckesson.com.  \n \n"}, "hash": "c0840b7f356a9fcd7e8bc767ae4697dd9e4725db80a095b5ffa9fa0e2cda40cc", "class_name": "RelatedNodeInfo"}}, "text": "During this call, we will discuss \nnon-GAAP financial measu res. ", "start_char_idx": 1509, "end_char_idx": 1574, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3ccac06-64f7-4d68-aade-c86c93406b78": {"__data__": {"id_": "d3ccac06-64f7-4d68-aade-c86c93406b78", "embedding": null, "metadata": {"window": "Today's \ndiscussion will include forward -looking statements, such as forecasts about McKesson's operations and future \nresults.  \n \n Please refer to the cautionary statements in today's press release and our slide presentation and for the Risk \nFactors section of our periodic SEC filings for additional information concerning risk factors that could cause our \nactual results to materially differ from those in our forward -looking statements.  During this call, we will discuss \nnon-GAAP financial measu res.  Additional information about our non -GAAP financial measures, including a \nreconciliation of those measures to GAAP results, is included in today's press release and presentation slides, \nwhich are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody. ", "original_text": "Additional information about our non -GAAP financial measures, including a \nreconciliation of those measures to GAAP results, is included in today's press release and presentation slides, \nwhich are available on our website at investor.mckesson.com.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9690d5c831bd1337e1b3ddb7c243f812a921c0fd8ce3cd5a0126a1b04902ab32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4fa1e4f9-e704-4798-b504-86c088fe22d0", "node_type": "1", "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  Today's \ndiscussion will include forward -looking statements, such as forecasts about McKesson's operations and future \nresults.  \n \n Please refer to the cautionary statements in today's press release and our slide presentation and for the Risk \nFactors section of our periodic SEC filings for additional information concerning risk factors that could cause our \nactual results to materially differ from those in our forward -looking statements.  During this call, we will discuss \nnon-GAAP financial measu res.  Additional information about our non -GAAP financial measures, including a \nreconciliation of those measures to GAAP results, is included in today's press release and presentation slides, \nwhich are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "During this call, we will discuss \nnon-GAAP financial measu res. ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3292b380560a8e9d815e75339025bffc10d5d159cd65592a0c55e31df60041e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d42212e-b4c0-42bf-8acc-f54a1397b396", "node_type": "1", "metadata": {"window": "Please refer to the cautionary statements in today's press release and our slide presentation and for the Risk \nFactors section of our periodic SEC filings for additional information concerning risk factors that could cause our \nactual results to materially differ from those in our forward -looking statements.  During this call, we will discuss \nnon-GAAP financial measu res.  Additional information about our non -GAAP financial measures, including a \nreconciliation of those measures to GAAP results, is included in today's press release and presentation slides, \nwhich are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our call this afternoon. ", "original_text": "With that, let me turn it over to Brian.  \n "}, "hash": "2fc733b9e9720e7098c5b151e6ef97098ba7c8d14e47ebcde95aaefa9dff065e", "class_name": "RelatedNodeInfo"}}, "text": "Additional information about our non -GAAP financial measures, including a \nreconciliation of those measures to GAAP results, is included in today's press release and presentation slides, \nwhich are available on our website at investor.mckesson.com.  \n \n", "start_char_idx": 1574, "end_char_idx": 1828, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d42212e-b4c0-42bf-8acc-f54a1397b396": {"__data__": {"id_": "1d42212e-b4c0-42bf-8acc-f54a1397b396", "embedding": null, "metadata": {"window": "Please refer to the cautionary statements in today's press release and our slide presentation and for the Risk \nFactors section of our periodic SEC filings for additional information concerning risk factors that could cause our \nactual results to materially differ from those in our forward -looking statements.  During this call, we will discuss \nnon-GAAP financial measu res.  Additional information about our non -GAAP financial measures, including a \nreconciliation of those measures to GAAP results, is included in today's press release and presentation slides, \nwhich are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our call this afternoon. ", "original_text": "With that, let me turn it over to Brian.  \n ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9690d5c831bd1337e1b3ddb7c243f812a921c0fd8ce3cd5a0126a1b04902ab32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3ccac06-64f7-4d68-aade-c86c93406b78", "node_type": "1", "metadata": {"window": "Today's \ndiscussion will include forward -looking statements, such as forecasts about McKesson's operations and future \nresults.  \n \n Please refer to the cautionary statements in today's press release and our slide presentation and for the Risk \nFactors section of our periodic SEC filings for additional information concerning risk factors that could cause our \nactual results to materially differ from those in our forward -looking statements.  During this call, we will discuss \nnon-GAAP financial measu res.  Additional information about our non -GAAP financial measures, including a \nreconciliation of those measures to GAAP results, is included in today's press release and presentation slides, \nwhich are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody. ", "original_text": "Additional information about our non -GAAP financial measures, including a \nreconciliation of those measures to GAAP results, is included in today's press release and presentation slides, \nwhich are available on our website at investor.mckesson.com.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d04e323b899a7d7dbd48c76f95c5fb4ef031300dc0d3c1b628ea82564e3f009", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62875154-38b4-42e6-80b3-c161e33c88a5", "node_type": "1", "metadata": {"window": "During this call, we will discuss \nnon-GAAP financial measu res.  Additional information about our non -GAAP financial measures, including a \nreconciliation of those measures to GAAP results, is included in today's press release and presentation slides, \nwhich are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our call this afternoon.  On our \nfourth quarter call last year, I talk ed about how the COVID -19 pandemic was beginning to impact our employees, \nour customers, our partners and the very communities in which we live. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "0f9aee517ac60ba26ca171cbb397ca6a5226efdeef03d895205ea353c3595bd8", "class_name": "RelatedNodeInfo"}}, "text": "With that, let me turn it over to Brian.  \n ", "start_char_idx": 1828, "end_char_idx": 1872, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62875154-38b4-42e6-80b3-c161e33c88a5": {"__data__": {"id_": "62875154-38b4-42e6-80b3-c161e33c88a5", "embedding": null, "metadata": {"window": "During this call, we will discuss \nnon-GAAP financial measu res.  Additional information about our non -GAAP financial measures, including a \nreconciliation of those measures to GAAP results, is included in today's press release and presentation slides, \nwhich are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our call this afternoon.  On our \nfourth quarter call last year, I talk ed about how the COVID -19 pandemic was beginning to impact our employees, \nour customers, our partners and the very communities in which we live. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9690d5c831bd1337e1b3ddb7c243f812a921c0fd8ce3cd5a0126a1b04902ab32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d42212e-b4c0-42bf-8acc-f54a1397b396", "node_type": "1", "metadata": {"window": "Please refer to the cautionary statements in today's press release and our slide presentation and for the Risk \nFactors section of our periodic SEC filings for additional information concerning risk factors that could cause our \nactual results to materially differ from those in our forward -looking statements.  During this call, we will discuss \nnon-GAAP financial measu res.  Additional information about our non -GAAP financial measures, including a \nreconciliation of those measures to GAAP results, is included in today's press release and presentation slides, \nwhich are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our call this afternoon. ", "original_text": "With that, let me turn it over to Brian.  \n ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4c93ed7fee45829f42d4f307cbf7e20ec6ea143ba4d5ef2ca49d5072f046e7d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4989ea59-e65d-40d3-8a21-ab07888bd2f3", "node_type": "1", "metadata": {"window": "Additional information about our non -GAAP financial measures, including a \nreconciliation of those measures to GAAP results, is included in today's press release and presentation slides, \nwhich are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our call this afternoon.  On our \nfourth quarter call last year, I talk ed about how the COVID -19 pandemic was beginning to impact our employees, \nour customers, our partners and the very communities in which we live.  As one of the largest healthcare \ncompanies in the world, I said that McKesson would play an essential role in p rotecting the health and safety of \nthe healthcare supply chain.  \n \n", "original_text": "Thank you, Holly, and good afternoon, everybody. "}, "hash": "62f278e8f3ac274ba8816ca99fd652e46a7bf17410d3aeaa66741d5e956e5e2f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 1872, "end_char_idx": 2202, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4989ea59-e65d-40d3-8a21-ab07888bd2f3": {"__data__": {"id_": "4989ea59-e65d-40d3-8a21-ab07888bd2f3", "embedding": null, "metadata": {"window": "Additional information about our non -GAAP financial measures, including a \nreconciliation of those measures to GAAP results, is included in today's press release and presentation slides, \nwhich are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our call this afternoon.  On our \nfourth quarter call last year, I talk ed about how the COVID -19 pandemic was beginning to impact our employees, \nour customers, our partners and the very communities in which we live.  As one of the largest healthcare \ncompanies in the world, I said that McKesson would play an essential role in p rotecting the health and safety of \nthe healthcare supply chain.  \n \n", "original_text": "Thank you, Holly, and good afternoon, everybody. ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9690d5c831bd1337e1b3ddb7c243f812a921c0fd8ce3cd5a0126a1b04902ab32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62875154-38b4-42e6-80b3-c161e33c88a5", "node_type": "1", "metadata": {"window": "During this call, we will discuss \nnon-GAAP financial measu res.  Additional information about our non -GAAP financial measures, including a \nreconciliation of those measures to GAAP results, is included in today's press release and presentation slides, \nwhich are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our call this afternoon.  On our \nfourth quarter call last year, I talk ed about how the COVID -19 pandemic was beginning to impact our employees, \nour customers, our partners and the very communities in which we live. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "657d6d32639f4345918e140bcd85f90baa4dbb6cb4f8c11af834fa988e21fbd3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e98f00df-cc60-42b7-aec0-95e9be34d4a9", "node_type": "1", "metadata": {"window": "With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our call this afternoon.  On our \nfourth quarter call last year, I talk ed about how the COVID -19 pandemic was beginning to impact our employees, \nour customers, our partners and the very communities in which we live.  As one of the largest healthcare \ncompanies in the world, I said that McKesson would play an essential role in p rotecting the health and safety of \nthe healthcare supply chain.  \n \n While we were confident in our abilities to help our customers during challenging times, what played out over the \ncourse of the year proved to be more unpredictable than anyone could have ima gined. ", "original_text": "Thank you for joining us on our call this afternoon. "}, "hash": "00b5eaf9e78b38c5b394de45922c12a1f2c1440609747bc800f8c22759d3515a", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Holly, and good afternoon, everybody. ", "start_char_idx": 2202, "end_char_idx": 2251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e98f00df-cc60-42b7-aec0-95e9be34d4a9": {"__data__": {"id_": "e98f00df-cc60-42b7-aec0-95e9be34d4a9", "embedding": null, "metadata": {"window": "With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our call this afternoon.  On our \nfourth quarter call last year, I talk ed about how the COVID -19 pandemic was beginning to impact our employees, \nour customers, our partners and the very communities in which we live.  As one of the largest healthcare \ncompanies in the world, I said that McKesson would play an essential role in p rotecting the health and safety of \nthe healthcare supply chain.  \n \n While we were confident in our abilities to help our customers during challenging times, what played out over the \ncourse of the year proved to be more unpredictable than anyone could have ima gined. ", "original_text": "Thank you for joining us on our call this afternoon. ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9690d5c831bd1337e1b3ddb7c243f812a921c0fd8ce3cd5a0126a1b04902ab32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4989ea59-e65d-40d3-8a21-ab07888bd2f3", "node_type": "1", "metadata": {"window": "Additional information about our non -GAAP financial measures, including a \nreconciliation of those measures to GAAP results, is included in today's press release and presentation slides, \nwhich are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our call this afternoon.  On our \nfourth quarter call last year, I talk ed about how the COVID -19 pandemic was beginning to impact our employees, \nour customers, our partners and the very communities in which we live.  As one of the largest healthcare \ncompanies in the world, I said that McKesson would play an essential role in p rotecting the health and safety of \nthe healthcare supply chain.  \n \n", "original_text": "Thank you, Holly, and good afternoon, everybody. ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b8586af75200c13c85eff9a774c221619e9de4b3849bd7aa94c85c556aacc227", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3c662b9-0b87-47cd-a36f-5588327d2de1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our call this afternoon.  On our \nfourth quarter call last year, I talk ed about how the COVID -19 pandemic was beginning to impact our employees, \nour customers, our partners and the very communities in which we live.  As one of the largest healthcare \ncompanies in the world, I said that McKesson would play an essential role in p rotecting the health and safety of \nthe healthcare supply chain.  \n \n While we were confident in our abilities to help our customers during challenging times, what played out over the \ncourse of the year proved to be more unpredictable than anyone could have ima gined.  The up and down \ntrajectory of the recovery was certainly different than we had originally anticipated. ", "original_text": "On our \nfourth quarter call last year, I talk ed about how the COVID -19 pandemic was beginning to impact our employees, \nour customers, our partners and the very communities in which we live. "}, "hash": "5acf6665c281dd48701319e41e32d1af5758e575aeea986580aa0263fd2db77c", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for joining us on our call this afternoon. ", "start_char_idx": 2251, "end_char_idx": 2304, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3c662b9-0b87-47cd-a36f-5588327d2de1": {"__data__": {"id_": "f3c662b9-0b87-47cd-a36f-5588327d2de1", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our call this afternoon.  On our \nfourth quarter call last year, I talk ed about how the COVID -19 pandemic was beginning to impact our employees, \nour customers, our partners and the very communities in which we live.  As one of the largest healthcare \ncompanies in the world, I said that McKesson would play an essential role in p rotecting the health and safety of \nthe healthcare supply chain.  \n \n While we were confident in our abilities to help our customers during challenging times, what played out over the \ncourse of the year proved to be more unpredictable than anyone could have ima gined.  The up and down \ntrajectory of the recovery was certainly different than we had originally anticipated. ", "original_text": "On our \nfourth quarter call last year, I talk ed about how the COVID -19 pandemic was beginning to impact our employees, \nour customers, our partners and the very communities in which we live. ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9690d5c831bd1337e1b3ddb7c243f812a921c0fd8ce3cd5a0126a1b04902ab32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e98f00df-cc60-42b7-aec0-95e9be34d4a9", "node_type": "1", "metadata": {"window": "With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our call this afternoon.  On our \nfourth quarter call last year, I talk ed about how the COVID -19 pandemic was beginning to impact our employees, \nour customers, our partners and the very communities in which we live.  As one of the largest healthcare \ncompanies in the world, I said that McKesson would play an essential role in p rotecting the health and safety of \nthe healthcare supply chain.  \n \n While we were confident in our abilities to help our customers during challenging times, what played out over the \ncourse of the year proved to be more unpredictable than anyone could have ima gined. ", "original_text": "Thank you for joining us on our call this afternoon. ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41c51e5df75a715a057e6cd2407f3b506553bc6a803f2b59a09911ed99022389", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f12fbbfc-69b2-4e15-98d2-50b84a8afd8f", "node_type": "1", "metadata": {"window": "Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our call this afternoon.  On our \nfourth quarter call last year, I talk ed about how the COVID -19 pandemic was beginning to impact our employees, \nour customers, our partners and the very communities in which we live.  As one of the largest healthcare \ncompanies in the world, I said that McKesson would play an essential role in p rotecting the health and safety of \nthe healthcare supply chain.  \n \n While we were confident in our abilities to help our customers during challenging times, what played out over the \ncourse of the year proved to be more unpredictable than anyone could have ima gined.  The up and down \ntrajectory of the recovery was certainly different than we had originally anticipated.  And our role in the COVID -19 \nresponse efforts evolved and expanded quickly as a result.  \n \n", "original_text": "As one of the largest healthcare \ncompanies in the world, I said that McKesson would play an essential role in p rotecting the health and safety of \nthe healthcare supply chain.  \n \n"}, "hash": "08b5baad3646f48abbb1030408842df38746a55771acf1db43e47e196d4e01bf", "class_name": "RelatedNodeInfo"}}, "text": "On our \nfourth quarter call last year, I talk ed about how the COVID -19 pandemic was beginning to impact our employees, \nour customers, our partners and the very communities in which we live. ", "start_char_idx": 2304, "end_char_idx": 2497, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f12fbbfc-69b2-4e15-98d2-50b84a8afd8f": {"__data__": {"id_": "f12fbbfc-69b2-4e15-98d2-50b84a8afd8f", "embedding": null, "metadata": {"window": "Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our call this afternoon.  On our \nfourth quarter call last year, I talk ed about how the COVID -19 pandemic was beginning to impact our employees, \nour customers, our partners and the very communities in which we live.  As one of the largest healthcare \ncompanies in the world, I said that McKesson would play an essential role in p rotecting the health and safety of \nthe healthcare supply chain.  \n \n While we were confident in our abilities to help our customers during challenging times, what played out over the \ncourse of the year proved to be more unpredictable than anyone could have ima gined.  The up and down \ntrajectory of the recovery was certainly different than we had originally anticipated.  And our role in the COVID -19 \nresponse efforts evolved and expanded quickly as a result.  \n \n", "original_text": "As one of the largest healthcare \ncompanies in the world, I said that McKesson would play an essential role in p rotecting the health and safety of \nthe healthcare supply chain.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9690d5c831bd1337e1b3ddb7c243f812a921c0fd8ce3cd5a0126a1b04902ab32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3c662b9-0b87-47cd-a36f-5588327d2de1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our call this afternoon.  On our \nfourth quarter call last year, I talk ed about how the COVID -19 pandemic was beginning to impact our employees, \nour customers, our partners and the very communities in which we live.  As one of the largest healthcare \ncompanies in the world, I said that McKesson would play an essential role in p rotecting the health and safety of \nthe healthcare supply chain.  \n \n While we were confident in our abilities to help our customers during challenging times, what played out over the \ncourse of the year proved to be more unpredictable than anyone could have ima gined.  The up and down \ntrajectory of the recovery was certainly different than we had originally anticipated. ", "original_text": "On our \nfourth quarter call last year, I talk ed about how the COVID -19 pandemic was beginning to impact our employees, \nour customers, our partners and the very communities in which we live. ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "47241185d373f8160f3dc97c2a1d265681f8a7f9b44b90f106f46c75abdb8746", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3084537-2fbc-4772-9539-353de900b0c1", "node_type": "1", "metadata": {"window": "Thank you for joining us on our call this afternoon.  On our \nfourth quarter call last year, I talk ed about how the COVID -19 pandemic was beginning to impact our employees, \nour customers, our partners and the very communities in which we live.  As one of the largest healthcare \ncompanies in the world, I said that McKesson would play an essential role in p rotecting the health and safety of \nthe healthcare supply chain.  \n \n While we were confident in our abilities to help our customers during challenging times, what played out over the \ncourse of the year proved to be more unpredictable than anyone could have ima gined.  The up and down \ntrajectory of the recovery was certainly different than we had originally anticipated.  And our role in the COVID -19 \nresponse efforts evolved and expanded quickly as a result.  \n \n Fiscal 2021 was one of the most challenging yet fulfillin g and inspiring years of my career, a year like no other in \nthe 188 -year history of our company. ", "original_text": "While we were confident in our abilities to help our customers during challenging times, what played out over the \ncourse of the year proved to be more unpredictable than anyone could have ima gined. "}, "hash": "ef8f1b9fd8ad2aca106e86a3eb436ebe341da5fbaf8a344d3893e58cda1b3b76", "class_name": "RelatedNodeInfo"}}, "text": "As one of the largest healthcare \ncompanies in the world, I said that McKesson would play an essential role in p rotecting the health and safety of \nthe healthcare supply chain.  \n \n", "start_char_idx": 2497, "end_char_idx": 2679, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3084537-2fbc-4772-9539-353de900b0c1": {"__data__": {"id_": "f3084537-2fbc-4772-9539-353de900b0c1", "embedding": null, "metadata": {"window": "Thank you for joining us on our call this afternoon.  On our \nfourth quarter call last year, I talk ed about how the COVID -19 pandemic was beginning to impact our employees, \nour customers, our partners and the very communities in which we live.  As one of the largest healthcare \ncompanies in the world, I said that McKesson would play an essential role in p rotecting the health and safety of \nthe healthcare supply chain.  \n \n While we were confident in our abilities to help our customers during challenging times, what played out over the \ncourse of the year proved to be more unpredictable than anyone could have ima gined.  The up and down \ntrajectory of the recovery was certainly different than we had originally anticipated.  And our role in the COVID -19 \nresponse efforts evolved and expanded quickly as a result.  \n \n Fiscal 2021 was one of the most challenging yet fulfillin g and inspiring years of my career, a year like no other in \nthe 188 -year history of our company. ", "original_text": "While we were confident in our abilities to help our customers during challenging times, what played out over the \ncourse of the year proved to be more unpredictable than anyone could have ima gined. ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9690d5c831bd1337e1b3ddb7c243f812a921c0fd8ce3cd5a0126a1b04902ab32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f12fbbfc-69b2-4e15-98d2-50b84a8afd8f", "node_type": "1", "metadata": {"window": "Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our call this afternoon.  On our \nfourth quarter call last year, I talk ed about how the COVID -19 pandemic was beginning to impact our employees, \nour customers, our partners and the very communities in which we live.  As one of the largest healthcare \ncompanies in the world, I said that McKesson would play an essential role in p rotecting the health and safety of \nthe healthcare supply chain.  \n \n While we were confident in our abilities to help our customers during challenging times, what played out over the \ncourse of the year proved to be more unpredictable than anyone could have ima gined.  The up and down \ntrajectory of the recovery was certainly different than we had originally anticipated.  And our role in the COVID -19 \nresponse efforts evolved and expanded quickly as a result.  \n \n", "original_text": "As one of the largest healthcare \ncompanies in the world, I said that McKesson would play an essential role in p rotecting the health and safety of \nthe healthcare supply chain.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53f9f42cf4658fd9f6a3f35150db5cef3e2535f5c9f80268fa3916d18f74faf8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ec1542b-2115-4ca4-a07f-2452f3411988", "node_type": "1", "metadata": {"window": "On our \nfourth quarter call last year, I talk ed about how the COVID -19 pandemic was beginning to impact our employees, \nour customers, our partners and the very communities in which we live.  As one of the largest healthcare \ncompanies in the world, I said that McKesson would play an essential role in p rotecting the health and safety of \nthe healthcare supply chain.  \n \n While we were confident in our abilities to help our customers during challenging times, what played out over the \ncourse of the year proved to be more unpredictable than anyone could have ima gined.  The up and down \ntrajectory of the recovery was certainly different than we had originally anticipated.  And our role in the COVID -19 \nresponse efforts evolved and expanded quickly as a result.  \n \n Fiscal 2021 was one of the most challenging yet fulfillin g and inspiring years of my career, a year like no other in \nthe 188 -year history of our company.  I want to thank the team McKesson and our innumerable public and private \npartners for their resilience, commitment to our values and service to our caregivers and patients.  \n \n", "original_text": "The up and down \ntrajectory of the recovery was certainly different than we had originally anticipated. "}, "hash": "db59c68e4a38b57c90615b840af94c6bb15c1e2d636950943e202880c6daf98a", "class_name": "RelatedNodeInfo"}}, "text": "While we were confident in our abilities to help our customers during challenging times, what played out over the \ncourse of the year proved to be more unpredictable than anyone could have ima gined. ", "start_char_idx": 2679, "end_char_idx": 2879, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ec1542b-2115-4ca4-a07f-2452f3411988": {"__data__": {"id_": "5ec1542b-2115-4ca4-a07f-2452f3411988", "embedding": null, "metadata": {"window": "On our \nfourth quarter call last year, I talk ed about how the COVID -19 pandemic was beginning to impact our employees, \nour customers, our partners and the very communities in which we live.  As one of the largest healthcare \ncompanies in the world, I said that McKesson would play an essential role in p rotecting the health and safety of \nthe healthcare supply chain.  \n \n While we were confident in our abilities to help our customers during challenging times, what played out over the \ncourse of the year proved to be more unpredictable than anyone could have ima gined.  The up and down \ntrajectory of the recovery was certainly different than we had originally anticipated.  And our role in the COVID -19 \nresponse efforts evolved and expanded quickly as a result.  \n \n Fiscal 2021 was one of the most challenging yet fulfillin g and inspiring years of my career, a year like no other in \nthe 188 -year history of our company.  I want to thank the team McKesson and our innumerable public and private \npartners for their resilience, commitment to our values and service to our caregivers and patients.  \n \n", "original_text": "The up and down \ntrajectory of the recovery was certainly different than we had originally anticipated. ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9690d5c831bd1337e1b3ddb7c243f812a921c0fd8ce3cd5a0126a1b04902ab32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3084537-2fbc-4772-9539-353de900b0c1", "node_type": "1", "metadata": {"window": "Thank you for joining us on our call this afternoon.  On our \nfourth quarter call last year, I talk ed about how the COVID -19 pandemic was beginning to impact our employees, \nour customers, our partners and the very communities in which we live.  As one of the largest healthcare \ncompanies in the world, I said that McKesson would play an essential role in p rotecting the health and safety of \nthe healthcare supply chain.  \n \n While we were confident in our abilities to help our customers during challenging times, what played out over the \ncourse of the year proved to be more unpredictable than anyone could have ima gined.  The up and down \ntrajectory of the recovery was certainly different than we had originally anticipated.  And our role in the COVID -19 \nresponse efforts evolved and expanded quickly as a result.  \n \n Fiscal 2021 was one of the most challenging yet fulfillin g and inspiring years of my career, a year like no other in \nthe 188 -year history of our company. ", "original_text": "While we were confident in our abilities to help our customers during challenging times, what played out over the \ncourse of the year proved to be more unpredictable than anyone could have ima gined. ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4c283a3c12398630623e3c74ec94320d9d320866f5014a4ad28d3618d80e546", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8e1accc-0d3b-41a2-8a4d-13e1b4a05618", "node_type": "1", "metadata": {"window": "As one of the largest healthcare \ncompanies in the world, I said that McKesson would play an essential role in p rotecting the health and safety of \nthe healthcare supply chain.  \n \n While we were confident in our abilities to help our customers during challenging times, what played out over the \ncourse of the year proved to be more unpredictable than anyone could have ima gined.  The up and down \ntrajectory of the recovery was certainly different than we had originally anticipated.  And our role in the COVID -19 \nresponse efforts evolved and expanded quickly as a result.  \n \n Fiscal 2021 was one of the most challenging yet fulfillin g and inspiring years of my career, a year like no other in \nthe 188 -year history of our company.  I want to thank the team McKesson and our innumerable public and private \npartners for their resilience, commitment to our values and service to our caregivers and patients.  \n \n From the onset of the pandemic, our sourcing teams worked closely with manufacturers and various government \nentities to better forecast changing pharmaceutical and medical product demand in order to extend supply and \nchannel inventory to cri tical areas of need, whether it was working to secure higher volumes of PPE for caregivers \nand frontline worker early in the pandemic or leveraging our expertise in lab capabilities to ramp up distribution of \nCOVID -19 tests as they came to market, McKesson  moved quickly to support our customers, our partners and \nour communities.  ", "original_text": "And our role in the COVID -19 \nresponse efforts evolved and expanded quickly as a result.  \n \n"}, "hash": "3def1efd4df7d4771e6aa30beae6c6fca11491dd94bbe638fa2709418317b17e", "class_name": "RelatedNodeInfo"}}, "text": "The up and down \ntrajectory of the recovery was certainly different than we had originally anticipated. ", "start_char_idx": 2879, "end_char_idx": 2983, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8e1accc-0d3b-41a2-8a4d-13e1b4a05618": {"__data__": {"id_": "d8e1accc-0d3b-41a2-8a4d-13e1b4a05618", "embedding": null, "metadata": {"window": "As one of the largest healthcare \ncompanies in the world, I said that McKesson would play an essential role in p rotecting the health and safety of \nthe healthcare supply chain.  \n \n While we were confident in our abilities to help our customers during challenging times, what played out over the \ncourse of the year proved to be more unpredictable than anyone could have ima gined.  The up and down \ntrajectory of the recovery was certainly different than we had originally anticipated.  And our role in the COVID -19 \nresponse efforts evolved and expanded quickly as a result.  \n \n Fiscal 2021 was one of the most challenging yet fulfillin g and inspiring years of my career, a year like no other in \nthe 188 -year history of our company.  I want to thank the team McKesson and our innumerable public and private \npartners for their resilience, commitment to our values and service to our caregivers and patients.  \n \n From the onset of the pandemic, our sourcing teams worked closely with manufacturers and various government \nentities to better forecast changing pharmaceutical and medical product demand in order to extend supply and \nchannel inventory to cri tical areas of need, whether it was working to secure higher volumes of PPE for caregivers \nand frontline worker early in the pandemic or leveraging our expertise in lab capabilities to ramp up distribution of \nCOVID -19 tests as they came to market, McKesson  moved quickly to support our customers, our partners and \nour communities.  ", "original_text": "And our role in the COVID -19 \nresponse efforts evolved and expanded quickly as a result.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9690d5c831bd1337e1b3ddb7c243f812a921c0fd8ce3cd5a0126a1b04902ab32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ec1542b-2115-4ca4-a07f-2452f3411988", "node_type": "1", "metadata": {"window": "On our \nfourth quarter call last year, I talk ed about how the COVID -19 pandemic was beginning to impact our employees, \nour customers, our partners and the very communities in which we live.  As one of the largest healthcare \ncompanies in the world, I said that McKesson would play an essential role in p rotecting the health and safety of \nthe healthcare supply chain.  \n \n While we were confident in our abilities to help our customers during challenging times, what played out over the \ncourse of the year proved to be more unpredictable than anyone could have ima gined.  The up and down \ntrajectory of the recovery was certainly different than we had originally anticipated.  And our role in the COVID -19 \nresponse efforts evolved and expanded quickly as a result.  \n \n Fiscal 2021 was one of the most challenging yet fulfillin g and inspiring years of my career, a year like no other in \nthe 188 -year history of our company.  I want to thank the team McKesson and our innumerable public and private \npartners for their resilience, commitment to our values and service to our caregivers and patients.  \n \n", "original_text": "The up and down \ntrajectory of the recovery was certainly different than we had originally anticipated. ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "622927d4ac0b4dedd0f96eb229fddd742eb8624eb5fbab4e124af9e157ab8546", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba6788d0-40c5-4519-b5c7-889d330f67a8", "node_type": "1", "metadata": {"window": "While we were confident in our abilities to help our customers during challenging times, what played out over the \ncourse of the year proved to be more unpredictable than anyone could have ima gined.  The up and down \ntrajectory of the recovery was certainly different than we had originally anticipated.  And our role in the COVID -19 \nresponse efforts evolved and expanded quickly as a result.  \n \n Fiscal 2021 was one of the most challenging yet fulfillin g and inspiring years of my career, a year like no other in \nthe 188 -year history of our company.  I want to thank the team McKesson and our innumerable public and private \npartners for their resilience, commitment to our values and service to our caregivers and patients.  \n \n From the onset of the pandemic, our sourcing teams worked closely with manufacturers and various government \nentities to better forecast changing pharmaceutical and medical product demand in order to extend supply and \nchannel inventory to cri tical areas of need, whether it was working to secure higher volumes of PPE for caregivers \nand frontline worker early in the pandemic or leveraging our expertise in lab capabilities to ramp up distribution of \nCOVID -19 tests as they came to market, McKesson  moved quickly to support our customers, our partners and \nour communities.  ", "original_text": "Fiscal 2021 was one of the most challenging yet fulfillin g and inspiring years of my career, a year like no other in \nthe 188 -year history of our company. "}, "hash": "38176629b095af3c0f77861aaa5f6f04b22b5d7d831685b52ef59333a6a2fee9", "class_name": "RelatedNodeInfo"}}, "text": "And our role in the COVID -19 \nresponse efforts evolved and expanded quickly as a result.  \n \n", "start_char_idx": 2983, "end_char_idx": 3077, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba6788d0-40c5-4519-b5c7-889d330f67a8": {"__data__": {"id_": "ba6788d0-40c5-4519-b5c7-889d330f67a8", "embedding": null, "metadata": {"window": "While we were confident in our abilities to help our customers during challenging times, what played out over the \ncourse of the year proved to be more unpredictable than anyone could have ima gined.  The up and down \ntrajectory of the recovery was certainly different than we had originally anticipated.  And our role in the COVID -19 \nresponse efforts evolved and expanded quickly as a result.  \n \n Fiscal 2021 was one of the most challenging yet fulfillin g and inspiring years of my career, a year like no other in \nthe 188 -year history of our company.  I want to thank the team McKesson and our innumerable public and private \npartners for their resilience, commitment to our values and service to our caregivers and patients.  \n \n From the onset of the pandemic, our sourcing teams worked closely with manufacturers and various government \nentities to better forecast changing pharmaceutical and medical product demand in order to extend supply and \nchannel inventory to cri tical areas of need, whether it was working to secure higher volumes of PPE for caregivers \nand frontline worker early in the pandemic or leveraging our expertise in lab capabilities to ramp up distribution of \nCOVID -19 tests as they came to market, McKesson  moved quickly to support our customers, our partners and \nour communities.  ", "original_text": "Fiscal 2021 was one of the most challenging yet fulfillin g and inspiring years of my career, a year like no other in \nthe 188 -year history of our company. ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9690d5c831bd1337e1b3ddb7c243f812a921c0fd8ce3cd5a0126a1b04902ab32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8e1accc-0d3b-41a2-8a4d-13e1b4a05618", "node_type": "1", "metadata": {"window": "As one of the largest healthcare \ncompanies in the world, I said that McKesson would play an essential role in p rotecting the health and safety of \nthe healthcare supply chain.  \n \n While we were confident in our abilities to help our customers during challenging times, what played out over the \ncourse of the year proved to be more unpredictable than anyone could have ima gined.  The up and down \ntrajectory of the recovery was certainly different than we had originally anticipated.  And our role in the COVID -19 \nresponse efforts evolved and expanded quickly as a result.  \n \n Fiscal 2021 was one of the most challenging yet fulfillin g and inspiring years of my career, a year like no other in \nthe 188 -year history of our company.  I want to thank the team McKesson and our innumerable public and private \npartners for their resilience, commitment to our values and service to our caregivers and patients.  \n \n From the onset of the pandemic, our sourcing teams worked closely with manufacturers and various government \nentities to better forecast changing pharmaceutical and medical product demand in order to extend supply and \nchannel inventory to cri tical areas of need, whether it was working to secure higher volumes of PPE for caregivers \nand frontline worker early in the pandemic or leveraging our expertise in lab capabilities to ramp up distribution of \nCOVID -19 tests as they came to market, McKesson  moved quickly to support our customers, our partners and \nour communities.  ", "original_text": "And our role in the COVID -19 \nresponse efforts evolved and expanded quickly as a result.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af12f641e225c57e92f8f809dbd823dde0a8faf5b72b478b7186d4363bce74c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee3d6f15-c39a-47cf-b477-e9164e2ded9b", "node_type": "1", "metadata": {"window": "The up and down \ntrajectory of the recovery was certainly different than we had originally anticipated.  And our role in the COVID -19 \nresponse efforts evolved and expanded quickly as a result.  \n \n Fiscal 2021 was one of the most challenging yet fulfillin g and inspiring years of my career, a year like no other in \nthe 188 -year history of our company.  I want to thank the team McKesson and our innumerable public and private \npartners for their resilience, commitment to our values and service to our caregivers and patients.  \n \n From the onset of the pandemic, our sourcing teams worked closely with manufacturers and various government \nentities to better forecast changing pharmaceutical and medical product demand in order to extend supply and \nchannel inventory to cri tical areas of need, whether it was working to secure higher volumes of PPE for caregivers \nand frontline worker early in the pandemic or leveraging our expertise in lab capabilities to ramp up distribution of \nCOVID -19 tests as they came to market, McKesson  moved quickly to support our customers, our partners and \nour communities.  ", "original_text": "I want to thank the team McKesson and our innumerable public and private \npartners for their resilience, commitment to our values and service to our caregivers and patients.  \n \n"}, "hash": "d7b0aaefc3b20bd6668090b9cee092bf207102c798361342a2ebc6d1696a78ed", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal 2021 was one of the most challenging yet fulfillin g and inspiring years of my career, a year like no other in \nthe 188 -year history of our company. ", "start_char_idx": 3077, "end_char_idx": 3234, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee3d6f15-c39a-47cf-b477-e9164e2ded9b": {"__data__": {"id_": "ee3d6f15-c39a-47cf-b477-e9164e2ded9b", "embedding": null, "metadata": {"window": "The up and down \ntrajectory of the recovery was certainly different than we had originally anticipated.  And our role in the COVID -19 \nresponse efforts evolved and expanded quickly as a result.  \n \n Fiscal 2021 was one of the most challenging yet fulfillin g and inspiring years of my career, a year like no other in \nthe 188 -year history of our company.  I want to thank the team McKesson and our innumerable public and private \npartners for their resilience, commitment to our values and service to our caregivers and patients.  \n \n From the onset of the pandemic, our sourcing teams worked closely with manufacturers and various government \nentities to better forecast changing pharmaceutical and medical product demand in order to extend supply and \nchannel inventory to cri tical areas of need, whether it was working to secure higher volumes of PPE for caregivers \nand frontline worker early in the pandemic or leveraging our expertise in lab capabilities to ramp up distribution of \nCOVID -19 tests as they came to market, McKesson  moved quickly to support our customers, our partners and \nour communities.  ", "original_text": "I want to thank the team McKesson and our innumerable public and private \npartners for their resilience, commitment to our values and service to our caregivers and patients.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9690d5c831bd1337e1b3ddb7c243f812a921c0fd8ce3cd5a0126a1b04902ab32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba6788d0-40c5-4519-b5c7-889d330f67a8", "node_type": "1", "metadata": {"window": "While we were confident in our abilities to help our customers during challenging times, what played out over the \ncourse of the year proved to be more unpredictable than anyone could have ima gined.  The up and down \ntrajectory of the recovery was certainly different than we had originally anticipated.  And our role in the COVID -19 \nresponse efforts evolved and expanded quickly as a result.  \n \n Fiscal 2021 was one of the most challenging yet fulfillin g and inspiring years of my career, a year like no other in \nthe 188 -year history of our company.  I want to thank the team McKesson and our innumerable public and private \npartners for their resilience, commitment to our values and service to our caregivers and patients.  \n \n From the onset of the pandemic, our sourcing teams worked closely with manufacturers and various government \nentities to better forecast changing pharmaceutical and medical product demand in order to extend supply and \nchannel inventory to cri tical areas of need, whether it was working to secure higher volumes of PPE for caregivers \nand frontline worker early in the pandemic or leveraging our expertise in lab capabilities to ramp up distribution of \nCOVID -19 tests as they came to market, McKesson  moved quickly to support our customers, our partners and \nour communities.  ", "original_text": "Fiscal 2021 was one of the most challenging yet fulfillin g and inspiring years of my career, a year like no other in \nthe 188 -year history of our company. ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ecdda0882a6fd2731e0a6e2b4c57eceb2fb24828f79510f3654ace8c5087e5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d562bafa-64e8-449f-bdba-dab5c7202afd", "node_type": "1", "metadata": {"window": "And our role in the COVID -19 \nresponse efforts evolved and expanded quickly as a result.  \n \n Fiscal 2021 was one of the most challenging yet fulfillin g and inspiring years of my career, a year like no other in \nthe 188 -year history of our company.  I want to thank the team McKesson and our innumerable public and private \npartners for their resilience, commitment to our values and service to our caregivers and patients.  \n \n From the onset of the pandemic, our sourcing teams worked closely with manufacturers and various government \nentities to better forecast changing pharmaceutical and medical product demand in order to extend supply and \nchannel inventory to cri tical areas of need, whether it was working to secure higher volumes of PPE for caregivers \nand frontline worker early in the pandemic or leveraging our expertise in lab capabilities to ramp up distribution of \nCOVID -19 tests as they came to market, McKesson  moved quickly to support our customers, our partners and \nour communities.  ", "original_text": "From the onset of the pandemic, our sourcing teams worked closely with manufacturers and various government \nentities to better forecast changing pharmaceutical and medical product demand in order to extend supply and \nchannel inventory to cri tical areas of need, whether it was working to secure higher volumes of PPE for caregivers \nand frontline worker early in the pandemic or leveraging our expertise in lab capabilities to ramp up distribution of \nCOVID -19 tests as they came to market, McKesson  moved quickly to support our customers, our partners and \nour communities.  "}, "hash": "0ef9a32eddb3ee03105766301f842a0af48f52ffff41f00e01b087b39d98a753", "class_name": "RelatedNodeInfo"}}, "text": "I want to thank the team McKesson and our innumerable public and private \npartners for their resilience, commitment to our values and service to our caregivers and patients.  \n \n", "start_char_idx": 3234, "end_char_idx": 3412, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d562bafa-64e8-449f-bdba-dab5c7202afd": {"__data__": {"id_": "d562bafa-64e8-449f-bdba-dab5c7202afd", "embedding": null, "metadata": {"window": "And our role in the COVID -19 \nresponse efforts evolved and expanded quickly as a result.  \n \n Fiscal 2021 was one of the most challenging yet fulfillin g and inspiring years of my career, a year like no other in \nthe 188 -year history of our company.  I want to thank the team McKesson and our innumerable public and private \npartners for their resilience, commitment to our values and service to our caregivers and patients.  \n \n From the onset of the pandemic, our sourcing teams worked closely with manufacturers and various government \nentities to better forecast changing pharmaceutical and medical product demand in order to extend supply and \nchannel inventory to cri tical areas of need, whether it was working to secure higher volumes of PPE for caregivers \nand frontline worker early in the pandemic or leveraging our expertise in lab capabilities to ramp up distribution of \nCOVID -19 tests as they came to market, McKesson  moved quickly to support our customers, our partners and \nour communities.  ", "original_text": "From the onset of the pandemic, our sourcing teams worked closely with manufacturers and various government \nentities to better forecast changing pharmaceutical and medical product demand in order to extend supply and \nchannel inventory to cri tical areas of need, whether it was working to secure higher volumes of PPE for caregivers \nand frontline worker early in the pandemic or leveraging our expertise in lab capabilities to ramp up distribution of \nCOVID -19 tests as they came to market, McKesson  moved quickly to support our customers, our partners and \nour communities.  ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9690d5c831bd1337e1b3ddb7c243f812a921c0fd8ce3cd5a0126a1b04902ab32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee3d6f15-c39a-47cf-b477-e9164e2ded9b", "node_type": "1", "metadata": {"window": "The up and down \ntrajectory of the recovery was certainly different than we had originally anticipated.  And our role in the COVID -19 \nresponse efforts evolved and expanded quickly as a result.  \n \n Fiscal 2021 was one of the most challenging yet fulfillin g and inspiring years of my career, a year like no other in \nthe 188 -year history of our company.  I want to thank the team McKesson and our innumerable public and private \npartners for their resilience, commitment to our values and service to our caregivers and patients.  \n \n From the onset of the pandemic, our sourcing teams worked closely with manufacturers and various government \nentities to better forecast changing pharmaceutical and medical product demand in order to extend supply and \nchannel inventory to cri tical areas of need, whether it was working to secure higher volumes of PPE for caregivers \nand frontline worker early in the pandemic or leveraging our expertise in lab capabilities to ramp up distribution of \nCOVID -19 tests as they came to market, McKesson  moved quickly to support our customers, our partners and \nour communities.  ", "original_text": "I want to thank the team McKesson and our innumerable public and private \npartners for their resilience, commitment to our values and service to our caregivers and patients.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b331cd5d5a220853b611d6dc9b6cb520561ef06a6147ac7498a26800071e3110", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6ef3b9f-1a91-434c-9da0-84980b4c1057", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOur role in the COVID -19 response was also highlighted by our partnership with the US government's COVID -19 \nvaccine distribution effort, having been selected as the centralized distributor of refrigerated and frozen COVID -19 \nvaccines and the ancillary kits used to administer those COVID -19 vaccines.  We distributed our first COVID -19 \nvaccine in December, shortly after Moderna's vaccine was granted Emergency Use Authorization by th e FDA.  On \nFebruary 27, Johnson & Johnson's COVID -19 became the third COVID -19 vaccine granted EUA by the FDA and \nthe second vaccine within the scope of our contract with the CDC.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "f135f8a3cff8270d2d68d25ab042157f6e02c7246c851a48876c035374b215a0", "class_name": "RelatedNodeInfo"}}, "text": "From the onset of the pandemic, our sourcing teams worked closely with manufacturers and various government \nentities to better forecast changing pharmaceutical and medical product demand in order to extend supply and \nchannel inventory to cri tical areas of need, whether it was working to secure higher volumes of PPE for caregivers \nand frontline worker early in the pandemic or leveraging our expertise in lab capabilities to ramp up distribution of \nCOVID -19 tests as they came to market, McKesson  moved quickly to support our customers, our partners and \nour communities.  ", "start_char_idx": 3412, "end_char_idx": 3993, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6ef3b9f-1a91-434c-9da0-84980b4c1057": {"__data__": {"id_": "f6ef3b9f-1a91-434c-9da0-84980b4c1057", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOur role in the COVID -19 response was also highlighted by our partnership with the US government's COVID -19 \nvaccine distribution effort, having been selected as the centralized distributor of refrigerated and frozen COVID -19 \nvaccines and the ancillary kits used to administer those COVID -19 vaccines.  We distributed our first COVID -19 \nvaccine in December, shortly after Moderna's vaccine was granted Emergency Use Authorization by th e FDA.  On \nFebruary 27, Johnson & Johnson's COVID -19 became the third COVID -19 vaccine granted EUA by the FDA and \nthe second vaccine within the scope of our contract with the CDC.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af78bec9f6e1efe0ff6760718d9969e4da8c810b25aedb8fca070b3fe220c9b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d562bafa-64e8-449f-bdba-dab5c7202afd", "node_type": "1", "metadata": {"window": "And our role in the COVID -19 \nresponse efforts evolved and expanded quickly as a result.  \n \n Fiscal 2021 was one of the most challenging yet fulfillin g and inspiring years of my career, a year like no other in \nthe 188 -year history of our company.  I want to thank the team McKesson and our innumerable public and private \npartners for their resilience, commitment to our values and service to our caregivers and patients.  \n \n From the onset of the pandemic, our sourcing teams worked closely with manufacturers and various government \nentities to better forecast changing pharmaceutical and medical product demand in order to extend supply and \nchannel inventory to cri tical areas of need, whether it was working to secure higher volumes of PPE for caregivers \nand frontline worker early in the pandemic or leveraging our expertise in lab capabilities to ramp up distribution of \nCOVID -19 tests as they came to market, McKesson  moved quickly to support our customers, our partners and \nour communities.  ", "original_text": "From the onset of the pandemic, our sourcing teams worked closely with manufacturers and various government \nentities to better forecast changing pharmaceutical and medical product demand in order to extend supply and \nchannel inventory to cri tical areas of need, whether it was working to secure higher volumes of PPE for caregivers \nand frontline worker early in the pandemic or leveraging our expertise in lab capabilities to ramp up distribution of \nCOVID -19 tests as they came to market, McKesson  moved quickly to support our customers, our partners and \nour communities.  ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c8a27904689b07751bf6bd4c82501374395062d5eac943c076da64ab516f438", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e211340f-2291-4035-88f4-ceff80156b0f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOur role in the COVID -19 response was also highlighted by our partnership with the US government's COVID -19 \nvaccine distribution effort, having been selected as the centralized distributor of refrigerated and frozen COVID -19 \nvaccines and the ancillary kits used to administer those COVID -19 vaccines.  We distributed our first COVID -19 \nvaccine in December, shortly after Moderna's vaccine was granted Emergency Use Authorization by th e FDA.  On \nFebruary 27, Johnson & Johnson's COVID -19 became the third COVID -19 vaccine granted EUA by the FDA and \nthe second vaccine within the scope of our contract with the CDC.  \n \n We began distributing the J&J vaccine within 48 hours of its authorization, and we're now distributing out of all 4 \nfit-for-purpose distribution centers we built for this program. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOur role in the COVID -19 response was also highlighted by our partnership with the US government's COVID -19 \nvaccine distribution effort, having been selected as the centralized distributor of refrigerated and frozen COVID -19 \nvaccines and the ancillary kits used to administer those COVID -19 vaccines. "}, "hash": "beffdb661750cc256acfa6b83bcb65ee890e2f4fccc5e18e221651fd107f804f", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e211340f-2291-4035-88f4-ceff80156b0f": {"__data__": {"id_": "e211340f-2291-4035-88f4-ceff80156b0f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOur role in the COVID -19 response was also highlighted by our partnership with the US government's COVID -19 \nvaccine distribution effort, having been selected as the centralized distributor of refrigerated and frozen COVID -19 \nvaccines and the ancillary kits used to administer those COVID -19 vaccines.  We distributed our first COVID -19 \nvaccine in December, shortly after Moderna's vaccine was granted Emergency Use Authorization by th e FDA.  On \nFebruary 27, Johnson & Johnson's COVID -19 became the third COVID -19 vaccine granted EUA by the FDA and \nthe second vaccine within the scope of our contract with the CDC.  \n \n We began distributing the J&J vaccine within 48 hours of its authorization, and we're now distributing out of all 4 \nfit-for-purpose distribution centers we built for this program. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOur role in the COVID -19 response was also highlighted by our partnership with the US government's COVID -19 \nvaccine distribution effort, having been selected as the centralized distributor of refrigerated and frozen COVID -19 \nvaccines and the ancillary kits used to administer those COVID -19 vaccines. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af78bec9f6e1efe0ff6760718d9969e4da8c810b25aedb8fca070b3fe220c9b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6ef3b9f-1a91-434c-9da0-84980b4c1057", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOur role in the COVID -19 response was also highlighted by our partnership with the US government's COVID -19 \nvaccine distribution effort, having been selected as the centralized distributor of refrigerated and frozen COVID -19 \nvaccines and the ancillary kits used to administer those COVID -19 vaccines.  We distributed our first COVID -19 \nvaccine in December, shortly after Moderna's vaccine was granted Emergency Use Authorization by th e FDA.  On \nFebruary 27, Johnson & Johnson's COVID -19 became the third COVID -19 vaccine granted EUA by the FDA and \nthe second vaccine within the scope of our contract with the CDC.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a303e1ea98e8bc42a3be994db91dabc6da7fa124c0de65fa0917e92a9a05d11", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04217e57-0f2b-4cd1-b64b-6a17d3ab291f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOur role in the COVID -19 response was also highlighted by our partnership with the US government's COVID -19 \nvaccine distribution effort, having been selected as the centralized distributor of refrigerated and frozen COVID -19 \nvaccines and the ancillary kits used to administer those COVID -19 vaccines.  We distributed our first COVID -19 \nvaccine in December, shortly after Moderna's vaccine was granted Emergency Use Authorization by th e FDA.  On \nFebruary 27, Johnson & Johnson's COVID -19 became the third COVID -19 vaccine granted EUA by the FDA and \nthe second vaccine within the scope of our contract with the CDC.  \n \n We began distributing the J&J vaccine within 48 hours of its authorization, and we're now distributing out of all 4 \nfit-for-purpose distribution centers we built for this program.  We stand ready to support the distribution of \nadditional vaccines as they come to market. ", "original_text": "We distributed our first COVID -19 \nvaccine in December, shortly after Moderna's vaccine was granted Emergency Use Authorization by th e FDA. "}, "hash": "fc8433afc07fc8e9084e41fb87269c894e805cc4623dc9a5ae980bb01aa18e09", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOur role in the COVID -19 response was also highlighted by our partnership with the US government's COVID -19 \nvaccine distribution effort, having been selected as the centralized distributor of refrigerated and frozen COVID -19 \nvaccines and the ancillary kits used to administer those COVID -19 vaccines. ", "start_char_idx": 16, "end_char_idx": 489, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04217e57-0f2b-4cd1-b64b-6a17d3ab291f": {"__data__": {"id_": "04217e57-0f2b-4cd1-b64b-6a17d3ab291f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOur role in the COVID -19 response was also highlighted by our partnership with the US government's COVID -19 \nvaccine distribution effort, having been selected as the centralized distributor of refrigerated and frozen COVID -19 \nvaccines and the ancillary kits used to administer those COVID -19 vaccines.  We distributed our first COVID -19 \nvaccine in December, shortly after Moderna's vaccine was granted Emergency Use Authorization by th e FDA.  On \nFebruary 27, Johnson & Johnson's COVID -19 became the third COVID -19 vaccine granted EUA by the FDA and \nthe second vaccine within the scope of our contract with the CDC.  \n \n We began distributing the J&J vaccine within 48 hours of its authorization, and we're now distributing out of all 4 \nfit-for-purpose distribution centers we built for this program.  We stand ready to support the distribution of \nadditional vaccines as they come to market. ", "original_text": "We distributed our first COVID -19 \nvaccine in December, shortly after Moderna's vaccine was granted Emergency Use Authorization by th e FDA. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af78bec9f6e1efe0ff6760718d9969e4da8c810b25aedb8fca070b3fe220c9b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e211340f-2291-4035-88f4-ceff80156b0f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOur role in the COVID -19 response was also highlighted by our partnership with the US government's COVID -19 \nvaccine distribution effort, having been selected as the centralized distributor of refrigerated and frozen COVID -19 \nvaccines and the ancillary kits used to administer those COVID -19 vaccines.  We distributed our first COVID -19 \nvaccine in December, shortly after Moderna's vaccine was granted Emergency Use Authorization by th e FDA.  On \nFebruary 27, Johnson & Johnson's COVID -19 became the third COVID -19 vaccine granted EUA by the FDA and \nthe second vaccine within the scope of our contract with the CDC.  \n \n We began distributing the J&J vaccine within 48 hours of its authorization, and we're now distributing out of all 4 \nfit-for-purpose distribution centers we built for this program. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOur role in the COVID -19 response was also highlighted by our partnership with the US government's COVID -19 \nvaccine distribution effort, having been selected as the centralized distributor of refrigerated and frozen COVID -19 \nvaccines and the ancillary kits used to administer those COVID -19 vaccines. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "42b25fd6404600756255217d4aaf407e786261da75dca33ff59348d5276e3dc8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74c5f79c-780d-456c-a5f0-afcb9e8963ca", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOur role in the COVID -19 response was also highlighted by our partnership with the US government's COVID -19 \nvaccine distribution effort, having been selected as the centralized distributor of refrigerated and frozen COVID -19 \nvaccines and the ancillary kits used to administer those COVID -19 vaccines.  We distributed our first COVID -19 \nvaccine in December, shortly after Moderna's vaccine was granted Emergency Use Authorization by th e FDA.  On \nFebruary 27, Johnson & Johnson's COVID -19 became the third COVID -19 vaccine granted EUA by the FDA and \nthe second vaccine within the scope of our contract with the CDC.  \n \n We began distributing the J&J vaccine within 48 hours of its authorization, and we're now distributing out of all 4 \nfit-for-purpose distribution centers we built for this program.  We stand ready to support the distribution of \nadditional vaccines as they come to market.  Through April, we've successfully distributed over 150 million  \nModerna and J&J COVID -19 vaccines to administration sites in the US, and we remain on target with the US \ngovernment's distribution schedule. ", "original_text": "On \nFebruary 27, Johnson & Johnson's COVID -19 became the third COVID -19 vaccine granted EUA by the FDA and \nthe second vaccine within the scope of our contract with the CDC.  \n \n"}, "hash": "1d02bd928c37c3d0ffec3110e59a3d4511a389c77ab2b655d1e7d7ab2e49a732", "class_name": "RelatedNodeInfo"}}, "text": "We distributed our first COVID -19 \nvaccine in December, shortly after Moderna's vaccine was granted Emergency Use Authorization by th e FDA. ", "start_char_idx": 489, "end_char_idx": 631, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74c5f79c-780d-456c-a5f0-afcb9e8963ca": {"__data__": {"id_": "74c5f79c-780d-456c-a5f0-afcb9e8963ca", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOur role in the COVID -19 response was also highlighted by our partnership with the US government's COVID -19 \nvaccine distribution effort, having been selected as the centralized distributor of refrigerated and frozen COVID -19 \nvaccines and the ancillary kits used to administer those COVID -19 vaccines.  We distributed our first COVID -19 \nvaccine in December, shortly after Moderna's vaccine was granted Emergency Use Authorization by th e FDA.  On \nFebruary 27, Johnson & Johnson's COVID -19 became the third COVID -19 vaccine granted EUA by the FDA and \nthe second vaccine within the scope of our contract with the CDC.  \n \n We began distributing the J&J vaccine within 48 hours of its authorization, and we're now distributing out of all 4 \nfit-for-purpose distribution centers we built for this program.  We stand ready to support the distribution of \nadditional vaccines as they come to market.  Through April, we've successfully distributed over 150 million  \nModerna and J&J COVID -19 vaccines to administration sites in the US, and we remain on target with the US \ngovernment's distribution schedule. ", "original_text": "On \nFebruary 27, Johnson & Johnson's COVID -19 became the third COVID -19 vaccine granted EUA by the FDA and \nthe second vaccine within the scope of our contract with the CDC.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af78bec9f6e1efe0ff6760718d9969e4da8c810b25aedb8fca070b3fe220c9b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04217e57-0f2b-4cd1-b64b-6a17d3ab291f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOur role in the COVID -19 response was also highlighted by our partnership with the US government's COVID -19 \nvaccine distribution effort, having been selected as the centralized distributor of refrigerated and frozen COVID -19 \nvaccines and the ancillary kits used to administer those COVID -19 vaccines.  We distributed our first COVID -19 \nvaccine in December, shortly after Moderna's vaccine was granted Emergency Use Authorization by th e FDA.  On \nFebruary 27, Johnson & Johnson's COVID -19 became the third COVID -19 vaccine granted EUA by the FDA and \nthe second vaccine within the scope of our contract with the CDC.  \n \n We began distributing the J&J vaccine within 48 hours of its authorization, and we're now distributing out of all 4 \nfit-for-purpose distribution centers we built for this program.  We stand ready to support the distribution of \nadditional vaccines as they come to market. ", "original_text": "We distributed our first COVID -19 \nvaccine in December, shortly after Moderna's vaccine was granted Emergency Use Authorization by th e FDA. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7be594195a6e315d9fbac75f7325857dd46935f7f4ea0e7659dfb73e215ddba1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5a56c69-47c5-4fe4-b1c9-5c9de4f06ab0", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOur role in the COVID -19 response was also highlighted by our partnership with the US government's COVID -19 \nvaccine distribution effort, having been selected as the centralized distributor of refrigerated and frozen COVID -19 \nvaccines and the ancillary kits used to administer those COVID -19 vaccines.  We distributed our first COVID -19 \nvaccine in December, shortly after Moderna's vaccine was granted Emergency Use Authorization by th e FDA.  On \nFebruary 27, Johnson & Johnson's COVID -19 became the third COVID -19 vaccine granted EUA by the FDA and \nthe second vaccine within the scope of our contract with the CDC.  \n \n We began distributing the J&J vaccine within 48 hours of its authorization, and we're now distributing out of all 4 \nfit-for-purpose distribution centers we built for this program.  We stand ready to support the distribution of \nadditional vaccines as they come to market.  Through April, we've successfully distributed over 150 million  \nModerna and J&J COVID -19 vaccines to administration sites in the US, and we remain on target with the US \ngovernment's distribution schedule.  Also through April, we have assembled enough kits to support the \nadministration of more than 550 million doses for  all vaccine types. ", "original_text": "We began distributing the J&J vaccine within 48 hours of its authorization, and we're now distributing out of all 4 \nfit-for-purpose distribution centers we built for this program. "}, "hash": "9d214bf00e5467b8d1a267a90ce05f7c82637ea5df45cc1d33261e37075e3779", "class_name": "RelatedNodeInfo"}}, "text": "On \nFebruary 27, Johnson & Johnson's COVID -19 became the third COVID -19 vaccine granted EUA by the FDA and \nthe second vaccine within the scope of our contract with the CDC.  \n \n", "start_char_idx": 631, "end_char_idx": 811, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5a56c69-47c5-4fe4-b1c9-5c9de4f06ab0": {"__data__": {"id_": "d5a56c69-47c5-4fe4-b1c9-5c9de4f06ab0", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOur role in the COVID -19 response was also highlighted by our partnership with the US government's COVID -19 \nvaccine distribution effort, having been selected as the centralized distributor of refrigerated and frozen COVID -19 \nvaccines and the ancillary kits used to administer those COVID -19 vaccines.  We distributed our first COVID -19 \nvaccine in December, shortly after Moderna's vaccine was granted Emergency Use Authorization by th e FDA.  On \nFebruary 27, Johnson & Johnson's COVID -19 became the third COVID -19 vaccine granted EUA by the FDA and \nthe second vaccine within the scope of our contract with the CDC.  \n \n We began distributing the J&J vaccine within 48 hours of its authorization, and we're now distributing out of all 4 \nfit-for-purpose distribution centers we built for this program.  We stand ready to support the distribution of \nadditional vaccines as they come to market.  Through April, we've successfully distributed over 150 million  \nModerna and J&J COVID -19 vaccines to administration sites in the US, and we remain on target with the US \ngovernment's distribution schedule.  Also through April, we have assembled enough kits to support the \nadministration of more than 550 million doses for  all vaccine types. ", "original_text": "We began distributing the J&J vaccine within 48 hours of its authorization, and we're now distributing out of all 4 \nfit-for-purpose distribution centers we built for this program. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af78bec9f6e1efe0ff6760718d9969e4da8c810b25aedb8fca070b3fe220c9b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74c5f79c-780d-456c-a5f0-afcb9e8963ca", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOur role in the COVID -19 response was also highlighted by our partnership with the US government's COVID -19 \nvaccine distribution effort, having been selected as the centralized distributor of refrigerated and frozen COVID -19 \nvaccines and the ancillary kits used to administer those COVID -19 vaccines.  We distributed our first COVID -19 \nvaccine in December, shortly after Moderna's vaccine was granted Emergency Use Authorization by th e FDA.  On \nFebruary 27, Johnson & Johnson's COVID -19 became the third COVID -19 vaccine granted EUA by the FDA and \nthe second vaccine within the scope of our contract with the CDC.  \n \n We began distributing the J&J vaccine within 48 hours of its authorization, and we're now distributing out of all 4 \nfit-for-purpose distribution centers we built for this program.  We stand ready to support the distribution of \nadditional vaccines as they come to market.  Through April, we've successfully distributed over 150 million  \nModerna and J&J COVID -19 vaccines to administration sites in the US, and we remain on target with the US \ngovernment's distribution schedule. ", "original_text": "On \nFebruary 27, Johnson & Johnson's COVID -19 became the third COVID -19 vaccine granted EUA by the FDA and \nthe second vaccine within the scope of our contract with the CDC.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3cd25e4ce94b010a708eb3c71e6968b418c8601985fc7edf6a901e6b62777e90", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "080ab470-5333-4ed4-b066-b14bf63381a1", "node_type": "1", "metadata": {"window": "We distributed our first COVID -19 \nvaccine in December, shortly after Moderna's vaccine was granted Emergency Use Authorization by th e FDA.  On \nFebruary 27, Johnson & Johnson's COVID -19 became the third COVID -19 vaccine granted EUA by the FDA and \nthe second vaccine within the scope of our contract with the CDC.  \n \n We began distributing the J&J vaccine within 48 hours of its authorization, and we're now distributing out of all 4 \nfit-for-purpose distribution centers we built for this program.  We stand ready to support the distribution of \nadditional vaccines as they come to market.  Through April, we've successfully distributed over 150 million  \nModerna and J&J COVID -19 vaccines to administration sites in the US, and we remain on target with the US \ngovernment's distribution schedule.  Also through April, we have assembled enough kits to support the \nadministration of more than 550 million doses for  all vaccine types.  This work remains our company's top priority. \n", "original_text": "We stand ready to support the distribution of \nadditional vaccines as they come to market. "}, "hash": "95a3cf344c1949877db495a44e65ce6a086f19c2f936f8291434455a340358b1", "class_name": "RelatedNodeInfo"}}, "text": "We began distributing the J&J vaccine within 48 hours of its authorization, and we're now distributing out of all 4 \nfit-for-purpose distribution centers we built for this program. ", "start_char_idx": 811, "end_char_idx": 992, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "080ab470-5333-4ed4-b066-b14bf63381a1": {"__data__": {"id_": "080ab470-5333-4ed4-b066-b14bf63381a1", "embedding": null, "metadata": {"window": "We distributed our first COVID -19 \nvaccine in December, shortly after Moderna's vaccine was granted Emergency Use Authorization by th e FDA.  On \nFebruary 27, Johnson & Johnson's COVID -19 became the third COVID -19 vaccine granted EUA by the FDA and \nthe second vaccine within the scope of our contract with the CDC.  \n \n We began distributing the J&J vaccine within 48 hours of its authorization, and we're now distributing out of all 4 \nfit-for-purpose distribution centers we built for this program.  We stand ready to support the distribution of \nadditional vaccines as they come to market.  Through April, we've successfully distributed over 150 million  \nModerna and J&J COVID -19 vaccines to administration sites in the US, and we remain on target with the US \ngovernment's distribution schedule.  Also through April, we have assembled enough kits to support the \nadministration of more than 550 million doses for  all vaccine types.  This work remains our company's top priority. \n", "original_text": "We stand ready to support the distribution of \nadditional vaccines as they come to market. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af78bec9f6e1efe0ff6760718d9969e4da8c810b25aedb8fca070b3fe220c9b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5a56c69-47c5-4fe4-b1c9-5c9de4f06ab0", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOur role in the COVID -19 response was also highlighted by our partnership with the US government's COVID -19 \nvaccine distribution effort, having been selected as the centralized distributor of refrigerated and frozen COVID -19 \nvaccines and the ancillary kits used to administer those COVID -19 vaccines.  We distributed our first COVID -19 \nvaccine in December, shortly after Moderna's vaccine was granted Emergency Use Authorization by th e FDA.  On \nFebruary 27, Johnson & Johnson's COVID -19 became the third COVID -19 vaccine granted EUA by the FDA and \nthe second vaccine within the scope of our contract with the CDC.  \n \n We began distributing the J&J vaccine within 48 hours of its authorization, and we're now distributing out of all 4 \nfit-for-purpose distribution centers we built for this program.  We stand ready to support the distribution of \nadditional vaccines as they come to market.  Through April, we've successfully distributed over 150 million  \nModerna and J&J COVID -19 vaccines to administration sites in the US, and we remain on target with the US \ngovernment's distribution schedule.  Also through April, we have assembled enough kits to support the \nadministration of more than 550 million doses for  all vaccine types. ", "original_text": "We began distributing the J&J vaccine within 48 hours of its authorization, and we're now distributing out of all 4 \nfit-for-purpose distribution centers we built for this program. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0fda2cce24a875efec7c47335e39aabf1195c072fc51e13dafda73f26e99e5f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d619075-fd38-4266-8524-8f0f03c12ec9", "node_type": "1", "metadata": {"window": "On \nFebruary 27, Johnson & Johnson's COVID -19 became the third COVID -19 vaccine granted EUA by the FDA and \nthe second vaccine within the scope of our contract with the CDC.  \n \n We began distributing the J&J vaccine within 48 hours of its authorization, and we're now distributing out of all 4 \nfit-for-purpose distribution centers we built for this program.  We stand ready to support the distribution of \nadditional vaccines as they come to market.  Through April, we've successfully distributed over 150 million  \nModerna and J&J COVID -19 vaccines to administration sites in the US, and we remain on target with the US \ngovernment's distribution schedule.  Also through April, we have assembled enough kits to support the \nadministration of more than 550 million doses for  all vaccine types.  This work remains our company's top priority. \n And we are prepared to support the US government for as long as they ask us to lead the centralized distribution \nmodel.  \n \n", "original_text": "Through April, we've successfully distributed over 150 million  \nModerna and J&J COVID -19 vaccines to administration sites in the US, and we remain on target with the US \ngovernment's distribution schedule. "}, "hash": "82da9d7df13c747b450b8d0755923bcb33899affd00284d7a2ecbab97037ed4b", "class_name": "RelatedNodeInfo"}}, "text": "We stand ready to support the distribution of \nadditional vaccines as they come to market. ", "start_char_idx": 992, "end_char_idx": 1083, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d619075-fd38-4266-8524-8f0f03c12ec9": {"__data__": {"id_": "5d619075-fd38-4266-8524-8f0f03c12ec9", "embedding": null, "metadata": {"window": "On \nFebruary 27, Johnson & Johnson's COVID -19 became the third COVID -19 vaccine granted EUA by the FDA and \nthe second vaccine within the scope of our contract with the CDC.  \n \n We began distributing the J&J vaccine within 48 hours of its authorization, and we're now distributing out of all 4 \nfit-for-purpose distribution centers we built for this program.  We stand ready to support the distribution of \nadditional vaccines as they come to market.  Through April, we've successfully distributed over 150 million  \nModerna and J&J COVID -19 vaccines to administration sites in the US, and we remain on target with the US \ngovernment's distribution schedule.  Also through April, we have assembled enough kits to support the \nadministration of more than 550 million doses for  all vaccine types.  This work remains our company's top priority. \n And we are prepared to support the US government for as long as they ask us to lead the centralized distribution \nmodel.  \n \n", "original_text": "Through April, we've successfully distributed over 150 million  \nModerna and J&J COVID -19 vaccines to administration sites in the US, and we remain on target with the US \ngovernment's distribution schedule. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af78bec9f6e1efe0ff6760718d9969e4da8c810b25aedb8fca070b3fe220c9b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "080ab470-5333-4ed4-b066-b14bf63381a1", "node_type": "1", "metadata": {"window": "We distributed our first COVID -19 \nvaccine in December, shortly after Moderna's vaccine was granted Emergency Use Authorization by th e FDA.  On \nFebruary 27, Johnson & Johnson's COVID -19 became the third COVID -19 vaccine granted EUA by the FDA and \nthe second vaccine within the scope of our contract with the CDC.  \n \n We began distributing the J&J vaccine within 48 hours of its authorization, and we're now distributing out of all 4 \nfit-for-purpose distribution centers we built for this program.  We stand ready to support the distribution of \nadditional vaccines as they come to market.  Through April, we've successfully distributed over 150 million  \nModerna and J&J COVID -19 vaccines to administration sites in the US, and we remain on target with the US \ngovernment's distribution schedule.  Also through April, we have assembled enough kits to support the \nadministration of more than 550 million doses for  all vaccine types.  This work remains our company's top priority. \n", "original_text": "We stand ready to support the distribution of \nadditional vaccines as they come to market. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c91abfb328ec8e322771ff9ab276f57a9a79571cafd1f80c3aff0dcb557fdd5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a22546f7-0d26-4631-81b9-6597b6285b9b", "node_type": "1", "metadata": {"window": "We began distributing the J&J vaccine within 48 hours of its authorization, and we're now distributing out of all 4 \nfit-for-purpose distribution centers we built for this program.  We stand ready to support the distribution of \nadditional vaccines as they come to market.  Through April, we've successfully distributed over 150 million  \nModerna and J&J COVID -19 vaccines to administration sites in the US, and we remain on target with the US \ngovernment's distribution schedule.  Also through April, we have assembled enough kits to support the \nadministration of more than 550 million doses for  all vaccine types.  This work remains our company's top priority. \n And we are prepared to support the US government for as long as they ask us to lead the centralized distribution \nmodel.  \n \n In Europe and Canada, we are also partnering with the local governmen ts in the COVID -19 vaccine effort through \nadministration in our owned and banner pharmacies as well as distribution efforts in selected markets and \ncountries.  \n \n", "original_text": "Also through April, we have assembled enough kits to support the \nadministration of more than 550 million doses for  all vaccine types. "}, "hash": "28c3347db8eab5ddebdc3cf3d17286bfaf9aa51d01a23656688f02344529e175", "class_name": "RelatedNodeInfo"}}, "text": "Through April, we've successfully distributed over 150 million  \nModerna and J&J COVID -19 vaccines to administration sites in the US, and we remain on target with the US \ngovernment's distribution schedule. ", "start_char_idx": 1083, "end_char_idx": 1291, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a22546f7-0d26-4631-81b9-6597b6285b9b": {"__data__": {"id_": "a22546f7-0d26-4631-81b9-6597b6285b9b", "embedding": null, "metadata": {"window": "We began distributing the J&J vaccine within 48 hours of its authorization, and we're now distributing out of all 4 \nfit-for-purpose distribution centers we built for this program.  We stand ready to support the distribution of \nadditional vaccines as they come to market.  Through April, we've successfully distributed over 150 million  \nModerna and J&J COVID -19 vaccines to administration sites in the US, and we remain on target with the US \ngovernment's distribution schedule.  Also through April, we have assembled enough kits to support the \nadministration of more than 550 million doses for  all vaccine types.  This work remains our company's top priority. \n And we are prepared to support the US government for as long as they ask us to lead the centralized distribution \nmodel.  \n \n In Europe and Canada, we are also partnering with the local governmen ts in the COVID -19 vaccine effort through \nadministration in our owned and banner pharmacies as well as distribution efforts in selected markets and \ncountries.  \n \n", "original_text": "Also through April, we have assembled enough kits to support the \nadministration of more than 550 million doses for  all vaccine types. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af78bec9f6e1efe0ff6760718d9969e4da8c810b25aedb8fca070b3fe220c9b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d619075-fd38-4266-8524-8f0f03c12ec9", "node_type": "1", "metadata": {"window": "On \nFebruary 27, Johnson & Johnson's COVID -19 became the third COVID -19 vaccine granted EUA by the FDA and \nthe second vaccine within the scope of our contract with the CDC.  \n \n We began distributing the J&J vaccine within 48 hours of its authorization, and we're now distributing out of all 4 \nfit-for-purpose distribution centers we built for this program.  We stand ready to support the distribution of \nadditional vaccines as they come to market.  Through April, we've successfully distributed over 150 million  \nModerna and J&J COVID -19 vaccines to administration sites in the US, and we remain on target with the US \ngovernment's distribution schedule.  Also through April, we have assembled enough kits to support the \nadministration of more than 550 million doses for  all vaccine types.  This work remains our company's top priority. \n And we are prepared to support the US government for as long as they ask us to lead the centralized distribution \nmodel.  \n \n", "original_text": "Through April, we've successfully distributed over 150 million  \nModerna and J&J COVID -19 vaccines to administration sites in the US, and we remain on target with the US \ngovernment's distribution schedule. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8eaa27afca707e447ca7039d5cfa98d9ed8ccd5db6eab5d9c317325eff7aee1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96b206c6-d381-435a-a90a-06fcf679a4ad", "node_type": "1", "metadata": {"window": "We stand ready to support the distribution of \nadditional vaccines as they come to market.  Through April, we've successfully distributed over 150 million  \nModerna and J&J COVID -19 vaccines to administration sites in the US, and we remain on target with the US \ngovernment's distribution schedule.  Also through April, we have assembled enough kits to support the \nadministration of more than 550 million doses for  all vaccine types.  This work remains our company's top priority. \n And we are prepared to support the US government for as long as they ask us to lead the centralized distribution \nmodel.  \n \n In Europe and Canada, we are also partnering with the local governmen ts in the COVID -19 vaccine effort through \nadministration in our owned and banner pharmacies as well as distribution efforts in selected markets and \ncountries.  \n \n Let me turn now to our financial performance. ", "original_text": "This work remains our company's top priority. \n"}, "hash": "363eb445e2114baa13dae78b67c851f3a7ab67e354b1e506dbcd1852057fae4e", "class_name": "RelatedNodeInfo"}}, "text": "Also through April, we have assembled enough kits to support the \nadministration of more than 550 million doses for  all vaccine types. ", "start_char_idx": 1291, "end_char_idx": 1427, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96b206c6-d381-435a-a90a-06fcf679a4ad": {"__data__": {"id_": "96b206c6-d381-435a-a90a-06fcf679a4ad", "embedding": null, "metadata": {"window": "We stand ready to support the distribution of \nadditional vaccines as they come to market.  Through April, we've successfully distributed over 150 million  \nModerna and J&J COVID -19 vaccines to administration sites in the US, and we remain on target with the US \ngovernment's distribution schedule.  Also through April, we have assembled enough kits to support the \nadministration of more than 550 million doses for  all vaccine types.  This work remains our company's top priority. \n And we are prepared to support the US government for as long as they ask us to lead the centralized distribution \nmodel.  \n \n In Europe and Canada, we are also partnering with the local governmen ts in the COVID -19 vaccine effort through \nadministration in our owned and banner pharmacies as well as distribution efforts in selected markets and \ncountries.  \n \n Let me turn now to our financial performance. ", "original_text": "This work remains our company's top priority. \n", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af78bec9f6e1efe0ff6760718d9969e4da8c810b25aedb8fca070b3fe220c9b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a22546f7-0d26-4631-81b9-6597b6285b9b", "node_type": "1", "metadata": {"window": "We began distributing the J&J vaccine within 48 hours of its authorization, and we're now distributing out of all 4 \nfit-for-purpose distribution centers we built for this program.  We stand ready to support the distribution of \nadditional vaccines as they come to market.  Through April, we've successfully distributed over 150 million  \nModerna and J&J COVID -19 vaccines to administration sites in the US, and we remain on target with the US \ngovernment's distribution schedule.  Also through April, we have assembled enough kits to support the \nadministration of more than 550 million doses for  all vaccine types.  This work remains our company's top priority. \n And we are prepared to support the US government for as long as they ask us to lead the centralized distribution \nmodel.  \n \n In Europe and Canada, we are also partnering with the local governmen ts in the COVID -19 vaccine effort through \nadministration in our owned and banner pharmacies as well as distribution efforts in selected markets and \ncountries.  \n \n", "original_text": "Also through April, we have assembled enough kits to support the \nadministration of more than 550 million doses for  all vaccine types. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b705efec917d1472ca992a1ee60ebca7aada40a02db7e11dda5eb6a929c4752", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b57444f-07dd-4b66-9d6f-30da16b17b0a", "node_type": "1", "metadata": {"window": "Through April, we've successfully distributed over 150 million  \nModerna and J&J COVID -19 vaccines to administration sites in the US, and we remain on target with the US \ngovernment's distribution schedule.  Also through April, we have assembled enough kits to support the \nadministration of more than 550 million doses for  all vaccine types.  This work remains our company's top priority. \n And we are prepared to support the US government for as long as they ask us to lead the centralized distribution \nmodel.  \n \n In Europe and Canada, we are also partnering with the local governmen ts in the COVID -19 vaccine effort through \nadministration in our owned and banner pharmacies as well as distribution efforts in selected markets and \ncountries.  \n \n Let me turn now to our financial performance.  Against a dynamic and challenging macroeconomic ba ckdrop in \nfiscal 2021, we grew revenues 3%, and our adjusted earnings per diluted share result of $17.21, was up 15% \nover prior year. ", "original_text": "And we are prepared to support the US government for as long as they ask us to lead the centralized distribution \nmodel.  \n \n"}, "hash": "9c33d3e2e807f67a2160a05b487f501cce33a4db1d1704da20e6c16f83f451c3", "class_name": "RelatedNodeInfo"}}, "text": "This work remains our company's top priority. \n", "start_char_idx": 1427, "end_char_idx": 1474, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b57444f-07dd-4b66-9d6f-30da16b17b0a": {"__data__": {"id_": "8b57444f-07dd-4b66-9d6f-30da16b17b0a", "embedding": null, "metadata": {"window": "Through April, we've successfully distributed over 150 million  \nModerna and J&J COVID -19 vaccines to administration sites in the US, and we remain on target with the US \ngovernment's distribution schedule.  Also through April, we have assembled enough kits to support the \nadministration of more than 550 million doses for  all vaccine types.  This work remains our company's top priority. \n And we are prepared to support the US government for as long as they ask us to lead the centralized distribution \nmodel.  \n \n In Europe and Canada, we are also partnering with the local governmen ts in the COVID -19 vaccine effort through \nadministration in our owned and banner pharmacies as well as distribution efforts in selected markets and \ncountries.  \n \n Let me turn now to our financial performance.  Against a dynamic and challenging macroeconomic ba ckdrop in \nfiscal 2021, we grew revenues 3%, and our adjusted earnings per diluted share result of $17.21, was up 15% \nover prior year. ", "original_text": "And we are prepared to support the US government for as long as they ask us to lead the centralized distribution \nmodel.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af78bec9f6e1efe0ff6760718d9969e4da8c810b25aedb8fca070b3fe220c9b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96b206c6-d381-435a-a90a-06fcf679a4ad", "node_type": "1", "metadata": {"window": "We stand ready to support the distribution of \nadditional vaccines as they come to market.  Through April, we've successfully distributed over 150 million  \nModerna and J&J COVID -19 vaccines to administration sites in the US, and we remain on target with the US \ngovernment's distribution schedule.  Also through April, we have assembled enough kits to support the \nadministration of more than 550 million doses for  all vaccine types.  This work remains our company's top priority. \n And we are prepared to support the US government for as long as they ask us to lead the centralized distribution \nmodel.  \n \n In Europe and Canada, we are also partnering with the local governmen ts in the COVID -19 vaccine effort through \nadministration in our owned and banner pharmacies as well as distribution efforts in selected markets and \ncountries.  \n \n Let me turn now to our financial performance. ", "original_text": "This work remains our company's top priority. \n", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b150ab1bdfc1325c6bd5ff6edc9163afa19985f4c11bd6bffe6dfdf25361778f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70ec0f27-d712-41e3-9c05-6d9c6a132502", "node_type": "1", "metadata": {"window": "Also through April, we have assembled enough kits to support the \nadministration of more than 550 million doses for  all vaccine types.  This work remains our company's top priority. \n And we are prepared to support the US government for as long as they ask us to lead the centralized distribution \nmodel.  \n \n In Europe and Canada, we are also partnering with the local governmen ts in the COVID -19 vaccine effort through \nadministration in our owned and banner pharmacies as well as distribution efforts in selected markets and \ncountries.  \n \n Let me turn now to our financial performance.  Against a dynamic and challenging macroeconomic ba ckdrop in \nfiscal 2021, we grew revenues 3%, and our adjusted earnings per diluted share result of $17.21, was up 15% \nover prior year.  When pressed with challenges and uncertainties, our customers and government partners \ncontinued to choose McKesson to help  ensure stability of supply for their patients.  \n \n", "original_text": "In Europe and Canada, we are also partnering with the local governmen ts in the COVID -19 vaccine effort through \nadministration in our owned and banner pharmacies as well as distribution efforts in selected markets and \ncountries.  \n \n"}, "hash": "5b4a8b90e01419cc92c1e3f70e14df3839da0ecb6d2b9e4ce4fbf593ffb74c26", "class_name": "RelatedNodeInfo"}}, "text": "And we are prepared to support the US government for as long as they ask us to lead the centralized distribution \nmodel.  \n \n", "start_char_idx": 1474, "end_char_idx": 1599, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70ec0f27-d712-41e3-9c05-6d9c6a132502": {"__data__": {"id_": "70ec0f27-d712-41e3-9c05-6d9c6a132502", "embedding": null, "metadata": {"window": "Also through April, we have assembled enough kits to support the \nadministration of more than 550 million doses for  all vaccine types.  This work remains our company's top priority. \n And we are prepared to support the US government for as long as they ask us to lead the centralized distribution \nmodel.  \n \n In Europe and Canada, we are also partnering with the local governmen ts in the COVID -19 vaccine effort through \nadministration in our owned and banner pharmacies as well as distribution efforts in selected markets and \ncountries.  \n \n Let me turn now to our financial performance.  Against a dynamic and challenging macroeconomic ba ckdrop in \nfiscal 2021, we grew revenues 3%, and our adjusted earnings per diluted share result of $17.21, was up 15% \nover prior year.  When pressed with challenges and uncertainties, our customers and government partners \ncontinued to choose McKesson to help  ensure stability of supply for their patients.  \n \n", "original_text": "In Europe and Canada, we are also partnering with the local governmen ts in the COVID -19 vaccine effort through \nadministration in our owned and banner pharmacies as well as distribution efforts in selected markets and \ncountries.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af78bec9f6e1efe0ff6760718d9969e4da8c810b25aedb8fca070b3fe220c9b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b57444f-07dd-4b66-9d6f-30da16b17b0a", "node_type": "1", "metadata": {"window": "Through April, we've successfully distributed over 150 million  \nModerna and J&J COVID -19 vaccines to administration sites in the US, and we remain on target with the US \ngovernment's distribution schedule.  Also through April, we have assembled enough kits to support the \nadministration of more than 550 million doses for  all vaccine types.  This work remains our company's top priority. \n And we are prepared to support the US government for as long as they ask us to lead the centralized distribution \nmodel.  \n \n In Europe and Canada, we are also partnering with the local governmen ts in the COVID -19 vaccine effort through \nadministration in our owned and banner pharmacies as well as distribution efforts in selected markets and \ncountries.  \n \n Let me turn now to our financial performance.  Against a dynamic and challenging macroeconomic ba ckdrop in \nfiscal 2021, we grew revenues 3%, and our adjusted earnings per diluted share result of $17.21, was up 15% \nover prior year. ", "original_text": "And we are prepared to support the US government for as long as they ask us to lead the centralized distribution \nmodel.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53151871a949a84346ab62085df539999af3ad603d40a17e7a1b9a4fdcd1439d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81828f5f-2dd8-4a1d-bd00-2c525770ccd0", "node_type": "1", "metadata": {"window": "This work remains our company's top priority. \n And we are prepared to support the US government for as long as they ask us to lead the centralized distribution \nmodel.  \n \n In Europe and Canada, we are also partnering with the local governmen ts in the COVID -19 vaccine effort through \nadministration in our owned and banner pharmacies as well as distribution efforts in selected markets and \ncountries.  \n \n Let me turn now to our financial performance.  Against a dynamic and challenging macroeconomic ba ckdrop in \nfiscal 2021, we grew revenues 3%, and our adjusted earnings per diluted share result of $17.21, was up 15% \nover prior year.  When pressed with challenges and uncertainties, our customers and government partners \ncontinued to choose McKesson to help  ensure stability of supply for their patients.  \n \n So while prescription volume and primary care patient visit trends negatively impacted the core business \nthroughout the fiscal year, the strength of our business model and our differentiated capabilities hel ped us to grow \nthe business and deliver value to our shareholders. ", "original_text": "Let me turn now to our financial performance. "}, "hash": "b0b1cadbc92d3aeb1dc1d5abddb6a956ec66574ec50fc55b6a58befa8540fbb9", "class_name": "RelatedNodeInfo"}}, "text": "In Europe and Canada, we are also partnering with the local governmen ts in the COVID -19 vaccine effort through \nadministration in our owned and banner pharmacies as well as distribution efforts in selected markets and \ncountries.  \n \n", "start_char_idx": 1599, "end_char_idx": 1835, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81828f5f-2dd8-4a1d-bd00-2c525770ccd0": {"__data__": {"id_": "81828f5f-2dd8-4a1d-bd00-2c525770ccd0", "embedding": null, "metadata": {"window": "This work remains our company's top priority. \n And we are prepared to support the US government for as long as they ask us to lead the centralized distribution \nmodel.  \n \n In Europe and Canada, we are also partnering with the local governmen ts in the COVID -19 vaccine effort through \nadministration in our owned and banner pharmacies as well as distribution efforts in selected markets and \ncountries.  \n \n Let me turn now to our financial performance.  Against a dynamic and challenging macroeconomic ba ckdrop in \nfiscal 2021, we grew revenues 3%, and our adjusted earnings per diluted share result of $17.21, was up 15% \nover prior year.  When pressed with challenges and uncertainties, our customers and government partners \ncontinued to choose McKesson to help  ensure stability of supply for their patients.  \n \n So while prescription volume and primary care patient visit trends negatively impacted the core business \nthroughout the fiscal year, the strength of our business model and our differentiated capabilities hel ped us to grow \nthe business and deliver value to our shareholders. ", "original_text": "Let me turn now to our financial performance. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af78bec9f6e1efe0ff6760718d9969e4da8c810b25aedb8fca070b3fe220c9b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70ec0f27-d712-41e3-9c05-6d9c6a132502", "node_type": "1", "metadata": {"window": "Also through April, we have assembled enough kits to support the \nadministration of more than 550 million doses for  all vaccine types.  This work remains our company's top priority. \n And we are prepared to support the US government for as long as they ask us to lead the centralized distribution \nmodel.  \n \n In Europe and Canada, we are also partnering with the local governmen ts in the COVID -19 vaccine effort through \nadministration in our owned and banner pharmacies as well as distribution efforts in selected markets and \ncountries.  \n \n Let me turn now to our financial performance.  Against a dynamic and challenging macroeconomic ba ckdrop in \nfiscal 2021, we grew revenues 3%, and our adjusted earnings per diluted share result of $17.21, was up 15% \nover prior year.  When pressed with challenges and uncertainties, our customers and government partners \ncontinued to choose McKesson to help  ensure stability of supply for their patients.  \n \n", "original_text": "In Europe and Canada, we are also partnering with the local governmen ts in the COVID -19 vaccine effort through \nadministration in our owned and banner pharmacies as well as distribution efforts in selected markets and \ncountries.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "42b5cfe5ac28119d3ae3be5a1b49458abfe35c81cc780dec1037d47359b54467", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ff40c8f-07b7-468c-9251-dd8eff5211a3", "node_type": "1", "metadata": {"window": "And we are prepared to support the US government for as long as they ask us to lead the centralized distribution \nmodel.  \n \n In Europe and Canada, we are also partnering with the local governmen ts in the COVID -19 vaccine effort through \nadministration in our owned and banner pharmacies as well as distribution efforts in selected markets and \ncountries.  \n \n Let me turn now to our financial performance.  Against a dynamic and challenging macroeconomic ba ckdrop in \nfiscal 2021, we grew revenues 3%, and our adjusted earnings per diluted share result of $17.21, was up 15% \nover prior year.  When pressed with challenges and uncertainties, our customers and government partners \ncontinued to choose McKesson to help  ensure stability of supply for their patients.  \n \n So while prescription volume and primary care patient visit trends negatively impacted the core business \nthroughout the fiscal year, the strength of our business model and our differentiated capabilities hel ped us to grow \nthe business and deliver value to our shareholders.  Our commitment to executing our strategy, transforming and \nsimplifying the operating model contributed to these strong financial results.  \n \n", "original_text": "Against a dynamic and challenging macroeconomic ba ckdrop in \nfiscal 2021, we grew revenues 3%, and our adjusted earnings per diluted share result of $17.21, was up 15% \nover prior year. "}, "hash": "3811c5982ac990a6e11da74991ba1283c20ea1c3ed556e592f7b2800de0c5134", "class_name": "RelatedNodeInfo"}}, "text": "Let me turn now to our financial performance. ", "start_char_idx": 1835, "end_char_idx": 1881, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ff40c8f-07b7-468c-9251-dd8eff5211a3": {"__data__": {"id_": "7ff40c8f-07b7-468c-9251-dd8eff5211a3", "embedding": null, "metadata": {"window": "And we are prepared to support the US government for as long as they ask us to lead the centralized distribution \nmodel.  \n \n In Europe and Canada, we are also partnering with the local governmen ts in the COVID -19 vaccine effort through \nadministration in our owned and banner pharmacies as well as distribution efforts in selected markets and \ncountries.  \n \n Let me turn now to our financial performance.  Against a dynamic and challenging macroeconomic ba ckdrop in \nfiscal 2021, we grew revenues 3%, and our adjusted earnings per diluted share result of $17.21, was up 15% \nover prior year.  When pressed with challenges and uncertainties, our customers and government partners \ncontinued to choose McKesson to help  ensure stability of supply for their patients.  \n \n So while prescription volume and primary care patient visit trends negatively impacted the core business \nthroughout the fiscal year, the strength of our business model and our differentiated capabilities hel ped us to grow \nthe business and deliver value to our shareholders.  Our commitment to executing our strategy, transforming and \nsimplifying the operating model contributed to these strong financial results.  \n \n", "original_text": "Against a dynamic and challenging macroeconomic ba ckdrop in \nfiscal 2021, we grew revenues 3%, and our adjusted earnings per diluted share result of $17.21, was up 15% \nover prior year. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af78bec9f6e1efe0ff6760718d9969e4da8c810b25aedb8fca070b3fe220c9b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81828f5f-2dd8-4a1d-bd00-2c525770ccd0", "node_type": "1", "metadata": {"window": "This work remains our company's top priority. \n And we are prepared to support the US government for as long as they ask us to lead the centralized distribution \nmodel.  \n \n In Europe and Canada, we are also partnering with the local governmen ts in the COVID -19 vaccine effort through \nadministration in our owned and banner pharmacies as well as distribution efforts in selected markets and \ncountries.  \n \n Let me turn now to our financial performance.  Against a dynamic and challenging macroeconomic ba ckdrop in \nfiscal 2021, we grew revenues 3%, and our adjusted earnings per diluted share result of $17.21, was up 15% \nover prior year.  When pressed with challenges and uncertainties, our customers and government partners \ncontinued to choose McKesson to help  ensure stability of supply for their patients.  \n \n So while prescription volume and primary care patient visit trends negatively impacted the core business \nthroughout the fiscal year, the strength of our business model and our differentiated capabilities hel ped us to grow \nthe business and deliver value to our shareholders. ", "original_text": "Let me turn now to our financial performance. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "95c330e67a0c22ba61d3bcc8ab41c1bb3a58d3c8dae0f2298b0a208ccb79656e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3eb3adf6-4b9b-4116-99a3-af479a13f7b4", "node_type": "1", "metadata": {"window": "In Europe and Canada, we are also partnering with the local governmen ts in the COVID -19 vaccine effort through \nadministration in our owned and banner pharmacies as well as distribution efforts in selected markets and \ncountries.  \n \n Let me turn now to our financial performance.  Against a dynamic and challenging macroeconomic ba ckdrop in \nfiscal 2021, we grew revenues 3%, and our adjusted earnings per diluted share result of $17.21, was up 15% \nover prior year.  When pressed with challenges and uncertainties, our customers and government partners \ncontinued to choose McKesson to help  ensure stability of supply for their patients.  \n \n So while prescription volume and primary care patient visit trends negatively impacted the core business \nthroughout the fiscal year, the strength of our business model and our differentiated capabilities hel ped us to grow \nthe business and deliver value to our shareholders.  Our commitment to executing our strategy, transforming and \nsimplifying the operating model contributed to these strong financial results.  \n \n Looking forward into fiscal 2022. ", "original_text": "When pressed with challenges and uncertainties, our customers and government partners \ncontinued to choose McKesson to help  ensure stability of supply for their patients.  \n \n"}, "hash": "1ca6184dbd8cc4feb089cbe02d9bdff8e166c6bbec6256a99d226de7059e3df0", "class_name": "RelatedNodeInfo"}}, "text": "Against a dynamic and challenging macroeconomic ba ckdrop in \nfiscal 2021, we grew revenues 3%, and our adjusted earnings per diluted share result of $17.21, was up 15% \nover prior year. ", "start_char_idx": 1881, "end_char_idx": 2068, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3eb3adf6-4b9b-4116-99a3-af479a13f7b4": {"__data__": {"id_": "3eb3adf6-4b9b-4116-99a3-af479a13f7b4", "embedding": null, "metadata": {"window": "In Europe and Canada, we are also partnering with the local governmen ts in the COVID -19 vaccine effort through \nadministration in our owned and banner pharmacies as well as distribution efforts in selected markets and \ncountries.  \n \n Let me turn now to our financial performance.  Against a dynamic and challenging macroeconomic ba ckdrop in \nfiscal 2021, we grew revenues 3%, and our adjusted earnings per diluted share result of $17.21, was up 15% \nover prior year.  When pressed with challenges and uncertainties, our customers and government partners \ncontinued to choose McKesson to help  ensure stability of supply for their patients.  \n \n So while prescription volume and primary care patient visit trends negatively impacted the core business \nthroughout the fiscal year, the strength of our business model and our differentiated capabilities hel ped us to grow \nthe business and deliver value to our shareholders.  Our commitment to executing our strategy, transforming and \nsimplifying the operating model contributed to these strong financial results.  \n \n Looking forward into fiscal 2022. ", "original_text": "When pressed with challenges and uncertainties, our customers and government partners \ncontinued to choose McKesson to help  ensure stability of supply for their patients.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af78bec9f6e1efe0ff6760718d9969e4da8c810b25aedb8fca070b3fe220c9b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ff40c8f-07b7-468c-9251-dd8eff5211a3", "node_type": "1", "metadata": {"window": "And we are prepared to support the US government for as long as they ask us to lead the centralized distribution \nmodel.  \n \n In Europe and Canada, we are also partnering with the local governmen ts in the COVID -19 vaccine effort through \nadministration in our owned and banner pharmacies as well as distribution efforts in selected markets and \ncountries.  \n \n Let me turn now to our financial performance.  Against a dynamic and challenging macroeconomic ba ckdrop in \nfiscal 2021, we grew revenues 3%, and our adjusted earnings per diluted share result of $17.21, was up 15% \nover prior year.  When pressed with challenges and uncertainties, our customers and government partners \ncontinued to choose McKesson to help  ensure stability of supply for their patients.  \n \n So while prescription volume and primary care patient visit trends negatively impacted the core business \nthroughout the fiscal year, the strength of our business model and our differentiated capabilities hel ped us to grow \nthe business and deliver value to our shareholders.  Our commitment to executing our strategy, transforming and \nsimplifying the operating model contributed to these strong financial results.  \n \n", "original_text": "Against a dynamic and challenging macroeconomic ba ckdrop in \nfiscal 2021, we grew revenues 3%, and our adjusted earnings per diluted share result of $17.21, was up 15% \nover prior year. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f11b98229833cd7b208bce26e52bb80418e86391234e461d56880abf062b064e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91163152-3365-43ed-be8d-6e4473e53344", "node_type": "1", "metadata": {"window": "Let me turn now to our financial performance.  Against a dynamic and challenging macroeconomic ba ckdrop in \nfiscal 2021, we grew revenues 3%, and our adjusted earnings per diluted share result of $17.21, was up 15% \nover prior year.  When pressed with challenges and uncertainties, our customers and government partners \ncontinued to choose McKesson to help  ensure stability of supply for their patients.  \n \n So while prescription volume and primary care patient visit trends negatively impacted the core business \nthroughout the fiscal year, the strength of our business model and our differentiated capabilities hel ped us to grow \nthe business and deliver value to our shareholders.  Our commitment to executing our strategy, transforming and \nsimplifying the operating model contributed to these strong financial results.  \n \n Looking forward into fiscal 2022.  I'm confident th at we operate in scaled and resilient markets with underlying \ntrends that support long -term growth. ", "original_text": "So while prescription volume and primary care patient visit trends negatively impacted the core business \nthroughout the fiscal year, the strength of our business model and our differentiated capabilities hel ped us to grow \nthe business and deliver value to our shareholders. "}, "hash": "812de66637f263e198f86453e2cce0ef1e828e832c1c328b0343eba91e66611f", "class_name": "RelatedNodeInfo"}}, "text": "When pressed with challenges and uncertainties, our customers and government partners \ncontinued to choose McKesson to help  ensure stability of supply for their patients.  \n \n", "start_char_idx": 2068, "end_char_idx": 2244, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91163152-3365-43ed-be8d-6e4473e53344": {"__data__": {"id_": "91163152-3365-43ed-be8d-6e4473e53344", "embedding": null, "metadata": {"window": "Let me turn now to our financial performance.  Against a dynamic and challenging macroeconomic ba ckdrop in \nfiscal 2021, we grew revenues 3%, and our adjusted earnings per diluted share result of $17.21, was up 15% \nover prior year.  When pressed with challenges and uncertainties, our customers and government partners \ncontinued to choose McKesson to help  ensure stability of supply for their patients.  \n \n So while prescription volume and primary care patient visit trends negatively impacted the core business \nthroughout the fiscal year, the strength of our business model and our differentiated capabilities hel ped us to grow \nthe business and deliver value to our shareholders.  Our commitment to executing our strategy, transforming and \nsimplifying the operating model contributed to these strong financial results.  \n \n Looking forward into fiscal 2022.  I'm confident th at we operate in scaled and resilient markets with underlying \ntrends that support long -term growth. ", "original_text": "So while prescription volume and primary care patient visit trends negatively impacted the core business \nthroughout the fiscal year, the strength of our business model and our differentiated capabilities hel ped us to grow \nthe business and deliver value to our shareholders. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af78bec9f6e1efe0ff6760718d9969e4da8c810b25aedb8fca070b3fe220c9b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3eb3adf6-4b9b-4116-99a3-af479a13f7b4", "node_type": "1", "metadata": {"window": "In Europe and Canada, we are also partnering with the local governmen ts in the COVID -19 vaccine effort through \nadministration in our owned and banner pharmacies as well as distribution efforts in selected markets and \ncountries.  \n \n Let me turn now to our financial performance.  Against a dynamic and challenging macroeconomic ba ckdrop in \nfiscal 2021, we grew revenues 3%, and our adjusted earnings per diluted share result of $17.21, was up 15% \nover prior year.  When pressed with challenges and uncertainties, our customers and government partners \ncontinued to choose McKesson to help  ensure stability of supply for their patients.  \n \n So while prescription volume and primary care patient visit trends negatively impacted the core business \nthroughout the fiscal year, the strength of our business model and our differentiated capabilities hel ped us to grow \nthe business and deliver value to our shareholders.  Our commitment to executing our strategy, transforming and \nsimplifying the operating model contributed to these strong financial results.  \n \n Looking forward into fiscal 2022. ", "original_text": "When pressed with challenges and uncertainties, our customers and government partners \ncontinued to choose McKesson to help  ensure stability of supply for their patients.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "21663999620fcec2539e38bb3571abbca40b8621ea00f7666f5ce9d40982de62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d2dcd97-687b-4681-9c6a-eb07e81036ea", "node_type": "1", "metadata": {"window": "Against a dynamic and challenging macroeconomic ba ckdrop in \nfiscal 2021, we grew revenues 3%, and our adjusted earnings per diluted share result of $17.21, was up 15% \nover prior year.  When pressed with challenges and uncertainties, our customers and government partners \ncontinued to choose McKesson to help  ensure stability of supply for their patients.  \n \n So while prescription volume and primary care patient visit trends negatively impacted the core business \nthroughout the fiscal year, the strength of our business model and our differentiated capabilities hel ped us to grow \nthe business and deliver value to our shareholders.  Our commitment to executing our strategy, transforming and \nsimplifying the operating model contributed to these strong financial results.  \n \n Looking forward into fiscal 2022.  I'm confident th at we operate in scaled and resilient markets with underlying \ntrends that support long -term growth.  We invest in our business to differentiate our solutions and create value for \ncustomers, patients and partners. ", "original_text": "Our commitment to executing our strategy, transforming and \nsimplifying the operating model contributed to these strong financial results.  \n \n"}, "hash": "63847378e50fd17ab08ed9a761176c4ffc674e03b4b01ca98ce72bd3900f00de", "class_name": "RelatedNodeInfo"}}, "text": "So while prescription volume and primary care patient visit trends negatively impacted the core business \nthroughout the fiscal year, the strength of our business model and our differentiated capabilities hel ped us to grow \nthe business and deliver value to our shareholders. ", "start_char_idx": 2244, "end_char_idx": 2521, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d2dcd97-687b-4681-9c6a-eb07e81036ea": {"__data__": {"id_": "6d2dcd97-687b-4681-9c6a-eb07e81036ea", "embedding": null, "metadata": {"window": "Against a dynamic and challenging macroeconomic ba ckdrop in \nfiscal 2021, we grew revenues 3%, and our adjusted earnings per diluted share result of $17.21, was up 15% \nover prior year.  When pressed with challenges and uncertainties, our customers and government partners \ncontinued to choose McKesson to help  ensure stability of supply for their patients.  \n \n So while prescription volume and primary care patient visit trends negatively impacted the core business \nthroughout the fiscal year, the strength of our business model and our differentiated capabilities hel ped us to grow \nthe business and deliver value to our shareholders.  Our commitment to executing our strategy, transforming and \nsimplifying the operating model contributed to these strong financial results.  \n \n Looking forward into fiscal 2022.  I'm confident th at we operate in scaled and resilient markets with underlying \ntrends that support long -term growth.  We invest in our business to differentiate our solutions and create value for \ncustomers, patients and partners. ", "original_text": "Our commitment to executing our strategy, transforming and \nsimplifying the operating model contributed to these strong financial results.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af78bec9f6e1efe0ff6760718d9969e4da8c810b25aedb8fca070b3fe220c9b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91163152-3365-43ed-be8d-6e4473e53344", "node_type": "1", "metadata": {"window": "Let me turn now to our financial performance.  Against a dynamic and challenging macroeconomic ba ckdrop in \nfiscal 2021, we grew revenues 3%, and our adjusted earnings per diluted share result of $17.21, was up 15% \nover prior year.  When pressed with challenges and uncertainties, our customers and government partners \ncontinued to choose McKesson to help  ensure stability of supply for their patients.  \n \n So while prescription volume and primary care patient visit trends negatively impacted the core business \nthroughout the fiscal year, the strength of our business model and our differentiated capabilities hel ped us to grow \nthe business and deliver value to our shareholders.  Our commitment to executing our strategy, transforming and \nsimplifying the operating model contributed to these strong financial results.  \n \n Looking forward into fiscal 2022.  I'm confident th at we operate in scaled and resilient markets with underlying \ntrends that support long -term growth. ", "original_text": "So while prescription volume and primary care patient visit trends negatively impacted the core business \nthroughout the fiscal year, the strength of our business model and our differentiated capabilities hel ped us to grow \nthe business and deliver value to our shareholders. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "76f9f8eaf72e2a32553c50b47c8adf620d183692f50b238bbfe933b85b379f5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac5ca5d8-40b4-4397-abf9-dfee9e1f96f9", "node_type": "1", "metadata": {"window": "When pressed with challenges and uncertainties, our customers and government partners \ncontinued to choose McKesson to help  ensure stability of supply for their patients.  \n \n So while prescription volume and primary care patient visit trends negatively impacted the core business \nthroughout the fiscal year, the strength of our business model and our differentiated capabilities hel ped us to grow \nthe business and deliver value to our shareholders.  Our commitment to executing our strategy, transforming and \nsimplifying the operating model contributed to these strong financial results.  \n \n Looking forward into fiscal 2022.  I'm confident th at we operate in scaled and resilient markets with underlying \ntrends that support long -term growth.  We invest in our business to differentiate our solutions and create value for \ncustomers, patients and partners.  The pandemic has not paused our progress on these strategic priorities. \n", "original_text": "Looking forward into fiscal 2022. "}, "hash": "7c3564ebf14731e165df7b08415ec9c723137a892c1d9550d322ea32c1ec5828", "class_name": "RelatedNodeInfo"}}, "text": "Our commitment to executing our strategy, transforming and \nsimplifying the operating model contributed to these strong financial results.  \n \n", "start_char_idx": 2521, "end_char_idx": 2664, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac5ca5d8-40b4-4397-abf9-dfee9e1f96f9": {"__data__": {"id_": "ac5ca5d8-40b4-4397-abf9-dfee9e1f96f9", "embedding": null, "metadata": {"window": "When pressed with challenges and uncertainties, our customers and government partners \ncontinued to choose McKesson to help  ensure stability of supply for their patients.  \n \n So while prescription volume and primary care patient visit trends negatively impacted the core business \nthroughout the fiscal year, the strength of our business model and our differentiated capabilities hel ped us to grow \nthe business and deliver value to our shareholders.  Our commitment to executing our strategy, transforming and \nsimplifying the operating model contributed to these strong financial results.  \n \n Looking forward into fiscal 2022.  I'm confident th at we operate in scaled and resilient markets with underlying \ntrends that support long -term growth.  We invest in our business to differentiate our solutions and create value for \ncustomers, patients and partners.  The pandemic has not paused our progress on these strategic priorities. \n", "original_text": "Looking forward into fiscal 2022. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af78bec9f6e1efe0ff6760718d9969e4da8c810b25aedb8fca070b3fe220c9b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d2dcd97-687b-4681-9c6a-eb07e81036ea", "node_type": "1", "metadata": {"window": "Against a dynamic and challenging macroeconomic ba ckdrop in \nfiscal 2021, we grew revenues 3%, and our adjusted earnings per diluted share result of $17.21, was up 15% \nover prior year.  When pressed with challenges and uncertainties, our customers and government partners \ncontinued to choose McKesson to help  ensure stability of supply for their patients.  \n \n So while prescription volume and primary care patient visit trends negatively impacted the core business \nthroughout the fiscal year, the strength of our business model and our differentiated capabilities hel ped us to grow \nthe business and deliver value to our shareholders.  Our commitment to executing our strategy, transforming and \nsimplifying the operating model contributed to these strong financial results.  \n \n Looking forward into fiscal 2022.  I'm confident th at we operate in scaled and resilient markets with underlying \ntrends that support long -term growth.  We invest in our business to differentiate our solutions and create value for \ncustomers, patients and partners. ", "original_text": "Our commitment to executing our strategy, transforming and \nsimplifying the operating model contributed to these strong financial results.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d3de6ddd9a19fa2cf0a16761146f369de6cc3bb26639d9acfc41f2fba87fe4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b893570-a290-4260-8e6f-b2769610c2fd", "node_type": "1", "metadata": {"window": "So while prescription volume and primary care patient visit trends negatively impacted the core business \nthroughout the fiscal year, the strength of our business model and our differentiated capabilities hel ped us to grow \nthe business and deliver value to our shareholders.  Our commitment to executing our strategy, transforming and \nsimplifying the operating model contributed to these strong financial results.  \n \n Looking forward into fiscal 2022.  I'm confident th at we operate in scaled and resilient markets with underlying \ntrends that support long -term growth.  We invest in our business to differentiate our solutions and create value for \ncustomers, patients and partners.  The pandemic has not paused our progress on these strategic priorities. \n Targeted investments into our business over time have positioned us well to succeed and respond quickly to \nchanging demands from our customers and government partners during these uncertain times.  \n \n", "original_text": "I'm confident th at we operate in scaled and resilient markets with underlying \ntrends that support long -term growth. "}, "hash": "9a0a4d3b5c6fee462e1ca8691f46a2c161a612e19a306a5ecc543d3afbcffbf8", "class_name": "RelatedNodeInfo"}}, "text": "Looking forward into fiscal 2022. ", "start_char_idx": 2664, "end_char_idx": 2698, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b893570-a290-4260-8e6f-b2769610c2fd": {"__data__": {"id_": "6b893570-a290-4260-8e6f-b2769610c2fd", "embedding": null, "metadata": {"window": "So while prescription volume and primary care patient visit trends negatively impacted the core business \nthroughout the fiscal year, the strength of our business model and our differentiated capabilities hel ped us to grow \nthe business and deliver value to our shareholders.  Our commitment to executing our strategy, transforming and \nsimplifying the operating model contributed to these strong financial results.  \n \n Looking forward into fiscal 2022.  I'm confident th at we operate in scaled and resilient markets with underlying \ntrends that support long -term growth.  We invest in our business to differentiate our solutions and create value for \ncustomers, patients and partners.  The pandemic has not paused our progress on these strategic priorities. \n Targeted investments into our business over time have positioned us well to succeed and respond quickly to \nchanging demands from our customers and government partners during these uncertain times.  \n \n", "original_text": "I'm confident th at we operate in scaled and resilient markets with underlying \ntrends that support long -term growth. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af78bec9f6e1efe0ff6760718d9969e4da8c810b25aedb8fca070b3fe220c9b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac5ca5d8-40b4-4397-abf9-dfee9e1f96f9", "node_type": "1", "metadata": {"window": "When pressed with challenges and uncertainties, our customers and government partners \ncontinued to choose McKesson to help  ensure stability of supply for their patients.  \n \n So while prescription volume and primary care patient visit trends negatively impacted the core business \nthroughout the fiscal year, the strength of our business model and our differentiated capabilities hel ped us to grow \nthe business and deliver value to our shareholders.  Our commitment to executing our strategy, transforming and \nsimplifying the operating model contributed to these strong financial results.  \n \n Looking forward into fiscal 2022.  I'm confident th at we operate in scaled and resilient markets with underlying \ntrends that support long -term growth.  We invest in our business to differentiate our solutions and create value for \ncustomers, patients and partners.  The pandemic has not paused our progress on these strategic priorities. \n", "original_text": "Looking forward into fiscal 2022. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d291e54435d6f2993c4603b0413d1e43734868e1aa0a222937e6f6d183771ff4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec1e6dcc-1a43-44cd-880c-bc957188b153", "node_type": "1", "metadata": {"window": "Our commitment to executing our strategy, transforming and \nsimplifying the operating model contributed to these strong financial results.  \n \n Looking forward into fiscal 2022.  I'm confident th at we operate in scaled and resilient markets with underlying \ntrends that support long -term growth.  We invest in our business to differentiate our solutions and create value for \ncustomers, patients and partners.  The pandemic has not paused our progress on these strategic priorities. \n Targeted investments into our business over time have positioned us well to succeed and respond quickly to \nchanging demands from our customers and government partners during these uncertain times.  \n \n We've been focused on building  out a connected ecosystem over the last several years in the areas of oncology \nand biopharma services. ", "original_text": "We invest in our business to differentiate our solutions and create value for \ncustomers, patients and partners. "}, "hash": "bd38660a869954e31399c74c3494e5b2c8d4a67e40cd57f6e490f0d146e83433", "class_name": "RelatedNodeInfo"}}, "text": "I'm confident th at we operate in scaled and resilient markets with underlying \ntrends that support long -term growth. ", "start_char_idx": 2698, "end_char_idx": 2817, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec1e6dcc-1a43-44cd-880c-bc957188b153": {"__data__": {"id_": "ec1e6dcc-1a43-44cd-880c-bc957188b153", "embedding": null, "metadata": {"window": "Our commitment to executing our strategy, transforming and \nsimplifying the operating model contributed to these strong financial results.  \n \n Looking forward into fiscal 2022.  I'm confident th at we operate in scaled and resilient markets with underlying \ntrends that support long -term growth.  We invest in our business to differentiate our solutions and create value for \ncustomers, patients and partners.  The pandemic has not paused our progress on these strategic priorities. \n Targeted investments into our business over time have positioned us well to succeed and respond quickly to \nchanging demands from our customers and government partners during these uncertain times.  \n \n We've been focused on building  out a connected ecosystem over the last several years in the areas of oncology \nand biopharma services. ", "original_text": "We invest in our business to differentiate our solutions and create value for \ncustomers, patients and partners. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af78bec9f6e1efe0ff6760718d9969e4da8c810b25aedb8fca070b3fe220c9b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b893570-a290-4260-8e6f-b2769610c2fd", "node_type": "1", "metadata": {"window": "So while prescription volume and primary care patient visit trends negatively impacted the core business \nthroughout the fiscal year, the strength of our business model and our differentiated capabilities hel ped us to grow \nthe business and deliver value to our shareholders.  Our commitment to executing our strategy, transforming and \nsimplifying the operating model contributed to these strong financial results.  \n \n Looking forward into fiscal 2022.  I'm confident th at we operate in scaled and resilient markets with underlying \ntrends that support long -term growth.  We invest in our business to differentiate our solutions and create value for \ncustomers, patients and partners.  The pandemic has not paused our progress on these strategic priorities. \n Targeted investments into our business over time have positioned us well to succeed and respond quickly to \nchanging demands from our customers and government partners during these uncertain times.  \n \n", "original_text": "I'm confident th at we operate in scaled and resilient markets with underlying \ntrends that support long -term growth. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdb9840324c6fccc572e41157805bd94ef8433df7fd9d22003548d9fb9878779", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec7595fb-58d3-4459-8acd-e6dad1e19ed8", "node_type": "1", "metadata": {"window": "Looking forward into fiscal 2022.  I'm confident th at we operate in scaled and resilient markets with underlying \ntrends that support long -term growth.  We invest in our business to differentiate our solutions and create value for \ncustomers, patients and partners.  The pandemic has not paused our progress on these strategic priorities. \n Targeted investments into our business over time have positioned us well to succeed and respond quickly to \nchanging demands from our customers and government partners during these uncertain times.  \n \n We've been focused on building  out a connected ecosystem over the last several years in the areas of oncology \nand biopharma services.  These are areas where we believe we have key differentiated capabilities. ", "original_text": "The pandemic has not paused our progress on these strategic priorities. \n"}, "hash": "136ee331d62b8129d9e0242c078c1e1a53d303b107c1b800ddec4893d3f66324", "class_name": "RelatedNodeInfo"}}, "text": "We invest in our business to differentiate our solutions and create value for \ncustomers, patients and partners. ", "start_char_idx": 2817, "end_char_idx": 2930, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec7595fb-58d3-4459-8acd-e6dad1e19ed8": {"__data__": {"id_": "ec7595fb-58d3-4459-8acd-e6dad1e19ed8", "embedding": null, "metadata": {"window": "Looking forward into fiscal 2022.  I'm confident th at we operate in scaled and resilient markets with underlying \ntrends that support long -term growth.  We invest in our business to differentiate our solutions and create value for \ncustomers, patients and partners.  The pandemic has not paused our progress on these strategic priorities. \n Targeted investments into our business over time have positioned us well to succeed and respond quickly to \nchanging demands from our customers and government partners during these uncertain times.  \n \n We've been focused on building  out a connected ecosystem over the last several years in the areas of oncology \nand biopharma services.  These are areas where we believe we have key differentiated capabilities. ", "original_text": "The pandemic has not paused our progress on these strategic priorities. \n", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af78bec9f6e1efe0ff6760718d9969e4da8c810b25aedb8fca070b3fe220c9b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec1e6dcc-1a43-44cd-880c-bc957188b153", "node_type": "1", "metadata": {"window": "Our commitment to executing our strategy, transforming and \nsimplifying the operating model contributed to these strong financial results.  \n \n Looking forward into fiscal 2022.  I'm confident th at we operate in scaled and resilient markets with underlying \ntrends that support long -term growth.  We invest in our business to differentiate our solutions and create value for \ncustomers, patients and partners.  The pandemic has not paused our progress on these strategic priorities. \n Targeted investments into our business over time have positioned us well to succeed and respond quickly to \nchanging demands from our customers and government partners during these uncertain times.  \n \n We've been focused on building  out a connected ecosystem over the last several years in the areas of oncology \nand biopharma services. ", "original_text": "We invest in our business to differentiate our solutions and create value for \ncustomers, patients and partners. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b43aea48f177f9ba20a5d446f8cb27b1d2a556ebbbfe2c05ea01532408a737d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6e0ac30-a3b0-446d-8ab2-c4789536ddd9", "node_type": "1", "metadata": {"window": "I'm confident th at we operate in scaled and resilient markets with underlying \ntrends that support long -term growth.  We invest in our business to differentiate our solutions and create value for \ncustomers, patients and partners.  The pandemic has not paused our progress on these strategic priorities. \n Targeted investments into our business over time have positioned us well to succeed and respond quickly to \nchanging demands from our customers and government partners during these uncertain times.  \n \n We've been focused on building  out a connected ecosystem over the last several years in the areas of oncology \nand biopharma services.  These are areas where we believe we have key differentiated capabilities.  Through \ninvestments in technology, we've been able to develop more robust solu tions that help connect patients, providers \nand manufacturers and support our growth.  \n \n", "original_text": "Targeted investments into our business over time have positioned us well to succeed and respond quickly to \nchanging demands from our customers and government partners during these uncertain times.  \n \n"}, "hash": "cb04534998cb483ac949a8842dfe8ee277bcb9d9764210d0c29456df73d1bc05", "class_name": "RelatedNodeInfo"}}, "text": "The pandemic has not paused our progress on these strategic priorities. \n", "start_char_idx": 2930, "end_char_idx": 3003, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6e0ac30-a3b0-446d-8ab2-c4789536ddd9": {"__data__": {"id_": "c6e0ac30-a3b0-446d-8ab2-c4789536ddd9", "embedding": null, "metadata": {"window": "I'm confident th at we operate in scaled and resilient markets with underlying \ntrends that support long -term growth.  We invest in our business to differentiate our solutions and create value for \ncustomers, patients and partners.  The pandemic has not paused our progress on these strategic priorities. \n Targeted investments into our business over time have positioned us well to succeed and respond quickly to \nchanging demands from our customers and government partners during these uncertain times.  \n \n We've been focused on building  out a connected ecosystem over the last several years in the areas of oncology \nand biopharma services.  These are areas where we believe we have key differentiated capabilities.  Through \ninvestments in technology, we've been able to develop more robust solu tions that help connect patients, providers \nand manufacturers and support our growth.  \n \n", "original_text": "Targeted investments into our business over time have positioned us well to succeed and respond quickly to \nchanging demands from our customers and government partners during these uncertain times.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af78bec9f6e1efe0ff6760718d9969e4da8c810b25aedb8fca070b3fe220c9b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec7595fb-58d3-4459-8acd-e6dad1e19ed8", "node_type": "1", "metadata": {"window": "Looking forward into fiscal 2022.  I'm confident th at we operate in scaled and resilient markets with underlying \ntrends that support long -term growth.  We invest in our business to differentiate our solutions and create value for \ncustomers, patients and partners.  The pandemic has not paused our progress on these strategic priorities. \n Targeted investments into our business over time have positioned us well to succeed and respond quickly to \nchanging demands from our customers and government partners during these uncertain times.  \n \n We've been focused on building  out a connected ecosystem over the last several years in the areas of oncology \nand biopharma services.  These are areas where we believe we have key differentiated capabilities. ", "original_text": "The pandemic has not paused our progress on these strategic priorities. \n", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d164cfd2e4f6a4241a9bfc28014250dce93b89d46d5460bfd5103ee15b855e8c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96dcb479-73fa-4d0a-ad87-1f1148a57c7f", "node_type": "1", "metadata": {"window": "We invest in our business to differentiate our solutions and create value for \ncustomers, patients and partners.  The pandemic has not paused our progress on these strategic priorities. \n Targeted investments into our business over time have positioned us well to succeed and respond quickly to \nchanging demands from our customers and government partners during these uncertain times.  \n \n We've been focused on building  out a connected ecosystem over the last several years in the areas of oncology \nand biopharma services.  These are areas where we believe we have key differentiated capabilities.  Through \ninvestments in technology, we've been able to develop more robust solu tions that help connect patients, providers \nand manufacturers and support our growth.  \n \n Starting first with our oncology assets, which have proven to be resilient throughout the pandemic. ", "original_text": "We've been focused on building  out a connected ecosystem over the last several years in the areas of oncology \nand biopharma services. "}, "hash": "935271bc11876e966c79f5ee5fe9bc1307052d34bbb271bbd70bac19b05e7061", "class_name": "RelatedNodeInfo"}}, "text": "Targeted investments into our business over time have positioned us well to succeed and respond quickly to \nchanging demands from our customers and government partners during these uncertain times.  \n \n", "start_char_idx": 3003, "end_char_idx": 3205, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96dcb479-73fa-4d0a-ad87-1f1148a57c7f": {"__data__": {"id_": "96dcb479-73fa-4d0a-ad87-1f1148a57c7f", "embedding": null, "metadata": {"window": "We invest in our business to differentiate our solutions and create value for \ncustomers, patients and partners.  The pandemic has not paused our progress on these strategic priorities. \n Targeted investments into our business over time have positioned us well to succeed and respond quickly to \nchanging demands from our customers and government partners during these uncertain times.  \n \n We've been focused on building  out a connected ecosystem over the last several years in the areas of oncology \nand biopharma services.  These are areas where we believe we have key differentiated capabilities.  Through \ninvestments in technology, we've been able to develop more robust solu tions that help connect patients, providers \nand manufacturers and support our growth.  \n \n Starting first with our oncology assets, which have proven to be resilient throughout the pandemic. ", "original_text": "We've been focused on building  out a connected ecosystem over the last several years in the areas of oncology \nand biopharma services. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af78bec9f6e1efe0ff6760718d9969e4da8c810b25aedb8fca070b3fe220c9b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6e0ac30-a3b0-446d-8ab2-c4789536ddd9", "node_type": "1", "metadata": {"window": "I'm confident th at we operate in scaled and resilient markets with underlying \ntrends that support long -term growth.  We invest in our business to differentiate our solutions and create value for \ncustomers, patients and partners.  The pandemic has not paused our progress on these strategic priorities. \n Targeted investments into our business over time have positioned us well to succeed and respond quickly to \nchanging demands from our customers and government partners during these uncertain times.  \n \n We've been focused on building  out a connected ecosystem over the last several years in the areas of oncology \nand biopharma services.  These are areas where we believe we have key differentiated capabilities.  Through \ninvestments in technology, we've been able to develop more robust solu tions that help connect patients, providers \nand manufacturers and support our growth.  \n \n", "original_text": "Targeted investments into our business over time have positioned us well to succeed and respond quickly to \nchanging demands from our customers and government partners during these uncertain times.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd57d1abf21c83154acb3ffcf7238d6beef38fcb350bcfea6bdab5d0ec43d2fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52a50802-ca5d-45e1-98f5-fa4fc6086bd4", "node_type": "1", "metadata": {"window": "The pandemic has not paused our progress on these strategic priorities. \n Targeted investments into our business over time have positioned us well to succeed and respond quickly to \nchanging demands from our customers and government partners during these uncertain times.  \n \n We've been focused on building  out a connected ecosystem over the last several years in the areas of oncology \nand biopharma services.  These are areas where we believe we have key differentiated capabilities.  Through \ninvestments in technology, we've been able to develop more robust solu tions that help connect patients, providers \nand manufacturers and support our growth.  \n \n Starting first with our oncology assets, which have proven to be resilient throughout the pandemic.  Through \nscaled distribution, GPO services in our US Oncology business , we're positioned well, as innovative therapies \ncome to market. ", "original_text": "These are areas where we believe we have key differentiated capabilities. "}, "hash": "6c47162b9cc11df7fe6aa224f6970a0d38b5f270133bc6e91fca0fa1ee69d390", "class_name": "RelatedNodeInfo"}}, "text": "We've been focused on building  out a connected ecosystem over the last several years in the areas of oncology \nand biopharma services. ", "start_char_idx": 3205, "end_char_idx": 3341, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52a50802-ca5d-45e1-98f5-fa4fc6086bd4": {"__data__": {"id_": "52a50802-ca5d-45e1-98f5-fa4fc6086bd4", "embedding": null, "metadata": {"window": "The pandemic has not paused our progress on these strategic priorities. \n Targeted investments into our business over time have positioned us well to succeed and respond quickly to \nchanging demands from our customers and government partners during these uncertain times.  \n \n We've been focused on building  out a connected ecosystem over the last several years in the areas of oncology \nand biopharma services.  These are areas where we believe we have key differentiated capabilities.  Through \ninvestments in technology, we've been able to develop more robust solu tions that help connect patients, providers \nand manufacturers and support our growth.  \n \n Starting first with our oncology assets, which have proven to be resilient throughout the pandemic.  Through \nscaled distribution, GPO services in our US Oncology business , we're positioned well, as innovative therapies \ncome to market. ", "original_text": "These are areas where we believe we have key differentiated capabilities. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af78bec9f6e1efe0ff6760718d9969e4da8c810b25aedb8fca070b3fe220c9b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96dcb479-73fa-4d0a-ad87-1f1148a57c7f", "node_type": "1", "metadata": {"window": "We invest in our business to differentiate our solutions and create value for \ncustomers, patients and partners.  The pandemic has not paused our progress on these strategic priorities. \n Targeted investments into our business over time have positioned us well to succeed and respond quickly to \nchanging demands from our customers and government partners during these uncertain times.  \n \n We've been focused on building  out a connected ecosystem over the last several years in the areas of oncology \nand biopharma services.  These are areas where we believe we have key differentiated capabilities.  Through \ninvestments in technology, we've been able to develop more robust solu tions that help connect patients, providers \nand manufacturers and support our growth.  \n \n Starting first with our oncology assets, which have proven to be resilient throughout the pandemic. ", "original_text": "We've been focused on building  out a connected ecosystem over the last several years in the areas of oncology \nand biopharma services. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4941a4ac87d425e2e2bd7b46b622d04586a590af9161aac918c550c61952d40a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d21fd5f-48f3-423b-8a62-8bb739d8f10e", "node_type": "1", "metadata": {"window": "Targeted investments into our business over time have positioned us well to succeed and respond quickly to \nchanging demands from our customers and government partners during these uncertain times.  \n \n We've been focused on building  out a connected ecosystem over the last several years in the areas of oncology \nand biopharma services.  These are areas where we believe we have key differentiated capabilities.  Through \ninvestments in technology, we've been able to develop more robust solu tions that help connect patients, providers \nand manufacturers and support our growth.  \n \n Starting first with our oncology assets, which have proven to be resilient throughout the pandemic.  Through \nscaled distribution, GPO services in our US Oncology business , we're positioned well, as innovative therapies \ncome to market.  Biosimilars are just one example where McKesson has been able to combine the breadth and \nscale of our specialty capabilities to help give providers choice and lower costs for patients.  \n ", "original_text": "Through \ninvestments in technology, we've been able to develop more robust solu tions that help connect patients, providers \nand manufacturers and support our growth.  \n \n"}, "hash": "9d5f2011268e8a7bddead52ce42518e8c327b4d3ee4d95244ef240f49700a932", "class_name": "RelatedNodeInfo"}}, "text": "These are areas where we believe we have key differentiated capabilities. ", "start_char_idx": 3341, "end_char_idx": 3415, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d21fd5f-48f3-423b-8a62-8bb739d8f10e": {"__data__": {"id_": "2d21fd5f-48f3-423b-8a62-8bb739d8f10e", "embedding": null, "metadata": {"window": "Targeted investments into our business over time have positioned us well to succeed and respond quickly to \nchanging demands from our customers and government partners during these uncertain times.  \n \n We've been focused on building  out a connected ecosystem over the last several years in the areas of oncology \nand biopharma services.  These are areas where we believe we have key differentiated capabilities.  Through \ninvestments in technology, we've been able to develop more robust solu tions that help connect patients, providers \nand manufacturers and support our growth.  \n \n Starting first with our oncology assets, which have proven to be resilient throughout the pandemic.  Through \nscaled distribution, GPO services in our US Oncology business , we're positioned well, as innovative therapies \ncome to market.  Biosimilars are just one example where McKesson has been able to combine the breadth and \nscale of our specialty capabilities to help give providers choice and lower costs for patients.  \n ", "original_text": "Through \ninvestments in technology, we've been able to develop more robust solu tions that help connect patients, providers \nand manufacturers and support our growth.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af78bec9f6e1efe0ff6760718d9969e4da8c810b25aedb8fca070b3fe220c9b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52a50802-ca5d-45e1-98f5-fa4fc6086bd4", "node_type": "1", "metadata": {"window": "The pandemic has not paused our progress on these strategic priorities. \n Targeted investments into our business over time have positioned us well to succeed and respond quickly to \nchanging demands from our customers and government partners during these uncertain times.  \n \n We've been focused on building  out a connected ecosystem over the last several years in the areas of oncology \nand biopharma services.  These are areas where we believe we have key differentiated capabilities.  Through \ninvestments in technology, we've been able to develop more robust solu tions that help connect patients, providers \nand manufacturers and support our growth.  \n \n Starting first with our oncology assets, which have proven to be resilient throughout the pandemic.  Through \nscaled distribution, GPO services in our US Oncology business , we're positioned well, as innovative therapies \ncome to market. ", "original_text": "These are areas where we believe we have key differentiated capabilities. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "83a7dd5155ed1bda07971d5aefc5e2e245453649c6f4f599a7654fa1051fbf2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be4361aa-c9b3-49f2-93b7-0db31011fd19", "node_type": "1", "metadata": {"window": "We've been focused on building  out a connected ecosystem over the last several years in the areas of oncology \nand biopharma services.  These are areas where we believe we have key differentiated capabilities.  Through \ninvestments in technology, we've been able to develop more robust solu tions that help connect patients, providers \nand manufacturers and support our growth.  \n \n Starting first with our oncology assets, which have proven to be resilient throughout the pandemic.  Through \nscaled distribution, GPO services in our US Oncology business , we're positioned well, as innovative therapies \ncome to market.  Biosimilars are just one example where McKesson has been able to combine the breadth and \nscale of our specialty capabilities to help give providers choice and lower costs for patients.  \n ", "original_text": "Starting first with our oncology assets, which have proven to be resilient throughout the pandemic. "}, "hash": "57f56dce61c8e6e733827d397907742451c4494e1afbd495e8981dc561287201", "class_name": "RelatedNodeInfo"}}, "text": "Through \ninvestments in technology, we've been able to develop more robust solu tions that help connect patients, providers \nand manufacturers and support our growth.  \n \n", "start_char_idx": 3415, "end_char_idx": 3586, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be4361aa-c9b3-49f2-93b7-0db31011fd19": {"__data__": {"id_": "be4361aa-c9b3-49f2-93b7-0db31011fd19", "embedding": null, "metadata": {"window": "We've been focused on building  out a connected ecosystem over the last several years in the areas of oncology \nand biopharma services.  These are areas where we believe we have key differentiated capabilities.  Through \ninvestments in technology, we've been able to develop more robust solu tions that help connect patients, providers \nand manufacturers and support our growth.  \n \n Starting first with our oncology assets, which have proven to be resilient throughout the pandemic.  Through \nscaled distribution, GPO services in our US Oncology business , we're positioned well, as innovative therapies \ncome to market.  Biosimilars are just one example where McKesson has been able to combine the breadth and \nscale of our specialty capabilities to help give providers choice and lower costs for patients.  \n ", "original_text": "Starting first with our oncology assets, which have proven to be resilient throughout the pandemic. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af78bec9f6e1efe0ff6760718d9969e4da8c810b25aedb8fca070b3fe220c9b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d21fd5f-48f3-423b-8a62-8bb739d8f10e", "node_type": "1", "metadata": {"window": "Targeted investments into our business over time have positioned us well to succeed and respond quickly to \nchanging demands from our customers and government partners during these uncertain times.  \n \n We've been focused on building  out a connected ecosystem over the last several years in the areas of oncology \nand biopharma services.  These are areas where we believe we have key differentiated capabilities.  Through \ninvestments in technology, we've been able to develop more robust solu tions that help connect patients, providers \nand manufacturers and support our growth.  \n \n Starting first with our oncology assets, which have proven to be resilient throughout the pandemic.  Through \nscaled distribution, GPO services in our US Oncology business , we're positioned well, as innovative therapies \ncome to market.  Biosimilars are just one example where McKesson has been able to combine the breadth and \nscale of our specialty capabilities to help give providers choice and lower costs for patients.  \n ", "original_text": "Through \ninvestments in technology, we've been able to develop more robust solu tions that help connect patients, providers \nand manufacturers and support our growth.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4dde27dd9eaba7d002c78d41d39b6e34446dff83fbac8584bd27658bae8ca5ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39a3d417-1a2a-413c-ac63-23c860778fab", "node_type": "1", "metadata": {"window": "These are areas where we believe we have key differentiated capabilities.  Through \ninvestments in technology, we've been able to develop more robust solu tions that help connect patients, providers \nand manufacturers and support our growth.  \n \n Starting first with our oncology assets, which have proven to be resilient throughout the pandemic.  Through \nscaled distribution, GPO services in our US Oncology business , we're positioned well, as innovative therapies \ncome to market.  Biosimilars are just one example where McKesson has been able to combine the breadth and \nscale of our specialty capabilities to help give providers choice and lower costs for patients.  \n ", "original_text": "Through \nscaled distribution, GPO services in our US Oncology business , we're positioned well, as innovative therapies \ncome to market. "}, "hash": "47e0db273997149163068594572e9123f976142c6299b9ad4f1ff5650365483f", "class_name": "RelatedNodeInfo"}}, "text": "Starting first with our oncology assets, which have proven to be resilient throughout the pandemic. ", "start_char_idx": 3586, "end_char_idx": 3686, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39a3d417-1a2a-413c-ac63-23c860778fab": {"__data__": {"id_": "39a3d417-1a2a-413c-ac63-23c860778fab", "embedding": null, "metadata": {"window": "These are areas where we believe we have key differentiated capabilities.  Through \ninvestments in technology, we've been able to develop more robust solu tions that help connect patients, providers \nand manufacturers and support our growth.  \n \n Starting first with our oncology assets, which have proven to be resilient throughout the pandemic.  Through \nscaled distribution, GPO services in our US Oncology business , we're positioned well, as innovative therapies \ncome to market.  Biosimilars are just one example where McKesson has been able to combine the breadth and \nscale of our specialty capabilities to help give providers choice and lower costs for patients.  \n ", "original_text": "Through \nscaled distribution, GPO services in our US Oncology business , we're positioned well, as innovative therapies \ncome to market. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af78bec9f6e1efe0ff6760718d9969e4da8c810b25aedb8fca070b3fe220c9b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be4361aa-c9b3-49f2-93b7-0db31011fd19", "node_type": "1", "metadata": {"window": "We've been focused on building  out a connected ecosystem over the last several years in the areas of oncology \nand biopharma services.  These are areas where we believe we have key differentiated capabilities.  Through \ninvestments in technology, we've been able to develop more robust solu tions that help connect patients, providers \nand manufacturers and support our growth.  \n \n Starting first with our oncology assets, which have proven to be resilient throughout the pandemic.  Through \nscaled distribution, GPO services in our US Oncology business , we're positioned well, as innovative therapies \ncome to market.  Biosimilars are just one example where McKesson has been able to combine the breadth and \nscale of our specialty capabilities to help give providers choice and lower costs for patients.  \n ", "original_text": "Starting first with our oncology assets, which have proven to be resilient throughout the pandemic. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f27d09c8ec8c9b7990f9cce1832f91e380d33e4022047be0cde359d8ac642a9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73020832-c1c3-40fa-bb90-9db428cd2b34", "node_type": "1", "metadata": {"window": "Through \ninvestments in technology, we've been able to develop more robust solu tions that help connect patients, providers \nand manufacturers and support our growth.  \n \n Starting first with our oncology assets, which have proven to be resilient throughout the pandemic.  Through \nscaled distribution, GPO services in our US Oncology business , we're positioned well, as innovative therapies \ncome to market.  Biosimilars are just one example where McKesson has been able to combine the breadth and \nscale of our specialty capabilities to help give providers choice and lower costs for patients.  \n ", "original_text": "Biosimilars are just one example where McKesson has been able to combine the breadth and \nscale of our specialty capabilities to help give providers choice and lower costs for patients.  \n "}, "hash": "f9890daca226aaa33024d3233544cfc8fdc62fb39492f74312d790ff2844f8aa", "class_name": "RelatedNodeInfo"}}, "text": "Through \nscaled distribution, GPO services in our US Oncology business , we're positioned well, as innovative therapies \ncome to market. ", "start_char_idx": 3686, "end_char_idx": 3823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73020832-c1c3-40fa-bb90-9db428cd2b34": {"__data__": {"id_": "73020832-c1c3-40fa-bb90-9db428cd2b34", "embedding": null, "metadata": {"window": "Through \ninvestments in technology, we've been able to develop more robust solu tions that help connect patients, providers \nand manufacturers and support our growth.  \n \n Starting first with our oncology assets, which have proven to be resilient throughout the pandemic.  Through \nscaled distribution, GPO services in our US Oncology business , we're positioned well, as innovative therapies \ncome to market.  Biosimilars are just one example where McKesson has been able to combine the breadth and \nscale of our specialty capabilities to help give providers choice and lower costs for patients.  \n ", "original_text": "Biosimilars are just one example where McKesson has been able to combine the breadth and \nscale of our specialty capabilities to help give providers choice and lower costs for patients.  \n ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af78bec9f6e1efe0ff6760718d9969e4da8c810b25aedb8fca070b3fe220c9b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39a3d417-1a2a-413c-ac63-23c860778fab", "node_type": "1", "metadata": {"window": "These are areas where we believe we have key differentiated capabilities.  Through \ninvestments in technology, we've been able to develop more robust solu tions that help connect patients, providers \nand manufacturers and support our growth.  \n \n Starting first with our oncology assets, which have proven to be resilient throughout the pandemic.  Through \nscaled distribution, GPO services in our US Oncology business , we're positioned well, as innovative therapies \ncome to market.  Biosimilars are just one example where McKesson has been able to combine the breadth and \nscale of our specialty capabilities to help give providers choice and lower costs for patients.  \n ", "original_text": "Through \nscaled distribution, GPO services in our US Oncology business , we're positioned well, as innovative therapies \ncome to market. ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f975dc6e436649769dd217fac93ea7801d9190882efea6dc70cda59b95dab012", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a935b6f-ce92-468f-8902-e653dabedd3a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe we re pleased to add more practices and over 100 providers to the US Oncology Network in fiscal 2021. \n Today, through US Oncology and our nonaffiliated provider business, we're connected to over 10,000 specialty \nphysicians.  And our oncology technology platform  has supported millions of patient journeys, providing us access \nto real -world outcomes data and research.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "5fb9d749a140ef5882864b8cfc29e344c3b7b1eaab068cec81aa9345cb3bdfbf", "class_name": "RelatedNodeInfo"}}, "text": "Biosimilars are just one example where McKesson has been able to combine the breadth and \nscale of our specialty capabilities to help give providers choice and lower costs for patients.  \n ", "start_char_idx": 3823, "end_char_idx": 4012, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a935b6f-ce92-468f-8902-e653dabedd3a": {"__data__": {"id_": "2a935b6f-ce92-468f-8902-e653dabedd3a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe we re pleased to add more practices and over 100 providers to the US Oncology Network in fiscal 2021. \n Today, through US Oncology and our nonaffiliated provider business, we're connected to over 10,000 specialty \nphysicians.  And our oncology technology platform  has supported millions of patient journeys, providing us access \nto real -world outcomes data and research.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f207edc-0ead-4320-8205-fc7e356f115c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6275a184f8bd8d594cc6c801bece3e9238396da4193218af4303f942621d4686", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73020832-c1c3-40fa-bb90-9db428cd2b34", "node_type": "1", "metadata": {"window": "Through \ninvestments in technology, we've been able to develop more robust solu tions that help connect patients, providers \nand manufacturers and support our growth.  \n \n Starting first with our oncology assets, which have proven to be resilient throughout the pandemic.  Through \nscaled distribution, GPO services in our US Oncology business , we're positioned well, as innovative therapies \ncome to market.  Biosimilars are just one example where McKesson has been able to combine the breadth and \nscale of our specialty capabilities to help give providers choice and lower costs for patients.  \n ", "original_text": "Biosimilars are just one example where McKesson has been able to combine the breadth and \nscale of our specialty capabilities to help give providers choice and lower costs for patients.  \n ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0ac81797a962479c8f9ed4ec269620d0e13865689f13cd1bfb65b0a6cc7ba4cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c3bd72f-0207-4e07-92e5-58c23035c2f2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe we re pleased to add more practices and over 100 providers to the US Oncology Network in fiscal 2021. \n Today, through US Oncology and our nonaffiliated provider business, we're connected to over 10,000 specialty \nphysicians.  And our oncology technology platform  has supported millions of patient journeys, providing us access \nto real -world outcomes data and research.  \n \n Our recently launched Technology and Real -World Insights business, which we call Ontada, is an extension of \nour oncology ecosystem and is a key area  of investment for us going forward. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe we re pleased to add more practices and over 100 providers to the US Oncology Network in fiscal 2021. \n"}, "hash": "610532b8becc1b21968f539eb182b78f50498e320cd3c87095fc2c65211f2caf", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c3bd72f-0207-4e07-92e5-58c23035c2f2": {"__data__": {"id_": "5c3bd72f-0207-4e07-92e5-58c23035c2f2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe we re pleased to add more practices and over 100 providers to the US Oncology Network in fiscal 2021. \n Today, through US Oncology and our nonaffiliated provider business, we're connected to over 10,000 specialty \nphysicians.  And our oncology technology platform  has supported millions of patient journeys, providing us access \nto real -world outcomes data and research.  \n \n Our recently launched Technology and Real -World Insights business, which we call Ontada, is an extension of \nour oncology ecosystem and is a key area  of investment for us going forward. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe we re pleased to add more practices and over 100 providers to the US Oncology Network in fiscal 2021. \n", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f207edc-0ead-4320-8205-fc7e356f115c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6275a184f8bd8d594cc6c801bece3e9238396da4193218af4303f942621d4686", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a935b6f-ce92-468f-8902-e653dabedd3a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe we re pleased to add more practices and over 100 providers to the US Oncology Network in fiscal 2021. \n Today, through US Oncology and our nonaffiliated provider business, we're connected to over 10,000 specialty \nphysicians.  And our oncology technology platform  has supported millions of patient journeys, providing us access \nto real -world outcomes data and research.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f25f1cb3621eb50f55d0a81f138f99b3ec6078008d3c6ecbe7fc0e6f14e5ac8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "292bbde4-7c9c-4793-9d67-b81e151819ab", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe we re pleased to add more practices and over 100 providers to the US Oncology Network in fiscal 2021. \n Today, through US Oncology and our nonaffiliated provider business, we're connected to over 10,000 specialty \nphysicians.  And our oncology technology platform  has supported millions of patient journeys, providing us access \nto real -world outcomes data and research.  \n \n Our recently launched Technology and Real -World Insights business, which we call Ontada, is an extension of \nour oncology ecosystem and is a key area  of investment for us going forward.  We believe this business \ndifferentiates our value proposition to providers looking to drive better outcomes for their patients and to \nmanufacturers focused on innovative therapies in the area of oncology.  \n \n", "original_text": "Today, through US Oncology and our nonaffiliated provider business, we're connected to over 10,000 specialty \nphysicians. "}, "hash": "d256266257f130cda0c183b159d6b02c0f57c49e7288fbae4ec0012007eb1781", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe we re pleased to add more practices and over 100 providers to the US Oncology Network in fiscal 2021. \n", "start_char_idx": 16, "end_char_idx": 286, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "292bbde4-7c9c-4793-9d67-b81e151819ab": {"__data__": {"id_": "292bbde4-7c9c-4793-9d67-b81e151819ab", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe we re pleased to add more practices and over 100 providers to the US Oncology Network in fiscal 2021. \n Today, through US Oncology and our nonaffiliated provider business, we're connected to over 10,000 specialty \nphysicians.  And our oncology technology platform  has supported millions of patient journeys, providing us access \nto real -world outcomes data and research.  \n \n Our recently launched Technology and Real -World Insights business, which we call Ontada, is an extension of \nour oncology ecosystem and is a key area  of investment for us going forward.  We believe this business \ndifferentiates our value proposition to providers looking to drive better outcomes for their patients and to \nmanufacturers focused on innovative therapies in the area of oncology.  \n \n", "original_text": "Today, through US Oncology and our nonaffiliated provider business, we're connected to over 10,000 specialty \nphysicians. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f207edc-0ead-4320-8205-fc7e356f115c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6275a184f8bd8d594cc6c801bece3e9238396da4193218af4303f942621d4686", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c3bd72f-0207-4e07-92e5-58c23035c2f2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe we re pleased to add more practices and over 100 providers to the US Oncology Network in fiscal 2021. \n Today, through US Oncology and our nonaffiliated provider business, we're connected to over 10,000 specialty \nphysicians.  And our oncology technology platform  has supported millions of patient journeys, providing us access \nto real -world outcomes data and research.  \n \n Our recently launched Technology and Real -World Insights business, which we call Ontada, is an extension of \nour oncology ecosystem and is a key area  of investment for us going forward. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe we re pleased to add more practices and over 100 providers to the US Oncology Network in fiscal 2021. \n", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f560ab1dffb916f2718f05467d4f203319eeffa93afe8ac19d8079df3c6986c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "934f0843-8d80-4b96-91eb-7085bde66fd4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe we re pleased to add more practices and over 100 providers to the US Oncology Network in fiscal 2021. \n Today, through US Oncology and our nonaffiliated provider business, we're connected to over 10,000 specialty \nphysicians.  And our oncology technology platform  has supported millions of patient journeys, providing us access \nto real -world outcomes data and research.  \n \n Our recently launched Technology and Real -World Insights business, which we call Ontada, is an extension of \nour oncology ecosystem and is a key area  of investment for us going forward.  We believe this business \ndifferentiates our value proposition to providers looking to drive better outcomes for their patients and to \nmanufacturers focused on innovative therapies in the area of oncology.  \n \n In terms of b iopharma services, in fiscal 2021, we brought together our RelayHealth Pharmacy, CoverMyMeds \nand RxCrossroads businesses. ", "original_text": "And our oncology technology platform  has supported millions of patient journeys, providing us access \nto real -world outcomes data and research.  \n \n"}, "hash": "9064588ef4d7a5cf8deae723d6c90c479a20cce6b2f902e03b743c85fc7951ed", "class_name": "RelatedNodeInfo"}}, "text": "Today, through US Oncology and our nonaffiliated provider business, we're connected to over 10,000 specialty \nphysicians. ", "start_char_idx": 286, "end_char_idx": 408, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "934f0843-8d80-4b96-91eb-7085bde66fd4": {"__data__": {"id_": "934f0843-8d80-4b96-91eb-7085bde66fd4", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe we re pleased to add more practices and over 100 providers to the US Oncology Network in fiscal 2021. \n Today, through US Oncology and our nonaffiliated provider business, we're connected to over 10,000 specialty \nphysicians.  And our oncology technology platform  has supported millions of patient journeys, providing us access \nto real -world outcomes data and research.  \n \n Our recently launched Technology and Real -World Insights business, which we call Ontada, is an extension of \nour oncology ecosystem and is a key area  of investment for us going forward.  We believe this business \ndifferentiates our value proposition to providers looking to drive better outcomes for their patients and to \nmanufacturers focused on innovative therapies in the area of oncology.  \n \n In terms of b iopharma services, in fiscal 2021, we brought together our RelayHealth Pharmacy, CoverMyMeds \nand RxCrossroads businesses. ", "original_text": "And our oncology technology platform  has supported millions of patient journeys, providing us access \nto real -world outcomes data and research.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f207edc-0ead-4320-8205-fc7e356f115c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6275a184f8bd8d594cc6c801bece3e9238396da4193218af4303f942621d4686", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "292bbde4-7c9c-4793-9d67-b81e151819ab", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe we re pleased to add more practices and over 100 providers to the US Oncology Network in fiscal 2021. \n Today, through US Oncology and our nonaffiliated provider business, we're connected to over 10,000 specialty \nphysicians.  And our oncology technology platform  has supported millions of patient journeys, providing us access \nto real -world outcomes data and research.  \n \n Our recently launched Technology and Real -World Insights business, which we call Ontada, is an extension of \nour oncology ecosystem and is a key area  of investment for us going forward.  We believe this business \ndifferentiates our value proposition to providers looking to drive better outcomes for their patients and to \nmanufacturers focused on innovative therapies in the area of oncology.  \n \n", "original_text": "Today, through US Oncology and our nonaffiliated provider business, we're connected to over 10,000 specialty \nphysicians. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8367b78b9639476705cea1cd93ca2abfa05a108aebf68d578b44e5e9e9b9d42a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69adfdbd-315e-4c1a-8781-47eb3fd8edff", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe we re pleased to add more practices and over 100 providers to the US Oncology Network in fiscal 2021. \n Today, through US Oncology and our nonaffiliated provider business, we're connected to over 10,000 specialty \nphysicians.  And our oncology technology platform  has supported millions of patient journeys, providing us access \nto real -world outcomes data and research.  \n \n Our recently launched Technology and Real -World Insights business, which we call Ontada, is an extension of \nour oncology ecosystem and is a key area  of investment for us going forward.  We believe this business \ndifferentiates our value proposition to providers looking to drive better outcomes for their patients and to \nmanufacturers focused on innovative therapies in the area of oncology.  \n \n In terms of b iopharma services, in fiscal 2021, we brought together our RelayHealth Pharmacy, CoverMyMeds \nand RxCrossroads businesses.  Together, these businesses are focused on innovating and automating the ways \nin which biopharma connects with patients, pharmacies and  providers, with the ultimate goal of providing stronger \naccess, affordability and better adherence outcomes.  \n \n", "original_text": "Our recently launched Technology and Real -World Insights business, which we call Ontada, is an extension of \nour oncology ecosystem and is a key area  of investment for us going forward. "}, "hash": "e9009dde7ac6b23b9b90daf4c6369b6c6e63839135a141d2b998f5b2f1ae24a4", "class_name": "RelatedNodeInfo"}}, "text": "And our oncology technology platform  has supported millions of patient journeys, providing us access \nto real -world outcomes data and research.  \n \n", "start_char_idx": 408, "end_char_idx": 558, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69adfdbd-315e-4c1a-8781-47eb3fd8edff": {"__data__": {"id_": "69adfdbd-315e-4c1a-8781-47eb3fd8edff", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe we re pleased to add more practices and over 100 providers to the US Oncology Network in fiscal 2021. \n Today, through US Oncology and our nonaffiliated provider business, we're connected to over 10,000 specialty \nphysicians.  And our oncology technology platform  has supported millions of patient journeys, providing us access \nto real -world outcomes data and research.  \n \n Our recently launched Technology and Real -World Insights business, which we call Ontada, is an extension of \nour oncology ecosystem and is a key area  of investment for us going forward.  We believe this business \ndifferentiates our value proposition to providers looking to drive better outcomes for their patients and to \nmanufacturers focused on innovative therapies in the area of oncology.  \n \n In terms of b iopharma services, in fiscal 2021, we brought together our RelayHealth Pharmacy, CoverMyMeds \nand RxCrossroads businesses.  Together, these businesses are focused on innovating and automating the ways \nin which biopharma connects with patients, pharmacies and  providers, with the ultimate goal of providing stronger \naccess, affordability and better adherence outcomes.  \n \n", "original_text": "Our recently launched Technology and Real -World Insights business, which we call Ontada, is an extension of \nour oncology ecosystem and is a key area  of investment for us going forward. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f207edc-0ead-4320-8205-fc7e356f115c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6275a184f8bd8d594cc6c801bece3e9238396da4193218af4303f942621d4686", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "934f0843-8d80-4b96-91eb-7085bde66fd4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe we re pleased to add more practices and over 100 providers to the US Oncology Network in fiscal 2021. \n Today, through US Oncology and our nonaffiliated provider business, we're connected to over 10,000 specialty \nphysicians.  And our oncology technology platform  has supported millions of patient journeys, providing us access \nto real -world outcomes data and research.  \n \n Our recently launched Technology and Real -World Insights business, which we call Ontada, is an extension of \nour oncology ecosystem and is a key area  of investment for us going forward.  We believe this business \ndifferentiates our value proposition to providers looking to drive better outcomes for their patients and to \nmanufacturers focused on innovative therapies in the area of oncology.  \n \n In terms of b iopharma services, in fiscal 2021, we brought together our RelayHealth Pharmacy, CoverMyMeds \nand RxCrossroads businesses. ", "original_text": "And our oncology technology platform  has supported millions of patient journeys, providing us access \nto real -world outcomes data and research.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7646dbd276c325c4cb069bd39eb7e86a9b13aeda39438b3a56ca7f1dbde23f46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f65c6fd4-820a-42fe-b922-6d2fd8a2805a", "node_type": "1", "metadata": {"window": "Today, through US Oncology and our nonaffiliated provider business, we're connected to over 10,000 specialty \nphysicians.  And our oncology technology platform  has supported millions of patient journeys, providing us access \nto real -world outcomes data and research.  \n \n Our recently launched Technology and Real -World Insights business, which we call Ontada, is an extension of \nour oncology ecosystem and is a key area  of investment for us going forward.  We believe this business \ndifferentiates our value proposition to providers looking to drive better outcomes for their patients and to \nmanufacturers focused on innovative therapies in the area of oncology.  \n \n In terms of b iopharma services, in fiscal 2021, we brought together our RelayHealth Pharmacy, CoverMyMeds \nand RxCrossroads businesses.  Together, these businesses are focused on innovating and automating the ways \nin which biopharma connects with patients, pharmacies and  providers, with the ultimate goal of providing stronger \naccess, affordability and better adherence outcomes.  \n \n These assets embed us in the daily workflows of over 50,000 pharmacies and more than 750,000 providers. \n", "original_text": "We believe this business \ndifferentiates our value proposition to providers looking to drive better outcomes for their patients and to \nmanufacturers focused on innovative therapies in the area of oncology.  \n \n"}, "hash": "742ee4ab278fb3b578d3462285bbfd301ac8f23646c51ca8fb76daae5d5cf409", "class_name": "RelatedNodeInfo"}}, "text": "Our recently launched Technology and Real -World Insights business, which we call Ontada, is an extension of \nour oncology ecosystem and is a key area  of investment for us going forward. ", "start_char_idx": 558, "end_char_idx": 746, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f65c6fd4-820a-42fe-b922-6d2fd8a2805a": {"__data__": {"id_": "f65c6fd4-820a-42fe-b922-6d2fd8a2805a", "embedding": null, "metadata": {"window": "Today, through US Oncology and our nonaffiliated provider business, we're connected to over 10,000 specialty \nphysicians.  And our oncology technology platform  has supported millions of patient journeys, providing us access \nto real -world outcomes data and research.  \n \n Our recently launched Technology and Real -World Insights business, which we call Ontada, is an extension of \nour oncology ecosystem and is a key area  of investment for us going forward.  We believe this business \ndifferentiates our value proposition to providers looking to drive better outcomes for their patients and to \nmanufacturers focused on innovative therapies in the area of oncology.  \n \n In terms of b iopharma services, in fiscal 2021, we brought together our RelayHealth Pharmacy, CoverMyMeds \nand RxCrossroads businesses.  Together, these businesses are focused on innovating and automating the ways \nin which biopharma connects with patients, pharmacies and  providers, with the ultimate goal of providing stronger \naccess, affordability and better adherence outcomes.  \n \n These assets embed us in the daily workflows of over 50,000 pharmacies and more than 750,000 providers. \n", "original_text": "We believe this business \ndifferentiates our value proposition to providers looking to drive better outcomes for their patients and to \nmanufacturers focused on innovative therapies in the area of oncology.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f207edc-0ead-4320-8205-fc7e356f115c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6275a184f8bd8d594cc6c801bece3e9238396da4193218af4303f942621d4686", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69adfdbd-315e-4c1a-8781-47eb3fd8edff", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe we re pleased to add more practices and over 100 providers to the US Oncology Network in fiscal 2021. \n Today, through US Oncology and our nonaffiliated provider business, we're connected to over 10,000 specialty \nphysicians.  And our oncology technology platform  has supported millions of patient journeys, providing us access \nto real -world outcomes data and research.  \n \n Our recently launched Technology and Real -World Insights business, which we call Ontada, is an extension of \nour oncology ecosystem and is a key area  of investment for us going forward.  We believe this business \ndifferentiates our value proposition to providers looking to drive better outcomes for their patients and to \nmanufacturers focused on innovative therapies in the area of oncology.  \n \n In terms of b iopharma services, in fiscal 2021, we brought together our RelayHealth Pharmacy, CoverMyMeds \nand RxCrossroads businesses.  Together, these businesses are focused on innovating and automating the ways \nin which biopharma connects with patients, pharmacies and  providers, with the ultimate goal of providing stronger \naccess, affordability and better adherence outcomes.  \n \n", "original_text": "Our recently launched Technology and Real -World Insights business, which we call Ontada, is an extension of \nour oncology ecosystem and is a key area  of investment for us going forward. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "30075f92ffaabaed9fa1e60438eca4ef9f4d4a242fa5eba37c84ff78eadaaf7e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a29b869-9b77-459f-a4e1-f551ffbf7341", "node_type": "1", "metadata": {"window": "And our oncology technology platform  has supported millions of patient journeys, providing us access \nto real -world outcomes data and research.  \n \n Our recently launched Technology and Real -World Insights business, which we call Ontada, is an extension of \nour oncology ecosystem and is a key area  of investment for us going forward.  We believe this business \ndifferentiates our value proposition to providers looking to drive better outcomes for their patients and to \nmanufacturers focused on innovative therapies in the area of oncology.  \n \n In terms of b iopharma services, in fiscal 2021, we brought together our RelayHealth Pharmacy, CoverMyMeds \nand RxCrossroads businesses.  Together, these businesses are focused on innovating and automating the ways \nin which biopharma connects with patients, pharmacies and  providers, with the ultimate goal of providing stronger \naccess, affordability and better adherence outcomes.  \n \n These assets embed us in the daily workflows of over 50,000 pharmacies and more than 750,000 providers. \n We're integrated into over 75% of EHRs to day. ", "original_text": "In terms of b iopharma services, in fiscal 2021, we brought together our RelayHealth Pharmacy, CoverMyMeds \nand RxCrossroads businesses. "}, "hash": "505c587cc4a66b06e84c1d3dbbeef3e0b34db38df0588fac6decd1cd587444ab", "class_name": "RelatedNodeInfo"}}, "text": "We believe this business \ndifferentiates our value proposition to providers looking to drive better outcomes for their patients and to \nmanufacturers focused on innovative therapies in the area of oncology.  \n \n", "start_char_idx": 746, "end_char_idx": 957, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a29b869-9b77-459f-a4e1-f551ffbf7341": {"__data__": {"id_": "9a29b869-9b77-459f-a4e1-f551ffbf7341", "embedding": null, "metadata": {"window": "And our oncology technology platform  has supported millions of patient journeys, providing us access \nto real -world outcomes data and research.  \n \n Our recently launched Technology and Real -World Insights business, which we call Ontada, is an extension of \nour oncology ecosystem and is a key area  of investment for us going forward.  We believe this business \ndifferentiates our value proposition to providers looking to drive better outcomes for their patients and to \nmanufacturers focused on innovative therapies in the area of oncology.  \n \n In terms of b iopharma services, in fiscal 2021, we brought together our RelayHealth Pharmacy, CoverMyMeds \nand RxCrossroads businesses.  Together, these businesses are focused on innovating and automating the ways \nin which biopharma connects with patients, pharmacies and  providers, with the ultimate goal of providing stronger \naccess, affordability and better adherence outcomes.  \n \n These assets embed us in the daily workflows of over 50,000 pharmacies and more than 750,000 providers. \n We're integrated into over 75% of EHRs to day. ", "original_text": "In terms of b iopharma services, in fiscal 2021, we brought together our RelayHealth Pharmacy, CoverMyMeds \nand RxCrossroads businesses. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f207edc-0ead-4320-8205-fc7e356f115c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6275a184f8bd8d594cc6c801bece3e9238396da4193218af4303f942621d4686", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f65c6fd4-820a-42fe-b922-6d2fd8a2805a", "node_type": "1", "metadata": {"window": "Today, through US Oncology and our nonaffiliated provider business, we're connected to over 10,000 specialty \nphysicians.  And our oncology technology platform  has supported millions of patient journeys, providing us access \nto real -world outcomes data and research.  \n \n Our recently launched Technology and Real -World Insights business, which we call Ontada, is an extension of \nour oncology ecosystem and is a key area  of investment for us going forward.  We believe this business \ndifferentiates our value proposition to providers looking to drive better outcomes for their patients and to \nmanufacturers focused on innovative therapies in the area of oncology.  \n \n In terms of b iopharma services, in fiscal 2021, we brought together our RelayHealth Pharmacy, CoverMyMeds \nand RxCrossroads businesses.  Together, these businesses are focused on innovating and automating the ways \nin which biopharma connects with patients, pharmacies and  providers, with the ultimate goal of providing stronger \naccess, affordability and better adherence outcomes.  \n \n These assets embed us in the daily workflows of over 50,000 pharmacies and more than 750,000 providers. \n", "original_text": "We believe this business \ndifferentiates our value proposition to providers looking to drive better outcomes for their patients and to \nmanufacturers focused on innovative therapies in the area of oncology.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d2fc4bfec733754829d9c516240bbb7186ea6833ed05d25905ac35222ed561d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2148298-c93f-4575-81af-8b40668d478e", "node_type": "1", "metadata": {"window": "Our recently launched Technology and Real -World Insights business, which we call Ontada, is an extension of \nour oncology ecosystem and is a key area  of investment for us going forward.  We believe this business \ndifferentiates our value proposition to providers looking to drive better outcomes for their patients and to \nmanufacturers focused on innovative therapies in the area of oncology.  \n \n In terms of b iopharma services, in fiscal 2021, we brought together our RelayHealth Pharmacy, CoverMyMeds \nand RxCrossroads businesses.  Together, these businesses are focused on innovating and automating the ways \nin which biopharma connects with patients, pharmacies and  providers, with the ultimate goal of providing stronger \naccess, affordability and better adherence outcomes.  \n \n These assets embed us in the daily workflows of over 50,000 pharmacies and more than 750,000 providers. \n We're integrated into over 75% of EHRs to day.  And through our market leading position and advanced solutions, \nwe're able to automate and simplify otherwise very manual processes. ", "original_text": "Together, these businesses are focused on innovating and automating the ways \nin which biopharma connects with patients, pharmacies and  providers, with the ultimate goal of providing stronger \naccess, affordability and better adherence outcomes.  \n \n"}, "hash": "a740bdbde0386121ece8576848c9bb9ee91469bedc2332fb352d64e9a2e870e1", "class_name": "RelatedNodeInfo"}}, "text": "In terms of b iopharma services, in fiscal 2021, we brought together our RelayHealth Pharmacy, CoverMyMeds \nand RxCrossroads businesses. ", "start_char_idx": 957, "end_char_idx": 1094, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2148298-c93f-4575-81af-8b40668d478e": {"__data__": {"id_": "d2148298-c93f-4575-81af-8b40668d478e", "embedding": null, "metadata": {"window": "Our recently launched Technology and Real -World Insights business, which we call Ontada, is an extension of \nour oncology ecosystem and is a key area  of investment for us going forward.  We believe this business \ndifferentiates our value proposition to providers looking to drive better outcomes for their patients and to \nmanufacturers focused on innovative therapies in the area of oncology.  \n \n In terms of b iopharma services, in fiscal 2021, we brought together our RelayHealth Pharmacy, CoverMyMeds \nand RxCrossroads businesses.  Together, these businesses are focused on innovating and automating the ways \nin which biopharma connects with patients, pharmacies and  providers, with the ultimate goal of providing stronger \naccess, affordability and better adherence outcomes.  \n \n These assets embed us in the daily workflows of over 50,000 pharmacies and more than 750,000 providers. \n We're integrated into over 75% of EHRs to day.  And through our market leading position and advanced solutions, \nwe're able to automate and simplify otherwise very manual processes. ", "original_text": "Together, these businesses are focused on innovating and automating the ways \nin which biopharma connects with patients, pharmacies and  providers, with the ultimate goal of providing stronger \naccess, affordability and better adherence outcomes.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f207edc-0ead-4320-8205-fc7e356f115c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6275a184f8bd8d594cc6c801bece3e9238396da4193218af4303f942621d4686", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a29b869-9b77-459f-a4e1-f551ffbf7341", "node_type": "1", "metadata": {"window": "And our oncology technology platform  has supported millions of patient journeys, providing us access \nto real -world outcomes data and research.  \n \n Our recently launched Technology and Real -World Insights business, which we call Ontada, is an extension of \nour oncology ecosystem and is a key area  of investment for us going forward.  We believe this business \ndifferentiates our value proposition to providers looking to drive better outcomes for their patients and to \nmanufacturers focused on innovative therapies in the area of oncology.  \n \n In terms of b iopharma services, in fiscal 2021, we brought together our RelayHealth Pharmacy, CoverMyMeds \nand RxCrossroads businesses.  Together, these businesses are focused on innovating and automating the ways \nin which biopharma connects with patients, pharmacies and  providers, with the ultimate goal of providing stronger \naccess, affordability and better adherence outcomes.  \n \n These assets embed us in the daily workflows of over 50,000 pharmacies and more than 750,000 providers. \n We're integrated into over 75% of EHRs to day. ", "original_text": "In terms of b iopharma services, in fiscal 2021, we brought together our RelayHealth Pharmacy, CoverMyMeds \nand RxCrossroads businesses. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f476f41a25043347ee0c43ae9b98eea3bb7d5e3e7c38ee477a433f63a3f9130", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6af438a-f874-4ced-8c0c-957efc6054f1", "node_type": "1", "metadata": {"window": "We believe this business \ndifferentiates our value proposition to providers looking to drive better outcomes for their patients and to \nmanufacturers focused on innovative therapies in the area of oncology.  \n \n In terms of b iopharma services, in fiscal 2021, we brought together our RelayHealth Pharmacy, CoverMyMeds \nand RxCrossroads businesses.  Together, these businesses are focused on innovating and automating the ways \nin which biopharma connects with patients, pharmacies and  providers, with the ultimate goal of providing stronger \naccess, affordability and better adherence outcomes.  \n \n These assets embed us in the daily workflows of over 50,000 pharmacies and more than 750,000 providers. \n We're integrated into over 75% of EHRs to day.  And through our market leading position and advanced solutions, \nwe're able to automate and simplify otherwise very manual processes.  Ultimately, our solutions help patients get \non therapies quicker and stay on those therapies longer. ", "original_text": "These assets embed us in the daily workflows of over 50,000 pharmacies and more than 750,000 providers. \n"}, "hash": "02350b6e230d00a9623136e060edda44db5a1d328a04f4298c6f2de5446ce05e", "class_name": "RelatedNodeInfo"}}, "text": "Together, these businesses are focused on innovating and automating the ways \nin which biopharma connects with patients, pharmacies and  providers, with the ultimate goal of providing stronger \naccess, affordability and better adherence outcomes.  \n \n", "start_char_idx": 1094, "end_char_idx": 1345, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6af438a-f874-4ced-8c0c-957efc6054f1": {"__data__": {"id_": "e6af438a-f874-4ced-8c0c-957efc6054f1", "embedding": null, "metadata": {"window": "We believe this business \ndifferentiates our value proposition to providers looking to drive better outcomes for their patients and to \nmanufacturers focused on innovative therapies in the area of oncology.  \n \n In terms of b iopharma services, in fiscal 2021, we brought together our RelayHealth Pharmacy, CoverMyMeds \nand RxCrossroads businesses.  Together, these businesses are focused on innovating and automating the ways \nin which biopharma connects with patients, pharmacies and  providers, with the ultimate goal of providing stronger \naccess, affordability and better adherence outcomes.  \n \n These assets embed us in the daily workflows of over 50,000 pharmacies and more than 750,000 providers. \n We're integrated into over 75% of EHRs to day.  And through our market leading position and advanced solutions, \nwe're able to automate and simplify otherwise very manual processes.  Ultimately, our solutions help patients get \non therapies quicker and stay on those therapies longer. ", "original_text": "These assets embed us in the daily workflows of over 50,000 pharmacies and more than 750,000 providers. \n", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f207edc-0ead-4320-8205-fc7e356f115c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6275a184f8bd8d594cc6c801bece3e9238396da4193218af4303f942621d4686", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2148298-c93f-4575-81af-8b40668d478e", "node_type": "1", "metadata": {"window": "Our recently launched Technology and Real -World Insights business, which we call Ontada, is an extension of \nour oncology ecosystem and is a key area  of investment for us going forward.  We believe this business \ndifferentiates our value proposition to providers looking to drive better outcomes for their patients and to \nmanufacturers focused on innovative therapies in the area of oncology.  \n \n In terms of b iopharma services, in fiscal 2021, we brought together our RelayHealth Pharmacy, CoverMyMeds \nand RxCrossroads businesses.  Together, these businesses are focused on innovating and automating the ways \nin which biopharma connects with patients, pharmacies and  providers, with the ultimate goal of providing stronger \naccess, affordability and better adherence outcomes.  \n \n These assets embed us in the daily workflows of over 50,000 pharmacies and more than 750,000 providers. \n We're integrated into over 75% of EHRs to day.  And through our market leading position and advanced solutions, \nwe're able to automate and simplify otherwise very manual processes. ", "original_text": "Together, these businesses are focused on innovating and automating the ways \nin which biopharma connects with patients, pharmacies and  providers, with the ultimate goal of providing stronger \naccess, affordability and better adherence outcomes.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1a14a76009ef7da14b3d41a5b454733e5b5621497e57aead9e7ce2ae55f74f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "933db460-0c73-407a-87f4-ad7648a45493", "node_type": "1", "metadata": {"window": "In terms of b iopharma services, in fiscal 2021, we brought together our RelayHealth Pharmacy, CoverMyMeds \nand RxCrossroads businesses.  Together, these businesses are focused on innovating and automating the ways \nin which biopharma connects with patients, pharmacies and  providers, with the ultimate goal of providing stronger \naccess, affordability and better adherence outcomes.  \n \n These assets embed us in the daily workflows of over 50,000 pharmacies and more than 750,000 providers. \n We're integrated into over 75% of EHRs to day.  And through our market leading position and advanced solutions, \nwe're able to automate and simplify otherwise very manual processes.  Ultimately, our solutions help patients get \non therapies quicker and stay on those therapies longer.  This value propos ition to our manufacturing partners is \nreflected by the over 500 brands we support today, covering nearly every therapeutic area.  \n \n", "original_text": "We're integrated into over 75% of EHRs to day. "}, "hash": "607e8e1add2ac283dbeccdf264e87404aae0e9aa258d8405dc88856d9550190e", "class_name": "RelatedNodeInfo"}}, "text": "These assets embed us in the daily workflows of over 50,000 pharmacies and more than 750,000 providers. \n", "start_char_idx": 1345, "end_char_idx": 1450, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "933db460-0c73-407a-87f4-ad7648a45493": {"__data__": {"id_": "933db460-0c73-407a-87f4-ad7648a45493", "embedding": null, "metadata": {"window": "In terms of b iopharma services, in fiscal 2021, we brought together our RelayHealth Pharmacy, CoverMyMeds \nand RxCrossroads businesses.  Together, these businesses are focused on innovating and automating the ways \nin which biopharma connects with patients, pharmacies and  providers, with the ultimate goal of providing stronger \naccess, affordability and better adherence outcomes.  \n \n These assets embed us in the daily workflows of over 50,000 pharmacies and more than 750,000 providers. \n We're integrated into over 75% of EHRs to day.  And through our market leading position and advanced solutions, \nwe're able to automate and simplify otherwise very manual processes.  Ultimately, our solutions help patients get \non therapies quicker and stay on those therapies longer.  This value propos ition to our manufacturing partners is \nreflected by the over 500 brands we support today, covering nearly every therapeutic area.  \n \n", "original_text": "We're integrated into over 75% of EHRs to day. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f207edc-0ead-4320-8205-fc7e356f115c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6275a184f8bd8d594cc6c801bece3e9238396da4193218af4303f942621d4686", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6af438a-f874-4ced-8c0c-957efc6054f1", "node_type": "1", "metadata": {"window": "We believe this business \ndifferentiates our value proposition to providers looking to drive better outcomes for their patients and to \nmanufacturers focused on innovative therapies in the area of oncology.  \n \n In terms of b iopharma services, in fiscal 2021, we brought together our RelayHealth Pharmacy, CoverMyMeds \nand RxCrossroads businesses.  Together, these businesses are focused on innovating and automating the ways \nin which biopharma connects with patients, pharmacies and  providers, with the ultimate goal of providing stronger \naccess, affordability and better adherence outcomes.  \n \n These assets embed us in the daily workflows of over 50,000 pharmacies and more than 750,000 providers. \n We're integrated into over 75% of EHRs to day.  And through our market leading position and advanced solutions, \nwe're able to automate and simplify otherwise very manual processes.  Ultimately, our solutions help patients get \non therapies quicker and stay on those therapies longer. ", "original_text": "These assets embed us in the daily workflows of over 50,000 pharmacies and more than 750,000 providers. \n", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2655d8c4632e42ab52472c489ee0483783b6e8f0b7cfa00f3d50012cb1278a9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "172b3c75-2222-48fa-a6c7-9a9d3c98c49e", "node_type": "1", "metadata": {"window": "Together, these businesses are focused on innovating and automating the ways \nin which biopharma connects with patients, pharmacies and  providers, with the ultimate goal of providing stronger \naccess, affordability and better adherence outcomes.  \n \n These assets embed us in the daily workflows of over 50,000 pharmacies and more than 750,000 providers. \n We're integrated into over 75% of EHRs to day.  And through our market leading position and advanced solutions, \nwe're able to automate and simplify otherwise very manual processes.  Ultimately, our solutions help patients get \non therapies quicker and stay on those therapies longer.  This value propos ition to our manufacturing partners is \nreflected by the over 500 brands we support today, covering nearly every therapeutic area.  \n \n In fiscal 2022, we will remain focused on these growth areas, and we will continue to look for ways to streamline \nthe busines s, so that we can operate with added speed and increased focus. ", "original_text": "And through our market leading position and advanced solutions, \nwe're able to automate and simplify otherwise very manual processes. "}, "hash": "e517d93b04c7e97d17dd5409aa68567be0a909e6e1ea554371b8f8393efe6236", "class_name": "RelatedNodeInfo"}}, "text": "We're integrated into over 75% of EHRs to day. ", "start_char_idx": 1450, "end_char_idx": 1497, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "172b3c75-2222-48fa-a6c7-9a9d3c98c49e": {"__data__": {"id_": "172b3c75-2222-48fa-a6c7-9a9d3c98c49e", "embedding": null, "metadata": {"window": "Together, these businesses are focused on innovating and automating the ways \nin which biopharma connects with patients, pharmacies and  providers, with the ultimate goal of providing stronger \naccess, affordability and better adherence outcomes.  \n \n These assets embed us in the daily workflows of over 50,000 pharmacies and more than 750,000 providers. \n We're integrated into over 75% of EHRs to day.  And through our market leading position and advanced solutions, \nwe're able to automate and simplify otherwise very manual processes.  Ultimately, our solutions help patients get \non therapies quicker and stay on those therapies longer.  This value propos ition to our manufacturing partners is \nreflected by the over 500 brands we support today, covering nearly every therapeutic area.  \n \n In fiscal 2022, we will remain focused on these growth areas, and we will continue to look for ways to streamline \nthe busines s, so that we can operate with added speed and increased focus. ", "original_text": "And through our market leading position and advanced solutions, \nwe're able to automate and simplify otherwise very manual processes. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f207edc-0ead-4320-8205-fc7e356f115c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6275a184f8bd8d594cc6c801bece3e9238396da4193218af4303f942621d4686", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "933db460-0c73-407a-87f4-ad7648a45493", "node_type": "1", "metadata": {"window": "In terms of b iopharma services, in fiscal 2021, we brought together our RelayHealth Pharmacy, CoverMyMeds \nand RxCrossroads businesses.  Together, these businesses are focused on innovating and automating the ways \nin which biopharma connects with patients, pharmacies and  providers, with the ultimate goal of providing stronger \naccess, affordability and better adherence outcomes.  \n \n These assets embed us in the daily workflows of over 50,000 pharmacies and more than 750,000 providers. \n We're integrated into over 75% of EHRs to day.  And through our market leading position and advanced solutions, \nwe're able to automate and simplify otherwise very manual processes.  Ultimately, our solutions help patients get \non therapies quicker and stay on those therapies longer.  This value propos ition to our manufacturing partners is \nreflected by the over 500 brands we support today, covering nearly every therapeutic area.  \n \n", "original_text": "We're integrated into over 75% of EHRs to day. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e2818285a194276c5737cbc27e34202c7bb34c9ed212da45ed1af10135c6f556", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb96956c-8e65-4301-8ca4-8e01814e53bf", "node_type": "1", "metadata": {"window": "These assets embed us in the daily workflows of over 50,000 pharmacies and more than 750,000 providers. \n We're integrated into over 75% of EHRs to day.  And through our market leading position and advanced solutions, \nwe're able to automate and simplify otherwise very manual processes.  Ultimately, our solutions help patients get \non therapies quicker and stay on those therapies longer.  This value propos ition to our manufacturing partners is \nreflected by the over 500 brands we support today, covering nearly every therapeutic area.  \n \n In fiscal 2022, we will remain focused on these growth areas, and we will continue to look for ways to streamline \nthe busines s, so that we can operate with added speed and increased focus.  Part of our commitment to grow the \nbusiness is to continually review and evaluate our portfolio. ", "original_text": "Ultimately, our solutions help patients get \non therapies quicker and stay on those therapies longer. "}, "hash": "f4205fd1c3bf350b8585649d43a1395c8d580ee459ae3fd7d39525085fe07da0", "class_name": "RelatedNodeInfo"}}, "text": "And through our market leading position and advanced solutions, \nwe're able to automate and simplify otherwise very manual processes. ", "start_char_idx": 1497, "end_char_idx": 1631, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb96956c-8e65-4301-8ca4-8e01814e53bf": {"__data__": {"id_": "cb96956c-8e65-4301-8ca4-8e01814e53bf", "embedding": null, "metadata": {"window": "These assets embed us in the daily workflows of over 50,000 pharmacies and more than 750,000 providers. \n We're integrated into over 75% of EHRs to day.  And through our market leading position and advanced solutions, \nwe're able to automate and simplify otherwise very manual processes.  Ultimately, our solutions help patients get \non therapies quicker and stay on those therapies longer.  This value propos ition to our manufacturing partners is \nreflected by the over 500 brands we support today, covering nearly every therapeutic area.  \n \n In fiscal 2022, we will remain focused on these growth areas, and we will continue to look for ways to streamline \nthe busines s, so that we can operate with added speed and increased focus.  Part of our commitment to grow the \nbusiness is to continually review and evaluate our portfolio. ", "original_text": "Ultimately, our solutions help patients get \non therapies quicker and stay on those therapies longer. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f207edc-0ead-4320-8205-fc7e356f115c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6275a184f8bd8d594cc6c801bece3e9238396da4193218af4303f942621d4686", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "172b3c75-2222-48fa-a6c7-9a9d3c98c49e", "node_type": "1", "metadata": {"window": "Together, these businesses are focused on innovating and automating the ways \nin which biopharma connects with patients, pharmacies and  providers, with the ultimate goal of providing stronger \naccess, affordability and better adherence outcomes.  \n \n These assets embed us in the daily workflows of over 50,000 pharmacies and more than 750,000 providers. \n We're integrated into over 75% of EHRs to day.  And through our market leading position and advanced solutions, \nwe're able to automate and simplify otherwise very manual processes.  Ultimately, our solutions help patients get \non therapies quicker and stay on those therapies longer.  This value propos ition to our manufacturing partners is \nreflected by the over 500 brands we support today, covering nearly every therapeutic area.  \n \n In fiscal 2022, we will remain focused on these growth areas, and we will continue to look for ways to streamline \nthe busines s, so that we can operate with added speed and increased focus. ", "original_text": "And through our market leading position and advanced solutions, \nwe're able to automate and simplify otherwise very manual processes. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ed7d0ed702aad22e0f6d46e471a0fd6ea27fa28711c068b2502137581847c13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0a1ddad-7e29-49c0-aeca-6775517f930a", "node_type": "1", "metadata": {"window": "We're integrated into over 75% of EHRs to day.  And through our market leading position and advanced solutions, \nwe're able to automate and simplify otherwise very manual processes.  Ultimately, our solutions help patients get \non therapies quicker and stay on those therapies longer.  This value propos ition to our manufacturing partners is \nreflected by the over 500 brands we support today, covering nearly every therapeutic area.  \n \n In fiscal 2022, we will remain focused on these growth areas, and we will continue to look for ways to streamline \nthe busines s, so that we can operate with added speed and increased focus.  Part of our commitment to grow the \nbusiness is to continually review and evaluate our portfolio.  Sometimes we find assets we're not the natural owner \nof, as was the case with our German wholes ale business, where we created a JV with Walgreens Boots Alliance \nin November.  \n \n", "original_text": "This value propos ition to our manufacturing partners is \nreflected by the over 500 brands we support today, covering nearly every therapeutic area.  \n \n"}, "hash": "f04318bdc8777ec56b2cb5de472d606fe5a5888794fd3ea582cd6f0a73efb1f3", "class_name": "RelatedNodeInfo"}}, "text": "Ultimately, our solutions help patients get \non therapies quicker and stay on those therapies longer. ", "start_char_idx": 1631, "end_char_idx": 1733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0a1ddad-7e29-49c0-aeca-6775517f930a": {"__data__": {"id_": "b0a1ddad-7e29-49c0-aeca-6775517f930a", "embedding": null, "metadata": {"window": "We're integrated into over 75% of EHRs to day.  And through our market leading position and advanced solutions, \nwe're able to automate and simplify otherwise very manual processes.  Ultimately, our solutions help patients get \non therapies quicker and stay on those therapies longer.  This value propos ition to our manufacturing partners is \nreflected by the over 500 brands we support today, covering nearly every therapeutic area.  \n \n In fiscal 2022, we will remain focused on these growth areas, and we will continue to look for ways to streamline \nthe busines s, so that we can operate with added speed and increased focus.  Part of our commitment to grow the \nbusiness is to continually review and evaluate our portfolio.  Sometimes we find assets we're not the natural owner \nof, as was the case with our German wholes ale business, where we created a JV with Walgreens Boots Alliance \nin November.  \n \n", "original_text": "This value propos ition to our manufacturing partners is \nreflected by the over 500 brands we support today, covering nearly every therapeutic area.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f207edc-0ead-4320-8205-fc7e356f115c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6275a184f8bd8d594cc6c801bece3e9238396da4193218af4303f942621d4686", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb96956c-8e65-4301-8ca4-8e01814e53bf", "node_type": "1", "metadata": {"window": "These assets embed us in the daily workflows of over 50,000 pharmacies and more than 750,000 providers. \n We're integrated into over 75% of EHRs to day.  And through our market leading position and advanced solutions, \nwe're able to automate and simplify otherwise very manual processes.  Ultimately, our solutions help patients get \non therapies quicker and stay on those therapies longer.  This value propos ition to our manufacturing partners is \nreflected by the over 500 brands we support today, covering nearly every therapeutic area.  \n \n In fiscal 2022, we will remain focused on these growth areas, and we will continue to look for ways to streamline \nthe busines s, so that we can operate with added speed and increased focus.  Part of our commitment to grow the \nbusiness is to continually review and evaluate our portfolio. ", "original_text": "Ultimately, our solutions help patients get \non therapies quicker and stay on those therapies longer. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f3d87dbd51dd08bdede1f0b57bf90708a080bd3a5be9a85507568ce96a487a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c81575c-6bcc-4aef-9a0c-3650b26fcaa2", "node_type": "1", "metadata": {"window": "And through our market leading position and advanced solutions, \nwe're able to automate and simplify otherwise very manual processes.  Ultimately, our solutions help patients get \non therapies quicker and stay on those therapies longer.  This value propos ition to our manufacturing partners is \nreflected by the over 500 brands we support today, covering nearly every therapeutic area.  \n \n In fiscal 2022, we will remain focused on these growth areas, and we will continue to look for ways to streamline \nthe busines s, so that we can operate with added speed and increased focus.  Part of our commitment to grow the \nbusiness is to continually review and evaluate our portfolio.  Sometimes we find assets we're not the natural owner \nof, as was the case with our German wholes ale business, where we created a JV with Walgreens Boots Alliance \nin November.  \n \n To further simplify the business, we continually evaluate and adapt the way in which we work. ", "original_text": "In fiscal 2022, we will remain focused on these growth areas, and we will continue to look for ways to streamline \nthe busines s, so that we can operate with added speed and increased focus. "}, "hash": "ccdb0a50154582cb3d1bcbdab44cd72958fc57327aa4c18557cdb61aed737478", "class_name": "RelatedNodeInfo"}}, "text": "This value propos ition to our manufacturing partners is \nreflected by the over 500 brands we support today, covering nearly every therapeutic area.  \n \n", "start_char_idx": 1733, "end_char_idx": 1886, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c81575c-6bcc-4aef-9a0c-3650b26fcaa2": {"__data__": {"id_": "2c81575c-6bcc-4aef-9a0c-3650b26fcaa2", "embedding": null, "metadata": {"window": "And through our market leading position and advanced solutions, \nwe're able to automate and simplify otherwise very manual processes.  Ultimately, our solutions help patients get \non therapies quicker and stay on those therapies longer.  This value propos ition to our manufacturing partners is \nreflected by the over 500 brands we support today, covering nearly every therapeutic area.  \n \n In fiscal 2022, we will remain focused on these growth areas, and we will continue to look for ways to streamline \nthe busines s, so that we can operate with added speed and increased focus.  Part of our commitment to grow the \nbusiness is to continually review and evaluate our portfolio.  Sometimes we find assets we're not the natural owner \nof, as was the case with our German wholes ale business, where we created a JV with Walgreens Boots Alliance \nin November.  \n \n To further simplify the business, we continually evaluate and adapt the way in which we work. ", "original_text": "In fiscal 2022, we will remain focused on these growth areas, and we will continue to look for ways to streamline \nthe busines s, so that we can operate with added speed and increased focus. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f207edc-0ead-4320-8205-fc7e356f115c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6275a184f8bd8d594cc6c801bece3e9238396da4193218af4303f942621d4686", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0a1ddad-7e29-49c0-aeca-6775517f930a", "node_type": "1", "metadata": {"window": "We're integrated into over 75% of EHRs to day.  And through our market leading position and advanced solutions, \nwe're able to automate and simplify otherwise very manual processes.  Ultimately, our solutions help patients get \non therapies quicker and stay on those therapies longer.  This value propos ition to our manufacturing partners is \nreflected by the over 500 brands we support today, covering nearly every therapeutic area.  \n \n In fiscal 2022, we will remain focused on these growth areas, and we will continue to look for ways to streamline \nthe busines s, so that we can operate with added speed and increased focus.  Part of our commitment to grow the \nbusiness is to continually review and evaluate our portfolio.  Sometimes we find assets we're not the natural owner \nof, as was the case with our German wholes ale business, where we created a JV with Walgreens Boots Alliance \nin November.  \n \n", "original_text": "This value propos ition to our manufacturing partners is \nreflected by the over 500 brands we support today, covering nearly every therapeutic area.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f1d3878d3946d2cf2ed25bbf831be95b3325c3bd027ce3a754b225b53f76c0a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23a3875d-f6bd-4349-b095-316595e63b22", "node_type": "1", "metadata": {"window": "Ultimately, our solutions help patients get \non therapies quicker and stay on those therapies longer.  This value propos ition to our manufacturing partners is \nreflected by the over 500 brands we support today, covering nearly every therapeutic area.  \n \n In fiscal 2022, we will remain focused on these growth areas, and we will continue to look for ways to streamline \nthe busines s, so that we can operate with added speed and increased focus.  Part of our commitment to grow the \nbusiness is to continually review and evaluate our portfolio.  Sometimes we find assets we're not the natural owner \nof, as was the case with our German wholes ale business, where we created a JV with Walgreens Boots Alliance \nin November.  \n \n To further simplify the business, we continually evaluate and adapt the way in which we work.  For McKesson, it's \nbeen over a year since we successfully transitioned all of our office -based employees to work -from-home \nseemingly overnight and without a loss of productivity. ", "original_text": "Part of our commitment to grow the \nbusiness is to continually review and evaluate our portfolio. "}, "hash": "8b8f677a118bc53be96db7bdc1e8f323f1360fd65ec26d07aa23221e41fe850b", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal 2022, we will remain focused on these growth areas, and we will continue to look for ways to streamline \nthe busines s, so that we can operate with added speed and increased focus. ", "start_char_idx": 1886, "end_char_idx": 2077, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23a3875d-f6bd-4349-b095-316595e63b22": {"__data__": {"id_": "23a3875d-f6bd-4349-b095-316595e63b22", "embedding": null, "metadata": {"window": "Ultimately, our solutions help patients get \non therapies quicker and stay on those therapies longer.  This value propos ition to our manufacturing partners is \nreflected by the over 500 brands we support today, covering nearly every therapeutic area.  \n \n In fiscal 2022, we will remain focused on these growth areas, and we will continue to look for ways to streamline \nthe busines s, so that we can operate with added speed and increased focus.  Part of our commitment to grow the \nbusiness is to continually review and evaluate our portfolio.  Sometimes we find assets we're not the natural owner \nof, as was the case with our German wholes ale business, where we created a JV with Walgreens Boots Alliance \nin November.  \n \n To further simplify the business, we continually evaluate and adapt the way in which we work.  For McKesson, it's \nbeen over a year since we successfully transitioned all of our office -based employees to work -from-home \nseemingly overnight and without a loss of productivity. ", "original_text": "Part of our commitment to grow the \nbusiness is to continually review and evaluate our portfolio. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f207edc-0ead-4320-8205-fc7e356f115c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6275a184f8bd8d594cc6c801bece3e9238396da4193218af4303f942621d4686", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c81575c-6bcc-4aef-9a0c-3650b26fcaa2", "node_type": "1", "metadata": {"window": "And through our market leading position and advanced solutions, \nwe're able to automate and simplify otherwise very manual processes.  Ultimately, our solutions help patients get \non therapies quicker and stay on those therapies longer.  This value propos ition to our manufacturing partners is \nreflected by the over 500 brands we support today, covering nearly every therapeutic area.  \n \n In fiscal 2022, we will remain focused on these growth areas, and we will continue to look for ways to streamline \nthe busines s, so that we can operate with added speed and increased focus.  Part of our commitment to grow the \nbusiness is to continually review and evaluate our portfolio.  Sometimes we find assets we're not the natural owner \nof, as was the case with our German wholes ale business, where we created a JV with Walgreens Boots Alliance \nin November.  \n \n To further simplify the business, we continually evaluate and adapt the way in which we work. ", "original_text": "In fiscal 2022, we will remain focused on these growth areas, and we will continue to look for ways to streamline \nthe busines s, so that we can operate with added speed and increased focus. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af8b9207821e074579215a51c81c2dfef4d5867395053906aafd2f5402a76748", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b580200-92df-4022-8bec-5e6f710fb092", "node_type": "1", "metadata": {"window": "This value propos ition to our manufacturing partners is \nreflected by the over 500 brands we support today, covering nearly every therapeutic area.  \n \n In fiscal 2022, we will remain focused on these growth areas, and we will continue to look for ways to streamline \nthe busines s, so that we can operate with added speed and increased focus.  Part of our commitment to grow the \nbusiness is to continually review and evaluate our portfolio.  Sometimes we find assets we're not the natural owner \nof, as was the case with our German wholes ale business, where we created a JV with Walgreens Boots Alliance \nin November.  \n \n To further simplify the business, we continually evaluate and adapt the way in which we work.  For McKesson, it's \nbeen over a year since we successfully transitioned all of our office -based employees to work -from-home \nseemingly overnight and without a loss of productivity.  While we are quite anxious to see each other in person \nsoon and at a time and place where it's appropriate and safe to do so, the success of our employees in t his \nremote work environment and their desire for more work flexibility has challenged us to reevaluate the way we \nwork and our real estate and existing office space footprint. ", "original_text": "Sometimes we find assets we're not the natural owner \nof, as was the case with our German wholes ale business, where we created a JV with Walgreens Boots Alliance \nin November.  \n \n"}, "hash": "0148aa2e0a2244ef824bee7887492ffdf731be92e98b11d0ec4a9131d824d79e", "class_name": "RelatedNodeInfo"}}, "text": "Part of our commitment to grow the \nbusiness is to continually review and evaluate our portfolio. ", "start_char_idx": 2077, "end_char_idx": 2175, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b580200-92df-4022-8bec-5e6f710fb092": {"__data__": {"id_": "3b580200-92df-4022-8bec-5e6f710fb092", "embedding": null, "metadata": {"window": "This value propos ition to our manufacturing partners is \nreflected by the over 500 brands we support today, covering nearly every therapeutic area.  \n \n In fiscal 2022, we will remain focused on these growth areas, and we will continue to look for ways to streamline \nthe busines s, so that we can operate with added speed and increased focus.  Part of our commitment to grow the \nbusiness is to continually review and evaluate our portfolio.  Sometimes we find assets we're not the natural owner \nof, as was the case with our German wholes ale business, where we created a JV with Walgreens Boots Alliance \nin November.  \n \n To further simplify the business, we continually evaluate and adapt the way in which we work.  For McKesson, it's \nbeen over a year since we successfully transitioned all of our office -based employees to work -from-home \nseemingly overnight and without a loss of productivity.  While we are quite anxious to see each other in person \nsoon and at a time and place where it's appropriate and safe to do so, the success of our employees in t his \nremote work environment and their desire for more work flexibility has challenged us to reevaluate the way we \nwork and our real estate and existing office space footprint. ", "original_text": "Sometimes we find assets we're not the natural owner \nof, as was the case with our German wholes ale business, where we created a JV with Walgreens Boots Alliance \nin November.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f207edc-0ead-4320-8205-fc7e356f115c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6275a184f8bd8d594cc6c801bece3e9238396da4193218af4303f942621d4686", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23a3875d-f6bd-4349-b095-316595e63b22", "node_type": "1", "metadata": {"window": "Ultimately, our solutions help patients get \non therapies quicker and stay on those therapies longer.  This value propos ition to our manufacturing partners is \nreflected by the over 500 brands we support today, covering nearly every therapeutic area.  \n \n In fiscal 2022, we will remain focused on these growth areas, and we will continue to look for ways to streamline \nthe busines s, so that we can operate with added speed and increased focus.  Part of our commitment to grow the \nbusiness is to continually review and evaluate our portfolio.  Sometimes we find assets we're not the natural owner \nof, as was the case with our German wholes ale business, where we created a JV with Walgreens Boots Alliance \nin November.  \n \n To further simplify the business, we continually evaluate and adapt the way in which we work.  For McKesson, it's \nbeen over a year since we successfully transitioned all of our office -based employees to work -from-home \nseemingly overnight and without a loss of productivity. ", "original_text": "Part of our commitment to grow the \nbusiness is to continually review and evaluate our portfolio. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbcc4833451dba7856f5952d57f18af8e960ca6138f0a46ff7ff9214d1b4524d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a015e5e-e0bf-4b58-a374-d85ca57bd404", "node_type": "1", "metadata": {"window": "In fiscal 2022, we will remain focused on these growth areas, and we will continue to look for ways to streamline \nthe busines s, so that we can operate with added speed and increased focus.  Part of our commitment to grow the \nbusiness is to continually review and evaluate our portfolio.  Sometimes we find assets we're not the natural owner \nof, as was the case with our German wholes ale business, where we created a JV with Walgreens Boots Alliance \nin November.  \n \n To further simplify the business, we continually evaluate and adapt the way in which we work.  For McKesson, it's \nbeen over a year since we successfully transitioned all of our office -based employees to work -from-home \nseemingly overnight and without a loss of productivity.  While we are quite anxious to see each other in person \nsoon and at a time and place where it's appropriate and safe to do so, the success of our employees in t his \nremote work environment and their desire for more work flexibility has challenged us to reevaluate the way we \nwork and our real estate and existing office space footprint.  This is yet another example of how we're looking to \nsimplify operations and grow  the business and do the right thing for our teams. ", "original_text": "To further simplify the business, we continually evaluate and adapt the way in which we work. "}, "hash": "7d955b725f581788418a13c3dca0d9822dc779ee50dda498858145f1badce0ad", "class_name": "RelatedNodeInfo"}}, "text": "Sometimes we find assets we're not the natural owner \nof, as was the case with our German wholes ale business, where we created a JV with Walgreens Boots Alliance \nin November.  \n \n", "start_char_idx": 2175, "end_char_idx": 2356, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a015e5e-e0bf-4b58-a374-d85ca57bd404": {"__data__": {"id_": "8a015e5e-e0bf-4b58-a374-d85ca57bd404", "embedding": null, "metadata": {"window": "In fiscal 2022, we will remain focused on these growth areas, and we will continue to look for ways to streamline \nthe busines s, so that we can operate with added speed and increased focus.  Part of our commitment to grow the \nbusiness is to continually review and evaluate our portfolio.  Sometimes we find assets we're not the natural owner \nof, as was the case with our German wholes ale business, where we created a JV with Walgreens Boots Alliance \nin November.  \n \n To further simplify the business, we continually evaluate and adapt the way in which we work.  For McKesson, it's \nbeen over a year since we successfully transitioned all of our office -based employees to work -from-home \nseemingly overnight and without a loss of productivity.  While we are quite anxious to see each other in person \nsoon and at a time and place where it's appropriate and safe to do so, the success of our employees in t his \nremote work environment and their desire for more work flexibility has challenged us to reevaluate the way we \nwork and our real estate and existing office space footprint.  This is yet another example of how we're looking to \nsimplify operations and grow  the business and do the right thing for our teams. ", "original_text": "To further simplify the business, we continually evaluate and adapt the way in which we work. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f207edc-0ead-4320-8205-fc7e356f115c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6275a184f8bd8d594cc6c801bece3e9238396da4193218af4303f942621d4686", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b580200-92df-4022-8bec-5e6f710fb092", "node_type": "1", "metadata": {"window": "This value propos ition to our manufacturing partners is \nreflected by the over 500 brands we support today, covering nearly every therapeutic area.  \n \n In fiscal 2022, we will remain focused on these growth areas, and we will continue to look for ways to streamline \nthe busines s, so that we can operate with added speed and increased focus.  Part of our commitment to grow the \nbusiness is to continually review and evaluate our portfolio.  Sometimes we find assets we're not the natural owner \nof, as was the case with our German wholes ale business, where we created a JV with Walgreens Boots Alliance \nin November.  \n \n To further simplify the business, we continually evaluate and adapt the way in which we work.  For McKesson, it's \nbeen over a year since we successfully transitioned all of our office -based employees to work -from-home \nseemingly overnight and without a loss of productivity.  While we are quite anxious to see each other in person \nsoon and at a time and place where it's appropriate and safe to do so, the success of our employees in t his \nremote work environment and their desire for more work flexibility has challenged us to reevaluate the way we \nwork and our real estate and existing office space footprint. ", "original_text": "Sometimes we find assets we're not the natural owner \nof, as was the case with our German wholes ale business, where we created a JV with Walgreens Boots Alliance \nin November.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e86d185f0d3c4f9fd5e5e8ad8807c5227e64cc99bff2fa33d21a183dd80f0f96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e06b3e9-85cd-42ea-a3aa-1397f44d10a8", "node_type": "1", "metadata": {"window": "Part of our commitment to grow the \nbusiness is to continually review and evaluate our portfolio.  Sometimes we find assets we're not the natural owner \nof, as was the case with our German wholes ale business, where we created a JV with Walgreens Boots Alliance \nin November.  \n \n To further simplify the business, we continually evaluate and adapt the way in which we work.  For McKesson, it's \nbeen over a year since we successfully transitioned all of our office -based employees to work -from-home \nseemingly overnight and without a loss of productivity.  While we are quite anxious to see each other in person \nsoon and at a time and place where it's appropriate and safe to do so, the success of our employees in t his \nremote work environment and their desire for more work flexibility has challenged us to reevaluate the way we \nwork and our real estate and existing office space footprint.  This is yet another example of how we're looking to \nsimplify operations and grow  the business and do the right thing for our teams.  Britt will go into more detail about \nour thinking on these impacts going forward.  \n \n", "original_text": "For McKesson, it's \nbeen over a year since we successfully transitioned all of our office -based employees to work -from-home \nseemingly overnight and without a loss of productivity. "}, "hash": "fbcf5e54fc0095907a18ce6952e73c55094405af6a5cb1411dd2f7dac780943e", "class_name": "RelatedNodeInfo"}}, "text": "To further simplify the business, we continually evaluate and adapt the way in which we work. ", "start_char_idx": 2356, "end_char_idx": 2450, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e06b3e9-85cd-42ea-a3aa-1397f44d10a8": {"__data__": {"id_": "3e06b3e9-85cd-42ea-a3aa-1397f44d10a8", "embedding": null, "metadata": {"window": "Part of our commitment to grow the \nbusiness is to continually review and evaluate our portfolio.  Sometimes we find assets we're not the natural owner \nof, as was the case with our German wholes ale business, where we created a JV with Walgreens Boots Alliance \nin November.  \n \n To further simplify the business, we continually evaluate and adapt the way in which we work.  For McKesson, it's \nbeen over a year since we successfully transitioned all of our office -based employees to work -from-home \nseemingly overnight and without a loss of productivity.  While we are quite anxious to see each other in person \nsoon and at a time and place where it's appropriate and safe to do so, the success of our employees in t his \nremote work environment and their desire for more work flexibility has challenged us to reevaluate the way we \nwork and our real estate and existing office space footprint.  This is yet another example of how we're looking to \nsimplify operations and grow  the business and do the right thing for our teams.  Britt will go into more detail about \nour thinking on these impacts going forward.  \n \n", "original_text": "For McKesson, it's \nbeen over a year since we successfully transitioned all of our office -based employees to work -from-home \nseemingly overnight and without a loss of productivity. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f207edc-0ead-4320-8205-fc7e356f115c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6275a184f8bd8d594cc6c801bece3e9238396da4193218af4303f942621d4686", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a015e5e-e0bf-4b58-a374-d85ca57bd404", "node_type": "1", "metadata": {"window": "In fiscal 2022, we will remain focused on these growth areas, and we will continue to look for ways to streamline \nthe busines s, so that we can operate with added speed and increased focus.  Part of our commitment to grow the \nbusiness is to continually review and evaluate our portfolio.  Sometimes we find assets we're not the natural owner \nof, as was the case with our German wholes ale business, where we created a JV with Walgreens Boots Alliance \nin November.  \n \n To further simplify the business, we continually evaluate and adapt the way in which we work.  For McKesson, it's \nbeen over a year since we successfully transitioned all of our office -based employees to work -from-home \nseemingly overnight and without a loss of productivity.  While we are quite anxious to see each other in person \nsoon and at a time and place where it's appropriate and safe to do so, the success of our employees in t his \nremote work environment and their desire for more work flexibility has challenged us to reevaluate the way we \nwork and our real estate and existing office space footprint.  This is yet another example of how we're looking to \nsimplify operations and grow  the business and do the right thing for our teams. ", "original_text": "To further simplify the business, we continually evaluate and adapt the way in which we work. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6079c654bd9090007a0b669642b8731138b962012ff71393ae0db57d7efd9fa4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30814fcf-6a7c-48c3-86fc-fe072d78b1af", "node_type": "1", "metadata": {"window": "Sometimes we find assets we're not the natural owner \nof, as was the case with our German wholes ale business, where we created a JV with Walgreens Boots Alliance \nin November.  \n \n To further simplify the business, we continually evaluate and adapt the way in which we work.  For McKesson, it's \nbeen over a year since we successfully transitioned all of our office -based employees to work -from-home \nseemingly overnight and without a loss of productivity.  While we are quite anxious to see each other in person \nsoon and at a time and place where it's appropriate and safe to do so, the success of our employees in t his \nremote work environment and their desire for more work flexibility has challenged us to reevaluate the way we \nwork and our real estate and existing office space footprint.  This is yet another example of how we're looking to \nsimplify operations and grow  the business and do the right thing for our teams.  Britt will go into more detail about \nour thinking on these impacts going forward.  \n \n Now, let me turn to the business and touch on how we're positioned for success heading into fiscal 2022. ", "original_text": "While we are quite anxious to see each other in person \nsoon and at a time and place where it's appropriate and safe to do so, the success of our employees in t his \nremote work environment and their desire for more work flexibility has challenged us to reevaluate the way we \nwork and our real estate and existing office space footprint. "}, "hash": "33b4c763934a4ce1f8c8153d818796beca17fdae8f048123f77fade494322495", "class_name": "RelatedNodeInfo"}}, "text": "For McKesson, it's \nbeen over a year since we successfully transitioned all of our office -based employees to work -from-home \nseemingly overnight and without a loss of productivity. ", "start_char_idx": 2450, "end_char_idx": 2633, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30814fcf-6a7c-48c3-86fc-fe072d78b1af": {"__data__": {"id_": "30814fcf-6a7c-48c3-86fc-fe072d78b1af", "embedding": null, "metadata": {"window": "Sometimes we find assets we're not the natural owner \nof, as was the case with our German wholes ale business, where we created a JV with Walgreens Boots Alliance \nin November.  \n \n To further simplify the business, we continually evaluate and adapt the way in which we work.  For McKesson, it's \nbeen over a year since we successfully transitioned all of our office -based employees to work -from-home \nseemingly overnight and without a loss of productivity.  While we are quite anxious to see each other in person \nsoon and at a time and place where it's appropriate and safe to do so, the success of our employees in t his \nremote work environment and their desire for more work flexibility has challenged us to reevaluate the way we \nwork and our real estate and existing office space footprint.  This is yet another example of how we're looking to \nsimplify operations and grow  the business and do the right thing for our teams.  Britt will go into more detail about \nour thinking on these impacts going forward.  \n \n Now, let me turn to the business and touch on how we're positioned for success heading into fiscal 2022. ", "original_text": "While we are quite anxious to see each other in person \nsoon and at a time and place where it's appropriate and safe to do so, the success of our employees in t his \nremote work environment and their desire for more work flexibility has challenged us to reevaluate the way we \nwork and our real estate and existing office space footprint. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f207edc-0ead-4320-8205-fc7e356f115c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6275a184f8bd8d594cc6c801bece3e9238396da4193218af4303f942621d4686", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e06b3e9-85cd-42ea-a3aa-1397f44d10a8", "node_type": "1", "metadata": {"window": "Part of our commitment to grow the \nbusiness is to continually review and evaluate our portfolio.  Sometimes we find assets we're not the natural owner \nof, as was the case with our German wholes ale business, where we created a JV with Walgreens Boots Alliance \nin November.  \n \n To further simplify the business, we continually evaluate and adapt the way in which we work.  For McKesson, it's \nbeen over a year since we successfully transitioned all of our office -based employees to work -from-home \nseemingly overnight and without a loss of productivity.  While we are quite anxious to see each other in person \nsoon and at a time and place where it's appropriate and safe to do so, the success of our employees in t his \nremote work environment and their desire for more work flexibility has challenged us to reevaluate the way we \nwork and our real estate and existing office space footprint.  This is yet another example of how we're looking to \nsimplify operations and grow  the business and do the right thing for our teams.  Britt will go into more detail about \nour thinking on these impacts going forward.  \n \n", "original_text": "For McKesson, it's \nbeen over a year since we successfully transitioned all of our office -based employees to work -from-home \nseemingly overnight and without a loss of productivity. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc367c0c8fd06d524f47ebd24b9d8fcd5a2faf9d9452b4aa84e0939c12345f7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63c96bce-fc94-4ef1-a189-9660b642787e", "node_type": "1", "metadata": {"window": "To further simplify the business, we continually evaluate and adapt the way in which we work.  For McKesson, it's \nbeen over a year since we successfully transitioned all of our office -based employees to work -from-home \nseemingly overnight and without a loss of productivity.  While we are quite anxious to see each other in person \nsoon and at a time and place where it's appropriate and safe to do so, the success of our employees in t his \nremote work environment and their desire for more work flexibility has challenged us to reevaluate the way we \nwork and our real estate and existing office space footprint.  This is yet another example of how we're looking to \nsimplify operations and grow  the business and do the right thing for our teams.  Britt will go into more detail about \nour thinking on these impacts going forward.  \n \n Now, let me turn to the business and touch on how we're positioned for success heading into fiscal 2022.  I'll start \nwith US Pharmaceutical, where we again grew adjusted operating profit despite soft prescription volume trends \nthroughout the fiscal year. ", "original_text": "This is yet another example of how we're looking to \nsimplify operations and grow  the business and do the right thing for our teams. "}, "hash": "ff7d0b36704a3ac78f0d490e0027ee93f2f31730360a63621e7ce95682324210", "class_name": "RelatedNodeInfo"}}, "text": "While we are quite anxious to see each other in person \nsoon and at a time and place where it's appropriate and safe to do so, the success of our employees in t his \nremote work environment and their desire for more work flexibility has challenged us to reevaluate the way we \nwork and our real estate and existing office space footprint. ", "start_char_idx": 2633, "end_char_idx": 2972, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63c96bce-fc94-4ef1-a189-9660b642787e": {"__data__": {"id_": "63c96bce-fc94-4ef1-a189-9660b642787e", "embedding": null, "metadata": {"window": "To further simplify the business, we continually evaluate and adapt the way in which we work.  For McKesson, it's \nbeen over a year since we successfully transitioned all of our office -based employees to work -from-home \nseemingly overnight and without a loss of productivity.  While we are quite anxious to see each other in person \nsoon and at a time and place where it's appropriate and safe to do so, the success of our employees in t his \nremote work environment and their desire for more work flexibility has challenged us to reevaluate the way we \nwork and our real estate and existing office space footprint.  This is yet another example of how we're looking to \nsimplify operations and grow  the business and do the right thing for our teams.  Britt will go into more detail about \nour thinking on these impacts going forward.  \n \n Now, let me turn to the business and touch on how we're positioned for success heading into fiscal 2022.  I'll start \nwith US Pharmaceutical, where we again grew adjusted operating profit despite soft prescription volume trends \nthroughout the fiscal year. ", "original_text": "This is yet another example of how we're looking to \nsimplify operations and grow  the business and do the right thing for our teams. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f207edc-0ead-4320-8205-fc7e356f115c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6275a184f8bd8d594cc6c801bece3e9238396da4193218af4303f942621d4686", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30814fcf-6a7c-48c3-86fc-fe072d78b1af", "node_type": "1", "metadata": {"window": "Sometimes we find assets we're not the natural owner \nof, as was the case with our German wholes ale business, where we created a JV with Walgreens Boots Alliance \nin November.  \n \n To further simplify the business, we continually evaluate and adapt the way in which we work.  For McKesson, it's \nbeen over a year since we successfully transitioned all of our office -based employees to work -from-home \nseemingly overnight and without a loss of productivity.  While we are quite anxious to see each other in person \nsoon and at a time and place where it's appropriate and safe to do so, the success of our employees in t his \nremote work environment and their desire for more work flexibility has challenged us to reevaluate the way we \nwork and our real estate and existing office space footprint.  This is yet another example of how we're looking to \nsimplify operations and grow  the business and do the right thing for our teams.  Britt will go into more detail about \nour thinking on these impacts going forward.  \n \n Now, let me turn to the business and touch on how we're positioned for success heading into fiscal 2022. ", "original_text": "While we are quite anxious to see each other in person \nsoon and at a time and place where it's appropriate and safe to do so, the success of our employees in t his \nremote work environment and their desire for more work flexibility has challenged us to reevaluate the way we \nwork and our real estate and existing office space footprint. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a9451023f8cb92ecf6452cd2335d069a51a7fcf2ad053fe7ffa516aea476fc95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38f0282c-42f4-460f-bffd-25bc6befdfe7", "node_type": "1", "metadata": {"window": "For McKesson, it's \nbeen over a year since we successfully transitioned all of our office -based employees to work -from-home \nseemingly overnight and without a loss of productivity.  While we are quite anxious to see each other in person \nsoon and at a time and place where it's appropriate and safe to do so, the success of our employees in t his \nremote work environment and their desire for more work flexibility has challenged us to reevaluate the way we \nwork and our real estate and existing office space footprint.  This is yet another example of how we're looking to \nsimplify operations and grow  the business and do the right thing for our teams.  Britt will go into more detail about \nour thinking on these impacts going forward.  \n \n Now, let me turn to the business and touch on how we're positioned for success heading into fiscal 2022.  I'll start \nwith US Pharmaceutical, where we again grew adjusted operating profit despite soft prescription volume trends \nthroughout the fiscal year.  Our priority in this business is to strengthen the core and deliver the world's highest -\nquality supply chain to our custome rs and manufacturing partners. ", "original_text": "Britt will go into more detail about \nour thinking on these impacts going forward.  \n \n"}, "hash": "e842448653b641803fcab5f0975e6a5bb18a9eda87e435d5472c68654d681c6a", "class_name": "RelatedNodeInfo"}}, "text": "This is yet another example of how we're looking to \nsimplify operations and grow  the business and do the right thing for our teams. ", "start_char_idx": 2972, "end_char_idx": 3106, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38f0282c-42f4-460f-bffd-25bc6befdfe7": {"__data__": {"id_": "38f0282c-42f4-460f-bffd-25bc6befdfe7", "embedding": null, "metadata": {"window": "For McKesson, it's \nbeen over a year since we successfully transitioned all of our office -based employees to work -from-home \nseemingly overnight and without a loss of productivity.  While we are quite anxious to see each other in person \nsoon and at a time and place where it's appropriate and safe to do so, the success of our employees in t his \nremote work environment and their desire for more work flexibility has challenged us to reevaluate the way we \nwork and our real estate and existing office space footprint.  This is yet another example of how we're looking to \nsimplify operations and grow  the business and do the right thing for our teams.  Britt will go into more detail about \nour thinking on these impacts going forward.  \n \n Now, let me turn to the business and touch on how we're positioned for success heading into fiscal 2022.  I'll start \nwith US Pharmaceutical, where we again grew adjusted operating profit despite soft prescription volume trends \nthroughout the fiscal year.  Our priority in this business is to strengthen the core and deliver the world's highest -\nquality supply chain to our custome rs and manufacturing partners. ", "original_text": "Britt will go into more detail about \nour thinking on these impacts going forward.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f207edc-0ead-4320-8205-fc7e356f115c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6275a184f8bd8d594cc6c801bece3e9238396da4193218af4303f942621d4686", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63c96bce-fc94-4ef1-a189-9660b642787e", "node_type": "1", "metadata": {"window": "To further simplify the business, we continually evaluate and adapt the way in which we work.  For McKesson, it's \nbeen over a year since we successfully transitioned all of our office -based employees to work -from-home \nseemingly overnight and without a loss of productivity.  While we are quite anxious to see each other in person \nsoon and at a time and place where it's appropriate and safe to do so, the success of our employees in t his \nremote work environment and their desire for more work flexibility has challenged us to reevaluate the way we \nwork and our real estate and existing office space footprint.  This is yet another example of how we're looking to \nsimplify operations and grow  the business and do the right thing for our teams.  Britt will go into more detail about \nour thinking on these impacts going forward.  \n \n Now, let me turn to the business and touch on how we're positioned for success heading into fiscal 2022.  I'll start \nwith US Pharmaceutical, where we again grew adjusted operating profit despite soft prescription volume trends \nthroughout the fiscal year. ", "original_text": "This is yet another example of how we're looking to \nsimplify operations and grow  the business and do the right thing for our teams. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a1967ed0b2a023dec3746157552b25573a9f48d7409004ffe4f5ede2899d7ef3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10999feb-9d28-4106-a8fc-1920b2a1fcdc", "node_type": "1", "metadata": {"window": "While we are quite anxious to see each other in person \nsoon and at a time and place where it's appropriate and safe to do so, the success of our employees in t his \nremote work environment and their desire for more work flexibility has challenged us to reevaluate the way we \nwork and our real estate and existing office space footprint.  This is yet another example of how we're looking to \nsimplify operations and grow  the business and do the right thing for our teams.  Britt will go into more detail about \nour thinking on these impacts going forward.  \n \n Now, let me turn to the business and touch on how we're positioned for success heading into fiscal 2022.  I'll start \nwith US Pharmaceutical, where we again grew adjusted operating profit despite soft prescription volume trends \nthroughout the fiscal year.  Our priority in this business is to strengthen the core and deliver the world's highest -\nquality supply chain to our custome rs and manufacturing partners.  Our focus on cost and working capital \nefficiencies underpin this growth and help fuel investments for growth across the business.  \n \n", "original_text": "Now, let me turn to the business and touch on how we're positioned for success heading into fiscal 2022. "}, "hash": "d13890f1bda96a4b22ec8e75015f1ba45c78483cfc90cf09d87b89c55ce9b2cc", "class_name": "RelatedNodeInfo"}}, "text": "Britt will go into more detail about \nour thinking on these impacts going forward.  \n \n", "start_char_idx": 3106, "end_char_idx": 3193, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10999feb-9d28-4106-a8fc-1920b2a1fcdc": {"__data__": {"id_": "10999feb-9d28-4106-a8fc-1920b2a1fcdc", "embedding": null, "metadata": {"window": "While we are quite anxious to see each other in person \nsoon and at a time and place where it's appropriate and safe to do so, the success of our employees in t his \nremote work environment and their desire for more work flexibility has challenged us to reevaluate the way we \nwork and our real estate and existing office space footprint.  This is yet another example of how we're looking to \nsimplify operations and grow  the business and do the right thing for our teams.  Britt will go into more detail about \nour thinking on these impacts going forward.  \n \n Now, let me turn to the business and touch on how we're positioned for success heading into fiscal 2022.  I'll start \nwith US Pharmaceutical, where we again grew adjusted operating profit despite soft prescription volume trends \nthroughout the fiscal year.  Our priority in this business is to strengthen the core and deliver the world's highest -\nquality supply chain to our custome rs and manufacturing partners.  Our focus on cost and working capital \nefficiencies underpin this growth and help fuel investments for growth across the business.  \n \n", "original_text": "Now, let me turn to the business and touch on how we're positioned for success heading into fiscal 2022. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f207edc-0ead-4320-8205-fc7e356f115c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6275a184f8bd8d594cc6c801bece3e9238396da4193218af4303f942621d4686", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38f0282c-42f4-460f-bffd-25bc6befdfe7", "node_type": "1", "metadata": {"window": "For McKesson, it's \nbeen over a year since we successfully transitioned all of our office -based employees to work -from-home \nseemingly overnight and without a loss of productivity.  While we are quite anxious to see each other in person \nsoon and at a time and place where it's appropriate and safe to do so, the success of our employees in t his \nremote work environment and their desire for more work flexibility has challenged us to reevaluate the way we \nwork and our real estate and existing office space footprint.  This is yet another example of how we're looking to \nsimplify operations and grow  the business and do the right thing for our teams.  Britt will go into more detail about \nour thinking on these impacts going forward.  \n \n Now, let me turn to the business and touch on how we're positioned for success heading into fiscal 2022.  I'll start \nwith US Pharmaceutical, where we again grew adjusted operating profit despite soft prescription volume trends \nthroughout the fiscal year.  Our priority in this business is to strengthen the core and deliver the world's highest -\nquality supply chain to our custome rs and manufacturing partners. ", "original_text": "Britt will go into more detail about \nour thinking on these impacts going forward.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d1b1518aa53b3b6d3d01fb64d84d0a045126e45ea17598d6e2eebd36af3b792", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28f4a599-b7ed-421d-9f7c-781848087bd7", "node_type": "1", "metadata": {"window": "This is yet another example of how we're looking to \nsimplify operations and grow  the business and do the right thing for our teams.  Britt will go into more detail about \nour thinking on these impacts going forward.  \n \n Now, let me turn to the business and touch on how we're positioned for success heading into fiscal 2022.  I'll start \nwith US Pharmaceutical, where we again grew adjusted operating profit despite soft prescription volume trends \nthroughout the fiscal year.  Our priority in this business is to strengthen the core and deliver the world's highest -\nquality supply chain to our custome rs and manufacturing partners.  Our focus on cost and working capital \nefficiencies underpin this growth and help fuel investments for growth across the business.  \n \n For generics, the pricing environment continues to track in line with our expectations. ", "original_text": "I'll start \nwith US Pharmaceutical, where we again grew adjusted operating profit despite soft prescription volume trends \nthroughout the fiscal year. "}, "hash": "5b79972e6f0ff62e596a25e573417e3ad95061909fce76b47c40357abdf50b79", "class_name": "RelatedNodeInfo"}}, "text": "Now, let me turn to the business and touch on how we're positioned for success heading into fiscal 2022. ", "start_char_idx": 3193, "end_char_idx": 3298, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28f4a599-b7ed-421d-9f7c-781848087bd7": {"__data__": {"id_": "28f4a599-b7ed-421d-9f7c-781848087bd7", "embedding": null, "metadata": {"window": "This is yet another example of how we're looking to \nsimplify operations and grow  the business and do the right thing for our teams.  Britt will go into more detail about \nour thinking on these impacts going forward.  \n \n Now, let me turn to the business and touch on how we're positioned for success heading into fiscal 2022.  I'll start \nwith US Pharmaceutical, where we again grew adjusted operating profit despite soft prescription volume trends \nthroughout the fiscal year.  Our priority in this business is to strengthen the core and deliver the world's highest -\nquality supply chain to our custome rs and manufacturing partners.  Our focus on cost and working capital \nefficiencies underpin this growth and help fuel investments for growth across the business.  \n \n For generics, the pricing environment continues to track in line with our expectations. ", "original_text": "I'll start \nwith US Pharmaceutical, where we again grew adjusted operating profit despite soft prescription volume trends \nthroughout the fiscal year. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f207edc-0ead-4320-8205-fc7e356f115c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6275a184f8bd8d594cc6c801bece3e9238396da4193218af4303f942621d4686", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10999feb-9d28-4106-a8fc-1920b2a1fcdc", "node_type": "1", "metadata": {"window": "While we are quite anxious to see each other in person \nsoon and at a time and place where it's appropriate and safe to do so, the success of our employees in t his \nremote work environment and their desire for more work flexibility has challenged us to reevaluate the way we \nwork and our real estate and existing office space footprint.  This is yet another example of how we're looking to \nsimplify operations and grow  the business and do the right thing for our teams.  Britt will go into more detail about \nour thinking on these impacts going forward.  \n \n Now, let me turn to the business and touch on how we're positioned for success heading into fiscal 2022.  I'll start \nwith US Pharmaceutical, where we again grew adjusted operating profit despite soft prescription volume trends \nthroughout the fiscal year.  Our priority in this business is to strengthen the core and deliver the world's highest -\nquality supply chain to our custome rs and manufacturing partners.  Our focus on cost and working capital \nefficiencies underpin this growth and help fuel investments for growth across the business.  \n \n", "original_text": "Now, let me turn to the business and touch on how we're positioned for success heading into fiscal 2022. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc2cb58d70235d527e253dd15c087e7a01c1a35354b47fcbb3d2fec16f5a45ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c778b4dd-0330-4e1c-a5d2-068586c7b46b", "node_type": "1", "metadata": {"window": "Britt will go into more detail about \nour thinking on these impacts going forward.  \n \n Now, let me turn to the business and touch on how we're positioned for success heading into fiscal 2022.  I'll start \nwith US Pharmaceutical, where we again grew adjusted operating profit despite soft prescription volume trends \nthroughout the fiscal year.  Our priority in this business is to strengthen the core and deliver the world's highest -\nquality supply chain to our custome rs and manufacturing partners.  Our focus on cost and working capital \nefficiencies underpin this growth and help fuel investments for growth across the business.  \n \n For generics, the pricing environment continues to track in line with our expectations.  On the  buy-side, we \nleverage our scale and our sourcing capabilities through ClarusONE to ensure stability of supply at low cost for \nour customers. ", "original_text": "Our priority in this business is to strengthen the core and deliver the world's highest -\nquality supply chain to our custome rs and manufacturing partners. "}, "hash": "0f5b63f88dc23e8b5df13b9bfacdc3402870164b3892cbc2779c7d57d90f442c", "class_name": "RelatedNodeInfo"}}, "text": "I'll start \nwith US Pharmaceutical, where we again grew adjusted operating profit despite soft prescription volume trends \nthroughout the fiscal year. ", "start_char_idx": 3298, "end_char_idx": 3449, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c778b4dd-0330-4e1c-a5d2-068586c7b46b": {"__data__": {"id_": "c778b4dd-0330-4e1c-a5d2-068586c7b46b", "embedding": null, "metadata": {"window": "Britt will go into more detail about \nour thinking on these impacts going forward.  \n \n Now, let me turn to the business and touch on how we're positioned for success heading into fiscal 2022.  I'll start \nwith US Pharmaceutical, where we again grew adjusted operating profit despite soft prescription volume trends \nthroughout the fiscal year.  Our priority in this business is to strengthen the core and deliver the world's highest -\nquality supply chain to our custome rs and manufacturing partners.  Our focus on cost and working capital \nefficiencies underpin this growth and help fuel investments for growth across the business.  \n \n For generics, the pricing environment continues to track in line with our expectations.  On the  buy-side, we \nleverage our scale and our sourcing capabilities through ClarusONE to ensure stability of supply at low cost for \nour customers. ", "original_text": "Our priority in this business is to strengthen the core and deliver the world's highest -\nquality supply chain to our custome rs and manufacturing partners. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f207edc-0ead-4320-8205-fc7e356f115c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6275a184f8bd8d594cc6c801bece3e9238396da4193218af4303f942621d4686", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28f4a599-b7ed-421d-9f7c-781848087bd7", "node_type": "1", "metadata": {"window": "This is yet another example of how we're looking to \nsimplify operations and grow  the business and do the right thing for our teams.  Britt will go into more detail about \nour thinking on these impacts going forward.  \n \n Now, let me turn to the business and touch on how we're positioned for success heading into fiscal 2022.  I'll start \nwith US Pharmaceutical, where we again grew adjusted operating profit despite soft prescription volume trends \nthroughout the fiscal year.  Our priority in this business is to strengthen the core and deliver the world's highest -\nquality supply chain to our custome rs and manufacturing partners.  Our focus on cost and working capital \nefficiencies underpin this growth and help fuel investments for growth across the business.  \n \n For generics, the pricing environment continues to track in line with our expectations. ", "original_text": "I'll start \nwith US Pharmaceutical, where we again grew adjusted operating profit despite soft prescription volume trends \nthroughout the fiscal year. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ed9a6de9011946364f4b5cf9a47ef05d92d2b0b86f905101478c17571ebffa0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e07df121-0bc7-4910-96e7-e92e557279c1", "node_type": "1", "metadata": {"window": "Now, let me turn to the business and touch on how we're positioned for success heading into fiscal 2022.  I'll start \nwith US Pharmaceutical, where we again grew adjusted operating profit despite soft prescription volume trends \nthroughout the fiscal year.  Our priority in this business is to strengthen the core and deliver the world's highest -\nquality supply chain to our custome rs and manufacturing partners.  Our focus on cost and working capital \nefficiencies underpin this growth and help fuel investments for growth across the business.  \n \n For generics, the pricing environment continues to track in line with our expectations.  On the  buy-side, we \nleverage our scale and our sourcing capabilities through ClarusONE to ensure stability of supply at low cost for \nour customers.  On the sell -side McKesson has taken a disciplined approach to pricing and the market continues \nto be competitive, but has been stable for years. ", "original_text": "Our focus on cost and working capital \nefficiencies underpin this growth and help fuel investments for growth across the business.  \n \n"}, "hash": "9c4be71b94c0a15a12e6eb0bc349677c98b6e547dc5d0bf1af8ccfebf552c56d", "class_name": "RelatedNodeInfo"}}, "text": "Our priority in this business is to strengthen the core and deliver the world's highest -\nquality supply chain to our custome rs and manufacturing partners. ", "start_char_idx": 3449, "end_char_idx": 3606, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e07df121-0bc7-4910-96e7-e92e557279c1": {"__data__": {"id_": "e07df121-0bc7-4910-96e7-e92e557279c1", "embedding": null, "metadata": {"window": "Now, let me turn to the business and touch on how we're positioned for success heading into fiscal 2022.  I'll start \nwith US Pharmaceutical, where we again grew adjusted operating profit despite soft prescription volume trends \nthroughout the fiscal year.  Our priority in this business is to strengthen the core and deliver the world's highest -\nquality supply chain to our custome rs and manufacturing partners.  Our focus on cost and working capital \nefficiencies underpin this growth and help fuel investments for growth across the business.  \n \n For generics, the pricing environment continues to track in line with our expectations.  On the  buy-side, we \nleverage our scale and our sourcing capabilities through ClarusONE to ensure stability of supply at low cost for \nour customers.  On the sell -side McKesson has taken a disciplined approach to pricing and the market continues \nto be competitive, but has been stable for years. ", "original_text": "Our focus on cost and working capital \nefficiencies underpin this growth and help fuel investments for growth across the business.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f207edc-0ead-4320-8205-fc7e356f115c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6275a184f8bd8d594cc6c801bece3e9238396da4193218af4303f942621d4686", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c778b4dd-0330-4e1c-a5d2-068586c7b46b", "node_type": "1", "metadata": {"window": "Britt will go into more detail about \nour thinking on these impacts going forward.  \n \n Now, let me turn to the business and touch on how we're positioned for success heading into fiscal 2022.  I'll start \nwith US Pharmaceutical, where we again grew adjusted operating profit despite soft prescription volume trends \nthroughout the fiscal year.  Our priority in this business is to strengthen the core and deliver the world's highest -\nquality supply chain to our custome rs and manufacturing partners.  Our focus on cost and working capital \nefficiencies underpin this growth and help fuel investments for growth across the business.  \n \n For generics, the pricing environment continues to track in line with our expectations.  On the  buy-side, we \nleverage our scale and our sourcing capabilities through ClarusONE to ensure stability of supply at low cost for \nour customers. ", "original_text": "Our priority in this business is to strengthen the core and deliver the world's highest -\nquality supply chain to our custome rs and manufacturing partners. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8bf857d6d6888eb71b20a4a259b6249c1046411e4f0e0baaf677639d034d1a43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68e5d07c-e347-4a11-8205-ed56e6e63b4d", "node_type": "1", "metadata": {"window": "I'll start \nwith US Pharmaceutical, where we again grew adjusted operating profit despite soft prescription volume trends \nthroughout the fiscal year.  Our priority in this business is to strengthen the core and deliver the world's highest -\nquality supply chain to our custome rs and manufacturing partners.  Our focus on cost and working capital \nefficiencies underpin this growth and help fuel investments for growth across the business.  \n \n For generics, the pricing environment continues to track in line with our expectations.  On the  buy-side, we \nleverage our scale and our sourcing capabilities through ClarusONE to ensure stability of supply at low cost for \nour customers.  On the sell -side McKesson has taken a disciplined approach to pricing and the market continues \nto be competitive, but has been stable for years.  While generics volume remained below pre -COVID levels in the \nquarter, we expect volume improvement over the course of our fiscal year.  \n ", "original_text": "For generics, the pricing environment continues to track in line with our expectations. "}, "hash": "a4e75449cf680461889afe7c48ccb4cd8649a1ad5458fed994b07b40a7b551df", "class_name": "RelatedNodeInfo"}}, "text": "Our focus on cost and working capital \nefficiencies underpin this growth and help fuel investments for growth across the business.  \n \n", "start_char_idx": 3606, "end_char_idx": 3741, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68e5d07c-e347-4a11-8205-ed56e6e63b4d": {"__data__": {"id_": "68e5d07c-e347-4a11-8205-ed56e6e63b4d", "embedding": null, "metadata": {"window": "I'll start \nwith US Pharmaceutical, where we again grew adjusted operating profit despite soft prescription volume trends \nthroughout the fiscal year.  Our priority in this business is to strengthen the core and deliver the world's highest -\nquality supply chain to our custome rs and manufacturing partners.  Our focus on cost and working capital \nefficiencies underpin this growth and help fuel investments for growth across the business.  \n \n For generics, the pricing environment continues to track in line with our expectations.  On the  buy-side, we \nleverage our scale and our sourcing capabilities through ClarusONE to ensure stability of supply at low cost for \nour customers.  On the sell -side McKesson has taken a disciplined approach to pricing and the market continues \nto be competitive, but has been stable for years.  While generics volume remained below pre -COVID levels in the \nquarter, we expect volume improvement over the course of our fiscal year.  \n ", "original_text": "For generics, the pricing environment continues to track in line with our expectations. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f207edc-0ead-4320-8205-fc7e356f115c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6275a184f8bd8d594cc6c801bece3e9238396da4193218af4303f942621d4686", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e07df121-0bc7-4910-96e7-e92e557279c1", "node_type": "1", "metadata": {"window": "Now, let me turn to the business and touch on how we're positioned for success heading into fiscal 2022.  I'll start \nwith US Pharmaceutical, where we again grew adjusted operating profit despite soft prescription volume trends \nthroughout the fiscal year.  Our priority in this business is to strengthen the core and deliver the world's highest -\nquality supply chain to our custome rs and manufacturing partners.  Our focus on cost and working capital \nefficiencies underpin this growth and help fuel investments for growth across the business.  \n \n For generics, the pricing environment continues to track in line with our expectations.  On the  buy-side, we \nleverage our scale and our sourcing capabilities through ClarusONE to ensure stability of supply at low cost for \nour customers.  On the sell -side McKesson has taken a disciplined approach to pricing and the market continues \nto be competitive, but has been stable for years. ", "original_text": "Our focus on cost and working capital \nefficiencies underpin this growth and help fuel investments for growth across the business.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "137a5713ed5132426c1ff02b37b5a525e245980b5d3ac2c4f3430bd28a180da9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03b20d68-83ed-4cd7-b6ee-3b594bdd6331", "node_type": "1", "metadata": {"window": "Our priority in this business is to strengthen the core and deliver the world's highest -\nquality supply chain to our custome rs and manufacturing partners.  Our focus on cost and working capital \nefficiencies underpin this growth and help fuel investments for growth across the business.  \n \n For generics, the pricing environment continues to track in line with our expectations.  On the  buy-side, we \nleverage our scale and our sourcing capabilities through ClarusONE to ensure stability of supply at low cost for \nour customers.  On the sell -side McKesson has taken a disciplined approach to pricing and the market continues \nto be competitive, but has been stable for years.  While generics volume remained below pre -COVID levels in the \nquarter, we expect volume improvement over the course of our fiscal year.  \n ", "original_text": "On the  buy-side, we \nleverage our scale and our sourcing capabilities through ClarusONE to ensure stability of supply at low cost for \nour customers. "}, "hash": "26a6a7c26489b5c33e12f297be1f5f295610616b28c86b32c7f4b4400ebd3eda", "class_name": "RelatedNodeInfo"}}, "text": "For generics, the pricing environment continues to track in line with our expectations. ", "start_char_idx": 3741, "end_char_idx": 3829, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03b20d68-83ed-4cd7-b6ee-3b594bdd6331": {"__data__": {"id_": "03b20d68-83ed-4cd7-b6ee-3b594bdd6331", "embedding": null, "metadata": {"window": "Our priority in this business is to strengthen the core and deliver the world's highest -\nquality supply chain to our custome rs and manufacturing partners.  Our focus on cost and working capital \nefficiencies underpin this growth and help fuel investments for growth across the business.  \n \n For generics, the pricing environment continues to track in line with our expectations.  On the  buy-side, we \nleverage our scale and our sourcing capabilities through ClarusONE to ensure stability of supply at low cost for \nour customers.  On the sell -side McKesson has taken a disciplined approach to pricing and the market continues \nto be competitive, but has been stable for years.  While generics volume remained below pre -COVID levels in the \nquarter, we expect volume improvement over the course of our fiscal year.  \n ", "original_text": "On the  buy-side, we \nleverage our scale and our sourcing capabilities through ClarusONE to ensure stability of supply at low cost for \nour customers. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f207edc-0ead-4320-8205-fc7e356f115c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6275a184f8bd8d594cc6c801bece3e9238396da4193218af4303f942621d4686", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68e5d07c-e347-4a11-8205-ed56e6e63b4d", "node_type": "1", "metadata": {"window": "I'll start \nwith US Pharmaceutical, where we again grew adjusted operating profit despite soft prescription volume trends \nthroughout the fiscal year.  Our priority in this business is to strengthen the core and deliver the world's highest -\nquality supply chain to our custome rs and manufacturing partners.  Our focus on cost and working capital \nefficiencies underpin this growth and help fuel investments for growth across the business.  \n \n For generics, the pricing environment continues to track in line with our expectations.  On the  buy-side, we \nleverage our scale and our sourcing capabilities through ClarusONE to ensure stability of supply at low cost for \nour customers.  On the sell -side McKesson has taken a disciplined approach to pricing and the market continues \nto be competitive, but has been stable for years.  While generics volume remained below pre -COVID levels in the \nquarter, we expect volume improvement over the course of our fiscal year.  \n ", "original_text": "For generics, the pricing environment continues to track in line with our expectations. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0091977b6d7e360932378e7916c2b4bd2c447b9ad82bf6fc1fdd9ab85815c543", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d99f87e5-b1a2-446c-81f4-4c819e8b126f", "node_type": "1", "metadata": {"window": "Our focus on cost and working capital \nefficiencies underpin this growth and help fuel investments for growth across the business.  \n \n For generics, the pricing environment continues to track in line with our expectations.  On the  buy-side, we \nleverage our scale and our sourcing capabilities through ClarusONE to ensure stability of supply at low cost for \nour customers.  On the sell -side McKesson has taken a disciplined approach to pricing and the market continues \nto be competitive, but has been stable for years.  While generics volume remained below pre -COVID levels in the \nquarter, we expect volume improvement over the course of our fiscal year.  \n ", "original_text": "On the sell -side McKesson has taken a disciplined approach to pricing and the market continues \nto be competitive, but has been stable for years. "}, "hash": "c45e740e9c189f814b95c75c0729c6ca6a13cf7a5853220e7a846648fca87637", "class_name": "RelatedNodeInfo"}}, "text": "On the  buy-side, we \nleverage our scale and our sourcing capabilities through ClarusONE to ensure stability of supply at low cost for \nour customers. ", "start_char_idx": 3829, "end_char_idx": 3980, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d99f87e5-b1a2-446c-81f4-4c819e8b126f": {"__data__": {"id_": "d99f87e5-b1a2-446c-81f4-4c819e8b126f", "embedding": null, "metadata": {"window": "Our focus on cost and working capital \nefficiencies underpin this growth and help fuel investments for growth across the business.  \n \n For generics, the pricing environment continues to track in line with our expectations.  On the  buy-side, we \nleverage our scale and our sourcing capabilities through ClarusONE to ensure stability of supply at low cost for \nour customers.  On the sell -side McKesson has taken a disciplined approach to pricing and the market continues \nto be competitive, but has been stable for years.  While generics volume remained below pre -COVID levels in the \nquarter, we expect volume improvement over the course of our fiscal year.  \n ", "original_text": "On the sell -side McKesson has taken a disciplined approach to pricing and the market continues \nto be competitive, but has been stable for years. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f207edc-0ead-4320-8205-fc7e356f115c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6275a184f8bd8d594cc6c801bece3e9238396da4193218af4303f942621d4686", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03b20d68-83ed-4cd7-b6ee-3b594bdd6331", "node_type": "1", "metadata": {"window": "Our priority in this business is to strengthen the core and deliver the world's highest -\nquality supply chain to our custome rs and manufacturing partners.  Our focus on cost and working capital \nefficiencies underpin this growth and help fuel investments for growth across the business.  \n \n For generics, the pricing environment continues to track in line with our expectations.  On the  buy-side, we \nleverage our scale and our sourcing capabilities through ClarusONE to ensure stability of supply at low cost for \nour customers.  On the sell -side McKesson has taken a disciplined approach to pricing and the market continues \nto be competitive, but has been stable for years.  While generics volume remained below pre -COVID levels in the \nquarter, we expect volume improvement over the course of our fiscal year.  \n ", "original_text": "On the  buy-side, we \nleverage our scale and our sourcing capabilities through ClarusONE to ensure stability of supply at low cost for \nour customers. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1667f4e7a9c907b0b8f493ce4538b5b062ab58855d86b7dbc4ddd67a47436734", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c2e5d57-1416-4f5e-b871-9ea3776f3715", "node_type": "1", "metadata": {"window": "For generics, the pricing environment continues to track in line with our expectations.  On the  buy-side, we \nleverage our scale and our sourcing capabilities through ClarusONE to ensure stability of supply at low cost for \nour customers.  On the sell -side McKesson has taken a disciplined approach to pricing and the market continues \nto be competitive, but has been stable for years.  While generics volume remained below pre -COVID levels in the \nquarter, we expect volume improvement over the course of our fiscal year.  \n ", "original_text": "While generics volume remained below pre -COVID levels in the \nquarter, we expect volume improvement over the course of our fiscal year.  \n "}, "hash": "8b50807a8e89265393132c04475bdf592e797ce319cd08858beba0e6abf6062c", "class_name": "RelatedNodeInfo"}}, "text": "On the sell -side McKesson has taken a disciplined approach to pricing and the market continues \nto be competitive, but has been stable for years. ", "start_char_idx": 3980, "end_char_idx": 4127, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c2e5d57-1416-4f5e-b871-9ea3776f3715": {"__data__": {"id_": "4c2e5d57-1416-4f5e-b871-9ea3776f3715", "embedding": null, "metadata": {"window": "For generics, the pricing environment continues to track in line with our expectations.  On the  buy-side, we \nleverage our scale and our sourcing capabilities through ClarusONE to ensure stability of supply at low cost for \nour customers.  On the sell -side McKesson has taken a disciplined approach to pricing and the market continues \nto be competitive, but has been stable for years.  While generics volume remained below pre -COVID levels in the \nquarter, we expect volume improvement over the course of our fiscal year.  \n ", "original_text": "While generics volume remained below pre -COVID levels in the \nquarter, we expect volume improvement over the course of our fiscal year.  \n ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f207edc-0ead-4320-8205-fc7e356f115c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6275a184f8bd8d594cc6c801bece3e9238396da4193218af4303f942621d4686", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d99f87e5-b1a2-446c-81f4-4c819e8b126f", "node_type": "1", "metadata": {"window": "Our focus on cost and working capital \nefficiencies underpin this growth and help fuel investments for growth across the business.  \n \n For generics, the pricing environment continues to track in line with our expectations.  On the  buy-side, we \nleverage our scale and our sourcing capabilities through ClarusONE to ensure stability of supply at low cost for \nour customers.  On the sell -side McKesson has taken a disciplined approach to pricing and the market continues \nto be competitive, but has been stable for years.  While generics volume remained below pre -COVID levels in the \nquarter, we expect volume improvement over the course of our fiscal year.  \n ", "original_text": "On the sell -side McKesson has taken a disciplined approach to pricing and the market continues \nto be competitive, but has been stable for years. ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5aa3aa234f654ed997109d9464ff0f83c23af8d8c3a680a6fe4371c183f6127c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "294ef126-98f9-4fd2-aea9-8d8e00f9d2ca", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nI'm also pleased with the performance of our specialty business this past year.  Our US On cology business, \npatient visits were at pre -COVID baselines in March, with many returning for in -person visits to their providers.  In \nfiscal 2022, we'll look to grow both our US Oncology and non -affiliated businesses, which are just another part of \nour con nected oncology ecosystem at McKesson.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "0ab458a87a5f569387063fcfab9575d6eb817613dd13b03a7ad580f572916c66", "class_name": "RelatedNodeInfo"}}, "text": "While generics volume remained below pre -COVID levels in the \nquarter, we expect volume improvement over the course of our fiscal year.  \n ", "start_char_idx": 4127, "end_char_idx": 4267, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "294ef126-98f9-4fd2-aea9-8d8e00f9d2ca": {"__data__": {"id_": "294ef126-98f9-4fd2-aea9-8d8e00f9d2ca", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nI'm also pleased with the performance of our specialty business this past year.  Our US On cology business, \npatient visits were at pre -COVID baselines in March, with many returning for in -person visits to their providers.  In \nfiscal 2022, we'll look to grow both our US Oncology and non -affiliated businesses, which are just another part of \nour con nected oncology ecosystem at McKesson.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c850470-3a0a-4880-b2ec-54135610be69", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a305784b8b89364cb419bc4dad266e1519ed1392381036044a2c6b16eeebbe93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c2e5d57-1416-4f5e-b871-9ea3776f3715", "node_type": "1", "metadata": {"window": "For generics, the pricing environment continues to track in line with our expectations.  On the  buy-side, we \nleverage our scale and our sourcing capabilities through ClarusONE to ensure stability of supply at low cost for \nour customers.  On the sell -side McKesson has taken a disciplined approach to pricing and the market continues \nto be competitive, but has been stable for years.  While generics volume remained below pre -COVID levels in the \nquarter, we expect volume improvement over the course of our fiscal year.  \n ", "original_text": "While generics volume remained below pre -COVID levels in the \nquarter, we expect volume improvement over the course of our fiscal year.  \n ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f411465f9d1346c49bdd8497bd96076a907c41c7daccfbd833d04368910e96a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b036ca4d-04fe-47fd-8c76-ded7694a6369", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nI'm also pleased with the performance of our specialty business this past year.  Our US On cology business, \npatient visits were at pre -COVID baselines in March, with many returning for in -person visits to their providers.  In \nfiscal 2022, we'll look to grow both our US Oncology and non -affiliated businesses, which are just another part of \nour con nected oncology ecosystem at McKesson.  \n \n Let me talk about Prescription Technology Solutions. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nI'm also pleased with the performance of our specialty business this past year. "}, "hash": "f66f01e495462f89cc99f7625022c3106e367993819cf28476fd391845beddaf", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b036ca4d-04fe-47fd-8c76-ded7694a6369": {"__data__": {"id_": "b036ca4d-04fe-47fd-8c76-ded7694a6369", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nI'm also pleased with the performance of our specialty business this past year.  Our US On cology business, \npatient visits were at pre -COVID baselines in March, with many returning for in -person visits to their providers.  In \nfiscal 2022, we'll look to grow both our US Oncology and non -affiliated businesses, which are just another part of \nour con nected oncology ecosystem at McKesson.  \n \n Let me talk about Prescription Technology Solutions. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nI'm also pleased with the performance of our specialty business this past year. ", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c850470-3a0a-4880-b2ec-54135610be69", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a305784b8b89364cb419bc4dad266e1519ed1392381036044a2c6b16eeebbe93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "294ef126-98f9-4fd2-aea9-8d8e00f9d2ca", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nI'm also pleased with the performance of our specialty business this past year.  Our US On cology business, \npatient visits were at pre -COVID baselines in March, with many returning for in -person visits to their providers.  In \nfiscal 2022, we'll look to grow both our US Oncology and non -affiliated businesses, which are just another part of \nour con nected oncology ecosystem at McKesson.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "388d53dc8657a4baac0577fa834b598c59c59ec263c4477ae6f234ddbd15d9ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99d23d9d-3092-4061-90c9-d6a54ed1d8cd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nI'm also pleased with the performance of our specialty business this past year.  Our US On cology business, \npatient visits were at pre -COVID baselines in March, with many returning for in -person visits to their providers.  In \nfiscal 2022, we'll look to grow both our US Oncology and non -affiliated businesses, which are just another part of \nour con nected oncology ecosystem at McKesson.  \n \n Let me talk about Prescription Technology Solutions.  They perform well this year despite prescription volumes \nbeing down since the onset of the pandemic. ", "original_text": "Our US On cology business, \npatient visits were at pre -COVID baselines in March, with many returning for in -person visits to their providers. "}, "hash": "7b03df9c00a2879a859bfe8130850a8e5326e0e2df13f237b20676d076b97742", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nI'm also pleased with the performance of our specialty business this past year. ", "start_char_idx": 16, "end_char_idx": 260, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99d23d9d-3092-4061-90c9-d6a54ed1d8cd": {"__data__": {"id_": "99d23d9d-3092-4061-90c9-d6a54ed1d8cd", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nI'm also pleased with the performance of our specialty business this past year.  Our US On cology business, \npatient visits were at pre -COVID baselines in March, with many returning for in -person visits to their providers.  In \nfiscal 2022, we'll look to grow both our US Oncology and non -affiliated businesses, which are just another part of \nour con nected oncology ecosystem at McKesson.  \n \n Let me talk about Prescription Technology Solutions.  They perform well this year despite prescription volumes \nbeing down since the onset of the pandemic. ", "original_text": "Our US On cology business, \npatient visits were at pre -COVID baselines in March, with many returning for in -person visits to their providers. ", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c850470-3a0a-4880-b2ec-54135610be69", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a305784b8b89364cb419bc4dad266e1519ed1392381036044a2c6b16eeebbe93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b036ca4d-04fe-47fd-8c76-ded7694a6369", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nI'm also pleased with the performance of our specialty business this past year.  Our US On cology business, \npatient visits were at pre -COVID baselines in March, with many returning for in -person visits to their providers.  In \nfiscal 2022, we'll look to grow both our US Oncology and non -affiliated businesses, which are just another part of \nour con nected oncology ecosystem at McKesson.  \n \n Let me talk about Prescription Technology Solutions. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nI'm also pleased with the performance of our specialty business this past year. ", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63419dbdc34b9d90016e7f3bfb66d28b9baa67b48db0effdc009ebf47f91e781", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85477257-d1d7-4302-9128-66c55d24767e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nI'm also pleased with the performance of our specialty business this past year.  Our US On cology business, \npatient visits were at pre -COVID baselines in March, with many returning for in -person visits to their providers.  In \nfiscal 2022, we'll look to grow both our US Oncology and non -affiliated businesses, which are just another part of \nour con nected oncology ecosystem at McKesson.  \n \n Let me talk about Prescription Technology Solutions.  They perform well this year despite prescription volumes \nbeing down since the onset of the pandemic.  We're continuing to invest in innovation in this business and despite \nthis year's challenges we've been very successful in adding new brands to our platforms.  \n \n", "original_text": "In \nfiscal 2022, we'll look to grow both our US Oncology and non -affiliated businesses, which are just another part of \nour con nected oncology ecosystem at McKesson.  \n \n"}, "hash": "a67706c27717a04829d65c00e58b7644e3a5485a443d051ac95fc9142e3bee41", "class_name": "RelatedNodeInfo"}}, "text": "Our US On cology business, \npatient visits were at pre -COVID baselines in March, with many returning for in -person visits to their providers. ", "start_char_idx": 260, "end_char_idx": 404, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85477257-d1d7-4302-9128-66c55d24767e": {"__data__": {"id_": "85477257-d1d7-4302-9128-66c55d24767e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nI'm also pleased with the performance of our specialty business this past year.  Our US On cology business, \npatient visits were at pre -COVID baselines in March, with many returning for in -person visits to their providers.  In \nfiscal 2022, we'll look to grow both our US Oncology and non -affiliated businesses, which are just another part of \nour con nected oncology ecosystem at McKesson.  \n \n Let me talk about Prescription Technology Solutions.  They perform well this year despite prescription volumes \nbeing down since the onset of the pandemic.  We're continuing to invest in innovation in this business and despite \nthis year's challenges we've been very successful in adding new brands to our platforms.  \n \n", "original_text": "In \nfiscal 2022, we'll look to grow both our US Oncology and non -affiliated businesses, which are just another part of \nour con nected oncology ecosystem at McKesson.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c850470-3a0a-4880-b2ec-54135610be69", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a305784b8b89364cb419bc4dad266e1519ed1392381036044a2c6b16eeebbe93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99d23d9d-3092-4061-90c9-d6a54ed1d8cd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nI'm also pleased with the performance of our specialty business this past year.  Our US On cology business, \npatient visits were at pre -COVID baselines in March, with many returning for in -person visits to their providers.  In \nfiscal 2022, we'll look to grow both our US Oncology and non -affiliated businesses, which are just another part of \nour con nected oncology ecosystem at McKesson.  \n \n Let me talk about Prescription Technology Solutions.  They perform well this year despite prescription volumes \nbeing down since the onset of the pandemic. ", "original_text": "Our US On cology business, \npatient visits were at pre -COVID baselines in March, with many returning for in -person visits to their providers. ", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3b7b979b90b310bc599ab67562d2845d82d837dbf672215a5f7ad1cac79b90c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b132a37-7c1f-4315-8729-4c1805fd44db", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nI'm also pleased with the performance of our specialty business this past year.  Our US On cology business, \npatient visits were at pre -COVID baselines in March, with many returning for in -person visits to their providers.  In \nfiscal 2022, we'll look to grow both our US Oncology and non -affiliated businesses, which are just another part of \nour con nected oncology ecosystem at McKesson.  \n \n Let me talk about Prescription Technology Solutions.  They perform well this year despite prescription volumes \nbeing down since the onset of the pandemic.  We're continuing to invest in innovation in this business and despite \nthis year's challenges we've been very successful in adding new brands to our platforms.  \n \n In fiscal 2021, our access solutions helped over 50 million patients get on therapies after their original prescription \nwas denied coverage, and our affordabi lity solutions helped patients save over $7 billion in out -of-pocket \nprescription costs. ", "original_text": "Let me talk about Prescription Technology Solutions. "}, "hash": "94aa99974b8b8e3ee47a12e860bcadd68fe6ff7792176a17843d6c2afebb5780", "class_name": "RelatedNodeInfo"}}, "text": "In \nfiscal 2022, we'll look to grow both our US Oncology and non -affiliated businesses, which are just another part of \nour con nected oncology ecosystem at McKesson.  \n \n", "start_char_idx": 404, "end_char_idx": 576, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b132a37-7c1f-4315-8729-4c1805fd44db": {"__data__": {"id_": "0b132a37-7c1f-4315-8729-4c1805fd44db", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nI'm also pleased with the performance of our specialty business this past year.  Our US On cology business, \npatient visits were at pre -COVID baselines in March, with many returning for in -person visits to their providers.  In \nfiscal 2022, we'll look to grow both our US Oncology and non -affiliated businesses, which are just another part of \nour con nected oncology ecosystem at McKesson.  \n \n Let me talk about Prescription Technology Solutions.  They perform well this year despite prescription volumes \nbeing down since the onset of the pandemic.  We're continuing to invest in innovation in this business and despite \nthis year's challenges we've been very successful in adding new brands to our platforms.  \n \n In fiscal 2021, our access solutions helped over 50 million patients get on therapies after their original prescription \nwas denied coverage, and our affordabi lity solutions helped patients save over $7 billion in out -of-pocket \nprescription costs. ", "original_text": "Let me talk about Prescription Technology Solutions. ", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c850470-3a0a-4880-b2ec-54135610be69", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a305784b8b89364cb419bc4dad266e1519ed1392381036044a2c6b16eeebbe93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85477257-d1d7-4302-9128-66c55d24767e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nI'm also pleased with the performance of our specialty business this past year.  Our US On cology business, \npatient visits were at pre -COVID baselines in March, with many returning for in -person visits to their providers.  In \nfiscal 2022, we'll look to grow both our US Oncology and non -affiliated businesses, which are just another part of \nour con nected oncology ecosystem at McKesson.  \n \n Let me talk about Prescription Technology Solutions.  They perform well this year despite prescription volumes \nbeing down since the onset of the pandemic.  We're continuing to invest in innovation in this business and despite \nthis year's challenges we've been very successful in adding new brands to our platforms.  \n \n", "original_text": "In \nfiscal 2022, we'll look to grow both our US Oncology and non -affiliated businesses, which are just another part of \nour con nected oncology ecosystem at McKesson.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f865057a7eaefa05e3906a67b1d40d12eaafd9263be9dbd0abaac5e3726b338", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "698e8ca5-27e2-466d-9eb0-5f5349feb92a", "node_type": "1", "metadata": {"window": "Our US On cology business, \npatient visits were at pre -COVID baselines in March, with many returning for in -person visits to their providers.  In \nfiscal 2022, we'll look to grow both our US Oncology and non -affiliated businesses, which are just another part of \nour con nected oncology ecosystem at McKesson.  \n \n Let me talk about Prescription Technology Solutions.  They perform well this year despite prescription volumes \nbeing down since the onset of the pandemic.  We're continuing to invest in innovation in this business and despite \nthis year's challenges we've been very successful in adding new brands to our platforms.  \n \n In fiscal 2021, our access solutions helped over 50 million patients get on therapies after their original prescription \nwas denied coverage, and our affordabi lity solutions helped patients save over $7 billion in out -of-pocket \nprescription costs.  Under a single cohesive go -to-market strategy, this segment is positioned to return to growth in \nfiscal 2022, as patient mobility improves and prescription trends reco ver. \n \n", "original_text": "They perform well this year despite prescription volumes \nbeing down since the onset of the pandemic. "}, "hash": "48622ce7800142c37b6b1ff1023f536142b2ca064cb6be69e84f0b8a4ffbd898", "class_name": "RelatedNodeInfo"}}, "text": "Let me talk about Prescription Technology Solutions. ", "start_char_idx": 576, "end_char_idx": 629, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "698e8ca5-27e2-466d-9eb0-5f5349feb92a": {"__data__": {"id_": "698e8ca5-27e2-466d-9eb0-5f5349feb92a", "embedding": null, "metadata": {"window": "Our US On cology business, \npatient visits were at pre -COVID baselines in March, with many returning for in -person visits to their providers.  In \nfiscal 2022, we'll look to grow both our US Oncology and non -affiliated businesses, which are just another part of \nour con nected oncology ecosystem at McKesson.  \n \n Let me talk about Prescription Technology Solutions.  They perform well this year despite prescription volumes \nbeing down since the onset of the pandemic.  We're continuing to invest in innovation in this business and despite \nthis year's challenges we've been very successful in adding new brands to our platforms.  \n \n In fiscal 2021, our access solutions helped over 50 million patients get on therapies after their original prescription \nwas denied coverage, and our affordabi lity solutions helped patients save over $7 billion in out -of-pocket \nprescription costs.  Under a single cohesive go -to-market strategy, this segment is positioned to return to growth in \nfiscal 2022, as patient mobility improves and prescription trends reco ver. \n \n", "original_text": "They perform well this year despite prescription volumes \nbeing down since the onset of the pandemic. ", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c850470-3a0a-4880-b2ec-54135610be69", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a305784b8b89364cb419bc4dad266e1519ed1392381036044a2c6b16eeebbe93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b132a37-7c1f-4315-8729-4c1805fd44db", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nI'm also pleased with the performance of our specialty business this past year.  Our US On cology business, \npatient visits were at pre -COVID baselines in March, with many returning for in -person visits to their providers.  In \nfiscal 2022, we'll look to grow both our US Oncology and non -affiliated businesses, which are just another part of \nour con nected oncology ecosystem at McKesson.  \n \n Let me talk about Prescription Technology Solutions.  They perform well this year despite prescription volumes \nbeing down since the onset of the pandemic.  We're continuing to invest in innovation in this business and despite \nthis year's challenges we've been very successful in adding new brands to our platforms.  \n \n In fiscal 2021, our access solutions helped over 50 million patients get on therapies after their original prescription \nwas denied coverage, and our affordabi lity solutions helped patients save over $7 billion in out -of-pocket \nprescription costs. ", "original_text": "Let me talk about Prescription Technology Solutions. ", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e30389c90f0f661f7acd40194668c84033e3d80da5bb91d9a0b4545313302243", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33888a5e-41ce-479e-88a6-30388cca3f01", "node_type": "1", "metadata": {"window": "In \nfiscal 2022, we'll look to grow both our US Oncology and non -affiliated businesses, which are just another part of \nour con nected oncology ecosystem at McKesson.  \n \n Let me talk about Prescription Technology Solutions.  They perform well this year despite prescription volumes \nbeing down since the onset of the pandemic.  We're continuing to invest in innovation in this business and despite \nthis year's challenges we've been very successful in adding new brands to our platforms.  \n \n In fiscal 2021, our access solutions helped over 50 million patients get on therapies after their original prescription \nwas denied coverage, and our affordabi lity solutions helped patients save over $7 billion in out -of-pocket \nprescription costs.  Under a single cohesive go -to-market strategy, this segment is positioned to return to growth in \nfiscal 2022, as patient mobility improves and prescription trends reco ver. \n \n In fiscal 2021, Medical -Surgical played a central role in providing supplies to our primary and extended care \ncustomers at a critical time of need. ", "original_text": "We're continuing to invest in innovation in this business and despite \nthis year's challenges we've been very successful in adding new brands to our platforms.  \n \n"}, "hash": "4e7b49c9bb03b3f370bcd550b087ffba481568d8e90f0ffd9b4af746b1f2437f", "class_name": "RelatedNodeInfo"}}, "text": "They perform well this year despite prescription volumes \nbeing down since the onset of the pandemic. ", "start_char_idx": 629, "end_char_idx": 731, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33888a5e-41ce-479e-88a6-30388cca3f01": {"__data__": {"id_": "33888a5e-41ce-479e-88a6-30388cca3f01", "embedding": null, "metadata": {"window": "In \nfiscal 2022, we'll look to grow both our US Oncology and non -affiliated businesses, which are just another part of \nour con nected oncology ecosystem at McKesson.  \n \n Let me talk about Prescription Technology Solutions.  They perform well this year despite prescription volumes \nbeing down since the onset of the pandemic.  We're continuing to invest in innovation in this business and despite \nthis year's challenges we've been very successful in adding new brands to our platforms.  \n \n In fiscal 2021, our access solutions helped over 50 million patients get on therapies after their original prescription \nwas denied coverage, and our affordabi lity solutions helped patients save over $7 billion in out -of-pocket \nprescription costs.  Under a single cohesive go -to-market strategy, this segment is positioned to return to growth in \nfiscal 2022, as patient mobility improves and prescription trends reco ver. \n \n In fiscal 2021, Medical -Surgical played a central role in providing supplies to our primary and extended care \ncustomers at a critical time of need. ", "original_text": "We're continuing to invest in innovation in this business and despite \nthis year's challenges we've been very successful in adding new brands to our platforms.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c850470-3a0a-4880-b2ec-54135610be69", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a305784b8b89364cb419bc4dad266e1519ed1392381036044a2c6b16eeebbe93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "698e8ca5-27e2-466d-9eb0-5f5349feb92a", "node_type": "1", "metadata": {"window": "Our US On cology business, \npatient visits were at pre -COVID baselines in March, with many returning for in -person visits to their providers.  In \nfiscal 2022, we'll look to grow both our US Oncology and non -affiliated businesses, which are just another part of \nour con nected oncology ecosystem at McKesson.  \n \n Let me talk about Prescription Technology Solutions.  They perform well this year despite prescription volumes \nbeing down since the onset of the pandemic.  We're continuing to invest in innovation in this business and despite \nthis year's challenges we've been very successful in adding new brands to our platforms.  \n \n In fiscal 2021, our access solutions helped over 50 million patients get on therapies after their original prescription \nwas denied coverage, and our affordabi lity solutions helped patients save over $7 billion in out -of-pocket \nprescription costs.  Under a single cohesive go -to-market strategy, this segment is positioned to return to growth in \nfiscal 2022, as patient mobility improves and prescription trends reco ver. \n \n", "original_text": "They perform well this year despite prescription volumes \nbeing down since the onset of the pandemic. ", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a9e17cea13ba298110b5193089b67cd377f9360aa788765be105df06a075687b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21ecf89d-34ae-435d-82b0-0a2836f422b8", "node_type": "1", "metadata": {"window": "Let me talk about Prescription Technology Solutions.  They perform well this year despite prescription volumes \nbeing down since the onset of the pandemic.  We're continuing to invest in innovation in this business and despite \nthis year's challenges we've been very successful in adding new brands to our platforms.  \n \n In fiscal 2021, our access solutions helped over 50 million patients get on therapies after their original prescription \nwas denied coverage, and our affordabi lity solutions helped patients save over $7 billion in out -of-pocket \nprescription costs.  Under a single cohesive go -to-market strategy, this segment is positioned to return to growth in \nfiscal 2022, as patient mobility improves and prescription trends reco ver. \n \n In fiscal 2021, Medical -Surgical played a central role in providing supplies to our primary and extended care \ncustomers at a critical time of need.  Demand within this segment was volatile throughout the fiscal year for \nproducts such as PPE and COVID -19 tests, and our procurement teams worked diligently to find the supplies our \ncustomers needed to treat their patients at a time when supply was constrained and pricing was volatile.  \n \n", "original_text": "In fiscal 2021, our access solutions helped over 50 million patients get on therapies after their original prescription \nwas denied coverage, and our affordabi lity solutions helped patients save over $7 billion in out -of-pocket \nprescription costs. "}, "hash": "605b88f94716226fd193a23b077f1981cf9d6fb051a1f6dd898569386e35472f", "class_name": "RelatedNodeInfo"}}, "text": "We're continuing to invest in innovation in this business and despite \nthis year's challenges we've been very successful in adding new brands to our platforms.  \n \n", "start_char_idx": 731, "end_char_idx": 895, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21ecf89d-34ae-435d-82b0-0a2836f422b8": {"__data__": {"id_": "21ecf89d-34ae-435d-82b0-0a2836f422b8", "embedding": null, "metadata": {"window": "Let me talk about Prescription Technology Solutions.  They perform well this year despite prescription volumes \nbeing down since the onset of the pandemic.  We're continuing to invest in innovation in this business and despite \nthis year's challenges we've been very successful in adding new brands to our platforms.  \n \n In fiscal 2021, our access solutions helped over 50 million patients get on therapies after their original prescription \nwas denied coverage, and our affordabi lity solutions helped patients save over $7 billion in out -of-pocket \nprescription costs.  Under a single cohesive go -to-market strategy, this segment is positioned to return to growth in \nfiscal 2022, as patient mobility improves and prescription trends reco ver. \n \n In fiscal 2021, Medical -Surgical played a central role in providing supplies to our primary and extended care \ncustomers at a critical time of need.  Demand within this segment was volatile throughout the fiscal year for \nproducts such as PPE and COVID -19 tests, and our procurement teams worked diligently to find the supplies our \ncustomers needed to treat their patients at a time when supply was constrained and pricing was volatile.  \n \n", "original_text": "In fiscal 2021, our access solutions helped over 50 million patients get on therapies after their original prescription \nwas denied coverage, and our affordabi lity solutions helped patients save over $7 billion in out -of-pocket \nprescription costs. ", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c850470-3a0a-4880-b2ec-54135610be69", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a305784b8b89364cb419bc4dad266e1519ed1392381036044a2c6b16eeebbe93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33888a5e-41ce-479e-88a6-30388cca3f01", "node_type": "1", "metadata": {"window": "In \nfiscal 2022, we'll look to grow both our US Oncology and non -affiliated businesses, which are just another part of \nour con nected oncology ecosystem at McKesson.  \n \n Let me talk about Prescription Technology Solutions.  They perform well this year despite prescription volumes \nbeing down since the onset of the pandemic.  We're continuing to invest in innovation in this business and despite \nthis year's challenges we've been very successful in adding new brands to our platforms.  \n \n In fiscal 2021, our access solutions helped over 50 million patients get on therapies after their original prescription \nwas denied coverage, and our affordabi lity solutions helped patients save over $7 billion in out -of-pocket \nprescription costs.  Under a single cohesive go -to-market strategy, this segment is positioned to return to growth in \nfiscal 2022, as patient mobility improves and prescription trends reco ver. \n \n In fiscal 2021, Medical -Surgical played a central role in providing supplies to our primary and extended care \ncustomers at a critical time of need. ", "original_text": "We're continuing to invest in innovation in this business and despite \nthis year's challenges we've been very successful in adding new brands to our platforms.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f20818a700e719776469681a6e55235dee94c4f80a160440e8bcde1cb8fa2099", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e5a138f-817a-445e-b199-7cd5970f5412", "node_type": "1", "metadata": {"window": "They perform well this year despite prescription volumes \nbeing down since the onset of the pandemic.  We're continuing to invest in innovation in this business and despite \nthis year's challenges we've been very successful in adding new brands to our platforms.  \n \n In fiscal 2021, our access solutions helped over 50 million patients get on therapies after their original prescription \nwas denied coverage, and our affordabi lity solutions helped patients save over $7 billion in out -of-pocket \nprescription costs.  Under a single cohesive go -to-market strategy, this segment is positioned to return to growth in \nfiscal 2022, as patient mobility improves and prescription trends reco ver. \n \n In fiscal 2021, Medical -Surgical played a central role in providing supplies to our primary and extended care \ncustomers at a critical time of need.  Demand within this segment was volatile throughout the fiscal year for \nproducts such as PPE and COVID -19 tests, and our procurement teams worked diligently to find the supplies our \ncustomers needed to treat their patients at a time when supply was constrained and pricing was volatile.  \n \n While we took measures to meet the needs of our customers for PPE -related products, demand has fluctuated \nand market dynamics for some of these products has changed since the onset of the pandemic. ", "original_text": "Under a single cohesive go -to-market strategy, this segment is positioned to return to growth in \nfiscal 2022, as patient mobility improves and prescription trends reco ver. \n \n"}, "hash": "f72ec5ea4761e71c8553eaca4eefdf7eb699515ed468573494985201e41b6abd", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal 2021, our access solutions helped over 50 million patients get on therapies after their original prescription \nwas denied coverage, and our affordabi lity solutions helped patients save over $7 billion in out -of-pocket \nprescription costs. ", "start_char_idx": 895, "end_char_idx": 1146, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e5a138f-817a-445e-b199-7cd5970f5412": {"__data__": {"id_": "2e5a138f-817a-445e-b199-7cd5970f5412", "embedding": null, "metadata": {"window": "They perform well this year despite prescription volumes \nbeing down since the onset of the pandemic.  We're continuing to invest in innovation in this business and despite \nthis year's challenges we've been very successful in adding new brands to our platforms.  \n \n In fiscal 2021, our access solutions helped over 50 million patients get on therapies after their original prescription \nwas denied coverage, and our affordabi lity solutions helped patients save over $7 billion in out -of-pocket \nprescription costs.  Under a single cohesive go -to-market strategy, this segment is positioned to return to growth in \nfiscal 2022, as patient mobility improves and prescription trends reco ver. \n \n In fiscal 2021, Medical -Surgical played a central role in providing supplies to our primary and extended care \ncustomers at a critical time of need.  Demand within this segment was volatile throughout the fiscal year for \nproducts such as PPE and COVID -19 tests, and our procurement teams worked diligently to find the supplies our \ncustomers needed to treat their patients at a time when supply was constrained and pricing was volatile.  \n \n While we took measures to meet the needs of our customers for PPE -related products, demand has fluctuated \nand market dynamics for some of these products has changed since the onset of the pandemic. ", "original_text": "Under a single cohesive go -to-market strategy, this segment is positioned to return to growth in \nfiscal 2022, as patient mobility improves and prescription trends reco ver. \n \n", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c850470-3a0a-4880-b2ec-54135610be69", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a305784b8b89364cb419bc4dad266e1519ed1392381036044a2c6b16eeebbe93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21ecf89d-34ae-435d-82b0-0a2836f422b8", "node_type": "1", "metadata": {"window": "Let me talk about Prescription Technology Solutions.  They perform well this year despite prescription volumes \nbeing down since the onset of the pandemic.  We're continuing to invest in innovation in this business and despite \nthis year's challenges we've been very successful in adding new brands to our platforms.  \n \n In fiscal 2021, our access solutions helped over 50 million patients get on therapies after their original prescription \nwas denied coverage, and our affordabi lity solutions helped patients save over $7 billion in out -of-pocket \nprescription costs.  Under a single cohesive go -to-market strategy, this segment is positioned to return to growth in \nfiscal 2022, as patient mobility improves and prescription trends reco ver. \n \n In fiscal 2021, Medical -Surgical played a central role in providing supplies to our primary and extended care \ncustomers at a critical time of need.  Demand within this segment was volatile throughout the fiscal year for \nproducts such as PPE and COVID -19 tests, and our procurement teams worked diligently to find the supplies our \ncustomers needed to treat their patients at a time when supply was constrained and pricing was volatile.  \n \n", "original_text": "In fiscal 2021, our access solutions helped over 50 million patients get on therapies after their original prescription \nwas denied coverage, and our affordabi lity solutions helped patients save over $7 billion in out -of-pocket \nprescription costs. ", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c209ed7f07364d5ec2219d67f45a9cae593247d107f893d4056da6065cfd9380", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd21e1c0-080f-42a3-b410-5160e3ed0737", "node_type": "1", "metadata": {"window": "We're continuing to invest in innovation in this business and despite \nthis year's challenges we've been very successful in adding new brands to our platforms.  \n \n In fiscal 2021, our access solutions helped over 50 million patients get on therapies after their original prescription \nwas denied coverage, and our affordabi lity solutions helped patients save over $7 billion in out -of-pocket \nprescription costs.  Under a single cohesive go -to-market strategy, this segment is positioned to return to growth in \nfiscal 2022, as patient mobility improves and prescription trends reco ver. \n \n In fiscal 2021, Medical -Surgical played a central role in providing supplies to our primary and extended care \ncustomers at a critical time of need.  Demand within this segment was volatile throughout the fiscal year for \nproducts such as PPE and COVID -19 tests, and our procurement teams worked diligently to find the supplies our \ncustomers needed to treat their patients at a time when supply was constrained and pricing was volatile.  \n \n While we took measures to meet the needs of our customers for PPE -related products, demand has fluctuated \nand market dynamics for some of these products has changed since the onset of the pandemic.  As a result, we \ntook action to position the business for lower demand levels, which resulted in inventory charges on some PPE \nand related products.  \n \n", "original_text": "In fiscal 2021, Medical -Surgical played a central role in providing supplies to our primary and extended care \ncustomers at a critical time of need. "}, "hash": "4c3ff53aaab47e0b601a1206009325c59b39f92a1848901a8a80511949fe19c2", "class_name": "RelatedNodeInfo"}}, "text": "Under a single cohesive go -to-market strategy, this segment is positioned to return to growth in \nfiscal 2022, as patient mobility improves and prescription trends reco ver. \n \n", "start_char_idx": 1146, "end_char_idx": 1324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd21e1c0-080f-42a3-b410-5160e3ed0737": {"__data__": {"id_": "dd21e1c0-080f-42a3-b410-5160e3ed0737", "embedding": null, "metadata": {"window": "We're continuing to invest in innovation in this business and despite \nthis year's challenges we've been very successful in adding new brands to our platforms.  \n \n In fiscal 2021, our access solutions helped over 50 million patients get on therapies after their original prescription \nwas denied coverage, and our affordabi lity solutions helped patients save over $7 billion in out -of-pocket \nprescription costs.  Under a single cohesive go -to-market strategy, this segment is positioned to return to growth in \nfiscal 2022, as patient mobility improves and prescription trends reco ver. \n \n In fiscal 2021, Medical -Surgical played a central role in providing supplies to our primary and extended care \ncustomers at a critical time of need.  Demand within this segment was volatile throughout the fiscal year for \nproducts such as PPE and COVID -19 tests, and our procurement teams worked diligently to find the supplies our \ncustomers needed to treat their patients at a time when supply was constrained and pricing was volatile.  \n \n While we took measures to meet the needs of our customers for PPE -related products, demand has fluctuated \nand market dynamics for some of these products has changed since the onset of the pandemic.  As a result, we \ntook action to position the business for lower demand levels, which resulted in inventory charges on some PPE \nand related products.  \n \n", "original_text": "In fiscal 2021, Medical -Surgical played a central role in providing supplies to our primary and extended care \ncustomers at a critical time of need. ", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c850470-3a0a-4880-b2ec-54135610be69", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a305784b8b89364cb419bc4dad266e1519ed1392381036044a2c6b16eeebbe93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e5a138f-817a-445e-b199-7cd5970f5412", "node_type": "1", "metadata": {"window": "They perform well this year despite prescription volumes \nbeing down since the onset of the pandemic.  We're continuing to invest in innovation in this business and despite \nthis year's challenges we've been very successful in adding new brands to our platforms.  \n \n In fiscal 2021, our access solutions helped over 50 million patients get on therapies after their original prescription \nwas denied coverage, and our affordabi lity solutions helped patients save over $7 billion in out -of-pocket \nprescription costs.  Under a single cohesive go -to-market strategy, this segment is positioned to return to growth in \nfiscal 2022, as patient mobility improves and prescription trends reco ver. \n \n In fiscal 2021, Medical -Surgical played a central role in providing supplies to our primary and extended care \ncustomers at a critical time of need.  Demand within this segment was volatile throughout the fiscal year for \nproducts such as PPE and COVID -19 tests, and our procurement teams worked diligently to find the supplies our \ncustomers needed to treat their patients at a time when supply was constrained and pricing was volatile.  \n \n While we took measures to meet the needs of our customers for PPE -related products, demand has fluctuated \nand market dynamics for some of these products has changed since the onset of the pandemic. ", "original_text": "Under a single cohesive go -to-market strategy, this segment is positioned to return to growth in \nfiscal 2022, as patient mobility improves and prescription trends reco ver. \n \n", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "90f59d2329c82045fbc0112f12b3975642314b12adaf4c6dc06c65c8e165acef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c290c30-7af3-4aef-bdb1-7ab3cb518ad5", "node_type": "1", "metadata": {"window": "In fiscal 2021, our access solutions helped over 50 million patients get on therapies after their original prescription \nwas denied coverage, and our affordabi lity solutions helped patients save over $7 billion in out -of-pocket \nprescription costs.  Under a single cohesive go -to-market strategy, this segment is positioned to return to growth in \nfiscal 2022, as patient mobility improves and prescription trends reco ver. \n \n In fiscal 2021, Medical -Surgical played a central role in providing supplies to our primary and extended care \ncustomers at a critical time of need.  Demand within this segment was volatile throughout the fiscal year for \nproducts such as PPE and COVID -19 tests, and our procurement teams worked diligently to find the supplies our \ncustomers needed to treat their patients at a time when supply was constrained and pricing was volatile.  \n \n While we took measures to meet the needs of our customers for PPE -related products, demand has fluctuated \nand market dynamics for some of these products has changed since the onset of the pandemic.  As a result, we \ntook action to position the business for lower demand levels, which resulted in inventory charges on some PPE \nand related products.  \n \n Further adapting to the impact of COVID -19 on our customers, we leveraged our existing lab capabilities to \nquickly distribute over 50 million COVID -19 tests into the provider settings we serve, demonstrating the breadth \nand expertise we  have in our market -leading lab business.  \n \n", "original_text": "Demand within this segment was volatile throughout the fiscal year for \nproducts such as PPE and COVID -19 tests, and our procurement teams worked diligently to find the supplies our \ncustomers needed to treat their patients at a time when supply was constrained and pricing was volatile.  \n \n"}, "hash": "8b3b60c901d837194ddc9686b94885aba7e008d77e5fc8cca04682cd5de52780", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal 2021, Medical -Surgical played a central role in providing supplies to our primary and extended care \ncustomers at a critical time of need. ", "start_char_idx": 1324, "end_char_idx": 1474, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c290c30-7af3-4aef-bdb1-7ab3cb518ad5": {"__data__": {"id_": "1c290c30-7af3-4aef-bdb1-7ab3cb518ad5", "embedding": null, "metadata": {"window": "In fiscal 2021, our access solutions helped over 50 million patients get on therapies after their original prescription \nwas denied coverage, and our affordabi lity solutions helped patients save over $7 billion in out -of-pocket \nprescription costs.  Under a single cohesive go -to-market strategy, this segment is positioned to return to growth in \nfiscal 2022, as patient mobility improves and prescription trends reco ver. \n \n In fiscal 2021, Medical -Surgical played a central role in providing supplies to our primary and extended care \ncustomers at a critical time of need.  Demand within this segment was volatile throughout the fiscal year for \nproducts such as PPE and COVID -19 tests, and our procurement teams worked diligently to find the supplies our \ncustomers needed to treat their patients at a time when supply was constrained and pricing was volatile.  \n \n While we took measures to meet the needs of our customers for PPE -related products, demand has fluctuated \nand market dynamics for some of these products has changed since the onset of the pandemic.  As a result, we \ntook action to position the business for lower demand levels, which resulted in inventory charges on some PPE \nand related products.  \n \n Further adapting to the impact of COVID -19 on our customers, we leveraged our existing lab capabilities to \nquickly distribute over 50 million COVID -19 tests into the provider settings we serve, demonstrating the breadth \nand expertise we  have in our market -leading lab business.  \n \n", "original_text": "Demand within this segment was volatile throughout the fiscal year for \nproducts such as PPE and COVID -19 tests, and our procurement teams worked diligently to find the supplies our \ncustomers needed to treat their patients at a time when supply was constrained and pricing was volatile.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c850470-3a0a-4880-b2ec-54135610be69", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a305784b8b89364cb419bc4dad266e1519ed1392381036044a2c6b16eeebbe93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd21e1c0-080f-42a3-b410-5160e3ed0737", "node_type": "1", "metadata": {"window": "We're continuing to invest in innovation in this business and despite \nthis year's challenges we've been very successful in adding new brands to our platforms.  \n \n In fiscal 2021, our access solutions helped over 50 million patients get on therapies after their original prescription \nwas denied coverage, and our affordabi lity solutions helped patients save over $7 billion in out -of-pocket \nprescription costs.  Under a single cohesive go -to-market strategy, this segment is positioned to return to growth in \nfiscal 2022, as patient mobility improves and prescription trends reco ver. \n \n In fiscal 2021, Medical -Surgical played a central role in providing supplies to our primary and extended care \ncustomers at a critical time of need.  Demand within this segment was volatile throughout the fiscal year for \nproducts such as PPE and COVID -19 tests, and our procurement teams worked diligently to find the supplies our \ncustomers needed to treat their patients at a time when supply was constrained and pricing was volatile.  \n \n While we took measures to meet the needs of our customers for PPE -related products, demand has fluctuated \nand market dynamics for some of these products has changed since the onset of the pandemic.  As a result, we \ntook action to position the business for lower demand levels, which resulted in inventory charges on some PPE \nand related products.  \n \n", "original_text": "In fiscal 2021, Medical -Surgical played a central role in providing supplies to our primary and extended care \ncustomers at a critical time of need. ", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ec1b3ec2e2352b61eb571ce1f6e5d80261a28c489992856ee3efda612792fbe4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8827647a-824b-4885-93ca-8c0b9a862436", "node_type": "1", "metadata": {"window": "Under a single cohesive go -to-market strategy, this segment is positioned to return to growth in \nfiscal 2022, as patient mobility improves and prescription trends reco ver. \n \n In fiscal 2021, Medical -Surgical played a central role in providing supplies to our primary and extended care \ncustomers at a critical time of need.  Demand within this segment was volatile throughout the fiscal year for \nproducts such as PPE and COVID -19 tests, and our procurement teams worked diligently to find the supplies our \ncustomers needed to treat their patients at a time when supply was constrained and pricing was volatile.  \n \n While we took measures to meet the needs of our customers for PPE -related products, demand has fluctuated \nand market dynamics for some of these products has changed since the onset of the pandemic.  As a result, we \ntook action to position the business for lower demand levels, which resulted in inventory charges on some PPE \nand related products.  \n \n Further adapting to the impact of COVID -19 on our customers, we leveraged our existing lab capabilities to \nquickly distribute over 50 million COVID -19 tests into the provider settings we serve, demonstrating the breadth \nand expertise we  have in our market -leading lab business.  \n \n Despite patient mobility trends below pre -COVID levels for much of fiscal 2021, I'm proud of the way the business \nresponded to the needs of our customers, and I am confident that as patients return to consume heal thcare and \nsee their community -based providers, our core business is positioned well for growth heading into fiscal 2022.  \n \n", "original_text": "While we took measures to meet the needs of our customers for PPE -related products, demand has fluctuated \nand market dynamics for some of these products has changed since the onset of the pandemic. "}, "hash": "e351e60b0265ecbfc9e27441234b6b890c7f696a30d0c34f0c9a17e441d57235", "class_name": "RelatedNodeInfo"}}, "text": "Demand within this segment was volatile throughout the fiscal year for \nproducts such as PPE and COVID -19 tests, and our procurement teams worked diligently to find the supplies our \ncustomers needed to treat their patients at a time when supply was constrained and pricing was volatile.  \n \n", "start_char_idx": 1474, "end_char_idx": 1767, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8827647a-824b-4885-93ca-8c0b9a862436": {"__data__": {"id_": "8827647a-824b-4885-93ca-8c0b9a862436", "embedding": null, "metadata": {"window": "Under a single cohesive go -to-market strategy, this segment is positioned to return to growth in \nfiscal 2022, as patient mobility improves and prescription trends reco ver. \n \n In fiscal 2021, Medical -Surgical played a central role in providing supplies to our primary and extended care \ncustomers at a critical time of need.  Demand within this segment was volatile throughout the fiscal year for \nproducts such as PPE and COVID -19 tests, and our procurement teams worked diligently to find the supplies our \ncustomers needed to treat their patients at a time when supply was constrained and pricing was volatile.  \n \n While we took measures to meet the needs of our customers for PPE -related products, demand has fluctuated \nand market dynamics for some of these products has changed since the onset of the pandemic.  As a result, we \ntook action to position the business for lower demand levels, which resulted in inventory charges on some PPE \nand related products.  \n \n Further adapting to the impact of COVID -19 on our customers, we leveraged our existing lab capabilities to \nquickly distribute over 50 million COVID -19 tests into the provider settings we serve, demonstrating the breadth \nand expertise we  have in our market -leading lab business.  \n \n Despite patient mobility trends below pre -COVID levels for much of fiscal 2021, I'm proud of the way the business \nresponded to the needs of our customers, and I am confident that as patients return to consume heal thcare and \nsee their community -based providers, our core business is positioned well for growth heading into fiscal 2022.  \n \n", "original_text": "While we took measures to meet the needs of our customers for PPE -related products, demand has fluctuated \nand market dynamics for some of these products has changed since the onset of the pandemic. ", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c850470-3a0a-4880-b2ec-54135610be69", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a305784b8b89364cb419bc4dad266e1519ed1392381036044a2c6b16eeebbe93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c290c30-7af3-4aef-bdb1-7ab3cb518ad5", "node_type": "1", "metadata": {"window": "In fiscal 2021, our access solutions helped over 50 million patients get on therapies after their original prescription \nwas denied coverage, and our affordabi lity solutions helped patients save over $7 billion in out -of-pocket \nprescription costs.  Under a single cohesive go -to-market strategy, this segment is positioned to return to growth in \nfiscal 2022, as patient mobility improves and prescription trends reco ver. \n \n In fiscal 2021, Medical -Surgical played a central role in providing supplies to our primary and extended care \ncustomers at a critical time of need.  Demand within this segment was volatile throughout the fiscal year for \nproducts such as PPE and COVID -19 tests, and our procurement teams worked diligently to find the supplies our \ncustomers needed to treat their patients at a time when supply was constrained and pricing was volatile.  \n \n While we took measures to meet the needs of our customers for PPE -related products, demand has fluctuated \nand market dynamics for some of these products has changed since the onset of the pandemic.  As a result, we \ntook action to position the business for lower demand levels, which resulted in inventory charges on some PPE \nand related products.  \n \n Further adapting to the impact of COVID -19 on our customers, we leveraged our existing lab capabilities to \nquickly distribute over 50 million COVID -19 tests into the provider settings we serve, demonstrating the breadth \nand expertise we  have in our market -leading lab business.  \n \n", "original_text": "Demand within this segment was volatile throughout the fiscal year for \nproducts such as PPE and COVID -19 tests, and our procurement teams worked diligently to find the supplies our \ncustomers needed to treat their patients at a time when supply was constrained and pricing was volatile.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9d02dbe35448bb2a80d3e39b8ad0e1ebbe34ae50c1b6373f9df404f89baeddfa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5043786b-e3df-469c-a062-4a2b2623d5d6", "node_type": "1", "metadata": {"window": "In fiscal 2021, Medical -Surgical played a central role in providing supplies to our primary and extended care \ncustomers at a critical time of need.  Demand within this segment was volatile throughout the fiscal year for \nproducts such as PPE and COVID -19 tests, and our procurement teams worked diligently to find the supplies our \ncustomers needed to treat their patients at a time when supply was constrained and pricing was volatile.  \n \n While we took measures to meet the needs of our customers for PPE -related products, demand has fluctuated \nand market dynamics for some of these products has changed since the onset of the pandemic.  As a result, we \ntook action to position the business for lower demand levels, which resulted in inventory charges on some PPE \nand related products.  \n \n Further adapting to the impact of COVID -19 on our customers, we leveraged our existing lab capabilities to \nquickly distribute over 50 million COVID -19 tests into the provider settings we serve, demonstrating the breadth \nand expertise we  have in our market -leading lab business.  \n \n Despite patient mobility trends below pre -COVID levels for much of fiscal 2021, I'm proud of the way the business \nresponded to the needs of our customers, and I am confident that as patients return to consume heal thcare and \nsee their community -based providers, our core business is positioned well for growth heading into fiscal 2022.  \n \n Finally, turning to International. ", "original_text": "As a result, we \ntook action to position the business for lower demand levels, which resulted in inventory charges on some PPE \nand related products.  \n \n"}, "hash": "e73712b0fe92f433c9b984f0b4b0bcef8053fe5511a4580c72a599d6e5f122ef", "class_name": "RelatedNodeInfo"}}, "text": "While we took measures to meet the needs of our customers for PPE -related products, demand has fluctuated \nand market dynamics for some of these products has changed since the onset of the pandemic. ", "start_char_idx": 1767, "end_char_idx": 1967, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5043786b-e3df-469c-a062-4a2b2623d5d6": {"__data__": {"id_": "5043786b-e3df-469c-a062-4a2b2623d5d6", "embedding": null, "metadata": {"window": "In fiscal 2021, Medical -Surgical played a central role in providing supplies to our primary and extended care \ncustomers at a critical time of need.  Demand within this segment was volatile throughout the fiscal year for \nproducts such as PPE and COVID -19 tests, and our procurement teams worked diligently to find the supplies our \ncustomers needed to treat their patients at a time when supply was constrained and pricing was volatile.  \n \n While we took measures to meet the needs of our customers for PPE -related products, demand has fluctuated \nand market dynamics for some of these products has changed since the onset of the pandemic.  As a result, we \ntook action to position the business for lower demand levels, which resulted in inventory charges on some PPE \nand related products.  \n \n Further adapting to the impact of COVID -19 on our customers, we leveraged our existing lab capabilities to \nquickly distribute over 50 million COVID -19 tests into the provider settings we serve, demonstrating the breadth \nand expertise we  have in our market -leading lab business.  \n \n Despite patient mobility trends below pre -COVID levels for much of fiscal 2021, I'm proud of the way the business \nresponded to the needs of our customers, and I am confident that as patients return to consume heal thcare and \nsee their community -based providers, our core business is positioned well for growth heading into fiscal 2022.  \n \n Finally, turning to International. ", "original_text": "As a result, we \ntook action to position the business for lower demand levels, which resulted in inventory charges on some PPE \nand related products.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c850470-3a0a-4880-b2ec-54135610be69", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a305784b8b89364cb419bc4dad266e1519ed1392381036044a2c6b16eeebbe93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8827647a-824b-4885-93ca-8c0b9a862436", "node_type": "1", "metadata": {"window": "Under a single cohesive go -to-market strategy, this segment is positioned to return to growth in \nfiscal 2022, as patient mobility improves and prescription trends reco ver. \n \n In fiscal 2021, Medical -Surgical played a central role in providing supplies to our primary and extended care \ncustomers at a critical time of need.  Demand within this segment was volatile throughout the fiscal year for \nproducts such as PPE and COVID -19 tests, and our procurement teams worked diligently to find the supplies our \ncustomers needed to treat their patients at a time when supply was constrained and pricing was volatile.  \n \n While we took measures to meet the needs of our customers for PPE -related products, demand has fluctuated \nand market dynamics for some of these products has changed since the onset of the pandemic.  As a result, we \ntook action to position the business for lower demand levels, which resulted in inventory charges on some PPE \nand related products.  \n \n Further adapting to the impact of COVID -19 on our customers, we leveraged our existing lab capabilities to \nquickly distribute over 50 million COVID -19 tests into the provider settings we serve, demonstrating the breadth \nand expertise we  have in our market -leading lab business.  \n \n Despite patient mobility trends below pre -COVID levels for much of fiscal 2021, I'm proud of the way the business \nresponded to the needs of our customers, and I am confident that as patients return to consume heal thcare and \nsee their community -based providers, our core business is positioned well for growth heading into fiscal 2022.  \n \n", "original_text": "While we took measures to meet the needs of our customers for PPE -related products, demand has fluctuated \nand market dynamics for some of these products has changed since the onset of the pandemic. ", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04a60ab41831e0abad625cf27bc717c99b7503da56cf10298a368221332b4cfe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1223f457-4806-4de3-8fd4-8db4ba421706", "node_type": "1", "metadata": {"window": "Demand within this segment was volatile throughout the fiscal year for \nproducts such as PPE and COVID -19 tests, and our procurement teams worked diligently to find the supplies our \ncustomers needed to treat their patients at a time when supply was constrained and pricing was volatile.  \n \n While we took measures to meet the needs of our customers for PPE -related products, demand has fluctuated \nand market dynamics for some of these products has changed since the onset of the pandemic.  As a result, we \ntook action to position the business for lower demand levels, which resulted in inventory charges on some PPE \nand related products.  \n \n Further adapting to the impact of COVID -19 on our customers, we leveraged our existing lab capabilities to \nquickly distribute over 50 million COVID -19 tests into the provider settings we serve, demonstrating the breadth \nand expertise we  have in our market -leading lab business.  \n \n Despite patient mobility trends below pre -COVID levels for much of fiscal 2021, I'm proud of the way the business \nresponded to the needs of our customers, and I am confident that as patients return to consume heal thcare and \nsee their community -based providers, our core business is positioned well for growth heading into fiscal 2022.  \n \n Finally, turning to International.  The segment grew full year adjusted operating profit despite lower foot traffic in \nmany of our ret ail pharmacies across Europe and Canada, where the pandemic still lags the recovery we're \nseeing in the US. ", "original_text": "Further adapting to the impact of COVID -19 on our customers, we leveraged our existing lab capabilities to \nquickly distribute over 50 million COVID -19 tests into the provider settings we serve, demonstrating the breadth \nand expertise we  have in our market -leading lab business.  \n \n"}, "hash": "27d99866bfa3cb0f42246eadcfabf51747ceb159241bae036c114732a874d35c", "class_name": "RelatedNodeInfo"}}, "text": "As a result, we \ntook action to position the business for lower demand levels, which resulted in inventory charges on some PPE \nand related products.  \n \n", "start_char_idx": 1967, "end_char_idx": 2121, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1223f457-4806-4de3-8fd4-8db4ba421706": {"__data__": {"id_": "1223f457-4806-4de3-8fd4-8db4ba421706", "embedding": null, "metadata": {"window": "Demand within this segment was volatile throughout the fiscal year for \nproducts such as PPE and COVID -19 tests, and our procurement teams worked diligently to find the supplies our \ncustomers needed to treat their patients at a time when supply was constrained and pricing was volatile.  \n \n While we took measures to meet the needs of our customers for PPE -related products, demand has fluctuated \nand market dynamics for some of these products has changed since the onset of the pandemic.  As a result, we \ntook action to position the business for lower demand levels, which resulted in inventory charges on some PPE \nand related products.  \n \n Further adapting to the impact of COVID -19 on our customers, we leveraged our existing lab capabilities to \nquickly distribute over 50 million COVID -19 tests into the provider settings we serve, demonstrating the breadth \nand expertise we  have in our market -leading lab business.  \n \n Despite patient mobility trends below pre -COVID levels for much of fiscal 2021, I'm proud of the way the business \nresponded to the needs of our customers, and I am confident that as patients return to consume heal thcare and \nsee their community -based providers, our core business is positioned well for growth heading into fiscal 2022.  \n \n Finally, turning to International.  The segment grew full year adjusted operating profit despite lower foot traffic in \nmany of our ret ail pharmacies across Europe and Canada, where the pandemic still lags the recovery we're \nseeing in the US. ", "original_text": "Further adapting to the impact of COVID -19 on our customers, we leveraged our existing lab capabilities to \nquickly distribute over 50 million COVID -19 tests into the provider settings we serve, demonstrating the breadth \nand expertise we  have in our market -leading lab business.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c850470-3a0a-4880-b2ec-54135610be69", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a305784b8b89364cb419bc4dad266e1519ed1392381036044a2c6b16eeebbe93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5043786b-e3df-469c-a062-4a2b2623d5d6", "node_type": "1", "metadata": {"window": "In fiscal 2021, Medical -Surgical played a central role in providing supplies to our primary and extended care \ncustomers at a critical time of need.  Demand within this segment was volatile throughout the fiscal year for \nproducts such as PPE and COVID -19 tests, and our procurement teams worked diligently to find the supplies our \ncustomers needed to treat their patients at a time when supply was constrained and pricing was volatile.  \n \n While we took measures to meet the needs of our customers for PPE -related products, demand has fluctuated \nand market dynamics for some of these products has changed since the onset of the pandemic.  As a result, we \ntook action to position the business for lower demand levels, which resulted in inventory charges on some PPE \nand related products.  \n \n Further adapting to the impact of COVID -19 on our customers, we leveraged our existing lab capabilities to \nquickly distribute over 50 million COVID -19 tests into the provider settings we serve, demonstrating the breadth \nand expertise we  have in our market -leading lab business.  \n \n Despite patient mobility trends below pre -COVID levels for much of fiscal 2021, I'm proud of the way the business \nresponded to the needs of our customers, and I am confident that as patients return to consume heal thcare and \nsee their community -based providers, our core business is positioned well for growth heading into fiscal 2022.  \n \n Finally, turning to International. ", "original_text": "As a result, we \ntook action to position the business for lower demand levels, which resulted in inventory charges on some PPE \nand related products.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "586de9d7dd26dc9ff2a2f5f6e03162f3aa8d2dc7dd5b0aad952b64a2434ac3a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a60703ab-809b-4a5f-b70d-cdaaba2d05eb", "node_type": "1", "metadata": {"window": "While we took measures to meet the needs of our customers for PPE -related products, demand has fluctuated \nand market dynamics for some of these products has changed since the onset of the pandemic.  As a result, we \ntook action to position the business for lower demand levels, which resulted in inventory charges on some PPE \nand related products.  \n \n Further adapting to the impact of COVID -19 on our customers, we leveraged our existing lab capabilities to \nquickly distribute over 50 million COVID -19 tests into the provider settings we serve, demonstrating the breadth \nand expertise we  have in our market -leading lab business.  \n \n Despite patient mobility trends below pre -COVID levels for much of fiscal 2021, I'm proud of the way the business \nresponded to the needs of our customers, and I am confident that as patients return to consume heal thcare and \nsee their community -based providers, our core business is positioned well for growth heading into fiscal 2022.  \n \n Finally, turning to International.  The segment grew full year adjusted operating profit despite lower foot traffic in \nmany of our ret ail pharmacies across Europe and Canada, where the pandemic still lags the recovery we're \nseeing in the US.  Over the past several years, we've taken deliberate actions to address our cost structure and to \nevolve our retail footprint in these markets, and w e saw benefits from those actions this fiscal year. ", "original_text": "Despite patient mobility trends below pre -COVID levels for much of fiscal 2021, I'm proud of the way the business \nresponded to the needs of our customers, and I am confident that as patients return to consume heal thcare and \nsee their community -based providers, our core business is positioned well for growth heading into fiscal 2022.  \n \n"}, "hash": "e5aff80ac876725c28b8403b98f37ed26cc45467a856b61c3d5a66b86759c17d", "class_name": "RelatedNodeInfo"}}, "text": "Further adapting to the impact of COVID -19 on our customers, we leveraged our existing lab capabilities to \nquickly distribute over 50 million COVID -19 tests into the provider settings we serve, demonstrating the breadth \nand expertise we  have in our market -leading lab business.  \n \n", "start_char_idx": 2121, "end_char_idx": 2409, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a60703ab-809b-4a5f-b70d-cdaaba2d05eb": {"__data__": {"id_": "a60703ab-809b-4a5f-b70d-cdaaba2d05eb", "embedding": null, "metadata": {"window": "While we took measures to meet the needs of our customers for PPE -related products, demand has fluctuated \nand market dynamics for some of these products has changed since the onset of the pandemic.  As a result, we \ntook action to position the business for lower demand levels, which resulted in inventory charges on some PPE \nand related products.  \n \n Further adapting to the impact of COVID -19 on our customers, we leveraged our existing lab capabilities to \nquickly distribute over 50 million COVID -19 tests into the provider settings we serve, demonstrating the breadth \nand expertise we  have in our market -leading lab business.  \n \n Despite patient mobility trends below pre -COVID levels for much of fiscal 2021, I'm proud of the way the business \nresponded to the needs of our customers, and I am confident that as patients return to consume heal thcare and \nsee their community -based providers, our core business is positioned well for growth heading into fiscal 2022.  \n \n Finally, turning to International.  The segment grew full year adjusted operating profit despite lower foot traffic in \nmany of our ret ail pharmacies across Europe and Canada, where the pandemic still lags the recovery we're \nseeing in the US.  Over the past several years, we've taken deliberate actions to address our cost structure and to \nevolve our retail footprint in these markets, and w e saw benefits from those actions this fiscal year. ", "original_text": "Despite patient mobility trends below pre -COVID levels for much of fiscal 2021, I'm proud of the way the business \nresponded to the needs of our customers, and I am confident that as patients return to consume heal thcare and \nsee their community -based providers, our core business is positioned well for growth heading into fiscal 2022.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c850470-3a0a-4880-b2ec-54135610be69", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a305784b8b89364cb419bc4dad266e1519ed1392381036044a2c6b16eeebbe93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1223f457-4806-4de3-8fd4-8db4ba421706", "node_type": "1", "metadata": {"window": "Demand within this segment was volatile throughout the fiscal year for \nproducts such as PPE and COVID -19 tests, and our procurement teams worked diligently to find the supplies our \ncustomers needed to treat their patients at a time when supply was constrained and pricing was volatile.  \n \n While we took measures to meet the needs of our customers for PPE -related products, demand has fluctuated \nand market dynamics for some of these products has changed since the onset of the pandemic.  As a result, we \ntook action to position the business for lower demand levels, which resulted in inventory charges on some PPE \nand related products.  \n \n Further adapting to the impact of COVID -19 on our customers, we leveraged our existing lab capabilities to \nquickly distribute over 50 million COVID -19 tests into the provider settings we serve, demonstrating the breadth \nand expertise we  have in our market -leading lab business.  \n \n Despite patient mobility trends below pre -COVID levels for much of fiscal 2021, I'm proud of the way the business \nresponded to the needs of our customers, and I am confident that as patients return to consume heal thcare and \nsee their community -based providers, our core business is positioned well for growth heading into fiscal 2022.  \n \n Finally, turning to International.  The segment grew full year adjusted operating profit despite lower foot traffic in \nmany of our ret ail pharmacies across Europe and Canada, where the pandemic still lags the recovery we're \nseeing in the US. ", "original_text": "Further adapting to the impact of COVID -19 on our customers, we leveraged our existing lab capabilities to \nquickly distribute over 50 million COVID -19 tests into the provider settings we serve, demonstrating the breadth \nand expertise we  have in our market -leading lab business.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94e2908fbbf6edf15942371004d4a70609517985f15ebc18afd46e13623959bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee860429-a866-4139-b0e4-42ef28e3d5bc", "node_type": "1", "metadata": {"window": "As a result, we \ntook action to position the business for lower demand levels, which resulted in inventory charges on some PPE \nand related products.  \n \n Further adapting to the impact of COVID -19 on our customers, we leveraged our existing lab capabilities to \nquickly distribute over 50 million COVID -19 tests into the provider settings we serve, demonstrating the breadth \nand expertise we  have in our market -leading lab business.  \n \n Despite patient mobility trends below pre -COVID levels for much of fiscal 2021, I'm proud of the way the business \nresponded to the needs of our customers, and I am confident that as patients return to consume heal thcare and \nsee their community -based providers, our core business is positioned well for growth heading into fiscal 2022.  \n \n Finally, turning to International.  The segment grew full year adjusted operating profit despite lower foot traffic in \nmany of our ret ail pharmacies across Europe and Canada, where the pandemic still lags the recovery we're \nseeing in the US.  Over the past several years, we've taken deliberate actions to address our cost structure and to \nevolve our retail footprint in these markets, and w e saw benefits from those actions this fiscal year.  We are also \nvery disciplined in how we operate these businesses, as evidenced by our thoughtful exit of unprofitable \ncustomers at the onset of the fiscal year in our Canadian business.  \n \n", "original_text": "Finally, turning to International. "}, "hash": "8cd0d33af8e39966b93550e48756854b89f68d500617de04c7c0a5e5d88ea391", "class_name": "RelatedNodeInfo"}}, "text": "Despite patient mobility trends below pre -COVID levels for much of fiscal 2021, I'm proud of the way the business \nresponded to the needs of our customers, and I am confident that as patients return to consume heal thcare and \nsee their community -based providers, our core business is positioned well for growth heading into fiscal 2022.  \n \n", "start_char_idx": 2409, "end_char_idx": 2753, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee860429-a866-4139-b0e4-42ef28e3d5bc": {"__data__": {"id_": "ee860429-a866-4139-b0e4-42ef28e3d5bc", "embedding": null, "metadata": {"window": "As a result, we \ntook action to position the business for lower demand levels, which resulted in inventory charges on some PPE \nand related products.  \n \n Further adapting to the impact of COVID -19 on our customers, we leveraged our existing lab capabilities to \nquickly distribute over 50 million COVID -19 tests into the provider settings we serve, demonstrating the breadth \nand expertise we  have in our market -leading lab business.  \n \n Despite patient mobility trends below pre -COVID levels for much of fiscal 2021, I'm proud of the way the business \nresponded to the needs of our customers, and I am confident that as patients return to consume heal thcare and \nsee their community -based providers, our core business is positioned well for growth heading into fiscal 2022.  \n \n Finally, turning to International.  The segment grew full year adjusted operating profit despite lower foot traffic in \nmany of our ret ail pharmacies across Europe and Canada, where the pandemic still lags the recovery we're \nseeing in the US.  Over the past several years, we've taken deliberate actions to address our cost structure and to \nevolve our retail footprint in these markets, and w e saw benefits from those actions this fiscal year.  We are also \nvery disciplined in how we operate these businesses, as evidenced by our thoughtful exit of unprofitable \ncustomers at the onset of the fiscal year in our Canadian business.  \n \n", "original_text": "Finally, turning to International. ", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c850470-3a0a-4880-b2ec-54135610be69", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a305784b8b89364cb419bc4dad266e1519ed1392381036044a2c6b16eeebbe93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a60703ab-809b-4a5f-b70d-cdaaba2d05eb", "node_type": "1", "metadata": {"window": "While we took measures to meet the needs of our customers for PPE -related products, demand has fluctuated \nand market dynamics for some of these products has changed since the onset of the pandemic.  As a result, we \ntook action to position the business for lower demand levels, which resulted in inventory charges on some PPE \nand related products.  \n \n Further adapting to the impact of COVID -19 on our customers, we leveraged our existing lab capabilities to \nquickly distribute over 50 million COVID -19 tests into the provider settings we serve, demonstrating the breadth \nand expertise we  have in our market -leading lab business.  \n \n Despite patient mobility trends below pre -COVID levels for much of fiscal 2021, I'm proud of the way the business \nresponded to the needs of our customers, and I am confident that as patients return to consume heal thcare and \nsee their community -based providers, our core business is positioned well for growth heading into fiscal 2022.  \n \n Finally, turning to International.  The segment grew full year adjusted operating profit despite lower foot traffic in \nmany of our ret ail pharmacies across Europe and Canada, where the pandemic still lags the recovery we're \nseeing in the US.  Over the past several years, we've taken deliberate actions to address our cost structure and to \nevolve our retail footprint in these markets, and w e saw benefits from those actions this fiscal year. ", "original_text": "Despite patient mobility trends below pre -COVID levels for much of fiscal 2021, I'm proud of the way the business \nresponded to the needs of our customers, and I am confident that as patients return to consume heal thcare and \nsee their community -based providers, our core business is positioned well for growth heading into fiscal 2022.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1c24c47897f3251d6955db8dc4423c45d4e901c4a35ca808e41805123ddcad5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3d8ea7d-1b99-44ab-97a9-7a97cd4e1e7f", "node_type": "1", "metadata": {"window": "Further adapting to the impact of COVID -19 on our customers, we leveraged our existing lab capabilities to \nquickly distribute over 50 million COVID -19 tests into the provider settings we serve, demonstrating the breadth \nand expertise we  have in our market -leading lab business.  \n \n Despite patient mobility trends below pre -COVID levels for much of fiscal 2021, I'm proud of the way the business \nresponded to the needs of our customers, and I am confident that as patients return to consume heal thcare and \nsee their community -based providers, our core business is positioned well for growth heading into fiscal 2022.  \n \n Finally, turning to International.  The segment grew full year adjusted operating profit despite lower foot traffic in \nmany of our ret ail pharmacies across Europe and Canada, where the pandemic still lags the recovery we're \nseeing in the US.  Over the past several years, we've taken deliberate actions to address our cost structure and to \nevolve our retail footprint in these markets, and w e saw benefits from those actions this fiscal year.  We are also \nvery disciplined in how we operate these businesses, as evidenced by our thoughtful exit of unprofitable \ncustomers at the onset of the fiscal year in our Canadian business.  \n \n These businesses p lay an important role in the pandemic response in their respective markets and through our \ninvestments into digital assets we're able to better reach patients who are increasingly choosing electronic means \nto access healthcare in those countries. ", "original_text": "The segment grew full year adjusted operating profit despite lower foot traffic in \nmany of our ret ail pharmacies across Europe and Canada, where the pandemic still lags the recovery we're \nseeing in the US. "}, "hash": "ddbe19f40b9dfe3b3992f550c3385ec8901f5012b015db12c3fd656576b08931", "class_name": "RelatedNodeInfo"}}, "text": "Finally, turning to International. ", "start_char_idx": 2753, "end_char_idx": 2788, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3d8ea7d-1b99-44ab-97a9-7a97cd4e1e7f": {"__data__": {"id_": "a3d8ea7d-1b99-44ab-97a9-7a97cd4e1e7f", "embedding": null, "metadata": {"window": "Further adapting to the impact of COVID -19 on our customers, we leveraged our existing lab capabilities to \nquickly distribute over 50 million COVID -19 tests into the provider settings we serve, demonstrating the breadth \nand expertise we  have in our market -leading lab business.  \n \n Despite patient mobility trends below pre -COVID levels for much of fiscal 2021, I'm proud of the way the business \nresponded to the needs of our customers, and I am confident that as patients return to consume heal thcare and \nsee their community -based providers, our core business is positioned well for growth heading into fiscal 2022.  \n \n Finally, turning to International.  The segment grew full year adjusted operating profit despite lower foot traffic in \nmany of our ret ail pharmacies across Europe and Canada, where the pandemic still lags the recovery we're \nseeing in the US.  Over the past several years, we've taken deliberate actions to address our cost structure and to \nevolve our retail footprint in these markets, and w e saw benefits from those actions this fiscal year.  We are also \nvery disciplined in how we operate these businesses, as evidenced by our thoughtful exit of unprofitable \ncustomers at the onset of the fiscal year in our Canadian business.  \n \n These businesses p lay an important role in the pandemic response in their respective markets and through our \ninvestments into digital assets we're able to better reach patients who are increasingly choosing electronic means \nto access healthcare in those countries. ", "original_text": "The segment grew full year adjusted operating profit despite lower foot traffic in \nmany of our ret ail pharmacies across Europe and Canada, where the pandemic still lags the recovery we're \nseeing in the US. ", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c850470-3a0a-4880-b2ec-54135610be69", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a305784b8b89364cb419bc4dad266e1519ed1392381036044a2c6b16eeebbe93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee860429-a866-4139-b0e4-42ef28e3d5bc", "node_type": "1", "metadata": {"window": "As a result, we \ntook action to position the business for lower demand levels, which resulted in inventory charges on some PPE \nand related products.  \n \n Further adapting to the impact of COVID -19 on our customers, we leveraged our existing lab capabilities to \nquickly distribute over 50 million COVID -19 tests into the provider settings we serve, demonstrating the breadth \nand expertise we  have in our market -leading lab business.  \n \n Despite patient mobility trends below pre -COVID levels for much of fiscal 2021, I'm proud of the way the business \nresponded to the needs of our customers, and I am confident that as patients return to consume heal thcare and \nsee their community -based providers, our core business is positioned well for growth heading into fiscal 2022.  \n \n Finally, turning to International.  The segment grew full year adjusted operating profit despite lower foot traffic in \nmany of our ret ail pharmacies across Europe and Canada, where the pandemic still lags the recovery we're \nseeing in the US.  Over the past several years, we've taken deliberate actions to address our cost structure and to \nevolve our retail footprint in these markets, and w e saw benefits from those actions this fiscal year.  We are also \nvery disciplined in how we operate these businesses, as evidenced by our thoughtful exit of unprofitable \ncustomers at the onset of the fiscal year in our Canadian business.  \n \n", "original_text": "Finally, turning to International. ", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3527ed7f9997a7c3c262a54e0ccbd1bcea05aacee10349ee58cf61114e45937b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f608bc54-dd54-4917-bb5c-d0f64b828672", "node_type": "1", "metadata": {"window": "Despite patient mobility trends below pre -COVID levels for much of fiscal 2021, I'm proud of the way the business \nresponded to the needs of our customers, and I am confident that as patients return to consume heal thcare and \nsee their community -based providers, our core business is positioned well for growth heading into fiscal 2022.  \n \n Finally, turning to International.  The segment grew full year adjusted operating profit despite lower foot traffic in \nmany of our ret ail pharmacies across Europe and Canada, where the pandemic still lags the recovery we're \nseeing in the US.  Over the past several years, we've taken deliberate actions to address our cost structure and to \nevolve our retail footprint in these markets, and w e saw benefits from those actions this fiscal year.  We are also \nvery disciplined in how we operate these businesses, as evidenced by our thoughtful exit of unprofitable \ncustomers at the onset of the fiscal year in our Canadian business.  \n \n These businesses p lay an important role in the pandemic response in their respective markets and through our \ninvestments into digital assets we're able to better reach patients who are increasingly choosing electronic means \nto access healthcare in those countries.  Going for ward, we'll continue to find ways to position these businesses \nfor future growth.  \n \n", "original_text": "Over the past several years, we've taken deliberate actions to address our cost structure and to \nevolve our retail footprint in these markets, and w e saw benefits from those actions this fiscal year. "}, "hash": "959c931b3ca628ab1ef8ae71f9bc35675f169a9ecec493a45fcd133d4ff3448c", "class_name": "RelatedNodeInfo"}}, "text": "The segment grew full year adjusted operating profit despite lower foot traffic in \nmany of our ret ail pharmacies across Europe and Canada, where the pandemic still lags the recovery we're \nseeing in the US. ", "start_char_idx": 2788, "end_char_idx": 2997, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f608bc54-dd54-4917-bb5c-d0f64b828672": {"__data__": {"id_": "f608bc54-dd54-4917-bb5c-d0f64b828672", "embedding": null, "metadata": {"window": "Despite patient mobility trends below pre -COVID levels for much of fiscal 2021, I'm proud of the way the business \nresponded to the needs of our customers, and I am confident that as patients return to consume heal thcare and \nsee their community -based providers, our core business is positioned well for growth heading into fiscal 2022.  \n \n Finally, turning to International.  The segment grew full year adjusted operating profit despite lower foot traffic in \nmany of our ret ail pharmacies across Europe and Canada, where the pandemic still lags the recovery we're \nseeing in the US.  Over the past several years, we've taken deliberate actions to address our cost structure and to \nevolve our retail footprint in these markets, and w e saw benefits from those actions this fiscal year.  We are also \nvery disciplined in how we operate these businesses, as evidenced by our thoughtful exit of unprofitable \ncustomers at the onset of the fiscal year in our Canadian business.  \n \n These businesses p lay an important role in the pandemic response in their respective markets and through our \ninvestments into digital assets we're able to better reach patients who are increasingly choosing electronic means \nto access healthcare in those countries.  Going for ward, we'll continue to find ways to position these businesses \nfor future growth.  \n \n", "original_text": "Over the past several years, we've taken deliberate actions to address our cost structure and to \nevolve our retail footprint in these markets, and w e saw benefits from those actions this fiscal year. ", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c850470-3a0a-4880-b2ec-54135610be69", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a305784b8b89364cb419bc4dad266e1519ed1392381036044a2c6b16eeebbe93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3d8ea7d-1b99-44ab-97a9-7a97cd4e1e7f", "node_type": "1", "metadata": {"window": "Further adapting to the impact of COVID -19 on our customers, we leveraged our existing lab capabilities to \nquickly distribute over 50 million COVID -19 tests into the provider settings we serve, demonstrating the breadth \nand expertise we  have in our market -leading lab business.  \n \n Despite patient mobility trends below pre -COVID levels for much of fiscal 2021, I'm proud of the way the business \nresponded to the needs of our customers, and I am confident that as patients return to consume heal thcare and \nsee their community -based providers, our core business is positioned well for growth heading into fiscal 2022.  \n \n Finally, turning to International.  The segment grew full year adjusted operating profit despite lower foot traffic in \nmany of our ret ail pharmacies across Europe and Canada, where the pandemic still lags the recovery we're \nseeing in the US.  Over the past several years, we've taken deliberate actions to address our cost structure and to \nevolve our retail footprint in these markets, and w e saw benefits from those actions this fiscal year.  We are also \nvery disciplined in how we operate these businesses, as evidenced by our thoughtful exit of unprofitable \ncustomers at the onset of the fiscal year in our Canadian business.  \n \n These businesses p lay an important role in the pandemic response in their respective markets and through our \ninvestments into digital assets we're able to better reach patients who are increasingly choosing electronic means \nto access healthcare in those countries. ", "original_text": "The segment grew full year adjusted operating profit despite lower foot traffic in \nmany of our ret ail pharmacies across Europe and Canada, where the pandemic still lags the recovery we're \nseeing in the US. ", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbaa30edca5d8be4587e3245007e8587e44d404a5e1a63decc6d6fb1df254f06", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7d706c2-4cb8-4007-8ec3-230eb4e5528b", "node_type": "1", "metadata": {"window": "Finally, turning to International.  The segment grew full year adjusted operating profit despite lower foot traffic in \nmany of our ret ail pharmacies across Europe and Canada, where the pandemic still lags the recovery we're \nseeing in the US.  Over the past several years, we've taken deliberate actions to address our cost structure and to \nevolve our retail footprint in these markets, and w e saw benefits from those actions this fiscal year.  We are also \nvery disciplined in how we operate these businesses, as evidenced by our thoughtful exit of unprofitable \ncustomers at the onset of the fiscal year in our Canadian business.  \n \n These businesses p lay an important role in the pandemic response in their respective markets and through our \ninvestments into digital assets we're able to better reach patients who are increasingly choosing electronic means \nto access healthcare in those countries.  Going for ward, we'll continue to find ways to position these businesses \nfor future growth.  \n \n The pandemic still presents many unknowns, and the trajectory of the recovery will likely show signs of \nnonlinearity at times in our fiscal 2022. ", "original_text": "We are also \nvery disciplined in how we operate these businesses, as evidenced by our thoughtful exit of unprofitable \ncustomers at the onset of the fiscal year in our Canadian business.  \n \n"}, "hash": "c7e6a30b3d235c3f2a5ac611ce94cd155ce30b500c189afd757d7f76ec4f404c", "class_name": "RelatedNodeInfo"}}, "text": "Over the past several years, we've taken deliberate actions to address our cost structure and to \nevolve our retail footprint in these markets, and w e saw benefits from those actions this fiscal year. ", "start_char_idx": 2997, "end_char_idx": 3199, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7d706c2-4cb8-4007-8ec3-230eb4e5528b": {"__data__": {"id_": "f7d706c2-4cb8-4007-8ec3-230eb4e5528b", "embedding": null, "metadata": {"window": "Finally, turning to International.  The segment grew full year adjusted operating profit despite lower foot traffic in \nmany of our ret ail pharmacies across Europe and Canada, where the pandemic still lags the recovery we're \nseeing in the US.  Over the past several years, we've taken deliberate actions to address our cost structure and to \nevolve our retail footprint in these markets, and w e saw benefits from those actions this fiscal year.  We are also \nvery disciplined in how we operate these businesses, as evidenced by our thoughtful exit of unprofitable \ncustomers at the onset of the fiscal year in our Canadian business.  \n \n These businesses p lay an important role in the pandemic response in their respective markets and through our \ninvestments into digital assets we're able to better reach patients who are increasingly choosing electronic means \nto access healthcare in those countries.  Going for ward, we'll continue to find ways to position these businesses \nfor future growth.  \n \n The pandemic still presents many unknowns, and the trajectory of the recovery will likely show signs of \nnonlinearity at times in our fiscal 2022. ", "original_text": "We are also \nvery disciplined in how we operate these businesses, as evidenced by our thoughtful exit of unprofitable \ncustomers at the onset of the fiscal year in our Canadian business.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c850470-3a0a-4880-b2ec-54135610be69", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a305784b8b89364cb419bc4dad266e1519ed1392381036044a2c6b16eeebbe93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f608bc54-dd54-4917-bb5c-d0f64b828672", "node_type": "1", "metadata": {"window": "Despite patient mobility trends below pre -COVID levels for much of fiscal 2021, I'm proud of the way the business \nresponded to the needs of our customers, and I am confident that as patients return to consume heal thcare and \nsee their community -based providers, our core business is positioned well for growth heading into fiscal 2022.  \n \n Finally, turning to International.  The segment grew full year adjusted operating profit despite lower foot traffic in \nmany of our ret ail pharmacies across Europe and Canada, where the pandemic still lags the recovery we're \nseeing in the US.  Over the past several years, we've taken deliberate actions to address our cost structure and to \nevolve our retail footprint in these markets, and w e saw benefits from those actions this fiscal year.  We are also \nvery disciplined in how we operate these businesses, as evidenced by our thoughtful exit of unprofitable \ncustomers at the onset of the fiscal year in our Canadian business.  \n \n These businesses p lay an important role in the pandemic response in their respective markets and through our \ninvestments into digital assets we're able to better reach patients who are increasingly choosing electronic means \nto access healthcare in those countries.  Going for ward, we'll continue to find ways to position these businesses \nfor future growth.  \n \n", "original_text": "Over the past several years, we've taken deliberate actions to address our cost structure and to \nevolve our retail footprint in these markets, and w e saw benefits from those actions this fiscal year. ", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd39bf4ae4488c176ff50913a21dc07b2e141755a211c401c8d79f2447762729", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75912faf-6a99-46b6-b094-4245f946f1ed", "node_type": "1", "metadata": {"window": "The segment grew full year adjusted operating profit despite lower foot traffic in \nmany of our ret ail pharmacies across Europe and Canada, where the pandemic still lags the recovery we're \nseeing in the US.  Over the past several years, we've taken deliberate actions to address our cost structure and to \nevolve our retail footprint in these markets, and w e saw benefits from those actions this fiscal year.  We are also \nvery disciplined in how we operate these businesses, as evidenced by our thoughtful exit of unprofitable \ncustomers at the onset of the fiscal year in our Canadian business.  \n \n These businesses p lay an important role in the pandemic response in their respective markets and through our \ninvestments into digital assets we're able to better reach patients who are increasingly choosing electronic means \nto access healthcare in those countries.  Going for ward, we'll continue to find ways to position these businesses \nfor future growth.  \n \n The pandemic still presents many unknowns, and the trajectory of the recovery will likely show signs of \nnonlinearity at times in our fiscal 2022.  But we do expect a return t o pre -COVID levels of prescription volumes and \npatient engagement levels in the second half of fiscal 2022. ", "original_text": "These businesses p lay an important role in the pandemic response in their respective markets and through our \ninvestments into digital assets we're able to better reach patients who are increasingly choosing electronic means \nto access healthcare in those countries. "}, "hash": "109ca7a025523cf4998fae7d7ab694565b058255403f61fdbe3625bcb917d7b2", "class_name": "RelatedNodeInfo"}}, "text": "We are also \nvery disciplined in how we operate these businesses, as evidenced by our thoughtful exit of unprofitable \ncustomers at the onset of the fiscal year in our Canadian business.  \n \n", "start_char_idx": 3199, "end_char_idx": 3390, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75912faf-6a99-46b6-b094-4245f946f1ed": {"__data__": {"id_": "75912faf-6a99-46b6-b094-4245f946f1ed", "embedding": null, "metadata": {"window": "The segment grew full year adjusted operating profit despite lower foot traffic in \nmany of our ret ail pharmacies across Europe and Canada, where the pandemic still lags the recovery we're \nseeing in the US.  Over the past several years, we've taken deliberate actions to address our cost structure and to \nevolve our retail footprint in these markets, and w e saw benefits from those actions this fiscal year.  We are also \nvery disciplined in how we operate these businesses, as evidenced by our thoughtful exit of unprofitable \ncustomers at the onset of the fiscal year in our Canadian business.  \n \n These businesses p lay an important role in the pandemic response in their respective markets and through our \ninvestments into digital assets we're able to better reach patients who are increasingly choosing electronic means \nto access healthcare in those countries.  Going for ward, we'll continue to find ways to position these businesses \nfor future growth.  \n \n The pandemic still presents many unknowns, and the trajectory of the recovery will likely show signs of \nnonlinearity at times in our fiscal 2022.  But we do expect a return t o pre -COVID levels of prescription volumes and \npatient engagement levels in the second half of fiscal 2022. ", "original_text": "These businesses p lay an important role in the pandemic response in their respective markets and through our \ninvestments into digital assets we're able to better reach patients who are increasingly choosing electronic means \nto access healthcare in those countries. ", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c850470-3a0a-4880-b2ec-54135610be69", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a305784b8b89364cb419bc4dad266e1519ed1392381036044a2c6b16eeebbe93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7d706c2-4cb8-4007-8ec3-230eb4e5528b", "node_type": "1", "metadata": {"window": "Finally, turning to International.  The segment grew full year adjusted operating profit despite lower foot traffic in \nmany of our ret ail pharmacies across Europe and Canada, where the pandemic still lags the recovery we're \nseeing in the US.  Over the past several years, we've taken deliberate actions to address our cost structure and to \nevolve our retail footprint in these markets, and w e saw benefits from those actions this fiscal year.  We are also \nvery disciplined in how we operate these businesses, as evidenced by our thoughtful exit of unprofitable \ncustomers at the onset of the fiscal year in our Canadian business.  \n \n These businesses p lay an important role in the pandemic response in their respective markets and through our \ninvestments into digital assets we're able to better reach patients who are increasingly choosing electronic means \nto access healthcare in those countries.  Going for ward, we'll continue to find ways to position these businesses \nfor future growth.  \n \n The pandemic still presents many unknowns, and the trajectory of the recovery will likely show signs of \nnonlinearity at times in our fiscal 2022. ", "original_text": "We are also \nvery disciplined in how we operate these businesses, as evidenced by our thoughtful exit of unprofitable \ncustomers at the onset of the fiscal year in our Canadian business.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aae3e58928d815431ffd2ea85858e649051922b36ee290331c23aadaa8d57dd7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24e8a5e4-1006-456d-8026-612103700f86", "node_type": "1", "metadata": {"window": "Over the past several years, we've taken deliberate actions to address our cost structure and to \nevolve our retail footprint in these markets, and w e saw benefits from those actions this fiscal year.  We are also \nvery disciplined in how we operate these businesses, as evidenced by our thoughtful exit of unprofitable \ncustomers at the onset of the fiscal year in our Canadian business.  \n \n These businesses p lay an important role in the pandemic response in their respective markets and through our \ninvestments into digital assets we're able to better reach patients who are increasingly choosing electronic means \nto access healthcare in those countries.  Going for ward, we'll continue to find ways to position these businesses \nfor future growth.  \n \n The pandemic still presents many unknowns, and the trajectory of the recovery will likely show signs of \nnonlinearity at times in our fiscal 2022.  But we do expect a return t o pre -COVID levels of prescription volumes and \npatient engagement levels in the second half of fiscal 2022.  As utilization improves over the course of our fiscal ", "original_text": "Going for ward, we'll continue to find ways to position these businesses \nfor future growth.  \n \n"}, "hash": "8338b05fcb7e0d7d480f6cf5aa3fc9ae30b11b3bff867e33d1c159f989537457", "class_name": "RelatedNodeInfo"}}, "text": "These businesses p lay an important role in the pandemic response in their respective markets and through our \ninvestments into digital assets we're able to better reach patients who are increasingly choosing electronic means \nto access healthcare in those countries. ", "start_char_idx": 3390, "end_char_idx": 3658, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24e8a5e4-1006-456d-8026-612103700f86": {"__data__": {"id_": "24e8a5e4-1006-456d-8026-612103700f86", "embedding": null, "metadata": {"window": "Over the past several years, we've taken deliberate actions to address our cost structure and to \nevolve our retail footprint in these markets, and w e saw benefits from those actions this fiscal year.  We are also \nvery disciplined in how we operate these businesses, as evidenced by our thoughtful exit of unprofitable \ncustomers at the onset of the fiscal year in our Canadian business.  \n \n These businesses p lay an important role in the pandemic response in their respective markets and through our \ninvestments into digital assets we're able to better reach patients who are increasingly choosing electronic means \nto access healthcare in those countries.  Going for ward, we'll continue to find ways to position these businesses \nfor future growth.  \n \n The pandemic still presents many unknowns, and the trajectory of the recovery will likely show signs of \nnonlinearity at times in our fiscal 2022.  But we do expect a return t o pre -COVID levels of prescription volumes and \npatient engagement levels in the second half of fiscal 2022.  As utilization improves over the course of our fiscal ", "original_text": "Going for ward, we'll continue to find ways to position these businesses \nfor future growth.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c850470-3a0a-4880-b2ec-54135610be69", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a305784b8b89364cb419bc4dad266e1519ed1392381036044a2c6b16eeebbe93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75912faf-6a99-46b6-b094-4245f946f1ed", "node_type": "1", "metadata": {"window": "The segment grew full year adjusted operating profit despite lower foot traffic in \nmany of our ret ail pharmacies across Europe and Canada, where the pandemic still lags the recovery we're \nseeing in the US.  Over the past several years, we've taken deliberate actions to address our cost structure and to \nevolve our retail footprint in these markets, and w e saw benefits from those actions this fiscal year.  We are also \nvery disciplined in how we operate these businesses, as evidenced by our thoughtful exit of unprofitable \ncustomers at the onset of the fiscal year in our Canadian business.  \n \n These businesses p lay an important role in the pandemic response in their respective markets and through our \ninvestments into digital assets we're able to better reach patients who are increasingly choosing electronic means \nto access healthcare in those countries.  Going for ward, we'll continue to find ways to position these businesses \nfor future growth.  \n \n The pandemic still presents many unknowns, and the trajectory of the recovery will likely show signs of \nnonlinearity at times in our fiscal 2022.  But we do expect a return t o pre -COVID levels of prescription volumes and \npatient engagement levels in the second half of fiscal 2022. ", "original_text": "These businesses p lay an important role in the pandemic response in their respective markets and through our \ninvestments into digital assets we're able to better reach patients who are increasingly choosing electronic means \nto access healthcare in those countries. ", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "81abbd10eb7fa6c4c7dc16fc23951cdfa5a0232c6a92ff61ea5dd38452312fee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe3be52b-f100-4a72-b79e-13c4b9e7b9ae", "node_type": "1", "metadata": {"window": "We are also \nvery disciplined in how we operate these businesses, as evidenced by our thoughtful exit of unprofitable \ncustomers at the onset of the fiscal year in our Canadian business.  \n \n These businesses p lay an important role in the pandemic response in their respective markets and through our \ninvestments into digital assets we're able to better reach patients who are increasingly choosing electronic means \nto access healthcare in those countries.  Going for ward, we'll continue to find ways to position these businesses \nfor future growth.  \n \n The pandemic still presents many unknowns, and the trajectory of the recovery will likely show signs of \nnonlinearity at times in our fiscal 2022.  But we do expect a return t o pre -COVID levels of prescription volumes and \npatient engagement levels in the second half of fiscal 2022.  As utilization improves over the course of our fiscal ", "original_text": "The pandemic still presents many unknowns, and the trajectory of the recovery will likely show signs of \nnonlinearity at times in our fiscal 2022. "}, "hash": "bfbb57ee4aba17bf2fff71272c9c0e3bc9a1a5d163600093df81e5d878eb6d87", "class_name": "RelatedNodeInfo"}}, "text": "Going for ward, we'll continue to find ways to position these businesses \nfor future growth.  \n \n", "start_char_idx": 3658, "end_char_idx": 3755, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe3be52b-f100-4a72-b79e-13c4b9e7b9ae": {"__data__": {"id_": "fe3be52b-f100-4a72-b79e-13c4b9e7b9ae", "embedding": null, "metadata": {"window": "We are also \nvery disciplined in how we operate these businesses, as evidenced by our thoughtful exit of unprofitable \ncustomers at the onset of the fiscal year in our Canadian business.  \n \n These businesses p lay an important role in the pandemic response in their respective markets and through our \ninvestments into digital assets we're able to better reach patients who are increasingly choosing electronic means \nto access healthcare in those countries.  Going for ward, we'll continue to find ways to position these businesses \nfor future growth.  \n \n The pandemic still presents many unknowns, and the trajectory of the recovery will likely show signs of \nnonlinearity at times in our fiscal 2022.  But we do expect a return t o pre -COVID levels of prescription volumes and \npatient engagement levels in the second half of fiscal 2022.  As utilization improves over the course of our fiscal ", "original_text": "The pandemic still presents many unknowns, and the trajectory of the recovery will likely show signs of \nnonlinearity at times in our fiscal 2022. ", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c850470-3a0a-4880-b2ec-54135610be69", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a305784b8b89364cb419bc4dad266e1519ed1392381036044a2c6b16eeebbe93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24e8a5e4-1006-456d-8026-612103700f86", "node_type": "1", "metadata": {"window": "Over the past several years, we've taken deliberate actions to address our cost structure and to \nevolve our retail footprint in these markets, and w e saw benefits from those actions this fiscal year.  We are also \nvery disciplined in how we operate these businesses, as evidenced by our thoughtful exit of unprofitable \ncustomers at the onset of the fiscal year in our Canadian business.  \n \n These businesses p lay an important role in the pandemic response in their respective markets and through our \ninvestments into digital assets we're able to better reach patients who are increasingly choosing electronic means \nto access healthcare in those countries.  Going for ward, we'll continue to find ways to position these businesses \nfor future growth.  \n \n The pandemic still presents many unknowns, and the trajectory of the recovery will likely show signs of \nnonlinearity at times in our fiscal 2022.  But we do expect a return t o pre -COVID levels of prescription volumes and \npatient engagement levels in the second half of fiscal 2022.  As utilization improves over the course of our fiscal ", "original_text": "Going for ward, we'll continue to find ways to position these businesses \nfor future growth.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59411ccb1b7e682fb3c40f2eb94c8a23f3c98c753fedadf3e6d93bd2754760ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d547419f-f3fd-4c1a-b23d-fc00376a368f", "node_type": "1", "metadata": {"window": "These businesses p lay an important role in the pandemic response in their respective markets and through our \ninvestments into digital assets we're able to better reach patients who are increasingly choosing electronic means \nto access healthcare in those countries.  Going for ward, we'll continue to find ways to position these businesses \nfor future growth.  \n \n The pandemic still presents many unknowns, and the trajectory of the recovery will likely show signs of \nnonlinearity at times in our fiscal 2022.  But we do expect a return t o pre -COVID levels of prescription volumes and \npatient engagement levels in the second half of fiscal 2022.  As utilization improves over the course of our fiscal ", "original_text": "But we do expect a return t o pre -COVID levels of prescription volumes and \npatient engagement levels in the second half of fiscal 2022. "}, "hash": "d26114c5b896997a230e2a1fbac3152120a91d591578a31392412b50881dae79", "class_name": "RelatedNodeInfo"}}, "text": "The pandemic still presents many unknowns, and the trajectory of the recovery will likely show signs of \nnonlinearity at times in our fiscal 2022. ", "start_char_idx": 3755, "end_char_idx": 3902, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d547419f-f3fd-4c1a-b23d-fc00376a368f": {"__data__": {"id_": "d547419f-f3fd-4c1a-b23d-fc00376a368f", "embedding": null, "metadata": {"window": "These businesses p lay an important role in the pandemic response in their respective markets and through our \ninvestments into digital assets we're able to better reach patients who are increasingly choosing electronic means \nto access healthcare in those countries.  Going for ward, we'll continue to find ways to position these businesses \nfor future growth.  \n \n The pandemic still presents many unknowns, and the trajectory of the recovery will likely show signs of \nnonlinearity at times in our fiscal 2022.  But we do expect a return t o pre -COVID levels of prescription volumes and \npatient engagement levels in the second half of fiscal 2022.  As utilization improves over the course of our fiscal ", "original_text": "But we do expect a return t o pre -COVID levels of prescription volumes and \npatient engagement levels in the second half of fiscal 2022. ", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c850470-3a0a-4880-b2ec-54135610be69", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a305784b8b89364cb419bc4dad266e1519ed1392381036044a2c6b16eeebbe93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe3be52b-f100-4a72-b79e-13c4b9e7b9ae", "node_type": "1", "metadata": {"window": "We are also \nvery disciplined in how we operate these businesses, as evidenced by our thoughtful exit of unprofitable \ncustomers at the onset of the fiscal year in our Canadian business.  \n \n These businesses p lay an important role in the pandemic response in their respective markets and through our \ninvestments into digital assets we're able to better reach patients who are increasingly choosing electronic means \nto access healthcare in those countries.  Going for ward, we'll continue to find ways to position these businesses \nfor future growth.  \n \n The pandemic still presents many unknowns, and the trajectory of the recovery will likely show signs of \nnonlinearity at times in our fiscal 2022.  But we do expect a return t o pre -COVID levels of prescription volumes and \npatient engagement levels in the second half of fiscal 2022.  As utilization improves over the course of our fiscal ", "original_text": "The pandemic still presents many unknowns, and the trajectory of the recovery will likely show signs of \nnonlinearity at times in our fiscal 2022. ", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72c1a45a46c6ead7ca2bbd4b9849afe7593fd80e0aa965418aa3bda7e7451b9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa7fdbbc-894c-4d5b-8c4f-64276172465c", "node_type": "1", "metadata": {"window": "Going for ward, we'll continue to find ways to position these businesses \nfor future growth.  \n \n The pandemic still presents many unknowns, and the trajectory of the recovery will likely show signs of \nnonlinearity at times in our fiscal 2022.  But we do expect a return t o pre -COVID levels of prescription volumes and \npatient engagement levels in the second half of fiscal 2022.  As utilization improves over the course of our fiscal ", "original_text": "As utilization improves over the course of our fiscal "}, "hash": "1c469e679504509d2dc4e70fd9419bf8a2507cefcd7aadb6857e15d6689594aa", "class_name": "RelatedNodeInfo"}}, "text": "But we do expect a return t o pre -COVID levels of prescription volumes and \npatient engagement levels in the second half of fiscal 2022. ", "start_char_idx": 3902, "end_char_idx": 4040, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa7fdbbc-894c-4d5b-8c4f-64276172465c": {"__data__": {"id_": "fa7fdbbc-894c-4d5b-8c4f-64276172465c", "embedding": null, "metadata": {"window": "Going for ward, we'll continue to find ways to position these businesses \nfor future growth.  \n \n The pandemic still presents many unknowns, and the trajectory of the recovery will likely show signs of \nnonlinearity at times in our fiscal 2022.  But we do expect a return t o pre -COVID levels of prescription volumes and \npatient engagement levels in the second half of fiscal 2022.  As utilization improves over the course of our fiscal ", "original_text": "As utilization improves over the course of our fiscal ", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7c850470-3a0a-4880-b2ec-54135610be69", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a305784b8b89364cb419bc4dad266e1519ed1392381036044a2c6b16eeebbe93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d547419f-f3fd-4c1a-b23d-fc00376a368f", "node_type": "1", "metadata": {"window": "These businesses p lay an important role in the pandemic response in their respective markets and through our \ninvestments into digital assets we're able to better reach patients who are increasingly choosing electronic means \nto access healthcare in those countries.  Going for ward, we'll continue to find ways to position these businesses \nfor future growth.  \n \n The pandemic still presents many unknowns, and the trajectory of the recovery will likely show signs of \nnonlinearity at times in our fiscal 2022.  But we do expect a return t o pre -COVID levels of prescription volumes and \npatient engagement levels in the second half of fiscal 2022.  As utilization improves over the course of our fiscal ", "original_text": "But we do expect a return t o pre -COVID levels of prescription volumes and \npatient engagement levels in the second half of fiscal 2022. ", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "78f698beaec2f688ee300cf68b7e8d0b524bdf9ea3e713516044279a57b2575c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6aa2ae21-7553-4e20-8b84-12ebb1086bfb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nyear, we expect the stable fundamentals underlying our core business to serve as the foundatio n for the outlook \nwe are providing you today.  \n \n Our fiscal 2022 outlook of $18.85 to $19.45 of adjusted earnings per diluted share includes a return to solid \ngrowth in our core businesses, a continuation of our role in the COVID -19 vaccine efforts, investme nts in growth \nand a balanced approach to capital deployment.  Britt will take you through additional detailed assumptions that \nmake up this outlook.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "f6b6af070abf188c33343ed042460f6bf8e2142aa2e0105fc7b6d0e6bebe281f", "class_name": "RelatedNodeInfo"}}, "text": "As utilization improves over the course of our fiscal ", "start_char_idx": 4040, "end_char_idx": 4094, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6aa2ae21-7553-4e20-8b84-12ebb1086bfb": {"__data__": {"id_": "6aa2ae21-7553-4e20-8b84-12ebb1086bfb", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nyear, we expect the stable fundamentals underlying our core business to serve as the foundatio n for the outlook \nwe are providing you today.  \n \n Our fiscal 2022 outlook of $18.85 to $19.45 of adjusted earnings per diluted share includes a return to solid \ngrowth in our core businesses, a continuation of our role in the COVID -19 vaccine efforts, investme nts in growth \nand a balanced approach to capital deployment.  Britt will take you through additional detailed assumptions that \nmake up this outlook.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1b76e8ab2129db5a441e0143ad525d0096f1de4730bca682d2fdec0dab1d518", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa7fdbbc-894c-4d5b-8c4f-64276172465c", "node_type": "1", "metadata": {"window": "Going for ward, we'll continue to find ways to position these businesses \nfor future growth.  \n \n The pandemic still presents many unknowns, and the trajectory of the recovery will likely show signs of \nnonlinearity at times in our fiscal 2022.  But we do expect a return t o pre -COVID levels of prescription volumes and \npatient engagement levels in the second half of fiscal 2022.  As utilization improves over the course of our fiscal ", "original_text": "As utilization improves over the course of our fiscal ", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66ae069285dd059ed514896186d39737e2b1c5ad8d434552d3fde255dfdd5575", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90acc317-59cd-405c-8d11-05f0c7b5653b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nyear, we expect the stable fundamentals underlying our core business to serve as the foundatio n for the outlook \nwe are providing you today.  \n \n Our fiscal 2022 outlook of $18.85 to $19.45 of adjusted earnings per diluted share includes a return to solid \ngrowth in our core businesses, a continuation of our role in the COVID -19 vaccine efforts, investme nts in growth \nand a balanced approach to capital deployment.  Britt will take you through additional detailed assumptions that \nmake up this outlook.  \n \n As I reflect back, fiscal 2021 has taught us a lot, and it showed us, once again, that our business model i s \npositioned well to adapt and succeed in uncertain times. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nyear, we expect the stable fundamentals underlying our core business to serve as the foundatio n for the outlook \nwe are providing you today.  \n \n"}, "hash": "df0cf07e2e38f34b20ccde5f97014ea1d84451cff1f189301971f15414e18309", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90acc317-59cd-405c-8d11-05f0c7b5653b": {"__data__": {"id_": "90acc317-59cd-405c-8d11-05f0c7b5653b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nyear, we expect the stable fundamentals underlying our core business to serve as the foundatio n for the outlook \nwe are providing you today.  \n \n Our fiscal 2022 outlook of $18.85 to $19.45 of adjusted earnings per diluted share includes a return to solid \ngrowth in our core businesses, a continuation of our role in the COVID -19 vaccine efforts, investme nts in growth \nand a balanced approach to capital deployment.  Britt will take you through additional detailed assumptions that \nmake up this outlook.  \n \n As I reflect back, fiscal 2021 has taught us a lot, and it showed us, once again, that our business model i s \npositioned well to adapt and succeed in uncertain times. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nyear, we expect the stable fundamentals underlying our core business to serve as the foundatio n for the outlook \nwe are providing you today.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1b76e8ab2129db5a441e0143ad525d0096f1de4730bca682d2fdec0dab1d518", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6aa2ae21-7553-4e20-8b84-12ebb1086bfb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nyear, we expect the stable fundamentals underlying our core business to serve as the foundatio n for the outlook \nwe are providing you today.  \n \n Our fiscal 2022 outlook of $18.85 to $19.45 of adjusted earnings per diluted share includes a return to solid \ngrowth in our core businesses, a continuation of our role in the COVID -19 vaccine efforts, investme nts in growth \nand a balanced approach to capital deployment.  Britt will take you through additional detailed assumptions that \nmake up this outlook.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d03b53a90dc517278d32b4fa4c0ff4df18ec88d4bdae36cb90bf583c97095c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10c1df44-2a24-4b7e-adf2-f3781d7d7d32", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nyear, we expect the stable fundamentals underlying our core business to serve as the foundatio n for the outlook \nwe are providing you today.  \n \n Our fiscal 2022 outlook of $18.85 to $19.45 of adjusted earnings per diluted share includes a return to solid \ngrowth in our core businesses, a continuation of our role in the COVID -19 vaccine efforts, investme nts in growth \nand a balanced approach to capital deployment.  Britt will take you through additional detailed assumptions that \nmake up this outlook.  \n \n As I reflect back, fiscal 2021 has taught us a lot, and it showed us, once again, that our business model i s \npositioned well to adapt and succeed in uncertain times.  Time and time again, we've proven our resiliency during \ncrisis, and I'm so proud of the way our employees rose to the challenges brought on by the pandemic and society \nmore broadly. ", "original_text": "Our fiscal 2022 outlook of $18.85 to $19.45 of adjusted earnings per diluted share includes a return to solid \ngrowth in our core businesses, a continuation of our role in the COVID -19 vaccine efforts, investme nts in growth \nand a balanced approach to capital deployment. "}, "hash": "5fbc4cece0219f42d248c78715ef4e8be125dbe0b617dff025c77a9c5b60f054", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nyear, we expect the stable fundamentals underlying our core business to serve as the foundatio n for the outlook \nwe are providing you today.  \n \n", "start_char_idx": 16, "end_char_idx": 326, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10c1df44-2a24-4b7e-adf2-f3781d7d7d32": {"__data__": {"id_": "10c1df44-2a24-4b7e-adf2-f3781d7d7d32", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nyear, we expect the stable fundamentals underlying our core business to serve as the foundatio n for the outlook \nwe are providing you today.  \n \n Our fiscal 2022 outlook of $18.85 to $19.45 of adjusted earnings per diluted share includes a return to solid \ngrowth in our core businesses, a continuation of our role in the COVID -19 vaccine efforts, investme nts in growth \nand a balanced approach to capital deployment.  Britt will take you through additional detailed assumptions that \nmake up this outlook.  \n \n As I reflect back, fiscal 2021 has taught us a lot, and it showed us, once again, that our business model i s \npositioned well to adapt and succeed in uncertain times.  Time and time again, we've proven our resiliency during \ncrisis, and I'm so proud of the way our employees rose to the challenges brought on by the pandemic and society \nmore broadly. ", "original_text": "Our fiscal 2022 outlook of $18.85 to $19.45 of adjusted earnings per diluted share includes a return to solid \ngrowth in our core businesses, a continuation of our role in the COVID -19 vaccine efforts, investme nts in growth \nand a balanced approach to capital deployment. ", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1b76e8ab2129db5a441e0143ad525d0096f1de4730bca682d2fdec0dab1d518", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90acc317-59cd-405c-8d11-05f0c7b5653b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nyear, we expect the stable fundamentals underlying our core business to serve as the foundatio n for the outlook \nwe are providing you today.  \n \n Our fiscal 2022 outlook of $18.85 to $19.45 of adjusted earnings per diluted share includes a return to solid \ngrowth in our core businesses, a continuation of our role in the COVID -19 vaccine efforts, investme nts in growth \nand a balanced approach to capital deployment.  Britt will take you through additional detailed assumptions that \nmake up this outlook.  \n \n As I reflect back, fiscal 2021 has taught us a lot, and it showed us, once again, that our business model i s \npositioned well to adapt and succeed in uncertain times. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nyear, we expect the stable fundamentals underlying our core business to serve as the foundatio n for the outlook \nwe are providing you today.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0e8365e9fb94f3412bff66302b9cc20b2b33d8e3cb076a6c3a1a21d1ab700810", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13587e9f-1974-478a-99e6-31fb1a69a4f0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nyear, we expect the stable fundamentals underlying our core business to serve as the foundatio n for the outlook \nwe are providing you today.  \n \n Our fiscal 2022 outlook of $18.85 to $19.45 of adjusted earnings per diluted share includes a return to solid \ngrowth in our core businesses, a continuation of our role in the COVID -19 vaccine efforts, investme nts in growth \nand a balanced approach to capital deployment.  Britt will take you through additional detailed assumptions that \nmake up this outlook.  \n \n As I reflect back, fiscal 2021 has taught us a lot, and it showed us, once again, that our business model i s \npositioned well to adapt and succeed in uncertain times.  Time and time again, we've proven our resiliency during \ncrisis, and I'm so proud of the way our employees rose to the challenges brought on by the pandemic and society \nmore broadly.  Our ability to be together, to stand together, focused on our values and purpose and service of the \nhealth care communities we serve makes me so proud.  \n \n", "original_text": "Britt will take you through additional detailed assumptions that \nmake up this outlook.  \n \n"}, "hash": "12fbfd4333d01e39e305eb687d38e177808904bdec1f9da3027d3a0fbd12ba6d", "class_name": "RelatedNodeInfo"}}, "text": "Our fiscal 2022 outlook of $18.85 to $19.45 of adjusted earnings per diluted share includes a return to solid \ngrowth in our core businesses, a continuation of our role in the COVID -19 vaccine efforts, investme nts in growth \nand a balanced approach to capital deployment. ", "start_char_idx": 326, "end_char_idx": 600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13587e9f-1974-478a-99e6-31fb1a69a4f0": {"__data__": {"id_": "13587e9f-1974-478a-99e6-31fb1a69a4f0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nyear, we expect the stable fundamentals underlying our core business to serve as the foundatio n for the outlook \nwe are providing you today.  \n \n Our fiscal 2022 outlook of $18.85 to $19.45 of adjusted earnings per diluted share includes a return to solid \ngrowth in our core businesses, a continuation of our role in the COVID -19 vaccine efforts, investme nts in growth \nand a balanced approach to capital deployment.  Britt will take you through additional detailed assumptions that \nmake up this outlook.  \n \n As I reflect back, fiscal 2021 has taught us a lot, and it showed us, once again, that our business model i s \npositioned well to adapt and succeed in uncertain times.  Time and time again, we've proven our resiliency during \ncrisis, and I'm so proud of the way our employees rose to the challenges brought on by the pandemic and society \nmore broadly.  Our ability to be together, to stand together, focused on our values and purpose and service of the \nhealth care communities we serve makes me so proud.  \n \n", "original_text": "Britt will take you through additional detailed assumptions that \nmake up this outlook.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1b76e8ab2129db5a441e0143ad525d0096f1de4730bca682d2fdec0dab1d518", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10c1df44-2a24-4b7e-adf2-f3781d7d7d32", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nyear, we expect the stable fundamentals underlying our core business to serve as the foundatio n for the outlook \nwe are providing you today.  \n \n Our fiscal 2022 outlook of $18.85 to $19.45 of adjusted earnings per diluted share includes a return to solid \ngrowth in our core businesses, a continuation of our role in the COVID -19 vaccine efforts, investme nts in growth \nand a balanced approach to capital deployment.  Britt will take you through additional detailed assumptions that \nmake up this outlook.  \n \n As I reflect back, fiscal 2021 has taught us a lot, and it showed us, once again, that our business model i s \npositioned well to adapt and succeed in uncertain times.  Time and time again, we've proven our resiliency during \ncrisis, and I'm so proud of the way our employees rose to the challenges brought on by the pandemic and society \nmore broadly. ", "original_text": "Our fiscal 2022 outlook of $18.85 to $19.45 of adjusted earnings per diluted share includes a return to solid \ngrowth in our core businesses, a continuation of our role in the COVID -19 vaccine efforts, investme nts in growth \nand a balanced approach to capital deployment. ", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8bff73f5f79c52121da35d5e1c1e18e4bf9dcf5c1ccff8bae42ab93ea99830e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f32a90bd-c8fc-45a9-92fc-dbbca3971165", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nyear, we expect the stable fundamentals underlying our core business to serve as the foundatio n for the outlook \nwe are providing you today.  \n \n Our fiscal 2022 outlook of $18.85 to $19.45 of adjusted earnings per diluted share includes a return to solid \ngrowth in our core businesses, a continuation of our role in the COVID -19 vaccine efforts, investme nts in growth \nand a balanced approach to capital deployment.  Britt will take you through additional detailed assumptions that \nmake up this outlook.  \n \n As I reflect back, fiscal 2021 has taught us a lot, and it showed us, once again, that our business model i s \npositioned well to adapt and succeed in uncertain times.  Time and time again, we've proven our resiliency during \ncrisis, and I'm so proud of the way our employees rose to the challenges brought on by the pandemic and society \nmore broadly.  Our ability to be together, to stand together, focused on our values and purpose and service of the \nhealth care communities we serve makes me so proud.  \n \n We will focus on building momentum on our fiscal 2021 accomplishments and we will look to embrace the \nchanges that hav e made us better to advance our growth strategy and grow the business. ", "original_text": "As I reflect back, fiscal 2021 has taught us a lot, and it showed us, once again, that our business model i s \npositioned well to adapt and succeed in uncertain times. "}, "hash": "d3b2babf7cef80be399c24fda825aa493f4db038e21b53b8a1fcd5b9c0adae29", "class_name": "RelatedNodeInfo"}}, "text": "Britt will take you through additional detailed assumptions that \nmake up this outlook.  \n \n", "start_char_idx": 600, "end_char_idx": 692, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f32a90bd-c8fc-45a9-92fc-dbbca3971165": {"__data__": {"id_": "f32a90bd-c8fc-45a9-92fc-dbbca3971165", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nyear, we expect the stable fundamentals underlying our core business to serve as the foundatio n for the outlook \nwe are providing you today.  \n \n Our fiscal 2022 outlook of $18.85 to $19.45 of adjusted earnings per diluted share includes a return to solid \ngrowth in our core businesses, a continuation of our role in the COVID -19 vaccine efforts, investme nts in growth \nand a balanced approach to capital deployment.  Britt will take you through additional detailed assumptions that \nmake up this outlook.  \n \n As I reflect back, fiscal 2021 has taught us a lot, and it showed us, once again, that our business model i s \npositioned well to adapt and succeed in uncertain times.  Time and time again, we've proven our resiliency during \ncrisis, and I'm so proud of the way our employees rose to the challenges brought on by the pandemic and society \nmore broadly.  Our ability to be together, to stand together, focused on our values and purpose and service of the \nhealth care communities we serve makes me so proud.  \n \n We will focus on building momentum on our fiscal 2021 accomplishments and we will look to embrace the \nchanges that hav e made us better to advance our growth strategy and grow the business. ", "original_text": "As I reflect back, fiscal 2021 has taught us a lot, and it showed us, once again, that our business model i s \npositioned well to adapt and succeed in uncertain times. ", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1b76e8ab2129db5a441e0143ad525d0096f1de4730bca682d2fdec0dab1d518", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13587e9f-1974-478a-99e6-31fb1a69a4f0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nyear, we expect the stable fundamentals underlying our core business to serve as the foundatio n for the outlook \nwe are providing you today.  \n \n Our fiscal 2022 outlook of $18.85 to $19.45 of adjusted earnings per diluted share includes a return to solid \ngrowth in our core businesses, a continuation of our role in the COVID -19 vaccine efforts, investme nts in growth \nand a balanced approach to capital deployment.  Britt will take you through additional detailed assumptions that \nmake up this outlook.  \n \n As I reflect back, fiscal 2021 has taught us a lot, and it showed us, once again, that our business model i s \npositioned well to adapt and succeed in uncertain times.  Time and time again, we've proven our resiliency during \ncrisis, and I'm so proud of the way our employees rose to the challenges brought on by the pandemic and society \nmore broadly.  Our ability to be together, to stand together, focused on our values and purpose and service of the \nhealth care communities we serve makes me so proud.  \n \n", "original_text": "Britt will take you through additional detailed assumptions that \nmake up this outlook.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "38d40cdebc88f7aa09d2a4beed2a451ad5138abfae8ad34cbccc6b7bfea9cc96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2b9d696-1430-43c4-b6e5-41bea3eb36ec", "node_type": "1", "metadata": {"window": "Our fiscal 2022 outlook of $18.85 to $19.45 of adjusted earnings per diluted share includes a return to solid \ngrowth in our core businesses, a continuation of our role in the COVID -19 vaccine efforts, investme nts in growth \nand a balanced approach to capital deployment.  Britt will take you through additional detailed assumptions that \nmake up this outlook.  \n \n As I reflect back, fiscal 2021 has taught us a lot, and it showed us, once again, that our business model i s \npositioned well to adapt and succeed in uncertain times.  Time and time again, we've proven our resiliency during \ncrisis, and I'm so proud of the way our employees rose to the challenges brought on by the pandemic and society \nmore broadly.  Our ability to be together, to stand together, focused on our values and purpose and service of the \nhealth care communities we serve makes me so proud.  \n \n We will focus on building momentum on our fiscal 2021 accomplishments and we will look to embrace the \nchanges that hav e made us better to advance our growth strategy and grow the business.  We will also continue \nto be front and center in the fight against COVID -19, helping to serve the communities in which we live and work.  \n \n", "original_text": "Time and time again, we've proven our resiliency during \ncrisis, and I'm so proud of the way our employees rose to the challenges brought on by the pandemic and society \nmore broadly. "}, "hash": "7123ea3cb17ffcbe7f62ebe1caca5f8267b1989beddb230e3df1af58388bb5e7", "class_name": "RelatedNodeInfo"}}, "text": "As I reflect back, fiscal 2021 has taught us a lot, and it showed us, once again, that our business model i s \npositioned well to adapt and succeed in uncertain times. ", "start_char_idx": 692, "end_char_idx": 860, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2b9d696-1430-43c4-b6e5-41bea3eb36ec": {"__data__": {"id_": "d2b9d696-1430-43c4-b6e5-41bea3eb36ec", "embedding": null, "metadata": {"window": "Our fiscal 2022 outlook of $18.85 to $19.45 of adjusted earnings per diluted share includes a return to solid \ngrowth in our core businesses, a continuation of our role in the COVID -19 vaccine efforts, investme nts in growth \nand a balanced approach to capital deployment.  Britt will take you through additional detailed assumptions that \nmake up this outlook.  \n \n As I reflect back, fiscal 2021 has taught us a lot, and it showed us, once again, that our business model i s \npositioned well to adapt and succeed in uncertain times.  Time and time again, we've proven our resiliency during \ncrisis, and I'm so proud of the way our employees rose to the challenges brought on by the pandemic and society \nmore broadly.  Our ability to be together, to stand together, focused on our values and purpose and service of the \nhealth care communities we serve makes me so proud.  \n \n We will focus on building momentum on our fiscal 2021 accomplishments and we will look to embrace the \nchanges that hav e made us better to advance our growth strategy and grow the business.  We will also continue \nto be front and center in the fight against COVID -19, helping to serve the communities in which we live and work.  \n \n", "original_text": "Time and time again, we've proven our resiliency during \ncrisis, and I'm so proud of the way our employees rose to the challenges brought on by the pandemic and society \nmore broadly. ", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1b76e8ab2129db5a441e0143ad525d0096f1de4730bca682d2fdec0dab1d518", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f32a90bd-c8fc-45a9-92fc-dbbca3971165", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nyear, we expect the stable fundamentals underlying our core business to serve as the foundatio n for the outlook \nwe are providing you today.  \n \n Our fiscal 2022 outlook of $18.85 to $19.45 of adjusted earnings per diluted share includes a return to solid \ngrowth in our core businesses, a continuation of our role in the COVID -19 vaccine efforts, investme nts in growth \nand a balanced approach to capital deployment.  Britt will take you through additional detailed assumptions that \nmake up this outlook.  \n \n As I reflect back, fiscal 2021 has taught us a lot, and it showed us, once again, that our business model i s \npositioned well to adapt and succeed in uncertain times.  Time and time again, we've proven our resiliency during \ncrisis, and I'm so proud of the way our employees rose to the challenges brought on by the pandemic and society \nmore broadly.  Our ability to be together, to stand together, focused on our values and purpose and service of the \nhealth care communities we serve makes me so proud.  \n \n We will focus on building momentum on our fiscal 2021 accomplishments and we will look to embrace the \nchanges that hav e made us better to advance our growth strategy and grow the business. ", "original_text": "As I reflect back, fiscal 2021 has taught us a lot, and it showed us, once again, that our business model i s \npositioned well to adapt and succeed in uncertain times. ", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c75d517fe05d5c268f993a3b42d74ae708b51975a5b0da495ce581272c6334d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8aa56fc8-72b2-471c-9f66-a79cc0418f15", "node_type": "1", "metadata": {"window": "Britt will take you through additional detailed assumptions that \nmake up this outlook.  \n \n As I reflect back, fiscal 2021 has taught us a lot, and it showed us, once again, that our business model i s \npositioned well to adapt and succeed in uncertain times.  Time and time again, we've proven our resiliency during \ncrisis, and I'm so proud of the way our employees rose to the challenges brought on by the pandemic and society \nmore broadly.  Our ability to be together, to stand together, focused on our values and purpose and service of the \nhealth care communities we serve makes me so proud.  \n \n We will focus on building momentum on our fiscal 2021 accomplishments and we will look to embrace the \nchanges that hav e made us better to advance our growth strategy and grow the business.  We will also continue \nto be front and center in the fight against COVID -19, helping to serve the communities in which we live and work.  \n \n I thank you again for your time and I'll turn it  over to Britt.  \n ", "original_text": "Our ability to be together, to stand together, focused on our values and purpose and service of the \nhealth care communities we serve makes me so proud.  \n \n"}, "hash": "d8e63ca8905fbb71146aac46c90f9326fa31712c312f0a211cf07e814ba65ba8", "class_name": "RelatedNodeInfo"}}, "text": "Time and time again, we've proven our resiliency during \ncrisis, and I'm so proud of the way our employees rose to the challenges brought on by the pandemic and society \nmore broadly. ", "start_char_idx": 860, "end_char_idx": 1044, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8aa56fc8-72b2-471c-9f66-a79cc0418f15": {"__data__": {"id_": "8aa56fc8-72b2-471c-9f66-a79cc0418f15", "embedding": null, "metadata": {"window": "Britt will take you through additional detailed assumptions that \nmake up this outlook.  \n \n As I reflect back, fiscal 2021 has taught us a lot, and it showed us, once again, that our business model i s \npositioned well to adapt and succeed in uncertain times.  Time and time again, we've proven our resiliency during \ncrisis, and I'm so proud of the way our employees rose to the challenges brought on by the pandemic and society \nmore broadly.  Our ability to be together, to stand together, focused on our values and purpose and service of the \nhealth care communities we serve makes me so proud.  \n \n We will focus on building momentum on our fiscal 2021 accomplishments and we will look to embrace the \nchanges that hav e made us better to advance our growth strategy and grow the business.  We will also continue \nto be front and center in the fight against COVID -19, helping to serve the communities in which we live and work.  \n \n I thank you again for your time and I'll turn it  over to Britt.  \n ", "original_text": "Our ability to be together, to stand together, focused on our values and purpose and service of the \nhealth care communities we serve makes me so proud.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1b76e8ab2129db5a441e0143ad525d0096f1de4730bca682d2fdec0dab1d518", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2b9d696-1430-43c4-b6e5-41bea3eb36ec", "node_type": "1", "metadata": {"window": "Our fiscal 2022 outlook of $18.85 to $19.45 of adjusted earnings per diluted share includes a return to solid \ngrowth in our core businesses, a continuation of our role in the COVID -19 vaccine efforts, investme nts in growth \nand a balanced approach to capital deployment.  Britt will take you through additional detailed assumptions that \nmake up this outlook.  \n \n As I reflect back, fiscal 2021 has taught us a lot, and it showed us, once again, that our business model i s \npositioned well to adapt and succeed in uncertain times.  Time and time again, we've proven our resiliency during \ncrisis, and I'm so proud of the way our employees rose to the challenges brought on by the pandemic and society \nmore broadly.  Our ability to be together, to stand together, focused on our values and purpose and service of the \nhealth care communities we serve makes me so proud.  \n \n We will focus on building momentum on our fiscal 2021 accomplishments and we will look to embrace the \nchanges that hav e made us better to advance our growth strategy and grow the business.  We will also continue \nto be front and center in the fight against COVID -19, helping to serve the communities in which we live and work.  \n \n", "original_text": "Time and time again, we've proven our resiliency during \ncrisis, and I'm so proud of the way our employees rose to the challenges brought on by the pandemic and society \nmore broadly. ", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2f24c1bd2d6fc1e595e2d8ce499ba0fd328986b43010d7b573304f6a56b8427", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6102cbff-33e6-44e7-acb3-1c695ec722bc", "node_type": "1", "metadata": {"window": "As I reflect back, fiscal 2021 has taught us a lot, and it showed us, once again, that our business model i s \npositioned well to adapt and succeed in uncertain times.  Time and time again, we've proven our resiliency during \ncrisis, and I'm so proud of the way our employees rose to the challenges brought on by the pandemic and society \nmore broadly.  Our ability to be together, to stand together, focused on our values and purpose and service of the \nhealth care communities we serve makes me so proud.  \n \n We will focus on building momentum on our fiscal 2021 accomplishments and we will look to embrace the \nchanges that hav e made us better to advance our growth strategy and grow the business.  We will also continue \nto be front and center in the fight against COVID -19, helping to serve the communities in which we live and work.  \n \n I thank you again for your time and I'll turn it  over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "original_text": "We will focus on building momentum on our fiscal 2021 accomplishments and we will look to embrace the \nchanges that hav e made us better to advance our growth strategy and grow the business. "}, "hash": "4e9ad18762cde444dac1e72be7acc6c786ccdc7bc164575c57c675acde32ec43", "class_name": "RelatedNodeInfo"}}, "text": "Our ability to be together, to stand together, focused on our values and purpose and service of the \nhealth care communities we serve makes me so proud.  \n \n", "start_char_idx": 1044, "end_char_idx": 1201, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6102cbff-33e6-44e7-acb3-1c695ec722bc": {"__data__": {"id_": "6102cbff-33e6-44e7-acb3-1c695ec722bc", "embedding": null, "metadata": {"window": "As I reflect back, fiscal 2021 has taught us a lot, and it showed us, once again, that our business model i s \npositioned well to adapt and succeed in uncertain times.  Time and time again, we've proven our resiliency during \ncrisis, and I'm so proud of the way our employees rose to the challenges brought on by the pandemic and society \nmore broadly.  Our ability to be together, to stand together, focused on our values and purpose and service of the \nhealth care communities we serve makes me so proud.  \n \n We will focus on building momentum on our fiscal 2021 accomplishments and we will look to embrace the \nchanges that hav e made us better to advance our growth strategy and grow the business.  We will also continue \nto be front and center in the fight against COVID -19, helping to serve the communities in which we live and work.  \n \n I thank you again for your time and I'll turn it  over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "original_text": "We will focus on building momentum on our fiscal 2021 accomplishments and we will look to embrace the \nchanges that hav e made us better to advance our growth strategy and grow the business. ", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1b76e8ab2129db5a441e0143ad525d0096f1de4730bca682d2fdec0dab1d518", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8aa56fc8-72b2-471c-9f66-a79cc0418f15", "node_type": "1", "metadata": {"window": "Britt will take you through additional detailed assumptions that \nmake up this outlook.  \n \n As I reflect back, fiscal 2021 has taught us a lot, and it showed us, once again, that our business model i s \npositioned well to adapt and succeed in uncertain times.  Time and time again, we've proven our resiliency during \ncrisis, and I'm so proud of the way our employees rose to the challenges brought on by the pandemic and society \nmore broadly.  Our ability to be together, to stand together, focused on our values and purpose and service of the \nhealth care communities we serve makes me so proud.  \n \n We will focus on building momentum on our fiscal 2021 accomplishments and we will look to embrace the \nchanges that hav e made us better to advance our growth strategy and grow the business.  We will also continue \nto be front and center in the fight against COVID -19, helping to serve the communities in which we live and work.  \n \n I thank you again for your time and I'll turn it  over to Britt.  \n ", "original_text": "Our ability to be together, to stand together, focused on our values and purpose and service of the \nhealth care communities we serve makes me so proud.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6274555298d43c7098f553812688ae2b697260172b5fdabba5e4988f0970a620", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d112ad8-8dcc-481c-b78c-16b5f3556c86", "node_type": "1", "metadata": {"window": "Time and time again, we've proven our resiliency during \ncrisis, and I'm so proud of the way our employees rose to the challenges brought on by the pandemic and society \nmore broadly.  Our ability to be together, to stand together, focused on our values and purpose and service of the \nhealth care communities we serve makes me so proud.  \n \n We will focus on building momentum on our fiscal 2021 accomplishments and we will look to embrace the \nchanges that hav e made us better to advance our growth strategy and grow the business.  We will also continue \nto be front and center in the fight against COVID -19, helping to serve the communities in which we live and work.  \n \n I thank you again for your time and I'll turn it  over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian and good afternoon, everyone. ", "original_text": "We will also continue \nto be front and center in the fight against COVID -19, helping to serve the communities in which we live and work.  \n \n"}, "hash": "28651e1cbd6b2d0bd15ab99182bb8e0e1f4b6f1c2445dfdff14213cea44d923a", "class_name": "RelatedNodeInfo"}}, "text": "We will focus on building momentum on our fiscal 2021 accomplishments and we will look to embrace the \nchanges that hav e made us better to advance our growth strategy and grow the business. ", "start_char_idx": 1201, "end_char_idx": 1392, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d112ad8-8dcc-481c-b78c-16b5f3556c86": {"__data__": {"id_": "0d112ad8-8dcc-481c-b78c-16b5f3556c86", "embedding": null, "metadata": {"window": "Time and time again, we've proven our resiliency during \ncrisis, and I'm so proud of the way our employees rose to the challenges brought on by the pandemic and society \nmore broadly.  Our ability to be together, to stand together, focused on our values and purpose and service of the \nhealth care communities we serve makes me so proud.  \n \n We will focus on building momentum on our fiscal 2021 accomplishments and we will look to embrace the \nchanges that hav e made us better to advance our growth strategy and grow the business.  We will also continue \nto be front and center in the fight against COVID -19, helping to serve the communities in which we live and work.  \n \n I thank you again for your time and I'll turn it  over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian and good afternoon, everyone. ", "original_text": "We will also continue \nto be front and center in the fight against COVID -19, helping to serve the communities in which we live and work.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1b76e8ab2129db5a441e0143ad525d0096f1de4730bca682d2fdec0dab1d518", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6102cbff-33e6-44e7-acb3-1c695ec722bc", "node_type": "1", "metadata": {"window": "As I reflect back, fiscal 2021 has taught us a lot, and it showed us, once again, that our business model i s \npositioned well to adapt and succeed in uncertain times.  Time and time again, we've proven our resiliency during \ncrisis, and I'm so proud of the way our employees rose to the challenges brought on by the pandemic and society \nmore broadly.  Our ability to be together, to stand together, focused on our values and purpose and service of the \nhealth care communities we serve makes me so proud.  \n \n We will focus on building momentum on our fiscal 2021 accomplishments and we will look to embrace the \nchanges that hav e made us better to advance our growth strategy and grow the business.  We will also continue \nto be front and center in the fight against COVID -19, helping to serve the communities in which we live and work.  \n \n I thank you again for your time and I'll turn it  over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "original_text": "We will focus on building momentum on our fiscal 2021 accomplishments and we will look to embrace the \nchanges that hav e made us better to advance our growth strategy and grow the business. ", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7fc45b183a64793877a36e3b9b36cb08757dac59d2975bd54a6d9d7b8674e076", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4efb2e70-068d-4862-b19f-d22921298a77", "node_type": "1", "metadata": {"window": "Our ability to be together, to stand together, focused on our values and purpose and service of the \nhealth care communities we serve makes me so proud.  \n \n We will focus on building momentum on our fiscal 2021 accomplishments and we will look to embrace the \nchanges that hav e made us better to advance our growth strategy and grow the business.  We will also continue \nto be front and center in the fight against COVID -19, helping to serve the communities in which we live and work.  \n \n I thank you again for your time and I'll turn it  over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian and good afternoon, everyone.  Fiscal 2021 was an unprecedented year, as Brian talked about \nearlier. ", "original_text": "I thank you again for your time and I'll turn it  over to Britt.  \n "}, "hash": "a8b13d95d8497cc600fe120212e620bafbcfe443ef623351997534196b2e150a", "class_name": "RelatedNodeInfo"}}, "text": "We will also continue \nto be front and center in the fight against COVID -19, helping to serve the communities in which we live and work.  \n \n", "start_char_idx": 1392, "end_char_idx": 1534, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4efb2e70-068d-4862-b19f-d22921298a77": {"__data__": {"id_": "4efb2e70-068d-4862-b19f-d22921298a77", "embedding": null, "metadata": {"window": "Our ability to be together, to stand together, focused on our values and purpose and service of the \nhealth care communities we serve makes me so proud.  \n \n We will focus on building momentum on our fiscal 2021 accomplishments and we will look to embrace the \nchanges that hav e made us better to advance our growth strategy and grow the business.  We will also continue \nto be front and center in the fight against COVID -19, helping to serve the communities in which we live and work.  \n \n I thank you again for your time and I'll turn it  over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian and good afternoon, everyone.  Fiscal 2021 was an unprecedented year, as Brian talked about \nearlier. ", "original_text": "I thank you again for your time and I'll turn it  over to Britt.  \n ", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1b76e8ab2129db5a441e0143ad525d0096f1de4730bca682d2fdec0dab1d518", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d112ad8-8dcc-481c-b78c-16b5f3556c86", "node_type": "1", "metadata": {"window": "Time and time again, we've proven our resiliency during \ncrisis, and I'm so proud of the way our employees rose to the challenges brought on by the pandemic and society \nmore broadly.  Our ability to be together, to stand together, focused on our values and purpose and service of the \nhealth care communities we serve makes me so proud.  \n \n We will focus on building momentum on our fiscal 2021 accomplishments and we will look to embrace the \nchanges that hav e made us better to advance our growth strategy and grow the business.  We will also continue \nto be front and center in the fight against COVID -19, helping to serve the communities in which we live and work.  \n \n I thank you again for your time and I'll turn it  over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian and good afternoon, everyone. ", "original_text": "We will also continue \nto be front and center in the fight against COVID -19, helping to serve the communities in which we live and work.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7fa8eae6d72abaaa1bd2d43cdf5093355c47ccadc83e9aefdb4430ed7e724f5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52d01260-eb13-4cc0-8693-fcf7fe3817fe", "node_type": "1", "metadata": {"window": "We will focus on building momentum on our fiscal 2021 accomplishments and we will look to embrace the \nchanges that hav e made us better to advance our growth strategy and grow the business.  We will also continue \nto be front and center in the fight against COVID -19, helping to serve the communities in which we live and work.  \n \n I thank you again for your time and I'll turn it  over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian and good afternoon, everyone.  Fiscal 2021 was an unprecedented year, as Brian talked about \nearlier.  When we spoke a year ago, we just fini shed our fiscal 2020 as the COVID pandemic was beginning to \ntake hold on our communities and economies.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n"}, "hash": "4f858ec2517515e53af89375e352f13f7c241a4d15bd1f76a462451df13c0e9e", "class_name": "RelatedNodeInfo"}}, "text": "I thank you again for your time and I'll turn it  over to Britt.  \n ", "start_char_idx": 1534, "end_char_idx": 1602, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52d01260-eb13-4cc0-8693-fcf7fe3817fe": {"__data__": {"id_": "52d01260-eb13-4cc0-8693-fcf7fe3817fe", "embedding": null, "metadata": {"window": "We will focus on building momentum on our fiscal 2021 accomplishments and we will look to embrace the \nchanges that hav e made us better to advance our growth strategy and grow the business.  We will also continue \nto be front and center in the fight against COVID -19, helping to serve the communities in which we live and work.  \n \n I thank you again for your time and I'll turn it  over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian and good afternoon, everyone.  Fiscal 2021 was an unprecedented year, as Brian talked about \nearlier.  When we spoke a year ago, we just fini shed our fiscal 2020 as the COVID pandemic was beginning to \ntake hold on our communities and economies.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1b76e8ab2129db5a441e0143ad525d0096f1de4730bca682d2fdec0dab1d518", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4efb2e70-068d-4862-b19f-d22921298a77", "node_type": "1", "metadata": {"window": "Our ability to be together, to stand together, focused on our values and purpose and service of the \nhealth care communities we serve makes me so proud.  \n \n We will focus on building momentum on our fiscal 2021 accomplishments and we will look to embrace the \nchanges that hav e made us better to advance our growth strategy and grow the business.  We will also continue \nto be front and center in the fight against COVID -19, helping to serve the communities in which we live and work.  \n \n I thank you again for your time and I'll turn it  over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian and good afternoon, everyone.  Fiscal 2021 was an unprecedented year, as Brian talked about \nearlier. ", "original_text": "I thank you again for your time and I'll turn it  over to Britt.  \n ", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1241d153b18fef2b824b3ba4591beff9da4a09ef732acc44c511512b1ddac9cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0b45abb-6c13-455a-9dcb-5da16eac4eab", "node_type": "1", "metadata": {"window": "We will also continue \nto be front and center in the fight against COVID -19, helping to serve the communities in which we live and work.  \n \n I thank you again for your time and I'll turn it  over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian and good afternoon, everyone.  Fiscal 2021 was an unprecedented year, as Brian talked about \nearlier.  When we spoke a year ago, we just fini shed our fiscal 2020 as the COVID pandemic was beginning to \ntake hold on our communities and economies.  \n \n During that call, we provided our full year fiscal 2021 outlook with quite possibly the highest level of uncertainty in \nMcKesson's 188 -year history. ", "original_text": "Thank you, Brian and good afternoon, everyone. "}, "hash": "5df1d94e0ba0b32401d185ce7b7ab3e913e565c741d3c587ab54ad84ed4d7802", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "start_char_idx": 1602, "end_char_idx": 1945, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0b45abb-6c13-455a-9dcb-5da16eac4eab": {"__data__": {"id_": "a0b45abb-6c13-455a-9dcb-5da16eac4eab", "embedding": null, "metadata": {"window": "We will also continue \nto be front and center in the fight against COVID -19, helping to serve the communities in which we live and work.  \n \n I thank you again for your time and I'll turn it  over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian and good afternoon, everyone.  Fiscal 2021 was an unprecedented year, as Brian talked about \nearlier.  When we spoke a year ago, we just fini shed our fiscal 2020 as the COVID pandemic was beginning to \ntake hold on our communities and economies.  \n \n During that call, we provided our full year fiscal 2021 outlook with quite possibly the highest level of uncertainty in \nMcKesson's 188 -year history. ", "original_text": "Thank you, Brian and good afternoon, everyone. ", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1b76e8ab2129db5a441e0143ad525d0096f1de4730bca682d2fdec0dab1d518", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52d01260-eb13-4cc0-8693-fcf7fe3817fe", "node_type": "1", "metadata": {"window": "We will focus on building momentum on our fiscal 2021 accomplishments and we will look to embrace the \nchanges that hav e made us better to advance our growth strategy and grow the business.  We will also continue \nto be front and center in the fight against COVID -19, helping to serve the communities in which we live and work.  \n \n I thank you again for your time and I'll turn it  over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian and good afternoon, everyone.  Fiscal 2021 was an unprecedented year, as Brian talked about \nearlier.  When we spoke a year ago, we just fini shed our fiscal 2020 as the COVID pandemic was beginning to \ntake hold on our communities and economies.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c23ba4d9b17227488bd70441d24558463cdc58ab847627bbde470a511b4a24aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7762bc6-059b-4735-b756-583a221c2f5b", "node_type": "1", "metadata": {"window": "I thank you again for your time and I'll turn it  over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian and good afternoon, everyone.  Fiscal 2021 was an unprecedented year, as Brian talked about \nearlier.  When we spoke a year ago, we just fini shed our fiscal 2020 as the COVID pandemic was beginning to \ntake hold on our communities and economies.  \n \n During that call, we provided our full year fiscal 2021 outlook with quite possibly the highest level of uncertainty in \nMcKesson's 188 -year history.  As  I've said since the outset of the pandemic, McKesson's operating momentum is \nthe result of our strategic clarity, focus, execution, and discipline.  \n \n", "original_text": "Fiscal 2021 was an unprecedented year, as Brian talked about \nearlier. "}, "hash": "e2e819d77497bf5a8121d0f68ae1c7a2b5cf40f253ccffea629db4f044a3408e", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Brian and good afternoon, everyone. ", "start_char_idx": 1945, "end_char_idx": 1992, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7762bc6-059b-4735-b756-583a221c2f5b": {"__data__": {"id_": "c7762bc6-059b-4735-b756-583a221c2f5b", "embedding": null, "metadata": {"window": "I thank you again for your time and I'll turn it  over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian and good afternoon, everyone.  Fiscal 2021 was an unprecedented year, as Brian talked about \nearlier.  When we spoke a year ago, we just fini shed our fiscal 2020 as the COVID pandemic was beginning to \ntake hold on our communities and economies.  \n \n During that call, we provided our full year fiscal 2021 outlook with quite possibly the highest level of uncertainty in \nMcKesson's 188 -year history.  As  I've said since the outset of the pandemic, McKesson's operating momentum is \nthe result of our strategic clarity, focus, execution, and discipline.  \n \n", "original_text": "Fiscal 2021 was an unprecedented year, as Brian talked about \nearlier. ", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1b76e8ab2129db5a441e0143ad525d0096f1de4730bca682d2fdec0dab1d518", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0b45abb-6c13-455a-9dcb-5da16eac4eab", "node_type": "1", "metadata": {"window": "We will also continue \nto be front and center in the fight against COVID -19, helping to serve the communities in which we live and work.  \n \n I thank you again for your time and I'll turn it  over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian and good afternoon, everyone.  Fiscal 2021 was an unprecedented year, as Brian talked about \nearlier.  When we spoke a year ago, we just fini shed our fiscal 2020 as the COVID pandemic was beginning to \ntake hold on our communities and economies.  \n \n During that call, we provided our full year fiscal 2021 outlook with quite possibly the highest level of uncertainty in \nMcKesson's 188 -year history. ", "original_text": "Thank you, Brian and good afternoon, everyone. ", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "388e504b4115af42c95e75cfa673292c329513283649f80391b99db7120a2098", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "848ee1e1-d449-4af5-9509-e67cfe31c4d1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian and good afternoon, everyone.  Fiscal 2021 was an unprecedented year, as Brian talked about \nearlier.  When we spoke a year ago, we just fini shed our fiscal 2020 as the COVID pandemic was beginning to \ntake hold on our communities and economies.  \n \n During that call, we provided our full year fiscal 2021 outlook with quite possibly the highest level of uncertainty in \nMcKesson's 188 -year history.  As  I've said since the outset of the pandemic, McKesson's operating momentum is \nthe result of our strategic clarity, focus, execution, and discipline.  \n \n As a company, we've been operating in new ways for over a year. ", "original_text": "When we spoke a year ago, we just fini shed our fiscal 2020 as the COVID pandemic was beginning to \ntake hold on our communities and economies.  \n \n"}, "hash": "f5a6aff640828a965f7eaa5c756aa0c2a5473cdf3118a1e238d6f2638df899db", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal 2021 was an unprecedented year, as Brian talked about \nearlier. ", "start_char_idx": 1992, "end_char_idx": 2063, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "848ee1e1-d449-4af5-9509-e67cfe31c4d1": {"__data__": {"id_": "848ee1e1-d449-4af5-9509-e67cfe31c4d1", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian and good afternoon, everyone.  Fiscal 2021 was an unprecedented year, as Brian talked about \nearlier.  When we spoke a year ago, we just fini shed our fiscal 2020 as the COVID pandemic was beginning to \ntake hold on our communities and economies.  \n \n During that call, we provided our full year fiscal 2021 outlook with quite possibly the highest level of uncertainty in \nMcKesson's 188 -year history.  As  I've said since the outset of the pandemic, McKesson's operating momentum is \nthe result of our strategic clarity, focus, execution, and discipline.  \n \n As a company, we've been operating in new ways for over a year. ", "original_text": "When we spoke a year ago, we just fini shed our fiscal 2020 as the COVID pandemic was beginning to \ntake hold on our communities and economies.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1b76e8ab2129db5a441e0143ad525d0096f1de4730bca682d2fdec0dab1d518", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7762bc6-059b-4735-b756-583a221c2f5b", "node_type": "1", "metadata": {"window": "I thank you again for your time and I'll turn it  over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian and good afternoon, everyone.  Fiscal 2021 was an unprecedented year, as Brian talked about \nearlier.  When we spoke a year ago, we just fini shed our fiscal 2020 as the COVID pandemic was beginning to \ntake hold on our communities and economies.  \n \n During that call, we provided our full year fiscal 2021 outlook with quite possibly the highest level of uncertainty in \nMcKesson's 188 -year history.  As  I've said since the outset of the pandemic, McKesson's operating momentum is \nthe result of our strategic clarity, focus, execution, and discipline.  \n \n", "original_text": "Fiscal 2021 was an unprecedented year, as Brian talked about \nearlier. ", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b66ee2e4eacbb261655a3fede1abe58678955f4f7ca2fc69e9efcaa2183695ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a27413a3-ae5d-49e2-8c44-7f2831966ae2", "node_type": "1", "metadata": {"window": "Thank you, Brian and good afternoon, everyone.  Fiscal 2021 was an unprecedented year, as Brian talked about \nearlier.  When we spoke a year ago, we just fini shed our fiscal 2020 as the COVID pandemic was beginning to \ntake hold on our communities and economies.  \n \n During that call, we provided our full year fiscal 2021 outlook with quite possibly the highest level of uncertainty in \nMcKesson's 188 -year history.  As  I've said since the outset of the pandemic, McKesson's operating momentum is \nthe result of our strategic clarity, focus, execution, and discipline.  \n \n As a company, we've been operating in new ways for over a year.  We're proud of the way our teams continue to \nexecute and innovate. ", "original_text": "During that call, we provided our full year fiscal 2021 outlook with quite possibly the highest level of uncertainty in \nMcKesson's 188 -year history. "}, "hash": "43555c0bd843ae5359f5c5d365351d85b50742cecea80839bfbdfe7d235fc5f1", "class_name": "RelatedNodeInfo"}}, "text": "When we spoke a year ago, we just fini shed our fiscal 2020 as the COVID pandemic was beginning to \ntake hold on our communities and economies.  \n \n", "start_char_idx": 2063, "end_char_idx": 2211, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a27413a3-ae5d-49e2-8c44-7f2831966ae2": {"__data__": {"id_": "a27413a3-ae5d-49e2-8c44-7f2831966ae2", "embedding": null, "metadata": {"window": "Thank you, Brian and good afternoon, everyone.  Fiscal 2021 was an unprecedented year, as Brian talked about \nearlier.  When we spoke a year ago, we just fini shed our fiscal 2020 as the COVID pandemic was beginning to \ntake hold on our communities and economies.  \n \n During that call, we provided our full year fiscal 2021 outlook with quite possibly the highest level of uncertainty in \nMcKesson's 188 -year history.  As  I've said since the outset of the pandemic, McKesson's operating momentum is \nthe result of our strategic clarity, focus, execution, and discipline.  \n \n As a company, we've been operating in new ways for over a year.  We're proud of the way our teams continue to \nexecute and innovate. ", "original_text": "During that call, we provided our full year fiscal 2021 outlook with quite possibly the highest level of uncertainty in \nMcKesson's 188 -year history. ", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1b76e8ab2129db5a441e0143ad525d0096f1de4730bca682d2fdec0dab1d518", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "848ee1e1-d449-4af5-9509-e67cfe31c4d1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian and good afternoon, everyone.  Fiscal 2021 was an unprecedented year, as Brian talked about \nearlier.  When we spoke a year ago, we just fini shed our fiscal 2020 as the COVID pandemic was beginning to \ntake hold on our communities and economies.  \n \n During that call, we provided our full year fiscal 2021 outlook with quite possibly the highest level of uncertainty in \nMcKesson's 188 -year history.  As  I've said since the outset of the pandemic, McKesson's operating momentum is \nthe result of our strategic clarity, focus, execution, and discipline.  \n \n As a company, we've been operating in new ways for over a year. ", "original_text": "When we spoke a year ago, we just fini shed our fiscal 2020 as the COVID pandemic was beginning to \ntake hold on our communities and economies.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "262064560719a0237ae92f240da70a0aa58bdde8080c0dab71c11bf55d11c210", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1e10b08-14c7-44f1-bedc-f8a7a7b663b6", "node_type": "1", "metadata": {"window": "Fiscal 2021 was an unprecedented year, as Brian talked about \nearlier.  When we spoke a year ago, we just fini shed our fiscal 2020 as the COVID pandemic was beginning to \ntake hold on our communities and economies.  \n \n During that call, we provided our full year fiscal 2021 outlook with quite possibly the highest level of uncertainty in \nMcKesson's 188 -year history.  As  I've said since the outset of the pandemic, McKesson's operating momentum is \nthe result of our strategic clarity, focus, execution, and discipline.  \n \n As a company, we've been operating in new ways for over a year.  We're proud of the way our teams continue to \nexecute and innovate.  We're stronger than before the pandemic and our fiscal 2021 financial results give us even \nmore confidence in our ability to continue delivering compelling performance in the future.  \n \n", "original_text": "As  I've said since the outset of the pandemic, McKesson's operating momentum is \nthe result of our strategic clarity, focus, execution, and discipline.  \n \n"}, "hash": "22f0d86416ba48b93103ff9ed0b8ca0ced59919545e2404fd72613c16e7b7610", "class_name": "RelatedNodeInfo"}}, "text": "During that call, we provided our full year fiscal 2021 outlook with quite possibly the highest level of uncertainty in \nMcKesson's 188 -year history. ", "start_char_idx": 2211, "end_char_idx": 2362, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1e10b08-14c7-44f1-bedc-f8a7a7b663b6": {"__data__": {"id_": "e1e10b08-14c7-44f1-bedc-f8a7a7b663b6", "embedding": null, "metadata": {"window": "Fiscal 2021 was an unprecedented year, as Brian talked about \nearlier.  When we spoke a year ago, we just fini shed our fiscal 2020 as the COVID pandemic was beginning to \ntake hold on our communities and economies.  \n \n During that call, we provided our full year fiscal 2021 outlook with quite possibly the highest level of uncertainty in \nMcKesson's 188 -year history.  As  I've said since the outset of the pandemic, McKesson's operating momentum is \nthe result of our strategic clarity, focus, execution, and discipline.  \n \n As a company, we've been operating in new ways for over a year.  We're proud of the way our teams continue to \nexecute and innovate.  We're stronger than before the pandemic and our fiscal 2021 financial results give us even \nmore confidence in our ability to continue delivering compelling performance in the future.  \n \n", "original_text": "As  I've said since the outset of the pandemic, McKesson's operating momentum is \nthe result of our strategic clarity, focus, execution, and discipline.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1b76e8ab2129db5a441e0143ad525d0096f1de4730bca682d2fdec0dab1d518", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a27413a3-ae5d-49e2-8c44-7f2831966ae2", "node_type": "1", "metadata": {"window": "Thank you, Brian and good afternoon, everyone.  Fiscal 2021 was an unprecedented year, as Brian talked about \nearlier.  When we spoke a year ago, we just fini shed our fiscal 2020 as the COVID pandemic was beginning to \ntake hold on our communities and economies.  \n \n During that call, we provided our full year fiscal 2021 outlook with quite possibly the highest level of uncertainty in \nMcKesson's 188 -year history.  As  I've said since the outset of the pandemic, McKesson's operating momentum is \nthe result of our strategic clarity, focus, execution, and discipline.  \n \n As a company, we've been operating in new ways for over a year.  We're proud of the way our teams continue to \nexecute and innovate. ", "original_text": "During that call, we provided our full year fiscal 2021 outlook with quite possibly the highest level of uncertainty in \nMcKesson's 188 -year history. ", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "278a56680792375d8f39f2e12c045e653e577e1aad13370905d5b2a05a23ae4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ac73ef0-1be2-492e-9a55-c2fc8c23dd9e", "node_type": "1", "metadata": {"window": "When we spoke a year ago, we just fini shed our fiscal 2020 as the COVID pandemic was beginning to \ntake hold on our communities and economies.  \n \n During that call, we provided our full year fiscal 2021 outlook with quite possibly the highest level of uncertainty in \nMcKesson's 188 -year history.  As  I've said since the outset of the pandemic, McKesson's operating momentum is \nthe result of our strategic clarity, focus, execution, and discipline.  \n \n As a company, we've been operating in new ways for over a year.  We're proud of the way our teams continue to \nexecute and innovate.  We're stronger than before the pandemic and our fiscal 2021 financial results give us even \nmore confidence in our ability to continue delivering compelling performance in the future.  \n \n Today, I'll provide an update on our fourth qua rter and fiscal 2021 results, including a detailed fiscal 2022 outlook, \nan overview which can be found in the Investors section of our website.  \n \n", "original_text": "As a company, we've been operating in new ways for over a year. "}, "hash": "d24af377c33e83d4db82fbf9b71b618ab95d17d4398e2e39eb24870f35e66ead", "class_name": "RelatedNodeInfo"}}, "text": "As  I've said since the outset of the pandemic, McKesson's operating momentum is \nthe result of our strategic clarity, focus, execution, and discipline.  \n \n", "start_char_idx": 2362, "end_char_idx": 2519, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ac73ef0-1be2-492e-9a55-c2fc8c23dd9e": {"__data__": {"id_": "7ac73ef0-1be2-492e-9a55-c2fc8c23dd9e", "embedding": null, "metadata": {"window": "When we spoke a year ago, we just fini shed our fiscal 2020 as the COVID pandemic was beginning to \ntake hold on our communities and economies.  \n \n During that call, we provided our full year fiscal 2021 outlook with quite possibly the highest level of uncertainty in \nMcKesson's 188 -year history.  As  I've said since the outset of the pandemic, McKesson's operating momentum is \nthe result of our strategic clarity, focus, execution, and discipline.  \n \n As a company, we've been operating in new ways for over a year.  We're proud of the way our teams continue to \nexecute and innovate.  We're stronger than before the pandemic and our fiscal 2021 financial results give us even \nmore confidence in our ability to continue delivering compelling performance in the future.  \n \n Today, I'll provide an update on our fourth qua rter and fiscal 2021 results, including a detailed fiscal 2022 outlook, \nan overview which can be found in the Investors section of our website.  \n \n", "original_text": "As a company, we've been operating in new ways for over a year. ", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1b76e8ab2129db5a441e0143ad525d0096f1de4730bca682d2fdec0dab1d518", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1e10b08-14c7-44f1-bedc-f8a7a7b663b6", "node_type": "1", "metadata": {"window": "Fiscal 2021 was an unprecedented year, as Brian talked about \nearlier.  When we spoke a year ago, we just fini shed our fiscal 2020 as the COVID pandemic was beginning to \ntake hold on our communities and economies.  \n \n During that call, we provided our full year fiscal 2021 outlook with quite possibly the highest level of uncertainty in \nMcKesson's 188 -year history.  As  I've said since the outset of the pandemic, McKesson's operating momentum is \nthe result of our strategic clarity, focus, execution, and discipline.  \n \n As a company, we've been operating in new ways for over a year.  We're proud of the way our teams continue to \nexecute and innovate.  We're stronger than before the pandemic and our fiscal 2021 financial results give us even \nmore confidence in our ability to continue delivering compelling performance in the future.  \n \n", "original_text": "As  I've said since the outset of the pandemic, McKesson's operating momentum is \nthe result of our strategic clarity, focus, execution, and discipline.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c0bb95730a234469c8b438f9b290e6c1cc5f44719ff2a346ebaa9bcac04a91d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a9fe624-3cd8-4eff-8c41-bef0098ce9e2", "node_type": "1", "metadata": {"window": "During that call, we provided our full year fiscal 2021 outlook with quite possibly the highest level of uncertainty in \nMcKesson's 188 -year history.  As  I've said since the outset of the pandemic, McKesson's operating momentum is \nthe result of our strategic clarity, focus, execution, and discipline.  \n \n As a company, we've been operating in new ways for over a year.  We're proud of the way our teams continue to \nexecute and innovate.  We're stronger than before the pandemic and our fiscal 2021 financial results give us even \nmore confidence in our ability to continue delivering compelling performance in the future.  \n \n Today, I'll provide an update on our fourth qua rter and fiscal 2021 results, including a detailed fiscal 2022 outlook, \nan overview which can be found in the Investors section of our website.  \n \n Let me start now with our fiscal 2021 results. ", "original_text": "We're proud of the way our teams continue to \nexecute and innovate. "}, "hash": "a2d0abdb2cd2d4bbcb4dc40cc245202fbe4dbc9ee612389c1480d12887724285", "class_name": "RelatedNodeInfo"}}, "text": "As a company, we've been operating in new ways for over a year. ", "start_char_idx": 2519, "end_char_idx": 2583, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a9fe624-3cd8-4eff-8c41-bef0098ce9e2": {"__data__": {"id_": "5a9fe624-3cd8-4eff-8c41-bef0098ce9e2", "embedding": null, "metadata": {"window": "During that call, we provided our full year fiscal 2021 outlook with quite possibly the highest level of uncertainty in \nMcKesson's 188 -year history.  As  I've said since the outset of the pandemic, McKesson's operating momentum is \nthe result of our strategic clarity, focus, execution, and discipline.  \n \n As a company, we've been operating in new ways for over a year.  We're proud of the way our teams continue to \nexecute and innovate.  We're stronger than before the pandemic and our fiscal 2021 financial results give us even \nmore confidence in our ability to continue delivering compelling performance in the future.  \n \n Today, I'll provide an update on our fourth qua rter and fiscal 2021 results, including a detailed fiscal 2022 outlook, \nan overview which can be found in the Investors section of our website.  \n \n Let me start now with our fiscal 2021 results. ", "original_text": "We're proud of the way our teams continue to \nexecute and innovate. ", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1b76e8ab2129db5a441e0143ad525d0096f1de4730bca682d2fdec0dab1d518", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ac73ef0-1be2-492e-9a55-c2fc8c23dd9e", "node_type": "1", "metadata": {"window": "When we spoke a year ago, we just fini shed our fiscal 2020 as the COVID pandemic was beginning to \ntake hold on our communities and economies.  \n \n During that call, we provided our full year fiscal 2021 outlook with quite possibly the highest level of uncertainty in \nMcKesson's 188 -year history.  As  I've said since the outset of the pandemic, McKesson's operating momentum is \nthe result of our strategic clarity, focus, execution, and discipline.  \n \n As a company, we've been operating in new ways for over a year.  We're proud of the way our teams continue to \nexecute and innovate.  We're stronger than before the pandemic and our fiscal 2021 financial results give us even \nmore confidence in our ability to continue delivering compelling performance in the future.  \n \n Today, I'll provide an update on our fourth qua rter and fiscal 2021 results, including a detailed fiscal 2022 outlook, \nan overview which can be found in the Investors section of our website.  \n \n", "original_text": "As a company, we've been operating in new ways for over a year. ", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f24d09fd5f8f96451e83c97866919191fc575e5b6d71cc3fb7567f9ca20331d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c2c8f23-03fd-409b-a61a-9e3f9085ba1e", "node_type": "1", "metadata": {"window": "As  I've said since the outset of the pandemic, McKesson's operating momentum is \nthe result of our strategic clarity, focus, execution, and discipline.  \n \n As a company, we've been operating in new ways for over a year.  We're proud of the way our teams continue to \nexecute and innovate.  We're stronger than before the pandemic and our fiscal 2021 financial results give us even \nmore confidence in our ability to continue delivering compelling performance in the future.  \n \n Today, I'll provide an update on our fourth qua rter and fiscal 2021 results, including a detailed fiscal 2022 outlook, \nan overview which can be found in the Investors section of our website.  \n \n Let me start now with our fiscal 2021 results.  Our full year adjusted earnings per diluted share of $17.21 grew  \n15% above fiscal 2020 and within our updated guidance range. ", "original_text": "We're stronger than before the pandemic and our fiscal 2021 financial results give us even \nmore confidence in our ability to continue delivering compelling performance in the future.  \n \n"}, "hash": "49fdc84f98a1c4d83d21739bbdfae9bb555ffc7411f0380202a9f7f48fee772e", "class_name": "RelatedNodeInfo"}}, "text": "We're proud of the way our teams continue to \nexecute and innovate. ", "start_char_idx": 2583, "end_char_idx": 2651, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c2c8f23-03fd-409b-a61a-9e3f9085ba1e": {"__data__": {"id_": "9c2c8f23-03fd-409b-a61a-9e3f9085ba1e", "embedding": null, "metadata": {"window": "As  I've said since the outset of the pandemic, McKesson's operating momentum is \nthe result of our strategic clarity, focus, execution, and discipline.  \n \n As a company, we've been operating in new ways for over a year.  We're proud of the way our teams continue to \nexecute and innovate.  We're stronger than before the pandemic and our fiscal 2021 financial results give us even \nmore confidence in our ability to continue delivering compelling performance in the future.  \n \n Today, I'll provide an update on our fourth qua rter and fiscal 2021 results, including a detailed fiscal 2022 outlook, \nan overview which can be found in the Investors section of our website.  \n \n Let me start now with our fiscal 2021 results.  Our full year adjusted earnings per diluted share of $17.21 grew  \n15% above fiscal 2020 and within our updated guidance range. ", "original_text": "We're stronger than before the pandemic and our fiscal 2021 financial results give us even \nmore confidence in our ability to continue delivering compelling performance in the future.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1b76e8ab2129db5a441e0143ad525d0096f1de4730bca682d2fdec0dab1d518", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a9fe624-3cd8-4eff-8c41-bef0098ce9e2", "node_type": "1", "metadata": {"window": "During that call, we provided our full year fiscal 2021 outlook with quite possibly the highest level of uncertainty in \nMcKesson's 188 -year history.  As  I've said since the outset of the pandemic, McKesson's operating momentum is \nthe result of our strategic clarity, focus, execution, and discipline.  \n \n As a company, we've been operating in new ways for over a year.  We're proud of the way our teams continue to \nexecute and innovate.  We're stronger than before the pandemic and our fiscal 2021 financial results give us even \nmore confidence in our ability to continue delivering compelling performance in the future.  \n \n Today, I'll provide an update on our fourth qua rter and fiscal 2021 results, including a detailed fiscal 2022 outlook, \nan overview which can be found in the Investors section of our website.  \n \n Let me start now with our fiscal 2021 results. ", "original_text": "We're proud of the way our teams continue to \nexecute and innovate. ", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c92aa24ed98e375a5613280d3891c950315609bfb13aed7dbbbd270ee7761878", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ef6b98a-a602-4bb6-a9d6-db46142f8b32", "node_type": "1", "metadata": {"window": "As a company, we've been operating in new ways for over a year.  We're proud of the way our teams continue to \nexecute and innovate.  We're stronger than before the pandemic and our fiscal 2021 financial results give us even \nmore confidence in our ability to continue delivering compelling performance in the future.  \n \n Today, I'll provide an update on our fourth qua rter and fiscal 2021 results, including a detailed fiscal 2022 outlook, \nan overview which can be found in the Investors section of our website.  \n \n Let me start now with our fiscal 2021 results.  Our full year adjusted earnings per diluted share of $17.21 grew  \n15% above fiscal 2020 and within our updated guidance range.  Our fiscal year began with each of our segments \nexperiencing volume declines due to the impact of COVID -19. ", "original_text": "Today, I'll provide an update on our fourth qua rter and fiscal 2021 results, including a detailed fiscal 2022 outlook, \nan overview which can be found in the Investors section of our website.  \n \n"}, "hash": "9f721010b73cf0738e6bd878c94fb83907a2f5935565528ff54bc82c7d598764", "class_name": "RelatedNodeInfo"}}, "text": "We're stronger than before the pandemic and our fiscal 2021 financial results give us even \nmore confidence in our ability to continue delivering compelling performance in the future.  \n \n", "start_char_idx": 2651, "end_char_idx": 2839, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ef6b98a-a602-4bb6-a9d6-db46142f8b32": {"__data__": {"id_": "3ef6b98a-a602-4bb6-a9d6-db46142f8b32", "embedding": null, "metadata": {"window": "As a company, we've been operating in new ways for over a year.  We're proud of the way our teams continue to \nexecute and innovate.  We're stronger than before the pandemic and our fiscal 2021 financial results give us even \nmore confidence in our ability to continue delivering compelling performance in the future.  \n \n Today, I'll provide an update on our fourth qua rter and fiscal 2021 results, including a detailed fiscal 2022 outlook, \nan overview which can be found in the Investors section of our website.  \n \n Let me start now with our fiscal 2021 results.  Our full year adjusted earnings per diluted share of $17.21 grew  \n15% above fiscal 2020 and within our updated guidance range.  Our fiscal year began with each of our segments \nexperiencing volume declines due to the impact of COVID -19. ", "original_text": "Today, I'll provide an update on our fourth qua rter and fiscal 2021 results, including a detailed fiscal 2022 outlook, \nan overview which can be found in the Investors section of our website.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1b76e8ab2129db5a441e0143ad525d0096f1de4730bca682d2fdec0dab1d518", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c2c8f23-03fd-409b-a61a-9e3f9085ba1e", "node_type": "1", "metadata": {"window": "As  I've said since the outset of the pandemic, McKesson's operating momentum is \nthe result of our strategic clarity, focus, execution, and discipline.  \n \n As a company, we've been operating in new ways for over a year.  We're proud of the way our teams continue to \nexecute and innovate.  We're stronger than before the pandemic and our fiscal 2021 financial results give us even \nmore confidence in our ability to continue delivering compelling performance in the future.  \n \n Today, I'll provide an update on our fourth qua rter and fiscal 2021 results, including a detailed fiscal 2022 outlook, \nan overview which can be found in the Investors section of our website.  \n \n Let me start now with our fiscal 2021 results.  Our full year adjusted earnings per diluted share of $17.21 grew  \n15% above fiscal 2020 and within our updated guidance range. ", "original_text": "We're stronger than before the pandemic and our fiscal 2021 financial results give us even \nmore confidence in our ability to continue delivering compelling performance in the future.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e2afdbf99ad14d1061a7c030732354423a4d404e0cb93f4713fb3a2b39ed9014", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8034d77-1756-4446-b07b-882ce38f26d9", "node_type": "1", "metadata": {"window": "We're proud of the way our teams continue to \nexecute and innovate.  We're stronger than before the pandemic and our fiscal 2021 financial results give us even \nmore confidence in our ability to continue delivering compelling performance in the future.  \n \n Today, I'll provide an update on our fourth qua rter and fiscal 2021 results, including a detailed fiscal 2022 outlook, \nan overview which can be found in the Investors section of our website.  \n \n Let me start now with our fiscal 2021 results.  Our full year adjusted earnings per diluted share of $17.21 grew  \n15% above fiscal 2020 and within our updated guidance range.  Our fiscal year began with each of our segments \nexperiencing volume declines due to the impact of COVID -19.  Volume improvements in our first quarter were \nearlier than originally anticipated and on a nonlinear trajectory followed to the remainder of the fiscal year, \ncorrelating to the trajectory of the COVID virus.  \n \n", "original_text": "Let me start now with our fiscal 2021 results. "}, "hash": "2e65a6ebee2a97a103c93bf9050e211462bd3c249407405647dc90842b590c43", "class_name": "RelatedNodeInfo"}}, "text": "Today, I'll provide an update on our fourth qua rter and fiscal 2021 results, including a detailed fiscal 2022 outlook, \nan overview which can be found in the Investors section of our website.  \n \n", "start_char_idx": 2839, "end_char_idx": 3036, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8034d77-1756-4446-b07b-882ce38f26d9": {"__data__": {"id_": "c8034d77-1756-4446-b07b-882ce38f26d9", "embedding": null, "metadata": {"window": "We're proud of the way our teams continue to \nexecute and innovate.  We're stronger than before the pandemic and our fiscal 2021 financial results give us even \nmore confidence in our ability to continue delivering compelling performance in the future.  \n \n Today, I'll provide an update on our fourth qua rter and fiscal 2021 results, including a detailed fiscal 2022 outlook, \nan overview which can be found in the Investors section of our website.  \n \n Let me start now with our fiscal 2021 results.  Our full year adjusted earnings per diluted share of $17.21 grew  \n15% above fiscal 2020 and within our updated guidance range.  Our fiscal year began with each of our segments \nexperiencing volume declines due to the impact of COVID -19.  Volume improvements in our first quarter were \nearlier than originally anticipated and on a nonlinear trajectory followed to the remainder of the fiscal year, \ncorrelating to the trajectory of the COVID virus.  \n \n", "original_text": "Let me start now with our fiscal 2021 results. ", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1b76e8ab2129db5a441e0143ad525d0096f1de4730bca682d2fdec0dab1d518", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ef6b98a-a602-4bb6-a9d6-db46142f8b32", "node_type": "1", "metadata": {"window": "As a company, we've been operating in new ways for over a year.  We're proud of the way our teams continue to \nexecute and innovate.  We're stronger than before the pandemic and our fiscal 2021 financial results give us even \nmore confidence in our ability to continue delivering compelling performance in the future.  \n \n Today, I'll provide an update on our fourth qua rter and fiscal 2021 results, including a detailed fiscal 2022 outlook, \nan overview which can be found in the Investors section of our website.  \n \n Let me start now with our fiscal 2021 results.  Our full year adjusted earnings per diluted share of $17.21 grew  \n15% above fiscal 2020 and within our updated guidance range.  Our fiscal year began with each of our segments \nexperiencing volume declines due to the impact of COVID -19. ", "original_text": "Today, I'll provide an update on our fourth qua rter and fiscal 2021 results, including a detailed fiscal 2022 outlook, \nan overview which can be found in the Investors section of our website.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ccb6f6d5b0f5de5d005b25846cb77dd49b7ab1548c38ad83d0261a4ac25830fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b808256-0eef-470c-bf66-d0920fe09855", "node_type": "1", "metadata": {"window": "We're stronger than before the pandemic and our fiscal 2021 financial results give us even \nmore confidence in our ability to continue delivering compelling performance in the future.  \n \n Today, I'll provide an update on our fourth qua rter and fiscal 2021 results, including a detailed fiscal 2022 outlook, \nan overview which can be found in the Investors section of our website.  \n \n Let me start now with our fiscal 2021 results.  Our full year adjusted earnings per diluted share of $17.21 grew  \n15% above fiscal 2020 and within our updated guidance range.  Our fiscal year began with each of our segments \nexperiencing volume declines due to the impact of COVID -19.  Volume improvements in our first quarter were \nearlier than originally anticipated and on a nonlinear trajectory followed to the remainder of the fiscal year, \ncorrelating to the trajectory of the COVID virus.  \n \n Our fiscal fourth quarter experienced a continuation of the volatility from COVID as well as a weak cold and flu \nseason and a winter storm that impacted portions of our US Pharmaceutical business.  \n ", "original_text": "Our full year adjusted earnings per diluted share of $17.21 grew  \n15% above fiscal 2020 and within our updated guidance range. "}, "hash": "077324012530b1bd4a18af2428d530e4bc1535e2f184c8d18bd20173fab3c78f", "class_name": "RelatedNodeInfo"}}, "text": "Let me start now with our fiscal 2021 results. ", "start_char_idx": 3036, "end_char_idx": 3083, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b808256-0eef-470c-bf66-d0920fe09855": {"__data__": {"id_": "2b808256-0eef-470c-bf66-d0920fe09855", "embedding": null, "metadata": {"window": "We're stronger than before the pandemic and our fiscal 2021 financial results give us even \nmore confidence in our ability to continue delivering compelling performance in the future.  \n \n Today, I'll provide an update on our fourth qua rter and fiscal 2021 results, including a detailed fiscal 2022 outlook, \nan overview which can be found in the Investors section of our website.  \n \n Let me start now with our fiscal 2021 results.  Our full year adjusted earnings per diluted share of $17.21 grew  \n15% above fiscal 2020 and within our updated guidance range.  Our fiscal year began with each of our segments \nexperiencing volume declines due to the impact of COVID -19.  Volume improvements in our first quarter were \nearlier than originally anticipated and on a nonlinear trajectory followed to the remainder of the fiscal year, \ncorrelating to the trajectory of the COVID virus.  \n \n Our fiscal fourth quarter experienced a continuation of the volatility from COVID as well as a weak cold and flu \nseason and a winter storm that impacted portions of our US Pharmaceutical business.  \n ", "original_text": "Our full year adjusted earnings per diluted share of $17.21 grew  \n15% above fiscal 2020 and within our updated guidance range. ", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1b76e8ab2129db5a441e0143ad525d0096f1de4730bca682d2fdec0dab1d518", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8034d77-1756-4446-b07b-882ce38f26d9", "node_type": "1", "metadata": {"window": "We're proud of the way our teams continue to \nexecute and innovate.  We're stronger than before the pandemic and our fiscal 2021 financial results give us even \nmore confidence in our ability to continue delivering compelling performance in the future.  \n \n Today, I'll provide an update on our fourth qua rter and fiscal 2021 results, including a detailed fiscal 2022 outlook, \nan overview which can be found in the Investors section of our website.  \n \n Let me start now with our fiscal 2021 results.  Our full year adjusted earnings per diluted share of $17.21 grew  \n15% above fiscal 2020 and within our updated guidance range.  Our fiscal year began with each of our segments \nexperiencing volume declines due to the impact of COVID -19.  Volume improvements in our first quarter were \nearlier than originally anticipated and on a nonlinear trajectory followed to the remainder of the fiscal year, \ncorrelating to the trajectory of the COVID virus.  \n \n", "original_text": "Let me start now with our fiscal 2021 results. ", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01ae873cc215a4a6dc6db8b00f8065ee97478eb67274fbfe6fbab8b1c3304140", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "016d993c-a585-40bd-8e2e-51c1688fe330", "node_type": "1", "metadata": {"window": "Today, I'll provide an update on our fourth qua rter and fiscal 2021 results, including a detailed fiscal 2022 outlook, \nan overview which can be found in the Investors section of our website.  \n \n Let me start now with our fiscal 2021 results.  Our full year adjusted earnings per diluted share of $17.21 grew  \n15% above fiscal 2020 and within our updated guidance range.  Our fiscal year began with each of our segments \nexperiencing volume declines due to the impact of COVID -19.  Volume improvements in our first quarter were \nearlier than originally anticipated and on a nonlinear trajectory followed to the remainder of the fiscal year, \ncorrelating to the trajectory of the COVID virus.  \n \n Our fiscal fourth quarter experienced a continuation of the volatility from COVID as well as a weak cold and flu \nseason and a winter storm that impacted portions of our US Pharmaceutical business.  \n ", "original_text": "Our fiscal year began with each of our segments \nexperiencing volume declines due to the impact of COVID -19. "}, "hash": "03beeac1f6c5218c9715e68bc341b6b3e83b2a243386fa0f5f6604907e6deab3", "class_name": "RelatedNodeInfo"}}, "text": "Our full year adjusted earnings per diluted share of $17.21 grew  \n15% above fiscal 2020 and within our updated guidance range. ", "start_char_idx": 3083, "end_char_idx": 3211, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "016d993c-a585-40bd-8e2e-51c1688fe330": {"__data__": {"id_": "016d993c-a585-40bd-8e2e-51c1688fe330", "embedding": null, "metadata": {"window": "Today, I'll provide an update on our fourth qua rter and fiscal 2021 results, including a detailed fiscal 2022 outlook, \nan overview which can be found in the Investors section of our website.  \n \n Let me start now with our fiscal 2021 results.  Our full year adjusted earnings per diluted share of $17.21 grew  \n15% above fiscal 2020 and within our updated guidance range.  Our fiscal year began with each of our segments \nexperiencing volume declines due to the impact of COVID -19.  Volume improvements in our first quarter were \nearlier than originally anticipated and on a nonlinear trajectory followed to the remainder of the fiscal year, \ncorrelating to the trajectory of the COVID virus.  \n \n Our fiscal fourth quarter experienced a continuation of the volatility from COVID as well as a weak cold and flu \nseason and a winter storm that impacted portions of our US Pharmaceutical business.  \n ", "original_text": "Our fiscal year began with each of our segments \nexperiencing volume declines due to the impact of COVID -19. ", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1b76e8ab2129db5a441e0143ad525d0096f1de4730bca682d2fdec0dab1d518", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b808256-0eef-470c-bf66-d0920fe09855", "node_type": "1", "metadata": {"window": "We're stronger than before the pandemic and our fiscal 2021 financial results give us even \nmore confidence in our ability to continue delivering compelling performance in the future.  \n \n Today, I'll provide an update on our fourth qua rter and fiscal 2021 results, including a detailed fiscal 2022 outlook, \nan overview which can be found in the Investors section of our website.  \n \n Let me start now with our fiscal 2021 results.  Our full year adjusted earnings per diluted share of $17.21 grew  \n15% above fiscal 2020 and within our updated guidance range.  Our fiscal year began with each of our segments \nexperiencing volume declines due to the impact of COVID -19.  Volume improvements in our first quarter were \nearlier than originally anticipated and on a nonlinear trajectory followed to the remainder of the fiscal year, \ncorrelating to the trajectory of the COVID virus.  \n \n Our fiscal fourth quarter experienced a continuation of the volatility from COVID as well as a weak cold and flu \nseason and a winter storm that impacted portions of our US Pharmaceutical business.  \n ", "original_text": "Our full year adjusted earnings per diluted share of $17.21 grew  \n15% above fiscal 2020 and within our updated guidance range. ", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db14ffdf6a01aaf6bdcf31a0addad93158f9876c4d4965761a413762475f647b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20cff1a1-d221-41c9-a568-a79c2aa7ea3d", "node_type": "1", "metadata": {"window": "Let me start now with our fiscal 2021 results.  Our full year adjusted earnings per diluted share of $17.21 grew  \n15% above fiscal 2020 and within our updated guidance range.  Our fiscal year began with each of our segments \nexperiencing volume declines due to the impact of COVID -19.  Volume improvements in our first quarter were \nearlier than originally anticipated and on a nonlinear trajectory followed to the remainder of the fiscal year, \ncorrelating to the trajectory of the COVID virus.  \n \n Our fiscal fourth quarter experienced a continuation of the volatility from COVID as well as a weak cold and flu \nseason and a winter storm that impacted portions of our US Pharmaceutical business.  \n ", "original_text": "Volume improvements in our first quarter were \nearlier than originally anticipated and on a nonlinear trajectory followed to the remainder of the fiscal year, \ncorrelating to the trajectory of the COVID virus.  \n \n"}, "hash": "36fa594f381f5b9534faba513573e385ce9c915d1af2883afad7fdd198825c55", "class_name": "RelatedNodeInfo"}}, "text": "Our fiscal year began with each of our segments \nexperiencing volume declines due to the impact of COVID -19. ", "start_char_idx": 3211, "end_char_idx": 3321, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20cff1a1-d221-41c9-a568-a79c2aa7ea3d": {"__data__": {"id_": "20cff1a1-d221-41c9-a568-a79c2aa7ea3d", "embedding": null, "metadata": {"window": "Let me start now with our fiscal 2021 results.  Our full year adjusted earnings per diluted share of $17.21 grew  \n15% above fiscal 2020 and within our updated guidance range.  Our fiscal year began with each of our segments \nexperiencing volume declines due to the impact of COVID -19.  Volume improvements in our first quarter were \nearlier than originally anticipated and on a nonlinear trajectory followed to the remainder of the fiscal year, \ncorrelating to the trajectory of the COVID virus.  \n \n Our fiscal fourth quarter experienced a continuation of the volatility from COVID as well as a weak cold and flu \nseason and a winter storm that impacted portions of our US Pharmaceutical business.  \n ", "original_text": "Volume improvements in our first quarter were \nearlier than originally anticipated and on a nonlinear trajectory followed to the remainder of the fiscal year, \ncorrelating to the trajectory of the COVID virus.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1b76e8ab2129db5a441e0143ad525d0096f1de4730bca682d2fdec0dab1d518", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "016d993c-a585-40bd-8e2e-51c1688fe330", "node_type": "1", "metadata": {"window": "Today, I'll provide an update on our fourth qua rter and fiscal 2021 results, including a detailed fiscal 2022 outlook, \nan overview which can be found in the Investors section of our website.  \n \n Let me start now with our fiscal 2021 results.  Our full year adjusted earnings per diluted share of $17.21 grew  \n15% above fiscal 2020 and within our updated guidance range.  Our fiscal year began with each of our segments \nexperiencing volume declines due to the impact of COVID -19.  Volume improvements in our first quarter were \nearlier than originally anticipated and on a nonlinear trajectory followed to the remainder of the fiscal year, \ncorrelating to the trajectory of the COVID virus.  \n \n Our fiscal fourth quarter experienced a continuation of the volatility from COVID as well as a weak cold and flu \nseason and a winter storm that impacted portions of our US Pharmaceutical business.  \n ", "original_text": "Our fiscal year began with each of our segments \nexperiencing volume declines due to the impact of COVID -19. ", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e477f2e28d42173d597f2064bf1d6ee1bd01dc3290fca05ca1a903ac476dc246", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9553870-80bf-46b5-8496-eb3bbaeddbda", "node_type": "1", "metadata": {"window": "Our full year adjusted earnings per diluted share of $17.21 grew  \n15% above fiscal 2020 and within our updated guidance range.  Our fiscal year began with each of our segments \nexperiencing volume declines due to the impact of COVID -19.  Volume improvements in our first quarter were \nearlier than originally anticipated and on a nonlinear trajectory followed to the remainder of the fiscal year, \ncorrelating to the trajectory of the COVID virus.  \n \n Our fiscal fourth quarter experienced a continuation of the volatility from COVID as well as a weak cold and flu \nseason and a winter storm that impacted portions of our US Pharmaceutical business.  \n ", "original_text": "Our fiscal fourth quarter experienced a continuation of the volatility from COVID as well as a weak cold and flu \nseason and a winter storm that impacted portions of our US Pharmaceutical business.  \n "}, "hash": "258a6a90d092b8697cd5baa43b2c7a9696ea4c648796a417c01e8019c3243047", "class_name": "RelatedNodeInfo"}}, "text": "Volume improvements in our first quarter were \nearlier than originally anticipated and on a nonlinear trajectory followed to the remainder of the fiscal year, \ncorrelating to the trajectory of the COVID virus.  \n \n", "start_char_idx": 3321, "end_char_idx": 3535, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9553870-80bf-46b5-8496-eb3bbaeddbda": {"__data__": {"id_": "e9553870-80bf-46b5-8496-eb3bbaeddbda", "embedding": null, "metadata": {"window": "Our full year adjusted earnings per diluted share of $17.21 grew  \n15% above fiscal 2020 and within our updated guidance range.  Our fiscal year began with each of our segments \nexperiencing volume declines due to the impact of COVID -19.  Volume improvements in our first quarter were \nearlier than originally anticipated and on a nonlinear trajectory followed to the remainder of the fiscal year, \ncorrelating to the trajectory of the COVID virus.  \n \n Our fiscal fourth quarter experienced a continuation of the volatility from COVID as well as a weak cold and flu \nseason and a winter storm that impacted portions of our US Pharmaceutical business.  \n ", "original_text": "Our fiscal fourth quarter experienced a continuation of the volatility from COVID as well as a weak cold and flu \nseason and a winter storm that impacted portions of our US Pharmaceutical business.  \n ", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1b76e8ab2129db5a441e0143ad525d0096f1de4730bca682d2fdec0dab1d518", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20cff1a1-d221-41c9-a568-a79c2aa7ea3d", "node_type": "1", "metadata": {"window": "Let me start now with our fiscal 2021 results.  Our full year adjusted earnings per diluted share of $17.21 grew  \n15% above fiscal 2020 and within our updated guidance range.  Our fiscal year began with each of our segments \nexperiencing volume declines due to the impact of COVID -19.  Volume improvements in our first quarter were \nearlier than originally anticipated and on a nonlinear trajectory followed to the remainder of the fiscal year, \ncorrelating to the trajectory of the COVID virus.  \n \n Our fiscal fourth quarter experienced a continuation of the volatility from COVID as well as a weak cold and flu \nseason and a winter storm that impacted portions of our US Pharmaceutical business.  \n ", "original_text": "Volume improvements in our first quarter were \nearlier than originally anticipated and on a nonlinear trajectory followed to the remainder of the fiscal year, \ncorrelating to the trajectory of the COVID virus.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0ed3c3f8ea9061438fe71910e18b604b2323ecd56afdd6ff8405fee61d18fe38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a2a79f6-7f6f-466c-9b28-74f8dcf3746f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe also recognized benefits from our leadership role distributing COVID -19 vaccines and ancillary supply kits in \nour US Pharmaceutical and Medical -Surgical segments, respectively.  And similar  to previous two quarters, in the \nfourth quarter, we recognized unplanned gains on equity investments within our McKesson Ventures' portfolio.  \n \n Let me move now to a discussion of our adjusted earnings results for the fourth quarter. ", "original_text": "McKesson Corp.  "}, "hash": "ea066db43a81becfb20c76c7e75d44169f39cd3d0865e9896b2bfc5b99976c5c", "class_name": "RelatedNodeInfo"}}, "text": "Our fiscal fourth quarter experienced a continuation of the volatility from COVID as well as a weak cold and flu \nseason and a winter storm that impacted portions of our US Pharmaceutical business.  \n ", "start_char_idx": 3535, "end_char_idx": 3736, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a2a79f6-7f6f-466c-9b28-74f8dcf3746f": {"__data__": {"id_": "0a2a79f6-7f6f-466c-9b28-74f8dcf3746f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe also recognized benefits from our leadership role distributing COVID -19 vaccines and ancillary supply kits in \nour US Pharmaceutical and Medical -Surgical segments, respectively.  And similar  to previous two quarters, in the \nfourth quarter, we recognized unplanned gains on equity investments within our McKesson Ventures' portfolio.  \n \n Let me move now to a discussion of our adjusted earnings results for the fourth quarter. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47c99048-affb-49f7-9b53-d38a3f456c08", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46a5839a97deec04bfaf8e0e8f72d85840f7b4b9c1be3b14f6c88546777d22d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9553870-80bf-46b5-8496-eb3bbaeddbda", "node_type": "1", "metadata": {"window": "Our full year adjusted earnings per diluted share of $17.21 grew  \n15% above fiscal 2020 and within our updated guidance range.  Our fiscal year began with each of our segments \nexperiencing volume declines due to the impact of COVID -19.  Volume improvements in our first quarter were \nearlier than originally anticipated and on a nonlinear trajectory followed to the remainder of the fiscal year, \ncorrelating to the trajectory of the COVID virus.  \n \n Our fiscal fourth quarter experienced a continuation of the volatility from COVID as well as a weak cold and flu \nseason and a winter storm that impacted portions of our US Pharmaceutical business.  \n ", "original_text": "Our fiscal fourth quarter experienced a continuation of the volatility from COVID as well as a weak cold and flu \nseason and a winter storm that impacted portions of our US Pharmaceutical business.  \n ", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9708a5fa301fa9b6c580bbe79167d059d750f4784a536405638dd804e9ba5fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4cff1a33-ea5c-4dd1-b411-8cd806610eb5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe also recognized benefits from our leadership role distributing COVID -19 vaccines and ancillary supply kits in \nour US Pharmaceutical and Medical -Surgical segments, respectively.  And similar  to previous two quarters, in the \nfourth quarter, we recognized unplanned gains on equity investments within our McKesson Ventures' portfolio.  \n \n Let me move now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted  \nearnings per diluted share was $5.05, an increase of 18% compared to the prior year driven by the contribution \nfrom COVID -19 vaccine distribution and kitting programs for the US government and a lower share count.  \n \n", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe also recognized benefits from our leadership role distributing COVID -19 vaccines and ancillary supply kits in \nour US Pharmaceutical and Medical -Surgical segments, respectively. "}, "hash": "98eace9a7079121bf3ba6e22fd2ea8c0e5fa2d79785af267cc1b8790f67757b0", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4cff1a33-ea5c-4dd1-b411-8cd806610eb5": {"__data__": {"id_": "4cff1a33-ea5c-4dd1-b411-8cd806610eb5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe also recognized benefits from our leadership role distributing COVID -19 vaccines and ancillary supply kits in \nour US Pharmaceutical and Medical -Surgical segments, respectively.  And similar  to previous two quarters, in the \nfourth quarter, we recognized unplanned gains on equity investments within our McKesson Ventures' portfolio.  \n \n Let me move now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted  \nearnings per diluted share was $5.05, an increase of 18% compared to the prior year driven by the contribution \nfrom COVID -19 vaccine distribution and kitting programs for the US government and a lower share count.  \n \n", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe also recognized benefits from our leadership role distributing COVID -19 vaccines and ancillary supply kits in \nour US Pharmaceutical and Medical -Surgical segments, respectively. ", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47c99048-affb-49f7-9b53-d38a3f456c08", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46a5839a97deec04bfaf8e0e8f72d85840f7b4b9c1be3b14f6c88546777d22d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a2a79f6-7f6f-466c-9b28-74f8dcf3746f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe also recognized benefits from our leadership role distributing COVID -19 vaccines and ancillary supply kits in \nour US Pharmaceutical and Medical -Surgical segments, respectively.  And similar  to previous two quarters, in the \nfourth quarter, we recognized unplanned gains on equity investments within our McKesson Ventures' portfolio.  \n \n Let me move now to a discussion of our adjusted earnings results for the fourth quarter. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "534b621956248af4f93216b0b02ef0c80be7f5b39444659782b2719644fb06b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0261475d-0036-40e8-9fd6-b5d5880e3769", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe also recognized benefits from our leadership role distributing COVID -19 vaccines and ancillary supply kits in \nour US Pharmaceutical and Medical -Surgical segments, respectively.  And similar  to previous two quarters, in the \nfourth quarter, we recognized unplanned gains on equity investments within our McKesson Ventures' portfolio.  \n \n Let me move now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted  \nearnings per diluted share was $5.05, an increase of 18% compared to the prior year driven by the contribution \nfrom COVID -19 vaccine distribution and kitting programs for the US government and a lower share count.  \n \n These items were partially offset by a h igher tax rate and the prior year contribution from the company's \ninvestment in Change Healthcare. ", "original_text": "And similar  to previous two quarters, in the \nfourth quarter, we recognized unplanned gains on equity investments within our McKesson Ventures' portfolio.  \n \n"}, "hash": "9c56d2b98709f26d6ab6f8cabefa1e3006231bc068b0d065886f0646171d5bd2", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe also recognized benefits from our leadership role distributing COVID -19 vaccines and ancillary supply kits in \nour US Pharmaceutical and Medical -Surgical segments, respectively. ", "start_char_idx": 16, "end_char_idx": 363, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0261475d-0036-40e8-9fd6-b5d5880e3769": {"__data__": {"id_": "0261475d-0036-40e8-9fd6-b5d5880e3769", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe also recognized benefits from our leadership role distributing COVID -19 vaccines and ancillary supply kits in \nour US Pharmaceutical and Medical -Surgical segments, respectively.  And similar  to previous two quarters, in the \nfourth quarter, we recognized unplanned gains on equity investments within our McKesson Ventures' portfolio.  \n \n Let me move now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted  \nearnings per diluted share was $5.05, an increase of 18% compared to the prior year driven by the contribution \nfrom COVID -19 vaccine distribution and kitting programs for the US government and a lower share count.  \n \n These items were partially offset by a h igher tax rate and the prior year contribution from the company's \ninvestment in Change Healthcare. ", "original_text": "And similar  to previous two quarters, in the \nfourth quarter, we recognized unplanned gains on equity investments within our McKesson Ventures' portfolio.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47c99048-affb-49f7-9b53-d38a3f456c08", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46a5839a97deec04bfaf8e0e8f72d85840f7b4b9c1be3b14f6c88546777d22d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4cff1a33-ea5c-4dd1-b411-8cd806610eb5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe also recognized benefits from our leadership role distributing COVID -19 vaccines and ancillary supply kits in \nour US Pharmaceutical and Medical -Surgical segments, respectively.  And similar  to previous two quarters, in the \nfourth quarter, we recognized unplanned gains on equity investments within our McKesson Ventures' portfolio.  \n \n Let me move now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted  \nearnings per diluted share was $5.05, an increase of 18% compared to the prior year driven by the contribution \nfrom COVID -19 vaccine distribution and kitting programs for the US government and a lower share count.  \n \n", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe also recognized benefits from our leadership role distributing COVID -19 vaccines and ancillary supply kits in \nour US Pharmaceutical and Medical -Surgical segments, respectively. ", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6100130694f8f6039794ca5283128059baf034acb0a05fee15bec4c9b4b1b9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4cbf4f4a-61a3-4ca0-8da7-5e1437e001f0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe also recognized benefits from our leadership role distributing COVID -19 vaccines and ancillary supply kits in \nour US Pharmaceutical and Medical -Surgical segments, respectively.  And similar  to previous two quarters, in the \nfourth quarter, we recognized unplanned gains on equity investments within our McKesson Ventures' portfolio.  \n \n Let me move now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted  \nearnings per diluted share was $5.05, an increase of 18% compared to the prior year driven by the contribution \nfrom COVID -19 vaccine distribution and kitting programs for the US government and a lower share count.  \n \n These items were partially offset by a h igher tax rate and the prior year contribution from the company's \ninvestment in Change Healthcare.  This transition [indiscernible] (19:15) details of our consolidated results, which \ncan be found on slide four.  \n \n", "original_text": "Let me move now to a discussion of our adjusted earnings results for the fourth quarter. "}, "hash": "e0804e2efdc5018815846ae369bf99ca152c369e1d40197088271900a4f015d0", "class_name": "RelatedNodeInfo"}}, "text": "And similar  to previous two quarters, in the \nfourth quarter, we recognized unplanned gains on equity investments within our McKesson Ventures' portfolio.  \n \n", "start_char_idx": 363, "end_char_idx": 523, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4cbf4f4a-61a3-4ca0-8da7-5e1437e001f0": {"__data__": {"id_": "4cbf4f4a-61a3-4ca0-8da7-5e1437e001f0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe also recognized benefits from our leadership role distributing COVID -19 vaccines and ancillary supply kits in \nour US Pharmaceutical and Medical -Surgical segments, respectively.  And similar  to previous two quarters, in the \nfourth quarter, we recognized unplanned gains on equity investments within our McKesson Ventures' portfolio.  \n \n Let me move now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted  \nearnings per diluted share was $5.05, an increase of 18% compared to the prior year driven by the contribution \nfrom COVID -19 vaccine distribution and kitting programs for the US government and a lower share count.  \n \n These items were partially offset by a h igher tax rate and the prior year contribution from the company's \ninvestment in Change Healthcare.  This transition [indiscernible] (19:15) details of our consolidated results, which \ncan be found on slide four.  \n \n", "original_text": "Let me move now to a discussion of our adjusted earnings results for the fourth quarter. ", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47c99048-affb-49f7-9b53-d38a3f456c08", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46a5839a97deec04bfaf8e0e8f72d85840f7b4b9c1be3b14f6c88546777d22d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0261475d-0036-40e8-9fd6-b5d5880e3769", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe also recognized benefits from our leadership role distributing COVID -19 vaccines and ancillary supply kits in \nour US Pharmaceutical and Medical -Surgical segments, respectively.  And similar  to previous two quarters, in the \nfourth quarter, we recognized unplanned gains on equity investments within our McKesson Ventures' portfolio.  \n \n Let me move now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted  \nearnings per diluted share was $5.05, an increase of 18% compared to the prior year driven by the contribution \nfrom COVID -19 vaccine distribution and kitting programs for the US government and a lower share count.  \n \n These items were partially offset by a h igher tax rate and the prior year contribution from the company's \ninvestment in Change Healthcare. ", "original_text": "And similar  to previous two quarters, in the \nfourth quarter, we recognized unplanned gains on equity investments within our McKesson Ventures' portfolio.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bad3fe356291405d252e13cdc31741f91140013b813ccd6bda28521c64b920d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d52751f-bd69-4118-ac4a-59774b9fcc99", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe also recognized benefits from our leadership role distributing COVID -19 vaccines and ancillary supply kits in \nour US Pharmaceutical and Medical -Surgical segments, respectively.  And similar  to previous two quarters, in the \nfourth quarter, we recognized unplanned gains on equity investments within our McKesson Ventures' portfolio.  \n \n Let me move now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted  \nearnings per diluted share was $5.05, an increase of 18% compared to the prior year driven by the contribution \nfrom COVID -19 vaccine distribution and kitting programs for the US government and a lower share count.  \n \n These items were partially offset by a h igher tax rate and the prior year contribution from the company's \ninvestment in Change Healthcare.  This transition [indiscernible] (19:15) details of our consolidated results, which \ncan be found on slide four.  \n \n Consolidated revenues of $59.1 billion increa sed 1% compared to the prior year primarily due to market growth \nand higher volumes from retail national account customers in the US Pharmaceutical segment, partially offset by \nthe prior year increase in demand driven by the onset of the COVID -19 pandemic and the contribution of our \nGerman wholesale business through a joint venture with Walgreens Boots Alliance.  \n \n", "original_text": "Fourth quarter adjusted  \nearnings per diluted share was $5.05, an increase of 18% compared to the prior year driven by the contribution \nfrom COVID -19 vaccine distribution and kitting programs for the US government and a lower share count.  \n \n"}, "hash": "c8d26c451d1e7adf4cb1b4b4dc3255f61cc94bc0482d83b8902f78df06f204a1", "class_name": "RelatedNodeInfo"}}, "text": "Let me move now to a discussion of our adjusted earnings results for the fourth quarter. ", "start_char_idx": 523, "end_char_idx": 612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d52751f-bd69-4118-ac4a-59774b9fcc99": {"__data__": {"id_": "9d52751f-bd69-4118-ac4a-59774b9fcc99", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe also recognized benefits from our leadership role distributing COVID -19 vaccines and ancillary supply kits in \nour US Pharmaceutical and Medical -Surgical segments, respectively.  And similar  to previous two quarters, in the \nfourth quarter, we recognized unplanned gains on equity investments within our McKesson Ventures' portfolio.  \n \n Let me move now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted  \nearnings per diluted share was $5.05, an increase of 18% compared to the prior year driven by the contribution \nfrom COVID -19 vaccine distribution and kitting programs for the US government and a lower share count.  \n \n These items were partially offset by a h igher tax rate and the prior year contribution from the company's \ninvestment in Change Healthcare.  This transition [indiscernible] (19:15) details of our consolidated results, which \ncan be found on slide four.  \n \n Consolidated revenues of $59.1 billion increa sed 1% compared to the prior year primarily due to market growth \nand higher volumes from retail national account customers in the US Pharmaceutical segment, partially offset by \nthe prior year increase in demand driven by the onset of the COVID -19 pandemic and the contribution of our \nGerman wholesale business through a joint venture with Walgreens Boots Alliance.  \n \n", "original_text": "Fourth quarter adjusted  \nearnings per diluted share was $5.05, an increase of 18% compared to the prior year driven by the contribution \nfrom COVID -19 vaccine distribution and kitting programs for the US government and a lower share count.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47c99048-affb-49f7-9b53-d38a3f456c08", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46a5839a97deec04bfaf8e0e8f72d85840f7b4b9c1be3b14f6c88546777d22d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4cbf4f4a-61a3-4ca0-8da7-5e1437e001f0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe also recognized benefits from our leadership role distributing COVID -19 vaccines and ancillary supply kits in \nour US Pharmaceutical and Medical -Surgical segments, respectively.  And similar  to previous two quarters, in the \nfourth quarter, we recognized unplanned gains on equity investments within our McKesson Ventures' portfolio.  \n \n Let me move now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted  \nearnings per diluted share was $5.05, an increase of 18% compared to the prior year driven by the contribution \nfrom COVID -19 vaccine distribution and kitting programs for the US government and a lower share count.  \n \n These items were partially offset by a h igher tax rate and the prior year contribution from the company's \ninvestment in Change Healthcare.  This transition [indiscernible] (19:15) details of our consolidated results, which \ncan be found on slide four.  \n \n", "original_text": "Let me move now to a discussion of our adjusted earnings results for the fourth quarter. ", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee1d3281195801a715b3f30dc9a34d224f6ea8863f95b2d774575407435852c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfeaeb82-42dd-4994-a600-416edaf1af23", "node_type": "1", "metadata": {"window": "And similar  to previous two quarters, in the \nfourth quarter, we recognized unplanned gains on equity investments within our McKesson Ventures' portfolio.  \n \n Let me move now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted  \nearnings per diluted share was $5.05, an increase of 18% compared to the prior year driven by the contribution \nfrom COVID -19 vaccine distribution and kitting programs for the US government and a lower share count.  \n \n These items were partially offset by a h igher tax rate and the prior year contribution from the company's \ninvestment in Change Healthcare.  This transition [indiscernible] (19:15) details of our consolidated results, which \ncan be found on slide four.  \n \n Consolidated revenues of $59.1 billion increa sed 1% compared to the prior year primarily due to market growth \nand higher volumes from retail national account customers in the US Pharmaceutical segment, partially offset by \nthe prior year increase in demand driven by the onset of the COVID -19 pandemic and the contribution of our \nGerman wholesale business through a joint venture with Walgreens Boots Alliance.  \n \n Adjusted gross profit was approximately flat to prior year as inventory charges in our Medical -Surgical segment \nand the previously mentioned prior  year demand increase driven by COVID largely offset the contribution of our \nCOVID -19 vaccine distribution and kitting programs and the distribution of COVID -19 tests.  \n \n", "original_text": "These items were partially offset by a h igher tax rate and the prior year contribution from the company's \ninvestment in Change Healthcare. "}, "hash": "260caf4a4d33258492e189fc650e0e9cadea2eedfce0ce3151af3e064b2ba668", "class_name": "RelatedNodeInfo"}}, "text": "Fourth quarter adjusted  \nearnings per diluted share was $5.05, an increase of 18% compared to the prior year driven by the contribution \nfrom COVID -19 vaccine distribution and kitting programs for the US government and a lower share count.  \n \n", "start_char_idx": 612, "end_char_idx": 858, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfeaeb82-42dd-4994-a600-416edaf1af23": {"__data__": {"id_": "dfeaeb82-42dd-4994-a600-416edaf1af23", "embedding": null, "metadata": {"window": "And similar  to previous two quarters, in the \nfourth quarter, we recognized unplanned gains on equity investments within our McKesson Ventures' portfolio.  \n \n Let me move now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted  \nearnings per diluted share was $5.05, an increase of 18% compared to the prior year driven by the contribution \nfrom COVID -19 vaccine distribution and kitting programs for the US government and a lower share count.  \n \n These items were partially offset by a h igher tax rate and the prior year contribution from the company's \ninvestment in Change Healthcare.  This transition [indiscernible] (19:15) details of our consolidated results, which \ncan be found on slide four.  \n \n Consolidated revenues of $59.1 billion increa sed 1% compared to the prior year primarily due to market growth \nand higher volumes from retail national account customers in the US Pharmaceutical segment, partially offset by \nthe prior year increase in demand driven by the onset of the COVID -19 pandemic and the contribution of our \nGerman wholesale business through a joint venture with Walgreens Boots Alliance.  \n \n Adjusted gross profit was approximately flat to prior year as inventory charges in our Medical -Surgical segment \nand the previously mentioned prior  year demand increase driven by COVID largely offset the contribution of our \nCOVID -19 vaccine distribution and kitting programs and the distribution of COVID -19 tests.  \n \n", "original_text": "These items were partially offset by a h igher tax rate and the prior year contribution from the company's \ninvestment in Change Healthcare. ", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47c99048-affb-49f7-9b53-d38a3f456c08", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46a5839a97deec04bfaf8e0e8f72d85840f7b4b9c1be3b14f6c88546777d22d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d52751f-bd69-4118-ac4a-59774b9fcc99", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe also recognized benefits from our leadership role distributing COVID -19 vaccines and ancillary supply kits in \nour US Pharmaceutical and Medical -Surgical segments, respectively.  And similar  to previous two quarters, in the \nfourth quarter, we recognized unplanned gains on equity investments within our McKesson Ventures' portfolio.  \n \n Let me move now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted  \nearnings per diluted share was $5.05, an increase of 18% compared to the prior year driven by the contribution \nfrom COVID -19 vaccine distribution and kitting programs for the US government and a lower share count.  \n \n These items were partially offset by a h igher tax rate and the prior year contribution from the company's \ninvestment in Change Healthcare.  This transition [indiscernible] (19:15) details of our consolidated results, which \ncan be found on slide four.  \n \n Consolidated revenues of $59.1 billion increa sed 1% compared to the prior year primarily due to market growth \nand higher volumes from retail national account customers in the US Pharmaceutical segment, partially offset by \nthe prior year increase in demand driven by the onset of the COVID -19 pandemic and the contribution of our \nGerman wholesale business through a joint venture with Walgreens Boots Alliance.  \n \n", "original_text": "Fourth quarter adjusted  \nearnings per diluted share was $5.05, an increase of 18% compared to the prior year driven by the contribution \nfrom COVID -19 vaccine distribution and kitting programs for the US government and a lower share count.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "274d6f4037dd4fe5d052534169a99d78095d97d671e0305297c2bf4c9dc96bfc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62db6f64-905e-497a-8e66-1b97e19b4422", "node_type": "1", "metadata": {"window": "Let me move now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted  \nearnings per diluted share was $5.05, an increase of 18% compared to the prior year driven by the contribution \nfrom COVID -19 vaccine distribution and kitting programs for the US government and a lower share count.  \n \n These items were partially offset by a h igher tax rate and the prior year contribution from the company's \ninvestment in Change Healthcare.  This transition [indiscernible] (19:15) details of our consolidated results, which \ncan be found on slide four.  \n \n Consolidated revenues of $59.1 billion increa sed 1% compared to the prior year primarily due to market growth \nand higher volumes from retail national account customers in the US Pharmaceutical segment, partially offset by \nthe prior year increase in demand driven by the onset of the COVID -19 pandemic and the contribution of our \nGerman wholesale business through a joint venture with Walgreens Boots Alliance.  \n \n Adjusted gross profit was approximately flat to prior year as inventory charges in our Medical -Surgical segment \nand the previously mentioned prior  year demand increase driven by COVID largely offset the contribution of our \nCOVID -19 vaccine distribution and kitting programs and the distribution of COVID -19 tests.  \n \n Adjusted operating expenses in the quarter decreased 6% year -over-year, led by a reduct ion in operating \nexpenses due to the impact of COVID -19 and the contribution of our German wholesale business to the joint \nventure with Walgreens Boots Alliance. ", "original_text": "This transition [indiscernible] (19:15) details of our consolidated results, which \ncan be found on slide four.  \n \n"}, "hash": "2d09d7d690d873e006591bf0e198780d4eea6b5593d36b6ecfd41c91fabd965e", "class_name": "RelatedNodeInfo"}}, "text": "These items were partially offset by a h igher tax rate and the prior year contribution from the company's \ninvestment in Change Healthcare. ", "start_char_idx": 858, "end_char_idx": 999, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62db6f64-905e-497a-8e66-1b97e19b4422": {"__data__": {"id_": "62db6f64-905e-497a-8e66-1b97e19b4422", "embedding": null, "metadata": {"window": "Let me move now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted  \nearnings per diluted share was $5.05, an increase of 18% compared to the prior year driven by the contribution \nfrom COVID -19 vaccine distribution and kitting programs for the US government and a lower share count.  \n \n These items were partially offset by a h igher tax rate and the prior year contribution from the company's \ninvestment in Change Healthcare.  This transition [indiscernible] (19:15) details of our consolidated results, which \ncan be found on slide four.  \n \n Consolidated revenues of $59.1 billion increa sed 1% compared to the prior year primarily due to market growth \nand higher volumes from retail national account customers in the US Pharmaceutical segment, partially offset by \nthe prior year increase in demand driven by the onset of the COVID -19 pandemic and the contribution of our \nGerman wholesale business through a joint venture with Walgreens Boots Alliance.  \n \n Adjusted gross profit was approximately flat to prior year as inventory charges in our Medical -Surgical segment \nand the previously mentioned prior  year demand increase driven by COVID largely offset the contribution of our \nCOVID -19 vaccine distribution and kitting programs and the distribution of COVID -19 tests.  \n \n Adjusted operating expenses in the quarter decreased 6% year -over-year, led by a reduct ion in operating \nexpenses due to the impact of COVID -19 and the contribution of our German wholesale business to the joint \nventure with Walgreens Boots Alliance. ", "original_text": "This transition [indiscernible] (19:15) details of our consolidated results, which \ncan be found on slide four.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47c99048-affb-49f7-9b53-d38a3f456c08", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46a5839a97deec04bfaf8e0e8f72d85840f7b4b9c1be3b14f6c88546777d22d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfeaeb82-42dd-4994-a600-416edaf1af23", "node_type": "1", "metadata": {"window": "And similar  to previous two quarters, in the \nfourth quarter, we recognized unplanned gains on equity investments within our McKesson Ventures' portfolio.  \n \n Let me move now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted  \nearnings per diluted share was $5.05, an increase of 18% compared to the prior year driven by the contribution \nfrom COVID -19 vaccine distribution and kitting programs for the US government and a lower share count.  \n \n These items were partially offset by a h igher tax rate and the prior year contribution from the company's \ninvestment in Change Healthcare.  This transition [indiscernible] (19:15) details of our consolidated results, which \ncan be found on slide four.  \n \n Consolidated revenues of $59.1 billion increa sed 1% compared to the prior year primarily due to market growth \nand higher volumes from retail national account customers in the US Pharmaceutical segment, partially offset by \nthe prior year increase in demand driven by the onset of the COVID -19 pandemic and the contribution of our \nGerman wholesale business through a joint venture with Walgreens Boots Alliance.  \n \n Adjusted gross profit was approximately flat to prior year as inventory charges in our Medical -Surgical segment \nand the previously mentioned prior  year demand increase driven by COVID largely offset the contribution of our \nCOVID -19 vaccine distribution and kitting programs and the distribution of COVID -19 tests.  \n \n", "original_text": "These items were partially offset by a h igher tax rate and the prior year contribution from the company's \ninvestment in Change Healthcare. ", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37dfcea756ba4db9e9fad1b23c2c4ceff37467538fad960edbf1b6c71f6c1d2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f24ddc5d-33bf-49cd-923a-5c1bee9cb8c6", "node_type": "1", "metadata": {"window": "Fourth quarter adjusted  \nearnings per diluted share was $5.05, an increase of 18% compared to the prior year driven by the contribution \nfrom COVID -19 vaccine distribution and kitting programs for the US government and a lower share count.  \n \n These items were partially offset by a h igher tax rate and the prior year contribution from the company's \ninvestment in Change Healthcare.  This transition [indiscernible] (19:15) details of our consolidated results, which \ncan be found on slide four.  \n \n Consolidated revenues of $59.1 billion increa sed 1% compared to the prior year primarily due to market growth \nand higher volumes from retail national account customers in the US Pharmaceutical segment, partially offset by \nthe prior year increase in demand driven by the onset of the COVID -19 pandemic and the contribution of our \nGerman wholesale business through a joint venture with Walgreens Boots Alliance.  \n \n Adjusted gross profit was approximately flat to prior year as inventory charges in our Medical -Surgical segment \nand the previously mentioned prior  year demand increase driven by COVID largely offset the contribution of our \nCOVID -19 vaccine distribution and kitting programs and the distribution of COVID -19 tests.  \n \n Adjusted operating expenses in the quarter decreased 6% year -over-year, led by a reduct ion in operating \nexpenses due to the impact of COVID -19 and the contribution of our German wholesale business to the joint \nventure with Walgreens Boots Alliance.  This was partially offset by increased expenses related to our role \ndistributing COVID -19 vacc ines and ancillary supply kits and higher operating expenses to support growth \ninvestments in oncology and biopharma services.  \n \n", "original_text": "Consolidated revenues of $59.1 billion increa sed 1% compared to the prior year primarily due to market growth \nand higher volumes from retail national account customers in the US Pharmaceutical segment, partially offset by \nthe prior year increase in demand driven by the onset of the COVID -19 pandemic and the contribution of our \nGerman wholesale business through a joint venture with Walgreens Boots Alliance.  \n \n"}, "hash": "381c261a01516f5650b24c5cbd113a158ef711555b79adc7c852838e898d4234", "class_name": "RelatedNodeInfo"}}, "text": "This transition [indiscernible] (19:15) details of our consolidated results, which \ncan be found on slide four.  \n \n", "start_char_idx": 999, "end_char_idx": 1115, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f24ddc5d-33bf-49cd-923a-5c1bee9cb8c6": {"__data__": {"id_": "f24ddc5d-33bf-49cd-923a-5c1bee9cb8c6", "embedding": null, "metadata": {"window": "Fourth quarter adjusted  \nearnings per diluted share was $5.05, an increase of 18% compared to the prior year driven by the contribution \nfrom COVID -19 vaccine distribution and kitting programs for the US government and a lower share count.  \n \n These items were partially offset by a h igher tax rate and the prior year contribution from the company's \ninvestment in Change Healthcare.  This transition [indiscernible] (19:15) details of our consolidated results, which \ncan be found on slide four.  \n \n Consolidated revenues of $59.1 billion increa sed 1% compared to the prior year primarily due to market growth \nand higher volumes from retail national account customers in the US Pharmaceutical segment, partially offset by \nthe prior year increase in demand driven by the onset of the COVID -19 pandemic and the contribution of our \nGerman wholesale business through a joint venture with Walgreens Boots Alliance.  \n \n Adjusted gross profit was approximately flat to prior year as inventory charges in our Medical -Surgical segment \nand the previously mentioned prior  year demand increase driven by COVID largely offset the contribution of our \nCOVID -19 vaccine distribution and kitting programs and the distribution of COVID -19 tests.  \n \n Adjusted operating expenses in the quarter decreased 6% year -over-year, led by a reduct ion in operating \nexpenses due to the impact of COVID -19 and the contribution of our German wholesale business to the joint \nventure with Walgreens Boots Alliance.  This was partially offset by increased expenses related to our role \ndistributing COVID -19 vacc ines and ancillary supply kits and higher operating expenses to support growth \ninvestments in oncology and biopharma services.  \n \n", "original_text": "Consolidated revenues of $59.1 billion increa sed 1% compared to the prior year primarily due to market growth \nand higher volumes from retail national account customers in the US Pharmaceutical segment, partially offset by \nthe prior year increase in demand driven by the onset of the COVID -19 pandemic and the contribution of our \nGerman wholesale business through a joint venture with Walgreens Boots Alliance.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47c99048-affb-49f7-9b53-d38a3f456c08", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46a5839a97deec04bfaf8e0e8f72d85840f7b4b9c1be3b14f6c88546777d22d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62db6f64-905e-497a-8e66-1b97e19b4422", "node_type": "1", "metadata": {"window": "Let me move now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted  \nearnings per diluted share was $5.05, an increase of 18% compared to the prior year driven by the contribution \nfrom COVID -19 vaccine distribution and kitting programs for the US government and a lower share count.  \n \n These items were partially offset by a h igher tax rate and the prior year contribution from the company's \ninvestment in Change Healthcare.  This transition [indiscernible] (19:15) details of our consolidated results, which \ncan be found on slide four.  \n \n Consolidated revenues of $59.1 billion increa sed 1% compared to the prior year primarily due to market growth \nand higher volumes from retail national account customers in the US Pharmaceutical segment, partially offset by \nthe prior year increase in demand driven by the onset of the COVID -19 pandemic and the contribution of our \nGerman wholesale business through a joint venture with Walgreens Boots Alliance.  \n \n Adjusted gross profit was approximately flat to prior year as inventory charges in our Medical -Surgical segment \nand the previously mentioned prior  year demand increase driven by COVID largely offset the contribution of our \nCOVID -19 vaccine distribution and kitting programs and the distribution of COVID -19 tests.  \n \n Adjusted operating expenses in the quarter decreased 6% year -over-year, led by a reduct ion in operating \nexpenses due to the impact of COVID -19 and the contribution of our German wholesale business to the joint \nventure with Walgreens Boots Alliance. ", "original_text": "This transition [indiscernible] (19:15) details of our consolidated results, which \ncan be found on slide four.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bf3c1c82a1ce30c800016b6b1564385548fd472efb8a706ef58f6bc80e5917c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9988fed4-896c-451a-8ebc-da58bff685d9", "node_type": "1", "metadata": {"window": "These items were partially offset by a h igher tax rate and the prior year contribution from the company's \ninvestment in Change Healthcare.  This transition [indiscernible] (19:15) details of our consolidated results, which \ncan be found on slide four.  \n \n Consolidated revenues of $59.1 billion increa sed 1% compared to the prior year primarily due to market growth \nand higher volumes from retail national account customers in the US Pharmaceutical segment, partially offset by \nthe prior year increase in demand driven by the onset of the COVID -19 pandemic and the contribution of our \nGerman wholesale business through a joint venture with Walgreens Boots Alliance.  \n \n Adjusted gross profit was approximately flat to prior year as inventory charges in our Medical -Surgical segment \nand the previously mentioned prior  year demand increase driven by COVID largely offset the contribution of our \nCOVID -19 vaccine distribution and kitting programs and the distribution of COVID -19 tests.  \n \n Adjusted operating expenses in the quarter decreased 6% year -over-year, led by a reduct ion in operating \nexpenses due to the impact of COVID -19 and the contribution of our German wholesale business to the joint \nventure with Walgreens Boots Alliance.  This was partially offset by increased expenses related to our role \ndistributing COVID -19 vacc ines and ancillary supply kits and higher operating expenses to support growth \ninvestments in oncology and biopharma services.  \n \n Adjusted operating profit was $1. ", "original_text": "Adjusted gross profit was approximately flat to prior year as inventory charges in our Medical -Surgical segment \nand the previously mentioned prior  year demand increase driven by COVID largely offset the contribution of our \nCOVID -19 vaccine distribution and kitting programs and the distribution of COVID -19 tests.  \n \n"}, "hash": "cc9ec444c93a091618b2227de6f9595ca15e9abe245ef41de81b4b5cf21f5ea6", "class_name": "RelatedNodeInfo"}}, "text": "Consolidated revenues of $59.1 billion increa sed 1% compared to the prior year primarily due to market growth \nand higher volumes from retail national account customers in the US Pharmaceutical segment, partially offset by \nthe prior year increase in demand driven by the onset of the COVID -19 pandemic and the contribution of our \nGerman wholesale business through a joint venture with Walgreens Boots Alliance.  \n \n", "start_char_idx": 1115, "end_char_idx": 1534, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9988fed4-896c-451a-8ebc-da58bff685d9": {"__data__": {"id_": "9988fed4-896c-451a-8ebc-da58bff685d9", "embedding": null, "metadata": {"window": "These items were partially offset by a h igher tax rate and the prior year contribution from the company's \ninvestment in Change Healthcare.  This transition [indiscernible] (19:15) details of our consolidated results, which \ncan be found on slide four.  \n \n Consolidated revenues of $59.1 billion increa sed 1% compared to the prior year primarily due to market growth \nand higher volumes from retail national account customers in the US Pharmaceutical segment, partially offset by \nthe prior year increase in demand driven by the onset of the COVID -19 pandemic and the contribution of our \nGerman wholesale business through a joint venture with Walgreens Boots Alliance.  \n \n Adjusted gross profit was approximately flat to prior year as inventory charges in our Medical -Surgical segment \nand the previously mentioned prior  year demand increase driven by COVID largely offset the contribution of our \nCOVID -19 vaccine distribution and kitting programs and the distribution of COVID -19 tests.  \n \n Adjusted operating expenses in the quarter decreased 6% year -over-year, led by a reduct ion in operating \nexpenses due to the impact of COVID -19 and the contribution of our German wholesale business to the joint \nventure with Walgreens Boots Alliance.  This was partially offset by increased expenses related to our role \ndistributing COVID -19 vacc ines and ancillary supply kits and higher operating expenses to support growth \ninvestments in oncology and biopharma services.  \n \n Adjusted operating profit was $1. ", "original_text": "Adjusted gross profit was approximately flat to prior year as inventory charges in our Medical -Surgical segment \nand the previously mentioned prior  year demand increase driven by COVID largely offset the contribution of our \nCOVID -19 vaccine distribution and kitting programs and the distribution of COVID -19 tests.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47c99048-affb-49f7-9b53-d38a3f456c08", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46a5839a97deec04bfaf8e0e8f72d85840f7b4b9c1be3b14f6c88546777d22d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f24ddc5d-33bf-49cd-923a-5c1bee9cb8c6", "node_type": "1", "metadata": {"window": "Fourth quarter adjusted  \nearnings per diluted share was $5.05, an increase of 18% compared to the prior year driven by the contribution \nfrom COVID -19 vaccine distribution and kitting programs for the US government and a lower share count.  \n \n These items were partially offset by a h igher tax rate and the prior year contribution from the company's \ninvestment in Change Healthcare.  This transition [indiscernible] (19:15) details of our consolidated results, which \ncan be found on slide four.  \n \n Consolidated revenues of $59.1 billion increa sed 1% compared to the prior year primarily due to market growth \nand higher volumes from retail national account customers in the US Pharmaceutical segment, partially offset by \nthe prior year increase in demand driven by the onset of the COVID -19 pandemic and the contribution of our \nGerman wholesale business through a joint venture with Walgreens Boots Alliance.  \n \n Adjusted gross profit was approximately flat to prior year as inventory charges in our Medical -Surgical segment \nand the previously mentioned prior  year demand increase driven by COVID largely offset the contribution of our \nCOVID -19 vaccine distribution and kitting programs and the distribution of COVID -19 tests.  \n \n Adjusted operating expenses in the quarter decreased 6% year -over-year, led by a reduct ion in operating \nexpenses due to the impact of COVID -19 and the contribution of our German wholesale business to the joint \nventure with Walgreens Boots Alliance.  This was partially offset by increased expenses related to our role \ndistributing COVID -19 vacc ines and ancillary supply kits and higher operating expenses to support growth \ninvestments in oncology and biopharma services.  \n \n", "original_text": "Consolidated revenues of $59.1 billion increa sed 1% compared to the prior year primarily due to market growth \nand higher volumes from retail national account customers in the US Pharmaceutical segment, partially offset by \nthe prior year increase in demand driven by the onset of the COVID -19 pandemic and the contribution of our \nGerman wholesale business through a joint venture with Walgreens Boots Alliance.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "123a219eb3af6704e843128ccec0d0ba2a1a2b2d5fe03ff6d9b64e15f4e0f1c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4bb69ca8-1cdc-458d-83e8-55babc933712", "node_type": "1", "metadata": {"window": "This transition [indiscernible] (19:15) details of our consolidated results, which \ncan be found on slide four.  \n \n Consolidated revenues of $59.1 billion increa sed 1% compared to the prior year primarily due to market growth \nand higher volumes from retail national account customers in the US Pharmaceutical segment, partially offset by \nthe prior year increase in demand driven by the onset of the COVID -19 pandemic and the contribution of our \nGerman wholesale business through a joint venture with Walgreens Boots Alliance.  \n \n Adjusted gross profit was approximately flat to prior year as inventory charges in our Medical -Surgical segment \nand the previously mentioned prior  year demand increase driven by COVID largely offset the contribution of our \nCOVID -19 vaccine distribution and kitting programs and the distribution of COVID -19 tests.  \n \n Adjusted operating expenses in the quarter decreased 6% year -over-year, led by a reduct ion in operating \nexpenses due to the impact of COVID -19 and the contribution of our German wholesale business to the joint \nventure with Walgreens Boots Alliance.  This was partially offset by increased expenses related to our role \ndistributing COVID -19 vacc ines and ancillary supply kits and higher operating expenses to support growth \ninvestments in oncology and biopharma services.  \n \n Adjusted operating profit was $1.  2 billion for the quarter, an increase of 12% compared to the prior year. ", "original_text": "Adjusted operating expenses in the quarter decreased 6% year -over-year, led by a reduct ion in operating \nexpenses due to the impact of COVID -19 and the contribution of our German wholesale business to the joint \nventure with Walgreens Boots Alliance. "}, "hash": "e68642314e1e16d518cfa27b8278948ac6adab655017fb3462caa5443156a366", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit was approximately flat to prior year as inventory charges in our Medical -Surgical segment \nand the previously mentioned prior  year demand increase driven by COVID largely offset the contribution of our \nCOVID -19 vaccine distribution and kitting programs and the distribution of COVID -19 tests.  \n \n", "start_char_idx": 1534, "end_char_idx": 1858, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4bb69ca8-1cdc-458d-83e8-55babc933712": {"__data__": {"id_": "4bb69ca8-1cdc-458d-83e8-55babc933712", "embedding": null, "metadata": {"window": "This transition [indiscernible] (19:15) details of our consolidated results, which \ncan be found on slide four.  \n \n Consolidated revenues of $59.1 billion increa sed 1% compared to the prior year primarily due to market growth \nand higher volumes from retail national account customers in the US Pharmaceutical segment, partially offset by \nthe prior year increase in demand driven by the onset of the COVID -19 pandemic and the contribution of our \nGerman wholesale business through a joint venture with Walgreens Boots Alliance.  \n \n Adjusted gross profit was approximately flat to prior year as inventory charges in our Medical -Surgical segment \nand the previously mentioned prior  year demand increase driven by COVID largely offset the contribution of our \nCOVID -19 vaccine distribution and kitting programs and the distribution of COVID -19 tests.  \n \n Adjusted operating expenses in the quarter decreased 6% year -over-year, led by a reduct ion in operating \nexpenses due to the impact of COVID -19 and the contribution of our German wholesale business to the joint \nventure with Walgreens Boots Alliance.  This was partially offset by increased expenses related to our role \ndistributing COVID -19 vacc ines and ancillary supply kits and higher operating expenses to support growth \ninvestments in oncology and biopharma services.  \n \n Adjusted operating profit was $1.  2 billion for the quarter, an increase of 12% compared to the prior year. ", "original_text": "Adjusted operating expenses in the quarter decreased 6% year -over-year, led by a reduct ion in operating \nexpenses due to the impact of COVID -19 and the contribution of our German wholesale business to the joint \nventure with Walgreens Boots Alliance. ", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47c99048-affb-49f7-9b53-d38a3f456c08", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46a5839a97deec04bfaf8e0e8f72d85840f7b4b9c1be3b14f6c88546777d22d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9988fed4-896c-451a-8ebc-da58bff685d9", "node_type": "1", "metadata": {"window": "These items were partially offset by a h igher tax rate and the prior year contribution from the company's \ninvestment in Change Healthcare.  This transition [indiscernible] (19:15) details of our consolidated results, which \ncan be found on slide four.  \n \n Consolidated revenues of $59.1 billion increa sed 1% compared to the prior year primarily due to market growth \nand higher volumes from retail national account customers in the US Pharmaceutical segment, partially offset by \nthe prior year increase in demand driven by the onset of the COVID -19 pandemic and the contribution of our \nGerman wholesale business through a joint venture with Walgreens Boots Alliance.  \n \n Adjusted gross profit was approximately flat to prior year as inventory charges in our Medical -Surgical segment \nand the previously mentioned prior  year demand increase driven by COVID largely offset the contribution of our \nCOVID -19 vaccine distribution and kitting programs and the distribution of COVID -19 tests.  \n \n Adjusted operating expenses in the quarter decreased 6% year -over-year, led by a reduct ion in operating \nexpenses due to the impact of COVID -19 and the contribution of our German wholesale business to the joint \nventure with Walgreens Boots Alliance.  This was partially offset by increased expenses related to our role \ndistributing COVID -19 vacc ines and ancillary supply kits and higher operating expenses to support growth \ninvestments in oncology and biopharma services.  \n \n Adjusted operating profit was $1. ", "original_text": "Adjusted gross profit was approximately flat to prior year as inventory charges in our Medical -Surgical segment \nand the previously mentioned prior  year demand increase driven by COVID largely offset the contribution of our \nCOVID -19 vaccine distribution and kitting programs and the distribution of COVID -19 tests.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5dcdae32b4e7582b943ba8e745b806f21962b8c7f63670b5731522674e9ccfb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13cddd67-a6bc-4bd5-91f5-52bb7450be41", "node_type": "1", "metadata": {"window": "Consolidated revenues of $59.1 billion increa sed 1% compared to the prior year primarily due to market growth \nand higher volumes from retail national account customers in the US Pharmaceutical segment, partially offset by \nthe prior year increase in demand driven by the onset of the COVID -19 pandemic and the contribution of our \nGerman wholesale business through a joint venture with Walgreens Boots Alliance.  \n \n Adjusted gross profit was approximately flat to prior year as inventory charges in our Medical -Surgical segment \nand the previously mentioned prior  year demand increase driven by COVID largely offset the contribution of our \nCOVID -19 vaccine distribution and kitting programs and the distribution of COVID -19 tests.  \n \n Adjusted operating expenses in the quarter decreased 6% year -over-year, led by a reduct ion in operating \nexpenses due to the impact of COVID -19 and the contribution of our German wholesale business to the joint \nventure with Walgreens Boots Alliance.  This was partially offset by increased expenses related to our role \ndistributing COVID -19 vacc ines and ancillary supply kits and higher operating expenses to support growth \ninvestments in oncology and biopharma services.  \n \n Adjusted operating profit was $1.  2 billion for the quarter, an increase of 12% compared to the prior year.  When \nexcluding the $ 55 million contributed by Change Healthcare in the fourth quarter of fiscal 2020, which was \npreviously recorded in Other; adjusted operating profit grew 19%. ", "original_text": "This was partially offset by increased expenses related to our role \ndistributing COVID -19 vacc ines and ancillary supply kits and higher operating expenses to support growth \ninvestments in oncology and biopharma services.  \n \n"}, "hash": "3618c5995ee4789e675eadd2972e3b56228da25301fdd431ac6bbd56af3daebb", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses in the quarter decreased 6% year -over-year, led by a reduct ion in operating \nexpenses due to the impact of COVID -19 and the contribution of our German wholesale business to the joint \nventure with Walgreens Boots Alliance. ", "start_char_idx": 1858, "end_char_idx": 2112, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13cddd67-a6bc-4bd5-91f5-52bb7450be41": {"__data__": {"id_": "13cddd67-a6bc-4bd5-91f5-52bb7450be41", "embedding": null, "metadata": {"window": "Consolidated revenues of $59.1 billion increa sed 1% compared to the prior year primarily due to market growth \nand higher volumes from retail national account customers in the US Pharmaceutical segment, partially offset by \nthe prior year increase in demand driven by the onset of the COVID -19 pandemic and the contribution of our \nGerman wholesale business through a joint venture with Walgreens Boots Alliance.  \n \n Adjusted gross profit was approximately flat to prior year as inventory charges in our Medical -Surgical segment \nand the previously mentioned prior  year demand increase driven by COVID largely offset the contribution of our \nCOVID -19 vaccine distribution and kitting programs and the distribution of COVID -19 tests.  \n \n Adjusted operating expenses in the quarter decreased 6% year -over-year, led by a reduct ion in operating \nexpenses due to the impact of COVID -19 and the contribution of our German wholesale business to the joint \nventure with Walgreens Boots Alliance.  This was partially offset by increased expenses related to our role \ndistributing COVID -19 vacc ines and ancillary supply kits and higher operating expenses to support growth \ninvestments in oncology and biopharma services.  \n \n Adjusted operating profit was $1.  2 billion for the quarter, an increase of 12% compared to the prior year.  When \nexcluding the $ 55 million contributed by Change Healthcare in the fourth quarter of fiscal 2020, which was \npreviously recorded in Other; adjusted operating profit grew 19%. ", "original_text": "This was partially offset by increased expenses related to our role \ndistributing COVID -19 vacc ines and ancillary supply kits and higher operating expenses to support growth \ninvestments in oncology and biopharma services.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47c99048-affb-49f7-9b53-d38a3f456c08", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46a5839a97deec04bfaf8e0e8f72d85840f7b4b9c1be3b14f6c88546777d22d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bb69ca8-1cdc-458d-83e8-55babc933712", "node_type": "1", "metadata": {"window": "This transition [indiscernible] (19:15) details of our consolidated results, which \ncan be found on slide four.  \n \n Consolidated revenues of $59.1 billion increa sed 1% compared to the prior year primarily due to market growth \nand higher volumes from retail national account customers in the US Pharmaceutical segment, partially offset by \nthe prior year increase in demand driven by the onset of the COVID -19 pandemic and the contribution of our \nGerman wholesale business through a joint venture with Walgreens Boots Alliance.  \n \n Adjusted gross profit was approximately flat to prior year as inventory charges in our Medical -Surgical segment \nand the previously mentioned prior  year demand increase driven by COVID largely offset the contribution of our \nCOVID -19 vaccine distribution and kitting programs and the distribution of COVID -19 tests.  \n \n Adjusted operating expenses in the quarter decreased 6% year -over-year, led by a reduct ion in operating \nexpenses due to the impact of COVID -19 and the contribution of our German wholesale business to the joint \nventure with Walgreens Boots Alliance.  This was partially offset by increased expenses related to our role \ndistributing COVID -19 vacc ines and ancillary supply kits and higher operating expenses to support growth \ninvestments in oncology and biopharma services.  \n \n Adjusted operating profit was $1.  2 billion for the quarter, an increase of 12% compared to the prior year. ", "original_text": "Adjusted operating expenses in the quarter decreased 6% year -over-year, led by a reduct ion in operating \nexpenses due to the impact of COVID -19 and the contribution of our German wholesale business to the joint \nventure with Walgreens Boots Alliance. ", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5cc80b352d891978ba18111ca947e822aaf092e9eb92d03576bfe7bdd0e5e4d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6aed691-fa96-4afa-b86f-7330d3dfc193", "node_type": "1", "metadata": {"window": "Adjusted gross profit was approximately flat to prior year as inventory charges in our Medical -Surgical segment \nand the previously mentioned prior  year demand increase driven by COVID largely offset the contribution of our \nCOVID -19 vaccine distribution and kitting programs and the distribution of COVID -19 tests.  \n \n Adjusted operating expenses in the quarter decreased 6% year -over-year, led by a reduct ion in operating \nexpenses due to the impact of COVID -19 and the contribution of our German wholesale business to the joint \nventure with Walgreens Boots Alliance.  This was partially offset by increased expenses related to our role \ndistributing COVID -19 vacc ines and ancillary supply kits and higher operating expenses to support growth \ninvestments in oncology and biopharma services.  \n \n Adjusted operating profit was $1.  2 billion for the quarter, an increase of 12% compared to the prior year.  When \nexcluding the $ 55 million contributed by Change Healthcare in the fourth quarter of fiscal 2020, which was \npreviously recorded in Other; adjusted operating profit grew 19%.  Interest expense was $52 million in the quarter, \na decline of 20% compared to the prior year, driv en by the retirement of approximately $1 billion of debt and lower \ncommercial paper balances.  \n \n", "original_text": "Adjusted operating profit was $1. "}, "hash": "1bb19b6f9bc6c755429481d68452875e738ecab4ba071c9e74e7cba84e143c2c", "class_name": "RelatedNodeInfo"}}, "text": "This was partially offset by increased expenses related to our role \ndistributing COVID -19 vacc ines and ancillary supply kits and higher operating expenses to support growth \ninvestments in oncology and biopharma services.  \n \n", "start_char_idx": 2112, "end_char_idx": 2341, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6aed691-fa96-4afa-b86f-7330d3dfc193": {"__data__": {"id_": "e6aed691-fa96-4afa-b86f-7330d3dfc193", "embedding": null, "metadata": {"window": "Adjusted gross profit was approximately flat to prior year as inventory charges in our Medical -Surgical segment \nand the previously mentioned prior  year demand increase driven by COVID largely offset the contribution of our \nCOVID -19 vaccine distribution and kitting programs and the distribution of COVID -19 tests.  \n \n Adjusted operating expenses in the quarter decreased 6% year -over-year, led by a reduct ion in operating \nexpenses due to the impact of COVID -19 and the contribution of our German wholesale business to the joint \nventure with Walgreens Boots Alliance.  This was partially offset by increased expenses related to our role \ndistributing COVID -19 vacc ines and ancillary supply kits and higher operating expenses to support growth \ninvestments in oncology and biopharma services.  \n \n Adjusted operating profit was $1.  2 billion for the quarter, an increase of 12% compared to the prior year.  When \nexcluding the $ 55 million contributed by Change Healthcare in the fourth quarter of fiscal 2020, which was \npreviously recorded in Other; adjusted operating profit grew 19%.  Interest expense was $52 million in the quarter, \na decline of 20% compared to the prior year, driv en by the retirement of approximately $1 billion of debt and lower \ncommercial paper balances.  \n \n", "original_text": "Adjusted operating profit was $1. ", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47c99048-affb-49f7-9b53-d38a3f456c08", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46a5839a97deec04bfaf8e0e8f72d85840f7b4b9c1be3b14f6c88546777d22d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13cddd67-a6bc-4bd5-91f5-52bb7450be41", "node_type": "1", "metadata": {"window": "Consolidated revenues of $59.1 billion increa sed 1% compared to the prior year primarily due to market growth \nand higher volumes from retail national account customers in the US Pharmaceutical segment, partially offset by \nthe prior year increase in demand driven by the onset of the COVID -19 pandemic and the contribution of our \nGerman wholesale business through a joint venture with Walgreens Boots Alliance.  \n \n Adjusted gross profit was approximately flat to prior year as inventory charges in our Medical -Surgical segment \nand the previously mentioned prior  year demand increase driven by COVID largely offset the contribution of our \nCOVID -19 vaccine distribution and kitting programs and the distribution of COVID -19 tests.  \n \n Adjusted operating expenses in the quarter decreased 6% year -over-year, led by a reduct ion in operating \nexpenses due to the impact of COVID -19 and the contribution of our German wholesale business to the joint \nventure with Walgreens Boots Alliance.  This was partially offset by increased expenses related to our role \ndistributing COVID -19 vacc ines and ancillary supply kits and higher operating expenses to support growth \ninvestments in oncology and biopharma services.  \n \n Adjusted operating profit was $1.  2 billion for the quarter, an increase of 12% compared to the prior year.  When \nexcluding the $ 55 million contributed by Change Healthcare in the fourth quarter of fiscal 2020, which was \npreviously recorded in Other; adjusted operating profit grew 19%. ", "original_text": "This was partially offset by increased expenses related to our role \ndistributing COVID -19 vacc ines and ancillary supply kits and higher operating expenses to support growth \ninvestments in oncology and biopharma services.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4a986af7429c7cd69a24d509bcb7e49c401ce6aa0a79b95f9a99aaafa538a9ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "016817e4-f9ec-4c3a-b94f-728c0830d050", "node_type": "1", "metadata": {"window": "Adjusted operating expenses in the quarter decreased 6% year -over-year, led by a reduct ion in operating \nexpenses due to the impact of COVID -19 and the contribution of our German wholesale business to the joint \nventure with Walgreens Boots Alliance.  This was partially offset by increased expenses related to our role \ndistributing COVID -19 vacc ines and ancillary supply kits and higher operating expenses to support growth \ninvestments in oncology and biopharma services.  \n \n Adjusted operating profit was $1.  2 billion for the quarter, an increase of 12% compared to the prior year.  When \nexcluding the $ 55 million contributed by Change Healthcare in the fourth quarter of fiscal 2020, which was \npreviously recorded in Other; adjusted operating profit grew 19%.  Interest expense was $52 million in the quarter, \na decline of 20% compared to the prior year, driv en by the retirement of approximately $1 billion of debt and lower \ncommercial paper balances.  \n \n Our adjusted tax rate was 22.9% for the quarter, in line with our expectations. ", "original_text": "2 billion for the quarter, an increase of 12% compared to the prior year. "}, "hash": "f7fa5eec36dec37f43d91e527489c002a16c1f580f69a729887b5b5784eb7f9e", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating profit was $1. ", "start_char_idx": 2341, "end_char_idx": 2375, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "016817e4-f9ec-4c3a-b94f-728c0830d050": {"__data__": {"id_": "016817e4-f9ec-4c3a-b94f-728c0830d050", "embedding": null, "metadata": {"window": "Adjusted operating expenses in the quarter decreased 6% year -over-year, led by a reduct ion in operating \nexpenses due to the impact of COVID -19 and the contribution of our German wholesale business to the joint \nventure with Walgreens Boots Alliance.  This was partially offset by increased expenses related to our role \ndistributing COVID -19 vacc ines and ancillary supply kits and higher operating expenses to support growth \ninvestments in oncology and biopharma services.  \n \n Adjusted operating profit was $1.  2 billion for the quarter, an increase of 12% compared to the prior year.  When \nexcluding the $ 55 million contributed by Change Healthcare in the fourth quarter of fiscal 2020, which was \npreviously recorded in Other; adjusted operating profit grew 19%.  Interest expense was $52 million in the quarter, \na decline of 20% compared to the prior year, driv en by the retirement of approximately $1 billion of debt and lower \ncommercial paper balances.  \n \n Our adjusted tax rate was 22.9% for the quarter, in line with our expectations. ", "original_text": "2 billion for the quarter, an increase of 12% compared to the prior year. ", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47c99048-affb-49f7-9b53-d38a3f456c08", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46a5839a97deec04bfaf8e0e8f72d85840f7b4b9c1be3b14f6c88546777d22d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6aed691-fa96-4afa-b86f-7330d3dfc193", "node_type": "1", "metadata": {"window": "Adjusted gross profit was approximately flat to prior year as inventory charges in our Medical -Surgical segment \nand the previously mentioned prior  year demand increase driven by COVID largely offset the contribution of our \nCOVID -19 vaccine distribution and kitting programs and the distribution of COVID -19 tests.  \n \n Adjusted operating expenses in the quarter decreased 6% year -over-year, led by a reduct ion in operating \nexpenses due to the impact of COVID -19 and the contribution of our German wholesale business to the joint \nventure with Walgreens Boots Alliance.  This was partially offset by increased expenses related to our role \ndistributing COVID -19 vacc ines and ancillary supply kits and higher operating expenses to support growth \ninvestments in oncology and biopharma services.  \n \n Adjusted operating profit was $1.  2 billion for the quarter, an increase of 12% compared to the prior year.  When \nexcluding the $ 55 million contributed by Change Healthcare in the fourth quarter of fiscal 2020, which was \npreviously recorded in Other; adjusted operating profit grew 19%.  Interest expense was $52 million in the quarter, \na decline of 20% compared to the prior year, driv en by the retirement of approximately $1 billion of debt and lower \ncommercial paper balances.  \n \n", "original_text": "Adjusted operating profit was $1. ", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae19328b9cd2d5b69b0e10a69beb0e6925a9ea13cb3fa71159748d50d059e122", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "026aef1e-bb88-4832-86c0-f63fc021df28", "node_type": "1", "metadata": {"window": "This was partially offset by increased expenses related to our role \ndistributing COVID -19 vacc ines and ancillary supply kits and higher operating expenses to support growth \ninvestments in oncology and biopharma services.  \n \n Adjusted operating profit was $1.  2 billion for the quarter, an increase of 12% compared to the prior year.  When \nexcluding the $ 55 million contributed by Change Healthcare in the fourth quarter of fiscal 2020, which was \npreviously recorded in Other; adjusted operating profit grew 19%.  Interest expense was $52 million in the quarter, \na decline of 20% compared to the prior year, driv en by the retirement of approximately $1 billion of debt and lower \ncommercial paper balances.  \n \n Our adjusted tax rate was 22.9% for the quarter, in line with our expectations.  Fourth quarter adjusted earnings \nper diluted share also includes net pre -tax gain s of approximately $44 million or $0.21 per diluted share \nassociated with McKesson Ventures' equity investments.  \n \n", "original_text": "When \nexcluding the $ 55 million contributed by Change Healthcare in the fourth quarter of fiscal 2020, which was \npreviously recorded in Other; adjusted operating profit grew 19%. "}, "hash": "29efa8d7f051dc2d852d4179ebc81845a034adb4b3e677f546113a6d6441788c", "class_name": "RelatedNodeInfo"}}, "text": "2 billion for the quarter, an increase of 12% compared to the prior year. ", "start_char_idx": 2375, "end_char_idx": 2449, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "026aef1e-bb88-4832-86c0-f63fc021df28": {"__data__": {"id_": "026aef1e-bb88-4832-86c0-f63fc021df28", "embedding": null, "metadata": {"window": "This was partially offset by increased expenses related to our role \ndistributing COVID -19 vacc ines and ancillary supply kits and higher operating expenses to support growth \ninvestments in oncology and biopharma services.  \n \n Adjusted operating profit was $1.  2 billion for the quarter, an increase of 12% compared to the prior year.  When \nexcluding the $ 55 million contributed by Change Healthcare in the fourth quarter of fiscal 2020, which was \npreviously recorded in Other; adjusted operating profit grew 19%.  Interest expense was $52 million in the quarter, \na decline of 20% compared to the prior year, driv en by the retirement of approximately $1 billion of debt and lower \ncommercial paper balances.  \n \n Our adjusted tax rate was 22.9% for the quarter, in line with our expectations.  Fourth quarter adjusted earnings \nper diluted share also includes net pre -tax gain s of approximately $44 million or $0.21 per diluted share \nassociated with McKesson Ventures' equity investments.  \n \n", "original_text": "When \nexcluding the $ 55 million contributed by Change Healthcare in the fourth quarter of fiscal 2020, which was \npreviously recorded in Other; adjusted operating profit grew 19%. ", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47c99048-affb-49f7-9b53-d38a3f456c08", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46a5839a97deec04bfaf8e0e8f72d85840f7b4b9c1be3b14f6c88546777d22d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "016817e4-f9ec-4c3a-b94f-728c0830d050", "node_type": "1", "metadata": {"window": "Adjusted operating expenses in the quarter decreased 6% year -over-year, led by a reduct ion in operating \nexpenses due to the impact of COVID -19 and the contribution of our German wholesale business to the joint \nventure with Walgreens Boots Alliance.  This was partially offset by increased expenses related to our role \ndistributing COVID -19 vacc ines and ancillary supply kits and higher operating expenses to support growth \ninvestments in oncology and biopharma services.  \n \n Adjusted operating profit was $1.  2 billion for the quarter, an increase of 12% compared to the prior year.  When \nexcluding the $ 55 million contributed by Change Healthcare in the fourth quarter of fiscal 2020, which was \npreviously recorded in Other; adjusted operating profit grew 19%.  Interest expense was $52 million in the quarter, \na decline of 20% compared to the prior year, driv en by the retirement of approximately $1 billion of debt and lower \ncommercial paper balances.  \n \n Our adjusted tax rate was 22.9% for the quarter, in line with our expectations. ", "original_text": "2 billion for the quarter, an increase of 12% compared to the prior year. ", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e19068075937a7c3a55232167cfe92872e001abf7e366fa4db400379841e2bb0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "143587a9-dcf9-433e-a58f-7752a54ece00", "node_type": "1", "metadata": {"window": "Adjusted operating profit was $1.  2 billion for the quarter, an increase of 12% compared to the prior year.  When \nexcluding the $ 55 million contributed by Change Healthcare in the fourth quarter of fiscal 2020, which was \npreviously recorded in Other; adjusted operating profit grew 19%.  Interest expense was $52 million in the quarter, \na decline of 20% compared to the prior year, driv en by the retirement of approximately $1 billion of debt and lower \ncommercial paper balances.  \n \n Our adjusted tax rate was 22.9% for the quarter, in line with our expectations.  Fourth quarter adjusted earnings \nper diluted share also includes net pre -tax gain s of approximately $44 million or $0.21 per diluted share \nassociated with McKesson Ventures' equity investments.  \n \n In wrapping up our consolidated results, fourth quarter diluted weighted average shares were $161 million, a \ndecrease of 8% year -over-year, dr iven by the successful tax re -exit of our investment in Change Healthcare at the \nend of fiscal 2020 and other open -market share repurchase activity. ", "original_text": "Interest expense was $52 million in the quarter, \na decline of 20% compared to the prior year, driv en by the retirement of approximately $1 billion of debt and lower \ncommercial paper balances.  \n \n"}, "hash": "8a4754b78cb70f0f5bbd5340c0b5f45ff9ab70f413d5300cc3d6aab58bf3798a", "class_name": "RelatedNodeInfo"}}, "text": "When \nexcluding the $ 55 million contributed by Change Healthcare in the fourth quarter of fiscal 2020, which was \npreviously recorded in Other; adjusted operating profit grew 19%. ", "start_char_idx": 2449, "end_char_idx": 2630, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "143587a9-dcf9-433e-a58f-7752a54ece00": {"__data__": {"id_": "143587a9-dcf9-433e-a58f-7752a54ece00", "embedding": null, "metadata": {"window": "Adjusted operating profit was $1.  2 billion for the quarter, an increase of 12% compared to the prior year.  When \nexcluding the $ 55 million contributed by Change Healthcare in the fourth quarter of fiscal 2020, which was \npreviously recorded in Other; adjusted operating profit grew 19%.  Interest expense was $52 million in the quarter, \na decline of 20% compared to the prior year, driv en by the retirement of approximately $1 billion of debt and lower \ncommercial paper balances.  \n \n Our adjusted tax rate was 22.9% for the quarter, in line with our expectations.  Fourth quarter adjusted earnings \nper diluted share also includes net pre -tax gain s of approximately $44 million or $0.21 per diluted share \nassociated with McKesson Ventures' equity investments.  \n \n In wrapping up our consolidated results, fourth quarter diluted weighted average shares were $161 million, a \ndecrease of 8% year -over-year, dr iven by the successful tax re -exit of our investment in Change Healthcare at the \nend of fiscal 2020 and other open -market share repurchase activity. ", "original_text": "Interest expense was $52 million in the quarter, \na decline of 20% compared to the prior year, driv en by the retirement of approximately $1 billion of debt and lower \ncommercial paper balances.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47c99048-affb-49f7-9b53-d38a3f456c08", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46a5839a97deec04bfaf8e0e8f72d85840f7b4b9c1be3b14f6c88546777d22d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "026aef1e-bb88-4832-86c0-f63fc021df28", "node_type": "1", "metadata": {"window": "This was partially offset by increased expenses related to our role \ndistributing COVID -19 vacc ines and ancillary supply kits and higher operating expenses to support growth \ninvestments in oncology and biopharma services.  \n \n Adjusted operating profit was $1.  2 billion for the quarter, an increase of 12% compared to the prior year.  When \nexcluding the $ 55 million contributed by Change Healthcare in the fourth quarter of fiscal 2020, which was \npreviously recorded in Other; adjusted operating profit grew 19%.  Interest expense was $52 million in the quarter, \na decline of 20% compared to the prior year, driv en by the retirement of approximately $1 billion of debt and lower \ncommercial paper balances.  \n \n Our adjusted tax rate was 22.9% for the quarter, in line with our expectations.  Fourth quarter adjusted earnings \nper diluted share also includes net pre -tax gain s of approximately $44 million or $0.21 per diluted share \nassociated with McKesson Ventures' equity investments.  \n \n", "original_text": "When \nexcluding the $ 55 million contributed by Change Healthcare in the fourth quarter of fiscal 2020, which was \npreviously recorded in Other; adjusted operating profit grew 19%. ", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1f4e635e7ff57f669706c58967bd260a5975b181cbc4d37c253a6dd870fa49e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a1f3a6f-7d36-400e-85e2-4a161574f43c", "node_type": "1", "metadata": {"window": "2 billion for the quarter, an increase of 12% compared to the prior year.  When \nexcluding the $ 55 million contributed by Change Healthcare in the fourth quarter of fiscal 2020, which was \npreviously recorded in Other; adjusted operating profit grew 19%.  Interest expense was $52 million in the quarter, \na decline of 20% compared to the prior year, driv en by the retirement of approximately $1 billion of debt and lower \ncommercial paper balances.  \n \n Our adjusted tax rate was 22.9% for the quarter, in line with our expectations.  Fourth quarter adjusted earnings \nper diluted share also includes net pre -tax gain s of approximately $44 million or $0.21 per diluted share \nassociated with McKesson Ventures' equity investments.  \n \n In wrapping up our consolidated results, fourth quarter diluted weighted average shares were $161 million, a \ndecrease of 8% year -over-year, dr iven by the successful tax re -exit of our investment in Change Healthcare at the \nend of fiscal 2020 and other open -market share repurchase activity.  As a reminder, the exit of our Change \nHealthcare investment lowered our shares outstanding by approximately  15.4 million shares.  \n \n", "original_text": "Our adjusted tax rate was 22.9% for the quarter, in line with our expectations. "}, "hash": "adc4e562b0928530e1ec382a8eef888a7cecb804e81c9a5f07a155a2fe4a8031", "class_name": "RelatedNodeInfo"}}, "text": "Interest expense was $52 million in the quarter, \na decline of 20% compared to the prior year, driv en by the retirement of approximately $1 billion of debt and lower \ncommercial paper balances.  \n \n", "start_char_idx": 2630, "end_char_idx": 2829, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a1f3a6f-7d36-400e-85e2-4a161574f43c": {"__data__": {"id_": "2a1f3a6f-7d36-400e-85e2-4a161574f43c", "embedding": null, "metadata": {"window": "2 billion for the quarter, an increase of 12% compared to the prior year.  When \nexcluding the $ 55 million contributed by Change Healthcare in the fourth quarter of fiscal 2020, which was \npreviously recorded in Other; adjusted operating profit grew 19%.  Interest expense was $52 million in the quarter, \na decline of 20% compared to the prior year, driv en by the retirement of approximately $1 billion of debt and lower \ncommercial paper balances.  \n \n Our adjusted tax rate was 22.9% for the quarter, in line with our expectations.  Fourth quarter adjusted earnings \nper diluted share also includes net pre -tax gain s of approximately $44 million or $0.21 per diluted share \nassociated with McKesson Ventures' equity investments.  \n \n In wrapping up our consolidated results, fourth quarter diluted weighted average shares were $161 million, a \ndecrease of 8% year -over-year, dr iven by the successful tax re -exit of our investment in Change Healthcare at the \nend of fiscal 2020 and other open -market share repurchase activity.  As a reminder, the exit of our Change \nHealthcare investment lowered our shares outstanding by approximately  15.4 million shares.  \n \n", "original_text": "Our adjusted tax rate was 22.9% for the quarter, in line with our expectations. ", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47c99048-affb-49f7-9b53-d38a3f456c08", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46a5839a97deec04bfaf8e0e8f72d85840f7b4b9c1be3b14f6c88546777d22d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "143587a9-dcf9-433e-a58f-7752a54ece00", "node_type": "1", "metadata": {"window": "Adjusted operating profit was $1.  2 billion for the quarter, an increase of 12% compared to the prior year.  When \nexcluding the $ 55 million contributed by Change Healthcare in the fourth quarter of fiscal 2020, which was \npreviously recorded in Other; adjusted operating profit grew 19%.  Interest expense was $52 million in the quarter, \na decline of 20% compared to the prior year, driv en by the retirement of approximately $1 billion of debt and lower \ncommercial paper balances.  \n \n Our adjusted tax rate was 22.9% for the quarter, in line with our expectations.  Fourth quarter adjusted earnings \nper diluted share also includes net pre -tax gain s of approximately $44 million or $0.21 per diluted share \nassociated with McKesson Ventures' equity investments.  \n \n In wrapping up our consolidated results, fourth quarter diluted weighted average shares were $161 million, a \ndecrease of 8% year -over-year, dr iven by the successful tax re -exit of our investment in Change Healthcare at the \nend of fiscal 2020 and other open -market share repurchase activity. ", "original_text": "Interest expense was $52 million in the quarter, \na decline of 20% compared to the prior year, driv en by the retirement of approximately $1 billion of debt and lower \ncommercial paper balances.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ccfb14eb95af6c63370f45a07b22095a996ac506e779b579ae54b1c811e71009", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8419f3f-4c67-4bec-9ca5-2e0cd21f6c84", "node_type": "1", "metadata": {"window": "When \nexcluding the $ 55 million contributed by Change Healthcare in the fourth quarter of fiscal 2020, which was \npreviously recorded in Other; adjusted operating profit grew 19%.  Interest expense was $52 million in the quarter, \na decline of 20% compared to the prior year, driv en by the retirement of approximately $1 billion of debt and lower \ncommercial paper balances.  \n \n Our adjusted tax rate was 22.9% for the quarter, in line with our expectations.  Fourth quarter adjusted earnings \nper diluted share also includes net pre -tax gain s of approximately $44 million or $0.21 per diluted share \nassociated with McKesson Ventures' equity investments.  \n \n In wrapping up our consolidated results, fourth quarter diluted weighted average shares were $161 million, a \ndecrease of 8% year -over-year, dr iven by the successful tax re -exit of our investment in Change Healthcare at the \nend of fiscal 2020 and other open -market share repurchase activity.  As a reminder, the exit of our Change \nHealthcare investment lowered our shares outstanding by approximately  15.4 million shares.  \n \n Moving now to our fourth quarter segment results which can be found on slides 5 through 9, starting with US \nPharmaceutical. ", "original_text": "Fourth quarter adjusted earnings \nper diluted share also includes net pre -tax gain s of approximately $44 million or $0.21 per diluted share \nassociated with McKesson Ventures' equity investments.  \n \n"}, "hash": "31d4bcedbd42085a908fb71d782bbe513fbf6c3f256cea93d804318fc6bb617d", "class_name": "RelatedNodeInfo"}}, "text": "Our adjusted tax rate was 22.9% for the quarter, in line with our expectations. ", "start_char_idx": 2829, "end_char_idx": 2909, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8419f3f-4c67-4bec-9ca5-2e0cd21f6c84": {"__data__": {"id_": "c8419f3f-4c67-4bec-9ca5-2e0cd21f6c84", "embedding": null, "metadata": {"window": "When \nexcluding the $ 55 million contributed by Change Healthcare in the fourth quarter of fiscal 2020, which was \npreviously recorded in Other; adjusted operating profit grew 19%.  Interest expense was $52 million in the quarter, \na decline of 20% compared to the prior year, driv en by the retirement of approximately $1 billion of debt and lower \ncommercial paper balances.  \n \n Our adjusted tax rate was 22.9% for the quarter, in line with our expectations.  Fourth quarter adjusted earnings \nper diluted share also includes net pre -tax gain s of approximately $44 million or $0.21 per diluted share \nassociated with McKesson Ventures' equity investments.  \n \n In wrapping up our consolidated results, fourth quarter diluted weighted average shares were $161 million, a \ndecrease of 8% year -over-year, dr iven by the successful tax re -exit of our investment in Change Healthcare at the \nend of fiscal 2020 and other open -market share repurchase activity.  As a reminder, the exit of our Change \nHealthcare investment lowered our shares outstanding by approximately  15.4 million shares.  \n \n Moving now to our fourth quarter segment results which can be found on slides 5 through 9, starting with US \nPharmaceutical. ", "original_text": "Fourth quarter adjusted earnings \nper diluted share also includes net pre -tax gain s of approximately $44 million or $0.21 per diluted share \nassociated with McKesson Ventures' equity investments.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47c99048-affb-49f7-9b53-d38a3f456c08", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46a5839a97deec04bfaf8e0e8f72d85840f7b4b9c1be3b14f6c88546777d22d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a1f3a6f-7d36-400e-85e2-4a161574f43c", "node_type": "1", "metadata": {"window": "2 billion for the quarter, an increase of 12% compared to the prior year.  When \nexcluding the $ 55 million contributed by Change Healthcare in the fourth quarter of fiscal 2020, which was \npreviously recorded in Other; adjusted operating profit grew 19%.  Interest expense was $52 million in the quarter, \na decline of 20% compared to the prior year, driv en by the retirement of approximately $1 billion of debt and lower \ncommercial paper balances.  \n \n Our adjusted tax rate was 22.9% for the quarter, in line with our expectations.  Fourth quarter adjusted earnings \nper diluted share also includes net pre -tax gain s of approximately $44 million or $0.21 per diluted share \nassociated with McKesson Ventures' equity investments.  \n \n In wrapping up our consolidated results, fourth quarter diluted weighted average shares were $161 million, a \ndecrease of 8% year -over-year, dr iven by the successful tax re -exit of our investment in Change Healthcare at the \nend of fiscal 2020 and other open -market share repurchase activity.  As a reminder, the exit of our Change \nHealthcare investment lowered our shares outstanding by approximately  15.4 million shares.  \n \n", "original_text": "Our adjusted tax rate was 22.9% for the quarter, in line with our expectations. ", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1136b5186d1f7dd6ff37ee03554f3519e8c32ccfa3a2c3af563237cd79beacec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71001735-dc83-4864-a502-df1c3eef5288", "node_type": "1", "metadata": {"window": "Interest expense was $52 million in the quarter, \na decline of 20% compared to the prior year, driv en by the retirement of approximately $1 billion of debt and lower \ncommercial paper balances.  \n \n Our adjusted tax rate was 22.9% for the quarter, in line with our expectations.  Fourth quarter adjusted earnings \nper diluted share also includes net pre -tax gain s of approximately $44 million or $0.21 per diluted share \nassociated with McKesson Ventures' equity investments.  \n \n In wrapping up our consolidated results, fourth quarter diluted weighted average shares were $161 million, a \ndecrease of 8% year -over-year, dr iven by the successful tax re -exit of our investment in Change Healthcare at the \nend of fiscal 2020 and other open -market share repurchase activity.  As a reminder, the exit of our Change \nHealthcare investment lowered our shares outstanding by approximately  15.4 million shares.  \n \n Moving now to our fourth quarter segment results which can be found on slides 5 through 9, starting with US \nPharmaceutical.  Revenues were $47 billion, an increase of 3%, driven by market growth and higher volumes from \nretail national  account customers, partially offset by the prior year increase in demand driven by the onset of the \nCOVID -19 pandemic and branded -to-generic conversions.  \n ", "original_text": "In wrapping up our consolidated results, fourth quarter diluted weighted average shares were $161 million, a \ndecrease of 8% year -over-year, dr iven by the successful tax re -exit of our investment in Change Healthcare at the \nend of fiscal 2020 and other open -market share repurchase activity. "}, "hash": "46e8d8dd2f5cba9db507b83eea6e5b513f1892752d6f7765aaca357dbfb504d7", "class_name": "RelatedNodeInfo"}}, "text": "Fourth quarter adjusted earnings \nper diluted share also includes net pre -tax gain s of approximately $44 million or $0.21 per diluted share \nassociated with McKesson Ventures' equity investments.  \n \n", "start_char_idx": 2909, "end_char_idx": 3111, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71001735-dc83-4864-a502-df1c3eef5288": {"__data__": {"id_": "71001735-dc83-4864-a502-df1c3eef5288", "embedding": null, "metadata": {"window": "Interest expense was $52 million in the quarter, \na decline of 20% compared to the prior year, driv en by the retirement of approximately $1 billion of debt and lower \ncommercial paper balances.  \n \n Our adjusted tax rate was 22.9% for the quarter, in line with our expectations.  Fourth quarter adjusted earnings \nper diluted share also includes net pre -tax gain s of approximately $44 million or $0.21 per diluted share \nassociated with McKesson Ventures' equity investments.  \n \n In wrapping up our consolidated results, fourth quarter diluted weighted average shares were $161 million, a \ndecrease of 8% year -over-year, dr iven by the successful tax re -exit of our investment in Change Healthcare at the \nend of fiscal 2020 and other open -market share repurchase activity.  As a reminder, the exit of our Change \nHealthcare investment lowered our shares outstanding by approximately  15.4 million shares.  \n \n Moving now to our fourth quarter segment results which can be found on slides 5 through 9, starting with US \nPharmaceutical.  Revenues were $47 billion, an increase of 3%, driven by market growth and higher volumes from \nretail national  account customers, partially offset by the prior year increase in demand driven by the onset of the \nCOVID -19 pandemic and branded -to-generic conversions.  \n ", "original_text": "In wrapping up our consolidated results, fourth quarter diluted weighted average shares were $161 million, a \ndecrease of 8% year -over-year, dr iven by the successful tax re -exit of our investment in Change Healthcare at the \nend of fiscal 2020 and other open -market share repurchase activity. ", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47c99048-affb-49f7-9b53-d38a3f456c08", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46a5839a97deec04bfaf8e0e8f72d85840f7b4b9c1be3b14f6c88546777d22d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8419f3f-4c67-4bec-9ca5-2e0cd21f6c84", "node_type": "1", "metadata": {"window": "When \nexcluding the $ 55 million contributed by Change Healthcare in the fourth quarter of fiscal 2020, which was \npreviously recorded in Other; adjusted operating profit grew 19%.  Interest expense was $52 million in the quarter, \na decline of 20% compared to the prior year, driv en by the retirement of approximately $1 billion of debt and lower \ncommercial paper balances.  \n \n Our adjusted tax rate was 22.9% for the quarter, in line with our expectations.  Fourth quarter adjusted earnings \nper diluted share also includes net pre -tax gain s of approximately $44 million or $0.21 per diluted share \nassociated with McKesson Ventures' equity investments.  \n \n In wrapping up our consolidated results, fourth quarter diluted weighted average shares were $161 million, a \ndecrease of 8% year -over-year, dr iven by the successful tax re -exit of our investment in Change Healthcare at the \nend of fiscal 2020 and other open -market share repurchase activity.  As a reminder, the exit of our Change \nHealthcare investment lowered our shares outstanding by approximately  15.4 million shares.  \n \n Moving now to our fourth quarter segment results which can be found on slides 5 through 9, starting with US \nPharmaceutical. ", "original_text": "Fourth quarter adjusted earnings \nper diluted share also includes net pre -tax gain s of approximately $44 million or $0.21 per diluted share \nassociated with McKesson Ventures' equity investments.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8570b7f5c9949d2c0ac9e88d55eb5a6dd5e7f859b71962225b2e7364202acf3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d49aefcc-2f24-4c7b-9ead-09ad2689d802", "node_type": "1", "metadata": {"window": "Our adjusted tax rate was 22.9% for the quarter, in line with our expectations.  Fourth quarter adjusted earnings \nper diluted share also includes net pre -tax gain s of approximately $44 million or $0.21 per diluted share \nassociated with McKesson Ventures' equity investments.  \n \n In wrapping up our consolidated results, fourth quarter diluted weighted average shares were $161 million, a \ndecrease of 8% year -over-year, dr iven by the successful tax re -exit of our investment in Change Healthcare at the \nend of fiscal 2020 and other open -market share repurchase activity.  As a reminder, the exit of our Change \nHealthcare investment lowered our shares outstanding by approximately  15.4 million shares.  \n \n Moving now to our fourth quarter segment results which can be found on slides 5 through 9, starting with US \nPharmaceutical.  Revenues were $47 billion, an increase of 3%, driven by market growth and higher volumes from \nretail national  account customers, partially offset by the prior year increase in demand driven by the onset of the \nCOVID -19 pandemic and branded -to-generic conversions.  \n ", "original_text": "As a reminder, the exit of our Change \nHealthcare investment lowered our shares outstanding by approximately  15.4 million shares.  \n \n"}, "hash": "f9fd61684f8c61fe8f6f029868202ad16909b31e9cdd1aeffffe9b27ab92bd69", "class_name": "RelatedNodeInfo"}}, "text": "In wrapping up our consolidated results, fourth quarter diluted weighted average shares were $161 million, a \ndecrease of 8% year -over-year, dr iven by the successful tax re -exit of our investment in Change Healthcare at the \nend of fiscal 2020 and other open -market share repurchase activity. ", "start_char_idx": 3111, "end_char_idx": 3408, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d49aefcc-2f24-4c7b-9ead-09ad2689d802": {"__data__": {"id_": "d49aefcc-2f24-4c7b-9ead-09ad2689d802", "embedding": null, "metadata": {"window": "Our adjusted tax rate was 22.9% for the quarter, in line with our expectations.  Fourth quarter adjusted earnings \nper diluted share also includes net pre -tax gain s of approximately $44 million or $0.21 per diluted share \nassociated with McKesson Ventures' equity investments.  \n \n In wrapping up our consolidated results, fourth quarter diluted weighted average shares were $161 million, a \ndecrease of 8% year -over-year, dr iven by the successful tax re -exit of our investment in Change Healthcare at the \nend of fiscal 2020 and other open -market share repurchase activity.  As a reminder, the exit of our Change \nHealthcare investment lowered our shares outstanding by approximately  15.4 million shares.  \n \n Moving now to our fourth quarter segment results which can be found on slides 5 through 9, starting with US \nPharmaceutical.  Revenues were $47 billion, an increase of 3%, driven by market growth and higher volumes from \nretail national  account customers, partially offset by the prior year increase in demand driven by the onset of the \nCOVID -19 pandemic and branded -to-generic conversions.  \n ", "original_text": "As a reminder, the exit of our Change \nHealthcare investment lowered our shares outstanding by approximately  15.4 million shares.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47c99048-affb-49f7-9b53-d38a3f456c08", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46a5839a97deec04bfaf8e0e8f72d85840f7b4b9c1be3b14f6c88546777d22d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71001735-dc83-4864-a502-df1c3eef5288", "node_type": "1", "metadata": {"window": "Interest expense was $52 million in the quarter, \na decline of 20% compared to the prior year, driv en by the retirement of approximately $1 billion of debt and lower \ncommercial paper balances.  \n \n Our adjusted tax rate was 22.9% for the quarter, in line with our expectations.  Fourth quarter adjusted earnings \nper diluted share also includes net pre -tax gain s of approximately $44 million or $0.21 per diluted share \nassociated with McKesson Ventures' equity investments.  \n \n In wrapping up our consolidated results, fourth quarter diluted weighted average shares were $161 million, a \ndecrease of 8% year -over-year, dr iven by the successful tax re -exit of our investment in Change Healthcare at the \nend of fiscal 2020 and other open -market share repurchase activity.  As a reminder, the exit of our Change \nHealthcare investment lowered our shares outstanding by approximately  15.4 million shares.  \n \n Moving now to our fourth quarter segment results which can be found on slides 5 through 9, starting with US \nPharmaceutical.  Revenues were $47 billion, an increase of 3%, driven by market growth and higher volumes from \nretail national  account customers, partially offset by the prior year increase in demand driven by the onset of the \nCOVID -19 pandemic and branded -to-generic conversions.  \n ", "original_text": "In wrapping up our consolidated results, fourth quarter diluted weighted average shares were $161 million, a \ndecrease of 8% year -over-year, dr iven by the successful tax re -exit of our investment in Change Healthcare at the \nend of fiscal 2020 and other open -market share repurchase activity. ", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df894192b95d95d4b91432f93204f35a5b58689f6be947ea51066ef8f6178769", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bdc2b03e-7a09-4f51-9596-a5f4bf94b440", "node_type": "1", "metadata": {"window": "Fourth quarter adjusted earnings \nper diluted share also includes net pre -tax gain s of approximately $44 million or $0.21 per diluted share \nassociated with McKesson Ventures' equity investments.  \n \n In wrapping up our consolidated results, fourth quarter diluted weighted average shares were $161 million, a \ndecrease of 8% year -over-year, dr iven by the successful tax re -exit of our investment in Change Healthcare at the \nend of fiscal 2020 and other open -market share repurchase activity.  As a reminder, the exit of our Change \nHealthcare investment lowered our shares outstanding by approximately  15.4 million shares.  \n \n Moving now to our fourth quarter segment results which can be found on slides 5 through 9, starting with US \nPharmaceutical.  Revenues were $47 billion, an increase of 3%, driven by market growth and higher volumes from \nretail national  account customers, partially offset by the prior year increase in demand driven by the onset of the \nCOVID -19 pandemic and branded -to-generic conversions.  \n ", "original_text": "Moving now to our fourth quarter segment results which can be found on slides 5 through 9, starting with US \nPharmaceutical. "}, "hash": "ebd9e7ae6dbc47187cecef374ae8d47a86e470b293500310f65c6a9444f34373", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, the exit of our Change \nHealthcare investment lowered our shares outstanding by approximately  15.4 million shares.  \n \n", "start_char_idx": 3408, "end_char_idx": 3543, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bdc2b03e-7a09-4f51-9596-a5f4bf94b440": {"__data__": {"id_": "bdc2b03e-7a09-4f51-9596-a5f4bf94b440", "embedding": null, "metadata": {"window": "Fourth quarter adjusted earnings \nper diluted share also includes net pre -tax gain s of approximately $44 million or $0.21 per diluted share \nassociated with McKesson Ventures' equity investments.  \n \n In wrapping up our consolidated results, fourth quarter diluted weighted average shares were $161 million, a \ndecrease of 8% year -over-year, dr iven by the successful tax re -exit of our investment in Change Healthcare at the \nend of fiscal 2020 and other open -market share repurchase activity.  As a reminder, the exit of our Change \nHealthcare investment lowered our shares outstanding by approximately  15.4 million shares.  \n \n Moving now to our fourth quarter segment results which can be found on slides 5 through 9, starting with US \nPharmaceutical.  Revenues were $47 billion, an increase of 3%, driven by market growth and higher volumes from \nretail national  account customers, partially offset by the prior year increase in demand driven by the onset of the \nCOVID -19 pandemic and branded -to-generic conversions.  \n ", "original_text": "Moving now to our fourth quarter segment results which can be found on slides 5 through 9, starting with US \nPharmaceutical. ", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47c99048-affb-49f7-9b53-d38a3f456c08", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46a5839a97deec04bfaf8e0e8f72d85840f7b4b9c1be3b14f6c88546777d22d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d49aefcc-2f24-4c7b-9ead-09ad2689d802", "node_type": "1", "metadata": {"window": "Our adjusted tax rate was 22.9% for the quarter, in line with our expectations.  Fourth quarter adjusted earnings \nper diluted share also includes net pre -tax gain s of approximately $44 million or $0.21 per diluted share \nassociated with McKesson Ventures' equity investments.  \n \n In wrapping up our consolidated results, fourth quarter diluted weighted average shares were $161 million, a \ndecrease of 8% year -over-year, dr iven by the successful tax re -exit of our investment in Change Healthcare at the \nend of fiscal 2020 and other open -market share repurchase activity.  As a reminder, the exit of our Change \nHealthcare investment lowered our shares outstanding by approximately  15.4 million shares.  \n \n Moving now to our fourth quarter segment results which can be found on slides 5 through 9, starting with US \nPharmaceutical.  Revenues were $47 billion, an increase of 3%, driven by market growth and higher volumes from \nretail national  account customers, partially offset by the prior year increase in demand driven by the onset of the \nCOVID -19 pandemic and branded -to-generic conversions.  \n ", "original_text": "As a reminder, the exit of our Change \nHealthcare investment lowered our shares outstanding by approximately  15.4 million shares.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a150eb5b07e97bb369f3ba4dd52c9c9bbe8927df63a47020f36263d4566c828d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35813a01-9550-4954-b3e7-1c50b4ae7b7e", "node_type": "1", "metadata": {"window": "In wrapping up our consolidated results, fourth quarter diluted weighted average shares were $161 million, a \ndecrease of 8% year -over-year, dr iven by the successful tax re -exit of our investment in Change Healthcare at the \nend of fiscal 2020 and other open -market share repurchase activity.  As a reminder, the exit of our Change \nHealthcare investment lowered our shares outstanding by approximately  15.4 million shares.  \n \n Moving now to our fourth quarter segment results which can be found on slides 5 through 9, starting with US \nPharmaceutical.  Revenues were $47 billion, an increase of 3%, driven by market growth and higher volumes from \nretail national  account customers, partially offset by the prior year increase in demand driven by the onset of the \nCOVID -19 pandemic and branded -to-generic conversions.  \n ", "original_text": "Revenues were $47 billion, an increase of 3%, driven by market growth and higher volumes from \nretail national  account customers, partially offset by the prior year increase in demand driven by the onset of the \nCOVID -19 pandemic and branded -to-generic conversions.  \n "}, "hash": "82ac0c40d9676c432b82bcf681cf1e3240695096ed16ecc682018bf73ec58195", "class_name": "RelatedNodeInfo"}}, "text": "Moving now to our fourth quarter segment results which can be found on slides 5 through 9, starting with US \nPharmaceutical. ", "start_char_idx": 3543, "end_char_idx": 3668, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35813a01-9550-4954-b3e7-1c50b4ae7b7e": {"__data__": {"id_": "35813a01-9550-4954-b3e7-1c50b4ae7b7e", "embedding": null, "metadata": {"window": "In wrapping up our consolidated results, fourth quarter diluted weighted average shares were $161 million, a \ndecrease of 8% year -over-year, dr iven by the successful tax re -exit of our investment in Change Healthcare at the \nend of fiscal 2020 and other open -market share repurchase activity.  As a reminder, the exit of our Change \nHealthcare investment lowered our shares outstanding by approximately  15.4 million shares.  \n \n Moving now to our fourth quarter segment results which can be found on slides 5 through 9, starting with US \nPharmaceutical.  Revenues were $47 billion, an increase of 3%, driven by market growth and higher volumes from \nretail national  account customers, partially offset by the prior year increase in demand driven by the onset of the \nCOVID -19 pandemic and branded -to-generic conversions.  \n ", "original_text": "Revenues were $47 billion, an increase of 3%, driven by market growth and higher volumes from \nretail national  account customers, partially offset by the prior year increase in demand driven by the onset of the \nCOVID -19 pandemic and branded -to-generic conversions.  \n ", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47c99048-affb-49f7-9b53-d38a3f456c08", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46a5839a97deec04bfaf8e0e8f72d85840f7b4b9c1be3b14f6c88546777d22d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bdc2b03e-7a09-4f51-9596-a5f4bf94b440", "node_type": "1", "metadata": {"window": "Fourth quarter adjusted earnings \nper diluted share also includes net pre -tax gain s of approximately $44 million or $0.21 per diluted share \nassociated with McKesson Ventures' equity investments.  \n \n In wrapping up our consolidated results, fourth quarter diluted weighted average shares were $161 million, a \ndecrease of 8% year -over-year, dr iven by the successful tax re -exit of our investment in Change Healthcare at the \nend of fiscal 2020 and other open -market share repurchase activity.  As a reminder, the exit of our Change \nHealthcare investment lowered our shares outstanding by approximately  15.4 million shares.  \n \n Moving now to our fourth quarter segment results which can be found on slides 5 through 9, starting with US \nPharmaceutical.  Revenues were $47 billion, an increase of 3%, driven by market growth and higher volumes from \nretail national  account customers, partially offset by the prior year increase in demand driven by the onset of the \nCOVID -19 pandemic and branded -to-generic conversions.  \n ", "original_text": "Moving now to our fourth quarter segment results which can be found on slides 5 through 9, starting with US \nPharmaceutical. ", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bb25efed819449de779b1f72cd069ac640d37e81a7330af6131c78c8d04d365b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94d72ad1-19b2-4ffb-bea7-ea9081d9505c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 7% to $813 million driven by the contribution fro m COVID -19 \nvaccine distribution, partially offset by the previously mentioned prior year COVID pandemic impact and higher \noperating costs in support of the company's oncology growth initiatives and the impact of a weak cold and flu \nseason.  \n \n Adjusted operat ing profit for the full year increased 3% to $2.7 billion driven by growth in specialty product \ndistribution and contribution from COVID -19 vaccine distribution, offset by the previously mentioned prior year \nincrease in demand driven by the onset of the pa ndemic and by higher operating costs in support of the \ncompany's oncology growth initiatives.  \n \n Next on to Prescription Technology Solutions. ", "original_text": "McKesson Corp.  "}, "hash": "0702571d3576844a593bb8f97bddf2c9d48900e16cfd78bf722608219e6790ef", "class_name": "RelatedNodeInfo"}}, "text": "Revenues were $47 billion, an increase of 3%, driven by market growth and higher volumes from \nretail national  account customers, partially offset by the prior year increase in demand driven by the onset of the \nCOVID -19 pandemic and branded -to-generic conversions.  \n ", "start_char_idx": 3668, "end_char_idx": 3940, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94d72ad1-19b2-4ffb-bea7-ea9081d9505c": {"__data__": {"id_": "94d72ad1-19b2-4ffb-bea7-ea9081d9505c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 7% to $813 million driven by the contribution fro m COVID -19 \nvaccine distribution, partially offset by the previously mentioned prior year COVID pandemic impact and higher \noperating costs in support of the company's oncology growth initiatives and the impact of a weak cold and flu \nseason.  \n \n Adjusted operat ing profit for the full year increased 3% to $2.7 billion driven by growth in specialty product \ndistribution and contribution from COVID -19 vaccine distribution, offset by the previously mentioned prior year \nincrease in demand driven by the onset of the pa ndemic and by higher operating costs in support of the \ncompany's oncology growth initiatives.  \n \n Next on to Prescription Technology Solutions. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4229d4351894ca10fe32a58b3b00ca3385f146d5f133963d7d9758a0b1f10fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35813a01-9550-4954-b3e7-1c50b4ae7b7e", "node_type": "1", "metadata": {"window": "In wrapping up our consolidated results, fourth quarter diluted weighted average shares were $161 million, a \ndecrease of 8% year -over-year, dr iven by the successful tax re -exit of our investment in Change Healthcare at the \nend of fiscal 2020 and other open -market share repurchase activity.  As a reminder, the exit of our Change \nHealthcare investment lowered our shares outstanding by approximately  15.4 million shares.  \n \n Moving now to our fourth quarter segment results which can be found on slides 5 through 9, starting with US \nPharmaceutical.  Revenues were $47 billion, an increase of 3%, driven by market growth and higher volumes from \nretail national  account customers, partially offset by the prior year increase in demand driven by the onset of the \nCOVID -19 pandemic and branded -to-generic conversions.  \n ", "original_text": "Revenues were $47 billion, an increase of 3%, driven by market growth and higher volumes from \nretail national  account customers, partially offset by the prior year increase in demand driven by the onset of the \nCOVID -19 pandemic and branded -to-generic conversions.  \n ", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c25b3913e0319dbf281d4b2008a79aaf9b96f1a8b3121c3bb07797e897a3d51f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e689fbf3-e647-4578-8588-44b4e154696f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 7% to $813 million driven by the contribution fro m COVID -19 \nvaccine distribution, partially offset by the previously mentioned prior year COVID pandemic impact and higher \noperating costs in support of the company's oncology growth initiatives and the impact of a weak cold and flu \nseason.  \n \n Adjusted operat ing profit for the full year increased 3% to $2.7 billion driven by growth in specialty product \ndistribution and contribution from COVID -19 vaccine distribution, offset by the previously mentioned prior year \nincrease in demand driven by the onset of the pa ndemic and by higher operating costs in support of the \ncompany's oncology growth initiatives.  \n \n Next on to Prescription Technology Solutions.  Revenues in the quarter were $789 million, an increase of 7%, \ndriven by higher volumes of technology and service of ferings to support biopharma customers. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 7% to $813 million driven by the contribution fro m COVID -19 \nvaccine distribution, partially offset by the previously mentioned prior year COVID pandemic impact and higher \noperating costs in support of the company's oncology growth initiatives and the impact of a weak cold and flu \nseason.  \n \n"}, "hash": "bf17831a4e9085e40284b19a0e22d91f621bfd8f66cb69589673b40f2f98905e", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e689fbf3-e647-4578-8588-44b4e154696f": {"__data__": {"id_": "e689fbf3-e647-4578-8588-44b4e154696f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 7% to $813 million driven by the contribution fro m COVID -19 \nvaccine distribution, partially offset by the previously mentioned prior year COVID pandemic impact and higher \noperating costs in support of the company's oncology growth initiatives and the impact of a weak cold and flu \nseason.  \n \n Adjusted operat ing profit for the full year increased 3% to $2.7 billion driven by growth in specialty product \ndistribution and contribution from COVID -19 vaccine distribution, offset by the previously mentioned prior year \nincrease in demand driven by the onset of the pa ndemic and by higher operating costs in support of the \ncompany's oncology growth initiatives.  \n \n Next on to Prescription Technology Solutions.  Revenues in the quarter were $789 million, an increase of 7%, \ndriven by higher volumes of technology and service of ferings to support biopharma customers. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 7% to $813 million driven by the contribution fro m COVID -19 \nvaccine distribution, partially offset by the previously mentioned prior year COVID pandemic impact and higher \noperating costs in support of the company's oncology growth initiatives and the impact of a weak cold and flu \nseason.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4229d4351894ca10fe32a58b3b00ca3385f146d5f133963d7d9758a0b1f10fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94d72ad1-19b2-4ffb-bea7-ea9081d9505c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 7% to $813 million driven by the contribution fro m COVID -19 \nvaccine distribution, partially offset by the previously mentioned prior year COVID pandemic impact and higher \noperating costs in support of the company's oncology growth initiatives and the impact of a weak cold and flu \nseason.  \n \n Adjusted operat ing profit for the full year increased 3% to $2.7 billion driven by growth in specialty product \ndistribution and contribution from COVID -19 vaccine distribution, offset by the previously mentioned prior year \nincrease in demand driven by the onset of the pa ndemic and by higher operating costs in support of the \ncompany's oncology growth initiatives.  \n \n Next on to Prescription Technology Solutions. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "321ff0802bd9ee4c30ff8c7127f498db04d831448d8a651198b96ff001b764b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "350ef8a8-b6dd-4234-8aa1-cea6f3332949", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 7% to $813 million driven by the contribution fro m COVID -19 \nvaccine distribution, partially offset by the previously mentioned prior year COVID pandemic impact and higher \noperating costs in support of the company's oncology growth initiatives and the impact of a weak cold and flu \nseason.  \n \n Adjusted operat ing profit for the full year increased 3% to $2.7 billion driven by growth in specialty product \ndistribution and contribution from COVID -19 vaccine distribution, offset by the previously mentioned prior year \nincrease in demand driven by the onset of the pa ndemic and by higher operating costs in support of the \ncompany's oncology growth initiatives.  \n \n Next on to Prescription Technology Solutions.  Revenues in the quarter were $789 million, an increase of 7%, \ndriven by higher volumes of technology and service of ferings to support biopharma customers.  Adjusted operating \nprofit in the quarter increased 11% to $146 million driven by organic growth from access and adherence programs \nsupported by our Technology Solutions. ", "original_text": "Adjusted operat ing profit for the full year increased 3% to $2.7 billion driven by growth in specialty product \ndistribution and contribution from COVID -19 vaccine distribution, offset by the previously mentioned prior year \nincrease in demand driven by the onset of the pa ndemic and by higher operating costs in support of the \ncompany's oncology growth initiatives.  \n \n"}, "hash": "97d91e15d92ca036a69323368cf9bdc413ceda14096b87fc01fce32d4ddd9f5a", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 7% to $813 million driven by the contribution fro m COVID -19 \nvaccine distribution, partially offset by the previously mentioned prior year COVID pandemic impact and higher \noperating costs in support of the company's oncology growth initiatives and the impact of a weak cold and flu \nseason.  \n \n", "start_char_idx": 16, "end_char_idx": 529, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "350ef8a8-b6dd-4234-8aa1-cea6f3332949": {"__data__": {"id_": "350ef8a8-b6dd-4234-8aa1-cea6f3332949", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 7% to $813 million driven by the contribution fro m COVID -19 \nvaccine distribution, partially offset by the previously mentioned prior year COVID pandemic impact and higher \noperating costs in support of the company's oncology growth initiatives and the impact of a weak cold and flu \nseason.  \n \n Adjusted operat ing profit for the full year increased 3% to $2.7 billion driven by growth in specialty product \ndistribution and contribution from COVID -19 vaccine distribution, offset by the previously mentioned prior year \nincrease in demand driven by the onset of the pa ndemic and by higher operating costs in support of the \ncompany's oncology growth initiatives.  \n \n Next on to Prescription Technology Solutions.  Revenues in the quarter were $789 million, an increase of 7%, \ndriven by higher volumes of technology and service of ferings to support biopharma customers.  Adjusted operating \nprofit in the quarter increased 11% to $146 million driven by organic growth from access and adherence programs \nsupported by our Technology Solutions. ", "original_text": "Adjusted operat ing profit for the full year increased 3% to $2.7 billion driven by growth in specialty product \ndistribution and contribution from COVID -19 vaccine distribution, offset by the previously mentioned prior year \nincrease in demand driven by the onset of the pa ndemic and by higher operating costs in support of the \ncompany's oncology growth initiatives.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4229d4351894ca10fe32a58b3b00ca3385f146d5f133963d7d9758a0b1f10fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e689fbf3-e647-4578-8588-44b4e154696f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 7% to $813 million driven by the contribution fro m COVID -19 \nvaccine distribution, partially offset by the previously mentioned prior year COVID pandemic impact and higher \noperating costs in support of the company's oncology growth initiatives and the impact of a weak cold and flu \nseason.  \n \n Adjusted operat ing profit for the full year increased 3% to $2.7 billion driven by growth in specialty product \ndistribution and contribution from COVID -19 vaccine distribution, offset by the previously mentioned prior year \nincrease in demand driven by the onset of the pa ndemic and by higher operating costs in support of the \ncompany's oncology growth initiatives.  \n \n Next on to Prescription Technology Solutions.  Revenues in the quarter were $789 million, an increase of 7%, \ndriven by higher volumes of technology and service of ferings to support biopharma customers. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 7% to $813 million driven by the contribution fro m COVID -19 \nvaccine distribution, partially offset by the previously mentioned prior year COVID pandemic impact and higher \noperating costs in support of the company's oncology growth initiatives and the impact of a weak cold and flu \nseason.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1148d0c61f4d163b6c25b84a7e9846e971546941cc63427c012c9e85d4298cbd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6cfc4e5e-cec3-46cc-83a7-e4f3edfb1926", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 7% to $813 million driven by the contribution fro m COVID -19 \nvaccine distribution, partially offset by the previously mentioned prior year COVID pandemic impact and higher \noperating costs in support of the company's oncology growth initiatives and the impact of a weak cold and flu \nseason.  \n \n Adjusted operat ing profit for the full year increased 3% to $2.7 billion driven by growth in specialty product \ndistribution and contribution from COVID -19 vaccine distribution, offset by the previously mentioned prior year \nincrease in demand driven by the onset of the pa ndemic and by higher operating costs in support of the \ncompany's oncology growth initiatives.  \n \n Next on to Prescription Technology Solutions.  Revenues in the quarter were $789 million, an increase of 7%, \ndriven by higher volumes of technology and service of ferings to support biopharma customers.  Adjusted operating \nprofit in the quarter increased 11% to $146 million driven by organic growth from access and adherence programs \nsupported by our Technology Solutions.  Full year adjusted operating profit was $467 m illion, which was flat to the \nprior year, as organic growth from access and adherence solutions was offset by higher investment costs to \nsupport the growth in the company's biopharma strategy. ", "original_text": "Next on to Prescription Technology Solutions. "}, "hash": "cf716e68420a6d63e79785894a76defc22d8acb0d53e603b6227e2856d4da6df", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operat ing profit for the full year increased 3% to $2.7 billion driven by growth in specialty product \ndistribution and contribution from COVID -19 vaccine distribution, offset by the previously mentioned prior year \nincrease in demand driven by the onset of the pa ndemic and by higher operating costs in support of the \ncompany's oncology growth initiatives.  \n \n", "start_char_idx": 529, "end_char_idx": 904, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6cfc4e5e-cec3-46cc-83a7-e4f3edfb1926": {"__data__": {"id_": "6cfc4e5e-cec3-46cc-83a7-e4f3edfb1926", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 7% to $813 million driven by the contribution fro m COVID -19 \nvaccine distribution, partially offset by the previously mentioned prior year COVID pandemic impact and higher \noperating costs in support of the company's oncology growth initiatives and the impact of a weak cold and flu \nseason.  \n \n Adjusted operat ing profit for the full year increased 3% to $2.7 billion driven by growth in specialty product \ndistribution and contribution from COVID -19 vaccine distribution, offset by the previously mentioned prior year \nincrease in demand driven by the onset of the pa ndemic and by higher operating costs in support of the \ncompany's oncology growth initiatives.  \n \n Next on to Prescription Technology Solutions.  Revenues in the quarter were $789 million, an increase of 7%, \ndriven by higher volumes of technology and service of ferings to support biopharma customers.  Adjusted operating \nprofit in the quarter increased 11% to $146 million driven by organic growth from access and adherence programs \nsupported by our Technology Solutions.  Full year adjusted operating profit was $467 m illion, which was flat to the \nprior year, as organic growth from access and adherence solutions was offset by higher investment costs to \nsupport the growth in the company's biopharma strategy. ", "original_text": "Next on to Prescription Technology Solutions. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4229d4351894ca10fe32a58b3b00ca3385f146d5f133963d7d9758a0b1f10fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "350ef8a8-b6dd-4234-8aa1-cea6f3332949", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 7% to $813 million driven by the contribution fro m COVID -19 \nvaccine distribution, partially offset by the previously mentioned prior year COVID pandemic impact and higher \noperating costs in support of the company's oncology growth initiatives and the impact of a weak cold and flu \nseason.  \n \n Adjusted operat ing profit for the full year increased 3% to $2.7 billion driven by growth in specialty product \ndistribution and contribution from COVID -19 vaccine distribution, offset by the previously mentioned prior year \nincrease in demand driven by the onset of the pa ndemic and by higher operating costs in support of the \ncompany's oncology growth initiatives.  \n \n Next on to Prescription Technology Solutions.  Revenues in the quarter were $789 million, an increase of 7%, \ndriven by higher volumes of technology and service of ferings to support biopharma customers.  Adjusted operating \nprofit in the quarter increased 11% to $146 million driven by organic growth from access and adherence programs \nsupported by our Technology Solutions. ", "original_text": "Adjusted operat ing profit for the full year increased 3% to $2.7 billion driven by growth in specialty product \ndistribution and contribution from COVID -19 vaccine distribution, offset by the previously mentioned prior year \nincrease in demand driven by the onset of the pa ndemic and by higher operating costs in support of the \ncompany's oncology growth initiatives.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6a112b22a45279332933338ccfdc0d258882ba00c1585ab9af0decf9adf3ae6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9b4917f-c11c-4126-82ba-9a375786dd13", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 7% to $813 million driven by the contribution fro m COVID -19 \nvaccine distribution, partially offset by the previously mentioned prior year COVID pandemic impact and higher \noperating costs in support of the company's oncology growth initiatives and the impact of a weak cold and flu \nseason.  \n \n Adjusted operat ing profit for the full year increased 3% to $2.7 billion driven by growth in specialty product \ndistribution and contribution from COVID -19 vaccine distribution, offset by the previously mentioned prior year \nincrease in demand driven by the onset of the pa ndemic and by higher operating costs in support of the \ncompany's oncology growth initiatives.  \n \n Next on to Prescription Technology Solutions.  Revenues in the quarter were $789 million, an increase of 7%, \ndriven by higher volumes of technology and service of ferings to support biopharma customers.  Adjusted operating \nprofit in the quarter increased 11% to $146 million driven by organic growth from access and adherence programs \nsupported by our Technology Solutions.  Full year adjusted operating profit was $467 m illion, which was flat to the \nprior year, as organic growth from access and adherence solutions was offset by higher investment costs to \nsupport the growth in the company's biopharma strategy.  We finished the year with strong momentum from these \ninvestment s, including our new product AMP, which contributed to profit growth in the fourth quarter.  \n \n", "original_text": "Revenues in the quarter were $789 million, an increase of 7%, \ndriven by higher volumes of technology and service of ferings to support biopharma customers. "}, "hash": "fda817a603eec8c2b955220630c65b1c04b01458ecbcf2bbce6b0624a90bddef", "class_name": "RelatedNodeInfo"}}, "text": "Next on to Prescription Technology Solutions. ", "start_char_idx": 904, "end_char_idx": 950, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9b4917f-c11c-4126-82ba-9a375786dd13": {"__data__": {"id_": "f9b4917f-c11c-4126-82ba-9a375786dd13", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 7% to $813 million driven by the contribution fro m COVID -19 \nvaccine distribution, partially offset by the previously mentioned prior year COVID pandemic impact and higher \noperating costs in support of the company's oncology growth initiatives and the impact of a weak cold and flu \nseason.  \n \n Adjusted operat ing profit for the full year increased 3% to $2.7 billion driven by growth in specialty product \ndistribution and contribution from COVID -19 vaccine distribution, offset by the previously mentioned prior year \nincrease in demand driven by the onset of the pa ndemic and by higher operating costs in support of the \ncompany's oncology growth initiatives.  \n \n Next on to Prescription Technology Solutions.  Revenues in the quarter were $789 million, an increase of 7%, \ndriven by higher volumes of technology and service of ferings to support biopharma customers.  Adjusted operating \nprofit in the quarter increased 11% to $146 million driven by organic growth from access and adherence programs \nsupported by our Technology Solutions.  Full year adjusted operating profit was $467 m illion, which was flat to the \nprior year, as organic growth from access and adherence solutions was offset by higher investment costs to \nsupport the growth in the company's biopharma strategy.  We finished the year with strong momentum from these \ninvestment s, including our new product AMP, which contributed to profit growth in the fourth quarter.  \n \n", "original_text": "Revenues in the quarter were $789 million, an increase of 7%, \ndriven by higher volumes of technology and service of ferings to support biopharma customers. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4229d4351894ca10fe32a58b3b00ca3385f146d5f133963d7d9758a0b1f10fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6cfc4e5e-cec3-46cc-83a7-e4f3edfb1926", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 7% to $813 million driven by the contribution fro m COVID -19 \nvaccine distribution, partially offset by the previously mentioned prior year COVID pandemic impact and higher \noperating costs in support of the company's oncology growth initiatives and the impact of a weak cold and flu \nseason.  \n \n Adjusted operat ing profit for the full year increased 3% to $2.7 billion driven by growth in specialty product \ndistribution and contribution from COVID -19 vaccine distribution, offset by the previously mentioned prior year \nincrease in demand driven by the onset of the pa ndemic and by higher operating costs in support of the \ncompany's oncology growth initiatives.  \n \n Next on to Prescription Technology Solutions.  Revenues in the quarter were $789 million, an increase of 7%, \ndriven by higher volumes of technology and service of ferings to support biopharma customers.  Adjusted operating \nprofit in the quarter increased 11% to $146 million driven by organic growth from access and adherence programs \nsupported by our Technology Solutions.  Full year adjusted operating profit was $467 m illion, which was flat to the \nprior year, as organic growth from access and adherence solutions was offset by higher investment costs to \nsupport the growth in the company's biopharma strategy. ", "original_text": "Next on to Prescription Technology Solutions. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72e214438d139cbf9efb0900b21009543c98eef060e95c86159ebd440d34693b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49c1d266-0e34-4e54-8f7d-aae7ce37e46f", "node_type": "1", "metadata": {"window": "Adjusted operat ing profit for the full year increased 3% to $2.7 billion driven by growth in specialty product \ndistribution and contribution from COVID -19 vaccine distribution, offset by the previously mentioned prior year \nincrease in demand driven by the onset of the pa ndemic and by higher operating costs in support of the \ncompany's oncology growth initiatives.  \n \n Next on to Prescription Technology Solutions.  Revenues in the quarter were $789 million, an increase of 7%, \ndriven by higher volumes of technology and service of ferings to support biopharma customers.  Adjusted operating \nprofit in the quarter increased 11% to $146 million driven by organic growth from access and adherence programs \nsupported by our Technology Solutions.  Full year adjusted operating profit was $467 m illion, which was flat to the \nprior year, as organic growth from access and adherence solutions was offset by higher investment costs to \nsupport the growth in the company's biopharma strategy.  We finished the year with strong momentum from these \ninvestment s, including our new product AMP, which contributed to profit growth in the fourth quarter.  \n \n Moving on to Medical Surgical Solutions. ", "original_text": "Adjusted operating \nprofit in the quarter increased 11% to $146 million driven by organic growth from access and adherence programs \nsupported by our Technology Solutions. "}, "hash": "84fad46e6f6ece47aaf64c7d114bff595bfc76822d13bf1495785b7d8abedf50", "class_name": "RelatedNodeInfo"}}, "text": "Revenues in the quarter were $789 million, an increase of 7%, \ndriven by higher volumes of technology and service of ferings to support biopharma customers. ", "start_char_idx": 950, "end_char_idx": 1107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49c1d266-0e34-4e54-8f7d-aae7ce37e46f": {"__data__": {"id_": "49c1d266-0e34-4e54-8f7d-aae7ce37e46f", "embedding": null, "metadata": {"window": "Adjusted operat ing profit for the full year increased 3% to $2.7 billion driven by growth in specialty product \ndistribution and contribution from COVID -19 vaccine distribution, offset by the previously mentioned prior year \nincrease in demand driven by the onset of the pa ndemic and by higher operating costs in support of the \ncompany's oncology growth initiatives.  \n \n Next on to Prescription Technology Solutions.  Revenues in the quarter were $789 million, an increase of 7%, \ndriven by higher volumes of technology and service of ferings to support biopharma customers.  Adjusted operating \nprofit in the quarter increased 11% to $146 million driven by organic growth from access and adherence programs \nsupported by our Technology Solutions.  Full year adjusted operating profit was $467 m illion, which was flat to the \nprior year, as organic growth from access and adherence solutions was offset by higher investment costs to \nsupport the growth in the company's biopharma strategy.  We finished the year with strong momentum from these \ninvestment s, including our new product AMP, which contributed to profit growth in the fourth quarter.  \n \n Moving on to Medical Surgical Solutions. ", "original_text": "Adjusted operating \nprofit in the quarter increased 11% to $146 million driven by organic growth from access and adherence programs \nsupported by our Technology Solutions. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4229d4351894ca10fe32a58b3b00ca3385f146d5f133963d7d9758a0b1f10fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9b4917f-c11c-4126-82ba-9a375786dd13", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 7% to $813 million driven by the contribution fro m COVID -19 \nvaccine distribution, partially offset by the previously mentioned prior year COVID pandemic impact and higher \noperating costs in support of the company's oncology growth initiatives and the impact of a weak cold and flu \nseason.  \n \n Adjusted operat ing profit for the full year increased 3% to $2.7 billion driven by growth in specialty product \ndistribution and contribution from COVID -19 vaccine distribution, offset by the previously mentioned prior year \nincrease in demand driven by the onset of the pa ndemic and by higher operating costs in support of the \ncompany's oncology growth initiatives.  \n \n Next on to Prescription Technology Solutions.  Revenues in the quarter were $789 million, an increase of 7%, \ndriven by higher volumes of technology and service of ferings to support biopharma customers.  Adjusted operating \nprofit in the quarter increased 11% to $146 million driven by organic growth from access and adherence programs \nsupported by our Technology Solutions.  Full year adjusted operating profit was $467 m illion, which was flat to the \nprior year, as organic growth from access and adherence solutions was offset by higher investment costs to \nsupport the growth in the company's biopharma strategy.  We finished the year with strong momentum from these \ninvestment s, including our new product AMP, which contributed to profit growth in the fourth quarter.  \n \n", "original_text": "Revenues in the quarter were $789 million, an increase of 7%, \ndriven by higher volumes of technology and service of ferings to support biopharma customers. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9fe009b9bb2cad9f555dfe6fb23fa2c8cb35cc345fabe017aef0cf4e4ba0d93c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a762b2be-fdb6-4b84-8e31-9f124322eba1", "node_type": "1", "metadata": {"window": "Next on to Prescription Technology Solutions.  Revenues in the quarter were $789 million, an increase of 7%, \ndriven by higher volumes of technology and service of ferings to support biopharma customers.  Adjusted operating \nprofit in the quarter increased 11% to $146 million driven by organic growth from access and adherence programs \nsupported by our Technology Solutions.  Full year adjusted operating profit was $467 m illion, which was flat to the \nprior year, as organic growth from access and adherence solutions was offset by higher investment costs to \nsupport the growth in the company's biopharma strategy.  We finished the year with strong momentum from these \ninvestment s, including our new product AMP, which contributed to profit growth in the fourth quarter.  \n \n Moving on to Medical Surgical Solutions.  Revenues were $2.7 billion in the quarter up 23%, primarily driven by \ndemand for COVID -19 tests. ", "original_text": "Full year adjusted operating profit was $467 m illion, which was flat to the \nprior year, as organic growth from access and adherence solutions was offset by higher investment costs to \nsupport the growth in the company's biopharma strategy. "}, "hash": "787f8cdec07ebc2eb8082654bbdbffb872edfb72693bb7e5dd925b7cd8299208", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating \nprofit in the quarter increased 11% to $146 million driven by organic growth from access and adherence programs \nsupported by our Technology Solutions. ", "start_char_idx": 1107, "end_char_idx": 1279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a762b2be-fdb6-4b84-8e31-9f124322eba1": {"__data__": {"id_": "a762b2be-fdb6-4b84-8e31-9f124322eba1", "embedding": null, "metadata": {"window": "Next on to Prescription Technology Solutions.  Revenues in the quarter were $789 million, an increase of 7%, \ndriven by higher volumes of technology and service of ferings to support biopharma customers.  Adjusted operating \nprofit in the quarter increased 11% to $146 million driven by organic growth from access and adherence programs \nsupported by our Technology Solutions.  Full year adjusted operating profit was $467 m illion, which was flat to the \nprior year, as organic growth from access and adherence solutions was offset by higher investment costs to \nsupport the growth in the company's biopharma strategy.  We finished the year with strong momentum from these \ninvestment s, including our new product AMP, which contributed to profit growth in the fourth quarter.  \n \n Moving on to Medical Surgical Solutions.  Revenues were $2.7 billion in the quarter up 23%, primarily driven by \ndemand for COVID -19 tests. ", "original_text": "Full year adjusted operating profit was $467 m illion, which was flat to the \nprior year, as organic growth from access and adherence solutions was offset by higher investment costs to \nsupport the growth in the company's biopharma strategy. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4229d4351894ca10fe32a58b3b00ca3385f146d5f133963d7d9758a0b1f10fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49c1d266-0e34-4e54-8f7d-aae7ce37e46f", "node_type": "1", "metadata": {"window": "Adjusted operat ing profit for the full year increased 3% to $2.7 billion driven by growth in specialty product \ndistribution and contribution from COVID -19 vaccine distribution, offset by the previously mentioned prior year \nincrease in demand driven by the onset of the pa ndemic and by higher operating costs in support of the \ncompany's oncology growth initiatives.  \n \n Next on to Prescription Technology Solutions.  Revenues in the quarter were $789 million, an increase of 7%, \ndriven by higher volumes of technology and service of ferings to support biopharma customers.  Adjusted operating \nprofit in the quarter increased 11% to $146 million driven by organic growth from access and adherence programs \nsupported by our Technology Solutions.  Full year adjusted operating profit was $467 m illion, which was flat to the \nprior year, as organic growth from access and adherence solutions was offset by higher investment costs to \nsupport the growth in the company's biopharma strategy.  We finished the year with strong momentum from these \ninvestment s, including our new product AMP, which contributed to profit growth in the fourth quarter.  \n \n Moving on to Medical Surgical Solutions. ", "original_text": "Adjusted operating \nprofit in the quarter increased 11% to $146 million driven by organic growth from access and adherence programs \nsupported by our Technology Solutions. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e5d311d663b6de556edaa730122a7ccb3f0eeab0f1c942747f0ae8cd1757499", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "940ccb52-a281-4aac-ba84-1b0a61298ca5", "node_type": "1", "metadata": {"window": "Revenues in the quarter were $789 million, an increase of 7%, \ndriven by higher volumes of technology and service of ferings to support biopharma customers.  Adjusted operating \nprofit in the quarter increased 11% to $146 million driven by organic growth from access and adherence programs \nsupported by our Technology Solutions.  Full year adjusted operating profit was $467 m illion, which was flat to the \nprior year, as organic growth from access and adherence solutions was offset by higher investment costs to \nsupport the growth in the company's biopharma strategy.  We finished the year with strong momentum from these \ninvestment s, including our new product AMP, which contributed to profit growth in the fourth quarter.  \n \n Moving on to Medical Surgical Solutions.  Revenues were $2.7 billion in the quarter up 23%, primarily driven by \ndemand for COVID -19 tests.  For the quarter, adjusted  operating profit increased 13% to $192 million and for the \nfull year increased 19% to $805 million. ", "original_text": "We finished the year with strong momentum from these \ninvestment s, including our new product AMP, which contributed to profit growth in the fourth quarter.  \n \n"}, "hash": "7606ce449416c7839764f2bc77151f68dce45c1c6829e1f622c597a1533c414b", "class_name": "RelatedNodeInfo"}}, "text": "Full year adjusted operating profit was $467 m illion, which was flat to the \nprior year, as organic growth from access and adherence solutions was offset by higher investment costs to \nsupport the growth in the company's biopharma strategy. ", "start_char_idx": 1279, "end_char_idx": 1521, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "940ccb52-a281-4aac-ba84-1b0a61298ca5": {"__data__": {"id_": "940ccb52-a281-4aac-ba84-1b0a61298ca5", "embedding": null, "metadata": {"window": "Revenues in the quarter were $789 million, an increase of 7%, \ndriven by higher volumes of technology and service of ferings to support biopharma customers.  Adjusted operating \nprofit in the quarter increased 11% to $146 million driven by organic growth from access and adherence programs \nsupported by our Technology Solutions.  Full year adjusted operating profit was $467 m illion, which was flat to the \nprior year, as organic growth from access and adherence solutions was offset by higher investment costs to \nsupport the growth in the company's biopharma strategy.  We finished the year with strong momentum from these \ninvestment s, including our new product AMP, which contributed to profit growth in the fourth quarter.  \n \n Moving on to Medical Surgical Solutions.  Revenues were $2.7 billion in the quarter up 23%, primarily driven by \ndemand for COVID -19 tests.  For the quarter, adjusted  operating profit increased 13% to $192 million and for the \nfull year increased 19% to $805 million. ", "original_text": "We finished the year with strong momentum from these \ninvestment s, including our new product AMP, which contributed to profit growth in the fourth quarter.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4229d4351894ca10fe32a58b3b00ca3385f146d5f133963d7d9758a0b1f10fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a762b2be-fdb6-4b84-8e31-9f124322eba1", "node_type": "1", "metadata": {"window": "Next on to Prescription Technology Solutions.  Revenues in the quarter were $789 million, an increase of 7%, \ndriven by higher volumes of technology and service of ferings to support biopharma customers.  Adjusted operating \nprofit in the quarter increased 11% to $146 million driven by organic growth from access and adherence programs \nsupported by our Technology Solutions.  Full year adjusted operating profit was $467 m illion, which was flat to the \nprior year, as organic growth from access and adherence solutions was offset by higher investment costs to \nsupport the growth in the company's biopharma strategy.  We finished the year with strong momentum from these \ninvestment s, including our new product AMP, which contributed to profit growth in the fourth quarter.  \n \n Moving on to Medical Surgical Solutions.  Revenues were $2.7 billion in the quarter up 23%, primarily driven by \ndemand for COVID -19 tests. ", "original_text": "Full year adjusted operating profit was $467 m illion, which was flat to the \nprior year, as organic growth from access and adherence solutions was offset by higher investment costs to \nsupport the growth in the company's biopharma strategy. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59305c69b4b71df7a1be40a90901a5de1a4c419f7952738ad17068f9b44c7764", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3142c0b3-763c-41ae-b26d-dee166dda5a6", "node_type": "1", "metadata": {"window": "Adjusted operating \nprofit in the quarter increased 11% to $146 million driven by organic growth from access and adherence programs \nsupported by our Technology Solutions.  Full year adjusted operating profit was $467 m illion, which was flat to the \nprior year, as organic growth from access and adherence solutions was offset by higher investment costs to \nsupport the growth in the company's biopharma strategy.  We finished the year with strong momentum from these \ninvestment s, including our new product AMP, which contributed to profit growth in the fourth quarter.  \n \n Moving on to Medical Surgical Solutions.  Revenues were $2.7 billion in the quarter up 23%, primarily driven by \ndemand for COVID -19 tests.  For the quarter, adjusted  operating profit increased 13% to $192 million and for the \nfull year increased 19% to $805 million.  We previously outlined that demand for COVID test kit and PPE products \nwere closely associated with the rate of COVID case levels. ", "original_text": "Moving on to Medical Surgical Solutions. "}, "hash": "f6110784820e83555b5c0c82a230efb6d420d0cf5ee9cf23cfef3a6f561b7636", "class_name": "RelatedNodeInfo"}}, "text": "We finished the year with strong momentum from these \ninvestment s, including our new product AMP, which contributed to profit growth in the fourth quarter.  \n \n", "start_char_idx": 1521, "end_char_idx": 1682, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3142c0b3-763c-41ae-b26d-dee166dda5a6": {"__data__": {"id_": "3142c0b3-763c-41ae-b26d-dee166dda5a6", "embedding": null, "metadata": {"window": "Adjusted operating \nprofit in the quarter increased 11% to $146 million driven by organic growth from access and adherence programs \nsupported by our Technology Solutions.  Full year adjusted operating profit was $467 m illion, which was flat to the \nprior year, as organic growth from access and adherence solutions was offset by higher investment costs to \nsupport the growth in the company's biopharma strategy.  We finished the year with strong momentum from these \ninvestment s, including our new product AMP, which contributed to profit growth in the fourth quarter.  \n \n Moving on to Medical Surgical Solutions.  Revenues were $2.7 billion in the quarter up 23%, primarily driven by \ndemand for COVID -19 tests.  For the quarter, adjusted  operating profit increased 13% to $192 million and for the \nfull year increased 19% to $805 million.  We previously outlined that demand for COVID test kit and PPE products \nwere closely associated with the rate of COVID case levels. ", "original_text": "Moving on to Medical Surgical Solutions. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4229d4351894ca10fe32a58b3b00ca3385f146d5f133963d7d9758a0b1f10fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "940ccb52-a281-4aac-ba84-1b0a61298ca5", "node_type": "1", "metadata": {"window": "Revenues in the quarter were $789 million, an increase of 7%, \ndriven by higher volumes of technology and service of ferings to support biopharma customers.  Adjusted operating \nprofit in the quarter increased 11% to $146 million driven by organic growth from access and adherence programs \nsupported by our Technology Solutions.  Full year adjusted operating profit was $467 m illion, which was flat to the \nprior year, as organic growth from access and adherence solutions was offset by higher investment costs to \nsupport the growth in the company's biopharma strategy.  We finished the year with strong momentum from these \ninvestment s, including our new product AMP, which contributed to profit growth in the fourth quarter.  \n \n Moving on to Medical Surgical Solutions.  Revenues were $2.7 billion in the quarter up 23%, primarily driven by \ndemand for COVID -19 tests.  For the quarter, adjusted  operating profit increased 13% to $192 million and for the \nfull year increased 19% to $805 million. ", "original_text": "We finished the year with strong momentum from these \ninvestment s, including our new product AMP, which contributed to profit growth in the fourth quarter.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c85676fdf5c93cb1685327dafcec2b6ea5823e3ef3337dd72e7e78b91ec87510", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6b17a47-ecea-4066-b28c-0e7e0bd73345", "node_type": "1", "metadata": {"window": "Full year adjusted operating profit was $467 m illion, which was flat to the \nprior year, as organic growth from access and adherence solutions was offset by higher investment costs to \nsupport the growth in the company's biopharma strategy.  We finished the year with strong momentum from these \ninvestment s, including our new product AMP, which contributed to profit growth in the fourth quarter.  \n \n Moving on to Medical Surgical Solutions.  Revenues were $2.7 billion in the quarter up 23%, primarily driven by \ndemand for COVID -19 tests.  For the quarter, adjusted  operating profit increased 13% to $192 million and for the \nfull year increased 19% to $805 million.  We previously outlined that demand for COVID test kit and PPE products \nwere closely associated with the rate of COVID case levels.  Although COVID -19 test k it volume continued \nthrough the fourth quarter, these levels moderated significantly from Q3 levels as US COVID cases trended lower \nthroughout the quarter.  \n \n", "original_text": "Revenues were $2.7 billion in the quarter up 23%, primarily driven by \ndemand for COVID -19 tests. "}, "hash": "c1464531a2af1c0c128ee4a87af398697b090c18332fbda75ac4c837cda7e5f4", "class_name": "RelatedNodeInfo"}}, "text": "Moving on to Medical Surgical Solutions. ", "start_char_idx": 1682, "end_char_idx": 1723, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6b17a47-ecea-4066-b28c-0e7e0bd73345": {"__data__": {"id_": "f6b17a47-ecea-4066-b28c-0e7e0bd73345", "embedding": null, "metadata": {"window": "Full year adjusted operating profit was $467 m illion, which was flat to the \nprior year, as organic growth from access and adherence solutions was offset by higher investment costs to \nsupport the growth in the company's biopharma strategy.  We finished the year with strong momentum from these \ninvestment s, including our new product AMP, which contributed to profit growth in the fourth quarter.  \n \n Moving on to Medical Surgical Solutions.  Revenues were $2.7 billion in the quarter up 23%, primarily driven by \ndemand for COVID -19 tests.  For the quarter, adjusted  operating profit increased 13% to $192 million and for the \nfull year increased 19% to $805 million.  We previously outlined that demand for COVID test kit and PPE products \nwere closely associated with the rate of COVID case levels.  Although COVID -19 test k it volume continued \nthrough the fourth quarter, these levels moderated significantly from Q3 levels as US COVID cases trended lower \nthroughout the quarter.  \n \n", "original_text": "Revenues were $2.7 billion in the quarter up 23%, primarily driven by \ndemand for COVID -19 tests. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4229d4351894ca10fe32a58b3b00ca3385f146d5f133963d7d9758a0b1f10fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3142c0b3-763c-41ae-b26d-dee166dda5a6", "node_type": "1", "metadata": {"window": "Adjusted operating \nprofit in the quarter increased 11% to $146 million driven by organic growth from access and adherence programs \nsupported by our Technology Solutions.  Full year adjusted operating profit was $467 m illion, which was flat to the \nprior year, as organic growth from access and adherence solutions was offset by higher investment costs to \nsupport the growth in the company's biopharma strategy.  We finished the year with strong momentum from these \ninvestment s, including our new product AMP, which contributed to profit growth in the fourth quarter.  \n \n Moving on to Medical Surgical Solutions.  Revenues were $2.7 billion in the quarter up 23%, primarily driven by \ndemand for COVID -19 tests.  For the quarter, adjusted  operating profit increased 13% to $192 million and for the \nfull year increased 19% to $805 million.  We previously outlined that demand for COVID test kit and PPE products \nwere closely associated with the rate of COVID case levels. ", "original_text": "Moving on to Medical Surgical Solutions. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0984df329b217685db0fcf393073e8d18176e500ad28c98e5be8dafb12f9cb7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "669febb1-46c0-418c-8412-8367671158e3", "node_type": "1", "metadata": {"window": "We finished the year with strong momentum from these \ninvestment s, including our new product AMP, which contributed to profit growth in the fourth quarter.  \n \n Moving on to Medical Surgical Solutions.  Revenues were $2.7 billion in the quarter up 23%, primarily driven by \ndemand for COVID -19 tests.  For the quarter, adjusted  operating profit increased 13% to $192 million and for the \nfull year increased 19% to $805 million.  We previously outlined that demand for COVID test kit and PPE products \nwere closely associated with the rate of COVID case levels.  Although COVID -19 test k it volume continued \nthrough the fourth quarter, these levels moderated significantly from Q3 levels as US COVID cases trended lower \nthroughout the quarter.  \n \n As we discussed at various conferences during our fourth quarter, we anticipated that these elevated levels of \ndemand would moderate. ", "original_text": "For the quarter, adjusted  operating profit increased 13% to $192 million and for the \nfull year increased 19% to $805 million. "}, "hash": "dabec25064688724635026682cf8491022d0834fd5f1697719879f6d668e6157", "class_name": "RelatedNodeInfo"}}, "text": "Revenues were $2.7 billion in the quarter up 23%, primarily driven by \ndemand for COVID -19 tests. ", "start_char_idx": 1723, "end_char_idx": 1822, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "669febb1-46c0-418c-8412-8367671158e3": {"__data__": {"id_": "669febb1-46c0-418c-8412-8367671158e3", "embedding": null, "metadata": {"window": "We finished the year with strong momentum from these \ninvestment s, including our new product AMP, which contributed to profit growth in the fourth quarter.  \n \n Moving on to Medical Surgical Solutions.  Revenues were $2.7 billion in the quarter up 23%, primarily driven by \ndemand for COVID -19 tests.  For the quarter, adjusted  operating profit increased 13% to $192 million and for the \nfull year increased 19% to $805 million.  We previously outlined that demand for COVID test kit and PPE products \nwere closely associated with the rate of COVID case levels.  Although COVID -19 test k it volume continued \nthrough the fourth quarter, these levels moderated significantly from Q3 levels as US COVID cases trended lower \nthroughout the quarter.  \n \n As we discussed at various conferences during our fourth quarter, we anticipated that these elevated levels of \ndemand would moderate. ", "original_text": "For the quarter, adjusted  operating profit increased 13% to $192 million and for the \nfull year increased 19% to $805 million. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4229d4351894ca10fe32a58b3b00ca3385f146d5f133963d7d9758a0b1f10fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6b17a47-ecea-4066-b28c-0e7e0bd73345", "node_type": "1", "metadata": {"window": "Full year adjusted operating profit was $467 m illion, which was flat to the \nprior year, as organic growth from access and adherence solutions was offset by higher investment costs to \nsupport the growth in the company's biopharma strategy.  We finished the year with strong momentum from these \ninvestment s, including our new product AMP, which contributed to profit growth in the fourth quarter.  \n \n Moving on to Medical Surgical Solutions.  Revenues were $2.7 billion in the quarter up 23%, primarily driven by \ndemand for COVID -19 tests.  For the quarter, adjusted  operating profit increased 13% to $192 million and for the \nfull year increased 19% to $805 million.  We previously outlined that demand for COVID test kit and PPE products \nwere closely associated with the rate of COVID case levels.  Although COVID -19 test k it volume continued \nthrough the fourth quarter, these levels moderated significantly from Q3 levels as US COVID cases trended lower \nthroughout the quarter.  \n \n", "original_text": "Revenues were $2.7 billion in the quarter up 23%, primarily driven by \ndemand for COVID -19 tests. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d3a25f68ba05c1de8b24ee48f8aa392e4fbb2828095a8115c768aeffacab56e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7ad7d59-80f9-4ec7-9f75-34a54f26aad9", "node_type": "1", "metadata": {"window": "Moving on to Medical Surgical Solutions.  Revenues were $2.7 billion in the quarter up 23%, primarily driven by \ndemand for COVID -19 tests.  For the quarter, adjusted  operating profit increased 13% to $192 million and for the \nfull year increased 19% to $805 million.  We previously outlined that demand for COVID test kit and PPE products \nwere closely associated with the rate of COVID case levels.  Although COVID -19 test k it volume continued \nthrough the fourth quarter, these levels moderated significantly from Q3 levels as US COVID cases trended lower \nthroughout the quarter.  \n \n As we discussed at various conferences during our fourth quarter, we anticipated that these elevated levels of \ndemand would moderate.  As we discussed in prior calls this year, early on in the pandemic, our Medical Surgical \nbusiness built supply quickly to meet demands from our customers for COVID -19 tests and elevated levels of \ndemand for PPE. ", "original_text": "We previously outlined that demand for COVID test kit and PPE products \nwere closely associated with the rate of COVID case levels. "}, "hash": "effbe1f46ebb50525644c1ac60c8ace4193bcabd11e36ad8778054427f26df14", "class_name": "RelatedNodeInfo"}}, "text": "For the quarter, adjusted  operating profit increased 13% to $192 million and for the \nfull year increased 19% to $805 million. ", "start_char_idx": 1822, "end_char_idx": 1950, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7ad7d59-80f9-4ec7-9f75-34a54f26aad9": {"__data__": {"id_": "f7ad7d59-80f9-4ec7-9f75-34a54f26aad9", "embedding": null, "metadata": {"window": "Moving on to Medical Surgical Solutions.  Revenues were $2.7 billion in the quarter up 23%, primarily driven by \ndemand for COVID -19 tests.  For the quarter, adjusted  operating profit increased 13% to $192 million and for the \nfull year increased 19% to $805 million.  We previously outlined that demand for COVID test kit and PPE products \nwere closely associated with the rate of COVID case levels.  Although COVID -19 test k it volume continued \nthrough the fourth quarter, these levels moderated significantly from Q3 levels as US COVID cases trended lower \nthroughout the quarter.  \n \n As we discussed at various conferences during our fourth quarter, we anticipated that these elevated levels of \ndemand would moderate.  As we discussed in prior calls this year, early on in the pandemic, our Medical Surgical \nbusiness built supply quickly to meet demands from our customers for COVID -19 tests and elevated levels of \ndemand for PPE. ", "original_text": "We previously outlined that demand for COVID test kit and PPE products \nwere closely associated with the rate of COVID case levels. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4229d4351894ca10fe32a58b3b00ca3385f146d5f133963d7d9758a0b1f10fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "669febb1-46c0-418c-8412-8367671158e3", "node_type": "1", "metadata": {"window": "We finished the year with strong momentum from these \ninvestment s, including our new product AMP, which contributed to profit growth in the fourth quarter.  \n \n Moving on to Medical Surgical Solutions.  Revenues were $2.7 billion in the quarter up 23%, primarily driven by \ndemand for COVID -19 tests.  For the quarter, adjusted  operating profit increased 13% to $192 million and for the \nfull year increased 19% to $805 million.  We previously outlined that demand for COVID test kit and PPE products \nwere closely associated with the rate of COVID case levels.  Although COVID -19 test k it volume continued \nthrough the fourth quarter, these levels moderated significantly from Q3 levels as US COVID cases trended lower \nthroughout the quarter.  \n \n As we discussed at various conferences during our fourth quarter, we anticipated that these elevated levels of \ndemand would moderate. ", "original_text": "For the quarter, adjusted  operating profit increased 13% to $192 million and for the \nfull year increased 19% to $805 million. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77eb9013d5e895dc2eca6fba470d3a61895d348eb040b9ef1f021a28e97af25f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa1d601e-ac29-4af8-a9d0-33abc1807b28", "node_type": "1", "metadata": {"window": "Revenues were $2.7 billion in the quarter up 23%, primarily driven by \ndemand for COVID -19 tests.  For the quarter, adjusted  operating profit increased 13% to $192 million and for the \nfull year increased 19% to $805 million.  We previously outlined that demand for COVID test kit and PPE products \nwere closely associated with the rate of COVID case levels.  Although COVID -19 test k it volume continued \nthrough the fourth quarter, these levels moderated significantly from Q3 levels as US COVID cases trended lower \nthroughout the quarter.  \n \n As we discussed at various conferences during our fourth quarter, we anticipated that these elevated levels of \ndemand would moderate.  As we discussed in prior calls this year, early on in the pandemic, our Medical Surgical \nbusiness built supply quickly to meet demands from our customers for COVID -19 tests and elevated levels of \ndemand for PPE.  We  procured these products in a market with unprecedented and unpredictable supply and \ndemand levels. ", "original_text": "Although COVID -19 test k it volume continued \nthrough the fourth quarter, these levels moderated significantly from Q3 levels as US COVID cases trended lower \nthroughout the quarter.  \n \n"}, "hash": "2295db01349b150db24c7c0a4e9b7658931020c17afb2a87c3aed91506ff5e57", "class_name": "RelatedNodeInfo"}}, "text": "We previously outlined that demand for COVID test kit and PPE products \nwere closely associated with the rate of COVID case levels. ", "start_char_idx": 1950, "end_char_idx": 2082, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa1d601e-ac29-4af8-a9d0-33abc1807b28": {"__data__": {"id_": "aa1d601e-ac29-4af8-a9d0-33abc1807b28", "embedding": null, "metadata": {"window": "Revenues were $2.7 billion in the quarter up 23%, primarily driven by \ndemand for COVID -19 tests.  For the quarter, adjusted  operating profit increased 13% to $192 million and for the \nfull year increased 19% to $805 million.  We previously outlined that demand for COVID test kit and PPE products \nwere closely associated with the rate of COVID case levels.  Although COVID -19 test k it volume continued \nthrough the fourth quarter, these levels moderated significantly from Q3 levels as US COVID cases trended lower \nthroughout the quarter.  \n \n As we discussed at various conferences during our fourth quarter, we anticipated that these elevated levels of \ndemand would moderate.  As we discussed in prior calls this year, early on in the pandemic, our Medical Surgical \nbusiness built supply quickly to meet demands from our customers for COVID -19 tests and elevated levels of \ndemand for PPE.  We  procured these products in a market with unprecedented and unpredictable supply and \ndemand levels. ", "original_text": "Although COVID -19 test k it volume continued \nthrough the fourth quarter, these levels moderated significantly from Q3 levels as US COVID cases trended lower \nthroughout the quarter.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4229d4351894ca10fe32a58b3b00ca3385f146d5f133963d7d9758a0b1f10fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7ad7d59-80f9-4ec7-9f75-34a54f26aad9", "node_type": "1", "metadata": {"window": "Moving on to Medical Surgical Solutions.  Revenues were $2.7 billion in the quarter up 23%, primarily driven by \ndemand for COVID -19 tests.  For the quarter, adjusted  operating profit increased 13% to $192 million and for the \nfull year increased 19% to $805 million.  We previously outlined that demand for COVID test kit and PPE products \nwere closely associated with the rate of COVID case levels.  Although COVID -19 test k it volume continued \nthrough the fourth quarter, these levels moderated significantly from Q3 levels as US COVID cases trended lower \nthroughout the quarter.  \n \n As we discussed at various conferences during our fourth quarter, we anticipated that these elevated levels of \ndemand would moderate.  As we discussed in prior calls this year, early on in the pandemic, our Medical Surgical \nbusiness built supply quickly to meet demands from our customers for COVID -19 tests and elevated levels of \ndemand for PPE. ", "original_text": "We previously outlined that demand for COVID test kit and PPE products \nwere closely associated with the rate of COVID case levels. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d796c054865ae67c43dcdba928be4afb73ed4342a10fe6e05a4ec1a272a13d5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a8b40d8-b136-4d46-9573-b96ccdaa5451", "node_type": "1", "metadata": {"window": "For the quarter, adjusted  operating profit increased 13% to $192 million and for the \nfull year increased 19% to $805 million.  We previously outlined that demand for COVID test kit and PPE products \nwere closely associated with the rate of COVID case levels.  Although COVID -19 test k it volume continued \nthrough the fourth quarter, these levels moderated significantly from Q3 levels as US COVID cases trended lower \nthroughout the quarter.  \n \n As we discussed at various conferences during our fourth quarter, we anticipated that these elevated levels of \ndemand would moderate.  As we discussed in prior calls this year, early on in the pandemic, our Medical Surgical \nbusiness built supply quickly to meet demands from our customers for COVID -19 tests and elevated levels of \ndemand for PPE.  We  procured these products in a market with unprecedented and unpredictable supply and \ndemand levels.  The volatility associated with COVID case levels impacted the demand levels for PPE.  \n \n", "original_text": "As we discussed at various conferences during our fourth quarter, we anticipated that these elevated levels of \ndemand would moderate. "}, "hash": "a58d13c6bfe2ae7b4e2f50d3f7de6f9ff8be9d5b9c87ccebf545b6855c652bce", "class_name": "RelatedNodeInfo"}}, "text": "Although COVID -19 test k it volume continued \nthrough the fourth quarter, these levels moderated significantly from Q3 levels as US COVID cases trended lower \nthroughout the quarter.  \n \n", "start_char_idx": 2082, "end_char_idx": 2270, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a8b40d8-b136-4d46-9573-b96ccdaa5451": {"__data__": {"id_": "7a8b40d8-b136-4d46-9573-b96ccdaa5451", "embedding": null, "metadata": {"window": "For the quarter, adjusted  operating profit increased 13% to $192 million and for the \nfull year increased 19% to $805 million.  We previously outlined that demand for COVID test kit and PPE products \nwere closely associated with the rate of COVID case levels.  Although COVID -19 test k it volume continued \nthrough the fourth quarter, these levels moderated significantly from Q3 levels as US COVID cases trended lower \nthroughout the quarter.  \n \n As we discussed at various conferences during our fourth quarter, we anticipated that these elevated levels of \ndemand would moderate.  As we discussed in prior calls this year, early on in the pandemic, our Medical Surgical \nbusiness built supply quickly to meet demands from our customers for COVID -19 tests and elevated levels of \ndemand for PPE.  We  procured these products in a market with unprecedented and unpredictable supply and \ndemand levels.  The volatility associated with COVID case levels impacted the demand levels for PPE.  \n \n", "original_text": "As we discussed at various conferences during our fourth quarter, we anticipated that these elevated levels of \ndemand would moderate. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4229d4351894ca10fe32a58b3b00ca3385f146d5f133963d7d9758a0b1f10fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa1d601e-ac29-4af8-a9d0-33abc1807b28", "node_type": "1", "metadata": {"window": "Revenues were $2.7 billion in the quarter up 23%, primarily driven by \ndemand for COVID -19 tests.  For the quarter, adjusted  operating profit increased 13% to $192 million and for the \nfull year increased 19% to $805 million.  We previously outlined that demand for COVID test kit and PPE products \nwere closely associated with the rate of COVID case levels.  Although COVID -19 test k it volume continued \nthrough the fourth quarter, these levels moderated significantly from Q3 levels as US COVID cases trended lower \nthroughout the quarter.  \n \n As we discussed at various conferences during our fourth quarter, we anticipated that these elevated levels of \ndemand would moderate.  As we discussed in prior calls this year, early on in the pandemic, our Medical Surgical \nbusiness built supply quickly to meet demands from our customers for COVID -19 tests and elevated levels of \ndemand for PPE.  We  procured these products in a market with unprecedented and unpredictable supply and \ndemand levels. ", "original_text": "Although COVID -19 test k it volume continued \nthrough the fourth quarter, these levels moderated significantly from Q3 levels as US COVID cases trended lower \nthroughout the quarter.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48a2ff52986194ea0d3b20d6b8fa99f74384d0c3a62daf1fdf74ca5b71e415d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfdede8a-f320-4261-be4a-5e9f2e33b2ac", "node_type": "1", "metadata": {"window": "We previously outlined that demand for COVID test kit and PPE products \nwere closely associated with the rate of COVID case levels.  Although COVID -19 test k it volume continued \nthrough the fourth quarter, these levels moderated significantly from Q3 levels as US COVID cases trended lower \nthroughout the quarter.  \n \n As we discussed at various conferences during our fourth quarter, we anticipated that these elevated levels of \ndemand would moderate.  As we discussed in prior calls this year, early on in the pandemic, our Medical Surgical \nbusiness built supply quickly to meet demands from our customers for COVID -19 tests and elevated levels of \ndemand for PPE.  We  procured these products in a market with unprecedented and unpredictable supply and \ndemand levels.  The volatility associated with COVID case levels impacted the demand levels for PPE.  \n \n The demand tapering occurred sooner than we had anticipated and we too k action to position the business for the \nlower demand levels. ", "original_text": "As we discussed in prior calls this year, early on in the pandemic, our Medical Surgical \nbusiness built supply quickly to meet demands from our customers for COVID -19 tests and elevated levels of \ndemand for PPE. "}, "hash": "7c4eaceb4c6c99fb6b84767332ab6bfab924dcbd8f3aab2de6333a6e979c959e", "class_name": "RelatedNodeInfo"}}, "text": "As we discussed at various conferences during our fourth quarter, we anticipated that these elevated levels of \ndemand would moderate. ", "start_char_idx": 2270, "end_char_idx": 2405, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfdede8a-f320-4261-be4a-5e9f2e33b2ac": {"__data__": {"id_": "dfdede8a-f320-4261-be4a-5e9f2e33b2ac", "embedding": null, "metadata": {"window": "We previously outlined that demand for COVID test kit and PPE products \nwere closely associated with the rate of COVID case levels.  Although COVID -19 test k it volume continued \nthrough the fourth quarter, these levels moderated significantly from Q3 levels as US COVID cases trended lower \nthroughout the quarter.  \n \n As we discussed at various conferences during our fourth quarter, we anticipated that these elevated levels of \ndemand would moderate.  As we discussed in prior calls this year, early on in the pandemic, our Medical Surgical \nbusiness built supply quickly to meet demands from our customers for COVID -19 tests and elevated levels of \ndemand for PPE.  We  procured these products in a market with unprecedented and unpredictable supply and \ndemand levels.  The volatility associated with COVID case levels impacted the demand levels for PPE.  \n \n The demand tapering occurred sooner than we had anticipated and we too k action to position the business for the \nlower demand levels. ", "original_text": "As we discussed in prior calls this year, early on in the pandemic, our Medical Surgical \nbusiness built supply quickly to meet demands from our customers for COVID -19 tests and elevated levels of \ndemand for PPE. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4229d4351894ca10fe32a58b3b00ca3385f146d5f133963d7d9758a0b1f10fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a8b40d8-b136-4d46-9573-b96ccdaa5451", "node_type": "1", "metadata": {"window": "For the quarter, adjusted  operating profit increased 13% to $192 million and for the \nfull year increased 19% to $805 million.  We previously outlined that demand for COVID test kit and PPE products \nwere closely associated with the rate of COVID case levels.  Although COVID -19 test k it volume continued \nthrough the fourth quarter, these levels moderated significantly from Q3 levels as US COVID cases trended lower \nthroughout the quarter.  \n \n As we discussed at various conferences during our fourth quarter, we anticipated that these elevated levels of \ndemand would moderate.  As we discussed in prior calls this year, early on in the pandemic, our Medical Surgical \nbusiness built supply quickly to meet demands from our customers for COVID -19 tests and elevated levels of \ndemand for PPE.  We  procured these products in a market with unprecedented and unpredictable supply and \ndemand levels.  The volatility associated with COVID case levels impacted the demand levels for PPE.  \n \n", "original_text": "As we discussed at various conferences during our fourth quarter, we anticipated that these elevated levels of \ndemand would moderate. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ac47d1620eee7684c265f054aecc6de22b4058f0ebd2e04a2c46a9807e7d2f40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5093e3af-ef58-4ffc-9219-78a57f05aec6", "node_type": "1", "metadata": {"window": "Although COVID -19 test k it volume continued \nthrough the fourth quarter, these levels moderated significantly from Q3 levels as US COVID cases trended lower \nthroughout the quarter.  \n \n As we discussed at various conferences during our fourth quarter, we anticipated that these elevated levels of \ndemand would moderate.  As we discussed in prior calls this year, early on in the pandemic, our Medical Surgical \nbusiness built supply quickly to meet demands from our customers for COVID -19 tests and elevated levels of \ndemand for PPE.  We  procured these products in a market with unprecedented and unpredictable supply and \ndemand levels.  The volatility associated with COVID case levels impacted the demand levels for PPE.  \n \n The demand tapering occurred sooner than we had anticipated and we too k action to position the business for the \nlower demand levels.  As a result, some PPE and related products experienced market driven inventory charges. \n", "original_text": "We  procured these products in a market with unprecedented and unpredictable supply and \ndemand levels. "}, "hash": "fe7c871a25e7d9fe4cedd97e3ef91817b146a0e2f2b7cfe1d6d5c69219c8aa6c", "class_name": "RelatedNodeInfo"}}, "text": "As we discussed in prior calls this year, early on in the pandemic, our Medical Surgical \nbusiness built supply quickly to meet demands from our customers for COVID -19 tests and elevated levels of \ndemand for PPE. ", "start_char_idx": 2405, "end_char_idx": 2620, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5093e3af-ef58-4ffc-9219-78a57f05aec6": {"__data__": {"id_": "5093e3af-ef58-4ffc-9219-78a57f05aec6", "embedding": null, "metadata": {"window": "Although COVID -19 test k it volume continued \nthrough the fourth quarter, these levels moderated significantly from Q3 levels as US COVID cases trended lower \nthroughout the quarter.  \n \n As we discussed at various conferences during our fourth quarter, we anticipated that these elevated levels of \ndemand would moderate.  As we discussed in prior calls this year, early on in the pandemic, our Medical Surgical \nbusiness built supply quickly to meet demands from our customers for COVID -19 tests and elevated levels of \ndemand for PPE.  We  procured these products in a market with unprecedented and unpredictable supply and \ndemand levels.  The volatility associated with COVID case levels impacted the demand levels for PPE.  \n \n The demand tapering occurred sooner than we had anticipated and we too k action to position the business for the \nlower demand levels.  As a result, some PPE and related products experienced market driven inventory charges. \n", "original_text": "We  procured these products in a market with unprecedented and unpredictable supply and \ndemand levels. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4229d4351894ca10fe32a58b3b00ca3385f146d5f133963d7d9758a0b1f10fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfdede8a-f320-4261-be4a-5e9f2e33b2ac", "node_type": "1", "metadata": {"window": "We previously outlined that demand for COVID test kit and PPE products \nwere closely associated with the rate of COVID case levels.  Although COVID -19 test k it volume continued \nthrough the fourth quarter, these levels moderated significantly from Q3 levels as US COVID cases trended lower \nthroughout the quarter.  \n \n As we discussed at various conferences during our fourth quarter, we anticipated that these elevated levels of \ndemand would moderate.  As we discussed in prior calls this year, early on in the pandemic, our Medical Surgical \nbusiness built supply quickly to meet demands from our customers for COVID -19 tests and elevated levels of \ndemand for PPE.  We  procured these products in a market with unprecedented and unpredictable supply and \ndemand levels.  The volatility associated with COVID case levels impacted the demand levels for PPE.  \n \n The demand tapering occurred sooner than we had anticipated and we too k action to position the business for the \nlower demand levels. ", "original_text": "As we discussed in prior calls this year, early on in the pandemic, our Medical Surgical \nbusiness built supply quickly to meet demands from our customers for COVID -19 tests and elevated levels of \ndemand for PPE. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c292be1ce6348202283d7e1636a304eefc405178b57811a1e3c3b3d3ee9c6a74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d6aa344-03e0-49d6-a675-09e99968378c", "node_type": "1", "metadata": {"window": "As we discussed at various conferences during our fourth quarter, we anticipated that these elevated levels of \ndemand would moderate.  As we discussed in prior calls this year, early on in the pandemic, our Medical Surgical \nbusiness built supply quickly to meet demands from our customers for COVID -19 tests and elevated levels of \ndemand for PPE.  We  procured these products in a market with unprecedented and unpredictable supply and \ndemand levels.  The volatility associated with COVID case levels impacted the demand levels for PPE.  \n \n The demand tapering occurred sooner than we had anticipated and we too k action to position the business for the \nlower demand levels.  As a result, some PPE and related products experienced market driven inventory charges. \n In our fourth quarter we recorded $87 million of charges related to these products. ", "original_text": "The volatility associated with COVID case levels impacted the demand levels for PPE.  \n \n"}, "hash": "d67fe99a9f360b47734723df8491d622f4c900598f4e04f7a2897e517edb889a", "class_name": "RelatedNodeInfo"}}, "text": "We  procured these products in a market with unprecedented and unpredictable supply and \ndemand levels. ", "start_char_idx": 2620, "end_char_idx": 2724, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d6aa344-03e0-49d6-a675-09e99968378c": {"__data__": {"id_": "0d6aa344-03e0-49d6-a675-09e99968378c", "embedding": null, "metadata": {"window": "As we discussed at various conferences during our fourth quarter, we anticipated that these elevated levels of \ndemand would moderate.  As we discussed in prior calls this year, early on in the pandemic, our Medical Surgical \nbusiness built supply quickly to meet demands from our customers for COVID -19 tests and elevated levels of \ndemand for PPE.  We  procured these products in a market with unprecedented and unpredictable supply and \ndemand levels.  The volatility associated with COVID case levels impacted the demand levels for PPE.  \n \n The demand tapering occurred sooner than we had anticipated and we too k action to position the business for the \nlower demand levels.  As a result, some PPE and related products experienced market driven inventory charges. \n In our fourth quarter we recorded $87 million of charges related to these products. ", "original_text": "The volatility associated with COVID case levels impacted the demand levels for PPE.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4229d4351894ca10fe32a58b3b00ca3385f146d5f133963d7d9758a0b1f10fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5093e3af-ef58-4ffc-9219-78a57f05aec6", "node_type": "1", "metadata": {"window": "Although COVID -19 test k it volume continued \nthrough the fourth quarter, these levels moderated significantly from Q3 levels as US COVID cases trended lower \nthroughout the quarter.  \n \n As we discussed at various conferences during our fourth quarter, we anticipated that these elevated levels of \ndemand would moderate.  As we discussed in prior calls this year, early on in the pandemic, our Medical Surgical \nbusiness built supply quickly to meet demands from our customers for COVID -19 tests and elevated levels of \ndemand for PPE.  We  procured these products in a market with unprecedented and unpredictable supply and \ndemand levels.  The volatility associated with COVID case levels impacted the demand levels for PPE.  \n \n The demand tapering occurred sooner than we had anticipated and we too k action to position the business for the \nlower demand levels.  As a result, some PPE and related products experienced market driven inventory charges. \n", "original_text": "We  procured these products in a market with unprecedented and unpredictable supply and \ndemand levels. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28975e3f748545b5cbbc82a3163b40038dbbe5571f522ad71501bd839e07a785", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9986ff9b-ed8c-4db2-a408-4ebf18119bb6", "node_type": "1", "metadata": {"window": "As we discussed in prior calls this year, early on in the pandemic, our Medical Surgical \nbusiness built supply quickly to meet demands from our customers for COVID -19 tests and elevated levels of \ndemand for PPE.  We  procured these products in a market with unprecedented and unpredictable supply and \ndemand levels.  The volatility associated with COVID case levels impacted the demand levels for PPE.  \n \n The demand tapering occurred sooner than we had anticipated and we too k action to position the business for the \nlower demand levels.  As a result, some PPE and related products experienced market driven inventory charges. \n In our fourth quarter we recorded $87 million of charges related to these products.  Our underlying busine ss was \nimpacted by lower levels of elective procedures and patient visits partially resulting from the continuation of a \nweaker cold and flu season. ", "original_text": "The demand tapering occurred sooner than we had anticipated and we too k action to position the business for the \nlower demand levels. "}, "hash": "228a355e5014ad93e2898fa0daadf7ee9c75f3da06df6fd4614cab2a7ff19086", "class_name": "RelatedNodeInfo"}}, "text": "The volatility associated with COVID case levels impacted the demand levels for PPE.  \n \n", "start_char_idx": 2724, "end_char_idx": 2813, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9986ff9b-ed8c-4db2-a408-4ebf18119bb6": {"__data__": {"id_": "9986ff9b-ed8c-4db2-a408-4ebf18119bb6", "embedding": null, "metadata": {"window": "As we discussed in prior calls this year, early on in the pandemic, our Medical Surgical \nbusiness built supply quickly to meet demands from our customers for COVID -19 tests and elevated levels of \ndemand for PPE.  We  procured these products in a market with unprecedented and unpredictable supply and \ndemand levels.  The volatility associated with COVID case levels impacted the demand levels for PPE.  \n \n The demand tapering occurred sooner than we had anticipated and we too k action to position the business for the \nlower demand levels.  As a result, some PPE and related products experienced market driven inventory charges. \n In our fourth quarter we recorded $87 million of charges related to these products.  Our underlying busine ss was \nimpacted by lower levels of elective procedures and patient visits partially resulting from the continuation of a \nweaker cold and flu season. ", "original_text": "The demand tapering occurred sooner than we had anticipated and we too k action to position the business for the \nlower demand levels. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4229d4351894ca10fe32a58b3b00ca3385f146d5f133963d7d9758a0b1f10fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d6aa344-03e0-49d6-a675-09e99968378c", "node_type": "1", "metadata": {"window": "As we discussed at various conferences during our fourth quarter, we anticipated that these elevated levels of \ndemand would moderate.  As we discussed in prior calls this year, early on in the pandemic, our Medical Surgical \nbusiness built supply quickly to meet demands from our customers for COVID -19 tests and elevated levels of \ndemand for PPE.  We  procured these products in a market with unprecedented and unpredictable supply and \ndemand levels.  The volatility associated with COVID case levels impacted the demand levels for PPE.  \n \n The demand tapering occurred sooner than we had anticipated and we too k action to position the business for the \nlower demand levels.  As a result, some PPE and related products experienced market driven inventory charges. \n In our fourth quarter we recorded $87 million of charges related to these products. ", "original_text": "The volatility associated with COVID case levels impacted the demand levels for PPE.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5532a9dec1403013de0066b8ac48e7bde5c69c6a54170b3b823e1bbcfe70cff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4bc6ee1-b9df-40c9-b01b-d412530d6206", "node_type": "1", "metadata": {"window": "We  procured these products in a market with unprecedented and unpredictable supply and \ndemand levels.  The volatility associated with COVID case levels impacted the demand levels for PPE.  \n \n The demand tapering occurred sooner than we had anticipated and we too k action to position the business for the \nlower demand levels.  As a result, some PPE and related products experienced market driven inventory charges. \n In our fourth quarter we recorded $87 million of charges related to these products.  Our underlying busine ss was \nimpacted by lower levels of elective procedures and patient visits partially resulting from the continuation of a \nweaker cold and flu season.  According to IQVIA elective procedures trended approximately 20% below the prior \nyear at times during the q uarter.  \n \n", "original_text": "As a result, some PPE and related products experienced market driven inventory charges. \n"}, "hash": "1f23dc945e55afb99072a298218610202896f6f006ac765a2eab07add7a7804d", "class_name": "RelatedNodeInfo"}}, "text": "The demand tapering occurred sooner than we had anticipated and we too k action to position the business for the \nlower demand levels. ", "start_char_idx": 2813, "end_char_idx": 2948, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4bc6ee1-b9df-40c9-b01b-d412530d6206": {"__data__": {"id_": "d4bc6ee1-b9df-40c9-b01b-d412530d6206", "embedding": null, "metadata": {"window": "We  procured these products in a market with unprecedented and unpredictable supply and \ndemand levels.  The volatility associated with COVID case levels impacted the demand levels for PPE.  \n \n The demand tapering occurred sooner than we had anticipated and we too k action to position the business for the \nlower demand levels.  As a result, some PPE and related products experienced market driven inventory charges. \n In our fourth quarter we recorded $87 million of charges related to these products.  Our underlying busine ss was \nimpacted by lower levels of elective procedures and patient visits partially resulting from the continuation of a \nweaker cold and flu season.  According to IQVIA elective procedures trended approximately 20% below the prior \nyear at times during the q uarter.  \n \n", "original_text": "As a result, some PPE and related products experienced market driven inventory charges. \n", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4229d4351894ca10fe32a58b3b00ca3385f146d5f133963d7d9758a0b1f10fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9986ff9b-ed8c-4db2-a408-4ebf18119bb6", "node_type": "1", "metadata": {"window": "As we discussed in prior calls this year, early on in the pandemic, our Medical Surgical \nbusiness built supply quickly to meet demands from our customers for COVID -19 tests and elevated levels of \ndemand for PPE.  We  procured these products in a market with unprecedented and unpredictable supply and \ndemand levels.  The volatility associated with COVID case levels impacted the demand levels for PPE.  \n \n The demand tapering occurred sooner than we had anticipated and we too k action to position the business for the \nlower demand levels.  As a result, some PPE and related products experienced market driven inventory charges. \n In our fourth quarter we recorded $87 million of charges related to these products.  Our underlying busine ss was \nimpacted by lower levels of elective procedures and patient visits partially resulting from the continuation of a \nweaker cold and flu season. ", "original_text": "The demand tapering occurred sooner than we had anticipated and we too k action to position the business for the \nlower demand levels. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94a327df3ce5b4fe618d7b8c21a60f4ed6fcae7619050eb43abab1826c96853f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c48105c3-ddf4-4f6a-85a5-7213455aa53d", "node_type": "1", "metadata": {"window": "The volatility associated with COVID case levels impacted the demand levels for PPE.  \n \n The demand tapering occurred sooner than we had anticipated and we too k action to position the business for the \nlower demand levels.  As a result, some PPE and related products experienced market driven inventory charges. \n In our fourth quarter we recorded $87 million of charges related to these products.  Our underlying busine ss was \nimpacted by lower levels of elective procedures and patient visits partially resulting from the continuation of a \nweaker cold and flu season.  According to IQVIA elective procedures trended approximately 20% below the prior \nyear at times during the q uarter.  \n \n Excluding the impact of the incremental COVID -19 tests, PPE and distribution of ancillary supply kits for COVID -\n19 vaccines, adjusted operating profit in this segment increased approximately 1% in the quarter.  \n \n", "original_text": "In our fourth quarter we recorded $87 million of charges related to these products. "}, "hash": "556258393c219490cc5fcff2390f815b7eb044635a5998fddbd1f37cee5714ff", "class_name": "RelatedNodeInfo"}}, "text": "As a result, some PPE and related products experienced market driven inventory charges. \n", "start_char_idx": 2948, "end_char_idx": 3037, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c48105c3-ddf4-4f6a-85a5-7213455aa53d": {"__data__": {"id_": "c48105c3-ddf4-4f6a-85a5-7213455aa53d", "embedding": null, "metadata": {"window": "The volatility associated with COVID case levels impacted the demand levels for PPE.  \n \n The demand tapering occurred sooner than we had anticipated and we too k action to position the business for the \nlower demand levels.  As a result, some PPE and related products experienced market driven inventory charges. \n In our fourth quarter we recorded $87 million of charges related to these products.  Our underlying busine ss was \nimpacted by lower levels of elective procedures and patient visits partially resulting from the continuation of a \nweaker cold and flu season.  According to IQVIA elective procedures trended approximately 20% below the prior \nyear at times during the q uarter.  \n \n Excluding the impact of the incremental COVID -19 tests, PPE and distribution of ancillary supply kits for COVID -\n19 vaccines, adjusted operating profit in this segment increased approximately 1% in the quarter.  \n \n", "original_text": "In our fourth quarter we recorded $87 million of charges related to these products. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4229d4351894ca10fe32a58b3b00ca3385f146d5f133963d7d9758a0b1f10fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4bc6ee1-b9df-40c9-b01b-d412530d6206", "node_type": "1", "metadata": {"window": "We  procured these products in a market with unprecedented and unpredictable supply and \ndemand levels.  The volatility associated with COVID case levels impacted the demand levels for PPE.  \n \n The demand tapering occurred sooner than we had anticipated and we too k action to position the business for the \nlower demand levels.  As a result, some PPE and related products experienced market driven inventory charges. \n In our fourth quarter we recorded $87 million of charges related to these products.  Our underlying busine ss was \nimpacted by lower levels of elective procedures and patient visits partially resulting from the continuation of a \nweaker cold and flu season.  According to IQVIA elective procedures trended approximately 20% below the prior \nyear at times during the q uarter.  \n \n", "original_text": "As a result, some PPE and related products experienced market driven inventory charges. \n", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a9d81e47c3d75a9b5c83024824fff0b4d9e495963aad5b5b810800f63618844", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9a0fec9-eadc-42be-9a37-18a6c9569b96", "node_type": "1", "metadata": {"window": "The demand tapering occurred sooner than we had anticipated and we too k action to position the business for the \nlower demand levels.  As a result, some PPE and related products experienced market driven inventory charges. \n In our fourth quarter we recorded $87 million of charges related to these products.  Our underlying busine ss was \nimpacted by lower levels of elective procedures and patient visits partially resulting from the continuation of a \nweaker cold and flu season.  According to IQVIA elective procedures trended approximately 20% below the prior \nyear at times during the q uarter.  \n \n Excluding the impact of the incremental COVID -19 tests, PPE and distribution of ancillary supply kits for COVID -\n19 vaccines, adjusted operating profit in this segment increased approximately 1% in the quarter.  \n \n Next, International where revenues i n the quarter were $8.6 billion, a decrease of 12% year over year. ", "original_text": "Our underlying busine ss was \nimpacted by lower levels of elective procedures and patient visits partially resulting from the continuation of a \nweaker cold and flu season. "}, "hash": "d127ad136e72e6b177d57924ee1ed4a49ae2996821ce0d03f581a4deabf4e34f", "class_name": "RelatedNodeInfo"}}, "text": "In our fourth quarter we recorded $87 million of charges related to these products. ", "start_char_idx": 3037, "end_char_idx": 3121, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9a0fec9-eadc-42be-9a37-18a6c9569b96": {"__data__": {"id_": "a9a0fec9-eadc-42be-9a37-18a6c9569b96", "embedding": null, "metadata": {"window": "The demand tapering occurred sooner than we had anticipated and we too k action to position the business for the \nlower demand levels.  As a result, some PPE and related products experienced market driven inventory charges. \n In our fourth quarter we recorded $87 million of charges related to these products.  Our underlying busine ss was \nimpacted by lower levels of elective procedures and patient visits partially resulting from the continuation of a \nweaker cold and flu season.  According to IQVIA elective procedures trended approximately 20% below the prior \nyear at times during the q uarter.  \n \n Excluding the impact of the incremental COVID -19 tests, PPE and distribution of ancillary supply kits for COVID -\n19 vaccines, adjusted operating profit in this segment increased approximately 1% in the quarter.  \n \n Next, International where revenues i n the quarter were $8.6 billion, a decrease of 12% year over year. ", "original_text": "Our underlying busine ss was \nimpacted by lower levels of elective procedures and patient visits partially resulting from the continuation of a \nweaker cold and flu season. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4229d4351894ca10fe32a58b3b00ca3385f146d5f133963d7d9758a0b1f10fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c48105c3-ddf4-4f6a-85a5-7213455aa53d", "node_type": "1", "metadata": {"window": "The volatility associated with COVID case levels impacted the demand levels for PPE.  \n \n The demand tapering occurred sooner than we had anticipated and we too k action to position the business for the \nlower demand levels.  As a result, some PPE and related products experienced market driven inventory charges. \n In our fourth quarter we recorded $87 million of charges related to these products.  Our underlying busine ss was \nimpacted by lower levels of elective procedures and patient visits partially resulting from the continuation of a \nweaker cold and flu season.  According to IQVIA elective procedures trended approximately 20% below the prior \nyear at times during the q uarter.  \n \n Excluding the impact of the incremental COVID -19 tests, PPE and distribution of ancillary supply kits for COVID -\n19 vaccines, adjusted operating profit in this segment increased approximately 1% in the quarter.  \n \n", "original_text": "In our fourth quarter we recorded $87 million of charges related to these products. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bf59787a4ed0cae6d82b76c78ad4c57818e152f56770d96d9ebd47ca35ba11e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b140341-94c3-490c-af68-f121e6b49453", "node_type": "1", "metadata": {"window": "As a result, some PPE and related products experienced market driven inventory charges. \n In our fourth quarter we recorded $87 million of charges related to these products.  Our underlying busine ss was \nimpacted by lower levels of elective procedures and patient visits partially resulting from the continuation of a \nweaker cold and flu season.  According to IQVIA elective procedures trended approximately 20% below the prior \nyear at times during the q uarter.  \n \n Excluding the impact of the incremental COVID -19 tests, PPE and distribution of ancillary supply kits for COVID -\n19 vaccines, adjusted operating profit in this segment increased approximately 1% in the quarter.  \n \n Next, International where revenues i n the quarter were $8.6 billion, a decrease of 12% year over year.  On an FX \nadjusted basis revenues decreased 18% primarily driven by the contribution of our German wholesale business to \na joint venture with Walgreens Boots Alliance effective November 1, 2 020. ", "original_text": "According to IQVIA elective procedures trended approximately 20% below the prior \nyear at times during the q uarter.  \n \n"}, "hash": "d8d0083c535f7dd07f1ddbb6d72d1ab3493b63b42075b1174f16aa1472cf4895", "class_name": "RelatedNodeInfo"}}, "text": "Our underlying busine ss was \nimpacted by lower levels of elective procedures and patient visits partially resulting from the continuation of a \nweaker cold and flu season. ", "start_char_idx": 3121, "end_char_idx": 3294, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b140341-94c3-490c-af68-f121e6b49453": {"__data__": {"id_": "7b140341-94c3-490c-af68-f121e6b49453", "embedding": null, "metadata": {"window": "As a result, some PPE and related products experienced market driven inventory charges. \n In our fourth quarter we recorded $87 million of charges related to these products.  Our underlying busine ss was \nimpacted by lower levels of elective procedures and patient visits partially resulting from the continuation of a \nweaker cold and flu season.  According to IQVIA elective procedures trended approximately 20% below the prior \nyear at times during the q uarter.  \n \n Excluding the impact of the incremental COVID -19 tests, PPE and distribution of ancillary supply kits for COVID -\n19 vaccines, adjusted operating profit in this segment increased approximately 1% in the quarter.  \n \n Next, International where revenues i n the quarter were $8.6 billion, a decrease of 12% year over year.  On an FX \nadjusted basis revenues decreased 18% primarily driven by the contribution of our German wholesale business to \na joint venture with Walgreens Boots Alliance effective November 1, 2 020. ", "original_text": "According to IQVIA elective procedures trended approximately 20% below the prior \nyear at times during the q uarter.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4229d4351894ca10fe32a58b3b00ca3385f146d5f133963d7d9758a0b1f10fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9a0fec9-eadc-42be-9a37-18a6c9569b96", "node_type": "1", "metadata": {"window": "The demand tapering occurred sooner than we had anticipated and we too k action to position the business for the \nlower demand levels.  As a result, some PPE and related products experienced market driven inventory charges. \n In our fourth quarter we recorded $87 million of charges related to these products.  Our underlying busine ss was \nimpacted by lower levels of elective procedures and patient visits partially resulting from the continuation of a \nweaker cold and flu season.  According to IQVIA elective procedures trended approximately 20% below the prior \nyear at times during the q uarter.  \n \n Excluding the impact of the incremental COVID -19 tests, PPE and distribution of ancillary supply kits for COVID -\n19 vaccines, adjusted operating profit in this segment increased approximately 1% in the quarter.  \n \n Next, International where revenues i n the quarter were $8.6 billion, a decrease of 12% year over year. ", "original_text": "Our underlying busine ss was \nimpacted by lower levels of elective procedures and patient visits partially resulting from the continuation of a \nweaker cold and flu season. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ffb5b6035ea7466cefdfb1cc4bcd1b674c9fe4a9ffda1aee71767f98e61e996", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0c03de6-26aa-43f8-b3d1-234ab0e15fb7", "node_type": "1", "metadata": {"window": "In our fourth quarter we recorded $87 million of charges related to these products.  Our underlying busine ss was \nimpacted by lower levels of elective procedures and patient visits partially resulting from the continuation of a \nweaker cold and flu season.  According to IQVIA elective procedures trended approximately 20% below the prior \nyear at times during the q uarter.  \n \n Excluding the impact of the incremental COVID -19 tests, PPE and distribution of ancillary supply kits for COVID -\n19 vaccines, adjusted operating profit in this segment increased approximately 1% in the quarter.  \n \n Next, International where revenues i n the quarter were $8.6 billion, a decrease of 12% year over year.  On an FX \nadjusted basis revenues decreased 18% primarily driven by the contribution of our German wholesale business to \na joint venture with Walgreens Boots Alliance effective November 1, 2 020.  Similar to the US Pharmaceutical \nsegment, the International segment was also impacted by the prior year increasing volume \\, which corresponded \nwith the onset of the COVID -19 pandemic. ", "original_text": "Excluding the impact of the incremental COVID -19 tests, PPE and distribution of ancillary supply kits for COVID -\n19 vaccines, adjusted operating profit in this segment increased approximately 1% in the quarter.  \n \n"}, "hash": "764bae476bbdf1a1e669596520547ebf6ee26af3de34a10f8f60c77eb9466a02", "class_name": "RelatedNodeInfo"}}, "text": "According to IQVIA elective procedures trended approximately 20% below the prior \nyear at times during the q uarter.  \n \n", "start_char_idx": 3294, "end_char_idx": 3415, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0c03de6-26aa-43f8-b3d1-234ab0e15fb7": {"__data__": {"id_": "b0c03de6-26aa-43f8-b3d1-234ab0e15fb7", "embedding": null, "metadata": {"window": "In our fourth quarter we recorded $87 million of charges related to these products.  Our underlying busine ss was \nimpacted by lower levels of elective procedures and patient visits partially resulting from the continuation of a \nweaker cold and flu season.  According to IQVIA elective procedures trended approximately 20% below the prior \nyear at times during the q uarter.  \n \n Excluding the impact of the incremental COVID -19 tests, PPE and distribution of ancillary supply kits for COVID -\n19 vaccines, adjusted operating profit in this segment increased approximately 1% in the quarter.  \n \n Next, International where revenues i n the quarter were $8.6 billion, a decrease of 12% year over year.  On an FX \nadjusted basis revenues decreased 18% primarily driven by the contribution of our German wholesale business to \na joint venture with Walgreens Boots Alliance effective November 1, 2 020.  Similar to the US Pharmaceutical \nsegment, the International segment was also impacted by the prior year increasing volume \\, which corresponded \nwith the onset of the COVID -19 pandemic. ", "original_text": "Excluding the impact of the incremental COVID -19 tests, PPE and distribution of ancillary supply kits for COVID -\n19 vaccines, adjusted operating profit in this segment increased approximately 1% in the quarter.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4229d4351894ca10fe32a58b3b00ca3385f146d5f133963d7d9758a0b1f10fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b140341-94c3-490c-af68-f121e6b49453", "node_type": "1", "metadata": {"window": "As a result, some PPE and related products experienced market driven inventory charges. \n In our fourth quarter we recorded $87 million of charges related to these products.  Our underlying busine ss was \nimpacted by lower levels of elective procedures and patient visits partially resulting from the continuation of a \nweaker cold and flu season.  According to IQVIA elective procedures trended approximately 20% below the prior \nyear at times during the q uarter.  \n \n Excluding the impact of the incremental COVID -19 tests, PPE and distribution of ancillary supply kits for COVID -\n19 vaccines, adjusted operating profit in this segment increased approximately 1% in the quarter.  \n \n Next, International where revenues i n the quarter were $8.6 billion, a decrease of 12% year over year.  On an FX \nadjusted basis revenues decreased 18% primarily driven by the contribution of our German wholesale business to \na joint venture with Walgreens Boots Alliance effective November 1, 2 020. ", "original_text": "According to IQVIA elective procedures trended approximately 20% below the prior \nyear at times during the q uarter.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc872ec78550333a212beaabea0ad7c39aca3f9bd03bd1e9e792859035ce4410", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98ba4198-ed24-4651-a995-bfb793f3113b", "node_type": "1", "metadata": {"window": "Our underlying busine ss was \nimpacted by lower levels of elective procedures and patient visits partially resulting from the continuation of a \nweaker cold and flu season.  According to IQVIA elective procedures trended approximately 20% below the prior \nyear at times during the q uarter.  \n \n Excluding the impact of the incremental COVID -19 tests, PPE and distribution of ancillary supply kits for COVID -\n19 vaccines, adjusted operating profit in this segment increased approximately 1% in the quarter.  \n \n Next, International where revenues i n the quarter were $8.6 billion, a decrease of 12% year over year.  On an FX \nadjusted basis revenues decreased 18% primarily driven by the contribution of our German wholesale business to \na joint venture with Walgreens Boots Alliance effective November 1, 2 020.  Similar to the US Pharmaceutical \nsegment, the International segment was also impacted by the prior year increasing volume \\, which corresponded \nwith the onset of the COVID -19 pandemic.  Excluding the impact of the divestiture of our German wholesale \nbusiness, segment revenue increased 4% year over year and was down 4% on an FX adjusted basis.  \n ", "original_text": "Next, International where revenues i n the quarter were $8.6 billion, a decrease of 12% year over year. "}, "hash": "09539a4d7ccd9295d8e0c0c68427173e45f52ca24f44ca2d2d9f8504fd5f3de1", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impact of the incremental COVID -19 tests, PPE and distribution of ancillary supply kits for COVID -\n19 vaccines, adjusted operating profit in this segment increased approximately 1% in the quarter.  \n \n", "start_char_idx": 3415, "end_char_idx": 3632, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98ba4198-ed24-4651-a995-bfb793f3113b": {"__data__": {"id_": "98ba4198-ed24-4651-a995-bfb793f3113b", "embedding": null, "metadata": {"window": "Our underlying busine ss was \nimpacted by lower levels of elective procedures and patient visits partially resulting from the continuation of a \nweaker cold and flu season.  According to IQVIA elective procedures trended approximately 20% below the prior \nyear at times during the q uarter.  \n \n Excluding the impact of the incremental COVID -19 tests, PPE and distribution of ancillary supply kits for COVID -\n19 vaccines, adjusted operating profit in this segment increased approximately 1% in the quarter.  \n \n Next, International where revenues i n the quarter were $8.6 billion, a decrease of 12% year over year.  On an FX \nadjusted basis revenues decreased 18% primarily driven by the contribution of our German wholesale business to \na joint venture with Walgreens Boots Alliance effective November 1, 2 020.  Similar to the US Pharmaceutical \nsegment, the International segment was also impacted by the prior year increasing volume \\, which corresponded \nwith the onset of the COVID -19 pandemic.  Excluding the impact of the divestiture of our German wholesale \nbusiness, segment revenue increased 4% year over year and was down 4% on an FX adjusted basis.  \n ", "original_text": "Next, International where revenues i n the quarter were $8.6 billion, a decrease of 12% year over year. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4229d4351894ca10fe32a58b3b00ca3385f146d5f133963d7d9758a0b1f10fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0c03de6-26aa-43f8-b3d1-234ab0e15fb7", "node_type": "1", "metadata": {"window": "In our fourth quarter we recorded $87 million of charges related to these products.  Our underlying busine ss was \nimpacted by lower levels of elective procedures and patient visits partially resulting from the continuation of a \nweaker cold and flu season.  According to IQVIA elective procedures trended approximately 20% below the prior \nyear at times during the q uarter.  \n \n Excluding the impact of the incremental COVID -19 tests, PPE and distribution of ancillary supply kits for COVID -\n19 vaccines, adjusted operating profit in this segment increased approximately 1% in the quarter.  \n \n Next, International where revenues i n the quarter were $8.6 billion, a decrease of 12% year over year.  On an FX \nadjusted basis revenues decreased 18% primarily driven by the contribution of our German wholesale business to \na joint venture with Walgreens Boots Alliance effective November 1, 2 020.  Similar to the US Pharmaceutical \nsegment, the International segment was also impacted by the prior year increasing volume \\, which corresponded \nwith the onset of the COVID -19 pandemic. ", "original_text": "Excluding the impact of the incremental COVID -19 tests, PPE and distribution of ancillary supply kits for COVID -\n19 vaccines, adjusted operating profit in this segment increased approximately 1% in the quarter.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4dd09a164c334ddd1f75695279c04e85847a783d875fd424d10346d6305632c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79e125bc-0789-4e37-bbb2-4cd3279dad6c", "node_type": "1", "metadata": {"window": "According to IQVIA elective procedures trended approximately 20% below the prior \nyear at times during the q uarter.  \n \n Excluding the impact of the incremental COVID -19 tests, PPE and distribution of ancillary supply kits for COVID -\n19 vaccines, adjusted operating profit in this segment increased approximately 1% in the quarter.  \n \n Next, International where revenues i n the quarter were $8.6 billion, a decrease of 12% year over year.  On an FX \nadjusted basis revenues decreased 18% primarily driven by the contribution of our German wholesale business to \na joint venture with Walgreens Boots Alliance effective November 1, 2 020.  Similar to the US Pharmaceutical \nsegment, the International segment was also impacted by the prior year increasing volume \\, which corresponded \nwith the onset of the COVID -19 pandemic.  Excluding the impact of the divestiture of our German wholesale \nbusiness, segment revenue increased 4% year over year and was down 4% on an FX adjusted basis.  \n ", "original_text": "On an FX \nadjusted basis revenues decreased 18% primarily driven by the contribution of our German wholesale business to \na joint venture with Walgreens Boots Alliance effective November 1, 2 020. "}, "hash": "6c4ea16e13be11d85f3fb64a7ed0f68bbafea7ec8a740ca0f2cf7a61c5692455", "class_name": "RelatedNodeInfo"}}, "text": "Next, International where revenues i n the quarter were $8.6 billion, a decrease of 12% year over year. ", "start_char_idx": 3632, "end_char_idx": 3736, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79e125bc-0789-4e37-bbb2-4cd3279dad6c": {"__data__": {"id_": "79e125bc-0789-4e37-bbb2-4cd3279dad6c", "embedding": null, "metadata": {"window": "According to IQVIA elective procedures trended approximately 20% below the prior \nyear at times during the q uarter.  \n \n Excluding the impact of the incremental COVID -19 tests, PPE and distribution of ancillary supply kits for COVID -\n19 vaccines, adjusted operating profit in this segment increased approximately 1% in the quarter.  \n \n Next, International where revenues i n the quarter were $8.6 billion, a decrease of 12% year over year.  On an FX \nadjusted basis revenues decreased 18% primarily driven by the contribution of our German wholesale business to \na joint venture with Walgreens Boots Alliance effective November 1, 2 020.  Similar to the US Pharmaceutical \nsegment, the International segment was also impacted by the prior year increasing volume \\, which corresponded \nwith the onset of the COVID -19 pandemic.  Excluding the impact of the divestiture of our German wholesale \nbusiness, segment revenue increased 4% year over year and was down 4% on an FX adjusted basis.  \n ", "original_text": "On an FX \nadjusted basis revenues decreased 18% primarily driven by the contribution of our German wholesale business to \na joint venture with Walgreens Boots Alliance effective November 1, 2 020. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4229d4351894ca10fe32a58b3b00ca3385f146d5f133963d7d9758a0b1f10fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98ba4198-ed24-4651-a995-bfb793f3113b", "node_type": "1", "metadata": {"window": "Our underlying busine ss was \nimpacted by lower levels of elective procedures and patient visits partially resulting from the continuation of a \nweaker cold and flu season.  According to IQVIA elective procedures trended approximately 20% below the prior \nyear at times during the q uarter.  \n \n Excluding the impact of the incremental COVID -19 tests, PPE and distribution of ancillary supply kits for COVID -\n19 vaccines, adjusted operating profit in this segment increased approximately 1% in the quarter.  \n \n Next, International where revenues i n the quarter were $8.6 billion, a decrease of 12% year over year.  On an FX \nadjusted basis revenues decreased 18% primarily driven by the contribution of our German wholesale business to \na joint venture with Walgreens Boots Alliance effective November 1, 2 020.  Similar to the US Pharmaceutical \nsegment, the International segment was also impacted by the prior year increasing volume \\, which corresponded \nwith the onset of the COVID -19 pandemic.  Excluding the impact of the divestiture of our German wholesale \nbusiness, segment revenue increased 4% year over year and was down 4% on an FX adjusted basis.  \n ", "original_text": "Next, International where revenues i n the quarter were $8.6 billion, a decrease of 12% year over year. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d69fe7df126d30682fd7f30fb6f1d00ea1e3212903556146368f8a1be942fbb0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5cd654fa-82ff-4dc9-833c-2a7d8525e9a3", "node_type": "1", "metadata": {"window": "Excluding the impact of the incremental COVID -19 tests, PPE and distribution of ancillary supply kits for COVID -\n19 vaccines, adjusted operating profit in this segment increased approximately 1% in the quarter.  \n \n Next, International where revenues i n the quarter were $8.6 billion, a decrease of 12% year over year.  On an FX \nadjusted basis revenues decreased 18% primarily driven by the contribution of our German wholesale business to \na joint venture with Walgreens Boots Alliance effective November 1, 2 020.  Similar to the US Pharmaceutical \nsegment, the International segment was also impacted by the prior year increasing volume \\, which corresponded \nwith the onset of the COVID -19 pandemic.  Excluding the impact of the divestiture of our German wholesale \nbusiness, segment revenue increased 4% year over year and was down 4% on an FX adjusted basis.  \n ", "original_text": "Similar to the US Pharmaceutical \nsegment, the International segment was also impacted by the prior year increasing volume \\, which corresponded \nwith the onset of the COVID -19 pandemic. "}, "hash": "8e9100fb339472de65f23bf2c9f8b12f61b55690d651b87264ce52b80b6709b8", "class_name": "RelatedNodeInfo"}}, "text": "On an FX \nadjusted basis revenues decreased 18% primarily driven by the contribution of our German wholesale business to \na joint venture with Walgreens Boots Alliance effective November 1, 2 020. ", "start_char_idx": 3736, "end_char_idx": 3933, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5cd654fa-82ff-4dc9-833c-2a7d8525e9a3": {"__data__": {"id_": "5cd654fa-82ff-4dc9-833c-2a7d8525e9a3", "embedding": null, "metadata": {"window": "Excluding the impact of the incremental COVID -19 tests, PPE and distribution of ancillary supply kits for COVID -\n19 vaccines, adjusted operating profit in this segment increased approximately 1% in the quarter.  \n \n Next, International where revenues i n the quarter were $8.6 billion, a decrease of 12% year over year.  On an FX \nadjusted basis revenues decreased 18% primarily driven by the contribution of our German wholesale business to \na joint venture with Walgreens Boots Alliance effective November 1, 2 020.  Similar to the US Pharmaceutical \nsegment, the International segment was also impacted by the prior year increasing volume \\, which corresponded \nwith the onset of the COVID -19 pandemic.  Excluding the impact of the divestiture of our German wholesale \nbusiness, segment revenue increased 4% year over year and was down 4% on an FX adjusted basis.  \n ", "original_text": "Similar to the US Pharmaceutical \nsegment, the International segment was also impacted by the prior year increasing volume \\, which corresponded \nwith the onset of the COVID -19 pandemic. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4229d4351894ca10fe32a58b3b00ca3385f146d5f133963d7d9758a0b1f10fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79e125bc-0789-4e37-bbb2-4cd3279dad6c", "node_type": "1", "metadata": {"window": "According to IQVIA elective procedures trended approximately 20% below the prior \nyear at times during the q uarter.  \n \n Excluding the impact of the incremental COVID -19 tests, PPE and distribution of ancillary supply kits for COVID -\n19 vaccines, adjusted operating profit in this segment increased approximately 1% in the quarter.  \n \n Next, International where revenues i n the quarter were $8.6 billion, a decrease of 12% year over year.  On an FX \nadjusted basis revenues decreased 18% primarily driven by the contribution of our German wholesale business to \na joint venture with Walgreens Boots Alliance effective November 1, 2 020.  Similar to the US Pharmaceutical \nsegment, the International segment was also impacted by the prior year increasing volume \\, which corresponded \nwith the onset of the COVID -19 pandemic.  Excluding the impact of the divestiture of our German wholesale \nbusiness, segment revenue increased 4% year over year and was down 4% on an FX adjusted basis.  \n ", "original_text": "On an FX \nadjusted basis revenues decreased 18% primarily driven by the contribution of our German wholesale business to \na joint venture with Walgreens Boots Alliance effective November 1, 2 020. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "024ec84c698827c26eeb9e2113792d9e53aaf6256b8e223c9d192b2d42074c8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1111dcb9-eb02-4036-9121-2564b8749144", "node_type": "1", "metadata": {"window": "Next, International where revenues i n the quarter were $8.6 billion, a decrease of 12% year over year.  On an FX \nadjusted basis revenues decreased 18% primarily driven by the contribution of our German wholesale business to \na joint venture with Walgreens Boots Alliance effective November 1, 2 020.  Similar to the US Pharmaceutical \nsegment, the International segment was also impacted by the prior year increasing volume \\, which corresponded \nwith the onset of the COVID -19 pandemic.  Excluding the impact of the divestiture of our German wholesale \nbusiness, segment revenue increased 4% year over year and was down 4% on an FX adjusted basis.  \n ", "original_text": "Excluding the impact of the divestiture of our German wholesale \nbusiness, segment revenue increased 4% year over year and was down 4% on an FX adjusted basis.  \n "}, "hash": "3381bf35cb9d47330dd0f4708921b49cdda4caff54b83da5dfb28e72935c8d5e", "class_name": "RelatedNodeInfo"}}, "text": "Similar to the US Pharmaceutical \nsegment, the International segment was also impacted by the prior year increasing volume \\, which corresponded \nwith the onset of the COVID -19 pandemic. ", "start_char_idx": 3933, "end_char_idx": 4121, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1111dcb9-eb02-4036-9121-2564b8749144": {"__data__": {"id_": "1111dcb9-eb02-4036-9121-2564b8749144", "embedding": null, "metadata": {"window": "Next, International where revenues i n the quarter were $8.6 billion, a decrease of 12% year over year.  On an FX \nadjusted basis revenues decreased 18% primarily driven by the contribution of our German wholesale business to \na joint venture with Walgreens Boots Alliance effective November 1, 2 020.  Similar to the US Pharmaceutical \nsegment, the International segment was also impacted by the prior year increasing volume \\, which corresponded \nwith the onset of the COVID -19 pandemic.  Excluding the impact of the divestiture of our German wholesale \nbusiness, segment revenue increased 4% year over year and was down 4% on an FX adjusted basis.  \n ", "original_text": "Excluding the impact of the divestiture of our German wholesale \nbusiness, segment revenue increased 4% year over year and was down 4% on an FX adjusted basis.  \n ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4229d4351894ca10fe32a58b3b00ca3385f146d5f133963d7d9758a0b1f10fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5cd654fa-82ff-4dc9-833c-2a7d8525e9a3", "node_type": "1", "metadata": {"window": "Excluding the impact of the incremental COVID -19 tests, PPE and distribution of ancillary supply kits for COVID -\n19 vaccines, adjusted operating profit in this segment increased approximately 1% in the quarter.  \n \n Next, International where revenues i n the quarter were $8.6 billion, a decrease of 12% year over year.  On an FX \nadjusted basis revenues decreased 18% primarily driven by the contribution of our German wholesale business to \na joint venture with Walgreens Boots Alliance effective November 1, 2 020.  Similar to the US Pharmaceutical \nsegment, the International segment was also impacted by the prior year increasing volume \\, which corresponded \nwith the onset of the COVID -19 pandemic.  Excluding the impact of the divestiture of our German wholesale \nbusiness, segment revenue increased 4% year over year and was down 4% on an FX adjusted basis.  \n ", "original_text": "Similar to the US Pharmaceutical \nsegment, the International segment was also impacted by the prior year increasing volume \\, which corresponded \nwith the onset of the COVID -19 pandemic. ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd850bd5a95cad688d4c730e8b71759a4ccc7aae34bae93e4d185ab4157de763", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22f68303-f56e-45d6-8a16-1d413f32c411", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted operating profit increased 1% year over year to $138 million, on an FX adjusted basis, \nadjusted operating profit decreased, 8% to $126 mill ion due to the previously mentioned fiscal 2020 volume \nincrease, again, driven by the onset of the COVID -19 pandemic.  Adjusted operating profit for the full year \nincreased 5% to $485 million, and on an FX adjusted basis, adjusted operating profit increased  1% to $466 \nmillion.  \n \n Moving on to Corporate, for the quarter, adjusted Corporate expenses were $125 million, a decrease of 42% year \nover year, driven by gains of approximately $44 million on equity investments within our McKesson Ventures' \nportfolio and p rior year one -time expenses. ", "original_text": "McKesson Corp.  "}, "hash": "6d42ce1527acbd312842b529f8f30188fed0b5ac579e6ddc1999c401cbb87b5b", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impact of the divestiture of our German wholesale \nbusiness, segment revenue increased 4% year over year and was down 4% on an FX adjusted basis.  \n ", "start_char_idx": 4121, "end_char_idx": 4284, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22f68303-f56e-45d6-8a16-1d413f32c411": {"__data__": {"id_": "22f68303-f56e-45d6-8a16-1d413f32c411", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted operating profit increased 1% year over year to $138 million, on an FX adjusted basis, \nadjusted operating profit decreased, 8% to $126 mill ion due to the previously mentioned fiscal 2020 volume \nincrease, again, driven by the onset of the COVID -19 pandemic.  Adjusted operating profit for the full year \nincreased 5% to $485 million, and on an FX adjusted basis, adjusted operating profit increased  1% to $466 \nmillion.  \n \n Moving on to Corporate, for the quarter, adjusted Corporate expenses were $125 million, a decrease of 42% year \nover year, driven by gains of approximately $44 million on equity investments within our McKesson Ventures' \nportfolio and p rior year one -time expenses. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d5fe244d752173bfa05665cfe854bf9d972042d92fa2048c25f1053c840950d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1111dcb9-eb02-4036-9121-2564b8749144", "node_type": "1", "metadata": {"window": "Next, International where revenues i n the quarter were $8.6 billion, a decrease of 12% year over year.  On an FX \nadjusted basis revenues decreased 18% primarily driven by the contribution of our German wholesale business to \na joint venture with Walgreens Boots Alliance effective November 1, 2 020.  Similar to the US Pharmaceutical \nsegment, the International segment was also impacted by the prior year increasing volume \\, which corresponded \nwith the onset of the COVID -19 pandemic.  Excluding the impact of the divestiture of our German wholesale \nbusiness, segment revenue increased 4% year over year and was down 4% on an FX adjusted basis.  \n ", "original_text": "Excluding the impact of the divestiture of our German wholesale \nbusiness, segment revenue increased 4% year over year and was down 4% on an FX adjusted basis.  \n ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e965528a5ae189e964817aed0a4bd9c04f68ec68770619e0495f53c72032afc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84f0009a-32da-4310-933a-9b374ed1ee03", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted operating profit increased 1% year over year to $138 million, on an FX adjusted basis, \nadjusted operating profit decreased, 8% to $126 mill ion due to the previously mentioned fiscal 2020 volume \nincrease, again, driven by the onset of the COVID -19 pandemic.  Adjusted operating profit for the full year \nincreased 5% to $485 million, and on an FX adjusted basis, adjusted operating profit increased  1% to $466 \nmillion.  \n \n Moving on to Corporate, for the quarter, adjusted Corporate expenses were $125 million, a decrease of 42% year \nover year, driven by gains of approximately $44 million on equity investments within our McKesson Ventures' \nportfolio and p rior year one -time expenses.  For the full year, adjusted Corporate expenses were $584 million, a \ndecrease of 9% compared to the prior year, driven by gains of approximately $132 million, or 60 cents of adjusted \nearnings per diluted share on equity investme nts within our McKesson Ventures' portfolio, partially offset by lower \ninterest income.  \n \n", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted operating profit increased 1% year over year to $138 million, on an FX adjusted basis, \nadjusted operating profit decreased, 8% to $126 mill ion due to the previously mentioned fiscal 2020 volume \nincrease, again, driven by the onset of the COVID -19 pandemic. "}, "hash": "9cef7d9d0d4e919e006c2cd0634b6f2942161f434eb18a319b2cc0625b6005af", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84f0009a-32da-4310-933a-9b374ed1ee03": {"__data__": {"id_": "84f0009a-32da-4310-933a-9b374ed1ee03", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted operating profit increased 1% year over year to $138 million, on an FX adjusted basis, \nadjusted operating profit decreased, 8% to $126 mill ion due to the previously mentioned fiscal 2020 volume \nincrease, again, driven by the onset of the COVID -19 pandemic.  Adjusted operating profit for the full year \nincreased 5% to $485 million, and on an FX adjusted basis, adjusted operating profit increased  1% to $466 \nmillion.  \n \n Moving on to Corporate, for the quarter, adjusted Corporate expenses were $125 million, a decrease of 42% year \nover year, driven by gains of approximately $44 million on equity investments within our McKesson Ventures' \nportfolio and p rior year one -time expenses.  For the full year, adjusted Corporate expenses were $584 million, a \ndecrease of 9% compared to the prior year, driven by gains of approximately $132 million, or 60 cents of adjusted \nearnings per diluted share on equity investme nts within our McKesson Ventures' portfolio, partially offset by lower \ninterest income.  \n \n", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted operating profit increased 1% year over year to $138 million, on an FX adjusted basis, \nadjusted operating profit decreased, 8% to $126 mill ion due to the previously mentioned fiscal 2020 volume \nincrease, again, driven by the onset of the COVID -19 pandemic. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d5fe244d752173bfa05665cfe854bf9d972042d92fa2048c25f1053c840950d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22f68303-f56e-45d6-8a16-1d413f32c411", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted operating profit increased 1% year over year to $138 million, on an FX adjusted basis, \nadjusted operating profit decreased, 8% to $126 mill ion due to the previously mentioned fiscal 2020 volume \nincrease, again, driven by the onset of the COVID -19 pandemic.  Adjusted operating profit for the full year \nincreased 5% to $485 million, and on an FX adjusted basis, adjusted operating profit increased  1% to $466 \nmillion.  \n \n Moving on to Corporate, for the quarter, adjusted Corporate expenses were $125 million, a decrease of 42% year \nover year, driven by gains of approximately $44 million on equity investments within our McKesson Ventures' \nportfolio and p rior year one -time expenses. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "363da4d0b3e0f674b70b4b3e46fa261fcc8be28fbf11b4e4c66235b7a04e1ec2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a9d9432-2457-4fd9-90c1-91daec7bd102", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted operating profit increased 1% year over year to $138 million, on an FX adjusted basis, \nadjusted operating profit decreased, 8% to $126 mill ion due to the previously mentioned fiscal 2020 volume \nincrease, again, driven by the onset of the COVID -19 pandemic.  Adjusted operating profit for the full year \nincreased 5% to $485 million, and on an FX adjusted basis, adjusted operating profit increased  1% to $466 \nmillion.  \n \n Moving on to Corporate, for the quarter, adjusted Corporate expenses were $125 million, a decrease of 42% year \nover year, driven by gains of approximately $44 million on equity investments within our McKesson Ventures' \nportfolio and p rior year one -time expenses.  For the full year, adjusted Corporate expenses were $584 million, a \ndecrease of 9% compared to the prior year, driven by gains of approximately $132 million, or 60 cents of adjusted \nearnings per diluted share on equity investme nts within our McKesson Ventures' portfolio, partially offset by lower \ninterest income.  \n \n As in the previous two quarters, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures. ", "original_text": "Adjusted operating profit for the full year \nincreased 5% to $485 million, and on an FX adjusted basis, adjusted operating profit increased  1% to $466 \nmillion.  \n \n"}, "hash": "67b5ef801352d5844a18bf13f76001cb24a1fb47bab09f5c8db635a532a48e11", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted operating profit increased 1% year over year to $138 million, on an FX adjusted basis, \nadjusted operating profit decreased, 8% to $126 mill ion due to the previously mentioned fiscal 2020 volume \nincrease, again, driven by the onset of the COVID -19 pandemic. ", "start_char_idx": 16, "end_char_idx": 466, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a9d9432-2457-4fd9-90c1-91daec7bd102": {"__data__": {"id_": "2a9d9432-2457-4fd9-90c1-91daec7bd102", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted operating profit increased 1% year over year to $138 million, on an FX adjusted basis, \nadjusted operating profit decreased, 8% to $126 mill ion due to the previously mentioned fiscal 2020 volume \nincrease, again, driven by the onset of the COVID -19 pandemic.  Adjusted operating profit for the full year \nincreased 5% to $485 million, and on an FX adjusted basis, adjusted operating profit increased  1% to $466 \nmillion.  \n \n Moving on to Corporate, for the quarter, adjusted Corporate expenses were $125 million, a decrease of 42% year \nover year, driven by gains of approximately $44 million on equity investments within our McKesson Ventures' \nportfolio and p rior year one -time expenses.  For the full year, adjusted Corporate expenses were $584 million, a \ndecrease of 9% compared to the prior year, driven by gains of approximately $132 million, or 60 cents of adjusted \nearnings per diluted share on equity investme nts within our McKesson Ventures' portfolio, partially offset by lower \ninterest income.  \n \n As in the previous two quarters, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures. ", "original_text": "Adjusted operating profit for the full year \nincreased 5% to $485 million, and on an FX adjusted basis, adjusted operating profit increased  1% to $466 \nmillion.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d5fe244d752173bfa05665cfe854bf9d972042d92fa2048c25f1053c840950d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84f0009a-32da-4310-933a-9b374ed1ee03", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted operating profit increased 1% year over year to $138 million, on an FX adjusted basis, \nadjusted operating profit decreased, 8% to $126 mill ion due to the previously mentioned fiscal 2020 volume \nincrease, again, driven by the onset of the COVID -19 pandemic.  Adjusted operating profit for the full year \nincreased 5% to $485 million, and on an FX adjusted basis, adjusted operating profit increased  1% to $466 \nmillion.  \n \n Moving on to Corporate, for the quarter, adjusted Corporate expenses were $125 million, a decrease of 42% year \nover year, driven by gains of approximately $44 million on equity investments within our McKesson Ventures' \nportfolio and p rior year one -time expenses.  For the full year, adjusted Corporate expenses were $584 million, a \ndecrease of 9% compared to the prior year, driven by gains of approximately $132 million, or 60 cents of adjusted \nearnings per diluted share on equity investme nts within our McKesson Ventures' portfolio, partially offset by lower \ninterest income.  \n \n", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted operating profit increased 1% year over year to $138 million, on an FX adjusted basis, \nadjusted operating profit decreased, 8% to $126 mill ion due to the previously mentioned fiscal 2020 volume \nincrease, again, driven by the onset of the COVID -19 pandemic. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "157b40003a27b052229ac7fd05217404e78ccaa4a29a15c5e9df7002894413c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "241ec7cc-7a2d-4164-a237-1da948683f53", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted operating profit increased 1% year over year to $138 million, on an FX adjusted basis, \nadjusted operating profit decreased, 8% to $126 mill ion due to the previously mentioned fiscal 2020 volume \nincrease, again, driven by the onset of the COVID -19 pandemic.  Adjusted operating profit for the full year \nincreased 5% to $485 million, and on an FX adjusted basis, adjusted operating profit increased  1% to $466 \nmillion.  \n \n Moving on to Corporate, for the quarter, adjusted Corporate expenses were $125 million, a decrease of 42% year \nover year, driven by gains of approximately $44 million on equity investments within our McKesson Ventures' \nportfolio and p rior year one -time expenses.  For the full year, adjusted Corporate expenses were $584 million, a \ndecrease of 9% compared to the prior year, driven by gains of approximately $132 million, or 60 cents of adjusted \nearnings per diluted share on equity investme nts within our McKesson Ventures' portfolio, partially offset by lower \ninterest income.  \n \n As in the previous two quarters, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  As we previously discussed, we c an't predict when gains or losses within our Ventures' \nportfolio companies may occur. ", "original_text": "Moving on to Corporate, for the quarter, adjusted Corporate expenses were $125 million, a decrease of 42% year \nover year, driven by gains of approximately $44 million on equity investments within our McKesson Ventures' \nportfolio and p rior year one -time expenses. "}, "hash": "ce7b348d1cb09000291e60a01447291ab9bdc378bb9837bbca7cbe716ae5e9d8", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating profit for the full year \nincreased 5% to $485 million, and on an FX adjusted basis, adjusted operating profit increased  1% to $466 \nmillion.  \n \n", "start_char_idx": 466, "end_char_idx": 632, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "241ec7cc-7a2d-4164-a237-1da948683f53": {"__data__": {"id_": "241ec7cc-7a2d-4164-a237-1da948683f53", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted operating profit increased 1% year over year to $138 million, on an FX adjusted basis, \nadjusted operating profit decreased, 8% to $126 mill ion due to the previously mentioned fiscal 2020 volume \nincrease, again, driven by the onset of the COVID -19 pandemic.  Adjusted operating profit for the full year \nincreased 5% to $485 million, and on an FX adjusted basis, adjusted operating profit increased  1% to $466 \nmillion.  \n \n Moving on to Corporate, for the quarter, adjusted Corporate expenses were $125 million, a decrease of 42% year \nover year, driven by gains of approximately $44 million on equity investments within our McKesson Ventures' \nportfolio and p rior year one -time expenses.  For the full year, adjusted Corporate expenses were $584 million, a \ndecrease of 9% compared to the prior year, driven by gains of approximately $132 million, or 60 cents of adjusted \nearnings per diluted share on equity investme nts within our McKesson Ventures' portfolio, partially offset by lower \ninterest income.  \n \n As in the previous two quarters, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  As we previously discussed, we c an't predict when gains or losses within our Ventures' \nportfolio companies may occur. ", "original_text": "Moving on to Corporate, for the quarter, adjusted Corporate expenses were $125 million, a decrease of 42% year \nover year, driven by gains of approximately $44 million on equity investments within our McKesson Ventures' \nportfolio and p rior year one -time expenses. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d5fe244d752173bfa05665cfe854bf9d972042d92fa2048c25f1053c840950d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a9d9432-2457-4fd9-90c1-91daec7bd102", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted operating profit increased 1% year over year to $138 million, on an FX adjusted basis, \nadjusted operating profit decreased, 8% to $126 mill ion due to the previously mentioned fiscal 2020 volume \nincrease, again, driven by the onset of the COVID -19 pandemic.  Adjusted operating profit for the full year \nincreased 5% to $485 million, and on an FX adjusted basis, adjusted operating profit increased  1% to $466 \nmillion.  \n \n Moving on to Corporate, for the quarter, adjusted Corporate expenses were $125 million, a decrease of 42% year \nover year, driven by gains of approximately $44 million on equity investments within our McKesson Ventures' \nportfolio and p rior year one -time expenses.  For the full year, adjusted Corporate expenses were $584 million, a \ndecrease of 9% compared to the prior year, driven by gains of approximately $132 million, or 60 cents of adjusted \nearnings per diluted share on equity investme nts within our McKesson Ventures' portfolio, partially offset by lower \ninterest income.  \n \n As in the previous two quarters, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures. ", "original_text": "Adjusted operating profit for the full year \nincreased 5% to $485 million, and on an FX adjusted basis, adjusted operating profit increased  1% to $466 \nmillion.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "837f9bd72e99b791b60e015b96761765d990b7b7dd7dbca82b3576e7336c2ba9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b960c37-abdd-443d-aea7-2844cf672772", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted operating profit increased 1% year over year to $138 million, on an FX adjusted basis, \nadjusted operating profit decreased, 8% to $126 mill ion due to the previously mentioned fiscal 2020 volume \nincrease, again, driven by the onset of the COVID -19 pandemic.  Adjusted operating profit for the full year \nincreased 5% to $485 million, and on an FX adjusted basis, adjusted operating profit increased  1% to $466 \nmillion.  \n \n Moving on to Corporate, for the quarter, adjusted Corporate expenses were $125 million, a decrease of 42% year \nover year, driven by gains of approximately $44 million on equity investments within our McKesson Ventures' \nportfolio and p rior year one -time expenses.  For the full year, adjusted Corporate expenses were $584 million, a \ndecrease of 9% compared to the prior year, driven by gains of approximately $132 million, or 60 cents of adjusted \nearnings per diluted share on equity investme nts within our McKesson Ventures' portfolio, partially offset by lower \ninterest income.  \n \n As in the previous two quarters, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  As we previously discussed, we c an't predict when gains or losses within our Ventures' \nportfolio companies may occur.  Therefore our practice has and will continue to not include Ventures' portfolio \nimpacts in our earnings guidance.  \n \n", "original_text": "For the full year, adjusted Corporate expenses were $584 million, a \ndecrease of 9% compared to the prior year, driven by gains of approximately $132 million, or 60 cents of adjusted \nearnings per diluted share on equity investme nts within our McKesson Ventures' portfolio, partially offset by lower \ninterest income.  \n \n"}, "hash": "34d5a8e56ad02c1e974875585a955c6def2f27c20526b7f017dc2d8dab4daba8", "class_name": "RelatedNodeInfo"}}, "text": "Moving on to Corporate, for the quarter, adjusted Corporate expenses were $125 million, a decrease of 42% year \nover year, driven by gains of approximately $44 million on equity investments within our McKesson Ventures' \nportfolio and p rior year one -time expenses. ", "start_char_idx": 632, "end_char_idx": 899, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b960c37-abdd-443d-aea7-2844cf672772": {"__data__": {"id_": "3b960c37-abdd-443d-aea7-2844cf672772", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted operating profit increased 1% year over year to $138 million, on an FX adjusted basis, \nadjusted operating profit decreased, 8% to $126 mill ion due to the previously mentioned fiscal 2020 volume \nincrease, again, driven by the onset of the COVID -19 pandemic.  Adjusted operating profit for the full year \nincreased 5% to $485 million, and on an FX adjusted basis, adjusted operating profit increased  1% to $466 \nmillion.  \n \n Moving on to Corporate, for the quarter, adjusted Corporate expenses were $125 million, a decrease of 42% year \nover year, driven by gains of approximately $44 million on equity investments within our McKesson Ventures' \nportfolio and p rior year one -time expenses.  For the full year, adjusted Corporate expenses were $584 million, a \ndecrease of 9% compared to the prior year, driven by gains of approximately $132 million, or 60 cents of adjusted \nearnings per diluted share on equity investme nts within our McKesson Ventures' portfolio, partially offset by lower \ninterest income.  \n \n As in the previous two quarters, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  As we previously discussed, we c an't predict when gains or losses within our Ventures' \nportfolio companies may occur.  Therefore our practice has and will continue to not include Ventures' portfolio \nimpacts in our earnings guidance.  \n \n", "original_text": "For the full year, adjusted Corporate expenses were $584 million, a \ndecrease of 9% compared to the prior year, driven by gains of approximately $132 million, or 60 cents of adjusted \nearnings per diluted share on equity investme nts within our McKesson Ventures' portfolio, partially offset by lower \ninterest income.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d5fe244d752173bfa05665cfe854bf9d972042d92fa2048c25f1053c840950d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "241ec7cc-7a2d-4164-a237-1da948683f53", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted operating profit increased 1% year over year to $138 million, on an FX adjusted basis, \nadjusted operating profit decreased, 8% to $126 mill ion due to the previously mentioned fiscal 2020 volume \nincrease, again, driven by the onset of the COVID -19 pandemic.  Adjusted operating profit for the full year \nincreased 5% to $485 million, and on an FX adjusted basis, adjusted operating profit increased  1% to $466 \nmillion.  \n \n Moving on to Corporate, for the quarter, adjusted Corporate expenses were $125 million, a decrease of 42% year \nover year, driven by gains of approximately $44 million on equity investments within our McKesson Ventures' \nportfolio and p rior year one -time expenses.  For the full year, adjusted Corporate expenses were $584 million, a \ndecrease of 9% compared to the prior year, driven by gains of approximately $132 million, or 60 cents of adjusted \nearnings per diluted share on equity investme nts within our McKesson Ventures' portfolio, partially offset by lower \ninterest income.  \n \n As in the previous two quarters, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  As we previously discussed, we c an't predict when gains or losses within our Ventures' \nportfolio companies may occur. ", "original_text": "Moving on to Corporate, for the quarter, adjusted Corporate expenses were $125 million, a decrease of 42% year \nover year, driven by gains of approximately $44 million on equity investments within our McKesson Ventures' \nportfolio and p rior year one -time expenses. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fb75c7e22477369320b3e89cabb2c62413cd3a2f7f2a4e555308e884a67219a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c7257f6-7f3a-4432-aa51-9a88aaf233a1", "node_type": "1", "metadata": {"window": "Adjusted operating profit for the full year \nincreased 5% to $485 million, and on an FX adjusted basis, adjusted operating profit increased  1% to $466 \nmillion.  \n \n Moving on to Corporate, for the quarter, adjusted Corporate expenses were $125 million, a decrease of 42% year \nover year, driven by gains of approximately $44 million on equity investments within our McKesson Ventures' \nportfolio and p rior year one -time expenses.  For the full year, adjusted Corporate expenses were $584 million, a \ndecrease of 9% compared to the prior year, driven by gains of approximately $132 million, or 60 cents of adjusted \nearnings per diluted share on equity investme nts within our McKesson Ventures' portfolio, partially offset by lower \ninterest income.  \n \n As in the previous two quarters, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  As we previously discussed, we c an't predict when gains or losses within our Ventures' \nportfolio companies may occur.  Therefore our practice has and will continue to not include Ventures' portfolio \nimpacts in our earnings guidance.  \n \n We reported opioid related litigation expenses of $153 million for fiscal 2021. ", "original_text": "As in the previous two quarters, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures. "}, "hash": "10a4052ae101d9a3633ded74478c97ea718b9362b894a7abc919740022afb459", "class_name": "RelatedNodeInfo"}}, "text": "For the full year, adjusted Corporate expenses were $584 million, a \ndecrease of 9% compared to the prior year, driven by gains of approximately $132 million, or 60 cents of adjusted \nearnings per diluted share on equity investme nts within our McKesson Ventures' portfolio, partially offset by lower \ninterest income.  \n \n", "start_char_idx": 899, "end_char_idx": 1222, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c7257f6-7f3a-4432-aa51-9a88aaf233a1": {"__data__": {"id_": "7c7257f6-7f3a-4432-aa51-9a88aaf233a1", "embedding": null, "metadata": {"window": "Adjusted operating profit for the full year \nincreased 5% to $485 million, and on an FX adjusted basis, adjusted operating profit increased  1% to $466 \nmillion.  \n \n Moving on to Corporate, for the quarter, adjusted Corporate expenses were $125 million, a decrease of 42% year \nover year, driven by gains of approximately $44 million on equity investments within our McKesson Ventures' \nportfolio and p rior year one -time expenses.  For the full year, adjusted Corporate expenses were $584 million, a \ndecrease of 9% compared to the prior year, driven by gains of approximately $132 million, or 60 cents of adjusted \nearnings per diluted share on equity investme nts within our McKesson Ventures' portfolio, partially offset by lower \ninterest income.  \n \n As in the previous two quarters, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  As we previously discussed, we c an't predict when gains or losses within our Ventures' \nportfolio companies may occur.  Therefore our practice has and will continue to not include Ventures' portfolio \nimpacts in our earnings guidance.  \n \n We reported opioid related litigation expenses of $153 million for fiscal 2021. ", "original_text": "As in the previous two quarters, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d5fe244d752173bfa05665cfe854bf9d972042d92fa2048c25f1053c840950d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b960c37-abdd-443d-aea7-2844cf672772", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted operating profit increased 1% year over year to $138 million, on an FX adjusted basis, \nadjusted operating profit decreased, 8% to $126 mill ion due to the previously mentioned fiscal 2020 volume \nincrease, again, driven by the onset of the COVID -19 pandemic.  Adjusted operating profit for the full year \nincreased 5% to $485 million, and on an FX adjusted basis, adjusted operating profit increased  1% to $466 \nmillion.  \n \n Moving on to Corporate, for the quarter, adjusted Corporate expenses were $125 million, a decrease of 42% year \nover year, driven by gains of approximately $44 million on equity investments within our McKesson Ventures' \nportfolio and p rior year one -time expenses.  For the full year, adjusted Corporate expenses were $584 million, a \ndecrease of 9% compared to the prior year, driven by gains of approximately $132 million, or 60 cents of adjusted \nearnings per diluted share on equity investme nts within our McKesson Ventures' portfolio, partially offset by lower \ninterest income.  \n \n As in the previous two quarters, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  As we previously discussed, we c an't predict when gains or losses within our Ventures' \nportfolio companies may occur.  Therefore our practice has and will continue to not include Ventures' portfolio \nimpacts in our earnings guidance.  \n \n", "original_text": "For the full year, adjusted Corporate expenses were $584 million, a \ndecrease of 9% compared to the prior year, driven by gains of approximately $132 million, or 60 cents of adjusted \nearnings per diluted share on equity investme nts within our McKesson Ventures' portfolio, partially offset by lower \ninterest income.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "212bbdd62e8f1ed1cbbe20810550eefb8a078abf3cd364e146cb27fe7f6d503f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3db129c-a587-4f2b-b98d-bbdca7fa548b", "node_type": "1", "metadata": {"window": "Moving on to Corporate, for the quarter, adjusted Corporate expenses were $125 million, a decrease of 42% year \nover year, driven by gains of approximately $44 million on equity investments within our McKesson Ventures' \nportfolio and p rior year one -time expenses.  For the full year, adjusted Corporate expenses were $584 million, a \ndecrease of 9% compared to the prior year, driven by gains of approximately $132 million, or 60 cents of adjusted \nearnings per diluted share on equity investme nts within our McKesson Ventures' portfolio, partially offset by lower \ninterest income.  \n \n As in the previous two quarters, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  As we previously discussed, we c an't predict when gains or losses within our Ventures' \nportfolio companies may occur.  Therefore our practice has and will continue to not include Ventures' portfolio \nimpacts in our earnings guidance.  \n \n We reported opioid related litigation expenses of $153 million for fiscal 2021.  Until a settlement is reached and \nexecuted we anticipate a similar level of spend. ", "original_text": "As we previously discussed, we c an't predict when gains or losses within our Ventures' \nportfolio companies may occur. "}, "hash": "05f2532c59925f74da3b01e4db087c83a1d9c36cbcf8468c17ae517db37c3206", "class_name": "RelatedNodeInfo"}}, "text": "As in the previous two quarters, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures. ", "start_char_idx": 1222, "end_char_idx": 1358, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3db129c-a587-4f2b-b98d-bbdca7fa548b": {"__data__": {"id_": "f3db129c-a587-4f2b-b98d-bbdca7fa548b", "embedding": null, "metadata": {"window": "Moving on to Corporate, for the quarter, adjusted Corporate expenses were $125 million, a decrease of 42% year \nover year, driven by gains of approximately $44 million on equity investments within our McKesson Ventures' \nportfolio and p rior year one -time expenses.  For the full year, adjusted Corporate expenses were $584 million, a \ndecrease of 9% compared to the prior year, driven by gains of approximately $132 million, or 60 cents of adjusted \nearnings per diluted share on equity investme nts within our McKesson Ventures' portfolio, partially offset by lower \ninterest income.  \n \n As in the previous two quarters, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  As we previously discussed, we c an't predict when gains or losses within our Ventures' \nportfolio companies may occur.  Therefore our practice has and will continue to not include Ventures' portfolio \nimpacts in our earnings guidance.  \n \n We reported opioid related litigation expenses of $153 million for fiscal 2021.  Until a settlement is reached and \nexecuted we anticipate a similar level of spend. ", "original_text": "As we previously discussed, we c an't predict when gains or losses within our Ventures' \nportfolio companies may occur. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d5fe244d752173bfa05665cfe854bf9d972042d92fa2048c25f1053c840950d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c7257f6-7f3a-4432-aa51-9a88aaf233a1", "node_type": "1", "metadata": {"window": "Adjusted operating profit for the full year \nincreased 5% to $485 million, and on an FX adjusted basis, adjusted operating profit increased  1% to $466 \nmillion.  \n \n Moving on to Corporate, for the quarter, adjusted Corporate expenses were $125 million, a decrease of 42% year \nover year, driven by gains of approximately $44 million on equity investments within our McKesson Ventures' \nportfolio and p rior year one -time expenses.  For the full year, adjusted Corporate expenses were $584 million, a \ndecrease of 9% compared to the prior year, driven by gains of approximately $132 million, or 60 cents of adjusted \nearnings per diluted share on equity investme nts within our McKesson Ventures' portfolio, partially offset by lower \ninterest income.  \n \n As in the previous two quarters, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  As we previously discussed, we c an't predict when gains or losses within our Ventures' \nportfolio companies may occur.  Therefore our practice has and will continue to not include Ventures' portfolio \nimpacts in our earnings guidance.  \n \n We reported opioid related litigation expenses of $153 million for fiscal 2021. ", "original_text": "As in the previous two quarters, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d5fe09e01ed4bb497230a203a908abbd08da7409e031eb4e9bacd9afb70ab9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0f35e06-0ef7-4621-bf89-273472543196", "node_type": "1", "metadata": {"window": "For the full year, adjusted Corporate expenses were $584 million, a \ndecrease of 9% compared to the prior year, driven by gains of approximately $132 million, or 60 cents of adjusted \nearnings per diluted share on equity investme nts within our McKesson Ventures' portfolio, partially offset by lower \ninterest income.  \n \n As in the previous two quarters, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  As we previously discussed, we c an't predict when gains or losses within our Ventures' \nportfolio companies may occur.  Therefore our practice has and will continue to not include Ventures' portfolio \nimpacts in our earnings guidance.  \n \n We reported opioid related litigation expenses of $153 million for fiscal 2021.  Until a settlement is reached and \nexecuted we anticipate a similar level of spend.  For fiscal 2022, we estimate opioid related litigation to \napproximate $155 million.  \n \n", "original_text": "Therefore our practice has and will continue to not include Ventures' portfolio \nimpacts in our earnings guidance.  \n \n"}, "hash": "1846982667215b882db33913a17ea86cd4087dfc3104ce548e53fd2b8be92bd3", "class_name": "RelatedNodeInfo"}}, "text": "As we previously discussed, we c an't predict when gains or losses within our Ventures' \nportfolio companies may occur. ", "start_char_idx": 1358, "end_char_idx": 1478, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0f35e06-0ef7-4621-bf89-273472543196": {"__data__": {"id_": "c0f35e06-0ef7-4621-bf89-273472543196", "embedding": null, "metadata": {"window": "For the full year, adjusted Corporate expenses were $584 million, a \ndecrease of 9% compared to the prior year, driven by gains of approximately $132 million, or 60 cents of adjusted \nearnings per diluted share on equity investme nts within our McKesson Ventures' portfolio, partially offset by lower \ninterest income.  \n \n As in the previous two quarters, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  As we previously discussed, we c an't predict when gains or losses within our Ventures' \nportfolio companies may occur.  Therefore our practice has and will continue to not include Ventures' portfolio \nimpacts in our earnings guidance.  \n \n We reported opioid related litigation expenses of $153 million for fiscal 2021.  Until a settlement is reached and \nexecuted we anticipate a similar level of spend.  For fiscal 2022, we estimate opioid related litigation to \napproximate $155 million.  \n \n", "original_text": "Therefore our practice has and will continue to not include Ventures' portfolio \nimpacts in our earnings guidance.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d5fe244d752173bfa05665cfe854bf9d972042d92fa2048c25f1053c840950d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3db129c-a587-4f2b-b98d-bbdca7fa548b", "node_type": "1", "metadata": {"window": "Moving on to Corporate, for the quarter, adjusted Corporate expenses were $125 million, a decrease of 42% year \nover year, driven by gains of approximately $44 million on equity investments within our McKesson Ventures' \nportfolio and p rior year one -time expenses.  For the full year, adjusted Corporate expenses were $584 million, a \ndecrease of 9% compared to the prior year, driven by gains of approximately $132 million, or 60 cents of adjusted \nearnings per diluted share on equity investme nts within our McKesson Ventures' portfolio, partially offset by lower \ninterest income.  \n \n As in the previous two quarters, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  As we previously discussed, we c an't predict when gains or losses within our Ventures' \nportfolio companies may occur.  Therefore our practice has and will continue to not include Ventures' portfolio \nimpacts in our earnings guidance.  \n \n We reported opioid related litigation expenses of $153 million for fiscal 2021.  Until a settlement is reached and \nexecuted we anticipate a similar level of spend. ", "original_text": "As we previously discussed, we c an't predict when gains or losses within our Ventures' \nportfolio companies may occur. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "718413041f7d0deafa6d6280ac258a35a4a8397451ed991769d4cf05476bd6b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8459964a-9aaf-4bc1-bc09-86eb329afb61", "node_type": "1", "metadata": {"window": "As in the previous two quarters, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  As we previously discussed, we c an't predict when gains or losses within our Ventures' \nportfolio companies may occur.  Therefore our practice has and will continue to not include Ventures' portfolio \nimpacts in our earnings guidance.  \n \n We reported opioid related litigation expenses of $153 million for fiscal 2021.  Until a settlement is reached and \nexecuted we anticipate a similar level of spend.  For fiscal 2022, we estimate opioid related litigation to \napproximate $155 million.  \n \n And, finally, fiscal 2021 also marked the end of our previously  announced three year program to transform our \noperating model and drive cost reductions across the enterprise. ", "original_text": "We reported opioid related litigation expenses of $153 million for fiscal 2021. "}, "hash": "395ac9d99e72a8a78385106469e7abc26734b530d60495201bbd92c3acad75de", "class_name": "RelatedNodeInfo"}}, "text": "Therefore our practice has and will continue to not include Ventures' portfolio \nimpacts in our earnings guidance.  \n \n", "start_char_idx": 1478, "end_char_idx": 1597, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8459964a-9aaf-4bc1-bc09-86eb329afb61": {"__data__": {"id_": "8459964a-9aaf-4bc1-bc09-86eb329afb61", "embedding": null, "metadata": {"window": "As in the previous two quarters, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  As we previously discussed, we c an't predict when gains or losses within our Ventures' \nportfolio companies may occur.  Therefore our practice has and will continue to not include Ventures' portfolio \nimpacts in our earnings guidance.  \n \n We reported opioid related litigation expenses of $153 million for fiscal 2021.  Until a settlement is reached and \nexecuted we anticipate a similar level of spend.  For fiscal 2022, we estimate opioid related litigation to \napproximate $155 million.  \n \n And, finally, fiscal 2021 also marked the end of our previously  announced three year program to transform our \noperating model and drive cost reductions across the enterprise. ", "original_text": "We reported opioid related litigation expenses of $153 million for fiscal 2021. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d5fe244d752173bfa05665cfe854bf9d972042d92fa2048c25f1053c840950d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0f35e06-0ef7-4621-bf89-273472543196", "node_type": "1", "metadata": {"window": "For the full year, adjusted Corporate expenses were $584 million, a \ndecrease of 9% compared to the prior year, driven by gains of approximately $132 million, or 60 cents of adjusted \nearnings per diluted share on equity investme nts within our McKesson Ventures' portfolio, partially offset by lower \ninterest income.  \n \n As in the previous two quarters, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  As we previously discussed, we c an't predict when gains or losses within our Ventures' \nportfolio companies may occur.  Therefore our practice has and will continue to not include Ventures' portfolio \nimpacts in our earnings guidance.  \n \n We reported opioid related litigation expenses of $153 million for fiscal 2021.  Until a settlement is reached and \nexecuted we anticipate a similar level of spend.  For fiscal 2022, we estimate opioid related litigation to \napproximate $155 million.  \n \n", "original_text": "Therefore our practice has and will continue to not include Ventures' portfolio \nimpacts in our earnings guidance.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b8c4873b0607cf51fc378955f9a7ea1e86755c16adf201afab9ca1d03b9bcac2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b65daf4-681d-4187-aea6-276d16fddf06", "node_type": "1", "metadata": {"window": "As we previously discussed, we c an't predict when gains or losses within our Ventures' \nportfolio companies may occur.  Therefore our practice has and will continue to not include Ventures' portfolio \nimpacts in our earnings guidance.  \n \n We reported opioid related litigation expenses of $153 million for fiscal 2021.  Until a settlement is reached and \nexecuted we anticipate a similar level of spend.  For fiscal 2022, we estimate opioid related litigation to \napproximate $155 million.  \n \n And, finally, fiscal 2021 also marked the end of our previously  announced three year program to transform our \noperating model and drive cost reductions across the enterprise.  We are proud to have achieved our original \nthree year target of $400 to $500 million in savings by the end of fiscal 2021. ", "original_text": "Until a settlement is reached and \nexecuted we anticipate a similar level of spend. "}, "hash": "effce8242f389343b0653b744eab438136dd40a5925b3c7b49b7ccaca10607a3", "class_name": "RelatedNodeInfo"}}, "text": "We reported opioid related litigation expenses of $153 million for fiscal 2021. ", "start_char_idx": 1597, "end_char_idx": 1677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b65daf4-681d-4187-aea6-276d16fddf06": {"__data__": {"id_": "0b65daf4-681d-4187-aea6-276d16fddf06", "embedding": null, "metadata": {"window": "As we previously discussed, we c an't predict when gains or losses within our Ventures' \nportfolio companies may occur.  Therefore our practice has and will continue to not include Ventures' portfolio \nimpacts in our earnings guidance.  \n \n We reported opioid related litigation expenses of $153 million for fiscal 2021.  Until a settlement is reached and \nexecuted we anticipate a similar level of spend.  For fiscal 2022, we estimate opioid related litigation to \napproximate $155 million.  \n \n And, finally, fiscal 2021 also marked the end of our previously  announced three year program to transform our \noperating model and drive cost reductions across the enterprise.  We are proud to have achieved our original \nthree year target of $400 to $500 million in savings by the end of fiscal 2021. ", "original_text": "Until a settlement is reached and \nexecuted we anticipate a similar level of spend. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d5fe244d752173bfa05665cfe854bf9d972042d92fa2048c25f1053c840950d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8459964a-9aaf-4bc1-bc09-86eb329afb61", "node_type": "1", "metadata": {"window": "As in the previous two quarters, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  As we previously discussed, we c an't predict when gains or losses within our Ventures' \nportfolio companies may occur.  Therefore our practice has and will continue to not include Ventures' portfolio \nimpacts in our earnings guidance.  \n \n We reported opioid related litigation expenses of $153 million for fiscal 2021.  Until a settlement is reached and \nexecuted we anticipate a similar level of spend.  For fiscal 2022, we estimate opioid related litigation to \napproximate $155 million.  \n \n And, finally, fiscal 2021 also marked the end of our previously  announced three year program to transform our \noperating model and drive cost reductions across the enterprise. ", "original_text": "We reported opioid related litigation expenses of $153 million for fiscal 2021. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26b012ead4a3b88bd951d4aa1d08918c5fe50cbb47f37d41a1f2766d6d361f89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a0a6a63-40b9-44c5-b0ba-c8665e4444b7", "node_type": "1", "metadata": {"window": "Therefore our practice has and will continue to not include Ventures' portfolio \nimpacts in our earnings guidance.  \n \n We reported opioid related litigation expenses of $153 million for fiscal 2021.  Until a settlement is reached and \nexecuted we anticipate a similar level of spend.  For fiscal 2022, we estimate opioid related litigation to \napproximate $155 million.  \n \n And, finally, fiscal 2021 also marked the end of our previously  announced three year program to transform our \noperating model and drive cost reductions across the enterprise.  We are proud to have achieved our original \nthree year target of $400 to $500 million in savings by the end of fiscal 2021.  A portion of this sav ings has been \nreinvested in our growth areas of oncology and biopharma services.  \n \n", "original_text": "For fiscal 2022, we estimate opioid related litigation to \napproximate $155 million.  \n \n"}, "hash": "6a2f9f7693ee29ccf6afd4d01874012f6f3493480efc4ed2421457f522f524f9", "class_name": "RelatedNodeInfo"}}, "text": "Until a settlement is reached and \nexecuted we anticipate a similar level of spend. ", "start_char_idx": 1677, "end_char_idx": 1761, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a0a6a63-40b9-44c5-b0ba-c8665e4444b7": {"__data__": {"id_": "6a0a6a63-40b9-44c5-b0ba-c8665e4444b7", "embedding": null, "metadata": {"window": "Therefore our practice has and will continue to not include Ventures' portfolio \nimpacts in our earnings guidance.  \n \n We reported opioid related litigation expenses of $153 million for fiscal 2021.  Until a settlement is reached and \nexecuted we anticipate a similar level of spend.  For fiscal 2022, we estimate opioid related litigation to \napproximate $155 million.  \n \n And, finally, fiscal 2021 also marked the end of our previously  announced three year program to transform our \noperating model and drive cost reductions across the enterprise.  We are proud to have achieved our original \nthree year target of $400 to $500 million in savings by the end of fiscal 2021.  A portion of this sav ings has been \nreinvested in our growth areas of oncology and biopharma services.  \n \n", "original_text": "For fiscal 2022, we estimate opioid related litigation to \napproximate $155 million.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d5fe244d752173bfa05665cfe854bf9d972042d92fa2048c25f1053c840950d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b65daf4-681d-4187-aea6-276d16fddf06", "node_type": "1", "metadata": {"window": "As we previously discussed, we c an't predict when gains or losses within our Ventures' \nportfolio companies may occur.  Therefore our practice has and will continue to not include Ventures' portfolio \nimpacts in our earnings guidance.  \n \n We reported opioid related litigation expenses of $153 million for fiscal 2021.  Until a settlement is reached and \nexecuted we anticipate a similar level of spend.  For fiscal 2022, we estimate opioid related litigation to \napproximate $155 million.  \n \n And, finally, fiscal 2021 also marked the end of our previously  announced three year program to transform our \noperating model and drive cost reductions across the enterprise.  We are proud to have achieved our original \nthree year target of $400 to $500 million in savings by the end of fiscal 2021. ", "original_text": "Until a settlement is reached and \nexecuted we anticipate a similar level of spend. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6d0aa5f50daa0bf4168fb1f3fa390e1de87157656a291510120dd8378198c1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cf11a54-d1a9-42d3-9edd-e0014570d3e2", "node_type": "1", "metadata": {"window": "We reported opioid related litigation expenses of $153 million for fiscal 2021.  Until a settlement is reached and \nexecuted we anticipate a similar level of spend.  For fiscal 2022, we estimate opioid related litigation to \napproximate $155 million.  \n \n And, finally, fiscal 2021 also marked the end of our previously  announced three year program to transform our \noperating model and drive cost reductions across the enterprise.  We are proud to have achieved our original \nthree year target of $400 to $500 million in savings by the end of fiscal 2021.  A portion of this sav ings has been \nreinvested in our growth areas of oncology and biopharma services.  \n \n Turning now to slide 11. ", "original_text": "And, finally, fiscal 2021 also marked the end of our previously  announced three year program to transform our \noperating model and drive cost reductions across the enterprise. "}, "hash": "98b8b8a4fccb2f26d53693bb6f43126b78be0a240825ec9039a005c2f9200af0", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal 2022, we estimate opioid related litigation to \napproximate $155 million.  \n \n", "start_char_idx": 1761, "end_char_idx": 1850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cf11a54-d1a9-42d3-9edd-e0014570d3e2": {"__data__": {"id_": "1cf11a54-d1a9-42d3-9edd-e0014570d3e2", "embedding": null, "metadata": {"window": "We reported opioid related litigation expenses of $153 million for fiscal 2021.  Until a settlement is reached and \nexecuted we anticipate a similar level of spend.  For fiscal 2022, we estimate opioid related litigation to \napproximate $155 million.  \n \n And, finally, fiscal 2021 also marked the end of our previously  announced three year program to transform our \noperating model and drive cost reductions across the enterprise.  We are proud to have achieved our original \nthree year target of $400 to $500 million in savings by the end of fiscal 2021.  A portion of this sav ings has been \nreinvested in our growth areas of oncology and biopharma services.  \n \n Turning now to slide 11. ", "original_text": "And, finally, fiscal 2021 also marked the end of our previously  announced three year program to transform our \noperating model and drive cost reductions across the enterprise. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d5fe244d752173bfa05665cfe854bf9d972042d92fa2048c25f1053c840950d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a0a6a63-40b9-44c5-b0ba-c8665e4444b7", "node_type": "1", "metadata": {"window": "Therefore our practice has and will continue to not include Ventures' portfolio \nimpacts in our earnings guidance.  \n \n We reported opioid related litigation expenses of $153 million for fiscal 2021.  Until a settlement is reached and \nexecuted we anticipate a similar level of spend.  For fiscal 2022, we estimate opioid related litigation to \napproximate $155 million.  \n \n And, finally, fiscal 2021 also marked the end of our previously  announced three year program to transform our \noperating model and drive cost reductions across the enterprise.  We are proud to have achieved our original \nthree year target of $400 to $500 million in savings by the end of fiscal 2021.  A portion of this sav ings has been \nreinvested in our growth areas of oncology and biopharma services.  \n \n", "original_text": "For fiscal 2022, we estimate opioid related litigation to \napproximate $155 million.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "81d374770d442d835c2d9024480117e1fe3e1179fb5152e7e0912198baa99c71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4066ec7-682a-4a58-85e2-b372005aa400", "node_type": "1", "metadata": {"window": "Until a settlement is reached and \nexecuted we anticipate a similar level of spend.  For fiscal 2022, we estimate opioid related litigation to \napproximate $155 million.  \n \n And, finally, fiscal 2021 also marked the end of our previously  announced three year program to transform our \noperating model and drive cost reductions across the enterprise.  We are proud to have achieved our original \nthree year target of $400 to $500 million in savings by the end of fiscal 2021.  A portion of this sav ings has been \nreinvested in our growth areas of oncology and biopharma services.  \n \n Turning now to slide 11.  We continued to place a sharp focus on working capital efficiency and cash flow \ngeneration. ", "original_text": "We are proud to have achieved our original \nthree year target of $400 to $500 million in savings by the end of fiscal 2021. "}, "hash": "b65d7618b996165d9973805b6ba3b944f89253f7a62aa3db4e3ab07193c09c2a", "class_name": "RelatedNodeInfo"}}, "text": "And, finally, fiscal 2021 also marked the end of our previously  announced three year program to transform our \noperating model and drive cost reductions across the enterprise. ", "start_char_idx": 1850, "end_char_idx": 2027, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4066ec7-682a-4a58-85e2-b372005aa400": {"__data__": {"id_": "a4066ec7-682a-4a58-85e2-b372005aa400", "embedding": null, "metadata": {"window": "Until a settlement is reached and \nexecuted we anticipate a similar level of spend.  For fiscal 2022, we estimate opioid related litigation to \napproximate $155 million.  \n \n And, finally, fiscal 2021 also marked the end of our previously  announced three year program to transform our \noperating model and drive cost reductions across the enterprise.  We are proud to have achieved our original \nthree year target of $400 to $500 million in savings by the end of fiscal 2021.  A portion of this sav ings has been \nreinvested in our growth areas of oncology and biopharma services.  \n \n Turning now to slide 11.  We continued to place a sharp focus on working capital efficiency and cash flow \ngeneration. ", "original_text": "We are proud to have achieved our original \nthree year target of $400 to $500 million in savings by the end of fiscal 2021. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d5fe244d752173bfa05665cfe854bf9d972042d92fa2048c25f1053c840950d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cf11a54-d1a9-42d3-9edd-e0014570d3e2", "node_type": "1", "metadata": {"window": "We reported opioid related litigation expenses of $153 million for fiscal 2021.  Until a settlement is reached and \nexecuted we anticipate a similar level of spend.  For fiscal 2022, we estimate opioid related litigation to \napproximate $155 million.  \n \n And, finally, fiscal 2021 also marked the end of our previously  announced three year program to transform our \noperating model and drive cost reductions across the enterprise.  We are proud to have achieved our original \nthree year target of $400 to $500 million in savings by the end of fiscal 2021.  A portion of this sav ings has been \nreinvested in our growth areas of oncology and biopharma services.  \n \n Turning now to slide 11. ", "original_text": "And, finally, fiscal 2021 also marked the end of our previously  announced three year program to transform our \noperating model and drive cost reductions across the enterprise. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "167631b26964098cf7e364e023fda7702749498087f7a62cce2de146a4b40a75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b4ae9f7-fe85-46d3-8f34-6434f23a8e19", "node_type": "1", "metadata": {"window": "For fiscal 2022, we estimate opioid related litigation to \napproximate $155 million.  \n \n And, finally, fiscal 2021 also marked the end of our previously  announced three year program to transform our \noperating model and drive cost reductions across the enterprise.  We are proud to have achieved our original \nthree year target of $400 to $500 million in savings by the end of fiscal 2021.  A portion of this sav ings has been \nreinvested in our growth areas of oncology and biopharma services.  \n \n Turning now to slide 11.  We continued to place a sharp focus on working capital efficiency and cash flow \ngeneration.  For fiscal 2021, we generated free cash flow of $3.9 bill ion and we ended the quarter with a cash \nbalance of $6.3 billion ahead of our expectations. ", "original_text": "A portion of this sav ings has been \nreinvested in our growth areas of oncology and biopharma services.  \n \n"}, "hash": "c9760738df9084a859fdd4a13a275e0d7d65c507eefec6e6400ff139726075aa", "class_name": "RelatedNodeInfo"}}, "text": "We are proud to have achieved our original \nthree year target of $400 to $500 million in savings by the end of fiscal 2021. ", "start_char_idx": 2027, "end_char_idx": 2151, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b4ae9f7-fe85-46d3-8f34-6434f23a8e19": {"__data__": {"id_": "9b4ae9f7-fe85-46d3-8f34-6434f23a8e19", "embedding": null, "metadata": {"window": "For fiscal 2022, we estimate opioid related litigation to \napproximate $155 million.  \n \n And, finally, fiscal 2021 also marked the end of our previously  announced three year program to transform our \noperating model and drive cost reductions across the enterprise.  We are proud to have achieved our original \nthree year target of $400 to $500 million in savings by the end of fiscal 2021.  A portion of this sav ings has been \nreinvested in our growth areas of oncology and biopharma services.  \n \n Turning now to slide 11.  We continued to place a sharp focus on working capital efficiency and cash flow \ngeneration.  For fiscal 2021, we generated free cash flow of $3.9 bill ion and we ended the quarter with a cash \nbalance of $6.3 billion ahead of our expectations. ", "original_text": "A portion of this sav ings has been \nreinvested in our growth areas of oncology and biopharma services.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d5fe244d752173bfa05665cfe854bf9d972042d92fa2048c25f1053c840950d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4066ec7-682a-4a58-85e2-b372005aa400", "node_type": "1", "metadata": {"window": "Until a settlement is reached and \nexecuted we anticipate a similar level of spend.  For fiscal 2022, we estimate opioid related litigation to \napproximate $155 million.  \n \n And, finally, fiscal 2021 also marked the end of our previously  announced three year program to transform our \noperating model and drive cost reductions across the enterprise.  We are proud to have achieved our original \nthree year target of $400 to $500 million in savings by the end of fiscal 2021.  A portion of this sav ings has been \nreinvested in our growth areas of oncology and biopharma services.  \n \n Turning now to slide 11.  We continued to place a sharp focus on working capital efficiency and cash flow \ngeneration. ", "original_text": "We are proud to have achieved our original \nthree year target of $400 to $500 million in savings by the end of fiscal 2021. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fef3f4704bc7dd3f31a782485ec6e1dc59a73f1c1fa08338df91edbfd3961cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44fea027-94b9-4243-9ab9-297cbdcfe4fc", "node_type": "1", "metadata": {"window": "And, finally, fiscal 2021 also marked the end of our previously  announced three year program to transform our \noperating model and drive cost reductions across the enterprise.  We are proud to have achieved our original \nthree year target of $400 to $500 million in savings by the end of fiscal 2021.  A portion of this sav ings has been \nreinvested in our growth areas of oncology and biopharma services.  \n \n Turning now to slide 11.  We continued to place a sharp focus on working capital efficiency and cash flow \ngeneration.  For fiscal 2021, we generated free cash flow of $3.9 bill ion and we ended the quarter with a cash \nbalance of $6.3 billion ahead of our expectations.  In fiscal 2021, we continued our long track record of solid cash \nflow generation, resulting from another year of operating profit growth and our continued focus on working capital \nefficiency. ", "original_text": "Turning now to slide 11. "}, "hash": "b5d7b03e52773f88edf14191fdd7335471556c5a4a6d15f05ead8a2d60998816", "class_name": "RelatedNodeInfo"}}, "text": "A portion of this sav ings has been \nreinvested in our growth areas of oncology and biopharma services.  \n \n", "start_char_idx": 2151, "end_char_idx": 2259, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44fea027-94b9-4243-9ab9-297cbdcfe4fc": {"__data__": {"id_": "44fea027-94b9-4243-9ab9-297cbdcfe4fc", "embedding": null, "metadata": {"window": "And, finally, fiscal 2021 also marked the end of our previously  announced three year program to transform our \noperating model and drive cost reductions across the enterprise.  We are proud to have achieved our original \nthree year target of $400 to $500 million in savings by the end of fiscal 2021.  A portion of this sav ings has been \nreinvested in our growth areas of oncology and biopharma services.  \n \n Turning now to slide 11.  We continued to place a sharp focus on working capital efficiency and cash flow \ngeneration.  For fiscal 2021, we generated free cash flow of $3.9 bill ion and we ended the quarter with a cash \nbalance of $6.3 billion ahead of our expectations.  In fiscal 2021, we continued our long track record of solid cash \nflow generation, resulting from another year of operating profit growth and our continued focus on working capital \nefficiency. ", "original_text": "Turning now to slide 11. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d5fe244d752173bfa05665cfe854bf9d972042d92fa2048c25f1053c840950d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b4ae9f7-fe85-46d3-8f34-6434f23a8e19", "node_type": "1", "metadata": {"window": "For fiscal 2022, we estimate opioid related litigation to \napproximate $155 million.  \n \n And, finally, fiscal 2021 also marked the end of our previously  announced three year program to transform our \noperating model and drive cost reductions across the enterprise.  We are proud to have achieved our original \nthree year target of $400 to $500 million in savings by the end of fiscal 2021.  A portion of this sav ings has been \nreinvested in our growth areas of oncology and biopharma services.  \n \n Turning now to slide 11.  We continued to place a sharp focus on working capital efficiency and cash flow \ngeneration.  For fiscal 2021, we generated free cash flow of $3.9 bill ion and we ended the quarter with a cash \nbalance of $6.3 billion ahead of our expectations. ", "original_text": "A portion of this sav ings has been \nreinvested in our growth areas of oncology and biopharma services.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc4bc68d7946b208e28a53f22d685b692db155704977baf494160009f289b66e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1be8b022-c6cd-48c2-922d-504cd520f4a7", "node_type": "1", "metadata": {"window": "We are proud to have achieved our original \nthree year target of $400 to $500 million in savings by the end of fiscal 2021.  A portion of this sav ings has been \nreinvested in our growth areas of oncology and biopharma services.  \n \n Turning now to slide 11.  We continued to place a sharp focus on working capital efficiency and cash flow \ngeneration.  For fiscal 2021, we generated free cash flow of $3.9 bill ion and we ended the quarter with a cash \nbalance of $6.3 billion ahead of our expectations.  In fiscal 2021, we continued our long track record of solid cash \nflow generation, resulting from another year of operating profit growth and our continued focus on working capital \nefficiency.  In fiscal 2021 our cash flow was impacted by the COVID -19 pandemic, including uneven levels of \ncustomer demand.  \n \n", "original_text": "We continued to place a sharp focus on working capital efficiency and cash flow \ngeneration. "}, "hash": "2ba7ae916ea39088dbe07edc230b74343b671f3da01dd5a0640d7bcfe2cc2ed3", "class_name": "RelatedNodeInfo"}}, "text": "Turning now to slide 11. ", "start_char_idx": 2259, "end_char_idx": 2284, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1be8b022-c6cd-48c2-922d-504cd520f4a7": {"__data__": {"id_": "1be8b022-c6cd-48c2-922d-504cd520f4a7", "embedding": null, "metadata": {"window": "We are proud to have achieved our original \nthree year target of $400 to $500 million in savings by the end of fiscal 2021.  A portion of this sav ings has been \nreinvested in our growth areas of oncology and biopharma services.  \n \n Turning now to slide 11.  We continued to place a sharp focus on working capital efficiency and cash flow \ngeneration.  For fiscal 2021, we generated free cash flow of $3.9 bill ion and we ended the quarter with a cash \nbalance of $6.3 billion ahead of our expectations.  In fiscal 2021, we continued our long track record of solid cash \nflow generation, resulting from another year of operating profit growth and our continued focus on working capital \nefficiency.  In fiscal 2021 our cash flow was impacted by the COVID -19 pandemic, including uneven levels of \ncustomer demand.  \n \n", "original_text": "We continued to place a sharp focus on working capital efficiency and cash flow \ngeneration. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d5fe244d752173bfa05665cfe854bf9d972042d92fa2048c25f1053c840950d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44fea027-94b9-4243-9ab9-297cbdcfe4fc", "node_type": "1", "metadata": {"window": "And, finally, fiscal 2021 also marked the end of our previously  announced three year program to transform our \noperating model and drive cost reductions across the enterprise.  We are proud to have achieved our original \nthree year target of $400 to $500 million in savings by the end of fiscal 2021.  A portion of this sav ings has been \nreinvested in our growth areas of oncology and biopharma services.  \n \n Turning now to slide 11.  We continued to place a sharp focus on working capital efficiency and cash flow \ngeneration.  For fiscal 2021, we generated free cash flow of $3.9 bill ion and we ended the quarter with a cash \nbalance of $6.3 billion ahead of our expectations.  In fiscal 2021, we continued our long track record of solid cash \nflow generation, resulting from another year of operating profit growth and our continued focus on working capital \nefficiency. ", "original_text": "Turning now to slide 11. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "76d19f94da71df45b24804e91203953771a2a8d5e4a8d02da7dcaccd199e0eca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1636556f-5a21-4e72-9818-2a390b9db52c", "node_type": "1", "metadata": {"window": "A portion of this sav ings has been \nreinvested in our growth areas of oncology and biopharma services.  \n \n Turning now to slide 11.  We continued to place a sharp focus on working capital efficiency and cash flow \ngeneration.  For fiscal 2021, we generated free cash flow of $3.9 bill ion and we ended the quarter with a cash \nbalance of $6.3 billion ahead of our expectations.  In fiscal 2021, we continued our long track record of solid cash \nflow generation, resulting from another year of operating profit growth and our continued focus on working capital \nefficiency.  In fiscal 2021 our cash flow was impacted by the COVID -19 pandemic, including uneven levels of \ncustomer demand.  \n \n Over the course of the year, the dynamics of the operating environment resulting from the early effects of COVID -\n19 introduced further volatility in our cash flow. ", "original_text": "For fiscal 2021, we generated free cash flow of $3.9 bill ion and we ended the quarter with a cash \nbalance of $6.3 billion ahead of our expectations. "}, "hash": "3a84d2b6d35ef66a241833a4b2ad6cff1803592362aeef02c1cd621affa3c024", "class_name": "RelatedNodeInfo"}}, "text": "We continued to place a sharp focus on working capital efficiency and cash flow \ngeneration. ", "start_char_idx": 2284, "end_char_idx": 2377, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1636556f-5a21-4e72-9818-2a390b9db52c": {"__data__": {"id_": "1636556f-5a21-4e72-9818-2a390b9db52c", "embedding": null, "metadata": {"window": "A portion of this sav ings has been \nreinvested in our growth areas of oncology and biopharma services.  \n \n Turning now to slide 11.  We continued to place a sharp focus on working capital efficiency and cash flow \ngeneration.  For fiscal 2021, we generated free cash flow of $3.9 bill ion and we ended the quarter with a cash \nbalance of $6.3 billion ahead of our expectations.  In fiscal 2021, we continued our long track record of solid cash \nflow generation, resulting from another year of operating profit growth and our continued focus on working capital \nefficiency.  In fiscal 2021 our cash flow was impacted by the COVID -19 pandemic, including uneven levels of \ncustomer demand.  \n \n Over the course of the year, the dynamics of the operating environment resulting from the early effects of COVID -\n19 introduced further volatility in our cash flow. ", "original_text": "For fiscal 2021, we generated free cash flow of $3.9 bill ion and we ended the quarter with a cash \nbalance of $6.3 billion ahead of our expectations. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d5fe244d752173bfa05665cfe854bf9d972042d92fa2048c25f1053c840950d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1be8b022-c6cd-48c2-922d-504cd520f4a7", "node_type": "1", "metadata": {"window": "We are proud to have achieved our original \nthree year target of $400 to $500 million in savings by the end of fiscal 2021.  A portion of this sav ings has been \nreinvested in our growth areas of oncology and biopharma services.  \n \n Turning now to slide 11.  We continued to place a sharp focus on working capital efficiency and cash flow \ngeneration.  For fiscal 2021, we generated free cash flow of $3.9 bill ion and we ended the quarter with a cash \nbalance of $6.3 billion ahead of our expectations.  In fiscal 2021, we continued our long track record of solid cash \nflow generation, resulting from another year of operating profit growth and our continued focus on working capital \nefficiency.  In fiscal 2021 our cash flow was impacted by the COVID -19 pandemic, including uneven levels of \ncustomer demand.  \n \n", "original_text": "We continued to place a sharp focus on working capital efficiency and cash flow \ngeneration. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7df509fccbc6cdcfd362d0660a91b30ce9379195ca5a86c0274018090b3b9d5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55cb9374-a7c5-4d9a-9d90-5c99ca4ffd15", "node_type": "1", "metadata": {"window": "Turning now to slide 11.  We continued to place a sharp focus on working capital efficiency and cash flow \ngeneration.  For fiscal 2021, we generated free cash flow of $3.9 bill ion and we ended the quarter with a cash \nbalance of $6.3 billion ahead of our expectations.  In fiscal 2021, we continued our long track record of solid cash \nflow generation, resulting from another year of operating profit growth and our continued focus on working capital \nefficiency.  In fiscal 2021 our cash flow was impacted by the COVID -19 pandemic, including uneven levels of \ncustomer demand.  \n \n Over the course of the year, the dynamics of the operating environment resulting from the early effects of COVID -\n19 introduced further volatility in our cash flow.  We experienced higher levels of inventory primarily resulting from \nthe increased quantities of COVID testing and PPE. ", "original_text": "In fiscal 2021, we continued our long track record of solid cash \nflow generation, resulting from another year of operating profit growth and our continued focus on working capital \nefficiency. "}, "hash": "79410080d1a24b697c71d0c5288e624d1f5ba0900a40116d88bb48ef1b5d0e03", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal 2021, we generated free cash flow of $3.9 bill ion and we ended the quarter with a cash \nbalance of $6.3 billion ahead of our expectations. ", "start_char_idx": 2377, "end_char_idx": 2528, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55cb9374-a7c5-4d9a-9d90-5c99ca4ffd15": {"__data__": {"id_": "55cb9374-a7c5-4d9a-9d90-5c99ca4ffd15", "embedding": null, "metadata": {"window": "Turning now to slide 11.  We continued to place a sharp focus on working capital efficiency and cash flow \ngeneration.  For fiscal 2021, we generated free cash flow of $3.9 bill ion and we ended the quarter with a cash \nbalance of $6.3 billion ahead of our expectations.  In fiscal 2021, we continued our long track record of solid cash \nflow generation, resulting from another year of operating profit growth and our continued focus on working capital \nefficiency.  In fiscal 2021 our cash flow was impacted by the COVID -19 pandemic, including uneven levels of \ncustomer demand.  \n \n Over the course of the year, the dynamics of the operating environment resulting from the early effects of COVID -\n19 introduced further volatility in our cash flow.  We experienced higher levels of inventory primarily resulting from \nthe increased quantities of COVID testing and PPE. ", "original_text": "In fiscal 2021, we continued our long track record of solid cash \nflow generation, resulting from another year of operating profit growth and our continued focus on working capital \nefficiency. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d5fe244d752173bfa05665cfe854bf9d972042d92fa2048c25f1053c840950d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1636556f-5a21-4e72-9818-2a390b9db52c", "node_type": "1", "metadata": {"window": "A portion of this sav ings has been \nreinvested in our growth areas of oncology and biopharma services.  \n \n Turning now to slide 11.  We continued to place a sharp focus on working capital efficiency and cash flow \ngeneration.  For fiscal 2021, we generated free cash flow of $3.9 bill ion and we ended the quarter with a cash \nbalance of $6.3 billion ahead of our expectations.  In fiscal 2021, we continued our long track record of solid cash \nflow generation, resulting from another year of operating profit growth and our continued focus on working capital \nefficiency.  In fiscal 2021 our cash flow was impacted by the COVID -19 pandemic, including uneven levels of \ncustomer demand.  \n \n Over the course of the year, the dynamics of the operating environment resulting from the early effects of COVID -\n19 introduced further volatility in our cash flow. ", "original_text": "For fiscal 2021, we generated free cash flow of $3.9 bill ion and we ended the quarter with a cash \nbalance of $6.3 billion ahead of our expectations. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c18b4bef465d23d126a56869a1878a596adf6eefb05e5a7a746ec2fff203e11", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c91f0dd0-553d-404a-a7b5-2433333989ce", "node_type": "1", "metadata": {"window": "We continued to place a sharp focus on working capital efficiency and cash flow \ngeneration.  For fiscal 2021, we generated free cash flow of $3.9 bill ion and we ended the quarter with a cash \nbalance of $6.3 billion ahead of our expectations.  In fiscal 2021, we continued our long track record of solid cash \nflow generation, resulting from another year of operating profit growth and our continued focus on working capital \nefficiency.  In fiscal 2021 our cash flow was impacted by the COVID -19 pandemic, including uneven levels of \ncustomer demand.  \n \n Over the course of the year, the dynamics of the operating environment resulting from the early effects of COVID -\n19 introduced further volatility in our cash flow.  We experienced higher levels of inventory primarily resulting from \nthe increased quantities of COVID testing and PPE.  We anticipated this additional working capital volatility, \nmeeting the evolving needs of our customers, all while we were increasing our work with the US government to \ndistribute COVID -19 vaccines and ancillary supply kits.  \n \n", "original_text": "In fiscal 2021 our cash flow was impacted by the COVID -19 pandemic, including uneven levels of \ncustomer demand.  \n \n"}, "hash": "e3c0cf117e11696bcf60afe4e904429b3077ef85b7685797831bfe29185c17b6", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal 2021, we continued our long track record of solid cash \nflow generation, resulting from another year of operating profit growth and our continued focus on working capital \nefficiency. ", "start_char_idx": 2528, "end_char_idx": 2722, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c91f0dd0-553d-404a-a7b5-2433333989ce": {"__data__": {"id_": "c91f0dd0-553d-404a-a7b5-2433333989ce", "embedding": null, "metadata": {"window": "We continued to place a sharp focus on working capital efficiency and cash flow \ngeneration.  For fiscal 2021, we generated free cash flow of $3.9 bill ion and we ended the quarter with a cash \nbalance of $6.3 billion ahead of our expectations.  In fiscal 2021, we continued our long track record of solid cash \nflow generation, resulting from another year of operating profit growth and our continued focus on working capital \nefficiency.  In fiscal 2021 our cash flow was impacted by the COVID -19 pandemic, including uneven levels of \ncustomer demand.  \n \n Over the course of the year, the dynamics of the operating environment resulting from the early effects of COVID -\n19 introduced further volatility in our cash flow.  We experienced higher levels of inventory primarily resulting from \nthe increased quantities of COVID testing and PPE.  We anticipated this additional working capital volatility, \nmeeting the evolving needs of our customers, all while we were increasing our work with the US government to \ndistribute COVID -19 vaccines and ancillary supply kits.  \n \n", "original_text": "In fiscal 2021 our cash flow was impacted by the COVID -19 pandemic, including uneven levels of \ncustomer demand.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d5fe244d752173bfa05665cfe854bf9d972042d92fa2048c25f1053c840950d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55cb9374-a7c5-4d9a-9d90-5c99ca4ffd15", "node_type": "1", "metadata": {"window": "Turning now to slide 11.  We continued to place a sharp focus on working capital efficiency and cash flow \ngeneration.  For fiscal 2021, we generated free cash flow of $3.9 bill ion and we ended the quarter with a cash \nbalance of $6.3 billion ahead of our expectations.  In fiscal 2021, we continued our long track record of solid cash \nflow generation, resulting from another year of operating profit growth and our continued focus on working capital \nefficiency.  In fiscal 2021 our cash flow was impacted by the COVID -19 pandemic, including uneven levels of \ncustomer demand.  \n \n Over the course of the year, the dynamics of the operating environment resulting from the early effects of COVID -\n19 introduced further volatility in our cash flow.  We experienced higher levels of inventory primarily resulting from \nthe increased quantities of COVID testing and PPE. ", "original_text": "In fiscal 2021, we continued our long track record of solid cash \nflow generation, resulting from another year of operating profit growth and our continued focus on working capital \nefficiency. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9eec656d3423da3cf61d11fd365d785c14732835575ba4c64a31a14c385d5f04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e62b8516-b0e8-49bc-93bb-7119312d0c95", "node_type": "1", "metadata": {"window": "For fiscal 2021, we generated free cash flow of $3.9 bill ion and we ended the quarter with a cash \nbalance of $6.3 billion ahead of our expectations.  In fiscal 2021, we continued our long track record of solid cash \nflow generation, resulting from another year of operating profit growth and our continued focus on working capital \nefficiency.  In fiscal 2021 our cash flow was impacted by the COVID -19 pandemic, including uneven levels of \ncustomer demand.  \n \n Over the course of the year, the dynamics of the operating environment resulting from the early effects of COVID -\n19 introduced further volatility in our cash flow.  We experienced higher levels of inventory primarily resulting from \nthe increased quantities of COVID testing and PPE.  We anticipated this additional working capital volatility, \nmeeting the evolving needs of our customers, all while we were increasing our work with the US government to \ndistribute COVID -19 vaccines and ancillary supply kits.  \n \n In Q3, we utilize a portion of our free cash flow to retire approximately $1 billion of debt and we issued a $500 \nmillio n bond at attractive market rates. ", "original_text": "Over the course of the year, the dynamics of the operating environment resulting from the early effects of COVID -\n19 introduced further volatility in our cash flow. "}, "hash": "1cf1dcccec15412a714dc4586c106d84ec30aa41a9616fc5b723466ae78c53e5", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal 2021 our cash flow was impacted by the COVID -19 pandemic, including uneven levels of \ncustomer demand.  \n \n", "start_char_idx": 2722, "end_char_idx": 2840, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e62b8516-b0e8-49bc-93bb-7119312d0c95": {"__data__": {"id_": "e62b8516-b0e8-49bc-93bb-7119312d0c95", "embedding": null, "metadata": {"window": "For fiscal 2021, we generated free cash flow of $3.9 bill ion and we ended the quarter with a cash \nbalance of $6.3 billion ahead of our expectations.  In fiscal 2021, we continued our long track record of solid cash \nflow generation, resulting from another year of operating profit growth and our continued focus on working capital \nefficiency.  In fiscal 2021 our cash flow was impacted by the COVID -19 pandemic, including uneven levels of \ncustomer demand.  \n \n Over the course of the year, the dynamics of the operating environment resulting from the early effects of COVID -\n19 introduced further volatility in our cash flow.  We experienced higher levels of inventory primarily resulting from \nthe increased quantities of COVID testing and PPE.  We anticipated this additional working capital volatility, \nmeeting the evolving needs of our customers, all while we were increasing our work with the US government to \ndistribute COVID -19 vaccines and ancillary supply kits.  \n \n In Q3, we utilize a portion of our free cash flow to retire approximately $1 billion of debt and we issued a $500 \nmillio n bond at attractive market rates. ", "original_text": "Over the course of the year, the dynamics of the operating environment resulting from the early effects of COVID -\n19 introduced further volatility in our cash flow. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d5fe244d752173bfa05665cfe854bf9d972042d92fa2048c25f1053c840950d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c91f0dd0-553d-404a-a7b5-2433333989ce", "node_type": "1", "metadata": {"window": "We continued to place a sharp focus on working capital efficiency and cash flow \ngeneration.  For fiscal 2021, we generated free cash flow of $3.9 bill ion and we ended the quarter with a cash \nbalance of $6.3 billion ahead of our expectations.  In fiscal 2021, we continued our long track record of solid cash \nflow generation, resulting from another year of operating profit growth and our continued focus on working capital \nefficiency.  In fiscal 2021 our cash flow was impacted by the COVID -19 pandemic, including uneven levels of \ncustomer demand.  \n \n Over the course of the year, the dynamics of the operating environment resulting from the early effects of COVID -\n19 introduced further volatility in our cash flow.  We experienced higher levels of inventory primarily resulting from \nthe increased quantities of COVID testing and PPE.  We anticipated this additional working capital volatility, \nmeeting the evolving needs of our customers, all while we were increasing our work with the US government to \ndistribute COVID -19 vaccines and ancillary supply kits.  \n \n", "original_text": "In fiscal 2021 our cash flow was impacted by the COVID -19 pandemic, including uneven levels of \ncustomer demand.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "616c3cd4640a6cac3c75ee34d4d62f38bfce43e8a31dc55e0fd2d08a14552bb5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "180aa042-b296-4d18-8307-52a6210a6494", "node_type": "1", "metadata": {"window": "In fiscal 2021, we continued our long track record of solid cash \nflow generation, resulting from another year of operating profit growth and our continued focus on working capital \nefficiency.  In fiscal 2021 our cash flow was impacted by the COVID -19 pandemic, including uneven levels of \ncustomer demand.  \n \n Over the course of the year, the dynamics of the operating environment resulting from the early effects of COVID -\n19 introduced further volatility in our cash flow.  We experienced higher levels of inventory primarily resulting from \nthe increased quantities of COVID testing and PPE.  We anticipated this additional working capital volatility, \nmeeting the evolving needs of our customers, all while we were increasing our work with the US government to \ndistribute COVID -19 vaccines and ancillary supply kits.  \n \n In Q3, we utilize a portion of our free cash flow to retire approximately $1 billion of debt and we issued a $500 \nmillio n bond at attractive market rates.  These actions which were in line with our stated intent to modestly de -lever \nfurther strengthened our balance sheet and financial position. ", "original_text": "We experienced higher levels of inventory primarily resulting from \nthe increased quantities of COVID testing and PPE. "}, "hash": "ad6be03356dc4d4355c4db1c9f280ebae8e6d941ebd5912b53d486c7de090bb5", "class_name": "RelatedNodeInfo"}}, "text": "Over the course of the year, the dynamics of the operating environment resulting from the early effects of COVID -\n19 introduced further volatility in our cash flow. ", "start_char_idx": 2840, "end_char_idx": 3006, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "180aa042-b296-4d18-8307-52a6210a6494": {"__data__": {"id_": "180aa042-b296-4d18-8307-52a6210a6494", "embedding": null, "metadata": {"window": "In fiscal 2021, we continued our long track record of solid cash \nflow generation, resulting from another year of operating profit growth and our continued focus on working capital \nefficiency.  In fiscal 2021 our cash flow was impacted by the COVID -19 pandemic, including uneven levels of \ncustomer demand.  \n \n Over the course of the year, the dynamics of the operating environment resulting from the early effects of COVID -\n19 introduced further volatility in our cash flow.  We experienced higher levels of inventory primarily resulting from \nthe increased quantities of COVID testing and PPE.  We anticipated this additional working capital volatility, \nmeeting the evolving needs of our customers, all while we were increasing our work with the US government to \ndistribute COVID -19 vaccines and ancillary supply kits.  \n \n In Q3, we utilize a portion of our free cash flow to retire approximately $1 billion of debt and we issued a $500 \nmillio n bond at attractive market rates.  These actions which were in line with our stated intent to modestly de -lever \nfurther strengthened our balance sheet and financial position. ", "original_text": "We experienced higher levels of inventory primarily resulting from \nthe increased quantities of COVID testing and PPE. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d5fe244d752173bfa05665cfe854bf9d972042d92fa2048c25f1053c840950d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e62b8516-b0e8-49bc-93bb-7119312d0c95", "node_type": "1", "metadata": {"window": "For fiscal 2021, we generated free cash flow of $3.9 bill ion and we ended the quarter with a cash \nbalance of $6.3 billion ahead of our expectations.  In fiscal 2021, we continued our long track record of solid cash \nflow generation, resulting from another year of operating profit growth and our continued focus on working capital \nefficiency.  In fiscal 2021 our cash flow was impacted by the COVID -19 pandemic, including uneven levels of \ncustomer demand.  \n \n Over the course of the year, the dynamics of the operating environment resulting from the early effects of COVID -\n19 introduced further volatility in our cash flow.  We experienced higher levels of inventory primarily resulting from \nthe increased quantities of COVID testing and PPE.  We anticipated this additional working capital volatility, \nmeeting the evolving needs of our customers, all while we were increasing our work with the US government to \ndistribute COVID -19 vaccines and ancillary supply kits.  \n \n In Q3, we utilize a portion of our free cash flow to retire approximately $1 billion of debt and we issued a $500 \nmillio n bond at attractive market rates. ", "original_text": "Over the course of the year, the dynamics of the operating environment resulting from the early effects of COVID -\n19 introduced further volatility in our cash flow. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e7e826b4abe9c10a928d5131d2256e60a33d5e53dad65e95f148f4f55a0206a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30f33b45-ce16-4558-ba34-81bead9d823e", "node_type": "1", "metadata": {"window": "In fiscal 2021 our cash flow was impacted by the COVID -19 pandemic, including uneven levels of \ncustomer demand.  \n \n Over the course of the year, the dynamics of the operating environment resulting from the early effects of COVID -\n19 introduced further volatility in our cash flow.  We experienced higher levels of inventory primarily resulting from \nthe increased quantities of COVID testing and PPE.  We anticipated this additional working capital volatility, \nmeeting the evolving needs of our customers, all while we were increasing our work with the US government to \ndistribute COVID -19 vaccines and ancillary supply kits.  \n \n In Q3, we utilize a portion of our free cash flow to retire approximately $1 billion of debt and we issued a $500 \nmillio n bond at attractive market rates.  These actions which were in line with our stated intent to modestly de -lever \nfurther strengthened our balance sheet and financial position.  In fiscal 2021, we made $641 million of capital \nexpenditures, which includes cont inued investments in our strategic growth initiatives of oncology and biopharma \nservices, as well as investments to support our COVID -19 vaccine and kitting efforts. ", "original_text": "We anticipated this additional working capital volatility, \nmeeting the evolving needs of our customers, all while we were increasing our work with the US government to \ndistribute COVID -19 vaccines and ancillary supply kits.  \n \n"}, "hash": "858f196ee12712f14f124218162028e27f8b1177d41beb3bc7eb3664f9f5cfe5", "class_name": "RelatedNodeInfo"}}, "text": "We experienced higher levels of inventory primarily resulting from \nthe increased quantities of COVID testing and PPE. ", "start_char_idx": 3006, "end_char_idx": 3125, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30f33b45-ce16-4558-ba34-81bead9d823e": {"__data__": {"id_": "30f33b45-ce16-4558-ba34-81bead9d823e", "embedding": null, "metadata": {"window": "In fiscal 2021 our cash flow was impacted by the COVID -19 pandemic, including uneven levels of \ncustomer demand.  \n \n Over the course of the year, the dynamics of the operating environment resulting from the early effects of COVID -\n19 introduced further volatility in our cash flow.  We experienced higher levels of inventory primarily resulting from \nthe increased quantities of COVID testing and PPE.  We anticipated this additional working capital volatility, \nmeeting the evolving needs of our customers, all while we were increasing our work with the US government to \ndistribute COVID -19 vaccines and ancillary supply kits.  \n \n In Q3, we utilize a portion of our free cash flow to retire approximately $1 billion of debt and we issued a $500 \nmillio n bond at attractive market rates.  These actions which were in line with our stated intent to modestly de -lever \nfurther strengthened our balance sheet and financial position.  In fiscal 2021, we made $641 million of capital \nexpenditures, which includes cont inued investments in our strategic growth initiatives of oncology and biopharma \nservices, as well as investments to support our COVID -19 vaccine and kitting efforts. ", "original_text": "We anticipated this additional working capital volatility, \nmeeting the evolving needs of our customers, all while we were increasing our work with the US government to \ndistribute COVID -19 vaccines and ancillary supply kits.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d5fe244d752173bfa05665cfe854bf9d972042d92fa2048c25f1053c840950d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "180aa042-b296-4d18-8307-52a6210a6494", "node_type": "1", "metadata": {"window": "In fiscal 2021, we continued our long track record of solid cash \nflow generation, resulting from another year of operating profit growth and our continued focus on working capital \nefficiency.  In fiscal 2021 our cash flow was impacted by the COVID -19 pandemic, including uneven levels of \ncustomer demand.  \n \n Over the course of the year, the dynamics of the operating environment resulting from the early effects of COVID -\n19 introduced further volatility in our cash flow.  We experienced higher levels of inventory primarily resulting from \nthe increased quantities of COVID testing and PPE.  We anticipated this additional working capital volatility, \nmeeting the evolving needs of our customers, all while we were increasing our work with the US government to \ndistribute COVID -19 vaccines and ancillary supply kits.  \n \n In Q3, we utilize a portion of our free cash flow to retire approximately $1 billion of debt and we issued a $500 \nmillio n bond at attractive market rates.  These actions which were in line with our stated intent to modestly de -lever \nfurther strengthened our balance sheet and financial position. ", "original_text": "We experienced higher levels of inventory primarily resulting from \nthe increased quantities of COVID testing and PPE. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f7bc619daa3a3c43fb9a81c251ffeba879e93396809b491080b92df9af252bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d81b22a-e393-4412-8e2e-8f36f32780c9", "node_type": "1", "metadata": {"window": "Over the course of the year, the dynamics of the operating environment resulting from the early effects of COVID -\n19 introduced further volatility in our cash flow.  We experienced higher levels of inventory primarily resulting from \nthe increased quantities of COVID testing and PPE.  We anticipated this additional working capital volatility, \nmeeting the evolving needs of our customers, all while we were increasing our work with the US government to \ndistribute COVID -19 vaccines and ancillary supply kits.  \n \n In Q3, we utilize a portion of our free cash flow to retire approximately $1 billion of debt and we issued a $500 \nmillio n bond at attractive market rates.  These actions which were in line with our stated intent to modestly de -lever \nfurther strengthened our balance sheet and financial position.  In fiscal 2021, we made $641 million of capital \nexpenditures, which includes cont inued investments in our strategic growth initiatives of oncology and biopharma \nservices, as well as investments to support our COVID -19 vaccine and kitting efforts.  We returned $1 billion of \ncash to our shareholders through $770 million of repurchases and  a payment of $276 million in dividends.  \n ", "original_text": "In Q3, we utilize a portion of our free cash flow to retire approximately $1 billion of debt and we issued a $500 \nmillio n bond at attractive market rates. "}, "hash": "efc480ca5b126c91dcaee5026a4062924a0c9f0b765fa4dfa26be766868f82c6", "class_name": "RelatedNodeInfo"}}, "text": "We anticipated this additional working capital volatility, \nmeeting the evolving needs of our customers, all while we were increasing our work with the US government to \ndistribute COVID -19 vaccines and ancillary supply kits.  \n \n", "start_char_idx": 3125, "end_char_idx": 3356, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d81b22a-e393-4412-8e2e-8f36f32780c9": {"__data__": {"id_": "1d81b22a-e393-4412-8e2e-8f36f32780c9", "embedding": null, "metadata": {"window": "Over the course of the year, the dynamics of the operating environment resulting from the early effects of COVID -\n19 introduced further volatility in our cash flow.  We experienced higher levels of inventory primarily resulting from \nthe increased quantities of COVID testing and PPE.  We anticipated this additional working capital volatility, \nmeeting the evolving needs of our customers, all while we were increasing our work with the US government to \ndistribute COVID -19 vaccines and ancillary supply kits.  \n \n In Q3, we utilize a portion of our free cash flow to retire approximately $1 billion of debt and we issued a $500 \nmillio n bond at attractive market rates.  These actions which were in line with our stated intent to modestly de -lever \nfurther strengthened our balance sheet and financial position.  In fiscal 2021, we made $641 million of capital \nexpenditures, which includes cont inued investments in our strategic growth initiatives of oncology and biopharma \nservices, as well as investments to support our COVID -19 vaccine and kitting efforts.  We returned $1 billion of \ncash to our shareholders through $770 million of repurchases and  a payment of $276 million in dividends.  \n ", "original_text": "In Q3, we utilize a portion of our free cash flow to retire approximately $1 billion of debt and we issued a $500 \nmillio n bond at attractive market rates. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d5fe244d752173bfa05665cfe854bf9d972042d92fa2048c25f1053c840950d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30f33b45-ce16-4558-ba34-81bead9d823e", "node_type": "1", "metadata": {"window": "In fiscal 2021 our cash flow was impacted by the COVID -19 pandemic, including uneven levels of \ncustomer demand.  \n \n Over the course of the year, the dynamics of the operating environment resulting from the early effects of COVID -\n19 introduced further volatility in our cash flow.  We experienced higher levels of inventory primarily resulting from \nthe increased quantities of COVID testing and PPE.  We anticipated this additional working capital volatility, \nmeeting the evolving needs of our customers, all while we were increasing our work with the US government to \ndistribute COVID -19 vaccines and ancillary supply kits.  \n \n In Q3, we utilize a portion of our free cash flow to retire approximately $1 billion of debt and we issued a $500 \nmillio n bond at attractive market rates.  These actions which were in line with our stated intent to modestly de -lever \nfurther strengthened our balance sheet and financial position.  In fiscal 2021, we made $641 million of capital \nexpenditures, which includes cont inued investments in our strategic growth initiatives of oncology and biopharma \nservices, as well as investments to support our COVID -19 vaccine and kitting efforts. ", "original_text": "We anticipated this additional working capital volatility, \nmeeting the evolving needs of our customers, all while we were increasing our work with the US government to \ndistribute COVID -19 vaccines and ancillary supply kits.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a8e2e347de541dcfd076251220a725f97bdaa95cfd10d04c82e50be10845db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27334829-188a-4488-a42d-30aed987dac8", "node_type": "1", "metadata": {"window": "We experienced higher levels of inventory primarily resulting from \nthe increased quantities of COVID testing and PPE.  We anticipated this additional working capital volatility, \nmeeting the evolving needs of our customers, all while we were increasing our work with the US government to \ndistribute COVID -19 vaccines and ancillary supply kits.  \n \n In Q3, we utilize a portion of our free cash flow to retire approximately $1 billion of debt and we issued a $500 \nmillio n bond at attractive market rates.  These actions which were in line with our stated intent to modestly de -lever \nfurther strengthened our balance sheet and financial position.  In fiscal 2021, we made $641 million of capital \nexpenditures, which includes cont inued investments in our strategic growth initiatives of oncology and biopharma \nservices, as well as investments to support our COVID -19 vaccine and kitting efforts.  We returned $1 billion of \ncash to our shareholders through $770 million of repurchases and  a payment of $276 million in dividends.  \n ", "original_text": "These actions which were in line with our stated intent to modestly de -lever \nfurther strengthened our balance sheet and financial position. "}, "hash": "d791370edcd6bc5774cd80fb7799c967f920d62c2973956c98c582acac028cdd", "class_name": "RelatedNodeInfo"}}, "text": "In Q3, we utilize a portion of our free cash flow to retire approximately $1 billion of debt and we issued a $500 \nmillio n bond at attractive market rates. ", "start_char_idx": 3356, "end_char_idx": 3513, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27334829-188a-4488-a42d-30aed987dac8": {"__data__": {"id_": "27334829-188a-4488-a42d-30aed987dac8", "embedding": null, "metadata": {"window": "We experienced higher levels of inventory primarily resulting from \nthe increased quantities of COVID testing and PPE.  We anticipated this additional working capital volatility, \nmeeting the evolving needs of our customers, all while we were increasing our work with the US government to \ndistribute COVID -19 vaccines and ancillary supply kits.  \n \n In Q3, we utilize a portion of our free cash flow to retire approximately $1 billion of debt and we issued a $500 \nmillio n bond at attractive market rates.  These actions which were in line with our stated intent to modestly de -lever \nfurther strengthened our balance sheet and financial position.  In fiscal 2021, we made $641 million of capital \nexpenditures, which includes cont inued investments in our strategic growth initiatives of oncology and biopharma \nservices, as well as investments to support our COVID -19 vaccine and kitting efforts.  We returned $1 billion of \ncash to our shareholders through $770 million of repurchases and  a payment of $276 million in dividends.  \n ", "original_text": "These actions which were in line with our stated intent to modestly de -lever \nfurther strengthened our balance sheet and financial position. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d5fe244d752173bfa05665cfe854bf9d972042d92fa2048c25f1053c840950d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d81b22a-e393-4412-8e2e-8f36f32780c9", "node_type": "1", "metadata": {"window": "Over the course of the year, the dynamics of the operating environment resulting from the early effects of COVID -\n19 introduced further volatility in our cash flow.  We experienced higher levels of inventory primarily resulting from \nthe increased quantities of COVID testing and PPE.  We anticipated this additional working capital volatility, \nmeeting the evolving needs of our customers, all while we were increasing our work with the US government to \ndistribute COVID -19 vaccines and ancillary supply kits.  \n \n In Q3, we utilize a portion of our free cash flow to retire approximately $1 billion of debt and we issued a $500 \nmillio n bond at attractive market rates.  These actions which were in line with our stated intent to modestly de -lever \nfurther strengthened our balance sheet and financial position.  In fiscal 2021, we made $641 million of capital \nexpenditures, which includes cont inued investments in our strategic growth initiatives of oncology and biopharma \nservices, as well as investments to support our COVID -19 vaccine and kitting efforts.  We returned $1 billion of \ncash to our shareholders through $770 million of repurchases and  a payment of $276 million in dividends.  \n ", "original_text": "In Q3, we utilize a portion of our free cash flow to retire approximately $1 billion of debt and we issued a $500 \nmillio n bond at attractive market rates. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d2ab796cfe33ed6b2342f2f1aa2f211b4b109dc389b8d5a5dc0873eb7828ca91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c33c7c7-7370-4ca2-a8d2-3306e749c9d4", "node_type": "1", "metadata": {"window": "We anticipated this additional working capital volatility, \nmeeting the evolving needs of our customers, all while we were increasing our work with the US government to \ndistribute COVID -19 vaccines and ancillary supply kits.  \n \n In Q3, we utilize a portion of our free cash flow to retire approximately $1 billion of debt and we issued a $500 \nmillio n bond at attractive market rates.  These actions which were in line with our stated intent to modestly de -lever \nfurther strengthened our balance sheet and financial position.  In fiscal 2021, we made $641 million of capital \nexpenditures, which includes cont inued investments in our strategic growth initiatives of oncology and biopharma \nservices, as well as investments to support our COVID -19 vaccine and kitting efforts.  We returned $1 billion of \ncash to our shareholders through $770 million of repurchases and  a payment of $276 million in dividends.  \n ", "original_text": "In fiscal 2021, we made $641 million of capital \nexpenditures, which includes cont inued investments in our strategic growth initiatives of oncology and biopharma \nservices, as well as investments to support our COVID -19 vaccine and kitting efforts. "}, "hash": "0c56206a985a249201d65788ce50536bf9b342779eeee1cd69e604749d06d97f", "class_name": "RelatedNodeInfo"}}, "text": "These actions which were in line with our stated intent to modestly de -lever \nfurther strengthened our balance sheet and financial position. ", "start_char_idx": 3513, "end_char_idx": 3655, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c33c7c7-7370-4ca2-a8d2-3306e749c9d4": {"__data__": {"id_": "7c33c7c7-7370-4ca2-a8d2-3306e749c9d4", "embedding": null, "metadata": {"window": "We anticipated this additional working capital volatility, \nmeeting the evolving needs of our customers, all while we were increasing our work with the US government to \ndistribute COVID -19 vaccines and ancillary supply kits.  \n \n In Q3, we utilize a portion of our free cash flow to retire approximately $1 billion of debt and we issued a $500 \nmillio n bond at attractive market rates.  These actions which were in line with our stated intent to modestly de -lever \nfurther strengthened our balance sheet and financial position.  In fiscal 2021, we made $641 million of capital \nexpenditures, which includes cont inued investments in our strategic growth initiatives of oncology and biopharma \nservices, as well as investments to support our COVID -19 vaccine and kitting efforts.  We returned $1 billion of \ncash to our shareholders through $770 million of repurchases and  a payment of $276 million in dividends.  \n ", "original_text": "In fiscal 2021, we made $641 million of capital \nexpenditures, which includes cont inued investments in our strategic growth initiatives of oncology and biopharma \nservices, as well as investments to support our COVID -19 vaccine and kitting efforts. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d5fe244d752173bfa05665cfe854bf9d972042d92fa2048c25f1053c840950d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27334829-188a-4488-a42d-30aed987dac8", "node_type": "1", "metadata": {"window": "We experienced higher levels of inventory primarily resulting from \nthe increased quantities of COVID testing and PPE.  We anticipated this additional working capital volatility, \nmeeting the evolving needs of our customers, all while we were increasing our work with the US government to \ndistribute COVID -19 vaccines and ancillary supply kits.  \n \n In Q3, we utilize a portion of our free cash flow to retire approximately $1 billion of debt and we issued a $500 \nmillio n bond at attractive market rates.  These actions which were in line with our stated intent to modestly de -lever \nfurther strengthened our balance sheet and financial position.  In fiscal 2021, we made $641 million of capital \nexpenditures, which includes cont inued investments in our strategic growth initiatives of oncology and biopharma \nservices, as well as investments to support our COVID -19 vaccine and kitting efforts.  We returned $1 billion of \ncash to our shareholders through $770 million of repurchases and  a payment of $276 million in dividends.  \n ", "original_text": "These actions which were in line with our stated intent to modestly de -lever \nfurther strengthened our balance sheet and financial position. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc7d5c6545e891814d1ba3a4e1f598be3d5321c5c71e5327155f9335a858f845", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b1a36d5-7f79-4385-905f-b6dfab1d1a8f", "node_type": "1", "metadata": {"window": "In Q3, we utilize a portion of our free cash flow to retire approximately $1 billion of debt and we issued a $500 \nmillio n bond at attractive market rates.  These actions which were in line with our stated intent to modestly de -lever \nfurther strengthened our balance sheet and financial position.  In fiscal 2021, we made $641 million of capital \nexpenditures, which includes cont inued investments in our strategic growth initiatives of oncology and biopharma \nservices, as well as investments to support our COVID -19 vaccine and kitting efforts.  We returned $1 billion of \ncash to our shareholders through $770 million of repurchases and  a payment of $276 million in dividends.  \n ", "original_text": "We returned $1 billion of \ncash to our shareholders through $770 million of repurchases and  a payment of $276 million in dividends.  \n "}, "hash": "dcddb4e9a2d6ea2073c4663f171befe92afe79c87baa689e1b5e7a6f2d046ab1", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal 2021, we made $641 million of capital \nexpenditures, which includes cont inued investments in our strategic growth initiatives of oncology and biopharma \nservices, as well as investments to support our COVID -19 vaccine and kitting efforts. ", "start_char_idx": 3655, "end_char_idx": 3906, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b1a36d5-7f79-4385-905f-b6dfab1d1a8f": {"__data__": {"id_": "9b1a36d5-7f79-4385-905f-b6dfab1d1a8f", "embedding": null, "metadata": {"window": "In Q3, we utilize a portion of our free cash flow to retire approximately $1 billion of debt and we issued a $500 \nmillio n bond at attractive market rates.  These actions which were in line with our stated intent to modestly de -lever \nfurther strengthened our balance sheet and financial position.  In fiscal 2021, we made $641 million of capital \nexpenditures, which includes cont inued investments in our strategic growth initiatives of oncology and biopharma \nservices, as well as investments to support our COVID -19 vaccine and kitting efforts.  We returned $1 billion of \ncash to our shareholders through $770 million of repurchases and  a payment of $276 million in dividends.  \n ", "original_text": "We returned $1 billion of \ncash to our shareholders through $770 million of repurchases and  a payment of $276 million in dividends.  \n ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d5fe244d752173bfa05665cfe854bf9d972042d92fa2048c25f1053c840950d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c33c7c7-7370-4ca2-a8d2-3306e749c9d4", "node_type": "1", "metadata": {"window": "We anticipated this additional working capital volatility, \nmeeting the evolving needs of our customers, all while we were increasing our work with the US government to \ndistribute COVID -19 vaccines and ancillary supply kits.  \n \n In Q3, we utilize a portion of our free cash flow to retire approximately $1 billion of debt and we issued a $500 \nmillio n bond at attractive market rates.  These actions which were in line with our stated intent to modestly de -lever \nfurther strengthened our balance sheet and financial position.  In fiscal 2021, we made $641 million of capital \nexpenditures, which includes cont inued investments in our strategic growth initiatives of oncology and biopharma \nservices, as well as investments to support our COVID -19 vaccine and kitting efforts.  We returned $1 billion of \ncash to our shareholders through $770 million of repurchases and  a payment of $276 million in dividends.  \n ", "original_text": "In fiscal 2021, we made $641 million of capital \nexpenditures, which includes cont inued investments in our strategic growth initiatives of oncology and biopharma \nservices, as well as investments to support our COVID -19 vaccine and kitting efforts. ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "567c76ee8a78715a0e5a5cbcae4d6cc7fd93569d9a409c6f9957739c0e2d1c83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "114bcc6f-cfd1-4fc7-b75b-352e1bfd36c5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nLet me now spend a few minutes on our fiscal 2022 outlook.  And, I'll start by framing a couple of key macro level \nassumptions that underpin our outlook for fiscal 2022.  We do not assume a return waive of the virus,  additional \nshelter in place or increased social distancing. ", "original_text": "McKesson Corp.  "}, "hash": "1320a1cfa48c8aac5a296e9c9a7b6118b4bfab1de425bc84c49abc0a8685fb54", "class_name": "RelatedNodeInfo"}}, "text": "We returned $1 billion of \ncash to our shareholders through $770 million of repurchases and  a payment of $276 million in dividends.  \n ", "start_char_idx": 3906, "end_char_idx": 4042, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "114bcc6f-cfd1-4fc7-b75b-352e1bfd36c5": {"__data__": {"id_": "114bcc6f-cfd1-4fc7-b75b-352e1bfd36c5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nLet me now spend a few minutes on our fiscal 2022 outlook.  And, I'll start by framing a couple of key macro level \nassumptions that underpin our outlook for fiscal 2022.  We do not assume a return waive of the virus,  additional \nshelter in place or increased social distancing. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f86456f2-58cd-4b88-b5c4-8660acccd329", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfe26cf50c6ced7cacc44059f89a7835ae4ac901eb797a03f9b9203c801527ce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b1a36d5-7f79-4385-905f-b6dfab1d1a8f", "node_type": "1", "metadata": {"window": "In Q3, we utilize a portion of our free cash flow to retire approximately $1 billion of debt and we issued a $500 \nmillio n bond at attractive market rates.  These actions which were in line with our stated intent to modestly de -lever \nfurther strengthened our balance sheet and financial position.  In fiscal 2021, we made $641 million of capital \nexpenditures, which includes cont inued investments in our strategic growth initiatives of oncology and biopharma \nservices, as well as investments to support our COVID -19 vaccine and kitting efforts.  We returned $1 billion of \ncash to our shareholders through $770 million of repurchases and  a payment of $276 million in dividends.  \n ", "original_text": "We returned $1 billion of \ncash to our shareholders through $770 million of repurchases and  a payment of $276 million in dividends.  \n ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bf4c7429d9ea2e5b2136b129516f49f6f7e60884ae1c4b748832adf4427c6e1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "180cd1bf-cf0b-4a54-b153-cd63ef799a68", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nLet me now spend a few minutes on our fiscal 2022 outlook.  And, I'll start by framing a couple of key macro level \nassumptions that underpin our outlook for fiscal 2022.  We do not assume a return waive of the virus,  additional \nshelter in place or increased social distancing.  As we've discussed throughout the year, volume trends in fiscal \n2021 were nonlinear and varied over the course of the year, our markets did not fully recover, and we remain in a \ndynamic environme nt. \n \n", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nLet me now spend a few minutes on our fiscal 2022 outlook. "}, "hash": "51294ea32c061caa367f82d80fa131490d8d50818a81372f1aea16a3b58a971f", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "180cd1bf-cf0b-4a54-b153-cd63ef799a68": {"__data__": {"id_": "180cd1bf-cf0b-4a54-b153-cd63ef799a68", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nLet me now spend a few minutes on our fiscal 2022 outlook.  And, I'll start by framing a couple of key macro level \nassumptions that underpin our outlook for fiscal 2022.  We do not assume a return waive of the virus,  additional \nshelter in place or increased social distancing.  As we've discussed throughout the year, volume trends in fiscal \n2021 were nonlinear and varied over the course of the year, our markets did not fully recover, and we remain in a \ndynamic environme nt. \n \n", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nLet me now spend a few minutes on our fiscal 2022 outlook. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f86456f2-58cd-4b88-b5c4-8660acccd329", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfe26cf50c6ced7cacc44059f89a7835ae4ac901eb797a03f9b9203c801527ce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "114bcc6f-cfd1-4fc7-b75b-352e1bfd36c5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nLet me now spend a few minutes on our fiscal 2022 outlook.  And, I'll start by framing a couple of key macro level \nassumptions that underpin our outlook for fiscal 2022.  We do not assume a return waive of the virus,  additional \nshelter in place or increased social distancing. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c05ef340db95e88ec59bda37b7796ba7135ee13d9ccb0e987f14649090e3a51e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0ad64e0-bd40-406a-b924-06b387e26519", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nLet me now spend a few minutes on our fiscal 2022 outlook.  And, I'll start by framing a couple of key macro level \nassumptions that underpin our outlook for fiscal 2022.  We do not assume a return waive of the virus,  additional \nshelter in place or increased social distancing.  As we've discussed throughout the year, volume trends in fiscal \n2021 were nonlinear and varied over the course of the year, our markets did not fully recover, and we remain in a \ndynamic environme nt. \n \n We are however encouraged by recent signs that a broader recovery is forthcoming. ", "original_text": "And, I'll start by framing a couple of key macro level \nassumptions that underpin our outlook for fiscal 2022. "}, "hash": "04be13fceb73bba9833c82228c59fd571a61e0a483531af5c958480509c4ce10", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nLet me now spend a few minutes on our fiscal 2022 outlook. ", "start_char_idx": 16, "end_char_idx": 240, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0ad64e0-bd40-406a-b924-06b387e26519": {"__data__": {"id_": "f0ad64e0-bd40-406a-b924-06b387e26519", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nLet me now spend a few minutes on our fiscal 2022 outlook.  And, I'll start by framing a couple of key macro level \nassumptions that underpin our outlook for fiscal 2022.  We do not assume a return waive of the virus,  additional \nshelter in place or increased social distancing.  As we've discussed throughout the year, volume trends in fiscal \n2021 were nonlinear and varied over the course of the year, our markets did not fully recover, and we remain in a \ndynamic environme nt. \n \n We are however encouraged by recent signs that a broader recovery is forthcoming. ", "original_text": "And, I'll start by framing a couple of key macro level \nassumptions that underpin our outlook for fiscal 2022. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f86456f2-58cd-4b88-b5c4-8660acccd329", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfe26cf50c6ced7cacc44059f89a7835ae4ac901eb797a03f9b9203c801527ce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "180cd1bf-cf0b-4a54-b153-cd63ef799a68", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nLet me now spend a few minutes on our fiscal 2022 outlook.  And, I'll start by framing a couple of key macro level \nassumptions that underpin our outlook for fiscal 2022.  We do not assume a return waive of the virus,  additional \nshelter in place or increased social distancing.  As we've discussed throughout the year, volume trends in fiscal \n2021 were nonlinear and varied over the course of the year, our markets did not fully recover, and we remain in a \ndynamic environme nt. \n \n", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nLet me now spend a few minutes on our fiscal 2022 outlook. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aceb199ce8dd5c0932dcf4874db45c2cab2785e144f9a9d7ffbd23baa5276998", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c3008ef-30b7-4763-81ae-4d41622ea4eb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nLet me now spend a few minutes on our fiscal 2022 outlook.  And, I'll start by framing a couple of key macro level \nassumptions that underpin our outlook for fiscal 2022.  We do not assume a return waive of the virus,  additional \nshelter in place or increased social distancing.  As we've discussed throughout the year, volume trends in fiscal \n2021 were nonlinear and varied over the course of the year, our markets did not fully recover, and we remain in a \ndynamic environme nt. \n \n We are however encouraged by recent signs that a broader recovery is forthcoming.  We expect prescription \nvolumes will continue to demonstrate steady improvement from volume levels at the end of our fiscal 2021 \nthrough the first half of our fiscal 2022 , in line with the rate of increasing vaccinations and decreasing COVID \ncases. ", "original_text": "We do not assume a return waive of the virus,  additional \nshelter in place or increased social distancing. "}, "hash": "0d2448e7abd43e15af5f4af7c81309bf747fd82dfe3ee9e49ad6c3d330fb1fd2", "class_name": "RelatedNodeInfo"}}, "text": "And, I'll start by framing a couple of key macro level \nassumptions that underpin our outlook for fiscal 2022. ", "start_char_idx": 240, "end_char_idx": 351, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c3008ef-30b7-4763-81ae-4d41622ea4eb": {"__data__": {"id_": "5c3008ef-30b7-4763-81ae-4d41622ea4eb", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nLet me now spend a few minutes on our fiscal 2022 outlook.  And, I'll start by framing a couple of key macro level \nassumptions that underpin our outlook for fiscal 2022.  We do not assume a return waive of the virus,  additional \nshelter in place or increased social distancing.  As we've discussed throughout the year, volume trends in fiscal \n2021 were nonlinear and varied over the course of the year, our markets did not fully recover, and we remain in a \ndynamic environme nt. \n \n We are however encouraged by recent signs that a broader recovery is forthcoming.  We expect prescription \nvolumes will continue to demonstrate steady improvement from volume levels at the end of our fiscal 2021 \nthrough the first half of our fiscal 2022 , in line with the rate of increasing vaccinations and decreasing COVID \ncases. ", "original_text": "We do not assume a return waive of the virus,  additional \nshelter in place or increased social distancing. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f86456f2-58cd-4b88-b5c4-8660acccd329", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfe26cf50c6ced7cacc44059f89a7835ae4ac901eb797a03f9b9203c801527ce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0ad64e0-bd40-406a-b924-06b387e26519", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nLet me now spend a few minutes on our fiscal 2022 outlook.  And, I'll start by framing a couple of key macro level \nassumptions that underpin our outlook for fiscal 2022.  We do not assume a return waive of the virus,  additional \nshelter in place or increased social distancing.  As we've discussed throughout the year, volume trends in fiscal \n2021 were nonlinear and varied over the course of the year, our markets did not fully recover, and we remain in a \ndynamic environme nt. \n \n We are however encouraged by recent signs that a broader recovery is forthcoming. ", "original_text": "And, I'll start by framing a couple of key macro level \nassumptions that underpin our outlook for fiscal 2022. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ceb706fbc4a2497f67f1cc5f27331b34bcd17b692e6dfee03305fc2a9b63b93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ad3680f-c4df-4ba4-a324-9ce544737211", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nLet me now spend a few minutes on our fiscal 2022 outlook.  And, I'll start by framing a couple of key macro level \nassumptions that underpin our outlook for fiscal 2022.  We do not assume a return waive of the virus,  additional \nshelter in place or increased social distancing.  As we've discussed throughout the year, volume trends in fiscal \n2021 were nonlinear and varied over the course of the year, our markets did not fully recover, and we remain in a \ndynamic environme nt. \n \n We are however encouraged by recent signs that a broader recovery is forthcoming.  We expect prescription \nvolumes will continue to demonstrate steady improvement from volume levels at the end of our fiscal 2021 \nthrough the first half of our fiscal 2022 , in line with the rate of increasing vaccinations and decreasing COVID \ncases.  We anticipate a return to pre -COVID prescription and patient engagement levels in the second half of our \nfiscal 2022. ", "original_text": "As we've discussed throughout the year, volume trends in fiscal \n2021 were nonlinear and varied over the course of the year, our markets did not fully recover, and we remain in a \ndynamic environme nt. \n \n"}, "hash": "da2902353235d9400f06d03ce8d85b07de6ab3412084214829e4bf813c006040", "class_name": "RelatedNodeInfo"}}, "text": "We do not assume a return waive of the virus,  additional \nshelter in place or increased social distancing. ", "start_char_idx": 351, "end_char_idx": 459, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ad3680f-c4df-4ba4-a324-9ce544737211": {"__data__": {"id_": "0ad3680f-c4df-4ba4-a324-9ce544737211", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nLet me now spend a few minutes on our fiscal 2022 outlook.  And, I'll start by framing a couple of key macro level \nassumptions that underpin our outlook for fiscal 2022.  We do not assume a return waive of the virus,  additional \nshelter in place or increased social distancing.  As we've discussed throughout the year, volume trends in fiscal \n2021 were nonlinear and varied over the course of the year, our markets did not fully recover, and we remain in a \ndynamic environme nt. \n \n We are however encouraged by recent signs that a broader recovery is forthcoming.  We expect prescription \nvolumes will continue to demonstrate steady improvement from volume levels at the end of our fiscal 2021 \nthrough the first half of our fiscal 2022 , in line with the rate of increasing vaccinations and decreasing COVID \ncases.  We anticipate a return to pre -COVID prescription and patient engagement levels in the second half of our \nfiscal 2022. ", "original_text": "As we've discussed throughout the year, volume trends in fiscal \n2021 were nonlinear and varied over the course of the year, our markets did not fully recover, and we remain in a \ndynamic environme nt. \n \n", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f86456f2-58cd-4b88-b5c4-8660acccd329", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfe26cf50c6ced7cacc44059f89a7835ae4ac901eb797a03f9b9203c801527ce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c3008ef-30b7-4763-81ae-4d41622ea4eb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nLet me now spend a few minutes on our fiscal 2022 outlook.  And, I'll start by framing a couple of key macro level \nassumptions that underpin our outlook for fiscal 2022.  We do not assume a return waive of the virus,  additional \nshelter in place or increased social distancing.  As we've discussed throughout the year, volume trends in fiscal \n2021 were nonlinear and varied over the course of the year, our markets did not fully recover, and we remain in a \ndynamic environme nt. \n \n We are however encouraged by recent signs that a broader recovery is forthcoming.  We expect prescription \nvolumes will continue to demonstrate steady improvement from volume levels at the end of our fiscal 2021 \nthrough the first half of our fiscal 2022 , in line with the rate of increasing vaccinations and decreasing COVID \ncases. ", "original_text": "We do not assume a return waive of the virus,  additional \nshelter in place or increased social distancing. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b59214516c9f5f8e6bbb10d74435304af5c399ad5683344a2d116ce257f81aac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9ebf426-8dcb-487b-982d-ac1a23fa1031", "node_type": "1", "metadata": {"window": "And, I'll start by framing a couple of key macro level \nassumptions that underpin our outlook for fiscal 2022.  We do not assume a return waive of the virus,  additional \nshelter in place or increased social distancing.  As we've discussed throughout the year, volume trends in fiscal \n2021 were nonlinear and varied over the course of the year, our markets did not fully recover, and we remain in a \ndynamic environme nt. \n \n We are however encouraged by recent signs that a broader recovery is forthcoming.  We expect prescription \nvolumes will continue to demonstrate steady improvement from volume levels at the end of our fiscal 2021 \nthrough the first half of our fiscal 2022 , in line with the rate of increasing vaccinations and decreasing COVID \ncases.  We anticipate a return to pre -COVID prescription and patient engagement levels in the second half of our \nfiscal 2022.  For fiscal 2022, we expect adjusted earnings per diluted sh are to be in the range of $18.85 to $19.45, \nmore heavily weighted towards the back half of the fiscal year. ", "original_text": "We are however encouraged by recent signs that a broader recovery is forthcoming. "}, "hash": "07d4b9cfc36b9f0962c3e40028e459acfa15dee9467865e539bf95759c814237", "class_name": "RelatedNodeInfo"}}, "text": "As we've discussed throughout the year, volume trends in fiscal \n2021 were nonlinear and varied over the course of the year, our markets did not fully recover, and we remain in a \ndynamic environme nt. \n \n", "start_char_idx": 459, "end_char_idx": 664, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9ebf426-8dcb-487b-982d-ac1a23fa1031": {"__data__": {"id_": "e9ebf426-8dcb-487b-982d-ac1a23fa1031", "embedding": null, "metadata": {"window": "And, I'll start by framing a couple of key macro level \nassumptions that underpin our outlook for fiscal 2022.  We do not assume a return waive of the virus,  additional \nshelter in place or increased social distancing.  As we've discussed throughout the year, volume trends in fiscal \n2021 were nonlinear and varied over the course of the year, our markets did not fully recover, and we remain in a \ndynamic environme nt. \n \n We are however encouraged by recent signs that a broader recovery is forthcoming.  We expect prescription \nvolumes will continue to demonstrate steady improvement from volume levels at the end of our fiscal 2021 \nthrough the first half of our fiscal 2022 , in line with the rate of increasing vaccinations and decreasing COVID \ncases.  We anticipate a return to pre -COVID prescription and patient engagement levels in the second half of our \nfiscal 2022.  For fiscal 2022, we expect adjusted earnings per diluted sh are to be in the range of $18.85 to $19.45, \nmore heavily weighted towards the back half of the fiscal year. ", "original_text": "We are however encouraged by recent signs that a broader recovery is forthcoming. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f86456f2-58cd-4b88-b5c4-8660acccd329", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfe26cf50c6ced7cacc44059f89a7835ae4ac901eb797a03f9b9203c801527ce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ad3680f-c4df-4ba4-a324-9ce544737211", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nLet me now spend a few minutes on our fiscal 2022 outlook.  And, I'll start by framing a couple of key macro level \nassumptions that underpin our outlook for fiscal 2022.  We do not assume a return waive of the virus,  additional \nshelter in place or increased social distancing.  As we've discussed throughout the year, volume trends in fiscal \n2021 were nonlinear and varied over the course of the year, our markets did not fully recover, and we remain in a \ndynamic environme nt. \n \n We are however encouraged by recent signs that a broader recovery is forthcoming.  We expect prescription \nvolumes will continue to demonstrate steady improvement from volume levels at the end of our fiscal 2021 \nthrough the first half of our fiscal 2022 , in line with the rate of increasing vaccinations and decreasing COVID \ncases.  We anticipate a return to pre -COVID prescription and patient engagement levels in the second half of our \nfiscal 2022. ", "original_text": "As we've discussed throughout the year, volume trends in fiscal \n2021 were nonlinear and varied over the course of the year, our markets did not fully recover, and we remain in a \ndynamic environme nt. \n \n", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "42c4389893e086a3312ad9c06a0b1e59486aa1c3b11c0b0923dd4c1cac6e621e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81b49e91-053b-4bd4-be5a-00a56e85cec4", "node_type": "1", "metadata": {"window": "We do not assume a return waive of the virus,  additional \nshelter in place or increased social distancing.  As we've discussed throughout the year, volume trends in fiscal \n2021 were nonlinear and varied over the course of the year, our markets did not fully recover, and we remain in a \ndynamic environme nt. \n \n We are however encouraged by recent signs that a broader recovery is forthcoming.  We expect prescription \nvolumes will continue to demonstrate steady improvement from volume levels at the end of our fiscal 2021 \nthrough the first half of our fiscal 2022 , in line with the rate of increasing vaccinations and decreasing COVID \ncases.  We anticipate a return to pre -COVID prescription and patient engagement levels in the second half of our \nfiscal 2022.  For fiscal 2022, we expect adjusted earnings per diluted sh are to be in the range of $18.85 to $19.45, \nmore heavily weighted towards the back half of the fiscal year.  We also expect core growth across all of our \nsegments.  \n \n", "original_text": "We expect prescription \nvolumes will continue to demonstrate steady improvement from volume levels at the end of our fiscal 2021 \nthrough the first half of our fiscal 2022 , in line with the rate of increasing vaccinations and decreasing COVID \ncases. "}, "hash": "bfa31321a27e480518797d3c63b7f7a75913bbdc5470d4859e47a4dd1e43af6c", "class_name": "RelatedNodeInfo"}}, "text": "We are however encouraged by recent signs that a broader recovery is forthcoming. ", "start_char_idx": 664, "end_char_idx": 746, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81b49e91-053b-4bd4-be5a-00a56e85cec4": {"__data__": {"id_": "81b49e91-053b-4bd4-be5a-00a56e85cec4", "embedding": null, "metadata": {"window": "We do not assume a return waive of the virus,  additional \nshelter in place or increased social distancing.  As we've discussed throughout the year, volume trends in fiscal \n2021 were nonlinear and varied over the course of the year, our markets did not fully recover, and we remain in a \ndynamic environme nt. \n \n We are however encouraged by recent signs that a broader recovery is forthcoming.  We expect prescription \nvolumes will continue to demonstrate steady improvement from volume levels at the end of our fiscal 2021 \nthrough the first half of our fiscal 2022 , in line with the rate of increasing vaccinations and decreasing COVID \ncases.  We anticipate a return to pre -COVID prescription and patient engagement levels in the second half of our \nfiscal 2022.  For fiscal 2022, we expect adjusted earnings per diluted sh are to be in the range of $18.85 to $19.45, \nmore heavily weighted towards the back half of the fiscal year.  We also expect core growth across all of our \nsegments.  \n \n", "original_text": "We expect prescription \nvolumes will continue to demonstrate steady improvement from volume levels at the end of our fiscal 2021 \nthrough the first half of our fiscal 2022 , in line with the rate of increasing vaccinations and decreasing COVID \ncases. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f86456f2-58cd-4b88-b5c4-8660acccd329", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfe26cf50c6ced7cacc44059f89a7835ae4ac901eb797a03f9b9203c801527ce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9ebf426-8dcb-487b-982d-ac1a23fa1031", "node_type": "1", "metadata": {"window": "And, I'll start by framing a couple of key macro level \nassumptions that underpin our outlook for fiscal 2022.  We do not assume a return waive of the virus,  additional \nshelter in place or increased social distancing.  As we've discussed throughout the year, volume trends in fiscal \n2021 were nonlinear and varied over the course of the year, our markets did not fully recover, and we remain in a \ndynamic environme nt. \n \n We are however encouraged by recent signs that a broader recovery is forthcoming.  We expect prescription \nvolumes will continue to demonstrate steady improvement from volume levels at the end of our fiscal 2021 \nthrough the first half of our fiscal 2022 , in line with the rate of increasing vaccinations and decreasing COVID \ncases.  We anticipate a return to pre -COVID prescription and patient engagement levels in the second half of our \nfiscal 2022.  For fiscal 2022, we expect adjusted earnings per diluted sh are to be in the range of $18.85 to $19.45, \nmore heavily weighted towards the back half of the fiscal year. ", "original_text": "We are however encouraged by recent signs that a broader recovery is forthcoming. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f545e8fb4c0593968c4a0e426c643f33d473c9e6306f1ce7015e42453e053e6e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d42dd6cd-5a47-4ee1-8b59-c70ac04325f7", "node_type": "1", "metadata": {"window": "As we've discussed throughout the year, volume trends in fiscal \n2021 were nonlinear and varied over the course of the year, our markets did not fully recover, and we remain in a \ndynamic environme nt. \n \n We are however encouraged by recent signs that a broader recovery is forthcoming.  We expect prescription \nvolumes will continue to demonstrate steady improvement from volume levels at the end of our fiscal 2021 \nthrough the first half of our fiscal 2022 , in line with the rate of increasing vaccinations and decreasing COVID \ncases.  We anticipate a return to pre -COVID prescription and patient engagement levels in the second half of our \nfiscal 2022.  For fiscal 2022, we expect adjusted earnings per diluted sh are to be in the range of $18.85 to $19.45, \nmore heavily weighted towards the back half of the fiscal year.  We also expect core growth across all of our \nsegments.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting  with the segments. ", "original_text": "We anticipate a return to pre -COVID prescription and patient engagement levels in the second half of our \nfiscal 2022. "}, "hash": "f7aadb9cccfdf2034dc8c678438379393518dae50b02e0074aca5c43a541dc7d", "class_name": "RelatedNodeInfo"}}, "text": "We expect prescription \nvolumes will continue to demonstrate steady improvement from volume levels at the end of our fiscal 2021 \nthrough the first half of our fiscal 2022 , in line with the rate of increasing vaccinations and decreasing COVID \ncases. ", "start_char_idx": 746, "end_char_idx": 998, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d42dd6cd-5a47-4ee1-8b59-c70ac04325f7": {"__data__": {"id_": "d42dd6cd-5a47-4ee1-8b59-c70ac04325f7", "embedding": null, "metadata": {"window": "As we've discussed throughout the year, volume trends in fiscal \n2021 were nonlinear and varied over the course of the year, our markets did not fully recover, and we remain in a \ndynamic environme nt. \n \n We are however encouraged by recent signs that a broader recovery is forthcoming.  We expect prescription \nvolumes will continue to demonstrate steady improvement from volume levels at the end of our fiscal 2021 \nthrough the first half of our fiscal 2022 , in line with the rate of increasing vaccinations and decreasing COVID \ncases.  We anticipate a return to pre -COVID prescription and patient engagement levels in the second half of our \nfiscal 2022.  For fiscal 2022, we expect adjusted earnings per diluted sh are to be in the range of $18.85 to $19.45, \nmore heavily weighted towards the back half of the fiscal year.  We also expect core growth across all of our \nsegments.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting  with the segments. ", "original_text": "We anticipate a return to pre -COVID prescription and patient engagement levels in the second half of our \nfiscal 2022. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f86456f2-58cd-4b88-b5c4-8660acccd329", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfe26cf50c6ced7cacc44059f89a7835ae4ac901eb797a03f9b9203c801527ce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81b49e91-053b-4bd4-be5a-00a56e85cec4", "node_type": "1", "metadata": {"window": "We do not assume a return waive of the virus,  additional \nshelter in place or increased social distancing.  As we've discussed throughout the year, volume trends in fiscal \n2021 were nonlinear and varied over the course of the year, our markets did not fully recover, and we remain in a \ndynamic environme nt. \n \n We are however encouraged by recent signs that a broader recovery is forthcoming.  We expect prescription \nvolumes will continue to demonstrate steady improvement from volume levels at the end of our fiscal 2021 \nthrough the first half of our fiscal 2022 , in line with the rate of increasing vaccinations and decreasing COVID \ncases.  We anticipate a return to pre -COVID prescription and patient engagement levels in the second half of our \nfiscal 2022.  For fiscal 2022, we expect adjusted earnings per diluted sh are to be in the range of $18.85 to $19.45, \nmore heavily weighted towards the back half of the fiscal year.  We also expect core growth across all of our \nsegments.  \n \n", "original_text": "We expect prescription \nvolumes will continue to demonstrate steady improvement from volume levels at the end of our fiscal 2021 \nthrough the first half of our fiscal 2022 , in line with the rate of increasing vaccinations and decreasing COVID \ncases. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "06ac0e0736095cda53fdbe7078df862ed57584d241e6f3038d1eb65d5c13254d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e225a95-9262-49ee-ad04-d1b26dab0c32", "node_type": "1", "metadata": {"window": "We are however encouraged by recent signs that a broader recovery is forthcoming.  We expect prescription \nvolumes will continue to demonstrate steady improvement from volume levels at the end of our fiscal 2021 \nthrough the first half of our fiscal 2022 , in line with the rate of increasing vaccinations and decreasing COVID \ncases.  We anticipate a return to pre -COVID prescription and patient engagement levels in the second half of our \nfiscal 2022.  For fiscal 2022, we expect adjusted earnings per diluted sh are to be in the range of $18.85 to $19.45, \nmore heavily weighted towards the back half of the fiscal year.  We also expect core growth across all of our \nsegments.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting  with the segments.  For \na full list of our fiscal 2022 assumptions, please refer to slides 13 through 16 in our supplemental slide \npresentation.  \n \n", "original_text": "For fiscal 2022, we expect adjusted earnings per diluted sh are to be in the range of $18.85 to $19.45, \nmore heavily weighted towards the back half of the fiscal year. "}, "hash": "5df581f1e96851f24e71fd7f5ba7a56c2723e704af3e2071d11bcb2827cfa3d9", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate a return to pre -COVID prescription and patient engagement levels in the second half of our \nfiscal 2022. ", "start_char_idx": 998, "end_char_idx": 1118, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e225a95-9262-49ee-ad04-d1b26dab0c32": {"__data__": {"id_": "6e225a95-9262-49ee-ad04-d1b26dab0c32", "embedding": null, "metadata": {"window": "We are however encouraged by recent signs that a broader recovery is forthcoming.  We expect prescription \nvolumes will continue to demonstrate steady improvement from volume levels at the end of our fiscal 2021 \nthrough the first half of our fiscal 2022 , in line with the rate of increasing vaccinations and decreasing COVID \ncases.  We anticipate a return to pre -COVID prescription and patient engagement levels in the second half of our \nfiscal 2022.  For fiscal 2022, we expect adjusted earnings per diluted sh are to be in the range of $18.85 to $19.45, \nmore heavily weighted towards the back half of the fiscal year.  We also expect core growth across all of our \nsegments.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting  with the segments.  For \na full list of our fiscal 2022 assumptions, please refer to slides 13 through 16 in our supplemental slide \npresentation.  \n \n", "original_text": "For fiscal 2022, we expect adjusted earnings per diluted sh are to be in the range of $18.85 to $19.45, \nmore heavily weighted towards the back half of the fiscal year. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f86456f2-58cd-4b88-b5c4-8660acccd329", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfe26cf50c6ced7cacc44059f89a7835ae4ac901eb797a03f9b9203c801527ce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d42dd6cd-5a47-4ee1-8b59-c70ac04325f7", "node_type": "1", "metadata": {"window": "As we've discussed throughout the year, volume trends in fiscal \n2021 were nonlinear and varied over the course of the year, our markets did not fully recover, and we remain in a \ndynamic environme nt. \n \n We are however encouraged by recent signs that a broader recovery is forthcoming.  We expect prescription \nvolumes will continue to demonstrate steady improvement from volume levels at the end of our fiscal 2021 \nthrough the first half of our fiscal 2022 , in line with the rate of increasing vaccinations and decreasing COVID \ncases.  We anticipate a return to pre -COVID prescription and patient engagement levels in the second half of our \nfiscal 2022.  For fiscal 2022, we expect adjusted earnings per diluted sh are to be in the range of $18.85 to $19.45, \nmore heavily weighted towards the back half of the fiscal year.  We also expect core growth across all of our \nsegments.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting  with the segments. ", "original_text": "We anticipate a return to pre -COVID prescription and patient engagement levels in the second half of our \nfiscal 2022. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0bf4d27adcb7ef63f8329b54becbebdaa97363f96ba80c89684ad4029d0b521d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e10c88dc-10a9-4955-8b9c-00fd95869850", "node_type": "1", "metadata": {"window": "We expect prescription \nvolumes will continue to demonstrate steady improvement from volume levels at the end of our fiscal 2021 \nthrough the first half of our fiscal 2022 , in line with the rate of increasing vaccinations and decreasing COVID \ncases.  We anticipate a return to pre -COVID prescription and patient engagement levels in the second half of our \nfiscal 2022.  For fiscal 2022, we expect adjusted earnings per diluted sh are to be in the range of $18.85 to $19.45, \nmore heavily weighted towards the back half of the fiscal year.  We also expect core growth across all of our \nsegments.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting  with the segments.  For \na full list of our fiscal 2022 assumptions, please refer to slides 13 through 16 in our supplemental slide \npresentation.  \n \n In the US Pharmaceutical segment, we expect revenue to increase 4% to 7% driven by market growth and strong \nperformance at our Specialty business. ", "original_text": "We also expect core growth across all of our \nsegments.  \n \n"}, "hash": "68a07e65ebe9704c962e57f71abf38121749a8cc95cd8ad4ea821a581c292f29", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal 2022, we expect adjusted earnings per diluted sh are to be in the range of $18.85 to $19.45, \nmore heavily weighted towards the back half of the fiscal year. ", "start_char_idx": 1118, "end_char_idx": 1287, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e10c88dc-10a9-4955-8b9c-00fd95869850": {"__data__": {"id_": "e10c88dc-10a9-4955-8b9c-00fd95869850", "embedding": null, "metadata": {"window": "We expect prescription \nvolumes will continue to demonstrate steady improvement from volume levels at the end of our fiscal 2021 \nthrough the first half of our fiscal 2022 , in line with the rate of increasing vaccinations and decreasing COVID \ncases.  We anticipate a return to pre -COVID prescription and patient engagement levels in the second half of our \nfiscal 2022.  For fiscal 2022, we expect adjusted earnings per diluted sh are to be in the range of $18.85 to $19.45, \nmore heavily weighted towards the back half of the fiscal year.  We also expect core growth across all of our \nsegments.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting  with the segments.  For \na full list of our fiscal 2022 assumptions, please refer to slides 13 through 16 in our supplemental slide \npresentation.  \n \n In the US Pharmaceutical segment, we expect revenue to increase 4% to 7% driven by market growth and strong \nperformance at our Specialty business. ", "original_text": "We also expect core growth across all of our \nsegments.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f86456f2-58cd-4b88-b5c4-8660acccd329", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfe26cf50c6ced7cacc44059f89a7835ae4ac901eb797a03f9b9203c801527ce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e225a95-9262-49ee-ad04-d1b26dab0c32", "node_type": "1", "metadata": {"window": "We are however encouraged by recent signs that a broader recovery is forthcoming.  We expect prescription \nvolumes will continue to demonstrate steady improvement from volume levels at the end of our fiscal 2021 \nthrough the first half of our fiscal 2022 , in line with the rate of increasing vaccinations and decreasing COVID \ncases.  We anticipate a return to pre -COVID prescription and patient engagement levels in the second half of our \nfiscal 2022.  For fiscal 2022, we expect adjusted earnings per diluted sh are to be in the range of $18.85 to $19.45, \nmore heavily weighted towards the back half of the fiscal year.  We also expect core growth across all of our \nsegments.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting  with the segments.  For \na full list of our fiscal 2022 assumptions, please refer to slides 13 through 16 in our supplemental slide \npresentation.  \n \n", "original_text": "For fiscal 2022, we expect adjusted earnings per diluted sh are to be in the range of $18.85 to $19.45, \nmore heavily weighted towards the back half of the fiscal year. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5f6ba865d5b3cdd081b4e31819bf6a04fb9df4399dcf5e5a2603c1122dfd1d76", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac42b52c-b9ba-4938-be5a-ff64b35f4ff3", "node_type": "1", "metadata": {"window": "We anticipate a return to pre -COVID prescription and patient engagement levels in the second half of our \nfiscal 2022.  For fiscal 2022, we expect adjusted earnings per diluted sh are to be in the range of $18.85 to $19.45, \nmore heavily weighted towards the back half of the fiscal year.  We also expect core growth across all of our \nsegments.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting  with the segments.  For \na full list of our fiscal 2022 assumptions, please refer to slides 13 through 16 in our supplemental slide \npresentation.  \n \n In the US Pharmaceutical segment, we expect revenue to increase 4% to 7% driven by market growth and strong \nperformance at our Specialty business.  Adjusted operating profit is expected to deliver 4% to 7% growth as \nvolumes continue to improve compared to fiscal 2021. ", "original_text": "Rather than outlining each assumption, I'll instead walk you through the key items, starting  with the segments. "}, "hash": "20b89708501f329f702b9b9cced28549aa1c5ce465e68b9d6c61e8021800219d", "class_name": "RelatedNodeInfo"}}, "text": "We also expect core growth across all of our \nsegments.  \n \n", "start_char_idx": 1287, "end_char_idx": 1347, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac42b52c-b9ba-4938-be5a-ff64b35f4ff3": {"__data__": {"id_": "ac42b52c-b9ba-4938-be5a-ff64b35f4ff3", "embedding": null, "metadata": {"window": "We anticipate a return to pre -COVID prescription and patient engagement levels in the second half of our \nfiscal 2022.  For fiscal 2022, we expect adjusted earnings per diluted sh are to be in the range of $18.85 to $19.45, \nmore heavily weighted towards the back half of the fiscal year.  We also expect core growth across all of our \nsegments.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting  with the segments.  For \na full list of our fiscal 2022 assumptions, please refer to slides 13 through 16 in our supplemental slide \npresentation.  \n \n In the US Pharmaceutical segment, we expect revenue to increase 4% to 7% driven by market growth and strong \nperformance at our Specialty business.  Adjusted operating profit is expected to deliver 4% to 7% growth as \nvolumes continue to improve compared to fiscal 2021. ", "original_text": "Rather than outlining each assumption, I'll instead walk you through the key items, starting  with the segments. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f86456f2-58cd-4b88-b5c4-8660acccd329", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfe26cf50c6ced7cacc44059f89a7835ae4ac901eb797a03f9b9203c801527ce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e10c88dc-10a9-4955-8b9c-00fd95869850", "node_type": "1", "metadata": {"window": "We expect prescription \nvolumes will continue to demonstrate steady improvement from volume levels at the end of our fiscal 2021 \nthrough the first half of our fiscal 2022 , in line with the rate of increasing vaccinations and decreasing COVID \ncases.  We anticipate a return to pre -COVID prescription and patient engagement levels in the second half of our \nfiscal 2022.  For fiscal 2022, we expect adjusted earnings per diluted sh are to be in the range of $18.85 to $19.45, \nmore heavily weighted towards the back half of the fiscal year.  We also expect core growth across all of our \nsegments.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting  with the segments.  For \na full list of our fiscal 2022 assumptions, please refer to slides 13 through 16 in our supplemental slide \npresentation.  \n \n In the US Pharmaceutical segment, we expect revenue to increase 4% to 7% driven by market growth and strong \nperformance at our Specialty business. ", "original_text": "We also expect core growth across all of our \nsegments.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45fc0fce2b76398b648142235f7fb1d4d55097d195952d19e5d5e486c00a63cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44d2040a-b5ae-4887-b5f7-2937b8fd87d0", "node_type": "1", "metadata": {"window": "For fiscal 2022, we expect adjusted earnings per diluted sh are to be in the range of $18.85 to $19.45, \nmore heavily weighted towards the back half of the fiscal year.  We also expect core growth across all of our \nsegments.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting  with the segments.  For \na full list of our fiscal 2022 assumptions, please refer to slides 13 through 16 in our supplemental slide \npresentation.  \n \n In the US Pharmaceutical segment, we expect revenue to increase 4% to 7% driven by market growth and strong \nperformance at our Specialty business.  Adjusted operating profit is expected to deliver 4% to 7% growth as \nvolumes continue to improve compared to fiscal 2021.  Our outlook also includes approximately $0.40 to $0.50 \nrelated to COVID -19 vaccine distribution in fiscal 2022, the majority expected to be realized in our first quarter. \n", "original_text": "For \na full list of our fiscal 2022 assumptions, please refer to slides 13 through 16 in our supplemental slide \npresentation.  \n \n"}, "hash": "7649dbcbbd5c443211bfd303b9d57f512f739cc7f74a8e71c6e8106aa60d129c", "class_name": "RelatedNodeInfo"}}, "text": "Rather than outlining each assumption, I'll instead walk you through the key items, starting  with the segments. ", "start_char_idx": 1347, "end_char_idx": 1460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44d2040a-b5ae-4887-b5f7-2937b8fd87d0": {"__data__": {"id_": "44d2040a-b5ae-4887-b5f7-2937b8fd87d0", "embedding": null, "metadata": {"window": "For fiscal 2022, we expect adjusted earnings per diluted sh are to be in the range of $18.85 to $19.45, \nmore heavily weighted towards the back half of the fiscal year.  We also expect core growth across all of our \nsegments.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting  with the segments.  For \na full list of our fiscal 2022 assumptions, please refer to slides 13 through 16 in our supplemental slide \npresentation.  \n \n In the US Pharmaceutical segment, we expect revenue to increase 4% to 7% driven by market growth and strong \nperformance at our Specialty business.  Adjusted operating profit is expected to deliver 4% to 7% growth as \nvolumes continue to improve compared to fiscal 2021.  Our outlook also includes approximately $0.40 to $0.50 \nrelated to COVID -19 vaccine distribution in fiscal 2022, the majority expected to be realized in our first quarter. \n", "original_text": "For \na full list of our fiscal 2022 assumptions, please refer to slides 13 through 16 in our supplemental slide \npresentation.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f86456f2-58cd-4b88-b5c4-8660acccd329", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfe26cf50c6ced7cacc44059f89a7835ae4ac901eb797a03f9b9203c801527ce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac42b52c-b9ba-4938-be5a-ff64b35f4ff3", "node_type": "1", "metadata": {"window": "We anticipate a return to pre -COVID prescription and patient engagement levels in the second half of our \nfiscal 2022.  For fiscal 2022, we expect adjusted earnings per diluted sh are to be in the range of $18.85 to $19.45, \nmore heavily weighted towards the back half of the fiscal year.  We also expect core growth across all of our \nsegments.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting  with the segments.  For \na full list of our fiscal 2022 assumptions, please refer to slides 13 through 16 in our supplemental slide \npresentation.  \n \n In the US Pharmaceutical segment, we expect revenue to increase 4% to 7% driven by market growth and strong \nperformance at our Specialty business.  Adjusted operating profit is expected to deliver 4% to 7% growth as \nvolumes continue to improve compared to fiscal 2021. ", "original_text": "Rather than outlining each assumption, I'll instead walk you through the key items, starting  with the segments. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "39fadbfeaf18334a8c7331408198ceb23cfa9b4c9711c794bbf089bf25e72b49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44afde78-60a0-4773-a43a-8ec42f267753", "node_type": "1", "metadata": {"window": "We also expect core growth across all of our \nsegments.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting  with the segments.  For \na full list of our fiscal 2022 assumptions, please refer to slides 13 through 16 in our supplemental slide \npresentation.  \n \n In the US Pharmaceutical segment, we expect revenue to increase 4% to 7% driven by market growth and strong \nperformance at our Specialty business.  Adjusted operating profit is expected to deliver 4% to 7% growth as \nvolumes continue to improve compared to fiscal 2021.  Our outlook also includes approximately $0.40 to $0.50 \nrelated to COVID -19 vaccine distribution in fiscal 2022, the majority expected to be realized in our first quarter. \n This compares with approximately $0.35 in fiscal 2021.  \n \n", "original_text": "In the US Pharmaceutical segment, we expect revenue to increase 4% to 7% driven by market growth and strong \nperformance at our Specialty business. "}, "hash": "8dec7259086691416ce132656df186255652a8122fa50293aee0760ba5bd11b8", "class_name": "RelatedNodeInfo"}}, "text": "For \na full list of our fiscal 2022 assumptions, please refer to slides 13 through 16 in our supplemental slide \npresentation.  \n \n", "start_char_idx": 1460, "end_char_idx": 1591, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44afde78-60a0-4773-a43a-8ec42f267753": {"__data__": {"id_": "44afde78-60a0-4773-a43a-8ec42f267753", "embedding": null, "metadata": {"window": "We also expect core growth across all of our \nsegments.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting  with the segments.  For \na full list of our fiscal 2022 assumptions, please refer to slides 13 through 16 in our supplemental slide \npresentation.  \n \n In the US Pharmaceutical segment, we expect revenue to increase 4% to 7% driven by market growth and strong \nperformance at our Specialty business.  Adjusted operating profit is expected to deliver 4% to 7% growth as \nvolumes continue to improve compared to fiscal 2021.  Our outlook also includes approximately $0.40 to $0.50 \nrelated to COVID -19 vaccine distribution in fiscal 2022, the majority expected to be realized in our first quarter. \n This compares with approximately $0.35 in fiscal 2021.  \n \n", "original_text": "In the US Pharmaceutical segment, we expect revenue to increase 4% to 7% driven by market growth and strong \nperformance at our Specialty business. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f86456f2-58cd-4b88-b5c4-8660acccd329", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfe26cf50c6ced7cacc44059f89a7835ae4ac901eb797a03f9b9203c801527ce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44d2040a-b5ae-4887-b5f7-2937b8fd87d0", "node_type": "1", "metadata": {"window": "For fiscal 2022, we expect adjusted earnings per diluted sh are to be in the range of $18.85 to $19.45, \nmore heavily weighted towards the back half of the fiscal year.  We also expect core growth across all of our \nsegments.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting  with the segments.  For \na full list of our fiscal 2022 assumptions, please refer to slides 13 through 16 in our supplemental slide \npresentation.  \n \n In the US Pharmaceutical segment, we expect revenue to increase 4% to 7% driven by market growth and strong \nperformance at our Specialty business.  Adjusted operating profit is expected to deliver 4% to 7% growth as \nvolumes continue to improve compared to fiscal 2021.  Our outlook also includes approximately $0.40 to $0.50 \nrelated to COVID -19 vaccine distribution in fiscal 2022, the majority expected to be realized in our first quarter. \n", "original_text": "For \na full list of our fiscal 2022 assumptions, please refer to slides 13 through 16 in our supplemental slide \npresentation.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c9fbbfb1094a9df02cb4581722c3fbc1c401001b09ab2c82f9727fde4e1cac4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb790ee9-fac1-4505-83b9-6967ec08ec4a", "node_type": "1", "metadata": {"window": "Rather than outlining each assumption, I'll instead walk you through the key items, starting  with the segments.  For \na full list of our fiscal 2022 assumptions, please refer to slides 13 through 16 in our supplemental slide \npresentation.  \n \n In the US Pharmaceutical segment, we expect revenue to increase 4% to 7% driven by market growth and strong \nperformance at our Specialty business.  Adjusted operating profit is expected to deliver 4% to 7% growth as \nvolumes continue to improve compared to fiscal 2021.  Our outlook also includes approximately $0.40 to $0.50 \nrelated to COVID -19 vaccine distribution in fiscal 2022, the majority expected to be realized in our first quarter. \n This compares with approximately $0.35 in fiscal 2021.  \n \n We will also continue to invest in our leading and differentiated position in oncology and increase investments to \nsupport fu ture growth. ", "original_text": "Adjusted operating profit is expected to deliver 4% to 7% growth as \nvolumes continue to improve compared to fiscal 2021. "}, "hash": "f27a4b1bf94575c861fa86bdadb30969a1b13d40c08221e8d0cc217e23bd411f", "class_name": "RelatedNodeInfo"}}, "text": "In the US Pharmaceutical segment, we expect revenue to increase 4% to 7% driven by market growth and strong \nperformance at our Specialty business. ", "start_char_idx": 1591, "end_char_idx": 1739, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb790ee9-fac1-4505-83b9-6967ec08ec4a": {"__data__": {"id_": "eb790ee9-fac1-4505-83b9-6967ec08ec4a", "embedding": null, "metadata": {"window": "Rather than outlining each assumption, I'll instead walk you through the key items, starting  with the segments.  For \na full list of our fiscal 2022 assumptions, please refer to slides 13 through 16 in our supplemental slide \npresentation.  \n \n In the US Pharmaceutical segment, we expect revenue to increase 4% to 7% driven by market growth and strong \nperformance at our Specialty business.  Adjusted operating profit is expected to deliver 4% to 7% growth as \nvolumes continue to improve compared to fiscal 2021.  Our outlook also includes approximately $0.40 to $0.50 \nrelated to COVID -19 vaccine distribution in fiscal 2022, the majority expected to be realized in our first quarter. \n This compares with approximately $0.35 in fiscal 2021.  \n \n We will also continue to invest in our leading and differentiated position in oncology and increase investments to \nsupport fu ture growth. ", "original_text": "Adjusted operating profit is expected to deliver 4% to 7% growth as \nvolumes continue to improve compared to fiscal 2021. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f86456f2-58cd-4b88-b5c4-8660acccd329", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfe26cf50c6ced7cacc44059f89a7835ae4ac901eb797a03f9b9203c801527ce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44afde78-60a0-4773-a43a-8ec42f267753", "node_type": "1", "metadata": {"window": "We also expect core growth across all of our \nsegments.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting  with the segments.  For \na full list of our fiscal 2022 assumptions, please refer to slides 13 through 16 in our supplemental slide \npresentation.  \n \n In the US Pharmaceutical segment, we expect revenue to increase 4% to 7% driven by market growth and strong \nperformance at our Specialty business.  Adjusted operating profit is expected to deliver 4% to 7% growth as \nvolumes continue to improve compared to fiscal 2021.  Our outlook also includes approximately $0.40 to $0.50 \nrelated to COVID -19 vaccine distribution in fiscal 2022, the majority expected to be realized in our first quarter. \n This compares with approximately $0.35 in fiscal 2021.  \n \n", "original_text": "In the US Pharmaceutical segment, we expect revenue to increase 4% to 7% driven by market growth and strong \nperformance at our Specialty business. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b51c155d0ef2676d7965e1c472fcfa20229edf6e099fe75b35fc1413f8bece2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a6dc8e8-6d5b-4106-8b1a-267b082aeeea", "node_type": "1", "metadata": {"window": "For \na full list of our fiscal 2022 assumptions, please refer to slides 13 through 16 in our supplemental slide \npresentation.  \n \n In the US Pharmaceutical segment, we expect revenue to increase 4% to 7% driven by market growth and strong \nperformance at our Specialty business.  Adjusted operating profit is expected to deliver 4% to 7% growth as \nvolumes continue to improve compared to fiscal 2021.  Our outlook also includes approximately $0.40 to $0.50 \nrelated to COVID -19 vaccine distribution in fiscal 2022, the majority expected to be realized in our first quarter. \n This compares with approximately $0.35 in fiscal 2021.  \n \n We will also continue to invest in our leading and differentiated position in oncology and increase investments to \nsupport fu ture growth.  We expect these investments will represent an approximate $0.20 headwind in fiscal 2022. \n", "original_text": "Our outlook also includes approximately $0.40 to $0.50 \nrelated to COVID -19 vaccine distribution in fiscal 2022, the majority expected to be realized in our first quarter. \n"}, "hash": "dfcb2fffbfcef92156fa4f154126663b97d64c0a9d88a4c4de8d5212b368727e", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating profit is expected to deliver 4% to 7% growth as \nvolumes continue to improve compared to fiscal 2021. ", "start_char_idx": 1739, "end_char_idx": 1861, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a6dc8e8-6d5b-4106-8b1a-267b082aeeea": {"__data__": {"id_": "4a6dc8e8-6d5b-4106-8b1a-267b082aeeea", "embedding": null, "metadata": {"window": "For \na full list of our fiscal 2022 assumptions, please refer to slides 13 through 16 in our supplemental slide \npresentation.  \n \n In the US Pharmaceutical segment, we expect revenue to increase 4% to 7% driven by market growth and strong \nperformance at our Specialty business.  Adjusted operating profit is expected to deliver 4% to 7% growth as \nvolumes continue to improve compared to fiscal 2021.  Our outlook also includes approximately $0.40 to $0.50 \nrelated to COVID -19 vaccine distribution in fiscal 2022, the majority expected to be realized in our first quarter. \n This compares with approximately $0.35 in fiscal 2021.  \n \n We will also continue to invest in our leading and differentiated position in oncology and increase investments to \nsupport fu ture growth.  We expect these investments will represent an approximate $0.20 headwind in fiscal 2022. \n", "original_text": "Our outlook also includes approximately $0.40 to $0.50 \nrelated to COVID -19 vaccine distribution in fiscal 2022, the majority expected to be realized in our first quarter. \n", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f86456f2-58cd-4b88-b5c4-8660acccd329", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfe26cf50c6ced7cacc44059f89a7835ae4ac901eb797a03f9b9203c801527ce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb790ee9-fac1-4505-83b9-6967ec08ec4a", "node_type": "1", "metadata": {"window": "Rather than outlining each assumption, I'll instead walk you through the key items, starting  with the segments.  For \na full list of our fiscal 2022 assumptions, please refer to slides 13 through 16 in our supplemental slide \npresentation.  \n \n In the US Pharmaceutical segment, we expect revenue to increase 4% to 7% driven by market growth and strong \nperformance at our Specialty business.  Adjusted operating profit is expected to deliver 4% to 7% growth as \nvolumes continue to improve compared to fiscal 2021.  Our outlook also includes approximately $0.40 to $0.50 \nrelated to COVID -19 vaccine distribution in fiscal 2022, the majority expected to be realized in our first quarter. \n This compares with approximately $0.35 in fiscal 2021.  \n \n We will also continue to invest in our leading and differentiated position in oncology and increase investments to \nsupport fu ture growth. ", "original_text": "Adjusted operating profit is expected to deliver 4% to 7% growth as \nvolumes continue to improve compared to fiscal 2021. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "84b6c4cbc54c844f15d1dc504d50115ec87600f2c1b700fb0b3358d17d44e089", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1fad07b0-aed6-4ae9-813f-d1bd09b11f23", "node_type": "1", "metadata": {"window": "In the US Pharmaceutical segment, we expect revenue to increase 4% to 7% driven by market growth and strong \nperformance at our Specialty business.  Adjusted operating profit is expected to deliver 4% to 7% growth as \nvolumes continue to improve compared to fiscal 2021.  Our outlook also includes approximately $0.40 to $0.50 \nrelated to COVID -19 vaccine distribution in fiscal 2022, the majority expected to be realized in our first quarter. \n This compares with approximately $0.35 in fiscal 2021.  \n \n We will also continue to invest in our leading and differentiated position in oncology and increase investments to \nsupport fu ture growth.  We expect these investments will represent an approximate $0.20 headwind in fiscal 2022. \n Normalizing for the COVID -19 vaccine distribution and our continued growth investments, we expect \napproximately 5% to 8% core adjusted operating profit gr owth.  \n \n", "original_text": "This compares with approximately $0.35 in fiscal 2021.  \n \n"}, "hash": "6be734550f5c266be669479ab37fc1a3549c18f9a973632793157ea2c6cd9953", "class_name": "RelatedNodeInfo"}}, "text": "Our outlook also includes approximately $0.40 to $0.50 \nrelated to COVID -19 vaccine distribution in fiscal 2022, the majority expected to be realized in our first quarter. \n", "start_char_idx": 1861, "end_char_idx": 2035, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1fad07b0-aed6-4ae9-813f-d1bd09b11f23": {"__data__": {"id_": "1fad07b0-aed6-4ae9-813f-d1bd09b11f23", "embedding": null, "metadata": {"window": "In the US Pharmaceutical segment, we expect revenue to increase 4% to 7% driven by market growth and strong \nperformance at our Specialty business.  Adjusted operating profit is expected to deliver 4% to 7% growth as \nvolumes continue to improve compared to fiscal 2021.  Our outlook also includes approximately $0.40 to $0.50 \nrelated to COVID -19 vaccine distribution in fiscal 2022, the majority expected to be realized in our first quarter. \n This compares with approximately $0.35 in fiscal 2021.  \n \n We will also continue to invest in our leading and differentiated position in oncology and increase investments to \nsupport fu ture growth.  We expect these investments will represent an approximate $0.20 headwind in fiscal 2022. \n Normalizing for the COVID -19 vaccine distribution and our continued growth investments, we expect \napproximately 5% to 8% core adjusted operating profit gr owth.  \n \n", "original_text": "This compares with approximately $0.35 in fiscal 2021.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f86456f2-58cd-4b88-b5c4-8660acccd329", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfe26cf50c6ced7cacc44059f89a7835ae4ac901eb797a03f9b9203c801527ce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a6dc8e8-6d5b-4106-8b1a-267b082aeeea", "node_type": "1", "metadata": {"window": "For \na full list of our fiscal 2022 assumptions, please refer to slides 13 through 16 in our supplemental slide \npresentation.  \n \n In the US Pharmaceutical segment, we expect revenue to increase 4% to 7% driven by market growth and strong \nperformance at our Specialty business.  Adjusted operating profit is expected to deliver 4% to 7% growth as \nvolumes continue to improve compared to fiscal 2021.  Our outlook also includes approximately $0.40 to $0.50 \nrelated to COVID -19 vaccine distribution in fiscal 2022, the majority expected to be realized in our first quarter. \n This compares with approximately $0.35 in fiscal 2021.  \n \n We will also continue to invest in our leading and differentiated position in oncology and increase investments to \nsupport fu ture growth.  We expect these investments will represent an approximate $0.20 headwind in fiscal 2022. \n", "original_text": "Our outlook also includes approximately $0.40 to $0.50 \nrelated to COVID -19 vaccine distribution in fiscal 2022, the majority expected to be realized in our first quarter. \n", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dcbe5963d55550d277d30fbc5f8d9db04ba99cc9fde207c94bcb9169e3e28ba2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fdbb39fc-e1f5-47a2-a28d-519b3f43ac48", "node_type": "1", "metadata": {"window": "Adjusted operating profit is expected to deliver 4% to 7% growth as \nvolumes continue to improve compared to fiscal 2021.  Our outlook also includes approximately $0.40 to $0.50 \nrelated to COVID -19 vaccine distribution in fiscal 2022, the majority expected to be realized in our first quarter. \n This compares with approximately $0.35 in fiscal 2021.  \n \n We will also continue to invest in our leading and differentiated position in oncology and increase investments to \nsupport fu ture growth.  We expect these investments will represent an approximate $0.20 headwind in fiscal 2022. \n Normalizing for the COVID -19 vaccine distribution and our continued growth investments, we expect \napproximately 5% to 8% core adjusted operating profit gr owth.  \n \n Finally, we anticipate branded pharmaceutical pricing to approximate mid single -digit increases, which is \nconsistent with fiscal 2021. ", "original_text": "We will also continue to invest in our leading and differentiated position in oncology and increase investments to \nsupport fu ture growth. "}, "hash": "2ad96d7fba8aa52df1eed80123dee544f2a88d5edc073c13759a86652f94a823", "class_name": "RelatedNodeInfo"}}, "text": "This compares with approximately $0.35 in fiscal 2021.  \n \n", "start_char_idx": 2035, "end_char_idx": 2094, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fdbb39fc-e1f5-47a2-a28d-519b3f43ac48": {"__data__": {"id_": "fdbb39fc-e1f5-47a2-a28d-519b3f43ac48", "embedding": null, "metadata": {"window": "Adjusted operating profit is expected to deliver 4% to 7% growth as \nvolumes continue to improve compared to fiscal 2021.  Our outlook also includes approximately $0.40 to $0.50 \nrelated to COVID -19 vaccine distribution in fiscal 2022, the majority expected to be realized in our first quarter. \n This compares with approximately $0.35 in fiscal 2021.  \n \n We will also continue to invest in our leading and differentiated position in oncology and increase investments to \nsupport fu ture growth.  We expect these investments will represent an approximate $0.20 headwind in fiscal 2022. \n Normalizing for the COVID -19 vaccine distribution and our continued growth investments, we expect \napproximately 5% to 8% core adjusted operating profit gr owth.  \n \n Finally, we anticipate branded pharmaceutical pricing to approximate mid single -digit increases, which is \nconsistent with fiscal 2021. ", "original_text": "We will also continue to invest in our leading and differentiated position in oncology and increase investments to \nsupport fu ture growth. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f86456f2-58cd-4b88-b5c4-8660acccd329", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfe26cf50c6ced7cacc44059f89a7835ae4ac901eb797a03f9b9203c801527ce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1fad07b0-aed6-4ae9-813f-d1bd09b11f23", "node_type": "1", "metadata": {"window": "In the US Pharmaceutical segment, we expect revenue to increase 4% to 7% driven by market growth and strong \nperformance at our Specialty business.  Adjusted operating profit is expected to deliver 4% to 7% growth as \nvolumes continue to improve compared to fiscal 2021.  Our outlook also includes approximately $0.40 to $0.50 \nrelated to COVID -19 vaccine distribution in fiscal 2022, the majority expected to be realized in our first quarter. \n This compares with approximately $0.35 in fiscal 2021.  \n \n We will also continue to invest in our leading and differentiated position in oncology and increase investments to \nsupport fu ture growth.  We expect these investments will represent an approximate $0.20 headwind in fiscal 2022. \n Normalizing for the COVID -19 vaccine distribution and our continued growth investments, we expect \napproximately 5% to 8% core adjusted operating profit gr owth.  \n \n", "original_text": "This compares with approximately $0.35 in fiscal 2021.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9b9ff011419b24184b16ae8987835b205b9e29e308fba7316eb825a4f48db9d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26c74fc3-0482-4ce0-af0b-d49a56f13976", "node_type": "1", "metadata": {"window": "Our outlook also includes approximately $0.40 to $0.50 \nrelated to COVID -19 vaccine distribution in fiscal 2022, the majority expected to be realized in our first quarter. \n This compares with approximately $0.35 in fiscal 2021.  \n \n We will also continue to invest in our leading and differentiated position in oncology and increase investments to \nsupport fu ture growth.  We expect these investments will represent an approximate $0.20 headwind in fiscal 2022. \n Normalizing for the COVID -19 vaccine distribution and our continued growth investments, we expect \napproximately 5% to 8% core adjusted operating profit gr owth.  \n \n Finally, we anticipate branded pharmaceutical pricing to approximate mid single -digit increases, which is \nconsistent with fiscal 2021.  And the generic market remains competitive yet stable. ", "original_text": "We expect these investments will represent an approximate $0.20 headwind in fiscal 2022. \n"}, "hash": "1c23d4b944fb8ceabd70dc86ac47e3b926f02bf48e479c93a0b8d0144f2a7a6c", "class_name": "RelatedNodeInfo"}}, "text": "We will also continue to invest in our leading and differentiated position in oncology and increase investments to \nsupport fu ture growth. ", "start_char_idx": 2094, "end_char_idx": 2234, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26c74fc3-0482-4ce0-af0b-d49a56f13976": {"__data__": {"id_": "26c74fc3-0482-4ce0-af0b-d49a56f13976", "embedding": null, "metadata": {"window": "Our outlook also includes approximately $0.40 to $0.50 \nrelated to COVID -19 vaccine distribution in fiscal 2022, the majority expected to be realized in our first quarter. \n This compares with approximately $0.35 in fiscal 2021.  \n \n We will also continue to invest in our leading and differentiated position in oncology and increase investments to \nsupport fu ture growth.  We expect these investments will represent an approximate $0.20 headwind in fiscal 2022. \n Normalizing for the COVID -19 vaccine distribution and our continued growth investments, we expect \napproximately 5% to 8% core adjusted operating profit gr owth.  \n \n Finally, we anticipate branded pharmaceutical pricing to approximate mid single -digit increases, which is \nconsistent with fiscal 2021.  And the generic market remains competitive yet stable. ", "original_text": "We expect these investments will represent an approximate $0.20 headwind in fiscal 2022. \n", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f86456f2-58cd-4b88-b5c4-8660acccd329", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfe26cf50c6ced7cacc44059f89a7835ae4ac901eb797a03f9b9203c801527ce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fdbb39fc-e1f5-47a2-a28d-519b3f43ac48", "node_type": "1", "metadata": {"window": "Adjusted operating profit is expected to deliver 4% to 7% growth as \nvolumes continue to improve compared to fiscal 2021.  Our outlook also includes approximately $0.40 to $0.50 \nrelated to COVID -19 vaccine distribution in fiscal 2022, the majority expected to be realized in our first quarter. \n This compares with approximately $0.35 in fiscal 2021.  \n \n We will also continue to invest in our leading and differentiated position in oncology and increase investments to \nsupport fu ture growth.  We expect these investments will represent an approximate $0.20 headwind in fiscal 2022. \n Normalizing for the COVID -19 vaccine distribution and our continued growth investments, we expect \napproximately 5% to 8% core adjusted operating profit gr owth.  \n \n Finally, we anticipate branded pharmaceutical pricing to approximate mid single -digit increases, which is \nconsistent with fiscal 2021. ", "original_text": "We will also continue to invest in our leading and differentiated position in oncology and increase investments to \nsupport fu ture growth. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6eb00f646d8446ea8103fe8e7d40458277152f9eb72399b86b1ffc1ddeba3a14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0bd52393-2422-4632-b63c-74b791b2e0cf", "node_type": "1", "metadata": {"window": "This compares with approximately $0.35 in fiscal 2021.  \n \n We will also continue to invest in our leading and differentiated position in oncology and increase investments to \nsupport fu ture growth.  We expect these investments will represent an approximate $0.20 headwind in fiscal 2022. \n Normalizing for the COVID -19 vaccine distribution and our continued growth investments, we expect \napproximately 5% to 8% core adjusted operating profit gr owth.  \n \n Finally, we anticipate branded pharmaceutical pricing to approximate mid single -digit increases, which is \nconsistent with fiscal 2021.  And the generic market remains competitive yet stable.  We continue to be pleased \nwith the performance of ClarusONE , which provides competitive costs and supply stability to our customers. ", "original_text": "Normalizing for the COVID -19 vaccine distribution and our continued growth investments, we expect \napproximately 5% to 8% core adjusted operating profit gr owth.  \n \n"}, "hash": "fb295ba00013406b487a0bc0594e8f40bd517e0a8869b8fbfd86176d9a1d92e8", "class_name": "RelatedNodeInfo"}}, "text": "We expect these investments will represent an approximate $0.20 headwind in fiscal 2022. \n", "start_char_idx": 2234, "end_char_idx": 2324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0bd52393-2422-4632-b63c-74b791b2e0cf": {"__data__": {"id_": "0bd52393-2422-4632-b63c-74b791b2e0cf", "embedding": null, "metadata": {"window": "This compares with approximately $0.35 in fiscal 2021.  \n \n We will also continue to invest in our leading and differentiated position in oncology and increase investments to \nsupport fu ture growth.  We expect these investments will represent an approximate $0.20 headwind in fiscal 2022. \n Normalizing for the COVID -19 vaccine distribution and our continued growth investments, we expect \napproximately 5% to 8% core adjusted operating profit gr owth.  \n \n Finally, we anticipate branded pharmaceutical pricing to approximate mid single -digit increases, which is \nconsistent with fiscal 2021.  And the generic market remains competitive yet stable.  We continue to be pleased \nwith the performance of ClarusONE , which provides competitive costs and supply stability to our customers. ", "original_text": "Normalizing for the COVID -19 vaccine distribution and our continued growth investments, we expect \napproximately 5% to 8% core adjusted operating profit gr owth.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f86456f2-58cd-4b88-b5c4-8660acccd329", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfe26cf50c6ced7cacc44059f89a7835ae4ac901eb797a03f9b9203c801527ce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26c74fc3-0482-4ce0-af0b-d49a56f13976", "node_type": "1", "metadata": {"window": "Our outlook also includes approximately $0.40 to $0.50 \nrelated to COVID -19 vaccine distribution in fiscal 2022, the majority expected to be realized in our first quarter. \n This compares with approximately $0.35 in fiscal 2021.  \n \n We will also continue to invest in our leading and differentiated position in oncology and increase investments to \nsupport fu ture growth.  We expect these investments will represent an approximate $0.20 headwind in fiscal 2022. \n Normalizing for the COVID -19 vaccine distribution and our continued growth investments, we expect \napproximately 5% to 8% core adjusted operating profit gr owth.  \n \n Finally, we anticipate branded pharmaceutical pricing to approximate mid single -digit increases, which is \nconsistent with fiscal 2021.  And the generic market remains competitive yet stable. ", "original_text": "We expect these investments will represent an approximate $0.20 headwind in fiscal 2022. \n", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e1d7e1e1f7d14882a2484be5e61e557f522731a703d50bc341c3159397e8703", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c53a4b3b-c1e3-4f51-93b2-bcdcd33b2be1", "node_type": "1", "metadata": {"window": "We will also continue to invest in our leading and differentiated position in oncology and increase investments to \nsupport fu ture growth.  We expect these investments will represent an approximate $0.20 headwind in fiscal 2022. \n Normalizing for the COVID -19 vaccine distribution and our continued growth investments, we expect \napproximately 5% to 8% core adjusted operating profit gr owth.  \n \n Finally, we anticipate branded pharmaceutical pricing to approximate mid single -digit increases, which is \nconsistent with fiscal 2021.  And the generic market remains competitive yet stable.  We continue to be pleased \nwith the performance of ClarusONE , which provides competitive costs and supply stability to our customers.  This \ncombined with our disciplined approach to pricing and improving overall volume and utilization, gives us \nconfidence in our ability to grow and generate positive spread.  \n \n", "original_text": "Finally, we anticipate branded pharmaceutical pricing to approximate mid single -digit increases, which is \nconsistent with fiscal 2021. "}, "hash": "c2ea364427d4b58cbd241cd9a3ebdf0136f4ea13c1f0cbd717b4be82996d5afa", "class_name": "RelatedNodeInfo"}}, "text": "Normalizing for the COVID -19 vaccine distribution and our continued growth investments, we expect \napproximately 5% to 8% core adjusted operating profit gr owth.  \n \n", "start_char_idx": 2324, "end_char_idx": 2491, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c53a4b3b-c1e3-4f51-93b2-bcdcd33b2be1": {"__data__": {"id_": "c53a4b3b-c1e3-4f51-93b2-bcdcd33b2be1", "embedding": null, "metadata": {"window": "We will also continue to invest in our leading and differentiated position in oncology and increase investments to \nsupport fu ture growth.  We expect these investments will represent an approximate $0.20 headwind in fiscal 2022. \n Normalizing for the COVID -19 vaccine distribution and our continued growth investments, we expect \napproximately 5% to 8% core adjusted operating profit gr owth.  \n \n Finally, we anticipate branded pharmaceutical pricing to approximate mid single -digit increases, which is \nconsistent with fiscal 2021.  And the generic market remains competitive yet stable.  We continue to be pleased \nwith the performance of ClarusONE , which provides competitive costs and supply stability to our customers.  This \ncombined with our disciplined approach to pricing and improving overall volume and utilization, gives us \nconfidence in our ability to grow and generate positive spread.  \n \n", "original_text": "Finally, we anticipate branded pharmaceutical pricing to approximate mid single -digit increases, which is \nconsistent with fiscal 2021. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f86456f2-58cd-4b88-b5c4-8660acccd329", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfe26cf50c6ced7cacc44059f89a7835ae4ac901eb797a03f9b9203c801527ce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0bd52393-2422-4632-b63c-74b791b2e0cf", "node_type": "1", "metadata": {"window": "This compares with approximately $0.35 in fiscal 2021.  \n \n We will also continue to invest in our leading and differentiated position in oncology and increase investments to \nsupport fu ture growth.  We expect these investments will represent an approximate $0.20 headwind in fiscal 2022. \n Normalizing for the COVID -19 vaccine distribution and our continued growth investments, we expect \napproximately 5% to 8% core adjusted operating profit gr owth.  \n \n Finally, we anticipate branded pharmaceutical pricing to approximate mid single -digit increases, which is \nconsistent with fiscal 2021.  And the generic market remains competitive yet stable.  We continue to be pleased \nwith the performance of ClarusONE , which provides competitive costs and supply stability to our customers. ", "original_text": "Normalizing for the COVID -19 vaccine distribution and our continued growth investments, we expect \napproximately 5% to 8% core adjusted operating profit gr owth.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "38969acc825e701d9fa073abf51db62df8fafd5e75528fdabc97ad04aea98f2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "149261ee-5760-49c3-808a-3f2fc03466ac", "node_type": "1", "metadata": {"window": "We expect these investments will represent an approximate $0.20 headwind in fiscal 2022. \n Normalizing for the COVID -19 vaccine distribution and our continued growth investments, we expect \napproximately 5% to 8% core adjusted operating profit gr owth.  \n \n Finally, we anticipate branded pharmaceutical pricing to approximate mid single -digit increases, which is \nconsistent with fiscal 2021.  And the generic market remains competitive yet stable.  We continue to be pleased \nwith the performance of ClarusONE , which provides competitive costs and supply stability to our customers.  This \ncombined with our disciplined approach to pricing and improving overall volume and utilization, gives us \nconfidence in our ability to grow and generate positive spread.  \n \n In our Prescription Technology Solutions segment, we expect revenue and adjusted operating profit growth of \n12% to 17% driven by organic growth as we continue to recognize the benefits of the investments we've been \nmaking in technology offerings for our biopharma  customers.  \n \n", "original_text": "And the generic market remains competitive yet stable. "}, "hash": "41d07ea9374641bee95fc7d3f6ee3528a13092806a7035a24c982edd46c4074c", "class_name": "RelatedNodeInfo"}}, "text": "Finally, we anticipate branded pharmaceutical pricing to approximate mid single -digit increases, which is \nconsistent with fiscal 2021. ", "start_char_idx": 2491, "end_char_idx": 2628, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "149261ee-5760-49c3-808a-3f2fc03466ac": {"__data__": {"id_": "149261ee-5760-49c3-808a-3f2fc03466ac", "embedding": null, "metadata": {"window": "We expect these investments will represent an approximate $0.20 headwind in fiscal 2022. \n Normalizing for the COVID -19 vaccine distribution and our continued growth investments, we expect \napproximately 5% to 8% core adjusted operating profit gr owth.  \n \n Finally, we anticipate branded pharmaceutical pricing to approximate mid single -digit increases, which is \nconsistent with fiscal 2021.  And the generic market remains competitive yet stable.  We continue to be pleased \nwith the performance of ClarusONE , which provides competitive costs and supply stability to our customers.  This \ncombined with our disciplined approach to pricing and improving overall volume and utilization, gives us \nconfidence in our ability to grow and generate positive spread.  \n \n In our Prescription Technology Solutions segment, we expect revenue and adjusted operating profit growth of \n12% to 17% driven by organic growth as we continue to recognize the benefits of the investments we've been \nmaking in technology offerings for our biopharma  customers.  \n \n", "original_text": "And the generic market remains competitive yet stable. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f86456f2-58cd-4b88-b5c4-8660acccd329", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfe26cf50c6ced7cacc44059f89a7835ae4ac901eb797a03f9b9203c801527ce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c53a4b3b-c1e3-4f51-93b2-bcdcd33b2be1", "node_type": "1", "metadata": {"window": "We will also continue to invest in our leading and differentiated position in oncology and increase investments to \nsupport fu ture growth.  We expect these investments will represent an approximate $0.20 headwind in fiscal 2022. \n Normalizing for the COVID -19 vaccine distribution and our continued growth investments, we expect \napproximately 5% to 8% core adjusted operating profit gr owth.  \n \n Finally, we anticipate branded pharmaceutical pricing to approximate mid single -digit increases, which is \nconsistent with fiscal 2021.  And the generic market remains competitive yet stable.  We continue to be pleased \nwith the performance of ClarusONE , which provides competitive costs and supply stability to our customers.  This \ncombined with our disciplined approach to pricing and improving overall volume and utilization, gives us \nconfidence in our ability to grow and generate positive spread.  \n \n", "original_text": "Finally, we anticipate branded pharmaceutical pricing to approximate mid single -digit increases, which is \nconsistent with fiscal 2021. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53382e1b3d9167bbcb956e0922a0cad3d14ea0e066963ae05e40d6c9a6bd61fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b8c7533-af81-4fcd-bddf-72578afa7352", "node_type": "1", "metadata": {"window": "Normalizing for the COVID -19 vaccine distribution and our continued growth investments, we expect \napproximately 5% to 8% core adjusted operating profit gr owth.  \n \n Finally, we anticipate branded pharmaceutical pricing to approximate mid single -digit increases, which is \nconsistent with fiscal 2021.  And the generic market remains competitive yet stable.  We continue to be pleased \nwith the performance of ClarusONE , which provides competitive costs and supply stability to our customers.  This \ncombined with our disciplined approach to pricing and improving overall volume and utilization, gives us \nconfidence in our ability to grow and generate positive spread.  \n \n In our Prescription Technology Solutions segment, we expect revenue and adjusted operating profit growth of \n12% to 17% driven by organic growth as we continue to recognize the benefits of the investments we've been \nmaking in technology offerings for our biopharma  customers.  \n \n Now transitioning to Medical -Surgical, fiscal 2021 saw notable impacts from the contribution of COVID test kits \nand personal protective equipment, as well as impacts to the underlying business due to office closures, social \ndistancing and redu ced patient visits. ", "original_text": "We continue to be pleased \nwith the performance of ClarusONE , which provides competitive costs and supply stability to our customers. "}, "hash": "5500498e33f615b5160445d8fe25c08322b0ab82d13b287bd8b31fec73c103cb", "class_name": "RelatedNodeInfo"}}, "text": "And the generic market remains competitive yet stable. ", "start_char_idx": 2628, "end_char_idx": 2683, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b8c7533-af81-4fcd-bddf-72578afa7352": {"__data__": {"id_": "3b8c7533-af81-4fcd-bddf-72578afa7352", "embedding": null, "metadata": {"window": "Normalizing for the COVID -19 vaccine distribution and our continued growth investments, we expect \napproximately 5% to 8% core adjusted operating profit gr owth.  \n \n Finally, we anticipate branded pharmaceutical pricing to approximate mid single -digit increases, which is \nconsistent with fiscal 2021.  And the generic market remains competitive yet stable.  We continue to be pleased \nwith the performance of ClarusONE , which provides competitive costs and supply stability to our customers.  This \ncombined with our disciplined approach to pricing and improving overall volume and utilization, gives us \nconfidence in our ability to grow and generate positive spread.  \n \n In our Prescription Technology Solutions segment, we expect revenue and adjusted operating profit growth of \n12% to 17% driven by organic growth as we continue to recognize the benefits of the investments we've been \nmaking in technology offerings for our biopharma  customers.  \n \n Now transitioning to Medical -Surgical, fiscal 2021 saw notable impacts from the contribution of COVID test kits \nand personal protective equipment, as well as impacts to the underlying business due to office closures, social \ndistancing and redu ced patient visits. ", "original_text": "We continue to be pleased \nwith the performance of ClarusONE , which provides competitive costs and supply stability to our customers. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f86456f2-58cd-4b88-b5c4-8660acccd329", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfe26cf50c6ced7cacc44059f89a7835ae4ac901eb797a03f9b9203c801527ce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "149261ee-5760-49c3-808a-3f2fc03466ac", "node_type": "1", "metadata": {"window": "We expect these investments will represent an approximate $0.20 headwind in fiscal 2022. \n Normalizing for the COVID -19 vaccine distribution and our continued growth investments, we expect \napproximately 5% to 8% core adjusted operating profit gr owth.  \n \n Finally, we anticipate branded pharmaceutical pricing to approximate mid single -digit increases, which is \nconsistent with fiscal 2021.  And the generic market remains competitive yet stable.  We continue to be pleased \nwith the performance of ClarusONE , which provides competitive costs and supply stability to our customers.  This \ncombined with our disciplined approach to pricing and improving overall volume and utilization, gives us \nconfidence in our ability to grow and generate positive spread.  \n \n In our Prescription Technology Solutions segment, we expect revenue and adjusted operating profit growth of \n12% to 17% driven by organic growth as we continue to recognize the benefits of the investments we've been \nmaking in technology offerings for our biopharma  customers.  \n \n", "original_text": "And the generic market remains competitive yet stable. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f0ace7fd083c96f2bc8c6d26aba28e771288e8bf10d7b13640a50464fd008a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f9df2d3-1f63-4743-9819-88d92349df77", "node_type": "1", "metadata": {"window": "Finally, we anticipate branded pharmaceutical pricing to approximate mid single -digit increases, which is \nconsistent with fiscal 2021.  And the generic market remains competitive yet stable.  We continue to be pleased \nwith the performance of ClarusONE , which provides competitive costs and supply stability to our customers.  This \ncombined with our disciplined approach to pricing and improving overall volume and utilization, gives us \nconfidence in our ability to grow and generate positive spread.  \n \n In our Prescription Technology Solutions segment, we expect revenue and adjusted operating profit growth of \n12% to 17% driven by organic growth as we continue to recognize the benefits of the investments we've been \nmaking in technology offerings for our biopharma  customers.  \n \n Now transitioning to Medical -Surgical, fiscal 2021 saw notable impacts from the contribution of COVID test kits \nand personal protective equipment, as well as impacts to the underlying business due to office closures, social \ndistancing and redu ced patient visits.  Our Medical -Surgical business delivered strong results against these \nchallenges, and we continue to position the business for long -term growth.  \n \n", "original_text": "This \ncombined with our disciplined approach to pricing and improving overall volume and utilization, gives us \nconfidence in our ability to grow and generate positive spread.  \n \n"}, "hash": "814c1f58abbb940ef1e4dca34e80fd7eff238788e2e84cf5a9d2b8981b963e68", "class_name": "RelatedNodeInfo"}}, "text": "We continue to be pleased \nwith the performance of ClarusONE , which provides competitive costs and supply stability to our customers. ", "start_char_idx": 2683, "end_char_idx": 2818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f9df2d3-1f63-4743-9819-88d92349df77": {"__data__": {"id_": "8f9df2d3-1f63-4743-9819-88d92349df77", "embedding": null, "metadata": {"window": "Finally, we anticipate branded pharmaceutical pricing to approximate mid single -digit increases, which is \nconsistent with fiscal 2021.  And the generic market remains competitive yet stable.  We continue to be pleased \nwith the performance of ClarusONE , which provides competitive costs and supply stability to our customers.  This \ncombined with our disciplined approach to pricing and improving overall volume and utilization, gives us \nconfidence in our ability to grow and generate positive spread.  \n \n In our Prescription Technology Solutions segment, we expect revenue and adjusted operating profit growth of \n12% to 17% driven by organic growth as we continue to recognize the benefits of the investments we've been \nmaking in technology offerings for our biopharma  customers.  \n \n Now transitioning to Medical -Surgical, fiscal 2021 saw notable impacts from the contribution of COVID test kits \nand personal protective equipment, as well as impacts to the underlying business due to office closures, social \ndistancing and redu ced patient visits.  Our Medical -Surgical business delivered strong results against these \nchallenges, and we continue to position the business for long -term growth.  \n \n", "original_text": "This \ncombined with our disciplined approach to pricing and improving overall volume and utilization, gives us \nconfidence in our ability to grow and generate positive spread.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f86456f2-58cd-4b88-b5c4-8660acccd329", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfe26cf50c6ced7cacc44059f89a7835ae4ac901eb797a03f9b9203c801527ce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b8c7533-af81-4fcd-bddf-72578afa7352", "node_type": "1", "metadata": {"window": "Normalizing for the COVID -19 vaccine distribution and our continued growth investments, we expect \napproximately 5% to 8% core adjusted operating profit gr owth.  \n \n Finally, we anticipate branded pharmaceutical pricing to approximate mid single -digit increases, which is \nconsistent with fiscal 2021.  And the generic market remains competitive yet stable.  We continue to be pleased \nwith the performance of ClarusONE , which provides competitive costs and supply stability to our customers.  This \ncombined with our disciplined approach to pricing and improving overall volume and utilization, gives us \nconfidence in our ability to grow and generate positive spread.  \n \n In our Prescription Technology Solutions segment, we expect revenue and adjusted operating profit growth of \n12% to 17% driven by organic growth as we continue to recognize the benefits of the investments we've been \nmaking in technology offerings for our biopharma  customers.  \n \n Now transitioning to Medical -Surgical, fiscal 2021 saw notable impacts from the contribution of COVID test kits \nand personal protective equipment, as well as impacts to the underlying business due to office closures, social \ndistancing and redu ced patient visits. ", "original_text": "We continue to be pleased \nwith the performance of ClarusONE , which provides competitive costs and supply stability to our customers. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "732d3539d4bfd0b2e3c1391c26284fb85dc6c30d78fe51169c0dfaa908923d61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66eb747a-927b-4063-a30a-abd7e7a9f354", "node_type": "1", "metadata": {"window": "And the generic market remains competitive yet stable.  We continue to be pleased \nwith the performance of ClarusONE , which provides competitive costs and supply stability to our customers.  This \ncombined with our disciplined approach to pricing and improving overall volume and utilization, gives us \nconfidence in our ability to grow and generate positive spread.  \n \n In our Prescription Technology Solutions segment, we expect revenue and adjusted operating profit growth of \n12% to 17% driven by organic growth as we continue to recognize the benefits of the investments we've been \nmaking in technology offerings for our biopharma  customers.  \n \n Now transitioning to Medical -Surgical, fiscal 2021 saw notable impacts from the contribution of COVID test kits \nand personal protective equipment, as well as impacts to the underlying business due to office closures, social \ndistancing and redu ced patient visits.  Our Medical -Surgical business delivered strong results against these \nchallenges, and we continue to position the business for long -term growth.  \n \n In fiscal 2022, we expect demand for COVID test kits and PPE to moderate further as vaccina tions increase and \ncase counts decrease. ", "original_text": "In our Prescription Technology Solutions segment, we expect revenue and adjusted operating profit growth of \n12% to 17% driven by organic growth as we continue to recognize the benefits of the investments we've been \nmaking in technology offerings for our biopharma  customers.  \n \n"}, "hash": "5dcf0a3da892f0ba426dcd42900560b1ed3a894d7f2d3ce739fb22afbdda4838", "class_name": "RelatedNodeInfo"}}, "text": "This \ncombined with our disciplined approach to pricing and improving overall volume and utilization, gives us \nconfidence in our ability to grow and generate positive spread.  \n \n", "start_char_idx": 2818, "end_char_idx": 2998, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66eb747a-927b-4063-a30a-abd7e7a9f354": {"__data__": {"id_": "66eb747a-927b-4063-a30a-abd7e7a9f354", "embedding": null, "metadata": {"window": "And the generic market remains competitive yet stable.  We continue to be pleased \nwith the performance of ClarusONE , which provides competitive costs and supply stability to our customers.  This \ncombined with our disciplined approach to pricing and improving overall volume and utilization, gives us \nconfidence in our ability to grow and generate positive spread.  \n \n In our Prescription Technology Solutions segment, we expect revenue and adjusted operating profit growth of \n12% to 17% driven by organic growth as we continue to recognize the benefits of the investments we've been \nmaking in technology offerings for our biopharma  customers.  \n \n Now transitioning to Medical -Surgical, fiscal 2021 saw notable impacts from the contribution of COVID test kits \nand personal protective equipment, as well as impacts to the underlying business due to office closures, social \ndistancing and redu ced patient visits.  Our Medical -Surgical business delivered strong results against these \nchallenges, and we continue to position the business for long -term growth.  \n \n In fiscal 2022, we expect demand for COVID test kits and PPE to moderate further as vaccina tions increase and \ncase counts decrease. ", "original_text": "In our Prescription Technology Solutions segment, we expect revenue and adjusted operating profit growth of \n12% to 17% driven by organic growth as we continue to recognize the benefits of the investments we've been \nmaking in technology offerings for our biopharma  customers.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f86456f2-58cd-4b88-b5c4-8660acccd329", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfe26cf50c6ced7cacc44059f89a7835ae4ac901eb797a03f9b9203c801527ce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f9df2d3-1f63-4743-9819-88d92349df77", "node_type": "1", "metadata": {"window": "Finally, we anticipate branded pharmaceutical pricing to approximate mid single -digit increases, which is \nconsistent with fiscal 2021.  And the generic market remains competitive yet stable.  We continue to be pleased \nwith the performance of ClarusONE , which provides competitive costs and supply stability to our customers.  This \ncombined with our disciplined approach to pricing and improving overall volume and utilization, gives us \nconfidence in our ability to grow and generate positive spread.  \n \n In our Prescription Technology Solutions segment, we expect revenue and adjusted operating profit growth of \n12% to 17% driven by organic growth as we continue to recognize the benefits of the investments we've been \nmaking in technology offerings for our biopharma  customers.  \n \n Now transitioning to Medical -Surgical, fiscal 2021 saw notable impacts from the contribution of COVID test kits \nand personal protective equipment, as well as impacts to the underlying business due to office closures, social \ndistancing and redu ced patient visits.  Our Medical -Surgical business delivered strong results against these \nchallenges, and we continue to position the business for long -term growth.  \n \n", "original_text": "This \ncombined with our disciplined approach to pricing and improving overall volume and utilization, gives us \nconfidence in our ability to grow and generate positive spread.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfeab9127b9ce5e5b2c815ec7688e3bd6d02c7f629aa9702dde593884838fc74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ee2d259-bee5-4c9a-811e-7ada37c0235d", "node_type": "1", "metadata": {"window": "We continue to be pleased \nwith the performance of ClarusONE , which provides competitive costs and supply stability to our customers.  This \ncombined with our disciplined approach to pricing and improving overall volume and utilization, gives us \nconfidence in our ability to grow and generate positive spread.  \n \n In our Prescription Technology Solutions segment, we expect revenue and adjusted operating profit growth of \n12% to 17% driven by organic growth as we continue to recognize the benefits of the investments we've been \nmaking in technology offerings for our biopharma  customers.  \n \n Now transitioning to Medical -Surgical, fiscal 2021 saw notable impacts from the contribution of COVID test kits \nand personal protective equipment, as well as impacts to the underlying business due to office closures, social \ndistancing and redu ced patient visits.  Our Medical -Surgical business delivered strong results against these \nchallenges, and we continue to position the business for long -term growth.  \n \n In fiscal 2022, we expect demand for COVID test kits and PPE to moderate further as vaccina tions increase and \ncase counts decrease.  As patients continue to return to their providers, we expect growth in our Primary and \nExtended Care segments of this business. ", "original_text": "Now transitioning to Medical -Surgical, fiscal 2021 saw notable impacts from the contribution of COVID test kits \nand personal protective equipment, as well as impacts to the underlying business due to office closures, social \ndistancing and redu ced patient visits. "}, "hash": "70888418c77aea3bb6514623e74c3a07702e2ce2e0c6d3838bf52a25c6cc99ea", "class_name": "RelatedNodeInfo"}}, "text": "In our Prescription Technology Solutions segment, we expect revenue and adjusted operating profit growth of \n12% to 17% driven by organic growth as we continue to recognize the benefits of the investments we've been \nmaking in technology offerings for our biopharma  customers.  \n \n", "start_char_idx": 2998, "end_char_idx": 3280, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ee2d259-bee5-4c9a-811e-7ada37c0235d": {"__data__": {"id_": "0ee2d259-bee5-4c9a-811e-7ada37c0235d", "embedding": null, "metadata": {"window": "We continue to be pleased \nwith the performance of ClarusONE , which provides competitive costs and supply stability to our customers.  This \ncombined with our disciplined approach to pricing and improving overall volume and utilization, gives us \nconfidence in our ability to grow and generate positive spread.  \n \n In our Prescription Technology Solutions segment, we expect revenue and adjusted operating profit growth of \n12% to 17% driven by organic growth as we continue to recognize the benefits of the investments we've been \nmaking in technology offerings for our biopharma  customers.  \n \n Now transitioning to Medical -Surgical, fiscal 2021 saw notable impacts from the contribution of COVID test kits \nand personal protective equipment, as well as impacts to the underlying business due to office closures, social \ndistancing and redu ced patient visits.  Our Medical -Surgical business delivered strong results against these \nchallenges, and we continue to position the business for long -term growth.  \n \n In fiscal 2022, we expect demand for COVID test kits and PPE to moderate further as vaccina tions increase and \ncase counts decrease.  As patients continue to return to their providers, we expect growth in our Primary and \nExtended Care segments of this business. ", "original_text": "Now transitioning to Medical -Surgical, fiscal 2021 saw notable impacts from the contribution of COVID test kits \nand personal protective equipment, as well as impacts to the underlying business due to office closures, social \ndistancing and redu ced patient visits. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f86456f2-58cd-4b88-b5c4-8660acccd329", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfe26cf50c6ced7cacc44059f89a7835ae4ac901eb797a03f9b9203c801527ce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66eb747a-927b-4063-a30a-abd7e7a9f354", "node_type": "1", "metadata": {"window": "And the generic market remains competitive yet stable.  We continue to be pleased \nwith the performance of ClarusONE , which provides competitive costs and supply stability to our customers.  This \ncombined with our disciplined approach to pricing and improving overall volume and utilization, gives us \nconfidence in our ability to grow and generate positive spread.  \n \n In our Prescription Technology Solutions segment, we expect revenue and adjusted operating profit growth of \n12% to 17% driven by organic growth as we continue to recognize the benefits of the investments we've been \nmaking in technology offerings for our biopharma  customers.  \n \n Now transitioning to Medical -Surgical, fiscal 2021 saw notable impacts from the contribution of COVID test kits \nand personal protective equipment, as well as impacts to the underlying business due to office closures, social \ndistancing and redu ced patient visits.  Our Medical -Surgical business delivered strong results against these \nchallenges, and we continue to position the business for long -term growth.  \n \n In fiscal 2022, we expect demand for COVID test kits and PPE to moderate further as vaccina tions increase and \ncase counts decrease. ", "original_text": "In our Prescription Technology Solutions segment, we expect revenue and adjusted operating profit growth of \n12% to 17% driven by organic growth as we continue to recognize the benefits of the investments we've been \nmaking in technology offerings for our biopharma  customers.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "907d4b9d8924733763786aea0b375c0fa1715d7649ba73bf0ba0da718b7ce935", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9f6eaee-0444-4904-a2d6-5b62da2bc853", "node_type": "1", "metadata": {"window": "This \ncombined with our disciplined approach to pricing and improving overall volume and utilization, gives us \nconfidence in our ability to grow and generate positive spread.  \n \n In our Prescription Technology Solutions segment, we expect revenue and adjusted operating profit growth of \n12% to 17% driven by organic growth as we continue to recognize the benefits of the investments we've been \nmaking in technology offerings for our biopharma  customers.  \n \n Now transitioning to Medical -Surgical, fiscal 2021 saw notable impacts from the contribution of COVID test kits \nand personal protective equipment, as well as impacts to the underlying business due to office closures, social \ndistancing and redu ced patient visits.  Our Medical -Surgical business delivered strong results against these \nchallenges, and we continue to position the business for long -term growth.  \n \n In fiscal 2022, we expect demand for COVID test kits and PPE to moderate further as vaccina tions increase and \ncase counts decrease.  As patients continue to return to their providers, we expect growth in our Primary and \nExtended Care segments of this business.  Given these dynamics, we expect revenue to be down 5% to 1% ", "original_text": "Our Medical -Surgical business delivered strong results against these \nchallenges, and we continue to position the business for long -term growth.  \n \n"}, "hash": "fe9314d29adee511e6b96484b39d759a460ff07e8828a5cac97d1fd8e332a9cd", "class_name": "RelatedNodeInfo"}}, "text": "Now transitioning to Medical -Surgical, fiscal 2021 saw notable impacts from the contribution of COVID test kits \nand personal protective equipment, as well as impacts to the underlying business due to office closures, social \ndistancing and redu ced patient visits. ", "start_char_idx": 3280, "end_char_idx": 3547, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9f6eaee-0444-4904-a2d6-5b62da2bc853": {"__data__": {"id_": "a9f6eaee-0444-4904-a2d6-5b62da2bc853", "embedding": null, "metadata": {"window": "This \ncombined with our disciplined approach to pricing and improving overall volume and utilization, gives us \nconfidence in our ability to grow and generate positive spread.  \n \n In our Prescription Technology Solutions segment, we expect revenue and adjusted operating profit growth of \n12% to 17% driven by organic growth as we continue to recognize the benefits of the investments we've been \nmaking in technology offerings for our biopharma  customers.  \n \n Now transitioning to Medical -Surgical, fiscal 2021 saw notable impacts from the contribution of COVID test kits \nand personal protective equipment, as well as impacts to the underlying business due to office closures, social \ndistancing and redu ced patient visits.  Our Medical -Surgical business delivered strong results against these \nchallenges, and we continue to position the business for long -term growth.  \n \n In fiscal 2022, we expect demand for COVID test kits and PPE to moderate further as vaccina tions increase and \ncase counts decrease.  As patients continue to return to their providers, we expect growth in our Primary and \nExtended Care segments of this business.  Given these dynamics, we expect revenue to be down 5% to 1% ", "original_text": "Our Medical -Surgical business delivered strong results against these \nchallenges, and we continue to position the business for long -term growth.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f86456f2-58cd-4b88-b5c4-8660acccd329", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfe26cf50c6ced7cacc44059f89a7835ae4ac901eb797a03f9b9203c801527ce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ee2d259-bee5-4c9a-811e-7ada37c0235d", "node_type": "1", "metadata": {"window": "We continue to be pleased \nwith the performance of ClarusONE , which provides competitive costs and supply stability to our customers.  This \ncombined with our disciplined approach to pricing and improving overall volume and utilization, gives us \nconfidence in our ability to grow and generate positive spread.  \n \n In our Prescription Technology Solutions segment, we expect revenue and adjusted operating profit growth of \n12% to 17% driven by organic growth as we continue to recognize the benefits of the investments we've been \nmaking in technology offerings for our biopharma  customers.  \n \n Now transitioning to Medical -Surgical, fiscal 2021 saw notable impacts from the contribution of COVID test kits \nand personal protective equipment, as well as impacts to the underlying business due to office closures, social \ndistancing and redu ced patient visits.  Our Medical -Surgical business delivered strong results against these \nchallenges, and we continue to position the business for long -term growth.  \n \n In fiscal 2022, we expect demand for COVID test kits and PPE to moderate further as vaccina tions increase and \ncase counts decrease.  As patients continue to return to their providers, we expect growth in our Primary and \nExtended Care segments of this business. ", "original_text": "Now transitioning to Medical -Surgical, fiscal 2021 saw notable impacts from the contribution of COVID test kits \nand personal protective equipment, as well as impacts to the underlying business due to office closures, social \ndistancing and redu ced patient visits. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "38f0b8043de0d82d5cf11e63ff407de704169115d923748a2f1545f591a6c48b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3b31664-00c6-4813-8c12-11e933441d59", "node_type": "1", "metadata": {"window": "In our Prescription Technology Solutions segment, we expect revenue and adjusted operating profit growth of \n12% to 17% driven by organic growth as we continue to recognize the benefits of the investments we've been \nmaking in technology offerings for our biopharma  customers.  \n \n Now transitioning to Medical -Surgical, fiscal 2021 saw notable impacts from the contribution of COVID test kits \nand personal protective equipment, as well as impacts to the underlying business due to office closures, social \ndistancing and redu ced patient visits.  Our Medical -Surgical business delivered strong results against these \nchallenges, and we continue to position the business for long -term growth.  \n \n In fiscal 2022, we expect demand for COVID test kits and PPE to moderate further as vaccina tions increase and \ncase counts decrease.  As patients continue to return to their providers, we expect growth in our Primary and \nExtended Care segments of this business.  Given these dynamics, we expect revenue to be down 5% to 1% ", "original_text": "In fiscal 2022, we expect demand for COVID test kits and PPE to moderate further as vaccina tions increase and \ncase counts decrease. "}, "hash": "3b2860dbfcebffa38ffec2a12dc113ffb47d87aa5eed4f5ff2fd555e22ae7f8f", "class_name": "RelatedNodeInfo"}}, "text": "Our Medical -Surgical business delivered strong results against these \nchallenges, and we continue to position the business for long -term growth.  \n \n", "start_char_idx": 3547, "end_char_idx": 3698, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3b31664-00c6-4813-8c12-11e933441d59": {"__data__": {"id_": "f3b31664-00c6-4813-8c12-11e933441d59", "embedding": null, "metadata": {"window": "In our Prescription Technology Solutions segment, we expect revenue and adjusted operating profit growth of \n12% to 17% driven by organic growth as we continue to recognize the benefits of the investments we've been \nmaking in technology offerings for our biopharma  customers.  \n \n Now transitioning to Medical -Surgical, fiscal 2021 saw notable impacts from the contribution of COVID test kits \nand personal protective equipment, as well as impacts to the underlying business due to office closures, social \ndistancing and redu ced patient visits.  Our Medical -Surgical business delivered strong results against these \nchallenges, and we continue to position the business for long -term growth.  \n \n In fiscal 2022, we expect demand for COVID test kits and PPE to moderate further as vaccina tions increase and \ncase counts decrease.  As patients continue to return to their providers, we expect growth in our Primary and \nExtended Care segments of this business.  Given these dynamics, we expect revenue to be down 5% to 1% ", "original_text": "In fiscal 2022, we expect demand for COVID test kits and PPE to moderate further as vaccina tions increase and \ncase counts decrease. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f86456f2-58cd-4b88-b5c4-8660acccd329", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfe26cf50c6ced7cacc44059f89a7835ae4ac901eb797a03f9b9203c801527ce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9f6eaee-0444-4904-a2d6-5b62da2bc853", "node_type": "1", "metadata": {"window": "This \ncombined with our disciplined approach to pricing and improving overall volume and utilization, gives us \nconfidence in our ability to grow and generate positive spread.  \n \n In our Prescription Technology Solutions segment, we expect revenue and adjusted operating profit growth of \n12% to 17% driven by organic growth as we continue to recognize the benefits of the investments we've been \nmaking in technology offerings for our biopharma  customers.  \n \n Now transitioning to Medical -Surgical, fiscal 2021 saw notable impacts from the contribution of COVID test kits \nand personal protective equipment, as well as impacts to the underlying business due to office closures, social \ndistancing and redu ced patient visits.  Our Medical -Surgical business delivered strong results against these \nchallenges, and we continue to position the business for long -term growth.  \n \n In fiscal 2022, we expect demand for COVID test kits and PPE to moderate further as vaccina tions increase and \ncase counts decrease.  As patients continue to return to their providers, we expect growth in our Primary and \nExtended Care segments of this business.  Given these dynamics, we expect revenue to be down 5% to 1% ", "original_text": "Our Medical -Surgical business delivered strong results against these \nchallenges, and we continue to position the business for long -term growth.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7310f12d673d1387d74b66d47cce5e2122f14accec2f595128a95166a8274bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52a79582-7588-423b-a5a9-7b14f4ab2dea", "node_type": "1", "metadata": {"window": "Now transitioning to Medical -Surgical, fiscal 2021 saw notable impacts from the contribution of COVID test kits \nand personal protective equipment, as well as impacts to the underlying business due to office closures, social \ndistancing and redu ced patient visits.  Our Medical -Surgical business delivered strong results against these \nchallenges, and we continue to position the business for long -term growth.  \n \n In fiscal 2022, we expect demand for COVID test kits and PPE to moderate further as vaccina tions increase and \ncase counts decrease.  As patients continue to return to their providers, we expect growth in our Primary and \nExtended Care segments of this business.  Given these dynamics, we expect revenue to be down 5% to 1% ", "original_text": "As patients continue to return to their providers, we expect growth in our Primary and \nExtended Care segments of this business. "}, "hash": "3280268d83e18a4a19ff9f3e29330200ecaec8b7570795a63116644be418fb5d", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal 2022, we expect demand for COVID test kits and PPE to moderate further as vaccina tions increase and \ncase counts decrease. ", "start_char_idx": 3698, "end_char_idx": 3832, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52a79582-7588-423b-a5a9-7b14f4ab2dea": {"__data__": {"id_": "52a79582-7588-423b-a5a9-7b14f4ab2dea", "embedding": null, "metadata": {"window": "Now transitioning to Medical -Surgical, fiscal 2021 saw notable impacts from the contribution of COVID test kits \nand personal protective equipment, as well as impacts to the underlying business due to office closures, social \ndistancing and redu ced patient visits.  Our Medical -Surgical business delivered strong results against these \nchallenges, and we continue to position the business for long -term growth.  \n \n In fiscal 2022, we expect demand for COVID test kits and PPE to moderate further as vaccina tions increase and \ncase counts decrease.  As patients continue to return to their providers, we expect growth in our Primary and \nExtended Care segments of this business.  Given these dynamics, we expect revenue to be down 5% to 1% ", "original_text": "As patients continue to return to their providers, we expect growth in our Primary and \nExtended Care segments of this business. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f86456f2-58cd-4b88-b5c4-8660acccd329", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfe26cf50c6ced7cacc44059f89a7835ae4ac901eb797a03f9b9203c801527ce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3b31664-00c6-4813-8c12-11e933441d59", "node_type": "1", "metadata": {"window": "In our Prescription Technology Solutions segment, we expect revenue and adjusted operating profit growth of \n12% to 17% driven by organic growth as we continue to recognize the benefits of the investments we've been \nmaking in technology offerings for our biopharma  customers.  \n \n Now transitioning to Medical -Surgical, fiscal 2021 saw notable impacts from the contribution of COVID test kits \nand personal protective equipment, as well as impacts to the underlying business due to office closures, social \ndistancing and redu ced patient visits.  Our Medical -Surgical business delivered strong results against these \nchallenges, and we continue to position the business for long -term growth.  \n \n In fiscal 2022, we expect demand for COVID test kits and PPE to moderate further as vaccina tions increase and \ncase counts decrease.  As patients continue to return to their providers, we expect growth in our Primary and \nExtended Care segments of this business.  Given these dynamics, we expect revenue to be down 5% to 1% ", "original_text": "In fiscal 2022, we expect demand for COVID test kits and PPE to moderate further as vaccina tions increase and \ncase counts decrease. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7fa9bf1c95bcd9c94e85d4248fea10a1603a1089ec54c07f3da26945db5142b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2d15e45-5ae9-4812-b4ff-109428ab2588", "node_type": "1", "metadata": {"window": "Our Medical -Surgical business delivered strong results against these \nchallenges, and we continue to position the business for long -term growth.  \n \n In fiscal 2022, we expect demand for COVID test kits and PPE to moderate further as vaccina tions increase and \ncase counts decrease.  As patients continue to return to their providers, we expect growth in our Primary and \nExtended Care segments of this business.  Given these dynamics, we expect revenue to be down 5% to 1% ", "original_text": "Given these dynamics, we expect revenue to be down 5% to 1% "}, "hash": "ddc761c75108552f5bc616bce0c92ea937967f4870055e6f1e9eb9cd8f7e0e2d", "class_name": "RelatedNodeInfo"}}, "text": "As patients continue to return to their providers, we expect growth in our Primary and \nExtended Care segments of this business. ", "start_char_idx": 3832, "end_char_idx": 3961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2d15e45-5ae9-4812-b4ff-109428ab2588": {"__data__": {"id_": "c2d15e45-5ae9-4812-b4ff-109428ab2588", "embedding": null, "metadata": {"window": "Our Medical -Surgical business delivered strong results against these \nchallenges, and we continue to position the business for long -term growth.  \n \n In fiscal 2022, we expect demand for COVID test kits and PPE to moderate further as vaccina tions increase and \ncase counts decrease.  As patients continue to return to their providers, we expect growth in our Primary and \nExtended Care segments of this business.  Given these dynamics, we expect revenue to be down 5% to 1% ", "original_text": "Given these dynamics, we expect revenue to be down 5% to 1% ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f86456f2-58cd-4b88-b5c4-8660acccd329", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfe26cf50c6ced7cacc44059f89a7835ae4ac901eb797a03f9b9203c801527ce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52a79582-7588-423b-a5a9-7b14f4ab2dea", "node_type": "1", "metadata": {"window": "Now transitioning to Medical -Surgical, fiscal 2021 saw notable impacts from the contribution of COVID test kits \nand personal protective equipment, as well as impacts to the underlying business due to office closures, social \ndistancing and redu ced patient visits.  Our Medical -Surgical business delivered strong results against these \nchallenges, and we continue to position the business for long -term growth.  \n \n In fiscal 2022, we expect demand for COVID test kits and PPE to moderate further as vaccina tions increase and \ncase counts decrease.  As patients continue to return to their providers, we expect growth in our Primary and \nExtended Care segments of this business.  Given these dynamics, we expect revenue to be down 5% to 1% ", "original_text": "As patients continue to return to their providers, we expect growth in our Primary and \nExtended Care segments of this business. ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d48b837598b93ab772c1cfd2f4febebf540b3a2fa1c9b00f2ebc5d158d8d16de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4dbafc38-19f1-4d69-85fe-dab741a29902", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ngrowth, and we expect adjus ted operating profit to be flat to 6% growth over the prior year, as growth in our \nunderlying business is offset by a lower contribution from COVID test kits.  \n \n Included in this guidance is $0.10 to $0.20 of contribution related to the kitting and distribut ion of ancillary supplies \nfor COVID -19 vaccines.  Again, the majority will be realized in our first quarter. ", "original_text": "McKesson Corp.  "}, "hash": "d597c19d8d15659bbcadde17e83ad9df2c23958fb01c1b3245b93699c197787b", "class_name": "RelatedNodeInfo"}}, "text": "Given these dynamics, we expect revenue to be down 5% to 1% ", "start_char_idx": 3961, "end_char_idx": 4021, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4dbafc38-19f1-4d69-85fe-dab741a29902": {"__data__": {"id_": "4dbafc38-19f1-4d69-85fe-dab741a29902", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ngrowth, and we expect adjus ted operating profit to be flat to 6% growth over the prior year, as growth in our \nunderlying business is offset by a lower contribution from COVID test kits.  \n \n Included in this guidance is $0.10 to $0.20 of contribution related to the kitting and distribut ion of ancillary supplies \nfor COVID -19 vaccines.  Again, the majority will be realized in our first quarter. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee009d0606c8b9e5178e95d741c140713a7092f917833880f6e95044828dda4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2d15e45-5ae9-4812-b4ff-109428ab2588", "node_type": "1", "metadata": {"window": "Our Medical -Surgical business delivered strong results against these \nchallenges, and we continue to position the business for long -term growth.  \n \n In fiscal 2022, we expect demand for COVID test kits and PPE to moderate further as vaccina tions increase and \ncase counts decrease.  As patients continue to return to their providers, we expect growth in our Primary and \nExtended Care segments of this business.  Given these dynamics, we expect revenue to be down 5% to 1% ", "original_text": "Given these dynamics, we expect revenue to be down 5% to 1% ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f0c1e643829587c6debe3c50e9313112f6d320d19e6de19277ba3898d8548b69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4167f3c-e528-41c0-b206-ea407a8c280e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ngrowth, and we expect adjus ted operating profit to be flat to 6% growth over the prior year, as growth in our \nunderlying business is offset by a lower contribution from COVID test kits.  \n \n Included in this guidance is $0.10 to $0.20 of contribution related to the kitting and distribut ion of ancillary supplies \nfor COVID -19 vaccines.  Again, the majority will be realized in our first quarter.  This compares to approximately \n$0.35 in fiscal 2021. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ngrowth, and we expect adjus ted operating profit to be flat to 6% growth over the prior year, as growth in our \nunderlying business is offset by a lower contribution from COVID test kits.  \n \n"}, "hash": "017a4c5e52c129d368187fdb451f6e99009bb15782b6c4312ad11314e10bdcbd", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4167f3c-e528-41c0-b206-ea407a8c280e": {"__data__": {"id_": "d4167f3c-e528-41c0-b206-ea407a8c280e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ngrowth, and we expect adjus ted operating profit to be flat to 6% growth over the prior year, as growth in our \nunderlying business is offset by a lower contribution from COVID test kits.  \n \n Included in this guidance is $0.10 to $0.20 of contribution related to the kitting and distribut ion of ancillary supplies \nfor COVID -19 vaccines.  Again, the majority will be realized in our first quarter.  This compares to approximately \n$0.35 in fiscal 2021. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ngrowth, and we expect adjus ted operating profit to be flat to 6% growth over the prior year, as growth in our \nunderlying business is offset by a lower contribution from COVID test kits.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee009d0606c8b9e5178e95d741c140713a7092f917833880f6e95044828dda4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4dbafc38-19f1-4d69-85fe-dab741a29902", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ngrowth, and we expect adjus ted operating profit to be flat to 6% growth over the prior year, as growth in our \nunderlying business is offset by a lower contribution from COVID test kits.  \n \n Included in this guidance is $0.10 to $0.20 of contribution related to the kitting and distribut ion of ancillary supplies \nfor COVID -19 vaccines.  Again, the majority will be realized in our first quarter. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9a5b97dfcd32bbacfe55422417fec0e7835c456a8b633490f457c09b70f14c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5058e852-00d5-4e2e-9e83-08c6e2ae541c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ngrowth, and we expect adjus ted operating profit to be flat to 6% growth over the prior year, as growth in our \nunderlying business is offset by a lower contribution from COVID test kits.  \n \n Included in this guidance is $0.10 to $0.20 of contribution related to the kitting and distribut ion of ancillary supplies \nfor COVID -19 vaccines.  Again, the majority will be realized in our first quarter.  This compares to approximately \n$0.35 in fiscal 2021.  Due to the timing of when we began executing our contract with HHS, a larger portion of \nkitting  revenue was realized in fiscal 2021.  \n \n", "original_text": "Included in this guidance is $0.10 to $0.20 of contribution related to the kitting and distribut ion of ancillary supplies \nfor COVID -19 vaccines. "}, "hash": "262916bf2d778f6930f0defd5cb1a89486dd200b4aa665982f48615ca7231619", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ngrowth, and we expect adjus ted operating profit to be flat to 6% growth over the prior year, as growth in our \nunderlying business is offset by a lower contribution from COVID test kits.  \n \n", "start_char_idx": 16, "end_char_idx": 373, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5058e852-00d5-4e2e-9e83-08c6e2ae541c": {"__data__": {"id_": "5058e852-00d5-4e2e-9e83-08c6e2ae541c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ngrowth, and we expect adjus ted operating profit to be flat to 6% growth over the prior year, as growth in our \nunderlying business is offset by a lower contribution from COVID test kits.  \n \n Included in this guidance is $0.10 to $0.20 of contribution related to the kitting and distribut ion of ancillary supplies \nfor COVID -19 vaccines.  Again, the majority will be realized in our first quarter.  This compares to approximately \n$0.35 in fiscal 2021.  Due to the timing of when we began executing our contract with HHS, a larger portion of \nkitting  revenue was realized in fiscal 2021.  \n \n", "original_text": "Included in this guidance is $0.10 to $0.20 of contribution related to the kitting and distribut ion of ancillary supplies \nfor COVID -19 vaccines. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee009d0606c8b9e5178e95d741c140713a7092f917833880f6e95044828dda4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4167f3c-e528-41c0-b206-ea407a8c280e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ngrowth, and we expect adjus ted operating profit to be flat to 6% growth over the prior year, as growth in our \nunderlying business is offset by a lower contribution from COVID test kits.  \n \n Included in this guidance is $0.10 to $0.20 of contribution related to the kitting and distribut ion of ancillary supplies \nfor COVID -19 vaccines.  Again, the majority will be realized in our first quarter.  This compares to approximately \n$0.35 in fiscal 2021. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ngrowth, and we expect adjus ted operating profit to be flat to 6% growth over the prior year, as growth in our \nunderlying business is offset by a lower contribution from COVID test kits.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22d8189c00c59a73a64b54ac0fc81128dd160dfc53bdb755992437fb6572dc08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb5ac963-6388-40a8-9f94-8ec88686db39", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ngrowth, and we expect adjus ted operating profit to be flat to 6% growth over the prior year, as growth in our \nunderlying business is offset by a lower contribution from COVID test kits.  \n \n Included in this guidance is $0.10 to $0.20 of contribution related to the kitting and distribut ion of ancillary supplies \nfor COVID -19 vaccines.  Again, the majority will be realized in our first quarter.  This compares to approximately \n$0.35 in fiscal 2021.  Due to the timing of when we began executing our contract with HHS, a larger portion of \nkitting  revenue was realized in fiscal 2021.  \n \n Excluding the contribution of our COVID -19 kitting and distribution program, the contribution from COVID -19 test \nkits, and the fiscal 2021 impairments for PPE and related products, we expect year -over-year adjusted op erating \nprofit growth of approximately 10% to 16%.  \n \n", "original_text": "Again, the majority will be realized in our first quarter. "}, "hash": "43dd57eec477dd419f79b149e7ede335f8109cf027fd704d781bb9f6a2d6703c", "class_name": "RelatedNodeInfo"}}, "text": "Included in this guidance is $0.10 to $0.20 of contribution related to the kitting and distribut ion of ancillary supplies \nfor COVID -19 vaccines. ", "start_char_idx": 373, "end_char_idx": 521, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb5ac963-6388-40a8-9f94-8ec88686db39": {"__data__": {"id_": "cb5ac963-6388-40a8-9f94-8ec88686db39", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ngrowth, and we expect adjus ted operating profit to be flat to 6% growth over the prior year, as growth in our \nunderlying business is offset by a lower contribution from COVID test kits.  \n \n Included in this guidance is $0.10 to $0.20 of contribution related to the kitting and distribut ion of ancillary supplies \nfor COVID -19 vaccines.  Again, the majority will be realized in our first quarter.  This compares to approximately \n$0.35 in fiscal 2021.  Due to the timing of when we began executing our contract with HHS, a larger portion of \nkitting  revenue was realized in fiscal 2021.  \n \n Excluding the contribution of our COVID -19 kitting and distribution program, the contribution from COVID -19 test \nkits, and the fiscal 2021 impairments for PPE and related products, we expect year -over-year adjusted op erating \nprofit growth of approximately 10% to 16%.  \n \n", "original_text": "Again, the majority will be realized in our first quarter. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee009d0606c8b9e5178e95d741c140713a7092f917833880f6e95044828dda4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5058e852-00d5-4e2e-9e83-08c6e2ae541c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ngrowth, and we expect adjus ted operating profit to be flat to 6% growth over the prior year, as growth in our \nunderlying business is offset by a lower contribution from COVID test kits.  \n \n Included in this guidance is $0.10 to $0.20 of contribution related to the kitting and distribut ion of ancillary supplies \nfor COVID -19 vaccines.  Again, the majority will be realized in our first quarter.  This compares to approximately \n$0.35 in fiscal 2021.  Due to the timing of when we began executing our contract with HHS, a larger portion of \nkitting  revenue was realized in fiscal 2021.  \n \n", "original_text": "Included in this guidance is $0.10 to $0.20 of contribution related to the kitting and distribut ion of ancillary supplies \nfor COVID -19 vaccines. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4432f08bd24121e0e9c0e464b1985e8d9a24782f5593b23b4e873807184678d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e65c9a7a-733e-4fbd-b5db-564c9b7a9f74", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ngrowth, and we expect adjus ted operating profit to be flat to 6% growth over the prior year, as growth in our \nunderlying business is offset by a lower contribution from COVID test kits.  \n \n Included in this guidance is $0.10 to $0.20 of contribution related to the kitting and distribut ion of ancillary supplies \nfor COVID -19 vaccines.  Again, the majority will be realized in our first quarter.  This compares to approximately \n$0.35 in fiscal 2021.  Due to the timing of when we began executing our contract with HHS, a larger portion of \nkitting  revenue was realized in fiscal 2021.  \n \n Excluding the contribution of our COVID -19 kitting and distribution program, the contribution from COVID -19 test \nkits, and the fiscal 2021 impairments for PPE and related products, we expect year -over-year adjusted op erating \nprofit growth of approximately 10% to 16%.  \n \n Finally, in the International segment, we expect revenues to decline 2% to grow 3% as compared to the prior \nyear, and this reflects the contribution of our German wholesale business to a joint venture wit h Walgreens Boots \nAlliance in the third quarter of our fiscal 2021. ", "original_text": "This compares to approximately \n$0.35 in fiscal 2021. "}, "hash": "66354e739eb97a35550bc7d7ce1f5226d2f5baf769ffd24e7d997cd9d2fc6cbe", "class_name": "RelatedNodeInfo"}}, "text": "Again, the majority will be realized in our first quarter. ", "start_char_idx": 521, "end_char_idx": 580, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e65c9a7a-733e-4fbd-b5db-564c9b7a9f74": {"__data__": {"id_": "e65c9a7a-733e-4fbd-b5db-564c9b7a9f74", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ngrowth, and we expect adjus ted operating profit to be flat to 6% growth over the prior year, as growth in our \nunderlying business is offset by a lower contribution from COVID test kits.  \n \n Included in this guidance is $0.10 to $0.20 of contribution related to the kitting and distribut ion of ancillary supplies \nfor COVID -19 vaccines.  Again, the majority will be realized in our first quarter.  This compares to approximately \n$0.35 in fiscal 2021.  Due to the timing of when we began executing our contract with HHS, a larger portion of \nkitting  revenue was realized in fiscal 2021.  \n \n Excluding the contribution of our COVID -19 kitting and distribution program, the contribution from COVID -19 test \nkits, and the fiscal 2021 impairments for PPE and related products, we expect year -over-year adjusted op erating \nprofit growth of approximately 10% to 16%.  \n \n Finally, in the International segment, we expect revenues to decline 2% to grow 3% as compared to the prior \nyear, and this reflects the contribution of our German wholesale business to a joint venture wit h Walgreens Boots \nAlliance in the third quarter of our fiscal 2021. ", "original_text": "This compares to approximately \n$0.35 in fiscal 2021. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee009d0606c8b9e5178e95d741c140713a7092f917833880f6e95044828dda4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb5ac963-6388-40a8-9f94-8ec88686db39", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ngrowth, and we expect adjus ted operating profit to be flat to 6% growth over the prior year, as growth in our \nunderlying business is offset by a lower contribution from COVID test kits.  \n \n Included in this guidance is $0.10 to $0.20 of contribution related to the kitting and distribut ion of ancillary supplies \nfor COVID -19 vaccines.  Again, the majority will be realized in our first quarter.  This compares to approximately \n$0.35 in fiscal 2021.  Due to the timing of when we began executing our contract with HHS, a larger portion of \nkitting  revenue was realized in fiscal 2021.  \n \n Excluding the contribution of our COVID -19 kitting and distribution program, the contribution from COVID -19 test \nkits, and the fiscal 2021 impairments for PPE and related products, we expect year -over-year adjusted op erating \nprofit growth of approximately 10% to 16%.  \n \n", "original_text": "Again, the majority will be realized in our first quarter. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4a934641309b3a7117d8e9905395e14b5eb01f25eefaeee6ec7dc476856bed32", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83c057ba-0c63-4475-b70c-769acfbbf52f", "node_type": "1", "metadata": {"window": "Included in this guidance is $0.10 to $0.20 of contribution related to the kitting and distribut ion of ancillary supplies \nfor COVID -19 vaccines.  Again, the majority will be realized in our first quarter.  This compares to approximately \n$0.35 in fiscal 2021.  Due to the timing of when we began executing our contract with HHS, a larger portion of \nkitting  revenue was realized in fiscal 2021.  \n \n Excluding the contribution of our COVID -19 kitting and distribution program, the contribution from COVID -19 test \nkits, and the fiscal 2021 impairments for PPE and related products, we expect year -over-year adjusted op erating \nprofit growth of approximately 10% to 16%.  \n \n Finally, in the International segment, we expect revenues to decline 2% to grow 3% as compared to the prior \nyear, and this reflects the contribution of our German wholesale business to a joint venture wit h Walgreens Boots \nAlliance in the third quarter of our fiscal 2021.  We expect adjusted operating profit growth in the segment of 4% to \n8%, led by core business improvement as our geographies continue the recovery from COVID -19. \n \n", "original_text": "Due to the timing of when we began executing our contract with HHS, a larger portion of \nkitting  revenue was realized in fiscal 2021.  \n \n"}, "hash": "08296bb8bc657220121d60d56a975e33f1a09f8b96928f84b4b69426dad6400d", "class_name": "RelatedNodeInfo"}}, "text": "This compares to approximately \n$0.35 in fiscal 2021. ", "start_char_idx": 580, "end_char_idx": 634, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83c057ba-0c63-4475-b70c-769acfbbf52f": {"__data__": {"id_": "83c057ba-0c63-4475-b70c-769acfbbf52f", "embedding": null, "metadata": {"window": "Included in this guidance is $0.10 to $0.20 of contribution related to the kitting and distribut ion of ancillary supplies \nfor COVID -19 vaccines.  Again, the majority will be realized in our first quarter.  This compares to approximately \n$0.35 in fiscal 2021.  Due to the timing of when we began executing our contract with HHS, a larger portion of \nkitting  revenue was realized in fiscal 2021.  \n \n Excluding the contribution of our COVID -19 kitting and distribution program, the contribution from COVID -19 test \nkits, and the fiscal 2021 impairments for PPE and related products, we expect year -over-year adjusted op erating \nprofit growth of approximately 10% to 16%.  \n \n Finally, in the International segment, we expect revenues to decline 2% to grow 3% as compared to the prior \nyear, and this reflects the contribution of our German wholesale business to a joint venture wit h Walgreens Boots \nAlliance in the third quarter of our fiscal 2021.  We expect adjusted operating profit growth in the segment of 4% to \n8%, led by core business improvement as our geographies continue the recovery from COVID -19. \n \n", "original_text": "Due to the timing of when we began executing our contract with HHS, a larger portion of \nkitting  revenue was realized in fiscal 2021.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee009d0606c8b9e5178e95d741c140713a7092f917833880f6e95044828dda4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e65c9a7a-733e-4fbd-b5db-564c9b7a9f74", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ngrowth, and we expect adjus ted operating profit to be flat to 6% growth over the prior year, as growth in our \nunderlying business is offset by a lower contribution from COVID test kits.  \n \n Included in this guidance is $0.10 to $0.20 of contribution related to the kitting and distribut ion of ancillary supplies \nfor COVID -19 vaccines.  Again, the majority will be realized in our first quarter.  This compares to approximately \n$0.35 in fiscal 2021.  Due to the timing of when we began executing our contract with HHS, a larger portion of \nkitting  revenue was realized in fiscal 2021.  \n \n Excluding the contribution of our COVID -19 kitting and distribution program, the contribution from COVID -19 test \nkits, and the fiscal 2021 impairments for PPE and related products, we expect year -over-year adjusted op erating \nprofit growth of approximately 10% to 16%.  \n \n Finally, in the International segment, we expect revenues to decline 2% to grow 3% as compared to the prior \nyear, and this reflects the contribution of our German wholesale business to a joint venture wit h Walgreens Boots \nAlliance in the third quarter of our fiscal 2021. ", "original_text": "This compares to approximately \n$0.35 in fiscal 2021. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d176ef202d4a613175dde444194e496c635ed87a9871621917491ae9c500ff6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a92cc9e3-177d-4a36-a174-9af134ae1528", "node_type": "1", "metadata": {"window": "Again, the majority will be realized in our first quarter.  This compares to approximately \n$0.35 in fiscal 2021.  Due to the timing of when we began executing our contract with HHS, a larger portion of \nkitting  revenue was realized in fiscal 2021.  \n \n Excluding the contribution of our COVID -19 kitting and distribution program, the contribution from COVID -19 test \nkits, and the fiscal 2021 impairments for PPE and related products, we expect year -over-year adjusted op erating \nprofit growth of approximately 10% to 16%.  \n \n Finally, in the International segment, we expect revenues to decline 2% to grow 3% as compared to the prior \nyear, and this reflects the contribution of our German wholesale business to a joint venture wit h Walgreens Boots \nAlliance in the third quarter of our fiscal 2021.  We expect adjusted operating profit growth in the segment of 4% to \n8%, led by core business improvement as our geographies continue the recovery from COVID -19. \n \n And now turning to the cons olidated view, we expect 3% to 6% revenue and adjusted operating profit growth \ncompared to fiscal 2021. ", "original_text": "Excluding the contribution of our COVID -19 kitting and distribution program, the contribution from COVID -19 test \nkits, and the fiscal 2021 impairments for PPE and related products, we expect year -over-year adjusted op erating \nprofit growth of approximately 10% to 16%.  \n \n"}, "hash": "66b652b674e6179745dfcff8f765e4baf6b44d624956c244597d80d5b5e4f08c", "class_name": "RelatedNodeInfo"}}, "text": "Due to the timing of when we began executing our contract with HHS, a larger portion of \nkitting  revenue was realized in fiscal 2021.  \n \n", "start_char_idx": 634, "end_char_idx": 773, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a92cc9e3-177d-4a36-a174-9af134ae1528": {"__data__": {"id_": "a92cc9e3-177d-4a36-a174-9af134ae1528", "embedding": null, "metadata": {"window": "Again, the majority will be realized in our first quarter.  This compares to approximately \n$0.35 in fiscal 2021.  Due to the timing of when we began executing our contract with HHS, a larger portion of \nkitting  revenue was realized in fiscal 2021.  \n \n Excluding the contribution of our COVID -19 kitting and distribution program, the contribution from COVID -19 test \nkits, and the fiscal 2021 impairments for PPE and related products, we expect year -over-year adjusted op erating \nprofit growth of approximately 10% to 16%.  \n \n Finally, in the International segment, we expect revenues to decline 2% to grow 3% as compared to the prior \nyear, and this reflects the contribution of our German wholesale business to a joint venture wit h Walgreens Boots \nAlliance in the third quarter of our fiscal 2021.  We expect adjusted operating profit growth in the segment of 4% to \n8%, led by core business improvement as our geographies continue the recovery from COVID -19. \n \n And now turning to the cons olidated view, we expect 3% to 6% revenue and adjusted operating profit growth \ncompared to fiscal 2021. ", "original_text": "Excluding the contribution of our COVID -19 kitting and distribution program, the contribution from COVID -19 test \nkits, and the fiscal 2021 impairments for PPE and related products, we expect year -over-year adjusted op erating \nprofit growth of approximately 10% to 16%.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee009d0606c8b9e5178e95d741c140713a7092f917833880f6e95044828dda4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83c057ba-0c63-4475-b70c-769acfbbf52f", "node_type": "1", "metadata": {"window": "Included in this guidance is $0.10 to $0.20 of contribution related to the kitting and distribut ion of ancillary supplies \nfor COVID -19 vaccines.  Again, the majority will be realized in our first quarter.  This compares to approximately \n$0.35 in fiscal 2021.  Due to the timing of when we began executing our contract with HHS, a larger portion of \nkitting  revenue was realized in fiscal 2021.  \n \n Excluding the contribution of our COVID -19 kitting and distribution program, the contribution from COVID -19 test \nkits, and the fiscal 2021 impairments for PPE and related products, we expect year -over-year adjusted op erating \nprofit growth of approximately 10% to 16%.  \n \n Finally, in the International segment, we expect revenues to decline 2% to grow 3% as compared to the prior \nyear, and this reflects the contribution of our German wholesale business to a joint venture wit h Walgreens Boots \nAlliance in the third quarter of our fiscal 2021.  We expect adjusted operating profit growth in the segment of 4% to \n8%, led by core business improvement as our geographies continue the recovery from COVID -19. \n \n", "original_text": "Due to the timing of when we began executing our contract with HHS, a larger portion of \nkitting  revenue was realized in fiscal 2021.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e18daacf2f7a5e901735aba4156321843d883c32edd7b99507e1847f373de711", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4352891-aeec-44e6-bcca-7bb2d6ef741b", "node_type": "1", "metadata": {"window": "This compares to approximately \n$0.35 in fiscal 2021.  Due to the timing of when we began executing our contract with HHS, a larger portion of \nkitting  revenue was realized in fiscal 2021.  \n \n Excluding the contribution of our COVID -19 kitting and distribution program, the contribution from COVID -19 test \nkits, and the fiscal 2021 impairments for PPE and related products, we expect year -over-year adjusted op erating \nprofit growth of approximately 10% to 16%.  \n \n Finally, in the International segment, we expect revenues to decline 2% to grow 3% as compared to the prior \nyear, and this reflects the contribution of our German wholesale business to a joint venture wit h Walgreens Boots \nAlliance in the third quarter of our fiscal 2021.  We expect adjusted operating profit growth in the segment of 4% to \n8%, led by core business improvement as our geographies continue the recovery from COVID -19. \n \n And now turning to the cons olidated view, we expect 3% to 6% revenue and adjusted operating profit growth \ncompared to fiscal 2021.  We expect corporate expenses to be $670 million to $720 million. ", "original_text": "Finally, in the International segment, we expect revenues to decline 2% to grow 3% as compared to the prior \nyear, and this reflects the contribution of our German wholesale business to a joint venture wit h Walgreens Boots \nAlliance in the third quarter of our fiscal 2021. "}, "hash": "10c23261f5569ee236c3afb40a1d03708501284831d9da20287199dcf6a99865", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the contribution of our COVID -19 kitting and distribution program, the contribution from COVID -19 test \nkits, and the fiscal 2021 impairments for PPE and related products, we expect year -over-year adjusted op erating \nprofit growth of approximately 10% to 16%.  \n \n", "start_char_idx": 773, "end_char_idx": 1051, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4352891-aeec-44e6-bcca-7bb2d6ef741b": {"__data__": {"id_": "b4352891-aeec-44e6-bcca-7bb2d6ef741b", "embedding": null, "metadata": {"window": "This compares to approximately \n$0.35 in fiscal 2021.  Due to the timing of when we began executing our contract with HHS, a larger portion of \nkitting  revenue was realized in fiscal 2021.  \n \n Excluding the contribution of our COVID -19 kitting and distribution program, the contribution from COVID -19 test \nkits, and the fiscal 2021 impairments for PPE and related products, we expect year -over-year adjusted op erating \nprofit growth of approximately 10% to 16%.  \n \n Finally, in the International segment, we expect revenues to decline 2% to grow 3% as compared to the prior \nyear, and this reflects the contribution of our German wholesale business to a joint venture wit h Walgreens Boots \nAlliance in the third quarter of our fiscal 2021.  We expect adjusted operating profit growth in the segment of 4% to \n8%, led by core business improvement as our geographies continue the recovery from COVID -19. \n \n And now turning to the cons olidated view, we expect 3% to 6% revenue and adjusted operating profit growth \ncompared to fiscal 2021.  We expect corporate expenses to be $670 million to $720 million. ", "original_text": "Finally, in the International segment, we expect revenues to decline 2% to grow 3% as compared to the prior \nyear, and this reflects the contribution of our German wholesale business to a joint venture wit h Walgreens Boots \nAlliance in the third quarter of our fiscal 2021. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee009d0606c8b9e5178e95d741c140713a7092f917833880f6e95044828dda4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a92cc9e3-177d-4a36-a174-9af134ae1528", "node_type": "1", "metadata": {"window": "Again, the majority will be realized in our first quarter.  This compares to approximately \n$0.35 in fiscal 2021.  Due to the timing of when we began executing our contract with HHS, a larger portion of \nkitting  revenue was realized in fiscal 2021.  \n \n Excluding the contribution of our COVID -19 kitting and distribution program, the contribution from COVID -19 test \nkits, and the fiscal 2021 impairments for PPE and related products, we expect year -over-year adjusted op erating \nprofit growth of approximately 10% to 16%.  \n \n Finally, in the International segment, we expect revenues to decline 2% to grow 3% as compared to the prior \nyear, and this reflects the contribution of our German wholesale business to a joint venture wit h Walgreens Boots \nAlliance in the third quarter of our fiscal 2021.  We expect adjusted operating profit growth in the segment of 4% to \n8%, led by core business improvement as our geographies continue the recovery from COVID -19. \n \n And now turning to the cons olidated view, we expect 3% to 6% revenue and adjusted operating profit growth \ncompared to fiscal 2021. ", "original_text": "Excluding the contribution of our COVID -19 kitting and distribution program, the contribution from COVID -19 test \nkits, and the fiscal 2021 impairments for PPE and related products, we expect year -over-year adjusted op erating \nprofit growth of approximately 10% to 16%.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4400f8dcc290722b6495ea657a85050323c6cda383b5054b5fdbfa5f764396a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a676e52-3c6b-43a4-bf9e-844a790a298c", "node_type": "1", "metadata": {"window": "Due to the timing of when we began executing our contract with HHS, a larger portion of \nkitting  revenue was realized in fiscal 2021.  \n \n Excluding the contribution of our COVID -19 kitting and distribution program, the contribution from COVID -19 test \nkits, and the fiscal 2021 impairments for PPE and related products, we expect year -over-year adjusted op erating \nprofit growth of approximately 10% to 16%.  \n \n Finally, in the International segment, we expect revenues to decline 2% to grow 3% as compared to the prior \nyear, and this reflects the contribution of our German wholesale business to a joint venture wit h Walgreens Boots \nAlliance in the third quarter of our fiscal 2021.  We expect adjusted operating profit growth in the segment of 4% to \n8%, led by core business improvement as our geographies continue the recovery from COVID -19. \n \n And now turning to the cons olidated view, we expect 3% to 6% revenue and adjusted operating profit growth \ncompared to fiscal 2021.  We expect corporate expenses to be $670 million to $720 million.  And as a reminder, \nour corporate expenses in fiscal 2021 were offset by net gains of ap proximately $133 million or $0.60 per diluted \nshare from equity investments within our McKesson Ventures' portfolio. ", "original_text": "We expect adjusted operating profit growth in the segment of 4% to \n8%, led by core business improvement as our geographies continue the recovery from COVID -19. \n \n"}, "hash": "7a101b4cda378e54fb4f8206a42bd20a9ed53a6180c1259a57bce49df37b77c9", "class_name": "RelatedNodeInfo"}}, "text": "Finally, in the International segment, we expect revenues to decline 2% to grow 3% as compared to the prior \nyear, and this reflects the contribution of our German wholesale business to a joint venture wit h Walgreens Boots \nAlliance in the third quarter of our fiscal 2021. ", "start_char_idx": 1051, "end_char_idx": 1326, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a676e52-3c6b-43a4-bf9e-844a790a298c": {"__data__": {"id_": "1a676e52-3c6b-43a4-bf9e-844a790a298c", "embedding": null, "metadata": {"window": "Due to the timing of when we began executing our contract with HHS, a larger portion of \nkitting  revenue was realized in fiscal 2021.  \n \n Excluding the contribution of our COVID -19 kitting and distribution program, the contribution from COVID -19 test \nkits, and the fiscal 2021 impairments for PPE and related products, we expect year -over-year adjusted op erating \nprofit growth of approximately 10% to 16%.  \n \n Finally, in the International segment, we expect revenues to decline 2% to grow 3% as compared to the prior \nyear, and this reflects the contribution of our German wholesale business to a joint venture wit h Walgreens Boots \nAlliance in the third quarter of our fiscal 2021.  We expect adjusted operating profit growth in the segment of 4% to \n8%, led by core business improvement as our geographies continue the recovery from COVID -19. \n \n And now turning to the cons olidated view, we expect 3% to 6% revenue and adjusted operating profit growth \ncompared to fiscal 2021.  We expect corporate expenses to be $670 million to $720 million.  And as a reminder, \nour corporate expenses in fiscal 2021 were offset by net gains of ap proximately $133 million or $0.60 per diluted \nshare from equity investments within our McKesson Ventures' portfolio. ", "original_text": "We expect adjusted operating profit growth in the segment of 4% to \n8%, led by core business improvement as our geographies continue the recovery from COVID -19. \n \n", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee009d0606c8b9e5178e95d741c140713a7092f917833880f6e95044828dda4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4352891-aeec-44e6-bcca-7bb2d6ef741b", "node_type": "1", "metadata": {"window": "This compares to approximately \n$0.35 in fiscal 2021.  Due to the timing of when we began executing our contract with HHS, a larger portion of \nkitting  revenue was realized in fiscal 2021.  \n \n Excluding the contribution of our COVID -19 kitting and distribution program, the contribution from COVID -19 test \nkits, and the fiscal 2021 impairments for PPE and related products, we expect year -over-year adjusted op erating \nprofit growth of approximately 10% to 16%.  \n \n Finally, in the International segment, we expect revenues to decline 2% to grow 3% as compared to the prior \nyear, and this reflects the contribution of our German wholesale business to a joint venture wit h Walgreens Boots \nAlliance in the third quarter of our fiscal 2021.  We expect adjusted operating profit growth in the segment of 4% to \n8%, led by core business improvement as our geographies continue the recovery from COVID -19. \n \n And now turning to the cons olidated view, we expect 3% to 6% revenue and adjusted operating profit growth \ncompared to fiscal 2021.  We expect corporate expenses to be $670 million to $720 million. ", "original_text": "Finally, in the International segment, we expect revenues to decline 2% to grow 3% as compared to the prior \nyear, and this reflects the contribution of our German wholesale business to a joint venture wit h Walgreens Boots \nAlliance in the third quarter of our fiscal 2021. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e306c1ce47d2f9b7e05abef327f98809dc5b1148727f70f4cd0444cd5c4c8fab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a81aa7ad-adaf-4667-8d24-d3a8f7282ab7", "node_type": "1", "metadata": {"window": "Excluding the contribution of our COVID -19 kitting and distribution program, the contribution from COVID -19 test \nkits, and the fiscal 2021 impairments for PPE and related products, we expect year -over-year adjusted op erating \nprofit growth of approximately 10% to 16%.  \n \n Finally, in the International segment, we expect revenues to decline 2% to grow 3% as compared to the prior \nyear, and this reflects the contribution of our German wholesale business to a joint venture wit h Walgreens Boots \nAlliance in the third quarter of our fiscal 2021.  We expect adjusted operating profit growth in the segment of 4% to \n8%, led by core business improvement as our geographies continue the recovery from COVID -19. \n \n And now turning to the cons olidated view, we expect 3% to 6% revenue and adjusted operating profit growth \ncompared to fiscal 2021.  We expect corporate expenses to be $670 million to $720 million.  And as a reminder, \nour corporate expenses in fiscal 2021 were offset by net gains of ap proximately $133 million or $0.60 per diluted \nshare from equity investments within our McKesson Ventures' portfolio.  We assume a full year adjusted tax rate of \napproximately 18% to 19%, which may vary from quarter -to-quarter. ", "original_text": "And now turning to the cons olidated view, we expect 3% to 6% revenue and adjusted operating profit growth \ncompared to fiscal 2021. "}, "hash": "d35e7d9178f03cce093ee5fc2d1663a1b3338cb07ca201695498f1b414b9b8b5", "class_name": "RelatedNodeInfo"}}, "text": "We expect adjusted operating profit growth in the segment of 4% to \n8%, led by core business improvement as our geographies continue the recovery from COVID -19. \n \n", "start_char_idx": 1326, "end_char_idx": 1491, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a81aa7ad-adaf-4667-8d24-d3a8f7282ab7": {"__data__": {"id_": "a81aa7ad-adaf-4667-8d24-d3a8f7282ab7", "embedding": null, "metadata": {"window": "Excluding the contribution of our COVID -19 kitting and distribution program, the contribution from COVID -19 test \nkits, and the fiscal 2021 impairments for PPE and related products, we expect year -over-year adjusted op erating \nprofit growth of approximately 10% to 16%.  \n \n Finally, in the International segment, we expect revenues to decline 2% to grow 3% as compared to the prior \nyear, and this reflects the contribution of our German wholesale business to a joint venture wit h Walgreens Boots \nAlliance in the third quarter of our fiscal 2021.  We expect adjusted operating profit growth in the segment of 4% to \n8%, led by core business improvement as our geographies continue the recovery from COVID -19. \n \n And now turning to the cons olidated view, we expect 3% to 6% revenue and adjusted operating profit growth \ncompared to fiscal 2021.  We expect corporate expenses to be $670 million to $720 million.  And as a reminder, \nour corporate expenses in fiscal 2021 were offset by net gains of ap proximately $133 million or $0.60 per diluted \nshare from equity investments within our McKesson Ventures' portfolio.  We assume a full year adjusted tax rate of \napproximately 18% to 19%, which may vary from quarter -to-quarter. ", "original_text": "And now turning to the cons olidated view, we expect 3% to 6% revenue and adjusted operating profit growth \ncompared to fiscal 2021. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee009d0606c8b9e5178e95d741c140713a7092f917833880f6e95044828dda4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a676e52-3c6b-43a4-bf9e-844a790a298c", "node_type": "1", "metadata": {"window": "Due to the timing of when we began executing our contract with HHS, a larger portion of \nkitting  revenue was realized in fiscal 2021.  \n \n Excluding the contribution of our COVID -19 kitting and distribution program, the contribution from COVID -19 test \nkits, and the fiscal 2021 impairments for PPE and related products, we expect year -over-year adjusted op erating \nprofit growth of approximately 10% to 16%.  \n \n Finally, in the International segment, we expect revenues to decline 2% to grow 3% as compared to the prior \nyear, and this reflects the contribution of our German wholesale business to a joint venture wit h Walgreens Boots \nAlliance in the third quarter of our fiscal 2021.  We expect adjusted operating profit growth in the segment of 4% to \n8%, led by core business improvement as our geographies continue the recovery from COVID -19. \n \n And now turning to the cons olidated view, we expect 3% to 6% revenue and adjusted operating profit growth \ncompared to fiscal 2021.  We expect corporate expenses to be $670 million to $720 million.  And as a reminder, \nour corporate expenses in fiscal 2021 were offset by net gains of ap proximately $133 million or $0.60 per diluted \nshare from equity investments within our McKesson Ventures' portfolio. ", "original_text": "We expect adjusted operating profit growth in the segment of 4% to \n8%, led by core business improvement as our geographies continue the recovery from COVID -19. \n \n", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e17cd4e831c82f5869ff17a9cb65c64cf7d215ae51126247adab66bc27b6b51d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b69bee02-98c2-48f6-8359-4f2899e39e22", "node_type": "1", "metadata": {"window": "Finally, in the International segment, we expect revenues to decline 2% to grow 3% as compared to the prior \nyear, and this reflects the contribution of our German wholesale business to a joint venture wit h Walgreens Boots \nAlliance in the third quarter of our fiscal 2021.  We expect adjusted operating profit growth in the segment of 4% to \n8%, led by core business improvement as our geographies continue the recovery from COVID -19. \n \n And now turning to the cons olidated view, we expect 3% to 6% revenue and adjusted operating profit growth \ncompared to fiscal 2021.  We expect corporate expenses to be $670 million to $720 million.  And as a reminder, \nour corporate expenses in fiscal 2021 were offset by net gains of ap proximately $133 million or $0.60 per diluted \nshare from equity investments within our McKesson Ventures' portfolio.  We assume a full year adjusted tax rate of \napproximately 18% to 19%, which may vary from quarter -to-quarter.  It includes anticipated discre te tax items that \nwe expect to realize during the course of the year.  \n \n", "original_text": "We expect corporate expenses to be $670 million to $720 million. "}, "hash": "9d35816375c3fc99fb56b2c1be1886342cec4de2533b5f2cc8186c79d024950e", "class_name": "RelatedNodeInfo"}}, "text": "And now turning to the cons olidated view, we expect 3% to 6% revenue and adjusted operating profit growth \ncompared to fiscal 2021. ", "start_char_idx": 1491, "end_char_idx": 1624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b69bee02-98c2-48f6-8359-4f2899e39e22": {"__data__": {"id_": "b69bee02-98c2-48f6-8359-4f2899e39e22", "embedding": null, "metadata": {"window": "Finally, in the International segment, we expect revenues to decline 2% to grow 3% as compared to the prior \nyear, and this reflects the contribution of our German wholesale business to a joint venture wit h Walgreens Boots \nAlliance in the third quarter of our fiscal 2021.  We expect adjusted operating profit growth in the segment of 4% to \n8%, led by core business improvement as our geographies continue the recovery from COVID -19. \n \n And now turning to the cons olidated view, we expect 3% to 6% revenue and adjusted operating profit growth \ncompared to fiscal 2021.  We expect corporate expenses to be $670 million to $720 million.  And as a reminder, \nour corporate expenses in fiscal 2021 were offset by net gains of ap proximately $133 million or $0.60 per diluted \nshare from equity investments within our McKesson Ventures' portfolio.  We assume a full year adjusted tax rate of \napproximately 18% to 19%, which may vary from quarter -to-quarter.  It includes anticipated discre te tax items that \nwe expect to realize during the course of the year.  \n \n", "original_text": "We expect corporate expenses to be $670 million to $720 million. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee009d0606c8b9e5178e95d741c140713a7092f917833880f6e95044828dda4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a81aa7ad-adaf-4667-8d24-d3a8f7282ab7", "node_type": "1", "metadata": {"window": "Excluding the contribution of our COVID -19 kitting and distribution program, the contribution from COVID -19 test \nkits, and the fiscal 2021 impairments for PPE and related products, we expect year -over-year adjusted op erating \nprofit growth of approximately 10% to 16%.  \n \n Finally, in the International segment, we expect revenues to decline 2% to grow 3% as compared to the prior \nyear, and this reflects the contribution of our German wholesale business to a joint venture wit h Walgreens Boots \nAlliance in the third quarter of our fiscal 2021.  We expect adjusted operating profit growth in the segment of 4% to \n8%, led by core business improvement as our geographies continue the recovery from COVID -19. \n \n And now turning to the cons olidated view, we expect 3% to 6% revenue and adjusted operating profit growth \ncompared to fiscal 2021.  We expect corporate expenses to be $670 million to $720 million.  And as a reminder, \nour corporate expenses in fiscal 2021 were offset by net gains of ap proximately $133 million or $0.60 per diluted \nshare from equity investments within our McKesson Ventures' portfolio.  We assume a full year adjusted tax rate of \napproximately 18% to 19%, which may vary from quarter -to-quarter. ", "original_text": "And now turning to the cons olidated view, we expect 3% to 6% revenue and adjusted operating profit growth \ncompared to fiscal 2021. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11846bc51e7fb2db5abb5bd4883c6c58c570f75c80f179bc9802a796e7524379", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "158c88e5-2874-415b-bc82-0236a65defae", "node_type": "1", "metadata": {"window": "We expect adjusted operating profit growth in the segment of 4% to \n8%, led by core business improvement as our geographies continue the recovery from COVID -19. \n \n And now turning to the cons olidated view, we expect 3% to 6% revenue and adjusted operating profit growth \ncompared to fiscal 2021.  We expect corporate expenses to be $670 million to $720 million.  And as a reminder, \nour corporate expenses in fiscal 2021 were offset by net gains of ap proximately $133 million or $0.60 per diluted \nshare from equity investments within our McKesson Ventures' portfolio.  We assume a full year adjusted tax rate of \napproximately 18% to 19%, which may vary from quarter -to-quarter.  It includes anticipated discre te tax items that \nwe expect to realize during the course of the year.  \n \n As Brian mentioned in his remarks, we continue to transform and evolve our operating models to drive \nefficiencies. ", "original_text": "And as a reminder, \nour corporate expenses in fiscal 2021 were offset by net gains of ap proximately $133 million or $0.60 per diluted \nshare from equity investments within our McKesson Ventures' portfolio. "}, "hash": "f730845997a6a23252bfdbf2396d51555ce23b20db2f50397fc3e0345c138374", "class_name": "RelatedNodeInfo"}}, "text": "We expect corporate expenses to be $670 million to $720 million. ", "start_char_idx": 1624, "end_char_idx": 1689, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "158c88e5-2874-415b-bc82-0236a65defae": {"__data__": {"id_": "158c88e5-2874-415b-bc82-0236a65defae", "embedding": null, "metadata": {"window": "We expect adjusted operating profit growth in the segment of 4% to \n8%, led by core business improvement as our geographies continue the recovery from COVID -19. \n \n And now turning to the cons olidated view, we expect 3% to 6% revenue and adjusted operating profit growth \ncompared to fiscal 2021.  We expect corporate expenses to be $670 million to $720 million.  And as a reminder, \nour corporate expenses in fiscal 2021 were offset by net gains of ap proximately $133 million or $0.60 per diluted \nshare from equity investments within our McKesson Ventures' portfolio.  We assume a full year adjusted tax rate of \napproximately 18% to 19%, which may vary from quarter -to-quarter.  It includes anticipated discre te tax items that \nwe expect to realize during the course of the year.  \n \n As Brian mentioned in his remarks, we continue to transform and evolve our operating models to drive \nefficiencies. ", "original_text": "And as a reminder, \nour corporate expenses in fiscal 2021 were offset by net gains of ap proximately $133 million or $0.60 per diluted \nshare from equity investments within our McKesson Ventures' portfolio. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee009d0606c8b9e5178e95d741c140713a7092f917833880f6e95044828dda4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b69bee02-98c2-48f6-8359-4f2899e39e22", "node_type": "1", "metadata": {"window": "Finally, in the International segment, we expect revenues to decline 2% to grow 3% as compared to the prior \nyear, and this reflects the contribution of our German wholesale business to a joint venture wit h Walgreens Boots \nAlliance in the third quarter of our fiscal 2021.  We expect adjusted operating profit growth in the segment of 4% to \n8%, led by core business improvement as our geographies continue the recovery from COVID -19. \n \n And now turning to the cons olidated view, we expect 3% to 6% revenue and adjusted operating profit growth \ncompared to fiscal 2021.  We expect corporate expenses to be $670 million to $720 million.  And as a reminder, \nour corporate expenses in fiscal 2021 were offset by net gains of ap proximately $133 million or $0.60 per diluted \nshare from equity investments within our McKesson Ventures' portfolio.  We assume a full year adjusted tax rate of \napproximately 18% to 19%, which may vary from quarter -to-quarter.  It includes anticipated discre te tax items that \nwe expect to realize during the course of the year.  \n \n", "original_text": "We expect corporate expenses to be $670 million to $720 million. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd5d92e2fb997b1aabe7102028fb43f569eb9e54568fe61cf4c7fd7354d8e821", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fb7d86e-06b7-4766-82bd-d1ab0a4fc3d9", "node_type": "1", "metadata": {"window": "And now turning to the cons olidated view, we expect 3% to 6% revenue and adjusted operating profit growth \ncompared to fiscal 2021.  We expect corporate expenses to be $670 million to $720 million.  And as a reminder, \nour corporate expenses in fiscal 2021 were offset by net gains of ap proximately $133 million or $0.60 per diluted \nshare from equity investments within our McKesson Ventures' portfolio.  We assume a full year adjusted tax rate of \napproximately 18% to 19%, which may vary from quarter -to-quarter.  It includes anticipated discre te tax items that \nwe expect to realize during the course of the year.  \n \n As Brian mentioned in his remarks, we continue to transform and evolve our operating models to drive \nefficiencies.  As part of this evolution, we plan to make changes to our real estate strategy to increase efficiencies, \nsupporting increased flexibility, including a transition to a partial remote work model for certain employees on a \ngo-forward basis. ", "original_text": "We assume a full year adjusted tax rate of \napproximately 18% to 19%, which may vary from quarter -to-quarter. "}, "hash": "b97ef1aca63cce1020bc59f45845bce8cce0484aa5965da725358f9848f5bb20", "class_name": "RelatedNodeInfo"}}, "text": "And as a reminder, \nour corporate expenses in fiscal 2021 were offset by net gains of ap proximately $133 million or $0.60 per diluted \nshare from equity investments within our McKesson Ventures' portfolio. ", "start_char_idx": 1689, "end_char_idx": 1896, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2fb7d86e-06b7-4766-82bd-d1ab0a4fc3d9": {"__data__": {"id_": "2fb7d86e-06b7-4766-82bd-d1ab0a4fc3d9", "embedding": null, "metadata": {"window": "And now turning to the cons olidated view, we expect 3% to 6% revenue and adjusted operating profit growth \ncompared to fiscal 2021.  We expect corporate expenses to be $670 million to $720 million.  And as a reminder, \nour corporate expenses in fiscal 2021 were offset by net gains of ap proximately $133 million or $0.60 per diluted \nshare from equity investments within our McKesson Ventures' portfolio.  We assume a full year adjusted tax rate of \napproximately 18% to 19%, which may vary from quarter -to-quarter.  It includes anticipated discre te tax items that \nwe expect to realize during the course of the year.  \n \n As Brian mentioned in his remarks, we continue to transform and evolve our operating models to drive \nefficiencies.  As part of this evolution, we plan to make changes to our real estate strategy to increase efficiencies, \nsupporting increased flexibility, including a transition to a partial remote work model for certain employees on a \ngo-forward basis. ", "original_text": "We assume a full year adjusted tax rate of \napproximately 18% to 19%, which may vary from quarter -to-quarter. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee009d0606c8b9e5178e95d741c140713a7092f917833880f6e95044828dda4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "158c88e5-2874-415b-bc82-0236a65defae", "node_type": "1", "metadata": {"window": "We expect adjusted operating profit growth in the segment of 4% to \n8%, led by core business improvement as our geographies continue the recovery from COVID -19. \n \n And now turning to the cons olidated view, we expect 3% to 6% revenue and adjusted operating profit growth \ncompared to fiscal 2021.  We expect corporate expenses to be $670 million to $720 million.  And as a reminder, \nour corporate expenses in fiscal 2021 were offset by net gains of ap proximately $133 million or $0.60 per diluted \nshare from equity investments within our McKesson Ventures' portfolio.  We assume a full year adjusted tax rate of \napproximately 18% to 19%, which may vary from quarter -to-quarter.  It includes anticipated discre te tax items that \nwe expect to realize during the course of the year.  \n \n As Brian mentioned in his remarks, we continue to transform and evolve our operating models to drive \nefficiencies. ", "original_text": "And as a reminder, \nour corporate expenses in fiscal 2021 were offset by net gains of ap proximately $133 million or $0.60 per diluted \nshare from equity investments within our McKesson Ventures' portfolio. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "90e5cc194bbcc974e4bb0e62f9e791837cccdf737e8a38c1600de3ba7c2e6a4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ef0f535-4256-4ada-859c-bece9652cc00", "node_type": "1", "metadata": {"window": "We expect corporate expenses to be $670 million to $720 million.  And as a reminder, \nour corporate expenses in fiscal 2021 were offset by net gains of ap proximately $133 million or $0.60 per diluted \nshare from equity investments within our McKesson Ventures' portfolio.  We assume a full year adjusted tax rate of \napproximately 18% to 19%, which may vary from quarter -to-quarter.  It includes anticipated discre te tax items that \nwe expect to realize during the course of the year.  \n \n As Brian mentioned in his remarks, we continue to transform and evolve our operating models to drive \nefficiencies.  As part of this evolution, we plan to make changes to our real estate strategy to increase efficiencies, \nsupporting increased flexibility, including a transition to a partial remote work model for certain employees on a \ngo-forward basis.  This will result in reduction to our real estate footprint.  \n \n", "original_text": "It includes anticipated discre te tax items that \nwe expect to realize during the course of the year.  \n \n"}, "hash": "290f77154839cba97c28b99b11790b3900bce39415e5de59c994057085d2ade3", "class_name": "RelatedNodeInfo"}}, "text": "We assume a full year adjusted tax rate of \napproximately 18% to 19%, which may vary from quarter -to-quarter. ", "start_char_idx": 1896, "end_char_idx": 2007, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ef0f535-4256-4ada-859c-bece9652cc00": {"__data__": {"id_": "5ef0f535-4256-4ada-859c-bece9652cc00", "embedding": null, "metadata": {"window": "We expect corporate expenses to be $670 million to $720 million.  And as a reminder, \nour corporate expenses in fiscal 2021 were offset by net gains of ap proximately $133 million or $0.60 per diluted \nshare from equity investments within our McKesson Ventures' portfolio.  We assume a full year adjusted tax rate of \napproximately 18% to 19%, which may vary from quarter -to-quarter.  It includes anticipated discre te tax items that \nwe expect to realize during the course of the year.  \n \n As Brian mentioned in his remarks, we continue to transform and evolve our operating models to drive \nefficiencies.  As part of this evolution, we plan to make changes to our real estate strategy to increase efficiencies, \nsupporting increased flexibility, including a transition to a partial remote work model for certain employees on a \ngo-forward basis.  This will result in reduction to our real estate footprint.  \n \n", "original_text": "It includes anticipated discre te tax items that \nwe expect to realize during the course of the year.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee009d0606c8b9e5178e95d741c140713a7092f917833880f6e95044828dda4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fb7d86e-06b7-4766-82bd-d1ab0a4fc3d9", "node_type": "1", "metadata": {"window": "And now turning to the cons olidated view, we expect 3% to 6% revenue and adjusted operating profit growth \ncompared to fiscal 2021.  We expect corporate expenses to be $670 million to $720 million.  And as a reminder, \nour corporate expenses in fiscal 2021 were offset by net gains of ap proximately $133 million or $0.60 per diluted \nshare from equity investments within our McKesson Ventures' portfolio.  We assume a full year adjusted tax rate of \napproximately 18% to 19%, which may vary from quarter -to-quarter.  It includes anticipated discre te tax items that \nwe expect to realize during the course of the year.  \n \n As Brian mentioned in his remarks, we continue to transform and evolve our operating models to drive \nefficiencies.  As part of this evolution, we plan to make changes to our real estate strategy to increase efficiencies, \nsupporting increased flexibility, including a transition to a partial remote work model for certain employees on a \ngo-forward basis. ", "original_text": "We assume a full year adjusted tax rate of \napproximately 18% to 19%, which may vary from quarter -to-quarter. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f068c3a19e85ab851cfe66cfadb9e9e231547a76008614d175a2afa743d9b40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5137c6d0-ed3c-4987-8b74-a096b96d63ca", "node_type": "1", "metadata": {"window": "And as a reminder, \nour corporate expenses in fiscal 2021 were offset by net gains of ap proximately $133 million or $0.60 per diluted \nshare from equity investments within our McKesson Ventures' portfolio.  We assume a full year adjusted tax rate of \napproximately 18% to 19%, which may vary from quarter -to-quarter.  It includes anticipated discre te tax items that \nwe expect to realize during the course of the year.  \n \n As Brian mentioned in his remarks, we continue to transform and evolve our operating models to drive \nefficiencies.  As part of this evolution, we plan to make changes to our real estate strategy to increase efficiencies, \nsupporting increased flexibility, including a transition to a partial remote work model for certain employees on a \ngo-forward basis.  This will result in reduction to our real estate footprint.  \n \n In executing this plan, we will incur GAAP -only restructuring charges of approximately $180 million to $280 million \nover the next year. ", "original_text": "As Brian mentioned in his remarks, we continue to transform and evolve our operating models to drive \nefficiencies. "}, "hash": "fcdd9b3f8501d06f7323c653b91c19eff27b69b78d1056f4b0437cdc3a9148dc", "class_name": "RelatedNodeInfo"}}, "text": "It includes anticipated discre te tax items that \nwe expect to realize during the course of the year.  \n \n", "start_char_idx": 2007, "end_char_idx": 2113, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5137c6d0-ed3c-4987-8b74-a096b96d63ca": {"__data__": {"id_": "5137c6d0-ed3c-4987-8b74-a096b96d63ca", "embedding": null, "metadata": {"window": "And as a reminder, \nour corporate expenses in fiscal 2021 were offset by net gains of ap proximately $133 million or $0.60 per diluted \nshare from equity investments within our McKesson Ventures' portfolio.  We assume a full year adjusted tax rate of \napproximately 18% to 19%, which may vary from quarter -to-quarter.  It includes anticipated discre te tax items that \nwe expect to realize during the course of the year.  \n \n As Brian mentioned in his remarks, we continue to transform and evolve our operating models to drive \nefficiencies.  As part of this evolution, we plan to make changes to our real estate strategy to increase efficiencies, \nsupporting increased flexibility, including a transition to a partial remote work model for certain employees on a \ngo-forward basis.  This will result in reduction to our real estate footprint.  \n \n In executing this plan, we will incur GAAP -only restructuring charges of approximately $180 million to $280 million \nover the next year. ", "original_text": "As Brian mentioned in his remarks, we continue to transform and evolve our operating models to drive \nefficiencies. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee009d0606c8b9e5178e95d741c140713a7092f917833880f6e95044828dda4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ef0f535-4256-4ada-859c-bece9652cc00", "node_type": "1", "metadata": {"window": "We expect corporate expenses to be $670 million to $720 million.  And as a reminder, \nour corporate expenses in fiscal 2021 were offset by net gains of ap proximately $133 million or $0.60 per diluted \nshare from equity investments within our McKesson Ventures' portfolio.  We assume a full year adjusted tax rate of \napproximately 18% to 19%, which may vary from quarter -to-quarter.  It includes anticipated discre te tax items that \nwe expect to realize during the course of the year.  \n \n As Brian mentioned in his remarks, we continue to transform and evolve our operating models to drive \nefficiencies.  As part of this evolution, we plan to make changes to our real estate strategy to increase efficiencies, \nsupporting increased flexibility, including a transition to a partial remote work model for certain employees on a \ngo-forward basis.  This will result in reduction to our real estate footprint.  \n \n", "original_text": "It includes anticipated discre te tax items that \nwe expect to realize during the course of the year.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a155a1df64c98ed45690bdbbb3c555c9348697be37cba4a9c10f09387b348b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79967c5a-3b95-45b6-96fc-66eb1fd801ce", "node_type": "1", "metadata": {"window": "We assume a full year adjusted tax rate of \napproximately 18% to 19%, which may vary from quarter -to-quarter.  It includes anticipated discre te tax items that \nwe expect to realize during the course of the year.  \n \n As Brian mentioned in his remarks, we continue to transform and evolve our operating models to drive \nefficiencies.  As part of this evolution, we plan to make changes to our real estate strategy to increase efficiencies, \nsupporting increased flexibility, including a transition to a partial remote work model for certain employees on a \ngo-forward basis.  This will result in reduction to our real estate footprint.  \n \n In executing this plan, we will incur GAAP -only restructuring charges of approximately $180 million to $280 million \nover the next year.  We expect these actions will result in the realization of annual savings of approximately $60 \nmillion to $80 million when fully implemented. ", "original_text": "As part of this evolution, we plan to make changes to our real estate strategy to increase efficiencies, \nsupporting increased flexibility, including a transition to a partial remote work model for certain employees on a \ngo-forward basis. "}, "hash": "05e81fb607111986e1134e1c3005bc7432347655d4bb3ddba14a0f618e3e18b2", "class_name": "RelatedNodeInfo"}}, "text": "As Brian mentioned in his remarks, we continue to transform and evolve our operating models to drive \nefficiencies. ", "start_char_idx": 2113, "end_char_idx": 2229, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79967c5a-3b95-45b6-96fc-66eb1fd801ce": {"__data__": {"id_": "79967c5a-3b95-45b6-96fc-66eb1fd801ce", "embedding": null, "metadata": {"window": "We assume a full year adjusted tax rate of \napproximately 18% to 19%, which may vary from quarter -to-quarter.  It includes anticipated discre te tax items that \nwe expect to realize during the course of the year.  \n \n As Brian mentioned in his remarks, we continue to transform and evolve our operating models to drive \nefficiencies.  As part of this evolution, we plan to make changes to our real estate strategy to increase efficiencies, \nsupporting increased flexibility, including a transition to a partial remote work model for certain employees on a \ngo-forward basis.  This will result in reduction to our real estate footprint.  \n \n In executing this plan, we will incur GAAP -only restructuring charges of approximately $180 million to $280 million \nover the next year.  We expect these actions will result in the realization of annual savings of approximately $60 \nmillion to $80 million when fully implemented. ", "original_text": "As part of this evolution, we plan to make changes to our real estate strategy to increase efficiencies, \nsupporting increased flexibility, including a transition to a partial remote work model for certain employees on a \ngo-forward basis. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee009d0606c8b9e5178e95d741c140713a7092f917833880f6e95044828dda4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5137c6d0-ed3c-4987-8b74-a096b96d63ca", "node_type": "1", "metadata": {"window": "And as a reminder, \nour corporate expenses in fiscal 2021 were offset by net gains of ap proximately $133 million or $0.60 per diluted \nshare from equity investments within our McKesson Ventures' portfolio.  We assume a full year adjusted tax rate of \napproximately 18% to 19%, which may vary from quarter -to-quarter.  It includes anticipated discre te tax items that \nwe expect to realize during the course of the year.  \n \n As Brian mentioned in his remarks, we continue to transform and evolve our operating models to drive \nefficiencies.  As part of this evolution, we plan to make changes to our real estate strategy to increase efficiencies, \nsupporting increased flexibility, including a transition to a partial remote work model for certain employees on a \ngo-forward basis.  This will result in reduction to our real estate footprint.  \n \n In executing this plan, we will incur GAAP -only restructuring charges of approximately $180 million to $280 million \nover the next year. ", "original_text": "As Brian mentioned in his remarks, we continue to transform and evolve our operating models to drive \nefficiencies. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3eaacbb8bed9498a102b416c599951002cb9961d867738b99f6681eb95c4b24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28f41f28-467a-41db-b24c-08869c1b7257", "node_type": "1", "metadata": {"window": "It includes anticipated discre te tax items that \nwe expect to realize during the course of the year.  \n \n As Brian mentioned in his remarks, we continue to transform and evolve our operating models to drive \nefficiencies.  As part of this evolution, we plan to make changes to our real estate strategy to increase efficiencies, \nsupporting increased flexibility, including a transition to a partial remote work model for certain employees on a \ngo-forward basis.  This will result in reduction to our real estate footprint.  \n \n In executing this plan, we will incur GAAP -only restructuring charges of approximately $180 million to $280 million \nover the next year.  We expect these actions will result in the realization of annual savings of approximately $60 \nmillion to $80 million when fully implemented.  These actions will get underway in this upcoming fiscal year, and \ntherefore, we do not expect to see a material benefit in fiscal 2022. ", "original_text": "This will result in reduction to our real estate footprint.  \n \n"}, "hash": "b80e7c650e952f580c9308ae558d19cd684f319a6cf63188d9598f6a9ab63221", "class_name": "RelatedNodeInfo"}}, "text": "As part of this evolution, we plan to make changes to our real estate strategy to increase efficiencies, \nsupporting increased flexibility, including a transition to a partial remote work model for certain employees on a \ngo-forward basis. ", "start_char_idx": 2229, "end_char_idx": 2469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28f41f28-467a-41db-b24c-08869c1b7257": {"__data__": {"id_": "28f41f28-467a-41db-b24c-08869c1b7257", "embedding": null, "metadata": {"window": "It includes anticipated discre te tax items that \nwe expect to realize during the course of the year.  \n \n As Brian mentioned in his remarks, we continue to transform and evolve our operating models to drive \nefficiencies.  As part of this evolution, we plan to make changes to our real estate strategy to increase efficiencies, \nsupporting increased flexibility, including a transition to a partial remote work model for certain employees on a \ngo-forward basis.  This will result in reduction to our real estate footprint.  \n \n In executing this plan, we will incur GAAP -only restructuring charges of approximately $180 million to $280 million \nover the next year.  We expect these actions will result in the realization of annual savings of approximately $60 \nmillion to $80 million when fully implemented.  These actions will get underway in this upcoming fiscal year, and \ntherefore, we do not expect to see a material benefit in fiscal 2022. ", "original_text": "This will result in reduction to our real estate footprint.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee009d0606c8b9e5178e95d741c140713a7092f917833880f6e95044828dda4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79967c5a-3b95-45b6-96fc-66eb1fd801ce", "node_type": "1", "metadata": {"window": "We assume a full year adjusted tax rate of \napproximately 18% to 19%, which may vary from quarter -to-quarter.  It includes anticipated discre te tax items that \nwe expect to realize during the course of the year.  \n \n As Brian mentioned in his remarks, we continue to transform and evolve our operating models to drive \nefficiencies.  As part of this evolution, we plan to make changes to our real estate strategy to increase efficiencies, \nsupporting increased flexibility, including a transition to a partial remote work model for certain employees on a \ngo-forward basis.  This will result in reduction to our real estate footprint.  \n \n In executing this plan, we will incur GAAP -only restructuring charges of approximately $180 million to $280 million \nover the next year.  We expect these actions will result in the realization of annual savings of approximately $60 \nmillion to $80 million when fully implemented. ", "original_text": "As part of this evolution, we plan to make changes to our real estate strategy to increase efficiencies, \nsupporting increased flexibility, including a transition to a partial remote work model for certain employees on a \ngo-forward basis. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17014ea13cbd4f477e3dda2e3e8d7242e131988b62f94b60d649178cb97f86a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7db1caa4-f667-46a5-807e-a6beb3e0921d", "node_type": "1", "metadata": {"window": "As Brian mentioned in his remarks, we continue to transform and evolve our operating models to drive \nefficiencies.  As part of this evolution, we plan to make changes to our real estate strategy to increase efficiencies, \nsupporting increased flexibility, including a transition to a partial remote work model for certain employees on a \ngo-forward basis.  This will result in reduction to our real estate footprint.  \n \n In executing this plan, we will incur GAAP -only restructuring charges of approximately $180 million to $280 million \nover the next year.  We expect these actions will result in the realization of annual savings of approximately $60 \nmillion to $80 million when fully implemented.  These actions will get underway in this upcoming fiscal year, and \ntherefore, we do not expect to see a material benefit in fiscal 2022.  We're in the early stages of this planning, and \nwe'll provide additional detail at a later time.  \n \n", "original_text": "In executing this plan, we will incur GAAP -only restructuring charges of approximately $180 million to $280 million \nover the next year. "}, "hash": "5691b015dd014b6ac885a7b51f9131d6fb4237c67eb467410912103fb7182009", "class_name": "RelatedNodeInfo"}}, "text": "This will result in reduction to our real estate footprint.  \n \n", "start_char_idx": 2469, "end_char_idx": 2533, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7db1caa4-f667-46a5-807e-a6beb3e0921d": {"__data__": {"id_": "7db1caa4-f667-46a5-807e-a6beb3e0921d", "embedding": null, "metadata": {"window": "As Brian mentioned in his remarks, we continue to transform and evolve our operating models to drive \nefficiencies.  As part of this evolution, we plan to make changes to our real estate strategy to increase efficiencies, \nsupporting increased flexibility, including a transition to a partial remote work model for certain employees on a \ngo-forward basis.  This will result in reduction to our real estate footprint.  \n \n In executing this plan, we will incur GAAP -only restructuring charges of approximately $180 million to $280 million \nover the next year.  We expect these actions will result in the realization of annual savings of approximately $60 \nmillion to $80 million when fully implemented.  These actions will get underway in this upcoming fiscal year, and \ntherefore, we do not expect to see a material benefit in fiscal 2022.  We're in the early stages of this planning, and \nwe'll provide additional detail at a later time.  \n \n", "original_text": "In executing this plan, we will incur GAAP -only restructuring charges of approximately $180 million to $280 million \nover the next year. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee009d0606c8b9e5178e95d741c140713a7092f917833880f6e95044828dda4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28f41f28-467a-41db-b24c-08869c1b7257", "node_type": "1", "metadata": {"window": "It includes anticipated discre te tax items that \nwe expect to realize during the course of the year.  \n \n As Brian mentioned in his remarks, we continue to transform and evolve our operating models to drive \nefficiencies.  As part of this evolution, we plan to make changes to our real estate strategy to increase efficiencies, \nsupporting increased flexibility, including a transition to a partial remote work model for certain employees on a \ngo-forward basis.  This will result in reduction to our real estate footprint.  \n \n In executing this plan, we will incur GAAP -only restructuring charges of approximately $180 million to $280 million \nover the next year.  We expect these actions will result in the realization of annual savings of approximately $60 \nmillion to $80 million when fully implemented.  These actions will get underway in this upcoming fiscal year, and \ntherefore, we do not expect to see a material benefit in fiscal 2022. ", "original_text": "This will result in reduction to our real estate footprint.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a792a4f5d68e6c2fd915e4c5f6bfebc563fa27e514d1d4d2460874344865383", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41c9e96c-c68b-4914-9b23-6fda06d54692", "node_type": "1", "metadata": {"window": "As part of this evolution, we plan to make changes to our real estate strategy to increase efficiencies, \nsupporting increased flexibility, including a transition to a partial remote work model for certain employees on a \ngo-forward basis.  This will result in reduction to our real estate footprint.  \n \n In executing this plan, we will incur GAAP -only restructuring charges of approximately $180 million to $280 million \nover the next year.  We expect these actions will result in the realization of annual savings of approximately $60 \nmillion to $80 million when fully implemented.  These actions will get underway in this upcoming fiscal year, and \ntherefore, we do not expect to see a material benefit in fiscal 2022.  We're in the early stages of this planning, and \nwe'll provide additional detail at a later time.  \n \n Let me wrap up our fiscal 20 22 outlook with a few comments on cash flow and capital deployment. ", "original_text": "We expect these actions will result in the realization of annual savings of approximately $60 \nmillion to $80 million when fully implemented. "}, "hash": "eed582a809866b8fb7a69eda7ce10844619b16302a24b9966eb2509d21f48e32", "class_name": "RelatedNodeInfo"}}, "text": "In executing this plan, we will incur GAAP -only restructuring charges of approximately $180 million to $280 million \nover the next year. ", "start_char_idx": 2533, "end_char_idx": 2671, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41c9e96c-c68b-4914-9b23-6fda06d54692": {"__data__": {"id_": "41c9e96c-c68b-4914-9b23-6fda06d54692", "embedding": null, "metadata": {"window": "As part of this evolution, we plan to make changes to our real estate strategy to increase efficiencies, \nsupporting increased flexibility, including a transition to a partial remote work model for certain employees on a \ngo-forward basis.  This will result in reduction to our real estate footprint.  \n \n In executing this plan, we will incur GAAP -only restructuring charges of approximately $180 million to $280 million \nover the next year.  We expect these actions will result in the realization of annual savings of approximately $60 \nmillion to $80 million when fully implemented.  These actions will get underway in this upcoming fiscal year, and \ntherefore, we do not expect to see a material benefit in fiscal 2022.  We're in the early stages of this planning, and \nwe'll provide additional detail at a later time.  \n \n Let me wrap up our fiscal 20 22 outlook with a few comments on cash flow and capital deployment. ", "original_text": "We expect these actions will result in the realization of annual savings of approximately $60 \nmillion to $80 million when fully implemented. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee009d0606c8b9e5178e95d741c140713a7092f917833880f6e95044828dda4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7db1caa4-f667-46a5-807e-a6beb3e0921d", "node_type": "1", "metadata": {"window": "As Brian mentioned in his remarks, we continue to transform and evolve our operating models to drive \nefficiencies.  As part of this evolution, we plan to make changes to our real estate strategy to increase efficiencies, \nsupporting increased flexibility, including a transition to a partial remote work model for certain employees on a \ngo-forward basis.  This will result in reduction to our real estate footprint.  \n \n In executing this plan, we will incur GAAP -only restructuring charges of approximately $180 million to $280 million \nover the next year.  We expect these actions will result in the realization of annual savings of approximately $60 \nmillion to $80 million when fully implemented.  These actions will get underway in this upcoming fiscal year, and \ntherefore, we do not expect to see a material benefit in fiscal 2022.  We're in the early stages of this planning, and \nwe'll provide additional detail at a later time.  \n \n", "original_text": "In executing this plan, we will incur GAAP -only restructuring charges of approximately $180 million to $280 million \nover the next year. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8ed9b95e6fe441bbab1d9a0518835729b8a97518ec61f9a445fd40431fbd049", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f90bed04-4b4f-4f83-a683-a5460046fcbe", "node_type": "1", "metadata": {"window": "This will result in reduction to our real estate footprint.  \n \n In executing this plan, we will incur GAAP -only restructuring charges of approximately $180 million to $280 million \nover the next year.  We expect these actions will result in the realization of annual savings of approximately $60 \nmillion to $80 million when fully implemented.  These actions will get underway in this upcoming fiscal year, and \ntherefore, we do not expect to see a material benefit in fiscal 2022.  We're in the early stages of this planning, and \nwe'll provide additional detail at a later time.  \n \n Let me wrap up our fiscal 20 22 outlook with a few comments on cash flow and capital deployment.  The past year \nhas reinforced the importance of managing our business for the long term through a disciplined and balanced \napproach to capital deployment with a sharp focus on investments f or innovation and growth to further enhance \nour competitive positioning and leverage our differentiated assets and capabilities.  \n \n", "original_text": "These actions will get underway in this upcoming fiscal year, and \ntherefore, we do not expect to see a material benefit in fiscal 2022. "}, "hash": "f66f0ce77dfdb510c9d8ea1f3416c16ee621d8308992eeac8b48993478f27ee3", "class_name": "RelatedNodeInfo"}}, "text": "We expect these actions will result in the realization of annual savings of approximately $60 \nmillion to $80 million when fully implemented. ", "start_char_idx": 2671, "end_char_idx": 2813, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f90bed04-4b4f-4f83-a683-a5460046fcbe": {"__data__": {"id_": "f90bed04-4b4f-4f83-a683-a5460046fcbe", "embedding": null, "metadata": {"window": "This will result in reduction to our real estate footprint.  \n \n In executing this plan, we will incur GAAP -only restructuring charges of approximately $180 million to $280 million \nover the next year.  We expect these actions will result in the realization of annual savings of approximately $60 \nmillion to $80 million when fully implemented.  These actions will get underway in this upcoming fiscal year, and \ntherefore, we do not expect to see a material benefit in fiscal 2022.  We're in the early stages of this planning, and \nwe'll provide additional detail at a later time.  \n \n Let me wrap up our fiscal 20 22 outlook with a few comments on cash flow and capital deployment.  The past year \nhas reinforced the importance of managing our business for the long term through a disciplined and balanced \napproach to capital deployment with a sharp focus on investments f or innovation and growth to further enhance \nour competitive positioning and leverage our differentiated assets and capabilities.  \n \n", "original_text": "These actions will get underway in this upcoming fiscal year, and \ntherefore, we do not expect to see a material benefit in fiscal 2022. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee009d0606c8b9e5178e95d741c140713a7092f917833880f6e95044828dda4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41c9e96c-c68b-4914-9b23-6fda06d54692", "node_type": "1", "metadata": {"window": "As part of this evolution, we plan to make changes to our real estate strategy to increase efficiencies, \nsupporting increased flexibility, including a transition to a partial remote work model for certain employees on a \ngo-forward basis.  This will result in reduction to our real estate footprint.  \n \n In executing this plan, we will incur GAAP -only restructuring charges of approximately $180 million to $280 million \nover the next year.  We expect these actions will result in the realization of annual savings of approximately $60 \nmillion to $80 million when fully implemented.  These actions will get underway in this upcoming fiscal year, and \ntherefore, we do not expect to see a material benefit in fiscal 2022.  We're in the early stages of this planning, and \nwe'll provide additional detail at a later time.  \n \n Let me wrap up our fiscal 20 22 outlook with a few comments on cash flow and capital deployment. ", "original_text": "We expect these actions will result in the realization of annual savings of approximately $60 \nmillion to $80 million when fully implemented. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e067ce57aeeb6c3cbdae3014fb219cc27b0fa9bb15cff4fa84d8c51bf8e6490a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c93a0e06-27f2-4493-b29e-b7b76146aad7", "node_type": "1", "metadata": {"window": "In executing this plan, we will incur GAAP -only restructuring charges of approximately $180 million to $280 million \nover the next year.  We expect these actions will result in the realization of annual savings of approximately $60 \nmillion to $80 million when fully implemented.  These actions will get underway in this upcoming fiscal year, and \ntherefore, we do not expect to see a material benefit in fiscal 2022.  We're in the early stages of this planning, and \nwe'll provide additional detail at a later time.  \n \n Let me wrap up our fiscal 20 22 outlook with a few comments on cash flow and capital deployment.  The past year \nhas reinforced the importance of managing our business for the long term through a disciplined and balanced \napproach to capital deployment with a sharp focus on investments f or innovation and growth to further enhance \nour competitive positioning and leverage our differentiated assets and capabilities.  \n \n We expect free cash flow of approximately $3.5 billion to $3.9 billion, which is net of property acquisitions and \ncapitalized software expenses. ", "original_text": "We're in the early stages of this planning, and \nwe'll provide additional detail at a later time.  \n \n"}, "hash": "0b2f91aec122fd7cd3f799052bcd1f24802e0b9a4a1b9f1b5e2182801cf387db", "class_name": "RelatedNodeInfo"}}, "text": "These actions will get underway in this upcoming fiscal year, and \ntherefore, we do not expect to see a material benefit in fiscal 2022. ", "start_char_idx": 2813, "end_char_idx": 2950, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c93a0e06-27f2-4493-b29e-b7b76146aad7": {"__data__": {"id_": "c93a0e06-27f2-4493-b29e-b7b76146aad7", "embedding": null, "metadata": {"window": "In executing this plan, we will incur GAAP -only restructuring charges of approximately $180 million to $280 million \nover the next year.  We expect these actions will result in the realization of annual savings of approximately $60 \nmillion to $80 million when fully implemented.  These actions will get underway in this upcoming fiscal year, and \ntherefore, we do not expect to see a material benefit in fiscal 2022.  We're in the early stages of this planning, and \nwe'll provide additional detail at a later time.  \n \n Let me wrap up our fiscal 20 22 outlook with a few comments on cash flow and capital deployment.  The past year \nhas reinforced the importance of managing our business for the long term through a disciplined and balanced \napproach to capital deployment with a sharp focus on investments f or innovation and growth to further enhance \nour competitive positioning and leverage our differentiated assets and capabilities.  \n \n We expect free cash flow of approximately $3.5 billion to $3.9 billion, which is net of property acquisitions and \ncapitalized software expenses. ", "original_text": "We're in the early stages of this planning, and \nwe'll provide additional detail at a later time.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee009d0606c8b9e5178e95d741c140713a7092f917833880f6e95044828dda4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f90bed04-4b4f-4f83-a683-a5460046fcbe", "node_type": "1", "metadata": {"window": "This will result in reduction to our real estate footprint.  \n \n In executing this plan, we will incur GAAP -only restructuring charges of approximately $180 million to $280 million \nover the next year.  We expect these actions will result in the realization of annual savings of approximately $60 \nmillion to $80 million when fully implemented.  These actions will get underway in this upcoming fiscal year, and \ntherefore, we do not expect to see a material benefit in fiscal 2022.  We're in the early stages of this planning, and \nwe'll provide additional detail at a later time.  \n \n Let me wrap up our fiscal 20 22 outlook with a few comments on cash flow and capital deployment.  The past year \nhas reinforced the importance of managing our business for the long term through a disciplined and balanced \napproach to capital deployment with a sharp focus on investments f or innovation and growth to further enhance \nour competitive positioning and leverage our differentiated assets and capabilities.  \n \n", "original_text": "These actions will get underway in this upcoming fiscal year, and \ntherefore, we do not expect to see a material benefit in fiscal 2022. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f44f086f39b3e2f99b31bdc7140fe76bb3331a5fe0cb9bfc653b78e54cd5bcf4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7fc4c663-7c94-4a4f-a9a3-fa05a461e7de", "node_type": "1", "metadata": {"window": "We expect these actions will result in the realization of annual savings of approximately $60 \nmillion to $80 million when fully implemented.  These actions will get underway in this upcoming fiscal year, and \ntherefore, we do not expect to see a material benefit in fiscal 2022.  We're in the early stages of this planning, and \nwe'll provide additional detail at a later time.  \n \n Let me wrap up our fiscal 20 22 outlook with a few comments on cash flow and capital deployment.  The past year \nhas reinforced the importance of managing our business for the long term through a disciplined and balanced \napproach to capital deployment with a sharp focus on investments f or innovation and growth to further enhance \nour competitive positioning and leverage our differentiated assets and capabilities.  \n \n We expect free cash flow of approximately $3.5 billion to $3.9 billion, which is net of property acquisitions and \ncapitalized software expenses.  As we consider our capital deployment options, we first start with our commitment \nto maintain our current investment -grade credit rating.  \n \n", "original_text": "Let me wrap up our fiscal 20 22 outlook with a few comments on cash flow and capital deployment. "}, "hash": "0246c8a6c1bddde50913ccaec7ca3d5b415680fcbfd4bda7e085570db7109cd6", "class_name": "RelatedNodeInfo"}}, "text": "We're in the early stages of this planning, and \nwe'll provide additional detail at a later time.  \n \n", "start_char_idx": 2950, "end_char_idx": 3052, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7fc4c663-7c94-4a4f-a9a3-fa05a461e7de": {"__data__": {"id_": "7fc4c663-7c94-4a4f-a9a3-fa05a461e7de", "embedding": null, "metadata": {"window": "We expect these actions will result in the realization of annual savings of approximately $60 \nmillion to $80 million when fully implemented.  These actions will get underway in this upcoming fiscal year, and \ntherefore, we do not expect to see a material benefit in fiscal 2022.  We're in the early stages of this planning, and \nwe'll provide additional detail at a later time.  \n \n Let me wrap up our fiscal 20 22 outlook with a few comments on cash flow and capital deployment.  The past year \nhas reinforced the importance of managing our business for the long term through a disciplined and balanced \napproach to capital deployment with a sharp focus on investments f or innovation and growth to further enhance \nour competitive positioning and leverage our differentiated assets and capabilities.  \n \n We expect free cash flow of approximately $3.5 billion to $3.9 billion, which is net of property acquisitions and \ncapitalized software expenses.  As we consider our capital deployment options, we first start with our commitment \nto maintain our current investment -grade credit rating.  \n \n", "original_text": "Let me wrap up our fiscal 20 22 outlook with a few comments on cash flow and capital deployment. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee009d0606c8b9e5178e95d741c140713a7092f917833880f6e95044828dda4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c93a0e06-27f2-4493-b29e-b7b76146aad7", "node_type": "1", "metadata": {"window": "In executing this plan, we will incur GAAP -only restructuring charges of approximately $180 million to $280 million \nover the next year.  We expect these actions will result in the realization of annual savings of approximately $60 \nmillion to $80 million when fully implemented.  These actions will get underway in this upcoming fiscal year, and \ntherefore, we do not expect to see a material benefit in fiscal 2022.  We're in the early stages of this planning, and \nwe'll provide additional detail at a later time.  \n \n Let me wrap up our fiscal 20 22 outlook with a few comments on cash flow and capital deployment.  The past year \nhas reinforced the importance of managing our business for the long term through a disciplined and balanced \napproach to capital deployment with a sharp focus on investments f or innovation and growth to further enhance \nour competitive positioning and leverage our differentiated assets and capabilities.  \n \n We expect free cash flow of approximately $3.5 billion to $3.9 billion, which is net of property acquisitions and \ncapitalized software expenses. ", "original_text": "We're in the early stages of this planning, and \nwe'll provide additional detail at a later time.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6ee031ebf3408e615a43eccdc904177ed0bade6230cf4e781a3bb16f282dc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a663b49-63b8-4dac-9308-5bd61941692a", "node_type": "1", "metadata": {"window": "These actions will get underway in this upcoming fiscal year, and \ntherefore, we do not expect to see a material benefit in fiscal 2022.  We're in the early stages of this planning, and \nwe'll provide additional detail at a later time.  \n \n Let me wrap up our fiscal 20 22 outlook with a few comments on cash flow and capital deployment.  The past year \nhas reinforced the importance of managing our business for the long term through a disciplined and balanced \napproach to capital deployment with a sharp focus on investments f or innovation and growth to further enhance \nour competitive positioning and leverage our differentiated assets and capabilities.  \n \n We expect free cash flow of approximately $3.5 billion to $3.9 billion, which is net of property acquisitions and \ncapitalized software expenses.  As we consider our capital deployment options, we first start with our commitment \nto maintain our current investment -grade credit rating.  \n \n With respect to capital deployment, our priority is growth, and the use of capital continues to be  focused on \nsupporting organic growth of our oncology and biopharma services strategies, followed by retaining flexibility for \nacquisitions to accelerate these strategies. ", "original_text": "The past year \nhas reinforced the importance of managing our business for the long term through a disciplined and balanced \napproach to capital deployment with a sharp focus on investments f or innovation and growth to further enhance \nour competitive positioning and leverage our differentiated assets and capabilities.  \n \n"}, "hash": "320948fa9ed305b6c87b918e5ab0e3959f0daac5e42b2b771b6798943c716ca0", "class_name": "RelatedNodeInfo"}}, "text": "Let me wrap up our fiscal 20 22 outlook with a few comments on cash flow and capital deployment. ", "start_char_idx": 3052, "end_char_idx": 3149, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a663b49-63b8-4dac-9308-5bd61941692a": {"__data__": {"id_": "1a663b49-63b8-4dac-9308-5bd61941692a", "embedding": null, "metadata": {"window": "These actions will get underway in this upcoming fiscal year, and \ntherefore, we do not expect to see a material benefit in fiscal 2022.  We're in the early stages of this planning, and \nwe'll provide additional detail at a later time.  \n \n Let me wrap up our fiscal 20 22 outlook with a few comments on cash flow and capital deployment.  The past year \nhas reinforced the importance of managing our business for the long term through a disciplined and balanced \napproach to capital deployment with a sharp focus on investments f or innovation and growth to further enhance \nour competitive positioning and leverage our differentiated assets and capabilities.  \n \n We expect free cash flow of approximately $3.5 billion to $3.9 billion, which is net of property acquisitions and \ncapitalized software expenses.  As we consider our capital deployment options, we first start with our commitment \nto maintain our current investment -grade credit rating.  \n \n With respect to capital deployment, our priority is growth, and the use of capital continues to be  focused on \nsupporting organic growth of our oncology and biopharma services strategies, followed by retaining flexibility for \nacquisitions to accelerate these strategies. ", "original_text": "The past year \nhas reinforced the importance of managing our business for the long term through a disciplined and balanced \napproach to capital deployment with a sharp focus on investments f or innovation and growth to further enhance \nour competitive positioning and leverage our differentiated assets and capabilities.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee009d0606c8b9e5178e95d741c140713a7092f917833880f6e95044828dda4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7fc4c663-7c94-4a4f-a9a3-fa05a461e7de", "node_type": "1", "metadata": {"window": "We expect these actions will result in the realization of annual savings of approximately $60 \nmillion to $80 million when fully implemented.  These actions will get underway in this upcoming fiscal year, and \ntherefore, we do not expect to see a material benefit in fiscal 2022.  We're in the early stages of this planning, and \nwe'll provide additional detail at a later time.  \n \n Let me wrap up our fiscal 20 22 outlook with a few comments on cash flow and capital deployment.  The past year \nhas reinforced the importance of managing our business for the long term through a disciplined and balanced \napproach to capital deployment with a sharp focus on investments f or innovation and growth to further enhance \nour competitive positioning and leverage our differentiated assets and capabilities.  \n \n We expect free cash flow of approximately $3.5 billion to $3.9 billion, which is net of property acquisitions and \ncapitalized software expenses.  As we consider our capital deployment options, we first start with our commitment \nto maintain our current investment -grade credit rating.  \n \n", "original_text": "Let me wrap up our fiscal 20 22 outlook with a few comments on cash flow and capital deployment. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05d0f63810cbde87bb38ca0516071b4d68ee9fe2c05019a19ef363c8e3e083c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "322403d3-50a7-4085-b20e-2de493502678", "node_type": "1", "metadata": {"window": "We're in the early stages of this planning, and \nwe'll provide additional detail at a later time.  \n \n Let me wrap up our fiscal 20 22 outlook with a few comments on cash flow and capital deployment.  The past year \nhas reinforced the importance of managing our business for the long term through a disciplined and balanced \napproach to capital deployment with a sharp focus on investments f or innovation and growth to further enhance \nour competitive positioning and leverage our differentiated assets and capabilities.  \n \n We expect free cash flow of approximately $3.5 billion to $3.9 billion, which is net of property acquisitions and \ncapitalized software expenses.  As we consider our capital deployment options, we first start with our commitment \nto maintain our current investment -grade credit rating.  \n \n With respect to capital deployment, our priority is growth, and the use of capital continues to be  focused on \nsupporting organic growth of our oncology and biopharma services strategies, followed by retaining flexibility for \nacquisitions to accelerate these strategies.  We complement these growth drivers with a return of capital to our \nshareholders, thr ough a modest yet growing dividend and share repurchases.  ", "original_text": "We expect free cash flow of approximately $3.5 billion to $3.9 billion, which is net of property acquisitions and \ncapitalized software expenses. "}, "hash": "0ec01fa8c82d9815349f91c897a566d2f2723a2e99d3f889bb626c012eacfba4", "class_name": "RelatedNodeInfo"}}, "text": "The past year \nhas reinforced the importance of managing our business for the long term through a disciplined and balanced \napproach to capital deployment with a sharp focus on investments f or innovation and growth to further enhance \nour competitive positioning and leverage our differentiated assets and capabilities.  \n \n", "start_char_idx": 3149, "end_char_idx": 3474, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "322403d3-50a7-4085-b20e-2de493502678": {"__data__": {"id_": "322403d3-50a7-4085-b20e-2de493502678", "embedding": null, "metadata": {"window": "We're in the early stages of this planning, and \nwe'll provide additional detail at a later time.  \n \n Let me wrap up our fiscal 20 22 outlook with a few comments on cash flow and capital deployment.  The past year \nhas reinforced the importance of managing our business for the long term through a disciplined and balanced \napproach to capital deployment with a sharp focus on investments f or innovation and growth to further enhance \nour competitive positioning and leverage our differentiated assets and capabilities.  \n \n We expect free cash flow of approximately $3.5 billion to $3.9 billion, which is net of property acquisitions and \ncapitalized software expenses.  As we consider our capital deployment options, we first start with our commitment \nto maintain our current investment -grade credit rating.  \n \n With respect to capital deployment, our priority is growth, and the use of capital continues to be  focused on \nsupporting organic growth of our oncology and biopharma services strategies, followed by retaining flexibility for \nacquisitions to accelerate these strategies.  We complement these growth drivers with a return of capital to our \nshareholders, thr ough a modest yet growing dividend and share repurchases.  ", "original_text": "We expect free cash flow of approximately $3.5 billion to $3.9 billion, which is net of property acquisitions and \ncapitalized software expenses. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee009d0606c8b9e5178e95d741c140713a7092f917833880f6e95044828dda4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a663b49-63b8-4dac-9308-5bd61941692a", "node_type": "1", "metadata": {"window": "These actions will get underway in this upcoming fiscal year, and \ntherefore, we do not expect to see a material benefit in fiscal 2022.  We're in the early stages of this planning, and \nwe'll provide additional detail at a later time.  \n \n Let me wrap up our fiscal 20 22 outlook with a few comments on cash flow and capital deployment.  The past year \nhas reinforced the importance of managing our business for the long term through a disciplined and balanced \napproach to capital deployment with a sharp focus on investments f or innovation and growth to further enhance \nour competitive positioning and leverage our differentiated assets and capabilities.  \n \n We expect free cash flow of approximately $3.5 billion to $3.9 billion, which is net of property acquisitions and \ncapitalized software expenses.  As we consider our capital deployment options, we first start with our commitment \nto maintain our current investment -grade credit rating.  \n \n With respect to capital deployment, our priority is growth, and the use of capital continues to be  focused on \nsupporting organic growth of our oncology and biopharma services strategies, followed by retaining flexibility for \nacquisitions to accelerate these strategies. ", "original_text": "The past year \nhas reinforced the importance of managing our business for the long term through a disciplined and balanced \napproach to capital deployment with a sharp focus on investments f or innovation and growth to further enhance \nour competitive positioning and leverage our differentiated assets and capabilities.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0722dbdbe34131113594ecd4e804c4c7d5a4b53c396dd666bb063b9477c35525", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "934f0ebf-9fdd-4541-affb-0d1c1c2351f6", "node_type": "1", "metadata": {"window": "Let me wrap up our fiscal 20 22 outlook with a few comments on cash flow and capital deployment.  The past year \nhas reinforced the importance of managing our business for the long term through a disciplined and balanced \napproach to capital deployment with a sharp focus on investments f or innovation and growth to further enhance \nour competitive positioning and leverage our differentiated assets and capabilities.  \n \n We expect free cash flow of approximately $3.5 billion to $3.9 billion, which is net of property acquisitions and \ncapitalized software expenses.  As we consider our capital deployment options, we first start with our commitment \nto maintain our current investment -grade credit rating.  \n \n With respect to capital deployment, our priority is growth, and the use of capital continues to be  focused on \nsupporting organic growth of our oncology and biopharma services strategies, followed by retaining flexibility for \nacquisitions to accelerate these strategies.  We complement these growth drivers with a return of capital to our \nshareholders, thr ough a modest yet growing dividend and share repurchases.  ", "original_text": "As we consider our capital deployment options, we first start with our commitment \nto maintain our current investment -grade credit rating.  \n \n"}, "hash": "a121e04903ce3b91335ce4508cfa59a6caa624f5e7a8120a56e5f55d948bf746", "class_name": "RelatedNodeInfo"}}, "text": "We expect free cash flow of approximately $3.5 billion to $3.9 billion, which is net of property acquisitions and \ncapitalized software expenses. ", "start_char_idx": 3474, "end_char_idx": 3620, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "934f0ebf-9fdd-4541-affb-0d1c1c2351f6": {"__data__": {"id_": "934f0ebf-9fdd-4541-affb-0d1c1c2351f6", "embedding": null, "metadata": {"window": "Let me wrap up our fiscal 20 22 outlook with a few comments on cash flow and capital deployment.  The past year \nhas reinforced the importance of managing our business for the long term through a disciplined and balanced \napproach to capital deployment with a sharp focus on investments f or innovation and growth to further enhance \nour competitive positioning and leverage our differentiated assets and capabilities.  \n \n We expect free cash flow of approximately $3.5 billion to $3.9 billion, which is net of property acquisitions and \ncapitalized software expenses.  As we consider our capital deployment options, we first start with our commitment \nto maintain our current investment -grade credit rating.  \n \n With respect to capital deployment, our priority is growth, and the use of capital continues to be  focused on \nsupporting organic growth of our oncology and biopharma services strategies, followed by retaining flexibility for \nacquisitions to accelerate these strategies.  We complement these growth drivers with a return of capital to our \nshareholders, thr ough a modest yet growing dividend and share repurchases.  ", "original_text": "As we consider our capital deployment options, we first start with our commitment \nto maintain our current investment -grade credit rating.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee009d0606c8b9e5178e95d741c140713a7092f917833880f6e95044828dda4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "322403d3-50a7-4085-b20e-2de493502678", "node_type": "1", "metadata": {"window": "We're in the early stages of this planning, and \nwe'll provide additional detail at a later time.  \n \n Let me wrap up our fiscal 20 22 outlook with a few comments on cash flow and capital deployment.  The past year \nhas reinforced the importance of managing our business for the long term through a disciplined and balanced \napproach to capital deployment with a sharp focus on investments f or innovation and growth to further enhance \nour competitive positioning and leverage our differentiated assets and capabilities.  \n \n We expect free cash flow of approximately $3.5 billion to $3.9 billion, which is net of property acquisitions and \ncapitalized software expenses.  As we consider our capital deployment options, we first start with our commitment \nto maintain our current investment -grade credit rating.  \n \n With respect to capital deployment, our priority is growth, and the use of capital continues to be  focused on \nsupporting organic growth of our oncology and biopharma services strategies, followed by retaining flexibility for \nacquisitions to accelerate these strategies.  We complement these growth drivers with a return of capital to our \nshareholders, thr ough a modest yet growing dividend and share repurchases.  ", "original_text": "We expect free cash flow of approximately $3.5 billion to $3.9 billion, which is net of property acquisitions and \ncapitalized software expenses. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2734419b70c3371e9940dd6f7a1c117ae4cb665bbb9e17546fb8edd04742444e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d62dd0d-5458-492a-80c6-1415e4826657", "node_type": "1", "metadata": {"window": "The past year \nhas reinforced the importance of managing our business for the long term through a disciplined and balanced \napproach to capital deployment with a sharp focus on investments f or innovation and growth to further enhance \nour competitive positioning and leverage our differentiated assets and capabilities.  \n \n We expect free cash flow of approximately $3.5 billion to $3.9 billion, which is net of property acquisitions and \ncapitalized software expenses.  As we consider our capital deployment options, we first start with our commitment \nto maintain our current investment -grade credit rating.  \n \n With respect to capital deployment, our priority is growth, and the use of capital continues to be  focused on \nsupporting organic growth of our oncology and biopharma services strategies, followed by retaining flexibility for \nacquisitions to accelerate these strategies.  We complement these growth drivers with a return of capital to our \nshareholders, thr ough a modest yet growing dividend and share repurchases.  ", "original_text": "With respect to capital deployment, our priority is growth, and the use of capital continues to be  focused on \nsupporting organic growth of our oncology and biopharma services strategies, followed by retaining flexibility for \nacquisitions to accelerate these strategies. "}, "hash": "cba9867d5128f95d982522d2268ce28c6b56051f19eb9406dfe6aca5af32301e", "class_name": "RelatedNodeInfo"}}, "text": "As we consider our capital deployment options, we first start with our commitment \nto maintain our current investment -grade credit rating.  \n \n", "start_char_idx": 3620, "end_char_idx": 3764, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d62dd0d-5458-492a-80c6-1415e4826657": {"__data__": {"id_": "1d62dd0d-5458-492a-80c6-1415e4826657", "embedding": null, "metadata": {"window": "The past year \nhas reinforced the importance of managing our business for the long term through a disciplined and balanced \napproach to capital deployment with a sharp focus on investments f or innovation and growth to further enhance \nour competitive positioning and leverage our differentiated assets and capabilities.  \n \n We expect free cash flow of approximately $3.5 billion to $3.9 billion, which is net of property acquisitions and \ncapitalized software expenses.  As we consider our capital deployment options, we first start with our commitment \nto maintain our current investment -grade credit rating.  \n \n With respect to capital deployment, our priority is growth, and the use of capital continues to be  focused on \nsupporting organic growth of our oncology and biopharma services strategies, followed by retaining flexibility for \nacquisitions to accelerate these strategies.  We complement these growth drivers with a return of capital to our \nshareholders, thr ough a modest yet growing dividend and share repurchases.  ", "original_text": "With respect to capital deployment, our priority is growth, and the use of capital continues to be  focused on \nsupporting organic growth of our oncology and biopharma services strategies, followed by retaining flexibility for \nacquisitions to accelerate these strategies. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee009d0606c8b9e5178e95d741c140713a7092f917833880f6e95044828dda4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "934f0ebf-9fdd-4541-affb-0d1c1c2351f6", "node_type": "1", "metadata": {"window": "Let me wrap up our fiscal 20 22 outlook with a few comments on cash flow and capital deployment.  The past year \nhas reinforced the importance of managing our business for the long term through a disciplined and balanced \napproach to capital deployment with a sharp focus on investments f or innovation and growth to further enhance \nour competitive positioning and leverage our differentiated assets and capabilities.  \n \n We expect free cash flow of approximately $3.5 billion to $3.9 billion, which is net of property acquisitions and \ncapitalized software expenses.  As we consider our capital deployment options, we first start with our commitment \nto maintain our current investment -grade credit rating.  \n \n With respect to capital deployment, our priority is growth, and the use of capital continues to be  focused on \nsupporting organic growth of our oncology and biopharma services strategies, followed by retaining flexibility for \nacquisitions to accelerate these strategies.  We complement these growth drivers with a return of capital to our \nshareholders, thr ough a modest yet growing dividend and share repurchases.  ", "original_text": "As we consider our capital deployment options, we first start with our commitment \nto maintain our current investment -grade credit rating.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "549f77c99831765a59383751f2f7dc4339ceff400cf8a387958f6cfbceb3c902", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af2ce118-7cc2-4d44-adc3-cd0694282dbc", "node_type": "1", "metadata": {"window": "We expect free cash flow of approximately $3.5 billion to $3.9 billion, which is net of property acquisitions and \ncapitalized software expenses.  As we consider our capital deployment options, we first start with our commitment \nto maintain our current investment -grade credit rating.  \n \n With respect to capital deployment, our priority is growth, and the use of capital continues to be  focused on \nsupporting organic growth of our oncology and biopharma services strategies, followed by retaining flexibility for \nacquisitions to accelerate these strategies.  We complement these growth drivers with a return of capital to our \nshareholders, thr ough a modest yet growing dividend and share repurchases.  ", "original_text": "We complement these growth drivers with a return of capital to our \nshareholders, thr ough a modest yet growing dividend and share repurchases.  "}, "hash": "70614bb649441997972e27b4e6f44423c3edb319c1e67045f661df83fab30d64", "class_name": "RelatedNodeInfo"}}, "text": "With respect to capital deployment, our priority is growth, and the use of capital continues to be  focused on \nsupporting organic growth of our oncology and biopharma services strategies, followed by retaining flexibility for \nacquisitions to accelerate these strategies. ", "start_char_idx": 3764, "end_char_idx": 4037, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af2ce118-7cc2-4d44-adc3-cd0694282dbc": {"__data__": {"id_": "af2ce118-7cc2-4d44-adc3-cd0694282dbc", "embedding": null, "metadata": {"window": "We expect free cash flow of approximately $3.5 billion to $3.9 billion, which is net of property acquisitions and \ncapitalized software expenses.  As we consider our capital deployment options, we first start with our commitment \nto maintain our current investment -grade credit rating.  \n \n With respect to capital deployment, our priority is growth, and the use of capital continues to be  focused on \nsupporting organic growth of our oncology and biopharma services strategies, followed by retaining flexibility for \nacquisitions to accelerate these strategies.  We complement these growth drivers with a return of capital to our \nshareholders, thr ough a modest yet growing dividend and share repurchases.  ", "original_text": "We complement these growth drivers with a return of capital to our \nshareholders, thr ough a modest yet growing dividend and share repurchases.  ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee009d0606c8b9e5178e95d741c140713a7092f917833880f6e95044828dda4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d62dd0d-5458-492a-80c6-1415e4826657", "node_type": "1", "metadata": {"window": "The past year \nhas reinforced the importance of managing our business for the long term through a disciplined and balanced \napproach to capital deployment with a sharp focus on investments f or innovation and growth to further enhance \nour competitive positioning and leverage our differentiated assets and capabilities.  \n \n We expect free cash flow of approximately $3.5 billion to $3.9 billion, which is net of property acquisitions and \ncapitalized software expenses.  As we consider our capital deployment options, we first start with our commitment \nto maintain our current investment -grade credit rating.  \n \n With respect to capital deployment, our priority is growth, and the use of capital continues to be  focused on \nsupporting organic growth of our oncology and biopharma services strategies, followed by retaining flexibility for \nacquisitions to accelerate these strategies.  We complement these growth drivers with a return of capital to our \nshareholders, thr ough a modest yet growing dividend and share repurchases.  ", "original_text": "With respect to capital deployment, our priority is growth, and the use of capital continues to be  focused on \nsupporting organic growth of our oncology and biopharma services strategies, followed by retaining flexibility for \nacquisitions to accelerate these strategies. ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "391e05232de18c144984a594aba642f9e605558879cace5b6e120a65b2be7659", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3bb05fac-d9ba-4ac0-9e39-68bd9cc7184d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nWe continue to execute at a high level, and we have confidence in the business today and in the future.  And we \ncontinue to believe that there's great value in our stock.  As indicated on slide 16, o ur fiscal 2022 outlook \nincorporates plans to repurchase approximately $2 billion of stock, which we expect will be more heavily weighted \nto the first half of the fiscal year.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "9aeb6cf0dfc64f72b69cf151bae5254a19236603fb253c4c9f2a1314620ddea2", "class_name": "RelatedNodeInfo"}}, "text": "We complement these growth drivers with a return of capital to our \nshareholders, thr ough a modest yet growing dividend and share repurchases.  ", "start_char_idx": 4037, "end_char_idx": 4182, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3bb05fac-d9ba-4ac0-9e39-68bd9cc7184d": {"__data__": {"id_": "3bb05fac-d9ba-4ac0-9e39-68bd9cc7184d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nWe continue to execute at a high level, and we have confidence in the business today and in the future.  And we \ncontinue to believe that there's great value in our stock.  As indicated on slide 16, o ur fiscal 2022 outlook \nincorporates plans to repurchase approximately $2 billion of stock, which we expect will be more heavily weighted \nto the first half of the fiscal year.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2f6785c986671ce0623f31884790d0e0d2d6a77b10e89f910169852a5d550d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af2ce118-7cc2-4d44-adc3-cd0694282dbc", "node_type": "1", "metadata": {"window": "We expect free cash flow of approximately $3.5 billion to $3.9 billion, which is net of property acquisitions and \ncapitalized software expenses.  As we consider our capital deployment options, we first start with our commitment \nto maintain our current investment -grade credit rating.  \n \n With respect to capital deployment, our priority is growth, and the use of capital continues to be  focused on \nsupporting organic growth of our oncology and biopharma services strategies, followed by retaining flexibility for \nacquisitions to accelerate these strategies.  We complement these growth drivers with a return of capital to our \nshareholders, thr ough a modest yet growing dividend and share repurchases.  ", "original_text": "We complement these growth drivers with a return of capital to our \nshareholders, thr ough a modest yet growing dividend and share repurchases.  ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98bf04b11ae293aa02230d83082afbc8db5c08284bcf6d5dd1401e932c5f6d78", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b0f41af-ceb2-4c04-8abb-a46168f2cde8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nWe continue to execute at a high level, and we have confidence in the business today and in the future.  And we \ncontinue to believe that there's great value in our stock.  As indicated on slide 16, o ur fiscal 2022 outlook \nincorporates plans to repurchase approximately $2 billion of stock, which we expect will be more heavily weighted \nto the first half of the fiscal year.  \n \n As a result of this activity, we estimate weighted average diluted shares outsta nding for fiscal 2022 to be in the \nrange of approximately 153.5 million to 155.5 million. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nWe continue to execute at a high level, and we have confidence in the business today and in the future. "}, "hash": "4e0e337669e842d240cdc020ce842f875adff7636d3a290aba5d11379f722edd", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b0f41af-ceb2-4c04-8abb-a46168f2cde8": {"__data__": {"id_": "7b0f41af-ceb2-4c04-8abb-a46168f2cde8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nWe continue to execute at a high level, and we have confidence in the business today and in the future.  And we \ncontinue to believe that there's great value in our stock.  As indicated on slide 16, o ur fiscal 2022 outlook \nincorporates plans to repurchase approximately $2 billion of stock, which we expect will be more heavily weighted \nto the first half of the fiscal year.  \n \n As a result of this activity, we estimate weighted average diluted shares outsta nding for fiscal 2022 to be in the \nrange of approximately 153.5 million to 155.5 million. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nWe continue to execute at a high level, and we have confidence in the business today and in the future. ", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2f6785c986671ce0623f31884790d0e0d2d6a77b10e89f910169852a5d550d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3bb05fac-d9ba-4ac0-9e39-68bd9cc7184d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nWe continue to execute at a high level, and we have confidence in the business today and in the future.  And we \ncontinue to believe that there's great value in our stock.  As indicated on slide 16, o ur fiscal 2022 outlook \nincorporates plans to repurchase approximately $2 billion of stock, which we expect will be more heavily weighted \nto the first half of the fiscal year.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ed3c5a8250b81335f4d8c50df69fd27aa8b27203a18e9b2eca8f00b849d98817", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9dccbde3-4356-4ced-b5fa-3fea65e53640", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nWe continue to execute at a high level, and we have confidence in the business today and in the future.  And we \ncontinue to believe that there's great value in our stock.  As indicated on slide 16, o ur fiscal 2022 outlook \nincorporates plans to repurchase approximately $2 billion of stock, which we expect will be more heavily weighted \nto the first half of the fiscal year.  \n \n As a result of this activity, we estimate weighted average diluted shares outsta nding for fiscal 2022 to be in the \nrange of approximately 153.5 million to 155.5 million.  We also anticipate use of cash to purchase shares in \nMcKesson Europe, through exercises of a put right option available to non -controlling shareholders.  \n \n", "original_text": "And we \ncontinue to believe that there's great value in our stock. "}, "hash": "2e0b1ebd4ead783ac5423df06892253a847de6990dc005f76044f67cb78ab87e", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nWe continue to execute at a high level, and we have confidence in the business today and in the future. ", "start_char_idx": 16, "end_char_idx": 287, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9dccbde3-4356-4ced-b5fa-3fea65e53640": {"__data__": {"id_": "9dccbde3-4356-4ced-b5fa-3fea65e53640", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nWe continue to execute at a high level, and we have confidence in the business today and in the future.  And we \ncontinue to believe that there's great value in our stock.  As indicated on slide 16, o ur fiscal 2022 outlook \nincorporates plans to repurchase approximately $2 billion of stock, which we expect will be more heavily weighted \nto the first half of the fiscal year.  \n \n As a result of this activity, we estimate weighted average diluted shares outsta nding for fiscal 2022 to be in the \nrange of approximately 153.5 million to 155.5 million.  We also anticipate use of cash to purchase shares in \nMcKesson Europe, through exercises of a put right option available to non -controlling shareholders.  \n \n", "original_text": "And we \ncontinue to believe that there's great value in our stock. ", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2f6785c986671ce0623f31884790d0e0d2d6a77b10e89f910169852a5d550d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b0f41af-ceb2-4c04-8abb-a46168f2cde8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nWe continue to execute at a high level, and we have confidence in the business today and in the future.  And we \ncontinue to believe that there's great value in our stock.  As indicated on slide 16, o ur fiscal 2022 outlook \nincorporates plans to repurchase approximately $2 billion of stock, which we expect will be more heavily weighted \nto the first half of the fiscal year.  \n \n As a result of this activity, we estimate weighted average diluted shares outsta nding for fiscal 2022 to be in the \nrange of approximately 153.5 million to 155.5 million. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nWe continue to execute at a high level, and we have confidence in the business today and in the future. ", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6396dd9396d858547b596747991c0e54bfcb643d310ee6bb59b52df274a4942f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc0e67ed-bc78-4ed0-8729-d60a430eef83", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nWe continue to execute at a high level, and we have confidence in the business today and in the future.  And we \ncontinue to believe that there's great value in our stock.  As indicated on slide 16, o ur fiscal 2022 outlook \nincorporates plans to repurchase approximately $2 billion of stock, which we expect will be more heavily weighted \nto the first half of the fiscal year.  \n \n As a result of this activity, we estimate weighted average diluted shares outsta nding for fiscal 2022 to be in the \nrange of approximately 153.5 million to 155.5 million.  We also anticipate use of cash to purchase shares in \nMcKesson Europe, through exercises of a put right option available to non -controlling shareholders.  \n \n As a reminder, McKesson originally acquired 77% of Celesio; the remaining non -controlling interest shareholders \nretained a put option for their shares. ", "original_text": "As indicated on slide 16, o ur fiscal 2022 outlook \nincorporates plans to repurchase approximately $2 billion of stock, which we expect will be more heavily weighted \nto the first half of the fiscal year.  \n \n"}, "hash": "517cb1370741f9f29d3670b3a28bf35d716bcf6a4e150e49efea46829298c590", "class_name": "RelatedNodeInfo"}}, "text": "And we \ncontinue to believe that there's great value in our stock. ", "start_char_idx": 287, "end_char_idx": 354, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc0e67ed-bc78-4ed0-8729-d60a430eef83": {"__data__": {"id_": "dc0e67ed-bc78-4ed0-8729-d60a430eef83", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nWe continue to execute at a high level, and we have confidence in the business today and in the future.  And we \ncontinue to believe that there's great value in our stock.  As indicated on slide 16, o ur fiscal 2022 outlook \nincorporates plans to repurchase approximately $2 billion of stock, which we expect will be more heavily weighted \nto the first half of the fiscal year.  \n \n As a result of this activity, we estimate weighted average diluted shares outsta nding for fiscal 2022 to be in the \nrange of approximately 153.5 million to 155.5 million.  We also anticipate use of cash to purchase shares in \nMcKesson Europe, through exercises of a put right option available to non -controlling shareholders.  \n \n As a reminder, McKesson originally acquired 77% of Celesio; the remaining non -controlling interest shareholders \nretained a put option for their shares. ", "original_text": "As indicated on slide 16, o ur fiscal 2022 outlook \nincorporates plans to repurchase approximately $2 billion of stock, which we expect will be more heavily weighted \nto the first half of the fiscal year.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2f6785c986671ce0623f31884790d0e0d2d6a77b10e89f910169852a5d550d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9dccbde3-4356-4ced-b5fa-3fea65e53640", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nWe continue to execute at a high level, and we have confidence in the business today and in the future.  And we \ncontinue to believe that there's great value in our stock.  As indicated on slide 16, o ur fiscal 2022 outlook \nincorporates plans to repurchase approximately $2 billion of stock, which we expect will be more heavily weighted \nto the first half of the fiscal year.  \n \n As a result of this activity, we estimate weighted average diluted shares outsta nding for fiscal 2022 to be in the \nrange of approximately 153.5 million to 155.5 million.  We also anticipate use of cash to purchase shares in \nMcKesson Europe, through exercises of a put right option available to non -controlling shareholders.  \n \n", "original_text": "And we \ncontinue to believe that there's great value in our stock. ", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b8cce1ac5aada7ae47d4bfb86fc3b6ba29c60be228c7cf00db98931444629e93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "790011c1-93bf-447e-8aa9-894ee270cae5", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nWe continue to execute at a high level, and we have confidence in the business today and in the future.  And we \ncontinue to believe that there's great value in our stock.  As indicated on slide 16, o ur fiscal 2022 outlook \nincorporates plans to repurchase approximately $2 billion of stock, which we expect will be more heavily weighted \nto the first half of the fiscal year.  \n \n As a result of this activity, we estimate weighted average diluted shares outsta nding for fiscal 2022 to be in the \nrange of approximately 153.5 million to 155.5 million.  We also anticipate use of cash to purchase shares in \nMcKesson Europe, through exercises of a put right option available to non -controlling shareholders.  \n \n As a reminder, McKesson originally acquired 77% of Celesio; the remaining non -controlling interest shareholders \nretained a put option for their shares.  The put right options of minority stakeholders expires in Q1 of fiscal 2022. \n", "original_text": "As a result of this activity, we estimate weighted average diluted shares outsta nding for fiscal 2022 to be in the \nrange of approximately 153.5 million to 155.5 million. "}, "hash": "a3e123abff664fc075793ad4117a1a5d9dd034ac18ba34a929ab139ff7e4264a", "class_name": "RelatedNodeInfo"}}, "text": "As indicated on slide 16, o ur fiscal 2022 outlook \nincorporates plans to repurchase approximately $2 billion of stock, which we expect will be more heavily weighted \nto the first half of the fiscal year.  \n \n", "start_char_idx": 354, "end_char_idx": 563, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "790011c1-93bf-447e-8aa9-894ee270cae5": {"__data__": {"id_": "790011c1-93bf-447e-8aa9-894ee270cae5", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nWe continue to execute at a high level, and we have confidence in the business today and in the future.  And we \ncontinue to believe that there's great value in our stock.  As indicated on slide 16, o ur fiscal 2022 outlook \nincorporates plans to repurchase approximately $2 billion of stock, which we expect will be more heavily weighted \nto the first half of the fiscal year.  \n \n As a result of this activity, we estimate weighted average diluted shares outsta nding for fiscal 2022 to be in the \nrange of approximately 153.5 million to 155.5 million.  We also anticipate use of cash to purchase shares in \nMcKesson Europe, through exercises of a put right option available to non -controlling shareholders.  \n \n As a reminder, McKesson originally acquired 77% of Celesio; the remaining non -controlling interest shareholders \nretained a put option for their shares.  The put right options of minority stakeholders expires in Q1 of fiscal 2022. \n", "original_text": "As a result of this activity, we estimate weighted average diluted shares outsta nding for fiscal 2022 to be in the \nrange of approximately 153.5 million to 155.5 million. ", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2f6785c986671ce0623f31884790d0e0d2d6a77b10e89f910169852a5d550d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc0e67ed-bc78-4ed0-8729-d60a430eef83", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nWe continue to execute at a high level, and we have confidence in the business today and in the future.  And we \ncontinue to believe that there's great value in our stock.  As indicated on slide 16, o ur fiscal 2022 outlook \nincorporates plans to repurchase approximately $2 billion of stock, which we expect will be more heavily weighted \nto the first half of the fiscal year.  \n \n As a result of this activity, we estimate weighted average diluted shares outsta nding for fiscal 2022 to be in the \nrange of approximately 153.5 million to 155.5 million.  We also anticipate use of cash to purchase shares in \nMcKesson Europe, through exercises of a put right option available to non -controlling shareholders.  \n \n As a reminder, McKesson originally acquired 77% of Celesio; the remaining non -controlling interest shareholders \nretained a put option for their shares. ", "original_text": "As indicated on slide 16, o ur fiscal 2022 outlook \nincorporates plans to repurchase approximately $2 billion of stock, which we expect will be more heavily weighted \nto the first half of the fiscal year.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ff2aa32a2d4fe626fb43994a1f13fd5a3925f49628effc61ccb71102323290a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19e70fac-31ab-43c3-83de-268588771c92", "node_type": "1", "metadata": {"window": "And we \ncontinue to believe that there's great value in our stock.  As indicated on slide 16, o ur fiscal 2022 outlook \nincorporates plans to repurchase approximately $2 billion of stock, which we expect will be more heavily weighted \nto the first half of the fiscal year.  \n \n As a result of this activity, we estimate weighted average diluted shares outsta nding for fiscal 2022 to be in the \nrange of approximately 153.5 million to 155.5 million.  We also anticipate use of cash to purchase shares in \nMcKesson Europe, through exercises of a put right option available to non -controlling shareholders.  \n \n As a reminder, McKesson originally acquired 77% of Celesio; the remaining non -controlling interest shareholders \nretained a put option for their shares.  The put right options of minority stakeholders expires in Q1 of fiscal 2022. \n We estimate that the remaining p ut right options could result in cash payments up to approximately $1.3 billion, \nwhich will be reflected in the financing activities section of our cash flow statement. ", "original_text": "We also anticipate use of cash to purchase shares in \nMcKesson Europe, through exercises of a put right option available to non -controlling shareholders.  \n \n"}, "hash": "f8b40cb12a68596b6e865621d716c725486875d43924f0cd3172241e313ae283", "class_name": "RelatedNodeInfo"}}, "text": "As a result of this activity, we estimate weighted average diluted shares outsta nding for fiscal 2022 to be in the \nrange of approximately 153.5 million to 155.5 million. ", "start_char_idx": 563, "end_char_idx": 735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19e70fac-31ab-43c3-83de-268588771c92": {"__data__": {"id_": "19e70fac-31ab-43c3-83de-268588771c92", "embedding": null, "metadata": {"window": "And we \ncontinue to believe that there's great value in our stock.  As indicated on slide 16, o ur fiscal 2022 outlook \nincorporates plans to repurchase approximately $2 billion of stock, which we expect will be more heavily weighted \nto the first half of the fiscal year.  \n \n As a result of this activity, we estimate weighted average diluted shares outsta nding for fiscal 2022 to be in the \nrange of approximately 153.5 million to 155.5 million.  We also anticipate use of cash to purchase shares in \nMcKesson Europe, through exercises of a put right option available to non -controlling shareholders.  \n \n As a reminder, McKesson originally acquired 77% of Celesio; the remaining non -controlling interest shareholders \nretained a put option for their shares.  The put right options of minority stakeholders expires in Q1 of fiscal 2022. \n We estimate that the remaining p ut right options could result in cash payments up to approximately $1.3 billion, \nwhich will be reflected in the financing activities section of our cash flow statement. ", "original_text": "We also anticipate use of cash to purchase shares in \nMcKesson Europe, through exercises of a put right option available to non -controlling shareholders.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2f6785c986671ce0623f31884790d0e0d2d6a77b10e89f910169852a5d550d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "790011c1-93bf-447e-8aa9-894ee270cae5", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nWe continue to execute at a high level, and we have confidence in the business today and in the future.  And we \ncontinue to believe that there's great value in our stock.  As indicated on slide 16, o ur fiscal 2022 outlook \nincorporates plans to repurchase approximately $2 billion of stock, which we expect will be more heavily weighted \nto the first half of the fiscal year.  \n \n As a result of this activity, we estimate weighted average diluted shares outsta nding for fiscal 2022 to be in the \nrange of approximately 153.5 million to 155.5 million.  We also anticipate use of cash to purchase shares in \nMcKesson Europe, through exercises of a put right option available to non -controlling shareholders.  \n \n As a reminder, McKesson originally acquired 77% of Celesio; the remaining non -controlling interest shareholders \nretained a put option for their shares.  The put right options of minority stakeholders expires in Q1 of fiscal 2022. \n", "original_text": "As a result of this activity, we estimate weighted average diluted shares outsta nding for fiscal 2022 to be in the \nrange of approximately 153.5 million to 155.5 million. ", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a9b8ad69159b37fab8f958bb0e551249bf4c9af869b599a4a20d71dff97d52e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5786cf50-b82a-404a-bdb2-3caefd7899b7", "node_type": "1", "metadata": {"window": "As indicated on slide 16, o ur fiscal 2022 outlook \nincorporates plans to repurchase approximately $2 billion of stock, which we expect will be more heavily weighted \nto the first half of the fiscal year.  \n \n As a result of this activity, we estimate weighted average diluted shares outsta nding for fiscal 2022 to be in the \nrange of approximately 153.5 million to 155.5 million.  We also anticipate use of cash to purchase shares in \nMcKesson Europe, through exercises of a put right option available to non -controlling shareholders.  \n \n As a reminder, McKesson originally acquired 77% of Celesio; the remaining non -controlling interest shareholders \nretained a put option for their shares.  The put right options of minority stakeholders expires in Q1 of fiscal 2022. \n We estimate that the remaining p ut right options could result in cash payments up to approximately $1.3 billion, \nwhich will be reflected in the financing activities section of our cash flow statement.  During fiscal 2021, McKesson \nused $49 million of cash for exercise of these put right o ptions.  \n \n", "original_text": "As a reminder, McKesson originally acquired 77% of Celesio; the remaining non -controlling interest shareholders \nretained a put option for their shares. "}, "hash": "b6f520a936ff6090e9b8a17ce07d5bdc4408f098b21fc60a0c85365e614eed5a", "class_name": "RelatedNodeInfo"}}, "text": "We also anticipate use of cash to purchase shares in \nMcKesson Europe, through exercises of a put right option available to non -controlling shareholders.  \n \n", "start_char_idx": 735, "end_char_idx": 894, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5786cf50-b82a-404a-bdb2-3caefd7899b7": {"__data__": {"id_": "5786cf50-b82a-404a-bdb2-3caefd7899b7", "embedding": null, "metadata": {"window": "As indicated on slide 16, o ur fiscal 2022 outlook \nincorporates plans to repurchase approximately $2 billion of stock, which we expect will be more heavily weighted \nto the first half of the fiscal year.  \n \n As a result of this activity, we estimate weighted average diluted shares outsta nding for fiscal 2022 to be in the \nrange of approximately 153.5 million to 155.5 million.  We also anticipate use of cash to purchase shares in \nMcKesson Europe, through exercises of a put right option available to non -controlling shareholders.  \n \n As a reminder, McKesson originally acquired 77% of Celesio; the remaining non -controlling interest shareholders \nretained a put option for their shares.  The put right options of minority stakeholders expires in Q1 of fiscal 2022. \n We estimate that the remaining p ut right options could result in cash payments up to approximately $1.3 billion, \nwhich will be reflected in the financing activities section of our cash flow statement.  During fiscal 2021, McKesson \nused $49 million of cash for exercise of these put right o ptions.  \n \n", "original_text": "As a reminder, McKesson originally acquired 77% of Celesio; the remaining non -controlling interest shareholders \nretained a put option for their shares. ", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2f6785c986671ce0623f31884790d0e0d2d6a77b10e89f910169852a5d550d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19e70fac-31ab-43c3-83de-268588771c92", "node_type": "1", "metadata": {"window": "And we \ncontinue to believe that there's great value in our stock.  As indicated on slide 16, o ur fiscal 2022 outlook \nincorporates plans to repurchase approximately $2 billion of stock, which we expect will be more heavily weighted \nto the first half of the fiscal year.  \n \n As a result of this activity, we estimate weighted average diluted shares outsta nding for fiscal 2022 to be in the \nrange of approximately 153.5 million to 155.5 million.  We also anticipate use of cash to purchase shares in \nMcKesson Europe, through exercises of a put right option available to non -controlling shareholders.  \n \n As a reminder, McKesson originally acquired 77% of Celesio; the remaining non -controlling interest shareholders \nretained a put option for their shares.  The put right options of minority stakeholders expires in Q1 of fiscal 2022. \n We estimate that the remaining p ut right options could result in cash payments up to approximately $1.3 billion, \nwhich will be reflected in the financing activities section of our cash flow statement. ", "original_text": "We also anticipate use of cash to purchase shares in \nMcKesson Europe, through exercises of a put right option available to non -controlling shareholders.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49a33fe31cf8a81eaee0c851b17d4d09cf606b6f862a05d2717190b00354d8f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4dc82ef6-00aa-485c-b824-3ae2322c5db6", "node_type": "1", "metadata": {"window": "As a result of this activity, we estimate weighted average diluted shares outsta nding for fiscal 2022 to be in the \nrange of approximately 153.5 million to 155.5 million.  We also anticipate use of cash to purchase shares in \nMcKesson Europe, through exercises of a put right option available to non -controlling shareholders.  \n \n As a reminder, McKesson originally acquired 77% of Celesio; the remaining non -controlling interest shareholders \nretained a put option for their shares.  The put right options of minority stakeholders expires in Q1 of fiscal 2022. \n We estimate that the remaining p ut right options could result in cash payments up to approximately $1.3 billion, \nwhich will be reflected in the financing activities section of our cash flow statement.  During fiscal 2021, McKesson \nused $49 million of cash for exercise of these put right o ptions.  \n \n In fiscal 2021, we delivered strong performance in an unprecedented environment, and we capped off our three -\nyear operating model transformation, setting the stage for an acceleration of growth. ", "original_text": "The put right options of minority stakeholders expires in Q1 of fiscal 2022. \n"}, "hash": "7a136d3be65b6c57ad98b40cbaa24e604ed3c35908bed9c2d9465febfd53e1b9", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, McKesson originally acquired 77% of Celesio; the remaining non -controlling interest shareholders \nretained a put option for their shares. ", "start_char_idx": 894, "end_char_idx": 1048, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4dc82ef6-00aa-485c-b824-3ae2322c5db6": {"__data__": {"id_": "4dc82ef6-00aa-485c-b824-3ae2322c5db6", "embedding": null, "metadata": {"window": "As a result of this activity, we estimate weighted average diluted shares outsta nding for fiscal 2022 to be in the \nrange of approximately 153.5 million to 155.5 million.  We also anticipate use of cash to purchase shares in \nMcKesson Europe, through exercises of a put right option available to non -controlling shareholders.  \n \n As a reminder, McKesson originally acquired 77% of Celesio; the remaining non -controlling interest shareholders \nretained a put option for their shares.  The put right options of minority stakeholders expires in Q1 of fiscal 2022. \n We estimate that the remaining p ut right options could result in cash payments up to approximately $1.3 billion, \nwhich will be reflected in the financing activities section of our cash flow statement.  During fiscal 2021, McKesson \nused $49 million of cash for exercise of these put right o ptions.  \n \n In fiscal 2021, we delivered strong performance in an unprecedented environment, and we capped off our three -\nyear operating model transformation, setting the stage for an acceleration of growth. ", "original_text": "The put right options of minority stakeholders expires in Q1 of fiscal 2022. \n", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2f6785c986671ce0623f31884790d0e0d2d6a77b10e89f910169852a5d550d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5786cf50-b82a-404a-bdb2-3caefd7899b7", "node_type": "1", "metadata": {"window": "As indicated on slide 16, o ur fiscal 2022 outlook \nincorporates plans to repurchase approximately $2 billion of stock, which we expect will be more heavily weighted \nto the first half of the fiscal year.  \n \n As a result of this activity, we estimate weighted average diluted shares outsta nding for fiscal 2022 to be in the \nrange of approximately 153.5 million to 155.5 million.  We also anticipate use of cash to purchase shares in \nMcKesson Europe, through exercises of a put right option available to non -controlling shareholders.  \n \n As a reminder, McKesson originally acquired 77% of Celesio; the remaining non -controlling interest shareholders \nretained a put option for their shares.  The put right options of minority stakeholders expires in Q1 of fiscal 2022. \n We estimate that the remaining p ut right options could result in cash payments up to approximately $1.3 billion, \nwhich will be reflected in the financing activities section of our cash flow statement.  During fiscal 2021, McKesson \nused $49 million of cash for exercise of these put right o ptions.  \n \n", "original_text": "As a reminder, McKesson originally acquired 77% of Celesio; the remaining non -controlling interest shareholders \nretained a put option for their shares. ", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25e107e93ffc7c7e989d09141e13276cf68983a860d1ab35ca58dbb2d4d163b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9e69df4-953d-46a8-8033-6545f4d478ec", "node_type": "1", "metadata": {"window": "We also anticipate use of cash to purchase shares in \nMcKesson Europe, through exercises of a put right option available to non -controlling shareholders.  \n \n As a reminder, McKesson originally acquired 77% of Celesio; the remaining non -controlling interest shareholders \nretained a put option for their shares.  The put right options of minority stakeholders expires in Q1 of fiscal 2022. \n We estimate that the remaining p ut right options could result in cash payments up to approximately $1.3 billion, \nwhich will be reflected in the financing activities section of our cash flow statement.  During fiscal 2021, McKesson \nused $49 million of cash for exercise of these put right o ptions.  \n \n In fiscal 2021, we delivered strong performance in an unprecedented environment, and we capped off our three -\nyear operating model transformation, setting the stage for an acceleration of growth.  We look forward to \ncontinuing our role in the pandem ic response by distributing COVID -19 vaccine and ancillary supply kits, as we \ncontinue our leadership role in the pandemic response.  \n \n", "original_text": "We estimate that the remaining p ut right options could result in cash payments up to approximately $1.3 billion, \nwhich will be reflected in the financing activities section of our cash flow statement. "}, "hash": "cde2dc658bb37a95018eb258a7b6e40068b13ba8be7dbbf69705db9df614bb1e", "class_name": "RelatedNodeInfo"}}, "text": "The put right options of minority stakeholders expires in Q1 of fiscal 2022. \n", "start_char_idx": 1048, "end_char_idx": 1126, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9e69df4-953d-46a8-8033-6545f4d478ec": {"__data__": {"id_": "c9e69df4-953d-46a8-8033-6545f4d478ec", "embedding": null, "metadata": {"window": "We also anticipate use of cash to purchase shares in \nMcKesson Europe, through exercises of a put right option available to non -controlling shareholders.  \n \n As a reminder, McKesson originally acquired 77% of Celesio; the remaining non -controlling interest shareholders \nretained a put option for their shares.  The put right options of minority stakeholders expires in Q1 of fiscal 2022. \n We estimate that the remaining p ut right options could result in cash payments up to approximately $1.3 billion, \nwhich will be reflected in the financing activities section of our cash flow statement.  During fiscal 2021, McKesson \nused $49 million of cash for exercise of these put right o ptions.  \n \n In fiscal 2021, we delivered strong performance in an unprecedented environment, and we capped off our three -\nyear operating model transformation, setting the stage for an acceleration of growth.  We look forward to \ncontinuing our role in the pandem ic response by distributing COVID -19 vaccine and ancillary supply kits, as we \ncontinue our leadership role in the pandemic response.  \n \n", "original_text": "We estimate that the remaining p ut right options could result in cash payments up to approximately $1.3 billion, \nwhich will be reflected in the financing activities section of our cash flow statement. ", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2f6785c986671ce0623f31884790d0e0d2d6a77b10e89f910169852a5d550d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4dc82ef6-00aa-485c-b824-3ae2322c5db6", "node_type": "1", "metadata": {"window": "As a result of this activity, we estimate weighted average diluted shares outsta nding for fiscal 2022 to be in the \nrange of approximately 153.5 million to 155.5 million.  We also anticipate use of cash to purchase shares in \nMcKesson Europe, through exercises of a put right option available to non -controlling shareholders.  \n \n As a reminder, McKesson originally acquired 77% of Celesio; the remaining non -controlling interest shareholders \nretained a put option for their shares.  The put right options of minority stakeholders expires in Q1 of fiscal 2022. \n We estimate that the remaining p ut right options could result in cash payments up to approximately $1.3 billion, \nwhich will be reflected in the financing activities section of our cash flow statement.  During fiscal 2021, McKesson \nused $49 million of cash for exercise of these put right o ptions.  \n \n In fiscal 2021, we delivered strong performance in an unprecedented environment, and we capped off our three -\nyear operating model transformation, setting the stage for an acceleration of growth. ", "original_text": "The put right options of minority stakeholders expires in Q1 of fiscal 2022. \n", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7891b47d027c9dc9e3c23300866a1e5d99248b6dac1a504cec831cb75592b3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77caddce-39bb-4c4c-b5fd-8a37e3b3dd26", "node_type": "1", "metadata": {"window": "As a reminder, McKesson originally acquired 77% of Celesio; the remaining non -controlling interest shareholders \nretained a put option for their shares.  The put right options of minority stakeholders expires in Q1 of fiscal 2022. \n We estimate that the remaining p ut right options could result in cash payments up to approximately $1.3 billion, \nwhich will be reflected in the financing activities section of our cash flow statement.  During fiscal 2021, McKesson \nused $49 million of cash for exercise of these put right o ptions.  \n \n In fiscal 2021, we delivered strong performance in an unprecedented environment, and we capped off our three -\nyear operating model transformation, setting the stage for an acceleration of growth.  We look forward to \ncontinuing our role in the pandem ic response by distributing COVID -19 vaccine and ancillary supply kits, as we \ncontinue our leadership role in the pandemic response.  \n \n Our outlook for fiscal 2022 reflects the continued confidence in our operating momentum with growth across all \nsegments of  the business, supported by the strength of our balance sheet and strong financial position.  \n \n", "original_text": "During fiscal 2021, McKesson \nused $49 million of cash for exercise of these put right o ptions.  \n \n"}, "hash": "40ddf197bcec0130dc8c7202cad4fc4039063f13c042f300f5d2bdd57876a03c", "class_name": "RelatedNodeInfo"}}, "text": "We estimate that the remaining p ut right options could result in cash payments up to approximately $1.3 billion, \nwhich will be reflected in the financing activities section of our cash flow statement. ", "start_char_idx": 1126, "end_char_idx": 1329, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77caddce-39bb-4c4c-b5fd-8a37e3b3dd26": {"__data__": {"id_": "77caddce-39bb-4c4c-b5fd-8a37e3b3dd26", "embedding": null, "metadata": {"window": "As a reminder, McKesson originally acquired 77% of Celesio; the remaining non -controlling interest shareholders \nretained a put option for their shares.  The put right options of minority stakeholders expires in Q1 of fiscal 2022. \n We estimate that the remaining p ut right options could result in cash payments up to approximately $1.3 billion, \nwhich will be reflected in the financing activities section of our cash flow statement.  During fiscal 2021, McKesson \nused $49 million of cash for exercise of these put right o ptions.  \n \n In fiscal 2021, we delivered strong performance in an unprecedented environment, and we capped off our three -\nyear operating model transformation, setting the stage for an acceleration of growth.  We look forward to \ncontinuing our role in the pandem ic response by distributing COVID -19 vaccine and ancillary supply kits, as we \ncontinue our leadership role in the pandemic response.  \n \n Our outlook for fiscal 2022 reflects the continued confidence in our operating momentum with growth across all \nsegments of  the business, supported by the strength of our balance sheet and strong financial position.  \n \n", "original_text": "During fiscal 2021, McKesson \nused $49 million of cash for exercise of these put right o ptions.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2f6785c986671ce0623f31884790d0e0d2d6a77b10e89f910169852a5d550d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9e69df4-953d-46a8-8033-6545f4d478ec", "node_type": "1", "metadata": {"window": "We also anticipate use of cash to purchase shares in \nMcKesson Europe, through exercises of a put right option available to non -controlling shareholders.  \n \n As a reminder, McKesson originally acquired 77% of Celesio; the remaining non -controlling interest shareholders \nretained a put option for their shares.  The put right options of minority stakeholders expires in Q1 of fiscal 2022. \n We estimate that the remaining p ut right options could result in cash payments up to approximately $1.3 billion, \nwhich will be reflected in the financing activities section of our cash flow statement.  During fiscal 2021, McKesson \nused $49 million of cash for exercise of these put right o ptions.  \n \n In fiscal 2021, we delivered strong performance in an unprecedented environment, and we capped off our three -\nyear operating model transformation, setting the stage for an acceleration of growth.  We look forward to \ncontinuing our role in the pandem ic response by distributing COVID -19 vaccine and ancillary supply kits, as we \ncontinue our leadership role in the pandemic response.  \n \n", "original_text": "We estimate that the remaining p ut right options could result in cash payments up to approximately $1.3 billion, \nwhich will be reflected in the financing activities section of our cash flow statement. ", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b11f850aca592bb325246355183ea2a446c43f267516122843c6140647a96f17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e69bf5d2-ee14-4579-b9ce-a6d7a0bbe44c", "node_type": "1", "metadata": {"window": "The put right options of minority stakeholders expires in Q1 of fiscal 2022. \n We estimate that the remaining p ut right options could result in cash payments up to approximately $1.3 billion, \nwhich will be reflected in the financing activities section of our cash flow statement.  During fiscal 2021, McKesson \nused $49 million of cash for exercise of these put right o ptions.  \n \n In fiscal 2021, we delivered strong performance in an unprecedented environment, and we capped off our three -\nyear operating model transformation, setting the stage for an acceleration of growth.  We look forward to \ncontinuing our role in the pandem ic response by distributing COVID -19 vaccine and ancillary supply kits, as we \ncontinue our leadership role in the pandemic response.  \n \n Our outlook for fiscal 2022 reflects the continued confidence in our operating momentum with growth across all \nsegments of  the business, supported by the strength of our balance sheet and strong financial position.  \n \n We will continue to invest in our strategies of oncology and biopharma services as we build out our connected \necosystems in these growth areas, delivering value t o our customers and partners. ", "original_text": "In fiscal 2021, we delivered strong performance in an unprecedented environment, and we capped off our three -\nyear operating model transformation, setting the stage for an acceleration of growth. "}, "hash": "c1aed7d115fa070ab4e12a00e3785dead43345e0cb16aac354d4a72748a496c6", "class_name": "RelatedNodeInfo"}}, "text": "During fiscal 2021, McKesson \nused $49 million of cash for exercise of these put right o ptions.  \n \n", "start_char_idx": 1329, "end_char_idx": 1430, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e69bf5d2-ee14-4579-b9ce-a6d7a0bbe44c": {"__data__": {"id_": "e69bf5d2-ee14-4579-b9ce-a6d7a0bbe44c", "embedding": null, "metadata": {"window": "The put right options of minority stakeholders expires in Q1 of fiscal 2022. \n We estimate that the remaining p ut right options could result in cash payments up to approximately $1.3 billion, \nwhich will be reflected in the financing activities section of our cash flow statement.  During fiscal 2021, McKesson \nused $49 million of cash for exercise of these put right o ptions.  \n \n In fiscal 2021, we delivered strong performance in an unprecedented environment, and we capped off our three -\nyear operating model transformation, setting the stage for an acceleration of growth.  We look forward to \ncontinuing our role in the pandem ic response by distributing COVID -19 vaccine and ancillary supply kits, as we \ncontinue our leadership role in the pandemic response.  \n \n Our outlook for fiscal 2022 reflects the continued confidence in our operating momentum with growth across all \nsegments of  the business, supported by the strength of our balance sheet and strong financial position.  \n \n We will continue to invest in our strategies of oncology and biopharma services as we build out our connected \necosystems in these growth areas, delivering value t o our customers and partners. ", "original_text": "In fiscal 2021, we delivered strong performance in an unprecedented environment, and we capped off our three -\nyear operating model transformation, setting the stage for an acceleration of growth. ", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2f6785c986671ce0623f31884790d0e0d2d6a77b10e89f910169852a5d550d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77caddce-39bb-4c4c-b5fd-8a37e3b3dd26", "node_type": "1", "metadata": {"window": "As a reminder, McKesson originally acquired 77% of Celesio; the remaining non -controlling interest shareholders \nretained a put option for their shares.  The put right options of minority stakeholders expires in Q1 of fiscal 2022. \n We estimate that the remaining p ut right options could result in cash payments up to approximately $1.3 billion, \nwhich will be reflected in the financing activities section of our cash flow statement.  During fiscal 2021, McKesson \nused $49 million of cash for exercise of these put right o ptions.  \n \n In fiscal 2021, we delivered strong performance in an unprecedented environment, and we capped off our three -\nyear operating model transformation, setting the stage for an acceleration of growth.  We look forward to \ncontinuing our role in the pandem ic response by distributing COVID -19 vaccine and ancillary supply kits, as we \ncontinue our leadership role in the pandemic response.  \n \n Our outlook for fiscal 2022 reflects the continued confidence in our operating momentum with growth across all \nsegments of  the business, supported by the strength of our balance sheet and strong financial position.  \n \n", "original_text": "During fiscal 2021, McKesson \nused $49 million of cash for exercise of these put right o ptions.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "788e5082a44ca1143c0a8d284cbb3e4d0d269223550086605e2bf521fb7521c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "606be6f0-6817-4272-94cc-6a73485bdf72", "node_type": "1", "metadata": {"window": "We estimate that the remaining p ut right options could result in cash payments up to approximately $1.3 billion, \nwhich will be reflected in the financing activities section of our cash flow statement.  During fiscal 2021, McKesson \nused $49 million of cash for exercise of these put right o ptions.  \n \n In fiscal 2021, we delivered strong performance in an unprecedented environment, and we capped off our three -\nyear operating model transformation, setting the stage for an acceleration of growth.  We look forward to \ncontinuing our role in the pandem ic response by distributing COVID -19 vaccine and ancillary supply kits, as we \ncontinue our leadership role in the pandemic response.  \n \n Our outlook for fiscal 2022 reflects the continued confidence in our operating momentum with growth across all \nsegments of  the business, supported by the strength of our balance sheet and strong financial position.  \n \n We will continue to invest in our strategies of oncology and biopharma services as we build out our connected \necosystems in these growth areas, delivering value t o our customers and partners.  We're confident in our ability \nto leverage our position and capabilities to accelerate growth.  \n \n", "original_text": "We look forward to \ncontinuing our role in the pandem ic response by distributing COVID -19 vaccine and ancillary supply kits, as we \ncontinue our leadership role in the pandemic response.  \n \n"}, "hash": "d9e90579903cdd2cbb9246a0df30aba561add20110fce360d5ecbc66bf0f284f", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal 2021, we delivered strong performance in an unprecedented environment, and we capped off our three -\nyear operating model transformation, setting the stage for an acceleration of growth. ", "start_char_idx": 1430, "end_char_idx": 1627, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "606be6f0-6817-4272-94cc-6a73485bdf72": {"__data__": {"id_": "606be6f0-6817-4272-94cc-6a73485bdf72", "embedding": null, "metadata": {"window": "We estimate that the remaining p ut right options could result in cash payments up to approximately $1.3 billion, \nwhich will be reflected in the financing activities section of our cash flow statement.  During fiscal 2021, McKesson \nused $49 million of cash for exercise of these put right o ptions.  \n \n In fiscal 2021, we delivered strong performance in an unprecedented environment, and we capped off our three -\nyear operating model transformation, setting the stage for an acceleration of growth.  We look forward to \ncontinuing our role in the pandem ic response by distributing COVID -19 vaccine and ancillary supply kits, as we \ncontinue our leadership role in the pandemic response.  \n \n Our outlook for fiscal 2022 reflects the continued confidence in our operating momentum with growth across all \nsegments of  the business, supported by the strength of our balance sheet and strong financial position.  \n \n We will continue to invest in our strategies of oncology and biopharma services as we build out our connected \necosystems in these growth areas, delivering value t o our customers and partners.  We're confident in our ability \nto leverage our position and capabilities to accelerate growth.  \n \n", "original_text": "We look forward to \ncontinuing our role in the pandem ic response by distributing COVID -19 vaccine and ancillary supply kits, as we \ncontinue our leadership role in the pandemic response.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2f6785c986671ce0623f31884790d0e0d2d6a77b10e89f910169852a5d550d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e69bf5d2-ee14-4579-b9ce-a6d7a0bbe44c", "node_type": "1", "metadata": {"window": "The put right options of minority stakeholders expires in Q1 of fiscal 2022. \n We estimate that the remaining p ut right options could result in cash payments up to approximately $1.3 billion, \nwhich will be reflected in the financing activities section of our cash flow statement.  During fiscal 2021, McKesson \nused $49 million of cash for exercise of these put right o ptions.  \n \n In fiscal 2021, we delivered strong performance in an unprecedented environment, and we capped off our three -\nyear operating model transformation, setting the stage for an acceleration of growth.  We look forward to \ncontinuing our role in the pandem ic response by distributing COVID -19 vaccine and ancillary supply kits, as we \ncontinue our leadership role in the pandemic response.  \n \n Our outlook for fiscal 2022 reflects the continued confidence in our operating momentum with growth across all \nsegments of  the business, supported by the strength of our balance sheet and strong financial position.  \n \n We will continue to invest in our strategies of oncology and biopharma services as we build out our connected \necosystems in these growth areas, delivering value t o our customers and partners. ", "original_text": "In fiscal 2021, we delivered strong performance in an unprecedented environment, and we capped off our three -\nyear operating model transformation, setting the stage for an acceleration of growth. ", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00f18e6b7830fd841631f00ecf13f18974597490a017a7252a6252775a3299a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "acf82775-cb72-4a4b-b87b-cb6d4dcaf039", "node_type": "1", "metadata": {"window": "During fiscal 2021, McKesson \nused $49 million of cash for exercise of these put right o ptions.  \n \n In fiscal 2021, we delivered strong performance in an unprecedented environment, and we capped off our three -\nyear operating model transformation, setting the stage for an acceleration of growth.  We look forward to \ncontinuing our role in the pandem ic response by distributing COVID -19 vaccine and ancillary supply kits, as we \ncontinue our leadership role in the pandemic response.  \n \n Our outlook for fiscal 2022 reflects the continued confidence in our operating momentum with growth across all \nsegments of  the business, supported by the strength of our balance sheet and strong financial position.  \n \n We will continue to invest in our strategies of oncology and biopharma services as we build out our connected \necosystems in these growth areas, delivering value t o our customers and partners.  We're confident in our ability \nto leverage our position and capabilities to accelerate growth.  \n \n In closing, I'd like to acknowledge and thank all the McKesson associates across the world for their dedication, \nexecution and unr elenting commitment to our customers and patients. ", "original_text": "Our outlook for fiscal 2022 reflects the continued confidence in our operating momentum with growth across all \nsegments of  the business, supported by the strength of our balance sheet and strong financial position.  \n \n"}, "hash": "024825c91e05e1275db97702b7bec50238dcfa75dca521fbc08cd60b098cacf9", "class_name": "RelatedNodeInfo"}}, "text": "We look forward to \ncontinuing our role in the pandem ic response by distributing COVID -19 vaccine and ancillary supply kits, as we \ncontinue our leadership role in the pandemic response.  \n \n", "start_char_idx": 1627, "end_char_idx": 1820, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "acf82775-cb72-4a4b-b87b-cb6d4dcaf039": {"__data__": {"id_": "acf82775-cb72-4a4b-b87b-cb6d4dcaf039", "embedding": null, "metadata": {"window": "During fiscal 2021, McKesson \nused $49 million of cash for exercise of these put right o ptions.  \n \n In fiscal 2021, we delivered strong performance in an unprecedented environment, and we capped off our three -\nyear operating model transformation, setting the stage for an acceleration of growth.  We look forward to \ncontinuing our role in the pandem ic response by distributing COVID -19 vaccine and ancillary supply kits, as we \ncontinue our leadership role in the pandemic response.  \n \n Our outlook for fiscal 2022 reflects the continued confidence in our operating momentum with growth across all \nsegments of  the business, supported by the strength of our balance sheet and strong financial position.  \n \n We will continue to invest in our strategies of oncology and biopharma services as we build out our connected \necosystems in these growth areas, delivering value t o our customers and partners.  We're confident in our ability \nto leverage our position and capabilities to accelerate growth.  \n \n In closing, I'd like to acknowledge and thank all the McKesson associates across the world for their dedication, \nexecution and unr elenting commitment to our customers and patients. ", "original_text": "Our outlook for fiscal 2022 reflects the continued confidence in our operating momentum with growth across all \nsegments of  the business, supported by the strength of our balance sheet and strong financial position.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2f6785c986671ce0623f31884790d0e0d2d6a77b10e89f910169852a5d550d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "606be6f0-6817-4272-94cc-6a73485bdf72", "node_type": "1", "metadata": {"window": "We estimate that the remaining p ut right options could result in cash payments up to approximately $1.3 billion, \nwhich will be reflected in the financing activities section of our cash flow statement.  During fiscal 2021, McKesson \nused $49 million of cash for exercise of these put right o ptions.  \n \n In fiscal 2021, we delivered strong performance in an unprecedented environment, and we capped off our three -\nyear operating model transformation, setting the stage for an acceleration of growth.  We look forward to \ncontinuing our role in the pandem ic response by distributing COVID -19 vaccine and ancillary supply kits, as we \ncontinue our leadership role in the pandemic response.  \n \n Our outlook for fiscal 2022 reflects the continued confidence in our operating momentum with growth across all \nsegments of  the business, supported by the strength of our balance sheet and strong financial position.  \n \n We will continue to invest in our strategies of oncology and biopharma services as we build out our connected \necosystems in these growth areas, delivering value t o our customers and partners.  We're confident in our ability \nto leverage our position and capabilities to accelerate growth.  \n \n", "original_text": "We look forward to \ncontinuing our role in the pandem ic response by distributing COVID -19 vaccine and ancillary supply kits, as we \ncontinue our leadership role in the pandemic response.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "86b08bb45daf5ddb650bb99ba3a046f906e7f1acc9d178a5e9b3214038cf97e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65e3ded5-5009-4bc5-9236-03ac7ac9bb97", "node_type": "1", "metadata": {"window": "In fiscal 2021, we delivered strong performance in an unprecedented environment, and we capped off our three -\nyear operating model transformation, setting the stage for an acceleration of growth.  We look forward to \ncontinuing our role in the pandem ic response by distributing COVID -19 vaccine and ancillary supply kits, as we \ncontinue our leadership role in the pandemic response.  \n \n Our outlook for fiscal 2022 reflects the continued confidence in our operating momentum with growth across all \nsegments of  the business, supported by the strength of our balance sheet and strong financial position.  \n \n We will continue to invest in our strategies of oncology and biopharma services as we build out our connected \necosystems in these growth areas, delivering value t o our customers and partners.  We're confident in our ability \nto leverage our position and capabilities to accelerate growth.  \n \n In closing, I'd like to acknowledge and thank all the McKesson associates across the world for their dedication, \nexecution and unr elenting commitment to our customers and patients.  The results we achieved this year could not \nhave been possible if not for the dedication of team McKesson. ", "original_text": "We will continue to invest in our strategies of oncology and biopharma services as we build out our connected \necosystems in these growth areas, delivering value t o our customers and partners. "}, "hash": "46b24e9ae6d95c5d26c2cd05fc0e6baa00bde86f3de8ff1d0c2c6ce2b6c52b6a", "class_name": "RelatedNodeInfo"}}, "text": "Our outlook for fiscal 2022 reflects the continued confidence in our operating momentum with growth across all \nsegments of  the business, supported by the strength of our balance sheet and strong financial position.  \n \n", "start_char_idx": 1820, "end_char_idx": 2041, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65e3ded5-5009-4bc5-9236-03ac7ac9bb97": {"__data__": {"id_": "65e3ded5-5009-4bc5-9236-03ac7ac9bb97", "embedding": null, "metadata": {"window": "In fiscal 2021, we delivered strong performance in an unprecedented environment, and we capped off our three -\nyear operating model transformation, setting the stage for an acceleration of growth.  We look forward to \ncontinuing our role in the pandem ic response by distributing COVID -19 vaccine and ancillary supply kits, as we \ncontinue our leadership role in the pandemic response.  \n \n Our outlook for fiscal 2022 reflects the continued confidence in our operating momentum with growth across all \nsegments of  the business, supported by the strength of our balance sheet and strong financial position.  \n \n We will continue to invest in our strategies of oncology and biopharma services as we build out our connected \necosystems in these growth areas, delivering value t o our customers and partners.  We're confident in our ability \nto leverage our position and capabilities to accelerate growth.  \n \n In closing, I'd like to acknowledge and thank all the McKesson associates across the world for their dedication, \nexecution and unr elenting commitment to our customers and patients.  The results we achieved this year could not \nhave been possible if not for the dedication of team McKesson. ", "original_text": "We will continue to invest in our strategies of oncology and biopharma services as we build out our connected \necosystems in these growth areas, delivering value t o our customers and partners. ", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2f6785c986671ce0623f31884790d0e0d2d6a77b10e89f910169852a5d550d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "acf82775-cb72-4a4b-b87b-cb6d4dcaf039", "node_type": "1", "metadata": {"window": "During fiscal 2021, McKesson \nused $49 million of cash for exercise of these put right o ptions.  \n \n In fiscal 2021, we delivered strong performance in an unprecedented environment, and we capped off our three -\nyear operating model transformation, setting the stage for an acceleration of growth.  We look forward to \ncontinuing our role in the pandem ic response by distributing COVID -19 vaccine and ancillary supply kits, as we \ncontinue our leadership role in the pandemic response.  \n \n Our outlook for fiscal 2022 reflects the continued confidence in our operating momentum with growth across all \nsegments of  the business, supported by the strength of our balance sheet and strong financial position.  \n \n We will continue to invest in our strategies of oncology and biopharma services as we build out our connected \necosystems in these growth areas, delivering value t o our customers and partners.  We're confident in our ability \nto leverage our position and capabilities to accelerate growth.  \n \n In closing, I'd like to acknowledge and thank all the McKesson associates across the world for their dedication, \nexecution and unr elenting commitment to our customers and patients. ", "original_text": "Our outlook for fiscal 2022 reflects the continued confidence in our operating momentum with growth across all \nsegments of  the business, supported by the strength of our balance sheet and strong financial position.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd4318e79e008ec83ae25df7e259a2472cc7219465f63097f5af1234edccac31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfc01c07-c2ef-41c8-b7ba-df4d0912f8b2", "node_type": "1", "metadata": {"window": "We look forward to \ncontinuing our role in the pandem ic response by distributing COVID -19 vaccine and ancillary supply kits, as we \ncontinue our leadership role in the pandemic response.  \n \n Our outlook for fiscal 2022 reflects the continued confidence in our operating momentum with growth across all \nsegments of  the business, supported by the strength of our balance sheet and strong financial position.  \n \n We will continue to invest in our strategies of oncology and biopharma services as we build out our connected \necosystems in these growth areas, delivering value t o our customers and partners.  We're confident in our ability \nto leverage our position and capabilities to accelerate growth.  \n \n In closing, I'd like to acknowledge and thank all the McKesson associates across the world for their dedication, \nexecution and unr elenting commitment to our customers and patients.  The results we achieved this year could not \nhave been possible if not for the dedication of team McKesson.  We're pleased with our results in fiscal 2021 and \nconfident in our outlook for fiscal 2022.  \n \n", "original_text": "We're confident in our ability \nto leverage our position and capabilities to accelerate growth.  \n \n"}, "hash": "eaa3b13856eeb90da0d4d83fd0fdba916287f7a889e45d2d6707a20b7e78081c", "class_name": "RelatedNodeInfo"}}, "text": "We will continue to invest in our strategies of oncology and biopharma services as we build out our connected \necosystems in these growth areas, delivering value t o our customers and partners. ", "start_char_idx": 2041, "end_char_idx": 2235, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfc01c07-c2ef-41c8-b7ba-df4d0912f8b2": {"__data__": {"id_": "dfc01c07-c2ef-41c8-b7ba-df4d0912f8b2", "embedding": null, "metadata": {"window": "We look forward to \ncontinuing our role in the pandem ic response by distributing COVID -19 vaccine and ancillary supply kits, as we \ncontinue our leadership role in the pandemic response.  \n \n Our outlook for fiscal 2022 reflects the continued confidence in our operating momentum with growth across all \nsegments of  the business, supported by the strength of our balance sheet and strong financial position.  \n \n We will continue to invest in our strategies of oncology and biopharma services as we build out our connected \necosystems in these growth areas, delivering value t o our customers and partners.  We're confident in our ability \nto leverage our position and capabilities to accelerate growth.  \n \n In closing, I'd like to acknowledge and thank all the McKesson associates across the world for their dedication, \nexecution and unr elenting commitment to our customers and patients.  The results we achieved this year could not \nhave been possible if not for the dedication of team McKesson.  We're pleased with our results in fiscal 2021 and \nconfident in our outlook for fiscal 2022.  \n \n", "original_text": "We're confident in our ability \nto leverage our position and capabilities to accelerate growth.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2f6785c986671ce0623f31884790d0e0d2d6a77b10e89f910169852a5d550d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65e3ded5-5009-4bc5-9236-03ac7ac9bb97", "node_type": "1", "metadata": {"window": "In fiscal 2021, we delivered strong performance in an unprecedented environment, and we capped off our three -\nyear operating model transformation, setting the stage for an acceleration of growth.  We look forward to \ncontinuing our role in the pandem ic response by distributing COVID -19 vaccine and ancillary supply kits, as we \ncontinue our leadership role in the pandemic response.  \n \n Our outlook for fiscal 2022 reflects the continued confidence in our operating momentum with growth across all \nsegments of  the business, supported by the strength of our balance sheet and strong financial position.  \n \n We will continue to invest in our strategies of oncology and biopharma services as we build out our connected \necosystems in these growth areas, delivering value t o our customers and partners.  We're confident in our ability \nto leverage our position and capabilities to accelerate growth.  \n \n In closing, I'd like to acknowledge and thank all the McKesson associates across the world for their dedication, \nexecution and unr elenting commitment to our customers and patients.  The results we achieved this year could not \nhave been possible if not for the dedication of team McKesson. ", "original_text": "We will continue to invest in our strategies of oncology and biopharma services as we build out our connected \necosystems in these growth areas, delivering value t o our customers and partners. ", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ab7f67cb4e4f5722d02856eec632e6bc456e116be30d0b1fc699083d61a5520", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8ce4a57-ac29-40e3-ad4e-fe53a241213f", "node_type": "1", "metadata": {"window": "Our outlook for fiscal 2022 reflects the continued confidence in our operating momentum with growth across all \nsegments of  the business, supported by the strength of our balance sheet and strong financial position.  \n \n We will continue to invest in our strategies of oncology and biopharma services as we build out our connected \necosystems in these growth areas, delivering value t o our customers and partners.  We're confident in our ability \nto leverage our position and capabilities to accelerate growth.  \n \n In closing, I'd like to acknowledge and thank all the McKesson associates across the world for their dedication, \nexecution and unr elenting commitment to our customers and patients.  The results we achieved this year could not \nhave been possible if not for the dedication of team McKesson.  We're pleased with our results in fiscal 2021 and \nconfident in our outlook for fiscal 2022.  \n \n And w ith that, Holly, let me turn the call back to you for Q&A.  \n ", "original_text": "In closing, I'd like to acknowledge and thank all the McKesson associates across the world for their dedication, \nexecution and unr elenting commitment to our customers and patients. "}, "hash": "c61cddd22df766bcb8a0e6262c6b30a5cf9ba31d8f9f914feb619b25a8f9013c", "class_name": "RelatedNodeInfo"}}, "text": "We're confident in our ability \nto leverage our position and capabilities to accelerate growth.  \n \n", "start_char_idx": 2235, "end_char_idx": 2335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8ce4a57-ac29-40e3-ad4e-fe53a241213f": {"__data__": {"id_": "d8ce4a57-ac29-40e3-ad4e-fe53a241213f", "embedding": null, "metadata": {"window": "Our outlook for fiscal 2022 reflects the continued confidence in our operating momentum with growth across all \nsegments of  the business, supported by the strength of our balance sheet and strong financial position.  \n \n We will continue to invest in our strategies of oncology and biopharma services as we build out our connected \necosystems in these growth areas, delivering value t o our customers and partners.  We're confident in our ability \nto leverage our position and capabilities to accelerate growth.  \n \n In closing, I'd like to acknowledge and thank all the McKesson associates across the world for their dedication, \nexecution and unr elenting commitment to our customers and patients.  The results we achieved this year could not \nhave been possible if not for the dedication of team McKesson.  We're pleased with our results in fiscal 2021 and \nconfident in our outlook for fiscal 2022.  \n \n And w ith that, Holly, let me turn the call back to you for Q&A.  \n ", "original_text": "In closing, I'd like to acknowledge and thank all the McKesson associates across the world for their dedication, \nexecution and unr elenting commitment to our customers and patients. ", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2f6785c986671ce0623f31884790d0e0d2d6a77b10e89f910169852a5d550d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfc01c07-c2ef-41c8-b7ba-df4d0912f8b2", "node_type": "1", "metadata": {"window": "We look forward to \ncontinuing our role in the pandem ic response by distributing COVID -19 vaccine and ancillary supply kits, as we \ncontinue our leadership role in the pandemic response.  \n \n Our outlook for fiscal 2022 reflects the continued confidence in our operating momentum with growth across all \nsegments of  the business, supported by the strength of our balance sheet and strong financial position.  \n \n We will continue to invest in our strategies of oncology and biopharma services as we build out our connected \necosystems in these growth areas, delivering value t o our customers and partners.  We're confident in our ability \nto leverage our position and capabilities to accelerate growth.  \n \n In closing, I'd like to acknowledge and thank all the McKesson associates across the world for their dedication, \nexecution and unr elenting commitment to our customers and patients.  The results we achieved this year could not \nhave been possible if not for the dedication of team McKesson.  We're pleased with our results in fiscal 2021 and \nconfident in our outlook for fiscal 2022.  \n \n", "original_text": "We're confident in our ability \nto leverage our position and capabilities to accelerate growth.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7491072ff0c48c46b6fcba542e138c93f98208be94f9f16f3e3af589a4342bb4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4a52ec3-914d-49bd-b062-7e327f994c45", "node_type": "1", "metadata": {"window": "We will continue to invest in our strategies of oncology and biopharma services as we build out our connected \necosystems in these growth areas, delivering value t o our customers and partners.  We're confident in our ability \nto leverage our position and capabilities to accelerate growth.  \n \n In closing, I'd like to acknowledge and thank all the McKesson associates across the world for their dedication, \nexecution and unr elenting commitment to our customers and patients.  The results we achieved this year could not \nhave been possible if not for the dedication of team McKesson.  We're pleased with our results in fiscal 2021 and \nconfident in our outlook for fiscal 2022.  \n \n And w ith that, Holly, let me turn the call back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "original_text": "The results we achieved this year could not \nhave been possible if not for the dedication of team McKesson. "}, "hash": "14581baef9f440670e4d9b31d4a2ec59cc219592a6e0e41f463ae93f1b1a0ced", "class_name": "RelatedNodeInfo"}}, "text": "In closing, I'd like to acknowledge and thank all the McKesson associates across the world for their dedication, \nexecution and unr elenting commitment to our customers and patients. ", "start_char_idx": 2335, "end_char_idx": 2518, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4a52ec3-914d-49bd-b062-7e327f994c45": {"__data__": {"id_": "a4a52ec3-914d-49bd-b062-7e327f994c45", "embedding": null, "metadata": {"window": "We will continue to invest in our strategies of oncology and biopharma services as we build out our connected \necosystems in these growth areas, delivering value t o our customers and partners.  We're confident in our ability \nto leverage our position and capabilities to accelerate growth.  \n \n In closing, I'd like to acknowledge and thank all the McKesson associates across the world for their dedication, \nexecution and unr elenting commitment to our customers and patients.  The results we achieved this year could not \nhave been possible if not for the dedication of team McKesson.  We're pleased with our results in fiscal 2021 and \nconfident in our outlook for fiscal 2022.  \n \n And w ith that, Holly, let me turn the call back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "original_text": "The results we achieved this year could not \nhave been possible if not for the dedication of team McKesson. ", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2f6785c986671ce0623f31884790d0e0d2d6a77b10e89f910169852a5d550d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8ce4a57-ac29-40e3-ad4e-fe53a241213f", "node_type": "1", "metadata": {"window": "Our outlook for fiscal 2022 reflects the continued confidence in our operating momentum with growth across all \nsegments of  the business, supported by the strength of our balance sheet and strong financial position.  \n \n We will continue to invest in our strategies of oncology and biopharma services as we build out our connected \necosystems in these growth areas, delivering value t o our customers and partners.  We're confident in our ability \nto leverage our position and capabilities to accelerate growth.  \n \n In closing, I'd like to acknowledge and thank all the McKesson associates across the world for their dedication, \nexecution and unr elenting commitment to our customers and patients.  The results we achieved this year could not \nhave been possible if not for the dedication of team McKesson.  We're pleased with our results in fiscal 2021 and \nconfident in our outlook for fiscal 2022.  \n \n And w ith that, Holly, let me turn the call back to you for Q&A.  \n ", "original_text": "In closing, I'd like to acknowledge and thank all the McKesson associates across the world for their dedication, \nexecution and unr elenting commitment to our customers and patients. ", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea92b14986e2b9e730e01acc5e986e35a78b34b84e828824a111000f89511f9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65a70996-b583-47d5-b956-5bb90e32a35d", "node_type": "1", "metadata": {"window": "We're confident in our ability \nto leverage our position and capabilities to accelerate growth.  \n \n In closing, I'd like to acknowledge and thank all the McKesson associates across the world for their dedication, \nexecution and unr elenting commitment to our customers and patients.  The results we achieved this year could not \nhave been possible if not for the dedication of team McKesson.  We're pleased with our results in fiscal 2021 and \nconfident in our outlook for fiscal 2022.  \n \n And w ith that, Holly, let me turn the call back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt. ", "original_text": "We're pleased with our results in fiscal 2021 and \nconfident in our outlook for fiscal 2022.  \n \n"}, "hash": "589ecedd7351e13e315357689a96d8e58874b4f861112c658f23d7728d9521c5", "class_name": "RelatedNodeInfo"}}, "text": "The results we achieved this year could not \nhave been possible if not for the dedication of team McKesson. ", "start_char_idx": 2518, "end_char_idx": 2626, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65a70996-b583-47d5-b956-5bb90e32a35d": {"__data__": {"id_": "65a70996-b583-47d5-b956-5bb90e32a35d", "embedding": null, "metadata": {"window": "We're confident in our ability \nto leverage our position and capabilities to accelerate growth.  \n \n In closing, I'd like to acknowledge and thank all the McKesson associates across the world for their dedication, \nexecution and unr elenting commitment to our customers and patients.  The results we achieved this year could not \nhave been possible if not for the dedication of team McKesson.  We're pleased with our results in fiscal 2021 and \nconfident in our outlook for fiscal 2022.  \n \n And w ith that, Holly, let me turn the call back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt. ", "original_text": "We're pleased with our results in fiscal 2021 and \nconfident in our outlook for fiscal 2022.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2f6785c986671ce0623f31884790d0e0d2d6a77b10e89f910169852a5d550d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4a52ec3-914d-49bd-b062-7e327f994c45", "node_type": "1", "metadata": {"window": "We will continue to invest in our strategies of oncology and biopharma services as we build out our connected \necosystems in these growth areas, delivering value t o our customers and partners.  We're confident in our ability \nto leverage our position and capabilities to accelerate growth.  \n \n In closing, I'd like to acknowledge and thank all the McKesson associates across the world for their dedication, \nexecution and unr elenting commitment to our customers and patients.  The results we achieved this year could not \nhave been possible if not for the dedication of team McKesson.  We're pleased with our results in fiscal 2021 and \nconfident in our outlook for fiscal 2022.  \n \n And w ith that, Holly, let me turn the call back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "original_text": "The results we achieved this year could not \nhave been possible if not for the dedication of team McKesson. ", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19100baaac170ce035d8a97422ece1b3b29d8e62c09af3ee8463a27f544f3b7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7fce1580-c9dc-480e-a1ad-cf705f133ad3", "node_type": "1", "metadata": {"window": "In closing, I'd like to acknowledge and thank all the McKesson associates across the world for their dedication, \nexecution and unr elenting commitment to our customers and patients.  The results we achieved this year could not \nhave been possible if not for the dedication of team McKesson.  We're pleased with our results in fiscal 2021 and \nconfident in our outlook for fiscal 2022.  \n \n And w ith that, Holly, let me turn the call back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt.  I'll now turn the call over to the operator for your questions. ", "original_text": "And w ith that, Holly, let me turn the call back to you for Q&A.  \n "}, "hash": "e0ab3a7c58874b8b50a6c0b81ea50847ceab8c8046c9f0ca589afcecca1164d6", "class_name": "RelatedNodeInfo"}}, "text": "We're pleased with our results in fiscal 2021 and \nconfident in our outlook for fiscal 2022.  \n \n", "start_char_idx": 2626, "end_char_idx": 2723, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7fce1580-c9dc-480e-a1ad-cf705f133ad3": {"__data__": {"id_": "7fce1580-c9dc-480e-a1ad-cf705f133ad3", "embedding": null, "metadata": {"window": "In closing, I'd like to acknowledge and thank all the McKesson associates across the world for their dedication, \nexecution and unr elenting commitment to our customers and patients.  The results we achieved this year could not \nhave been possible if not for the dedication of team McKesson.  We're pleased with our results in fiscal 2021 and \nconfident in our outlook for fiscal 2022.  \n \n And w ith that, Holly, let me turn the call back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt.  I'll now turn the call over to the operator for your questions. ", "original_text": "And w ith that, Holly, let me turn the call back to you for Q&A.  \n ", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2f6785c986671ce0623f31884790d0e0d2d6a77b10e89f910169852a5d550d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65a70996-b583-47d5-b956-5bb90e32a35d", "node_type": "1", "metadata": {"window": "We're confident in our ability \nto leverage our position and capabilities to accelerate growth.  \n \n In closing, I'd like to acknowledge and thank all the McKesson associates across the world for their dedication, \nexecution and unr elenting commitment to our customers and patients.  The results we achieved this year could not \nhave been possible if not for the dedication of team McKesson.  We're pleased with our results in fiscal 2021 and \nconfident in our outlook for fiscal 2022.  \n \n And w ith that, Holly, let me turn the call back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt. ", "original_text": "We're pleased with our results in fiscal 2021 and \nconfident in our outlook for fiscal 2022.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8abf69df2ca7486c74ba0b41277522add2907845e7506ab542ed05bcd8bf4857", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "881dbf0a-db4b-4076-9fac-4be10a655695", "node_type": "1", "metadata": {"window": "The results we achieved this year could not \nhave been possible if not for the dedication of team McKesson.  We're pleased with our results in fiscal 2021 and \nconfident in our outlook for fiscal 2022.  \n \n And w ith that, Holly, let me turn the call back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt.  I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n"}, "hash": "bbf46ecb313cea06282b0f03607a3cd096d19061deb3084f52906f6eb842c58d", "class_name": "RelatedNodeInfo"}}, "text": "And w ith that, Holly, let me turn the call back to you for Q&A.  \n ", "start_char_idx": 2723, "end_char_idx": 2791, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "881dbf0a-db4b-4076-9fac-4be10a655695": {"__data__": {"id_": "881dbf0a-db4b-4076-9fac-4be10a655695", "embedding": null, "metadata": {"window": "The results we achieved this year could not \nhave been possible if not for the dedication of team McKesson.  We're pleased with our results in fiscal 2021 and \nconfident in our outlook for fiscal 2022.  \n \n And w ith that, Holly, let me turn the call back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt.  I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2f6785c986671ce0623f31884790d0e0d2d6a77b10e89f910169852a5d550d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7fce1580-c9dc-480e-a1ad-cf705f133ad3", "node_type": "1", "metadata": {"window": "In closing, I'd like to acknowledge and thank all the McKesson associates across the world for their dedication, \nexecution and unr elenting commitment to our customers and patients.  The results we achieved this year could not \nhave been possible if not for the dedication of team McKesson.  We're pleased with our results in fiscal 2021 and \nconfident in our outlook for fiscal 2022.  \n \n And w ith that, Holly, let me turn the call back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt.  I'll now turn the call over to the operator for your questions. ", "original_text": "And w ith that, Holly, let me turn the call back to you for Q&A.  \n ", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01ef8b66dd1452d7bcfcabbd9544b242ab436f139a6716a858eb4260c90706fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16ab6417-51ba-4e65-adf4-f9eec3d4f257", "node_type": "1", "metadata": {"window": "We're pleased with our results in fiscal 2021 and \nconfident in our outlook for fiscal 2022.  \n \n And w ith that, Holly, let me turn the call back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt.  I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate.  Operator?  \n  ", "original_text": "Thank you, Britt. "}, "hash": "8cea6209529808d5db22f1dc14c2bd9749d55a9f129a89e0d9ea0a275abe1a8d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "start_char_idx": 2791, "end_char_idx": 3133, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16ab6417-51ba-4e65-adf4-f9eec3d4f257": {"__data__": {"id_": "16ab6417-51ba-4e65-adf4-f9eec3d4f257", "embedding": null, "metadata": {"window": "We're pleased with our results in fiscal 2021 and \nconfident in our outlook for fiscal 2022.  \n \n And w ith that, Holly, let me turn the call back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt.  I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate.  Operator?  \n  ", "original_text": "Thank you, Britt. ", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2f6785c986671ce0623f31884790d0e0d2d6a77b10e89f910169852a5d550d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "881dbf0a-db4b-4076-9fac-4be10a655695", "node_type": "1", "metadata": {"window": "The results we achieved this year could not \nhave been possible if not for the dedication of team McKesson.  We're pleased with our results in fiscal 2021 and \nconfident in our outlook for fiscal 2022.  \n \n And w ith that, Holly, let me turn the call back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt.  I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d179d3873b1331b2c04939bdcefc836d8d1229cb4f7b730b1523e8ffbcebbdac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "651fb490-b2b6-459b-ad2c-6beb207d2ffe", "node_type": "1", "metadata": {"window": "And w ith that, Holly, let me turn the call back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt.  I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate.  Operator?  \n  ", "original_text": "I'll now turn the call over to the operator for your questions. "}, "hash": "ff4029b2d8a0af0c36320195a7c96cea1a8a297ce52b9eb30fe4cb95320a4479", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Britt. ", "start_char_idx": 3133, "end_char_idx": 3151, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "651fb490-b2b6-459b-ad2c-6beb207d2ffe": {"__data__": {"id_": "651fb490-b2b6-459b-ad2c-6beb207d2ffe", "embedding": null, "metadata": {"window": "And w ith that, Holly, let me turn the call back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt.  I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate.  Operator?  \n  ", "original_text": "I'll now turn the call over to the operator for your questions. ", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2f6785c986671ce0623f31884790d0e0d2d6a77b10e89f910169852a5d550d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16ab6417-51ba-4e65-adf4-f9eec3d4f257", "node_type": "1", "metadata": {"window": "We're pleased with our results in fiscal 2021 and \nconfident in our outlook for fiscal 2022.  \n \n And w ith that, Holly, let me turn the call back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt.  I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate.  Operator?  \n  ", "original_text": "Thank you, Britt. ", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63a646851d294de1b289d9056b1dbda9d00233654af27297325bc13a7f8b7925", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2776000-4899-4c8f-8431-727679a356b6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt.  I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate.  Operator?  \n  ", "original_text": "In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate. "}, "hash": "a16f8603ba4a2f579f7e672102c7a78a9782623a98c0ce8145c6b3d06a14602f", "class_name": "RelatedNodeInfo"}}, "text": "I'll now turn the call over to the operator for your questions. ", "start_char_idx": 3151, "end_char_idx": 3215, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2776000-4899-4c8f-8431-727679a356b6": {"__data__": {"id_": "b2776000-4899-4c8f-8431-727679a356b6", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt.  I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate.  Operator?  \n  ", "original_text": "In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate. ", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2f6785c986671ce0623f31884790d0e0d2d6a77b10e89f910169852a5d550d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "651fb490-b2b6-459b-ad2c-6beb207d2ffe", "node_type": "1", "metadata": {"window": "And w ith that, Holly, let me turn the call back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt.  I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate.  Operator?  \n  ", "original_text": "I'll now turn the call over to the operator for your questions. ", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2954853ac190f67fde45d8e88482127f88e5e82a8088f88e4a7e5bd80261bb65", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b12bb143-29fa-4775-bc55-e27dda00b60d", "node_type": "1", "metadata": {"window": "Thank you, Britt.  I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate.  Operator?  \n  ", "original_text": "Operator?  \n  "}, "hash": "cbffaa808007dab5f9a6004a190be0116911c4038ebfb7f01e44b83683acbeb1", "class_name": "RelatedNodeInfo"}}, "text": "In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate. ", "start_char_idx": 3215, "end_char_idx": 3339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b12bb143-29fa-4775-bc55-e27dda00b60d": {"__data__": {"id_": "b12bb143-29fa-4775-bc55-e27dda00b60d", "embedding": null, "metadata": {"window": "Thank you, Britt.  I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate.  Operator?  \n  ", "original_text": "Operator?  \n  ", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2f6785c986671ce0623f31884790d0e0d2d6a77b10e89f910169852a5d550d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2776000-4899-4c8f-8431-727679a356b6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt.  I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate.  Operator?  \n  ", "original_text": "In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate. ", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57928d1dbc51fadf3b4b9531c068eb69729091a28f9a1ce469447fdfbe51437e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65dcfc06-2a95-4ce3-be9b-871fc4942819", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalys t, JPMorgan Securities LLC  Q \nThanks. ", "original_text": "McKesson Corp.  "}, "hash": "a0ffae99b5db3d7cef7ece1a597442868a2f54bde96a4a8b0c1521bbf5858a7a", "class_name": "RelatedNodeInfo"}}, "text": "Operator?  \n  ", "start_char_idx": 3339, "end_char_idx": 3353, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65dcfc06-2a95-4ce3-be9b-871fc4942819": {"__data__": {"id_": "65dcfc06-2a95-4ce3-be9b-871fc4942819", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalys t, JPMorgan Securities LLC  Q \nThanks. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b12bb143-29fa-4775-bc55-e27dda00b60d", "node_type": "1", "metadata": {"window": "Thank you, Britt.  I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate.  Operator?  \n  ", "original_text": "Operator?  \n  ", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f86445f1aa5438316491acf4b4ba4cf219f571234adb72a65b485a57e24aff9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53b52341-4e79-4b05-9d19-5ae14c99317b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalys t, JPMorgan Securities LLC  Q \nThanks.  Thanks very much. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. "}, "hash": "73d6916ce733e4dae953837a8b47211c53621b1561bc0c6a89791b3514f9aab1", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53b52341-4e79-4b05-9d19-5ae14c99317b": {"__data__": {"id_": "53b52341-4e79-4b05-9d19-5ae14c99317b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalys t, JPMorgan Securities LLC  Q \nThanks.  Thanks very much. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65dcfc06-2a95-4ce3-be9b-871fc4942819", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalys t, JPMorgan Securities LLC  Q \nThanks. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "10de65301bf32fe9b03fe076116a4e19003a3b33b90211f68cf35c4cead0f01a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1921d992-8d4f-40c8-9b2b-12d8fa76fbe5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalys t, JPMorgan Securities LLC  Q \nThanks.  Thanks very much.  Good afternoon. ", "original_text": "[Operator Instructions] Our first question comes from Lisa Gill with JPMorgan.  \n "}, "hash": "07ac52de4d9244a9f0d16515e05db56ff2494d8c8813df72187ca8ea7668da3e", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "start_char_idx": 16, "end_char_idx": 238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1921d992-8d4f-40c8-9b2b-12d8fa76fbe5": {"__data__": {"id_": "1921d992-8d4f-40c8-9b2b-12d8fa76fbe5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalys t, JPMorgan Securities LLC  Q \nThanks.  Thanks very much.  Good afternoon. ", "original_text": "[Operator Instructions] Our first question comes from Lisa Gill with JPMorgan.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53b52341-4e79-4b05-9d19-5ae14c99317b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalys t, JPMorgan Securities LLC  Q \nThanks.  Thanks very much. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9c2e02ae1e2af12b8ad51d207933ec21cb8e4c866e163986c1eb037266868b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f51b231f-9469-4d9e-b6ce-e5e659e1f798", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalys t, JPMorgan Securities LLC  Q \nThanks.  Thanks very much.  Good afternoon.  Brian and Britt, I just really want to start with the oncology business. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalys t, JPMorgan Securities LLC  Q \nThanks. "}, "hash": "f157443d21cd53ab5e1dcc6ed6d1b37d18ef80d61176f21733d61c1397b4ce59", "class_name": "RelatedNodeInfo"}}, "text": "[Operator Instructions] Our first question comes from Lisa Gill with JPMorgan.  \n ", "start_char_idx": 238, "end_char_idx": 320, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f51b231f-9469-4d9e-b6ce-e5e659e1f798": {"__data__": {"id_": "f51b231f-9469-4d9e-b6ce-e5e659e1f798", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalys t, JPMorgan Securities LLC  Q \nThanks.  Thanks very much.  Good afternoon.  Brian and Britt, I just really want to start with the oncology business. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalys t, JPMorgan Securities LLC  Q \nThanks. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1921d992-8d4f-40c8-9b2b-12d8fa76fbe5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalys t, JPMorgan Securities LLC  Q \nThanks.  Thanks very much.  Good afternoon. ", "original_text": "[Operator Instructions] Our first question comes from Lisa Gill with JPMorgan.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e11c298693d2b5a61df2e1cf2761649e5187d3937b58b0d2839b1748a3402fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "097c9896-d355-49b6-aad5-0dad2577047b", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalys t, JPMorgan Securities LLC  Q \nThanks.  Thanks very much.  Good afternoon.  Brian and Britt, I just really want to start with the oncology business. \n So Britt, I want to better understand the $0.20 of investment that you talked about in the guidance and help me  to \nunderstand what type of investments you're making there. ", "original_text": "Thanks very much. "}, "hash": "ed48a93c470243e0879f4b6b56073b67273308e49597903fa133284904eb7e91", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalys t, JPMorgan Securities LLC  Q \nThanks. ", "start_char_idx": 320, "end_char_idx": 638, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "097c9896-d355-49b6-aad5-0dad2577047b": {"__data__": {"id_": "097c9896-d355-49b6-aad5-0dad2577047b", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalys t, JPMorgan Securities LLC  Q \nThanks.  Thanks very much.  Good afternoon.  Brian and Britt, I just really want to start with the oncology business. \n So Britt, I want to better understand the $0.20 of investment that you talked about in the guidance and help me  to \nunderstand what type of investments you're making there. ", "original_text": "Thanks very much. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f51b231f-9469-4d9e-b6ce-e5e659e1f798", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalys t, JPMorgan Securities LLC  Q \nThanks.  Thanks very much.  Good afternoon.  Brian and Britt, I just really want to start with the oncology business. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalys t, JPMorgan Securities LLC  Q \nThanks. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2050b821b1e6ffb834fd83394460dbd6a28f6e23795ca2f559dfcda6970f88c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "997c0e27-cad6-40fd-87bd-3e7f712beaf1", "node_type": "1", "metadata": {"window": "[Operator Instructions] Our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalys t, JPMorgan Securities LLC  Q \nThanks.  Thanks very much.  Good afternoon.  Brian and Britt, I just really want to start with the oncology business. \n So Britt, I want to better understand the $0.20 of investment that you talked about in the guidance and help me  to \nunderstand what type of investments you're making there.  Are they tuck -in acquisitions? ", "original_text": "Good afternoon. "}, "hash": "8ba7cb2f2c73f9a13fcf8160092bb8cf7c1a1b4e5ccd781c99eae10ca1fe32e4", "class_name": "RelatedNodeInfo"}}, "text": "Thanks very much. ", "start_char_idx": 638, "end_char_idx": 656, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "997c0e27-cad6-40fd-87bd-3e7f712beaf1": {"__data__": {"id_": "997c0e27-cad6-40fd-87bd-3e7f712beaf1", "embedding": null, "metadata": {"window": "[Operator Instructions] Our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalys t, JPMorgan Securities LLC  Q \nThanks.  Thanks very much.  Good afternoon.  Brian and Britt, I just really want to start with the oncology business. \n So Britt, I want to better understand the $0.20 of investment that you talked about in the guidance and help me  to \nunderstand what type of investments you're making there.  Are they tuck -in acquisitions? ", "original_text": "Good afternoon. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "097c9896-d355-49b6-aad5-0dad2577047b", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalys t, JPMorgan Securities LLC  Q \nThanks.  Thanks very much.  Good afternoon.  Brian and Britt, I just really want to start with the oncology business. \n So Britt, I want to better understand the $0.20 of investment that you talked about in the guidance and help me  to \nunderstand what type of investments you're making there. ", "original_text": "Thanks very much. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ac89cb9a092e4a69b3548dddaf5d5b81e582b8fb3f77f914363de6f027f4645", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "151cae69-7c00-4b42-9dd9-ae31aeeb1a31", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalys t, JPMorgan Securities LLC  Q \nThanks.  Thanks very much.  Good afternoon.  Brian and Britt, I just really want to start with the oncology business. \n So Britt, I want to better understand the $0.20 of investment that you talked about in the guidance and help me  to \nunderstand what type of investments you're making there.  Are they tuck -in acquisitions?  Is it technology, those \nkinds of things? ", "original_text": "Brian and Britt, I just really want to start with the oncology business. \n"}, "hash": "d3963df27250516c9dc7ceb1610bfa75d96b8be323c1d371af316951b639a68f", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon. ", "start_char_idx": 656, "end_char_idx": 672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "151cae69-7c00-4b42-9dd9-ae31aeeb1a31": {"__data__": {"id_": "151cae69-7c00-4b42-9dd9-ae31aeeb1a31", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalys t, JPMorgan Securities LLC  Q \nThanks.  Thanks very much.  Good afternoon.  Brian and Britt, I just really want to start with the oncology business. \n So Britt, I want to better understand the $0.20 of investment that you talked about in the guidance and help me  to \nunderstand what type of investments you're making there.  Are they tuck -in acquisitions?  Is it technology, those \nkinds of things? ", "original_text": "Brian and Britt, I just really want to start with the oncology business. \n", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "997c0e27-cad6-40fd-87bd-3e7f712beaf1", "node_type": "1", "metadata": {"window": "[Operator Instructions] Our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalys t, JPMorgan Securities LLC  Q \nThanks.  Thanks very much.  Good afternoon.  Brian and Britt, I just really want to start with the oncology business. \n So Britt, I want to better understand the $0.20 of investment that you talked about in the guidance and help me  to \nunderstand what type of investments you're making there.  Are they tuck -in acquisitions? ", "original_text": "Good afternoon. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "700cf6b73b966dfd8da5b8c6b06eea13ba7dfa98ffdcbdd71f68a437e3833342", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ab24049-7e5c-4dd2-9a5e-a3c961f46751", "node_type": "1", "metadata": {"window": "Thanks very much.  Good afternoon.  Brian and Britt, I just really want to start with the oncology business. \n So Britt, I want to better understand the $0.20 of investment that you talked about in the guidance and help me  to \nunderstand what type of investments you're making there.  Are they tuck -in acquisitions?  Is it technology, those \nkinds of things?  And then secondly, as we think about growth in the oncology and specialty business, can you \nmaybe just talk about the impac t of biosimilars, what you've seen in the quarter and kind of your expectations \ngoing into 2022?  \n ", "original_text": "So Britt, I want to better understand the $0.20 of investment that you talked about in the guidance and help me  to \nunderstand what type of investments you're making there. "}, "hash": "59c05b505f2ed76a951c18e195be1ce822fe54ed121e63decebe2f6b149bf75e", "class_name": "RelatedNodeInfo"}}, "text": "Brian and Britt, I just really want to start with the oncology business. \n", "start_char_idx": 672, "end_char_idx": 746, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ab24049-7e5c-4dd2-9a5e-a3c961f46751": {"__data__": {"id_": "2ab24049-7e5c-4dd2-9a5e-a3c961f46751", "embedding": null, "metadata": {"window": "Thanks very much.  Good afternoon.  Brian and Britt, I just really want to start with the oncology business. \n So Britt, I want to better understand the $0.20 of investment that you talked about in the guidance and help me  to \nunderstand what type of investments you're making there.  Are they tuck -in acquisitions?  Is it technology, those \nkinds of things?  And then secondly, as we think about growth in the oncology and specialty business, can you \nmaybe just talk about the impac t of biosimilars, what you've seen in the quarter and kind of your expectations \ngoing into 2022?  \n ", "original_text": "So Britt, I want to better understand the $0.20 of investment that you talked about in the guidance and help me  to \nunderstand what type of investments you're making there. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "151cae69-7c00-4b42-9dd9-ae31aeeb1a31", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalys t, JPMorgan Securities LLC  Q \nThanks.  Thanks very much.  Good afternoon.  Brian and Britt, I just really want to start with the oncology business. \n So Britt, I want to better understand the $0.20 of investment that you talked about in the guidance and help me  to \nunderstand what type of investments you're making there.  Are they tuck -in acquisitions?  Is it technology, those \nkinds of things? ", "original_text": "Brian and Britt, I just really want to start with the oncology business. \n", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9fe08f109111d349d7a2901fc5308ba0c0846d795682fe2e9d91582fc2236e34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b625f16-01db-4595-87d2-e859baf4ff89", "node_type": "1", "metadata": {"window": "Good afternoon.  Brian and Britt, I just really want to start with the oncology business. \n So Britt, I want to better understand the $0.20 of investment that you talked about in the guidance and help me  to \nunderstand what type of investments you're making there.  Are they tuck -in acquisitions?  Is it technology, those \nkinds of things?  And then secondly, as we think about growth in the oncology and specialty business, can you \nmaybe just talk about the impac t of biosimilars, what you've seen in the quarter and kind of your expectations \ngoing into 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Are they tuck -in acquisitions? "}, "hash": "e49ee43944df8520cc7665ff624fdeb8f81c550a43dabf3c263c1d0d32f47f99", "class_name": "RelatedNodeInfo"}}, "text": "So Britt, I want to better understand the $0.20 of investment that you talked about in the guidance and help me  to \nunderstand what type of investments you're making there. ", "start_char_idx": 746, "end_char_idx": 920, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b625f16-01db-4595-87d2-e859baf4ff89": {"__data__": {"id_": "7b625f16-01db-4595-87d2-e859baf4ff89", "embedding": null, "metadata": {"window": "Good afternoon.  Brian and Britt, I just really want to start with the oncology business. \n So Britt, I want to better understand the $0.20 of investment that you talked about in the guidance and help me  to \nunderstand what type of investments you're making there.  Are they tuck -in acquisitions?  Is it technology, those \nkinds of things?  And then secondly, as we think about growth in the oncology and specialty business, can you \nmaybe just talk about the impac t of biosimilars, what you've seen in the quarter and kind of your expectations \ngoing into 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Are they tuck -in acquisitions? ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ab24049-7e5c-4dd2-9a5e-a3c961f46751", "node_type": "1", "metadata": {"window": "Thanks very much.  Good afternoon.  Brian and Britt, I just really want to start with the oncology business. \n So Britt, I want to better understand the $0.20 of investment that you talked about in the guidance and help me  to \nunderstand what type of investments you're making there.  Are they tuck -in acquisitions?  Is it technology, those \nkinds of things?  And then secondly, as we think about growth in the oncology and specialty business, can you \nmaybe just talk about the impac t of biosimilars, what you've seen in the quarter and kind of your expectations \ngoing into 2022?  \n ", "original_text": "So Britt, I want to better understand the $0.20 of investment that you talked about in the guidance and help me  to \nunderstand what type of investments you're making there. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc25771dede64e136dea177f55166f5366187c253905a45ef21e826ba2f9d25b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c106903-50be-441c-b3cc-8e411b183928", "node_type": "1", "metadata": {"window": "Brian and Britt, I just really want to start with the oncology business. \n So Britt, I want to better understand the $0.20 of investment that you talked about in the guidance and help me  to \nunderstand what type of investments you're making there.  Are they tuck -in acquisitions?  Is it technology, those \nkinds of things?  And then secondly, as we think about growth in the oncology and specialty business, can you \nmaybe just talk about the impac t of biosimilars, what you've seen in the quarter and kind of your expectations \ngoing into 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nGood afternoon, Lisa. ", "original_text": "Is it technology, those \nkinds of things? "}, "hash": "71b04293397d74a876dc0c750acbbc650de158067116c8f71ae5db33aaab9800", "class_name": "RelatedNodeInfo"}}, "text": "Are they tuck -in acquisitions? ", "start_char_idx": 920, "end_char_idx": 952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c106903-50be-441c-b3cc-8e411b183928": {"__data__": {"id_": "8c106903-50be-441c-b3cc-8e411b183928", "embedding": null, "metadata": {"window": "Brian and Britt, I just really want to start with the oncology business. \n So Britt, I want to better understand the $0.20 of investment that you talked about in the guidance and help me  to \nunderstand what type of investments you're making there.  Are they tuck -in acquisitions?  Is it technology, those \nkinds of things?  And then secondly, as we think about growth in the oncology and specialty business, can you \nmaybe just talk about the impac t of biosimilars, what you've seen in the quarter and kind of your expectations \ngoing into 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nGood afternoon, Lisa. ", "original_text": "Is it technology, those \nkinds of things? ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b625f16-01db-4595-87d2-e859baf4ff89", "node_type": "1", "metadata": {"window": "Good afternoon.  Brian and Britt, I just really want to start with the oncology business. \n So Britt, I want to better understand the $0.20 of investment that you talked about in the guidance and help me  to \nunderstand what type of investments you're making there.  Are they tuck -in acquisitions?  Is it technology, those \nkinds of things?  And then secondly, as we think about growth in the oncology and specialty business, can you \nmaybe just talk about the impac t of biosimilars, what you've seen in the quarter and kind of your expectations \ngoing into 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Are they tuck -in acquisitions? ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "177511ae461b81795c897a920737c54114d5d7cba150b118313dd16c4c60c7a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a75d9e7c-7683-4191-937e-d40ad810eb32", "node_type": "1", "metadata": {"window": "So Britt, I want to better understand the $0.20 of investment that you talked about in the guidance and help me  to \nunderstand what type of investments you're making there.  Are they tuck -in acquisitions?  Is it technology, those \nkinds of things?  And then secondly, as we think about growth in the oncology and specialty business, can you \nmaybe just talk about the impac t of biosimilars, what you've seen in the quarter and kind of your expectations \ngoing into 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nGood afternoon, Lisa.  Thanks for that question. ", "original_text": "And then secondly, as we think about growth in the oncology and specialty business, can you \nmaybe just talk about the impac t of biosimilars, what you've seen in the quarter and kind of your expectations \ngoing into 2022?  \n "}, "hash": "b1251f44d3927bb32b578e124f515f0765d8e74936729e10e11ae3a8001cf527", "class_name": "RelatedNodeInfo"}}, "text": "Is it technology, those \nkinds of things? ", "start_char_idx": 952, "end_char_idx": 994, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a75d9e7c-7683-4191-937e-d40ad810eb32": {"__data__": {"id_": "a75d9e7c-7683-4191-937e-d40ad810eb32", "embedding": null, "metadata": {"window": "So Britt, I want to better understand the $0.20 of investment that you talked about in the guidance and help me  to \nunderstand what type of investments you're making there.  Are they tuck -in acquisitions?  Is it technology, those \nkinds of things?  And then secondly, as we think about growth in the oncology and specialty business, can you \nmaybe just talk about the impac t of biosimilars, what you've seen in the quarter and kind of your expectations \ngoing into 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nGood afternoon, Lisa.  Thanks for that question. ", "original_text": "And then secondly, as we think about growth in the oncology and specialty business, can you \nmaybe just talk about the impac t of biosimilars, what you've seen in the quarter and kind of your expectations \ngoing into 2022?  \n ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c106903-50be-441c-b3cc-8e411b183928", "node_type": "1", "metadata": {"window": "Brian and Britt, I just really want to start with the oncology business. \n So Britt, I want to better understand the $0.20 of investment that you talked about in the guidance and help me  to \nunderstand what type of investments you're making there.  Are they tuck -in acquisitions?  Is it technology, those \nkinds of things?  And then secondly, as we think about growth in the oncology and specialty business, can you \nmaybe just talk about the impac t of biosimilars, what you've seen in the quarter and kind of your expectations \ngoing into 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nGood afternoon, Lisa. ", "original_text": "Is it technology, those \nkinds of things? ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "404cf7fcf2df7fee788bd540f2c61d26249653404396a2d6a8c5656653f630fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59356e4a-76d5-45ff-b07f-525c6c5d7a32", "node_type": "1", "metadata": {"window": "Are they tuck -in acquisitions?  Is it technology, those \nkinds of things?  And then secondly, as we think about growth in the oncology and specialty business, can you \nmaybe just talk about the impac t of biosimilars, what you've seen in the quarter and kind of your expectations \ngoing into 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nGood afternoon, Lisa.  Thanks for that question.  Let me just talk a littl e bit about the mechanics, and then Brian \ncan talk a little bit about some of the specific investments that we're making. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "f841b83e52fd3db365547260782728eecfc5c950c56ff6528a72bddd5906edb2", "class_name": "RelatedNodeInfo"}}, "text": "And then secondly, as we think about growth in the oncology and specialty business, can you \nmaybe just talk about the impac t of biosimilars, what you've seen in the quarter and kind of your expectations \ngoing into 2022?  \n ", "start_char_idx": 994, "end_char_idx": 1220, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59356e4a-76d5-45ff-b07f-525c6c5d7a32": {"__data__": {"id_": "59356e4a-76d5-45ff-b07f-525c6c5d7a32", "embedding": null, "metadata": {"window": "Are they tuck -in acquisitions?  Is it technology, those \nkinds of things?  And then secondly, as we think about growth in the oncology and specialty business, can you \nmaybe just talk about the impac t of biosimilars, what you've seen in the quarter and kind of your expectations \ngoing into 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nGood afternoon, Lisa.  Thanks for that question.  Let me just talk a littl e bit about the mechanics, and then Brian \ncan talk a little bit about some of the specific investments that we're making. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a75d9e7c-7683-4191-937e-d40ad810eb32", "node_type": "1", "metadata": {"window": "So Britt, I want to better understand the $0.20 of investment that you talked about in the guidance and help me  to \nunderstand what type of investments you're making there.  Are they tuck -in acquisitions?  Is it technology, those \nkinds of things?  And then secondly, as we think about growth in the oncology and specialty business, can you \nmaybe just talk about the impac t of biosimilars, what you've seen in the quarter and kind of your expectations \ngoing into 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nGood afternoon, Lisa.  Thanks for that question. ", "original_text": "And then secondly, as we think about growth in the oncology and specialty business, can you \nmaybe just talk about the impac t of biosimilars, what you've seen in the quarter and kind of your expectations \ngoing into 2022?  \n ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe962e9bf7064aaa04a1f5cf8874a691324be736c2a971d718ed386f35c9caf0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "730d8759-eb66-4a63-bba8-449b1755d6bc", "node_type": "1", "metadata": {"window": "Is it technology, those \nkinds of things?  And then secondly, as we think about growth in the oncology and specialty business, can you \nmaybe just talk about the impac t of biosimilars, what you've seen in the quarter and kind of your expectations \ngoing into 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nGood afternoon, Lisa.  Thanks for that question.  Let me just talk a littl e bit about the mechanics, and then Brian \ncan talk a little bit about some of the specific investments that we're making.  We did talk on our Q3 call about the \nsecond half having investments in our oncology business and how that would be a modest headwind t o the \nsecond half of the year. ", "original_text": "A \nGood afternoon, Lisa. "}, "hash": "6569f91724e2dd7f0641f0ba9805e042a84321cb271528f8eb2539101e6607e3", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 1220, "end_char_idx": 1562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "730d8759-eb66-4a63-bba8-449b1755d6bc": {"__data__": {"id_": "730d8759-eb66-4a63-bba8-449b1755d6bc", "embedding": null, "metadata": {"window": "Is it technology, those \nkinds of things?  And then secondly, as we think about growth in the oncology and specialty business, can you \nmaybe just talk about the impac t of biosimilars, what you've seen in the quarter and kind of your expectations \ngoing into 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nGood afternoon, Lisa.  Thanks for that question.  Let me just talk a littl e bit about the mechanics, and then Brian \ncan talk a little bit about some of the specific investments that we're making.  We did talk on our Q3 call about the \nsecond half having investments in our oncology business and how that would be a modest headwind t o the \nsecond half of the year. ", "original_text": "A \nGood afternoon, Lisa. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59356e4a-76d5-45ff-b07f-525c6c5d7a32", "node_type": "1", "metadata": {"window": "Are they tuck -in acquisitions?  Is it technology, those \nkinds of things?  And then secondly, as we think about growth in the oncology and specialty business, can you \nmaybe just talk about the impac t of biosimilars, what you've seen in the quarter and kind of your expectations \ngoing into 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nGood afternoon, Lisa.  Thanks for that question.  Let me just talk a littl e bit about the mechanics, and then Brian \ncan talk a little bit about some of the specific investments that we're making. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0aebe91620f1f9179ac05d1e493490cc0724b1d7a241d12da6ad4e1ca3ea4e13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9b0d033-ff1c-4fd5-8eeb-29e18cd6865e", "node_type": "1", "metadata": {"window": "And then secondly, as we think about growth in the oncology and specialty business, can you \nmaybe just talk about the impac t of biosimilars, what you've seen in the quarter and kind of your expectations \ngoing into 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nGood afternoon, Lisa.  Thanks for that question.  Let me just talk a littl e bit about the mechanics, and then Brian \ncan talk a little bit about some of the specific investments that we're making.  We did talk on our Q3 call about the \nsecond half having investments in our oncology business and how that would be a modest headwind t o the \nsecond half of the year.  And we did make those investments. ", "original_text": "Thanks for that question. "}, "hash": "0bc92e865aa4d041b87a1437e834458eeb16f17c3850b76bf21ca647c7cddfa7", "class_name": "RelatedNodeInfo"}}, "text": "A \nGood afternoon, Lisa. ", "start_char_idx": 1562, "end_char_idx": 1587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9b0d033-ff1c-4fd5-8eeb-29e18cd6865e": {"__data__": {"id_": "e9b0d033-ff1c-4fd5-8eeb-29e18cd6865e", "embedding": null, "metadata": {"window": "And then secondly, as we think about growth in the oncology and specialty business, can you \nmaybe just talk about the impac t of biosimilars, what you've seen in the quarter and kind of your expectations \ngoing into 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nGood afternoon, Lisa.  Thanks for that question.  Let me just talk a littl e bit about the mechanics, and then Brian \ncan talk a little bit about some of the specific investments that we're making.  We did talk on our Q3 call about the \nsecond half having investments in our oncology business and how that would be a modest headwind t o the \nsecond half of the year.  And we did make those investments. ", "original_text": "Thanks for that question. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "730d8759-eb66-4a63-bba8-449b1755d6bc", "node_type": "1", "metadata": {"window": "Is it technology, those \nkinds of things?  And then secondly, as we think about growth in the oncology and specialty business, can you \nmaybe just talk about the impac t of biosimilars, what you've seen in the quarter and kind of your expectations \ngoing into 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nGood afternoon, Lisa.  Thanks for that question.  Let me just talk a littl e bit about the mechanics, and then Brian \ncan talk a little bit about some of the specific investments that we're making.  We did talk on our Q3 call about the \nsecond half having investments in our oncology business and how that would be a modest headwind t o the \nsecond half of the year. ", "original_text": "A \nGood afternoon, Lisa. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d523c53976953c84658339c1fa7c8adc262c731f1eecd8281039247a163e6ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b964a8a-0859-4c94-b8b7-8119bbd4245d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nGood afternoon, Lisa.  Thanks for that question.  Let me just talk a littl e bit about the mechanics, and then Brian \ncan talk a little bit about some of the specific investments that we're making.  We did talk on our Q3 call about the \nsecond half having investments in our oncology business and how that would be a modest headwind t o the \nsecond half of the year.  And we did make those investments.  We're increasing our investments next year. ", "original_text": "Let me just talk a littl e bit about the mechanics, and then Brian \ncan talk a little bit about some of the specific investments that we're making. "}, "hash": "0dae527dcd85bc8128089a3e603a50234be417bfdae2989f3d39395033e463cf", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for that question. ", "start_char_idx": 1587, "end_char_idx": 1613, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b964a8a-0859-4c94-b8b7-8119bbd4245d": {"__data__": {"id_": "6b964a8a-0859-4c94-b8b7-8119bbd4245d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nGood afternoon, Lisa.  Thanks for that question.  Let me just talk a littl e bit about the mechanics, and then Brian \ncan talk a little bit about some of the specific investments that we're making.  We did talk on our Q3 call about the \nsecond half having investments in our oncology business and how that would be a modest headwind t o the \nsecond half of the year.  And we did make those investments.  We're increasing our investments next year. ", "original_text": "Let me just talk a littl e bit about the mechanics, and then Brian \ncan talk a little bit about some of the specific investments that we're making. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9b0d033-ff1c-4fd5-8eeb-29e18cd6865e", "node_type": "1", "metadata": {"window": "And then secondly, as we think about growth in the oncology and specialty business, can you \nmaybe just talk about the impac t of biosimilars, what you've seen in the quarter and kind of your expectations \ngoing into 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nGood afternoon, Lisa.  Thanks for that question.  Let me just talk a littl e bit about the mechanics, and then Brian \ncan talk a little bit about some of the specific investments that we're making.  We did talk on our Q3 call about the \nsecond half having investments in our oncology business and how that would be a modest headwind t o the \nsecond half of the year.  And we did make those investments. ", "original_text": "Thanks for that question. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9b20b1e2dee5f16376090a5c72059c77cca909c1bb2671865c2ac8fd8534d1ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67f47496-4e66-414e-b9ad-9ef80a071fde", "node_type": "1", "metadata": {"window": "A \nGood afternoon, Lisa.  Thanks for that question.  Let me just talk a littl e bit about the mechanics, and then Brian \ncan talk a little bit about some of the specific investments that we're making.  We did talk on our Q3 call about the \nsecond half having investments in our oncology business and how that would be a modest headwind t o the \nsecond half of the year.  And we did make those investments.  We're increasing our investments next year.  We've \ntalked about our Ontada business publicly now, and we're making some good traction and having some good \npartnerships that we're, that we've been announcing. ", "original_text": "We did talk on our Q3 call about the \nsecond half having investments in our oncology business and how that would be a modest headwind t o the \nsecond half of the year. "}, "hash": "23d275d4310ebdb1388b799a8e6867f13fdc8d0ea38b76b9a1ccc2003e9b83fd", "class_name": "RelatedNodeInfo"}}, "text": "Let me just talk a littl e bit about the mechanics, and then Brian \ncan talk a little bit about some of the specific investments that we're making. ", "start_char_idx": 1613, "end_char_idx": 1761, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67f47496-4e66-414e-b9ad-9ef80a071fde": {"__data__": {"id_": "67f47496-4e66-414e-b9ad-9ef80a071fde", "embedding": null, "metadata": {"window": "A \nGood afternoon, Lisa.  Thanks for that question.  Let me just talk a littl e bit about the mechanics, and then Brian \ncan talk a little bit about some of the specific investments that we're making.  We did talk on our Q3 call about the \nsecond half having investments in our oncology business and how that would be a modest headwind t o the \nsecond half of the year.  And we did make those investments.  We're increasing our investments next year.  We've \ntalked about our Ontada business publicly now, and we're making some good traction and having some good \npartnerships that we're, that we've been announcing. ", "original_text": "We did talk on our Q3 call about the \nsecond half having investments in our oncology business and how that would be a modest headwind t o the \nsecond half of the year. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b964a8a-0859-4c94-b8b7-8119bbd4245d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nGood afternoon, Lisa.  Thanks for that question.  Let me just talk a littl e bit about the mechanics, and then Brian \ncan talk a little bit about some of the specific investments that we're making.  We did talk on our Q3 call about the \nsecond half having investments in our oncology business and how that would be a modest headwind t o the \nsecond half of the year.  And we did make those investments.  We're increasing our investments next year. ", "original_text": "Let me just talk a littl e bit about the mechanics, and then Brian \ncan talk a little bit about some of the specific investments that we're making. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c3f9058de5d6f1ab2e90bf4218a1af60daaf775ea47de81ba23f62e02a2cffb7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "729bbe2f-a8a6-4467-aba3-b987c7601fc5", "node_type": "1", "metadata": {"window": "Thanks for that question.  Let me just talk a littl e bit about the mechanics, and then Brian \ncan talk a little bit about some of the specific investments that we're making.  We did talk on our Q3 call about the \nsecond half having investments in our oncology business and how that would be a modest headwind t o the \nsecond half of the year.  And we did make those investments.  We're increasing our investments next year.  We've \ntalked about our Ontada business publicly now, and we're making some good traction and having some good \npartnerships that we're, that we've been announcing.  And so we're going to continue to invest in our oncology \necosystem in FY 2022. ", "original_text": "And we did make those investments. "}, "hash": "1f0e28ab698feee45f070844b22f2bea59846abe7264b46adf1bf0292fd7fdeb", "class_name": "RelatedNodeInfo"}}, "text": "We did talk on our Q3 call about the \nsecond half having investments in our oncology business and how that would be a modest headwind t o the \nsecond half of the year. ", "start_char_idx": 1761, "end_char_idx": 1929, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "729bbe2f-a8a6-4467-aba3-b987c7601fc5": {"__data__": {"id_": "729bbe2f-a8a6-4467-aba3-b987c7601fc5", "embedding": null, "metadata": {"window": "Thanks for that question.  Let me just talk a littl e bit about the mechanics, and then Brian \ncan talk a little bit about some of the specific investments that we're making.  We did talk on our Q3 call about the \nsecond half having investments in our oncology business and how that would be a modest headwind t o the \nsecond half of the year.  And we did make those investments.  We're increasing our investments next year.  We've \ntalked about our Ontada business publicly now, and we're making some good traction and having some good \npartnerships that we're, that we've been announcing.  And so we're going to continue to invest in our oncology \necosystem in FY 2022. ", "original_text": "And we did make those investments. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67f47496-4e66-414e-b9ad-9ef80a071fde", "node_type": "1", "metadata": {"window": "A \nGood afternoon, Lisa.  Thanks for that question.  Let me just talk a littl e bit about the mechanics, and then Brian \ncan talk a little bit about some of the specific investments that we're making.  We did talk on our Q3 call about the \nsecond half having investments in our oncology business and how that would be a modest headwind t o the \nsecond half of the year.  And we did make those investments.  We're increasing our investments next year.  We've \ntalked about our Ontada business publicly now, and we're making some good traction and having some good \npartnerships that we're, that we've been announcing. ", "original_text": "We did talk on our Q3 call about the \nsecond half having investments in our oncology business and how that would be a modest headwind t o the \nsecond half of the year. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e2e95800a49bcac4bbebf98527f2dad3b41badd99cd7cb5924b6d8990f6dd1c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7fbfc3c1-3875-4381-9cfd-0e36c60e8832", "node_type": "1", "metadata": {"window": "Let me just talk a littl e bit about the mechanics, and then Brian \ncan talk a little bit about some of the specific investments that we're making.  We did talk on our Q3 call about the \nsecond half having investments in our oncology business and how that would be a modest headwind t o the \nsecond half of the year.  And we did make those investments.  We're increasing our investments next year.  We've \ntalked about our Ontada business publicly now, and we're making some good traction and having some good \npartnerships that we're, that we've been announcing.  And so we're going to continue to invest in our oncology \necosystem in FY 2022.  It's another investment year. ", "original_text": "We're increasing our investments next year. "}, "hash": "caafd7ecbb5fa694c0b10023d17c7240fbd25d9c537f361d28c5c66a1c11c032", "class_name": "RelatedNodeInfo"}}, "text": "And we did make those investments. ", "start_char_idx": 1929, "end_char_idx": 1964, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7fbfc3c1-3875-4381-9cfd-0e36c60e8832": {"__data__": {"id_": "7fbfc3c1-3875-4381-9cfd-0e36c60e8832", "embedding": null, "metadata": {"window": "Let me just talk a littl e bit about the mechanics, and then Brian \ncan talk a little bit about some of the specific investments that we're making.  We did talk on our Q3 call about the \nsecond half having investments in our oncology business and how that would be a modest headwind t o the \nsecond half of the year.  And we did make those investments.  We're increasing our investments next year.  We've \ntalked about our Ontada business publicly now, and we're making some good traction and having some good \npartnerships that we're, that we've been announcing.  And so we're going to continue to invest in our oncology \necosystem in FY 2022.  It's another investment year. ", "original_text": "We're increasing our investments next year. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "729bbe2f-a8a6-4467-aba3-b987c7601fc5", "node_type": "1", "metadata": {"window": "Thanks for that question.  Let me just talk a littl e bit about the mechanics, and then Brian \ncan talk a little bit about some of the specific investments that we're making.  We did talk on our Q3 call about the \nsecond half having investments in our oncology business and how that would be a modest headwind t o the \nsecond half of the year.  And we did make those investments.  We're increasing our investments next year.  We've \ntalked about our Ontada business publicly now, and we're making some good traction and having some good \npartnerships that we're, that we've been announcing.  And so we're going to continue to invest in our oncology \necosystem in FY 2022. ", "original_text": "And we did make those investments. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "61872d9f922e817a17ab0f7e321826fd4720e27e63bc3ec139a8bc4859088318", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29a809e6-8458-49c9-a90a-2297d488bf4e", "node_type": "1", "metadata": {"window": "We did talk on our Q3 call about the \nsecond half having investments in our oncology business and how that would be a modest headwind t o the \nsecond half of the year.  And we did make those investments.  We're increasing our investments next year.  We've \ntalked about our Ontada business publicly now, and we're making some good traction and having some good \npartnerships that we're, that we've been announcing.  And so we're going to continue to invest in our oncology \necosystem in FY 2022.  It's another investment year.  But we do see that we're going to be turning profitability in \nyears after. ", "original_text": "We've \ntalked about our Ontada business publicly now, and we're making some good traction and having some good \npartnerships that we're, that we've been announcing. "}, "hash": "769fc3a7a82198ad692ff245b0510b2c938bd41a58180131edd872f1ba8c042b", "class_name": "RelatedNodeInfo"}}, "text": "We're increasing our investments next year. ", "start_char_idx": 1964, "end_char_idx": 2008, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29a809e6-8458-49c9-a90a-2297d488bf4e": {"__data__": {"id_": "29a809e6-8458-49c9-a90a-2297d488bf4e", "embedding": null, "metadata": {"window": "We did talk on our Q3 call about the \nsecond half having investments in our oncology business and how that would be a modest headwind t o the \nsecond half of the year.  And we did make those investments.  We're increasing our investments next year.  We've \ntalked about our Ontada business publicly now, and we're making some good traction and having some good \npartnerships that we're, that we've been announcing.  And so we're going to continue to invest in our oncology \necosystem in FY 2022.  It's another investment year.  But we do see that we're going to be turning profitability in \nyears after. ", "original_text": "We've \ntalked about our Ontada business publicly now, and we're making some good traction and having some good \npartnerships that we're, that we've been announcing. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7fbfc3c1-3875-4381-9cfd-0e36c60e8832", "node_type": "1", "metadata": {"window": "Let me just talk a littl e bit about the mechanics, and then Brian \ncan talk a little bit about some of the specific investments that we're making.  We did talk on our Q3 call about the \nsecond half having investments in our oncology business and how that would be a modest headwind t o the \nsecond half of the year.  And we did make those investments.  We're increasing our investments next year.  We've \ntalked about our Ontada business publicly now, and we're making some good traction and having some good \npartnerships that we're, that we've been announcing.  And so we're going to continue to invest in our oncology \necosystem in FY 2022.  It's another investment year. ", "original_text": "We're increasing our investments next year. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c55071bd2e0e72978492574e025fd2f1bb1086d16212d0c9ac52dbdfbb8368d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e5a67aa-b88b-4dde-818f-83cdb684f450", "node_type": "1", "metadata": {"window": "And we did make those investments.  We're increasing our investments next year.  We've \ntalked about our Ontada business publicly now, and we're making some good traction and having some good \npartnerships that we're, that we've been announcing.  And so we're going to continue to invest in our oncology \necosystem in FY 2022.  It's another investment year.  But we do see that we're going to be turning profitability in \nyears after.  We feel very confident that these investments in the on cology business, and specifically in Ontada, \nwill bear fruit. ", "original_text": "And so we're going to continue to invest in our oncology \necosystem in FY 2022. "}, "hash": "4ad4031dc7dbe5b1788c42f678372797b4c2e1404b77ea11c484b81055b58a16", "class_name": "RelatedNodeInfo"}}, "text": "We've \ntalked about our Ontada business publicly now, and we're making some good traction and having some good \npartnerships that we're, that we've been announcing. ", "start_char_idx": 2008, "end_char_idx": 2173, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e5a67aa-b88b-4dde-818f-83cdb684f450": {"__data__": {"id_": "3e5a67aa-b88b-4dde-818f-83cdb684f450", "embedding": null, "metadata": {"window": "And we did make those investments.  We're increasing our investments next year.  We've \ntalked about our Ontada business publicly now, and we're making some good traction and having some good \npartnerships that we're, that we've been announcing.  And so we're going to continue to invest in our oncology \necosystem in FY 2022.  It's another investment year.  But we do see that we're going to be turning profitability in \nyears after.  We feel very confident that these investments in the on cology business, and specifically in Ontada, \nwill bear fruit. ", "original_text": "And so we're going to continue to invest in our oncology \necosystem in FY 2022. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29a809e6-8458-49c9-a90a-2297d488bf4e", "node_type": "1", "metadata": {"window": "We did talk on our Q3 call about the \nsecond half having investments in our oncology business and how that would be a modest headwind t o the \nsecond half of the year.  And we did make those investments.  We're increasing our investments next year.  We've \ntalked about our Ontada business publicly now, and we're making some good traction and having some good \npartnerships that we're, that we've been announcing.  And so we're going to continue to invest in our oncology \necosystem in FY 2022.  It's another investment year.  But we do see that we're going to be turning profitability in \nyears after. ", "original_text": "We've \ntalked about our Ontada business publicly now, and we're making some good traction and having some good \npartnerships that we're, that we've been announcing. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1bba10e15d517278cec0319c928b7134ca30fdcbbd8f0b733a0061781a069837", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb5c6bc2-657b-412d-b0ff-9a03ade3fc17", "node_type": "1", "metadata": {"window": "We're increasing our investments next year.  We've \ntalked about our Ontada business publicly now, and we're making some good traction and having some good \npartnerships that we're, that we've been announcing.  And so we're going to continue to invest in our oncology \necosystem in FY 2022.  It's another investment year.  But we do see that we're going to be turning profitability in \nyears after.  We feel very confident that these investments in the on cology business, and specifically in Ontada, \nwill bear fruit.  And, Brian, maybe you talk about the specific investments?  \n ", "original_text": "It's another investment year. "}, "hash": "7b04aa6843c4a58bd330b37069a84f3274f3164086e7e16ba52dfa12c1b230c2", "class_name": "RelatedNodeInfo"}}, "text": "And so we're going to continue to invest in our oncology \necosystem in FY 2022. ", "start_char_idx": 2173, "end_char_idx": 2253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb5c6bc2-657b-412d-b0ff-9a03ade3fc17": {"__data__": {"id_": "cb5c6bc2-657b-412d-b0ff-9a03ade3fc17", "embedding": null, "metadata": {"window": "We're increasing our investments next year.  We've \ntalked about our Ontada business publicly now, and we're making some good traction and having some good \npartnerships that we're, that we've been announcing.  And so we're going to continue to invest in our oncology \necosystem in FY 2022.  It's another investment year.  But we do see that we're going to be turning profitability in \nyears after.  We feel very confident that these investments in the on cology business, and specifically in Ontada, \nwill bear fruit.  And, Brian, maybe you talk about the specific investments?  \n ", "original_text": "It's another investment year. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e5a67aa-b88b-4dde-818f-83cdb684f450", "node_type": "1", "metadata": {"window": "And we did make those investments.  We're increasing our investments next year.  We've \ntalked about our Ontada business publicly now, and we're making some good traction and having some good \npartnerships that we're, that we've been announcing.  And so we're going to continue to invest in our oncology \necosystem in FY 2022.  It's another investment year.  But we do see that we're going to be turning profitability in \nyears after.  We feel very confident that these investments in the on cology business, and specifically in Ontada, \nwill bear fruit. ", "original_text": "And so we're going to continue to invest in our oncology \necosystem in FY 2022. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d489f12c0344d3fc2127b8c8fe4afd926c5852a5d218085c15c816f6229fa73c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0abb394-1e10-4184-8637-1a13f6ed881d", "node_type": "1", "metadata": {"window": "We've \ntalked about our Ontada business publicly now, and we're making some good traction and having some good \npartnerships that we're, that we've been announcing.  And so we're going to continue to invest in our oncology \necosystem in FY 2022.  It's another investment year.  But we do see that we're going to be turning profitability in \nyears after.  We feel very confident that these investments in the on cology business, and specifically in Ontada, \nwill bear fruit.  And, Brian, maybe you talk about the specific investments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "But we do see that we're going to be turning profitability in \nyears after. "}, "hash": "24572da0d7e59020325f885c68dd5de96b4d4d298ef4888827e3734a95898597", "class_name": "RelatedNodeInfo"}}, "text": "It's another investment year. ", "start_char_idx": 2253, "end_char_idx": 2283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0abb394-1e10-4184-8637-1a13f6ed881d": {"__data__": {"id_": "c0abb394-1e10-4184-8637-1a13f6ed881d", "embedding": null, "metadata": {"window": "We've \ntalked about our Ontada business publicly now, and we're making some good traction and having some good \npartnerships that we're, that we've been announcing.  And so we're going to continue to invest in our oncology \necosystem in FY 2022.  It's another investment year.  But we do see that we're going to be turning profitability in \nyears after.  We feel very confident that these investments in the on cology business, and specifically in Ontada, \nwill bear fruit.  And, Brian, maybe you talk about the specific investments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "But we do see that we're going to be turning profitability in \nyears after. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb5c6bc2-657b-412d-b0ff-9a03ade3fc17", "node_type": "1", "metadata": {"window": "We're increasing our investments next year.  We've \ntalked about our Ontada business publicly now, and we're making some good traction and having some good \npartnerships that we're, that we've been announcing.  And so we're going to continue to invest in our oncology \necosystem in FY 2022.  It's another investment year.  But we do see that we're going to be turning profitability in \nyears after.  We feel very confident that these investments in the on cology business, and specifically in Ontada, \nwill bear fruit.  And, Brian, maybe you talk about the specific investments?  \n ", "original_text": "It's another investment year. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c3e88f3f3fd2e05bdf82768466dd389a34f16205ccfd546023044856311c1979", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "849555d4-487d-4543-802d-540ea3507588", "node_type": "1", "metadata": {"window": "And so we're going to continue to invest in our oncology \necosystem in FY 2022.  It's another investment year.  But we do see that we're going to be turning profitability in \nyears after.  We feel very confident that these investments in the on cology business, and specifically in Ontada, \nwill bear fruit.  And, Brian, maybe you talk about the specific investments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes. ", "original_text": "We feel very confident that these investments in the on cology business, and specifically in Ontada, \nwill bear fruit. "}, "hash": "e66952365428fb331e60161f65a6e766fd374faa6ab2418a8acaa4c3ee13d0e3", "class_name": "RelatedNodeInfo"}}, "text": "But we do see that we're going to be turning profitability in \nyears after. ", "start_char_idx": 2283, "end_char_idx": 2359, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "849555d4-487d-4543-802d-540ea3507588": {"__data__": {"id_": "849555d4-487d-4543-802d-540ea3507588", "embedding": null, "metadata": {"window": "And so we're going to continue to invest in our oncology \necosystem in FY 2022.  It's another investment year.  But we do see that we're going to be turning profitability in \nyears after.  We feel very confident that these investments in the on cology business, and specifically in Ontada, \nwill bear fruit.  And, Brian, maybe you talk about the specific investments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes. ", "original_text": "We feel very confident that these investments in the on cology business, and specifically in Ontada, \nwill bear fruit. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0abb394-1e10-4184-8637-1a13f6ed881d", "node_type": "1", "metadata": {"window": "We've \ntalked about our Ontada business publicly now, and we're making some good traction and having some good \npartnerships that we're, that we've been announcing.  And so we're going to continue to invest in our oncology \necosystem in FY 2022.  It's another investment year.  But we do see that we're going to be turning profitability in \nyears after.  We feel very confident that these investments in the on cology business, and specifically in Ontada, \nwill bear fruit.  And, Brian, maybe you talk about the specific investments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "But we do see that we're going to be turning profitability in \nyears after. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b53520c2bb691c4849efaf0e8fb6c20392bfc0825d0e65502bbb76e3042d39ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f338aa94-b162-4719-9a72-2a3337866fda", "node_type": "1", "metadata": {"window": "It's another investment year.  But we do see that we're going to be turning profitability in \nyears after.  We feel very confident that these investments in the on cology business, and specifically in Ontada, \nwill bear fruit.  And, Brian, maybe you talk about the specific investments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  I think that's right, Britt. ", "original_text": "And, Brian, maybe you talk about the specific investments?  \n "}, "hash": "f53ec072277a1f80becffe64a2dfc49a79a0b0f3c01fda8b32bb95163e7d92a2", "class_name": "RelatedNodeInfo"}}, "text": "We feel very confident that these investments in the on cology business, and specifically in Ontada, \nwill bear fruit. ", "start_char_idx": 2359, "end_char_idx": 2478, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f338aa94-b162-4719-9a72-2a3337866fda": {"__data__": {"id_": "f338aa94-b162-4719-9a72-2a3337866fda", "embedding": null, "metadata": {"window": "It's another investment year.  But we do see that we're going to be turning profitability in \nyears after.  We feel very confident that these investments in the on cology business, and specifically in Ontada, \nwill bear fruit.  And, Brian, maybe you talk about the specific investments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  I think that's right, Britt. ", "original_text": "And, Brian, maybe you talk about the specific investments?  \n ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "849555d4-487d-4543-802d-540ea3507588", "node_type": "1", "metadata": {"window": "And so we're going to continue to invest in our oncology \necosystem in FY 2022.  It's another investment year.  But we do see that we're going to be turning profitability in \nyears after.  We feel very confident that these investments in the on cology business, and specifically in Ontada, \nwill bear fruit.  And, Brian, maybe you talk about the specific investments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes. ", "original_text": "We feel very confident that these investments in the on cology business, and specifically in Ontada, \nwill bear fruit. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "34eb4e990bb2ae0f8e3cdedac5d3ec842dfe318c5a8b9b463be12efeed91b141", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ceefd178-a24e-4634-bb71-c6e72a4141a4", "node_type": "1", "metadata": {"window": "But we do see that we're going to be turning profitability in \nyears after.  We feel very confident that these investments in the on cology business, and specifically in Ontada, \nwill bear fruit.  And, Brian, maybe you talk about the specific investments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  I think that's right, Britt.  I mean I think of the inves tments in a couple of buckets, right? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "f502b48a4a2441ebb5c8a9d2ee3e4ec50ec50f9f27f6e31f8747b0a98878b76d", "class_name": "RelatedNodeInfo"}}, "text": "And, Brian, maybe you talk about the specific investments?  \n ", "start_char_idx": 2478, "end_char_idx": 2540, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ceefd178-a24e-4634-bb71-c6e72a4141a4": {"__data__": {"id_": "ceefd178-a24e-4634-bb71-c6e72a4141a4", "embedding": null, "metadata": {"window": "But we do see that we're going to be turning profitability in \nyears after.  We feel very confident that these investments in the on cology business, and specifically in Ontada, \nwill bear fruit.  And, Brian, maybe you talk about the specific investments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  I think that's right, Britt.  I mean I think of the inves tments in a couple of buckets, right? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f338aa94-b162-4719-9a72-2a3337866fda", "node_type": "1", "metadata": {"window": "It's another investment year.  But we do see that we're going to be turning profitability in \nyears after.  We feel very confident that these investments in the on cology business, and specifically in Ontada, \nwill bear fruit.  And, Brian, maybe you talk about the specific investments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  I think that's right, Britt. ", "original_text": "And, Brian, maybe you talk about the specific investments?  \n ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0cbd9bf254eeead5bda176eeeca25754e5dacb428f3c3950077e68ac0841a0b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb07e1e6-1edf-4f1f-9cb3-a241f08d6dc9", "node_type": "1", "metadata": {"window": "We feel very confident that these investments in the on cology business, and specifically in Ontada, \nwill bear fruit.  And, Brian, maybe you talk about the specific investments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  I think that's right, Britt.  I mean I think of the inves tments in a couple of buckets, right?  We've got a leading \nEMR in oncology. ", "original_text": "A \nYes. "}, "hash": "11cee12562c3759a592b83c5a429f7815733970b1da64620918417cfd4d7a39d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 2540, "end_char_idx": 2869, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb07e1e6-1edf-4f1f-9cb3-a241f08d6dc9": {"__data__": {"id_": "eb07e1e6-1edf-4f1f-9cb3-a241f08d6dc9", "embedding": null, "metadata": {"window": "We feel very confident that these investments in the on cology business, and specifically in Ontada, \nwill bear fruit.  And, Brian, maybe you talk about the specific investments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  I think that's right, Britt.  I mean I think of the inves tments in a couple of buckets, right?  We've got a leading \nEMR in oncology. ", "original_text": "A \nYes. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ceefd178-a24e-4634-bb71-c6e72a4141a4", "node_type": "1", "metadata": {"window": "But we do see that we're going to be turning profitability in \nyears after.  We feel very confident that these investments in the on cology business, and specifically in Ontada, \nwill bear fruit.  And, Brian, maybe you talk about the specific investments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  I think that's right, Britt.  I mean I think of the inves tments in a couple of buckets, right? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c31bc32d641a40055d377fcdbbdafae57a69f881e2832e529a596f38c9396c78", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd8e5518-ca3d-45b2-8605-08f9c12d6bd3", "node_type": "1", "metadata": {"window": "And, Brian, maybe you talk about the specific investments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  I think that's right, Britt.  I mean I think of the inves tments in a couple of buckets, right?  We've got a leading \nEMR in oncology.  We need to continue to invest in that as the practice of oncology changes and the complexity of \nthe therapies continue to evolve and things like genomics and all these advanced diag nostics start to fold in. \n", "original_text": "I think that's right, Britt. "}, "hash": "4fb76455874599a7fccb5357ad30050156aeb269c11d5668833b201400190ff7", "class_name": "RelatedNodeInfo"}}, "text": "A \nYes. ", "start_char_idx": 2869, "end_char_idx": 2877, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd8e5518-ca3d-45b2-8605-08f9c12d6bd3": {"__data__": {"id_": "dd8e5518-ca3d-45b2-8605-08f9c12d6bd3", "embedding": null, "metadata": {"window": "And, Brian, maybe you talk about the specific investments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  I think that's right, Britt.  I mean I think of the inves tments in a couple of buckets, right?  We've got a leading \nEMR in oncology.  We need to continue to invest in that as the practice of oncology changes and the complexity of \nthe therapies continue to evolve and things like genomics and all these advanced diag nostics start to fold in. \n", "original_text": "I think that's right, Britt. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb07e1e6-1edf-4f1f-9cb3-a241f08d6dc9", "node_type": "1", "metadata": {"window": "We feel very confident that these investments in the on cology business, and specifically in Ontada, \nwill bear fruit.  And, Brian, maybe you talk about the specific investments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  I think that's right, Britt.  I mean I think of the inves tments in a couple of buckets, right?  We've got a leading \nEMR in oncology. ", "original_text": "A \nYes. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "14cdd05ac7ca6682d8428f3cc4b03c88fb5e7207501c150d4b5eb501fc50267c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07d7bcfb-280e-4fdc-a6bb-d1bc296debbc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  I think that's right, Britt.  I mean I think of the inves tments in a couple of buckets, right?  We've got a leading \nEMR in oncology.  We need to continue to invest in that as the practice of oncology changes and the complexity of \nthe therapies continue to evolve and things like genomics and all these advanced diag nostics start to fold in. \n That's a bit of just infrastructure investment. ", "original_text": "I mean I think of the inves tments in a couple of buckets, right? "}, "hash": "929713d907259d7d502071674868aac971ab459c5554d592515b8396cfb0e201", "class_name": "RelatedNodeInfo"}}, "text": "I think that's right, Britt. ", "start_char_idx": 2877, "end_char_idx": 2906, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07d7bcfb-280e-4fdc-a6bb-d1bc296debbc": {"__data__": {"id_": "07d7bcfb-280e-4fdc-a6bb-d1bc296debbc", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  I think that's right, Britt.  I mean I think of the inves tments in a couple of buckets, right?  We've got a leading \nEMR in oncology.  We need to continue to invest in that as the practice of oncology changes and the complexity of \nthe therapies continue to evolve and things like genomics and all these advanced diag nostics start to fold in. \n That's a bit of just infrastructure investment. ", "original_text": "I mean I think of the inves tments in a couple of buckets, right? ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd8e5518-ca3d-45b2-8605-08f9c12d6bd3", "node_type": "1", "metadata": {"window": "And, Brian, maybe you talk about the specific investments?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  I think that's right, Britt.  I mean I think of the inves tments in a couple of buckets, right?  We've got a leading \nEMR in oncology.  We need to continue to invest in that as the practice of oncology changes and the complexity of \nthe therapies continue to evolve and things like genomics and all these advanced diag nostics start to fold in. \n", "original_text": "I think that's right, Britt. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee7a4f53fa6a7d41b0233258b609928c6b81946ffede91265587b30037c78453", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e797675-320f-42d3-a96d-6e37f96b78ef", "node_type": "1", "metadata": {"window": "A \nYes.  I think that's right, Britt.  I mean I think of the inves tments in a couple of buckets, right?  We've got a leading \nEMR in oncology.  We need to continue to invest in that as the practice of oncology changes and the complexity of \nthe therapies continue to evolve and things like genomics and all these advanced diag nostics start to fold in. \n That's a bit of just infrastructure investment.  Britt talked about Ontada, that's our technology and data insights \nbusiness that we're investing in. ", "original_text": "We've got a leading \nEMR in oncology. "}, "hash": "38c16efbd7be9386aaa84e50d42e4ccd774c534c922f71735ba947c70d561ae5", "class_name": "RelatedNodeInfo"}}, "text": "I mean I think of the inves tments in a couple of buckets, right? ", "start_char_idx": 2906, "end_char_idx": 2972, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e797675-320f-42d3-a96d-6e37f96b78ef": {"__data__": {"id_": "0e797675-320f-42d3-a96d-6e37f96b78ef", "embedding": null, "metadata": {"window": "A \nYes.  I think that's right, Britt.  I mean I think of the inves tments in a couple of buckets, right?  We've got a leading \nEMR in oncology.  We need to continue to invest in that as the practice of oncology changes and the complexity of \nthe therapies continue to evolve and things like genomics and all these advanced diag nostics start to fold in. \n That's a bit of just infrastructure investment.  Britt talked about Ontada, that's our technology and data insights \nbusiness that we're investing in. ", "original_text": "We've got a leading \nEMR in oncology. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07d7bcfb-280e-4fdc-a6bb-d1bc296debbc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  I think that's right, Britt.  I mean I think of the inves tments in a couple of buckets, right?  We've got a leading \nEMR in oncology.  We need to continue to invest in that as the practice of oncology changes and the complexity of \nthe therapies continue to evolve and things like genomics and all these advanced diag nostics start to fold in. \n That's a bit of just infrastructure investment. ", "original_text": "I mean I think of the inves tments in a couple of buckets, right? ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "447f44e5490fb181513bf429d584cbe9dc72d87f9e88c5d4acf353169a1fd3f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "300788c9-f838-43f4-bbba-c8925b8beacd", "node_type": "1", "metadata": {"window": "I think that's right, Britt.  I mean I think of the inves tments in a couple of buckets, right?  We've got a leading \nEMR in oncology.  We need to continue to invest in that as the practice of oncology changes and the complexity of \nthe therapies continue to evolve and things like genomics and all these advanced diag nostics start to fold in. \n That's a bit of just infrastructure investment.  Britt talked about Ontada, that's our technology and data insights \nbusiness that we're investing in.  That's a growth, future growth area of opportunity for us. ", "original_text": "We need to continue to invest in that as the practice of oncology changes and the complexity of \nthe therapies continue to evolve and things like genomics and all these advanced diag nostics start to fold in. \n"}, "hash": "a8363b8f1f54239c87f121b5afad8ae7a12ec804962ca1e821b561170359232a", "class_name": "RelatedNodeInfo"}}, "text": "We've got a leading \nEMR in oncology. ", "start_char_idx": 2972, "end_char_idx": 3010, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "300788c9-f838-43f4-bbba-c8925b8beacd": {"__data__": {"id_": "300788c9-f838-43f4-bbba-c8925b8beacd", "embedding": null, "metadata": {"window": "I think that's right, Britt.  I mean I think of the inves tments in a couple of buckets, right?  We've got a leading \nEMR in oncology.  We need to continue to invest in that as the practice of oncology changes and the complexity of \nthe therapies continue to evolve and things like genomics and all these advanced diag nostics start to fold in. \n That's a bit of just infrastructure investment.  Britt talked about Ontada, that's our technology and data insights \nbusiness that we're investing in.  That's a growth, future growth area of opportunity for us. ", "original_text": "We need to continue to invest in that as the practice of oncology changes and the complexity of \nthe therapies continue to evolve and things like genomics and all these advanced diag nostics start to fold in. \n", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e797675-320f-42d3-a96d-6e37f96b78ef", "node_type": "1", "metadata": {"window": "A \nYes.  I think that's right, Britt.  I mean I think of the inves tments in a couple of buckets, right?  We've got a leading \nEMR in oncology.  We need to continue to invest in that as the practice of oncology changes and the complexity of \nthe therapies continue to evolve and things like genomics and all these advanced diag nostics start to fold in. \n That's a bit of just infrastructure investment.  Britt talked about Ontada, that's our technology and data insights \nbusiness that we're investing in. ", "original_text": "We've got a leading \nEMR in oncology. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5f77d3b885be011ddc08192c5bee13ade9ef1bed2ebbe510833141d9a6c22a68", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "681f68fa-d616-4c37-9dec-b6fe9864fef1", "node_type": "1", "metadata": {"window": "I mean I think of the inves tments in a couple of buckets, right?  We've got a leading \nEMR in oncology.  We need to continue to invest in that as the practice of oncology changes and the complexity of \nthe therapies continue to evolve and things like genomics and all these advanced diag nostics start to fold in. \n That's a bit of just infrastructure investment.  Britt talked about Ontada, that's our technology and data insights \nbusiness that we're investing in.  That's a growth, future growth area of opportunity for us.  And then we did not \nhave any M&A in oncology in this quarter. ", "original_text": "That's a bit of just infrastructure investment. "}, "hash": "92eb2453bc54d57ec4aceb43d05fc0358f74c0e7335b7d8f56b17684e353d430", "class_name": "RelatedNodeInfo"}}, "text": "We need to continue to invest in that as the practice of oncology changes and the complexity of \nthe therapies continue to evolve and things like genomics and all these advanced diag nostics start to fold in. \n", "start_char_idx": 3010, "end_char_idx": 3220, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "681f68fa-d616-4c37-9dec-b6fe9864fef1": {"__data__": {"id_": "681f68fa-d616-4c37-9dec-b6fe9864fef1", "embedding": null, "metadata": {"window": "I mean I think of the inves tments in a couple of buckets, right?  We've got a leading \nEMR in oncology.  We need to continue to invest in that as the practice of oncology changes and the complexity of \nthe therapies continue to evolve and things like genomics and all these advanced diag nostics start to fold in. \n That's a bit of just infrastructure investment.  Britt talked about Ontada, that's our technology and data insights \nbusiness that we're investing in.  That's a growth, future growth area of opportunity for us.  And then we did not \nhave any M&A in oncology in this quarter. ", "original_text": "That's a bit of just infrastructure investment. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "300788c9-f838-43f4-bbba-c8925b8beacd", "node_type": "1", "metadata": {"window": "I think that's right, Britt.  I mean I think of the inves tments in a couple of buckets, right?  We've got a leading \nEMR in oncology.  We need to continue to invest in that as the practice of oncology changes and the complexity of \nthe therapies continue to evolve and things like genomics and all these advanced diag nostics start to fold in. \n That's a bit of just infrastructure investment.  Britt talked about Ontada, that's our technology and data insights \nbusiness that we're investing in.  That's a growth, future growth area of opportunity for us. ", "original_text": "We need to continue to invest in that as the practice of oncology changes and the complexity of \nthe therapies continue to evolve and things like genomics and all these advanced diag nostics start to fold in. \n", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c0f0b5b3a9b8f6938705a1e3b828896afb64f2865524475dd6d04a7eec4d2c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b40c7059-5529-4fb3-aac2-d996a440c780", "node_type": "1", "metadata": {"window": "We've got a leading \nEMR in oncology.  We need to continue to invest in that as the practice of oncology changes and the complexity of \nthe therapies continue to evolve and things like genomics and all these advanced diag nostics start to fold in. \n That's a bit of just infrastructure investment.  Britt talked about Ontada, that's our technology and data insights \nbusiness that we're investing in.  That's a growth, future growth area of opportunity for us.  And then we did not \nhave any M&A in oncology in this quarter.  We had some great partnerships. ", "original_text": "Britt talked about Ontada, that's our technology and data insights \nbusiness that we're investing in. "}, "hash": "05baf3b05bda3a752776172933ddc2d6aad49d0ca84a98225ae038cda2450982", "class_name": "RelatedNodeInfo"}}, "text": "That's a bit of just infrastructure investment. ", "start_char_idx": 3220, "end_char_idx": 3268, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b40c7059-5529-4fb3-aac2-d996a440c780": {"__data__": {"id_": "b40c7059-5529-4fb3-aac2-d996a440c780", "embedding": null, "metadata": {"window": "We've got a leading \nEMR in oncology.  We need to continue to invest in that as the practice of oncology changes and the complexity of \nthe therapies continue to evolve and things like genomics and all these advanced diag nostics start to fold in. \n That's a bit of just infrastructure investment.  Britt talked about Ontada, that's our technology and data insights \nbusiness that we're investing in.  That's a growth, future growth area of opportunity for us.  And then we did not \nhave any M&A in oncology in this quarter.  We had some great partnerships. ", "original_text": "Britt talked about Ontada, that's our technology and data insights \nbusiness that we're investing in. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "681f68fa-d616-4c37-9dec-b6fe9864fef1", "node_type": "1", "metadata": {"window": "I mean I think of the inves tments in a couple of buckets, right?  We've got a leading \nEMR in oncology.  We need to continue to invest in that as the practice of oncology changes and the complexity of \nthe therapies continue to evolve and things like genomics and all these advanced diag nostics start to fold in. \n That's a bit of just infrastructure investment.  Britt talked about Ontada, that's our technology and data insights \nbusiness that we're investing in.  That's a growth, future growth area of opportunity for us.  And then we did not \nhave any M&A in oncology in this quarter. ", "original_text": "That's a bit of just infrastructure investment. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4a02f7584e2ce42f1d504060b4918573be5f3c8c1af917060c984947e2e1351", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7784ae6e-168c-46f8-8a8d-84135ff02788", "node_type": "1", "metadata": {"window": "We need to continue to invest in that as the practice of oncology changes and the complexity of \nthe therapies continue to evolve and things like genomics and all these advanced diag nostics start to fold in. \n That's a bit of just infrastructure investment.  Britt talked about Ontada, that's our technology and data insights \nbusiness that we're investing in.  That's a growth, future growth area of opportunity for us.  And then we did not \nhave any M&A in oncology in this quarter.  We had some great partnerships.  We got some great momentum on \nthat front. ", "original_text": "That's a growth, future growth area of opportunity for us. "}, "hash": "00448beb060018cba359acc9afad5bb51bb45e26952dee36e80a9191d0652169", "class_name": "RelatedNodeInfo"}}, "text": "Britt talked about Ontada, that's our technology and data insights \nbusiness that we're investing in. ", "start_char_idx": 3268, "end_char_idx": 3370, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7784ae6e-168c-46f8-8a8d-84135ff02788": {"__data__": {"id_": "7784ae6e-168c-46f8-8a8d-84135ff02788", "embedding": null, "metadata": {"window": "We need to continue to invest in that as the practice of oncology changes and the complexity of \nthe therapies continue to evolve and things like genomics and all these advanced diag nostics start to fold in. \n That's a bit of just infrastructure investment.  Britt talked about Ontada, that's our technology and data insights \nbusiness that we're investing in.  That's a growth, future growth area of opportunity for us.  And then we did not \nhave any M&A in oncology in this quarter.  We had some great partnerships.  We got some great momentum on \nthat front. ", "original_text": "That's a growth, future growth area of opportunity for us. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b40c7059-5529-4fb3-aac2-d996a440c780", "node_type": "1", "metadata": {"window": "We've got a leading \nEMR in oncology.  We need to continue to invest in that as the practice of oncology changes and the complexity of \nthe therapies continue to evolve and things like genomics and all these advanced diag nostics start to fold in. \n That's a bit of just infrastructure investment.  Britt talked about Ontada, that's our technology and data insights \nbusiness that we're investing in.  That's a growth, future growth area of opportunity for us.  And then we did not \nhave any M&A in oncology in this quarter.  We had some great partnerships. ", "original_text": "Britt talked about Ontada, that's our technology and data insights \nbusiness that we're investing in. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a217dfdb3a3edd5fdd3060b520eac3332a84c2f0d540c045393d8f20d3b87c0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8bd8898-9327-48e2-97d1-3e5e8045645d", "node_type": "1", "metadata": {"window": "That's a bit of just infrastructure investment.  Britt talked about Ontada, that's our technology and data insights \nbusiness that we're investing in.  That's a growth, future growth area of opportunity for us.  And then we did not \nhave any M&A in oncology in this quarter.  We had some great partnerships.  We got some great momentum on \nthat front.  This is an area that is strategically is aligned to our enterprise strategy, and we would certainly be open \nto doing M&A if it was on strategy  and met our financial thresholds for good M&A.  \n ", "original_text": "And then we did not \nhave any M&A in oncology in this quarter. "}, "hash": "3fa343951029d7d4dad2b7cd1501efc8b6b377ef22e8d0f0319e57c867f38ffc", "class_name": "RelatedNodeInfo"}}, "text": "That's a growth, future growth area of opportunity for us. ", "start_char_idx": 3370, "end_char_idx": 3429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8bd8898-9327-48e2-97d1-3e5e8045645d": {"__data__": {"id_": "a8bd8898-9327-48e2-97d1-3e5e8045645d", "embedding": null, "metadata": {"window": "That's a bit of just infrastructure investment.  Britt talked about Ontada, that's our technology and data insights \nbusiness that we're investing in.  That's a growth, future growth area of opportunity for us.  And then we did not \nhave any M&A in oncology in this quarter.  We had some great partnerships.  We got some great momentum on \nthat front.  This is an area that is strategically is aligned to our enterprise strategy, and we would certainly be open \nto doing M&A if it was on strategy  and met our financial thresholds for good M&A.  \n ", "original_text": "And then we did not \nhave any M&A in oncology in this quarter. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7784ae6e-168c-46f8-8a8d-84135ff02788", "node_type": "1", "metadata": {"window": "We need to continue to invest in that as the practice of oncology changes and the complexity of \nthe therapies continue to evolve and things like genomics and all these advanced diag nostics start to fold in. \n That's a bit of just infrastructure investment.  Britt talked about Ontada, that's our technology and data insights \nbusiness that we're investing in.  That's a growth, future growth area of opportunity for us.  And then we did not \nhave any M&A in oncology in this quarter.  We had some great partnerships.  We got some great momentum on \nthat front. ", "original_text": "That's a growth, future growth area of opportunity for us. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "460e9d2801cc0768f0ba0b8e6e65298425c2b65fa708154ae189936f903be3c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9fe49024-d372-4396-94bf-24e3e255f591", "node_type": "1", "metadata": {"window": "Britt talked about Ontada, that's our technology and data insights \nbusiness that we're investing in.  That's a growth, future growth area of opportunity for us.  And then we did not \nhave any M&A in oncology in this quarter.  We had some great partnerships.  We got some great momentum on \nthat front.  This is an area that is strategically is aligned to our enterprise strategy, and we would certainly be open \nto doing M&A if it was on strategy  and met our financial thresholds for good M&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "We had some great partnerships. "}, "hash": "d837621db0855af527bbeb609e6954486aacd50cafdaef34744956fbc4c0e37c", "class_name": "RelatedNodeInfo"}}, "text": "And then we did not \nhave any M&A in oncology in this quarter. ", "start_char_idx": 3429, "end_char_idx": 3492, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9fe49024-d372-4396-94bf-24e3e255f591": {"__data__": {"id_": "9fe49024-d372-4396-94bf-24e3e255f591", "embedding": null, "metadata": {"window": "Britt talked about Ontada, that's our technology and data insights \nbusiness that we're investing in.  That's a growth, future growth area of opportunity for us.  And then we did not \nhave any M&A in oncology in this quarter.  We had some great partnerships.  We got some great momentum on \nthat front.  This is an area that is strategically is aligned to our enterprise strategy, and we would certainly be open \nto doing M&A if it was on strategy  and met our financial thresholds for good M&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "We had some great partnerships. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8bd8898-9327-48e2-97d1-3e5e8045645d", "node_type": "1", "metadata": {"window": "That's a bit of just infrastructure investment.  Britt talked about Ontada, that's our technology and data insights \nbusiness that we're investing in.  That's a growth, future growth area of opportunity for us.  And then we did not \nhave any M&A in oncology in this quarter.  We had some great partnerships.  We got some great momentum on \nthat front.  This is an area that is strategically is aligned to our enterprise strategy, and we would certainly be open \nto doing M&A if it was on strategy  and met our financial thresholds for good M&A.  \n ", "original_text": "And then we did not \nhave any M&A in oncology in this quarter. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63de840e28602e86e3390ffe3e30b9eed6c3ab871b23a37b93f85ca7c48ad6a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a941cc02-98bc-40ad-8c5c-afe67046d690", "node_type": "1", "metadata": {"window": "That's a growth, future growth area of opportunity for us.  And then we did not \nhave any M&A in oncology in this quarter.  We had some great partnerships.  We got some great momentum on \nthat front.  This is an area that is strategically is aligned to our enterprise strategy, and we would certainly be open \nto doing M&A if it was on strategy  and met our financial thresholds for good M&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe I'll just finish up on your biosimilars question. ", "original_text": "We got some great momentum on \nthat front. "}, "hash": "4fe84aee70907f0b0eb41f52cb992932f1ff7bdb186443801d3308944d91f98b", "class_name": "RelatedNodeInfo"}}, "text": "We had some great partnerships. ", "start_char_idx": 3492, "end_char_idx": 3524, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a941cc02-98bc-40ad-8c5c-afe67046d690": {"__data__": {"id_": "a941cc02-98bc-40ad-8c5c-afe67046d690", "embedding": null, "metadata": {"window": "That's a growth, future growth area of opportunity for us.  And then we did not \nhave any M&A in oncology in this quarter.  We had some great partnerships.  We got some great momentum on \nthat front.  This is an area that is strategically is aligned to our enterprise strategy, and we would certainly be open \nto doing M&A if it was on strategy  and met our financial thresholds for good M&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe I'll just finish up on your biosimilars question. ", "original_text": "We got some great momentum on \nthat front. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9fe49024-d372-4396-94bf-24e3e255f591", "node_type": "1", "metadata": {"window": "Britt talked about Ontada, that's our technology and data insights \nbusiness that we're investing in.  That's a growth, future growth area of opportunity for us.  And then we did not \nhave any M&A in oncology in this quarter.  We had some great partnerships.  We got some great momentum on \nthat front.  This is an area that is strategically is aligned to our enterprise strategy, and we would certainly be open \nto doing M&A if it was on strategy  and met our financial thresholds for good M&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "We had some great partnerships. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a77171e218a21726d4a8431811be97c563fa362483188ef9fabe590660011ea0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fdcedf5-24e7-45d8-b78b-aab0c57fefb7", "node_type": "1", "metadata": {"window": "And then we did not \nhave any M&A in oncology in this quarter.  We had some great partnerships.  We got some great momentum on \nthat front.  This is an area that is strategically is aligned to our enterprise strategy, and we would certainly be open \nto doing M&A if it was on strategy  and met our financial thresholds for good M&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe I'll just finish up on your biosimilars question.  We're very pleased with how biosimilars are \nbeginning to hit the market. ", "original_text": "This is an area that is strategically is aligned to our enterprise strategy, and we would certainly be open \nto doing M&A if it was on strategy  and met our financial thresholds for good M&A.  \n "}, "hash": "70f2e01ef1e2b1619e9b32fb7a147d958a4db25df7135dd177e7514b6bd1443e", "class_name": "RelatedNodeInfo"}}, "text": "We got some great momentum on \nthat front. ", "start_char_idx": 3524, "end_char_idx": 3567, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2fdcedf5-24e7-45d8-b78b-aab0c57fefb7": {"__data__": {"id_": "2fdcedf5-24e7-45d8-b78b-aab0c57fefb7", "embedding": null, "metadata": {"window": "And then we did not \nhave any M&A in oncology in this quarter.  We had some great partnerships.  We got some great momentum on \nthat front.  This is an area that is strategically is aligned to our enterprise strategy, and we would certainly be open \nto doing M&A if it was on strategy  and met our financial thresholds for good M&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe I'll just finish up on your biosimilars question.  We're very pleased with how biosimilars are \nbeginning to hit the market. ", "original_text": "This is an area that is strategically is aligned to our enterprise strategy, and we would certainly be open \nto doing M&A if it was on strategy  and met our financial thresholds for good M&A.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a941cc02-98bc-40ad-8c5c-afe67046d690", "node_type": "1", "metadata": {"window": "That's a growth, future growth area of opportunity for us.  And then we did not \nhave any M&A in oncology in this quarter.  We had some great partnerships.  We got some great momentum on \nthat front.  This is an area that is strategically is aligned to our enterprise strategy, and we would certainly be open \nto doing M&A if it was on strategy  and met our financial thresholds for good M&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe I'll just finish up on your biosimilars question. ", "original_text": "We got some great momentum on \nthat front. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "066fdac8832328c029342356b3f3ca41a96bea4ce10f00dc0a857063c6b49744", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03dbf9ff-5ec7-430d-bdc8-2f235f21a7c1", "node_type": "1", "metadata": {"window": "We had some great partnerships.  We got some great momentum on \nthat front.  This is an area that is strategically is aligned to our enterprise strategy, and we would certainly be open \nto doing M&A if it was on strategy  and met our financial thresholds for good M&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe I'll just finish up on your biosimilars question.  We're very pleased with how biosimilars are \nbeginning to hit the market.  We see the pipeline growing, particularly in the oncology space. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "9aae2c00793d1445c95b7fc5187c8ca33d82e48b9f10d9422a89ff1ebfbf09ce", "class_name": "RelatedNodeInfo"}}, "text": "This is an area that is strategically is aligned to our enterprise strategy, and we would certainly be open \nto doing M&A if it was on strategy  and met our financial thresholds for good M&A.  \n ", "start_char_idx": 3567, "end_char_idx": 3762, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03dbf9ff-5ec7-430d-bdc8-2f235f21a7c1": {"__data__": {"id_": "03dbf9ff-5ec7-430d-bdc8-2f235f21a7c1", "embedding": null, "metadata": {"window": "We had some great partnerships.  We got some great momentum on \nthat front.  This is an area that is strategically is aligned to our enterprise strategy, and we would certainly be open \nto doing M&A if it was on strategy  and met our financial thresholds for good M&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe I'll just finish up on your biosimilars question.  We're very pleased with how biosimilars are \nbeginning to hit the market.  We see the pipeline growing, particularly in the oncology space. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fdcedf5-24e7-45d8-b78b-aab0c57fefb7", "node_type": "1", "metadata": {"window": "And then we did not \nhave any M&A in oncology in this quarter.  We had some great partnerships.  We got some great momentum on \nthat front.  This is an area that is strategically is aligned to our enterprise strategy, and we would certainly be open \nto doing M&A if it was on strategy  and met our financial thresholds for good M&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe I'll just finish up on your biosimilars question.  We're very pleased with how biosimilars are \nbeginning to hit the market. ", "original_text": "This is an area that is strategically is aligned to our enterprise strategy, and we would certainly be open \nto doing M&A if it was on strategy  and met our financial thresholds for good M&A.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f025f4c50f453a7d7478adecf8327589a6643fe3eb6db9d996790e21d6f6cb78", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09594367-112a-4fe4-b024-73bc5ca88650", "node_type": "1", "metadata": {"window": "We got some great momentum on \nthat front.  This is an area that is strategically is aligned to our enterprise strategy, and we would certainly be open \nto doing M&A if it was on strategy  and met our financial thresholds for good M&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe I'll just finish up on your biosimilars question.  We're very pleased with how biosimilars are \nbeginning to hit the market.  We see the pipeline growing, particularly in the oncology space.  It's not a material \ndriver to our results right now, but we are encouraged by the pipeline. ", "original_text": "A \nAnd Lisa, maybe I'll just finish up on your biosimilars question. "}, "hash": "a9959e47740ce8a33aeda8eee94c91509da9458e721ff40eb5baf5ee8b504630", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 1220, "end_char_idx": 1562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09594367-112a-4fe4-b024-73bc5ca88650": {"__data__": {"id_": "09594367-112a-4fe4-b024-73bc5ca88650", "embedding": null, "metadata": {"window": "We got some great momentum on \nthat front.  This is an area that is strategically is aligned to our enterprise strategy, and we would certainly be open \nto doing M&A if it was on strategy  and met our financial thresholds for good M&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe I'll just finish up on your biosimilars question.  We're very pleased with how biosimilars are \nbeginning to hit the market.  We see the pipeline growing, particularly in the oncology space.  It's not a material \ndriver to our results right now, but we are encouraged by the pipeline. ", "original_text": "A \nAnd Lisa, maybe I'll just finish up on your biosimilars question. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03dbf9ff-5ec7-430d-bdc8-2f235f21a7c1", "node_type": "1", "metadata": {"window": "We had some great partnerships.  We got some great momentum on \nthat front.  This is an area that is strategically is aligned to our enterprise strategy, and we would certainly be open \nto doing M&A if it was on strategy  and met our financial thresholds for good M&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe I'll just finish up on your biosimilars question.  We're very pleased with how biosimilars are \nbeginning to hit the market.  We see the pipeline growing, particularly in the oncology space. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "375774f85233f645b0f32ea7844617254cd041bc6ce5a468b28470f67e0964e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9270fce-21e6-4a76-863b-6abdd454a7f1", "node_type": "1", "metadata": {"window": "This is an area that is strategically is aligned to our enterprise strategy, and we would certainly be open \nto doing M&A if it was on strategy  and met our financial thresholds for good M&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe I'll just finish up on your biosimilars question.  We're very pleased with how biosimilars are \nbeginning to hit the market.  We see the pipeline growing, particularly in the oncology space.  It's not a material \ndriver to our results right now, but we are encouraged by the pipeline.  We're encouraged by the opportunities in \nthe next, in the coming years. ", "original_text": "We're very pleased with how biosimilars are \nbeginning to hit the market. "}, "hash": "08c285305831833c0676eec6266b7ccf41b75ebf0f92d8738449dcab29892173", "class_name": "RelatedNodeInfo"}}, "text": "A \nAnd Lisa, maybe I'll just finish up on your biosimilars question. ", "start_char_idx": 4104, "end_char_idx": 4173, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9270fce-21e6-4a76-863b-6abdd454a7f1": {"__data__": {"id_": "a9270fce-21e6-4a76-863b-6abdd454a7f1", "embedding": null, "metadata": {"window": "This is an area that is strategically is aligned to our enterprise strategy, and we would certainly be open \nto doing M&A if it was on strategy  and met our financial thresholds for good M&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe I'll just finish up on your biosimilars question.  We're very pleased with how biosimilars are \nbeginning to hit the market.  We see the pipeline growing, particularly in the oncology space.  It's not a material \ndriver to our results right now, but we are encouraged by the pipeline.  We're encouraged by the opportunities in \nthe next, in the coming years. ", "original_text": "We're very pleased with how biosimilars are \nbeginning to hit the market. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09594367-112a-4fe4-b024-73bc5ca88650", "node_type": "1", "metadata": {"window": "We got some great momentum on \nthat front.  This is an area that is strategically is aligned to our enterprise strategy, and we would certainly be open \nto doing M&A if it was on strategy  and met our financial thresholds for good M&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe I'll just finish up on your biosimilars question.  We're very pleased with how biosimilars are \nbeginning to hit the market.  We see the pipeline growing, particularly in the oncology space.  It's not a material \ndriver to our results right now, but we are encouraged by the pipeline. ", "original_text": "A \nAnd Lisa, maybe I'll just finish up on your biosimilars question. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "02d9b992e3b701e32f5a3593b97bc0d96151c3df08f007a71d35ab4673eed27f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b28d0dc7-1690-47ab-a872-9ec72639343d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe I'll just finish up on your biosimilars question.  We're very pleased with how biosimilars are \nbeginning to hit the market.  We see the pipeline growing, particularly in the oncology space.  It's not a material \ndriver to our results right now, but we are encouraged by the pipeline.  We're encouraged by the opportunities in \nthe next, in the coming years.  So we th ink that biosimilars are going to continue to be a positive driver for the \nbusiness, for the providers and for patients. ", "original_text": "We see the pipeline growing, particularly in the oncology space. "}, "hash": "77bb9a9b353534cf874620d084fde76bd435eddda257e68c2d914db101e03481", "class_name": "RelatedNodeInfo"}}, "text": "We're very pleased with how biosimilars are \nbeginning to hit the market. ", "start_char_idx": 4173, "end_char_idx": 4247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b28d0dc7-1690-47ab-a872-9ec72639343d": {"__data__": {"id_": "b28d0dc7-1690-47ab-a872-9ec72639343d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe I'll just finish up on your biosimilars question.  We're very pleased with how biosimilars are \nbeginning to hit the market.  We see the pipeline growing, particularly in the oncology space.  It's not a material \ndriver to our results right now, but we are encouraged by the pipeline.  We're encouraged by the opportunities in \nthe next, in the coming years.  So we th ink that biosimilars are going to continue to be a positive driver for the \nbusiness, for the providers and for patients. ", "original_text": "We see the pipeline growing, particularly in the oncology space. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9270fce-21e6-4a76-863b-6abdd454a7f1", "node_type": "1", "metadata": {"window": "This is an area that is strategically is aligned to our enterprise strategy, and we would certainly be open \nto doing M&A if it was on strategy  and met our financial thresholds for good M&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe I'll just finish up on your biosimilars question.  We're very pleased with how biosimilars are \nbeginning to hit the market.  We see the pipeline growing, particularly in the oncology space.  It's not a material \ndriver to our results right now, but we are encouraged by the pipeline.  We're encouraged by the opportunities in \nthe next, in the coming years. ", "original_text": "We're very pleased with how biosimilars are \nbeginning to hit the market. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7f8ba0c3d603f011474777abf3583cdcd92e283780b684ade496ecdc4131e42d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "350a34a7-c5a1-4bd8-a5f3-c001b3a5c56a", "node_type": "1", "metadata": {"window": "A \nAnd Lisa, maybe I'll just finish up on your biosimilars question.  We're very pleased with how biosimilars are \nbeginning to hit the market.  We see the pipeline growing, particularly in the oncology space.  It's not a material \ndriver to our results right now, but we are encouraged by the pipeline.  We're encouraged by the opportunities in \nthe next, in the coming years.  So we th ink that biosimilars are going to continue to be a positive driver for the \nbusiness, for the providers and for patients.  And we expect with our scale and reach that we'll continue to get that \ncontribution as adoption continues to increase.  \n ", "original_text": "It's not a material \ndriver to our results right now, but we are encouraged by the pipeline. "}, "hash": "e8298cadef2669e0a0f5720f7ac25d0f5f5f6d9c9aad6f5c0cb1853089c2982f", "class_name": "RelatedNodeInfo"}}, "text": "We see the pipeline growing, particularly in the oncology space. ", "start_char_idx": 4247, "end_char_idx": 4312, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "350a34a7-c5a1-4bd8-a5f3-c001b3a5c56a": {"__data__": {"id_": "350a34a7-c5a1-4bd8-a5f3-c001b3a5c56a", "embedding": null, "metadata": {"window": "A \nAnd Lisa, maybe I'll just finish up on your biosimilars question.  We're very pleased with how biosimilars are \nbeginning to hit the market.  We see the pipeline growing, particularly in the oncology space.  It's not a material \ndriver to our results right now, but we are encouraged by the pipeline.  We're encouraged by the opportunities in \nthe next, in the coming years.  So we th ink that biosimilars are going to continue to be a positive driver for the \nbusiness, for the providers and for patients.  And we expect with our scale and reach that we'll continue to get that \ncontribution as adoption continues to increase.  \n ", "original_text": "It's not a material \ndriver to our results right now, but we are encouraged by the pipeline. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b28d0dc7-1690-47ab-a872-9ec72639343d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe I'll just finish up on your biosimilars question.  We're very pleased with how biosimilars are \nbeginning to hit the market.  We see the pipeline growing, particularly in the oncology space.  It's not a material \ndriver to our results right now, but we are encouraged by the pipeline.  We're encouraged by the opportunities in \nthe next, in the coming years.  So we th ink that biosimilars are going to continue to be a positive driver for the \nbusiness, for the providers and for patients. ", "original_text": "We see the pipeline growing, particularly in the oncology space. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5054205cb5137f1fc6c9ed0f7eef790dffe3ce1b0880f27b20244909e954fdd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "599f6c04-513d-4365-bb7f-978f9b70326e", "node_type": "1", "metadata": {"window": "We're very pleased with how biosimilars are \nbeginning to hit the market.  We see the pipeline growing, particularly in the oncology space.  It's not a material \ndriver to our results right now, but we are encouraged by the pipeline.  We're encouraged by the opportunities in \nthe next, in the coming years.  So we th ink that biosimilars are going to continue to be a positive driver for the \nbusiness, for the providers and for patients.  And we expect with our scale and reach that we'll continue to get that \ncontribution as adoption continues to increase.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "We're encouraged by the opportunities in \nthe next, in the coming years. "}, "hash": "9538771f1acb6ba3a7a74db0994b5fd3b67a2fa455cb95dd636499c365651ec7", "class_name": "RelatedNodeInfo"}}, "text": "It's not a material \ndriver to our results right now, but we are encouraged by the pipeline. ", "start_char_idx": 4312, "end_char_idx": 4405, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "599f6c04-513d-4365-bb7f-978f9b70326e": {"__data__": {"id_": "599f6c04-513d-4365-bb7f-978f9b70326e", "embedding": null, "metadata": {"window": "We're very pleased with how biosimilars are \nbeginning to hit the market.  We see the pipeline growing, particularly in the oncology space.  It's not a material \ndriver to our results right now, but we are encouraged by the pipeline.  We're encouraged by the opportunities in \nthe next, in the coming years.  So we th ink that biosimilars are going to continue to be a positive driver for the \nbusiness, for the providers and for patients.  And we expect with our scale and reach that we'll continue to get that \ncontribution as adoption continues to increase.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "We're encouraged by the opportunities in \nthe next, in the coming years. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "350a34a7-c5a1-4bd8-a5f3-c001b3a5c56a", "node_type": "1", "metadata": {"window": "A \nAnd Lisa, maybe I'll just finish up on your biosimilars question.  We're very pleased with how biosimilars are \nbeginning to hit the market.  We see the pipeline growing, particularly in the oncology space.  It's not a material \ndriver to our results right now, but we are encouraged by the pipeline.  We're encouraged by the opportunities in \nthe next, in the coming years.  So we th ink that biosimilars are going to continue to be a positive driver for the \nbusiness, for the providers and for patients.  And we expect with our scale and reach that we'll continue to get that \ncontribution as adoption continues to increase.  \n ", "original_text": "It's not a material \ndriver to our results right now, but we are encouraged by the pipeline. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d99920eb4c23ced85f15cf2ade389e5d6bd7dc1c782d4d3f5e03f02bce91b55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5397df4-5c65-4682-930f-62a4f67e7fc5", "node_type": "1", "metadata": {"window": "We see the pipeline growing, particularly in the oncology space.  It's not a material \ndriver to our results right now, but we are encouraged by the pipeline.  We're encouraged by the opportunities in \nthe next, in the coming years.  So we th ink that biosimilars are going to continue to be a positive driver for the \nbusiness, for the providers and for patients.  And we expect with our scale and reach that we'll continue to get that \ncontribution as adoption continues to increase.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "So we th ink that biosimilars are going to continue to be a positive driver for the \nbusiness, for the providers and for patients. "}, "hash": "36b119d66d3763ef826d57e98d0fce0e8ea131cb2e340080444f51b90a408557", "class_name": "RelatedNodeInfo"}}, "text": "We're encouraged by the opportunities in \nthe next, in the coming years. ", "start_char_idx": 4405, "end_char_idx": 4478, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5397df4-5c65-4682-930f-62a4f67e7fc5": {"__data__": {"id_": "c5397df4-5c65-4682-930f-62a4f67e7fc5", "embedding": null, "metadata": {"window": "We see the pipeline growing, particularly in the oncology space.  It's not a material \ndriver to our results right now, but we are encouraged by the pipeline.  We're encouraged by the opportunities in \nthe next, in the coming years.  So we th ink that biosimilars are going to continue to be a positive driver for the \nbusiness, for the providers and for patients.  And we expect with our scale and reach that we'll continue to get that \ncontribution as adoption continues to increase.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "So we th ink that biosimilars are going to continue to be a positive driver for the \nbusiness, for the providers and for patients. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "599f6c04-513d-4365-bb7f-978f9b70326e", "node_type": "1", "metadata": {"window": "We're very pleased with how biosimilars are \nbeginning to hit the market.  We see the pipeline growing, particularly in the oncology space.  It's not a material \ndriver to our results right now, but we are encouraged by the pipeline.  We're encouraged by the opportunities in \nthe next, in the coming years.  So we th ink that biosimilars are going to continue to be a positive driver for the \nbusiness, for the providers and for patients.  And we expect with our scale and reach that we'll continue to get that \ncontribution as adoption continues to increase.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "We're encouraged by the opportunities in \nthe next, in the coming years. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "005c5f6795dc71d17d35bde6ddd093b5530661b9ac98498de31f75172bc6d1f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51ef9ba8-964b-40ca-8a1b-0a21b0c9cf0a", "node_type": "1", "metadata": {"window": "It's not a material \ndriver to our results right now, but we are encouraged by the pipeline.  We're encouraged by the opportunities in \nthe next, in the coming years.  So we th ink that biosimilars are going to continue to be a positive driver for the \nbusiness, for the providers and for patients.  And we expect with our scale and reach that we'll continue to get that \ncontribution as adoption continues to increase.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "And we expect with our scale and reach that we'll continue to get that \ncontribution as adoption continues to increase.  \n "}, "hash": "a895b06ba710e6725bbfa1ef4f6c2dea3eba390fa4f098e431591e29152ed0da", "class_name": "RelatedNodeInfo"}}, "text": "So we th ink that biosimilars are going to continue to be a positive driver for the \nbusiness, for the providers and for patients. ", "start_char_idx": 4478, "end_char_idx": 4609, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51ef9ba8-964b-40ca-8a1b-0a21b0c9cf0a": {"__data__": {"id_": "51ef9ba8-964b-40ca-8a1b-0a21b0c9cf0a", "embedding": null, "metadata": {"window": "It's not a material \ndriver to our results right now, but we are encouraged by the pipeline.  We're encouraged by the opportunities in \nthe next, in the coming years.  So we th ink that biosimilars are going to continue to be a positive driver for the \nbusiness, for the providers and for patients.  And we expect with our scale and reach that we'll continue to get that \ncontribution as adoption continues to increase.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "And we expect with our scale and reach that we'll continue to get that \ncontribution as adoption continues to increase.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5397df4-5c65-4682-930f-62a4f67e7fc5", "node_type": "1", "metadata": {"window": "We see the pipeline growing, particularly in the oncology space.  It's not a material \ndriver to our results right now, but we are encouraged by the pipeline.  We're encouraged by the opportunities in \nthe next, in the coming years.  So we th ink that biosimilars are going to continue to be a positive driver for the \nbusiness, for the providers and for patients.  And we expect with our scale and reach that we'll continue to get that \ncontribution as adoption continues to increase.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "So we th ink that biosimilars are going to continue to be a positive driver for the \nbusiness, for the providers and for patients. ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0e8289161b0aef89d5960db1bffef33aa50bb4ca007fbee95f5123735bb08a3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46eeec39-f094-4d05-9afa-e92b23630238", "node_type": "1", "metadata": {"window": "We're encouraged by the opportunities in \nthe next, in the coming years.  So we th ink that biosimilars are going to continue to be a positive driver for the \nbusiness, for the providers and for patients.  And we expect with our scale and reach that we'll continue to get that \ncontribution as adoption continues to increase.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   "}, "hash": "b030f0489d6ce3f96fcafd3b2f66bb82d9a50b29772db8fe66e6a98c9fbb8172", "class_name": "RelatedNodeInfo"}}, "text": "And we expect with our scale and reach that we'll continue to get that \ncontribution as adoption continues to increase.  \n ", "start_char_idx": 4609, "end_char_idx": 4732, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46eeec39-f094-4d05-9afa-e92b23630238": {"__data__": {"id_": "46eeec39-f094-4d05-9afa-e92b23630238", "embedding": null, "metadata": {"window": "We're encouraged by the opportunities in \nthe next, in the coming years.  So we th ink that biosimilars are going to continue to be a positive driver for the \nbusiness, for the providers and for patients.  And we expect with our scale and reach that we'll continue to get that \ncontribution as adoption continues to increase.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2085630e-ddcb-47a1-b1bc-0b859656a877", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a4fab62155b5a0aa3dfa577513397dd73064a40975f709fe968f02b37c684f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51ef9ba8-964b-40ca-8a1b-0a21b0c9cf0a", "node_type": "1", "metadata": {"window": "It's not a material \ndriver to our results right now, but we are encouraged by the pipeline.  We're encouraged by the opportunities in \nthe next, in the coming years.  So we th ink that biosimilars are going to continue to be a positive driver for the \nbusiness, for the providers and for patients.  And we expect with our scale and reach that we'll continue to get that \ncontribution as adoption continues to increase.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "And we expect with our scale and reach that we'll continue to get that \ncontribution as adoption continues to increase.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2df91e744e3f04be379bca5fc6f683ac9412b58188cd0cb4a35d462527bfa0b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7025d7b-d4d8-42d3-b538-a51010dfcc65", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you.  Our next question comes from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "McKesson Corp.  "}, "hash": "67dfbb15bab15112edd99738eeb98e83cd71560b7a6aa79d93068a59933d4978", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "start_char_idx": 320, "end_char_idx": 576, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7025d7b-d4d8-42d3-b538-a51010dfcc65": {"__data__": {"id_": "e7025d7b-d4d8-42d3-b538-a51010dfcc65", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you.  Our next question comes from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46eeec39-f094-4d05-9afa-e92b23630238", "node_type": "1", "metadata": {"window": "We're encouraged by the opportunities in \nthe next, in the coming years.  So we th ink that biosimilars are going to continue to be a positive driver for the \nbusiness, for the providers and for patients.  And we expect with our scale and reach that we'll continue to get that \ncontribution as adoption continues to increase.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "025729ecd47876dd75e96681c6ad99675de385e86ffc25e71bc5ab6af26d3f7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "369f66a5-b991-44ab-8847-30979ffb663c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you.  Our next question comes from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGood, thanks for the question. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you. "}, "hash": "61e8211968884d42831e977e63c6c19cf8f7ea9f737d5a66ee04cedc6c2d761b", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "369f66a5-b991-44ab-8847-30979ffb663c": {"__data__": {"id_": "369f66a5-b991-44ab-8847-30979ffb663c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you.  Our next question comes from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGood, thanks for the question. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7025d7b-d4d8-42d3-b538-a51010dfcc65", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you.  Our next question comes from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "571fb7f552acab7fff280df3a99be19d1c5273be8a8ac1de65ea2d829a4acc0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca3781a3-fc7e-4e64-bf5f-cef323db783e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you.  Our next question comes from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGood, thanks for the question.  I guess, just on the guidance within the pharma segment, the core growth of 5% to \n8%, Britt, seems re ally strong, especially considering your assumption that scripts won't be back to pre -COVID \nlevel until the second half. ", "original_text": "Our next question comes from Robert Jones with Goldman Sachs.  \n "}, "hash": "1ddc8137b8280ffd4d3a6180d3fceb2f3a9bc5515aa6c6c97be12bf43aa19452", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you. ", "start_char_idx": 16, "end_char_idx": 205, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca3781a3-fc7e-4e64-bf5f-cef323db783e": {"__data__": {"id_": "ca3781a3-fc7e-4e64-bf5f-cef323db783e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you.  Our next question comes from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGood, thanks for the question.  I guess, just on the guidance within the pharma segment, the core growth of 5% to \n8%, Britt, seems re ally strong, especially considering your assumption that scripts won't be back to pre -COVID \nlevel until the second half. ", "original_text": "Our next question comes from Robert Jones with Goldman Sachs.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "369f66a5-b991-44ab-8847-30979ffb663c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you.  Our next question comes from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGood, thanks for the question. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "89a1626833ad066760bfbb6f48c12752e4cd78d29233a583cfded8ca68711a42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a10f302c-2ca5-4093-a4bf-306c0f28c076", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you.  Our next question comes from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGood, thanks for the question.  I guess, just on the guidance within the pharma segment, the core growth of 5% to \n8%, Britt, seems re ally strong, especially considering your assumption that scripts won't be back to pre -COVID \nlevel until the second half.  So just any additional kind of building blocks or thoughts there would be helpful. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. "}, "hash": "c26cacccaaad08736c262a57ea8187a77821d8d98303b1f432a9bc52269b3764", "class_name": "RelatedNodeInfo"}}, "text": "Our next question comes from Robert Jones with Goldman Sachs.  \n ", "start_char_idx": 205, "end_char_idx": 270, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a10f302c-2ca5-4093-a4bf-306c0f28c076": {"__data__": {"id_": "a10f302c-2ca5-4093-a4bf-306c0f28c076", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you.  Our next question comes from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGood, thanks for the question.  I guess, just on the guidance within the pharma segment, the core growth of 5% to \n8%, Britt, seems re ally strong, especially considering your assumption that scripts won't be back to pre -COVID \nlevel until the second half.  So just any additional kind of building blocks or thoughts there would be helpful. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca3781a3-fc7e-4e64-bf5f-cef323db783e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you.  Our next question comes from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGood, thanks for the question.  I guess, just on the guidance within the pharma segment, the core growth of 5% to \n8%, Britt, seems re ally strong, especially considering your assumption that scripts won't be back to pre -COVID \nlevel until the second half. ", "original_text": "Our next question comes from Robert Jones with Goldman Sachs.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dbb8028c11b70e9637c53622c45a6cf43bcf0184c44cb627dd4f6d614b1d49f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36aec282-ec62-4ede-b7c5-8593b7a3cd65", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you.  Our next question comes from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGood, thanks for the question.  I guess, just on the guidance within the pharma segment, the core growth of 5% to \n8%, Britt, seems re ally strong, especially considering your assumption that scripts won't be back to pre -COVID \nlevel until the second half.  So just any additional kind of building blocks or thoughts there would be helpful.  And \nthen just to clarify, your peers have talked a l ot about pockets of pricing pressure in generics and pockets of \nvolume weakness. ", "original_text": "LLC  Q \nGood, thanks for the question. "}, "hash": "ad7c7e3c1e9926abf5de6cfce616670a9aa04c3dcccfc9542472b2a55372961d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "start_char_idx": 270, "end_char_idx": 574, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36aec282-ec62-4ede-b7c5-8593b7a3cd65": {"__data__": {"id_": "36aec282-ec62-4ede-b7c5-8593b7a3cd65", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you.  Our next question comes from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGood, thanks for the question.  I guess, just on the guidance within the pharma segment, the core growth of 5% to \n8%, Britt, seems re ally strong, especially considering your assumption that scripts won't be back to pre -COVID \nlevel until the second half.  So just any additional kind of building blocks or thoughts there would be helpful.  And \nthen just to clarify, your peers have talked a l ot about pockets of pricing pressure in generics and pockets of \nvolume weakness. ", "original_text": "LLC  Q \nGood, thanks for the question. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a10f302c-2ca5-4093-a4bf-306c0f28c076", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you.  Our next question comes from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGood, thanks for the question.  I guess, just on the guidance within the pharma segment, the core growth of 5% to \n8%, Britt, seems re ally strong, especially considering your assumption that scripts won't be back to pre -COVID \nlevel until the second half.  So just any additional kind of building blocks or thoughts there would be helpful. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "43f5893d35e57070f14555cbe9b17c8a30ac9cefd265aa7d37e7a7c57ee639c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7c28033-e520-4fb6-865a-90c2228b62cc", "node_type": "1", "metadata": {"window": "Our next question comes from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGood, thanks for the question.  I guess, just on the guidance within the pharma segment, the core growth of 5% to \n8%, Britt, seems re ally strong, especially considering your assumption that scripts won't be back to pre -COVID \nlevel until the second half.  So just any additional kind of building blocks or thoughts there would be helpful.  And \nthen just to clarify, your peers have talked a l ot about pockets of pricing pressure in generics and pockets of \nvolume weakness.  Just want to understand clearly what your assumptions are from what you're seeing today and \nin guidance relative to the generic book.  \n ", "original_text": "I guess, just on the guidance within the pharma segment, the core growth of 5% to \n8%, Britt, seems re ally strong, especially considering your assumption that scripts won't be back to pre -COVID \nlevel until the second half. "}, "hash": "f8b9a54c567b79ce0222eb93440ed503669dae3b21dcc14d11523cd07a73e9e7", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nGood, thanks for the question. ", "start_char_idx": 574, "end_char_idx": 613, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7c28033-e520-4fb6-865a-90c2228b62cc": {"__data__": {"id_": "c7c28033-e520-4fb6-865a-90c2228b62cc", "embedding": null, "metadata": {"window": "Our next question comes from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGood, thanks for the question.  I guess, just on the guidance within the pharma segment, the core growth of 5% to \n8%, Britt, seems re ally strong, especially considering your assumption that scripts won't be back to pre -COVID \nlevel until the second half.  So just any additional kind of building blocks or thoughts there would be helpful.  And \nthen just to clarify, your peers have talked a l ot about pockets of pricing pressure in generics and pockets of \nvolume weakness.  Just want to understand clearly what your assumptions are from what you're seeing today and \nin guidance relative to the generic book.  \n ", "original_text": "I guess, just on the guidance within the pharma segment, the core growth of 5% to \n8%, Britt, seems re ally strong, especially considering your assumption that scripts won't be back to pre -COVID \nlevel until the second half. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36aec282-ec62-4ede-b7c5-8593b7a3cd65", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you.  Our next question comes from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGood, thanks for the question.  I guess, just on the guidance within the pharma segment, the core growth of 5% to \n8%, Britt, seems re ally strong, especially considering your assumption that scripts won't be back to pre -COVID \nlevel until the second half.  So just any additional kind of building blocks or thoughts there would be helpful.  And \nthen just to clarify, your peers have talked a l ot about pockets of pricing pressure in generics and pockets of \nvolume weakness. ", "original_text": "LLC  Q \nGood, thanks for the question. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7bc4c6be203b20aa128745f8bf5db46f6d33707891ce8af6079f57da2fe5b30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8c0bbf7-4784-460e-8b2e-fea0828c9fe9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGood, thanks for the question.  I guess, just on the guidance within the pharma segment, the core growth of 5% to \n8%, Britt, seems re ally strong, especially considering your assumption that scripts won't be back to pre -COVID \nlevel until the second half.  So just any additional kind of building blocks or thoughts there would be helpful.  And \nthen just to clarify, your peers have talked a l ot about pockets of pricing pressure in generics and pockets of \nvolume weakness.  Just want to understand clearly what your assumptions are from what you're seeing today and \nin guidance relative to the generic book.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "So just any additional kind of building blocks or thoughts there would be helpful. "}, "hash": "b08b48f13cb8ea21cdd7cb39cbeba672733e7c2bce1d8fad90c10b92ee4452cc", "class_name": "RelatedNodeInfo"}}, "text": "I guess, just on the guidance within the pharma segment, the core growth of 5% to \n8%, Britt, seems re ally strong, especially considering your assumption that scripts won't be back to pre -COVID \nlevel until the second half. ", "start_char_idx": 613, "end_char_idx": 839, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8c0bbf7-4784-460e-8b2e-fea0828c9fe9": {"__data__": {"id_": "a8c0bbf7-4784-460e-8b2e-fea0828c9fe9", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGood, thanks for the question.  I guess, just on the guidance within the pharma segment, the core growth of 5% to \n8%, Britt, seems re ally strong, especially considering your assumption that scripts won't be back to pre -COVID \nlevel until the second half.  So just any additional kind of building blocks or thoughts there would be helpful.  And \nthen just to clarify, your peers have talked a l ot about pockets of pricing pressure in generics and pockets of \nvolume weakness.  Just want to understand clearly what your assumptions are from what you're seeing today and \nin guidance relative to the generic book.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "So just any additional kind of building blocks or thoughts there would be helpful. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7c28033-e520-4fb6-865a-90c2228b62cc", "node_type": "1", "metadata": {"window": "Our next question comes from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGood, thanks for the question.  I guess, just on the guidance within the pharma segment, the core growth of 5% to \n8%, Britt, seems re ally strong, especially considering your assumption that scripts won't be back to pre -COVID \nlevel until the second half.  So just any additional kind of building blocks or thoughts there would be helpful.  And \nthen just to clarify, your peers have talked a l ot about pockets of pricing pressure in generics and pockets of \nvolume weakness.  Just want to understand clearly what your assumptions are from what you're seeing today and \nin guidance relative to the generic book.  \n ", "original_text": "I guess, just on the guidance within the pharma segment, the core growth of 5% to \n8%, Britt, seems re ally strong, especially considering your assumption that scripts won't be back to pre -COVID \nlevel until the second half. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "33f88f4c35fe80739b17f3d76060f69a1570d9cc0f7299a2b068295ce3f88799", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f00cc933-a4f1-4a48-b797-f589bf6da184", "node_type": "1", "metadata": {"window": "LLC  Q \nGood, thanks for the question.  I guess, just on the guidance within the pharma segment, the core growth of 5% to \n8%, Britt, seems re ally strong, especially considering your assumption that scripts won't be back to pre -COVID \nlevel until the second half.  So just any additional kind of building blocks or thoughts there would be helpful.  And \nthen just to clarify, your peers have talked a l ot about pockets of pricing pressure in generics and pockets of \nvolume weakness.  Just want to understand clearly what your assumptions are from what you're seeing today and \nin guidance relative to the generic book.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question, Bob. ", "original_text": "And \nthen just to clarify, your peers have talked a l ot about pockets of pricing pressure in generics and pockets of \nvolume weakness. "}, "hash": "2ac9b0d5994889fa1db49f971f103526b357d05455bf823ca46d45f4af193090", "class_name": "RelatedNodeInfo"}}, "text": "So just any additional kind of building blocks or thoughts there would be helpful. ", "start_char_idx": 839, "end_char_idx": 922, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f00cc933-a4f1-4a48-b797-f589bf6da184": {"__data__": {"id_": "f00cc933-a4f1-4a48-b797-f589bf6da184", "embedding": null, "metadata": {"window": "LLC  Q \nGood, thanks for the question.  I guess, just on the guidance within the pharma segment, the core growth of 5% to \n8%, Britt, seems re ally strong, especially considering your assumption that scripts won't be back to pre -COVID \nlevel until the second half.  So just any additional kind of building blocks or thoughts there would be helpful.  And \nthen just to clarify, your peers have talked a l ot about pockets of pricing pressure in generics and pockets of \nvolume weakness.  Just want to understand clearly what your assumptions are from what you're seeing today and \nin guidance relative to the generic book.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question, Bob. ", "original_text": "And \nthen just to clarify, your peers have talked a l ot about pockets of pricing pressure in generics and pockets of \nvolume weakness. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8c0bbf7-4784-460e-8b2e-fea0828c9fe9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGood, thanks for the question.  I guess, just on the guidance within the pharma segment, the core growth of 5% to \n8%, Britt, seems re ally strong, especially considering your assumption that scripts won't be back to pre -COVID \nlevel until the second half.  So just any additional kind of building blocks or thoughts there would be helpful.  And \nthen just to clarify, your peers have talked a l ot about pockets of pricing pressure in generics and pockets of \nvolume weakness.  Just want to understand clearly what your assumptions are from what you're seeing today and \nin guidance relative to the generic book.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "So just any additional kind of building blocks or thoughts there would be helpful. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c76b81bc2fe308ac4a77f2f551a3e3d2aa37675e9fbc8e34a84df566fef1586", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a6ebd35-2e22-4d60-99b0-db416e2e7e12", "node_type": "1", "metadata": {"window": "I guess, just on the guidance within the pharma segment, the core growth of 5% to \n8%, Britt, seems re ally strong, especially considering your assumption that scripts won't be back to pre -COVID \nlevel until the second half.  So just any additional kind of building blocks or thoughts there would be helpful.  And \nthen just to clarify, your peers have talked a l ot about pockets of pricing pressure in generics and pockets of \nvolume weakness.  Just want to understand clearly what your assumptions are from what you're seeing today and \nin guidance relative to the generic book.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question, Bob.  Look, we're very pleased with how the business has continued to grow and \ngain momentum. ", "original_text": "Just want to understand clearly what your assumptions are from what you're seeing today and \nin guidance relative to the generic book.  \n "}, "hash": "7f9018afbc8b933a618adb46bf1bcf3121cbb3b9ed84a4e7386235f87c1c1296", "class_name": "RelatedNodeInfo"}}, "text": "And \nthen just to clarify, your peers have talked a l ot about pockets of pricing pressure in generics and pockets of \nvolume weakness. ", "start_char_idx": 922, "end_char_idx": 1058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a6ebd35-2e22-4d60-99b0-db416e2e7e12": {"__data__": {"id_": "5a6ebd35-2e22-4d60-99b0-db416e2e7e12", "embedding": null, "metadata": {"window": "I guess, just on the guidance within the pharma segment, the core growth of 5% to \n8%, Britt, seems re ally strong, especially considering your assumption that scripts won't be back to pre -COVID \nlevel until the second half.  So just any additional kind of building blocks or thoughts there would be helpful.  And \nthen just to clarify, your peers have talked a l ot about pockets of pricing pressure in generics and pockets of \nvolume weakness.  Just want to understand clearly what your assumptions are from what you're seeing today and \nin guidance relative to the generic book.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question, Bob.  Look, we're very pleased with how the business has continued to grow and \ngain momentum. ", "original_text": "Just want to understand clearly what your assumptions are from what you're seeing today and \nin guidance relative to the generic book.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f00cc933-a4f1-4a48-b797-f589bf6da184", "node_type": "1", "metadata": {"window": "LLC  Q \nGood, thanks for the question.  I guess, just on the guidance within the pharma segment, the core growth of 5% to \n8%, Britt, seems re ally strong, especially considering your assumption that scripts won't be back to pre -COVID \nlevel until the second half.  So just any additional kind of building blocks or thoughts there would be helpful.  And \nthen just to clarify, your peers have talked a l ot about pockets of pricing pressure in generics and pockets of \nvolume weakness.  Just want to understand clearly what your assumptions are from what you're seeing today and \nin guidance relative to the generic book.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question, Bob. ", "original_text": "And \nthen just to clarify, your peers have talked a l ot about pockets of pricing pressure in generics and pockets of \nvolume weakness. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c6731eac39c822924df41f66e22c8485ab99d74c19c792d09dabd257ce13661", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de0457fc-5153-4c00-9f6c-f21da442df3a", "node_type": "1", "metadata": {"window": "So just any additional kind of building blocks or thoughts there would be helpful.  And \nthen just to clarify, your peers have talked a l ot about pockets of pricing pressure in generics and pockets of \nvolume weakness.  Just want to understand clearly what your assumptions are from what you're seeing today and \nin guidance relative to the generic book.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question, Bob.  Look, we're very pleased with how the business has continued to grow and \ngain momentum.  This is the second year in a row now where this business has grown. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "02ab32bec914e838e4ba546f7c2bc237772bd160b098b8f4b9ffe225a12a505f", "class_name": "RelatedNodeInfo"}}, "text": "Just want to understand clearly what your assumptions are from what you're seeing today and \nin guidance relative to the generic book.  \n ", "start_char_idx": 1058, "end_char_idx": 1196, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de0457fc-5153-4c00-9f6c-f21da442df3a": {"__data__": {"id_": "de0457fc-5153-4c00-9f6c-f21da442df3a", "embedding": null, "metadata": {"window": "So just any additional kind of building blocks or thoughts there would be helpful.  And \nthen just to clarify, your peers have talked a l ot about pockets of pricing pressure in generics and pockets of \nvolume weakness.  Just want to understand clearly what your assumptions are from what you're seeing today and \nin guidance relative to the generic book.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question, Bob.  Look, we're very pleased with how the business has continued to grow and \ngain momentum.  This is the second year in a row now where this business has grown. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a6ebd35-2e22-4d60-99b0-db416e2e7e12", "node_type": "1", "metadata": {"window": "I guess, just on the guidance within the pharma segment, the core growth of 5% to \n8%, Britt, seems re ally strong, especially considering your assumption that scripts won't be back to pre -COVID \nlevel until the second half.  So just any additional kind of building blocks or thoughts there would be helpful.  And \nthen just to clarify, your peers have talked a l ot about pockets of pricing pressure in generics and pockets of \nvolume weakness.  Just want to understand clearly what your assumptions are from what you're seeing today and \nin guidance relative to the generic book.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question, Bob.  Look, we're very pleased with how the business has continued to grow and \ngain momentum. ", "original_text": "Just want to understand clearly what your assumptions are from what you're seeing today and \nin guidance relative to the generic book.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "89c83edcb73490cf5680ec0b527bcdbc96cb3c1209a80166632d7c7401583460", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7aba5d1f-f843-42d9-9915-7fde58ed1cf0", "node_type": "1", "metadata": {"window": "And \nthen just to clarify, your peers have talked a l ot about pockets of pricing pressure in generics and pockets of \nvolume weakness.  Just want to understand clearly what your assumptions are from what you're seeing today and \nin guidance relative to the generic book.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question, Bob.  Look, we're very pleased with how the business has continued to grow and \ngain momentum.  This is the second year in a row now where this business has grown.  We've got really good \nscale and reach across all of our businesses. ", "original_text": "A \nYeah, thanks for the question, Bob. "}, "hash": "d2ef30384a138e2249f3355f49cfa15cad6a8c139d6734625fd8a1d781db0817", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 1196, "end_char_idx": 1538, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7aba5d1f-f843-42d9-9915-7fde58ed1cf0": {"__data__": {"id_": "7aba5d1f-f843-42d9-9915-7fde58ed1cf0", "embedding": null, "metadata": {"window": "And \nthen just to clarify, your peers have talked a l ot about pockets of pricing pressure in generics and pockets of \nvolume weakness.  Just want to understand clearly what your assumptions are from what you're seeing today and \nin guidance relative to the generic book.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question, Bob.  Look, we're very pleased with how the business has continued to grow and \ngain momentum.  This is the second year in a row now where this business has grown.  We've got really good \nscale and reach across all of our businesses. ", "original_text": "A \nYeah, thanks for the question, Bob. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de0457fc-5153-4c00-9f6c-f21da442df3a", "node_type": "1", "metadata": {"window": "So just any additional kind of building blocks or thoughts there would be helpful.  And \nthen just to clarify, your peers have talked a l ot about pockets of pricing pressure in generics and pockets of \nvolume weakness.  Just want to understand clearly what your assumptions are from what you're seeing today and \nin guidance relative to the generic book.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question, Bob.  Look, we're very pleased with how the business has continued to grow and \ngain momentum.  This is the second year in a row now where this business has grown. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f90089e3315d3e65f903d5533087058105f56b937eb5e05ee248ece61aab89f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3e0a852-120a-465e-96b2-eced63741ed3", "node_type": "1", "metadata": {"window": "Just want to understand clearly what your assumptions are from what you're seeing today and \nin guidance relative to the generic book.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question, Bob.  Look, we're very pleased with how the business has continued to grow and \ngain momentum.  This is the second year in a row now where this business has grown.  We've got really good \nscale and reach across all of our businesses.  Brian talked about our specialty businesses and particularly \ndifferentiation that we have in oncology. ", "original_text": "Look, we're very pleased with how the business has continued to grow and \ngain momentum. "}, "hash": "793b382c8b31560f264e1a2e2a032838947c0172ab5a3b1c712a12a5a740a12d", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah, thanks for the question, Bob. ", "start_char_idx": 1538, "end_char_idx": 1577, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3e0a852-120a-465e-96b2-eced63741ed3": {"__data__": {"id_": "b3e0a852-120a-465e-96b2-eced63741ed3", "embedding": null, "metadata": {"window": "Just want to understand clearly what your assumptions are from what you're seeing today and \nin guidance relative to the generic book.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question, Bob.  Look, we're very pleased with how the business has continued to grow and \ngain momentum.  This is the second year in a row now where this business has grown.  We've got really good \nscale and reach across all of our businesses.  Brian talked about our specialty businesses and particularly \ndifferentiation that we have in oncology. ", "original_text": "Look, we're very pleased with how the business has continued to grow and \ngain momentum. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7aba5d1f-f843-42d9-9915-7fde58ed1cf0", "node_type": "1", "metadata": {"window": "And \nthen just to clarify, your peers have talked a l ot about pockets of pricing pressure in generics and pockets of \nvolume weakness.  Just want to understand clearly what your assumptions are from what you're seeing today and \nin guidance relative to the generic book.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question, Bob.  Look, we're very pleased with how the business has continued to grow and \ngain momentum.  This is the second year in a row now where this business has grown.  We've got really good \nscale and reach across all of our businesses. ", "original_text": "A \nYeah, thanks for the question, Bob. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c17a692d6ca03aa1aac1afd296a0a52356b81cfc71c29403932f5128155b462", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c531e3aa-ebaa-44ae-a1e1-31d8ae5dece2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question, Bob.  Look, we're very pleased with how the business has continued to grow and \ngain momentum.  This is the second year in a row now where this business has grown.  We've got really good \nscale and reach across all of our businesses.  Brian talked about our specialty businesses and particularly \ndifferentiation that we have in oncology.  And so we think that the momentum is going to continue. ", "original_text": "This is the second year in a row now where this business has grown. "}, "hash": "dfcda9dc461cc87ef6f5aa611bfc36b77b3f28684709f1ea17326656a607b22b", "class_name": "RelatedNodeInfo"}}, "text": "Look, we're very pleased with how the business has continued to grow and \ngain momentum. ", "start_char_idx": 1577, "end_char_idx": 1666, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c531e3aa-ebaa-44ae-a1e1-31d8ae5dece2": {"__data__": {"id_": "c531e3aa-ebaa-44ae-a1e1-31d8ae5dece2", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question, Bob.  Look, we're very pleased with how the business has continued to grow and \ngain momentum.  This is the second year in a row now where this business has grown.  We've got really good \nscale and reach across all of our businesses.  Brian talked about our specialty businesses and particularly \ndifferentiation that we have in oncology.  And so we think that the momentum is going to continue. ", "original_text": "This is the second year in a row now where this business has grown. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3e0a852-120a-465e-96b2-eced63741ed3", "node_type": "1", "metadata": {"window": "Just want to understand clearly what your assumptions are from what you're seeing today and \nin guidance relative to the generic book.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question, Bob.  Look, we're very pleased with how the business has continued to grow and \ngain momentum.  This is the second year in a row now where this business has grown.  We've got really good \nscale and reach across all of our businesses.  Brian talked about our specialty businesses and particularly \ndifferentiation that we have in oncology. ", "original_text": "Look, we're very pleased with how the business has continued to grow and \ngain momentum. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2289040301d239ce7058bfd6d6892e2268ce10904150745547738fa6bc712d2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22c2f9aa-c8e5-4854-ac1d-85468f2a87d5", "node_type": "1", "metadata": {"window": "A \nYeah, thanks for the question, Bob.  Look, we're very pleased with how the business has continued to grow and \ngain momentum.  This is the second year in a row now where this business has grown.  We've got really good \nscale and reach across all of our businesses.  Brian talked about our specialty businesses and particularly \ndifferentiation that we have in oncology.  And so we think that the momentum is going to continue.  As I mentioned \nin my remarks, we're seeing som e encouraging signs, and we think that as utilization comes back, the momentum \nwill just continue.  \n \n", "original_text": "We've got really good \nscale and reach across all of our businesses. "}, "hash": "e135ff997223494d25c0ed7385290369f904ff9495a71a9f5f2bd1d1e0a46e3b", "class_name": "RelatedNodeInfo"}}, "text": "This is the second year in a row now where this business has grown. ", "start_char_idx": 1666, "end_char_idx": 1734, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22c2f9aa-c8e5-4854-ac1d-85468f2a87d5": {"__data__": {"id_": "22c2f9aa-c8e5-4854-ac1d-85468f2a87d5", "embedding": null, "metadata": {"window": "A \nYeah, thanks for the question, Bob.  Look, we're very pleased with how the business has continued to grow and \ngain momentum.  This is the second year in a row now where this business has grown.  We've got really good \nscale and reach across all of our businesses.  Brian talked about our specialty businesses and particularly \ndifferentiation that we have in oncology.  And so we think that the momentum is going to continue.  As I mentioned \nin my remarks, we're seeing som e encouraging signs, and we think that as utilization comes back, the momentum \nwill just continue.  \n \n", "original_text": "We've got really good \nscale and reach across all of our businesses. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c531e3aa-ebaa-44ae-a1e1-31d8ae5dece2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question, Bob.  Look, we're very pleased with how the business has continued to grow and \ngain momentum.  This is the second year in a row now where this business has grown.  We've got really good \nscale and reach across all of our businesses.  Brian talked about our specialty businesses and particularly \ndifferentiation that we have in oncology.  And so we think that the momentum is going to continue. ", "original_text": "This is the second year in a row now where this business has grown. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "432e7ebb3d95849278e7798cc676cae9d76d1a17233675981f3e14e8d45740ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "165ae2ab-7754-4e5e-87cb-880009e129f2", "node_type": "1", "metadata": {"window": "Look, we're very pleased with how the business has continued to grow and \ngain momentum.  This is the second year in a row now where this business has grown.  We've got really good \nscale and reach across all of our businesses.  Brian talked about our specialty businesses and particularly \ndifferentiation that we have in oncology.  And so we think that the momentum is going to continue.  As I mentioned \nin my remarks, we're seeing som e encouraging signs, and we think that as utilization comes back, the momentum \nwill just continue.  \n \n As it relates to our thought on the pricing environment, again, from a branded pricing perspective, we expect that \nFY 2022 will look a lot like FY 2021. ", "original_text": "Brian talked about our specialty businesses and particularly \ndifferentiation that we have in oncology. "}, "hash": "e594533a6a269298b571dd5a502631309b1198cf7b5f693c26473e45ab33324a", "class_name": "RelatedNodeInfo"}}, "text": "We've got really good \nscale and reach across all of our businesses. ", "start_char_idx": 1734, "end_char_idx": 1803, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "165ae2ab-7754-4e5e-87cb-880009e129f2": {"__data__": {"id_": "165ae2ab-7754-4e5e-87cb-880009e129f2", "embedding": null, "metadata": {"window": "Look, we're very pleased with how the business has continued to grow and \ngain momentum.  This is the second year in a row now where this business has grown.  We've got really good \nscale and reach across all of our businesses.  Brian talked about our specialty businesses and particularly \ndifferentiation that we have in oncology.  And so we think that the momentum is going to continue.  As I mentioned \nin my remarks, we're seeing som e encouraging signs, and we think that as utilization comes back, the momentum \nwill just continue.  \n \n As it relates to our thought on the pricing environment, again, from a branded pricing perspective, we expect that \nFY 2022 will look a lot like FY 2021. ", "original_text": "Brian talked about our specialty businesses and particularly \ndifferentiation that we have in oncology. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22c2f9aa-c8e5-4854-ac1d-85468f2a87d5", "node_type": "1", "metadata": {"window": "A \nYeah, thanks for the question, Bob.  Look, we're very pleased with how the business has continued to grow and \ngain momentum.  This is the second year in a row now where this business has grown.  We've got really good \nscale and reach across all of our businesses.  Brian talked about our specialty businesses and particularly \ndifferentiation that we have in oncology.  And so we think that the momentum is going to continue.  As I mentioned \nin my remarks, we're seeing som e encouraging signs, and we think that as utilization comes back, the momentum \nwill just continue.  \n \n", "original_text": "We've got really good \nscale and reach across all of our businesses. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b24f65949f64c2242a1bf7b2e30ba5c31e3e3c01e524441146d43f95f2db6c44", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74172b2e-f37f-4e1d-b8f1-89f3ce3bab23", "node_type": "1", "metadata": {"window": "This is the second year in a row now where this business has grown.  We've got really good \nscale and reach across all of our businesses.  Brian talked about our specialty businesses and particularly \ndifferentiation that we have in oncology.  And so we think that the momentum is going to continue.  As I mentioned \nin my remarks, we're seeing som e encouraging signs, and we think that as utilization comes back, the momentum \nwill just continue.  \n \n As it relates to our thought on the pricing environment, again, from a branded pricing perspective, we expect that \nFY 2022 will look a lot like FY 2021.  Fro m a generic perspective, we have a great sourcing capability in \nClarusONE. ", "original_text": "And so we think that the momentum is going to continue. "}, "hash": "ed86a87e38242b6799b6b09f035b247299976c3a0cc5a43635cf137a71c05582", "class_name": "RelatedNodeInfo"}}, "text": "Brian talked about our specialty businesses and particularly \ndifferentiation that we have in oncology. ", "start_char_idx": 1803, "end_char_idx": 1907, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74172b2e-f37f-4e1d-b8f1-89f3ce3bab23": {"__data__": {"id_": "74172b2e-f37f-4e1d-b8f1-89f3ce3bab23", "embedding": null, "metadata": {"window": "This is the second year in a row now where this business has grown.  We've got really good \nscale and reach across all of our businesses.  Brian talked about our specialty businesses and particularly \ndifferentiation that we have in oncology.  And so we think that the momentum is going to continue.  As I mentioned \nin my remarks, we're seeing som e encouraging signs, and we think that as utilization comes back, the momentum \nwill just continue.  \n \n As it relates to our thought on the pricing environment, again, from a branded pricing perspective, we expect that \nFY 2022 will look a lot like FY 2021.  Fro m a generic perspective, we have a great sourcing capability in \nClarusONE. ", "original_text": "And so we think that the momentum is going to continue. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "165ae2ab-7754-4e5e-87cb-880009e129f2", "node_type": "1", "metadata": {"window": "Look, we're very pleased with how the business has continued to grow and \ngain momentum.  This is the second year in a row now where this business has grown.  We've got really good \nscale and reach across all of our businesses.  Brian talked about our specialty businesses and particularly \ndifferentiation that we have in oncology.  And so we think that the momentum is going to continue.  As I mentioned \nin my remarks, we're seeing som e encouraging signs, and we think that as utilization comes back, the momentum \nwill just continue.  \n \n As it relates to our thought on the pricing environment, again, from a branded pricing perspective, we expect that \nFY 2022 will look a lot like FY 2021. ", "original_text": "Brian talked about our specialty businesses and particularly \ndifferentiation that we have in oncology. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b9803080610df34c1ab6f34ae48aec4ddc489f12f1c92847e01070e9ccbc9800", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77e260e0-bbef-4d7c-a0aa-d300cba8fe3d", "node_type": "1", "metadata": {"window": "We've got really good \nscale and reach across all of our businesses.  Brian talked about our specialty businesses and particularly \ndifferentiation that we have in oncology.  And so we think that the momentum is going to continue.  As I mentioned \nin my remarks, we're seeing som e encouraging signs, and we think that as utilization comes back, the momentum \nwill just continue.  \n \n As it relates to our thought on the pricing environment, again, from a branded pricing perspective, we expect that \nFY 2022 will look a lot like FY 2021.  Fro m a generic perspective, we have a great sourcing capability in \nClarusONE.  We continue to do a great job for our customers in providing stability of supply and low cost. ", "original_text": "As I mentioned \nin my remarks, we're seeing som e encouraging signs, and we think that as utilization comes back, the momentum \nwill just continue.  \n \n"}, "hash": "d687a7cc42b7a2c451f7740df7f129c85adb3006a532872bd88c9f137ad6828b", "class_name": "RelatedNodeInfo"}}, "text": "And so we think that the momentum is going to continue. ", "start_char_idx": 1907, "end_char_idx": 1963, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77e260e0-bbef-4d7c-a0aa-d300cba8fe3d": {"__data__": {"id_": "77e260e0-bbef-4d7c-a0aa-d300cba8fe3d", "embedding": null, "metadata": {"window": "We've got really good \nscale and reach across all of our businesses.  Brian talked about our specialty businesses and particularly \ndifferentiation that we have in oncology.  And so we think that the momentum is going to continue.  As I mentioned \nin my remarks, we're seeing som e encouraging signs, and we think that as utilization comes back, the momentum \nwill just continue.  \n \n As it relates to our thought on the pricing environment, again, from a branded pricing perspective, we expect that \nFY 2022 will look a lot like FY 2021.  Fro m a generic perspective, we have a great sourcing capability in \nClarusONE.  We continue to do a great job for our customers in providing stability of supply and low cost. ", "original_text": "As I mentioned \nin my remarks, we're seeing som e encouraging signs, and we think that as utilization comes back, the momentum \nwill just continue.  \n \n", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74172b2e-f37f-4e1d-b8f1-89f3ce3bab23", "node_type": "1", "metadata": {"window": "This is the second year in a row now where this business has grown.  We've got really good \nscale and reach across all of our businesses.  Brian talked about our specialty businesses and particularly \ndifferentiation that we have in oncology.  And so we think that the momentum is going to continue.  As I mentioned \nin my remarks, we're seeing som e encouraging signs, and we think that as utilization comes back, the momentum \nwill just continue.  \n \n As it relates to our thought on the pricing environment, again, from a branded pricing perspective, we expect that \nFY 2022 will look a lot like FY 2021.  Fro m a generic perspective, we have a great sourcing capability in \nClarusONE. ", "original_text": "And so we think that the momentum is going to continue. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9383c342c952d3176b89e9d2396471a693bde8c8ee52a839874d245122c6bf6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c7c6448-9fa0-4308-8a66-42192560c70e", "node_type": "1", "metadata": {"window": "Brian talked about our specialty businesses and particularly \ndifferentiation that we have in oncology.  And so we think that the momentum is going to continue.  As I mentioned \nin my remarks, we're seeing som e encouraging signs, and we think that as utilization comes back, the momentum \nwill just continue.  \n \n As it relates to our thought on the pricing environment, again, from a branded pricing perspective, we expect that \nFY 2022 will look a lot like FY 2021.  Fro m a generic perspective, we have a great sourcing capability in \nClarusONE.  We continue to do a great job for our customers in providing stability of supply and low cost.  We don't \nsee anything that's really changed the dynamics around either the buy side or  the sell side. ", "original_text": "As it relates to our thought on the pricing environment, again, from a branded pricing perspective, we expect that \nFY 2022 will look a lot like FY 2021. "}, "hash": "d4247d1cd8ca830a8bb5b867d701bc77b03217db56670412f062f299379159eb", "class_name": "RelatedNodeInfo"}}, "text": "As I mentioned \nin my remarks, we're seeing som e encouraging signs, and we think that as utilization comes back, the momentum \nwill just continue.  \n \n", "start_char_idx": 1963, "end_char_idx": 2115, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c7c6448-9fa0-4308-8a66-42192560c70e": {"__data__": {"id_": "8c7c6448-9fa0-4308-8a66-42192560c70e", "embedding": null, "metadata": {"window": "Brian talked about our specialty businesses and particularly \ndifferentiation that we have in oncology.  And so we think that the momentum is going to continue.  As I mentioned \nin my remarks, we're seeing som e encouraging signs, and we think that as utilization comes back, the momentum \nwill just continue.  \n \n As it relates to our thought on the pricing environment, again, from a branded pricing perspective, we expect that \nFY 2022 will look a lot like FY 2021.  Fro m a generic perspective, we have a great sourcing capability in \nClarusONE.  We continue to do a great job for our customers in providing stability of supply and low cost.  We don't \nsee anything that's really changed the dynamics around either the buy side or  the sell side. ", "original_text": "As it relates to our thought on the pricing environment, again, from a branded pricing perspective, we expect that \nFY 2022 will look a lot like FY 2021. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77e260e0-bbef-4d7c-a0aa-d300cba8fe3d", "node_type": "1", "metadata": {"window": "We've got really good \nscale and reach across all of our businesses.  Brian talked about our specialty businesses and particularly \ndifferentiation that we have in oncology.  And so we think that the momentum is going to continue.  As I mentioned \nin my remarks, we're seeing som e encouraging signs, and we think that as utilization comes back, the momentum \nwill just continue.  \n \n As it relates to our thought on the pricing environment, again, from a branded pricing perspective, we expect that \nFY 2022 will look a lot like FY 2021.  Fro m a generic perspective, we have a great sourcing capability in \nClarusONE.  We continue to do a great job for our customers in providing stability of supply and low cost. ", "original_text": "As I mentioned \nin my remarks, we're seeing som e encouraging signs, and we think that as utilization comes back, the momentum \nwill just continue.  \n \n", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bb6695ea7357c3446c8c18682a6d475074d2f56e1e4041954d782fa9e0215f0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be3e252d-fa08-4555-9b6a-16a98ed64afd", "node_type": "1", "metadata": {"window": "And so we think that the momentum is going to continue.  As I mentioned \nin my remarks, we're seeing som e encouraging signs, and we think that as utilization comes back, the momentum \nwill just continue.  \n \n As it relates to our thought on the pricing environment, again, from a branded pricing perspective, we expect that \nFY 2022 will look a lot like FY 2021.  Fro m a generic perspective, we have a great sourcing capability in \nClarusONE.  We continue to do a great job for our customers in providing stability of supply and low cost.  We don't \nsee anything that's really changed the dynamics around either the buy side or  the sell side.  It's a competitive \nmarket, but it's been stable now for several quarters. ", "original_text": "Fro m a generic perspective, we have a great sourcing capability in \nClarusONE. "}, "hash": "747c607a40bd635f954b850543e715538b63558da5eef7c4e73934817aac42eb", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to our thought on the pricing environment, again, from a branded pricing perspective, we expect that \nFY 2022 will look a lot like FY 2021. ", "start_char_idx": 2115, "end_char_idx": 2269, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be3e252d-fa08-4555-9b6a-16a98ed64afd": {"__data__": {"id_": "be3e252d-fa08-4555-9b6a-16a98ed64afd", "embedding": null, "metadata": {"window": "And so we think that the momentum is going to continue.  As I mentioned \nin my remarks, we're seeing som e encouraging signs, and we think that as utilization comes back, the momentum \nwill just continue.  \n \n As it relates to our thought on the pricing environment, again, from a branded pricing perspective, we expect that \nFY 2022 will look a lot like FY 2021.  Fro m a generic perspective, we have a great sourcing capability in \nClarusONE.  We continue to do a great job for our customers in providing stability of supply and low cost.  We don't \nsee anything that's really changed the dynamics around either the buy side or  the sell side.  It's a competitive \nmarket, but it's been stable now for several quarters. ", "original_text": "Fro m a generic perspective, we have a great sourcing capability in \nClarusONE. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c7c6448-9fa0-4308-8a66-42192560c70e", "node_type": "1", "metadata": {"window": "Brian talked about our specialty businesses and particularly \ndifferentiation that we have in oncology.  And so we think that the momentum is going to continue.  As I mentioned \nin my remarks, we're seeing som e encouraging signs, and we think that as utilization comes back, the momentum \nwill just continue.  \n \n As it relates to our thought on the pricing environment, again, from a branded pricing perspective, we expect that \nFY 2022 will look a lot like FY 2021.  Fro m a generic perspective, we have a great sourcing capability in \nClarusONE.  We continue to do a great job for our customers in providing stability of supply and low cost.  We don't \nsee anything that's really changed the dynamics around either the buy side or  the sell side. ", "original_text": "As it relates to our thought on the pricing environment, again, from a branded pricing perspective, we expect that \nFY 2022 will look a lot like FY 2021. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2bc266c9c6b2c1ebe09ca7de90d7a444e9c3a1157983b1f9d65284d7ad073d82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b2c292b-02b4-4247-90a5-0bde5292fda5", "node_type": "1", "metadata": {"window": "As I mentioned \nin my remarks, we're seeing som e encouraging signs, and we think that as utilization comes back, the momentum \nwill just continue.  \n \n As it relates to our thought on the pricing environment, again, from a branded pricing perspective, we expect that \nFY 2022 will look a lot like FY 2021.  Fro m a generic perspective, we have a great sourcing capability in \nClarusONE.  We continue to do a great job for our customers in providing stability of supply and low cost.  We don't \nsee anything that's really changed the dynamics around either the buy side or  the sell side.  It's a competitive \nmarket, but it's been stable now for several quarters.  And we feel with the strength of our sourcing operation and \nour disciplined approach on the sell side that we'll continue to see the same types of contribution that w e've seen \nnow for several quarters.  \n ", "original_text": "We continue to do a great job for our customers in providing stability of supply and low cost. "}, "hash": "268236fed45f6f8149586113fce30d1361d866b57434259151a104cb3f265d55", "class_name": "RelatedNodeInfo"}}, "text": "Fro m a generic perspective, we have a great sourcing capability in \nClarusONE. ", "start_char_idx": 2269, "end_char_idx": 2349, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b2c292b-02b4-4247-90a5-0bde5292fda5": {"__data__": {"id_": "6b2c292b-02b4-4247-90a5-0bde5292fda5", "embedding": null, "metadata": {"window": "As I mentioned \nin my remarks, we're seeing som e encouraging signs, and we think that as utilization comes back, the momentum \nwill just continue.  \n \n As it relates to our thought on the pricing environment, again, from a branded pricing perspective, we expect that \nFY 2022 will look a lot like FY 2021.  Fro m a generic perspective, we have a great sourcing capability in \nClarusONE.  We continue to do a great job for our customers in providing stability of supply and low cost.  We don't \nsee anything that's really changed the dynamics around either the buy side or  the sell side.  It's a competitive \nmarket, but it's been stable now for several quarters.  And we feel with the strength of our sourcing operation and \nour disciplined approach on the sell side that we'll continue to see the same types of contribution that w e've seen \nnow for several quarters.  \n ", "original_text": "We continue to do a great job for our customers in providing stability of supply and low cost. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be3e252d-fa08-4555-9b6a-16a98ed64afd", "node_type": "1", "metadata": {"window": "And so we think that the momentum is going to continue.  As I mentioned \nin my remarks, we're seeing som e encouraging signs, and we think that as utilization comes back, the momentum \nwill just continue.  \n \n As it relates to our thought on the pricing environment, again, from a branded pricing perspective, we expect that \nFY 2022 will look a lot like FY 2021.  Fro m a generic perspective, we have a great sourcing capability in \nClarusONE.  We continue to do a great job for our customers in providing stability of supply and low cost.  We don't \nsee anything that's really changed the dynamics around either the buy side or  the sell side.  It's a competitive \nmarket, but it's been stable now for several quarters. ", "original_text": "Fro m a generic perspective, we have a great sourcing capability in \nClarusONE. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "267890bcad70aa46914d59db40dbecbf8d88dc83c4198402154ca146643c6366", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "141cc841-a90d-4407-ae97-d2f55df05a38", "node_type": "1", "metadata": {"window": "As it relates to our thought on the pricing environment, again, from a branded pricing perspective, we expect that \nFY 2022 will look a lot like FY 2021.  Fro m a generic perspective, we have a great sourcing capability in \nClarusONE.  We continue to do a great job for our customers in providing stability of supply and low cost.  We don't \nsee anything that's really changed the dynamics around either the buy side or  the sell side.  It's a competitive \nmarket, but it's been stable now for several quarters.  And we feel with the strength of our sourcing operation and \nour disciplined approach on the sell side that we'll continue to see the same types of contribution that w e've seen \nnow for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "We don't \nsee anything that's really changed the dynamics around either the buy side or  the sell side. "}, "hash": "ebebcadf296496cd6e9761f66a9546632c507196d6adc9779f60c5204cde1f1a", "class_name": "RelatedNodeInfo"}}, "text": "We continue to do a great job for our customers in providing stability of supply and low cost. ", "start_char_idx": 2349, "end_char_idx": 2444, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "141cc841-a90d-4407-ae97-d2f55df05a38": {"__data__": {"id_": "141cc841-a90d-4407-ae97-d2f55df05a38", "embedding": null, "metadata": {"window": "As it relates to our thought on the pricing environment, again, from a branded pricing perspective, we expect that \nFY 2022 will look a lot like FY 2021.  Fro m a generic perspective, we have a great sourcing capability in \nClarusONE.  We continue to do a great job for our customers in providing stability of supply and low cost.  We don't \nsee anything that's really changed the dynamics around either the buy side or  the sell side.  It's a competitive \nmarket, but it's been stable now for several quarters.  And we feel with the strength of our sourcing operation and \nour disciplined approach on the sell side that we'll continue to see the same types of contribution that w e've seen \nnow for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "We don't \nsee anything that's really changed the dynamics around either the buy side or  the sell side. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b2c292b-02b4-4247-90a5-0bde5292fda5", "node_type": "1", "metadata": {"window": "As I mentioned \nin my remarks, we're seeing som e encouraging signs, and we think that as utilization comes back, the momentum \nwill just continue.  \n \n As it relates to our thought on the pricing environment, again, from a branded pricing perspective, we expect that \nFY 2022 will look a lot like FY 2021.  Fro m a generic perspective, we have a great sourcing capability in \nClarusONE.  We continue to do a great job for our customers in providing stability of supply and low cost.  We don't \nsee anything that's really changed the dynamics around either the buy side or  the sell side.  It's a competitive \nmarket, but it's been stable now for several quarters.  And we feel with the strength of our sourcing operation and \nour disciplined approach on the sell side that we'll continue to see the same types of contribution that w e've seen \nnow for several quarters.  \n ", "original_text": "We continue to do a great job for our customers in providing stability of supply and low cost. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bcc216bcfa467f8e3d3eb21abdc5a8e50ae69913d45350a9f3f743f8a1533d43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d19c4f66-da40-4fb8-95d4-6508237f6e2f", "node_type": "1", "metadata": {"window": "Fro m a generic perspective, we have a great sourcing capability in \nClarusONE.  We continue to do a great job for our customers in providing stability of supply and low cost.  We don't \nsee anything that's really changed the dynamics around either the buy side or  the sell side.  It's a competitive \nmarket, but it's been stable now for several quarters.  And we feel with the strength of our sourcing operation and \nour disciplined approach on the sell side that we'll continue to see the same types of contribution that w e've seen \nnow for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYears, actually.  \n ", "original_text": "It's a competitive \nmarket, but it's been stable now for several quarters. "}, "hash": "c1530442d6c4dcc2e498e1224d0a90e170b78c6741c95754be7dc58c2246280d", "class_name": "RelatedNodeInfo"}}, "text": "We don't \nsee anything that's really changed the dynamics around either the buy side or  the sell side. ", "start_char_idx": 2444, "end_char_idx": 2548, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d19c4f66-da40-4fb8-95d4-6508237f6e2f": {"__data__": {"id_": "d19c4f66-da40-4fb8-95d4-6508237f6e2f", "embedding": null, "metadata": {"window": "Fro m a generic perspective, we have a great sourcing capability in \nClarusONE.  We continue to do a great job for our customers in providing stability of supply and low cost.  We don't \nsee anything that's really changed the dynamics around either the buy side or  the sell side.  It's a competitive \nmarket, but it's been stable now for several quarters.  And we feel with the strength of our sourcing operation and \nour disciplined approach on the sell side that we'll continue to see the same types of contribution that w e've seen \nnow for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYears, actually.  \n ", "original_text": "It's a competitive \nmarket, but it's been stable now for several quarters. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "141cc841-a90d-4407-ae97-d2f55df05a38", "node_type": "1", "metadata": {"window": "As it relates to our thought on the pricing environment, again, from a branded pricing perspective, we expect that \nFY 2022 will look a lot like FY 2021.  Fro m a generic perspective, we have a great sourcing capability in \nClarusONE.  We continue to do a great job for our customers in providing stability of supply and low cost.  We don't \nsee anything that's really changed the dynamics around either the buy side or  the sell side.  It's a competitive \nmarket, but it's been stable now for several quarters.  And we feel with the strength of our sourcing operation and \nour disciplined approach on the sell side that we'll continue to see the same types of contribution that w e've seen \nnow for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "We don't \nsee anything that's really changed the dynamics around either the buy side or  the sell side. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6690d93505dbdb0380791746eafad2e787713cca94739b2f188ee06775db662b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "672857f9-882d-4ac1-a349-9fcc13f6e296", "node_type": "1", "metadata": {"window": "We continue to do a great job for our customers in providing stability of supply and low cost.  We don't \nsee anything that's really changed the dynamics around either the buy side or  the sell side.  It's a competitive \nmarket, but it's been stable now for several quarters.  And we feel with the strength of our sourcing operation and \nour disciplined approach on the sell side that we'll continue to see the same types of contribution that w e've seen \nnow for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYears, actually.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "And we feel with the strength of our sourcing operation and \nour disciplined approach on the sell side that we'll continue to see the same types of contribution that w e've seen \nnow for several quarters.  \n "}, "hash": "e8bf496547e619b3fde654d467bed7e94093dc40a97a3d6e6754cdd86cf86875", "class_name": "RelatedNodeInfo"}}, "text": "It's a competitive \nmarket, but it's been stable now for several quarters. ", "start_char_idx": 2548, "end_char_idx": 2623, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "672857f9-882d-4ac1-a349-9fcc13f6e296": {"__data__": {"id_": "672857f9-882d-4ac1-a349-9fcc13f6e296", "embedding": null, "metadata": {"window": "We continue to do a great job for our customers in providing stability of supply and low cost.  We don't \nsee anything that's really changed the dynamics around either the buy side or  the sell side.  It's a competitive \nmarket, but it's been stable now for several quarters.  And we feel with the strength of our sourcing operation and \nour disciplined approach on the sell side that we'll continue to see the same types of contribution that w e've seen \nnow for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYears, actually.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "And we feel with the strength of our sourcing operation and \nour disciplined approach on the sell side that we'll continue to see the same types of contribution that w e've seen \nnow for several quarters.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d19c4f66-da40-4fb8-95d4-6508237f6e2f", "node_type": "1", "metadata": {"window": "Fro m a generic perspective, we have a great sourcing capability in \nClarusONE.  We continue to do a great job for our customers in providing stability of supply and low cost.  We don't \nsee anything that's really changed the dynamics around either the buy side or  the sell side.  It's a competitive \nmarket, but it's been stable now for several quarters.  And we feel with the strength of our sourcing operation and \nour disciplined approach on the sell side that we'll continue to see the same types of contribution that w e've seen \nnow for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYears, actually.  \n ", "original_text": "It's a competitive \nmarket, but it's been stable now for several quarters. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "532bdb9ebfd80ae55555ff73268be0b42d61204ee0a4e0abf6b635db81d78ac0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f4c7692-65e1-44ae-ab68-00a10bfb257a", "node_type": "1", "metadata": {"window": "We don't \nsee anything that's really changed the dynamics around either the buy side or  the sell side.  It's a competitive \nmarket, but it's been stable now for several quarters.  And we feel with the strength of our sourcing operation and \nour disciplined approach on the sell side that we'll continue to see the same types of contribution that w e've seen \nnow for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYears, actually.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYears, yes.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "47da3401eb1d85640c60f58abf9f44e6b71bfe7123f0943e248e8b7258d7200c", "class_name": "RelatedNodeInfo"}}, "text": "And we feel with the strength of our sourcing operation and \nour disciplined approach on the sell side that we'll continue to see the same types of contribution that w e've seen \nnow for several quarters.  \n ", "start_char_idx": 2623, "end_char_idx": 2831, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f4c7692-65e1-44ae-ab68-00a10bfb257a": {"__data__": {"id_": "2f4c7692-65e1-44ae-ab68-00a10bfb257a", "embedding": null, "metadata": {"window": "We don't \nsee anything that's really changed the dynamics around either the buy side or  the sell side.  It's a competitive \nmarket, but it's been stable now for several quarters.  And we feel with the strength of our sourcing operation and \nour disciplined approach on the sell side that we'll continue to see the same types of contribution that w e've seen \nnow for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYears, actually.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYears, yes.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "672857f9-882d-4ac1-a349-9fcc13f6e296", "node_type": "1", "metadata": {"window": "We continue to do a great job for our customers in providing stability of supply and low cost.  We don't \nsee anything that's really changed the dynamics around either the buy side or  the sell side.  It's a competitive \nmarket, but it's been stable now for several quarters.  And we feel with the strength of our sourcing operation and \nour disciplined approach on the sell side that we'll continue to see the same types of contribution that w e've seen \nnow for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYears, actually.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "And we feel with the strength of our sourcing operation and \nour disciplined approach on the sell side that we'll continue to see the same types of contribution that w e've seen \nnow for several quarters.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e8f3087c8ea221f6f02a55e4b63f2c2279c2c22a00087a2aa9d1dc4a95a73c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "288524dd-9ae5-4f6c-9544-32cc3698a00e", "node_type": "1", "metadata": {"window": "It's a competitive \nmarket, but it's been stable now for several quarters.  And we feel with the strength of our sourcing operation and \nour disciplined approach on the sell side that we'll continue to see the same types of contribution that w e've seen \nnow for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYears, actually.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYears, yes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "A \nYears, actually.  \n "}, "hash": "45b77f01d2385fe93634dff65a9db2dbcbfc842509395130dd737f8e5dfc6d91", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 2831, "end_char_idx": 3160, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "288524dd-9ae5-4f6c-9544-32cc3698a00e": {"__data__": {"id_": "288524dd-9ae5-4f6c-9544-32cc3698a00e", "embedding": null, "metadata": {"window": "It's a competitive \nmarket, but it's been stable now for several quarters.  And we feel with the strength of our sourcing operation and \nour disciplined approach on the sell side that we'll continue to see the same types of contribution that w e've seen \nnow for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYears, actually.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYears, yes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "A \nYears, actually.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f4c7692-65e1-44ae-ab68-00a10bfb257a", "node_type": "1", "metadata": {"window": "We don't \nsee anything that's really changed the dynamics around either the buy side or  the sell side.  It's a competitive \nmarket, but it's been stable now for several quarters.  And we feel with the strength of our sourcing operation and \nour disciplined approach on the sell side that we'll continue to see the same types of contribution that w e've seen \nnow for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYears, actually.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYears, yes.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "000c939de24b730152d16b89c2ca2ad09b0e5802c393c874e464bd31ce62d19a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "932b306a-8a0d-4443-817e-e3929411e8cb", "node_type": "1", "metadata": {"window": "And we feel with the strength of our sourcing operation and \nour disciplined approach on the sell side that we'll continue to see the same types of contribution that w e've seen \nnow for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYears, actually.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYears, yes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Mike Cherny with Bank of America.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "057b99e99ba833e6b3800dd47012ed2294384f70b9c0be8dbc72567c1da2381d", "class_name": "RelatedNodeInfo"}}, "text": "A \nYears, actually.  \n ", "start_char_idx": 3160, "end_char_idx": 3183, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "932b306a-8a0d-4443-817e-e3929411e8cb": {"__data__": {"id_": "932b306a-8a0d-4443-817e-e3929411e8cb", "embedding": null, "metadata": {"window": "And we feel with the strength of our sourcing operation and \nour disciplined approach on the sell side that we'll continue to see the same types of contribution that w e've seen \nnow for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYears, actually.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYears, yes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Mike Cherny with Bank of America.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "288524dd-9ae5-4f6c-9544-32cc3698a00e", "node_type": "1", "metadata": {"window": "It's a competitive \nmarket, but it's been stable now for several quarters.  And we feel with the strength of our sourcing operation and \nour disciplined approach on the sell side that we'll continue to see the same types of contribution that w e've seen \nnow for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYears, actually.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYears, yes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "A \nYears, actually.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "372e84277d4fd032ac71ab182ff5ae8fdcb844b519e8545be1c8c4dced1c1800", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd342539-8ef6-42a5-a448-17b8e47c3945", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYears, actually.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYears, yes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Mike Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "A \nYears, yes.  \n "}, "hash": "041cf780566a8870ea9097b94e0176401fcb933c5474b9a48025557886486c3d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 1196, "end_char_idx": 1538, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd342539-8ef6-42a5-a448-17b8e47c3945": {"__data__": {"id_": "cd342539-8ef6-42a5-a448-17b8e47c3945", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYears, actually.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYears, yes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Mike Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "A \nYears, yes.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "932b306a-8a0d-4443-817e-e3929411e8cb", "node_type": "1", "metadata": {"window": "And we feel with the strength of our sourcing operation and \nour disciplined approach on the sell side that we'll continue to see the same types of contribution that w e've seen \nnow for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYears, actually.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYears, yes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Mike Cherny with Bank of America.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "10f6ae324ebea3c4209c6188c3f77fd0460fc07820287cbc84b4ef7366aea38b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2ee87be-1f69-451b-b7e8-f3158b1cc68f", "node_type": "1", "metadata": {"window": "A \nYears, actually.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYears, yes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Mike Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. "}, "hash": "25ab12ae58a5f25505c0bd55e91f2f5314ab1dd5280637544a61b51982251198", "class_name": "RelatedNodeInfo"}}, "text": "A \nYears, yes.  \n ", "start_char_idx": 3525, "end_char_idx": 3543, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2ee87be-1f69-451b-b7e8-f3158b1cc68f": {"__data__": {"id_": "a2ee87be-1f69-451b-b7e8-f3158b1cc68f", "embedding": null, "metadata": {"window": "A \nYears, actually.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYears, yes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Mike Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd342539-8ef6-42a5-a448-17b8e47c3945", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYears, actually.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYears, yes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Mike Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "A \nYears, yes.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7fcc8e6b713446360f5266144ae74ce7510fd9087721cc4397cc8cb0f617fb4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1459fbb8-3a3f-448e-9135-0af802e7dbc1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYears, yes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Mike Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thanks for taking the question. ", "original_text": "Our next question comes from Mike Cherny with Bank of America.  \n "}, "hash": "9133104527641e63798d61d3ede6220ef17f79d79a0f273ae75b543d19cc8d6a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "start_char_idx": 3543, "end_char_idx": 3824, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1459fbb8-3a3f-448e-9135-0af802e7dbc1": {"__data__": {"id_": "1459fbb8-3a3f-448e-9135-0af802e7dbc1", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYears, yes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Mike Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thanks for taking the question. ", "original_text": "Our next question comes from Mike Cherny with Bank of America.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2ee87be-1f69-451b-b7e8-f3158b1cc68f", "node_type": "1", "metadata": {"window": "A \nYears, actually.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYears, yes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Mike Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ebbe67b47d3e9d821fd631b4b9396e04bd6e67e2629d83e11a36daa4c5f39e2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90bbbf4b-3770-4a2f-9624-6a44703c8923", "node_type": "1", "metadata": {"window": "A \nYears, yes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Mike Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thanks for taking the question.  Maybe if we could talk a little bit about pharmacy tech solutions a \nbit. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  "}, "hash": "d9f5b7c75e34facc0a42eefbd33b628e100ae75211c986fca7d5cb3fd8a60c75", "class_name": "RelatedNodeInfo"}}, "text": "Our next question comes from Mike Cherny with Bank of America.  \n ", "start_char_idx": 3824, "end_char_idx": 3890, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90bbbf4b-3770-4a2f-9624-6a44703c8923": {"__data__": {"id_": "90bbbf4b-3770-4a2f-9624-6a44703c8923", "embedding": null, "metadata": {"window": "A \nYears, yes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Mike Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thanks for taking the question.  Maybe if we could talk a little bit about pharmacy tech solutions a \nbit. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1459fbb8-3a3f-448e-9135-0af802e7dbc1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYears, yes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Mike Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thanks for taking the question. ", "original_text": "Our next question comes from Mike Cherny with Bank of America.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa22948383afab06739d0d059bf398eab363a2be91d8a9e7fae6c503522ec35b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6094c13a-ba2e-42b5-b3f5-7d1c78dec922", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Mike Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thanks for taking the question.  Maybe if we could talk a little bit about pharmacy tech solutions a \nbit.  It doesn't really get a t on of attention, but clearly, it's become a big piece of the EBIT. ", "original_text": "Q \nGood afternoon. "}, "hash": "960ec22fa26eded8532a1f961c9134c2d47f6936e8b6bfc33b07cbfbe59f6b8e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "start_char_idx": 3890, "end_char_idx": 4196, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6094c13a-ba2e-42b5-b3f5-7d1c78dec922": {"__data__": {"id_": "6094c13a-ba2e-42b5-b3f5-7d1c78dec922", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Mike Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thanks for taking the question.  Maybe if we could talk a little bit about pharmacy tech solutions a \nbit.  It doesn't really get a t on of attention, but clearly, it's become a big piece of the EBIT. ", "original_text": "Q \nGood afternoon. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90bbbf4b-3770-4a2f-9624-6a44703c8923", "node_type": "1", "metadata": {"window": "A \nYears, yes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Mike Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thanks for taking the question.  Maybe if we could talk a little bit about pharmacy tech solutions a \nbit. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c2da1b5b5b71a83a243253fa3a5b64d4d67647a32cc9cdf3ecb8bd4ec864af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8cadea9f-30ab-438e-8c2d-94283815088b", "node_type": "1", "metadata": {"window": "Our next question comes from Mike Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thanks for taking the question.  Maybe if we could talk a little bit about pharmacy tech solutions a \nbit.  It doesn't really get a t on of attention, but clearly, it's become a big piece of the EBIT.  As you think about the \ndemand curve that you've seen heading into fiscal 2022, and obviously, in terms of how pharmacies are reacting \nfrom fiscal 2021 and all the changes they've had around  COVID, can you just give us a sense on what drives that \ngrowth? ", "original_text": "Thanks for taking the question. "}, "hash": "c7d864e3ccfd6bc29fe6bd56956a81a25be30cab6b2c394cf1e145adeba41cf5", "class_name": "RelatedNodeInfo"}}, "text": "Q \nGood afternoon. ", "start_char_idx": 4196, "end_char_idx": 4215, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8cadea9f-30ab-438e-8c2d-94283815088b": {"__data__": {"id_": "8cadea9f-30ab-438e-8c2d-94283815088b", "embedding": null, "metadata": {"window": "Our next question comes from Mike Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thanks for taking the question.  Maybe if we could talk a little bit about pharmacy tech solutions a \nbit.  It doesn't really get a t on of attention, but clearly, it's become a big piece of the EBIT.  As you think about the \ndemand curve that you've seen heading into fiscal 2022, and obviously, in terms of how pharmacies are reacting \nfrom fiscal 2021 and all the changes they've had around  COVID, can you just give us a sense on what drives that \ngrowth? ", "original_text": "Thanks for taking the question. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6094c13a-ba2e-42b5-b3f5-7d1c78dec922", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Mike Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thanks for taking the question.  Maybe if we could talk a little bit about pharmacy tech solutions a \nbit.  It doesn't really get a t on of attention, but clearly, it's become a big piece of the EBIT. ", "original_text": "Q \nGood afternoon. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a1e795b46fbb8e3d4daaccffa49f794bab8a9b1a580447c8ae4c3d6a3788fe19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "932ec76e-cb47-4547-b9f1-a47f3da00d0c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thanks for taking the question.  Maybe if we could talk a little bit about pharmacy tech solutions a \nbit.  It doesn't really get a t on of attention, but clearly, it's become a big piece of the EBIT.  As you think about the \ndemand curve that you've seen heading into fiscal 2022, and obviously, in terms of how pharmacies are reacting \nfrom fiscal 2021 and all the changes they've had around  COVID, can you just give us a sense on what drives that \ngrowth?  It's clearly a stand out in terms of your overall revenue, overall profitability. ", "original_text": "Maybe if we could talk a little bit about pharmacy tech solutions a \nbit. "}, "hash": "f1acc0de9b63ee3dff9d2c69064494154e4c11b928854337206dd9b0a930353d", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the question. ", "start_char_idx": 4215, "end_char_idx": 4247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "932ec76e-cb47-4547-b9f1-a47f3da00d0c": {"__data__": {"id_": "932ec76e-cb47-4547-b9f1-a47f3da00d0c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thanks for taking the question.  Maybe if we could talk a little bit about pharmacy tech solutions a \nbit.  It doesn't really get a t on of attention, but clearly, it's become a big piece of the EBIT.  As you think about the \ndemand curve that you've seen heading into fiscal 2022, and obviously, in terms of how pharmacies are reacting \nfrom fiscal 2021 and all the changes they've had around  COVID, can you just give us a sense on what drives that \ngrowth?  It's clearly a stand out in terms of your overall revenue, overall profitability. ", "original_text": "Maybe if we could talk a little bit about pharmacy tech solutions a \nbit. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8cadea9f-30ab-438e-8c2d-94283815088b", "node_type": "1", "metadata": {"window": "Our next question comes from Mike Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thanks for taking the question.  Maybe if we could talk a little bit about pharmacy tech solutions a \nbit.  It doesn't really get a t on of attention, but clearly, it's become a big piece of the EBIT.  As you think about the \ndemand curve that you've seen heading into fiscal 2022, and obviously, in terms of how pharmacies are reacting \nfrom fiscal 2021 and all the changes they've had around  COVID, can you just give us a sense on what drives that \ngrowth? ", "original_text": "Thanks for taking the question. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "200f7e0533030ca14491a6db6b1c96c7594c5892ce652be77769193c0b028592", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4df76e31-1373-457a-9513-aafe795df3f0", "node_type": "1", "metadata": {"window": "Q \nGood afternoon.  Thanks for taking the question.  Maybe if we could talk a little bit about pharmacy tech solutions a \nbit.  It doesn't really get a t on of attention, but clearly, it's become a big piece of the EBIT.  As you think about the \ndemand curve that you've seen heading into fiscal 2022, and obviously, in terms of how pharmacies are reacting \nfrom fiscal 2021 and all the changes they've had around  COVID, can you just give us a sense on what drives that \ngrowth?  It's clearly a stand out in terms of your overall revenue, overall profitability.  It's higher margin. ", "original_text": "It doesn't really get a t on of attention, but clearly, it's become a big piece of the EBIT. "}, "hash": "53b028162749bf8b5b5cf283643dde36b6eef3f9775255bfe51c1e9043d57ad1", "class_name": "RelatedNodeInfo"}}, "text": "Maybe if we could talk a little bit about pharmacy tech solutions a \nbit. ", "start_char_idx": 4247, "end_char_idx": 4321, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4df76e31-1373-457a-9513-aafe795df3f0": {"__data__": {"id_": "4df76e31-1373-457a-9513-aafe795df3f0", "embedding": null, "metadata": {"window": "Q \nGood afternoon.  Thanks for taking the question.  Maybe if we could talk a little bit about pharmacy tech solutions a \nbit.  It doesn't really get a t on of attention, but clearly, it's become a big piece of the EBIT.  As you think about the \ndemand curve that you've seen heading into fiscal 2022, and obviously, in terms of how pharmacies are reacting \nfrom fiscal 2021 and all the changes they've had around  COVID, can you just give us a sense on what drives that \ngrowth?  It's clearly a stand out in terms of your overall revenue, overall profitability.  It's higher margin. ", "original_text": "It doesn't really get a t on of attention, but clearly, it's become a big piece of the EBIT. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "932ec76e-cb47-4547-b9f1-a47f3da00d0c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thanks for taking the question.  Maybe if we could talk a little bit about pharmacy tech solutions a \nbit.  It doesn't really get a t on of attention, but clearly, it's become a big piece of the EBIT.  As you think about the \ndemand curve that you've seen heading into fiscal 2022, and obviously, in terms of how pharmacies are reacting \nfrom fiscal 2021 and all the changes they've had around  COVID, can you just give us a sense on what drives that \ngrowth?  It's clearly a stand out in terms of your overall revenue, overall profitability. ", "original_text": "Maybe if we could talk a little bit about pharmacy tech solutions a \nbit. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50a0130209883429f2fd65ef637d50ac11f67ab8d8ee40e3d76c5afa7e5b8849", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8f8f6ce-379f-4270-af3a-c8df66be45af", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Maybe if we could talk a little bit about pharmacy tech solutions a \nbit.  It doesn't really get a t on of attention, but clearly, it's become a big piece of the EBIT.  As you think about the \ndemand curve that you've seen heading into fiscal 2022, and obviously, in terms of how pharmacies are reacting \nfrom fiscal 2021 and all the changes they've had around  COVID, can you just give us a sense on what drives that \ngrowth?  It's clearly a stand out in terms of your overall revenue, overall profitability.  It's higher margin.  So how ", "original_text": "As you think about the \ndemand curve that you've seen heading into fiscal 2022, and obviously, in terms of how pharmacies are reacting \nfrom fiscal 2021 and all the changes they've had around  COVID, can you just give us a sense on what drives that \ngrowth? "}, "hash": "c01373d70346eb483ae0479f57a7b77fde5486dedd7a0110c8fc220ec67fdf59", "class_name": "RelatedNodeInfo"}}, "text": "It doesn't really get a t on of attention, but clearly, it's become a big piece of the EBIT. ", "start_char_idx": 4321, "end_char_idx": 4414, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8f8f6ce-379f-4270-af3a-c8df66be45af": {"__data__": {"id_": "f8f8f6ce-379f-4270-af3a-c8df66be45af", "embedding": null, "metadata": {"window": "Thanks for taking the question.  Maybe if we could talk a little bit about pharmacy tech solutions a \nbit.  It doesn't really get a t on of attention, but clearly, it's become a big piece of the EBIT.  As you think about the \ndemand curve that you've seen heading into fiscal 2022, and obviously, in terms of how pharmacies are reacting \nfrom fiscal 2021 and all the changes they've had around  COVID, can you just give us a sense on what drives that \ngrowth?  It's clearly a stand out in terms of your overall revenue, overall profitability.  It's higher margin.  So how ", "original_text": "As you think about the \ndemand curve that you've seen heading into fiscal 2022, and obviously, in terms of how pharmacies are reacting \nfrom fiscal 2021 and all the changes they've had around  COVID, can you just give us a sense on what drives that \ngrowth? ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4df76e31-1373-457a-9513-aafe795df3f0", "node_type": "1", "metadata": {"window": "Q \nGood afternoon.  Thanks for taking the question.  Maybe if we could talk a little bit about pharmacy tech solutions a \nbit.  It doesn't really get a t on of attention, but clearly, it's become a big piece of the EBIT.  As you think about the \ndemand curve that you've seen heading into fiscal 2022, and obviously, in terms of how pharmacies are reacting \nfrom fiscal 2021 and all the changes they've had around  COVID, can you just give us a sense on what drives that \ngrowth?  It's clearly a stand out in terms of your overall revenue, overall profitability.  It's higher margin. ", "original_text": "It doesn't really get a t on of attention, but clearly, it's become a big piece of the EBIT. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b7fbb86d203adcb923076708d5e1939f5d891bbb93d1505d871b16297ac8ba5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29e2f8db-4564-4703-a42b-3b17fc7a6ae1", "node_type": "1", "metadata": {"window": "Maybe if we could talk a little bit about pharmacy tech solutions a \nbit.  It doesn't really get a t on of attention, but clearly, it's become a big piece of the EBIT.  As you think about the \ndemand curve that you've seen heading into fiscal 2022, and obviously, in terms of how pharmacies are reacting \nfrom fiscal 2021 and all the changes they've had around  COVID, can you just give us a sense on what drives that \ngrowth?  It's clearly a stand out in terms of your overall revenue, overall profitability.  It's higher margin.  So how ", "original_text": "It's clearly a stand out in terms of your overall revenue, overall profitability. "}, "hash": "1c8af1f26d818af78a6283cf79e6cf03340c09bf918e56578a947c40a66ebc4e", "class_name": "RelatedNodeInfo"}}, "text": "As you think about the \ndemand curve that you've seen heading into fiscal 2022, and obviously, in terms of how pharmacies are reacting \nfrom fiscal 2021 and all the changes they've had around  COVID, can you just give us a sense on what drives that \ngrowth? ", "start_char_idx": 4414, "end_char_idx": 4672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29e2f8db-4564-4703-a42b-3b17fc7a6ae1": {"__data__": {"id_": "29e2f8db-4564-4703-a42b-3b17fc7a6ae1", "embedding": null, "metadata": {"window": "Maybe if we could talk a little bit about pharmacy tech solutions a \nbit.  It doesn't really get a t on of attention, but clearly, it's become a big piece of the EBIT.  As you think about the \ndemand curve that you've seen heading into fiscal 2022, and obviously, in terms of how pharmacies are reacting \nfrom fiscal 2021 and all the changes they've had around  COVID, can you just give us a sense on what drives that \ngrowth?  It's clearly a stand out in terms of your overall revenue, overall profitability.  It's higher margin.  So how ", "original_text": "It's clearly a stand out in terms of your overall revenue, overall profitability. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8f8f6ce-379f-4270-af3a-c8df66be45af", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Maybe if we could talk a little bit about pharmacy tech solutions a \nbit.  It doesn't really get a t on of attention, but clearly, it's become a big piece of the EBIT.  As you think about the \ndemand curve that you've seen heading into fiscal 2022, and obviously, in terms of how pharmacies are reacting \nfrom fiscal 2021 and all the changes they've had around  COVID, can you just give us a sense on what drives that \ngrowth?  It's clearly a stand out in terms of your overall revenue, overall profitability.  It's higher margin.  So how ", "original_text": "As you think about the \ndemand curve that you've seen heading into fiscal 2022, and obviously, in terms of how pharmacies are reacting \nfrom fiscal 2021 and all the changes they've had around  COVID, can you just give us a sense on what drives that \ngrowth? ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc0352026f9d7a0c4008eab7d85f9920321e2a171123f4d771671a34a52a4bf1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "acdd6eb9-b69e-4be4-ad96-4ead0937b868", "node_type": "1", "metadata": {"window": "It doesn't really get a t on of attention, but clearly, it's become a big piece of the EBIT.  As you think about the \ndemand curve that you've seen heading into fiscal 2022, and obviously, in terms of how pharmacies are reacting \nfrom fiscal 2021 and all the changes they've had around  COVID, can you just give us a sense on what drives that \ngrowth?  It's clearly a stand out in terms of your overall revenue, overall profitability.  It's higher margin.  So how ", "original_text": "It's higher margin. "}, "hash": "f1ce843736f9b1691278c2a0690b7835e225fe4133cbf683ff73e1dbc04f2293", "class_name": "RelatedNodeInfo"}}, "text": "It's clearly a stand out in terms of your overall revenue, overall profitability. ", "start_char_idx": 4672, "end_char_idx": 4754, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "acdd6eb9-b69e-4be4-ad96-4ead0937b868": {"__data__": {"id_": "acdd6eb9-b69e-4be4-ad96-4ead0937b868", "embedding": null, "metadata": {"window": "It doesn't really get a t on of attention, but clearly, it's become a big piece of the EBIT.  As you think about the \ndemand curve that you've seen heading into fiscal 2022, and obviously, in terms of how pharmacies are reacting \nfrom fiscal 2021 and all the changes they've had around  COVID, can you just give us a sense on what drives that \ngrowth?  It's clearly a stand out in terms of your overall revenue, overall profitability.  It's higher margin.  So how ", "original_text": "It's higher margin. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29e2f8db-4564-4703-a42b-3b17fc7a6ae1", "node_type": "1", "metadata": {"window": "Maybe if we could talk a little bit about pharmacy tech solutions a \nbit.  It doesn't really get a t on of attention, but clearly, it's become a big piece of the EBIT.  As you think about the \ndemand curve that you've seen heading into fiscal 2022, and obviously, in terms of how pharmacies are reacting \nfrom fiscal 2021 and all the changes they've had around  COVID, can you just give us a sense on what drives that \ngrowth?  It's clearly a stand out in terms of your overall revenue, overall profitability.  It's higher margin.  So how ", "original_text": "It's clearly a stand out in terms of your overall revenue, overall profitability. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0999000c78f0babc3172f68b966404c6b2ad1dc5b13146daab75cf17fd0d0b2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be6b322b-5eac-4e01-a484-b77c37d2b11a", "node_type": "1", "metadata": {"window": "As you think about the \ndemand curve that you've seen heading into fiscal 2022, and obviously, in terms of how pharmacies are reacting \nfrom fiscal 2021 and all the changes they've had around  COVID, can you just give us a sense on what drives that \ngrowth?  It's clearly a stand out in terms of your overall revenue, overall profitability.  It's higher margin.  So how ", "original_text": "So how "}, "hash": "80c0320463cf9857ebce0f7ecf4e9bc2d4c825aa06063bc46a442ce66837ae5b", "class_name": "RelatedNodeInfo"}}, "text": "It's higher margin. ", "start_char_idx": 4754, "end_char_idx": 4774, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be6b322b-5eac-4e01-a484-b77c37d2b11a": {"__data__": {"id_": "be6b322b-5eac-4e01-a484-b77c37d2b11a", "embedding": null, "metadata": {"window": "As you think about the \ndemand curve that you've seen heading into fiscal 2022, and obviously, in terms of how pharmacies are reacting \nfrom fiscal 2021 and all the changes they've had around  COVID, can you just give us a sense on what drives that \ngrowth?  It's clearly a stand out in terms of your overall revenue, overall profitability.  It's higher margin.  So how ", "original_text": "So how ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c142558-d937-4cde-883b-b05268c55f66", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3bce73315984e233dd18b24d92f1e4fb9938a6a61b884fbd9985c55de90921", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "acdd6eb9-b69e-4be4-ad96-4ead0937b868", "node_type": "1", "metadata": {"window": "It doesn't really get a t on of attention, but clearly, it's become a big piece of the EBIT.  As you think about the \ndemand curve that you've seen heading into fiscal 2022, and obviously, in terms of how pharmacies are reacting \nfrom fiscal 2021 and all the changes they've had around  COVID, can you just give us a sense on what drives that \ngrowth?  It's clearly a stand out in terms of your overall revenue, overall profitability.  It's higher margin.  So how ", "original_text": "It's higher margin. ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a22025863fb842c35b560f17cd9ad146e9bc80d82d953659419159b68ce80f5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c8cb61b-3c73-4614-b689-eacabe2c96da", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nshould we think about where the adoption levels are coming from your customers in terms of supporting that \nunderlying growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "McKesson Corp.  "}, "hash": "be263f7e670a4f75ec4d02e1f6bf5eb89268743422e2144d567fa17f1ff0c5d6", "class_name": "RelatedNodeInfo"}}, "text": "So how ", "start_char_idx": 4774, "end_char_idx": 4781, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c8cb61b-3c73-4614-b689-eacabe2c96da": {"__data__": {"id_": "4c8cb61b-3c73-4614-b689-eacabe2c96da", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nshould we think about where the adoption levels are coming from your customers in terms of supporting that \nunderlying growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be6b322b-5eac-4e01-a484-b77c37d2b11a", "node_type": "1", "metadata": {"window": "As you think about the \ndemand curve that you've seen heading into fiscal 2022, and obviously, in terms of how pharmacies are reacting \nfrom fiscal 2021 and all the changes they've had around  COVID, can you just give us a sense on what drives that \ngrowth?  It's clearly a stand out in terms of your overall revenue, overall profitability.  It's higher margin.  So how ", "original_text": "So how ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bba4af63fbd12c9862c139e6e3ed0f2d6212f2b290f96ea26355e0773e6aba75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5a0a4c2-17e6-49ce-8e63-4f6786fc2ed8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nshould we think about where the adoption levels are coming from your customers in terms of supporting that \nunderlying growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I mean, thanks, great question. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nshould we think about where the adoption levels are coming from your customers in terms of supporting that \nunderlying growth?  \n "}, "hash": "738de1f1646cac17ba1ff6ad43c8a7ae31bd88dd1f4383de3701859526000fad", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5a0a4c2-17e6-49ce-8e63-4f6786fc2ed8": {"__data__": {"id_": "b5a0a4c2-17e6-49ce-8e63-4f6786fc2ed8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nshould we think about where the adoption levels are coming from your customers in terms of supporting that \nunderlying growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I mean, thanks, great question. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nshould we think about where the adoption levels are coming from your customers in terms of supporting that \nunderlying growth?  \n ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c8cb61b-3c73-4614-b689-eacabe2c96da", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nshould we think about where the adoption levels are coming from your customers in terms of supporting that \nunderlying growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa870397de2abd3bc20f562d473b8048c91dc039215054a8f516b2fc594819a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4046fb1b-a97e-452b-8748-85b4bc6f03d0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nshould we think about where the adoption levels are coming from your customers in terms of supporting that \nunderlying growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I mean, thanks, great question.  So fundamentally, this is a transaction volume -based business. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "13906258967b9239c88cbec6b71fd536ae2faacf4676c245fe9adf3f130a8371", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nshould we think about where the adoption levels are coming from your customers in terms of supporting that \nunderlying growth?  \n ", "start_char_idx": 16, "end_char_idx": 311, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4046fb1b-a97e-452b-8748-85b4bc6f03d0": {"__data__": {"id_": "4046fb1b-a97e-452b-8748-85b4bc6f03d0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nshould we think about where the adoption levels are coming from your customers in terms of supporting that \nunderlying growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I mean, thanks, great question.  So fundamentally, this is a transaction volume -based business. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5a0a4c2-17e6-49ce-8e63-4f6786fc2ed8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nshould we think about where the adoption levels are coming from your customers in terms of supporting that \nunderlying growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I mean, thanks, great question. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nshould we think about where the adoption levels are coming from your customers in terms of supporting that \nunderlying growth?  \n ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2d93fca8dee5e6ebec3fabdc773582cb89fb04ab0260235e1c904b90fdb51bd1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0bd91752-423f-4720-8c7a-c4a4694c83c2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nshould we think about where the adoption levels are coming from your customers in terms of supporting that \nunderlying growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I mean, thanks, great question.  So fundamentally, this is a transaction volume -based business.  So as script \ngrowth retu rns, that's a good fundamental underlying driver of this business. ", "original_text": "A \nYeah. "}, "hash": "5c781d048580a9e477bda706668559bfd2ac9904f6252dd13abeb515b84ed388", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 311, "end_char_idx": 653, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0bd91752-423f-4720-8c7a-c4a4694c83c2": {"__data__": {"id_": "0bd91752-423f-4720-8c7a-c4a4694c83c2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nshould we think about where the adoption levels are coming from your customers in terms of supporting that \nunderlying growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I mean, thanks, great question.  So fundamentally, this is a transaction volume -based business.  So as script \ngrowth retu rns, that's a good fundamental underlying driver of this business. ", "original_text": "A \nYeah. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4046fb1b-a97e-452b-8748-85b4bc6f03d0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nshould we think about where the adoption levels are coming from your customers in terms of supporting that \nunderlying growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I mean, thanks, great question.  So fundamentally, this is a transaction volume -based business. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "76d42655f4463d416409efb00c13bfabe49373883c51dad94d36bde2ca40996f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32035201-ac6b-4533-a6af-9d95fd7ba73c", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nshould we think about where the adoption levels are coming from your customers in terms of supporting that \nunderlying growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I mean, thanks, great question.  So fundamentally, this is a transaction volume -based business.  So as script \ngrowth retu rns, that's a good fundamental underlying driver of this business.  We also grow this business by \nsigning more brands onto our programs and to innovating and putting more value on our network that delivers \nvalue to a pharmacist, to a provider or to a biopha rma that allows us to grow our services revenue. ", "original_text": "I mean, thanks, great question. "}, "hash": "e60ede67cce2d414416c421439181c74cbceb733dbe4022916567da2b7742b17", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 653, "end_char_idx": 662, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32035201-ac6b-4533-a6af-9d95fd7ba73c": {"__data__": {"id_": "32035201-ac6b-4533-a6af-9d95fd7ba73c", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nshould we think about where the adoption levels are coming from your customers in terms of supporting that \nunderlying growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I mean, thanks, great question.  So fundamentally, this is a transaction volume -based business.  So as script \ngrowth retu rns, that's a good fundamental underlying driver of this business.  We also grow this business by \nsigning more brands onto our programs and to innovating and putting more value on our network that delivers \nvalue to a pharmacist, to a provider or to a biopha rma that allows us to grow our services revenue. ", "original_text": "I mean, thanks, great question. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0bd91752-423f-4720-8c7a-c4a4694c83c2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nshould we think about where the adoption levels are coming from your customers in terms of supporting that \nunderlying growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I mean, thanks, great question.  So fundamentally, this is a transaction volume -based business.  So as script \ngrowth retu rns, that's a good fundamental underlying driver of this business. ", "original_text": "A \nYeah. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2a75c66aedc9015b423021739929123b3eb6b2b7756b56ee52e3ca893bf3bfe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b593d46-f981-48bc-8a76-996210e8b3b0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I mean, thanks, great question.  So fundamentally, this is a transaction volume -based business.  So as script \ngrowth retu rns, that's a good fundamental underlying driver of this business.  We also grow this business by \nsigning more brands onto our programs and to innovating and putting more value on our network that delivers \nvalue to a pharmacist, to a provider or to a biopha rma that allows us to grow our services revenue.  I mean, \nfundamentally, this is about growing transactions.  \n ", "original_text": "So fundamentally, this is a transaction volume -based business. "}, "hash": "fb992dfd7e848345f730d62ccc03984cb94e30b68edfdc63fe2c330d53f715bc", "class_name": "RelatedNodeInfo"}}, "text": "I mean, thanks, great question. ", "start_char_idx": 662, "end_char_idx": 694, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b593d46-f981-48bc-8a76-996210e8b3b0": {"__data__": {"id_": "5b593d46-f981-48bc-8a76-996210e8b3b0", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I mean, thanks, great question.  So fundamentally, this is a transaction volume -based business.  So as script \ngrowth retu rns, that's a good fundamental underlying driver of this business.  We also grow this business by \nsigning more brands onto our programs and to innovating and putting more value on our network that delivers \nvalue to a pharmacist, to a provider or to a biopha rma that allows us to grow our services revenue.  I mean, \nfundamentally, this is about growing transactions.  \n ", "original_text": "So fundamentally, this is a transaction volume -based business. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32035201-ac6b-4533-a6af-9d95fd7ba73c", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nshould we think about where the adoption levels are coming from your customers in terms of supporting that \nunderlying growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I mean, thanks, great question.  So fundamentally, this is a transaction volume -based business.  So as script \ngrowth retu rns, that's a good fundamental underlying driver of this business.  We also grow this business by \nsigning more brands onto our programs and to innovating and putting more value on our network that delivers \nvalue to a pharmacist, to a provider or to a biopha rma that allows us to grow our services revenue. ", "original_text": "I mean, thanks, great question. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd853412367e60aeb03bd1aeb3b593c8cbf1dc5f3d2b45c6460efe4f28fbe681", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a4d086f-19f9-4db9-8d13-ba0105bc5b15", "node_type": "1", "metadata": {"window": "A \nYeah.  I mean, thanks, great question.  So fundamentally, this is a transaction volume -based business.  So as script \ngrowth retu rns, that's a good fundamental underlying driver of this business.  We also grow this business by \nsigning more brands onto our programs and to innovating and putting more value on our network that delivers \nvalue to a pharmacist, to a provider or to a biopha rma that allows us to grow our services revenue.  I mean, \nfundamentally, this is about growing transactions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So as script \ngrowth retu rns, that's a good fundamental underlying driver of this business. "}, "hash": "1ef31d0ccc2598b421b0f63449d08c7d533a2106ac78d16a8660024682da70c1", "class_name": "RelatedNodeInfo"}}, "text": "So fundamentally, this is a transaction volume -based business. ", "start_char_idx": 694, "end_char_idx": 758, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a4d086f-19f9-4db9-8d13-ba0105bc5b15": {"__data__": {"id_": "9a4d086f-19f9-4db9-8d13-ba0105bc5b15", "embedding": null, "metadata": {"window": "A \nYeah.  I mean, thanks, great question.  So fundamentally, this is a transaction volume -based business.  So as script \ngrowth retu rns, that's a good fundamental underlying driver of this business.  We also grow this business by \nsigning more brands onto our programs and to innovating and putting more value on our network that delivers \nvalue to a pharmacist, to a provider or to a biopha rma that allows us to grow our services revenue.  I mean, \nfundamentally, this is about growing transactions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So as script \ngrowth retu rns, that's a good fundamental underlying driver of this business. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b593d46-f981-48bc-8a76-996210e8b3b0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I mean, thanks, great question.  So fundamentally, this is a transaction volume -based business.  So as script \ngrowth retu rns, that's a good fundamental underlying driver of this business.  We also grow this business by \nsigning more brands onto our programs and to innovating and putting more value on our network that delivers \nvalue to a pharmacist, to a provider or to a biopha rma that allows us to grow our services revenue.  I mean, \nfundamentally, this is about growing transactions.  \n ", "original_text": "So fundamentally, this is a transaction volume -based business. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "092f8ba30472137c36318a5293579e38533b8fddc001dd549989080a8dfccee1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1f4d929-4edb-414e-b292-8cf2494e8d3b", "node_type": "1", "metadata": {"window": "I mean, thanks, great question.  So fundamentally, this is a transaction volume -based business.  So as script \ngrowth retu rns, that's a good fundamental underlying driver of this business.  We also grow this business by \nsigning more brands onto our programs and to innovating and putting more value on our network that delivers \nvalue to a pharmacist, to a provider or to a biopha rma that allows us to grow our services revenue.  I mean, \nfundamentally, this is about growing transactions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nPete, just the other thing I would add there, the way that we're growing the transactions is we're utilizing \ntechnology. ", "original_text": "We also grow this business by \nsigning more brands onto our programs and to innovating and putting more value on our network that delivers \nvalue to a pharmacist, to a provider or to a biopha rma that allows us to grow our services revenue. "}, "hash": "6c62c4b5a8ffef0ec123792f1f5ec6034159c6b8fad56017e5563978351bcc5f", "class_name": "RelatedNodeInfo"}}, "text": "So as script \ngrowth retu rns, that's a good fundamental underlying driver of this business. ", "start_char_idx": 758, "end_char_idx": 851, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1f4d929-4edb-414e-b292-8cf2494e8d3b": {"__data__": {"id_": "e1f4d929-4edb-414e-b292-8cf2494e8d3b", "embedding": null, "metadata": {"window": "I mean, thanks, great question.  So fundamentally, this is a transaction volume -based business.  So as script \ngrowth retu rns, that's a good fundamental underlying driver of this business.  We also grow this business by \nsigning more brands onto our programs and to innovating and putting more value on our network that delivers \nvalue to a pharmacist, to a provider or to a biopha rma that allows us to grow our services revenue.  I mean, \nfundamentally, this is about growing transactions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nPete, just the other thing I would add there, the way that we're growing the transactions is we're utilizing \ntechnology. ", "original_text": "We also grow this business by \nsigning more brands onto our programs and to innovating and putting more value on our network that delivers \nvalue to a pharmacist, to a provider or to a biopha rma that allows us to grow our services revenue. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a4d086f-19f9-4db9-8d13-ba0105bc5b15", "node_type": "1", "metadata": {"window": "A \nYeah.  I mean, thanks, great question.  So fundamentally, this is a transaction volume -based business.  So as script \ngrowth retu rns, that's a good fundamental underlying driver of this business.  We also grow this business by \nsigning more brands onto our programs and to innovating and putting more value on our network that delivers \nvalue to a pharmacist, to a provider or to a biopha rma that allows us to grow our services revenue.  I mean, \nfundamentally, this is about growing transactions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So as script \ngrowth retu rns, that's a good fundamental underlying driver of this business. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ce94aedfc3ef5db4c162782de2d4c3c70ff2f4099061578bedb43cf057d487e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a3a4e8f-a754-4894-a953-d5defcc5b3b5", "node_type": "1", "metadata": {"window": "So fundamentally, this is a transaction volume -based business.  So as script \ngrowth retu rns, that's a good fundamental underlying driver of this business.  We also grow this business by \nsigning more brands onto our programs and to innovating and putting more value on our network that delivers \nvalue to a pharmacist, to a provider or to a biopha rma that allows us to grow our services revenue.  I mean, \nfundamentally, this is about growing transactions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nPete, just the other thing I would add there, the way that we're growing the transactions is we're utilizing \ntechnology.  We have great technology and capabilities within that business, and that allows us to leverage our \ncapabilities in a unique way.  \n ", "original_text": "I mean, \nfundamentally, this is about growing transactions.  \n "}, "hash": "e4649b351b372d721b8c6ec3447787a3c200c9b70697bc66972a457671573c7d", "class_name": "RelatedNodeInfo"}}, "text": "We also grow this business by \nsigning more brands onto our programs and to innovating and putting more value on our network that delivers \nvalue to a pharmacist, to a provider or to a biopha rma that allows us to grow our services revenue. ", "start_char_idx": 851, "end_char_idx": 1092, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a3a4e8f-a754-4894-a953-d5defcc5b3b5": {"__data__": {"id_": "3a3a4e8f-a754-4894-a953-d5defcc5b3b5", "embedding": null, "metadata": {"window": "So fundamentally, this is a transaction volume -based business.  So as script \ngrowth retu rns, that's a good fundamental underlying driver of this business.  We also grow this business by \nsigning more brands onto our programs and to innovating and putting more value on our network that delivers \nvalue to a pharmacist, to a provider or to a biopha rma that allows us to grow our services revenue.  I mean, \nfundamentally, this is about growing transactions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nPete, just the other thing I would add there, the way that we're growing the transactions is we're utilizing \ntechnology.  We have great technology and capabilities within that business, and that allows us to leverage our \ncapabilities in a unique way.  \n ", "original_text": "I mean, \nfundamentally, this is about growing transactions.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1f4d929-4edb-414e-b292-8cf2494e8d3b", "node_type": "1", "metadata": {"window": "I mean, thanks, great question.  So fundamentally, this is a transaction volume -based business.  So as script \ngrowth retu rns, that's a good fundamental underlying driver of this business.  We also grow this business by \nsigning more brands onto our programs and to innovating and putting more value on our network that delivers \nvalue to a pharmacist, to a provider or to a biopha rma that allows us to grow our services revenue.  I mean, \nfundamentally, this is about growing transactions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nPete, just the other thing I would add there, the way that we're growing the transactions is we're utilizing \ntechnology. ", "original_text": "We also grow this business by \nsigning more brands onto our programs and to innovating and putting more value on our network that delivers \nvalue to a pharmacist, to a provider or to a biopha rma that allows us to grow our services revenue. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f4e310d5b411d7f7102292ce7f02e1c932e8da77cb109aab673ee5ad642c60d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef360279-0b62-452d-9c2c-719e7d825e51", "node_type": "1", "metadata": {"window": "So as script \ngrowth retu rns, that's a good fundamental underlying driver of this business.  We also grow this business by \nsigning more brands onto our programs and to innovating and putting more value on our network that delivers \nvalue to a pharmacist, to a provider or to a biopha rma that allows us to grow our services revenue.  I mean, \nfundamentally, this is about growing transactions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nPete, just the other thing I would add there, the way that we're growing the transactions is we're utilizing \ntechnology.  We have great technology and capabilities within that business, and that allows us to leverage our \ncapabilities in a unique way.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "622162667cb439c16fbd096b067e70ba6fe0b429cf0a807cf6c8828b278acdc1", "class_name": "RelatedNodeInfo"}}, "text": "I mean, \nfundamentally, this is about growing transactions.  \n ", "start_char_idx": 1092, "end_char_idx": 1155, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef360279-0b62-452d-9c2c-719e7d825e51": {"__data__": {"id_": "ef360279-0b62-452d-9c2c-719e7d825e51", "embedding": null, "metadata": {"window": "So as script \ngrowth retu rns, that's a good fundamental underlying driver of this business.  We also grow this business by \nsigning more brands onto our programs and to innovating and putting more value on our network that delivers \nvalue to a pharmacist, to a provider or to a biopha rma that allows us to grow our services revenue.  I mean, \nfundamentally, this is about growing transactions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nPete, just the other thing I would add there, the way that we're growing the transactions is we're utilizing \ntechnology.  We have great technology and capabilities within that business, and that allows us to leverage our \ncapabilities in a unique way.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a3a4e8f-a754-4894-a953-d5defcc5b3b5", "node_type": "1", "metadata": {"window": "So fundamentally, this is a transaction volume -based business.  So as script \ngrowth retu rns, that's a good fundamental underlying driver of this business.  We also grow this business by \nsigning more brands onto our programs and to innovating and putting more value on our network that delivers \nvalue to a pharmacist, to a provider or to a biopha rma that allows us to grow our services revenue.  I mean, \nfundamentally, this is about growing transactions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nPete, just the other thing I would add there, the way that we're growing the transactions is we're utilizing \ntechnology.  We have great technology and capabilities within that business, and that allows us to leverage our \ncapabilities in a unique way.  \n ", "original_text": "I mean, \nfundamentally, this is about growing transactions.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45affb9188f94139b7408da09caa9d90279bf68207f312d108a03327311ee069", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac64550b-0b28-4da6-8068-ea7c8102f38d", "node_type": "1", "metadata": {"window": "We also grow this business by \nsigning more brands onto our programs and to innovating and putting more value on our network that delivers \nvalue to a pharmacist, to a provider or to a biopha rma that allows us to grow our services revenue.  I mean, \nfundamentally, this is about growing transactions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nPete, just the other thing I would add there, the way that we're growing the transactions is we're utilizing \ntechnology.  We have great technology and capabilities within that business, and that allows us to leverage our \ncapabilities in a unique way.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah. ", "original_text": "A \nPete, just the other thing I would add there, the way that we're growing the transactions is we're utilizing \ntechnology. "}, "hash": "8a19d5365d962b9827e76eaa2f0255e06a503847f515c9202f1ba0e6cc0c4080", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1155, "end_char_idx": 1484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac64550b-0b28-4da6-8068-ea7c8102f38d": {"__data__": {"id_": "ac64550b-0b28-4da6-8068-ea7c8102f38d", "embedding": null, "metadata": {"window": "We also grow this business by \nsigning more brands onto our programs and to innovating and putting more value on our network that delivers \nvalue to a pharmacist, to a provider or to a biopha rma that allows us to grow our services revenue.  I mean, \nfundamentally, this is about growing transactions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nPete, just the other thing I would add there, the way that we're growing the transactions is we're utilizing \ntechnology.  We have great technology and capabilities within that business, and that allows us to leverage our \ncapabilities in a unique way.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah. ", "original_text": "A \nPete, just the other thing I would add there, the way that we're growing the transactions is we're utilizing \ntechnology. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef360279-0b62-452d-9c2c-719e7d825e51", "node_type": "1", "metadata": {"window": "So as script \ngrowth retu rns, that's a good fundamental underlying driver of this business.  We also grow this business by \nsigning more brands onto our programs and to innovating and putting more value on our network that delivers \nvalue to a pharmacist, to a provider or to a biopha rma that allows us to grow our services revenue.  I mean, \nfundamentally, this is about growing transactions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nPete, just the other thing I would add there, the way that we're growing the transactions is we're utilizing \ntechnology.  We have great technology and capabilities within that business, and that allows us to leverage our \ncapabilities in a unique way.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7af6b3c3fbe628f23eb1189f9789741f88c27630f83766529828d698749d31fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "190ba9e3-0ca7-4f8e-9dea-4d3b1889c7a7", "node_type": "1", "metadata": {"window": "I mean, \nfundamentally, this is about growing transactions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nPete, just the other thing I would add there, the way that we're growing the transactions is we're utilizing \ntechnology.  We have great technology and capabilities within that business, and that allows us to leverage our \ncapabilities in a unique way.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah.  So our access to workflow, our ability to automate, what we're doing is creating new solutions that drive \nvolume through, transaction volume through our networks by solving real customer problems.  \n ", "original_text": "We have great technology and capabilities within that business, and that allows us to leverage our \ncapabilities in a unique way.  \n "}, "hash": "05e67a6819f0bf220fa190c8ac7d423b6de48ff2d58b7cf4bee062733655c8e0", "class_name": "RelatedNodeInfo"}}, "text": "A \nPete, just the other thing I would add there, the way that we're growing the transactions is we're utilizing \ntechnology. ", "start_char_idx": 1484, "end_char_idx": 1609, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "190ba9e3-0ca7-4f8e-9dea-4d3b1889c7a7": {"__data__": {"id_": "190ba9e3-0ca7-4f8e-9dea-4d3b1889c7a7", "embedding": null, "metadata": {"window": "I mean, \nfundamentally, this is about growing transactions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nPete, just the other thing I would add there, the way that we're growing the transactions is we're utilizing \ntechnology.  We have great technology and capabilities within that business, and that allows us to leverage our \ncapabilities in a unique way.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah.  So our access to workflow, our ability to automate, what we're doing is creating new solutions that drive \nvolume through, transaction volume through our networks by solving real customer problems.  \n ", "original_text": "We have great technology and capabilities within that business, and that allows us to leverage our \ncapabilities in a unique way.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac64550b-0b28-4da6-8068-ea7c8102f38d", "node_type": "1", "metadata": {"window": "We also grow this business by \nsigning more brands onto our programs and to innovating and putting more value on our network that delivers \nvalue to a pharmacist, to a provider or to a biopha rma that allows us to grow our services revenue.  I mean, \nfundamentally, this is about growing transactions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nPete, just the other thing I would add there, the way that we're growing the transactions is we're utilizing \ntechnology.  We have great technology and capabilities within that business, and that allows us to leverage our \ncapabilities in a unique way.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah. ", "original_text": "A \nPete, just the other thing I would add there, the way that we're growing the transactions is we're utilizing \ntechnology. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3b73759372af1d7796911afc48c4a517d16978b5dc2f21e481b5b2248ca10281", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c1668a8-38e7-4217-ae80-94d99891c87d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nPete, just the other thing I would add there, the way that we're growing the transactions is we're utilizing \ntechnology.  We have great technology and capabilities within that business, and that allows us to leverage our \ncapabilities in a unique way.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah.  So our access to workflow, our ability to automate, what we're doing is creating new solutions that drive \nvolume through, transaction volume through our networks by solving real customer problems.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.  "}, "hash": "888ca1df343717e682033c8ae9a42cb407f37ba8eefdf3a99bb352f4937fd9bd", "class_name": "RelatedNodeInfo"}}, "text": "We have great technology and capabilities within that business, and that allows us to leverage our \ncapabilities in a unique way.  \n ", "start_char_idx": 1609, "end_char_idx": 1742, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c1668a8-38e7-4217-ae80-94d99891c87d": {"__data__": {"id_": "9c1668a8-38e7-4217-ae80-94d99891c87d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nPete, just the other thing I would add there, the way that we're growing the transactions is we're utilizing \ntechnology.  We have great technology and capabilities within that business, and that allows us to leverage our \ncapabilities in a unique way.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah.  So our access to workflow, our ability to automate, what we're doing is creating new solutions that drive \nvolume through, transaction volume through our networks by solving real customer problems.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.  ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "190ba9e3-0ca7-4f8e-9dea-4d3b1889c7a7", "node_type": "1", "metadata": {"window": "I mean, \nfundamentally, this is about growing transactions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nPete, just the other thing I would add there, the way that we're growing the transactions is we're utilizing \ntechnology.  We have great technology and capabilities within that business, and that allows us to leverage our \ncapabilities in a unique way.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah.  So our access to workflow, our ability to automate, what we're doing is creating new solutions that drive \nvolume through, transaction volume through our networks by solving real customer problems.  \n ", "original_text": "We have great technology and capabilities within that business, and that allows us to leverage our \ncapabilities in a unique way.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e599a7345b745dca172dcd8d54fb195311fab24949f75575f1a10d0d0f656bfd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0298f8ac-7a35-4b7b-9c60-e8023b4a5761", "node_type": "1", "metadata": {"window": "A \nPete, just the other thing I would add there, the way that we're growing the transactions is we're utilizing \ntechnology.  We have great technology and capabilities within that business, and that allows us to leverage our \ncapabilities in a unique way.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah.  So our access to workflow, our ability to automate, what we're doing is creating new solutions that drive \nvolume through, transaction volume through our networks by solving real customer problems.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question com es from Eric Percher with Nephron Research.  \n ", "original_text": "A \nYeah. "}, "hash": "3185c2c186f4166577aaf3b9380cec89dfbfbaba0eba4df2b7d54bc34bdfe163", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.  ", "start_char_idx": 1742, "end_char_idx": 2085, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0298f8ac-7a35-4b7b-9c60-e8023b4a5761": {"__data__": {"id_": "0298f8ac-7a35-4b7b-9c60-e8023b4a5761", "embedding": null, "metadata": {"window": "A \nPete, just the other thing I would add there, the way that we're growing the transactions is we're utilizing \ntechnology.  We have great technology and capabilities within that business, and that allows us to leverage our \ncapabilities in a unique way.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah.  So our access to workflow, our ability to automate, what we're doing is creating new solutions that drive \nvolume through, transaction volume through our networks by solving real customer problems.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question com es from Eric Percher with Nephron Research.  \n ", "original_text": "A \nYeah. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c1668a8-38e7-4217-ae80-94d99891c87d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nPete, just the other thing I would add there, the way that we're growing the transactions is we're utilizing \ntechnology.  We have great technology and capabilities within that business, and that allows us to leverage our \ncapabilities in a unique way.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah.  So our access to workflow, our ability to automate, what we're doing is creating new solutions that drive \nvolume through, transaction volume through our networks by solving real customer problems.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.  ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "40e89babbaef8187d0d73aebf346504b11fc6393703f349813b53da9cbf4719b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28082d02-63c9-4ec8-a638-e105a56c68bc", "node_type": "1", "metadata": {"window": "We have great technology and capabilities within that business, and that allows us to leverage our \ncapabilities in a unique way.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah.  So our access to workflow, our ability to automate, what we're doing is creating new solutions that drive \nvolume through, transaction volume through our networks by solving real customer problems.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question com es from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "original_text": "So our access to workflow, our ability to automate, what we're doing is creating new solutions that drive \nvolume through, transaction volume through our networks by solving real customer problems.  \n "}, "hash": "d53f6dcd520be9602cd7f0b2a03c24c7b4dc154d0fa57bd76c7a7b882b1960cc", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 653, "end_char_idx": 662, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28082d02-63c9-4ec8-a638-e105a56c68bc": {"__data__": {"id_": "28082d02-63c9-4ec8-a638-e105a56c68bc", "embedding": null, "metadata": {"window": "We have great technology and capabilities within that business, and that allows us to leverage our \ncapabilities in a unique way.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah.  So our access to workflow, our ability to automate, what we're doing is creating new solutions that drive \nvolume through, transaction volume through our networks by solving real customer problems.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question com es from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "original_text": "So our access to workflow, our ability to automate, what we're doing is creating new solutions that drive \nvolume through, transaction volume through our networks by solving real customer problems.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0298f8ac-7a35-4b7b-9c60-e8023b4a5761", "node_type": "1", "metadata": {"window": "A \nPete, just the other thing I would add there, the way that we're growing the transactions is we're utilizing \ntechnology.  We have great technology and capabilities within that business, and that allows us to leverage our \ncapabilities in a unique way.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah.  So our access to workflow, our ability to automate, what we're doing is creating new solutions that drive \nvolume through, transaction volume through our networks by solving real customer problems.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question com es from Eric Percher with Nephron Research.  \n ", "original_text": "A \nYeah. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85d6b8de1f9cf30bdb8cf9d0a761b69d2aaa0a53e0a9f37927a496f5bdfc2720", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8038bff8-8994-4136-833b-b00045bedf23", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah.  So our access to workflow, our ability to automate, what we're doing is creating new solutions that drive \nvolume through, transaction volume through our networks by solving real customer problems.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question com es from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question on the medical side. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. "}, "hash": "8314a18f62b439ab88214605b35e339cf2025fdde7d3ea75fabcf36fb1e112dc", "class_name": "RelatedNodeInfo"}}, "text": "So our access to workflow, our ability to automate, what we're doing is creating new solutions that drive \nvolume through, transaction volume through our networks by solving real customer problems.  \n ", "start_char_idx": 2094, "end_char_idx": 2295, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8038bff8-8994-4136-833b-b00045bedf23": {"__data__": {"id_": "8038bff8-8994-4136-833b-b00045bedf23", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah.  So our access to workflow, our ability to automate, what we're doing is creating new solutions that drive \nvolume through, transaction volume through our networks by solving real customer problems.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question com es from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question on the medical side. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28082d02-63c9-4ec8-a638-e105a56c68bc", "node_type": "1", "metadata": {"window": "We have great technology and capabilities within that business, and that allows us to leverage our \ncapabilities in a unique way.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah.  So our access to workflow, our ability to automate, what we're doing is creating new solutions that drive \nvolume through, transaction volume through our networks by solving real customer problems.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question com es from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "original_text": "So our access to workflow, our ability to automate, what we're doing is creating new solutions that drive \nvolume through, transaction volume through our networks by solving real customer problems.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "35dcb4e529b7c377ef8afa2930309855c7d22f7909a4a39e14bc7c1c306926f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a585891-2934-4cc7-b6d1-1d0eb3a439a7", "node_type": "1", "metadata": {"window": "A \nYeah.  So our access to workflow, our ability to automate, what we're doing is creating new solutions that drive \nvolume through, transaction volume through our networks by solving real customer problems.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question com es from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question on the medical side.  The core growth of 10% to 16% is notable. ", "original_text": "Our next question com es from Eric Percher with Nephron Research.  \n "}, "hash": "12ea2c9d083f8abb2c68976efc0d1a708cdfa453faafa096f691a07b9713097c", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "start_char_idx": 2295, "end_char_idx": 2576, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a585891-2934-4cc7-b6d1-1d0eb3a439a7": {"__data__": {"id_": "5a585891-2934-4cc7-b6d1-1d0eb3a439a7", "embedding": null, "metadata": {"window": "A \nYeah.  So our access to workflow, our ability to automate, what we're doing is creating new solutions that drive \nvolume through, transaction volume through our networks by solving real customer problems.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question com es from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question on the medical side.  The core growth of 10% to 16% is notable. ", "original_text": "Our next question com es from Eric Percher with Nephron Research.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8038bff8-8994-4136-833b-b00045bedf23", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah.  So our access to workflow, our ability to automate, what we're doing is creating new solutions that drive \nvolume through, transaction volume through our networks by solving real customer problems.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question com es from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question on the medical side. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3914030848a3b6af4af28124e45793ffb2c790e21c22b1b507353564f6e9dd01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57c3804f-28a9-4625-ad3a-6a33bfa0136c", "node_type": "1", "metadata": {"window": "So our access to workflow, our ability to automate, what we're doing is creating new solutions that drive \nvolume through, transaction volume through our networks by solving real customer problems.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question com es from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question on the medical side.  The core growth of 10% to 16% is notable.  Be interested to hear how \nthe medical business has changed as you continue to pro gress through the COVID pandemic. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. "}, "hash": "86b2bd8e3f086b98a03db00fc1e9fb160238601807ef0872ca7555ca5580f5b8", "class_name": "RelatedNodeInfo"}}, "text": "Our next question com es from Eric Percher with Nephron Research.  \n ", "start_char_idx": 2576, "end_char_idx": 2645, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57c3804f-28a9-4625-ad3a-6a33bfa0136c": {"__data__": {"id_": "57c3804f-28a9-4625-ad3a-6a33bfa0136c", "embedding": null, "metadata": {"window": "So our access to workflow, our ability to automate, what we're doing is creating new solutions that drive \nvolume through, transaction volume through our networks by solving real customer problems.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question com es from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question on the medical side.  The core growth of 10% to 16% is notable.  Be interested to hear how \nthe medical business has changed as you continue to pro gress through the COVID pandemic. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a585891-2934-4cc7-b6d1-1d0eb3a439a7", "node_type": "1", "metadata": {"window": "A \nYeah.  So our access to workflow, our ability to automate, what we're doing is creating new solutions that drive \nvolume through, transaction volume through our networks by solving real customer problems.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question com es from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question on the medical side.  The core growth of 10% to 16% is notable. ", "original_text": "Our next question com es from Eric Percher with Nephron Research.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d49387d0cdca140b5af70eebe71e8ef450ccd461d3b92ebed0dde86b3404170d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "650145ed-7cf6-468f-8091-0e450f6d5b87", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question com es from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question on the medical side.  The core growth of 10% to 16% is notable.  Be interested to hear how \nthe medical business has changed as you continue to pro gress through the COVID pandemic.  And then how \nmuch or to what extent can you follow testing? ", "original_text": "Question on the medical side. "}, "hash": "a79f31aa7400e46519729adf9c46a43d84cd6332d43287a205a1296c5544b387", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "start_char_idx": 2645, "end_char_idx": 2962, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "650145ed-7cf6-468f-8091-0e450f6d5b87": {"__data__": {"id_": "650145ed-7cf6-468f-8091-0e450f6d5b87", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question com es from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question on the medical side.  The core growth of 10% to 16% is notable.  Be interested to hear how \nthe medical business has changed as you continue to pro gress through the COVID pandemic.  And then how \nmuch or to what extent can you follow testing? ", "original_text": "Question on the medical side. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57c3804f-28a9-4625-ad3a-6a33bfa0136c", "node_type": "1", "metadata": {"window": "So our access to workflow, our ability to automate, what we're doing is creating new solutions that drive \nvolume through, transaction volume through our networks by solving real customer problems.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question com es from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question on the medical side.  The core growth of 10% to 16% is notable.  Be interested to hear how \nthe medical business has changed as you continue to pro gress through the COVID pandemic. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ec795f351fa95936fdf338c9d460223db45ab1412802b5023af56cce8a3cefed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad77fb84-f263-4028-b9a5-c3a591318165", "node_type": "1", "metadata": {"window": "Our next question com es from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question on the medical side.  The core growth of 10% to 16% is notable.  Be interested to hear how \nthe medical business has changed as you continue to pro gress through the COVID pandemic.  And then how \nmuch or to what extent can you follow testing?  Of course, it's declining. ", "original_text": "The core growth of 10% to 16% is notable. "}, "hash": "e5dbd3d5656f42832991b12c7fb8c067e16bdecb40e087ae66a6d688d0883176", "class_name": "RelatedNodeInfo"}}, "text": "Question on the medical side. ", "start_char_idx": 2962, "end_char_idx": 2992, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad77fb84-f263-4028-b9a5-c3a591318165": {"__data__": {"id_": "ad77fb84-f263-4028-b9a5-c3a591318165", "embedding": null, "metadata": {"window": "Our next question com es from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question on the medical side.  The core growth of 10% to 16% is notable.  Be interested to hear how \nthe medical business has changed as you continue to pro gress through the COVID pandemic.  And then how \nmuch or to what extent can you follow testing?  Of course, it's declining. ", "original_text": "The core growth of 10% to 16% is notable. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "650145ed-7cf6-468f-8091-0e450f6d5b87", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question com es from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question on the medical side.  The core growth of 10% to 16% is notable.  Be interested to hear how \nthe medical business has changed as you continue to pro gress through the COVID pandemic.  And then how \nmuch or to what extent can you follow testing? ", "original_text": "Question on the medical side. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d67e26b99608e12d8454ac6c40a2739077b3ae646e5bcf10337cc54414961426", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20dbabd5-5a99-4a50-af3a-ebf6a6948285", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question on the medical side.  The core growth of 10% to 16% is notable.  Be interested to hear how \nthe medical business has changed as you continue to pro gress through the COVID pandemic.  And then how \nmuch or to what extent can you follow testing?  Of course, it's declining.  It's also moving toward retail and home. \n", "original_text": "Be interested to hear how \nthe medical business has changed as you continue to pro gress through the COVID pandemic. "}, "hash": "38570224fbce80956d76e1f1f67eb0c404aff86b73b5ea9c356e658652e4b966", "class_name": "RelatedNodeInfo"}}, "text": "The core growth of 10% to 16% is notable. ", "start_char_idx": 2992, "end_char_idx": 3034, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20dbabd5-5a99-4a50-af3a-ebf6a6948285": {"__data__": {"id_": "20dbabd5-5a99-4a50-af3a-ebf6a6948285", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question on the medical side.  The core growth of 10% to 16% is notable.  Be interested to hear how \nthe medical business has changed as you continue to pro gress through the COVID pandemic.  And then how \nmuch or to what extent can you follow testing?  Of course, it's declining.  It's also moving toward retail and home. \n", "original_text": "Be interested to hear how \nthe medical business has changed as you continue to pro gress through the COVID pandemic. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad77fb84-f263-4028-b9a5-c3a591318165", "node_type": "1", "metadata": {"window": "Our next question com es from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question on the medical side.  The core growth of 10% to 16% is notable.  Be interested to hear how \nthe medical business has changed as you continue to pro gress through the COVID pandemic.  And then how \nmuch or to what extent can you follow testing?  Of course, it's declining. ", "original_text": "The core growth of 10% to 16% is notable. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "02cee3c1385f6e0fc430d4752f4bc5acef931812ed31358a71c0a14370d6efe4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21379790-4405-4bd5-b8fa-0e091c26df15", "node_type": "1", "metadata": {"window": "Question on the medical side.  The core growth of 10% to 16% is notable.  Be interested to hear how \nthe medical business has changed as you continue to pro gress through the COVID pandemic.  And then how \nmuch or to what extent can you follow testing?  Of course, it's declining.  It's also moving toward retail and home. \n We saw the alignment with [ph] Cardell (49:58). ", "original_text": "And then how \nmuch or to what extent can you follow testing? "}, "hash": "4fbb996629b4a2ea67aed7e99a3efa505cd76c6d76f60de038303e1f18f09444", "class_name": "RelatedNodeInfo"}}, "text": "Be interested to hear how \nthe medical business has changed as you continue to pro gress through the COVID pandemic. ", "start_char_idx": 3034, "end_char_idx": 3151, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21379790-4405-4bd5-b8fa-0e091c26df15": {"__data__": {"id_": "21379790-4405-4bd5-b8fa-0e091c26df15", "embedding": null, "metadata": {"window": "Question on the medical side.  The core growth of 10% to 16% is notable.  Be interested to hear how \nthe medical business has changed as you continue to pro gress through the COVID pandemic.  And then how \nmuch or to what extent can you follow testing?  Of course, it's declining.  It's also moving toward retail and home. \n We saw the alignment with [ph] Cardell (49:58). ", "original_text": "And then how \nmuch or to what extent can you follow testing? ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20dbabd5-5a99-4a50-af3a-ebf6a6948285", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Question on the medical side.  The core growth of 10% to 16% is notable.  Be interested to hear how \nthe medical business has changed as you continue to pro gress through the COVID pandemic.  And then how \nmuch or to what extent can you follow testing?  Of course, it's declining.  It's also moving toward retail and home. \n", "original_text": "Be interested to hear how \nthe medical business has changed as you continue to pro gress through the COVID pandemic. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5053a6d982dba18e4f77ab90fbfc2e36ea18d2a59c12c61aa9a4deb27f209e4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce3a8a59-2e71-473a-9cb1-f09edbf88a72", "node_type": "1", "metadata": {"window": "The core growth of 10% to 16% is notable.  Be interested to hear how \nthe medical business has changed as you continue to pro gress through the COVID pandemic.  And then how \nmuch or to what extent can you follow testing?  Of course, it's declining.  It's also moving toward retail and home. \n We saw the alignment with [ph] Cardell (49:58).  Where else or how material could that be to yo u? \n ", "original_text": "Of course, it's declining. "}, "hash": "242fc1a09329cf623c163c7b0505e8fe901180f022323444f3eaab86dee44a6b", "class_name": "RelatedNodeInfo"}}, "text": "And then how \nmuch or to what extent can you follow testing? ", "start_char_idx": 3151, "end_char_idx": 3212, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce3a8a59-2e71-473a-9cb1-f09edbf88a72": {"__data__": {"id_": "ce3a8a59-2e71-473a-9cb1-f09edbf88a72", "embedding": null, "metadata": {"window": "The core growth of 10% to 16% is notable.  Be interested to hear how \nthe medical business has changed as you continue to pro gress through the COVID pandemic.  And then how \nmuch or to what extent can you follow testing?  Of course, it's declining.  It's also moving toward retail and home. \n We saw the alignment with [ph] Cardell (49:58).  Where else or how material could that be to yo u? \n ", "original_text": "Of course, it's declining. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21379790-4405-4bd5-b8fa-0e091c26df15", "node_type": "1", "metadata": {"window": "Question on the medical side.  The core growth of 10% to 16% is notable.  Be interested to hear how \nthe medical business has changed as you continue to pro gress through the COVID pandemic.  And then how \nmuch or to what extent can you follow testing?  Of course, it's declining.  It's also moving toward retail and home. \n We saw the alignment with [ph] Cardell (49:58). ", "original_text": "And then how \nmuch or to what extent can you follow testing? ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49624618e68d0c8c7ece002493d82bf77ffe29e4df5c63a13f676c0514e44302", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93faee8a-d64a-4815-8178-38510273f9d8", "node_type": "1", "metadata": {"window": "Be interested to hear how \nthe medical business has changed as you continue to pro gress through the COVID pandemic.  And then how \nmuch or to what extent can you follow testing?  Of course, it's declining.  It's also moving toward retail and home. \n We saw the alignment with [ph] Cardell (49:58).  Where else or how material could that be to yo u? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "It's also moving toward retail and home. \n"}, "hash": "acad33965af01e679df71b7d0b295bb314a8bbe753686a500ebe41c30e7806ec", "class_name": "RelatedNodeInfo"}}, "text": "Of course, it's declining. ", "start_char_idx": 3212, "end_char_idx": 3239, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93faee8a-d64a-4815-8178-38510273f9d8": {"__data__": {"id_": "93faee8a-d64a-4815-8178-38510273f9d8", "embedding": null, "metadata": {"window": "Be interested to hear how \nthe medical business has changed as you continue to pro gress through the COVID pandemic.  And then how \nmuch or to what extent can you follow testing?  Of course, it's declining.  It's also moving toward retail and home. \n We saw the alignment with [ph] Cardell (49:58).  Where else or how material could that be to yo u? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "It's also moving toward retail and home. \n", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce3a8a59-2e71-473a-9cb1-f09edbf88a72", "node_type": "1", "metadata": {"window": "The core growth of 10% to 16% is notable.  Be interested to hear how \nthe medical business has changed as you continue to pro gress through the COVID pandemic.  And then how \nmuch or to what extent can you follow testing?  Of course, it's declining.  It's also moving toward retail and home. \n We saw the alignment with [ph] Cardell (49:58).  Where else or how material could that be to yo u? \n ", "original_text": "Of course, it's declining. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01ae1ba70421dfaec82cd21f50de6293f07a7fa8286465f190d306e1364704b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce482aa2-d31f-49dc-8932-bedc038eb9f7", "node_type": "1", "metadata": {"window": "And then how \nmuch or to what extent can you follow testing?  Of course, it's declining.  It's also moving toward retail and home. \n We saw the alignment with [ph] Cardell (49:58).  Where else or how material could that be to yo u? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start and give a few comments, Eric. ", "original_text": "We saw the alignment with [ph] Cardell (49:58). "}, "hash": "a07224018d30003f8471f78e0b8b59feb575a8ec60814a7d1be595d88b0794ca", "class_name": "RelatedNodeInfo"}}, "text": "It's also moving toward retail and home. \n", "start_char_idx": 3239, "end_char_idx": 3281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce482aa2-d31f-49dc-8932-bedc038eb9f7": {"__data__": {"id_": "ce482aa2-d31f-49dc-8932-bedc038eb9f7", "embedding": null, "metadata": {"window": "And then how \nmuch or to what extent can you follow testing?  Of course, it's declining.  It's also moving toward retail and home. \n We saw the alignment with [ph] Cardell (49:58).  Where else or how material could that be to yo u? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start and give a few comments, Eric. ", "original_text": "We saw the alignment with [ph] Cardell (49:58). ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93faee8a-d64a-4815-8178-38510273f9d8", "node_type": "1", "metadata": {"window": "Be interested to hear how \nthe medical business has changed as you continue to pro gress through the COVID pandemic.  And then how \nmuch or to what extent can you follow testing?  Of course, it's declining.  It's also moving toward retail and home. \n We saw the alignment with [ph] Cardell (49:58).  Where else or how material could that be to yo u? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "It's also moving toward retail and home. \n", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9deb87dc577d5fb183d99cffefe192b99c8cd67c414804adada28440cf179e93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a98d155d-a709-4ca9-927d-af4fcdb34486", "node_type": "1", "metadata": {"window": "Of course, it's declining.  It's also moving toward retail and home. \n We saw the alignment with [ph] Cardell (49:58).  Where else or how material could that be to yo u? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start and give a few comments, Eric.  Look, it was certainly a dynamic year in the medical business, I mean, out \nof the gates with PPE, demand outstripping supply by a wide margin. ", "original_text": "Where else or how material could that be to yo u? \n "}, "hash": "1d27d4e394da339933145e4114248ba21aa4570c43237a42037d44c92750fb1d", "class_name": "RelatedNodeInfo"}}, "text": "We saw the alignment with [ph] Cardell (49:58). ", "start_char_idx": 3281, "end_char_idx": 3329, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a98d155d-a709-4ca9-927d-af4fcdb34486": {"__data__": {"id_": "a98d155d-a709-4ca9-927d-af4fcdb34486", "embedding": null, "metadata": {"window": "Of course, it's declining.  It's also moving toward retail and home. \n We saw the alignment with [ph] Cardell (49:58).  Where else or how material could that be to yo u? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start and give a few comments, Eric.  Look, it was certainly a dynamic year in the medical business, I mean, out \nof the gates with PPE, demand outstripping supply by a wide margin. ", "original_text": "Where else or how material could that be to yo u? \n ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce482aa2-d31f-49dc-8932-bedc038eb9f7", "node_type": "1", "metadata": {"window": "And then how \nmuch or to what extent can you follow testing?  Of course, it's declining.  It's also moving toward retail and home. \n We saw the alignment with [ph] Cardell (49:58).  Where else or how material could that be to yo u? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start and give a few comments, Eric. ", "original_text": "We saw the alignment with [ph] Cardell (49:58). ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54d590a67e421e11404caf2ec70f673a71f71c37a1b382e2faec8b1140bb30fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0aaf1c1f-0592-485d-a941-2e8ee2401cc3", "node_type": "1", "metadata": {"window": "It's also moving toward retail and home. \n We saw the alignment with [ph] Cardell (49:58).  Where else or how material could that be to yo u? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start and give a few comments, Eric.  Look, it was certainly a dynamic year in the medical business, I mean, out \nof the gates with PPE, demand outstripping supply by a wide margin.  You're well familiar with the early period of \nthis fiscal year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "85ed9df2deada7958cff80608b8a681af7b21034f61b8df511a75f16f377bf93", "class_name": "RelatedNodeInfo"}}, "text": "Where else or how material could that be to yo u? \n ", "start_char_idx": 3329, "end_char_idx": 3381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0aaf1c1f-0592-485d-a941-2e8ee2401cc3": {"__data__": {"id_": "0aaf1c1f-0592-485d-a941-2e8ee2401cc3", "embedding": null, "metadata": {"window": "It's also moving toward retail and home. \n We saw the alignment with [ph] Cardell (49:58).  Where else or how material could that be to yo u? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start and give a few comments, Eric.  Look, it was certainly a dynamic year in the medical business, I mean, out \nof the gates with PPE, demand outstripping supply by a wide margin.  You're well familiar with the early period of \nthis fiscal year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a98d155d-a709-4ca9-927d-af4fcdb34486", "node_type": "1", "metadata": {"window": "Of course, it's declining.  It's also moving toward retail and home. \n We saw the alignment with [ph] Cardell (49:58).  Where else or how material could that be to yo u? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start and give a few comments, Eric.  Look, it was certainly a dynamic year in the medical business, I mean, out \nof the gates with PPE, demand outstripping supply by a wide margin. ", "original_text": "Where else or how material could that be to yo u? \n ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9b52546d5fb96b9feb31cd3e7d31725e737b236abd049c7e5064a9bc90f0dc72", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca7a92d4-d03a-4892-a870-6aa18286fd0e", "node_type": "1", "metadata": {"window": "We saw the alignment with [ph] Cardell (49:58).  Where else or how material could that be to yo u? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start and give a few comments, Eric.  Look, it was certainly a dynamic year in the medical business, I mean, out \nof the gates with PPE, demand outstripping supply by a wide margin.  You're well familiar with the early period of \nthis fiscal year.  Mid -part of the year, we start to see COVID test kits really come to market. ", "original_text": "A \nI'll start and give a few comments, Eric. "}, "hash": "6b71f0e39ea495eb94121bc11fa2263a958eee4778bbd23b5e469f5e85c4f828", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1155, "end_char_idx": 1484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca7a92d4-d03a-4892-a870-6aa18286fd0e": {"__data__": {"id_": "ca7a92d4-d03a-4892-a870-6aa18286fd0e", "embedding": null, "metadata": {"window": "We saw the alignment with [ph] Cardell (49:58).  Where else or how material could that be to yo u? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start and give a few comments, Eric.  Look, it was certainly a dynamic year in the medical business, I mean, out \nof the gates with PPE, demand outstripping supply by a wide margin.  You're well familiar with the early period of \nthis fiscal year.  Mid -part of the year, we start to see COVID test kits really come to market. ", "original_text": "A \nI'll start and give a few comments, Eric. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0aaf1c1f-0592-485d-a941-2e8ee2401cc3", "node_type": "1", "metadata": {"window": "It's also moving toward retail and home. \n We saw the alignment with [ph] Cardell (49:58).  Where else or how material could that be to yo u? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start and give a few comments, Eric.  Look, it was certainly a dynamic year in the medical business, I mean, out \nof the gates with PPE, demand outstripping supply by a wide margin.  You're well familiar with the early period of \nthis fiscal year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7e434ff16faac47ce4443f4efb9aa3905921e5bab385261c135c83627d4dccea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00c23de5-0ad6-4f1f-8102-30e7121b5ffd", "node_type": "1", "metadata": {"window": "Where else or how material could that be to yo u? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start and give a few comments, Eric.  Look, it was certainly a dynamic year in the medical business, I mean, out \nof the gates with PPE, demand outstripping supply by a wide margin.  You're well familiar with the early period of \nthis fiscal year.  Mid -part of the year, we start to see COVID test kits really come to market.  And through our \nleading position as a lab distributor, think our team did a fantastic job working with real ly a broad spectrum of \nthose providers across all types of tests, molecular, antigen, antibody, to get those into the provider communities \nthat we serve. ", "original_text": "Look, it was certainly a dynamic year in the medical business, I mean, out \nof the gates with PPE, demand outstripping supply by a wide margin. "}, "hash": "642f8810ac1230db8cd43b41d221865836470d838d8a4932efb1713f8461d50a", "class_name": "RelatedNodeInfo"}}, "text": "A \nI'll start and give a few comments, Eric. ", "start_char_idx": 3710, "end_char_idx": 3755, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00c23de5-0ad6-4f1f-8102-30e7121b5ffd": {"__data__": {"id_": "00c23de5-0ad6-4f1f-8102-30e7121b5ffd", "embedding": null, "metadata": {"window": "Where else or how material could that be to yo u? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start and give a few comments, Eric.  Look, it was certainly a dynamic year in the medical business, I mean, out \nof the gates with PPE, demand outstripping supply by a wide margin.  You're well familiar with the early period of \nthis fiscal year.  Mid -part of the year, we start to see COVID test kits really come to market.  And through our \nleading position as a lab distributor, think our team did a fantastic job working with real ly a broad spectrum of \nthose providers across all types of tests, molecular, antigen, antibody, to get those into the provider communities \nthat we serve. ", "original_text": "Look, it was certainly a dynamic year in the medical business, I mean, out \nof the gates with PPE, demand outstripping supply by a wide margin. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca7a92d4-d03a-4892-a870-6aa18286fd0e", "node_type": "1", "metadata": {"window": "We saw the alignment with [ph] Cardell (49:58).  Where else or how material could that be to yo u? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start and give a few comments, Eric.  Look, it was certainly a dynamic year in the medical business, I mean, out \nof the gates with PPE, demand outstripping supply by a wide margin.  You're well familiar with the early period of \nthis fiscal year.  Mid -part of the year, we start to see COVID test kits really come to market. ", "original_text": "A \nI'll start and give a few comments, Eric. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22877814e377912301df6989f079fb933b0ae692093d3070dbed3ba492d5a9d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e401b9e-a17d-4b16-95e2-de110819d0b0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start and give a few comments, Eric.  Look, it was certainly a dynamic year in the medical business, I mean, out \nof the gates with PPE, demand outstripping supply by a wide margin.  You're well familiar with the early period of \nthis fiscal year.  Mid -part of the year, we start to see COVID test kits really come to market.  And through our \nleading position as a lab distributor, think our team did a fantastic job working with real ly a broad spectrum of \nthose providers across all types of tests, molecular, antigen, antibody, to get those into the provider communities \nthat we serve.  And we had tremendous growth.  \n \n", "original_text": "You're well familiar with the early period of \nthis fiscal year. "}, "hash": "ed9ecb8ec6628cc3b856f385b2a126510434224acaddceea494151097caf56dd", "class_name": "RelatedNodeInfo"}}, "text": "Look, it was certainly a dynamic year in the medical business, I mean, out \nof the gates with PPE, demand outstripping supply by a wide margin. ", "start_char_idx": 3755, "end_char_idx": 3899, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e401b9e-a17d-4b16-95e2-de110819d0b0": {"__data__": {"id_": "0e401b9e-a17d-4b16-95e2-de110819d0b0", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start and give a few comments, Eric.  Look, it was certainly a dynamic year in the medical business, I mean, out \nof the gates with PPE, demand outstripping supply by a wide margin.  You're well familiar with the early period of \nthis fiscal year.  Mid -part of the year, we start to see COVID test kits really come to market.  And through our \nleading position as a lab distributor, think our team did a fantastic job working with real ly a broad spectrum of \nthose providers across all types of tests, molecular, antigen, antibody, to get those into the provider communities \nthat we serve.  And we had tremendous growth.  \n \n", "original_text": "You're well familiar with the early period of \nthis fiscal year. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00c23de5-0ad6-4f1f-8102-30e7121b5ffd", "node_type": "1", "metadata": {"window": "Where else or how material could that be to yo u? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start and give a few comments, Eric.  Look, it was certainly a dynamic year in the medical business, I mean, out \nof the gates with PPE, demand outstripping supply by a wide margin.  You're well familiar with the early period of \nthis fiscal year.  Mid -part of the year, we start to see COVID test kits really come to market.  And through our \nleading position as a lab distributor, think our team did a fantastic job working with real ly a broad spectrum of \nthose providers across all types of tests, molecular, antigen, antibody, to get those into the provider communities \nthat we serve. ", "original_text": "Look, it was certainly a dynamic year in the medical business, I mean, out \nof the gates with PPE, demand outstripping supply by a wide margin. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee791932753e76f40b7c11acb5646f332459d9dfc17e200119bfdb84d4a895f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7adb4104-5c53-4d44-b1bf-c255f6aa4e02", "node_type": "1", "metadata": {"window": "A \nI'll start and give a few comments, Eric.  Look, it was certainly a dynamic year in the medical business, I mean, out \nof the gates with PPE, demand outstripping supply by a wide margin.  You're well familiar with the early period of \nthis fiscal year.  Mid -part of the year, we start to see COVID test kits really come to market.  And through our \nleading position as a lab distributor, think our team did a fantastic job working with real ly a broad spectrum of \nthose providers across all types of tests, molecular, antigen, antibody, to get those into the provider communities \nthat we serve.  And we had tremendous growth.  \n \n That growth probably peaked in Q3. ", "original_text": "Mid -part of the year, we start to see COVID test kits really come to market. "}, "hash": "b19d199917859ecce94fb919445c7fecbfbb6bc921df152933bd860b5a75ee93", "class_name": "RelatedNodeInfo"}}, "text": "You're well familiar with the early period of \nthis fiscal year. ", "start_char_idx": 3899, "end_char_idx": 3964, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7adb4104-5c53-4d44-b1bf-c255f6aa4e02": {"__data__": {"id_": "7adb4104-5c53-4d44-b1bf-c255f6aa4e02", "embedding": null, "metadata": {"window": "A \nI'll start and give a few comments, Eric.  Look, it was certainly a dynamic year in the medical business, I mean, out \nof the gates with PPE, demand outstripping supply by a wide margin.  You're well familiar with the early period of \nthis fiscal year.  Mid -part of the year, we start to see COVID test kits really come to market.  And through our \nleading position as a lab distributor, think our team did a fantastic job working with real ly a broad spectrum of \nthose providers across all types of tests, molecular, antigen, antibody, to get those into the provider communities \nthat we serve.  And we had tremendous growth.  \n \n That growth probably peaked in Q3. ", "original_text": "Mid -part of the year, we start to see COVID test kits really come to market. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e401b9e-a17d-4b16-95e2-de110819d0b0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start and give a few comments, Eric.  Look, it was certainly a dynamic year in the medical business, I mean, out \nof the gates with PPE, demand outstripping supply by a wide margin.  You're well familiar with the early period of \nthis fiscal year.  Mid -part of the year, we start to see COVID test kits really come to market.  And through our \nleading position as a lab distributor, think our team did a fantastic job working with real ly a broad spectrum of \nthose providers across all types of tests, molecular, antigen, antibody, to get those into the provider communities \nthat we serve.  And we had tremendous growth.  \n \n", "original_text": "You're well familiar with the early period of \nthis fiscal year. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ec1bc5603a3c687b383018f24f98094edfbe0acdf541201a26e1669060adbe10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f01571f-3220-4e44-b565-d1b9ca1ca625", "node_type": "1", "metadata": {"window": "Look, it was certainly a dynamic year in the medical business, I mean, out \nof the gates with PPE, demand outstripping supply by a wide margin.  You're well familiar with the early period of \nthis fiscal year.  Mid -part of the year, we start to see COVID test kits really come to market.  And through our \nleading position as a lab distributor, think our team did a fantastic job working with real ly a broad spectrum of \nthose providers across all types of tests, molecular, antigen, antibody, to get those into the provider communities \nthat we serve.  And we had tremendous growth.  \n \n That growth probably peaked in Q3.  It was, frankly, it fell away quicke r than we had anticipated when we had our \nearnings call in that third quarter. ", "original_text": "And through our \nleading position as a lab distributor, think our team did a fantastic job working with real ly a broad spectrum of \nthose providers across all types of tests, molecular, antigen, antibody, to get those into the provider communities \nthat we serve. "}, "hash": "73b27e7df34d76319fea9cd2ac1906aa7e7ee93602fafd454ca145f7727391b5", "class_name": "RelatedNodeInfo"}}, "text": "Mid -part of the year, we start to see COVID test kits really come to market. ", "start_char_idx": 3964, "end_char_idx": 4042, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f01571f-3220-4e44-b565-d1b9ca1ca625": {"__data__": {"id_": "8f01571f-3220-4e44-b565-d1b9ca1ca625", "embedding": null, "metadata": {"window": "Look, it was certainly a dynamic year in the medical business, I mean, out \nof the gates with PPE, demand outstripping supply by a wide margin.  You're well familiar with the early period of \nthis fiscal year.  Mid -part of the year, we start to see COVID test kits really come to market.  And through our \nleading position as a lab distributor, think our team did a fantastic job working with real ly a broad spectrum of \nthose providers across all types of tests, molecular, antigen, antibody, to get those into the provider communities \nthat we serve.  And we had tremendous growth.  \n \n That growth probably peaked in Q3.  It was, frankly, it fell away quicke r than we had anticipated when we had our \nearnings call in that third quarter. ", "original_text": "And through our \nleading position as a lab distributor, think our team did a fantastic job working with real ly a broad spectrum of \nthose providers across all types of tests, molecular, antigen, antibody, to get those into the provider communities \nthat we serve. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7adb4104-5c53-4d44-b1bf-c255f6aa4e02", "node_type": "1", "metadata": {"window": "A \nI'll start and give a few comments, Eric.  Look, it was certainly a dynamic year in the medical business, I mean, out \nof the gates with PPE, demand outstripping supply by a wide margin.  You're well familiar with the early period of \nthis fiscal year.  Mid -part of the year, we start to see COVID test kits really come to market.  And through our \nleading position as a lab distributor, think our team did a fantastic job working with real ly a broad spectrum of \nthose providers across all types of tests, molecular, antigen, antibody, to get those into the provider communities \nthat we serve.  And we had tremendous growth.  \n \n That growth probably peaked in Q3. ", "original_text": "Mid -part of the year, we start to see COVID test kits really come to market. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb22ca7eb1381ca85608fba7d73056efbc691d0b06e012e37f72cc400e5c6156", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cac4d553-587f-46dc-9037-83675490d454", "node_type": "1", "metadata": {"window": "You're well familiar with the early period of \nthis fiscal year.  Mid -part of the year, we start to see COVID test kits really come to market.  And through our \nleading position as a lab distributor, think our team did a fantastic job working with real ly a broad spectrum of \nthose providers across all types of tests, molecular, antigen, antibody, to get those into the provider communities \nthat we serve.  And we had tremendous growth.  \n \n That growth probably peaked in Q3.  It was, frankly, it fell away quicke r than we had anticipated when we had our \nearnings call in that third quarter.  We still, there is still COVID test kit volume out there, but it certainly was, if any, \nof all of our businesses, I would say the medical business was the most dynamic in terms of the market dynamics \nthis year.  \n ", "original_text": "And we had tremendous growth.  \n \n"}, "hash": "a7c954cd4a5e6bb57b658c2be746a0185be5602fec639f4f6606b38ddf478c7a", "class_name": "RelatedNodeInfo"}}, "text": "And through our \nleading position as a lab distributor, think our team did a fantastic job working with real ly a broad spectrum of \nthose providers across all types of tests, molecular, antigen, antibody, to get those into the provider communities \nthat we serve. ", "start_char_idx": 4042, "end_char_idx": 4307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cac4d553-587f-46dc-9037-83675490d454": {"__data__": {"id_": "cac4d553-587f-46dc-9037-83675490d454", "embedding": null, "metadata": {"window": "You're well familiar with the early period of \nthis fiscal year.  Mid -part of the year, we start to see COVID test kits really come to market.  And through our \nleading position as a lab distributor, think our team did a fantastic job working with real ly a broad spectrum of \nthose providers across all types of tests, molecular, antigen, antibody, to get those into the provider communities \nthat we serve.  And we had tremendous growth.  \n \n That growth probably peaked in Q3.  It was, frankly, it fell away quicke r than we had anticipated when we had our \nearnings call in that third quarter.  We still, there is still COVID test kit volume out there, but it certainly was, if any, \nof all of our businesses, I would say the medical business was the most dynamic in terms of the market dynamics \nthis year.  \n ", "original_text": "And we had tremendous growth.  \n \n", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f01571f-3220-4e44-b565-d1b9ca1ca625", "node_type": "1", "metadata": {"window": "Look, it was certainly a dynamic year in the medical business, I mean, out \nof the gates with PPE, demand outstripping supply by a wide margin.  You're well familiar with the early period of \nthis fiscal year.  Mid -part of the year, we start to see COVID test kits really come to market.  And through our \nleading position as a lab distributor, think our team did a fantastic job working with real ly a broad spectrum of \nthose providers across all types of tests, molecular, antigen, antibody, to get those into the provider communities \nthat we serve.  And we had tremendous growth.  \n \n That growth probably peaked in Q3.  It was, frankly, it fell away quicke r than we had anticipated when we had our \nearnings call in that third quarter. ", "original_text": "And through our \nleading position as a lab distributor, think our team did a fantastic job working with real ly a broad spectrum of \nthose providers across all types of tests, molecular, antigen, antibody, to get those into the provider communities \nthat we serve. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72d3af297d4db6f3dce0aaead7209e08adb0830f78a89a9c68dbb9186a18e4bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e057e82-30de-43f6-b214-890bb942fe45", "node_type": "1", "metadata": {"window": "Mid -part of the year, we start to see COVID test kits really come to market.  And through our \nleading position as a lab distributor, think our team did a fantastic job working with real ly a broad spectrum of \nthose providers across all types of tests, molecular, antigen, antibody, to get those into the provider communities \nthat we serve.  And we had tremendous growth.  \n \n That growth probably peaked in Q3.  It was, frankly, it fell away quicke r than we had anticipated when we had our \nearnings call in that third quarter.  We still, there is still COVID test kit volume out there, but it certainly was, if any, \nof all of our businesses, I would say the medical business was the most dynamic in terms of the market dynamics \nthis year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "That growth probably peaked in Q3. "}, "hash": "ee7c66268314b679a869c0ffe0f244e81c8667126e2fef2520e36fc274b841d8", "class_name": "RelatedNodeInfo"}}, "text": "And we had tremendous growth.  \n \n", "start_char_idx": 4307, "end_char_idx": 4341, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e057e82-30de-43f6-b214-890bb942fe45": {"__data__": {"id_": "7e057e82-30de-43f6-b214-890bb942fe45", "embedding": null, "metadata": {"window": "Mid -part of the year, we start to see COVID test kits really come to market.  And through our \nleading position as a lab distributor, think our team did a fantastic job working with real ly a broad spectrum of \nthose providers across all types of tests, molecular, antigen, antibody, to get those into the provider communities \nthat we serve.  And we had tremendous growth.  \n \n That growth probably peaked in Q3.  It was, frankly, it fell away quicke r than we had anticipated when we had our \nearnings call in that third quarter.  We still, there is still COVID test kit volume out there, but it certainly was, if any, \nof all of our businesses, I would say the medical business was the most dynamic in terms of the market dynamics \nthis year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "That growth probably peaked in Q3. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cac4d553-587f-46dc-9037-83675490d454", "node_type": "1", "metadata": {"window": "You're well familiar with the early period of \nthis fiscal year.  Mid -part of the year, we start to see COVID test kits really come to market.  And through our \nleading position as a lab distributor, think our team did a fantastic job working with real ly a broad spectrum of \nthose providers across all types of tests, molecular, antigen, antibody, to get those into the provider communities \nthat we serve.  And we had tremendous growth.  \n \n That growth probably peaked in Q3.  It was, frankly, it fell away quicke r than we had anticipated when we had our \nearnings call in that third quarter.  We still, there is still COVID test kit volume out there, but it certainly was, if any, \nof all of our businesses, I would say the medical business was the most dynamic in terms of the market dynamics \nthis year.  \n ", "original_text": "And we had tremendous growth.  \n \n", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f00357b43f88279812e706178664abe905e0016a05f724833d03212e02d7de5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0eb526c-23f8-49ae-aec5-2b3665f31e77", "node_type": "1", "metadata": {"window": "And through our \nleading position as a lab distributor, think our team did a fantastic job working with real ly a broad spectrum of \nthose providers across all types of tests, molecular, antigen, antibody, to get those into the provider communities \nthat we serve.  And we had tremendous growth.  \n \n That growth probably peaked in Q3.  It was, frankly, it fell away quicke r than we had anticipated when we had our \nearnings call in that third quarter.  We still, there is still COVID test kit volume out there, but it certainly was, if any, \nof all of our businesses, I would say the medical business was the most dynamic in terms of the market dynamics \nthis year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "It was, frankly, it fell away quicke r than we had anticipated when we had our \nearnings call in that third quarter. "}, "hash": "4adbc183b0aec437906cbb68c5b7192bc735c7745451314e3a1a8c161a524fe0", "class_name": "RelatedNodeInfo"}}, "text": "That growth probably peaked in Q3. ", "start_char_idx": 4341, "end_char_idx": 4376, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0eb526c-23f8-49ae-aec5-2b3665f31e77": {"__data__": {"id_": "f0eb526c-23f8-49ae-aec5-2b3665f31e77", "embedding": null, "metadata": {"window": "And through our \nleading position as a lab distributor, think our team did a fantastic job working with real ly a broad spectrum of \nthose providers across all types of tests, molecular, antigen, antibody, to get those into the provider communities \nthat we serve.  And we had tremendous growth.  \n \n That growth probably peaked in Q3.  It was, frankly, it fell away quicke r than we had anticipated when we had our \nearnings call in that third quarter.  We still, there is still COVID test kit volume out there, but it certainly was, if any, \nof all of our businesses, I would say the medical business was the most dynamic in terms of the market dynamics \nthis year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "It was, frankly, it fell away quicke r than we had anticipated when we had our \nearnings call in that third quarter. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e057e82-30de-43f6-b214-890bb942fe45", "node_type": "1", "metadata": {"window": "Mid -part of the year, we start to see COVID test kits really come to market.  And through our \nleading position as a lab distributor, think our team did a fantastic job working with real ly a broad spectrum of \nthose providers across all types of tests, molecular, antigen, antibody, to get those into the provider communities \nthat we serve.  And we had tremendous growth.  \n \n That growth probably peaked in Q3.  It was, frankly, it fell away quicke r than we had anticipated when we had our \nearnings call in that third quarter.  We still, there is still COVID test kit volume out there, but it certainly was, if any, \nof all of our businesses, I would say the medical business was the most dynamic in terms of the market dynamics \nthis year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "That growth probably peaked in Q3. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1d79e1e700ad89c678af667abcfd6bccf679e6d7d6ea626eb5731d8fcf79510", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0352525-9cbf-45eb-b070-99720a29b9d6", "node_type": "1", "metadata": {"window": "And we had tremendous growth.  \n \n That growth probably peaked in Q3.  It was, frankly, it fell away quicke r than we had anticipated when we had our \nearnings call in that third quarter.  We still, there is still COVID test kit volume out there, but it certainly was, if any, \nof all of our businesses, I would say the medical business was the most dynamic in terms of the market dynamics \nthis year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "We still, there is still COVID test kit volume out there, but it certainly was, if any, \nof all of our businesses, I would say the medical business was the most dynamic in terms of the market dynamics \nthis year.  \n "}, "hash": "b9147cd91e1e1c65b7c51971510b645af3cd1e9c1e2b503cba4d0be77390c2e4", "class_name": "RelatedNodeInfo"}}, "text": "It was, frankly, it fell away quicke r than we had anticipated when we had our \nearnings call in that third quarter. ", "start_char_idx": 4376, "end_char_idx": 4493, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0352525-9cbf-45eb-b070-99720a29b9d6": {"__data__": {"id_": "b0352525-9cbf-45eb-b070-99720a29b9d6", "embedding": null, "metadata": {"window": "And we had tremendous growth.  \n \n That growth probably peaked in Q3.  It was, frankly, it fell away quicke r than we had anticipated when we had our \nearnings call in that third quarter.  We still, there is still COVID test kit volume out there, but it certainly was, if any, \nof all of our businesses, I would say the medical business was the most dynamic in terms of the market dynamics \nthis year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "We still, there is still COVID test kit volume out there, but it certainly was, if any, \nof all of our businesses, I would say the medical business was the most dynamic in terms of the market dynamics \nthis year.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0eb526c-23f8-49ae-aec5-2b3665f31e77", "node_type": "1", "metadata": {"window": "And through our \nleading position as a lab distributor, think our team did a fantastic job working with real ly a broad spectrum of \nthose providers across all types of tests, molecular, antigen, antibody, to get those into the provider communities \nthat we serve.  And we had tremendous growth.  \n \n That growth probably peaked in Q3.  It was, frankly, it fell away quicke r than we had anticipated when we had our \nearnings call in that third quarter.  We still, there is still COVID test kit volume out there, but it certainly was, if any, \nof all of our businesses, I would say the medical business was the most dynamic in terms of the market dynamics \nthis year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "It was, frankly, it fell away quicke r than we had anticipated when we had our \nearnings call in that third quarter. ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5371c73de22699b4c608320e65b5d28897f86a5f86da03c62417d3d4f8cb6cdc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c16a8aab-9004-48bd-8f7d-3d96326cf24c", "node_type": "1", "metadata": {"window": "That growth probably peaked in Q3.  It was, frankly, it fell away quicke r than we had anticipated when we had our \nearnings call in that third quarter.  We still, there is still COVID test kit volume out there, but it certainly was, if any, \nof all of our businesses, I would say the medical business was the most dynamic in terms of the market dynamics \nthis year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   "}, "hash": "5358c4010b6aba00867bc498e4b0d2b176cb2f05c42c36d34970f67af157467e", "class_name": "RelatedNodeInfo"}}, "text": "We still, there is still COVID test kit volume out there, but it certainly was, if any, \nof all of our businesses, I would say the medical business was the most dynamic in terms of the market dynamics \nthis year.  \n ", "start_char_idx": 4493, "end_char_idx": 4709, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c16a8aab-9004-48bd-8f7d-3d96326cf24c": {"__data__": {"id_": "c16a8aab-9004-48bd-8f7d-3d96326cf24c", "embedding": null, "metadata": {"window": "That growth probably peaked in Q3.  It was, frankly, it fell away quicke r than we had anticipated when we had our \nearnings call in that third quarter.  We still, there is still COVID test kit volume out there, but it certainly was, if any, \nof all of our businesses, I would say the medical business was the most dynamic in terms of the market dynamics \nthis year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e2c9dd7bd1b51dbf6e5a9637fb97c8539d1f126a0d1c45d372ab11764ced4df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0352525-9cbf-45eb-b070-99720a29b9d6", "node_type": "1", "metadata": {"window": "And we had tremendous growth.  \n \n That growth probably peaked in Q3.  It was, frankly, it fell away quicke r than we had anticipated when we had our \nearnings call in that third quarter.  We still, there is still COVID test kit volume out there, but it certainly was, if any, \nof all of our businesses, I would say the medical business was the most dynamic in terms of the market dynamics \nthis year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "We still, there is still COVID test kit volume out there, but it certainly was, if any, \nof all of our businesses, I would say the medical business was the most dynamic in terms of the market dynamics \nthis year.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fb18173fc2edc1de2186e9c881d151584bc25cf3a389380ba2cf7c214ea956d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00e0a688-6cc5-4096-b9bb-387afb1c3f82", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd maybe, Eric, just to follow up on that, as Brian talked about the breadth of our, the markets that we serve and \nthe breadth of prod ucts and capabilities that we have, our leading capabilities go across Rx, private brand, lab, as \nBrian talked about.  And, if you go before the pandemic, FY 2020, we had growth \u2013 AOP growth of about 12%. ", "original_text": "McKesson Corp.  "}, "hash": "b8489ccd39eeafc7f494a72c1503ef1c06d7d5e8cef8bf9fbe244e69cf838fd2", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "start_char_idx": 311, "end_char_idx": 567, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00e0a688-6cc5-4096-b9bb-387afb1c3f82": {"__data__": {"id_": "00e0a688-6cc5-4096-b9bb-387afb1c3f82", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd maybe, Eric, just to follow up on that, as Brian talked about the breadth of our, the markets that we serve and \nthe breadth of prod ucts and capabilities that we have, our leading capabilities go across Rx, private brand, lab, as \nBrian talked about.  And, if you go before the pandemic, FY 2020, we had growth \u2013 AOP growth of about 12%. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c16a8aab-9004-48bd-8f7d-3d96326cf24c", "node_type": "1", "metadata": {"window": "That growth probably peaked in Q3.  It was, frankly, it fell away quicke r than we had anticipated when we had our \nearnings call in that third quarter.  We still, there is still COVID test kit volume out there, but it certainly was, if any, \nof all of our businesses, I would say the medical business was the most dynamic in terms of the market dynamics \nthis year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "704d4bbafdb06678032c7e79a9f250d0362acd02ac30903ff1f716c8d9500e88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c686f040-c7e6-4f73-984e-ee6d9057e717", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd maybe, Eric, just to follow up on that, as Brian talked about the breadth of our, the markets that we serve and \nthe breadth of prod ucts and capabilities that we have, our leading capabilities go across Rx, private brand, lab, as \nBrian talked about.  And, if you go before the pandemic, FY 2020, we had growth \u2013 AOP growth of about 12%.  So \nI think as we look at our guide for next year, it  really speaks to the fundamentals of the business have remained \nvery strong all the way through the pandemic. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "07a147b684cb2b6b23fb911fcc869e31ff1398bf63e774f99b3e26df74b2e309", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c686f040-c7e6-4f73-984e-ee6d9057e717": {"__data__": {"id_": "c686f040-c7e6-4f73-984e-ee6d9057e717", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd maybe, Eric, just to follow up on that, as Brian talked about the breadth of our, the markets that we serve and \nthe breadth of prod ucts and capabilities that we have, our leading capabilities go across Rx, private brand, lab, as \nBrian talked about.  And, if you go before the pandemic, FY 2020, we had growth \u2013 AOP growth of about 12%.  So \nI think as we look at our guide for next year, it  really speaks to the fundamentals of the business have remained \nvery strong all the way through the pandemic. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00e0a688-6cc5-4096-b9bb-387afb1c3f82", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd maybe, Eric, just to follow up on that, as Brian talked about the breadth of our, the markets that we serve and \nthe breadth of prod ucts and capabilities that we have, our leading capabilities go across Rx, private brand, lab, as \nBrian talked about.  And, if you go before the pandemic, FY 2020, we had growth \u2013 AOP growth of about 12%. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ca5d8e6a50f74a470f5182a65e6d4dcca97847e31fc8cc0dfae3b6c8f9c8be2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb8721ce-03c9-45a5-b08c-60d0abdb5d1e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd maybe, Eric, just to follow up on that, as Brian talked about the breadth of our, the markets that we serve and \nthe breadth of prod ucts and capabilities that we have, our leading capabilities go across Rx, private brand, lab, as \nBrian talked about.  And, if you go before the pandemic, FY 2020, we had growth \u2013 AOP growth of about 12%.  So \nI think as we look at our guide for next year, it  really speaks to the fundamentals of the business have remained \nvery strong all the way through the pandemic.  And as volumes begin to come back and utilization comes back \nonline, we would expect that the business could continue to grow in that historical range.  \n ", "original_text": "A \nAnd maybe, Eric, just to follow up on that, as Brian talked about the breadth of our, the markets that we serve and \nthe breadth of prod ucts and capabilities that we have, our leading capabilities go across Rx, private brand, lab, as \nBrian talked about. "}, "hash": "cdeef8b93e79871b932326af19c8018b21e721e86dbeb9533e06f8fc1142ea0f", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 266, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb8721ce-03c9-45a5-b08c-60d0abdb5d1e": {"__data__": {"id_": "bb8721ce-03c9-45a5-b08c-60d0abdb5d1e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd maybe, Eric, just to follow up on that, as Brian talked about the breadth of our, the markets that we serve and \nthe breadth of prod ucts and capabilities that we have, our leading capabilities go across Rx, private brand, lab, as \nBrian talked about.  And, if you go before the pandemic, FY 2020, we had growth \u2013 AOP growth of about 12%.  So \nI think as we look at our guide for next year, it  really speaks to the fundamentals of the business have remained \nvery strong all the way through the pandemic.  And as volumes begin to come back and utilization comes back \nonline, we would expect that the business could continue to grow in that historical range.  \n ", "original_text": "A \nAnd maybe, Eric, just to follow up on that, as Brian talked about the breadth of our, the markets that we serve and \nthe breadth of prod ucts and capabilities that we have, our leading capabilities go across Rx, private brand, lab, as \nBrian talked about. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c686f040-c7e6-4f73-984e-ee6d9057e717", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd maybe, Eric, just to follow up on that, as Brian talked about the breadth of our, the markets that we serve and \nthe breadth of prod ucts and capabilities that we have, our leading capabilities go across Rx, private brand, lab, as \nBrian talked about.  And, if you go before the pandemic, FY 2020, we had growth \u2013 AOP growth of about 12%.  So \nI think as we look at our guide for next year, it  really speaks to the fundamentals of the business have remained \nvery strong all the way through the pandemic. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e35b1f4afb1c0cbe7ec06bfc1b15ad3f948b64f70f1ee4e469a245e7ecf460f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf4e3a05-7138-4431-9b86-0b5014d3ef6f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd maybe, Eric, just to follow up on that, as Brian talked about the breadth of our, the markets that we serve and \nthe breadth of prod ucts and capabilities that we have, our leading capabilities go across Rx, private brand, lab, as \nBrian talked about.  And, if you go before the pandemic, FY 2020, we had growth \u2013 AOP growth of about 12%.  So \nI think as we look at our guide for next year, it  really speaks to the fundamentals of the business have remained \nvery strong all the way through the pandemic.  And as volumes begin to come back and utilization comes back \nonline, we would expect that the business could continue to grow in that historical range.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "And, if you go before the pandemic, FY 2020, we had growth \u2013 AOP growth of about 12%. "}, "hash": "d24b2c8600701f14dfb984dd3618f7ad6205dcfbc4227e2e0afdfa31ea251a97", "class_name": "RelatedNodeInfo"}}, "text": "A \nAnd maybe, Eric, just to follow up on that, as Brian talked about the breadth of our, the markets that we serve and \nthe breadth of prod ucts and capabilities that we have, our leading capabilities go across Rx, private brand, lab, as \nBrian talked about. ", "start_char_idx": 266, "end_char_idx": 525, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf4e3a05-7138-4431-9b86-0b5014d3ef6f": {"__data__": {"id_": "cf4e3a05-7138-4431-9b86-0b5014d3ef6f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd maybe, Eric, just to follow up on that, as Brian talked about the breadth of our, the markets that we serve and \nthe breadth of prod ucts and capabilities that we have, our leading capabilities go across Rx, private brand, lab, as \nBrian talked about.  And, if you go before the pandemic, FY 2020, we had growth \u2013 AOP growth of about 12%.  So \nI think as we look at our guide for next year, it  really speaks to the fundamentals of the business have remained \nvery strong all the way through the pandemic.  And as volumes begin to come back and utilization comes back \nonline, we would expect that the business could continue to grow in that historical range.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "And, if you go before the pandemic, FY 2020, we had growth \u2013 AOP growth of about 12%. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb8721ce-03c9-45a5-b08c-60d0abdb5d1e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd maybe, Eric, just to follow up on that, as Brian talked about the breadth of our, the markets that we serve and \nthe breadth of prod ucts and capabilities that we have, our leading capabilities go across Rx, private brand, lab, as \nBrian talked about.  And, if you go before the pandemic, FY 2020, we had growth \u2013 AOP growth of about 12%.  So \nI think as we look at our guide for next year, it  really speaks to the fundamentals of the business have remained \nvery strong all the way through the pandemic.  And as volumes begin to come back and utilization comes back \nonline, we would expect that the business could continue to grow in that historical range.  \n ", "original_text": "A \nAnd maybe, Eric, just to follow up on that, as Brian talked about the breadth of our, the markets that we serve and \nthe breadth of prod ucts and capabilities that we have, our leading capabilities go across Rx, private brand, lab, as \nBrian talked about. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edf8fbb1ee9a76de7dc98ab810bbc48147c9742c781601a4b9082075b0237910", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c04cfd1f-92f4-482c-b5c8-f0bbcddd9a69", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd maybe, Eric, just to follow up on that, as Brian talked about the breadth of our, the markets that we serve and \nthe breadth of prod ucts and capabilities that we have, our leading capabilities go across Rx, private brand, lab, as \nBrian talked about.  And, if you go before the pandemic, FY 2020, we had growth \u2013 AOP growth of about 12%.  So \nI think as we look at our guide for next year, it  really speaks to the fundamentals of the business have remained \nvery strong all the way through the pandemic.  And as volumes begin to come back and utilization comes back \nonline, we would expect that the business could continue to grow in that historical range.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Kevin Caliendo with UBS.  \n ", "original_text": "So \nI think as we look at our guide for next year, it  really speaks to the fundamentals of the business have remained \nvery strong all the way through the pandemic. "}, "hash": "e8e54d9dcf5a9c8899a55d1cf7a00a530e3fbb1a7ab1e56e4b31bbd88c40f8ef", "class_name": "RelatedNodeInfo"}}, "text": "And, if you go before the pandemic, FY 2020, we had growth \u2013 AOP growth of about 12%. ", "start_char_idx": 525, "end_char_idx": 611, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c04cfd1f-92f4-482c-b5c8-f0bbcddd9a69": {"__data__": {"id_": "c04cfd1f-92f4-482c-b5c8-f0bbcddd9a69", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd maybe, Eric, just to follow up on that, as Brian talked about the breadth of our, the markets that we serve and \nthe breadth of prod ucts and capabilities that we have, our leading capabilities go across Rx, private brand, lab, as \nBrian talked about.  And, if you go before the pandemic, FY 2020, we had growth \u2013 AOP growth of about 12%.  So \nI think as we look at our guide for next year, it  really speaks to the fundamentals of the business have remained \nvery strong all the way through the pandemic.  And as volumes begin to come back and utilization comes back \nonline, we would expect that the business could continue to grow in that historical range.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Kevin Caliendo with UBS.  \n ", "original_text": "So \nI think as we look at our guide for next year, it  really speaks to the fundamentals of the business have remained \nvery strong all the way through the pandemic. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf4e3a05-7138-4431-9b86-0b5014d3ef6f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd maybe, Eric, just to follow up on that, as Brian talked about the breadth of our, the markets that we serve and \nthe breadth of prod ucts and capabilities that we have, our leading capabilities go across Rx, private brand, lab, as \nBrian talked about.  And, if you go before the pandemic, FY 2020, we had growth \u2013 AOP growth of about 12%.  So \nI think as we look at our guide for next year, it  really speaks to the fundamentals of the business have remained \nvery strong all the way through the pandemic.  And as volumes begin to come back and utilization comes back \nonline, we would expect that the business could continue to grow in that historical range.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "And, if you go before the pandemic, FY 2020, we had growth \u2013 AOP growth of about 12%. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ddd066f4ad46799256053bfa8057bbaa8d65d5805bc6ac9cc555e37ebb4730f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0bb33e2b-d942-4676-8db9-57e7f57a1030", "node_type": "1", "metadata": {"window": "A \nAnd maybe, Eric, just to follow up on that, as Brian talked about the breadth of our, the markets that we serve and \nthe breadth of prod ucts and capabilities that we have, our leading capabilities go across Rx, private brand, lab, as \nBrian talked about.  And, if you go before the pandemic, FY 2020, we had growth \u2013 AOP growth of about 12%.  So \nI think as we look at our guide for next year, it  really speaks to the fundamentals of the business have remained \nvery strong all the way through the pandemic.  And as volumes begin to come back and utilization comes back \nonline, we would expect that the business could continue to grow in that historical range.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my call. ", "original_text": "And as volumes begin to come back and utilization comes back \nonline, we would expect that the business could continue to grow in that historical range.  \n "}, "hash": "46530e103ea27ff96c6ff8f465ecf76ad0ab32ad5e356ef573520ba6d5979405", "class_name": "RelatedNodeInfo"}}, "text": "So \nI think as we look at our guide for next year, it  really speaks to the fundamentals of the business have remained \nvery strong all the way through the pandemic. ", "start_char_idx": 611, "end_char_idx": 777, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0bb33e2b-d942-4676-8db9-57e7f57a1030": {"__data__": {"id_": "0bb33e2b-d942-4676-8db9-57e7f57a1030", "embedding": null, "metadata": {"window": "A \nAnd maybe, Eric, just to follow up on that, as Brian talked about the breadth of our, the markets that we serve and \nthe breadth of prod ucts and capabilities that we have, our leading capabilities go across Rx, private brand, lab, as \nBrian talked about.  And, if you go before the pandemic, FY 2020, we had growth \u2013 AOP growth of about 12%.  So \nI think as we look at our guide for next year, it  really speaks to the fundamentals of the business have remained \nvery strong all the way through the pandemic.  And as volumes begin to come back and utilization comes back \nonline, we would expect that the business could continue to grow in that historical range.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my call. ", "original_text": "And as volumes begin to come back and utilization comes back \nonline, we would expect that the business could continue to grow in that historical range.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c04cfd1f-92f4-482c-b5c8-f0bbcddd9a69", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd maybe, Eric, just to follow up on that, as Brian talked about the breadth of our, the markets that we serve and \nthe breadth of prod ucts and capabilities that we have, our leading capabilities go across Rx, private brand, lab, as \nBrian talked about.  And, if you go before the pandemic, FY 2020, we had growth \u2013 AOP growth of about 12%.  So \nI think as we look at our guide for next year, it  really speaks to the fundamentals of the business have remained \nvery strong all the way through the pandemic.  And as volumes begin to come back and utilization comes back \nonline, we would expect that the business could continue to grow in that historical range.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Kevin Caliendo with UBS.  \n ", "original_text": "So \nI think as we look at our guide for next year, it  really speaks to the fundamentals of the business have remained \nvery strong all the way through the pandemic. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5c91a0f41317656f27053fcc1fa99e3623e390cb709f11af8279077d4dc3ab5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72bd4890-3a06-4722-a9de-0ba0a4add025", "node_type": "1", "metadata": {"window": "And, if you go before the pandemic, FY 2020, we had growth \u2013 AOP growth of about 12%.  So \nI think as we look at our guide for next year, it  really speaks to the fundamentals of the business have remained \nvery strong all the way through the pandemic.  And as volumes begin to come back and utilization comes back \nonline, we would expect that the business could continue to grow in that historical range.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my call.  So you guys have $6 billion of cash in your balance sheet. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. "}, "hash": "9d80e21240a7fe09d5be54d080e0ea6561cc99f8ce087636fc73edd53bd59737", "class_name": "RelatedNodeInfo"}}, "text": "And as volumes begin to come back and utilization comes back \nonline, we would expect that the business could continue to grow in that historical range.  \n ", "start_char_idx": 777, "end_char_idx": 933, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72bd4890-3a06-4722-a9de-0ba0a4add025": {"__data__": {"id_": "72bd4890-3a06-4722-a9de-0ba0a4add025", "embedding": null, "metadata": {"window": "And, if you go before the pandemic, FY 2020, we had growth \u2013 AOP growth of about 12%.  So \nI think as we look at our guide for next year, it  really speaks to the fundamentals of the business have remained \nvery strong all the way through the pandemic.  And as volumes begin to come back and utilization comes back \nonline, we would expect that the business could continue to grow in that historical range.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my call.  So you guys have $6 billion of cash in your balance sheet. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0bb33e2b-d942-4676-8db9-57e7f57a1030", "node_type": "1", "metadata": {"window": "A \nAnd maybe, Eric, just to follow up on that, as Brian talked about the breadth of our, the markets that we serve and \nthe breadth of prod ucts and capabilities that we have, our leading capabilities go across Rx, private brand, lab, as \nBrian talked about.  And, if you go before the pandemic, FY 2020, we had growth \u2013 AOP growth of about 12%.  So \nI think as we look at our guide for next year, it  really speaks to the fundamentals of the business have remained \nvery strong all the way through the pandemic.  And as volumes begin to come back and utilization comes back \nonline, we would expect that the business could continue to grow in that historical range.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my call. ", "original_text": "And as volumes begin to come back and utilization comes back \nonline, we would expect that the business could continue to grow in that historical range.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c3dde60d7fcc89ae69e97a2804022082c1ba3070176c1b144754edf7cdad806e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4f31c62-405e-4089-9485-01bf650cd158", "node_type": "1", "metadata": {"window": "So \nI think as we look at our guide for next year, it  really speaks to the fundamentals of the business have remained \nvery strong all the way through the pandemic.  And as volumes begin to come back and utilization comes back \nonline, we would expect that the business could continue to grow in that historical range.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my call.  So you guys have $6 billion of cash in your balance sheet.  Looking at the cash flows \nfrom this year, even with the larger buyback and the dividend, like, you're still likely to add cash net -net. ", "original_text": "Our next question comes from Kevin Caliendo with UBS.  \n "}, "hash": "5429f50bbb7b7ca869451cdbf48b56b50b25eed1cf724b6cc5352a48e1b206e9", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "start_char_idx": 933, "end_char_idx": 1214, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4f31c62-405e-4089-9485-01bf650cd158": {"__data__": {"id_": "f4f31c62-405e-4089-9485-01bf650cd158", "embedding": null, "metadata": {"window": "So \nI think as we look at our guide for next year, it  really speaks to the fundamentals of the business have remained \nvery strong all the way through the pandemic.  And as volumes begin to come back and utilization comes back \nonline, we would expect that the business could continue to grow in that historical range.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my call.  So you guys have $6 billion of cash in your balance sheet.  Looking at the cash flows \nfrom this year, even with the larger buyback and the dividend, like, you're still likely to add cash net -net. ", "original_text": "Our next question comes from Kevin Caliendo with UBS.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72bd4890-3a06-4722-a9de-0ba0a4add025", "node_type": "1", "metadata": {"window": "And, if you go before the pandemic, FY 2020, we had growth \u2013 AOP growth of about 12%.  So \nI think as we look at our guide for next year, it  really speaks to the fundamentals of the business have remained \nvery strong all the way through the pandemic.  And as volumes begin to come back and utilization comes back \nonline, we would expect that the business could continue to grow in that historical range.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my call.  So you guys have $6 billion of cash in your balance sheet. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "594f6c92256d07fe4dca8c4a8d92622096c3db92e83a54ca015797c337081693", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71e0336d-896d-4b27-9ee9-2cdbbaf2d00c", "node_type": "1", "metadata": {"window": "And as volumes begin to come back and utilization comes back \nonline, we would expect that the business could continue to grow in that historical range.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my call.  So you guys have $6 billion of cash in your balance sheet.  Looking at the cash flows \nfrom this year, even with the larger buyback and the dividend, like, you're still likely to add cash net -net.  There's \nbeen a lot of talk about potentially what you might do in terms of M&A going forward. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my call. "}, "hash": "bf643153e27ee1a883a01c3c8387c23939e0217131b3c47b425ee7a69d9500ab", "class_name": "RelatedNodeInfo"}}, "text": "Our next question comes from Kevin Caliendo with UBS.  \n ", "start_char_idx": 1214, "end_char_idx": 1271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71e0336d-896d-4b27-9ee9-2cdbbaf2d00c": {"__data__": {"id_": "71e0336d-896d-4b27-9ee9-2cdbbaf2d00c", "embedding": null, "metadata": {"window": "And as volumes begin to come back and utilization comes back \nonline, we would expect that the business could continue to grow in that historical range.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my call.  So you guys have $6 billion of cash in your balance sheet.  Looking at the cash flows \nfrom this year, even with the larger buyback and the dividend, like, you're still likely to add cash net -net.  There's \nbeen a lot of talk about potentially what you might do in terms of M&A going forward. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my call. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4f31c62-405e-4089-9485-01bf650cd158", "node_type": "1", "metadata": {"window": "So \nI think as we look at our guide for next year, it  really speaks to the fundamentals of the business have remained \nvery strong all the way through the pandemic.  And as volumes begin to come back and utilization comes back \nonline, we would expect that the business could continue to grow in that historical range.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my call.  So you guys have $6 billion of cash in your balance sheet.  Looking at the cash flows \nfrom this year, even with the larger buyback and the dividend, like, you're still likely to add cash net -net. ", "original_text": "Our next question comes from Kevin Caliendo with UBS.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f6fdcba6b8caa69b8a443321164397da37115263223c76b225da9fd37f24498", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7bd655b9-5bc5-4067-a4f7-d8e2efa64df0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my call.  So you guys have $6 billion of cash in your balance sheet.  Looking at the cash flows \nfrom this year, even with the larger buyback and the dividend, like, you're still likely to add cash net -net.  There's \nbeen a lot of talk about potentially what you might do in terms of M&A going forward.  What's your appetite in \nterms of M&A? ", "original_text": "So you guys have $6 billion of cash in your balance sheet. "}, "hash": "421a9c5ff0f5be565a2694486f219c4ee71ad19895476e11e20f41d35fc2bdb3", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my call. ", "start_char_idx": 1271, "end_char_idx": 1608, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7bd655b9-5bc5-4067-a4f7-d8e2efa64df0": {"__data__": {"id_": "7bd655b9-5bc5-4067-a4f7-d8e2efa64df0", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my call.  So you guys have $6 billion of cash in your balance sheet.  Looking at the cash flows \nfrom this year, even with the larger buyback and the dividend, like, you're still likely to add cash net -net.  There's \nbeen a lot of talk about potentially what you might do in terms of M&A going forward.  What's your appetite in \nterms of M&A? ", "original_text": "So you guys have $6 billion of cash in your balance sheet. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71e0336d-896d-4b27-9ee9-2cdbbaf2d00c", "node_type": "1", "metadata": {"window": "And as volumes begin to come back and utilization comes back \nonline, we would expect that the business could continue to grow in that historical range.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my call.  So you guys have $6 billion of cash in your balance sheet.  Looking at the cash flows \nfrom this year, even with the larger buyback and the dividend, like, you're still likely to add cash net -net.  There's \nbeen a lot of talk about potentially what you might do in terms of M&A going forward. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my call. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b16201d28ac0403b039f7f549f3cbc43997cee3255af69e32a0b2be62d02a7ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c774587-de1a-4d23-872e-c59ba7dcefc2", "node_type": "1", "metadata": {"window": "Our next question comes from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my call.  So you guys have $6 billion of cash in your balance sheet.  Looking at the cash flows \nfrom this year, even with the larger buyback and the dividend, like, you're still likely to add cash net -net.  There's \nbeen a lot of talk about potentially what you might do in terms of M&A going forward.  What's your appetite in \nterms of M&A?  Are you looking to just add on and bolt on? ", "original_text": "Looking at the cash flows \nfrom this year, even with the larger buyback and the dividend, like, you're still likely to add cash net -net. "}, "hash": "1b004861a1b6ca6be9aa2b7c44b83a5c3d20f45096ab57db695218b029c5ee28", "class_name": "RelatedNodeInfo"}}, "text": "So you guys have $6 billion of cash in your balance sheet. ", "start_char_idx": 1608, "end_char_idx": 1667, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c774587-de1a-4d23-872e-c59ba7dcefc2": {"__data__": {"id_": "8c774587-de1a-4d23-872e-c59ba7dcefc2", "embedding": null, "metadata": {"window": "Our next question comes from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my call.  So you guys have $6 billion of cash in your balance sheet.  Looking at the cash flows \nfrom this year, even with the larger buyback and the dividend, like, you're still likely to add cash net -net.  There's \nbeen a lot of talk about potentially what you might do in terms of M&A going forward.  What's your appetite in \nterms of M&A?  Are you looking to just add on and bolt on? ", "original_text": "Looking at the cash flows \nfrom this year, even with the larger buyback and the dividend, like, you're still likely to add cash net -net. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7bd655b9-5bc5-4067-a4f7-d8e2efa64df0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my call.  So you guys have $6 billion of cash in your balance sheet.  Looking at the cash flows \nfrom this year, even with the larger buyback and the dividend, like, you're still likely to add cash net -net.  There's \nbeen a lot of talk about potentially what you might do in terms of M&A going forward.  What's your appetite in \nterms of M&A? ", "original_text": "So you guys have $6 billion of cash in your balance sheet. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bb4103089e868edc34cb8e59d559cf6247c82f0a3cf0fcfc290fa289849f333b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45ffffe3-9b46-4770-b53b-95c6e571b92d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my call.  So you guys have $6 billion of cash in your balance sheet.  Looking at the cash flows \nfrom this year, even with the larger buyback and the dividend, like, you're still likely to add cash net -net.  There's \nbeen a lot of talk about potentially what you might do in terms of M&A going forward.  What's your appetite in \nterms of M&A?  Are you looking to just add on and bolt on?  Is there a meaningful acquisition you'd be looking to \ndo? ", "original_text": "There's \nbeen a lot of talk about potentially what you might do in terms of M&A going forward. "}, "hash": "ff17ec01e7c11a46db987e34ce5c3a25f1564cd1860b49f609d7a896c6d93c35", "class_name": "RelatedNodeInfo"}}, "text": "Looking at the cash flows \nfrom this year, even with the larger buyback and the dividend, like, you're still likely to add cash net -net. ", "start_char_idx": 1667, "end_char_idx": 1805, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45ffffe3-9b46-4770-b53b-95c6e571b92d": {"__data__": {"id_": "45ffffe3-9b46-4770-b53b-95c6e571b92d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my call.  So you guys have $6 billion of cash in your balance sheet.  Looking at the cash flows \nfrom this year, even with the larger buyback and the dividend, like, you're still likely to add cash net -net.  There's \nbeen a lot of talk about potentially what you might do in terms of M&A going forward.  What's your appetite in \nterms of M&A?  Are you looking to just add on and bolt on?  Is there a meaningful acquisition you'd be looking to \ndo? ", "original_text": "There's \nbeen a lot of talk about potentially what you might do in terms of M&A going forward. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c774587-de1a-4d23-872e-c59ba7dcefc2", "node_type": "1", "metadata": {"window": "Our next question comes from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my call.  So you guys have $6 billion of cash in your balance sheet.  Looking at the cash flows \nfrom this year, even with the larger buyback and the dividend, like, you're still likely to add cash net -net.  There's \nbeen a lot of talk about potentially what you might do in terms of M&A going forward.  What's your appetite in \nterms of M&A?  Are you looking to just add on and bolt on? ", "original_text": "Looking at the cash flows \nfrom this year, even with the larger buyback and the dividend, like, you're still likely to add cash net -net. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f1d7f3a9d4908e835ff76f094caf561229fb74e5dd8ec0ca3f80297beaae15b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f98aa26-a7d1-42b7-a0b8-7a1bcb4fbbb1", "node_type": "1", "metadata": {"window": "So you guys have $6 billion of cash in your balance sheet.  Looking at the cash flows \nfrom this year, even with the larger buyback and the dividend, like, you're still likely to add cash net -net.  There's \nbeen a lot of talk about potentially what you might do in terms of M&A going forward.  What's your appetite in \nterms of M&A?  Are you looking to just add on and bolt on?  Is there a meaningful acquisition you'd be looking to \ndo?  Anything notable? ", "original_text": "What's your appetite in \nterms of M&A? "}, "hash": "40d1c7c3eaae94cf96111e30756271a3e3c3352ff57bbc531ad91871f01f4c33", "class_name": "RelatedNodeInfo"}}, "text": "There's \nbeen a lot of talk about potentially what you might do in terms of M&A going forward. ", "start_char_idx": 1805, "end_char_idx": 1900, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f98aa26-a7d1-42b7-a0b8-7a1bcb4fbbb1": {"__data__": {"id_": "5f98aa26-a7d1-42b7-a0b8-7a1bcb4fbbb1", "embedding": null, "metadata": {"window": "So you guys have $6 billion of cash in your balance sheet.  Looking at the cash flows \nfrom this year, even with the larger buyback and the dividend, like, you're still likely to add cash net -net.  There's \nbeen a lot of talk about potentially what you might do in terms of M&A going forward.  What's your appetite in \nterms of M&A?  Are you looking to just add on and bolt on?  Is there a meaningful acquisition you'd be looking to \ndo?  Anything notable? ", "original_text": "What's your appetite in \nterms of M&A? ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45ffffe3-9b46-4770-b53b-95c6e571b92d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my call.  So you guys have $6 billion of cash in your balance sheet.  Looking at the cash flows \nfrom this year, even with the larger buyback and the dividend, like, you're still likely to add cash net -net.  There's \nbeen a lot of talk about potentially what you might do in terms of M&A going forward.  What's your appetite in \nterms of M&A?  Are you looking to just add on and bolt on?  Is there a meaningful acquisition you'd be looking to \ndo? ", "original_text": "There's \nbeen a lot of talk about potentially what you might do in terms of M&A going forward. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "128736796fdf5f10e6bc9c2eb00175ec001c8e40e289a4b1155f0b164d36ba6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "978d4b28-6f15-45b1-9e0c-6b15d188e6d9", "node_type": "1", "metadata": {"window": "Looking at the cash flows \nfrom this year, even with the larger buyback and the dividend, like, you're still likely to add cash net -net.  There's \nbeen a lot of talk about potentially what you might do in terms of M&A going forward.  What's your appetite in \nterms of M&A?  Are you looking to just add on and bolt on?  Is there a meaningful acquisition you'd be looking to \ndo?  Anything notable?  Sort of, talk about where you sit now versus maybe where you had been in the past?  \n ", "original_text": "Are you looking to just add on and bolt on? "}, "hash": "f934b354a89ef61a11997740d928dbd6e216f986a0b721de846e1f89907c3f6a", "class_name": "RelatedNodeInfo"}}, "text": "What's your appetite in \nterms of M&A? ", "start_char_idx": 1900, "end_char_idx": 1939, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "978d4b28-6f15-45b1-9e0c-6b15d188e6d9": {"__data__": {"id_": "978d4b28-6f15-45b1-9e0c-6b15d188e6d9", "embedding": null, "metadata": {"window": "Looking at the cash flows \nfrom this year, even with the larger buyback and the dividend, like, you're still likely to add cash net -net.  There's \nbeen a lot of talk about potentially what you might do in terms of M&A going forward.  What's your appetite in \nterms of M&A?  Are you looking to just add on and bolt on?  Is there a meaningful acquisition you'd be looking to \ndo?  Anything notable?  Sort of, talk about where you sit now versus maybe where you had been in the past?  \n ", "original_text": "Are you looking to just add on and bolt on? ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f98aa26-a7d1-42b7-a0b8-7a1bcb4fbbb1", "node_type": "1", "metadata": {"window": "So you guys have $6 billion of cash in your balance sheet.  Looking at the cash flows \nfrom this year, even with the larger buyback and the dividend, like, you're still likely to add cash net -net.  There's \nbeen a lot of talk about potentially what you might do in terms of M&A going forward.  What's your appetite in \nterms of M&A?  Are you looking to just add on and bolt on?  Is there a meaningful acquisition you'd be looking to \ndo?  Anything notable? ", "original_text": "What's your appetite in \nterms of M&A? ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4cfd8e50e4d0a587e01351df518325826550ace15132ee464ab3c53720b38dac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b63d9a2-32ee-420c-aef1-f086ad8394e2", "node_type": "1", "metadata": {"window": "There's \nbeen a lot of talk about potentially what you might do in terms of M&A going forward.  What's your appetite in \nterms of M&A?  Are you looking to just add on and bolt on?  Is there a meaningful acquisition you'd be looking to \ndo?  Anything notable?  Sort of, talk about where you sit now versus maybe where you had been in the past?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Is there a meaningful acquisition you'd be looking to \ndo? "}, "hash": "c2e0f8c975b1c6bb402a64fc927506df7df314306acb3078b4b0bc43fd108b47", "class_name": "RelatedNodeInfo"}}, "text": "Are you looking to just add on and bolt on? ", "start_char_idx": 1939, "end_char_idx": 1983, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b63d9a2-32ee-420c-aef1-f086ad8394e2": {"__data__": {"id_": "4b63d9a2-32ee-420c-aef1-f086ad8394e2", "embedding": null, "metadata": {"window": "There's \nbeen a lot of talk about potentially what you might do in terms of M&A going forward.  What's your appetite in \nterms of M&A?  Are you looking to just add on and bolt on?  Is there a meaningful acquisition you'd be looking to \ndo?  Anything notable?  Sort of, talk about where you sit now versus maybe where you had been in the past?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Is there a meaningful acquisition you'd be looking to \ndo? ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "978d4b28-6f15-45b1-9e0c-6b15d188e6d9", "node_type": "1", "metadata": {"window": "Looking at the cash flows \nfrom this year, even with the larger buyback and the dividend, like, you're still likely to add cash net -net.  There's \nbeen a lot of talk about potentially what you might do in terms of M&A going forward.  What's your appetite in \nterms of M&A?  Are you looking to just add on and bolt on?  Is there a meaningful acquisition you'd be looking to \ndo?  Anything notable?  Sort of, talk about where you sit now versus maybe where you had been in the past?  \n ", "original_text": "Are you looking to just add on and bolt on? ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bedef38c19439518289d61c7ab1be1c6d1ace6f584aae6de3e0c296f51fa8ac2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc9d5413-b1aa-4330-a42f-655ee56cde26", "node_type": "1", "metadata": {"window": "What's your appetite in \nterms of M&A?  Are you looking to just add on and bolt on?  Is there a meaningful acquisition you'd be looking to \ndo?  Anything notable?  Sort of, talk about where you sit now versus maybe where you had been in the past?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "Anything notable? "}, "hash": "ce7a4a592343788da9ffbe7cefe60c80a1f57019562705cbfc4b3ce5fff2b34b", "class_name": "RelatedNodeInfo"}}, "text": "Is there a meaningful acquisition you'd be looking to \ndo? ", "start_char_idx": 1983, "end_char_idx": 2042, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc9d5413-b1aa-4330-a42f-655ee56cde26": {"__data__": {"id_": "fc9d5413-b1aa-4330-a42f-655ee56cde26", "embedding": null, "metadata": {"window": "What's your appetite in \nterms of M&A?  Are you looking to just add on and bolt on?  Is there a meaningful acquisition you'd be looking to \ndo?  Anything notable?  Sort of, talk about where you sit now versus maybe where you had been in the past?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "Anything notable? ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b63d9a2-32ee-420c-aef1-f086ad8394e2", "node_type": "1", "metadata": {"window": "There's \nbeen a lot of talk about potentially what you might do in terms of M&A going forward.  What's your appetite in \nterms of M&A?  Are you looking to just add on and bolt on?  Is there a meaningful acquisition you'd be looking to \ndo?  Anything notable?  Sort of, talk about where you sit now versus maybe where you had been in the past?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Is there a meaningful acquisition you'd be looking to \ndo? ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93c654cf3931ee491b5e67eb3cf4bae71da56311f02dcc7b1bbf96dc2ccba106", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4771c77f-d2af-45ac-b840-3fb94b84a574", "node_type": "1", "metadata": {"window": "Are you looking to just add on and bolt on?  Is there a meaningful acquisition you'd be looking to \ndo?  Anything notable?  Sort of, talk about where you sit now versus maybe where you had been in the past?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, let me give you just a couple of framing comments on how we think of M&A. ", "original_text": "Sort of, talk about where you sit now versus maybe where you had been in the past?  \n "}, "hash": "3a637d62f7fc0cb08e0ad509a07175477140b53fc423286ce12a8d929e387515", "class_name": "RelatedNodeInfo"}}, "text": "Anything notable? ", "start_char_idx": 2042, "end_char_idx": 2060, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4771c77f-d2af-45ac-b840-3fb94b84a574": {"__data__": {"id_": "4771c77f-d2af-45ac-b840-3fb94b84a574", "embedding": null, "metadata": {"window": "Are you looking to just add on and bolt on?  Is there a meaningful acquisition you'd be looking to \ndo?  Anything notable?  Sort of, talk about where you sit now versus maybe where you had been in the past?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, let me give you just a couple of framing comments on how we think of M&A. ", "original_text": "Sort of, talk about where you sit now versus maybe where you had been in the past?  \n ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc9d5413-b1aa-4330-a42f-655ee56cde26", "node_type": "1", "metadata": {"window": "What's your appetite in \nterms of M&A?  Are you looking to just add on and bolt on?  Is there a meaningful acquisition you'd be looking to \ndo?  Anything notable?  Sort of, talk about where you sit now versus maybe where you had been in the past?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "Anything notable? ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aeb6740c2d396ea16bb2b1462141150963c1177e97f9c3f611ba320bbbd0b61c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "369dd560-62ef-4687-b3fb-adbcb7ac48ae", "node_type": "1", "metadata": {"window": "Is there a meaningful acquisition you'd be looking to \ndo?  Anything notable?  Sort of, talk about where you sit now versus maybe where you had been in the past?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, let me give you just a couple of framing comments on how we think of M&A.  So first, if it's what we \nwould call tuck -in or it's a core business, we're in the business today, we understand the business. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "d2f883365e81c427468da407fe8ddae251b85fc9c4b9c6064902f2ed1637b5a0", "class_name": "RelatedNodeInfo"}}, "text": "Sort of, talk about where you sit now versus maybe where you had been in the past?  \n ", "start_char_idx": 2060, "end_char_idx": 2146, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "369dd560-62ef-4687-b3fb-adbcb7ac48ae": {"__data__": {"id_": "369dd560-62ef-4687-b3fb-adbcb7ac48ae", "embedding": null, "metadata": {"window": "Is there a meaningful acquisition you'd be looking to \ndo?  Anything notable?  Sort of, talk about where you sit now versus maybe where you had been in the past?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, let me give you just a couple of framing comments on how we think of M&A.  So first, if it's what we \nwould call tuck -in or it's a core business, we're in the business today, we understand the business. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4771c77f-d2af-45ac-b840-3fb94b84a574", "node_type": "1", "metadata": {"window": "Are you looking to just add on and bolt on?  Is there a meaningful acquisition you'd be looking to \ndo?  Anything notable?  Sort of, talk about where you sit now versus maybe where you had been in the past?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, let me give you just a couple of framing comments on how we think of M&A. ", "original_text": "Sort of, talk about where you sit now versus maybe where you had been in the past?  \n ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5321a21603a8e89fb8fe1ba3185ee9125c725b06e24973a0ab4e7f0379176474", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0d51709-9ade-4496-8fdb-6ae3a4406917", "node_type": "1", "metadata": {"window": "Anything notable?  Sort of, talk about where you sit now versus maybe where you had been in the past?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, let me give you just a couple of framing comments on how we think of M&A.  So first, if it's what we \nwould call tuck -in or it's a core business, we're in the business today, we understand the business.  It's just about \nreally adding customers  or maybe a capability but, and scale to a platform we already have, that's attractive M&A. \n", "original_text": "A \nYeah. "}, "hash": "be1a6d0e7a2e0f75cd51dfd8f79f8826a1bc8ee7e5971d2b2a458f90faf34e1d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 2146, "end_char_idx": 2475, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0d51709-9ade-4496-8fdb-6ae3a4406917": {"__data__": {"id_": "e0d51709-9ade-4496-8fdb-6ae3a4406917", "embedding": null, "metadata": {"window": "Anything notable?  Sort of, talk about where you sit now versus maybe where you had been in the past?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, let me give you just a couple of framing comments on how we think of M&A.  So first, if it's what we \nwould call tuck -in or it's a core business, we're in the business today, we understand the business.  It's just about \nreally adding customers  or maybe a capability but, and scale to a platform we already have, that's attractive M&A. \n", "original_text": "A \nYeah. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "369dd560-62ef-4687-b3fb-adbcb7ac48ae", "node_type": "1", "metadata": {"window": "Is there a meaningful acquisition you'd be looking to \ndo?  Anything notable?  Sort of, talk about where you sit now versus maybe where you had been in the past?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, let me give you just a couple of framing comments on how we think of M&A.  So first, if it's what we \nwould call tuck -in or it's a core business, we're in the business today, we understand the business. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1c1f7d3046da27d0656439ced1879edf5a4c6fa7f7156f6b17213b3441f8432f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f024ab4-a0fa-47f8-8fee-00065c7287ce", "node_type": "1", "metadata": {"window": "Sort of, talk about where you sit now versus maybe where you had been in the past?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, let me give you just a couple of framing comments on how we think of M&A.  So first, if it's what we \nwould call tuck -in or it's a core business, we're in the business today, we understand the business.  It's just about \nreally adding customers  or maybe a capability but, and scale to a platform we already have, that's attractive M&A. \n And over the history of this company, we've been very successful doing that kind of M&A.  \n \n", "original_text": "I mean, let me give you just a couple of framing comments on how we think of M&A. "}, "hash": "2f61d4f0b203d2b29dbdb04bfd4dd7e3ed67815e4ed94390784a67e520ac1de7", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 2475, "end_char_idx": 2484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f024ab4-a0fa-47f8-8fee-00065c7287ce": {"__data__": {"id_": "5f024ab4-a0fa-47f8-8fee-00065c7287ce", "embedding": null, "metadata": {"window": "Sort of, talk about where you sit now versus maybe where you had been in the past?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, let me give you just a couple of framing comments on how we think of M&A.  So first, if it's what we \nwould call tuck -in or it's a core business, we're in the business today, we understand the business.  It's just about \nreally adding customers  or maybe a capability but, and scale to a platform we already have, that's attractive M&A. \n And over the history of this company, we've been very successful doing that kind of M&A.  \n \n", "original_text": "I mean, let me give you just a couple of framing comments on how we think of M&A. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0d51709-9ade-4496-8fdb-6ae3a4406917", "node_type": "1", "metadata": {"window": "Anything notable?  Sort of, talk about where you sit now versus maybe where you had been in the past?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, let me give you just a couple of framing comments on how we think of M&A.  So first, if it's what we \nwould call tuck -in or it's a core business, we're in the business today, we understand the business.  It's just about \nreally adding customers  or maybe a capability but, and scale to a platform we already have, that's attractive M&A. \n", "original_text": "A \nYeah. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9d5146d74c19da11f3ab1a8532e3a4c1b2c5e24da76d9105a006283f301b3ef8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33fbd059-f491-4c04-8da1-cc8ed1166636", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, let me give you just a couple of framing comments on how we think of M&A.  So first, if it's what we \nwould call tuck -in or it's a core business, we're in the business today, we understand the business.  It's just about \nreally adding customers  or maybe a capability but, and scale to a platform we already have, that's attractive M&A. \n And over the history of this company, we've been very successful doing that kind of M&A.  \n \n The second kind that we \u2013 the second criteria we really have is to assess its alignment to our enterprise strategy. \n", "original_text": "So first, if it's what we \nwould call tuck -in or it's a core business, we're in the business today, we understand the business. "}, "hash": "a8a70fc429d3989be88e4d4bec14fe0167ee18b5213356ec16e759eb7898a779", "class_name": "RelatedNodeInfo"}}, "text": "I mean, let me give you just a couple of framing comments on how we think of M&A. ", "start_char_idx": 2484, "end_char_idx": 2566, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33fbd059-f491-4c04-8da1-cc8ed1166636": {"__data__": {"id_": "33fbd059-f491-4c04-8da1-cc8ed1166636", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, let me give you just a couple of framing comments on how we think of M&A.  So first, if it's what we \nwould call tuck -in or it's a core business, we're in the business today, we understand the business.  It's just about \nreally adding customers  or maybe a capability but, and scale to a platform we already have, that's attractive M&A. \n And over the history of this company, we've been very successful doing that kind of M&A.  \n \n The second kind that we \u2013 the second criteria we really have is to assess its alignment to our enterprise strategy. \n", "original_text": "So first, if it's what we \nwould call tuck -in or it's a core business, we're in the business today, we understand the business. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f024ab4-a0fa-47f8-8fee-00065c7287ce", "node_type": "1", "metadata": {"window": "Sort of, talk about where you sit now versus maybe where you had been in the past?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, let me give you just a couple of framing comments on how we think of M&A.  So first, if it's what we \nwould call tuck -in or it's a core business, we're in the business today, we understand the business.  It's just about \nreally adding customers  or maybe a capability but, and scale to a platform we already have, that's attractive M&A. \n And over the history of this company, we've been very successful doing that kind of M&A.  \n \n", "original_text": "I mean, let me give you just a couple of framing comments on how we think of M&A. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3b4517359b937a27c0aa1d482d8bb9a861377a5d8c9d18b0ee50cb43f0458217", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "744e3815-0b84-4c2c-a839-b497f2f934b7", "node_type": "1", "metadata": {"window": "A \nYeah.  I mean, let me give you just a couple of framing comments on how we think of M&A.  So first, if it's what we \nwould call tuck -in or it's a core business, we're in the business today, we understand the business.  It's just about \nreally adding customers  or maybe a capability but, and scale to a platform we already have, that's attractive M&A. \n And over the history of this company, we've been very successful doing that kind of M&A.  \n \n The second kind that we \u2013 the second criteria we really have is to assess its alignment to our enterprise strategy. \n We've articulated our oncology ecosystem and our biopharma services business as areas that we want to deploy \ngrowth capital against. ", "original_text": "It's just about \nreally adding customers  or maybe a capability but, and scale to a platform we already have, that's attractive M&A. \n"}, "hash": "6e6a0df7cc5f8f1ee0822964665cced6e6b415f4ba52d0fa7c9638174500fd12", "class_name": "RelatedNodeInfo"}}, "text": "So first, if it's what we \nwould call tuck -in or it's a core business, we're in the business today, we understand the business. ", "start_char_idx": 2566, "end_char_idx": 2695, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "744e3815-0b84-4c2c-a839-b497f2f934b7": {"__data__": {"id_": "744e3815-0b84-4c2c-a839-b497f2f934b7", "embedding": null, "metadata": {"window": "A \nYeah.  I mean, let me give you just a couple of framing comments on how we think of M&A.  So first, if it's what we \nwould call tuck -in or it's a core business, we're in the business today, we understand the business.  It's just about \nreally adding customers  or maybe a capability but, and scale to a platform we already have, that's attractive M&A. \n And over the history of this company, we've been very successful doing that kind of M&A.  \n \n The second kind that we \u2013 the second criteria we really have is to assess its alignment to our enterprise strategy. \n We've articulated our oncology ecosystem and our biopharma services business as areas that we want to deploy \ngrowth capital against. ", "original_text": "It's just about \nreally adding customers  or maybe a capability but, and scale to a platform we already have, that's attractive M&A. \n", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33fbd059-f491-4c04-8da1-cc8ed1166636", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, let me give you just a couple of framing comments on how we think of M&A.  So first, if it's what we \nwould call tuck -in or it's a core business, we're in the business today, we understand the business.  It's just about \nreally adding customers  or maybe a capability but, and scale to a platform we already have, that's attractive M&A. \n And over the history of this company, we've been very successful doing that kind of M&A.  \n \n The second kind that we \u2013 the second criteria we really have is to assess its alignment to our enterprise strategy. \n", "original_text": "So first, if it's what we \nwould call tuck -in or it's a core business, we're in the business today, we understand the business. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1e4907a4d7ad4cccde5d7487b7801fd299ea65997f0f8e3548ea3830e8b249a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "426dbe8f-d944-4f6f-93f8-79ce6d0bfa0e", "node_type": "1", "metadata": {"window": "I mean, let me give you just a couple of framing comments on how we think of M&A.  So first, if it's what we \nwould call tuck -in or it's a core business, we're in the business today, we understand the business.  It's just about \nreally adding customers  or maybe a capability but, and scale to a platform we already have, that's attractive M&A. \n And over the history of this company, we've been very successful doing that kind of M&A.  \n \n The second kind that we \u2013 the second criteria we really have is to assess its alignment to our enterprise strategy. \n We've articulated our oncology ecosystem and our biopharma services business as areas that we want to deploy \ngrowth capital against.  But it's got to meet our third criteria, which is we're very financially discipli ned about the \nway we approach these things. ", "original_text": "And over the history of this company, we've been very successful doing that kind of M&A.  \n \n"}, "hash": "9a0994159862fbbe46d4ea4fe8f42021f26553b82e8906bc778533d77c5243b8", "class_name": "RelatedNodeInfo"}}, "text": "It's just about \nreally adding customers  or maybe a capability but, and scale to a platform we already have, that's attractive M&A. \n", "start_char_idx": 2695, "end_char_idx": 2829, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "426dbe8f-d944-4f6f-93f8-79ce6d0bfa0e": {"__data__": {"id_": "426dbe8f-d944-4f6f-93f8-79ce6d0bfa0e", "embedding": null, "metadata": {"window": "I mean, let me give you just a couple of framing comments on how we think of M&A.  So first, if it's what we \nwould call tuck -in or it's a core business, we're in the business today, we understand the business.  It's just about \nreally adding customers  or maybe a capability but, and scale to a platform we already have, that's attractive M&A. \n And over the history of this company, we've been very successful doing that kind of M&A.  \n \n The second kind that we \u2013 the second criteria we really have is to assess its alignment to our enterprise strategy. \n We've articulated our oncology ecosystem and our biopharma services business as areas that we want to deploy \ngrowth capital against.  But it's got to meet our third criteria, which is we're very financially discipli ned about the \nway we approach these things. ", "original_text": "And over the history of this company, we've been very successful doing that kind of M&A.  \n \n", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "744e3815-0b84-4c2c-a839-b497f2f934b7", "node_type": "1", "metadata": {"window": "A \nYeah.  I mean, let me give you just a couple of framing comments on how we think of M&A.  So first, if it's what we \nwould call tuck -in or it's a core business, we're in the business today, we understand the business.  It's just about \nreally adding customers  or maybe a capability but, and scale to a platform we already have, that's attractive M&A. \n And over the history of this company, we've been very successful doing that kind of M&A.  \n \n The second kind that we \u2013 the second criteria we really have is to assess its alignment to our enterprise strategy. \n We've articulated our oncology ecosystem and our biopharma services business as areas that we want to deploy \ngrowth capital against. ", "original_text": "It's just about \nreally adding customers  or maybe a capability but, and scale to a platform we already have, that's attractive M&A. \n", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "123fdfdde15493c9428128875b6fb36033661a9d6dcfca5de6c24f5858a668e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a5e0e16-f798-4e2e-a617-6a006532218c", "node_type": "1", "metadata": {"window": "So first, if it's what we \nwould call tuck -in or it's a core business, we're in the business today, we understand the business.  It's just about \nreally adding customers  or maybe a capability but, and scale to a platform we already have, that's attractive M&A. \n And over the history of this company, we've been very successful doing that kind of M&A.  \n \n The second kind that we \u2013 the second criteria we really have is to assess its alignment to our enterprise strategy. \n We've articulated our oncology ecosystem and our biopharma services business as areas that we want to deploy \ngrowth capital against.  But it's got to meet our third criteria, which is we're very financially discipli ned about the \nway we approach these things.  We know we have alternate uses to deploy our capital. ", "original_text": "The second kind that we \u2013 the second criteria we really have is to assess its alignment to our enterprise strategy. \n"}, "hash": "3397a0bbe0f5f4046fe3c2c04d68c25f0dd325669ee70e1250d88f190196320c", "class_name": "RelatedNodeInfo"}}, "text": "And over the history of this company, we've been very successful doing that kind of M&A.  \n \n", "start_char_idx": 2829, "end_char_idx": 2922, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a5e0e16-f798-4e2e-a617-6a006532218c": {"__data__": {"id_": "1a5e0e16-f798-4e2e-a617-6a006532218c", "embedding": null, "metadata": {"window": "So first, if it's what we \nwould call tuck -in or it's a core business, we're in the business today, we understand the business.  It's just about \nreally adding customers  or maybe a capability but, and scale to a platform we already have, that's attractive M&A. \n And over the history of this company, we've been very successful doing that kind of M&A.  \n \n The second kind that we \u2013 the second criteria we really have is to assess its alignment to our enterprise strategy. \n We've articulated our oncology ecosystem and our biopharma services business as areas that we want to deploy \ngrowth capital against.  But it's got to meet our third criteria, which is we're very financially discipli ned about the \nway we approach these things.  We know we have alternate uses to deploy our capital. ", "original_text": "The second kind that we \u2013 the second criteria we really have is to assess its alignment to our enterprise strategy. \n", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "426dbe8f-d944-4f6f-93f8-79ce6d0bfa0e", "node_type": "1", "metadata": {"window": "I mean, let me give you just a couple of framing comments on how we think of M&A.  So first, if it's what we \nwould call tuck -in or it's a core business, we're in the business today, we understand the business.  It's just about \nreally adding customers  or maybe a capability but, and scale to a platform we already have, that's attractive M&A. \n And over the history of this company, we've been very successful doing that kind of M&A.  \n \n The second kind that we \u2013 the second criteria we really have is to assess its alignment to our enterprise strategy. \n We've articulated our oncology ecosystem and our biopharma services business as areas that we want to deploy \ngrowth capital against.  But it's got to meet our third criteria, which is we're very financially discipli ned about the \nway we approach these things. ", "original_text": "And over the history of this company, we've been very successful doing that kind of M&A.  \n \n", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85a17caa72c715589365b808358325680391bc60b71b2b270d2ae2b9daffefb0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca81a4d5-7730-4d5b-a677-a1b18010263c", "node_type": "1", "metadata": {"window": "It's just about \nreally adding customers  or maybe a capability but, and scale to a platform we already have, that's attractive M&A. \n And over the history of this company, we've been very successful doing that kind of M&A.  \n \n The second kind that we \u2013 the second criteria we really have is to assess its alignment to our enterprise strategy. \n We've articulated our oncology ecosystem and our biopharma services business as areas that we want to deploy \ngrowth capital against.  But it's got to meet our third criteria, which is we're very financially discipli ned about the \nway we approach these things.  We know we have alternate uses to deploy our capital.  M&A is just one of them. \n", "original_text": "We've articulated our oncology ecosystem and our biopharma services business as areas that we want to deploy \ngrowth capital against. "}, "hash": "e3d77de21b1404f53a5f37c5b926ffafbf3aab618d02487e4aa3f9fb1539288f", "class_name": "RelatedNodeInfo"}}, "text": "The second kind that we \u2013 the second criteria we really have is to assess its alignment to our enterprise strategy. \n", "start_char_idx": 2922, "end_char_idx": 3039, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca81a4d5-7730-4d5b-a677-a1b18010263c": {"__data__": {"id_": "ca81a4d5-7730-4d5b-a677-a1b18010263c", "embedding": null, "metadata": {"window": "It's just about \nreally adding customers  or maybe a capability but, and scale to a platform we already have, that's attractive M&A. \n And over the history of this company, we've been very successful doing that kind of M&A.  \n \n The second kind that we \u2013 the second criteria we really have is to assess its alignment to our enterprise strategy. \n We've articulated our oncology ecosystem and our biopharma services business as areas that we want to deploy \ngrowth capital against.  But it's got to meet our third criteria, which is we're very financially discipli ned about the \nway we approach these things.  We know we have alternate uses to deploy our capital.  M&A is just one of them. \n", "original_text": "We've articulated our oncology ecosystem and our biopharma services business as areas that we want to deploy \ngrowth capital against. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a5e0e16-f798-4e2e-a617-6a006532218c", "node_type": "1", "metadata": {"window": "So first, if it's what we \nwould call tuck -in or it's a core business, we're in the business today, we understand the business.  It's just about \nreally adding customers  or maybe a capability but, and scale to a platform we already have, that's attractive M&A. \n And over the history of this company, we've been very successful doing that kind of M&A.  \n \n The second kind that we \u2013 the second criteria we really have is to assess its alignment to our enterprise strategy. \n We've articulated our oncology ecosystem and our biopharma services business as areas that we want to deploy \ngrowth capital against.  But it's got to meet our third criteria, which is we're very financially discipli ned about the \nway we approach these things.  We know we have alternate uses to deploy our capital. ", "original_text": "The second kind that we \u2013 the second criteria we really have is to assess its alignment to our enterprise strategy. \n", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a74682d3ad8d4933d32b3ecd2c72fa8684f7749d9e5068a71f55c3a78dcfdcd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d67c4c6c-c072-4cb7-a4ee-79d4d1d50e3f", "node_type": "1", "metadata": {"window": "And over the history of this company, we've been very successful doing that kind of M&A.  \n \n The second kind that we \u2013 the second criteria we really have is to assess its alignment to our enterprise strategy. \n We've articulated our oncology ecosystem and our biopharma services business as areas that we want to deploy \ngrowth capital against.  But it's got to meet our third criteria, which is we're very financially discipli ned about the \nway we approach these things.  We know we have alternate uses to deploy our capital.  M&A is just one of them. \n And so we're very disciplined as we think about approaching M&A. ", "original_text": "But it's got to meet our third criteria, which is we're very financially discipli ned about the \nway we approach these things. "}, "hash": "bb1fde9355bf28c1f2b0d4d75d8a64e18f3721b7cb4cfcd6ef8be23a8ea93d4c", "class_name": "RelatedNodeInfo"}}, "text": "We've articulated our oncology ecosystem and our biopharma services business as areas that we want to deploy \ngrowth capital against. ", "start_char_idx": 3039, "end_char_idx": 3173, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d67c4c6c-c072-4cb7-a4ee-79d4d1d50e3f": {"__data__": {"id_": "d67c4c6c-c072-4cb7-a4ee-79d4d1d50e3f", "embedding": null, "metadata": {"window": "And over the history of this company, we've been very successful doing that kind of M&A.  \n \n The second kind that we \u2013 the second criteria we really have is to assess its alignment to our enterprise strategy. \n We've articulated our oncology ecosystem and our biopharma services business as areas that we want to deploy \ngrowth capital against.  But it's got to meet our third criteria, which is we're very financially discipli ned about the \nway we approach these things.  We know we have alternate uses to deploy our capital.  M&A is just one of them. \n And so we're very disciplined as we think about approaching M&A. ", "original_text": "But it's got to meet our third criteria, which is we're very financially discipli ned about the \nway we approach these things. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca81a4d5-7730-4d5b-a677-a1b18010263c", "node_type": "1", "metadata": {"window": "It's just about \nreally adding customers  or maybe a capability but, and scale to a platform we already have, that's attractive M&A. \n And over the history of this company, we've been very successful doing that kind of M&A.  \n \n The second kind that we \u2013 the second criteria we really have is to assess its alignment to our enterprise strategy. \n We've articulated our oncology ecosystem and our biopharma services business as areas that we want to deploy \ngrowth capital against.  But it's got to meet our third criteria, which is we're very financially discipli ned about the \nway we approach these things.  We know we have alternate uses to deploy our capital.  M&A is just one of them. \n", "original_text": "We've articulated our oncology ecosystem and our biopharma services business as areas that we want to deploy \ngrowth capital against. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99accc577628fc535e8ccaeecfe4a3d572efc77dcb25a68b86183af789e4874b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1bdc43c-124d-4e09-a9f8-94d763245b89", "node_type": "1", "metadata": {"window": "The second kind that we \u2013 the second criteria we really have is to assess its alignment to our enterprise strategy. \n We've articulated our oncology ecosystem and our biopharma services business as areas that we want to deploy \ngrowth capital against.  But it's got to meet our third criteria, which is we're very financially discipli ned about the \nway we approach these things.  We know we have alternate uses to deploy our capital.  M&A is just one of them. \n And so we're very disciplined as we think about approaching M&A.  But I would say we would do M&A if it was \naligned to our strategy, i t fits that first type of M&A, a tuck -in and it met our financial discipline business criteria.  \n ", "original_text": "We know we have alternate uses to deploy our capital. "}, "hash": "5d0cd8ab09be72005b50f57d21ecfd0f7bb895871bdb7d12e8757fc629d2c1a0", "class_name": "RelatedNodeInfo"}}, "text": "But it's got to meet our third criteria, which is we're very financially discipli ned about the \nway we approach these things. ", "start_char_idx": 3173, "end_char_idx": 3300, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1bdc43c-124d-4e09-a9f8-94d763245b89": {"__data__": {"id_": "e1bdc43c-124d-4e09-a9f8-94d763245b89", "embedding": null, "metadata": {"window": "The second kind that we \u2013 the second criteria we really have is to assess its alignment to our enterprise strategy. \n We've articulated our oncology ecosystem and our biopharma services business as areas that we want to deploy \ngrowth capital against.  But it's got to meet our third criteria, which is we're very financially discipli ned about the \nway we approach these things.  We know we have alternate uses to deploy our capital.  M&A is just one of them. \n And so we're very disciplined as we think about approaching M&A.  But I would say we would do M&A if it was \naligned to our strategy, i t fits that first type of M&A, a tuck -in and it met our financial discipline business criteria.  \n ", "original_text": "We know we have alternate uses to deploy our capital. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d67c4c6c-c072-4cb7-a4ee-79d4d1d50e3f", "node_type": "1", "metadata": {"window": "And over the history of this company, we've been very successful doing that kind of M&A.  \n \n The second kind that we \u2013 the second criteria we really have is to assess its alignment to our enterprise strategy. \n We've articulated our oncology ecosystem and our biopharma services business as areas that we want to deploy \ngrowth capital against.  But it's got to meet our third criteria, which is we're very financially discipli ned about the \nway we approach these things.  We know we have alternate uses to deploy our capital.  M&A is just one of them. \n And so we're very disciplined as we think about approaching M&A. ", "original_text": "But it's got to meet our third criteria, which is we're very financially discipli ned about the \nway we approach these things. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bb86e127016311eab814b120e2609c86898c14755654819a9577c4a93b3b0b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "327c78b2-015d-463a-ad62-6a8ac7554e8a", "node_type": "1", "metadata": {"window": "We've articulated our oncology ecosystem and our biopharma services business as areas that we want to deploy \ngrowth capital against.  But it's got to meet our third criteria, which is we're very financially discipli ned about the \nway we approach these things.  We know we have alternate uses to deploy our capital.  M&A is just one of them. \n And so we're very disciplined as we think about approaching M&A.  But I would say we would do M&A if it was \naligned to our strategy, i t fits that first type of M&A, a tuck -in and it met our financial discipline business criteria.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "M&A is just one of them. \n"}, "hash": "c2dcaa8517d8b70bb70743766aacbacf1b8a5fd0f8eec4dd0e53fcec983b88ba", "class_name": "RelatedNodeInfo"}}, "text": "We know we have alternate uses to deploy our capital. ", "start_char_idx": 3300, "end_char_idx": 3354, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "327c78b2-015d-463a-ad62-6a8ac7554e8a": {"__data__": {"id_": "327c78b2-015d-463a-ad62-6a8ac7554e8a", "embedding": null, "metadata": {"window": "We've articulated our oncology ecosystem and our biopharma services business as areas that we want to deploy \ngrowth capital against.  But it's got to meet our third criteria, which is we're very financially discipli ned about the \nway we approach these things.  We know we have alternate uses to deploy our capital.  M&A is just one of them. \n And so we're very disciplined as we think about approaching M&A.  But I would say we would do M&A if it was \naligned to our strategy, i t fits that first type of M&A, a tuck -in and it met our financial discipline business criteria.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "M&A is just one of them. \n", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1bdc43c-124d-4e09-a9f8-94d763245b89", "node_type": "1", "metadata": {"window": "The second kind that we \u2013 the second criteria we really have is to assess its alignment to our enterprise strategy. \n We've articulated our oncology ecosystem and our biopharma services business as areas that we want to deploy \ngrowth capital against.  But it's got to meet our third criteria, which is we're very financially discipli ned about the \nway we approach these things.  We know we have alternate uses to deploy our capital.  M&A is just one of them. \n And so we're very disciplined as we think about approaching M&A.  But I would say we would do M&A if it was \naligned to our strategy, i t fits that first type of M&A, a tuck -in and it met our financial discipline business criteria.  \n ", "original_text": "We know we have alternate uses to deploy our capital. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "33d1a160405bc2bc9e58da1baeedec69d26a29ca5f3679399a95935bec6ed9bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23d812ed-2ca4-4e64-8ca1-3e0b1fd9f5e3", "node_type": "1", "metadata": {"window": "But it's got to meet our third criteria, which is we're very financially discipli ned about the \nway we approach these things.  We know we have alternate uses to deploy our capital.  M&A is just one of them. \n And so we're very disciplined as we think about approaching M&A.  But I would say we would do M&A if it was \naligned to our strategy, i t fits that first type of M&A, a tuck -in and it met our financial discipline business criteria.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen & Company.  \n ", "original_text": "And so we're very disciplined as we think about approaching M&A. "}, "hash": "1eb9f385e23decb4ec09a1f5deb684286bdb104084a1cf55ebc9096ee9d3bb2f", "class_name": "RelatedNodeInfo"}}, "text": "M&A is just one of them. \n", "start_char_idx": 3354, "end_char_idx": 3380, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23d812ed-2ca4-4e64-8ca1-3e0b1fd9f5e3": {"__data__": {"id_": "23d812ed-2ca4-4e64-8ca1-3e0b1fd9f5e3", "embedding": null, "metadata": {"window": "But it's got to meet our third criteria, which is we're very financially discipli ned about the \nway we approach these things.  We know we have alternate uses to deploy our capital.  M&A is just one of them. \n And so we're very disciplined as we think about approaching M&A.  But I would say we would do M&A if it was \naligned to our strategy, i t fits that first type of M&A, a tuck -in and it met our financial discipline business criteria.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen & Company.  \n ", "original_text": "And so we're very disciplined as we think about approaching M&A. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "327c78b2-015d-463a-ad62-6a8ac7554e8a", "node_type": "1", "metadata": {"window": "We've articulated our oncology ecosystem and our biopharma services business as areas that we want to deploy \ngrowth capital against.  But it's got to meet our third criteria, which is we're very financially discipli ned about the \nway we approach these things.  We know we have alternate uses to deploy our capital.  M&A is just one of them. \n And so we're very disciplined as we think about approaching M&A.  But I would say we would do M&A if it was \naligned to our strategy, i t fits that first type of M&A, a tuck -in and it met our financial discipline business criteria.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "M&A is just one of them. \n", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ed9e49ca3b69fe7d8892b1080c3260a80e68961bfafafd38280febf298861570", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54242132-4b72-49a2-be02-9c52d5ef81b3", "node_type": "1", "metadata": {"window": "We know we have alternate uses to deploy our capital.  M&A is just one of them. \n And so we're very disciplined as we think about approaching M&A.  But I would say we would do M&A if it was \naligned to our strategy, i t fits that first type of M&A, a tuck -in and it met our financial discipline business criteria.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "But I would say we would do M&A if it was \naligned to our strategy, i t fits that first type of M&A, a tuck -in and it met our financial discipline business criteria.  \n "}, "hash": "6abb495b2f5067f51bed1aa4d6bab682efccccd03c786ca782aec11bec89b065", "class_name": "RelatedNodeInfo"}}, "text": "And so we're very disciplined as we think about approaching M&A. ", "start_char_idx": 3380, "end_char_idx": 3445, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54242132-4b72-49a2-be02-9c52d5ef81b3": {"__data__": {"id_": "54242132-4b72-49a2-be02-9c52d5ef81b3", "embedding": null, "metadata": {"window": "We know we have alternate uses to deploy our capital.  M&A is just one of them. \n And so we're very disciplined as we think about approaching M&A.  But I would say we would do M&A if it was \naligned to our strategy, i t fits that first type of M&A, a tuck -in and it met our financial discipline business criteria.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "But I would say we would do M&A if it was \naligned to our strategy, i t fits that first type of M&A, a tuck -in and it met our financial discipline business criteria.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23d812ed-2ca4-4e64-8ca1-3e0b1fd9f5e3", "node_type": "1", "metadata": {"window": "But it's got to meet our third criteria, which is we're very financially discipli ned about the \nway we approach these things.  We know we have alternate uses to deploy our capital.  M&A is just one of them. \n And so we're very disciplined as we think about approaching M&A.  But I would say we would do M&A if it was \naligned to our strategy, i t fits that first type of M&A, a tuck -in and it met our financial discipline business criteria.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen & Company.  \n ", "original_text": "And so we're very disciplined as we think about approaching M&A. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c3574b0bd9da5db39d660bcf2be72cd0ba8024af5ff16db92e419d4fed31e428", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3c3c690-ecc2-4145-a66d-3f93d9c1ce6f", "node_type": "1", "metadata": {"window": "M&A is just one of them. \n And so we're very disciplined as we think about approaching M&A.  But I would say we would do M&A if it was \naligned to our strategy, i t fits that first type of M&A, a tuck -in and it met our financial discipline business criteria.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, thanks for taking the  question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. "}, "hash": "cb43c41d17838494ea83e6561ea5d6357ef3b57329e940fb079b6edf4814512d", "class_name": "RelatedNodeInfo"}}, "text": "But I would say we would do M&A if it was \naligned to our strategy, i t fits that first type of M&A, a tuck -in and it met our financial discipline business criteria.  \n ", "start_char_idx": 3445, "end_char_idx": 3615, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3c3c690-ecc2-4145-a66d-3f93d9c1ce6f": {"__data__": {"id_": "c3c3c690-ecc2-4145-a66d-3f93d9c1ce6f", "embedding": null, "metadata": {"window": "M&A is just one of them. \n And so we're very disciplined as we think about approaching M&A.  But I would say we would do M&A if it was \naligned to our strategy, i t fits that first type of M&A, a tuck -in and it met our financial discipline business criteria.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, thanks for taking the  question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54242132-4b72-49a2-be02-9c52d5ef81b3", "node_type": "1", "metadata": {"window": "We know we have alternate uses to deploy our capital.  M&A is just one of them. \n And so we're very disciplined as we think about approaching M&A.  But I would say we would do M&A if it was \naligned to our strategy, i t fits that first type of M&A, a tuck -in and it met our financial discipline business criteria.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "But I would say we would do M&A if it was \naligned to our strategy, i t fits that first type of M&A, a tuck -in and it met our financial discipline business criteria.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b2d42910fae0ab4bc7cdce8ea56dd817665e9f03bac257866a5123676be0618", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aed0427d-32fb-4776-82fe-9bab74c18d9f", "node_type": "1", "metadata": {"window": "And so we're very disciplined as we think about approaching M&A.  But I would say we would do M&A if it was \naligned to our strategy, i t fits that first type of M&A, a tuck -in and it met our financial discipline business criteria.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, thanks for taking the  question.  Wanted to ask about the vaccine guidance, contribution guidance, the $0.40 \nto $0.50. ", "original_text": "Our next question comes from Charles Rhyee with Cowen & Company.  \n "}, "hash": "af01d79ac4397c47a91a522fc9929c0c77d37e5159d6dcd20452034d5a2c9192", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "start_char_idx": 933, "end_char_idx": 1214, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aed0427d-32fb-4776-82fe-9bab74c18d9f": {"__data__": {"id_": "aed0427d-32fb-4776-82fe-9bab74c18d9f", "embedding": null, "metadata": {"window": "And so we're very disciplined as we think about approaching M&A.  But I would say we would do M&A if it was \naligned to our strategy, i t fits that first type of M&A, a tuck -in and it met our financial discipline business criteria.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, thanks for taking the  question.  Wanted to ask about the vaccine guidance, contribution guidance, the $0.40 \nto $0.50. ", "original_text": "Our next question comes from Charles Rhyee with Cowen & Company.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3c3c690-ecc2-4145-a66d-3f93d9c1ce6f", "node_type": "1", "metadata": {"window": "M&A is just one of them. \n And so we're very disciplined as we think about approaching M&A.  But I would say we would do M&A if it was \naligned to our strategy, i t fits that first type of M&A, a tuck -in and it met our financial discipline business criteria.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, thanks for taking the  question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03023c4ce97cb914bf678f60ff51fc88ef68bdfdca3cb2f64731699ef6cdefbb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d19f3c7-91c7-4ef6-b345-2818b3fcb5b8", "node_type": "1", "metadata": {"window": "But I would say we would do M&A if it was \naligned to our strategy, i t fits that first type of M&A, a tuck -in and it met our financial discipline business criteria.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, thanks for taking the  question.  Wanted to ask about the vaccine guidance, contribution guidance, the $0.40 \nto $0.50.  Should we assume that's pretty much front -end weighted into the fiscal year? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. "}, "hash": "3da41f77af84d20310f00ed6c469a9d5f1f668a4e5a47721df64dd8bb138d82d", "class_name": "RelatedNodeInfo"}}, "text": "Our next question comes from Charles Rhyee with Cowen & Company.  \n ", "start_char_idx": 3896, "end_char_idx": 3964, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d19f3c7-91c7-4ef6-b345-2818b3fcb5b8": {"__data__": {"id_": "5d19f3c7-91c7-4ef6-b345-2818b3fcb5b8", "embedding": null, "metadata": {"window": "But I would say we would do M&A if it was \naligned to our strategy, i t fits that first type of M&A, a tuck -in and it met our financial discipline business criteria.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, thanks for taking the  question.  Wanted to ask about the vaccine guidance, contribution guidance, the $0.40 \nto $0.50.  Should we assume that's pretty much front -end weighted into the fiscal year? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aed0427d-32fb-4776-82fe-9bab74c18d9f", "node_type": "1", "metadata": {"window": "And so we're very disciplined as we think about approaching M&A.  But I would say we would do M&A if it was \naligned to our strategy, i t fits that first type of M&A, a tuck -in and it met our financial discipline business criteria.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, thanks for taking the  question.  Wanted to ask about the vaccine guidance, contribution guidance, the $0.40 \nto $0.50. ", "original_text": "Our next question comes from Charles Rhyee with Cowen & Company.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f68767c6ae9e7ccdf827c9028ef6af2b41e92449201025410cf94b83748b1807", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3a4f2f0-90a4-4797-acc7-418bffeccf40", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, thanks for taking the  question.  Wanted to ask about the vaccine guidance, contribution guidance, the $0.40 \nto $0.50.  Should we assume that's pretty much front -end weighted into the fiscal year?  And have you taken into \naccount some of the concerns around vaccine hesitancy and t he fact that \u2013 whether the pace of vaccine \nadministration is going to slow down? ", "original_text": "LLC  Q \nYeah, thanks for taking the  question. "}, "hash": "61b0871f4a39c571a7681b8912cc4591e21f614a08865bafa4704bd40c49f919", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "start_char_idx": 3964, "end_char_idx": 4258, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3a4f2f0-90a4-4797-acc7-418bffeccf40": {"__data__": {"id_": "a3a4f2f0-90a4-4797-acc7-418bffeccf40", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, thanks for taking the  question.  Wanted to ask about the vaccine guidance, contribution guidance, the $0.40 \nto $0.50.  Should we assume that's pretty much front -end weighted into the fiscal year?  And have you taken into \naccount some of the concerns around vaccine hesitancy and t he fact that \u2013 whether the pace of vaccine \nadministration is going to slow down? ", "original_text": "LLC  Q \nYeah, thanks for taking the  question. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d19f3c7-91c7-4ef6-b345-2818b3fcb5b8", "node_type": "1", "metadata": {"window": "But I would say we would do M&A if it was \naligned to our strategy, i t fits that first type of M&A, a tuck -in and it met our financial discipline business criteria.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, thanks for taking the  question.  Wanted to ask about the vaccine guidance, contribution guidance, the $0.40 \nto $0.50.  Should we assume that's pretty much front -end weighted into the fiscal year? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "272a2f6db844e0dc7fe72826532bf124a410766698b89a4e6f74aa97cbf84170", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "777a3fa9-8a65-4e4e-bd1a-1b15caf1863f", "node_type": "1", "metadata": {"window": "Our next question comes from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, thanks for taking the  question.  Wanted to ask about the vaccine guidance, contribution guidance, the $0.40 \nto $0.50.  Should we assume that's pretty much front -end weighted into the fiscal year?  And have you taken into \naccount some of the concerns around vaccine hesitancy and t he fact that \u2013 whether the pace of vaccine \nadministration is going to slow down?  Thanks.  \n ", "original_text": "Wanted to ask about the vaccine guidance, contribution guidance, the $0.40 \nto $0.50. "}, "hash": "d82a8a50038998d768605f95dc7eeb9da315efd89a1e603d850215d60aa93a64", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nYeah, thanks for taking the  question. ", "start_char_idx": 4258, "end_char_idx": 4305, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "777a3fa9-8a65-4e4e-bd1a-1b15caf1863f": {"__data__": {"id_": "777a3fa9-8a65-4e4e-bd1a-1b15caf1863f", "embedding": null, "metadata": {"window": "Our next question comes from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, thanks for taking the  question.  Wanted to ask about the vaccine guidance, contribution guidance, the $0.40 \nto $0.50.  Should we assume that's pretty much front -end weighted into the fiscal year?  And have you taken into \naccount some of the concerns around vaccine hesitancy and t he fact that \u2013 whether the pace of vaccine \nadministration is going to slow down?  Thanks.  \n ", "original_text": "Wanted to ask about the vaccine guidance, contribution guidance, the $0.40 \nto $0.50. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3a4f2f0-90a4-4797-acc7-418bffeccf40", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, thanks for taking the  question.  Wanted to ask about the vaccine guidance, contribution guidance, the $0.40 \nto $0.50.  Should we assume that's pretty much front -end weighted into the fiscal year?  And have you taken into \naccount some of the concerns around vaccine hesitancy and t he fact that \u2013 whether the pace of vaccine \nadministration is going to slow down? ", "original_text": "LLC  Q \nYeah, thanks for taking the  question. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "649c935da3c4466126752c68f57b44a3cd5e27f47887f97f03b948654faeabf7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e0fee1a-4158-498a-96f7-b071d1dd7c1a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, thanks for taking the  question.  Wanted to ask about the vaccine guidance, contribution guidance, the $0.40 \nto $0.50.  Should we assume that's pretty much front -end weighted into the fiscal year?  And have you taken into \naccount some of the concerns around vaccine hesitancy and t he fact that \u2013 whether the pace of vaccine \nadministration is going to slow down?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Should we assume that's pretty much front -end weighted into the fiscal year? "}, "hash": "830fb23024904f455285dce64139ab6a6218012e2ff888ab08ca7953d2e75641", "class_name": "RelatedNodeInfo"}}, "text": "Wanted to ask about the vaccine guidance, contribution guidance, the $0.40 \nto $0.50. ", "start_char_idx": 4305, "end_char_idx": 4391, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e0fee1a-4158-498a-96f7-b071d1dd7c1a": {"__data__": {"id_": "8e0fee1a-4158-498a-96f7-b071d1dd7c1a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, thanks for taking the  question.  Wanted to ask about the vaccine guidance, contribution guidance, the $0.40 \nto $0.50.  Should we assume that's pretty much front -end weighted into the fiscal year?  And have you taken into \naccount some of the concerns around vaccine hesitancy and t he fact that \u2013 whether the pace of vaccine \nadministration is going to slow down?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Should we assume that's pretty much front -end weighted into the fiscal year? ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "777a3fa9-8a65-4e4e-bd1a-1b15caf1863f", "node_type": "1", "metadata": {"window": "Our next question comes from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, thanks for taking the  question.  Wanted to ask about the vaccine guidance, contribution guidance, the $0.40 \nto $0.50.  Should we assume that's pretty much front -end weighted into the fiscal year?  And have you taken into \naccount some of the concerns around vaccine hesitancy and t he fact that \u2013 whether the pace of vaccine \nadministration is going to slow down?  Thanks.  \n ", "original_text": "Wanted to ask about the vaccine guidance, contribution guidance, the $0.40 \nto $0.50. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1449e6827bb7b0628005cf9789859decfa7ddfdc0c5afd04c7443b25822024f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e50770bb-cd9b-405f-848e-917ac02de75e", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah, thanks for taking the  question.  Wanted to ask about the vaccine guidance, contribution guidance, the $0.40 \nto $0.50.  Should we assume that's pretty much front -end weighted into the fiscal year?  And have you taken into \naccount some of the concerns around vaccine hesitancy and t he fact that \u2013 whether the pace of vaccine \nadministration is going to slow down?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question. ", "original_text": "And have you taken into \naccount some of the concerns around vaccine hesitancy and t he fact that \u2013 whether the pace of vaccine \nadministration is going to slow down? "}, "hash": "c408f43ee6c4c3e624e6ccddf62618b0f63421e27b24ed49e93f00e005b5d2ba", "class_name": "RelatedNodeInfo"}}, "text": "Should we assume that's pretty much front -end weighted into the fiscal year? ", "start_char_idx": 4391, "end_char_idx": 4469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e50770bb-cd9b-405f-848e-917ac02de75e": {"__data__": {"id_": "e50770bb-cd9b-405f-848e-917ac02de75e", "embedding": null, "metadata": {"window": "LLC  Q \nYeah, thanks for taking the  question.  Wanted to ask about the vaccine guidance, contribution guidance, the $0.40 \nto $0.50.  Should we assume that's pretty much front -end weighted into the fiscal year?  And have you taken into \naccount some of the concerns around vaccine hesitancy and t he fact that \u2013 whether the pace of vaccine \nadministration is going to slow down?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question. ", "original_text": "And have you taken into \naccount some of the concerns around vaccine hesitancy and t he fact that \u2013 whether the pace of vaccine \nadministration is going to slow down? ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e0fee1a-4158-498a-96f7-b071d1dd7c1a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, thanks for taking the  question.  Wanted to ask about the vaccine guidance, contribution guidance, the $0.40 \nto $0.50.  Should we assume that's pretty much front -end weighted into the fiscal year?  And have you taken into \naccount some of the concerns around vaccine hesitancy and t he fact that \u2013 whether the pace of vaccine \nadministration is going to slow down?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Should we assume that's pretty much front -end weighted into the fiscal year? ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "322baa6eedcb934c0bba2fac706e493baba31f9b8b605f20741f1fc569765e6e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c7c2e3b-1751-4476-9e9f-6dd0c50a5df2", "node_type": "1", "metadata": {"window": "Wanted to ask about the vaccine guidance, contribution guidance, the $0.40 \nto $0.50.  Should we assume that's pretty much front -end weighted into the fiscal year?  And have you taken into \naccount some of the concerns around vaccine hesitancy and t he fact that \u2013 whether the pace of vaccine \nadministration is going to slow down?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question.  Let me address that. ", "original_text": "Thanks.  \n "}, "hash": "e940684526999cdb05dc3e7f2b6e09eb7f512f280ddf004a9905334ce715c182", "class_name": "RelatedNodeInfo"}}, "text": "And have you taken into \naccount some of the concerns around vaccine hesitancy and t he fact that \u2013 whether the pace of vaccine \nadministration is going to slow down? ", "start_char_idx": 4469, "end_char_idx": 4636, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c7c2e3b-1751-4476-9e9f-6dd0c50a5df2": {"__data__": {"id_": "7c7c2e3b-1751-4476-9e9f-6dd0c50a5df2", "embedding": null, "metadata": {"window": "Wanted to ask about the vaccine guidance, contribution guidance, the $0.40 \nto $0.50.  Should we assume that's pretty much front -end weighted into the fiscal year?  And have you taken into \naccount some of the concerns around vaccine hesitancy and t he fact that \u2013 whether the pace of vaccine \nadministration is going to slow down?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question.  Let me address that. ", "original_text": "Thanks.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e50770bb-cd9b-405f-848e-917ac02de75e", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah, thanks for taking the  question.  Wanted to ask about the vaccine guidance, contribution guidance, the $0.40 \nto $0.50.  Should we assume that's pretty much front -end weighted into the fiscal year?  And have you taken into \naccount some of the concerns around vaccine hesitancy and t he fact that \u2013 whether the pace of vaccine \nadministration is going to slow down?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question. ", "original_text": "And have you taken into \naccount some of the concerns around vaccine hesitancy and t he fact that \u2013 whether the pace of vaccine \nadministration is going to slow down? ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cab015969d804e73f5c2d427189d2cda1707c7a79ed3b29cbf3f3560f863b06c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3df16078-79a9-4975-a85a-97372b2d0582", "node_type": "1", "metadata": {"window": "Should we assume that's pretty much front -end weighted into the fiscal year?  And have you taken into \naccount some of the concerns around vaccine hesitancy and t he fact that \u2013 whether the pace of vaccine \nadministration is going to slow down?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question.  Let me address that.  As I think I mentioned in past cal ls, we take our guidance from the \nUS government. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "f36a7f9eac508b46b14a9cc41bcd969bd25f1ec91c1bdba8267389a6b947e492", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 4636, "end_char_idx": 4647, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3df16078-79a9-4975-a85a-97372b2d0582": {"__data__": {"id_": "3df16078-79a9-4975-a85a-97372b2d0582", "embedding": null, "metadata": {"window": "Should we assume that's pretty much front -end weighted into the fiscal year?  And have you taken into \naccount some of the concerns around vaccine hesitancy and t he fact that \u2013 whether the pace of vaccine \nadministration is going to slow down?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question.  Let me address that.  As I think I mentioned in past cal ls, we take our guidance from the \nUS government. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c7c2e3b-1751-4476-9e9f-6dd0c50a5df2", "node_type": "1", "metadata": {"window": "Wanted to ask about the vaccine guidance, contribution guidance, the $0.40 \nto $0.50.  Should we assume that's pretty much front -end weighted into the fiscal year?  And have you taken into \naccount some of the concerns around vaccine hesitancy and t he fact that \u2013 whether the pace of vaccine \nadministration is going to slow down?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question.  Let me address that. ", "original_text": "Thanks.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ea392814696bc4c8f3b9b4aef3ad8ca5078b33f4267b176164008aa902e09fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0c47b71-fe9f-483a-ab7e-c6c393419fcb", "node_type": "1", "metadata": {"window": "And have you taken into \naccount some of the concerns around vaccine hesitancy and t he fact that \u2013 whether the pace of vaccine \nadministration is going to slow down?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question.  Let me address that.  As I think I mentioned in past cal ls, we take our guidance from the \nUS government.  They make all the decisions on the administration of the program. ", "original_text": "A \nThanks for the question. "}, "hash": "4ff55a0a625e1c6e89724b8b534184ca9bde72fb31314e1dd7944326dc3abdc9", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 4647, "end_char_idx": 4989, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0c47b71-fe9f-483a-ab7e-c6c393419fcb": {"__data__": {"id_": "b0c47b71-fe9f-483a-ab7e-c6c393419fcb", "embedding": null, "metadata": {"window": "And have you taken into \naccount some of the concerns around vaccine hesitancy and t he fact that \u2013 whether the pace of vaccine \nadministration is going to slow down?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question.  Let me address that.  As I think I mentioned in past cal ls, we take our guidance from the \nUS government.  They make all the decisions on the administration of the program. ", "original_text": "A \nThanks for the question. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3df16078-79a9-4975-a85a-97372b2d0582", "node_type": "1", "metadata": {"window": "Should we assume that's pretty much front -end weighted into the fiscal year?  And have you taken into \naccount some of the concerns around vaccine hesitancy and t he fact that \u2013 whether the pace of vaccine \nadministration is going to slow down?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question.  Let me address that.  As I think I mentioned in past cal ls, we take our guidance from the \nUS government. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2418c2c7d63846a97c89d39451ed7ec843abe0d716bd54dd768537fe988fb313", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2eb3a4f-bdfc-480c-8204-6586e624550a", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question.  Let me address that.  As I think I mentioned in past cal ls, we take our guidance from the \nUS government.  They make all the decisions on the administration of the program.  And so, we leverage the ", "original_text": "Let me address that. "}, "hash": "5810a143dbf387b0459512be8eaa078f80a128864647bb15c69fb5c56ed7aa6f", "class_name": "RelatedNodeInfo"}}, "text": "A \nThanks for the question. ", "start_char_idx": 4989, "end_char_idx": 5017, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2eb3a4f-bdfc-480c-8204-6586e624550a": {"__data__": {"id_": "c2eb3a4f-bdfc-480c-8204-6586e624550a", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question.  Let me address that.  As I think I mentioned in past cal ls, we take our guidance from the \nUS government.  They make all the decisions on the administration of the program.  And so, we leverage the ", "original_text": "Let me address that. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0c47b71-fe9f-483a-ab7e-c6c393419fcb", "node_type": "1", "metadata": {"window": "And have you taken into \naccount some of the concerns around vaccine hesitancy and t he fact that \u2013 whether the pace of vaccine \nadministration is going to slow down?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question.  Let me address that.  As I think I mentioned in past cal ls, we take our guidance from the \nUS government.  They make all the decisions on the administration of the program. ", "original_text": "A \nThanks for the question. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7900e8b179dc3fcb015b762b7f9f43f53764b874b72eedd31515bb81b04e26f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d17b3e28-4c13-4921-bcc6-769b1a01d5b2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question.  Let me address that.  As I think I mentioned in past cal ls, we take our guidance from the \nUS government.  They make all the decisions on the administration of the program.  And so, we leverage the ", "original_text": "As I think I mentioned in past cal ls, we take our guidance from the \nUS government. "}, "hash": "c7d62bc9a4ec5ab5db167350278b11c6aac93d10566157ecac498f246e2deb60", "class_name": "RelatedNodeInfo"}}, "text": "Let me address that. ", "start_char_idx": 5017, "end_char_idx": 5038, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d17b3e28-4c13-4921-bcc6-769b1a01d5b2": {"__data__": {"id_": "d17b3e28-4c13-4921-bcc6-769b1a01d5b2", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question.  Let me address that.  As I think I mentioned in past cal ls, we take our guidance from the \nUS government.  They make all the decisions on the administration of the program.  And so, we leverage the ", "original_text": "As I think I mentioned in past cal ls, we take our guidance from the \nUS government. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2eb3a4f-bdfc-480c-8204-6586e624550a", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question.  Let me address that.  As I think I mentioned in past cal ls, we take our guidance from the \nUS government.  They make all the decisions on the administration of the program.  And so, we leverage the ", "original_text": "Let me address that. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "986b8324e9644c1da891ee24d7c2fb9799cfa69a5c2341cd40b70c9d0efbd11b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbd694e8-591a-453e-8532-ad527cb369d3", "node_type": "1", "metadata": {"window": "A \nThanks for the question.  Let me address that.  As I think I mentioned in past cal ls, we take our guidance from the \nUS government.  They make all the decisions on the administration of the program.  And so, we leverage the ", "original_text": "They make all the decisions on the administration of the program. "}, "hash": "263768b3b8d9506fc9ae6b47b7e3f719bef7e11f7d8a948eb71955c0970ef052", "class_name": "RelatedNodeInfo"}}, "text": "As I think I mentioned in past cal ls, we take our guidance from the \nUS government. ", "start_char_idx": 5038, "end_char_idx": 5123, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbd694e8-591a-453e-8532-ad527cb369d3": {"__data__": {"id_": "bbd694e8-591a-453e-8532-ad527cb369d3", "embedding": null, "metadata": {"window": "A \nThanks for the question.  Let me address that.  As I think I mentioned in past cal ls, we take our guidance from the \nUS government.  They make all the decisions on the administration of the program.  And so, we leverage the ", "original_text": "They make all the decisions on the administration of the program. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d17b3e28-4c13-4921-bcc6-769b1a01d5b2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question.  Let me address that.  As I think I mentioned in past cal ls, we take our guidance from the \nUS government.  They make all the decisions on the administration of the program.  And so, we leverage the ", "original_text": "As I think I mentioned in past cal ls, we take our guidance from the \nUS government. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "06d1cd825888206d0c8546e9bf5d85ff5aad2f4132ada6623f20120363732a9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f040d98e-50fd-4554-80e6-c0fea90bda01", "node_type": "1", "metadata": {"window": "Let me address that.  As I think I mentioned in past cal ls, we take our guidance from the \nUS government.  They make all the decisions on the administration of the program.  And so, we leverage the ", "original_text": "And so, we leverage the "}, "hash": "31a5ea91b3c7851c0867088bae3dab3a5681f3b78f7d5933816db663dfd7dad8", "class_name": "RelatedNodeInfo"}}, "text": "They make all the decisions on the administration of the program. ", "start_char_idx": 5123, "end_char_idx": 5189, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f040d98e-50fd-4554-80e6-c0fea90bda01": {"__data__": {"id_": "f040d98e-50fd-4554-80e6-c0fea90bda01", "embedding": null, "metadata": {"window": "Let me address that.  As I think I mentioned in past cal ls, we take our guidance from the \nUS government.  They make all the decisions on the administration of the program.  And so, we leverage the ", "original_text": "And so, we leverage the ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93792125-cca4-4866-bd7c-c7add3dd62ca", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1fb521e0e341b9095a08880c7bdf2b500acdcc714c96014db4cdf969888572", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbd694e8-591a-453e-8532-ad527cb369d3", "node_type": "1", "metadata": {"window": "A \nThanks for the question.  Let me address that.  As I think I mentioned in past cal ls, we take our guidance from the \nUS government.  They make all the decisions on the administration of the program.  And so, we leverage the ", "original_text": "They make all the decisions on the administration of the program. ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c586a918f9b79200f154b83e9cc23a003301b8b7002d649c09ae1a6a8065b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a9be002-440f-4c84-84db-7fc60323df41", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nguidance that they give us in terms of volumes and where those volumes need to be distributed.  And that's how \nwe put this guide together.  \n \n So, that's how we formed the basis of the $0.40 to $0.50 for the vaccine distribution and the $0.10 to $0.20 for the \nkit distribution. ", "original_text": "McKesson Corp.  "}, "hash": "d43854b735c62184bded90f3440bc2d5135473becfa7023535c4ecb440b410e1", "class_name": "RelatedNodeInfo"}}, "text": "And so, we leverage the ", "start_char_idx": 5189, "end_char_idx": 5213, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a9be002-440f-4c84-84db-7fc60323df41": {"__data__": {"id_": "2a9be002-440f-4c84-84db-7fc60323df41", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nguidance that they give us in terms of volumes and where those volumes need to be distributed.  And that's how \nwe put this guide together.  \n \n So, that's how we formed the basis of the $0.40 to $0.50 for the vaccine distribution and the $0.10 to $0.20 for the \nkit distribution. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f040d98e-50fd-4554-80e6-c0fea90bda01", "node_type": "1", "metadata": {"window": "Let me address that.  As I think I mentioned in past cal ls, we take our guidance from the \nUS government.  They make all the decisions on the administration of the program.  And so, we leverage the ", "original_text": "And so, we leverage the ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "58453df9795273e34c98ccd3c9e00c99e8fb31564264f2284156695d9065f920", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7f4096b-9ceb-4fde-9b3e-fb7e72d2317f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nguidance that they give us in terms of volumes and where those volumes need to be distributed.  And that's how \nwe put this guide together.  \n \n So, that's how we formed the basis of the $0.40 to $0.50 for the vaccine distribution and the $0.10 to $0.20 for the \nkit distribution.  And as I mentioned in my opening remarks, that's going to be weighted more toward the first half \nof the year or first quarter of the year primarily.  \n ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nguidance that they give us in terms of volumes and where those volumes need to be distributed. "}, "hash": "3df925e8de8f96b5ec132ca8b347ebbeeec0ccbd4bf702cabf62cf9bf672af72", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7f4096b-9ceb-4fde-9b3e-fb7e72d2317f": {"__data__": {"id_": "d7f4096b-9ceb-4fde-9b3e-fb7e72d2317f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nguidance that they give us in terms of volumes and where those volumes need to be distributed.  And that's how \nwe put this guide together.  \n \n So, that's how we formed the basis of the $0.40 to $0.50 for the vaccine distribution and the $0.10 to $0.20 for the \nkit distribution.  And as I mentioned in my opening remarks, that's going to be weighted more toward the first half \nof the year or first quarter of the year primarily.  \n ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nguidance that they give us in terms of volumes and where those volumes need to be distributed. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a9be002-440f-4c84-84db-7fc60323df41", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nguidance that they give us in terms of volumes and where those volumes need to be distributed.  And that's how \nwe put this guide together.  \n \n So, that's how we formed the basis of the $0.40 to $0.50 for the vaccine distribution and the $0.10 to $0.20 for the \nkit distribution. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a2823dc982756f8f8fdbe9321e11d1b09e47c43dec433107f1a98f9e40b581c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b31fbb0-02dc-4b64-b0ff-91be9f7eb37b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nguidance that they give us in terms of volumes and where those volumes need to be distributed.  And that's how \nwe put this guide together.  \n \n So, that's how we formed the basis of the $0.40 to $0.50 for the vaccine distribution and the $0.10 to $0.20 for the \nkit distribution.  And as I mentioned in my opening remarks, that's going to be weighted more toward the first half \nof the year or first quarter of the year primarily.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "And that's how \nwe put this guide together.  \n \n"}, "hash": "b7131938c1fb4789441383fef12132f5e7f99efe0172507699ebb96a1d7858a7", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nguidance that they give us in terms of volumes and where those volumes need to be distributed. ", "start_char_idx": 16, "end_char_idx": 276, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b31fbb0-02dc-4b64-b0ff-91be9f7eb37b": {"__data__": {"id_": "3b31fbb0-02dc-4b64-b0ff-91be9f7eb37b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nguidance that they give us in terms of volumes and where those volumes need to be distributed.  And that's how \nwe put this guide together.  \n \n So, that's how we formed the basis of the $0.40 to $0.50 for the vaccine distribution and the $0.10 to $0.20 for the \nkit distribution.  And as I mentioned in my opening remarks, that's going to be weighted more toward the first half \nof the year or first quarter of the year primarily.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "And that's how \nwe put this guide together.  \n \n", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7f4096b-9ceb-4fde-9b3e-fb7e72d2317f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nguidance that they give us in terms of volumes and where those volumes need to be distributed.  And that's how \nwe put this guide together.  \n \n So, that's how we formed the basis of the $0.40 to $0.50 for the vaccine distribution and the $0.10 to $0.20 for the \nkit distribution.  And as I mentioned in my opening remarks, that's going to be weighted more toward the first half \nof the year or first quarter of the year primarily.  \n ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nguidance that they give us in terms of volumes and where those volumes need to be distributed. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7813f41ce404704a3e9adea9a35651620fb9369fd33f5405cd4c2baa07a5f81f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf556962-4bb0-4a13-bdd6-e24c3a3d7212", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nguidance that they give us in terms of volumes and where those volumes need to be distributed.  And that's how \nwe put this guide together.  \n \n So, that's how we formed the basis of the $0.40 to $0.50 for the vaccine distribution and the $0.10 to $0.20 for the \nkit distribution.  And as I mentioned in my opening remarks, that's going to be weighted more toward the first half \nof the year or first quarter of the year primarily.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n ", "original_text": "So, that's how we formed the basis of the $0.40 to $0.50 for the vaccine distribution and the $0.10 to $0.20 for the \nkit distribution. "}, "hash": "8baa8c64e55a0ba1b6abf9a9c69162c2a954b2b72450d93cbf44117274776f4a", "class_name": "RelatedNodeInfo"}}, "text": "And that's how \nwe put this guide together.  \n \n", "start_char_idx": 276, "end_char_idx": 324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf556962-4bb0-4a13-bdd6-e24c3a3d7212": {"__data__": {"id_": "cf556962-4bb0-4a13-bdd6-e24c3a3d7212", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nguidance that they give us in terms of volumes and where those volumes need to be distributed.  And that's how \nwe put this guide together.  \n \n So, that's how we formed the basis of the $0.40 to $0.50 for the vaccine distribution and the $0.10 to $0.20 for the \nkit distribution.  And as I mentioned in my opening remarks, that's going to be weighted more toward the first half \nof the year or first quarter of the year primarily.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n ", "original_text": "So, that's how we formed the basis of the $0.40 to $0.50 for the vaccine distribution and the $0.10 to $0.20 for the \nkit distribution. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b31fbb0-02dc-4b64-b0ff-91be9f7eb37b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nguidance that they give us in terms of volumes and where those volumes need to be distributed.  And that's how \nwe put this guide together.  \n \n So, that's how we formed the basis of the $0.40 to $0.50 for the vaccine distribution and the $0.10 to $0.20 for the \nkit distribution.  And as I mentioned in my opening remarks, that's going to be weighted more toward the first half \nof the year or first quarter of the year primarily.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "And that's how \nwe put this guide together.  \n \n", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9962c1bd77aaefa2812ce9d1d06869a9e784b71d52aa0e0c5ddc17187d8d28e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92a82a42-60c1-4c33-9448-4ecb1719a01f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nguidance that they give us in terms of volumes and where those volumes need to be distributed.  And that's how \nwe put this guide together.  \n \n So, that's how we formed the basis of the $0.40 to $0.50 for the vaccine distribution and the $0.10 to $0.20 for the \nkit distribution.  And as I mentioned in my opening remarks, that's going to be weighted more toward the first half \nof the year or first quarter of the year primarily.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nGreat, thanks. ", "original_text": "And as I mentioned in my opening remarks, that's going to be weighted more toward the first half \nof the year or first quarter of the year primarily.  \n "}, "hash": "01dc362ab65a5c4b55e784f655f9ff31e11a2035850aced7c222fad05d18d0d3", "class_name": "RelatedNodeInfo"}}, "text": "So, that's how we formed the basis of the $0.40 to $0.50 for the vaccine distribution and the $0.10 to $0.20 for the \nkit distribution. ", "start_char_idx": 324, "end_char_idx": 460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92a82a42-60c1-4c33-9448-4ecb1719a01f": {"__data__": {"id_": "92a82a42-60c1-4c33-9448-4ecb1719a01f", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nguidance that they give us in terms of volumes and where those volumes need to be distributed.  And that's how \nwe put this guide together.  \n \n So, that's how we formed the basis of the $0.40 to $0.50 for the vaccine distribution and the $0.10 to $0.20 for the \nkit distribution.  And as I mentioned in my opening remarks, that's going to be weighted more toward the first half \nof the year or first quarter of the year primarily.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nGreat, thanks. ", "original_text": "And as I mentioned in my opening remarks, that's going to be weighted more toward the first half \nof the year or first quarter of the year primarily.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf556962-4bb0-4a13-bdd6-e24c3a3d7212", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nguidance that they give us in terms of volumes and where those volumes need to be distributed.  And that's how \nwe put this guide together.  \n \n So, that's how we formed the basis of the $0.40 to $0.50 for the vaccine distribution and the $0.10 to $0.20 for the \nkit distribution.  And as I mentioned in my opening remarks, that's going to be weighted more toward the first half \nof the year or first quarter of the year primarily.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n ", "original_text": "So, that's how we formed the basis of the $0.40 to $0.50 for the vaccine distribution and the $0.10 to $0.20 for the \nkit distribution. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "86d354f72d2eb05a3839381a0802c8ae705f6c34a0b75c9ec7c33ae3749da2a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97cd0062-0935-44b2-aa3c-6af9342e0ec4", "node_type": "1", "metadata": {"window": "And that's how \nwe put this guide together.  \n \n So, that's how we formed the basis of the $0.40 to $0.50 for the vaccine distribution and the $0.10 to $0.20 for the \nkit distribution.  And as I mentioned in my opening remarks, that's going to be weighted more toward the first half \nof the year or first quarter of the year primarily.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nGreat, thanks.  Good afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. "}, "hash": "ff88bc31b47b0465747f9cc7b59bf91efd0137be8cc55860255b865a6d80b179", "class_name": "RelatedNodeInfo"}}, "text": "And as I mentioned in my opening remarks, that's going to be weighted more toward the first half \nof the year or first quarter of the year primarily.  \n ", "start_char_idx": 460, "end_char_idx": 613, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97cd0062-0935-44b2-aa3c-6af9342e0ec4": {"__data__": {"id_": "97cd0062-0935-44b2-aa3c-6af9342e0ec4", "embedding": null, "metadata": {"window": "And that's how \nwe put this guide together.  \n \n So, that's how we formed the basis of the $0.40 to $0.50 for the vaccine distribution and the $0.10 to $0.20 for the \nkit distribution.  And as I mentioned in my opening remarks, that's going to be weighted more toward the first half \nof the year or first quarter of the year primarily.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nGreat, thanks.  Good afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92a82a42-60c1-4c33-9448-4ecb1719a01f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nguidance that they give us in terms of volumes and where those volumes need to be distributed.  And that's how \nwe put this guide together.  \n \n So, that's how we formed the basis of the $0.40 to $0.50 for the vaccine distribution and the $0.10 to $0.20 for the \nkit distribution.  And as I mentioned in my opening remarks, that's going to be weighted more toward the first half \nof the year or first quarter of the year primarily.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nGreat, thanks. ", "original_text": "And as I mentioned in my opening remarks, that's going to be weighted more toward the first half \nof the year or first quarter of the year primarily.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8eb8d39fb437fc989bf9f4662702c9952879f0a191e9a455452eacc23ece9136", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f094787-572c-4777-af0a-a1b94c6f0886", "node_type": "1", "metadata": {"window": "So, that's how we formed the basis of the $0.40 to $0.50 for the vaccine distribution and the $0.10 to $0.20 for the \nkit distribution.  And as I mentioned in my opening remarks, that's going to be weighted more toward the first half \nof the year or first quarter of the year primarily.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nGreat, thanks.  Good afternoon.  So, Britt, in your prepared remarks, you called out the weak cold and flu season, \nthat did have some impact on the fiscal 4Q results just reported. ", "original_text": "Our next question comes from Steven Valiquette with Barclays.  \n "}, "hash": "30130dec2d8e9210aaeb67c5fdb54e6816d9169d925976a7afcc54762a31d434", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "start_char_idx": 613, "end_char_idx": 894, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f094787-572c-4777-af0a-a1b94c6f0886": {"__data__": {"id_": "2f094787-572c-4777-af0a-a1b94c6f0886", "embedding": null, "metadata": {"window": "So, that's how we formed the basis of the $0.40 to $0.50 for the vaccine distribution and the $0.10 to $0.20 for the \nkit distribution.  And as I mentioned in my opening remarks, that's going to be weighted more toward the first half \nof the year or first quarter of the year primarily.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nGreat, thanks.  Good afternoon.  So, Britt, in your prepared remarks, you called out the weak cold and flu season, \nthat did have some impact on the fiscal 4Q results just reported. ", "original_text": "Our next question comes from Steven Valiquette with Barclays.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97cd0062-0935-44b2-aa3c-6af9342e0ec4", "node_type": "1", "metadata": {"window": "And that's how \nwe put this guide together.  \n \n So, that's how we formed the basis of the $0.40 to $0.50 for the vaccine distribution and the $0.10 to $0.20 for the \nkit distribution.  And as I mentioned in my opening remarks, that's going to be weighted more toward the first half \nof the year or first quarter of the year primarily.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nGreat, thanks.  Good afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3af94fd7e5d406b4bc21d9d16b641b7384e8bc73b96fd168118c10b1560fd206", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "168a7d2d-0f47-4fba-ad8a-25e652fc9efb", "node_type": "1", "metadata": {"window": "And as I mentioned in my opening remarks, that's going to be weighted more toward the first half \nof the year or first quarter of the year primarily.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nGreat, thanks.  Good afternoon.  So, Britt, in your prepared remarks, you called out the weak cold and flu season, \nthat did have some impact on the fiscal 4Q results just reported.  It seems like that dynamic did cause a wide \nvariation in financial impact across all three distributors. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nGreat, thanks. "}, "hash": "74f993ae463800398842898a46addbeabbf99eca6379028d36eef3018a39df47", "class_name": "RelatedNodeInfo"}}, "text": "Our next question comes from Steven Valiquette with Barclays.  \n ", "start_char_idx": 894, "end_char_idx": 959, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "168a7d2d-0f47-4fba-ad8a-25e652fc9efb": {"__data__": {"id_": "168a7d2d-0f47-4fba-ad8a-25e652fc9efb", "embedding": null, "metadata": {"window": "And as I mentioned in my opening remarks, that's going to be weighted more toward the first half \nof the year or first quarter of the year primarily.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nGreat, thanks.  Good afternoon.  So, Britt, in your prepared remarks, you called out the weak cold and flu season, \nthat did have some impact on the fiscal 4Q results just reported.  It seems like that dynamic did cause a wide \nvariation in financial impact across all three distributors. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nGreat, thanks. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f094787-572c-4777-af0a-a1b94c6f0886", "node_type": "1", "metadata": {"window": "So, that's how we formed the basis of the $0.40 to $0.50 for the vaccine distribution and the $0.10 to $0.20 for the \nkit distribution.  And as I mentioned in my opening remarks, that's going to be weighted more toward the first half \nof the year or first quarter of the year primarily.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nGreat, thanks.  Good afternoon.  So, Britt, in your prepared remarks, you called out the weak cold and flu season, \nthat did have some impact on the fiscal 4Q results just reported. ", "original_text": "Our next question comes from Steven Valiquette with Barclays.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afabb6c443936bff0c8a13dc32c0383b2bed432c2fc20c05eb31280e13ec78b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0b2903b-affe-4a96-8c61-a6d142a87b43", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nGreat, thanks.  Good afternoon.  So, Britt, in your prepared remarks, you called out the weak cold and flu season, \nthat did have some impact on the fiscal 4Q results just reported.  It seems like that dynamic did cause a wide \nvariation in financial impact across all three distributors.  But I guess as we think about t he fiscal 2022 guidance \nfrom you guys, you mentioned the return to the pre -COVID levels of prescriptions and patient levels in the back \nhalf of the year. ", "original_text": "Good afternoon. "}, "hash": "db16e7b1ba7ddc712d0e01a2602305ce3120e30f4625a4941700db6f80682758", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nGreat, thanks. ", "start_char_idx": 959, "end_char_idx": 1289, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0b2903b-affe-4a96-8c61-a6d142a87b43": {"__data__": {"id_": "c0b2903b-affe-4a96-8c61-a6d142a87b43", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nGreat, thanks.  Good afternoon.  So, Britt, in your prepared remarks, you called out the weak cold and flu season, \nthat did have some impact on the fiscal 4Q results just reported.  It seems like that dynamic did cause a wide \nvariation in financial impact across all three distributors.  But I guess as we think about t he fiscal 2022 guidance \nfrom you guys, you mentioned the return to the pre -COVID levels of prescriptions and patient levels in the back \nhalf of the year. ", "original_text": "Good afternoon. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "168a7d2d-0f47-4fba-ad8a-25e652fc9efb", "node_type": "1", "metadata": {"window": "And as I mentioned in my opening remarks, that's going to be weighted more toward the first half \nof the year or first quarter of the year primarily.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nGreat, thanks.  Good afternoon.  So, Britt, in your prepared remarks, you called out the weak cold and flu season, \nthat did have some impact on the fiscal 4Q results just reported.  It seems like that dynamic did cause a wide \nvariation in financial impact across all three distributors. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nGreat, thanks. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f9f4bdac34615b84fba1bff8d57641e66e7bbdc45f9786c45c7d41a71dcfbeef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a51a973-221e-4e0f-9506-b146288889d7", "node_type": "1", "metadata": {"window": "Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nGreat, thanks.  Good afternoon.  So, Britt, in your prepared remarks, you called out the weak cold and flu season, \nthat did have some impact on the fiscal 4Q results just reported.  It seems like that dynamic did cause a wide \nvariation in financial impact across all three distributors.  But I guess as we think about t he fiscal 2022 guidance \nfrom you guys, you mentioned the return to the pre -COVID levels of prescriptions and patient levels in the back \nhalf of the year.  I just want to confirm whether or not that includes the normal cough, cold, flu season. ", "original_text": "So, Britt, in your prepared remarks, you called out the weak cold and flu season, \nthat did have some impact on the fiscal 4Q results just reported. "}, "hash": "7991adce6ad6a0c3c64dfd3bcbfeab71e8f2e8d72e9572662c8e2d2276880e02", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon. ", "start_char_idx": 1289, "end_char_idx": 1305, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a51a973-221e-4e0f-9506-b146288889d7": {"__data__": {"id_": "2a51a973-221e-4e0f-9506-b146288889d7", "embedding": null, "metadata": {"window": "Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nGreat, thanks.  Good afternoon.  So, Britt, in your prepared remarks, you called out the weak cold and flu season, \nthat did have some impact on the fiscal 4Q results just reported.  It seems like that dynamic did cause a wide \nvariation in financial impact across all three distributors.  But I guess as we think about t he fiscal 2022 guidance \nfrom you guys, you mentioned the return to the pre -COVID levels of prescriptions and patient levels in the back \nhalf of the year.  I just want to confirm whether or not that includes the normal cough, cold, flu season. ", "original_text": "So, Britt, in your prepared remarks, you called out the weak cold and flu season, \nthat did have some impact on the fiscal 4Q results just reported. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0b2903b-affe-4a96-8c61-a6d142a87b43", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nGreat, thanks.  Good afternoon.  So, Britt, in your prepared remarks, you called out the weak cold and flu season, \nthat did have some impact on the fiscal 4Q results just reported.  It seems like that dynamic did cause a wide \nvariation in financial impact across all three distributors.  But I guess as we think about t he fiscal 2022 guidance \nfrom you guys, you mentioned the return to the pre -COVID levels of prescriptions and patient levels in the back \nhalf of the year. ", "original_text": "Good afternoon. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6a5d293460a8c58d3fd99b0b849026f902ab5fc7d56aa471f31387b21900468", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b67db03c-915c-4af0-a072-6f86f78387df", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nGreat, thanks.  Good afternoon.  So, Britt, in your prepared remarks, you called out the weak cold and flu season, \nthat did have some impact on the fiscal 4Q results just reported.  It seems like that dynamic did cause a wide \nvariation in financial impact across all three distributors.  But I guess as we think about t he fiscal 2022 guidance \nfrom you guys, you mentioned the return to the pre -COVID levels of prescriptions and patient levels in the back \nhalf of the year.  I just want to confirm whether or not that includes the normal cough, cold, flu season.  And is that \nalso a large factor or a small factor in that 5% to 8% core EBIT growth in US pharma? ", "original_text": "It seems like that dynamic did cause a wide \nvariation in financial impact across all three distributors. "}, "hash": "06514a54fa93e99108032623b8b40ab02e49901d604115529991c59c5362f18e", "class_name": "RelatedNodeInfo"}}, "text": "So, Britt, in your prepared remarks, you called out the weak cold and flu season, \nthat did have some impact on the fiscal 4Q results just reported. ", "start_char_idx": 1305, "end_char_idx": 1454, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b67db03c-915c-4af0-a072-6f86f78387df": {"__data__": {"id_": "b67db03c-915c-4af0-a072-6f86f78387df", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nGreat, thanks.  Good afternoon.  So, Britt, in your prepared remarks, you called out the weak cold and flu season, \nthat did have some impact on the fiscal 4Q results just reported.  It seems like that dynamic did cause a wide \nvariation in financial impact across all three distributors.  But I guess as we think about t he fiscal 2022 guidance \nfrom you guys, you mentioned the return to the pre -COVID levels of prescriptions and patient levels in the back \nhalf of the year.  I just want to confirm whether or not that includes the normal cough, cold, flu season.  And is that \nalso a large factor or a small factor in that 5% to 8% core EBIT growth in US pharma? ", "original_text": "It seems like that dynamic did cause a wide \nvariation in financial impact across all three distributors. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a51a973-221e-4e0f-9506-b146288889d7", "node_type": "1", "metadata": {"window": "Our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nGreat, thanks.  Good afternoon.  So, Britt, in your prepared remarks, you called out the weak cold and flu season, \nthat did have some impact on the fiscal 4Q results just reported.  It seems like that dynamic did cause a wide \nvariation in financial impact across all three distributors.  But I guess as we think about t he fiscal 2022 guidance \nfrom you guys, you mentioned the return to the pre -COVID levels of prescriptions and patient levels in the back \nhalf of the year.  I just want to confirm whether or not that includes the normal cough, cold, flu season. ", "original_text": "So, Britt, in your prepared remarks, you called out the weak cold and flu season, \nthat did have some impact on the fiscal 4Q results just reported. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f790719cfe6ac55c01303a5268f444e807109fadb1489d03dee27e1bdf8d1256", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6ba3b26-4f76-4f12-a4a5-95388067f8aa", "node_type": "1", "metadata": {"window": "Good afternoon.  So, Britt, in your prepared remarks, you called out the weak cold and flu season, \nthat did have some impact on the fiscal 4Q results just reported.  It seems like that dynamic did cause a wide \nvariation in financial impact across all three distributors.  But I guess as we think about t he fiscal 2022 guidance \nfrom you guys, you mentioned the return to the pre -COVID levels of prescriptions and patient levels in the back \nhalf of the year.  I just want to confirm whether or not that includes the normal cough, cold, flu season.  And is that \nalso a large factor or a small factor in that 5% to 8% core EBIT growth in US pharma?  Thanks.  \n ", "original_text": "But I guess as we think about t he fiscal 2022 guidance \nfrom you guys, you mentioned the return to the pre -COVID levels of prescriptions and patient levels in the back \nhalf of the year. "}, "hash": "4f5cbf33bf00d5c145ef00f48368c63736f4892c78580825688e13a3180b3661", "class_name": "RelatedNodeInfo"}}, "text": "It seems like that dynamic did cause a wide \nvariation in financial impact across all three distributors. ", "start_char_idx": 1454, "end_char_idx": 1560, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6ba3b26-4f76-4f12-a4a5-95388067f8aa": {"__data__": {"id_": "c6ba3b26-4f76-4f12-a4a5-95388067f8aa", "embedding": null, "metadata": {"window": "Good afternoon.  So, Britt, in your prepared remarks, you called out the weak cold and flu season, \nthat did have some impact on the fiscal 4Q results just reported.  It seems like that dynamic did cause a wide \nvariation in financial impact across all three distributors.  But I guess as we think about t he fiscal 2022 guidance \nfrom you guys, you mentioned the return to the pre -COVID levels of prescriptions and patient levels in the back \nhalf of the year.  I just want to confirm whether or not that includes the normal cough, cold, flu season.  And is that \nalso a large factor or a small factor in that 5% to 8% core EBIT growth in US pharma?  Thanks.  \n ", "original_text": "But I guess as we think about t he fiscal 2022 guidance \nfrom you guys, you mentioned the return to the pre -COVID levels of prescriptions and patient levels in the back \nhalf of the year. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b67db03c-915c-4af0-a072-6f86f78387df", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven Valiquette  \nAnalyst, Barclays Investment Bank  Q \nGreat, thanks.  Good afternoon.  So, Britt, in your prepared remarks, you called out the weak cold and flu season, \nthat did have some impact on the fiscal 4Q results just reported.  It seems like that dynamic did cause a wide \nvariation in financial impact across all three distributors.  But I guess as we think about t he fiscal 2022 guidance \nfrom you guys, you mentioned the return to the pre -COVID levels of prescriptions and patient levels in the back \nhalf of the year.  I just want to confirm whether or not that includes the normal cough, cold, flu season.  And is that \nalso a large factor or a small factor in that 5% to 8% core EBIT growth in US pharma? ", "original_text": "It seems like that dynamic did cause a wide \nvariation in financial impact across all three distributors. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1c0877b4e900d10923d4b5ad370aa2aaa937de5551cc223a1e8c2a9db5d57e88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9ee9cd2-7e05-4ccd-8a6e-bd9b7d6459f4", "node_type": "1", "metadata": {"window": "So, Britt, in your prepared remarks, you called out the weak cold and flu season, \nthat did have some impact on the fiscal 4Q results just reported.  It seems like that dynamic did cause a wide \nvariation in financial impact across all three distributors.  But I guess as we think about t he fiscal 2022 guidance \nfrom you guys, you mentioned the return to the pre -COVID levels of prescriptions and patient levels in the back \nhalf of the year.  I just want to confirm whether or not that includes the normal cough, cold, flu season.  And is that \nalso a large factor or a small factor in that 5% to 8% core EBIT growth in US pharma?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "I just want to confirm whether or not that includes the normal cough, cold, flu season. "}, "hash": "75c2dfbabccb7194462ca13d882e387f525a58762851147b062c440a05dfc1ba", "class_name": "RelatedNodeInfo"}}, "text": "But I guess as we think about t he fiscal 2022 guidance \nfrom you guys, you mentioned the return to the pre -COVID levels of prescriptions and patient levels in the back \nhalf of the year. ", "start_char_idx": 1560, "end_char_idx": 1749, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9ee9cd2-7e05-4ccd-8a6e-bd9b7d6459f4": {"__data__": {"id_": "a9ee9cd2-7e05-4ccd-8a6e-bd9b7d6459f4", "embedding": null, "metadata": {"window": "So, Britt, in your prepared remarks, you called out the weak cold and flu season, \nthat did have some impact on the fiscal 4Q results just reported.  It seems like that dynamic did cause a wide \nvariation in financial impact across all three distributors.  But I guess as we think about t he fiscal 2022 guidance \nfrom you guys, you mentioned the return to the pre -COVID levels of prescriptions and patient levels in the back \nhalf of the year.  I just want to confirm whether or not that includes the normal cough, cold, flu season.  And is that \nalso a large factor or a small factor in that 5% to 8% core EBIT growth in US pharma?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "I just want to confirm whether or not that includes the normal cough, cold, flu season. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6ba3b26-4f76-4f12-a4a5-95388067f8aa", "node_type": "1", "metadata": {"window": "Good afternoon.  So, Britt, in your prepared remarks, you called out the weak cold and flu season, \nthat did have some impact on the fiscal 4Q results just reported.  It seems like that dynamic did cause a wide \nvariation in financial impact across all three distributors.  But I guess as we think about t he fiscal 2022 guidance \nfrom you guys, you mentioned the return to the pre -COVID levels of prescriptions and patient levels in the back \nhalf of the year.  I just want to confirm whether or not that includes the normal cough, cold, flu season.  And is that \nalso a large factor or a small factor in that 5% to 8% core EBIT growth in US pharma?  Thanks.  \n ", "original_text": "But I guess as we think about t he fiscal 2022 guidance \nfrom you guys, you mentioned the return to the pre -COVID levels of prescriptions and patient levels in the back \nhalf of the year. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c4fa9ef490e96ae327775de3ab4144a301668a203a66f658e5d4a2a2d0ea287d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf08f4a6-91d4-4c75-9105-4ede4f49aac7", "node_type": "1", "metadata": {"window": "It seems like that dynamic did cause a wide \nvariation in financial impact across all three distributors.  But I guess as we think about t he fiscal 2022 guidance \nfrom you guys, you mentioned the return to the pre -COVID levels of prescriptions and patient levels in the back \nhalf of the year.  I just want to confirm whether or not that includes the normal cough, cold, flu season.  And is that \nalso a large factor or a small factor in that 5% to 8% core EBIT growth in US pharma?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure. ", "original_text": "And is that \nalso a large factor or a small factor in that 5% to 8% core EBIT growth in US pharma? "}, "hash": "f01c23c4e48032c61ace2415e863bc19542795e645ec511b09bd840610cae10e", "class_name": "RelatedNodeInfo"}}, "text": "I just want to confirm whether or not that includes the normal cough, cold, flu season. ", "start_char_idx": 1749, "end_char_idx": 1837, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf08f4a6-91d4-4c75-9105-4ede4f49aac7": {"__data__": {"id_": "cf08f4a6-91d4-4c75-9105-4ede4f49aac7", "embedding": null, "metadata": {"window": "It seems like that dynamic did cause a wide \nvariation in financial impact across all three distributors.  But I guess as we think about t he fiscal 2022 guidance \nfrom you guys, you mentioned the return to the pre -COVID levels of prescriptions and patient levels in the back \nhalf of the year.  I just want to confirm whether or not that includes the normal cough, cold, flu season.  And is that \nalso a large factor or a small factor in that 5% to 8% core EBIT growth in US pharma?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure. ", "original_text": "And is that \nalso a large factor or a small factor in that 5% to 8% core EBIT growth in US pharma? ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9ee9cd2-7e05-4ccd-8a6e-bd9b7d6459f4", "node_type": "1", "metadata": {"window": "So, Britt, in your prepared remarks, you called out the weak cold and flu season, \nthat did have some impact on the fiscal 4Q results just reported.  It seems like that dynamic did cause a wide \nvariation in financial impact across all three distributors.  But I guess as we think about t he fiscal 2022 guidance \nfrom you guys, you mentioned the return to the pre -COVID levels of prescriptions and patient levels in the back \nhalf of the year.  I just want to confirm whether or not that includes the normal cough, cold, flu season.  And is that \nalso a large factor or a small factor in that 5% to 8% core EBIT growth in US pharma?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "I just want to confirm whether or not that includes the normal cough, cold, flu season. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8acb70c533395183ad1e7d67970687ea608266f4409ac9a07ba3c01a7839a84", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d1ecd0d-b7fd-4e0a-83ce-4ccc2f837d57", "node_type": "1", "metadata": {"window": "But I guess as we think about t he fiscal 2022 guidance \nfrom you guys, you mentioned the return to the pre -COVID levels of prescriptions and patient levels in the back \nhalf of the year.  I just want to confirm whether or not that includes the normal cough, cold, flu season.  And is that \nalso a large factor or a small factor in that 5% to 8% core EBIT growth in US pharma?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure.  Thanks for the question. ", "original_text": "Thanks.  \n "}, "hash": "6f269ae41f6973b1f0076105ae9427fb5e05389df3bc927d5c0cc1326f3402a7", "class_name": "RelatedNodeInfo"}}, "text": "And is that \nalso a large factor or a small factor in that 5% to 8% core EBIT growth in US pharma? ", "start_char_idx": 1837, "end_char_idx": 1936, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d1ecd0d-b7fd-4e0a-83ce-4ccc2f837d57": {"__data__": {"id_": "7d1ecd0d-b7fd-4e0a-83ce-4ccc2f837d57", "embedding": null, "metadata": {"window": "But I guess as we think about t he fiscal 2022 guidance \nfrom you guys, you mentioned the return to the pre -COVID levels of prescriptions and patient levels in the back \nhalf of the year.  I just want to confirm whether or not that includes the normal cough, cold, flu season.  And is that \nalso a large factor or a small factor in that 5% to 8% core EBIT growth in US pharma?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure.  Thanks for the question. ", "original_text": "Thanks.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf08f4a6-91d4-4c75-9105-4ede4f49aac7", "node_type": "1", "metadata": {"window": "It seems like that dynamic did cause a wide \nvariation in financial impact across all three distributors.  But I guess as we think about t he fiscal 2022 guidance \nfrom you guys, you mentioned the return to the pre -COVID levels of prescriptions and patient levels in the back \nhalf of the year.  I just want to confirm whether or not that includes the normal cough, cold, flu season.  And is that \nalso a large factor or a small factor in that 5% to 8% core EBIT growth in US pharma?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure. ", "original_text": "And is that \nalso a large factor or a small factor in that 5% to 8% core EBIT growth in US pharma? ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "472bbaef397470abec173ed389635ba1fde34e162797b08b30ccf9e502c55cf1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c74742b-acb8-49db-8e70-f90b071b2030", "node_type": "1", "metadata": {"window": "I just want to confirm whether or not that includes the normal cough, cold, flu season.  And is that \nalso a large factor or a small factor in that 5% to 8% core EBIT growth in US pharma?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure.  Thanks for the question.  Look, as I talked about, there were a couple o f factors that really occurred during \nthe fourth quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "17baf3c58ebb7fc82e69e1dfc65f08b73ffd844d953dc4f2d88aa44f53874e61", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 1936, "end_char_idx": 1947, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c74742b-acb8-49db-8e70-f90b071b2030": {"__data__": {"id_": "3c74742b-acb8-49db-8e70-f90b071b2030", "embedding": null, "metadata": {"window": "I just want to confirm whether or not that includes the normal cough, cold, flu season.  And is that \nalso a large factor or a small factor in that 5% to 8% core EBIT growth in US pharma?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure.  Thanks for the question.  Look, as I talked about, there were a couple o f factors that really occurred during \nthe fourth quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d1ecd0d-b7fd-4e0a-83ce-4ccc2f837d57", "node_type": "1", "metadata": {"window": "But I guess as we think about t he fiscal 2022 guidance \nfrom you guys, you mentioned the return to the pre -COVID levels of prescriptions and patient levels in the back \nhalf of the year.  I just want to confirm whether or not that includes the normal cough, cold, flu season.  And is that \nalso a large factor or a small factor in that 5% to 8% core EBIT growth in US pharma?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure.  Thanks for the question. ", "original_text": "Thanks.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bf529561e9f6ee91740a8d24e514a3f0df28d83204be197c47c7f9fd29976384", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6fdf144f-4c74-4435-8083-b6cde6aebda2", "node_type": "1", "metadata": {"window": "And is that \nalso a large factor or a small factor in that 5% to 8% core EBIT growth in US pharma?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure.  Thanks for the question.  Look, as I talked about, there were a couple o f factors that really occurred during \nthe fourth quarter.  Weak cold and flu season was one of those. ", "original_text": "A \nSure. "}, "hash": "d6cff7818ff2a9cff7d34d90aa3cd1c1ea1b7a0e8e7c562d9f9de3e946940380", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 1947, "end_char_idx": 2289, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6fdf144f-4c74-4435-8083-b6cde6aebda2": {"__data__": {"id_": "6fdf144f-4c74-4435-8083-b6cde6aebda2", "embedding": null, "metadata": {"window": "And is that \nalso a large factor or a small factor in that 5% to 8% core EBIT growth in US pharma?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure.  Thanks for the question.  Look, as I talked about, there were a couple o f factors that really occurred during \nthe fourth quarter.  Weak cold and flu season was one of those. ", "original_text": "A \nSure. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c74742b-acb8-49db-8e70-f90b071b2030", "node_type": "1", "metadata": {"window": "I just want to confirm whether or not that includes the normal cough, cold, flu season.  And is that \nalso a large factor or a small factor in that 5% to 8% core EBIT growth in US pharma?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure.  Thanks for the question.  Look, as I talked about, there were a couple o f factors that really occurred during \nthe fourth quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "79930b4e3fc6e7fa78ecbbbfbd4bbcad5210d35a485a9767f49a10ea9035f8e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c4e1582-a9b3-4d02-8c1f-57b27a8b4f7c", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure.  Thanks for the question.  Look, as I talked about, there were a couple o f factors that really occurred during \nthe fourth quarter.  Weak cold and flu season was one of those.  We also had a winter storm. ", "original_text": "Thanks for the question. "}, "hash": "c3343d9ecdc4bb56e6d025aab38c0f4dc2cd6f16822e86d68361e671e0bdc0ad", "class_name": "RelatedNodeInfo"}}, "text": "A \nSure. ", "start_char_idx": 2289, "end_char_idx": 2298, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c4e1582-a9b3-4d02-8c1f-57b27a8b4f7c": {"__data__": {"id_": "1c4e1582-a9b3-4d02-8c1f-57b27a8b4f7c", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure.  Thanks for the question.  Look, as I talked about, there were a couple o f factors that really occurred during \nthe fourth quarter.  Weak cold and flu season was one of those.  We also had a winter storm. ", "original_text": "Thanks for the question. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6fdf144f-4c74-4435-8083-b6cde6aebda2", "node_type": "1", "metadata": {"window": "And is that \nalso a large factor or a small factor in that 5% to 8% core EBIT growth in US pharma?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure.  Thanks for the question.  Look, as I talked about, there were a couple o f factors that really occurred during \nthe fourth quarter.  Weak cold and flu season was one of those. ", "original_text": "A \nSure. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50774765a75dae24728a1a1d3fce1b82b05d5ad398c40b56528eb0f741da7c89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eabd42df-8596-46cc-9b7f-77c05a737ba4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure.  Thanks for the question.  Look, as I talked about, there were a couple o f factors that really occurred during \nthe fourth quarter.  Weak cold and flu season was one of those.  We also had a winter storm.  Those had modest \nimpacts on our results. ", "original_text": "Look, as I talked about, there were a couple o f factors that really occurred during \nthe fourth quarter. "}, "hash": "8999fe208a947e4e855ccc759720a42d3d4ddb3fde0232ddd5e3e4648c0aa2bd", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question. ", "start_char_idx": 2298, "end_char_idx": 2323, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eabd42df-8596-46cc-9b7f-77c05a737ba4": {"__data__": {"id_": "eabd42df-8596-46cc-9b7f-77c05a737ba4", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure.  Thanks for the question.  Look, as I talked about, there were a couple o f factors that really occurred during \nthe fourth quarter.  Weak cold and flu season was one of those.  We also had a winter storm.  Those had modest \nimpacts on our results. ", "original_text": "Look, as I talked about, there were a couple o f factors that really occurred during \nthe fourth quarter. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c4e1582-a9b3-4d02-8c1f-57b27a8b4f7c", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure.  Thanks for the question.  Look, as I talked about, there were a couple o f factors that really occurred during \nthe fourth quarter.  Weak cold and flu season was one of those.  We also had a winter storm. ", "original_text": "Thanks for the question. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c131be0cd81509bec503093c80d7a8df317dd7ed323fcadd972c883aff3ae49e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8d71549-94a6-407d-aa3c-ded26c639bc3", "node_type": "1", "metadata": {"window": "A \nSure.  Thanks for the question.  Look, as I talked about, there were a couple o f factors that really occurred during \nthe fourth quarter.  Weak cold and flu season was one of those.  We also had a winter storm.  Those had modest \nimpacts on our results.  We do expect next year that we would have a normal flu season. ", "original_text": "Weak cold and flu season was one of those. "}, "hash": "f1c8cb5e13d55184ebf93b143daf637fd15e6377ec434b96909cf6c7ab1b5966", "class_name": "RelatedNodeInfo"}}, "text": "Look, as I talked about, there were a couple o f factors that really occurred during \nthe fourth quarter. ", "start_char_idx": 2323, "end_char_idx": 2429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8d71549-94a6-407d-aa3c-ded26c639bc3": {"__data__": {"id_": "b8d71549-94a6-407d-aa3c-ded26c639bc3", "embedding": null, "metadata": {"window": "A \nSure.  Thanks for the question.  Look, as I talked about, there were a couple o f factors that really occurred during \nthe fourth quarter.  Weak cold and flu season was one of those.  We also had a winter storm.  Those had modest \nimpacts on our results.  We do expect next year that we would have a normal flu season. ", "original_text": "Weak cold and flu season was one of those. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eabd42df-8596-46cc-9b7f-77c05a737ba4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure.  Thanks for the question.  Look, as I talked about, there were a couple o f factors that really occurred during \nthe fourth quarter.  Weak cold and flu season was one of those.  We also had a winter storm.  Those had modest \nimpacts on our results. ", "original_text": "Look, as I talked about, there were a couple o f factors that really occurred during \nthe fourth quarter. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d3580a66fd6f4392a313c065b7b3138254062716d3ec672349bccee1528e3a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f981d8b-8780-4273-9065-e74022052c0a", "node_type": "1", "metadata": {"window": "Thanks for the question.  Look, as I talked about, there were a couple o f factors that really occurred during \nthe fourth quarter.  Weak cold and flu season was one of those.  We also had a winter storm.  Those had modest \nimpacts on our results.  We do expect next year that we would have a normal flu season.  Those are very difficul t \nto predict. ", "original_text": "We also had a winter storm. "}, "hash": "4986805016f323478c4280fcea179f79f27c4ceb49650925225feed5ccb68466", "class_name": "RelatedNodeInfo"}}, "text": "Weak cold and flu season was one of those. ", "start_char_idx": 2429, "end_char_idx": 2472, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f981d8b-8780-4273-9065-e74022052c0a": {"__data__": {"id_": "1f981d8b-8780-4273-9065-e74022052c0a", "embedding": null, "metadata": {"window": "Thanks for the question.  Look, as I talked about, there were a couple o f factors that really occurred during \nthe fourth quarter.  Weak cold and flu season was one of those.  We also had a winter storm.  Those had modest \nimpacts on our results.  We do expect next year that we would have a normal flu season.  Those are very difficul t \nto predict. ", "original_text": "We also had a winter storm. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8d71549-94a6-407d-aa3c-ded26c639bc3", "node_type": "1", "metadata": {"window": "A \nSure.  Thanks for the question.  Look, as I talked about, there were a couple o f factors that really occurred during \nthe fourth quarter.  Weak cold and flu season was one of those.  We also had a winter storm.  Those had modest \nimpacts on our results.  We do expect next year that we would have a normal flu season. ", "original_text": "Weak cold and flu season was one of those. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e04b1b7b17539fdfd0370af97117345f51f00dc8d6c370c5a7900691012ed1ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "236e91fe-d288-4151-b243-f22c80ce465f", "node_type": "1", "metadata": {"window": "Look, as I talked about, there were a couple o f factors that really occurred during \nthe fourth quarter.  Weak cold and flu season was one of those.  We also had a winter storm.  Those had modest \nimpacts on our results.  We do expect next year that we would have a normal flu season.  Those are very difficul t \nto predict.  In the last several years, we've had some variations within what normal is based on history. ", "original_text": "Those had modest \nimpacts on our results. "}, "hash": "0aeff0993d3fa1042fcc0c3294c2e0755bc1935d2f969080feedf25378ebc954", "class_name": "RelatedNodeInfo"}}, "text": "We also had a winter storm. ", "start_char_idx": 2472, "end_char_idx": 2500, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "236e91fe-d288-4151-b243-f22c80ce465f": {"__data__": {"id_": "236e91fe-d288-4151-b243-f22c80ce465f", "embedding": null, "metadata": {"window": "Look, as I talked about, there were a couple o f factors that really occurred during \nthe fourth quarter.  Weak cold and flu season was one of those.  We also had a winter storm.  Those had modest \nimpacts on our results.  We do expect next year that we would have a normal flu season.  Those are very difficul t \nto predict.  In the last several years, we've had some variations within what normal is based on history. ", "original_text": "Those had modest \nimpacts on our results. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f981d8b-8780-4273-9065-e74022052c0a", "node_type": "1", "metadata": {"window": "Thanks for the question.  Look, as I talked about, there were a couple o f factors that really occurred during \nthe fourth quarter.  Weak cold and flu season was one of those.  We also had a winter storm.  Those had modest \nimpacts on our results.  We do expect next year that we would have a normal flu season.  Those are very difficul t \nto predict. ", "original_text": "We also had a winter storm. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a0e90c7616fe9022bf2d02cf09ead6a5513e7c23e6a8fd2fe75ea42ff70f1b2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0e2ff4b-cc8e-4532-a381-a8a015ee632f", "node_type": "1", "metadata": {"window": "Weak cold and flu season was one of those.  We also had a winter storm.  Those had modest \nimpacts on our results.  We do expect next year that we would have a normal flu season.  Those are very difficul t \nto predict.  In the last several years, we've had some variations within what normal is based on history.  But we \nexpect that the cold and flu season will be back to a normal cadence historically. ", "original_text": "We do expect next year that we would have a normal flu season. "}, "hash": "ce9d3a43845716a8fe18a575243dc06581cc8bb405a1b7426c82a20c7f1fd800", "class_name": "RelatedNodeInfo"}}, "text": "Those had modest \nimpacts on our results. ", "start_char_idx": 2500, "end_char_idx": 2542, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0e2ff4b-cc8e-4532-a381-a8a015ee632f": {"__data__": {"id_": "a0e2ff4b-cc8e-4532-a381-a8a015ee632f", "embedding": null, "metadata": {"window": "Weak cold and flu season was one of those.  We also had a winter storm.  Those had modest \nimpacts on our results.  We do expect next year that we would have a normal flu season.  Those are very difficul t \nto predict.  In the last several years, we've had some variations within what normal is based on history.  But we \nexpect that the cold and flu season will be back to a normal cadence historically. ", "original_text": "We do expect next year that we would have a normal flu season. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "236e91fe-d288-4151-b243-f22c80ce465f", "node_type": "1", "metadata": {"window": "Look, as I talked about, there were a couple o f factors that really occurred during \nthe fourth quarter.  Weak cold and flu season was one of those.  We also had a winter storm.  Those had modest \nimpacts on our results.  We do expect next year that we would have a normal flu season.  Those are very difficul t \nto predict.  In the last several years, we've had some variations within what normal is based on history. ", "original_text": "Those had modest \nimpacts on our results. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "847c4285cfbdd0701683f4f1de3639b8840800000194d66a9005d0bc885c6a66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebe52e4c-ee80-4d86-b74d-07fbcd070a96", "node_type": "1", "metadata": {"window": "We also had a winter storm.  Those had modest \nimpacts on our results.  We do expect next year that we would have a normal flu season.  Those are very difficul t \nto predict.  In the last several years, we've had some variations within what normal is based on history.  But we \nexpect that the cold and flu season will be back to a normal cadence historically.  And as utilization starts to \nimprove over our first half of  the year and get back to pre -COVID levels in the second half of the year, that's \nwhere we expect volumes will begin to ramp.  \n ", "original_text": "Those are very difficul t \nto predict. "}, "hash": "c2a8ba71356da2463a2ff2fe7e02fa76b5d1bfc3e55f224deb92489bb6c41ce2", "class_name": "RelatedNodeInfo"}}, "text": "We do expect next year that we would have a normal flu season. ", "start_char_idx": 2542, "end_char_idx": 2605, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebe52e4c-ee80-4d86-b74d-07fbcd070a96": {"__data__": {"id_": "ebe52e4c-ee80-4d86-b74d-07fbcd070a96", "embedding": null, "metadata": {"window": "We also had a winter storm.  Those had modest \nimpacts on our results.  We do expect next year that we would have a normal flu season.  Those are very difficul t \nto predict.  In the last several years, we've had some variations within what normal is based on history.  But we \nexpect that the cold and flu season will be back to a normal cadence historically.  And as utilization starts to \nimprove over our first half of  the year and get back to pre -COVID levels in the second half of the year, that's \nwhere we expect volumes will begin to ramp.  \n ", "original_text": "Those are very difficul t \nto predict. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0e2ff4b-cc8e-4532-a381-a8a015ee632f", "node_type": "1", "metadata": {"window": "Weak cold and flu season was one of those.  We also had a winter storm.  Those had modest \nimpacts on our results.  We do expect next year that we would have a normal flu season.  Those are very difficul t \nto predict.  In the last several years, we've had some variations within what normal is based on history.  But we \nexpect that the cold and flu season will be back to a normal cadence historically. ", "original_text": "We do expect next year that we would have a normal flu season. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de30d40a616bd74444c2f040037ac3c706ffbb7e1e5b89394b4301823547b626", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c52e36d1-a77b-4d47-adea-534b9b2d4ff5", "node_type": "1", "metadata": {"window": "Those had modest \nimpacts on our results.  We do expect next year that we would have a normal flu season.  Those are very difficul t \nto predict.  In the last several years, we've had some variations within what normal is based on history.  But we \nexpect that the cold and flu season will be back to a normal cadence historically.  And as utilization starts to \nimprove over our first half of  the year and get back to pre -COVID levels in the second half of the year, that's \nwhere we expect volumes will begin to ramp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "In the last several years, we've had some variations within what normal is based on history. "}, "hash": "42a9942b89cde8e6265e4be7d6875d1487139921b7aea5f45aa9de8b144fe6f1", "class_name": "RelatedNodeInfo"}}, "text": "Those are very difficul t \nto predict. ", "start_char_idx": 2605, "end_char_idx": 2644, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c52e36d1-a77b-4d47-adea-534b9b2d4ff5": {"__data__": {"id_": "c52e36d1-a77b-4d47-adea-534b9b2d4ff5", "embedding": null, "metadata": {"window": "Those had modest \nimpacts on our results.  We do expect next year that we would have a normal flu season.  Those are very difficul t \nto predict.  In the last several years, we've had some variations within what normal is based on history.  But we \nexpect that the cold and flu season will be back to a normal cadence historically.  And as utilization starts to \nimprove over our first half of  the year and get back to pre -COVID levels in the second half of the year, that's \nwhere we expect volumes will begin to ramp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "In the last several years, we've had some variations within what normal is based on history. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebe52e4c-ee80-4d86-b74d-07fbcd070a96", "node_type": "1", "metadata": {"window": "We also had a winter storm.  Those had modest \nimpacts on our results.  We do expect next year that we would have a normal flu season.  Those are very difficul t \nto predict.  In the last several years, we've had some variations within what normal is based on history.  But we \nexpect that the cold and flu season will be back to a normal cadence historically.  And as utilization starts to \nimprove over our first half of  the year and get back to pre -COVID levels in the second half of the year, that's \nwhere we expect volumes will begin to ramp.  \n ", "original_text": "Those are very difficul t \nto predict. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d3a6ef53aeefe0fa4d9dba6497ee7cc1579d8845f54d17bb5f45a3e9df8593d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17230693-17b4-4952-9150-273bd41b4391", "node_type": "1", "metadata": {"window": "We do expect next year that we would have a normal flu season.  Those are very difficul t \nto predict.  In the last several years, we've had some variations within what normal is based on history.  But we \nexpect that the cold and flu season will be back to a normal cadence historically.  And as utilization starts to \nimprove over our first half of  the year and get back to pre -COVID levels in the second half of the year, that's \nwhere we expect volumes will begin to ramp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with Baird.  \n ", "original_text": "But we \nexpect that the cold and flu season will be back to a normal cadence historically. "}, "hash": "b62e46065933f21aaef8ca816272e948f4e810dc488d054882637b09734b6658", "class_name": "RelatedNodeInfo"}}, "text": "In the last several years, we've had some variations within what normal is based on history. ", "start_char_idx": 2644, "end_char_idx": 2737, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17230693-17b4-4952-9150-273bd41b4391": {"__data__": {"id_": "17230693-17b4-4952-9150-273bd41b4391", "embedding": null, "metadata": {"window": "We do expect next year that we would have a normal flu season.  Those are very difficul t \nto predict.  In the last several years, we've had some variations within what normal is based on history.  But we \nexpect that the cold and flu season will be back to a normal cadence historically.  And as utilization starts to \nimprove over our first half of  the year and get back to pre -COVID levels in the second half of the year, that's \nwhere we expect volumes will begin to ramp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with Baird.  \n ", "original_text": "But we \nexpect that the cold and flu season will be back to a normal cadence historically. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c52e36d1-a77b-4d47-adea-534b9b2d4ff5", "node_type": "1", "metadata": {"window": "Those had modest \nimpacts on our results.  We do expect next year that we would have a normal flu season.  Those are very difficul t \nto predict.  In the last several years, we've had some variations within what normal is based on history.  But we \nexpect that the cold and flu season will be back to a normal cadence historically.  And as utilization starts to \nimprove over our first half of  the year and get back to pre -COVID levels in the second half of the year, that's \nwhere we expect volumes will begin to ramp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "In the last several years, we've had some variations within what normal is based on history. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbb5740f614cf15f1aa122deb345f332b08f43c2abfdc80a36445e28d9b204ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a322f617-15ad-403f-bca0-20e0b4d52b68", "node_type": "1", "metadata": {"window": "Those are very difficul t \nto predict.  In the last several years, we've had some variations within what normal is based on history.  But we \nexpect that the cold and flu season will be back to a normal cadence historically.  And as utilization starts to \nimprove over our first half of  the year and get back to pre -COVID levels in the second half of the year, that's \nwhere we expect volumes will begin to ramp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "And as utilization starts to \nimprove over our first half of  the year and get back to pre -COVID levels in the second half of the year, that's \nwhere we expect volumes will begin to ramp.  \n "}, "hash": "bb981fcfb1c2d7f5563f129f4a3315d245d116601aa4cc94a39cad5b2392d837", "class_name": "RelatedNodeInfo"}}, "text": "But we \nexpect that the cold and flu season will be back to a normal cadence historically. ", "start_char_idx": 2737, "end_char_idx": 2828, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a322f617-15ad-403f-bca0-20e0b4d52b68": {"__data__": {"id_": "a322f617-15ad-403f-bca0-20e0b4d52b68", "embedding": null, "metadata": {"window": "Those are very difficul t \nto predict.  In the last several years, we've had some variations within what normal is based on history.  But we \nexpect that the cold and flu season will be back to a normal cadence historically.  And as utilization starts to \nimprove over our first half of  the year and get back to pre -COVID levels in the second half of the year, that's \nwhere we expect volumes will begin to ramp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "And as utilization starts to \nimprove over our first half of  the year and get back to pre -COVID levels in the second half of the year, that's \nwhere we expect volumes will begin to ramp.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17230693-17b4-4952-9150-273bd41b4391", "node_type": "1", "metadata": {"window": "We do expect next year that we would have a normal flu season.  Those are very difficul t \nto predict.  In the last several years, we've had some variations within what normal is based on history.  But we \nexpect that the cold and flu season will be back to a normal cadence historically.  And as utilization starts to \nimprove over our first half of  the year and get back to pre -COVID levels in the second half of the year, that's \nwhere we expect volumes will begin to ramp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with Baird.  \n ", "original_text": "But we \nexpect that the cold and flu season will be back to a normal cadence historically. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e995ede85a8a53a8c23a452b1870e606f771ab87d7d23c295c1efd2f9aaa5507", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4acc5b8d-0847-4fe5-8293-5389c28126ef", "node_type": "1", "metadata": {"window": "In the last several years, we've had some variations within what normal is based on history.  But we \nexpect that the cold and flu season will be back to a normal cadence historically.  And as utilization starts to \nimprove over our first half of  the year and get back to pre -COVID levels in the second half of the year, that's \nwhere we expect volumes will begin to ramp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. "}, "hash": "e4aa249e30f5385ffc4bec68a5681fe4c7c96e0f22dfde615d61fdeb525093cd", "class_name": "RelatedNodeInfo"}}, "text": "And as utilization starts to \nimprove over our first half of  the year and get back to pre -COVID levels in the second half of the year, that's \nwhere we expect volumes will begin to ramp.  \n ", "start_char_idx": 2828, "end_char_idx": 3020, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4acc5b8d-0847-4fe5-8293-5389c28126ef": {"__data__": {"id_": "4acc5b8d-0847-4fe5-8293-5389c28126ef", "embedding": null, "metadata": {"window": "In the last several years, we've had some variations within what normal is based on history.  But we \nexpect that the cold and flu season will be back to a normal cadence historically.  And as utilization starts to \nimprove over our first half of  the year and get back to pre -COVID levels in the second half of the year, that's \nwhere we expect volumes will begin to ramp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a322f617-15ad-403f-bca0-20e0b4d52b68", "node_type": "1", "metadata": {"window": "Those are very difficul t \nto predict.  In the last several years, we've had some variations within what normal is based on history.  But we \nexpect that the cold and flu season will be back to a normal cadence historically.  And as utilization starts to \nimprove over our first half of  the year and get back to pre -COVID levels in the second half of the year, that's \nwhere we expect volumes will begin to ramp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "And as utilization starts to \nimprove over our first half of  the year and get back to pre -COVID levels in the second half of the year, that's \nwhere we expect volumes will begin to ramp.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "092f8503d2cfe93b03a2126d37795e5eb63890297e8879b88d28ae4ff744887a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50828a2a-4e2a-4509-80fc-9375ebaaa3f2", "node_type": "1", "metadata": {"window": "But we \nexpect that the cold and flu season will be back to a normal cadence historically.  And as utilization starts to \nimprove over our first half of  the year and get back to pre -COVID levels in the second half of the year, that's \nwhere we expect volumes will begin to ramp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey.  Thanks very much. ", "original_text": "Our next question comes from Eric Coldwell with Baird.  \n "}, "hash": "7ae922899d9f833fd22c02c6d37056085a5d6ef7dd2d3e001246a28cb2d8ff92", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "start_char_idx": 613, "end_char_idx": 894, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50828a2a-4e2a-4509-80fc-9375ebaaa3f2": {"__data__": {"id_": "50828a2a-4e2a-4509-80fc-9375ebaaa3f2", "embedding": null, "metadata": {"window": "But we \nexpect that the cold and flu season will be back to a normal cadence historically.  And as utilization starts to \nimprove over our first half of  the year and get back to pre -COVID levels in the second half of the year, that's \nwhere we expect volumes will begin to ramp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey.  Thanks very much. ", "original_text": "Our next question comes from Eric Coldwell with Baird.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4acc5b8d-0847-4fe5-8293-5389c28126ef", "node_type": "1", "metadata": {"window": "In the last several years, we've had some variations within what normal is based on history.  But we \nexpect that the cold and flu season will be back to a normal cadence historically.  And as utilization starts to \nimprove over our first half of  the year and get back to pre -COVID levels in the second half of the year, that's \nwhere we expect volumes will begin to ramp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aaab85c8fd4559727343e132a6623a9502a4b3a9c19f5d9030241ec7fdffd21b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb8bc770-58fb-4338-a24e-c69c956773e1", "node_type": "1", "metadata": {"window": "And as utilization starts to \nimprove over our first half of  the year and get back to pre -COVID levels in the second half of the year, that's \nwhere we expect volumes will begin to ramp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey.  Thanks very much.  This somewhat tails on Charles' question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  "}, "hash": "3b4522bc0354ac34a1050bc3e2fa6c491ddbb5c39c184105f5551cedac1b9b76", "class_name": "RelatedNodeInfo"}}, "text": "Our next question comes from Eric Coldwell with Baird.  \n ", "start_char_idx": 3301, "end_char_idx": 3359, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb8bc770-58fb-4338-a24e-c69c956773e1": {"__data__": {"id_": "eb8bc770-58fb-4338-a24e-c69c956773e1", "embedding": null, "metadata": {"window": "And as utilization starts to \nimprove over our first half of  the year and get back to pre -COVID levels in the second half of the year, that's \nwhere we expect volumes will begin to ramp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey.  Thanks very much.  This somewhat tails on Charles' question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50828a2a-4e2a-4509-80fc-9375ebaaa3f2", "node_type": "1", "metadata": {"window": "But we \nexpect that the cold and flu season will be back to a normal cadence historically.  And as utilization starts to \nimprove over our first half of  the year and get back to pre -COVID levels in the second half of the year, that's \nwhere we expect volumes will begin to ramp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey.  Thanks very much. ", "original_text": "Our next question comes from Eric Coldwell with Baird.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "090b9f3a108f896507f0ce5e990eab30ea27c9b4f18e48bc2d2b1e8fb3ccfe02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ed39b28-2f95-4c0b-ba29-7d63a096d546", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey.  Thanks very much.  This somewhat tails on Charles' question.  It was, in a nutshell, you guided to earnings \nbeing back -half weighted again. ", "original_text": "Q \nHey. "}, "hash": "1465d79ffeb684a43679983bd777805475f97119554ebef01b8768439bcb6f3f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "start_char_idx": 3359, "end_char_idx": 3676, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ed39b28-2f95-4c0b-ba29-7d63a096d546": {"__data__": {"id_": "6ed39b28-2f95-4c0b-ba29-7d63a096d546", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey.  Thanks very much.  This somewhat tails on Charles' question.  It was, in a nutshell, you guided to earnings \nbeing back -half weighted again. ", "original_text": "Q \nHey. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb8bc770-58fb-4338-a24e-c69c956773e1", "node_type": "1", "metadata": {"window": "And as utilization starts to \nimprove over our first half of  the year and get back to pre -COVID levels in the second half of the year, that's \nwhere we expect volumes will begin to ramp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey.  Thanks very much.  This somewhat tails on Charles' question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "421ffea24fe7c17da7e7ffc8326cc0f41ed9fb81821bcd6db44effe5b58c0bd3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73b70eb9-d272-4c7a-84fd-b08e603b0215", "node_type": "1", "metadata": {"window": "Our next question comes from Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey.  Thanks very much.  This somewhat tails on Charles' question.  It was, in a nutshell, you guided to earnings \nbeing back -half weighted again.  And frankly, if I look at the three years prior to COVID, your contribution was, on \naverage, 54% of full year earnings. ", "original_text": "Thanks very much. "}, "hash": "4935d8dfcdba24fe8cad793af51cb7d84567eea900c59e965feb79edda9b04db", "class_name": "RelatedNodeInfo"}}, "text": "Q \nHey. ", "start_char_idx": 3676, "end_char_idx": 3684, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73b70eb9-d272-4c7a-84fd-b08e603b0215": {"__data__": {"id_": "73b70eb9-d272-4c7a-84fd-b08e603b0215", "embedding": null, "metadata": {"window": "Our next question comes from Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey.  Thanks very much.  This somewhat tails on Charles' question.  It was, in a nutshell, you guided to earnings \nbeing back -half weighted again.  And frankly, if I look at the three years prior to COVID, your contribution was, on \naverage, 54% of full year earnings. ", "original_text": "Thanks very much. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ed39b28-2f95-4c0b-ba29-7d63a096d546", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey.  Thanks very much.  This somewhat tails on Charles' question.  It was, in a nutshell, you guided to earnings \nbeing back -half weighted again. ", "original_text": "Q \nHey. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce4976c439e9cbc0dccdadf747c13530320d284da3d66cf0e7e4a68319ddddc4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f81f03c-d3c4-4e12-89c8-60ab3fbdb5da", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey.  Thanks very much.  This somewhat tails on Charles' question.  It was, in a nutshell, you guided to earnings \nbeing back -half weighted again.  And frankly, if I look at the three years prior to COVID, your contribution was, on \naverage, 54% of full year earnings.  So, I just want to make sure that this is more than anything kind of a \nreiteration of what happened in the past prior to COVID impacts, number one.  \n \n", "original_text": "This somewhat tails on Charles' question. "}, "hash": "fb79d0f7259b5086c3fed945973a37d411d18db7feb735dab3aee3ca515a357d", "class_name": "RelatedNodeInfo"}}, "text": "Thanks very much. ", "start_char_idx": 3684, "end_char_idx": 3702, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f81f03c-d3c4-4e12-89c8-60ab3fbdb5da": {"__data__": {"id_": "1f81f03c-d3c4-4e12-89c8-60ab3fbdb5da", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey.  Thanks very much.  This somewhat tails on Charles' question.  It was, in a nutshell, you guided to earnings \nbeing back -half weighted again.  And frankly, if I look at the three years prior to COVID, your contribution was, on \naverage, 54% of full year earnings.  So, I just want to make sure that this is more than anything kind of a \nreiteration of what happened in the past prior to COVID impacts, number one.  \n \n", "original_text": "This somewhat tails on Charles' question. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73b70eb9-d272-4c7a-84fd-b08e603b0215", "node_type": "1", "metadata": {"window": "Our next question comes from Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey.  Thanks very much.  This somewhat tails on Charles' question.  It was, in a nutshell, you guided to earnings \nbeing back -half weighted again.  And frankly, if I look at the three years prior to COVID, your contribution was, on \naverage, 54% of full year earnings. ", "original_text": "Thanks very much. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2907046d3af2bd30fd426553bc018308b1f3d7e677af2e623e9606d7a4ea2f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9fb87b9c-7e74-4ff7-b3a6-bd898cfc6642", "node_type": "1", "metadata": {"window": "Q \nHey.  Thanks very much.  This somewhat tails on Charles' question.  It was, in a nutshell, you guided to earnings \nbeing back -half weighted again.  And frankly, if I look at the three years prior to COVID, your contribution was, on \naverage, 54% of full year earnings.  So, I just want to make sure that this is more than anything kind of a \nreiteration of what happened in the past prior to COVID impacts, number one.  \n \n And then number two, if the heavy weighting of your vaccine and kitting, $0.50 to $0.70  is in the first quarter, how \ndo we true that up with earnings being weighted towards the back half; is by default is the implication that we \nshould be a bit more cautious on 2Q results? ", "original_text": "It was, in a nutshell, you guided to earnings \nbeing back -half weighted again. "}, "hash": "da568c4830112d13ba3d20fa25b52a758e266980e7cfae8204f44c91bfbe44a0", "class_name": "RelatedNodeInfo"}}, "text": "This somewhat tails on Charles' question. ", "start_char_idx": 3702, "end_char_idx": 3744, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9fb87b9c-7e74-4ff7-b3a6-bd898cfc6642": {"__data__": {"id_": "9fb87b9c-7e74-4ff7-b3a6-bd898cfc6642", "embedding": null, "metadata": {"window": "Q \nHey.  Thanks very much.  This somewhat tails on Charles' question.  It was, in a nutshell, you guided to earnings \nbeing back -half weighted again.  And frankly, if I look at the three years prior to COVID, your contribution was, on \naverage, 54% of full year earnings.  So, I just want to make sure that this is more than anything kind of a \nreiteration of what happened in the past prior to COVID impacts, number one.  \n \n And then number two, if the heavy weighting of your vaccine and kitting, $0.50 to $0.70  is in the first quarter, how \ndo we true that up with earnings being weighted towards the back half; is by default is the implication that we \nshould be a bit more cautious on 2Q results? ", "original_text": "It was, in a nutshell, you guided to earnings \nbeing back -half weighted again. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f81f03c-d3c4-4e12-89c8-60ab3fbdb5da", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHey.  Thanks very much.  This somewhat tails on Charles' question.  It was, in a nutshell, you guided to earnings \nbeing back -half weighted again.  And frankly, if I look at the three years prior to COVID, your contribution was, on \naverage, 54% of full year earnings.  So, I just want to make sure that this is more than anything kind of a \nreiteration of what happened in the past prior to COVID impacts, number one.  \n \n", "original_text": "This somewhat tails on Charles' question. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "90ab0353bd6f4761a87d6036e2efbeb43ccf763f69296ccf3cfa10b7f3fddf72", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe97ce2a-af68-4da8-9126-f95e0a46022f", "node_type": "1", "metadata": {"window": "Thanks very much.  This somewhat tails on Charles' question.  It was, in a nutshell, you guided to earnings \nbeing back -half weighted again.  And frankly, if I look at the three years prior to COVID, your contribution was, on \naverage, 54% of full year earnings.  So, I just want to make sure that this is more than anything kind of a \nreiteration of what happened in the past prior to COVID impacts, number one.  \n \n And then number two, if the heavy weighting of your vaccine and kitting, $0.50 to $0.70  is in the first quarter, how \ndo we true that up with earnings being weighted towards the back half; is by default is the implication that we \nshould be a bit more cautious on 2Q results?  Just trying to bridge all these moving pieces. ", "original_text": "And frankly, if I look at the three years prior to COVID, your contribution was, on \naverage, 54% of full year earnings. "}, "hash": "6ae414ac784cd6ef06ef2f4738a3748b8f5b6e427c0aa2e6d5d982fb5578de6d", "class_name": "RelatedNodeInfo"}}, "text": "It was, in a nutshell, you guided to earnings \nbeing back -half weighted again. ", "start_char_idx": 3744, "end_char_idx": 3824, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe97ce2a-af68-4da8-9126-f95e0a46022f": {"__data__": {"id_": "fe97ce2a-af68-4da8-9126-f95e0a46022f", "embedding": null, "metadata": {"window": "Thanks very much.  This somewhat tails on Charles' question.  It was, in a nutshell, you guided to earnings \nbeing back -half weighted again.  And frankly, if I look at the three years prior to COVID, your contribution was, on \naverage, 54% of full year earnings.  So, I just want to make sure that this is more than anything kind of a \nreiteration of what happened in the past prior to COVID impacts, number one.  \n \n And then number two, if the heavy weighting of your vaccine and kitting, $0.50 to $0.70  is in the first quarter, how \ndo we true that up with earnings being weighted towards the back half; is by default is the implication that we \nshould be a bit more cautious on 2Q results?  Just trying to bridge all these moving pieces. ", "original_text": "And frankly, if I look at the three years prior to COVID, your contribution was, on \naverage, 54% of full year earnings. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9fb87b9c-7e74-4ff7-b3a6-bd898cfc6642", "node_type": "1", "metadata": {"window": "Q \nHey.  Thanks very much.  This somewhat tails on Charles' question.  It was, in a nutshell, you guided to earnings \nbeing back -half weighted again.  And frankly, if I look at the three years prior to COVID, your contribution was, on \naverage, 54% of full year earnings.  So, I just want to make sure that this is more than anything kind of a \nreiteration of what happened in the past prior to COVID impacts, number one.  \n \n And then number two, if the heavy weighting of your vaccine and kitting, $0.50 to $0.70  is in the first quarter, how \ndo we true that up with earnings being weighted towards the back half; is by default is the implication that we \nshould be a bit more cautious on 2Q results? ", "original_text": "It was, in a nutshell, you guided to earnings \nbeing back -half weighted again. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c71eb1468e1ab683579349b5ddc844930f3209a059bde9f4d3ad62baacb2bc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84cecdfa-55dc-47f7-ae99-aa8e93d09446", "node_type": "1", "metadata": {"window": "This somewhat tails on Charles' question.  It was, in a nutshell, you guided to earnings \nbeing back -half weighted again.  And frankly, if I look at the three years prior to COVID, your contribution was, on \naverage, 54% of full year earnings.  So, I just want to make sure that this is more than anything kind of a \nreiteration of what happened in the past prior to COVID impacts, number one.  \n \n And then number two, if the heavy weighting of your vaccine and kitting, $0.50 to $0.70  is in the first quarter, how \ndo we true that up with earnings being weighted towards the back half; is by default is the implication that we \nshould be a bit more cautious on 2Q results?  Just trying to bridge all these moving pieces.  Thanks.  \n ", "original_text": "So, I just want to make sure that this is more than anything kind of a \nreiteration of what happened in the past prior to COVID impacts, number one.  \n \n"}, "hash": "acd5ecf097576a4fc1ca7ca6db5b3945830c837dfb186581d37cfa494e84897b", "class_name": "RelatedNodeInfo"}}, "text": "And frankly, if I look at the three years prior to COVID, your contribution was, on \naverage, 54% of full year earnings. ", "start_char_idx": 3824, "end_char_idx": 3945, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84cecdfa-55dc-47f7-ae99-aa8e93d09446": {"__data__": {"id_": "84cecdfa-55dc-47f7-ae99-aa8e93d09446", "embedding": null, "metadata": {"window": "This somewhat tails on Charles' question.  It was, in a nutshell, you guided to earnings \nbeing back -half weighted again.  And frankly, if I look at the three years prior to COVID, your contribution was, on \naverage, 54% of full year earnings.  So, I just want to make sure that this is more than anything kind of a \nreiteration of what happened in the past prior to COVID impacts, number one.  \n \n And then number two, if the heavy weighting of your vaccine and kitting, $0.50 to $0.70  is in the first quarter, how \ndo we true that up with earnings being weighted towards the back half; is by default is the implication that we \nshould be a bit more cautious on 2Q results?  Just trying to bridge all these moving pieces.  Thanks.  \n ", "original_text": "So, I just want to make sure that this is more than anything kind of a \nreiteration of what happened in the past prior to COVID impacts, number one.  \n \n", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe97ce2a-af68-4da8-9126-f95e0a46022f", "node_type": "1", "metadata": {"window": "Thanks very much.  This somewhat tails on Charles' question.  It was, in a nutshell, you guided to earnings \nbeing back -half weighted again.  And frankly, if I look at the three years prior to COVID, your contribution was, on \naverage, 54% of full year earnings.  So, I just want to make sure that this is more than anything kind of a \nreiteration of what happened in the past prior to COVID impacts, number one.  \n \n And then number two, if the heavy weighting of your vaccine and kitting, $0.50 to $0.70  is in the first quarter, how \ndo we true that up with earnings being weighted towards the back half; is by default is the implication that we \nshould be a bit more cautious on 2Q results?  Just trying to bridge all these moving pieces. ", "original_text": "And frankly, if I look at the three years prior to COVID, your contribution was, on \naverage, 54% of full year earnings. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ec4c3215c3af4b93580c967a91717e4fd7275614282fcaa5e582afd39999bc86", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "128bbbbe-1df9-4c96-b501-17815c5ba5c0", "node_type": "1", "metadata": {"window": "It was, in a nutshell, you guided to earnings \nbeing back -half weighted again.  And frankly, if I look at the three years prior to COVID, your contribution was, on \naverage, 54% of full year earnings.  So, I just want to make sure that this is more than anything kind of a \nreiteration of what happened in the past prior to COVID impacts, number one.  \n \n And then number two, if the heavy weighting of your vaccine and kitting, $0.50 to $0.70  is in the first quarter, how \ndo we true that up with earnings being weighted towards the back half; is by default is the implication that we \nshould be a bit more cautious on 2Q results?  Just trying to bridge all these moving pieces.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "And then number two, if the heavy weighting of your vaccine and kitting, $0.50 to $0.70  is in the first quarter, how \ndo we true that up with earnings being weighted towards the back half; is by default is the implication that we \nshould be a bit more cautious on 2Q results? "}, "hash": "cea4e11e98cf90df1565a4d9f91dc7d9b6ccd4d451a21eb43bd374f93e3efc5a", "class_name": "RelatedNodeInfo"}}, "text": "So, I just want to make sure that this is more than anything kind of a \nreiteration of what happened in the past prior to COVID impacts, number one.  \n \n", "start_char_idx": 3945, "end_char_idx": 4098, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "128bbbbe-1df9-4c96-b501-17815c5ba5c0": {"__data__": {"id_": "128bbbbe-1df9-4c96-b501-17815c5ba5c0", "embedding": null, "metadata": {"window": "It was, in a nutshell, you guided to earnings \nbeing back -half weighted again.  And frankly, if I look at the three years prior to COVID, your contribution was, on \naverage, 54% of full year earnings.  So, I just want to make sure that this is more than anything kind of a \nreiteration of what happened in the past prior to COVID impacts, number one.  \n \n And then number two, if the heavy weighting of your vaccine and kitting, $0.50 to $0.70  is in the first quarter, how \ndo we true that up with earnings being weighted towards the back half; is by default is the implication that we \nshould be a bit more cautious on 2Q results?  Just trying to bridge all these moving pieces.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "And then number two, if the heavy weighting of your vaccine and kitting, $0.50 to $0.70  is in the first quarter, how \ndo we true that up with earnings being weighted towards the back half; is by default is the implication that we \nshould be a bit more cautious on 2Q results? ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84cecdfa-55dc-47f7-ae99-aa8e93d09446", "node_type": "1", "metadata": {"window": "This somewhat tails on Charles' question.  It was, in a nutshell, you guided to earnings \nbeing back -half weighted again.  And frankly, if I look at the three years prior to COVID, your contribution was, on \naverage, 54% of full year earnings.  So, I just want to make sure that this is more than anything kind of a \nreiteration of what happened in the past prior to COVID impacts, number one.  \n \n And then number two, if the heavy weighting of your vaccine and kitting, $0.50 to $0.70  is in the first quarter, how \ndo we true that up with earnings being weighted towards the back half; is by default is the implication that we \nshould be a bit more cautious on 2Q results?  Just trying to bridge all these moving pieces.  Thanks.  \n ", "original_text": "So, I just want to make sure that this is more than anything kind of a \nreiteration of what happened in the past prior to COVID impacts, number one.  \n \n", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a331c8e9dac10c142e17d1d265b7407a002c9618c0162256ffbfc6bf747ce5ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80a07412-0bb9-45f1-9264-3aab5d0b71b7", "node_type": "1", "metadata": {"window": "And frankly, if I look at the three years prior to COVID, your contribution was, on \naverage, 54% of full year earnings.  So, I just want to make sure that this is more than anything kind of a \nreiteration of what happened in the past prior to COVID impacts, number one.  \n \n And then number two, if the heavy weighting of your vaccine and kitting, $0.50 to $0.70  is in the first quarter, how \ndo we true that up with earnings being weighted towards the back half; is by default is the implication that we \nshould be a bit more cautious on 2Q results?  Just trying to bridge all these moving pieces.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes. ", "original_text": "Just trying to bridge all these moving pieces. "}, "hash": "60667a2310f048c0eccc246effc9c85f697e4aca36c09a7fa56a0636e1f88a05", "class_name": "RelatedNodeInfo"}}, "text": "And then number two, if the heavy weighting of your vaccine and kitting, $0.50 to $0.70  is in the first quarter, how \ndo we true that up with earnings being weighted towards the back half; is by default is the implication that we \nshould be a bit more cautious on 2Q results? ", "start_char_idx": 4098, "end_char_idx": 4375, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80a07412-0bb9-45f1-9264-3aab5d0b71b7": {"__data__": {"id_": "80a07412-0bb9-45f1-9264-3aab5d0b71b7", "embedding": null, "metadata": {"window": "And frankly, if I look at the three years prior to COVID, your contribution was, on \naverage, 54% of full year earnings.  So, I just want to make sure that this is more than anything kind of a \nreiteration of what happened in the past prior to COVID impacts, number one.  \n \n And then number two, if the heavy weighting of your vaccine and kitting, $0.50 to $0.70  is in the first quarter, how \ndo we true that up with earnings being weighted towards the back half; is by default is the implication that we \nshould be a bit more cautious on 2Q results?  Just trying to bridge all these moving pieces.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes. ", "original_text": "Just trying to bridge all these moving pieces. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "128bbbbe-1df9-4c96-b501-17815c5ba5c0", "node_type": "1", "metadata": {"window": "It was, in a nutshell, you guided to earnings \nbeing back -half weighted again.  And frankly, if I look at the three years prior to COVID, your contribution was, on \naverage, 54% of full year earnings.  So, I just want to make sure that this is more than anything kind of a \nreiteration of what happened in the past prior to COVID impacts, number one.  \n \n And then number two, if the heavy weighting of your vaccine and kitting, $0.50 to $0.70  is in the first quarter, how \ndo we true that up with earnings being weighted towards the back half; is by default is the implication that we \nshould be a bit more cautious on 2Q results?  Just trying to bridge all these moving pieces.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "And then number two, if the heavy weighting of your vaccine and kitting, $0.50 to $0.70  is in the first quarter, how \ndo we true that up with earnings being weighted towards the back half; is by default is the implication that we \nshould be a bit more cautious on 2Q results? ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64dc8235959db8a8365b32ebb4d0015fe1890f40d5463391865aa564380301df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76f4aefc-3c96-45ae-84bf-d83d448be46b", "node_type": "1", "metadata": {"window": "So, I just want to make sure that this is more than anything kind of a \nreiteration of what happened in the past prior to COVID impacts, number one.  \n \n And then number two, if the heavy weighting of your vaccine and kitting, $0.50 to $0.70  is in the first quarter, how \ndo we true that up with earnings being weighted towards the back half; is by default is the implication that we \nshould be a bit more cautious on 2Q results?  Just trying to bridge all these moving pieces.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  Sure. ", "original_text": "Thanks.  \n "}, "hash": "b83a04fa5b7fa67e0fd9ec2708e955fd9955d384a6f43e2fbcc4eaedfefce2a7", "class_name": "RelatedNodeInfo"}}, "text": "Just trying to bridge all these moving pieces. ", "start_char_idx": 4375, "end_char_idx": 4422, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76f4aefc-3c96-45ae-84bf-d83d448be46b": {"__data__": {"id_": "76f4aefc-3c96-45ae-84bf-d83d448be46b", "embedding": null, "metadata": {"window": "So, I just want to make sure that this is more than anything kind of a \nreiteration of what happened in the past prior to COVID impacts, number one.  \n \n And then number two, if the heavy weighting of your vaccine and kitting, $0.50 to $0.70  is in the first quarter, how \ndo we true that up with earnings being weighted towards the back half; is by default is the implication that we \nshould be a bit more cautious on 2Q results?  Just trying to bridge all these moving pieces.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  Sure. ", "original_text": "Thanks.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80a07412-0bb9-45f1-9264-3aab5d0b71b7", "node_type": "1", "metadata": {"window": "And frankly, if I look at the three years prior to COVID, your contribution was, on \naverage, 54% of full year earnings.  So, I just want to make sure that this is more than anything kind of a \nreiteration of what happened in the past prior to COVID impacts, number one.  \n \n And then number two, if the heavy weighting of your vaccine and kitting, $0.50 to $0.70  is in the first quarter, how \ndo we true that up with earnings being weighted towards the back half; is by default is the implication that we \nshould be a bit more cautious on 2Q results?  Just trying to bridge all these moving pieces.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes. ", "original_text": "Just trying to bridge all these moving pieces. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c958bc1e46652b4a896d68b2caca135da5d60231e8175e2aed676a1056a801c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2985e563-0903-44d7-9565-1315702e8f02", "node_type": "1", "metadata": {"window": "And then number two, if the heavy weighting of your vaccine and kitting, $0.50 to $0.70  is in the first quarter, how \ndo we true that up with earnings being weighted towards the back half; is by default is the implication that we \nshould be a bit more cautious on 2Q results?  Just trying to bridge all these moving pieces.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  Sure.  Let me see if I can help you out. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "4a4e14bd605fb86cba33186683ac10371c1593931fe746e655a108eea7285d84", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 1936, "end_char_idx": 1947, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2985e563-0903-44d7-9565-1315702e8f02": {"__data__": {"id_": "2985e563-0903-44d7-9565-1315702e8f02", "embedding": null, "metadata": {"window": "And then number two, if the heavy weighting of your vaccine and kitting, $0.50 to $0.70  is in the first quarter, how \ndo we true that up with earnings being weighted towards the back half; is by default is the implication that we \nshould be a bit more cautious on 2Q results?  Just trying to bridge all these moving pieces.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  Sure.  Let me see if I can help you out. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76f4aefc-3c96-45ae-84bf-d83d448be46b", "node_type": "1", "metadata": {"window": "So, I just want to make sure that this is more than anything kind of a \nreiteration of what happened in the past prior to COVID impacts, number one.  \n \n And then number two, if the heavy weighting of your vaccine and kitting, $0.50 to $0.70  is in the first quarter, how \ndo we true that up with earnings being weighted towards the back half; is by default is the implication that we \nshould be a bit more cautious on 2Q results?  Just trying to bridge all these moving pieces.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  Sure. ", "original_text": "Thanks.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ca142dedec90bea1cbaabe18604c8d4127e9048a0b73d46114a3d22a997eede7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef37376a-a31b-4ff0-99ef-732953969620", "node_type": "1", "metadata": {"window": "Just trying to bridge all these moving pieces.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  Sure.  Let me see if I can help you out.  You are correct. ", "original_text": "A \nYes. "}, "hash": "cedcc2de32649f5b9c1d72dac99cc1e0a742fea357584ccfadff4d0011961db4", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 4433, "end_char_idx": 4775, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef37376a-a31b-4ff0-99ef-732953969620": {"__data__": {"id_": "ef37376a-a31b-4ff0-99ef-732953969620", "embedding": null, "metadata": {"window": "Just trying to bridge all these moving pieces.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  Sure.  Let me see if I can help you out.  You are correct. ", "original_text": "A \nYes. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2985e563-0903-44d7-9565-1315702e8f02", "node_type": "1", "metadata": {"window": "And then number two, if the heavy weighting of your vaccine and kitting, $0.50 to $0.70  is in the first quarter, how \ndo we true that up with earnings being weighted towards the back half; is by default is the implication that we \nshould be a bit more cautious on 2Q results?  Just trying to bridge all these moving pieces.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  Sure.  Let me see if I can help you out. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc91fc035ceac0516cbe6530f31b39b5b3b42bd4cbca4cd1b1cd8bb118642a38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8973678-110f-4901-844f-395824426440", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  Sure.  Let me see if I can help you out.  You are correct.  Historically, our earnings have been generated \nprimarily heavier in the second half of the year. ", "original_text": "Sure. "}, "hash": "7707523a9ec4ead98613846671d885d5e0652cb585ec46532ddfc978d36f7226", "class_name": "RelatedNodeInfo"}}, "text": "A \nYes. ", "start_char_idx": 4775, "end_char_idx": 4783, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8973678-110f-4901-844f-395824426440": {"__data__": {"id_": "b8973678-110f-4901-844f-395824426440", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  Sure.  Let me see if I can help you out.  You are correct.  Historically, our earnings have been generated \nprimarily heavier in the second half of the year. ", "original_text": "Sure. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef37376a-a31b-4ff0-99ef-732953969620", "node_type": "1", "metadata": {"window": "Just trying to bridge all these moving pieces.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  Sure.  Let me see if I can help you out.  You are correct. ", "original_text": "A \nYes. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3dce07a80c9b40c3f868a2276e47e85e14c0486db932631f50fefe15cd2f65a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "734b6e39-704a-4b4b-8cd7-477f916245a9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  Sure.  Let me see if I can help you out.  You are correct.  Historically, our earnings have been generated \nprimarily heavier in the second half of the year.  And we would expect that  we would have a slightly higher second \nhalf contribution than the first half again this year. ", "original_text": "Let me see if I can help you out. "}, "hash": "80cda1a29685c3f07a2d1ec24e3b79bf02969c839c6093f784bbc23714070061", "class_name": "RelatedNodeInfo"}}, "text": "Sure. ", "start_char_idx": 2292, "end_char_idx": 2298, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "734b6e39-704a-4b4b-8cd7-477f916245a9": {"__data__": {"id_": "734b6e39-704a-4b4b-8cd7-477f916245a9", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  Sure.  Let me see if I can help you out.  You are correct.  Historically, our earnings have been generated \nprimarily heavier in the second half of the year.  And we would expect that  we would have a slightly higher second \nhalf contribution than the first half again this year. ", "original_text": "Let me see if I can help you out. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8973678-110f-4901-844f-395824426440", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  Sure.  Let me see if I can help you out.  You are correct.  Historically, our earnings have been generated \nprimarily heavier in the second half of the year. ", "original_text": "Sure. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89abb9b78b50b8c211cee338e00315f7846e7969b31770cda24c01d33e11a9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44c31dd2-2008-4c29-be17-a497581a5d79", "node_type": "1", "metadata": {"window": "A \nYes.  Sure.  Let me see if I can help you out.  You are correct.  Historically, our earnings have been generated \nprimarily heavier in the second half of the year.  And we would expect that  we would have a slightly higher second \nhalf contribution than the first half again this year.  I think when you look at our guide and you look at the vaccine ", "original_text": "You are correct. "}, "hash": "032b960ef0390434b4a0889d05e4fc7251fe902d6cd7b5a1a7140d9a8fb00b2e", "class_name": "RelatedNodeInfo"}}, "text": "Let me see if I can help you out. ", "start_char_idx": 4789, "end_char_idx": 4823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44c31dd2-2008-4c29-be17-a497581a5d79": {"__data__": {"id_": "44c31dd2-2008-4c29-be17-a497581a5d79", "embedding": null, "metadata": {"window": "A \nYes.  Sure.  Let me see if I can help you out.  You are correct.  Historically, our earnings have been generated \nprimarily heavier in the second half of the year.  And we would expect that  we would have a slightly higher second \nhalf contribution than the first half again this year.  I think when you look at our guide and you look at the vaccine ", "original_text": "You are correct. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "734b6e39-704a-4b4b-8cd7-477f916245a9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  Sure.  Let me see if I can help you out.  You are correct.  Historically, our earnings have been generated \nprimarily heavier in the second half of the year.  And we would expect that  we would have a slightly higher second \nhalf contribution than the first half again this year. ", "original_text": "Let me see if I can help you out. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7dbd32a2da4755ea68059e18e2c0a90646de3b573bd128dbc3e580f4ee28626", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87a4e057-47ea-4649-b6b3-1d4db1908b95", "node_type": "1", "metadata": {"window": "Sure.  Let me see if I can help you out.  You are correct.  Historically, our earnings have been generated \nprimarily heavier in the second half of the year.  And we would expect that  we would have a slightly higher second \nhalf contribution than the first half again this year.  I think when you look at our guide and you look at the vaccine ", "original_text": "Historically, our earnings have been generated \nprimarily heavier in the second half of the year. "}, "hash": "2833ac328d1b56684a2082baa764e5106eb9f3856acdcd637c4dba06d94d52f3", "class_name": "RelatedNodeInfo"}}, "text": "You are correct. ", "start_char_idx": 4823, "end_char_idx": 4840, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87a4e057-47ea-4649-b6b3-1d4db1908b95": {"__data__": {"id_": "87a4e057-47ea-4649-b6b3-1d4db1908b95", "embedding": null, "metadata": {"window": "Sure.  Let me see if I can help you out.  You are correct.  Historically, our earnings have been generated \nprimarily heavier in the second half of the year.  And we would expect that  we would have a slightly higher second \nhalf contribution than the first half again this year.  I think when you look at our guide and you look at the vaccine ", "original_text": "Historically, our earnings have been generated \nprimarily heavier in the second half of the year. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44c31dd2-2008-4c29-be17-a497581a5d79", "node_type": "1", "metadata": {"window": "A \nYes.  Sure.  Let me see if I can help you out.  You are correct.  Historically, our earnings have been generated \nprimarily heavier in the second half of the year.  And we would expect that  we would have a slightly higher second \nhalf contribution than the first half again this year.  I think when you look at our guide and you look at the vaccine ", "original_text": "You are correct. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4c7d96e31a5b575d0250d0647a905e0573c3e2d05b7ff83db805383724edaa30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "124cf7bb-1e57-4489-9624-9571f502973e", "node_type": "1", "metadata": {"window": "Let me see if I can help you out.  You are correct.  Historically, our earnings have been generated \nprimarily heavier in the second half of the year.  And we would expect that  we would have a slightly higher second \nhalf contribution than the first half again this year.  I think when you look at our guide and you look at the vaccine ", "original_text": "And we would expect that  we would have a slightly higher second \nhalf contribution than the first half again this year. "}, "hash": "e67383028f43f6923c83197c0096a244396f9cd42671c0946d70523f1f9eee82", "class_name": "RelatedNodeInfo"}}, "text": "Historically, our earnings have been generated \nprimarily heavier in the second half of the year. ", "start_char_idx": 4840, "end_char_idx": 4938, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "124cf7bb-1e57-4489-9624-9571f502973e": {"__data__": {"id_": "124cf7bb-1e57-4489-9624-9571f502973e", "embedding": null, "metadata": {"window": "Let me see if I can help you out.  You are correct.  Historically, our earnings have been generated \nprimarily heavier in the second half of the year.  And we would expect that  we would have a slightly higher second \nhalf contribution than the first half again this year.  I think when you look at our guide and you look at the vaccine ", "original_text": "And we would expect that  we would have a slightly higher second \nhalf contribution than the first half again this year. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87a4e057-47ea-4649-b6b3-1d4db1908b95", "node_type": "1", "metadata": {"window": "Sure.  Let me see if I can help you out.  You are correct.  Historically, our earnings have been generated \nprimarily heavier in the second half of the year.  And we would expect that  we would have a slightly higher second \nhalf contribution than the first half again this year.  I think when you look at our guide and you look at the vaccine ", "original_text": "Historically, our earnings have been generated \nprimarily heavier in the second half of the year. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "615e53a0f4953e319548beecf5dc01b7db8621a66801bc7704edc84dfdb4a018", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dadc6c31-8e96-4f3a-a4f6-22307b8574cb", "node_type": "1", "metadata": {"window": "You are correct.  Historically, our earnings have been generated \nprimarily heavier in the second half of the year.  And we would expect that  we would have a slightly higher second \nhalf contribution than the first half again this year.  I think when you look at our guide and you look at the vaccine ", "original_text": "I think when you look at our guide and you look at the vaccine "}, "hash": "35c71a725a8df7cbfc78f6f6dd21561d989eebff7e4886670e400203402c9a6e", "class_name": "RelatedNodeInfo"}}, "text": "And we would expect that  we would have a slightly higher second \nhalf contribution than the first half again this year. ", "start_char_idx": 4938, "end_char_idx": 5059, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dadc6c31-8e96-4f3a-a4f6-22307b8574cb": {"__data__": {"id_": "dadc6c31-8e96-4f3a-a4f6-22307b8574cb", "embedding": null, "metadata": {"window": "You are correct.  Historically, our earnings have been generated \nprimarily heavier in the second half of the year.  And we would expect that  we would have a slightly higher second \nhalf contribution than the first half again this year.  I think when you look at our guide and you look at the vaccine ", "original_text": "I think when you look at our guide and you look at the vaccine ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "496ce0d1-7c51-4c96-9335-401f24ef2563", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872839f02286023bc6fc10b2d00ce3ccafccf6fb7b2e29b535632927d477cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "124cf7bb-1e57-4489-9624-9571f502973e", "node_type": "1", "metadata": {"window": "Let me see if I can help you out.  You are correct.  Historically, our earnings have been generated \nprimarily heavier in the second half of the year.  And we would expect that  we would have a slightly higher second \nhalf contribution than the first half again this year.  I think when you look at our guide and you look at the vaccine ", "original_text": "And we would expect that  we would have a slightly higher second \nhalf contribution than the first half again this year. ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c02ad3365f31db067b96a6b01e6c79aeff0e7efee8f890ef6731a5cf43302346", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4204a6e-92ed-40f0-88b7-34a6a5f7fd7b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution of $0.40 to $0.50 on the range of $18.85 to $19.45, inside of that, the core business  is still growing. \n And we would expect that as utilization continues to improve through the first half and gets back to pre -COVID in \nthe second half that those core earnings would reflect that.  \n \n So again, I think historically, we've had higher second half contribution than the first half. ", "original_text": "McKesson Corp.  "}, "hash": "eefcbc48f0f2fca8d97c898071b54ae1256ee7e13a2e2608a4ef7df7d485e599", "class_name": "RelatedNodeInfo"}}, "text": "I think when you look at our guide and you look at the vaccine ", "start_char_idx": 5059, "end_char_idx": 5122, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4204a6e-92ed-40f0-88b7-34a6a5f7fd7b": {"__data__": {"id_": "b4204a6e-92ed-40f0-88b7-34a6a5f7fd7b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution of $0.40 to $0.50 on the range of $18.85 to $19.45, inside of that, the core business  is still growing. \n And we would expect that as utilization continues to improve through the first half and gets back to pre -COVID in \nthe second half that those core earnings would reflect that.  \n \n So again, I think historically, we've had higher second half contribution than the first half. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dadc6c31-8e96-4f3a-a4f6-22307b8574cb", "node_type": "1", "metadata": {"window": "You are correct.  Historically, our earnings have been generated \nprimarily heavier in the second half of the year.  And we would expect that  we would have a slightly higher second \nhalf contribution than the first half again this year.  I think when you look at our guide and you look at the vaccine ", "original_text": "I think when you look at our guide and you look at the vaccine ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8d30ee6b952f63dbc4316b2efd01d19835d0d285d8292e56a653135f4a069f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d56d5304-60db-4bda-997a-6ab2f78f15b9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution of $0.40 to $0.50 on the range of $18.85 to $19.45, inside of that, the core business  is still growing. \n And we would expect that as utilization continues to improve through the first half and gets back to pre -COVID in \nthe second half that those core earnings would reflect that.  \n \n So again, I think historically, we've had higher second half contribution than the first half.  We expect that we'll \nhave a slightly higher second half than first half contribution as well. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution of $0.40 to $0.50 on the range of $18.85 to $19.45, inside of that, the core business  is still growing. \n"}, "hash": "5e488b3a996c93928474573b3aaa9f2cddeaa5f84d0c2c732bbbabd08345d696", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d56d5304-60db-4bda-997a-6ab2f78f15b9": {"__data__": {"id_": "d56d5304-60db-4bda-997a-6ab2f78f15b9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution of $0.40 to $0.50 on the range of $18.85 to $19.45, inside of that, the core business  is still growing. \n And we would expect that as utilization continues to improve through the first half and gets back to pre -COVID in \nthe second half that those core earnings would reflect that.  \n \n So again, I think historically, we've had higher second half contribution than the first half.  We expect that we'll \nhave a slightly higher second half than first half contribution as well. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution of $0.40 to $0.50 on the range of $18.85 to $19.45, inside of that, the core business  is still growing. \n", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4204a6e-92ed-40f0-88b7-34a6a5f7fd7b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution of $0.40 to $0.50 on the range of $18.85 to $19.45, inside of that, the core business  is still growing. \n And we would expect that as utilization continues to improve through the first half and gets back to pre -COVID in \nthe second half that those core earnings would reflect that.  \n \n So again, I think historically, we've had higher second half contribution than the first half. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b70772f84f587c3f8cd7be450705ac539d993498e5d9fe1d4be54a0bf34eae08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e31dcb8f-8b2a-40db-9ab2-8fd39f7d536a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution of $0.40 to $0.50 on the range of $18.85 to $19.45, inside of that, the core business  is still growing. \n And we would expect that as utilization continues to improve through the first half and gets back to pre -COVID in \nthe second half that those core earnings would reflect that.  \n \n So again, I think historically, we've had higher second half contribution than the first half.  We expect that we'll \nhave a slightly higher second half than first half contribution as well.  We don't guide to quarters, so I'm really not \ngoing to comment on second quarter versus first quarter. ", "original_text": "And we would expect that as utilization continues to improve through the first half and gets back to pre -COVID in \nthe second half that those core earnings would reflect that.  \n \n"}, "hash": "61d68b4bc967250520dcc8cc35108a41fbc14b0c3d92aac8ed4a3a775825226f", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution of $0.40 to $0.50 on the range of $18.85 to $19.45, inside of that, the core business  is still growing. \n", "start_char_idx": 16, "end_char_idx": 300, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e31dcb8f-8b2a-40db-9ab2-8fd39f7d536a": {"__data__": {"id_": "e31dcb8f-8b2a-40db-9ab2-8fd39f7d536a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution of $0.40 to $0.50 on the range of $18.85 to $19.45, inside of that, the core business  is still growing. \n And we would expect that as utilization continues to improve through the first half and gets back to pre -COVID in \nthe second half that those core earnings would reflect that.  \n \n So again, I think historically, we've had higher second half contribution than the first half.  We expect that we'll \nhave a slightly higher second half than first half contribution as well.  We don't guide to quarters, so I'm really not \ngoing to comment on second quarter versus first quarter. ", "original_text": "And we would expect that as utilization continues to improve through the first half and gets back to pre -COVID in \nthe second half that those core earnings would reflect that.  \n \n", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d56d5304-60db-4bda-997a-6ab2f78f15b9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution of $0.40 to $0.50 on the range of $18.85 to $19.45, inside of that, the core business  is still growing. \n And we would expect that as utilization continues to improve through the first half and gets back to pre -COVID in \nthe second half that those core earnings would reflect that.  \n \n So again, I think historically, we've had higher second half contribution than the first half.  We expect that we'll \nhave a slightly higher second half than first half contribution as well. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution of $0.40 to $0.50 on the range of $18.85 to $19.45, inside of that, the core business  is still growing. \n", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2285f64114a24701941713569c8f063f5557708cf22d95960e90bb02e180f303", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5533079a-c095-4316-8368-3ee7eec07c7b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution of $0.40 to $0.50 on the range of $18.85 to $19.45, inside of that, the core business  is still growing. \n And we would expect that as utilization continues to improve through the first half and gets back to pre -COVID in \nthe second half that those core earnings would reflect that.  \n \n So again, I think historically, we've had higher second half contribution than the first half.  We expect that we'll \nhave a slightly higher second half than first half contribution as well.  We don't guide to quarters, so I'm really not \ngoing to comment on second quarter versus first quarter.  I think you should take o ur thinking on how utilization \ncomes back online.  \n ", "original_text": "So again, I think historically, we've had higher second half contribution than the first half. "}, "hash": "f0b86c5d2907ba80dd95a1a01bea0c0c7952fb5c4ed29553eed0800dcdb75258", "class_name": "RelatedNodeInfo"}}, "text": "And we would expect that as utilization continues to improve through the first half and gets back to pre -COVID in \nthe second half that those core earnings would reflect that.  \n \n", "start_char_idx": 300, "end_char_idx": 481, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5533079a-c095-4316-8368-3ee7eec07c7b": {"__data__": {"id_": "5533079a-c095-4316-8368-3ee7eec07c7b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution of $0.40 to $0.50 on the range of $18.85 to $19.45, inside of that, the core business  is still growing. \n And we would expect that as utilization continues to improve through the first half and gets back to pre -COVID in \nthe second half that those core earnings would reflect that.  \n \n So again, I think historically, we've had higher second half contribution than the first half.  We expect that we'll \nhave a slightly higher second half than first half contribution as well.  We don't guide to quarters, so I'm really not \ngoing to comment on second quarter versus first quarter.  I think you should take o ur thinking on how utilization \ncomes back online.  \n ", "original_text": "So again, I think historically, we've had higher second half contribution than the first half. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e31dcb8f-8b2a-40db-9ab2-8fd39f7d536a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution of $0.40 to $0.50 on the range of $18.85 to $19.45, inside of that, the core business  is still growing. \n And we would expect that as utilization continues to improve through the first half and gets back to pre -COVID in \nthe second half that those core earnings would reflect that.  \n \n So again, I think historically, we've had higher second half contribution than the first half.  We expect that we'll \nhave a slightly higher second half than first half contribution as well.  We don't guide to quarters, so I'm really not \ngoing to comment on second quarter versus first quarter. ", "original_text": "And we would expect that as utilization continues to improve through the first half and gets back to pre -COVID in \nthe second half that those core earnings would reflect that.  \n \n", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ac636f13d435b0de9b6dfba3ba4f06a903e3a57b37f5fe79c790a08a892f20da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58cc9867-15e2-4b8b-b9e5-e8e9d028dd66", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution of $0.40 to $0.50 on the range of $18.85 to $19.45, inside of that, the core business  is still growing. \n And we would expect that as utilization continues to improve through the first half and gets back to pre -COVID in \nthe second half that those core earnings would reflect that.  \n \n So again, I think historically, we've had higher second half contribution than the first half.  We expect that we'll \nhave a slightly higher second half than first half contribution as well.  We don't guide to quarters, so I'm really not \ngoing to comment on second quarter versus first quarter.  I think you should take o ur thinking on how utilization \ncomes back online.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "We expect that we'll \nhave a slightly higher second half than first half contribution as well. "}, "hash": "8d3e696a2d655340117918abe1d12d5df9e73742974a0762184766e65dbccd23", "class_name": "RelatedNodeInfo"}}, "text": "So again, I think historically, we've had higher second half contribution than the first half. ", "start_char_idx": 481, "end_char_idx": 576, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58cc9867-15e2-4b8b-b9e5-e8e9d028dd66": {"__data__": {"id_": "58cc9867-15e2-4b8b-b9e5-e8e9d028dd66", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution of $0.40 to $0.50 on the range of $18.85 to $19.45, inside of that, the core business  is still growing. \n And we would expect that as utilization continues to improve through the first half and gets back to pre -COVID in \nthe second half that those core earnings would reflect that.  \n \n So again, I think historically, we've had higher second half contribution than the first half.  We expect that we'll \nhave a slightly higher second half than first half contribution as well.  We don't guide to quarters, so I'm really not \ngoing to comment on second quarter versus first quarter.  I think you should take o ur thinking on how utilization \ncomes back online.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "We expect that we'll \nhave a slightly higher second half than first half contribution as well. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5533079a-c095-4316-8368-3ee7eec07c7b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution of $0.40 to $0.50 on the range of $18.85 to $19.45, inside of that, the core business  is still growing. \n And we would expect that as utilization continues to improve through the first half and gets back to pre -COVID in \nthe second half that those core earnings would reflect that.  \n \n So again, I think historically, we've had higher second half contribution than the first half.  We expect that we'll \nhave a slightly higher second half than first half contribution as well.  We don't guide to quarters, so I'm really not \ngoing to comment on second quarter versus first quarter.  I think you should take o ur thinking on how utilization \ncomes back online.  \n ", "original_text": "So again, I think historically, we've had higher second half contribution than the first half. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7bf21fbe176eee16dfa24e8ea3767947b419acfa1130e2c7506f0d5bd6dacbc5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee1f618c-9e9d-4ec2-aec8-beb9c152ded2", "node_type": "1", "metadata": {"window": "And we would expect that as utilization continues to improve through the first half and gets back to pre -COVID in \nthe second half that those core earnings would reflect that.  \n \n So again, I think historically, we've had higher second half contribution than the first half.  We expect that we'll \nhave a slightly higher second half than first half contribution as well.  We don't guide to quarters, so I'm really not \ngoing to comment on second quarter versus first quarter.  I think you should take o ur thinking on how utilization \ncomes back online.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Ricky Goldwasser with Morgan Stanley.  \n ", "original_text": "We don't guide to quarters, so I'm really not \ngoing to comment on second quarter versus first quarter. "}, "hash": "046155cf92efbb1453e302b54abcb230b639331a8ca3c0876a4779559db2285a", "class_name": "RelatedNodeInfo"}}, "text": "We expect that we'll \nhave a slightly higher second half than first half contribution as well. ", "start_char_idx": 576, "end_char_idx": 671, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee1f618c-9e9d-4ec2-aec8-beb9c152ded2": {"__data__": {"id_": "ee1f618c-9e9d-4ec2-aec8-beb9c152ded2", "embedding": null, "metadata": {"window": "And we would expect that as utilization continues to improve through the first half and gets back to pre -COVID in \nthe second half that those core earnings would reflect that.  \n \n So again, I think historically, we've had higher second half contribution than the first half.  We expect that we'll \nhave a slightly higher second half than first half contribution as well.  We don't guide to quarters, so I'm really not \ngoing to comment on second quarter versus first quarter.  I think you should take o ur thinking on how utilization \ncomes back online.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Ricky Goldwasser with Morgan Stanley.  \n ", "original_text": "We don't guide to quarters, so I'm really not \ngoing to comment on second quarter versus first quarter. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58cc9867-15e2-4b8b-b9e5-e8e9d028dd66", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution of $0.40 to $0.50 on the range of $18.85 to $19.45, inside of that, the core business  is still growing. \n And we would expect that as utilization continues to improve through the first half and gets back to pre -COVID in \nthe second half that those core earnings would reflect that.  \n \n So again, I think historically, we've had higher second half contribution than the first half.  We expect that we'll \nhave a slightly higher second half than first half contribution as well.  We don't guide to quarters, so I'm really not \ngoing to comment on second quarter versus first quarter.  I think you should take o ur thinking on how utilization \ncomes back online.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "We expect that we'll \nhave a slightly higher second half than first half contribution as well. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a89140abe805bfe8e698fa097a3ffb476e1ed754d0d4013a78cd671c2159864", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3aee708-71b5-45da-92dd-736aae46e86a", "node_type": "1", "metadata": {"window": "So again, I think historically, we've had higher second half contribution than the first half.  We expect that we'll \nhave a slightly higher second half than first half contribution as well.  We don't guide to quarters, so I'm really not \ngoing to comment on second quarter versus first quarter.  I think you should take o ur thinking on how utilization \ncomes back online.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "I think you should take o ur thinking on how utilization \ncomes back online.  \n "}, "hash": "32ded462f3c5a5f35a7c88aafb61342397d9c4f41af8663039b8259831a0c96d", "class_name": "RelatedNodeInfo"}}, "text": "We don't guide to quarters, so I'm really not \ngoing to comment on second quarter versus first quarter. ", "start_char_idx": 671, "end_char_idx": 775, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3aee708-71b5-45da-92dd-736aae46e86a": {"__data__": {"id_": "f3aee708-71b5-45da-92dd-736aae46e86a", "embedding": null, "metadata": {"window": "So again, I think historically, we've had higher second half contribution than the first half.  We expect that we'll \nhave a slightly higher second half than first half contribution as well.  We don't guide to quarters, so I'm really not \ngoing to comment on second quarter versus first quarter.  I think you should take o ur thinking on how utilization \ncomes back online.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "I think you should take o ur thinking on how utilization \ncomes back online.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee1f618c-9e9d-4ec2-aec8-beb9c152ded2", "node_type": "1", "metadata": {"window": "And we would expect that as utilization continues to improve through the first half and gets back to pre -COVID in \nthe second half that those core earnings would reflect that.  \n \n So again, I think historically, we've had higher second half contribution than the first half.  We expect that we'll \nhave a slightly higher second half than first half contribution as well.  We don't guide to quarters, so I'm really not \ngoing to comment on second quarter versus first quarter.  I think you should take o ur thinking on how utilization \ncomes back online.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Ricky Goldwasser with Morgan Stanley.  \n ", "original_text": "We don't guide to quarters, so I'm really not \ngoing to comment on second quarter versus first quarter. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a7046bfc6d12a49c183701f9fc55625f8e36ca034f6095b177e445306d6e30d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8de0eeb5-c2cb-4c3d-b2d7-1de75823286a", "node_type": "1", "metadata": {"window": "We expect that we'll \nhave a slightly higher second half than first half contribution as well.  We don't guide to quarters, so I'm really not \ngoing to comment on second quarter versus first quarter.  I think you should take o ur thinking on how utilization \ncomes back online.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. "}, "hash": "685a918a2bd18f9f4bb7ca0f41a1a45cd66cfc7c67c54944bf33a91e941ade30", "class_name": "RelatedNodeInfo"}}, "text": "I think you should take o ur thinking on how utilization \ncomes back online.  \n ", "start_char_idx": 775, "end_char_idx": 855, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8de0eeb5-c2cb-4c3d-b2d7-1de75823286a": {"__data__": {"id_": "8de0eeb5-c2cb-4c3d-b2d7-1de75823286a", "embedding": null, "metadata": {"window": "We expect that we'll \nhave a slightly higher second half than first half contribution as well.  We don't guide to quarters, so I'm really not \ngoing to comment on second quarter versus first quarter.  I think you should take o ur thinking on how utilization \ncomes back online.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3aee708-71b5-45da-92dd-736aae46e86a", "node_type": "1", "metadata": {"window": "So again, I think historically, we've had higher second half contribution than the first half.  We expect that we'll \nhave a slightly higher second half than first half contribution as well.  We don't guide to quarters, so I'm really not \ngoing to comment on second quarter versus first quarter.  I think you should take o ur thinking on how utilization \ncomes back online.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "I think you should take o ur thinking on how utilization \ncomes back online.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7562d1769e6ca774b21db37bc54e9e4e5cc92b07d07827cf30c730382dffaaea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bae11217-3b65-446c-afc8-e148b4e035f6", "node_type": "1", "metadata": {"window": "We don't guide to quarters, so I'm really not \ngoing to comment on second quarter versus first quarter.  I think you should take o ur thinking on how utilization \ncomes back online.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi.  Good evening. ", "original_text": "Our next question comes from Ricky Goldwasser with Morgan Stanley.  \n "}, "hash": "747f216e75d50348a6b32cf6db6ecb790ffa24b50f99404a52f0bd86f96963e1", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "start_char_idx": 855, "end_char_idx": 1136, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bae11217-3b65-446c-afc8-e148b4e035f6": {"__data__": {"id_": "bae11217-3b65-446c-afc8-e148b4e035f6", "embedding": null, "metadata": {"window": "We don't guide to quarters, so I'm really not \ngoing to comment on second quarter versus first quarter.  I think you should take o ur thinking on how utilization \ncomes back online.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi.  Good evening. ", "original_text": "Our next question comes from Ricky Goldwasser with Morgan Stanley.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8de0eeb5-c2cb-4c3d-b2d7-1de75823286a", "node_type": "1", "metadata": {"window": "We expect that we'll \nhave a slightly higher second half than first half contribution as well.  We don't guide to quarters, so I'm really not \ngoing to comment on second quarter versus first quarter.  I think you should take o ur thinking on how utilization \ncomes back online.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b926f3e6d8428a9108df2ba9412ccd6d643d01964d5ef30936faf48eb737ccf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46baeb0a-6c58-492e-a731-c603984e09a9", "node_type": "1", "metadata": {"window": "I think you should take o ur thinking on how utilization \ncomes back online.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi.  Good evening.  So, my question goes back to the  guidance for 2022 for core distribution operating \nincome growth. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. "}, "hash": "9107d67fca15a73405bd29ec40ddf1a94eb2459d39ead35fe43e10850f778fd5", "class_name": "RelatedNodeInfo"}}, "text": "Our next question comes from Ricky Goldwasser with Morgan Stanley.  \n ", "start_char_idx": 1136, "end_char_idx": 1206, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46baeb0a-6c58-492e-a731-c603984e09a9": {"__data__": {"id_": "46baeb0a-6c58-492e-a731-c603984e09a9", "embedding": null, "metadata": {"window": "I think you should take o ur thinking on how utilization \ncomes back online.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi.  Good evening.  So, my question goes back to the  guidance for 2022 for core distribution operating \nincome growth. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bae11217-3b65-446c-afc8-e148b4e035f6", "node_type": "1", "metadata": {"window": "We don't guide to quarters, so I'm really not \ngoing to comment on second quarter versus first quarter.  I think you should take o ur thinking on how utilization \ncomes back online.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi.  Good evening. ", "original_text": "Our next question comes from Ricky Goldwasser with Morgan Stanley.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5a4ce0faf79baa537cc024ea5410ba42ba3294847ff41575903298b43166b32f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a36e7f5d-d6d5-4ece-824f-1a785f6dd417", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi.  Good evening.  So, my question goes back to the  guidance for 2022 for core distribution operating \nincome growth.  We get often questions from investors around what's the long -term growth algorithm for the \nbusiness. ", "original_text": "LLC  Q \nYeah, hi. "}, "hash": "96717e695c59161a39b3b2ef78f86b940f0097371e58b37637ab1b6371c706a2", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 1206, "end_char_idx": 1515, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a36e7f5d-d6d5-4ece-824f-1a785f6dd417": {"__data__": {"id_": "a36e7f5d-d6d5-4ece-824f-1a785f6dd417", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi.  Good evening.  So, my question goes back to the  guidance for 2022 for core distribution operating \nincome growth.  We get often questions from investors around what's the long -term growth algorithm for the \nbusiness. ", "original_text": "LLC  Q \nYeah, hi. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46baeb0a-6c58-492e-a731-c603984e09a9", "node_type": "1", "metadata": {"window": "I think you should take o ur thinking on how utilization \ncomes back online.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi.  Good evening.  So, my question goes back to the  guidance for 2022 for core distribution operating \nincome growth. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c150e08a34d99eb1068b19f4addd9d0f1081438738c9865dc5e40f6d74b26ab2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4273a581-c405-4a22-b028-142825308571", "node_type": "1", "metadata": {"window": "Our next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi.  Good evening.  So, my question goes back to the  guidance for 2022 for core distribution operating \nincome growth.  We get often questions from investors around what's the long -term growth algorithm for the \nbusiness.  I think it's really helpful that you separated your core. ", "original_text": "Good evening. "}, "hash": "792d91ed1e0fa6971d87529729a2c3b6181f0eb049662837e21034af6267ccb5", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nYeah, hi. ", "start_char_idx": 1515, "end_char_idx": 1533, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4273a581-c405-4a22-b028-142825308571": {"__data__": {"id_": "4273a581-c405-4a22-b028-142825308571", "embedding": null, "metadata": {"window": "Our next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi.  Good evening.  So, my question goes back to the  guidance for 2022 for core distribution operating \nincome growth.  We get often questions from investors around what's the long -term growth algorithm for the \nbusiness.  I think it's really helpful that you separated your core. ", "original_text": "Good evening. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a36e7f5d-d6d5-4ece-824f-1a785f6dd417", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi.  Good evening.  So, my question goes back to the  guidance for 2022 for core distribution operating \nincome growth.  We get often questions from investors around what's the long -term growth algorithm for the \nbusiness. ", "original_text": "LLC  Q \nYeah, hi. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8598517a78dc68256d27b08b0c6991f985c92a511ff8cf0c21e0d0ef49cef0c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb2c9e93-c23e-423d-9b9e-9fe0127167f0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi.  Good evening.  So, my question goes back to the  guidance for 2022 for core distribution operating \nincome growth.  We get often questions from investors around what's the long -term growth algorithm for the \nbusiness.  I think it's really helpful that you separated your core.  So when we think about this cor e growth of 5% to \n8%, and while it doesn't include some of the COVID impacts, it does include lower volumes in the first half of the \nyear.  \n \n", "original_text": "So, my question goes back to the  guidance for 2022 for core distribution operating \nincome growth. "}, "hash": "611aa20247217bab237cfff32d646620f1bdd57dc74fedd2bda5363a2548c302", "class_name": "RelatedNodeInfo"}}, "text": "Good evening. ", "start_char_idx": 1533, "end_char_idx": 1547, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb2c9e93-c23e-423d-9b9e-9fe0127167f0": {"__data__": {"id_": "fb2c9e93-c23e-423d-9b9e-9fe0127167f0", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi.  Good evening.  So, my question goes back to the  guidance for 2022 for core distribution operating \nincome growth.  We get often questions from investors around what's the long -term growth algorithm for the \nbusiness.  I think it's really helpful that you separated your core.  So when we think about this cor e growth of 5% to \n8%, and while it doesn't include some of the COVID impacts, it does include lower volumes in the first half of the \nyear.  \n \n", "original_text": "So, my question goes back to the  guidance for 2022 for core distribution operating \nincome growth. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4273a581-c405-4a22-b028-142825308571", "node_type": "1", "metadata": {"window": "Our next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi.  Good evening.  So, my question goes back to the  guidance for 2022 for core distribution operating \nincome growth.  We get often questions from investors around what's the long -term growth algorithm for the \nbusiness.  I think it's really helpful that you separated your core. ", "original_text": "Good evening. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3ed23531a7de0ab8fa43fa48bc2507e5ee281932109029215e49c0e5647caed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "593de646-e717-4d4e-bd1d-5b747ba09602", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah, hi.  Good evening.  So, my question goes back to the  guidance for 2022 for core distribution operating \nincome growth.  We get often questions from investors around what's the long -term growth algorithm for the \nbusiness.  I think it's really helpful that you separated your core.  So when we think about this cor e growth of 5% to \n8%, and while it doesn't include some of the COVID impacts, it does include lower volumes in the first half of the \nyear.  \n \n Should we think about that as sort of the starting point or a baseline for longer -term growth and when volumes \naccel erate that that starting point could be even higher? ", "original_text": "We get often questions from investors around what's the long -term growth algorithm for the \nbusiness. "}, "hash": "9579093410111e2cfcc75bd8edf31602b207ca2e74d8c30557bb9f4f0463979e", "class_name": "RelatedNodeInfo"}}, "text": "So, my question goes back to the  guidance for 2022 for core distribution operating \nincome growth. ", "start_char_idx": 1547, "end_char_idx": 1647, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "593de646-e717-4d4e-bd1d-5b747ba09602": {"__data__": {"id_": "593de646-e717-4d4e-bd1d-5b747ba09602", "embedding": null, "metadata": {"window": "LLC  Q \nYeah, hi.  Good evening.  So, my question goes back to the  guidance for 2022 for core distribution operating \nincome growth.  We get often questions from investors around what's the long -term growth algorithm for the \nbusiness.  I think it's really helpful that you separated your core.  So when we think about this cor e growth of 5% to \n8%, and while it doesn't include some of the COVID impacts, it does include lower volumes in the first half of the \nyear.  \n \n Should we think about that as sort of the starting point or a baseline for longer -term growth and when volumes \naccel erate that that starting point could be even higher? ", "original_text": "We get often questions from investors around what's the long -term growth algorithm for the \nbusiness. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb2c9e93-c23e-423d-9b9e-9fe0127167f0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi.  Good evening.  So, my question goes back to the  guidance for 2022 for core distribution operating \nincome growth.  We get often questions from investors around what's the long -term growth algorithm for the \nbusiness.  I think it's really helpful that you separated your core.  So when we think about this cor e growth of 5% to \n8%, and while it doesn't include some of the COVID impacts, it does include lower volumes in the first half of the \nyear.  \n \n", "original_text": "So, my question goes back to the  guidance for 2022 for core distribution operating \nincome growth. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "79b0c199c0e668cac9591fa2fad4b2e6fe5163ed5cb4e192efbf76b368da2605", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f630778e-171c-4d2c-bab5-1e2b63cba821", "node_type": "1", "metadata": {"window": "Good evening.  So, my question goes back to the  guidance for 2022 for core distribution operating \nincome growth.  We get often questions from investors around what's the long -term growth algorithm for the \nbusiness.  I think it's really helpful that you separated your core.  So when we think about this cor e growth of 5% to \n8%, and while it doesn't include some of the COVID impacts, it does include lower volumes in the first half of the \nyear.  \n \n Should we think about that as sort of the starting point or a baseline for longer -term growth and when volumes \naccel erate that that starting point could be even higher?  And then my follow -up question is just on the opioids \nlitigation. ", "original_text": "I think it's really helpful that you separated your core. "}, "hash": "586ded768ce704b611b96b4c21b7ca1f08669826567a5597f5fd6f976544467a", "class_name": "RelatedNodeInfo"}}, "text": "We get often questions from investors around what's the long -term growth algorithm for the \nbusiness. ", "start_char_idx": 1647, "end_char_idx": 1750, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f630778e-171c-4d2c-bab5-1e2b63cba821": {"__data__": {"id_": "f630778e-171c-4d2c-bab5-1e2b63cba821", "embedding": null, "metadata": {"window": "Good evening.  So, my question goes back to the  guidance for 2022 for core distribution operating \nincome growth.  We get often questions from investors around what's the long -term growth algorithm for the \nbusiness.  I think it's really helpful that you separated your core.  So when we think about this cor e growth of 5% to \n8%, and while it doesn't include some of the COVID impacts, it does include lower volumes in the first half of the \nyear.  \n \n Should we think about that as sort of the starting point or a baseline for longer -term growth and when volumes \naccel erate that that starting point could be even higher?  And then my follow -up question is just on the opioids \nlitigation. ", "original_text": "I think it's really helpful that you separated your core. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "593de646-e717-4d4e-bd1d-5b747ba09602", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah, hi.  Good evening.  So, my question goes back to the  guidance for 2022 for core distribution operating \nincome growth.  We get often questions from investors around what's the long -term growth algorithm for the \nbusiness.  I think it's really helpful that you separated your core.  So when we think about this cor e growth of 5% to \n8%, and while it doesn't include some of the COVID impacts, it does include lower volumes in the first half of the \nyear.  \n \n Should we think about that as sort of the starting point or a baseline for longer -term growth and when volumes \naccel erate that that starting point could be even higher? ", "original_text": "We get often questions from investors around what's the long -term growth algorithm for the \nbusiness. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97d34c82757dc4a3d7bcfbb8f526ccdc6e09c03a2f1e96a8bac4f3aa48cf41d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19f61c7a-5a14-4ef4-99fb-c28527ac8c94", "node_type": "1", "metadata": {"window": "So, my question goes back to the  guidance for 2022 for core distribution operating \nincome growth.  We get often questions from investors around what's the long -term growth algorithm for the \nbusiness.  I think it's really helpful that you separated your core.  So when we think about this cor e growth of 5% to \n8%, and while it doesn't include some of the COVID impacts, it does include lower volumes in the first half of the \nyear.  \n \n Should we think about that as sort of the starting point or a baseline for longer -term growth and when volumes \naccel erate that that starting point could be even higher?  And then my follow -up question is just on the opioids \nlitigation.  Your guidance assumes sort of the same legal expenses in 2022 as in 2021. ", "original_text": "So when we think about this cor e growth of 5% to \n8%, and while it doesn't include some of the COVID impacts, it does include lower volumes in the first half of the \nyear.  \n \n"}, "hash": "9e36ddb5de35c91cc78026d4dcf99c8c872e75fcec25047f3736759a31c9289d", "class_name": "RelatedNodeInfo"}}, "text": "I think it's really helpful that you separated your core. ", "start_char_idx": 1750, "end_char_idx": 1808, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19f61c7a-5a14-4ef4-99fb-c28527ac8c94": {"__data__": {"id_": "19f61c7a-5a14-4ef4-99fb-c28527ac8c94", "embedding": null, "metadata": {"window": "So, my question goes back to the  guidance for 2022 for core distribution operating \nincome growth.  We get often questions from investors around what's the long -term growth algorithm for the \nbusiness.  I think it's really helpful that you separated your core.  So when we think about this cor e growth of 5% to \n8%, and while it doesn't include some of the COVID impacts, it does include lower volumes in the first half of the \nyear.  \n \n Should we think about that as sort of the starting point or a baseline for longer -term growth and when volumes \naccel erate that that starting point could be even higher?  And then my follow -up question is just on the opioids \nlitigation.  Your guidance assumes sort of the same legal expenses in 2022 as in 2021. ", "original_text": "So when we think about this cor e growth of 5% to \n8%, and while it doesn't include some of the COVID impacts, it does include lower volumes in the first half of the \nyear.  \n \n", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f630778e-171c-4d2c-bab5-1e2b63cba821", "node_type": "1", "metadata": {"window": "Good evening.  So, my question goes back to the  guidance for 2022 for core distribution operating \nincome growth.  We get often questions from investors around what's the long -term growth algorithm for the \nbusiness.  I think it's really helpful that you separated your core.  So when we think about this cor e growth of 5% to \n8%, and while it doesn't include some of the COVID impacts, it does include lower volumes in the first half of the \nyear.  \n \n Should we think about that as sort of the starting point or a baseline for longer -term growth and when volumes \naccel erate that that starting point could be even higher?  And then my follow -up question is just on the opioids \nlitigation. ", "original_text": "I think it's really helpful that you separated your core. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5fae0ede021f48b4bbdb6de78ebfefb0d26ce5019210b1dd39d2758c17d49b68", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5bfba8ec-5496-40ce-ab9c-e2c06582bc99", "node_type": "1", "metadata": {"window": "We get often questions from investors around what's the long -term growth algorithm for the \nbusiness.  I think it's really helpful that you separated your core.  So when we think about this cor e growth of 5% to \n8%, and while it doesn't include some of the COVID impacts, it does include lower volumes in the first half of the \nyear.  \n \n Should we think about that as sort of the starting point or a baseline for longer -term growth and when volumes \naccel erate that that starting point could be even higher?  And then my follow -up question is just on the opioids \nlitigation.  Your guidance assumes sort of the same legal expenses in 2022 as in 2021.  So, if we can get any \nupdates on where you are in the process. ", "original_text": "Should we think about that as sort of the starting point or a baseline for longer -term growth and when volumes \naccel erate that that starting point could be even higher? "}, "hash": "e399e3a5f536f5380a7d0ed912a87972a129ea2dc27f2842d6f42ee6a2e7f32a", "class_name": "RelatedNodeInfo"}}, "text": "So when we think about this cor e growth of 5% to \n8%, and while it doesn't include some of the COVID impacts, it does include lower volumes in the first half of the \nyear.  \n \n", "start_char_idx": 1808, "end_char_idx": 1985, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bfba8ec-5496-40ce-ab9c-e2c06582bc99": {"__data__": {"id_": "5bfba8ec-5496-40ce-ab9c-e2c06582bc99", "embedding": null, "metadata": {"window": "We get often questions from investors around what's the long -term growth algorithm for the \nbusiness.  I think it's really helpful that you separated your core.  So when we think about this cor e growth of 5% to \n8%, and while it doesn't include some of the COVID impacts, it does include lower volumes in the first half of the \nyear.  \n \n Should we think about that as sort of the starting point or a baseline for longer -term growth and when volumes \naccel erate that that starting point could be even higher?  And then my follow -up question is just on the opioids \nlitigation.  Your guidance assumes sort of the same legal expenses in 2022 as in 2021.  So, if we can get any \nupdates on where you are in the process. ", "original_text": "Should we think about that as sort of the starting point or a baseline for longer -term growth and when volumes \naccel erate that that starting point could be even higher? ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19f61c7a-5a14-4ef4-99fb-c28527ac8c94", "node_type": "1", "metadata": {"window": "So, my question goes back to the  guidance for 2022 for core distribution operating \nincome growth.  We get often questions from investors around what's the long -term growth algorithm for the \nbusiness.  I think it's really helpful that you separated your core.  So when we think about this cor e growth of 5% to \n8%, and while it doesn't include some of the COVID impacts, it does include lower volumes in the first half of the \nyear.  \n \n Should we think about that as sort of the starting point or a baseline for longer -term growth and when volumes \naccel erate that that starting point could be even higher?  And then my follow -up question is just on the opioids \nlitigation.  Your guidance assumes sort of the same legal expenses in 2022 as in 2021. ", "original_text": "So when we think about this cor e growth of 5% to \n8%, and while it doesn't include some of the COVID impacts, it does include lower volumes in the first half of the \nyear.  \n \n", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "165e5c4e72df3f8aae6ad858b1f7f4721fce52b3db263c2b9322922fc5246644", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9fe9255e-4685-4305-8484-a9bc76173b0d", "node_type": "1", "metadata": {"window": "I think it's really helpful that you separated your core.  So when we think about this cor e growth of 5% to \n8%, and while it doesn't include some of the COVID impacts, it does include lower volumes in the first half of the \nyear.  \n \n Should we think about that as sort of the starting point or a baseline for longer -term growth and when volumes \naccel erate that that starting point could be even higher?  And then my follow -up question is just on the opioids \nlitigation.  Your guidance assumes sort of the same legal expenses in 2022 as in 2021.  So, if we can get any \nupdates on where you are in the process.  Thank you.  \n ", "original_text": "And then my follow -up question is just on the opioids \nlitigation. "}, "hash": "60ddbd53c3451ae80ee6c44de17b66d30f16a7ed637f9b6a67369f06b8c4aefb", "class_name": "RelatedNodeInfo"}}, "text": "Should we think about that as sort of the starting point or a baseline for longer -term growth and when volumes \naccel erate that that starting point could be even higher? ", "start_char_idx": 1985, "end_char_idx": 2157, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9fe9255e-4685-4305-8484-a9bc76173b0d": {"__data__": {"id_": "9fe9255e-4685-4305-8484-a9bc76173b0d", "embedding": null, "metadata": {"window": "I think it's really helpful that you separated your core.  So when we think about this cor e growth of 5% to \n8%, and while it doesn't include some of the COVID impacts, it does include lower volumes in the first half of the \nyear.  \n \n Should we think about that as sort of the starting point or a baseline for longer -term growth and when volumes \naccel erate that that starting point could be even higher?  And then my follow -up question is just on the opioids \nlitigation.  Your guidance assumes sort of the same legal expenses in 2022 as in 2021.  So, if we can get any \nupdates on where you are in the process.  Thank you.  \n ", "original_text": "And then my follow -up question is just on the opioids \nlitigation. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bfba8ec-5496-40ce-ab9c-e2c06582bc99", "node_type": "1", "metadata": {"window": "We get often questions from investors around what's the long -term growth algorithm for the \nbusiness.  I think it's really helpful that you separated your core.  So when we think about this cor e growth of 5% to \n8%, and while it doesn't include some of the COVID impacts, it does include lower volumes in the first half of the \nyear.  \n \n Should we think about that as sort of the starting point or a baseline for longer -term growth and when volumes \naccel erate that that starting point could be even higher?  And then my follow -up question is just on the opioids \nlitigation.  Your guidance assumes sort of the same legal expenses in 2022 as in 2021.  So, if we can get any \nupdates on where you are in the process. ", "original_text": "Should we think about that as sort of the starting point or a baseline for longer -term growth and when volumes \naccel erate that that starting point could be even higher? ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e5e3cd0ae7c318f30680e9658b481dda3630c051a63928b1b38f7f8f12e7c6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "079018c0-5f4d-4396-8524-d225a4fafca4", "node_type": "1", "metadata": {"window": "So when we think about this cor e growth of 5% to \n8%, and while it doesn't include some of the COVID impacts, it does include lower volumes in the first half of the \nyear.  \n \n Should we think about that as sort of the starting point or a baseline for longer -term growth and when volumes \naccel erate that that starting point could be even higher?  And then my follow -up question is just on the opioids \nlitigation.  Your guidance assumes sort of the same legal expenses in 2022 as in 2021.  So, if we can get any \nupdates on where you are in the process.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Your guidance assumes sort of the same legal expenses in 2022 as in 2021. "}, "hash": "2f6058db33be6359c1da921f1a7b284f443569362d27e5e10ae3fc15d8e299ec", "class_name": "RelatedNodeInfo"}}, "text": "And then my follow -up question is just on the opioids \nlitigation. ", "start_char_idx": 2157, "end_char_idx": 2225, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "079018c0-5f4d-4396-8524-d225a4fafca4": {"__data__": {"id_": "079018c0-5f4d-4396-8524-d225a4fafca4", "embedding": null, "metadata": {"window": "So when we think about this cor e growth of 5% to \n8%, and while it doesn't include some of the COVID impacts, it does include lower volumes in the first half of the \nyear.  \n \n Should we think about that as sort of the starting point or a baseline for longer -term growth and when volumes \naccel erate that that starting point could be even higher?  And then my follow -up question is just on the opioids \nlitigation.  Your guidance assumes sort of the same legal expenses in 2022 as in 2021.  So, if we can get any \nupdates on where you are in the process.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Your guidance assumes sort of the same legal expenses in 2022 as in 2021. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9fe9255e-4685-4305-8484-a9bc76173b0d", "node_type": "1", "metadata": {"window": "I think it's really helpful that you separated your core.  So when we think about this cor e growth of 5% to \n8%, and while it doesn't include some of the COVID impacts, it does include lower volumes in the first half of the \nyear.  \n \n Should we think about that as sort of the starting point or a baseline for longer -term growth and when volumes \naccel erate that that starting point could be even higher?  And then my follow -up question is just on the opioids \nlitigation.  Your guidance assumes sort of the same legal expenses in 2022 as in 2021.  So, if we can get any \nupdates on where you are in the process.  Thank you.  \n ", "original_text": "And then my follow -up question is just on the opioids \nlitigation. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94f02adbd57b61ec45b69b95a65b9575960e2f21773768144bf495e3dd624691", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41f6213d-16db-4f48-bfcd-413d0fcf71b4", "node_type": "1", "metadata": {"window": "Should we think about that as sort of the starting point or a baseline for longer -term growth and when volumes \naccel erate that that starting point could be even higher?  And then my follow -up question is just on the opioids \nlitigation.  Your guidance assumes sort of the same legal expenses in 2022 as in 2021.  So, if we can get any \nupdates on where you are in the process.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Ricky, for the question. ", "original_text": "So, if we can get any \nupdates on where you are in the process. "}, "hash": "7aa405a7c17ee08b28caa778e8245db2c754dcaebc289afd4979fb8787021463", "class_name": "RelatedNodeInfo"}}, "text": "Your guidance assumes sort of the same legal expenses in 2022 as in 2021. ", "start_char_idx": 2225, "end_char_idx": 2299, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41f6213d-16db-4f48-bfcd-413d0fcf71b4": {"__data__": {"id_": "41f6213d-16db-4f48-bfcd-413d0fcf71b4", "embedding": null, "metadata": {"window": "Should we think about that as sort of the starting point or a baseline for longer -term growth and when volumes \naccel erate that that starting point could be even higher?  And then my follow -up question is just on the opioids \nlitigation.  Your guidance assumes sort of the same legal expenses in 2022 as in 2021.  So, if we can get any \nupdates on where you are in the process.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Ricky, for the question. ", "original_text": "So, if we can get any \nupdates on where you are in the process. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "079018c0-5f4d-4396-8524-d225a4fafca4", "node_type": "1", "metadata": {"window": "So when we think about this cor e growth of 5% to \n8%, and while it doesn't include some of the COVID impacts, it does include lower volumes in the first half of the \nyear.  \n \n Should we think about that as sort of the starting point or a baseline for longer -term growth and when volumes \naccel erate that that starting point could be even higher?  And then my follow -up question is just on the opioids \nlitigation.  Your guidance assumes sort of the same legal expenses in 2022 as in 2021.  So, if we can get any \nupdates on where you are in the process.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Your guidance assumes sort of the same legal expenses in 2022 as in 2021. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "470710398709085c905899382f7206266a082681ad9ae47ba2a61aad81b57ebd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d106dc4-6ae8-48e5-99ba-9f4bbd8323cd", "node_type": "1", "metadata": {"window": "And then my follow -up question is just on the opioids \nlitigation.  Your guidance assumes sort of the same legal expenses in 2022 as in 2021.  So, if we can get any \nupdates on where you are in the process.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Ricky, for the question.  Let me see if I can start with your first question. ", "original_text": "Thank you.  \n "}, "hash": "5f53193d9352b780def4baefae12622c301f494e2885685d2704c046a48f4162", "class_name": "RelatedNodeInfo"}}, "text": "So, if we can get any \nupdates on where you are in the process. ", "start_char_idx": 2299, "end_char_idx": 2363, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d106dc4-6ae8-48e5-99ba-9f4bbd8323cd": {"__data__": {"id_": "8d106dc4-6ae8-48e5-99ba-9f4bbd8323cd", "embedding": null, "metadata": {"window": "And then my follow -up question is just on the opioids \nlitigation.  Your guidance assumes sort of the same legal expenses in 2022 as in 2021.  So, if we can get any \nupdates on where you are in the process.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Ricky, for the question.  Let me see if I can start with your first question. ", "original_text": "Thank you.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41f6213d-16db-4f48-bfcd-413d0fcf71b4", "node_type": "1", "metadata": {"window": "Should we think about that as sort of the starting point or a baseline for longer -term growth and when volumes \naccel erate that that starting point could be even higher?  And then my follow -up question is just on the opioids \nlitigation.  Your guidance assumes sort of the same legal expenses in 2022 as in 2021.  So, if we can get any \nupdates on where you are in the process.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Ricky, for the question. ", "original_text": "So, if we can get any \nupdates on where you are in the process. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "89e75bdca9321dff7a3935ee751a684897f36fc0994d494762b3d2acd4eb7e67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b81db33e-abe4-4cd2-bdf6-a63efa946e16", "node_type": "1", "metadata": {"window": "Your guidance assumes sort of the same legal expenses in 2022 as in 2021.  So, if we can get any \nupdates on where you are in the process.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Ricky, for the question.  Let me see if I can start with your first question.  Look, we have talked about \nimproving momentum in our business for the las t several quarters, and you referenced 5% to 8% core. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "0828dbf917064432c5c364237ece6d0720398a555e2220875d0d56a4174191ca", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n ", "start_char_idx": 2363, "end_char_idx": 2377, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b81db33e-abe4-4cd2-bdf6-a63efa946e16": {"__data__": {"id_": "b81db33e-abe4-4cd2-bdf6-a63efa946e16", "embedding": null, "metadata": {"window": "Your guidance assumes sort of the same legal expenses in 2022 as in 2021.  So, if we can get any \nupdates on where you are in the process.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Ricky, for the question.  Let me see if I can start with your first question.  Look, we have talked about \nimproving momentum in our business for the las t several quarters, and you referenced 5% to 8% core. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d106dc4-6ae8-48e5-99ba-9f4bbd8323cd", "node_type": "1", "metadata": {"window": "And then my follow -up question is just on the opioids \nlitigation.  Your guidance assumes sort of the same legal expenses in 2022 as in 2021.  So, if we can get any \nupdates on where you are in the process.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Ricky, for the question.  Let me see if I can start with your first question. ", "original_text": "Thank you.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20673bf60a00b4ebede2527bae70d7bf835ea6220836dbafc8c98e7e89d37b08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f450fdd-8053-43c8-94cc-803a26353d83", "node_type": "1", "metadata": {"window": "So, if we can get any \nupdates on where you are in the process.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Ricky, for the question.  Let me see if I can start with your first question.  Look, we have talked about \nimproving momentum in our business for the las t several quarters, and you referenced 5% to 8% core.  That's for \nour US Pharmaceutical business. ", "original_text": "A \nThanks, Ricky, for the question. "}, "hash": "67fabf6625af80097c48ba06ba71faba1aa13f376703d6a544cced06e7e01419", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 2377, "end_char_idx": 2719, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f450fdd-8053-43c8-94cc-803a26353d83": {"__data__": {"id_": "6f450fdd-8053-43c8-94cc-803a26353d83", "embedding": null, "metadata": {"window": "So, if we can get any \nupdates on where you are in the process.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Ricky, for the question.  Let me see if I can start with your first question.  Look, we have talked about \nimproving momentum in our business for the las t several quarters, and you referenced 5% to 8% core.  That's for \nour US Pharmaceutical business. ", "original_text": "A \nThanks, Ricky, for the question. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b81db33e-abe4-4cd2-bdf6-a63efa946e16", "node_type": "1", "metadata": {"window": "Your guidance assumes sort of the same legal expenses in 2022 as in 2021.  So, if we can get any \nupdates on where you are in the process.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Ricky, for the question.  Let me see if I can start with your first question.  Look, we have talked about \nimproving momentum in our business for the las t several quarters, and you referenced 5% to 8% core. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ed770ffee06f261df5e09802c60a5fa06fc9acb0bfa1304a7b97fbfe1311a42f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84c1e973-68b3-4b1e-a69c-cce9298cc746", "node_type": "1", "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Ricky, for the question.  Let me see if I can start with your first question.  Look, we have talked about \nimproving momentum in our business for the las t several quarters, and you referenced 5% to 8% core.  That's for \nour US Pharmaceutical business.  We expect that our business is going to continue to generate improving \nmomentum over the course of FY 2022. ", "original_text": "Let me see if I can start with your first question. "}, "hash": "5ea068e283daa312ca827122d35f0f477c66523c767bd84d36a998f7ca63be52", "class_name": "RelatedNodeInfo"}}, "text": "A \nThanks, Ricky, for the question. ", "start_char_idx": 2719, "end_char_idx": 2755, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84c1e973-68b3-4b1e-a69c-cce9298cc746": {"__data__": {"id_": "84c1e973-68b3-4b1e-a69c-cce9298cc746", "embedding": null, "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Ricky, for the question.  Let me see if I can start with your first question.  Look, we have talked about \nimproving momentum in our business for the las t several quarters, and you referenced 5% to 8% core.  That's for \nour US Pharmaceutical business.  We expect that our business is going to continue to generate improving \nmomentum over the course of FY 2022. ", "original_text": "Let me see if I can start with your first question. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f450fdd-8053-43c8-94cc-803a26353d83", "node_type": "1", "metadata": {"window": "So, if we can get any \nupdates on where you are in the process.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Ricky, for the question.  Let me see if I can start with your first question.  Look, we have talked about \nimproving momentum in our business for the las t several quarters, and you referenced 5% to 8% core.  That's for \nour US Pharmaceutical business. ", "original_text": "A \nThanks, Ricky, for the question. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8bf523ac756dabf9562fdba883042a368f1e7ba4291ea7d3a799f06d284c3a36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27343d8a-e15d-4dd6-ae2c-16ce97af2ac0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Ricky, for the question.  Let me see if I can start with your first question.  Look, we have talked about \nimproving momentum in our business for the las t several quarters, and you referenced 5% to 8% core.  That's for \nour US Pharmaceutical business.  We expect that our business is going to continue to generate improving \nmomentum over the course of FY 2022.  And so we feel very good that we've had a return to  growth in that \nsegment, really the whole business over the last two years, that we would expect that that will continue. ", "original_text": "Look, we have talked about \nimproving momentum in our business for the las t several quarters, and you referenced 5% to 8% core. "}, "hash": "a531386f41ab33003a8be30b976ddddaa2ea5a5c035b0c6e070ce631d2fb0716", "class_name": "RelatedNodeInfo"}}, "text": "Let me see if I can start with your first question. ", "start_char_idx": 2755, "end_char_idx": 2807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27343d8a-e15d-4dd6-ae2c-16ce97af2ac0": {"__data__": {"id_": "27343d8a-e15d-4dd6-ae2c-16ce97af2ac0", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Ricky, for the question.  Let me see if I can start with your first question.  Look, we have talked about \nimproving momentum in our business for the las t several quarters, and you referenced 5% to 8% core.  That's for \nour US Pharmaceutical business.  We expect that our business is going to continue to generate improving \nmomentum over the course of FY 2022.  And so we feel very good that we've had a return to  growth in that \nsegment, really the whole business over the last two years, that we would expect that that will continue. ", "original_text": "Look, we have talked about \nimproving momentum in our business for the las t several quarters, and you referenced 5% to 8% core. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84c1e973-68b3-4b1e-a69c-cce9298cc746", "node_type": "1", "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Ricky, for the question.  Let me see if I can start with your first question.  Look, we have talked about \nimproving momentum in our business for the las t several quarters, and you referenced 5% to 8% core.  That's for \nour US Pharmaceutical business.  We expect that our business is going to continue to generate improving \nmomentum over the course of FY 2022. ", "original_text": "Let me see if I can start with your first question. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d1811de8cbf5a98dbb754aaf9a3132ea0ca16ceebb1a8eb15f9c7a77d5ed619a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68a4ce23-c9b8-4a53-b0af-c45fdc14b3f5", "node_type": "1", "metadata": {"window": "A \nThanks, Ricky, for the question.  Let me see if I can start with your first question.  Look, we have talked about \nimproving momentum in our business for the las t several quarters, and you referenced 5% to 8% core.  That's for \nour US Pharmaceutical business.  We expect that our business is going to continue to generate improving \nmomentum over the course of FY 2022.  And so we feel very good that we've had a return to  growth in that \nsegment, really the whole business over the last two years, that we would expect that that will continue.  We've \ntalked about some of the investments that we're making in the business and how we're leveraging some of those \ninvestments.  \n \n", "original_text": "That's for \nour US Pharmaceutical business. "}, "hash": "e0d1fd897f9f372230ae9b169d36139eae1fcdec51d7f5f318095abfbb75772f", "class_name": "RelatedNodeInfo"}}, "text": "Look, we have talked about \nimproving momentum in our business for the las t several quarters, and you referenced 5% to 8% core. ", "start_char_idx": 2807, "end_char_idx": 2936, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68a4ce23-c9b8-4a53-b0af-c45fdc14b3f5": {"__data__": {"id_": "68a4ce23-c9b8-4a53-b0af-c45fdc14b3f5", "embedding": null, "metadata": {"window": "A \nThanks, Ricky, for the question.  Let me see if I can start with your first question.  Look, we have talked about \nimproving momentum in our business for the las t several quarters, and you referenced 5% to 8% core.  That's for \nour US Pharmaceutical business.  We expect that our business is going to continue to generate improving \nmomentum over the course of FY 2022.  And so we feel very good that we've had a return to  growth in that \nsegment, really the whole business over the last two years, that we would expect that that will continue.  We've \ntalked about some of the investments that we're making in the business and how we're leveraging some of those \ninvestments.  \n \n", "original_text": "That's for \nour US Pharmaceutical business. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27343d8a-e15d-4dd6-ae2c-16ce97af2ac0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Ricky, for the question.  Let me see if I can start with your first question.  Look, we have talked about \nimproving momentum in our business for the las t several quarters, and you referenced 5% to 8% core.  That's for \nour US Pharmaceutical business.  We expect that our business is going to continue to generate improving \nmomentum over the course of FY 2022.  And so we feel very good that we've had a return to  growth in that \nsegment, really the whole business over the last two years, that we would expect that that will continue. ", "original_text": "Look, we have talked about \nimproving momentum in our business for the las t several quarters, and you referenced 5% to 8% core. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fb841812201dcf8a467446996cae381ea2a4af1689f9c0996fff8417585f77a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ef42afe-58c4-4e86-a798-dc3ce35c4644", "node_type": "1", "metadata": {"window": "Let me see if I can start with your first question.  Look, we have talked about \nimproving momentum in our business for the las t several quarters, and you referenced 5% to 8% core.  That's for \nour US Pharmaceutical business.  We expect that our business is going to continue to generate improving \nmomentum over the course of FY 2022.  And so we feel very good that we've had a return to  growth in that \nsegment, really the whole business over the last two years, that we would expect that that will continue.  We've \ntalked about some of the investments that we're making in the business and how we're leveraging some of those \ninvestments.  \n \n And so I think what you should \u2013 you should not think about this as a long -term jumping off point. ", "original_text": "We expect that our business is going to continue to generate improving \nmomentum over the course of FY 2022. "}, "hash": "9395de0057e44741e7cb3fff887d05033186f653e95e3679b94b7ae5da51b1be", "class_name": "RelatedNodeInfo"}}, "text": "That's for \nour US Pharmaceutical business. ", "start_char_idx": 2936, "end_char_idx": 2980, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ef42afe-58c4-4e86-a798-dc3ce35c4644": {"__data__": {"id_": "2ef42afe-58c4-4e86-a798-dc3ce35c4644", "embedding": null, "metadata": {"window": "Let me see if I can start with your first question.  Look, we have talked about \nimproving momentum in our business for the las t several quarters, and you referenced 5% to 8% core.  That's for \nour US Pharmaceutical business.  We expect that our business is going to continue to generate improving \nmomentum over the course of FY 2022.  And so we feel very good that we've had a return to  growth in that \nsegment, really the whole business over the last two years, that we would expect that that will continue.  We've \ntalked about some of the investments that we're making in the business and how we're leveraging some of those \ninvestments.  \n \n And so I think what you should \u2013 you should not think about this as a long -term jumping off point. ", "original_text": "We expect that our business is going to continue to generate improving \nmomentum over the course of FY 2022. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68a4ce23-c9b8-4a53-b0af-c45fdc14b3f5", "node_type": "1", "metadata": {"window": "A \nThanks, Ricky, for the question.  Let me see if I can start with your first question.  Look, we have talked about \nimproving momentum in our business for the las t several quarters, and you referenced 5% to 8% core.  That's for \nour US Pharmaceutical business.  We expect that our business is going to continue to generate improving \nmomentum over the course of FY 2022.  And so we feel very good that we've had a return to  growth in that \nsegment, really the whole business over the last two years, that we would expect that that will continue.  We've \ntalked about some of the investments that we're making in the business and how we're leveraging some of those \ninvestments.  \n \n", "original_text": "That's for \nour US Pharmaceutical business. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea3d285767eb74f3bbfb75ca257e4eb6c2d078f14cc1c7ef9aa516fb080ddb69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4de5ba6-4b1c-4031-b88f-09af677a551c", "node_type": "1", "metadata": {"window": "Look, we have talked about \nimproving momentum in our business for the las t several quarters, and you referenced 5% to 8% core.  That's for \nour US Pharmaceutical business.  We expect that our business is going to continue to generate improving \nmomentum over the course of FY 2022.  And so we feel very good that we've had a return to  growth in that \nsegment, really the whole business over the last two years, that we would expect that that will continue.  We've \ntalked about some of the investments that we're making in the business and how we're leveraging some of those \ninvestments.  \n \n And so I think what you should \u2013 you should not think about this as a long -term jumping off point.  We don't \nprovide long -term guidance and I would hesitate for you to just take that 5% to 8% and take it out over the long \nterm. ", "original_text": "And so we feel very good that we've had a return to  growth in that \nsegment, really the whole business over the last two years, that we would expect that that will continue. "}, "hash": "6ff7aa632fb396533936a8d7238afc65a587450c6738fa4f9a656d2f82b0c622", "class_name": "RelatedNodeInfo"}}, "text": "We expect that our business is going to continue to generate improving \nmomentum over the course of FY 2022. ", "start_char_idx": 2980, "end_char_idx": 3089, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4de5ba6-4b1c-4031-b88f-09af677a551c": {"__data__": {"id_": "b4de5ba6-4b1c-4031-b88f-09af677a551c", "embedding": null, "metadata": {"window": "Look, we have talked about \nimproving momentum in our business for the las t several quarters, and you referenced 5% to 8% core.  That's for \nour US Pharmaceutical business.  We expect that our business is going to continue to generate improving \nmomentum over the course of FY 2022.  And so we feel very good that we've had a return to  growth in that \nsegment, really the whole business over the last two years, that we would expect that that will continue.  We've \ntalked about some of the investments that we're making in the business and how we're leveraging some of those \ninvestments.  \n \n And so I think what you should \u2013 you should not think about this as a long -term jumping off point.  We don't \nprovide long -term guidance and I would hesitate for you to just take that 5% to 8% and take it out over the long \nterm. ", "original_text": "And so we feel very good that we've had a return to  growth in that \nsegment, really the whole business over the last two years, that we would expect that that will continue. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ef42afe-58c4-4e86-a798-dc3ce35c4644", "node_type": "1", "metadata": {"window": "Let me see if I can start with your first question.  Look, we have talked about \nimproving momentum in our business for the las t several quarters, and you referenced 5% to 8% core.  That's for \nour US Pharmaceutical business.  We expect that our business is going to continue to generate improving \nmomentum over the course of FY 2022.  And so we feel very good that we've had a return to  growth in that \nsegment, really the whole business over the last two years, that we would expect that that will continue.  We've \ntalked about some of the investments that we're making in the business and how we're leveraging some of those \ninvestments.  \n \n And so I think what you should \u2013 you should not think about this as a long -term jumping off point. ", "original_text": "We expect that our business is going to continue to generate improving \nmomentum over the course of FY 2022. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f02e37ac0127fd6fc334ebc27e0fd89cf8a7f0e9d2788f3320ffdf65edaa25b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6cc768d-f809-4de4-ab21-b7db3c1d5355", "node_type": "1", "metadata": {"window": "That's for \nour US Pharmaceutical business.  We expect that our business is going to continue to generate improving \nmomentum over the course of FY 2022.  And so we feel very good that we've had a return to  growth in that \nsegment, really the whole business over the last two years, that we would expect that that will continue.  We've \ntalked about some of the investments that we're making in the business and how we're leveraging some of those \ninvestments.  \n \n And so I think what you should \u2013 you should not think about this as a long -term jumping off point.  We don't \nprovide long -term guidance and I would hesitate for you to just take that 5% to 8% and take it out over the long \nterm.  But what you should take from thi s is we expect continuing improvement in utilization, continuing \nmomentum in the business, and I think our core growth rate really reflects that. ", "original_text": "We've \ntalked about some of the investments that we're making in the business and how we're leveraging some of those \ninvestments.  \n \n"}, "hash": "808ab3bce420687753daf4011212f05bba70fd06f48fe1abfe21be9fb6fb6fe6", "class_name": "RelatedNodeInfo"}}, "text": "And so we feel very good that we've had a return to  growth in that \nsegment, really the whole business over the last two years, that we would expect that that will continue. ", "start_char_idx": 3089, "end_char_idx": 3264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6cc768d-f809-4de4-ab21-b7db3c1d5355": {"__data__": {"id_": "f6cc768d-f809-4de4-ab21-b7db3c1d5355", "embedding": null, "metadata": {"window": "That's for \nour US Pharmaceutical business.  We expect that our business is going to continue to generate improving \nmomentum over the course of FY 2022.  And so we feel very good that we've had a return to  growth in that \nsegment, really the whole business over the last two years, that we would expect that that will continue.  We've \ntalked about some of the investments that we're making in the business and how we're leveraging some of those \ninvestments.  \n \n And so I think what you should \u2013 you should not think about this as a long -term jumping off point.  We don't \nprovide long -term guidance and I would hesitate for you to just take that 5% to 8% and take it out over the long \nterm.  But what you should take from thi s is we expect continuing improvement in utilization, continuing \nmomentum in the business, and I think our core growth rate really reflects that. ", "original_text": "We've \ntalked about some of the investments that we're making in the business and how we're leveraging some of those \ninvestments.  \n \n", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4de5ba6-4b1c-4031-b88f-09af677a551c", "node_type": "1", "metadata": {"window": "Look, we have talked about \nimproving momentum in our business for the las t several quarters, and you referenced 5% to 8% core.  That's for \nour US Pharmaceutical business.  We expect that our business is going to continue to generate improving \nmomentum over the course of FY 2022.  And so we feel very good that we've had a return to  growth in that \nsegment, really the whole business over the last two years, that we would expect that that will continue.  We've \ntalked about some of the investments that we're making in the business and how we're leveraging some of those \ninvestments.  \n \n And so I think what you should \u2013 you should not think about this as a long -term jumping off point.  We don't \nprovide long -term guidance and I would hesitate for you to just take that 5% to 8% and take it out over the long \nterm. ", "original_text": "And so we feel very good that we've had a return to  growth in that \nsegment, really the whole business over the last two years, that we would expect that that will continue. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba483ba5ec22f54fff707a9c3c011799dfadaf6ac123059ade9b9405e61eac1b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a99a24b-c139-4793-979f-cd692689fe50", "node_type": "1", "metadata": {"window": "We expect that our business is going to continue to generate improving \nmomentum over the course of FY 2022.  And so we feel very good that we've had a return to  growth in that \nsegment, really the whole business over the last two years, that we would expect that that will continue.  We've \ntalked about some of the investments that we're making in the business and how we're leveraging some of those \ninvestments.  \n \n And so I think what you should \u2013 you should not think about this as a long -term jumping off point.  We don't \nprovide long -term guidance and I would hesitate for you to just take that 5% to 8% and take it out over the long \nterm.  But what you should take from thi s is we expect continuing improvement in utilization, continuing \nmomentum in the business, and I think our core growth rate really reflects that.  Brian, if you wanted to...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And so I think what you should \u2013 you should not think about this as a long -term jumping off point. "}, "hash": "2ae2b906875598b7c3b93c2c441ba15cf26ac1ef2b6ad9ed803467f56c5d2fdd", "class_name": "RelatedNodeInfo"}}, "text": "We've \ntalked about some of the investments that we're making in the business and how we're leveraging some of those \ninvestments.  \n \n", "start_char_idx": 3264, "end_char_idx": 3399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a99a24b-c139-4793-979f-cd692689fe50": {"__data__": {"id_": "8a99a24b-c139-4793-979f-cd692689fe50", "embedding": null, "metadata": {"window": "We expect that our business is going to continue to generate improving \nmomentum over the course of FY 2022.  And so we feel very good that we've had a return to  growth in that \nsegment, really the whole business over the last two years, that we would expect that that will continue.  We've \ntalked about some of the investments that we're making in the business and how we're leveraging some of those \ninvestments.  \n \n And so I think what you should \u2013 you should not think about this as a long -term jumping off point.  We don't \nprovide long -term guidance and I would hesitate for you to just take that 5% to 8% and take it out over the long \nterm.  But what you should take from thi s is we expect continuing improvement in utilization, continuing \nmomentum in the business, and I think our core growth rate really reflects that.  Brian, if you wanted to...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And so I think what you should \u2013 you should not think about this as a long -term jumping off point. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6cc768d-f809-4de4-ab21-b7db3c1d5355", "node_type": "1", "metadata": {"window": "That's for \nour US Pharmaceutical business.  We expect that our business is going to continue to generate improving \nmomentum over the course of FY 2022.  And so we feel very good that we've had a return to  growth in that \nsegment, really the whole business over the last two years, that we would expect that that will continue.  We've \ntalked about some of the investments that we're making in the business and how we're leveraging some of those \ninvestments.  \n \n And so I think what you should \u2013 you should not think about this as a long -term jumping off point.  We don't \nprovide long -term guidance and I would hesitate for you to just take that 5% to 8% and take it out over the long \nterm.  But what you should take from thi s is we expect continuing improvement in utilization, continuing \nmomentum in the business, and I think our core growth rate really reflects that. ", "original_text": "We've \ntalked about some of the investments that we're making in the business and how we're leveraging some of those \ninvestments.  \n \n", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a6ef235aa0baa99ca1cff5c39c39d89057c7c56ff94c2e43bb19155edc4d442", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "642a7a29-65f9-418b-9a89-f172fe33caf3", "node_type": "1", "metadata": {"window": "And so we feel very good that we've had a return to  growth in that \nsegment, really the whole business over the last two years, that we would expect that that will continue.  We've \ntalked about some of the investments that we're making in the business and how we're leveraging some of those \ninvestments.  \n \n And so I think what you should \u2013 you should not think about this as a long -term jumping off point.  We don't \nprovide long -term guidance and I would hesitate for you to just take that 5% to 8% and take it out over the long \nterm.  But what you should take from thi s is we expect continuing improvement in utilization, continuing \nmomentum in the business, and I think our core growth rate really reflects that.  Brian, if you wanted to...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "We don't \nprovide long -term guidance and I would hesitate for you to just take that 5% to 8% and take it out over the long \nterm. "}, "hash": "51dcdb30b7811fc5a818930ecb0b6dc6050160bad07405aef8030f8c9491f4ca", "class_name": "RelatedNodeInfo"}}, "text": "And so I think what you should \u2013 you should not think about this as a long -term jumping off point. ", "start_char_idx": 3399, "end_char_idx": 3499, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "642a7a29-65f9-418b-9a89-f172fe33caf3": {"__data__": {"id_": "642a7a29-65f9-418b-9a89-f172fe33caf3", "embedding": null, "metadata": {"window": "And so we feel very good that we've had a return to  growth in that \nsegment, really the whole business over the last two years, that we would expect that that will continue.  We've \ntalked about some of the investments that we're making in the business and how we're leveraging some of those \ninvestments.  \n \n And so I think what you should \u2013 you should not think about this as a long -term jumping off point.  We don't \nprovide long -term guidance and I would hesitate for you to just take that 5% to 8% and take it out over the long \nterm.  But what you should take from thi s is we expect continuing improvement in utilization, continuing \nmomentum in the business, and I think our core growth rate really reflects that.  Brian, if you wanted to...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "We don't \nprovide long -term guidance and I would hesitate for you to just take that 5% to 8% and take it out over the long \nterm. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a99a24b-c139-4793-979f-cd692689fe50", "node_type": "1", "metadata": {"window": "We expect that our business is going to continue to generate improving \nmomentum over the course of FY 2022.  And so we feel very good that we've had a return to  growth in that \nsegment, really the whole business over the last two years, that we would expect that that will continue.  We've \ntalked about some of the investments that we're making in the business and how we're leveraging some of those \ninvestments.  \n \n And so I think what you should \u2013 you should not think about this as a long -term jumping off point.  We don't \nprovide long -term guidance and I would hesitate for you to just take that 5% to 8% and take it out over the long \nterm.  But what you should take from thi s is we expect continuing improvement in utilization, continuing \nmomentum in the business, and I think our core growth rate really reflects that.  Brian, if you wanted to...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And so I think what you should \u2013 you should not think about this as a long -term jumping off point. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9ff89eac08157bc8b58d08ebfd010c1981f7bfaa6219e5ce7a6879311f7caf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "184b3869-a5eb-4a3b-b2b7-22bcad9bf306", "node_type": "1", "metadata": {"window": "We've \ntalked about some of the investments that we're making in the business and how we're leveraging some of those \ninvestments.  \n \n And so I think what you should \u2013 you should not think about this as a long -term jumping off point.  We don't \nprovide long -term guidance and I would hesitate for you to just take that 5% to 8% and take it out over the long \nterm.  But what you should take from thi s is we expect continuing improvement in utilization, continuing \nmomentum in the business, and I think our core growth rate really reflects that.  Brian, if you wanted to...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  And, also embedded in the US pharma segment is the assumption that the flu season returns to normal. \n", "original_text": "But what you should take from thi s is we expect continuing improvement in utilization, continuing \nmomentum in the business, and I think our core growth rate really reflects that. "}, "hash": "d8a6b0263948db269a61dff178da4b87e85dbcb5b09359f0bb582f5b7b15b403", "class_name": "RelatedNodeInfo"}}, "text": "We don't \nprovide long -term guidance and I would hesitate for you to just take that 5% to 8% and take it out over the long \nterm. ", "start_char_idx": 3499, "end_char_idx": 3630, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "184b3869-a5eb-4a3b-b2b7-22bcad9bf306": {"__data__": {"id_": "184b3869-a5eb-4a3b-b2b7-22bcad9bf306", "embedding": null, "metadata": {"window": "We've \ntalked about some of the investments that we're making in the business and how we're leveraging some of those \ninvestments.  \n \n And so I think what you should \u2013 you should not think about this as a long -term jumping off point.  We don't \nprovide long -term guidance and I would hesitate for you to just take that 5% to 8% and take it out over the long \nterm.  But what you should take from thi s is we expect continuing improvement in utilization, continuing \nmomentum in the business, and I think our core growth rate really reflects that.  Brian, if you wanted to...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  And, also embedded in the US pharma segment is the assumption that the flu season returns to normal. \n", "original_text": "But what you should take from thi s is we expect continuing improvement in utilization, continuing \nmomentum in the business, and I think our core growth rate really reflects that. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "642a7a29-65f9-418b-9a89-f172fe33caf3", "node_type": "1", "metadata": {"window": "And so we feel very good that we've had a return to  growth in that \nsegment, really the whole business over the last two years, that we would expect that that will continue.  We've \ntalked about some of the investments that we're making in the business and how we're leveraging some of those \ninvestments.  \n \n And so I think what you should \u2013 you should not think about this as a long -term jumping off point.  We don't \nprovide long -term guidance and I would hesitate for you to just take that 5% to 8% and take it out over the long \nterm.  But what you should take from thi s is we expect continuing improvement in utilization, continuing \nmomentum in the business, and I think our core growth rate really reflects that.  Brian, if you wanted to...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "We don't \nprovide long -term guidance and I would hesitate for you to just take that 5% to 8% and take it out over the long \nterm. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d02cb0ec1fb6c3501adb0acdd7ff2ef326a044e363967cba960aefd47dd69d58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea6fb941-62ae-4bb3-afad-a0e472e44104", "node_type": "1", "metadata": {"window": "And so I think what you should \u2013 you should not think about this as a long -term jumping off point.  We don't \nprovide long -term guidance and I would hesitate for you to just take that 5% to 8% and take it out over the long \nterm.  But what you should take from thi s is we expect continuing improvement in utilization, continuing \nmomentum in the business, and I think our core growth rate really reflects that.  Brian, if you wanted to...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  And, also embedded in the US pharma segment is the assumption that the flu season returns to normal. \n That, historically, would have been in the run rate and not incremental growth for the segment.  \n \n", "original_text": "Brian, if you wanted to...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "0f602b3136245fcc5a6a254895f65e14f41f92880ccd37f9267b9a14ba49a177", "class_name": "RelatedNodeInfo"}}, "text": "But what you should take from thi s is we expect continuing improvement in utilization, continuing \nmomentum in the business, and I think our core growth rate really reflects that. ", "start_char_idx": 3630, "end_char_idx": 3811, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea6fb941-62ae-4bb3-afad-a0e472e44104": {"__data__": {"id_": "ea6fb941-62ae-4bb3-afad-a0e472e44104", "embedding": null, "metadata": {"window": "And so I think what you should \u2013 you should not think about this as a long -term jumping off point.  We don't \nprovide long -term guidance and I would hesitate for you to just take that 5% to 8% and take it out over the long \nterm.  But what you should take from thi s is we expect continuing improvement in utilization, continuing \nmomentum in the business, and I think our core growth rate really reflects that.  Brian, if you wanted to...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  And, also embedded in the US pharma segment is the assumption that the flu season returns to normal. \n That, historically, would have been in the run rate and not incremental growth for the segment.  \n \n", "original_text": "Brian, if you wanted to...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "184b3869-a5eb-4a3b-b2b7-22bcad9bf306", "node_type": "1", "metadata": {"window": "We've \ntalked about some of the investments that we're making in the business and how we're leveraging some of those \ninvestments.  \n \n And so I think what you should \u2013 you should not think about this as a long -term jumping off point.  We don't \nprovide long -term guidance and I would hesitate for you to just take that 5% to 8% and take it out over the long \nterm.  But what you should take from thi s is we expect continuing improvement in utilization, continuing \nmomentum in the business, and I think our core growth rate really reflects that.  Brian, if you wanted to...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  And, also embedded in the US pharma segment is the assumption that the flu season returns to normal. \n", "original_text": "But what you should take from thi s is we expect continuing improvement in utilization, continuing \nmomentum in the business, and I think our core growth rate really reflects that. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "535422880a322e502838b33239ce9bdf65d7a2a295a045e60dbf63316b7cbee3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d99ab600-d4e6-4682-b243-88e550fcfa6c", "node_type": "1", "metadata": {"window": "We don't \nprovide long -term guidance and I would hesitate for you to just take that 5% to 8% and take it out over the long \nterm.  But what you should take from thi s is we expect continuing improvement in utilization, continuing \nmomentum in the business, and I think our core growth rate really reflects that.  Brian, if you wanted to...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  And, also embedded in the US pharma segment is the assumption that the flu season returns to normal. \n That, historically, would have been in the run rate and not incremental growth for the segment.  \n \n Relative to opioids, the second part of your question, Ric ky, we continue to have constructive discussions around \na broad settlement framework and structure. ", "original_text": "A \nYeah. "}, "hash": "a2a6019da394f7f68c29ad6350c6f7104ffb4dc5df984a5eb49b96adc7705df7", "class_name": "RelatedNodeInfo"}}, "text": "Brian, if you wanted to...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 3811, "end_char_idx": 4170, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d99ab600-d4e6-4682-b243-88e550fcfa6c": {"__data__": {"id_": "d99ab600-d4e6-4682-b243-88e550fcfa6c", "embedding": null, "metadata": {"window": "We don't \nprovide long -term guidance and I would hesitate for you to just take that 5% to 8% and take it out over the long \nterm.  But what you should take from thi s is we expect continuing improvement in utilization, continuing \nmomentum in the business, and I think our core growth rate really reflects that.  Brian, if you wanted to...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  And, also embedded in the US pharma segment is the assumption that the flu season returns to normal. \n That, historically, would have been in the run rate and not incremental growth for the segment.  \n \n Relative to opioids, the second part of your question, Ric ky, we continue to have constructive discussions around \na broad settlement framework and structure. ", "original_text": "A \nYeah. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea6fb941-62ae-4bb3-afad-a0e472e44104", "node_type": "1", "metadata": {"window": "And so I think what you should \u2013 you should not think about this as a long -term jumping off point.  We don't \nprovide long -term guidance and I would hesitate for you to just take that 5% to 8% and take it out over the long \nterm.  But what you should take from thi s is we expect continuing improvement in utilization, continuing \nmomentum in the business, and I think our core growth rate really reflects that.  Brian, if you wanted to...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  And, also embedded in the US pharma segment is the assumption that the flu season returns to normal. \n That, historically, would have been in the run rate and not incremental growth for the segment.  \n \n", "original_text": "Brian, if you wanted to...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a1d0edc7afabf07be458c29942c1f46d5e4ae9b64d3d97e233b0319ce64af798", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2683e485-48c1-4ff2-8a6b-2e7d59711964", "node_type": "1", "metadata": {"window": "But what you should take from thi s is we expect continuing improvement in utilization, continuing \nmomentum in the business, and I think our core growth rate really reflects that.  Brian, if you wanted to...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  And, also embedded in the US pharma segment is the assumption that the flu season returns to normal. \n That, historically, would have been in the run rate and not incremental growth for the segment.  \n \n Relative to opioids, the second part of your question, Ric ky, we continue to have constructive discussions around \na broad settlement framework and structure.  The parameters of that have been pretty consistent over the last ", "original_text": "And, also embedded in the US pharma segment is the assumption that the flu season returns to normal. \n"}, "hash": "994bc1c0b53578c88ee090da3febeeb2a6d2dff3990cc08d21b93ccbb8e286a9", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 4170, "end_char_idx": 4179, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2683e485-48c1-4ff2-8a6b-2e7d59711964": {"__data__": {"id_": "2683e485-48c1-4ff2-8a6b-2e7d59711964", "embedding": null, "metadata": {"window": "But what you should take from thi s is we expect continuing improvement in utilization, continuing \nmomentum in the business, and I think our core growth rate really reflects that.  Brian, if you wanted to...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  And, also embedded in the US pharma segment is the assumption that the flu season returns to normal. \n That, historically, would have been in the run rate and not incremental growth for the segment.  \n \n Relative to opioids, the second part of your question, Ric ky, we continue to have constructive discussions around \na broad settlement framework and structure.  The parameters of that have been pretty consistent over the last ", "original_text": "And, also embedded in the US pharma segment is the assumption that the flu season returns to normal. \n", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d99ab600-d4e6-4682-b243-88e550fcfa6c", "node_type": "1", "metadata": {"window": "We don't \nprovide long -term guidance and I would hesitate for you to just take that 5% to 8% and take it out over the long \nterm.  But what you should take from thi s is we expect continuing improvement in utilization, continuing \nmomentum in the business, and I think our core growth rate really reflects that.  Brian, if you wanted to...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  And, also embedded in the US pharma segment is the assumption that the flu season returns to normal. \n That, historically, would have been in the run rate and not incremental growth for the segment.  \n \n Relative to opioids, the second part of your question, Ric ky, we continue to have constructive discussions around \na broad settlement framework and structure. ", "original_text": "A \nYeah. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "636f46999867be43de7f83581c40f419d7950b3ed5026bedf3522e07c9b3305d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e38ddda0-bf89-4111-b637-4a28f550d461", "node_type": "1", "metadata": {"window": "Brian, if you wanted to...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  And, also embedded in the US pharma segment is the assumption that the flu season returns to normal. \n That, historically, would have been in the run rate and not incremental growth for the segment.  \n \n Relative to opioids, the second part of your question, Ric ky, we continue to have constructive discussions around \na broad settlement framework and structure.  The parameters of that have been pretty consistent over the last ", "original_text": "That, historically, would have been in the run rate and not incremental growth for the segment.  \n \n"}, "hash": "f5585ebe7f18616c254ee5128ace472a47ef0de3cb6d773e48a9914cba666317", "class_name": "RelatedNodeInfo"}}, "text": "And, also embedded in the US pharma segment is the assumption that the flu season returns to normal. \n", "start_char_idx": 4179, "end_char_idx": 4281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e38ddda0-bf89-4111-b637-4a28f550d461": {"__data__": {"id_": "e38ddda0-bf89-4111-b637-4a28f550d461", "embedding": null, "metadata": {"window": "Brian, if you wanted to...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  And, also embedded in the US pharma segment is the assumption that the flu season returns to normal. \n That, historically, would have been in the run rate and not incremental growth for the segment.  \n \n Relative to opioids, the second part of your question, Ric ky, we continue to have constructive discussions around \na broad settlement framework and structure.  The parameters of that have been pretty consistent over the last ", "original_text": "That, historically, would have been in the run rate and not incremental growth for the segment.  \n \n", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2683e485-48c1-4ff2-8a6b-2e7d59711964", "node_type": "1", "metadata": {"window": "But what you should take from thi s is we expect continuing improvement in utilization, continuing \nmomentum in the business, and I think our core growth rate really reflects that.  Brian, if you wanted to...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  And, also embedded in the US pharma segment is the assumption that the flu season returns to normal. \n That, historically, would have been in the run rate and not incremental growth for the segment.  \n \n Relative to opioids, the second part of your question, Ric ky, we continue to have constructive discussions around \na broad settlement framework and structure.  The parameters of that have been pretty consistent over the last ", "original_text": "And, also embedded in the US pharma segment is the assumption that the flu season returns to normal. \n", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "42dee96e6415b22c836d255cc5c42812c393684f06642d3a1b40698ff127d355", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5907f793-b866-4199-924c-ffb969315bf4", "node_type": "1", "metadata": {"window": "A \nYeah.  And, also embedded in the US pharma segment is the assumption that the flu season returns to normal. \n That, historically, would have been in the run rate and not incremental growth for the segment.  \n \n Relative to opioids, the second part of your question, Ric ky, we continue to have constructive discussions around \na broad settlement framework and structure.  The parameters of that have been pretty consistent over the last ", "original_text": "Relative to opioids, the second part of your question, Ric ky, we continue to have constructive discussions around \na broad settlement framework and structure. "}, "hash": "6dfd31a345ee61d7e55e46fe1472b747e11fb14509fd227c440e629824cecb0a", "class_name": "RelatedNodeInfo"}}, "text": "That, historically, would have been in the run rate and not incremental growth for the segment.  \n \n", "start_char_idx": 4281, "end_char_idx": 4381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5907f793-b866-4199-924c-ffb969315bf4": {"__data__": {"id_": "5907f793-b866-4199-924c-ffb969315bf4", "embedding": null, "metadata": {"window": "A \nYeah.  And, also embedded in the US pharma segment is the assumption that the flu season returns to normal. \n That, historically, would have been in the run rate and not incremental growth for the segment.  \n \n Relative to opioids, the second part of your question, Ric ky, we continue to have constructive discussions around \na broad settlement framework and structure.  The parameters of that have been pretty consistent over the last ", "original_text": "Relative to opioids, the second part of your question, Ric ky, we continue to have constructive discussions around \na broad settlement framework and structure. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e38ddda0-bf89-4111-b637-4a28f550d461", "node_type": "1", "metadata": {"window": "Brian, if you wanted to...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  And, also embedded in the US pharma segment is the assumption that the flu season returns to normal. \n That, historically, would have been in the run rate and not incremental growth for the segment.  \n \n Relative to opioids, the second part of your question, Ric ky, we continue to have constructive discussions around \na broad settlement framework and structure.  The parameters of that have been pretty consistent over the last ", "original_text": "That, historically, would have been in the run rate and not incremental growth for the segment.  \n \n", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e86ed0da8e27484302607465b47510125f7faad3a8b4994a8ca38a76c920b87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65162f28-f7c4-4a8e-b264-ef9843ad4885", "node_type": "1", "metadata": {"window": "And, also embedded in the US pharma segment is the assumption that the flu season returns to normal. \n That, historically, would have been in the run rate and not incremental growth for the segment.  \n \n Relative to opioids, the second part of your question, Ric ky, we continue to have constructive discussions around \na broad settlement framework and structure.  The parameters of that have been pretty consistent over the last ", "original_text": "The parameters of that have been pretty consistent over the last "}, "hash": "db205eda376da27633ab1dd67b41e95b88df767bf7dbbda592761efe211c3282", "class_name": "RelatedNodeInfo"}}, "text": "Relative to opioids, the second part of your question, Ric ky, we continue to have constructive discussions around \na broad settlement framework and structure. ", "start_char_idx": 4381, "end_char_idx": 4541, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65162f28-f7c4-4a8e-b264-ef9843ad4885": {"__data__": {"id_": "65162f28-f7c4-4a8e-b264-ef9843ad4885", "embedding": null, "metadata": {"window": "And, also embedded in the US pharma segment is the assumption that the flu season returns to normal. \n That, historically, would have been in the run rate and not incremental growth for the segment.  \n \n Relative to opioids, the second part of your question, Ric ky, we continue to have constructive discussions around \na broad settlement framework and structure.  The parameters of that have been pretty consistent over the last ", "original_text": "The parameters of that have been pretty consistent over the last ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a0c1db226c47066446cffc9a3f6aa3eb0a03d1fd28ab87ed227b4860bf01c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5907f793-b866-4199-924c-ffb969315bf4", "node_type": "1", "metadata": {"window": "A \nYeah.  And, also embedded in the US pharma segment is the assumption that the flu season returns to normal. \n That, historically, would have been in the run rate and not incremental growth for the segment.  \n \n Relative to opioids, the second part of your question, Ric ky, we continue to have constructive discussions around \na broad settlement framework and structure.  The parameters of that have been pretty consistent over the last ", "original_text": "Relative to opioids, the second part of your question, Ric ky, we continue to have constructive discussions around \na broad settlement framework and structure. ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2cd7eec90e06c59eb30da424867eeaea0aac4bab4c17d5cf6df1783bceebaae5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8dde9cbc-516b-4c3e-b117-afa0e1d7dc09", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nseveral quarters.  I'm very encouraged.  We're hopeful we can reach resolution. ", "original_text": "McKesson Corp.  "}, "hash": "b0652d4cc2cbc4fae87fb12b9e37a35aa47860816d6339665a07e768bac43e6a", "class_name": "RelatedNodeInfo"}}, "text": "The parameters of that have been pretty consistent over the last ", "start_char_idx": 4541, "end_char_idx": 4606, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8dde9cbc-516b-4c3e-b117-afa0e1d7dc09": {"__data__": {"id_": "8dde9cbc-516b-4c3e-b117-afa0e1d7dc09", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nseveral quarters.  I'm very encouraged.  We're hopeful we can reach resolution. ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610365c071c7b4a48816accdeeb3e7409dbdef61529d5837d381384ca57cc1fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65162f28-f7c4-4a8e-b264-ef9843ad4885", "node_type": "1", "metadata": {"window": "And, also embedded in the US pharma segment is the assumption that the flu season returns to normal. \n That, historically, would have been in the run rate and not incremental growth for the segment.  \n \n Relative to opioids, the second part of your question, Ric ky, we continue to have constructive discussions around \na broad settlement framework and structure.  The parameters of that have been pretty consistent over the last ", "original_text": "The parameters of that have been pretty consistent over the last ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aac549c7f980cebe63870dd706e173ce6d6258c77853d466e4d09fcdbfc078aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22c1c59d-a956-46b0-8755-1fb296b4d386", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nseveral quarters.  I'm very encouraged.  We're hopeful we can reach resolution.  We think it w ill be great for patients \nand communities.  \n \n", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nseveral quarters. "}, "hash": "b2fffaf32eb4c57e6aac7365a2bbb21af8780b4e68fde0ae5c6116a09e7a3792", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22c1c59d-a956-46b0-8755-1fb296b4d386": {"__data__": {"id_": "22c1c59d-a956-46b0-8755-1fb296b4d386", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nseveral quarters.  I'm very encouraged.  We're hopeful we can reach resolution.  We think it w ill be great for patients \nand communities.  \n \n", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nseveral quarters. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610365c071c7b4a48816accdeeb3e7409dbdef61529d5837d381384ca57cc1fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8dde9cbc-516b-4c3e-b117-afa0e1d7dc09", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nseveral quarters.  I'm very encouraged.  We're hopeful we can reach resolution. ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d1bb25313f1ca92fc6d3e37df25d397182d82a21e6c485c5aa4fb9c550715df1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5ef75bb-3f84-43ab-84a5-41fe0a9afc12", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nseveral quarters.  I'm very encouraged.  We're hopeful we can reach resolution.  We think it w ill be great for patients \nand communities.  \n \n But as we said last quarter, until we have a deal, we are going to continue to prepare to defend ourselves, and \nwe've made significant investments in that defense. ", "original_text": "I'm very encouraged. "}, "hash": "56730799cfbae17d000edaa4b89008cdafeee204e4d488fa3ed903b49c446a59", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nseveral quarters. ", "start_char_idx": 16, "end_char_idx": 199, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5ef75bb-3f84-43ab-84a5-41fe0a9afc12": {"__data__": {"id_": "b5ef75bb-3f84-43ab-84a5-41fe0a9afc12", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nseveral quarters.  I'm very encouraged.  We're hopeful we can reach resolution.  We think it w ill be great for patients \nand communities.  \n \n But as we said last quarter, until we have a deal, we are going to continue to prepare to defend ourselves, and \nwe've made significant investments in that defense. ", "original_text": "I'm very encouraged. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610365c071c7b4a48816accdeeb3e7409dbdef61529d5837d381384ca57cc1fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22c1c59d-a956-46b0-8755-1fb296b4d386", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nseveral quarters.  I'm very encouraged.  We're hopeful we can reach resolution.  We think it w ill be great for patients \nand communities.  \n \n", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nseveral quarters. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "75940422a6fcded436166469f4a479e84050c7da8dff4e2f36d725a98965ccf0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3800a2e3-994b-4aea-9bcd-33c78d67c8bc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nseveral quarters.  I'm very encouraged.  We're hopeful we can reach resolution.  We think it w ill be great for patients \nand communities.  \n \n But as we said last quarter, until we have a deal, we are going to continue to prepare to defend ourselves, and \nwe've made significant investments in that defense.  We're prepared to rigorously and vigorously defe nd ourselves \nin court if it comes to that. ", "original_text": "We're hopeful we can reach resolution. "}, "hash": "f491ddf21d27f0cdb1f1429d37cc99d6c8c74afda9d484d7528f682e7697d83e", "class_name": "RelatedNodeInfo"}}, "text": "I'm very encouraged. ", "start_char_idx": 199, "end_char_idx": 220, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3800a2e3-994b-4aea-9bcd-33c78d67c8bc": {"__data__": {"id_": "3800a2e3-994b-4aea-9bcd-33c78d67c8bc", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nseveral quarters.  I'm very encouraged.  We're hopeful we can reach resolution.  We think it w ill be great for patients \nand communities.  \n \n But as we said last quarter, until we have a deal, we are going to continue to prepare to defend ourselves, and \nwe've made significant investments in that defense.  We're prepared to rigorously and vigorously defe nd ourselves \nin court if it comes to that. ", "original_text": "We're hopeful we can reach resolution. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610365c071c7b4a48816accdeeb3e7409dbdef61529d5837d381384ca57cc1fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5ef75bb-3f84-43ab-84a5-41fe0a9afc12", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nseveral quarters.  I'm very encouraged.  We're hopeful we can reach resolution.  We think it w ill be great for patients \nand communities.  \n \n But as we said last quarter, until we have a deal, we are going to continue to prepare to defend ourselves, and \nwe've made significant investments in that defense. ", "original_text": "I'm very encouraged. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc0a6670a23218a56118f8dcafcead1031ff1d9dec75c6f9d1beaa914558d125", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d13c4a0b-4d76-4775-b418-2d19fbe2b4d4", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nseveral quarters.  I'm very encouraged.  We're hopeful we can reach resolution.  We think it w ill be great for patients \nand communities.  \n \n But as we said last quarter, until we have a deal, we are going to continue to prepare to defend ourselves, and \nwe've made significant investments in that defense.  We're prepared to rigorously and vigorously defe nd ourselves \nin court if it comes to that.  So our assumption, until such point in time that we have a resolution, is that we'll \ncontinue to make the ongoing investment in our defense.  \n ", "original_text": "We think it w ill be great for patients \nand communities.  \n \n"}, "hash": "82dcc3c646be1d1185fcc8eaff3a454ccf7a060a7fc78024e21b60037e603b59", "class_name": "RelatedNodeInfo"}}, "text": "We're hopeful we can reach resolution. ", "start_char_idx": 220, "end_char_idx": 259, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d13c4a0b-4d76-4775-b418-2d19fbe2b4d4": {"__data__": {"id_": "d13c4a0b-4d76-4775-b418-2d19fbe2b4d4", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nseveral quarters.  I'm very encouraged.  We're hopeful we can reach resolution.  We think it w ill be great for patients \nand communities.  \n \n But as we said last quarter, until we have a deal, we are going to continue to prepare to defend ourselves, and \nwe've made significant investments in that defense.  We're prepared to rigorously and vigorously defe nd ourselves \nin court if it comes to that.  So our assumption, until such point in time that we have a resolution, is that we'll \ncontinue to make the ongoing investment in our defense.  \n ", "original_text": "We think it w ill be great for patients \nand communities.  \n \n", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610365c071c7b4a48816accdeeb3e7409dbdef61529d5837d381384ca57cc1fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3800a2e3-994b-4aea-9bcd-33c78d67c8bc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nseveral quarters.  I'm very encouraged.  We're hopeful we can reach resolution.  We think it w ill be great for patients \nand communities.  \n \n But as we said last quarter, until we have a deal, we are going to continue to prepare to defend ourselves, and \nwe've made significant investments in that defense.  We're prepared to rigorously and vigorously defe nd ourselves \nin court if it comes to that. ", "original_text": "We're hopeful we can reach resolution. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "067ea7aa9845fcad2b818ed0ac5abdb86b56071cddfa47787612d7b5cd184d40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf47a742-1dcd-4306-b476-4a854f64669a", "node_type": "1", "metadata": {"window": "I'm very encouraged.  We're hopeful we can reach resolution.  We think it w ill be great for patients \nand communities.  \n \n But as we said last quarter, until we have a deal, we are going to continue to prepare to defend ourselves, and \nwe've made significant investments in that defense.  We're prepared to rigorously and vigorously defe nd ourselves \nin court if it comes to that.  So our assumption, until such point in time that we have a resolution, is that we'll \ncontinue to make the ongoing investment in our defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "But as we said last quarter, until we have a deal, we are going to continue to prepare to defend ourselves, and \nwe've made significant investments in that defense. "}, "hash": "76c608262321837e7d765d44935f8ad367b8cc73431f99eea96232bbed65cdb9", "class_name": "RelatedNodeInfo"}}, "text": "We think it w ill be great for patients \nand communities.  \n \n", "start_char_idx": 259, "end_char_idx": 321, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf47a742-1dcd-4306-b476-4a854f64669a": {"__data__": {"id_": "bf47a742-1dcd-4306-b476-4a854f64669a", "embedding": null, "metadata": {"window": "I'm very encouraged.  We're hopeful we can reach resolution.  We think it w ill be great for patients \nand communities.  \n \n But as we said last quarter, until we have a deal, we are going to continue to prepare to defend ourselves, and \nwe've made significant investments in that defense.  We're prepared to rigorously and vigorously defe nd ourselves \nin court if it comes to that.  So our assumption, until such point in time that we have a resolution, is that we'll \ncontinue to make the ongoing investment in our defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "But as we said last quarter, until we have a deal, we are going to continue to prepare to defend ourselves, and \nwe've made significant investments in that defense. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610365c071c7b4a48816accdeeb3e7409dbdef61529d5837d381384ca57cc1fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d13c4a0b-4d76-4775-b418-2d19fbe2b4d4", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nseveral quarters.  I'm very encouraged.  We're hopeful we can reach resolution.  We think it w ill be great for patients \nand communities.  \n \n But as we said last quarter, until we have a deal, we are going to continue to prepare to defend ourselves, and \nwe've made significant investments in that defense.  We're prepared to rigorously and vigorously defe nd ourselves \nin court if it comes to that.  So our assumption, until such point in time that we have a resolution, is that we'll \ncontinue to make the ongoing investment in our defense.  \n ", "original_text": "We think it w ill be great for patients \nand communities.  \n \n", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b5973dcb3ebc86c7864b3942f85246142f36d89538007f014fa8d24812c2905", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d933f17-f70c-4a92-9521-a9160c3bdf22", "node_type": "1", "metadata": {"window": "We're hopeful we can reach resolution.  We think it w ill be great for patients \nand communities.  \n \n But as we said last quarter, until we have a deal, we are going to continue to prepare to defend ourselves, and \nwe've made significant investments in that defense.  We're prepared to rigorously and vigorously defe nd ourselves \nin court if it comes to that.  So our assumption, until such point in time that we have a resolution, is that we'll \ncontinue to make the ongoing investment in our defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from George Hill with De utsche Bank.  \n ", "original_text": "We're prepared to rigorously and vigorously defe nd ourselves \nin court if it comes to that. "}, "hash": "f9988aa2a7ea35c9482eed3596f1027b9a3803386e409302143bcb4b5d3ccc2f", "class_name": "RelatedNodeInfo"}}, "text": "But as we said last quarter, until we have a deal, we are going to continue to prepare to defend ourselves, and \nwe've made significant investments in that defense. ", "start_char_idx": 321, "end_char_idx": 486, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d933f17-f70c-4a92-9521-a9160c3bdf22": {"__data__": {"id_": "1d933f17-f70c-4a92-9521-a9160c3bdf22", "embedding": null, "metadata": {"window": "We're hopeful we can reach resolution.  We think it w ill be great for patients \nand communities.  \n \n But as we said last quarter, until we have a deal, we are going to continue to prepare to defend ourselves, and \nwe've made significant investments in that defense.  We're prepared to rigorously and vigorously defe nd ourselves \nin court if it comes to that.  So our assumption, until such point in time that we have a resolution, is that we'll \ncontinue to make the ongoing investment in our defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from George Hill with De utsche Bank.  \n ", "original_text": "We're prepared to rigorously and vigorously defe nd ourselves \nin court if it comes to that. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610365c071c7b4a48816accdeeb3e7409dbdef61529d5837d381384ca57cc1fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf47a742-1dcd-4306-b476-4a854f64669a", "node_type": "1", "metadata": {"window": "I'm very encouraged.  We're hopeful we can reach resolution.  We think it w ill be great for patients \nand communities.  \n \n But as we said last quarter, until we have a deal, we are going to continue to prepare to defend ourselves, and \nwe've made significant investments in that defense.  We're prepared to rigorously and vigorously defe nd ourselves \nin court if it comes to that.  So our assumption, until such point in time that we have a resolution, is that we'll \ncontinue to make the ongoing investment in our defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "But as we said last quarter, until we have a deal, we are going to continue to prepare to defend ourselves, and \nwe've made significant investments in that defense. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51b3a5f5d1167a8ccae3c7784cd7ff76f4d66a7fbe619d051927974022088792", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09029745-b23d-4ab5-9dc3-a8b7a0634f0b", "node_type": "1", "metadata": {"window": "We think it w ill be great for patients \nand communities.  \n \n But as we said last quarter, until we have a deal, we are going to continue to prepare to defend ourselves, and \nwe've made significant investments in that defense.  We're prepared to rigorously and vigorously defe nd ourselves \nin court if it comes to that.  So our assumption, until such point in time that we have a resolution, is that we'll \ncontinue to make the ongoing investment in our defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from George Hill with De utsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "So our assumption, until such point in time that we have a resolution, is that we'll \ncontinue to make the ongoing investment in our defense.  \n "}, "hash": "5e28d987e1b6dbb46f555861f460053e24e0e3bc3cfa90b728593bc3990658d5", "class_name": "RelatedNodeInfo"}}, "text": "We're prepared to rigorously and vigorously defe nd ourselves \nin court if it comes to that. ", "start_char_idx": 486, "end_char_idx": 579, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09029745-b23d-4ab5-9dc3-a8b7a0634f0b": {"__data__": {"id_": "09029745-b23d-4ab5-9dc3-a8b7a0634f0b", "embedding": null, "metadata": {"window": "We think it w ill be great for patients \nand communities.  \n \n But as we said last quarter, until we have a deal, we are going to continue to prepare to defend ourselves, and \nwe've made significant investments in that defense.  We're prepared to rigorously and vigorously defe nd ourselves \nin court if it comes to that.  So our assumption, until such point in time that we have a resolution, is that we'll \ncontinue to make the ongoing investment in our defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from George Hill with De utsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "So our assumption, until such point in time that we have a resolution, is that we'll \ncontinue to make the ongoing investment in our defense.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610365c071c7b4a48816accdeeb3e7409dbdef61529d5837d381384ca57cc1fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d933f17-f70c-4a92-9521-a9160c3bdf22", "node_type": "1", "metadata": {"window": "We're hopeful we can reach resolution.  We think it w ill be great for patients \nand communities.  \n \n But as we said last quarter, until we have a deal, we are going to continue to prepare to defend ourselves, and \nwe've made significant investments in that defense.  We're prepared to rigorously and vigorously defe nd ourselves \nin court if it comes to that.  So our assumption, until such point in time that we have a resolution, is that we'll \ncontinue to make the ongoing investment in our defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from George Hill with De utsche Bank.  \n ", "original_text": "We're prepared to rigorously and vigorously defe nd ourselves \nin court if it comes to that. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e6dc2f2d7a0e8eea76f443a67469d89ff2747dfc3d687197f88edee4e6d22ef7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e855c02-55ec-41bc-94a6-c7ee1859cfb4", "node_type": "1", "metadata": {"window": "But as we said last quarter, until we have a deal, we are going to continue to prepare to defend ourselves, and \nwe've made significant investments in that defense.  We're prepared to rigorously and vigorously defe nd ourselves \nin court if it comes to that.  So our assumption, until such point in time that we have a resolution, is that we'll \ncontinue to make the ongoing investment in our defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from George Hill with De utsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good afternoon, guys. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. "}, "hash": "d879fca4679b3c43178fe46c4fa17a133060a785dba513e8d1a6f9b239b14533", "class_name": "RelatedNodeInfo"}}, "text": "So our assumption, until such point in time that we have a resolution, is that we'll \ncontinue to make the ongoing investment in our defense.  \n ", "start_char_idx": 579, "end_char_idx": 724, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e855c02-55ec-41bc-94a6-c7ee1859cfb4": {"__data__": {"id_": "7e855c02-55ec-41bc-94a6-c7ee1859cfb4", "embedding": null, "metadata": {"window": "But as we said last quarter, until we have a deal, we are going to continue to prepare to defend ourselves, and \nwe've made significant investments in that defense.  We're prepared to rigorously and vigorously defe nd ourselves \nin court if it comes to that.  So our assumption, until such point in time that we have a resolution, is that we'll \ncontinue to make the ongoing investment in our defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from George Hill with De utsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good afternoon, guys. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610365c071c7b4a48816accdeeb3e7409dbdef61529d5837d381384ca57cc1fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09029745-b23d-4ab5-9dc3-a8b7a0634f0b", "node_type": "1", "metadata": {"window": "We think it w ill be great for patients \nand communities.  \n \n But as we said last quarter, until we have a deal, we are going to continue to prepare to defend ourselves, and \nwe've made significant investments in that defense.  We're prepared to rigorously and vigorously defe nd ourselves \nin court if it comes to that.  So our assumption, until such point in time that we have a resolution, is that we'll \ncontinue to make the ongoing investment in our defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from George Hill with De utsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "So our assumption, until such point in time that we have a resolution, is that we'll \ncontinue to make the ongoing investment in our defense.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "645ceab8397d9d34b4799894a04fab487220a6622fcb62f21e5e8079b14fccb5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4914a5e-dcca-4526-8830-f90f72f6bd9d", "node_type": "1", "metadata": {"window": "We're prepared to rigorously and vigorously defe nd ourselves \nin court if it comes to that.  So our assumption, until such point in time that we have a resolution, is that we'll \ncontinue to make the ongoing investment in our defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from George Hill with De utsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good afternoon, guys.  And, thanks for the taking the question. ", "original_text": "Our next question comes from George Hill with De utsche Bank.  \n "}, "hash": "b974ff74214a588630907405cee7c4c31760852274fd47d3e153b338d05d93ef", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "start_char_idx": 724, "end_char_idx": 1005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4914a5e-dcca-4526-8830-f90f72f6bd9d": {"__data__": {"id_": "f4914a5e-dcca-4526-8830-f90f72f6bd9d", "embedding": null, "metadata": {"window": "We're prepared to rigorously and vigorously defe nd ourselves \nin court if it comes to that.  So our assumption, until such point in time that we have a resolution, is that we'll \ncontinue to make the ongoing investment in our defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from George Hill with De utsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good afternoon, guys.  And, thanks for the taking the question. ", "original_text": "Our next question comes from George Hill with De utsche Bank.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610365c071c7b4a48816accdeeb3e7409dbdef61529d5837d381384ca57cc1fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e855c02-55ec-41bc-94a6-c7ee1859cfb4", "node_type": "1", "metadata": {"window": "But as we said last quarter, until we have a deal, we are going to continue to prepare to defend ourselves, and \nwe've made significant investments in that defense.  We're prepared to rigorously and vigorously defe nd ourselves \nin court if it comes to that.  So our assumption, until such point in time that we have a resolution, is that we'll \ncontinue to make the ongoing investment in our defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from George Hill with De utsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good afternoon, guys. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df17a1d6a6182f73e1f0c28869bf47986ea051a71184983fdeaf939f822e2823", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "afa00742-dfca-4ef4-aa03-5b05d169c801", "node_type": "1", "metadata": {"window": "So our assumption, until such point in time that we have a resolution, is that we'll \ncontinue to make the ongoing investment in our defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from George Hill with De utsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good afternoon, guys.  And, thanks for the taking the question.  I was hoping you might be able to give me an \nanswer to a question that would settle some debate in the investor community, which is, I guess, could you talk \nabout your appetite for maybe adding another leg to the operational stool through M&A and kind of how we \nshould think about the company's appetite for deals that could be dilutive or value transferred, if that's  the right \nword, in the short term for \u2013 to enter segments that could relate to your core customers and might have a better \nlong-term growth profile? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  "}, "hash": "4e6fc6a266522e589c025458ed21ec29a9e756d3ee794a867a9208a7392b41e1", "class_name": "RelatedNodeInfo"}}, "text": "Our next question comes from George Hill with De utsche Bank.  \n ", "start_char_idx": 1005, "end_char_idx": 1070, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "afa00742-dfca-4ef4-aa03-5b05d169c801": {"__data__": {"id_": "afa00742-dfca-4ef4-aa03-5b05d169c801", "embedding": null, "metadata": {"window": "So our assumption, until such point in time that we have a resolution, is that we'll \ncontinue to make the ongoing investment in our defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from George Hill with De utsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good afternoon, guys.  And, thanks for the taking the question.  I was hoping you might be able to give me an \nanswer to a question that would settle some debate in the investor community, which is, I guess, could you talk \nabout your appetite for maybe adding another leg to the operational stool through M&A and kind of how we \nshould think about the company's appetite for deals that could be dilutive or value transferred, if that's  the right \nword, in the short term for \u2013 to enter segments that could relate to your core customers and might have a better \nlong-term growth profile? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610365c071c7b4a48816accdeeb3e7409dbdef61529d5837d381384ca57cc1fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4914a5e-dcca-4526-8830-f90f72f6bd9d", "node_type": "1", "metadata": {"window": "We're prepared to rigorously and vigorously defe nd ourselves \nin court if it comes to that.  So our assumption, until such point in time that we have a resolution, is that we'll \ncontinue to make the ongoing investment in our defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from George Hill with De utsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good afternoon, guys.  And, thanks for the taking the question. ", "original_text": "Our next question comes from George Hill with De utsche Bank.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65bb487d0e5f45e0d734763abed56f04bc36c8126d7370f8c69e6ab128c5b212", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88adea1e-9728-4dc4-89ae-3bdce7a8235d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from George Hill with De utsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good afternoon, guys.  And, thanks for the taking the question.  I was hoping you might be able to give me an \nanswer to a question that would settle some debate in the investor community, which is, I guess, could you talk \nabout your appetite for maybe adding another leg to the operational stool through M&A and kind of how we \nshould think about the company's appetite for deals that could be dilutive or value transferred, if that's  the right \nword, in the short term for \u2013 to enter segments that could relate to your core customers and might have a better \nlong-term growth profile?  So that's kind of the really broad M&A question, but just interested in how you're \nthinking about the kind  of the risk appetite versus valuation.  \n ", "original_text": "Q \nHey, good afternoon, guys. "}, "hash": "2bf17c36ad5a7817036e4b20904a169968ead4a11afeb6d7629adc739a51ccc3", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "start_char_idx": 1070, "end_char_idx": 1382, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88adea1e-9728-4dc4-89ae-3bdce7a8235d": {"__data__": {"id_": "88adea1e-9728-4dc4-89ae-3bdce7a8235d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from George Hill with De utsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good afternoon, guys.  And, thanks for the taking the question.  I was hoping you might be able to give me an \nanswer to a question that would settle some debate in the investor community, which is, I guess, could you talk \nabout your appetite for maybe adding another leg to the operational stool through M&A and kind of how we \nshould think about the company's appetite for deals that could be dilutive or value transferred, if that's  the right \nword, in the short term for \u2013 to enter segments that could relate to your core customers and might have a better \nlong-term growth profile?  So that's kind of the really broad M&A question, but just interested in how you're \nthinking about the kind  of the risk appetite versus valuation.  \n ", "original_text": "Q \nHey, good afternoon, guys. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610365c071c7b4a48816accdeeb3e7409dbdef61529d5837d381384ca57cc1fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "afa00742-dfca-4ef4-aa03-5b05d169c801", "node_type": "1", "metadata": {"window": "So our assumption, until such point in time that we have a resolution, is that we'll \ncontinue to make the ongoing investment in our defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from George Hill with De utsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good afternoon, guys.  And, thanks for the taking the question.  I was hoping you might be able to give me an \nanswer to a question that would settle some debate in the investor community, which is, I guess, could you talk \nabout your appetite for maybe adding another leg to the operational stool through M&A and kind of how we \nshould think about the company's appetite for deals that could be dilutive or value transferred, if that's  the right \nword, in the short term for \u2013 to enter segments that could relate to your core customers and might have a better \nlong-term growth profile? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "053bb7b5739ec25e1c8b3efbf7af505d3cd3a215f155d7297366d899db66271f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab53d07a-c838-4b6a-88ec-bbcd3b987530", "node_type": "1", "metadata": {"window": "Our next question comes from George Hill with De utsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good afternoon, guys.  And, thanks for the taking the question.  I was hoping you might be able to give me an \nanswer to a question that would settle some debate in the investor community, which is, I guess, could you talk \nabout your appetite for maybe adding another leg to the operational stool through M&A and kind of how we \nshould think about the company's appetite for deals that could be dilutive or value transferred, if that's  the right \nword, in the short term for \u2013 to enter segments that could relate to your core customers and might have a better \nlong-term growth profile?  So that's kind of the really broad M&A question, but just interested in how you're \nthinking about the kind  of the risk appetite versus valuation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And, thanks for the taking the question. "}, "hash": "b9d315b4ca4e5250325666ac561fb4e3ae9486b655d85e2234b5c1ca7abebe64", "class_name": "RelatedNodeInfo"}}, "text": "Q \nHey, good afternoon, guys. ", "start_char_idx": 1382, "end_char_idx": 1412, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab53d07a-c838-4b6a-88ec-bbcd3b987530": {"__data__": {"id_": "ab53d07a-c838-4b6a-88ec-bbcd3b987530", "embedding": null, "metadata": {"window": "Our next question comes from George Hill with De utsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good afternoon, guys.  And, thanks for the taking the question.  I was hoping you might be able to give me an \nanswer to a question that would settle some debate in the investor community, which is, I guess, could you talk \nabout your appetite for maybe adding another leg to the operational stool through M&A and kind of how we \nshould think about the company's appetite for deals that could be dilutive or value transferred, if that's  the right \nword, in the short term for \u2013 to enter segments that could relate to your core customers and might have a better \nlong-term growth profile?  So that's kind of the really broad M&A question, but just interested in how you're \nthinking about the kind  of the risk appetite versus valuation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And, thanks for the taking the question. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610365c071c7b4a48816accdeeb3e7409dbdef61529d5837d381384ca57cc1fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88adea1e-9728-4dc4-89ae-3bdce7a8235d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from George Hill with De utsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good afternoon, guys.  And, thanks for the taking the question.  I was hoping you might be able to give me an \nanswer to a question that would settle some debate in the investor community, which is, I guess, could you talk \nabout your appetite for maybe adding another leg to the operational stool through M&A and kind of how we \nshould think about the company's appetite for deals that could be dilutive or value transferred, if that's  the right \nword, in the short term for \u2013 to enter segments that could relate to your core customers and might have a better \nlong-term growth profile?  So that's kind of the really broad M&A question, but just interested in how you're \nthinking about the kind  of the risk appetite versus valuation.  \n ", "original_text": "Q \nHey, good afternoon, guys. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5de3524c188552213484a57d80694ddf2b2a1f958fa8730c20e94138213a824", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6cc9a3d0-eadc-454c-a66f-7e6b72244309", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good afternoon, guys.  And, thanks for the taking the question.  I was hoping you might be able to give me an \nanswer to a question that would settle some debate in the investor community, which is, I guess, could you talk \nabout your appetite for maybe adding another leg to the operational stool through M&A and kind of how we \nshould think about the company's appetite for deals that could be dilutive or value transferred, if that's  the right \nword, in the short term for \u2013 to enter segments that could relate to your core customers and might have a better \nlong-term growth profile?  So that's kind of the really broad M&A question, but just interested in how you're \nthinking about the kind  of the risk appetite versus valuation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, first, we're always looking at the landscape. ", "original_text": "I was hoping you might be able to give me an \nanswer to a question that would settle some debate in the investor community, which is, I guess, could you talk \nabout your appetite for maybe adding another leg to the operational stool through M&A and kind of how we \nshould think about the company's appetite for deals that could be dilutive or value transferred, if that's  the right \nword, in the short term for \u2013 to enter segments that could relate to your core customers and might have a better \nlong-term growth profile? "}, "hash": "8f288b030d159efa08487ef53443372e384e6ae4fdda83a7a7a1260467702509", "class_name": "RelatedNodeInfo"}}, "text": "And, thanks for the taking the question. ", "start_char_idx": 1412, "end_char_idx": 1453, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6cc9a3d0-eadc-454c-a66f-7e6b72244309": {"__data__": {"id_": "6cc9a3d0-eadc-454c-a66f-7e6b72244309", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good afternoon, guys.  And, thanks for the taking the question.  I was hoping you might be able to give me an \nanswer to a question that would settle some debate in the investor community, which is, I guess, could you talk \nabout your appetite for maybe adding another leg to the operational stool through M&A and kind of how we \nshould think about the company's appetite for deals that could be dilutive or value transferred, if that's  the right \nword, in the short term for \u2013 to enter segments that could relate to your core customers and might have a better \nlong-term growth profile?  So that's kind of the really broad M&A question, but just interested in how you're \nthinking about the kind  of the risk appetite versus valuation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, first, we're always looking at the landscape. ", "original_text": "I was hoping you might be able to give me an \nanswer to a question that would settle some debate in the investor community, which is, I guess, could you talk \nabout your appetite for maybe adding another leg to the operational stool through M&A and kind of how we \nshould think about the company's appetite for deals that could be dilutive or value transferred, if that's  the right \nword, in the short term for \u2013 to enter segments that could relate to your core customers and might have a better \nlong-term growth profile? ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610365c071c7b4a48816accdeeb3e7409dbdef61529d5837d381384ca57cc1fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab53d07a-c838-4b6a-88ec-bbcd3b987530", "node_type": "1", "metadata": {"window": "Our next question comes from George Hill with De utsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good afternoon, guys.  And, thanks for the taking the question.  I was hoping you might be able to give me an \nanswer to a question that would settle some debate in the investor community, which is, I guess, could you talk \nabout your appetite for maybe adding another leg to the operational stool through M&A and kind of how we \nshould think about the company's appetite for deals that could be dilutive or value transferred, if that's  the right \nword, in the short term for \u2013 to enter segments that could relate to your core customers and might have a better \nlong-term growth profile?  So that's kind of the really broad M&A question, but just interested in how you're \nthinking about the kind  of the risk appetite versus valuation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And, thanks for the taking the question. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b8041228e6b095fe136d0b40503bc7dd70174829a9ecdce6007b892eb7aacf3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5bbd9a82-436f-432a-a033-e4be866c6af0", "node_type": "1", "metadata": {"window": "Q \nHey, good afternoon, guys.  And, thanks for the taking the question.  I was hoping you might be able to give me an \nanswer to a question that would settle some debate in the investor community, which is, I guess, could you talk \nabout your appetite for maybe adding another leg to the operational stool through M&A and kind of how we \nshould think about the company's appetite for deals that could be dilutive or value transferred, if that's  the right \nword, in the short term for \u2013 to enter segments that could relate to your core customers and might have a better \nlong-term growth profile?  So that's kind of the really broad M&A question, but just interested in how you're \nthinking about the kind  of the risk appetite versus valuation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, first, we're always looking at the landscape.  And if you look at the landscape in healthcare this year, \nobviously, with the pandem ic, we saw a lot of the telehealth assets really catch a lot of momentum. ", "original_text": "So that's kind of the really broad M&A question, but just interested in how you're \nthinking about the kind  of the risk appetite versus valuation.  \n "}, "hash": "7624a6514c0423093cd2e361e8fae2f3f2d5fe9ef23be4d8e17633c1d031a90d", "class_name": "RelatedNodeInfo"}}, "text": "I was hoping you might be able to give me an \nanswer to a question that would settle some debate in the investor community, which is, I guess, could you talk \nabout your appetite for maybe adding another leg to the operational stool through M&A and kind of how we \nshould think about the company's appetite for deals that could be dilutive or value transferred, if that's  the right \nword, in the short term for \u2013 to enter segments that could relate to your core customers and might have a better \nlong-term growth profile? ", "start_char_idx": 1453, "end_char_idx": 1977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bbd9a82-436f-432a-a033-e4be866c6af0": {"__data__": {"id_": "5bbd9a82-436f-432a-a033-e4be866c6af0", "embedding": null, "metadata": {"window": "Q \nHey, good afternoon, guys.  And, thanks for the taking the question.  I was hoping you might be able to give me an \nanswer to a question that would settle some debate in the investor community, which is, I guess, could you talk \nabout your appetite for maybe adding another leg to the operational stool through M&A and kind of how we \nshould think about the company's appetite for deals that could be dilutive or value transferred, if that's  the right \nword, in the short term for \u2013 to enter segments that could relate to your core customers and might have a better \nlong-term growth profile?  So that's kind of the really broad M&A question, but just interested in how you're \nthinking about the kind  of the risk appetite versus valuation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, first, we're always looking at the landscape.  And if you look at the landscape in healthcare this year, \nobviously, with the pandem ic, we saw a lot of the telehealth assets really catch a lot of momentum. ", "original_text": "So that's kind of the really broad M&A question, but just interested in how you're \nthinking about the kind  of the risk appetite versus valuation.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610365c071c7b4a48816accdeeb3e7409dbdef61529d5837d381384ca57cc1fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6cc9a3d0-eadc-454c-a66f-7e6b72244309", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good afternoon, guys.  And, thanks for the taking the question.  I was hoping you might be able to give me an \nanswer to a question that would settle some debate in the investor community, which is, I guess, could you talk \nabout your appetite for maybe adding another leg to the operational stool through M&A and kind of how we \nshould think about the company's appetite for deals that could be dilutive or value transferred, if that's  the right \nword, in the short term for \u2013 to enter segments that could relate to your core customers and might have a better \nlong-term growth profile?  So that's kind of the really broad M&A question, but just interested in how you're \nthinking about the kind  of the risk appetite versus valuation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, first, we're always looking at the landscape. ", "original_text": "I was hoping you might be able to give me an \nanswer to a question that would settle some debate in the investor community, which is, I guess, could you talk \nabout your appetite for maybe adding another leg to the operational stool through M&A and kind of how we \nshould think about the company's appetite for deals that could be dilutive or value transferred, if that's  the right \nword, in the short term for \u2013 to enter segments that could relate to your core customers and might have a better \nlong-term growth profile? ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ed9898ca50262c66d19be660ffd4ffc5317803ed09a7bf8eb13b59f1c78e3746", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82aa1c64-fab3-42ef-8035-baea2c6fd92f", "node_type": "1", "metadata": {"window": "And, thanks for the taking the question.  I was hoping you might be able to give me an \nanswer to a question that would settle some debate in the investor community, which is, I guess, could you talk \nabout your appetite for maybe adding another leg to the operational stool through M&A and kind of how we \nshould think about the company's appetite for deals that could be dilutive or value transferred, if that's  the right \nword, in the short term for \u2013 to enter segments that could relate to your core customers and might have a better \nlong-term growth profile?  So that's kind of the really broad M&A question, but just interested in how you're \nthinking about the kind  of the risk appetite versus valuation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, first, we're always looking at the landscape.  And if you look at the landscape in healthcare this year, \nobviously, with the pandem ic, we saw a lot of the telehealth assets really catch a lot of momentum.  We've gone \nback. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "b34b669ee8db0a8c7f0d8c550f852d001e271226b24284c18d5b87ce9356e1b9", "class_name": "RelatedNodeInfo"}}, "text": "So that's kind of the really broad M&A question, but just interested in how you're \nthinking about the kind  of the risk appetite versus valuation.  \n ", "start_char_idx": 1977, "end_char_idx": 2128, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82aa1c64-fab3-42ef-8035-baea2c6fd92f": {"__data__": {"id_": "82aa1c64-fab3-42ef-8035-baea2c6fd92f", "embedding": null, "metadata": {"window": "And, thanks for the taking the question.  I was hoping you might be able to give me an \nanswer to a question that would settle some debate in the investor community, which is, I guess, could you talk \nabout your appetite for maybe adding another leg to the operational stool through M&A and kind of how we \nshould think about the company's appetite for deals that could be dilutive or value transferred, if that's  the right \nword, in the short term for \u2013 to enter segments that could relate to your core customers and might have a better \nlong-term growth profile?  So that's kind of the really broad M&A question, but just interested in how you're \nthinking about the kind  of the risk appetite versus valuation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, first, we're always looking at the landscape.  And if you look at the landscape in healthcare this year, \nobviously, with the pandem ic, we saw a lot of the telehealth assets really catch a lot of momentum.  We've gone \nback. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610365c071c7b4a48816accdeeb3e7409dbdef61529d5837d381384ca57cc1fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bbd9a82-436f-432a-a033-e4be866c6af0", "node_type": "1", "metadata": {"window": "Q \nHey, good afternoon, guys.  And, thanks for the taking the question.  I was hoping you might be able to give me an \nanswer to a question that would settle some debate in the investor community, which is, I guess, could you talk \nabout your appetite for maybe adding another leg to the operational stool through M&A and kind of how we \nshould think about the company's appetite for deals that could be dilutive or value transferred, if that's  the right \nword, in the short term for \u2013 to enter segments that could relate to your core customers and might have a better \nlong-term growth profile?  So that's kind of the really broad M&A question, but just interested in how you're \nthinking about the kind  of the risk appetite versus valuation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, first, we're always looking at the landscape.  And if you look at the landscape in healthcare this year, \nobviously, with the pandem ic, we saw a lot of the telehealth assets really catch a lot of momentum. ", "original_text": "So that's kind of the really broad M&A question, but just interested in how you're \nthinking about the kind  of the risk appetite versus valuation.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c4a6a39eeee28901ad8c958df8c8608c2f7333269399d94be1e4d2191f80c22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9eb814d3-b4f7-447a-914f-ce6efefdafdc", "node_type": "1", "metadata": {"window": "I was hoping you might be able to give me an \nanswer to a question that would settle some debate in the investor community, which is, I guess, could you talk \nabout your appetite for maybe adding another leg to the operational stool through M&A and kind of how we \nshould think about the company's appetite for deals that could be dilutive or value transferred, if that's  the right \nword, in the short term for \u2013 to enter segments that could relate to your core customers and might have a better \nlong-term growth profile?  So that's kind of the really broad M&A question, but just interested in how you're \nthinking about the kind  of the risk appetite versus valuation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, first, we're always looking at the landscape.  And if you look at the landscape in healthcare this year, \nobviously, with the pandem ic, we saw a lot of the telehealth assets really catch a lot of momentum.  We've gone \nback.  We've checked our strategies based on how we've seen the landscape change over the past year.  \n \n", "original_text": "A \nWell, look, first, we're always looking at the landscape. "}, "hash": "ee096ccae6c0638743b1fc105978cb6771d0bc4ca6876782f573d6c12e8b0da7", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 2128, "end_char_idx": 2457, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9eb814d3-b4f7-447a-914f-ce6efefdafdc": {"__data__": {"id_": "9eb814d3-b4f7-447a-914f-ce6efefdafdc", "embedding": null, "metadata": {"window": "I was hoping you might be able to give me an \nanswer to a question that would settle some debate in the investor community, which is, I guess, could you talk \nabout your appetite for maybe adding another leg to the operational stool through M&A and kind of how we \nshould think about the company's appetite for deals that could be dilutive or value transferred, if that's  the right \nword, in the short term for \u2013 to enter segments that could relate to your core customers and might have a better \nlong-term growth profile?  So that's kind of the really broad M&A question, but just interested in how you're \nthinking about the kind  of the risk appetite versus valuation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, first, we're always looking at the landscape.  And if you look at the landscape in healthcare this year, \nobviously, with the pandem ic, we saw a lot of the telehealth assets really catch a lot of momentum.  We've gone \nback.  We've checked our strategies based on how we've seen the landscape change over the past year.  \n \n", "original_text": "A \nWell, look, first, we're always looking at the landscape. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610365c071c7b4a48816accdeeb3e7409dbdef61529d5837d381384ca57cc1fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82aa1c64-fab3-42ef-8035-baea2c6fd92f", "node_type": "1", "metadata": {"window": "And, thanks for the taking the question.  I was hoping you might be able to give me an \nanswer to a question that would settle some debate in the investor community, which is, I guess, could you talk \nabout your appetite for maybe adding another leg to the operational stool through M&A and kind of how we \nshould think about the company's appetite for deals that could be dilutive or value transferred, if that's  the right \nword, in the short term for \u2013 to enter segments that could relate to your core customers and might have a better \nlong-term growth profile?  So that's kind of the really broad M&A question, but just interested in how you're \nthinking about the kind  of the risk appetite versus valuation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, first, we're always looking at the landscape.  And if you look at the landscape in healthcare this year, \nobviously, with the pandem ic, we saw a lot of the telehealth assets really catch a lot of momentum.  We've gone \nback. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7bef5c7fa2b0c9e2b998e46312dec41ff27cb788c709e36e4a2dbc600183aed2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3b77f4a-8e69-46b7-bc81-8414ba2ed7cb", "node_type": "1", "metadata": {"window": "So that's kind of the really broad M&A question, but just interested in how you're \nthinking about the kind  of the risk appetite versus valuation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, first, we're always looking at the landscape.  And if you look at the landscape in healthcare this year, \nobviously, with the pandem ic, we saw a lot of the telehealth assets really catch a lot of momentum.  We've gone \nback.  We've checked our strategies based on how we've seen the landscape change over the past year.  \n \n And I'll just say this, we have a lot of conviction that our strategy,  which is built around continuing to get growth \nout of the core, continuing to focus on oncology and continuing to focus on biopharma services, where we think \nwe have unique and distinguished capabilities, we have the opportunity to do internal innovation to drive growth. \n", "original_text": "And if you look at the landscape in healthcare this year, \nobviously, with the pandem ic, we saw a lot of the telehealth assets really catch a lot of momentum. "}, "hash": "8934b72097ebd556d1c486820cf8e9770d023306a012010a03e0bd94c1981c65", "class_name": "RelatedNodeInfo"}}, "text": "A \nWell, look, first, we're always looking at the landscape. ", "start_char_idx": 2457, "end_char_idx": 2518, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3b77f4a-8e69-46b7-bc81-8414ba2ed7cb": {"__data__": {"id_": "d3b77f4a-8e69-46b7-bc81-8414ba2ed7cb", "embedding": null, "metadata": {"window": "So that's kind of the really broad M&A question, but just interested in how you're \nthinking about the kind  of the risk appetite versus valuation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, first, we're always looking at the landscape.  And if you look at the landscape in healthcare this year, \nobviously, with the pandem ic, we saw a lot of the telehealth assets really catch a lot of momentum.  We've gone \nback.  We've checked our strategies based on how we've seen the landscape change over the past year.  \n \n And I'll just say this, we have a lot of conviction that our strategy,  which is built around continuing to get growth \nout of the core, continuing to focus on oncology and continuing to focus on biopharma services, where we think \nwe have unique and distinguished capabilities, we have the opportunity to do internal innovation to drive growth. \n", "original_text": "And if you look at the landscape in healthcare this year, \nobviously, with the pandem ic, we saw a lot of the telehealth assets really catch a lot of momentum. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610365c071c7b4a48816accdeeb3e7409dbdef61529d5837d381384ca57cc1fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9eb814d3-b4f7-447a-914f-ce6efefdafdc", "node_type": "1", "metadata": {"window": "I was hoping you might be able to give me an \nanswer to a question that would settle some debate in the investor community, which is, I guess, could you talk \nabout your appetite for maybe adding another leg to the operational stool through M&A and kind of how we \nshould think about the company's appetite for deals that could be dilutive or value transferred, if that's  the right \nword, in the short term for \u2013 to enter segments that could relate to your core customers and might have a better \nlong-term growth profile?  So that's kind of the really broad M&A question, but just interested in how you're \nthinking about the kind  of the risk appetite versus valuation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, first, we're always looking at the landscape.  And if you look at the landscape in healthcare this year, \nobviously, with the pandem ic, we saw a lot of the telehealth assets really catch a lot of momentum.  We've gone \nback.  We've checked our strategies based on how we've seen the landscape change over the past year.  \n \n", "original_text": "A \nWell, look, first, we're always looking at the landscape. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc1f0db3979928a48256737428c944e577f12de532d482c9c593a935a41ba3f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "197881cf-f331-4d4c-b1b9-727d0a3cc1fa", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, first, we're always looking at the landscape.  And if you look at the landscape in healthcare this year, \nobviously, with the pandem ic, we saw a lot of the telehealth assets really catch a lot of momentum.  We've gone \nback.  We've checked our strategies based on how we've seen the landscape change over the past year.  \n \n And I'll just say this, we have a lot of conviction that our strategy,  which is built around continuing to get growth \nout of the core, continuing to focus on oncology and continuing to focus on biopharma services, where we think \nwe have unique and distinguished capabilities, we have the opportunity to do internal innovation to drive growth. \n And we have appetite to do external growth, if we can find the right asset, align to the strategy in the right way \nthat meets our return thresholds.  \n ", "original_text": "We've gone \nback. "}, "hash": "4da4923817c66103a016d6a1b2d40afedc30fb9e2bcc6246aa114564f8793ed9", "class_name": "RelatedNodeInfo"}}, "text": "And if you look at the landscape in healthcare this year, \nobviously, with the pandem ic, we saw a lot of the telehealth assets really catch a lot of momentum. ", "start_char_idx": 2518, "end_char_idx": 2678, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "197881cf-f331-4d4c-b1b9-727d0a3cc1fa": {"__data__": {"id_": "197881cf-f331-4d4c-b1b9-727d0a3cc1fa", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, first, we're always looking at the landscape.  And if you look at the landscape in healthcare this year, \nobviously, with the pandem ic, we saw a lot of the telehealth assets really catch a lot of momentum.  We've gone \nback.  We've checked our strategies based on how we've seen the landscape change over the past year.  \n \n And I'll just say this, we have a lot of conviction that our strategy,  which is built around continuing to get growth \nout of the core, continuing to focus on oncology and continuing to focus on biopharma services, where we think \nwe have unique and distinguished capabilities, we have the opportunity to do internal innovation to drive growth. \n And we have appetite to do external growth, if we can find the right asset, align to the strategy in the right way \nthat meets our return thresholds.  \n ", "original_text": "We've gone \nback. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610365c071c7b4a48816accdeeb3e7409dbdef61529d5837d381384ca57cc1fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3b77f4a-8e69-46b7-bc81-8414ba2ed7cb", "node_type": "1", "metadata": {"window": "So that's kind of the really broad M&A question, but just interested in how you're \nthinking about the kind  of the risk appetite versus valuation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, first, we're always looking at the landscape.  And if you look at the landscape in healthcare this year, \nobviously, with the pandem ic, we saw a lot of the telehealth assets really catch a lot of momentum.  We've gone \nback.  We've checked our strategies based on how we've seen the landscape change over the past year.  \n \n And I'll just say this, we have a lot of conviction that our strategy,  which is built around continuing to get growth \nout of the core, continuing to focus on oncology and continuing to focus on biopharma services, where we think \nwe have unique and distinguished capabilities, we have the opportunity to do internal innovation to drive growth. \n", "original_text": "And if you look at the landscape in healthcare this year, \nobviously, with the pandem ic, we saw a lot of the telehealth assets really catch a lot of momentum. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28ba78bf1432650dd7377d693d7dad6747d1a072628aa2283ce8f70631529589", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47636be0-dda0-4bca-95f5-9faf847b8c7b", "node_type": "1", "metadata": {"window": "A \nWell, look, first, we're always looking at the landscape.  And if you look at the landscape in healthcare this year, \nobviously, with the pandem ic, we saw a lot of the telehealth assets really catch a lot of momentum.  We've gone \nback.  We've checked our strategies based on how we've seen the landscape change over the past year.  \n \n And I'll just say this, we have a lot of conviction that our strategy,  which is built around continuing to get growth \nout of the core, continuing to focus on oncology and continuing to focus on biopharma services, where we think \nwe have unique and distinguished capabilities, we have the opportunity to do internal innovation to drive growth. \n And we have appetite to do external growth, if we can find the right asset, align to the strategy in the right way \nthat meets our return thresholds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "We've checked our strategies based on how we've seen the landscape change over the past year.  \n \n"}, "hash": "74382693fb730c48b7a380b08a142cea5d7f9cb58fd34b55de63de99d63a4a01", "class_name": "RelatedNodeInfo"}}, "text": "We've gone \nback. ", "start_char_idx": 2678, "end_char_idx": 2696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47636be0-dda0-4bca-95f5-9faf847b8c7b": {"__data__": {"id_": "47636be0-dda0-4bca-95f5-9faf847b8c7b", "embedding": null, "metadata": {"window": "A \nWell, look, first, we're always looking at the landscape.  And if you look at the landscape in healthcare this year, \nobviously, with the pandem ic, we saw a lot of the telehealth assets really catch a lot of momentum.  We've gone \nback.  We've checked our strategies based on how we've seen the landscape change over the past year.  \n \n And I'll just say this, we have a lot of conviction that our strategy,  which is built around continuing to get growth \nout of the core, continuing to focus on oncology and continuing to focus on biopharma services, where we think \nwe have unique and distinguished capabilities, we have the opportunity to do internal innovation to drive growth. \n And we have appetite to do external growth, if we can find the right asset, align to the strategy in the right way \nthat meets our return thresholds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "We've checked our strategies based on how we've seen the landscape change over the past year.  \n \n", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610365c071c7b4a48816accdeeb3e7409dbdef61529d5837d381384ca57cc1fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "197881cf-f331-4d4c-b1b9-727d0a3cc1fa", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, first, we're always looking at the landscape.  And if you look at the landscape in healthcare this year, \nobviously, with the pandem ic, we saw a lot of the telehealth assets really catch a lot of momentum.  We've gone \nback.  We've checked our strategies based on how we've seen the landscape change over the past year.  \n \n And I'll just say this, we have a lot of conviction that our strategy,  which is built around continuing to get growth \nout of the core, continuing to focus on oncology and continuing to focus on biopharma services, where we think \nwe have unique and distinguished capabilities, we have the opportunity to do internal innovation to drive growth. \n And we have appetite to do external growth, if we can find the right asset, align to the strategy in the right way \nthat meets our return thresholds.  \n ", "original_text": "We've gone \nback. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d04ddac2e688a47d9af4de1878bf7a54748ac77584a38dbb5c8b5af0512c828", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19206760-d2a6-4f7d-bd68-1f0281c7f171", "node_type": "1", "metadata": {"window": "And if you look at the landscape in healthcare this year, \nobviously, with the pandem ic, we saw a lot of the telehealth assets really catch a lot of momentum.  We've gone \nback.  We've checked our strategies based on how we've seen the landscape change over the past year.  \n \n And I'll just say this, we have a lot of conviction that our strategy,  which is built around continuing to get growth \nout of the core, continuing to focus on oncology and continuing to focus on biopharma services, where we think \nwe have unique and distinguished capabilities, we have the opportunity to do internal innovation to drive growth. \n And we have appetite to do external growth, if we can find the right asset, align to the strategy in the right way \nthat meets our return thresholds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Jailendra Singh with Credit Suisse.  \n ", "original_text": "And I'll just say this, we have a lot of conviction that our strategy,  which is built around continuing to get growth \nout of the core, continuing to focus on oncology and continuing to focus on biopharma services, where we think \nwe have unique and distinguished capabilities, we have the opportunity to do internal innovation to drive growth. \n"}, "hash": "7acb4ef388b508affb63087dd61db0bb6232be9614923cd6a924a67b54ac971d", "class_name": "RelatedNodeInfo"}}, "text": "We've checked our strategies based on how we've seen the landscape change over the past year.  \n \n", "start_char_idx": 2696, "end_char_idx": 2794, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19206760-d2a6-4f7d-bd68-1f0281c7f171": {"__data__": {"id_": "19206760-d2a6-4f7d-bd68-1f0281c7f171", "embedding": null, "metadata": {"window": "And if you look at the landscape in healthcare this year, \nobviously, with the pandem ic, we saw a lot of the telehealth assets really catch a lot of momentum.  We've gone \nback.  We've checked our strategies based on how we've seen the landscape change over the past year.  \n \n And I'll just say this, we have a lot of conviction that our strategy,  which is built around continuing to get growth \nout of the core, continuing to focus on oncology and continuing to focus on biopharma services, where we think \nwe have unique and distinguished capabilities, we have the opportunity to do internal innovation to drive growth. \n And we have appetite to do external growth, if we can find the right asset, align to the strategy in the right way \nthat meets our return thresholds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Jailendra Singh with Credit Suisse.  \n ", "original_text": "And I'll just say this, we have a lot of conviction that our strategy,  which is built around continuing to get growth \nout of the core, continuing to focus on oncology and continuing to focus on biopharma services, where we think \nwe have unique and distinguished capabilities, we have the opportunity to do internal innovation to drive growth. \n", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610365c071c7b4a48816accdeeb3e7409dbdef61529d5837d381384ca57cc1fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47636be0-dda0-4bca-95f5-9faf847b8c7b", "node_type": "1", "metadata": {"window": "A \nWell, look, first, we're always looking at the landscape.  And if you look at the landscape in healthcare this year, \nobviously, with the pandem ic, we saw a lot of the telehealth assets really catch a lot of momentum.  We've gone \nback.  We've checked our strategies based on how we've seen the landscape change over the past year.  \n \n And I'll just say this, we have a lot of conviction that our strategy,  which is built around continuing to get growth \nout of the core, continuing to focus on oncology and continuing to focus on biopharma services, where we think \nwe have unique and distinguished capabilities, we have the opportunity to do internal innovation to drive growth. \n And we have appetite to do external growth, if we can find the right asset, align to the strategy in the right way \nthat meets our return thresholds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "We've checked our strategies based on how we've seen the landscape change over the past year.  \n \n", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f913895d5091969425f935932e0e8fed3d61ad3b28e40fc8b9b5909a8daf33", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35a6e226-9c60-4599-aab8-bf54b47f6896", "node_type": "1", "metadata": {"window": "We've gone \nback.  We've checked our strategies based on how we've seen the landscape change over the past year.  \n \n And I'll just say this, we have a lot of conviction that our strategy,  which is built around continuing to get growth \nout of the core, continuing to focus on oncology and continuing to focus on biopharma services, where we think \nwe have unique and distinguished capabilities, we have the opportunity to do internal innovation to drive growth. \n And we have appetite to do external growth, if we can find the right asset, align to the strategy in the right way \nthat meets our return thresholds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you. ", "original_text": "And we have appetite to do external growth, if we can find the right asset, align to the strategy in the right way \nthat meets our return thresholds.  \n "}, "hash": "b25ab7dcb1d1094b3a1cb9dc65b1cdc88faba198d2604518a5b2839b23e84342", "class_name": "RelatedNodeInfo"}}, "text": "And I'll just say this, we have a lot of conviction that our strategy,  which is built around continuing to get growth \nout of the core, continuing to focus on oncology and continuing to focus on biopharma services, where we think \nwe have unique and distinguished capabilities, we have the opportunity to do internal innovation to drive growth. \n", "start_char_idx": 2794, "end_char_idx": 3141, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35a6e226-9c60-4599-aab8-bf54b47f6896": {"__data__": {"id_": "35a6e226-9c60-4599-aab8-bf54b47f6896", "embedding": null, "metadata": {"window": "We've gone \nback.  We've checked our strategies based on how we've seen the landscape change over the past year.  \n \n And I'll just say this, we have a lot of conviction that our strategy,  which is built around continuing to get growth \nout of the core, continuing to focus on oncology and continuing to focus on biopharma services, where we think \nwe have unique and distinguished capabilities, we have the opportunity to do internal innovation to drive growth. \n And we have appetite to do external growth, if we can find the right asset, align to the strategy in the right way \nthat meets our return thresholds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you. ", "original_text": "And we have appetite to do external growth, if we can find the right asset, align to the strategy in the right way \nthat meets our return thresholds.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610365c071c7b4a48816accdeeb3e7409dbdef61529d5837d381384ca57cc1fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19206760-d2a6-4f7d-bd68-1f0281c7f171", "node_type": "1", "metadata": {"window": "And if you look at the landscape in healthcare this year, \nobviously, with the pandem ic, we saw a lot of the telehealth assets really catch a lot of momentum.  We've gone \nback.  We've checked our strategies based on how we've seen the landscape change over the past year.  \n \n And I'll just say this, we have a lot of conviction that our strategy,  which is built around continuing to get growth \nout of the core, continuing to focus on oncology and continuing to focus on biopharma services, where we think \nwe have unique and distinguished capabilities, we have the opportunity to do internal innovation to drive growth. \n And we have appetite to do external growth, if we can find the right asset, align to the strategy in the right way \nthat meets our return thresholds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Jailendra Singh with Credit Suisse.  \n ", "original_text": "And I'll just say this, we have a lot of conviction that our strategy,  which is built around continuing to get growth \nout of the core, continuing to focus on oncology and continuing to focus on biopharma services, where we think \nwe have unique and distinguished capabilities, we have the opportunity to do internal innovation to drive growth. \n", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdee1762ce17963c3a7bd968104628f96668d8a959b1d97c94dcae0a9db7fbec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25a48da2-c76a-4a4a-8e97-731c1699260a", "node_type": "1", "metadata": {"window": "We've checked our strategies based on how we've seen the landscape change over the past year.  \n \n And I'll just say this, we have a lot of conviction that our strategy,  which is built around continuing to get growth \nout of the core, continuing to focus on oncology and continuing to focus on biopharma services, where we think \nwe have unique and distinguished capabilities, we have the opportunity to do internal innovation to drive growth. \n And we have appetite to do external growth, if we can find the right asset, align to the strategy in the right way \nthat meets our return thresholds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you.  I actually want to talk, ask about your International segment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. "}, "hash": "3686c68502a06da634176852dc889fa840fed107b00c07874a4432aca5a0fcbf", "class_name": "RelatedNodeInfo"}}, "text": "And we have appetite to do external growth, if we can find the right asset, align to the strategy in the right way \nthat meets our return thresholds.  \n ", "start_char_idx": 3141, "end_char_idx": 3294, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25a48da2-c76a-4a4a-8e97-731c1699260a": {"__data__": {"id_": "25a48da2-c76a-4a4a-8e97-731c1699260a", "embedding": null, "metadata": {"window": "We've checked our strategies based on how we've seen the landscape change over the past year.  \n \n And I'll just say this, we have a lot of conviction that our strategy,  which is built around continuing to get growth \nout of the core, continuing to focus on oncology and continuing to focus on biopharma services, where we think \nwe have unique and distinguished capabilities, we have the opportunity to do internal innovation to drive growth. \n And we have appetite to do external growth, if we can find the right asset, align to the strategy in the right way \nthat meets our return thresholds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you.  I actually want to talk, ask about your International segment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610365c071c7b4a48816accdeeb3e7409dbdef61529d5837d381384ca57cc1fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35a6e226-9c60-4599-aab8-bf54b47f6896", "node_type": "1", "metadata": {"window": "We've gone \nback.  We've checked our strategies based on how we've seen the landscape change over the past year.  \n \n And I'll just say this, we have a lot of conviction that our strategy,  which is built around continuing to get growth \nout of the core, continuing to focus on oncology and continuing to focus on biopharma services, where we think \nwe have unique and distinguished capabilities, we have the opportunity to do internal innovation to drive growth. \n And we have appetite to do external growth, if we can find the right asset, align to the strategy in the right way \nthat meets our return thresholds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you. ", "original_text": "And we have appetite to do external growth, if we can find the right asset, align to the strategy in the right way \nthat meets our return thresholds.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5113993c0e17da74fa092d74b08d35a259eecbc1a7691966701cf09d45f4b173", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7252e85-6aff-4d87-b677-c7108d8aca00", "node_type": "1", "metadata": {"window": "And I'll just say this, we have a lot of conviction that our strategy,  which is built around continuing to get growth \nout of the core, continuing to focus on oncology and continuing to focus on biopharma services, where we think \nwe have unique and distinguished capabilities, we have the opportunity to do internal innovation to drive growth. \n And we have appetite to do external growth, if we can find the right asset, align to the strategy in the right way \nthat meets our return thresholds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you.  I actually want to talk, ask about your International segment.  Maybe if you can provide some, little bit \nmore details on the key drivers behind 4% to 8% core growth you expect in that business in fiscal 2022?  \n ", "original_text": "Our next question comes from Jailendra Singh with Credit Suisse.  \n "}, "hash": "5777685b866eb3df75d8b20f6d4e213a4f04be7b81555622f7c346874dd676d1", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "start_char_idx": 724, "end_char_idx": 1005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7252e85-6aff-4d87-b677-c7108d8aca00": {"__data__": {"id_": "f7252e85-6aff-4d87-b677-c7108d8aca00", "embedding": null, "metadata": {"window": "And I'll just say this, we have a lot of conviction that our strategy,  which is built around continuing to get growth \nout of the core, continuing to focus on oncology and continuing to focus on biopharma services, where we think \nwe have unique and distinguished capabilities, we have the opportunity to do internal innovation to drive growth. \n And we have appetite to do external growth, if we can find the right asset, align to the strategy in the right way \nthat meets our return thresholds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you.  I actually want to talk, ask about your International segment.  Maybe if you can provide some, little bit \nmore details on the key drivers behind 4% to 8% core growth you expect in that business in fiscal 2022?  \n ", "original_text": "Our next question comes from Jailendra Singh with Credit Suisse.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610365c071c7b4a48816accdeeb3e7409dbdef61529d5837d381384ca57cc1fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25a48da2-c76a-4a4a-8e97-731c1699260a", "node_type": "1", "metadata": {"window": "We've checked our strategies based on how we've seen the landscape change over the past year.  \n \n And I'll just say this, we have a lot of conviction that our strategy,  which is built around continuing to get growth \nout of the core, continuing to focus on oncology and continuing to focus on biopharma services, where we think \nwe have unique and distinguished capabilities, we have the opportunity to do internal innovation to drive growth. \n And we have appetite to do external growth, if we can find the right asset, align to the strategy in the right way \nthat meets our return thresholds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you.  I actually want to talk, ask about your International segment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "166ef6f2bfd68d46d8b4a705566e45e2d5dce4c0cbd631e2d85212c6cf87030e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ace2958c-1dee-40b4-87c4-76bab5f884b0", "node_type": "1", "metadata": {"window": "And we have appetite to do external growth, if we can find the right asset, align to the strategy in the right way \nthat meets our return thresholds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you.  I actually want to talk, ask about your International segment.  Maybe if you can provide some, little bit \nmore details on the key drivers behind 4% to 8% core growth you expect in that business in fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you. "}, "hash": "b56da5af07796ba4b96e14ee3af4d4a3ba21b208a902449cfd79bee12d979f13", "class_name": "RelatedNodeInfo"}}, "text": "Our next question comes from Jailendra Singh with Credit Suisse.  \n ", "start_char_idx": 3575, "end_char_idx": 3643, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ace2958c-1dee-40b4-87c4-76bab5f884b0": {"__data__": {"id_": "ace2958c-1dee-40b4-87c4-76bab5f884b0", "embedding": null, "metadata": {"window": "And we have appetite to do external growth, if we can find the right asset, align to the strategy in the right way \nthat meets our return thresholds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you.  I actually want to talk, ask about your International segment.  Maybe if you can provide some, little bit \nmore details on the key drivers behind 4% to 8% core growth you expect in that business in fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610365c071c7b4a48816accdeeb3e7409dbdef61529d5837d381384ca57cc1fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7252e85-6aff-4d87-b677-c7108d8aca00", "node_type": "1", "metadata": {"window": "And I'll just say this, we have a lot of conviction that our strategy,  which is built around continuing to get growth \nout of the core, continuing to focus on oncology and continuing to focus on biopharma services, where we think \nwe have unique and distinguished capabilities, we have the opportunity to do internal innovation to drive growth. \n And we have appetite to do external growth, if we can find the right asset, align to the strategy in the right way \nthat meets our return thresholds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you.  I actually want to talk, ask about your International segment.  Maybe if you can provide some, little bit \nmore details on the key drivers behind 4% to 8% core growth you expect in that business in fiscal 2022?  \n ", "original_text": "Our next question comes from Jailendra Singh with Credit Suisse.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9b3b48362e55a0ee23195847a036053c439c97bd41129a12ef38e58a7d32e426", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7892e6cb-c0bc-4c39-90ec-fa7bc2b0c94f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you.  I actually want to talk, ask about your International segment.  Maybe if you can provide some, little bit \nmore details on the key drivers behind 4% to 8% core growth you expect in that business in fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure. ", "original_text": "I actually want to talk, ask about your International segment. "}, "hash": "288b7f6a37ca97680f8c30d2bcd83af493a14732e8340031aefe8109b7b33a0e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you. ", "start_char_idx": 3643, "end_char_idx": 3977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7892e6cb-c0bc-4c39-90ec-fa7bc2b0c94f": {"__data__": {"id_": "7892e6cb-c0bc-4c39-90ec-fa7bc2b0c94f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you.  I actually want to talk, ask about your International segment.  Maybe if you can provide some, little bit \nmore details on the key drivers behind 4% to 8% core growth you expect in that business in fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure. ", "original_text": "I actually want to talk, ask about your International segment. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610365c071c7b4a48816accdeeb3e7409dbdef61529d5837d381384ca57cc1fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ace2958c-1dee-40b4-87c4-76bab5f884b0", "node_type": "1", "metadata": {"window": "And we have appetite to do external growth, if we can find the right asset, align to the strategy in the right way \nthat meets our return thresholds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you.  I actually want to talk, ask about your International segment.  Maybe if you can provide some, little bit \nmore details on the key drivers behind 4% to 8% core growth you expect in that business in fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3492bd472b25113066be8e7061779d699da2d59d20a44bc2fa211e9d29818adf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4526b873-46b5-4085-a373-e2fb7f36bff5", "node_type": "1", "metadata": {"window": "Our next question comes from Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you.  I actually want to talk, ask about your International segment.  Maybe if you can provide some, little bit \nmore details on the key drivers behind 4% to 8% core growth you expect in that business in fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure.  I'll start. ", "original_text": "Maybe if you can provide some, little bit \nmore details on the key drivers behind 4% to 8% core growth you expect in that business in fiscal 2022?  \n "}, "hash": "fbca3db8e489f099fd32ac72b8d102bea04d730ecdd5c0aff606beae83d5c512", "class_name": "RelatedNodeInfo"}}, "text": "I actually want to talk, ask about your International segment. ", "start_char_idx": 3977, "end_char_idx": 4040, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4526b873-46b5-4085-a373-e2fb7f36bff5": {"__data__": {"id_": "4526b873-46b5-4085-a373-e2fb7f36bff5", "embedding": null, "metadata": {"window": "Our next question comes from Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you.  I actually want to talk, ask about your International segment.  Maybe if you can provide some, little bit \nmore details on the key drivers behind 4% to 8% core growth you expect in that business in fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure.  I'll start. ", "original_text": "Maybe if you can provide some, little bit \nmore details on the key drivers behind 4% to 8% core growth you expect in that business in fiscal 2022?  \n ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610365c071c7b4a48816accdeeb3e7409dbdef61529d5837d381384ca57cc1fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7892e6cb-c0bc-4c39-90ec-fa7bc2b0c94f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Our next question comes from Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you.  I actually want to talk, ask about your International segment.  Maybe if you can provide some, little bit \nmore details on the key drivers behind 4% to 8% core growth you expect in that business in fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure. ", "original_text": "I actually want to talk, ask about your International segment. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d13f7791a3866d26e20fc0c3931f02aaee24e4ea1d00d2fb1516769b19d64224", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "091c0a5a-27e4-421f-8865-15abc19c6f73", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you.  I actually want to talk, ask about your International segment.  Maybe if you can provide some, little bit \nmore details on the key drivers behind 4% to 8% core growth you expect in that business in fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure.  I'll start.  I mean, let's, first, we should recognize that in the International segment, the pandemic recovery is \nlagging what we're seeing in the US a little bit.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "854c776daaebd2479ca98a913d1c00608569e74dfb8eedabc38b0b721d0d04b7", "class_name": "RelatedNodeInfo"}}, "text": "Maybe if you can provide some, little bit \nmore details on the key drivers behind 4% to 8% core growth you expect in that business in fiscal 2022?  \n ", "start_char_idx": 4040, "end_char_idx": 4190, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "091c0a5a-27e4-421f-8865-15abc19c6f73": {"__data__": {"id_": "091c0a5a-27e4-421f-8865-15abc19c6f73", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you.  I actually want to talk, ask about your International segment.  Maybe if you can provide some, little bit \nmore details on the key drivers behind 4% to 8% core growth you expect in that business in fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure.  I'll start.  I mean, let's, first, we should recognize that in the International segment, the pandemic recovery is \nlagging what we're seeing in the US a little bit.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610365c071c7b4a48816accdeeb3e7409dbdef61529d5837d381384ca57cc1fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4526b873-46b5-4085-a373-e2fb7f36bff5", "node_type": "1", "metadata": {"window": "Our next question comes from Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you.  I actually want to talk, ask about your International segment.  Maybe if you can provide some, little bit \nmore details on the key drivers behind 4% to 8% core growth you expect in that business in fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure.  I'll start. ", "original_text": "Maybe if you can provide some, little bit \nmore details on the key drivers behind 4% to 8% core growth you expect in that business in fiscal 2022?  \n ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7debc7f9c720ea00cc9769cbdae6821c19ac7327a0c7e5769e21f6e19af537c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46aebbcd-6b35-49b3-aeab-606a899b1b86", "node_type": "1", "metadata": {"window": "I actually want to talk, ask about your International segment.  Maybe if you can provide some, little bit \nmore details on the key drivers behind 4% to 8% core growth you expect in that business in fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure.  I'll start.  I mean, let's, first, we should recognize that in the International segment, the pandemic recovery is \nlagging what we're seeing in the US a little bit.  \n ", "original_text": "A \nSure. "}, "hash": "e6fd2534c01879cd9cd9b6859e8326e10d8496b3e835979f7edd8f925234ab81", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 4190, "end_char_idx": 4532, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46aebbcd-6b35-49b3-aeab-606a899b1b86": {"__data__": {"id_": "46aebbcd-6b35-49b3-aeab-606a899b1b86", "embedding": null, "metadata": {"window": "I actually want to talk, ask about your International segment.  Maybe if you can provide some, little bit \nmore details on the key drivers behind 4% to 8% core growth you expect in that business in fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure.  I'll start.  I mean, let's, first, we should recognize that in the International segment, the pandemic recovery is \nlagging what we're seeing in the US a little bit.  \n ", "original_text": "A \nSure. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610365c071c7b4a48816accdeeb3e7409dbdef61529d5837d381384ca57cc1fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "091c0a5a-27e4-421f-8865-15abc19c6f73", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you.  I actually want to talk, ask about your International segment.  Maybe if you can provide some, little bit \nmore details on the key drivers behind 4% to 8% core growth you expect in that business in fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure.  I'll start.  I mean, let's, first, we should recognize that in the International segment, the pandemic recovery is \nlagging what we're seeing in the US a little bit.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "02a40872935ab8b784e92463e06e3ec2863c4586ce3e81b1cdd66e6310f55088", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "062f9cdb-e08c-4810-abf9-9f13d4c3f195", "node_type": "1", "metadata": {"window": "Maybe if you can provide some, little bit \nmore details on the key drivers behind 4% to 8% core growth you expect in that business in fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure.  I'll start.  I mean, let's, first, we should recognize that in the International segment, the pandemic recovery is \nlagging what we're seeing in the US a little bit.  \n ", "original_text": "I'll start. "}, "hash": "30d30bfa54f734e7425dc761c1b5ba990651b13b251a81c6a2d8909fb90ba933", "class_name": "RelatedNodeInfo"}}, "text": "A \nSure. ", "start_char_idx": 4532, "end_char_idx": 4541, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "062f9cdb-e08c-4810-abf9-9f13d4c3f195": {"__data__": {"id_": "062f9cdb-e08c-4810-abf9-9f13d4c3f195", "embedding": null, "metadata": {"window": "Maybe if you can provide some, little bit \nmore details on the key drivers behind 4% to 8% core growth you expect in that business in fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure.  I'll start.  I mean, let's, first, we should recognize that in the International segment, the pandemic recovery is \nlagging what we're seeing in the US a little bit.  \n ", "original_text": "I'll start. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610365c071c7b4a48816accdeeb3e7409dbdef61529d5837d381384ca57cc1fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46aebbcd-6b35-49b3-aeab-606a899b1b86", "node_type": "1", "metadata": {"window": "I actually want to talk, ask about your International segment.  Maybe if you can provide some, little bit \nmore details on the key drivers behind 4% to 8% core growth you expect in that business in fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure.  I'll start.  I mean, let's, first, we should recognize that in the International segment, the pandemic recovery is \nlagging what we're seeing in the US a little bit.  \n ", "original_text": "A \nSure. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5f0b09305add624aa1d9e0ca0ca3459569a8156a64bffdb3ef0d6ddb7748774", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56315fca-6a5d-46e0-b292-0b40b887d6c0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure.  I'll start.  I mean, let's, first, we should recognize that in the International segment, the pandemic recovery is \nlagging what we're seeing in the US a little bit.  \n ", "original_text": "I mean, let's, first, we should recognize that in the International segment, the pandemic recovery is \nlagging what we're seeing in the US a little bit.  \n "}, "hash": "e633f15b1aecfd7e784c9b9118dfc541265bb1c9ef255fe5b52f492c8c84e91e", "class_name": "RelatedNodeInfo"}}, "text": "I'll start. ", "start_char_idx": 4541, "end_char_idx": 4553, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56315fca-6a5d-46e0-b292-0b40b887d6c0": {"__data__": {"id_": "56315fca-6a5d-46e0-b292-0b40b887d6c0", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure.  I'll start.  I mean, let's, first, we should recognize that in the International segment, the pandemic recovery is \nlagging what we're seeing in the US a little bit.  \n ", "original_text": "I mean, let's, first, we should recognize that in the International segment, the pandemic recovery is \nlagging what we're seeing in the US a little bit.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610365c071c7b4a48816accdeeb3e7409dbdef61529d5837d381384ca57cc1fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "062f9cdb-e08c-4810-abf9-9f13d4c3f195", "node_type": "1", "metadata": {"window": "Maybe if you can provide some, little bit \nmore details on the key drivers behind 4% to 8% core growth you expect in that business in fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure.  I'll start.  I mean, let's, first, we should recognize that in the International segment, the pandemic recovery is \nlagging what we're seeing in the US a little bit.  \n ", "original_text": "I'll start. ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "09b1bbca38405d58685c6d132425c0218a7ad0dd7834ef6917e761b291253d6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "770365a1-3f5a-4479-ac8c-d33c1ae2892b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBut we're very pleased with the performance that this business has had.  We have worked diligently over the last \nfew years to really think about, how we organize and streamline and make that business more efficient, capturing  \nsome of the scale across all of the countries.  \n \n We've been rigorous in looking at our retail footprints. ", "original_text": "McKesson Corp.  "}, "hash": "8167f3eaab5c80b490e97831983de8563fa74e247e22bb9da435fb8325f482e7", "class_name": "RelatedNodeInfo"}}, "text": "I mean, let's, first, we should recognize that in the International segment, the pandemic recovery is \nlagging what we're seeing in the US a little bit.  \n ", "start_char_idx": 4553, "end_char_idx": 4709, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "770365a1-3f5a-4479-ac8c-d33c1ae2892b": {"__data__": {"id_": "770365a1-3f5a-4479-ac8c-d33c1ae2892b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBut we're very pleased with the performance that this business has had.  We have worked diligently over the last \nfew years to really think about, how we organize and streamline and make that business more efficient, capturing  \nsome of the scale across all of the countries.  \n \n We've been rigorous in looking at our retail footprints. ", "original_text": "McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56315fca-6a5d-46e0-b292-0b40b887d6c0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure.  I'll start.  I mean, let's, first, we should recognize that in the International segment, the pandemic recovery is \nlagging what we're seeing in the US a little bit.  \n ", "original_text": "I mean, let's, first, we should recognize that in the International segment, the pandemic recovery is \nlagging what we're seeing in the US a little bit.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50ebfbd4bd69879086634b88e65aaea29e4786204331526030615fac926816a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a73ff41-44d1-4c3e-b7ef-eac21312c5fb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBut we're very pleased with the performance that this business has had.  We have worked diligently over the last \nfew years to really think about, how we organize and streamline and make that business more efficient, capturing  \nsome of the scale across all of the countries.  \n \n We've been rigorous in looking at our retail footprints.  And we've done some rationalization of our physical estate \nthere. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBut we're very pleased with the performance that this business has had. "}, "hash": "679499e2ecbba3e2be505697c91e12d8c03550d24391cf5b82c1b0a9ce07ddfd", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a73ff41-44d1-4c3e-b7ef-eac21312c5fb": {"__data__": {"id_": "4a73ff41-44d1-4c3e-b7ef-eac21312c5fb", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBut we're very pleased with the performance that this business has had.  We have worked diligently over the last \nfew years to really think about, how we organize and streamline and make that business more efficient, capturing  \nsome of the scale across all of the countries.  \n \n We've been rigorous in looking at our retail footprints.  And we've done some rationalization of our physical estate \nthere. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBut we're very pleased with the performance that this business has had. ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "770365a1-3f5a-4479-ac8c-d33c1ae2892b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBut we're very pleased with the performance that this business has had.  We have worked diligently over the last \nfew years to really think about, how we organize and streamline and make that business more efficient, capturing  \nsome of the scale across all of the countries.  \n \n We've been rigorous in looking at our retail footprints. ", "original_text": "McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "deb3dc959d3261863b509b44e092df097dc7e7871bdeabd76b688f17dd63c829", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65f3f973-f28a-497e-995a-088aeb9adadb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBut we're very pleased with the performance that this business has had.  We have worked diligently over the last \nfew years to really think about, how we organize and streamline and make that business more efficient, capturing  \nsome of the scale across all of the countries.  \n \n We've been rigorous in looking at our retail footprints.  And we've done some rationalization of our physical estate \nthere.  And we've made some investments, frankly, in some digital technologies that really w ere, turned out to be \nquite timely and important this year as patients decided they wanted to use digital health services more.  \n \n", "original_text": "We have worked diligently over the last \nfew years to really think about, how we organize and streamline and make that business more efficient, capturing  \nsome of the scale across all of the countries.  \n \n"}, "hash": "7b337b147feb7ec64a2d0d8f5fd5df7938f82c7998e173f1260bd8cdff8f0db0", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBut we're very pleased with the performance that this business has had. ", "start_char_idx": 16, "end_char_idx": 253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65f3f973-f28a-497e-995a-088aeb9adadb": {"__data__": {"id_": "65f3f973-f28a-497e-995a-088aeb9adadb", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBut we're very pleased with the performance that this business has had.  We have worked diligently over the last \nfew years to really think about, how we organize and streamline and make that business more efficient, capturing  \nsome of the scale across all of the countries.  \n \n We've been rigorous in looking at our retail footprints.  And we've done some rationalization of our physical estate \nthere.  And we've made some investments, frankly, in some digital technologies that really w ere, turned out to be \nquite timely and important this year as patients decided they wanted to use digital health services more.  \n \n", "original_text": "We have worked diligently over the last \nfew years to really think about, how we organize and streamline and make that business more efficient, capturing  \nsome of the scale across all of the countries.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a73ff41-44d1-4c3e-b7ef-eac21312c5fb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBut we're very pleased with the performance that this business has had.  We have worked diligently over the last \nfew years to really think about, how we organize and streamline and make that business more efficient, capturing  \nsome of the scale across all of the countries.  \n \n We've been rigorous in looking at our retail footprints.  And we've done some rationalization of our physical estate \nthere. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBut we're very pleased with the performance that this business has had. ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1bf25914ed612462cccb7856af3cabff960d45ee4bf3d9629b4ff56f68aad11b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5fa4d053-ef2f-4a39-9be2-028c95e4aed1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBut we're very pleased with the performance that this business has had.  We have worked diligently over the last \nfew years to really think about, how we organize and streamline and make that business more efficient, capturing  \nsome of the scale across all of the countries.  \n \n We've been rigorous in looking at our retail footprints.  And we've done some rationalization of our physical estate \nthere.  And we've made some investments, frankly, in some digital technologies that really w ere, turned out to be \nquite timely and important this year as patients decided they wanted to use digital health services more.  \n \n So we're very pleased with the performance of the European business. ", "original_text": "We've been rigorous in looking at our retail footprints. "}, "hash": "724f466e6f5e55a681437e509ad14853e22374a24b1c45669db8b6a76731dec0", "class_name": "RelatedNodeInfo"}}, "text": "We have worked diligently over the last \nfew years to really think about, how we organize and streamline and make that business more efficient, capturing  \nsome of the scale across all of the countries.  \n \n", "start_char_idx": 253, "end_char_idx": 460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5fa4d053-ef2f-4a39-9be2-028c95e4aed1": {"__data__": {"id_": "5fa4d053-ef2f-4a39-9be2-028c95e4aed1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBut we're very pleased with the performance that this business has had.  We have worked diligently over the last \nfew years to really think about, how we organize and streamline and make that business more efficient, capturing  \nsome of the scale across all of the countries.  \n \n We've been rigorous in looking at our retail footprints.  And we've done some rationalization of our physical estate \nthere.  And we've made some investments, frankly, in some digital technologies that really w ere, turned out to be \nquite timely and important this year as patients decided they wanted to use digital health services more.  \n \n So we're very pleased with the performance of the European business. ", "original_text": "We've been rigorous in looking at our retail footprints. ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65f3f973-f28a-497e-995a-088aeb9adadb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBut we're very pleased with the performance that this business has had.  We have worked diligently over the last \nfew years to really think about, how we organize and streamline and make that business more efficient, capturing  \nsome of the scale across all of the countries.  \n \n We've been rigorous in looking at our retail footprints.  And we've done some rationalization of our physical estate \nthere.  And we've made some investments, frankly, in some digital technologies that really w ere, turned out to be \nquite timely and important this year as patients decided they wanted to use digital health services more.  \n \n", "original_text": "We have worked diligently over the last \nfew years to really think about, how we organize and streamline and make that business more efficient, capturing  \nsome of the scale across all of the countries.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "786698034b1223666a4a440205a0264e117753f03592fa8b00e1f9f65dafbdc5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d76db69-6cca-4508-8f2b-618fba7a474c", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBut we're very pleased with the performance that this business has had.  We have worked diligently over the last \nfew years to really think about, how we organize and streamline and make that business more efficient, capturing  \nsome of the scale across all of the countries.  \n \n We've been rigorous in looking at our retail footprints.  And we've done some rationalization of our physical estate \nthere.  And we've made some investments, frankly, in some digital technologies that really w ere, turned out to be \nquite timely and important this year as patients decided they wanted to use digital health services more.  \n \n So we're very pleased with the performance of the European business.  We run it in a very, disciplined, very tight \nway. ", "original_text": "And we've done some rationalization of our physical estate \nthere. "}, "hash": "4d2f88c6dc312c6e169a7767d85e65ab819ed179403b4c4dd15cfeef999654f0", "class_name": "RelatedNodeInfo"}}, "text": "We've been rigorous in looking at our retail footprints. ", "start_char_idx": 460, "end_char_idx": 517, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d76db69-6cca-4508-8f2b-618fba7a474c": {"__data__": {"id_": "1d76db69-6cca-4508-8f2b-618fba7a474c", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBut we're very pleased with the performance that this business has had.  We have worked diligently over the last \nfew years to really think about, how we organize and streamline and make that business more efficient, capturing  \nsome of the scale across all of the countries.  \n \n We've been rigorous in looking at our retail footprints.  And we've done some rationalization of our physical estate \nthere.  And we've made some investments, frankly, in some digital technologies that really w ere, turned out to be \nquite timely and important this year as patients decided they wanted to use digital health services more.  \n \n So we're very pleased with the performance of the European business.  We run it in a very, disciplined, very tight \nway. ", "original_text": "And we've done some rationalization of our physical estate \nthere. ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5fa4d053-ef2f-4a39-9be2-028c95e4aed1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBut we're very pleased with the performance that this business has had.  We have worked diligently over the last \nfew years to really think about, how we organize and streamline and make that business more efficient, capturing  \nsome of the scale across all of the countries.  \n \n We've been rigorous in looking at our retail footprints.  And we've done some rationalization of our physical estate \nthere.  And we've made some investments, frankly, in some digital technologies that really w ere, turned out to be \nquite timely and important this year as patients decided they wanted to use digital health services more.  \n \n So we're very pleased with the performance of the European business. ", "original_text": "We've been rigorous in looking at our retail footprints. ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f6696e5c1da193808ea13f266f27bb41bf752bb9788fff709cb69c3547696905", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "040b4728-d88f-4fec-8608-0469b2cd0701", "node_type": "1", "metadata": {"window": "We have worked diligently over the last \nfew years to really think about, how we organize and streamline and make that business more efficient, capturing  \nsome of the scale across all of the countries.  \n \n We've been rigorous in looking at our retail footprints.  And we've done some rationalization of our physical estate \nthere.  And we've made some investments, frankly, in some digital technologies that really w ere, turned out to be \nquite timely and important this year as patients decided they wanted to use digital health services more.  \n \n So we're very pleased with the performance of the European business.  We run it in a very, disciplined, very tight \nway.  It is no t inherently high -growth markets. ", "original_text": "And we've made some investments, frankly, in some digital technologies that really w ere, turned out to be \nquite timely and important this year as patients decided they wanted to use digital health services more.  \n \n"}, "hash": "3684f9db4be8092ebde032338b4e8d5ed71c042b6bd63e7bb59eef5d860bed9b", "class_name": "RelatedNodeInfo"}}, "text": "And we've done some rationalization of our physical estate \nthere. ", "start_char_idx": 517, "end_char_idx": 584, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "040b4728-d88f-4fec-8608-0469b2cd0701": {"__data__": {"id_": "040b4728-d88f-4fec-8608-0469b2cd0701", "embedding": null, "metadata": {"window": "We have worked diligently over the last \nfew years to really think about, how we organize and streamline and make that business more efficient, capturing  \nsome of the scale across all of the countries.  \n \n We've been rigorous in looking at our retail footprints.  And we've done some rationalization of our physical estate \nthere.  And we've made some investments, frankly, in some digital technologies that really w ere, turned out to be \nquite timely and important this year as patients decided they wanted to use digital health services more.  \n \n So we're very pleased with the performance of the European business.  We run it in a very, disciplined, very tight \nway.  It is no t inherently high -growth markets. ", "original_text": "And we've made some investments, frankly, in some digital technologies that really w ere, turned out to be \nquite timely and important this year as patients decided they wanted to use digital health services more.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d76db69-6cca-4508-8f2b-618fba7a474c", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBut we're very pleased with the performance that this business has had.  We have worked diligently over the last \nfew years to really think about, how we organize and streamline and make that business more efficient, capturing  \nsome of the scale across all of the countries.  \n \n We've been rigorous in looking at our retail footprints.  And we've done some rationalization of our physical estate \nthere.  And we've made some investments, frankly, in some digital technologies that really w ere, turned out to be \nquite timely and important this year as patients decided they wanted to use digital health services more.  \n \n So we're very pleased with the performance of the European business.  We run it in a very, disciplined, very tight \nway. ", "original_text": "And we've done some rationalization of our physical estate \nthere. ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f8cdfaf14f412deb3ee5c0b0e91b38f4c79fb1c1f4bc960604ed8ec69a316f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf93af5a-3cb1-479d-b706-3b20919a617d", "node_type": "1", "metadata": {"window": "We've been rigorous in looking at our retail footprints.  And we've done some rationalization of our physical estate \nthere.  And we've made some investments, frankly, in some digital technologies that really w ere, turned out to be \nquite timely and important this year as patients decided they wanted to use digital health services more.  \n \n So we're very pleased with the performance of the European business.  We run it in a very, disciplined, very tight \nway.  It is no t inherently high -growth markets.  So to get the growth that we see, we're very pleased with the team.  \n ", "original_text": "So we're very pleased with the performance of the European business. "}, "hash": "546d1ecd19f01d5151cd16ab37ded9a8d6546ffdc94c39a90a8ef00bc8f738ff", "class_name": "RelatedNodeInfo"}}, "text": "And we've made some investments, frankly, in some digital technologies that really w ere, turned out to be \nquite timely and important this year as patients decided they wanted to use digital health services more.  \n \n", "start_char_idx": 584, "end_char_idx": 802, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf93af5a-3cb1-479d-b706-3b20919a617d": {"__data__": {"id_": "bf93af5a-3cb1-479d-b706-3b20919a617d", "embedding": null, "metadata": {"window": "We've been rigorous in looking at our retail footprints.  And we've done some rationalization of our physical estate \nthere.  And we've made some investments, frankly, in some digital technologies that really w ere, turned out to be \nquite timely and important this year as patients decided they wanted to use digital health services more.  \n \n So we're very pleased with the performance of the European business.  We run it in a very, disciplined, very tight \nway.  It is no t inherently high -growth markets.  So to get the growth that we see, we're very pleased with the team.  \n ", "original_text": "So we're very pleased with the performance of the European business. ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "040b4728-d88f-4fec-8608-0469b2cd0701", "node_type": "1", "metadata": {"window": "We have worked diligently over the last \nfew years to really think about, how we organize and streamline and make that business more efficient, capturing  \nsome of the scale across all of the countries.  \n \n We've been rigorous in looking at our retail footprints.  And we've done some rationalization of our physical estate \nthere.  And we've made some investments, frankly, in some digital technologies that really w ere, turned out to be \nquite timely and important this year as patients decided they wanted to use digital health services more.  \n \n So we're very pleased with the performance of the European business.  We run it in a very, disciplined, very tight \nway.  It is no t inherently high -growth markets. ", "original_text": "And we've made some investments, frankly, in some digital technologies that really w ere, turned out to be \nquite timely and important this year as patients decided they wanted to use digital health services more.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "177c29df31078e9c38d2676474da583d78dd0fc21bc9282b83a42a2de1557ff5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32089699-1801-497b-a2d3-ff7679df6331", "node_type": "1", "metadata": {"window": "And we've done some rationalization of our physical estate \nthere.  And we've made some investments, frankly, in some digital technologies that really w ere, turned out to be \nquite timely and important this year as patients decided they wanted to use digital health services more.  \n \n So we're very pleased with the performance of the European business.  We run it in a very, disciplined, very tight \nway.  It is no t inherently high -growth markets.  So to get the growth that we see, we're very pleased with the team.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "We run it in a very, disciplined, very tight \nway. "}, "hash": "70a545ed136374c340e976db20398c1aee1dc9b3c39b31c236a459bf2239da57", "class_name": "RelatedNodeInfo"}}, "text": "So we're very pleased with the performance of the European business. ", "start_char_idx": 802, "end_char_idx": 871, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32089699-1801-497b-a2d3-ff7679df6331": {"__data__": {"id_": "32089699-1801-497b-a2d3-ff7679df6331", "embedding": null, "metadata": {"window": "And we've done some rationalization of our physical estate \nthere.  And we've made some investments, frankly, in some digital technologies that really w ere, turned out to be \nquite timely and important this year as patients decided they wanted to use digital health services more.  \n \n So we're very pleased with the performance of the European business.  We run it in a very, disciplined, very tight \nway.  It is no t inherently high -growth markets.  So to get the growth that we see, we're very pleased with the team.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "We run it in a very, disciplined, very tight \nway. ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf93af5a-3cb1-479d-b706-3b20919a617d", "node_type": "1", "metadata": {"window": "We've been rigorous in looking at our retail footprints.  And we've done some rationalization of our physical estate \nthere.  And we've made some investments, frankly, in some digital technologies that really w ere, turned out to be \nquite timely and important this year as patients decided they wanted to use digital health services more.  \n \n So we're very pleased with the performance of the European business.  We run it in a very, disciplined, very tight \nway.  It is no t inherently high -growth markets.  So to get the growth that we see, we're very pleased with the team.  \n ", "original_text": "So we're very pleased with the performance of the European business. ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e40d69487fcd3baf8c727607e3cff2015b5d6505ed661e9caa43e962320240f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c85c724-65ea-4c7d-9b0d-f495e574407d", "node_type": "1", "metadata": {"window": "And we've made some investments, frankly, in some digital technologies that really w ere, turned out to be \nquite timely and important this year as patients decided they wanted to use digital health services more.  \n \n So we're very pleased with the performance of the European business.  We run it in a very, disciplined, very tight \nway.  It is no t inherently high -growth markets.  So to get the growth that we see, we're very pleased with the team.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI guess, I would just add, similar to the US market, our international markets have also faced COVID headwinds. \n", "original_text": "It is no t inherently high -growth markets. "}, "hash": "4bdce65e6f63b418654775db36298eb188704b025010e789a118ffb1049079fa", "class_name": "RelatedNodeInfo"}}, "text": "We run it in a very, disciplined, very tight \nway. ", "start_char_idx": 871, "end_char_idx": 922, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c85c724-65ea-4c7d-9b0d-f495e574407d": {"__data__": {"id_": "0c85c724-65ea-4c7d-9b0d-f495e574407d", "embedding": null, "metadata": {"window": "And we've made some investments, frankly, in some digital technologies that really w ere, turned out to be \nquite timely and important this year as patients decided they wanted to use digital health services more.  \n \n So we're very pleased with the performance of the European business.  We run it in a very, disciplined, very tight \nway.  It is no t inherently high -growth markets.  So to get the growth that we see, we're very pleased with the team.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI guess, I would just add, similar to the US market, our international markets have also faced COVID headwinds. \n", "original_text": "It is no t inherently high -growth markets. ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32089699-1801-497b-a2d3-ff7679df6331", "node_type": "1", "metadata": {"window": "And we've done some rationalization of our physical estate \nthere.  And we've made some investments, frankly, in some digital technologies that really w ere, turned out to be \nquite timely and important this year as patients decided they wanted to use digital health services more.  \n \n So we're very pleased with the performance of the European business.  We run it in a very, disciplined, very tight \nway.  It is no t inherently high -growth markets.  So to get the growth that we see, we're very pleased with the team.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "We run it in a very, disciplined, very tight \nway. ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfab438818b6e3802121320fe7c09cdc047aa3dd80b6428b47c55915336e1953", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9db9abdb-108b-47e0-bad5-638c90d680cc", "node_type": "1", "metadata": {"window": "So we're very pleased with the performance of the European business.  We run it in a very, disciplined, very tight \nway.  It is no t inherently high -growth markets.  So to get the growth that we see, we're very pleased with the team.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI guess, I would just add, similar to the US market, our international markets have also faced COVID headwinds. \n And we would expect that those markets will begin to recover along the same type of time lines we laid out in our \nbroader comments.  \n ", "original_text": "So to get the growth that we see, we're very pleased with the team.  \n "}, "hash": "f9b204e8aea7eb3a504595a5e94960342a97ec834e9e773d76783b4485b105b7", "class_name": "RelatedNodeInfo"}}, "text": "It is no t inherently high -growth markets. ", "start_char_idx": 922, "end_char_idx": 966, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9db9abdb-108b-47e0-bad5-638c90d680cc": {"__data__": {"id_": "9db9abdb-108b-47e0-bad5-638c90d680cc", "embedding": null, "metadata": {"window": "So we're very pleased with the performance of the European business.  We run it in a very, disciplined, very tight \nway.  It is no t inherently high -growth markets.  So to get the growth that we see, we're very pleased with the team.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI guess, I would just add, similar to the US market, our international markets have also faced COVID headwinds. \n And we would expect that those markets will begin to recover along the same type of time lines we laid out in our \nbroader comments.  \n ", "original_text": "So to get the growth that we see, we're very pleased with the team.  \n ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c85c724-65ea-4c7d-9b0d-f495e574407d", "node_type": "1", "metadata": {"window": "And we've made some investments, frankly, in some digital technologies that really w ere, turned out to be \nquite timely and important this year as patients decided they wanted to use digital health services more.  \n \n So we're very pleased with the performance of the European business.  We run it in a very, disciplined, very tight \nway.  It is no t inherently high -growth markets.  So to get the growth that we see, we're very pleased with the team.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI guess, I would just add, similar to the US market, our international markets have also faced COVID headwinds. \n", "original_text": "It is no t inherently high -growth markets. ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6919bfe5abc84585203337fa6e0fb0987432b8467e11b00575ff9780dabb858", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dab714cd-4972-4df5-a657-d5d2319e77ec", "node_type": "1", "metadata": {"window": "We run it in a very, disciplined, very tight \nway.  It is no t inherently high -growth markets.  So to get the growth that we see, we're very pleased with the team.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI guess, I would just add, similar to the US market, our international markets have also faced COVID headwinds. \n And we would expect that those markets will begin to recover along the same type of time lines we laid out in our \nbroader comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "48b3248a44b302e4c322110382ee92ef6e90aa118acb9843a8e34b6c371c9a76", "class_name": "RelatedNodeInfo"}}, "text": "So to get the growth that we see, we're very pleased with the team.  \n ", "start_char_idx": 966, "end_char_idx": 1037, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dab714cd-4972-4df5-a657-d5d2319e77ec": {"__data__": {"id_": "dab714cd-4972-4df5-a657-d5d2319e77ec", "embedding": null, "metadata": {"window": "We run it in a very, disciplined, very tight \nway.  It is no t inherently high -growth markets.  So to get the growth that we see, we're very pleased with the team.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI guess, I would just add, similar to the US market, our international markets have also faced COVID headwinds. \n And we would expect that those markets will begin to recover along the same type of time lines we laid out in our \nbroader comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9db9abdb-108b-47e0-bad5-638c90d680cc", "node_type": "1", "metadata": {"window": "So we're very pleased with the performance of the European business.  We run it in a very, disciplined, very tight \nway.  It is no t inherently high -growth markets.  So to get the growth that we see, we're very pleased with the team.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI guess, I would just add, similar to the US market, our international markets have also faced COVID headwinds. \n And we would expect that those markets will begin to recover along the same type of time lines we laid out in our \nbroader comments.  \n ", "original_text": "So to get the growth that we see, we're very pleased with the team.  \n ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4a2a684fec1e7bda295ded4497816c6ef4281ad1e3f9bfbf089e2a771391733a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3d8d701-03aa-4853-949e-16d192d1730d", "node_type": "1", "metadata": {"window": "It is no t inherently high -growth markets.  So to get the growth that we see, we're very pleased with the team.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI guess, I would just add, similar to the US market, our international markets have also faced COVID headwinds. \n And we would expect that those markets will begin to recover along the same type of time lines we laid out in our \nbroader comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, we have time for one more question.  \n ", "original_text": "A \nI guess, I would just add, similar to the US market, our international markets have also faced COVID headwinds. \n"}, "hash": "5fe459d2fd1a19dc8c4518cac46dea7c699cbbf789acb7bd1599e6a98755565a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1037, "end_char_idx": 1366, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3d8d701-03aa-4853-949e-16d192d1730d": {"__data__": {"id_": "f3d8d701-03aa-4853-949e-16d192d1730d", "embedding": null, "metadata": {"window": "It is no t inherently high -growth markets.  So to get the growth that we see, we're very pleased with the team.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI guess, I would just add, similar to the US market, our international markets have also faced COVID headwinds. \n And we would expect that those markets will begin to recover along the same type of time lines we laid out in our \nbroader comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, we have time for one more question.  \n ", "original_text": "A \nI guess, I would just add, similar to the US market, our international markets have also faced COVID headwinds. \n", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dab714cd-4972-4df5-a657-d5d2319e77ec", "node_type": "1", "metadata": {"window": "We run it in a very, disciplined, very tight \nway.  It is no t inherently high -growth markets.  So to get the growth that we see, we're very pleased with the team.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI guess, I would just add, similar to the US market, our international markets have also faced COVID headwinds. \n And we would expect that those markets will begin to recover along the same type of time lines we laid out in our \nbroader comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f6790ee5acc0b5e6e412cddb1fb9e368ef45ade28ee7abff2bd843e1a3ff2599", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be724035-8296-441a-9799-6d76e5943385", "node_type": "1", "metadata": {"window": "So to get the growth that we see, we're very pleased with the team.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI guess, I would just add, similar to the US market, our international markets have also faced COVID headwinds. \n And we would expect that those markets will begin to recover along the same type of time lines we laid out in our \nbroader comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly, that question comes from Brian Tanquilut with Jefferies.  \n ", "original_text": "And we would expect that those markets will begin to recover along the same type of time lines we laid out in our \nbroader comments.  \n "}, "hash": "ee0c16dc8b29a92db8e147744fd429a6e7140d23b3bf4bd92f5a60c9e2485c91", "class_name": "RelatedNodeInfo"}}, "text": "A \nI guess, I would just add, similar to the US market, our international markets have also faced COVID headwinds. \n", "start_char_idx": 1366, "end_char_idx": 1482, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be724035-8296-441a-9799-6d76e5943385": {"__data__": {"id_": "be724035-8296-441a-9799-6d76e5943385", "embedding": null, "metadata": {"window": "So to get the growth that we see, we're very pleased with the team.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI guess, I would just add, similar to the US market, our international markets have also faced COVID headwinds. \n And we would expect that those markets will begin to recover along the same type of time lines we laid out in our \nbroader comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly, that question comes from Brian Tanquilut with Jefferies.  \n ", "original_text": "And we would expect that those markets will begin to recover along the same type of time lines we laid out in our \nbroader comments.  \n ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3d8d701-03aa-4853-949e-16d192d1730d", "node_type": "1", "metadata": {"window": "It is no t inherently high -growth markets.  So to get the growth that we see, we're very pleased with the team.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI guess, I would just add, similar to the US market, our international markets have also faced COVID headwinds. \n And we would expect that those markets will begin to recover along the same type of time lines we laid out in our \nbroader comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, we have time for one more question.  \n ", "original_text": "A \nI guess, I would just add, similar to the US market, our international markets have also faced COVID headwinds. \n", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f1dcb9f75cac23f12f43c07f0381c9895319b3e931ae698dddc1999b7c1445e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c61e8c4a-82c9-4837-9b03-fb14c268cc01", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI guess, I would just add, similar to the US market, our international markets have also faced COVID headwinds. \n And we would expect that those markets will begin to recover along the same type of time lines we laid out in our \nbroader comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly, that question comes from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi good afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  "}, "hash": "72e3217755fcc94b068a234181207049aafe1e8b5bc6d076a9c89f9795fd23e3", "class_name": "RelatedNodeInfo"}}, "text": "And we would expect that those markets will begin to recover along the same type of time lines we laid out in our \nbroader comments.  \n ", "start_char_idx": 1482, "end_char_idx": 1618, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c61e8c4a-82c9-4837-9b03-fb14c268cc01": {"__data__": {"id_": "c61e8c4a-82c9-4837-9b03-fb14c268cc01", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI guess, I would just add, similar to the US market, our international markets have also faced COVID headwinds. \n And we would expect that those markets will begin to recover along the same type of time lines we laid out in our \nbroader comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly, that question comes from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi good afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be724035-8296-441a-9799-6d76e5943385", "node_type": "1", "metadata": {"window": "So to get the growth that we see, we're very pleased with the team.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI guess, I would just add, similar to the US market, our international markets have also faced COVID headwinds. \n And we would expect that those markets will begin to recover along the same type of time lines we laid out in our \nbroader comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly, that question comes from Brian Tanquilut with Jefferies.  \n ", "original_text": "And we would expect that those markets will begin to recover along the same type of time lines we laid out in our \nbroader comments.  \n ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6b013675dcf0221d37492725af611f9bd9f7e8284b7d0b8108b7c2070c21b29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98cf9980-b7e6-4875-bc1c-b9b1a4617da0", "node_type": "1", "metadata": {"window": "A \nI guess, I would just add, similar to the US market, our international markets have also faced COVID headwinds. \n And we would expect that those markets will begin to recover along the same type of time lines we laid out in our \nbroader comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly, that question comes from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi good afternoon.  Thanks for taking the question. ", "original_text": "A \nOpera tor, we have time for one more question.  \n "}, "hash": "1c4d39ce78ebdf781b70be8f8079b6ff30ad645e4c0752e24e7808c8ddd56f13", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "start_char_idx": 1618, "end_char_idx": 1959, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98cf9980-b7e6-4875-bc1c-b9b1a4617da0": {"__data__": {"id_": "98cf9980-b7e6-4875-bc1c-b9b1a4617da0", "embedding": null, "metadata": {"window": "A \nI guess, I would just add, similar to the US market, our international markets have also faced COVID headwinds. \n And we would expect that those markets will begin to recover along the same type of time lines we laid out in our \nbroader comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly, that question comes from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi good afternoon.  Thanks for taking the question. ", "original_text": "A \nOpera tor, we have time for one more question.  \n ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c61e8c4a-82c9-4837-9b03-fb14c268cc01", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI guess, I would just add, similar to the US market, our international markets have also faced COVID headwinds. \n And we would expect that those markets will begin to recover along the same type of time lines we laid out in our \nbroader comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly, that question comes from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi good afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "84f3d6160920000996fc6dff4c9c16fb5327a173f435ce239c82634e6a85abe4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "407881ef-94ad-4f88-9917-9e3e711fc792", "node_type": "1", "metadata": {"window": "And we would expect that those markets will begin to recover along the same type of time lines we laid out in our \nbroader comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly, that question comes from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi good afternoon.  Thanks for taking the question.  Brian, just in your prepared remark s, you've talked about \nexpanding US Oncology, so just curious how you see that.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly, that question comes from Brian Tanquilut with Jefferies.  \n "}, "hash": "29490ad7b11c1054ab52d246b10b0bfd35fab9f57a1cb3be230200bcbf1c4378", "class_name": "RelatedNodeInfo"}}, "text": "A \nOpera tor, we have time for one more question.  \n ", "start_char_idx": 1959, "end_char_idx": 2012, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "407881ef-94ad-4f88-9917-9e3e711fc792": {"__data__": {"id_": "407881ef-94ad-4f88-9917-9e3e711fc792", "embedding": null, "metadata": {"window": "And we would expect that those markets will begin to recover along the same type of time lines we laid out in our \nbroader comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly, that question comes from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi good afternoon.  Thanks for taking the question.  Brian, just in your prepared remark s, you've talked about \nexpanding US Oncology, so just curious how you see that.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly, that question comes from Brian Tanquilut with Jefferies.  \n ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98cf9980-b7e6-4875-bc1c-b9b1a4617da0", "node_type": "1", "metadata": {"window": "A \nI guess, I would just add, similar to the US market, our international markets have also faced COVID headwinds. \n And we would expect that those markets will begin to recover along the same type of time lines we laid out in our \nbroader comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly, that question comes from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi good afternoon.  Thanks for taking the question. ", "original_text": "A \nOpera tor, we have time for one more question.  \n ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df74bd763a5f4a455c98325091104077ef722f029595760c7601a684e9cab5bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7aecef13-3210-4b82-9a89-86a633c9ab66", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly, that question comes from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi good afternoon.  Thanks for taking the question.  Brian, just in your prepared remark s, you've talked about \nexpanding US Oncology, so just curious how you see that.  \n \n Philosophically, is that, how will that play out? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi good afternoon. "}, "hash": "07f17adac264e9da87f01d2c46937b44cf4f0ea6f2d16a99ffbdac28a7008c21", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly, that question comes from Brian Tanquilut with Jefferies.  \n ", "start_char_idx": 2012, "end_char_idx": 2353, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7aecef13-3210-4b82-9a89-86a633c9ab66": {"__data__": {"id_": "7aecef13-3210-4b82-9a89-86a633c9ab66", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly, that question comes from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi good afternoon.  Thanks for taking the question.  Brian, just in your prepared remark s, you've talked about \nexpanding US Oncology, so just curious how you see that.  \n \n Philosophically, is that, how will that play out? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi good afternoon. ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "407881ef-94ad-4f88-9917-9e3e711fc792", "node_type": "1", "metadata": {"window": "And we would expect that those markets will begin to recover along the same type of time lines we laid out in our \nbroader comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly, that question comes from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi good afternoon.  Thanks for taking the question.  Brian, just in your prepared remark s, you've talked about \nexpanding US Oncology, so just curious how you see that.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly, that question comes from Brian Tanquilut with Jefferies.  \n ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "927e6627351aa99d0f07ee7a47fdda86a082f69cbff8f09801db4192030b76f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "572db1e6-c772-4994-8af1-ef48b96d0dd7", "node_type": "1", "metadata": {"window": "A \nOpera tor, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly, that question comes from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi good afternoon.  Thanks for taking the question.  Brian, just in your prepared remark s, you've talked about \nexpanding US Oncology, so just curious how you see that.  \n \n Philosophically, is that, how will that play out?  Is that an expansion in terms of footprint, number of practices, \ncapabilities? ", "original_text": "Thanks for taking the question. "}, "hash": "ef2abcb7ce32796d59c055f2cd327d496e222c09d964f3eb402e348d5cb34ac8", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi good afternoon. ", "start_char_idx": 2353, "end_char_idx": 2678, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "572db1e6-c772-4994-8af1-ef48b96d0dd7": {"__data__": {"id_": "572db1e6-c772-4994-8af1-ef48b96d0dd7", "embedding": null, "metadata": {"window": "A \nOpera tor, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly, that question comes from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi good afternoon.  Thanks for taking the question.  Brian, just in your prepared remark s, you've talked about \nexpanding US Oncology, so just curious how you see that.  \n \n Philosophically, is that, how will that play out?  Is that an expansion in terms of footprint, number of practices, \ncapabilities? ", "original_text": "Thanks for taking the question. ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7aecef13-3210-4b82-9a89-86a633c9ab66", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly, that question comes from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi good afternoon.  Thanks for taking the question.  Brian, just in your prepared remark s, you've talked about \nexpanding US Oncology, so just curious how you see that.  \n \n Philosophically, is that, how will that play out? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi good afternoon. ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff191716e128eb30dbf777e1aec20dc9d82eb0086d96ac6e9466ccc902748c60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f36d7ca8-d8c0-4678-b14a-e59ad9f2bfdd", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly, that question comes from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi good afternoon.  Thanks for taking the question.  Brian, just in your prepared remark s, you've talked about \nexpanding US Oncology, so just curious how you see that.  \n \n Philosophically, is that, how will that play out?  Is that an expansion in terms of footprint, number of practices, \ncapabilities?  And how are you thinking about the shift of that business or evolution of that to value base as the \noncology world changes?  \n ", "original_text": "Brian, just in your prepared remark s, you've talked about \nexpanding US Oncology, so just curious how you see that.  \n \n"}, "hash": "171f6a1dbd7b170bdbfdd2dd1297054e33a36e8bb0d31ebc6992ee6f38d57fac", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the question. ", "start_char_idx": 2678, "end_char_idx": 2710, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f36d7ca8-d8c0-4678-b14a-e59ad9f2bfdd": {"__data__": {"id_": "f36d7ca8-d8c0-4678-b14a-e59ad9f2bfdd", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly, that question comes from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi good afternoon.  Thanks for taking the question.  Brian, just in your prepared remark s, you've talked about \nexpanding US Oncology, so just curious how you see that.  \n \n Philosophically, is that, how will that play out?  Is that an expansion in terms of footprint, number of practices, \ncapabilities?  And how are you thinking about the shift of that business or evolution of that to value base as the \noncology world changes?  \n ", "original_text": "Brian, just in your prepared remark s, you've talked about \nexpanding US Oncology, so just curious how you see that.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "572db1e6-c772-4994-8af1-ef48b96d0dd7", "node_type": "1", "metadata": {"window": "A \nOpera tor, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly, that question comes from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi good afternoon.  Thanks for taking the question.  Brian, just in your prepared remark s, you've talked about \nexpanding US Oncology, so just curious how you see that.  \n \n Philosophically, is that, how will that play out?  Is that an expansion in terms of footprint, number of practices, \ncapabilities? ", "original_text": "Thanks for taking the question. ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "870f672dc904cdb6c77f279a8b80fc29f05da25140c0f39b7ea0374b7dc46390", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8befbb6-ec59-4e25-bdc9-4636672ca3ac", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi good afternoon.  Thanks for taking the question.  Brian, just in your prepared remark s, you've talked about \nexpanding US Oncology, so just curious how you see that.  \n \n Philosophically, is that, how will that play out?  Is that an expansion in terms of footprint, number of practices, \ncapabilities?  And how are you thinking about the shift of that business or evolution of that to value base as the \noncology world changes?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Philosophically, is that, how will that play out? "}, "hash": "52c2954a9b45c5be4a44f9d98f20b25ddc8423d113355d9d9bcd352332149191", "class_name": "RelatedNodeInfo"}}, "text": "Brian, just in your prepared remark s, you've talked about \nexpanding US Oncology, so just curious how you see that.  \n \n", "start_char_idx": 2710, "end_char_idx": 2831, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8befbb6-ec59-4e25-bdc9-4636672ca3ac": {"__data__": {"id_": "a8befbb6-ec59-4e25-bdc9-4636672ca3ac", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi good afternoon.  Thanks for taking the question.  Brian, just in your prepared remark s, you've talked about \nexpanding US Oncology, so just curious how you see that.  \n \n Philosophically, is that, how will that play out?  Is that an expansion in terms of footprint, number of practices, \ncapabilities?  And how are you thinking about the shift of that business or evolution of that to value base as the \noncology world changes?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Philosophically, is that, how will that play out? ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f36d7ca8-d8c0-4678-b14a-e59ad9f2bfdd", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly, that question comes from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi good afternoon.  Thanks for taking the question.  Brian, just in your prepared remark s, you've talked about \nexpanding US Oncology, so just curious how you see that.  \n \n Philosophically, is that, how will that play out?  Is that an expansion in terms of footprint, number of practices, \ncapabilities?  And how are you thinking about the shift of that business or evolution of that to value base as the \noncology world changes?  \n ", "original_text": "Brian, just in your prepared remark s, you've talked about \nexpanding US Oncology, so just curious how you see that.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77d3e371a51fb422f63479b9ec3a487d043d466ec02e2441873bb76c0f6b282d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ea25ae6-3c58-4966-8450-f3ca11ca105d", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Brian, just in your prepared remark s, you've talked about \nexpanding US Oncology, so just curious how you see that.  \n \n Philosophically, is that, how will that play out?  Is that an expansion in terms of footprint, number of practices, \ncapabilities?  And how are you thinking about the shift of that business or evolution of that to value base as the \noncology world changes?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great question. ", "original_text": "Is that an expansion in terms of footprint, number of practices, \ncapabilities? "}, "hash": "6edd459014aa04524162dcc8f8548bc6ace529a83586fdc36dab49e726f9112f", "class_name": "RelatedNodeInfo"}}, "text": "Philosophically, is that, how will that play out? ", "start_char_idx": 2831, "end_char_idx": 2881, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ea25ae6-3c58-4966-8450-f3ca11ca105d": {"__data__": {"id_": "5ea25ae6-3c58-4966-8450-f3ca11ca105d", "embedding": null, "metadata": {"window": "Thanks for taking the question.  Brian, just in your prepared remark s, you've talked about \nexpanding US Oncology, so just curious how you see that.  \n \n Philosophically, is that, how will that play out?  Is that an expansion in terms of footprint, number of practices, \ncapabilities?  And how are you thinking about the shift of that business or evolution of that to value base as the \noncology world changes?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great question. ", "original_text": "Is that an expansion in terms of footprint, number of practices, \ncapabilities? ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8befbb6-ec59-4e25-bdc9-4636672ca3ac", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi good afternoon.  Thanks for taking the question.  Brian, just in your prepared remark s, you've talked about \nexpanding US Oncology, so just curious how you see that.  \n \n Philosophically, is that, how will that play out?  Is that an expansion in terms of footprint, number of practices, \ncapabilities?  And how are you thinking about the shift of that business or evolution of that to value base as the \noncology world changes?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Philosophically, is that, how will that play out? ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "39f752b2d766b5150f72c3f8531505e57e1a1a59d957088ad25186432bb3374a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7246bd4-09e2-4eb9-adf6-2518bc4f13c8", "node_type": "1", "metadata": {"window": "Brian, just in your prepared remark s, you've talked about \nexpanding US Oncology, so just curious how you see that.  \n \n Philosophically, is that, how will that play out?  Is that an expansion in terms of footprint, number of practices, \ncapabilities?  And how are you thinking about the shift of that business or evolution of that to value base as the \noncology world changes?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great question.  So look, we think we have a terrific value proposition for independent community -based \noncologists. ", "original_text": "And how are you thinking about the shift of that business or evolution of that to value base as the \noncology world changes?  \n "}, "hash": "e25742a447325476ff182045f0a58e71334f2a5d954b1116a6a9793d9c546218", "class_name": "RelatedNodeInfo"}}, "text": "Is that an expansion in terms of footprint, number of practices, \ncapabilities? ", "start_char_idx": 2881, "end_char_idx": 2961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7246bd4-09e2-4eb9-adf6-2518bc4f13c8": {"__data__": {"id_": "b7246bd4-09e2-4eb9-adf6-2518bc4f13c8", "embedding": null, "metadata": {"window": "Brian, just in your prepared remark s, you've talked about \nexpanding US Oncology, so just curious how you see that.  \n \n Philosophically, is that, how will that play out?  Is that an expansion in terms of footprint, number of practices, \ncapabilities?  And how are you thinking about the shift of that business or evolution of that to value base as the \noncology world changes?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great question.  So look, we think we have a terrific value proposition for independent community -based \noncologists. ", "original_text": "And how are you thinking about the shift of that business or evolution of that to value base as the \noncology world changes?  \n ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ea25ae6-3c58-4966-8450-f3ca11ca105d", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Brian, just in your prepared remark s, you've talked about \nexpanding US Oncology, so just curious how you see that.  \n \n Philosophically, is that, how will that play out?  Is that an expansion in terms of footprint, number of practices, \ncapabilities?  And how are you thinking about the shift of that business or evolution of that to value base as the \noncology world changes?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great question. ", "original_text": "Is that an expansion in terms of footprint, number of practices, \ncapabilities? ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18005ea1d30d9ccd30cb8469f5e77c4f7d735fac02b5ab805bbad0a7d432f3d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ccf5b2e8-0c53-48ee-8bae-cc1fa89f34a1", "node_type": "1", "metadata": {"window": "Philosophically, is that, how will that play out?  Is that an expansion in terms of footprint, number of practices, \ncapabilities?  And how are you thinking about the shift of that business or evolution of that to value base as the \noncology world changes?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great question.  So look, we think we have a terrific value proposition for independent community -based \noncologists.  And we look to grow our practices and our, the number of oncologists in those practices. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "6c6decbc655d9e0438fcbe7db1070c5ab0566199be2a9ea171679e3837846a12", "class_name": "RelatedNodeInfo"}}, "text": "And how are you thinking about the shift of that business or evolution of that to value base as the \noncology world changes?  \n ", "start_char_idx": 2961, "end_char_idx": 3089, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ccf5b2e8-0c53-48ee-8bae-cc1fa89f34a1": {"__data__": {"id_": "ccf5b2e8-0c53-48ee-8bae-cc1fa89f34a1", "embedding": null, "metadata": {"window": "Philosophically, is that, how will that play out?  Is that an expansion in terms of footprint, number of practices, \ncapabilities?  And how are you thinking about the shift of that business or evolution of that to value base as the \noncology world changes?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great question.  So look, we think we have a terrific value proposition for independent community -based \noncologists.  And we look to grow our practices and our, the number of oncologists in those practices. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7246bd4-09e2-4eb9-adf6-2518bc4f13c8", "node_type": "1", "metadata": {"window": "Brian, just in your prepared remark s, you've talked about \nexpanding US Oncology, so just curious how you see that.  \n \n Philosophically, is that, how will that play out?  Is that an expansion in terms of footprint, number of practices, \ncapabilities?  And how are you thinking about the shift of that business or evolution of that to value base as the \noncology world changes?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great question.  So look, we think we have a terrific value proposition for independent community -based \noncologists. ", "original_text": "And how are you thinking about the shift of that business or evolution of that to value base as the \noncology world changes?  \n ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a477b3821be47e86910d2d91e503f2e5b8b4d6650394e0e342339dfe7fb76855", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f0ebd66-9796-4d59-a99d-6d339b5bc01a", "node_type": "1", "metadata": {"window": "Is that an expansion in terms of footprint, number of practices, \ncapabilities?  And how are you thinking about the shift of that business or evolution of that to value base as the \noncology world changes?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great question.  So look, we think we have a terrific value proposition for independent community -based \noncologists.  And we look to grow our practices and our, the number of oncologists in those practices.  That is part \nof the growth. ", "original_text": "A \nYeah, great question. "}, "hash": "7a0477f53c78989db83c5b127b8b2da0730d0c5306b49b4a09d16e3c9586e881", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1037, "end_char_idx": 1366, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f0ebd66-9796-4d59-a99d-6d339b5bc01a": {"__data__": {"id_": "1f0ebd66-9796-4d59-a99d-6d339b5bc01a", "embedding": null, "metadata": {"window": "Is that an expansion in terms of footprint, number of practices, \ncapabilities?  And how are you thinking about the shift of that business or evolution of that to value base as the \noncology world changes?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great question.  So look, we think we have a terrific value proposition for independent community -based \noncologists.  And we look to grow our practices and our, the number of oncologists in those practices.  That is part \nof the growth. ", "original_text": "A \nYeah, great question. ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ccf5b2e8-0c53-48ee-8bae-cc1fa89f34a1", "node_type": "1", "metadata": {"window": "Philosophically, is that, how will that play out?  Is that an expansion in terms of footprint, number of practices, \ncapabilities?  And how are you thinking about the shift of that business or evolution of that to value base as the \noncology world changes?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great question.  So look, we think we have a terrific value proposition for independent community -based \noncologists.  And we look to grow our practices and our, the number of oncologists in those practices. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9a666fe63cc570b6a265bd057085854eac46356a0f364343bb16cb9ab3bc691", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79598a5f-c938-4b55-9171-b39c9c992e79", "node_type": "1", "metadata": {"window": "And how are you thinking about the shift of that business or evolution of that to value base as the \noncology world changes?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great question.  So look, we think we have a terrific value proposition for independent community -based \noncologists.  And we look to grow our practices and our, the number of oncologists in those practices.  That is part \nof the growth.  I mean, and we like that growth.  \n \n", "original_text": "So look, we think we have a terrific value proposition for independent community -based \noncologists. "}, "hash": "531c87ff0c95c90ae13ed48f6856d75f4d9e8ec529c054331684d8cc80d4d5b6", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah, great question. ", "start_char_idx": 3418, "end_char_idx": 3443, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79598a5f-c938-4b55-9171-b39c9c992e79": {"__data__": {"id_": "79598a5f-c938-4b55-9171-b39c9c992e79", "embedding": null, "metadata": {"window": "And how are you thinking about the shift of that business or evolution of that to value base as the \noncology world changes?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great question.  So look, we think we have a terrific value proposition for independent community -based \noncologists.  And we look to grow our practices and our, the number of oncologists in those practices.  That is part \nof the growth.  I mean, and we like that growth.  \n \n", "original_text": "So look, we think we have a terrific value proposition for independent community -based \noncologists. ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f0ebd66-9796-4d59-a99d-6d339b5bc01a", "node_type": "1", "metadata": {"window": "Is that an expansion in terms of footprint, number of practices, \ncapabilities?  And how are you thinking about the shift of that business or evolution of that to value base as the \noncology world changes?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great question.  So look, we think we have a terrific value proposition for independent community -based \noncologists.  And we look to grow our practices and our, the number of oncologists in those practices.  That is part \nof the growth. ", "original_text": "A \nYeah, great question. ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1c3ca0d318743c05228fc9cb8cdc38c38aa0aee1e9eec0967f06ba1bb30668c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be3975d9-acab-44d5-8f84-4cc0879a21be", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great question.  So look, we think we have a terrific value proposition for independent community -based \noncologists.  And we look to grow our practices and our, the number of oncologists in those practices.  That is part \nof the growth.  I mean, and we like that growth.  \n \n But we also think we have the opportunity to grow our research, efforts, to grow our data and analytics and insight \nbusiness. ", "original_text": "And we look to grow our practices and our, the number of oncologists in those practices. "}, "hash": "c9b5d120b0f8eb8c8bc3f0cb473c04d3e37c408d291ee63eb8843acf330eb331", "class_name": "RelatedNodeInfo"}}, "text": "So look, we think we have a terrific value proposition for independent community -based \noncologists. ", "start_char_idx": 3443, "end_char_idx": 3545, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be3975d9-acab-44d5-8f84-4cc0879a21be": {"__data__": {"id_": "be3975d9-acab-44d5-8f84-4cc0879a21be", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great question.  So look, we think we have a terrific value proposition for independent community -based \noncologists.  And we look to grow our practices and our, the number of oncologists in those practices.  That is part \nof the growth.  I mean, and we like that growth.  \n \n But we also think we have the opportunity to grow our research, efforts, to grow our data and analytics and insight \nbusiness. ", "original_text": "And we look to grow our practices and our, the number of oncologists in those practices. ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79598a5f-c938-4b55-9171-b39c9c992e79", "node_type": "1", "metadata": {"window": "And how are you thinking about the shift of that business or evolution of that to value base as the \noncology world changes?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great question.  So look, we think we have a terrific value proposition for independent community -based \noncologists.  And we look to grow our practices and our, the number of oncologists in those practices.  That is part \nof the growth.  I mean, and we like that growth.  \n \n", "original_text": "So look, we think we have a terrific value proposition for independent community -based \noncologists. ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54d2d7f257305805c194e49467ebda37d67356f8f11e72ac26c3a27268eb7ab7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d58b7259-d8f5-4f5a-8cb5-762ff264cf18", "node_type": "1", "metadata": {"window": "A \nYeah, great question.  So look, we think we have a terrific value proposition for independent community -based \noncologists.  And we look to grow our practices and our, the number of oncologists in those practices.  That is part \nof the growth.  I mean, and we like that growth.  \n \n But we also think we have the opportunity to grow our research, efforts, to grow our data and analytics and insight \nbusiness.  We've got opportunity to put more value into our EMR so that we stay contemporary with patient care \nand that we're innovating ahead of the marketplace.  \n \n", "original_text": "That is part \nof the growth. "}, "hash": "1475481d3b8077daeca7b5d51005c908fe0dd7603cf7690326c18e54091fc270", "class_name": "RelatedNodeInfo"}}, "text": "And we look to grow our practices and our, the number of oncologists in those practices. ", "start_char_idx": 3545, "end_char_idx": 3634, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d58b7259-d8f5-4f5a-8cb5-762ff264cf18": {"__data__": {"id_": "d58b7259-d8f5-4f5a-8cb5-762ff264cf18", "embedding": null, "metadata": {"window": "A \nYeah, great question.  So look, we think we have a terrific value proposition for independent community -based \noncologists.  And we look to grow our practices and our, the number of oncologists in those practices.  That is part \nof the growth.  I mean, and we like that growth.  \n \n But we also think we have the opportunity to grow our research, efforts, to grow our data and analytics and insight \nbusiness.  We've got opportunity to put more value into our EMR so that we stay contemporary with patient care \nand that we're innovating ahead of the marketplace.  \n \n", "original_text": "That is part \nof the growth. ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be3975d9-acab-44d5-8f84-4cc0879a21be", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great question.  So look, we think we have a terrific value proposition for independent community -based \noncologists.  And we look to grow our practices and our, the number of oncologists in those practices.  That is part \nof the growth.  I mean, and we like that growth.  \n \n But we also think we have the opportunity to grow our research, efforts, to grow our data and analytics and insight \nbusiness. ", "original_text": "And we look to grow our practices and our, the number of oncologists in those practices. ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3e5d730d657ccb8ea325e30622183e258e319618399b4fe554a184ba6762477a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bdb8b7a6-371e-4789-9c27-109b7eed7252", "node_type": "1", "metadata": {"window": "So look, we think we have a terrific value proposition for independent community -based \noncologists.  And we look to grow our practices and our, the number of oncologists in those practices.  That is part \nof the growth.  I mean, and we like that growth.  \n \n But we also think we have the opportunity to grow our research, efforts, to grow our data and analytics and insight \nbusiness.  We've got opportunity to put more value into our EMR so that we stay contemporary with patient care \nand that we're innovating ahead of the marketplace.  \n \n And we view all of these things as kind of reinforcing each ot her, right? ", "original_text": "I mean, and we like that growth.  \n \n"}, "hash": "4a5c035f30149f28c0b0028062279c7c85bcc4e64655331bc88458a8792d79c3", "class_name": "RelatedNodeInfo"}}, "text": "That is part \nof the growth. ", "start_char_idx": 3634, "end_char_idx": 3663, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bdb8b7a6-371e-4789-9c27-109b7eed7252": {"__data__": {"id_": "bdb8b7a6-371e-4789-9c27-109b7eed7252", "embedding": null, "metadata": {"window": "So look, we think we have a terrific value proposition for independent community -based \noncologists.  And we look to grow our practices and our, the number of oncologists in those practices.  That is part \nof the growth.  I mean, and we like that growth.  \n \n But we also think we have the opportunity to grow our research, efforts, to grow our data and analytics and insight \nbusiness.  We've got opportunity to put more value into our EMR so that we stay contemporary with patient care \nand that we're innovating ahead of the marketplace.  \n \n And we view all of these things as kind of reinforcing each ot her, right? ", "original_text": "I mean, and we like that growth.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d58b7259-d8f5-4f5a-8cb5-762ff264cf18", "node_type": "1", "metadata": {"window": "A \nYeah, great question.  So look, we think we have a terrific value proposition for independent community -based \noncologists.  And we look to grow our practices and our, the number of oncologists in those practices.  That is part \nof the growth.  I mean, and we like that growth.  \n \n But we also think we have the opportunity to grow our research, efforts, to grow our data and analytics and insight \nbusiness.  We've got opportunity to put more value into our EMR so that we stay contemporary with patient care \nand that we're innovating ahead of the marketplace.  \n \n", "original_text": "That is part \nof the growth. ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "91dc548a0a3a9eb41579a6e13c8cbaa25af32e970c6263d6e166c98540cd8266", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "174d23b4-3890-4ca6-8d48-0c9cdf92a2f6", "node_type": "1", "metadata": {"window": "And we look to grow our practices and our, the number of oncologists in those practices.  That is part \nof the growth.  I mean, and we like that growth.  \n \n But we also think we have the opportunity to grow our research, efforts, to grow our data and analytics and insight \nbusiness.  We've got opportunity to put more value into our EMR so that we stay contemporary with patient care \nand that we're innovating ahead of the marketplace.  \n \n And we view all of these things as kind of reinforcing each ot her, right?  More scale in the network gives you a \nbigger distribution channel for the products and services that you develop, more impact back upstream to the \nbiopharmas. ", "original_text": "But we also think we have the opportunity to grow our research, efforts, to grow our data and analytics and insight \nbusiness. "}, "hash": "a08b09f0655a90a500c71bf5ea187a3dee733a23ec2afb61550907892afe87d6", "class_name": "RelatedNodeInfo"}}, "text": "I mean, and we like that growth.  \n \n", "start_char_idx": 3663, "end_char_idx": 3700, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "174d23b4-3890-4ca6-8d48-0c9cdf92a2f6": {"__data__": {"id_": "174d23b4-3890-4ca6-8d48-0c9cdf92a2f6", "embedding": null, "metadata": {"window": "And we look to grow our practices and our, the number of oncologists in those practices.  That is part \nof the growth.  I mean, and we like that growth.  \n \n But we also think we have the opportunity to grow our research, efforts, to grow our data and analytics and insight \nbusiness.  We've got opportunity to put more value into our EMR so that we stay contemporary with patient care \nand that we're innovating ahead of the marketplace.  \n \n And we view all of these things as kind of reinforcing each ot her, right?  More scale in the network gives you a \nbigger distribution channel for the products and services that you develop, more impact back upstream to the \nbiopharmas. ", "original_text": "But we also think we have the opportunity to grow our research, efforts, to grow our data and analytics and insight \nbusiness. ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bdb8b7a6-371e-4789-9c27-109b7eed7252", "node_type": "1", "metadata": {"window": "So look, we think we have a terrific value proposition for independent community -based \noncologists.  And we look to grow our practices and our, the number of oncologists in those practices.  That is part \nof the growth.  I mean, and we like that growth.  \n \n But we also think we have the opportunity to grow our research, efforts, to grow our data and analytics and insight \nbusiness.  We've got opportunity to put more value into our EMR so that we stay contemporary with patient care \nand that we're innovating ahead of the marketplace.  \n \n And we view all of these things as kind of reinforcing each ot her, right? ", "original_text": "I mean, and we like that growth.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cf7e0ca650e0e6225020a40bbdef6b630c8226d0a26261012f0a30369f0969ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c510c6c0-c56d-4a56-afb7-6945ccc00c9f", "node_type": "1", "metadata": {"window": "That is part \nof the growth.  I mean, and we like that growth.  \n \n But we also think we have the opportunity to grow our research, efforts, to grow our data and analytics and insight \nbusiness.  We've got opportunity to put more value into our EMR so that we stay contemporary with patient care \nand that we're innovating ahead of the marketplace.  \n \n And we view all of these things as kind of reinforcing each ot her, right?  More scale in the network gives you a \nbigger distribution channel for the products and services that you develop, more impact back upstream to the \nbiopharmas.  And that's why we've actually been referring to it as an ecosystem because these are not really \ndisconnected growth strategies they're actually quite connected under the umbrella of oncology.  \n ", "original_text": "We've got opportunity to put more value into our EMR so that we stay contemporary with patient care \nand that we're innovating ahead of the marketplace.  \n \n"}, "hash": "48869248bed0a54b219f1b9d00b3ee7048f9bca7964f0d6bfe865bbdff4c528a", "class_name": "RelatedNodeInfo"}}, "text": "But we also think we have the opportunity to grow our research, efforts, to grow our data and analytics and insight \nbusiness. ", "start_char_idx": 3700, "end_char_idx": 3827, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c510c6c0-c56d-4a56-afb7-6945ccc00c9f": {"__data__": {"id_": "c510c6c0-c56d-4a56-afb7-6945ccc00c9f", "embedding": null, "metadata": {"window": "That is part \nof the growth.  I mean, and we like that growth.  \n \n But we also think we have the opportunity to grow our research, efforts, to grow our data and analytics and insight \nbusiness.  We've got opportunity to put more value into our EMR so that we stay contemporary with patient care \nand that we're innovating ahead of the marketplace.  \n \n And we view all of these things as kind of reinforcing each ot her, right?  More scale in the network gives you a \nbigger distribution channel for the products and services that you develop, more impact back upstream to the \nbiopharmas.  And that's why we've actually been referring to it as an ecosystem because these are not really \ndisconnected growth strategies they're actually quite connected under the umbrella of oncology.  \n ", "original_text": "We've got opportunity to put more value into our EMR so that we stay contemporary with patient care \nand that we're innovating ahead of the marketplace.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "174d23b4-3890-4ca6-8d48-0c9cdf92a2f6", "node_type": "1", "metadata": {"window": "And we look to grow our practices and our, the number of oncologists in those practices.  That is part \nof the growth.  I mean, and we like that growth.  \n \n But we also think we have the opportunity to grow our research, efforts, to grow our data and analytics and insight \nbusiness.  We've got opportunity to put more value into our EMR so that we stay contemporary with patient care \nand that we're innovating ahead of the marketplace.  \n \n And we view all of these things as kind of reinforcing each ot her, right?  More scale in the network gives you a \nbigger distribution channel for the products and services that you develop, more impact back upstream to the \nbiopharmas. ", "original_text": "But we also think we have the opportunity to grow our research, efforts, to grow our data and analytics and insight \nbusiness. ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b299e627669f8c764dde1e7c6c778b6f666804b405e2b279b913dc5b7119a1cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4905637a-72f0-496f-9b61-b36b6e945970", "node_type": "1", "metadata": {"window": "I mean, and we like that growth.  \n \n But we also think we have the opportunity to grow our research, efforts, to grow our data and analytics and insight \nbusiness.  We've got opportunity to put more value into our EMR so that we stay contemporary with patient care \nand that we're innovating ahead of the marketplace.  \n \n And we view all of these things as kind of reinforcing each ot her, right?  More scale in the network gives you a \nbigger distribution channel for the products and services that you develop, more impact back upstream to the \nbiopharmas.  And that's why we've actually been referring to it as an ecosystem because these are not really \ndisconnected growth strategies they're actually quite connected under the umbrella of oncology.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "And we view all of these things as kind of reinforcing each ot her, right? "}, "hash": "3c8a80d07959adffdbf0a4e71bab9432bf61777a19380c0c65c786b485719f2e", "class_name": "RelatedNodeInfo"}}, "text": "We've got opportunity to put more value into our EMR so that we stay contemporary with patient care \nand that we're innovating ahead of the marketplace.  \n \n", "start_char_idx": 3827, "end_char_idx": 3984, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4905637a-72f0-496f-9b61-b36b6e945970": {"__data__": {"id_": "4905637a-72f0-496f-9b61-b36b6e945970", "embedding": null, "metadata": {"window": "I mean, and we like that growth.  \n \n But we also think we have the opportunity to grow our research, efforts, to grow our data and analytics and insight \nbusiness.  We've got opportunity to put more value into our EMR so that we stay contemporary with patient care \nand that we're innovating ahead of the marketplace.  \n \n And we view all of these things as kind of reinforcing each ot her, right?  More scale in the network gives you a \nbigger distribution channel for the products and services that you develop, more impact back upstream to the \nbiopharmas.  And that's why we've actually been referring to it as an ecosystem because these are not really \ndisconnected growth strategies they're actually quite connected under the umbrella of oncology.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "And we view all of these things as kind of reinforcing each ot her, right? ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c510c6c0-c56d-4a56-afb7-6945ccc00c9f", "node_type": "1", "metadata": {"window": "That is part \nof the growth.  I mean, and we like that growth.  \n \n But we also think we have the opportunity to grow our research, efforts, to grow our data and analytics and insight \nbusiness.  We've got opportunity to put more value into our EMR so that we stay contemporary with patient care \nand that we're innovating ahead of the marketplace.  \n \n And we view all of these things as kind of reinforcing each ot her, right?  More scale in the network gives you a \nbigger distribution channel for the products and services that you develop, more impact back upstream to the \nbiopharmas.  And that's why we've actually been referring to it as an ecosystem because these are not really \ndisconnected growth strategies they're actually quite connected under the umbrella of oncology.  \n ", "original_text": "We've got opportunity to put more value into our EMR so that we stay contemporary with patient care \nand that we're innovating ahead of the marketplace.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53d52c189c68473177128fa43a13ac241d67112cd3790aff9f9f26cd1f122f03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "423d2421-a962-45c4-8a0c-c8d62212a5ec", "node_type": "1", "metadata": {"window": "But we also think we have the opportunity to grow our research, efforts, to grow our data and analytics and insight \nbusiness.  We've got opportunity to put more value into our EMR so that we stay contemporary with patient care \nand that we're innovating ahead of the marketplace.  \n \n And we view all of these things as kind of reinforcing each ot her, right?  More scale in the network gives you a \nbigger distribution channel for the products and services that you develop, more impact back upstream to the \nbiopharmas.  And that's why we've actually been referring to it as an ecosystem because these are not really \ndisconnected growth strategies they're actually quite connected under the umbrella of oncology.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "More scale in the network gives you a \nbigger distribution channel for the products and services that you develop, more impact back upstream to the \nbiopharmas. "}, "hash": "3b6a46015b71a8905cb8a46bfc131655827c376ec7b651f45f7d85fa9532fe14", "class_name": "RelatedNodeInfo"}}, "text": "And we view all of these things as kind of reinforcing each ot her, right? ", "start_char_idx": 3984, "end_char_idx": 4059, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "423d2421-a962-45c4-8a0c-c8d62212a5ec": {"__data__": {"id_": "423d2421-a962-45c4-8a0c-c8d62212a5ec", "embedding": null, "metadata": {"window": "But we also think we have the opportunity to grow our research, efforts, to grow our data and analytics and insight \nbusiness.  We've got opportunity to put more value into our EMR so that we stay contemporary with patient care \nand that we're innovating ahead of the marketplace.  \n \n And we view all of these things as kind of reinforcing each ot her, right?  More scale in the network gives you a \nbigger distribution channel for the products and services that you develop, more impact back upstream to the \nbiopharmas.  And that's why we've actually been referring to it as an ecosystem because these are not really \ndisconnected growth strategies they're actually quite connected under the umbrella of oncology.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "More scale in the network gives you a \nbigger distribution channel for the products and services that you develop, more impact back upstream to the \nbiopharmas. ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4905637a-72f0-496f-9b61-b36b6e945970", "node_type": "1", "metadata": {"window": "I mean, and we like that growth.  \n \n But we also think we have the opportunity to grow our research, efforts, to grow our data and analytics and insight \nbusiness.  We've got opportunity to put more value into our EMR so that we stay contemporary with patient care \nand that we're innovating ahead of the marketplace.  \n \n And we view all of these things as kind of reinforcing each ot her, right?  More scale in the network gives you a \nbigger distribution channel for the products and services that you develop, more impact back upstream to the \nbiopharmas.  And that's why we've actually been referring to it as an ecosystem because these are not really \ndisconnected growth strategies they're actually quite connected under the umbrella of oncology.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "And we view all of these things as kind of reinforcing each ot her, right? ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5f13d67a1fe8cd3d282c4e79599c92bdde8172e696131f36c8638dd69d416e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c52b3fa-e0b8-49a4-820b-b9652c1f3edf", "node_type": "1", "metadata": {"window": "We've got opportunity to put more value into our EMR so that we stay contemporary with patient care \nand that we're innovating ahead of the marketplace.  \n \n And we view all of these things as kind of reinforcing each ot her, right?  More scale in the network gives you a \nbigger distribution channel for the products and services that you develop, more impact back upstream to the \nbiopharmas.  And that's why we've actually been referring to it as an ecosystem because these are not really \ndisconnected growth strategies they're actually quite connected under the umbrella of oncology.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "And that's why we've actually been referring to it as an ecosystem because these are not really \ndisconnected growth strategies they're actually quite connected under the umbrella of oncology.  \n "}, "hash": "02cbad0926ac9434f336593e961f65a603c757cd2d993749a2f957e62f55bc81", "class_name": "RelatedNodeInfo"}}, "text": "More scale in the network gives you a \nbigger distribution channel for the products and services that you develop, more impact back upstream to the \nbiopharmas. ", "start_char_idx": 4059, "end_char_idx": 4220, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c52b3fa-e0b8-49a4-820b-b9652c1f3edf": {"__data__": {"id_": "2c52b3fa-e0b8-49a4-820b-b9652c1f3edf", "embedding": null, "metadata": {"window": "We've got opportunity to put more value into our EMR so that we stay contemporary with patient care \nand that we're innovating ahead of the marketplace.  \n \n And we view all of these things as kind of reinforcing each ot her, right?  More scale in the network gives you a \nbigger distribution channel for the products and services that you develop, more impact back upstream to the \nbiopharmas.  And that's why we've actually been referring to it as an ecosystem because these are not really \ndisconnected growth strategies they're actually quite connected under the umbrella of oncology.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "And that's why we've actually been referring to it as an ecosystem because these are not really \ndisconnected growth strategies they're actually quite connected under the umbrella of oncology.  \n ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "423d2421-a962-45c4-8a0c-c8d62212a5ec", "node_type": "1", "metadata": {"window": "But we also think we have the opportunity to grow our research, efforts, to grow our data and analytics and insight \nbusiness.  We've got opportunity to put more value into our EMR so that we stay contemporary with patient care \nand that we're innovating ahead of the marketplace.  \n \n And we view all of these things as kind of reinforcing each ot her, right?  More scale in the network gives you a \nbigger distribution channel for the products and services that you develop, more impact back upstream to the \nbiopharmas.  And that's why we've actually been referring to it as an ecosystem because these are not really \ndisconnected growth strategies they're actually quite connected under the umbrella of oncology.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "More scale in the network gives you a \nbigger distribution channel for the products and services that you develop, more impact back upstream to the \nbiopharmas. ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "094ecf898bf642bc097ecc00fc3466430c6a6e3986eaee707a9c0232fbccdd1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3132dc3a-44bd-4cb9-81ea-a3719f433f82", "node_type": "1", "metadata": {"window": "And we view all of these things as kind of reinforcing each ot her, right?  More scale in the network gives you a \nbigger distribution channel for the products and services that you develop, more impact back upstream to the \nbiopharmas.  And that's why we've actually been referring to it as an ecosystem because these are not really \ndisconnected growth strategies they're actually quite connected under the umbrella of oncology.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   "}, "hash": "ff24ad6c91444e858eca650c6738819e16d3d5c512a05869fd4fab7ab62a9fc3", "class_name": "RelatedNodeInfo"}}, "text": "And that's why we've actually been referring to it as an ecosystem because these are not really \ndisconnected growth strategies they're actually quite connected under the umbrella of oncology.  \n ", "start_char_idx": 4220, "end_char_idx": 4416, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3132dc3a-44bd-4cb9-81ea-a3719f433f82": {"__data__": {"id_": "3132dc3a-44bd-4cb9-81ea-a3719f433f82", "embedding": null, "metadata": {"window": "And we view all of these things as kind of reinforcing each ot her, right?  More scale in the network gives you a \nbigger distribution channel for the products and services that you develop, more impact back upstream to the \nbiopharmas.  And that's why we've actually been referring to it as an ecosystem because these are not really \ndisconnected growth strategies they're actually quite connected under the umbrella of oncology.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4626bade-5d38-4ff7-8aca-d885252f9706", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7badec5e2b90880786cb4db5ad11924192c63e3d61b6a387bd63ad2cfd11c733", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c52b3fa-e0b8-49a4-820b-b9652c1f3edf", "node_type": "1", "metadata": {"window": "We've got opportunity to put more value into our EMR so that we stay contemporary with patient care \nand that we're innovating ahead of the marketplace.  \n \n And we view all of these things as kind of reinforcing each ot her, right?  More scale in the network gives you a \nbigger distribution channel for the products and services that you develop, more impact back upstream to the \nbiopharmas.  And that's why we've actually been referring to it as an ecosystem because these are not really \ndisconnected growth strategies they're actually quite connected under the umbrella of oncology.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "And that's why we've actually been referring to it as an ecosystem because these are not really \ndisconnected growth strategies they're actually quite connected under the umbrella of oncology.  \n ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "164239a382d79b209420e7c1ed0648b5a34e141bd9f4835d9bc711c96355996c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbcc49a2-bf53-4faf-bd97-9715bbf02610", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everybody. ", "original_text": "McKesson Corp.  "}, "hash": "a0b82cc7e8d5daf667afe158b19ee63ace7b60dcdb6e710dbd8103ba478377e3", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "start_char_idx": 1037, "end_char_idx": 1293, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbcc49a2-bf53-4faf-bd97-9715bbf02610": {"__data__": {"id_": "cbcc49a2-bf53-4faf-bd97-9715bbf02610", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everybody. ", "original_text": "McKesson Corp.  ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c112cf2f94209b5cfa9a737d84d9594bebf8e0fc989c58264dacdfaad5e759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3132dc3a-44bd-4cb9-81ea-a3719f433f82", "node_type": "1", "metadata": {"window": "And we view all of these things as kind of reinforcing each ot her, right?  More scale in the network gives you a \nbigger distribution channel for the products and services that you develop, more impact back upstream to the \nbiopharmas.  And that's why we've actually been referring to it as an ecosystem because these are not really \ndisconnected growth strategies they're actually quite connected under the umbrella of oncology.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "062209e62cf2713314b93c4c0ca2716bbe39c5a9f4392f1101c77467a566a239", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23f16354-28f7-4e5e-b0b4-271f96ea5196", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everybody.  [indiscernible] (1:00:34) enters our fiscal  2022, I'm excited about the \nbusinesses and the markets that we operate in today. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "c7fdc77df380a0be35919e4f7e0ad4b669af82c7684251f26e10b113aebcd581", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23f16354-28f7-4e5e-b0b4-271f96ea5196": {"__data__": {"id_": "23f16354-28f7-4e5e-b0b4-271f96ea5196", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everybody.  [indiscernible] (1:00:34) enters our fiscal  2022, I'm excited about the \nbusinesses and the markets that we operate in today. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c112cf2f94209b5cfa9a737d84d9594bebf8e0fc989c58264dacdfaad5e759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbcc49a2-bf53-4faf-bd97-9715bbf02610", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everybody. ", "original_text": "McKesson Corp.  ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05de1dbd05862b8dd5d5f32713d7ebfc172181748a0edc1d6d97c00cbfce36f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0cf9abf-2a0d-49fb-9d72-f6ae39d413c9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everybody.  [indiscernible] (1:00:34) enters our fiscal  2022, I'm excited about the \nbusinesses and the markets that we operate in today.  I'm very pleased with our performance and the momentum \nthat gives us and I really do believe we are positioned for long -term success. ", "original_text": "Okay. "}, "hash": "25950cc03be7efac43c737a5f11d06ab20c34aa3a19642fdc4967bb2d0c28ce3", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 16, "end_char_idx": 254, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0cf9abf-2a0d-49fb-9d72-f6ae39d413c9": {"__data__": {"id_": "c0cf9abf-2a0d-49fb-9d72-f6ae39d413c9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everybody.  [indiscernible] (1:00:34) enters our fiscal  2022, I'm excited about the \nbusinesses and the markets that we operate in today.  I'm very pleased with our performance and the momentum \nthat gives us and I really do believe we are positioned for long -term success. ", "original_text": "Okay. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c112cf2f94209b5cfa9a737d84d9594bebf8e0fc989c58264dacdfaad5e759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23f16354-28f7-4e5e-b0b4-271f96ea5196", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everybody.  [indiscernible] (1:00:34) enters our fiscal  2022, I'm excited about the \nbusinesses and the markets that we operate in today. ", "original_text": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ea76b03fd9259701ee3ec1ccbe253dd8b2887d1131406a92a1888280de2cf42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72d3d22f-0332-4497-9121-ebaf55545488", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everybody.  [indiscernible] (1:00:34) enters our fiscal  2022, I'm excited about the \nbusinesses and the markets that we operate in today.  I'm very pleased with our performance and the momentum \nthat gives us and I really do believe we are positioned for long -term success.  I'm again, so proud of how resilient \nour employees have been throughout the pandemic. ", "original_text": "Well, thank you, everybody. "}, "hash": "ab039c765de38d6110b49af04b2e167b870299ebaf0af98948d51345a2fafe19", "class_name": "RelatedNodeInfo"}}, "text": "Okay. ", "start_char_idx": 254, "end_char_idx": 260, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72d3d22f-0332-4497-9121-ebaf55545488": {"__data__": {"id_": "72d3d22f-0332-4497-9121-ebaf55545488", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everybody.  [indiscernible] (1:00:34) enters our fiscal  2022, I'm excited about the \nbusinesses and the markets that we operate in today.  I'm very pleased with our performance and the momentum \nthat gives us and I really do believe we are positioned for long -term success.  I'm again, so proud of how resilient \nour employees have been throughout the pandemic. ", "original_text": "Well, thank you, everybody. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c112cf2f94209b5cfa9a737d84d9594bebf8e0fc989c58264dacdfaad5e759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0cf9abf-2a0d-49fb-9d72-f6ae39d413c9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everybody.  [indiscernible] (1:00:34) enters our fiscal  2022, I'm excited about the \nbusinesses and the markets that we operate in today.  I'm very pleased with our performance and the momentum \nthat gives us and I really do believe we are positioned for long -term success. ", "original_text": "Okay. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c78981cc11fbd4cb116644c21a79aaea71b8079368d31aafb31b0335f80afb1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23e1f468-48eb-49d5-98d4-0d0242787ab5", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everybody.  [indiscernible] (1:00:34) enters our fiscal  2022, I'm excited about the \nbusinesses and the markets that we operate in today.  I'm very pleased with our performance and the momentum \nthat gives us and I really do believe we are positioned for long -term success.  I'm again, so proud of how resilient \nour employees have been throughout the pandemic.  And in fiscal 2022, we look forward to supporting our \ncustomers, partners and communities as we hopefully resolve these uncertain times. ", "original_text": "[indiscernible] (1:00:34) enters our fiscal  2022, I'm excited about the \nbusinesses and the markets that we operate in today. "}, "hash": "1a7d3434a77d832a5efdc9c733d14661df6e901dac368fe9588f3fd626b816c0", "class_name": "RelatedNodeInfo"}}, "text": "Well, thank you, everybody. ", "start_char_idx": 260, "end_char_idx": 288, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23e1f468-48eb-49d5-98d4-0d0242787ab5": {"__data__": {"id_": "23e1f468-48eb-49d5-98d4-0d0242787ab5", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everybody.  [indiscernible] (1:00:34) enters our fiscal  2022, I'm excited about the \nbusinesses and the markets that we operate in today.  I'm very pleased with our performance and the momentum \nthat gives us and I really do believe we are positioned for long -term success.  I'm again, so proud of how resilient \nour employees have been throughout the pandemic.  And in fiscal 2022, we look forward to supporting our \ncustomers, partners and communities as we hopefully resolve these uncertain times. ", "original_text": "[indiscernible] (1:00:34) enters our fiscal  2022, I'm excited about the \nbusinesses and the markets that we operate in today. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c112cf2f94209b5cfa9a737d84d9594bebf8e0fc989c58264dacdfaad5e759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72d3d22f-0332-4497-9121-ebaf55545488", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everybody.  [indiscernible] (1:00:34) enters our fiscal  2022, I'm excited about the \nbusinesses and the markets that we operate in today.  I'm very pleased with our performance and the momentum \nthat gives us and I really do believe we are positioned for long -term success.  I'm again, so proud of how resilient \nour employees have been throughout the pandemic. ", "original_text": "Well, thank you, everybody. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a7f2b611775165563ad44fe27f4d989293f6a4f0e67782d8a5ba42059c4a67b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35ef8034-0bdd-4be9-8be6-1a1d98d27fcd", "node_type": "1", "metadata": {"window": "Okay.  Well, thank you, everybody.  [indiscernible] (1:00:34) enters our fiscal  2022, I'm excited about the \nbusinesses and the markets that we operate in today.  I'm very pleased with our performance and the momentum \nthat gives us and I really do believe we are positioned for long -term success.  I'm again, so proud of how resilient \nour employees have been throughout the pandemic.  And in fiscal 2022, we look forward to supporting our \ncustomers, partners and communities as we hopefully resolve these uncertain times.  We wish you and your \nfamilies, good health and wellness. ", "original_text": "I'm very pleased with our performance and the momentum \nthat gives us and I really do believe we are positioned for long -term success. "}, "hash": "77944c09209066a342fd6acc846b005e9b03c12a336ff72a54d9c7ec18e1f038", "class_name": "RelatedNodeInfo"}}, "text": "[indiscernible] (1:00:34) enters our fiscal  2022, I'm excited about the \nbusinesses and the markets that we operate in today. ", "start_char_idx": 288, "end_char_idx": 415, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35ef8034-0bdd-4be9-8be6-1a1d98d27fcd": {"__data__": {"id_": "35ef8034-0bdd-4be9-8be6-1a1d98d27fcd", "embedding": null, "metadata": {"window": "Okay.  Well, thank you, everybody.  [indiscernible] (1:00:34) enters our fiscal  2022, I'm excited about the \nbusinesses and the markets that we operate in today.  I'm very pleased with our performance and the momentum \nthat gives us and I really do believe we are positioned for long -term success.  I'm again, so proud of how resilient \nour employees have been throughout the pandemic.  And in fiscal 2022, we look forward to supporting our \ncustomers, partners and communities as we hopefully resolve these uncertain times.  We wish you and your \nfamilies, good health and wellness. ", "original_text": "I'm very pleased with our performance and the momentum \nthat gives us and I really do believe we are positioned for long -term success. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c112cf2f94209b5cfa9a737d84d9594bebf8e0fc989c58264dacdfaad5e759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23e1f468-48eb-49d5-98d4-0d0242787ab5", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everybody.  [indiscernible] (1:00:34) enters our fiscal  2022, I'm excited about the \nbusinesses and the markets that we operate in today.  I'm very pleased with our performance and the momentum \nthat gives us and I really do believe we are positioned for long -term success.  I'm again, so proud of how resilient \nour employees have been throughout the pandemic.  And in fiscal 2022, we look forward to supporting our \ncustomers, partners and communities as we hopefully resolve these uncertain times. ", "original_text": "[indiscernible] (1:00:34) enters our fiscal  2022, I'm excited about the \nbusinesses and the markets that we operate in today. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "088e5425ce506da8b7f8d7de2ec3892e91713a34f194adde3cd298ae5067bfaf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0624576-2a5f-4dbd-a14e-6e0bc48e031e", "node_type": "1", "metadata": {"window": "Well, thank you, everybody.  [indiscernible] (1:00:34) enters our fiscal  2022, I'm excited about the \nbusinesses and the markets that we operate in today.  I'm very pleased with our performance and the momentum \nthat gives us and I really do believe we are positioned for long -term success.  I'm again, so proud of how resilient \nour employees have been throughout the pandemic.  And in fiscal 2022, we look forward to supporting our \ncustomers, partners and communities as we hopefully resolve these uncertain times.  We wish you and your \nfamilies, good health and wellness.  Get vaccinated. ", "original_text": "I'm again, so proud of how resilient \nour employees have been throughout the pandemic. "}, "hash": "a105a1bf33e2b1434957ca01b3f86a29284d438430bab12211f55949d3aa42d7", "class_name": "RelatedNodeInfo"}}, "text": "I'm very pleased with our performance and the momentum \nthat gives us and I really do believe we are positioned for long -term success. ", "start_char_idx": 415, "end_char_idx": 551, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0624576-2a5f-4dbd-a14e-6e0bc48e031e": {"__data__": {"id_": "f0624576-2a5f-4dbd-a14e-6e0bc48e031e", "embedding": null, "metadata": {"window": "Well, thank you, everybody.  [indiscernible] (1:00:34) enters our fiscal  2022, I'm excited about the \nbusinesses and the markets that we operate in today.  I'm very pleased with our performance and the momentum \nthat gives us and I really do believe we are positioned for long -term success.  I'm again, so proud of how resilient \nour employees have been throughout the pandemic.  And in fiscal 2022, we look forward to supporting our \ncustomers, partners and communities as we hopefully resolve these uncertain times.  We wish you and your \nfamilies, good health and wellness.  Get vaccinated. ", "original_text": "I'm again, so proud of how resilient \nour employees have been throughout the pandemic. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c112cf2f94209b5cfa9a737d84d9594bebf8e0fc989c58264dacdfaad5e759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35ef8034-0bdd-4be9-8be6-1a1d98d27fcd", "node_type": "1", "metadata": {"window": "Okay.  Well, thank you, everybody.  [indiscernible] (1:00:34) enters our fiscal  2022, I'm excited about the \nbusinesses and the markets that we operate in today.  I'm very pleased with our performance and the momentum \nthat gives us and I really do believe we are positioned for long -term success.  I'm again, so proud of how resilient \nour employees have been throughout the pandemic.  And in fiscal 2022, we look forward to supporting our \ncustomers, partners and communities as we hopefully resolve these uncertain times.  We wish you and your \nfamilies, good health and wellness. ", "original_text": "I'm very pleased with our performance and the momentum \nthat gives us and I really do believe we are positioned for long -term success. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94841f45bd44b854a884744f5bb22e2fd52c98e5bb803e0820683853c8b7e15a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a00abec0-2820-40e5-a297-667bb5048947", "node_type": "1", "metadata": {"window": "[indiscernible] (1:00:34) enters our fiscal  2022, I'm excited about the \nbusinesses and the markets that we operate in today.  I'm very pleased with our performance and the momentum \nthat gives us and I really do believe we are positioned for long -term success.  I'm again, so proud of how resilient \nour employees have been throughout the pandemic.  And in fiscal 2022, we look forward to supporting our \ncustomers, partners and communities as we hopefully resolve these uncertain times.  We wish you and your \nfamilies, good health and wellness.  Get vaccinated.  And I want to wish everybody a Happy Nurses Day. ", "original_text": "And in fiscal 2022, we look forward to supporting our \ncustomers, partners and communities as we hopefully resolve these uncertain times. "}, "hash": "20e0799e64bef935280ffb4cf0ce11f3bdf0519d02c71db3f2e4434ecf94173a", "class_name": "RelatedNodeInfo"}}, "text": "I'm again, so proud of how resilient \nour employees have been throughout the pandemic. ", "start_char_idx": 551, "end_char_idx": 638, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a00abec0-2820-40e5-a297-667bb5048947": {"__data__": {"id_": "a00abec0-2820-40e5-a297-667bb5048947", "embedding": null, "metadata": {"window": "[indiscernible] (1:00:34) enters our fiscal  2022, I'm excited about the \nbusinesses and the markets that we operate in today.  I'm very pleased with our performance and the momentum \nthat gives us and I really do believe we are positioned for long -term success.  I'm again, so proud of how resilient \nour employees have been throughout the pandemic.  And in fiscal 2022, we look forward to supporting our \ncustomers, partners and communities as we hopefully resolve these uncertain times.  We wish you and your \nfamilies, good health and wellness.  Get vaccinated.  And I want to wish everybody a Happy Nurses Day. ", "original_text": "And in fiscal 2022, we look forward to supporting our \ncustomers, partners and communities as we hopefully resolve these uncertain times. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c112cf2f94209b5cfa9a737d84d9594bebf8e0fc989c58264dacdfaad5e759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0624576-2a5f-4dbd-a14e-6e0bc48e031e", "node_type": "1", "metadata": {"window": "Well, thank you, everybody.  [indiscernible] (1:00:34) enters our fiscal  2022, I'm excited about the \nbusinesses and the markets that we operate in today.  I'm very pleased with our performance and the momentum \nthat gives us and I really do believe we are positioned for long -term success.  I'm again, so proud of how resilient \nour employees have been throughout the pandemic.  And in fiscal 2022, we look forward to supporting our \ncustomers, partners and communities as we hopefully resolve these uncertain times.  We wish you and your \nfamilies, good health and wellness.  Get vaccinated. ", "original_text": "I'm again, so proud of how resilient \nour employees have been throughout the pandemic. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4861f614bef6d4ee19fc93771d987ab944eb469a448d6236bcd43ef8395642", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1644832d-437a-4169-bef7-d9980b93d4bf", "node_type": "1", "metadata": {"window": "I'm very pleased with our performance and the momentum \nthat gives us and I really do believe we are positioned for long -term success.  I'm again, so proud of how resilient \nour employees have been throughout the pandemic.  And in fiscal 2022, we look forward to supporting our \ncustomers, partners and communities as we hopefully resolve these uncertain times.  We wish you and your \nfamilies, good health and wellness.  Get vaccinated.  And I want to wish everybody a Happy Nurses Day.  Thanks \nto all those amazing nurses out there on the front lines. ", "original_text": "We wish you and your \nfamilies, good health and wellness. "}, "hash": "ddf1d9bd91f3b8c8011aa5a7d29be271bcb61e2989819f9eb9ee07ed6d425917", "class_name": "RelatedNodeInfo"}}, "text": "And in fiscal 2022, we look forward to supporting our \ncustomers, partners and communities as we hopefully resolve these uncertain times. ", "start_char_idx": 638, "end_char_idx": 776, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1644832d-437a-4169-bef7-d9980b93d4bf": {"__data__": {"id_": "1644832d-437a-4169-bef7-d9980b93d4bf", "embedding": null, "metadata": {"window": "I'm very pleased with our performance and the momentum \nthat gives us and I really do believe we are positioned for long -term success.  I'm again, so proud of how resilient \nour employees have been throughout the pandemic.  And in fiscal 2022, we look forward to supporting our \ncustomers, partners and communities as we hopefully resolve these uncertain times.  We wish you and your \nfamilies, good health and wellness.  Get vaccinated.  And I want to wish everybody a Happy Nurses Day.  Thanks \nto all those amazing nurses out there on the front lines. ", "original_text": "We wish you and your \nfamilies, good health and wellness. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c112cf2f94209b5cfa9a737d84d9594bebf8e0fc989c58264dacdfaad5e759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a00abec0-2820-40e5-a297-667bb5048947", "node_type": "1", "metadata": {"window": "[indiscernible] (1:00:34) enters our fiscal  2022, I'm excited about the \nbusinesses and the markets that we operate in today.  I'm very pleased with our performance and the momentum \nthat gives us and I really do believe we are positioned for long -term success.  I'm again, so proud of how resilient \nour employees have been throughout the pandemic.  And in fiscal 2022, we look forward to supporting our \ncustomers, partners and communities as we hopefully resolve these uncertain times.  We wish you and your \nfamilies, good health and wellness.  Get vaccinated.  And I want to wish everybody a Happy Nurses Day. ", "original_text": "And in fiscal 2022, we look forward to supporting our \ncustomers, partners and communities as we hopefully resolve these uncertain times. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f211582647e6bd534bc8e96b137ccfc54af9a079291ceb76c06ebbf0d176b9b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33e240ff-f971-42ed-9128-8ffc09ac405b", "node_type": "1", "metadata": {"window": "I'm again, so proud of how resilient \nour employees have been throughout the pandemic.  And in fiscal 2022, we look forward to supporting our \ncustomers, partners and communities as we hopefully resolve these uncertain times.  We wish you and your \nfamilies, good health and wellness.  Get vaccinated.  And I want to wish everybody a Happy Nurses Day.  Thanks \nto all those amazing nurses out there on the front lines.  Thanks, everybody. ", "original_text": "Get vaccinated. "}, "hash": "6871621e60d71c61ed298461a72bd671d7f505943ed3aa5b272442b81175bce7", "class_name": "RelatedNodeInfo"}}, "text": "We wish you and your \nfamilies, good health and wellness. ", "start_char_idx": 776, "end_char_idx": 834, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33e240ff-f971-42ed-9128-8ffc09ac405b": {"__data__": {"id_": "33e240ff-f971-42ed-9128-8ffc09ac405b", "embedding": null, "metadata": {"window": "I'm again, so proud of how resilient \nour employees have been throughout the pandemic.  And in fiscal 2022, we look forward to supporting our \ncustomers, partners and communities as we hopefully resolve these uncertain times.  We wish you and your \nfamilies, good health and wellness.  Get vaccinated.  And I want to wish everybody a Happy Nurses Day.  Thanks \nto all those amazing nurses out there on the front lines.  Thanks, everybody. ", "original_text": "Get vaccinated. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c112cf2f94209b5cfa9a737d84d9594bebf8e0fc989c58264dacdfaad5e759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1644832d-437a-4169-bef7-d9980b93d4bf", "node_type": "1", "metadata": {"window": "I'm very pleased with our performance and the momentum \nthat gives us and I really do believe we are positioned for long -term success.  I'm again, so proud of how resilient \nour employees have been throughout the pandemic.  And in fiscal 2022, we look forward to supporting our \ncustomers, partners and communities as we hopefully resolve these uncertain times.  We wish you and your \nfamilies, good health and wellness.  Get vaccinated.  And I want to wish everybody a Happy Nurses Day.  Thanks \nto all those amazing nurses out there on the front lines. ", "original_text": "We wish you and your \nfamilies, good health and wellness. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6b0b7e19409f2cbc549406466e7c3c39c00a4600c7f65d3cd02aaba4f30037d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79895b5e-d630-45f6-b86e-dc6c4df143a2", "node_type": "1", "metadata": {"window": "And in fiscal 2022, we look forward to supporting our \ncustomers, partners and communities as we hopefully resolve these uncertain times.  We wish you and your \nfamilies, good health and wellness.  Get vaccinated.  And I want to wish everybody a Happy Nurses Day.  Thanks \nto all those amazing nurses out there on the front lines.  Thanks, everybody.  Have a great evening.  \n ", "original_text": "And I want to wish everybody a Happy Nurses Day. "}, "hash": "96e978847457a7853638b060be892ce5050b19eeb6734b08f52fbd9754b98606", "class_name": "RelatedNodeInfo"}}, "text": "Get vaccinated. ", "start_char_idx": 834, "end_char_idx": 850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79895b5e-d630-45f6-b86e-dc6c4df143a2": {"__data__": {"id_": "79895b5e-d630-45f6-b86e-dc6c4df143a2", "embedding": null, "metadata": {"window": "And in fiscal 2022, we look forward to supporting our \ncustomers, partners and communities as we hopefully resolve these uncertain times.  We wish you and your \nfamilies, good health and wellness.  Get vaccinated.  And I want to wish everybody a Happy Nurses Day.  Thanks \nto all those amazing nurses out there on the front lines.  Thanks, everybody.  Have a great evening.  \n ", "original_text": "And I want to wish everybody a Happy Nurses Day. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c112cf2f94209b5cfa9a737d84d9594bebf8e0fc989c58264dacdfaad5e759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33e240ff-f971-42ed-9128-8ffc09ac405b", "node_type": "1", "metadata": {"window": "I'm again, so proud of how resilient \nour employees have been throughout the pandemic.  And in fiscal 2022, we look forward to supporting our \ncustomers, partners and communities as we hopefully resolve these uncertain times.  We wish you and your \nfamilies, good health and wellness.  Get vaccinated.  And I want to wish everybody a Happy Nurses Day.  Thanks \nto all those amazing nurses out there on the front lines.  Thanks, everybody. ", "original_text": "Get vaccinated. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b9bc986bec6b85c674e87e830401f3da84270fd27b4667a35632725d8d09c078", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce8452d8-f369-4157-bc13-09169ef4a196", "node_type": "1", "metadata": {"window": "We wish you and your \nfamilies, good health and wellness.  Get vaccinated.  And I want to wish everybody a Happy Nurses Day.  Thanks \nto all those amazing nurses out there on the front lines.  Thanks, everybody.  Have a great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. ", "original_text": "Thanks \nto all those amazing nurses out there on the front lines. "}, "hash": "6556e5b9ab80585a870407d3ba3be9022d02d20acaf65e9aa5179c7360ba3824", "class_name": "RelatedNodeInfo"}}, "text": "And I want to wish everybody a Happy Nurses Day. ", "start_char_idx": 850, "end_char_idx": 899, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce8452d8-f369-4157-bc13-09169ef4a196": {"__data__": {"id_": "ce8452d8-f369-4157-bc13-09169ef4a196", "embedding": null, "metadata": {"window": "We wish you and your \nfamilies, good health and wellness.  Get vaccinated.  And I want to wish everybody a Happy Nurses Day.  Thanks \nto all those amazing nurses out there on the front lines.  Thanks, everybody.  Have a great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. ", "original_text": "Thanks \nto all those amazing nurses out there on the front lines. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c112cf2f94209b5cfa9a737d84d9594bebf8e0fc989c58264dacdfaad5e759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79895b5e-d630-45f6-b86e-dc6c4df143a2", "node_type": "1", "metadata": {"window": "And in fiscal 2022, we look forward to supporting our \ncustomers, partners and communities as we hopefully resolve these uncertain times.  We wish you and your \nfamilies, good health and wellness.  Get vaccinated.  And I want to wish everybody a Happy Nurses Day.  Thanks \nto all those amazing nurses out there on the front lines.  Thanks, everybody.  Have a great evening.  \n ", "original_text": "And I want to wish everybody a Happy Nurses Day. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66458b81d90788d6bd89efb192ff201860c8ab47ed1dcee5efbb5ce380b0991f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e198f658-8e5a-43ab-9204-af0d8b624059", "node_type": "1", "metadata": {"window": "Get vaccinated.  And I want to wish everybody a Happy Nurses Day.  Thanks \nto all those amazing nurses out there on the front lines.  Thanks, everybody.  Have a great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n", "original_text": "Thanks, everybody. "}, "hash": "dd5f543c11f7e5627ce554f67f5410924f30d998bb9f599c5409bfd34484c345", "class_name": "RelatedNodeInfo"}}, "text": "Thanks \nto all those amazing nurses out there on the front lines. ", "start_char_idx": 899, "end_char_idx": 965, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e198f658-8e5a-43ab-9204-af0d8b624059": {"__data__": {"id_": "e198f658-8e5a-43ab-9204-af0d8b624059", "embedding": null, "metadata": {"window": "Get vaccinated.  And I want to wish everybody a Happy Nurses Day.  Thanks \nto all those amazing nurses out there on the front lines.  Thanks, everybody.  Have a great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n", "original_text": "Thanks, everybody. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c112cf2f94209b5cfa9a737d84d9594bebf8e0fc989c58264dacdfaad5e759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce8452d8-f369-4157-bc13-09169ef4a196", "node_type": "1", "metadata": {"window": "We wish you and your \nfamilies, good health and wellness.  Get vaccinated.  And I want to wish everybody a Happy Nurses Day.  Thanks \nto all those amazing nurses out there on the front lines.  Thanks, everybody.  Have a great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. ", "original_text": "Thanks \nto all those amazing nurses out there on the front lines. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da11809e210328ddd7f74405eb936892d5cb44b2f979b61753003539c842e557", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0a7ea59-520e-4560-83ff-3b17e6a0e7c8", "node_type": "1", "metadata": {"window": "And I want to wish everybody a Happy Nurses Day.  Thanks \nto all those amazing nurses out there on the front lines.  Thanks, everybody.  Have a great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "original_text": "Have a great evening.  \n "}, "hash": "0f854770782b3cf119c7fe5ccc351ffdd592c0949f1b8d860c9daf0e4717c646", "class_name": "RelatedNodeInfo"}}, "text": "Thanks, everybody. ", "start_char_idx": 965, "end_char_idx": 984, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0a7ea59-520e-4560-83ff-3b17e6a0e7c8": {"__data__": {"id_": "f0a7ea59-520e-4560-83ff-3b17e6a0e7c8", "embedding": null, "metadata": {"window": "And I want to wish everybody a Happy Nurses Day.  Thanks \nto all those amazing nurses out there on the front lines.  Thanks, everybody.  Have a great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "original_text": "Have a great evening.  \n ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c112cf2f94209b5cfa9a737d84d9594bebf8e0fc989c58264dacdfaad5e759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e198f658-8e5a-43ab-9204-af0d8b624059", "node_type": "1", "metadata": {"window": "Get vaccinated.  And I want to wish everybody a Happy Nurses Day.  Thanks \nto all those amazing nurses out there on the front lines.  Thanks, everybody.  Have a great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n", "original_text": "Thanks, everybody. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "930cef41dfade3bd0890b896aa24365232a4055792f00896fb3b89cce8b5983e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b032a67-446e-4f34-9c94-590aa42ee728", "node_type": "1", "metadata": {"window": "Thanks \nto all those amazing nurses out there on the front lines.  Thanks, everybody.  Have a great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. "}, "hash": "47d60ebf452bd7219b42a429b6033230fbf37d4f2db395a59d7d6cd524948a1c", "class_name": "RelatedNodeInfo"}}, "text": "Have a great evening.  \n ", "start_char_idx": 984, "end_char_idx": 1009, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b032a67-446e-4f34-9c94-590aa42ee728": {"__data__": {"id_": "1b032a67-446e-4f34-9c94-590aa42ee728", "embedding": null, "metadata": {"window": "Thanks \nto all those amazing nurses out there on the front lines.  Thanks, everybody.  Have a great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c112cf2f94209b5cfa9a737d84d9594bebf8e0fc989c58264dacdfaad5e759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0a7ea59-520e-4560-83ff-3b17e6a0e7c8", "node_type": "1", "metadata": {"window": "And I want to wish everybody a Happy Nurses Day.  Thanks \nto all those amazing nurses out there on the front lines.  Thanks, everybody.  Have a great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "original_text": "Have a great evening.  \n ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5b86e8169d14daba06b520dd8bf977e83acb41f7e18d7973c445e842e6ead70", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e26efc7-9480-4dcb-924f-54fd25b1c190", "node_type": "1", "metadata": {"window": "Thanks, everybody.  Have a great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information. ", "original_text": "You may now disconnect, and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n"}, "hash": "ce5f0e845d516a2755de41a7c24eef2b65197984bff813c74f66c3d83be60c20", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. ", "start_char_idx": 1009, "end_char_idx": 1326, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e26efc7-9480-4dcb-924f-54fd25b1c190": {"__data__": {"id_": "1e26efc7-9480-4dcb-924f-54fd25b1c190", "embedding": null, "metadata": {"window": "Thanks, everybody.  Have a great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information. ", "original_text": "You may now disconnect, and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c112cf2f94209b5cfa9a737d84d9594bebf8e0fc989c58264dacdfaad5e759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b032a67-446e-4f34-9c94-590aa42ee728", "node_type": "1", "metadata": {"window": "Thanks \nto all those amazing nurses out there on the front lines.  Thanks, everybody.  Have a great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "261641fda7225346a8694dd2f4cf023ca8f1b6e18412f3787e1cbbb83994dc6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "357ba423-ac63-45e3-8fc9-48efa523b06b", "node_type": "1", "metadata": {"window": "Have a great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n"}, "hash": "0be4d5ceb3756a6034c633500e1be253fadd8d9f7aae83972dc6cda9e9c8a458", "class_name": "RelatedNodeInfo"}}, "text": "You may now disconnect, and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n", "start_char_idx": 1326, "end_char_idx": 1395, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "357ba423-ac63-45e3-8fc9-48efa523b06b": {"__data__": {"id_": "357ba423-ac63-45e3-8fc9-48efa523b06b", "embedding": null, "metadata": {"window": "Have a great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c112cf2f94209b5cfa9a737d84d9594bebf8e0fc989c58264dacdfaad5e759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e26efc7-9480-4dcb-924f-54fd25b1c190", "node_type": "1", "metadata": {"window": "Thanks, everybody.  Have a great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information. ", "original_text": "You may now disconnect, and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "140c9e00d928a386758a71212d48a41bcfb4732c3a095d471a5ca4703a233f17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0386035a-d096-4d5f-bf30-5954fef3337d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. "}, "hash": "17f765a571cd0ca2416fc4182cb26d6ddefe2ce525fa501e21750c09bba56748", "class_name": "RelatedNodeInfo"}}, "text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "start_char_idx": 1395, "end_char_idx": 1604, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0386035a-d096-4d5f-bf30-5954fef3337d": {"__data__": {"id_": "0386035a-d096-4d5f-bf30-5954fef3337d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c112cf2f94209b5cfa9a737d84d9594bebf8e0fc989c58264dacdfaad5e759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "357ba423-ac63-45e3-8fc9-48efa523b06b", "node_type": "1", "metadata": {"window": "Have a great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e266c0adf95226311e6c98831cd77361206b454a97ebb6d287c2bb110299cb16", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b74dedfd-736c-4b6f-90ec-82b572afbca4", "node_type": "1", "metadata": {"window": "You may now disconnect, and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice. ", "original_text": "You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information. "}, "hash": "d74ad6a0a71ed4339308b90fef39e1190fc1b08fae0b2c9fae8ad544a0997f7d", "class_name": "RelatedNodeInfo"}}, "text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "start_char_idx": 1604, "end_char_idx": 1726, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b74dedfd-736c-4b6f-90ec-82b572afbca4": {"__data__": {"id_": "b74dedfd-736c-4b6f-90ec-82b572afbca4", "embedding": null, "metadata": {"window": "You may now disconnect, and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice. ", "original_text": "You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c112cf2f94209b5cfa9a737d84d9594bebf8e0fc989c58264dacdfaad5e759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0386035a-d096-4d5f-bf30-5954fef3337d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bb744b8d232dddc7aff30c795fc0b5b7ee08d147c67226f5ef163917e896e980", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b25ddfb-9637-40a3-bc69-316cab4d9963", "node_type": "1", "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "This information is not intended to be used as the primary basis \nof investment decisions. "}, "hash": "cc0e225ed3af95bc2ae159a86054a8b6dc20342c5cc3ed0ca369490c41c572ce", "class_name": "RelatedNodeInfo"}}, "text": "You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information. ", "start_char_idx": 1726, "end_char_idx": 1927, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b25ddfb-9637-40a3-bc69-316cab4d9963": {"__data__": {"id_": "1b25ddfb-9637-40a3-bc69-316cab4d9963", "embedding": null, "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "This information is not intended to be used as the primary basis \nof investment decisions. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c112cf2f94209b5cfa9a737d84d9594bebf8e0fc989c58264dacdfaad5e759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b74dedfd-736c-4b6f-90ec-82b572afbca4", "node_type": "1", "metadata": {"window": "You may now disconnect, and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice. ", "original_text": "You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "618d1f06329e4d3b6ed11331e7a466b76ab523328c2372aad5101e560b5f733a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c694b9f9-00f5-42b1-baba-ef887fa665a6", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. "}, "hash": "d6a13ca7fbbe8e99d6359c8734b288a0f1b1f4448f3841f4c0dc29f35cf676b9", "class_name": "RelatedNodeInfo"}}, "text": "This information is not intended to be used as the primary basis \nof investment decisions. ", "start_char_idx": 1927, "end_char_idx": 2018, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c694b9f9-00f5-42b1-baba-ef887fa665a6": {"__data__": {"id_": "c694b9f9-00f5-42b1-baba-ef887fa665a6", "embedding": null, "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c112cf2f94209b5cfa9a737d84d9594bebf8e0fc989c58264dacdfaad5e759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b25ddfb-9637-40a3-bc69-316cab4d9963", "node_type": "1", "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "This information is not intended to be used as the primary basis \nof investment decisions. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3578d69217cf2ed93ac0105a65300efb846605cf867917e4366c960480ad802a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d9bf935-9433-49ba-a4a4-fcf4f926df03", "node_type": "1", "metadata": {"window": "You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT . ", "original_text": "Any \ninformation expressed h erein on this date is subject to change without notice. "}, "hash": "288bb34afeeaa8aaf078f46181699e110dd98cd4a0595a6eeda1a2888fcb2fb3", "class_name": "RelatedNodeInfo"}}, "text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "start_char_idx": 2018, "end_char_idx": 2381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d9bf935-9433-49ba-a4a4-fcf4f926df03": {"__data__": {"id_": "9d9bf935-9433-49ba-a4a4-fcf4f926df03", "embedding": null, "metadata": {"window": "You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT . ", "original_text": "Any \ninformation expressed h erein on this date is subject to change without notice. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c112cf2f94209b5cfa9a737d84d9594bebf8e0fc989c58264dacdfaad5e759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c694b9f9-00f5-42b1-baba-ef887fa665a6", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e57e7c8b5e4e4bcfc70fe0d246408a67ea2f43e4e64284872057d7b79774c4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85a04192-4410-4c48-a55c-2cf9d8c56c35", "node_type": "1", "metadata": {"window": "This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC. "}, "hash": "f8e64db90c9a6e57b2c8eb9aac5d7516ebdecf459e30bc3d8e1b7ea904b69265", "class_name": "RelatedNodeInfo"}}, "text": "Any \ninformation expressed h erein on this date is subject to change without notice. ", "start_char_idx": 2381, "end_char_idx": 2466, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85a04192-4410-4c48-a55c-2cf9d8c56c35": {"__data__": {"id_": "85a04192-4410-4c48-a55c-2cf9d8c56c35", "embedding": null, "metadata": {"window": "This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c112cf2f94209b5cfa9a737d84d9594bebf8e0fc989c58264dacdfaad5e759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d9bf935-9433-49ba-a4a4-fcf4f926df03", "node_type": "1", "metadata": {"window": "You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT . ", "original_text": "Any \ninformation expressed h erein on this date is subject to change without notice. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6782d85e1b0ed4734d72f043179df2d663d3bfc9a7bb159fd5c06579b67651c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5fa34bf0-2c5e-40db-b4c9-0a294c88af02", "node_type": "1", "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n"}, "hash": "3267b01187c98613a6c4cc19a6341eab97f12621a3526fcede01610140a1dbf9", "class_name": "RelatedNodeInfo"}}, "text": "Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "start_char_idx": 2466, "end_char_idx": 2594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5fa34bf0-2c5e-40db-b4c9-0a294c88af02": {"__data__": {"id_": "5fa34bf0-2c5e-40db-b4c9-0a294c88af02", "embedding": null, "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c112cf2f94209b5cfa9a737d84d9594bebf8e0fc989c58264dacdfaad5e759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85a04192-4410-4c48-a55c-2cf9d8c56c35", "node_type": "1", "metadata": {"window": "This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c16472bf90677adfd040f394855dd18878608774ceefa44afad1f9d699085195", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f23c31a4-da06-4e82-b662-0a4c3043ca22", "node_type": "1", "metadata": {"window": "Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT . "}, "hash": "5132c92dbf346d52dd6a8ada7f5a51ac21e6f051fb76ca0f3e3c2bc3dcc272e9", "class_name": "RelatedNodeInfo"}}, "text": "FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n", "start_char_idx": 2594, "end_char_idx": 2757, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f23c31a4-da06-4e82-b662-0a4c3043ca22": {"__data__": {"id_": "f23c31a4-da06-4e82-b662-0a4c3043ca22", "embedding": null, "metadata": {"window": "Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT . ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c112cf2f94209b5cfa9a737d84d9594bebf8e0fc989c58264dacdfaad5e759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5fa34bf0-2c5e-40db-b4c9-0a294c88af02", "node_type": "1", "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56fbad70efc5de6653e4a048ee5e49048d335b12d4a24d52ac4ec367f4264007", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b64f4b6-6184-4c2b-9c09-a20ccb30fad0", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n"}, "hash": "f20beb91866b2ab8f12a181e0a495e15851348d1055c507ff4efb13b75bafd27", "class_name": "RelatedNodeInfo"}}, "text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT . ", "start_char_idx": 2757, "end_char_idx": 3193, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b64f4b6-6184-4c2b-9c09-a20ccb30fad0": {"__data__": {"id_": "4b64f4b6-6184-4c2b-9c09-a20ccb30fad0", "embedding": null, "metadata": {"window": "Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c112cf2f94209b5cfa9a737d84d9594bebf8e0fc989c58264dacdfaad5e759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f23c31a4-da06-4e82-b662-0a4c3043ca22", "node_type": "1", "metadata": {"window": "Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT . ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab34ac85c9b8e357175c184736b53e3af56d310f21f2ae146d4842e90a3b51c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed18e989-4840-4c98-ac3e-df621d8008b8", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. "}, "hash": "9e5c7d910c8a1a12cc64d54a9684c58e5fde0baeb0c0ce5e11e181fadfc95f4f", "class_name": "RelatedNodeInfo"}}, "text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "start_char_idx": 3193, "end_char_idx": 3873, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed18e989-4840-4c98-ac3e-df621d8008b8": {"__data__": {"id_": "ed18e989-4840-4c98-ac3e-df621d8008b8", "embedding": null, "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c112cf2f94209b5cfa9a737d84d9594bebf8e0fc989c58264dacdfaad5e759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b64f4b6-6184-4c2b-9c09-a20ccb30fad0", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "15ab4736573f955b22a18b503a1ad25ec42a0f85140d77af76eba4c79bd2023a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0735e7c-c2b1-42fd-a1fe-192cf98f3409", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. "}, "hash": "58cff2742942843f801b301fe49b405b9fc4946e7fbb4937974df78a6815375a", "class_name": "RelatedNodeInfo"}}, "text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "start_char_idx": 3873, "end_char_idx": 4063, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0735e7c-c2b1-42fd-a1fe-192cf98f3409": {"__data__": {"id_": "f0735e7c-c2b1-42fd-a1fe-192cf98f3409", "embedding": null, "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c112cf2f94209b5cfa9a737d84d9594bebf8e0fc989c58264dacdfaad5e759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed18e989-4840-4c98-ac3e-df621d8008b8", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2d52ea32050d6c74b520946b2baa536ae23609fab3337d1cfc267e96f7590db1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4531cc07-445b-4503-8969-e4f08f7e397c", "node_type": "1", "metadata": {"window": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  "}, "hash": "5f611b6695a5a74401a5a4b800ff4e3cbe8745f9efb938b7f3f7117ac9d2d4a7", "class_name": "RelatedNodeInfo"}}, "text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "start_char_idx": 4063, "end_char_idx": 4141, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4531cc07-445b-4503-8969-e4f08f7e397c": {"__data__": {"id_": "4531cc07-445b-4503-8969-e4f08f7e397c", "embedding": null, "metadata": {"window": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c112cf2f94209b5cfa9a737d84d9594bebf8e0fc989c58264dacdfaad5e759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0735e7c-c2b1-42fd-a1fe-192cf98f3409", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73e12875a6b420b9ecd8d2dc819ebb94c38d7416406bf8d6b94306fbf971d36b", "class_name": "RelatedNodeInfo"}}, "text": "All rights reserved.  ", "start_char_idx": 4141, "end_char_idx": 4163, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"df68f982-117d-44fb-a91a-bcfb23d17447": {"doc_hash": "47ea468c4c745e317ce081d2b7ea01caaf137185d8a65a7585ac2c6b838051f8", "ref_doc_id": "70020eb5-2224-4543-aef8-9b1b4fe4eba0"}, "a5f7a822-4b25-43c8-925c-3fcc0f1286b9": {"doc_hash": "6260ca9d536e8c57ff0aac560c0fb5d96b461c8bc3f911cc09cc969b86c1cded", "ref_doc_id": "70020eb5-2224-4543-aef8-9b1b4fe4eba0"}, "bfb2ae1f-2076-4e7c-baee-61a8862bba9c": {"doc_hash": "be861166aeae70b7bb4fd7dd179374c4ef0a7427b5d1b5cd316c2fe84c3ea3e1", "ref_doc_id": "78cda6f2-9cf3-42b7-afb0-13841559d1cb"}, "2df6c36c-4f4a-460d-a679-b39cbc4bb868": {"doc_hash": "a66eb319e91aaea6c09da4e25af62af9d043cfc707c0fab0f6eef46c4d5e171a", "ref_doc_id": "78cda6f2-9cf3-42b7-afb0-13841559d1cb"}, "1ab4f5f4-5b10-40ae-bc79-af33632e1362": {"doc_hash": "cf263bb2538c210712b2940c7e4c7ea44aa5bcf9cb57dfdc3c91e04ab14b37d2", "ref_doc_id": "78cda6f2-9cf3-42b7-afb0-13841559d1cb"}, "1aa3b904-8c18-49bc-97de-f374134132db": {"doc_hash": "99f7b248d195c200a6ac7dc72819db7e1c3b950c8a97092457f4792e16d3d868", "ref_doc_id": "78cda6f2-9cf3-42b7-afb0-13841559d1cb"}, "3ff117b0-5756-4ff3-ba1c-18b9d8d0d7c5": {"doc_hash": "011c6317c8ea471033b98b361a42cf4aaee8960cba4d2583f01800f7cac3f33b", "ref_doc_id": "78cda6f2-9cf3-42b7-afb0-13841559d1cb"}, "252a33a3-581a-4ab5-b953-420d28e71cd3": {"doc_hash": "e2fb7ce14cbc34e9a3b7eee8604ebbb32cf728e254d80fa2003aa99060b79a2c", "ref_doc_id": "78cda6f2-9cf3-42b7-afb0-13841559d1cb"}, "947bb482-9404-4616-8412-88bbea06c3da": {"doc_hash": "44dee6215097ed0454dc7a8b83012ae6de947af251de8b3954e31febc9ff459b", "ref_doc_id": "78cda6f2-9cf3-42b7-afb0-13841559d1cb"}, "0d1d3c3b-02d8-4731-8392-5f3d7b54597e": {"doc_hash": "62109a57519e6075c89793da3fd4cb2c141ca46a8da1a170d0fda1f27be62dfc", "ref_doc_id": "78cda6f2-9cf3-42b7-afb0-13841559d1cb"}, "98666372-6af5-4092-bb4a-17551a9a62c2": {"doc_hash": "616006bcceb33e747fed86d3760634a705b046d10c91acc0d7a05ff2aebd82b2", "ref_doc_id": "78cda6f2-9cf3-42b7-afb0-13841559d1cb"}, "39a88a04-d677-4a52-8e24-06ea81bf3fee": {"doc_hash": "4537d8d75373dc7407413c67bfcd8deac2370673afb8a4089b5fedcceea51ab0", "ref_doc_id": "78cda6f2-9cf3-42b7-afb0-13841559d1cb"}, "0742350f-efea-4952-9288-7335deefb584": {"doc_hash": "923ccbef13f3f58817f4019e7396279d35a6a95c874d80daba7c7191f4fa626e", "ref_doc_id": "78cda6f2-9cf3-42b7-afb0-13841559d1cb"}, "046d6f12-1632-429b-a3f7-0d64d8bb59a4": {"doc_hash": "4910acc111d69cd87041c0654a95bc5689153b65b8ca5a3996cf3524727efe0b", "ref_doc_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f"}, "b5750b52-ab4f-49fe-92ff-73db09976056": {"doc_hash": "1013fe6c83d9f8bf976c1dd45d56056009a0870b9fcebc07e6ddc78648ce49d5", "ref_doc_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f"}, "886628b5-e9a3-4183-a9e5-80b14e8659b1": {"doc_hash": "30912c53e2fa39fe6d41100aaaacb9dca3018f3e93222467fa4e777463e294ed", "ref_doc_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f"}, "47ea722d-01e4-438e-81b0-39daaffa86d5": {"doc_hash": "b555df537496fec2a87a6581c79f8775de848efe8f99fa1701f8e64132c7dd27", "ref_doc_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f"}, "531eec11-982b-4b38-951d-21bc222149a6": {"doc_hash": "70c6b3ae1d53a1098896cf9016a8b7cc31240b096ae73e334ead3ffa004404cf", "ref_doc_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f"}, "ae751d68-767b-460c-bfb2-10175e94e806": {"doc_hash": "56ba08014df18c9142798b1e8e76fc1f1b6d6de56698aa13ea4625895c1dae4d", "ref_doc_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f"}, "bb1e1204-820d-43fa-8211-08284f889719": {"doc_hash": "a9716cf1f034cbaf9d2a046a15881894c6d11185cf434d94e278a36bd2e22405", "ref_doc_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f"}, "b0ccf3ef-daf4-49d2-9701-e8a350c2d4b7": {"doc_hash": "a1a6bf831217d2e4d12c00e061c0ee3b23fc73d236c429031bbf9b078c381a72", "ref_doc_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f"}, "742dce34-a795-4152-ba46-c7ef2aa2f9d7": {"doc_hash": "7cc3aee520604f1b5c11a9657b0eebf7f91452cd0b8b9dc9bd620d6ce72c6632", "ref_doc_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f"}, "49093942-6be4-4761-a1f4-3150419318fc": {"doc_hash": "82d2e36d224ae0f16ad9c26bfaa20fc165f474b9fba548bd43b3a1c1bfc99e38", "ref_doc_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f"}, "93f22f59-4782-4460-9bc4-6ddd2939cffb": {"doc_hash": "5589c282b94e8fc5985e117de758cc3cc4124fc1f426b733ce0600c838a77773", "ref_doc_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f"}, "0a80ee28-ca18-4332-87e0-a25a56427d1f": {"doc_hash": "85036c0d3cf12c5ced76cb451b051d9ab2f355be40c8d42ced5366831c960fe8", "ref_doc_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f"}, "4fa1e4f9-e704-4798-b504-86c088fe22d0": {"doc_hash": "3292b380560a8e9d815e75339025bffc10d5d159cd65592a0c55e31df60041e0", "ref_doc_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f"}, "d3ccac06-64f7-4d68-aade-c86c93406b78": {"doc_hash": "7d04e323b899a7d7dbd48c76f95c5fb4ef031300dc0d3c1b628ea82564e3f009", "ref_doc_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f"}, "1d42212e-b4c0-42bf-8acc-f54a1397b396": {"doc_hash": "4c93ed7fee45829f42d4f307cbf7e20ec6ea143ba4d5ef2ca49d5072f046e7d9", "ref_doc_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f"}, "62875154-38b4-42e6-80b3-c161e33c88a5": {"doc_hash": "657d6d32639f4345918e140bcd85f90baa4dbb6cb4f8c11af834fa988e21fbd3", "ref_doc_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f"}, "4989ea59-e65d-40d3-8a21-ab07888bd2f3": {"doc_hash": "b8586af75200c13c85eff9a774c221619e9de4b3849bd7aa94c85c556aacc227", "ref_doc_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f"}, "e98f00df-cc60-42b7-aec0-95e9be34d4a9": {"doc_hash": "41c51e5df75a715a057e6cd2407f3b506553bc6a803f2b59a09911ed99022389", "ref_doc_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f"}, "f3c662b9-0b87-47cd-a36f-5588327d2de1": {"doc_hash": "47241185d373f8160f3dc97c2a1d265681f8a7f9b44b90f106f46c75abdb8746", "ref_doc_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f"}, "f12fbbfc-69b2-4e15-98d2-50b84a8afd8f": {"doc_hash": "53f9f42cf4658fd9f6a3f35150db5cef3e2535f5c9f80268fa3916d18f74faf8", "ref_doc_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f"}, "f3084537-2fbc-4772-9539-353de900b0c1": {"doc_hash": "e4c283a3c12398630623e3c74ec94320d9d320866f5014a4ad28d3618d80e546", "ref_doc_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f"}, "5ec1542b-2115-4ca4-a07f-2452f3411988": {"doc_hash": "622927d4ac0b4dedd0f96eb229fddd742eb8624eb5fbab4e124af9e157ab8546", "ref_doc_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f"}, "d8e1accc-0d3b-41a2-8a4d-13e1b4a05618": {"doc_hash": "af12f641e225c57e92f8f809dbd823dde0a8faf5b72b478b7186d4363bce74c8", "ref_doc_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f"}, "ba6788d0-40c5-4519-b5c7-889d330f67a8": {"doc_hash": "3ecdda0882a6fd2731e0a6e2b4c57eceb2fb24828f79510f3654ace8c5087e5c", "ref_doc_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f"}, "ee3d6f15-c39a-47cf-b477-e9164e2ded9b": {"doc_hash": "b331cd5d5a220853b611d6dc9b6cb520561ef06a6147ac7498a26800071e3110", "ref_doc_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f"}, "d562bafa-64e8-449f-bdba-dab5c7202afd": {"doc_hash": "8c8a27904689b07751bf6bd4c82501374395062d5eac943c076da64ab516f438", "ref_doc_id": "4568d7c2-ac61-4065-94af-1af8cf739d2f"}, "f6ef3b9f-1a91-434c-9da0-84980b4c1057": {"doc_hash": "3a303e1ea98e8bc42a3be994db91dabc6da7fa124c0de65fa0917e92a9a05d11", "ref_doc_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff"}, "e211340f-2291-4035-88f4-ceff80156b0f": {"doc_hash": "42b25fd6404600756255217d4aaf407e786261da75dca33ff59348d5276e3dc8", "ref_doc_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff"}, "04217e57-0f2b-4cd1-b64b-6a17d3ab291f": {"doc_hash": "7be594195a6e315d9fbac75f7325857dd46935f7f4ea0e7659dfb73e215ddba1", "ref_doc_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff"}, "74c5f79c-780d-456c-a5f0-afcb9e8963ca": {"doc_hash": "3cd25e4ce94b010a708eb3c71e6968b418c8601985fc7edf6a901e6b62777e90", "ref_doc_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff"}, "d5a56c69-47c5-4fe4-b1c9-5c9de4f06ab0": {"doc_hash": "0fda2cce24a875efec7c47335e39aabf1195c072fc51e13dafda73f26e99e5f6", "ref_doc_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff"}, "080ab470-5333-4ed4-b066-b14bf63381a1": {"doc_hash": "c91abfb328ec8e322771ff9ab276f57a9a79571cafd1f80c3aff0dcb557fdd5a", "ref_doc_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff"}, "5d619075-fd38-4266-8524-8f0f03c12ec9": {"doc_hash": "a8eaa27afca707e447ca7039d5cfa98d9ed8ccd5db6eab5d9c317325eff7aee1", "ref_doc_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff"}, "a22546f7-0d26-4631-81b9-6597b6285b9b": {"doc_hash": "8b705efec917d1472ca992a1ee60ebca7aada40a02db7e11dda5eb6a929c4752", "ref_doc_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff"}, "96b206c6-d381-435a-a90a-06fcf679a4ad": {"doc_hash": "b150ab1bdfc1325c6bd5ff6edc9163afa19985f4c11bd6bffe6dfdf25361778f", "ref_doc_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff"}, "8b57444f-07dd-4b66-9d6f-30da16b17b0a": {"doc_hash": "53151871a949a84346ab62085df539999af3ad603d40a17e7a1b9a4fdcd1439d", "ref_doc_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff"}, "70ec0f27-d712-41e3-9c05-6d9c6a132502": {"doc_hash": "42b5cfe5ac28119d3ae3be5a1b49458abfe35c81cc780dec1037d47359b54467", "ref_doc_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff"}, "81828f5f-2dd8-4a1d-bd00-2c525770ccd0": {"doc_hash": "95c330e67a0c22ba61d3bcc8ab41c1bb3a58d3c8dae0f2298b0a208ccb79656e", "ref_doc_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff"}, "7ff40c8f-07b7-468c-9251-dd8eff5211a3": {"doc_hash": "f11b98229833cd7b208bce26e52bb80418e86391234e461d56880abf062b064e", "ref_doc_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff"}, "3eb3adf6-4b9b-4116-99a3-af479a13f7b4": {"doc_hash": "21663999620fcec2539e38bb3571abbca40b8621ea00f7666f5ce9d40982de62", "ref_doc_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff"}, "91163152-3365-43ed-be8d-6e4473e53344": {"doc_hash": "76f9f8eaf72e2a32553c50b47c8adf620d183692f50b238bbfe933b85b379f5f", "ref_doc_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff"}, "6d2dcd97-687b-4681-9c6a-eb07e81036ea": {"doc_hash": "7d3de6ddd9a19fa2cf0a16761146f369de6cc3bb26639d9acfc41f2fba87fe4a", "ref_doc_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff"}, "ac5ca5d8-40b4-4397-abf9-dfee9e1f96f9": {"doc_hash": "d291e54435d6f2993c4603b0413d1e43734868e1aa0a222937e6f6d183771ff4", "ref_doc_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff"}, "6b893570-a290-4260-8e6f-b2769610c2fd": {"doc_hash": "fdb9840324c6fccc572e41157805bd94ef8433df7fd9d22003548d9fb9878779", "ref_doc_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff"}, "ec1e6dcc-1a43-44cd-880c-bc957188b153": {"doc_hash": "b43aea48f177f9ba20a5d446f8cb27b1d2a556ebbbfe2c05ea01532408a737d4", "ref_doc_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff"}, "ec7595fb-58d3-4459-8acd-e6dad1e19ed8": {"doc_hash": "d164cfd2e4f6a4241a9bfc28014250dce93b89d46d5460bfd5103ee15b855e8c", "ref_doc_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff"}, "c6e0ac30-a3b0-446d-8ab2-c4789536ddd9": {"doc_hash": "fd57d1abf21c83154acb3ffcf7238d6beef38fcb350bcfea6bdab5d0ec43d2fe", "ref_doc_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff"}, "96dcb479-73fa-4d0a-ad87-1f1148a57c7f": {"doc_hash": "4941a4ac87d425e2e2bd7b46b622d04586a590af9161aac918c550c61952d40a", "ref_doc_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff"}, "52a50802-ca5d-45e1-98f5-fa4fc6086bd4": {"doc_hash": "83a7dd5155ed1bda07971d5aefc5e2e245453649c6f4f599a7654fa1051fbf2c", "ref_doc_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff"}, "2d21fd5f-48f3-423b-8a62-8bb739d8f10e": {"doc_hash": "4dde27dd9eaba7d002c78d41d39b6e34446dff83fbac8584bd27658bae8ca5ce", "ref_doc_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff"}, "be4361aa-c9b3-49f2-93b7-0db31011fd19": {"doc_hash": "f27d09c8ec8c9b7990f9cce1832f91e380d33e4022047be0cde359d8ac642a9a", "ref_doc_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff"}, "39a3d417-1a2a-413c-ac63-23c860778fab": {"doc_hash": "f975dc6e436649769dd217fac93ea7801d9190882efea6dc70cda59b95dab012", "ref_doc_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff"}, "73020832-c1c3-40fa-bb90-9db428cd2b34": {"doc_hash": "0ac81797a962479c8f9ed4ec269620d0e13865689f13cd1bfb65b0a6cc7ba4cf", "ref_doc_id": "0a7c6e97-6ab5-4d2e-ad00-44839db06cff"}, "2a935b6f-ce92-468f-8902-e653dabedd3a": {"doc_hash": "4f25f1cb3621eb50f55d0a81f138f99b3ec6078008d3c6ecbe7fc0e6f14e5ac8", "ref_doc_id": "9f207edc-0ead-4320-8205-fc7e356f115c"}, "5c3bd72f-0207-4e07-92e5-58c23035c2f2": {"doc_hash": "f560ab1dffb916f2718f05467d4f203319eeffa93afe8ac19d8079df3c6986c2", "ref_doc_id": "9f207edc-0ead-4320-8205-fc7e356f115c"}, "292bbde4-7c9c-4793-9d67-b81e151819ab": {"doc_hash": "8367b78b9639476705cea1cd93ca2abfa05a108aebf68d578b44e5e9e9b9d42a", "ref_doc_id": "9f207edc-0ead-4320-8205-fc7e356f115c"}, "934f0843-8d80-4b96-91eb-7085bde66fd4": {"doc_hash": "7646dbd276c325c4cb069bd39eb7e86a9b13aeda39438b3a56ca7f1dbde23f46", "ref_doc_id": "9f207edc-0ead-4320-8205-fc7e356f115c"}, "69adfdbd-315e-4c1a-8781-47eb3fd8edff": {"doc_hash": "30075f92ffaabaed9fa1e60438eca4ef9f4d4a242fa5eba37c84ff78eadaaf7e", "ref_doc_id": "9f207edc-0ead-4320-8205-fc7e356f115c"}, "f65c6fd4-820a-42fe-b922-6d2fd8a2805a": {"doc_hash": "3d2fc4bfec733754829d9c516240bbb7186ea6833ed05d25905ac35222ed561d", "ref_doc_id": "9f207edc-0ead-4320-8205-fc7e356f115c"}, "9a29b869-9b77-459f-a4e1-f551ffbf7341": {"doc_hash": "4f476f41a25043347ee0c43ae9b98eea3bb7d5e3e7c38ee477a433f63a3f9130", "ref_doc_id": "9f207edc-0ead-4320-8205-fc7e356f115c"}, "d2148298-c93f-4575-81af-8b40668d478e": {"doc_hash": "c1a14a76009ef7da14b3d41a5b454733e5b5621497e57aead9e7ce2ae55f74f2", "ref_doc_id": "9f207edc-0ead-4320-8205-fc7e356f115c"}, "e6af438a-f874-4ced-8c0c-957efc6054f1": {"doc_hash": "2655d8c4632e42ab52472c489ee0483783b6e8f0b7cfa00f3d50012cb1278a9a", "ref_doc_id": "9f207edc-0ead-4320-8205-fc7e356f115c"}, "933db460-0c73-407a-87f4-ad7648a45493": {"doc_hash": "e2818285a194276c5737cbc27e34202c7bb34c9ed212da45ed1af10135c6f556", "ref_doc_id": "9f207edc-0ead-4320-8205-fc7e356f115c"}, "172b3c75-2222-48fa-a6c7-9a9d3c98c49e": {"doc_hash": "6ed7d0ed702aad22e0f6d46e471a0fd6ea27fa28711c068b2502137581847c13", "ref_doc_id": "9f207edc-0ead-4320-8205-fc7e356f115c"}, "cb96956c-8e65-4301-8ca4-8e01814e53bf": {"doc_hash": "0f3d87dbd51dd08bdede1f0b57bf90708a080bd3a5be9a85507568ce96a487a5", "ref_doc_id": "9f207edc-0ead-4320-8205-fc7e356f115c"}, "b0a1ddad-7e29-49c0-aeca-6775517f930a": {"doc_hash": "f1d3878d3946d2cf2ed25bbf831be95b3325c3bd027ce3a754b225b53f76c0a2", "ref_doc_id": "9f207edc-0ead-4320-8205-fc7e356f115c"}, "2c81575c-6bcc-4aef-9a0c-3650b26fcaa2": {"doc_hash": "af8b9207821e074579215a51c81c2dfef4d5867395053906aafd2f5402a76748", "ref_doc_id": "9f207edc-0ead-4320-8205-fc7e356f115c"}, "23a3875d-f6bd-4349-b095-316595e63b22": {"doc_hash": "fbcc4833451dba7856f5952d57f18af8e960ca6138f0a46ff7ff9214d1b4524d", "ref_doc_id": "9f207edc-0ead-4320-8205-fc7e356f115c"}, "3b580200-92df-4022-8bec-5e6f710fb092": {"doc_hash": "e86d185f0d3c4f9fd5e5e8ad8807c5227e64cc99bff2fa33d21a183dd80f0f96", "ref_doc_id": "9f207edc-0ead-4320-8205-fc7e356f115c"}, "8a015e5e-e0bf-4b58-a374-d85ca57bd404": {"doc_hash": "6079c654bd9090007a0b669642b8731138b962012ff71393ae0db57d7efd9fa4", "ref_doc_id": "9f207edc-0ead-4320-8205-fc7e356f115c"}, "3e06b3e9-85cd-42ea-a3aa-1397f44d10a8": {"doc_hash": "dc367c0c8fd06d524f47ebd24b9d8fcd5a2faf9d9452b4aa84e0939c12345f7b", "ref_doc_id": "9f207edc-0ead-4320-8205-fc7e356f115c"}, "30814fcf-6a7c-48c3-86fc-fe072d78b1af": {"doc_hash": "a9451023f8cb92ecf6452cd2335d069a51a7fcf2ad053fe7ffa516aea476fc95", "ref_doc_id": "9f207edc-0ead-4320-8205-fc7e356f115c"}, "63c96bce-fc94-4ef1-a189-9660b642787e": {"doc_hash": "a1967ed0b2a023dec3746157552b25573a9f48d7409004ffe4f5ede2899d7ef3", "ref_doc_id": "9f207edc-0ead-4320-8205-fc7e356f115c"}, "38f0282c-42f4-460f-bffd-25bc6befdfe7": {"doc_hash": "4d1b1518aa53b3b6d3d01fb64d84d0a045126e45ea17598d6e2eebd36af3b792", "ref_doc_id": "9f207edc-0ead-4320-8205-fc7e356f115c"}, "10999feb-9d28-4106-a8fc-1920b2a1fcdc": {"doc_hash": "fc2cb58d70235d527e253dd15c087e7a01c1a35354b47fcbb3d2fec16f5a45ab", "ref_doc_id": "9f207edc-0ead-4320-8205-fc7e356f115c"}, "28f4a599-b7ed-421d-9f7c-781848087bd7": {"doc_hash": "1ed9a6de9011946364f4b5cf9a47ef05d92d2b0b86f905101478c17571ebffa0", "ref_doc_id": "9f207edc-0ead-4320-8205-fc7e356f115c"}, "c778b4dd-0330-4e1c-a5d2-068586c7b46b": {"doc_hash": "8bf857d6d6888eb71b20a4a259b6249c1046411e4f0e0baaf677639d034d1a43", "ref_doc_id": "9f207edc-0ead-4320-8205-fc7e356f115c"}, "e07df121-0bc7-4910-96e7-e92e557279c1": {"doc_hash": "137a5713ed5132426c1ff02b37b5a525e245980b5d3ac2c4f3430bd28a180da9", "ref_doc_id": "9f207edc-0ead-4320-8205-fc7e356f115c"}, "68e5d07c-e347-4a11-8205-ed56e6e63b4d": {"doc_hash": "0091977b6d7e360932378e7916c2b4bd2c447b9ad82bf6fc1fdd9ab85815c543", "ref_doc_id": "9f207edc-0ead-4320-8205-fc7e356f115c"}, "03b20d68-83ed-4cd7-b6ee-3b594bdd6331": {"doc_hash": "1667f4e7a9c907b0b8f493ce4538b5b062ab58855d86b7dbc4ddd67a47436734", "ref_doc_id": "9f207edc-0ead-4320-8205-fc7e356f115c"}, "d99f87e5-b1a2-446c-81f4-4c819e8b126f": {"doc_hash": "5aa3aa234f654ed997109d9464ff0f83c23af8d8c3a680a6fe4371c183f6127c", "ref_doc_id": "9f207edc-0ead-4320-8205-fc7e356f115c"}, "4c2e5d57-1416-4f5e-b871-9ea3776f3715": {"doc_hash": "6f411465f9d1346c49bdd8497bd96076a907c41c7daccfbd833d04368910e96a", "ref_doc_id": "9f207edc-0ead-4320-8205-fc7e356f115c"}, "294ef126-98f9-4fd2-aea9-8d8e00f9d2ca": {"doc_hash": "388d53dc8657a4baac0577fa834b598c59c59ec263c4477ae6f234ddbd15d9ad", "ref_doc_id": "7c850470-3a0a-4880-b2ec-54135610be69"}, "b036ca4d-04fe-47fd-8c76-ded7694a6369": {"doc_hash": "63419dbdc34b9d90016e7f3bfb66d28b9baa67b48db0effdc009ebf47f91e781", "ref_doc_id": "7c850470-3a0a-4880-b2ec-54135610be69"}, "99d23d9d-3092-4061-90c9-d6a54ed1d8cd": {"doc_hash": "3b7b979b90b310bc599ab67562d2845d82d837dbf672215a5f7ad1cac79b90c0", "ref_doc_id": "7c850470-3a0a-4880-b2ec-54135610be69"}, "85477257-d1d7-4302-9128-66c55d24767e": {"doc_hash": "0f865057a7eaefa05e3906a67b1d40d12eaafd9263be9dbd0abaac5e3726b338", "ref_doc_id": "7c850470-3a0a-4880-b2ec-54135610be69"}, "0b132a37-7c1f-4315-8729-4c1805fd44db": {"doc_hash": "e30389c90f0f661f7acd40194668c84033e3d80da5bb91d9a0b4545313302243", "ref_doc_id": "7c850470-3a0a-4880-b2ec-54135610be69"}, "698e8ca5-27e2-466d-9eb0-5f5349feb92a": {"doc_hash": "a9e17cea13ba298110b5193089b67cd377f9360aa788765be105df06a075687b", "ref_doc_id": "7c850470-3a0a-4880-b2ec-54135610be69"}, "33888a5e-41ce-479e-88a6-30388cca3f01": {"doc_hash": "f20818a700e719776469681a6e55235dee94c4f80a160440e8bcde1cb8fa2099", "ref_doc_id": "7c850470-3a0a-4880-b2ec-54135610be69"}, "21ecf89d-34ae-435d-82b0-0a2836f422b8": {"doc_hash": "c209ed7f07364d5ec2219d67f45a9cae593247d107f893d4056da6065cfd9380", "ref_doc_id": "7c850470-3a0a-4880-b2ec-54135610be69"}, "2e5a138f-817a-445e-b199-7cd5970f5412": {"doc_hash": "90f59d2329c82045fbc0112f12b3975642314b12adaf4c6dc06c65c8e165acef", "ref_doc_id": "7c850470-3a0a-4880-b2ec-54135610be69"}, "dd21e1c0-080f-42a3-b410-5160e3ed0737": {"doc_hash": "ec1b3ec2e2352b61eb571ce1f6e5d80261a28c489992856ee3efda612792fbe4", "ref_doc_id": "7c850470-3a0a-4880-b2ec-54135610be69"}, "1c290c30-7af3-4aef-bdb1-7ab3cb518ad5": {"doc_hash": "9d02dbe35448bb2a80d3e39b8ad0e1ebbe34ae50c1b6373f9df404f89baeddfa", "ref_doc_id": "7c850470-3a0a-4880-b2ec-54135610be69"}, "8827647a-824b-4885-93ca-8c0b9a862436": {"doc_hash": "04a60ab41831e0abad625cf27bc717c99b7503da56cf10298a368221332b4cfe", "ref_doc_id": "7c850470-3a0a-4880-b2ec-54135610be69"}, "5043786b-e3df-469c-a062-4a2b2623d5d6": {"doc_hash": "586de9d7dd26dc9ff2a2f5f6e03162f3aa8d2dc7dd5b0aad952b64a2434ac3a7", "ref_doc_id": "7c850470-3a0a-4880-b2ec-54135610be69"}, "1223f457-4806-4de3-8fd4-8db4ba421706": {"doc_hash": "94e2908fbbf6edf15942371004d4a70609517985f15ebc18afd46e13623959bc", "ref_doc_id": "7c850470-3a0a-4880-b2ec-54135610be69"}, "a60703ab-809b-4a5f-b70d-cdaaba2d05eb": {"doc_hash": "1c24c47897f3251d6955db8dc4423c45d4e901c4a35ca808e41805123ddcad5c", "ref_doc_id": "7c850470-3a0a-4880-b2ec-54135610be69"}, "ee860429-a866-4139-b0e4-42ef28e3d5bc": {"doc_hash": "3527ed7f9997a7c3c262a54e0ccbd1bcea05aacee10349ee58cf61114e45937b", "ref_doc_id": "7c850470-3a0a-4880-b2ec-54135610be69"}, "a3d8ea7d-1b99-44ab-97a9-7a97cd4e1e7f": {"doc_hash": "cbaa30edca5d8be4587e3245007e8587e44d404a5e1a63decc6d6fb1df254f06", "ref_doc_id": "7c850470-3a0a-4880-b2ec-54135610be69"}, "f608bc54-dd54-4917-bb5c-d0f64b828672": {"doc_hash": "fd39bf4ae4488c176ff50913a21dc07b2e141755a211c401c8d79f2447762729", "ref_doc_id": "7c850470-3a0a-4880-b2ec-54135610be69"}, "f7d706c2-4cb8-4007-8ec3-230eb4e5528b": {"doc_hash": "aae3e58928d815431ffd2ea85858e649051922b36ee290331c23aadaa8d57dd7", "ref_doc_id": "7c850470-3a0a-4880-b2ec-54135610be69"}, "75912faf-6a99-46b6-b094-4245f946f1ed": {"doc_hash": "81abbd10eb7fa6c4c7dc16fc23951cdfa5a0232c6a92ff61ea5dd38452312fee", "ref_doc_id": "7c850470-3a0a-4880-b2ec-54135610be69"}, "24e8a5e4-1006-456d-8026-612103700f86": {"doc_hash": "59411ccb1b7e682fb3c40f2eb94c8a23f3c98c753fedadf3e6d93bd2754760ad", "ref_doc_id": "7c850470-3a0a-4880-b2ec-54135610be69"}, "fe3be52b-f100-4a72-b79e-13c4b9e7b9ae": {"doc_hash": "72c1a45a46c6ead7ca2bbd4b9849afe7593fd80e0aa965418aa3bda7e7451b9d", "ref_doc_id": "7c850470-3a0a-4880-b2ec-54135610be69"}, "d547419f-f3fd-4c1a-b23d-fc00376a368f": {"doc_hash": "78f698beaec2f688ee300cf68b7e8d0b524bdf9ea3e713516044279a57b2575c", "ref_doc_id": "7c850470-3a0a-4880-b2ec-54135610be69"}, "fa7fdbbc-894c-4d5b-8c4f-64276172465c": {"doc_hash": "66ae069285dd059ed514896186d39737e2b1c5ad8d434552d3fde255dfdd5575", "ref_doc_id": "7c850470-3a0a-4880-b2ec-54135610be69"}, "6aa2ae21-7553-4e20-8b84-12ebb1086bfb": {"doc_hash": "1d03b53a90dc517278d32b4fa4c0ff4df18ec88d4bdae36cb90bf583c97095c2", "ref_doc_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009"}, "90acc317-59cd-405c-8d11-05f0c7b5653b": {"doc_hash": "0e8365e9fb94f3412bff66302b9cc20b2b33d8e3cb076a6c3a1a21d1ab700810", "ref_doc_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009"}, "10c1df44-2a24-4b7e-adf2-f3781d7d7d32": {"doc_hash": "8bff73f5f79c52121da35d5e1c1e18e4bf9dcf5c1ccff8bae42ab93ea99830e6", "ref_doc_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009"}, "13587e9f-1974-478a-99e6-31fb1a69a4f0": {"doc_hash": "38d40cdebc88f7aa09d2a4beed2a451ad5138abfae8ad34cbccc6b7bfea9cc96", "ref_doc_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009"}, "f32a90bd-c8fc-45a9-92fc-dbbca3971165": {"doc_hash": "6c75d517fe05d5c268f993a3b42d74ae708b51975a5b0da495ce581272c6334d", "ref_doc_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009"}, "d2b9d696-1430-43c4-b6e5-41bea3eb36ec": {"doc_hash": "a2f24c1bd2d6fc1e595e2d8ce499ba0fd328986b43010d7b573304f6a56b8427", "ref_doc_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009"}, "8aa56fc8-72b2-471c-9f66-a79cc0418f15": {"doc_hash": "6274555298d43c7098f553812688ae2b697260172b5fdabba5e4988f0970a620", "ref_doc_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009"}, "6102cbff-33e6-44e7-acb3-1c695ec722bc": {"doc_hash": "7fc45b183a64793877a36e3b9b36cb08757dac59d2975bd54a6d9d7b8674e076", "ref_doc_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009"}, "0d112ad8-8dcc-481c-b78c-16b5f3556c86": {"doc_hash": "7fa8eae6d72abaaa1bd2d43cdf5093355c47ccadc83e9aefdb4430ed7e724f5b", "ref_doc_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009"}, "4efb2e70-068d-4862-b19f-d22921298a77": {"doc_hash": "1241d153b18fef2b824b3ba4591beff9da4a09ef732acc44c511512b1ddac9cc", "ref_doc_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009"}, "52d01260-eb13-4cc0-8693-fcf7fe3817fe": {"doc_hash": "c23ba4d9b17227488bd70441d24558463cdc58ab847627bbde470a511b4a24aa", "ref_doc_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009"}, "a0b45abb-6c13-455a-9dcb-5da16eac4eab": {"doc_hash": "388e504b4115af42c95e75cfa673292c329513283649f80391b99db7120a2098", "ref_doc_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009"}, "c7762bc6-059b-4735-b756-583a221c2f5b": {"doc_hash": "b66ee2e4eacbb261655a3fede1abe58678955f4f7ca2fc69e9efcaa2183695ed", "ref_doc_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009"}, "848ee1e1-d449-4af5-9509-e67cfe31c4d1": {"doc_hash": "262064560719a0237ae92f240da70a0aa58bdde8080c0dab71c11bf55d11c210", "ref_doc_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009"}, "a27413a3-ae5d-49e2-8c44-7f2831966ae2": {"doc_hash": "278a56680792375d8f39f2e12c045e653e577e1aad13370905d5b2a05a23ae4d", "ref_doc_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009"}, "e1e10b08-14c7-44f1-bedc-f8a7a7b663b6": {"doc_hash": "0c0bb95730a234469c8b438f9b290e6c1cc5f44719ff2a346ebaa9bcac04a91d", "ref_doc_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009"}, "7ac73ef0-1be2-492e-9a55-c2fc8c23dd9e": {"doc_hash": "f24d09fd5f8f96451e83c97866919191fc575e5b6d71cc3fb7567f9ca20331d3", "ref_doc_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009"}, "5a9fe624-3cd8-4eff-8c41-bef0098ce9e2": {"doc_hash": "c92aa24ed98e375a5613280d3891c950315609bfb13aed7dbbbd270ee7761878", "ref_doc_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009"}, "9c2c8f23-03fd-409b-a61a-9e3f9085ba1e": {"doc_hash": "e2afdbf99ad14d1061a7c030732354423a4d404e0cb93f4713fb3a2b39ed9014", "ref_doc_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009"}, "3ef6b98a-a602-4bb6-a9d6-db46142f8b32": {"doc_hash": "ccb6f6d5b0f5de5d005b25846cb77dd49b7ab1548c38ad83d0261a4ac25830fd", "ref_doc_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009"}, "c8034d77-1756-4446-b07b-882ce38f26d9": {"doc_hash": "01ae873cc215a4a6dc6db8b00f8065ee97478eb67274fbfe6fbab8b1c3304140", "ref_doc_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009"}, "2b808256-0eef-470c-bf66-d0920fe09855": {"doc_hash": "db14ffdf6a01aaf6bdcf31a0addad93158f9876c4d4965761a413762475f647b", "ref_doc_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009"}, "016d993c-a585-40bd-8e2e-51c1688fe330": {"doc_hash": "e477f2e28d42173d597f2064bf1d6ee1bd01dc3290fca05ca1a903ac476dc246", "ref_doc_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009"}, "20cff1a1-d221-41c9-a568-a79c2aa7ea3d": {"doc_hash": "0ed3c3f8ea9061438fe71910e18b604b2323ecd56afdd6ff8405fee61d18fe38", "ref_doc_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009"}, "e9553870-80bf-46b5-8496-eb3bbaeddbda": {"doc_hash": "c9708a5fa301fa9b6c580bbe79167d059d750f4784a536405638dd804e9ba5fa", "ref_doc_id": "4964b67a-25c4-4eda-8bed-ee9ceda78009"}, "0a2a79f6-7f6f-466c-9b28-74f8dcf3746f": {"doc_hash": "534b621956248af4f93216b0b02ef0c80be7f5b39444659782b2719644fb06b8", "ref_doc_id": "47c99048-affb-49f7-9b53-d38a3f456c08"}, "4cff1a33-ea5c-4dd1-b411-8cd806610eb5": {"doc_hash": "a6100130694f8f6039794ca5283128059baf034acb0a05fee15bec4c9b4b1b9e", "ref_doc_id": "47c99048-affb-49f7-9b53-d38a3f456c08"}, "0261475d-0036-40e8-9fd6-b5d5880e3769": {"doc_hash": "bad3fe356291405d252e13cdc31741f91140013b813ccd6bda28521c64b920d5", "ref_doc_id": "47c99048-affb-49f7-9b53-d38a3f456c08"}, "4cbf4f4a-61a3-4ca0-8da7-5e1437e001f0": {"doc_hash": "ee1d3281195801a715b3f30dc9a34d224f6ea8863f95b2d774575407435852c8", "ref_doc_id": "47c99048-affb-49f7-9b53-d38a3f456c08"}, "9d52751f-bd69-4118-ac4a-59774b9fcc99": {"doc_hash": "274d6f4037dd4fe5d052534169a99d78095d97d671e0305297c2bf4c9dc96bfc", "ref_doc_id": "47c99048-affb-49f7-9b53-d38a3f456c08"}, "dfeaeb82-42dd-4994-a600-416edaf1af23": {"doc_hash": "37dfcea756ba4db9e9fad1b23c2c4ceff37467538fad960edbf1b6c71f6c1d2f", "ref_doc_id": "47c99048-affb-49f7-9b53-d38a3f456c08"}, "62db6f64-905e-497a-8e66-1b97e19b4422": {"doc_hash": "bf3c1c82a1ce30c800016b6b1564385548fd472efb8a706ef58f6bc80e5917c3", "ref_doc_id": "47c99048-affb-49f7-9b53-d38a3f456c08"}, "f24ddc5d-33bf-49cd-923a-5c1bee9cb8c6": {"doc_hash": "123a219eb3af6704e843128ccec0d0ba2a1a2b2d5fe03ff6d9b64e15f4e0f1c3", "ref_doc_id": "47c99048-affb-49f7-9b53-d38a3f456c08"}, "9988fed4-896c-451a-8ebc-da58bff685d9": {"doc_hash": "d5dcdae32b4e7582b943ba8e745b806f21962b8c7f63670b5731522674e9ccfb", "ref_doc_id": "47c99048-affb-49f7-9b53-d38a3f456c08"}, "4bb69ca8-1cdc-458d-83e8-55babc933712": {"doc_hash": "5cc80b352d891978ba18111ca947e822aaf092e9eb92d03576bfe7bdd0e5e4d5", "ref_doc_id": "47c99048-affb-49f7-9b53-d38a3f456c08"}, "13cddd67-a6bc-4bd5-91f5-52bb7450be41": {"doc_hash": "4a986af7429c7cd69a24d509bcb7e49c401ce6aa0a79b95f9a99aaafa538a9ad", "ref_doc_id": "47c99048-affb-49f7-9b53-d38a3f456c08"}, "e6aed691-fa96-4afa-b86f-7330d3dfc193": {"doc_hash": "ae19328b9cd2d5b69b0e10a69beb0e6925a9ea13cb3fa71159748d50d059e122", "ref_doc_id": "47c99048-affb-49f7-9b53-d38a3f456c08"}, "016817e4-f9ec-4c3a-b94f-728c0830d050": {"doc_hash": "e19068075937a7c3a55232167cfe92872e001abf7e366fa4db400379841e2bb0", "ref_doc_id": "47c99048-affb-49f7-9b53-d38a3f456c08"}, "026aef1e-bb88-4832-86c0-f63fc021df28": {"doc_hash": "c1f4e635e7ff57f669706c58967bd260a5975b181cbc4d37c253a6dd870fa49e", "ref_doc_id": "47c99048-affb-49f7-9b53-d38a3f456c08"}, "143587a9-dcf9-433e-a58f-7752a54ece00": {"doc_hash": "ccfb14eb95af6c63370f45a07b22095a996ac506e779b579ae54b1c811e71009", "ref_doc_id": "47c99048-affb-49f7-9b53-d38a3f456c08"}, "2a1f3a6f-7d36-400e-85e2-4a161574f43c": {"doc_hash": "1136b5186d1f7dd6ff37ee03554f3519e8c32ccfa3a2c3af563237cd79beacec", "ref_doc_id": "47c99048-affb-49f7-9b53-d38a3f456c08"}, "c8419f3f-4c67-4bec-9ca5-2e0cd21f6c84": {"doc_hash": "8570b7f5c9949d2c0ac9e88d55eb5a6dd5e7f859b71962225b2e7364202acf3c", "ref_doc_id": "47c99048-affb-49f7-9b53-d38a3f456c08"}, "71001735-dc83-4864-a502-df1c3eef5288": {"doc_hash": "df894192b95d95d4b91432f93204f35a5b58689f6be947ea51066ef8f6178769", "ref_doc_id": "47c99048-affb-49f7-9b53-d38a3f456c08"}, "d49aefcc-2f24-4c7b-9ead-09ad2689d802": {"doc_hash": "a150eb5b07e97bb369f3ba4dd52c9c9bbe8927df63a47020f36263d4566c828d", "ref_doc_id": "47c99048-affb-49f7-9b53-d38a3f456c08"}, "bdc2b03e-7a09-4f51-9596-a5f4bf94b440": {"doc_hash": "bb25efed819449de779b1f72cd069ac640d37e81a7330af6131c78c8d04d365b", "ref_doc_id": "47c99048-affb-49f7-9b53-d38a3f456c08"}, "35813a01-9550-4954-b3e7-1c50b4ae7b7e": {"doc_hash": "c25b3913e0319dbf281d4b2008a79aaf9b96f1a8b3121c3bb07797e897a3d51f", "ref_doc_id": "47c99048-affb-49f7-9b53-d38a3f456c08"}, "94d72ad1-19b2-4ffb-bea7-ea9081d9505c": {"doc_hash": "321ff0802bd9ee4c30ff8c7127f498db04d831448d8a651198b96ff001b764b7", "ref_doc_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456"}, "e689fbf3-e647-4578-8588-44b4e154696f": {"doc_hash": "1148d0c61f4d163b6c25b84a7e9846e971546941cc63427c012c9e85d4298cbd", "ref_doc_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456"}, "350ef8a8-b6dd-4234-8aa1-cea6f3332949": {"doc_hash": "d6a112b22a45279332933338ccfdc0d258882ba00c1585ab9af0decf9adf3ae6", "ref_doc_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456"}, "6cfc4e5e-cec3-46cc-83a7-e4f3edfb1926": {"doc_hash": "72e214438d139cbf9efb0900b21009543c98eef060e95c86159ebd440d34693b", "ref_doc_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456"}, "f9b4917f-c11c-4126-82ba-9a375786dd13": {"doc_hash": "9fe009b9bb2cad9f555dfe6fb23fa2c8cb35cc345fabe017aef0cf4e4ba0d93c", "ref_doc_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456"}, "49c1d266-0e34-4e54-8f7d-aae7ce37e46f": {"doc_hash": "5e5d311d663b6de556edaa730122a7ccb3f0eeab0f1c942747f0ae8cd1757499", "ref_doc_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456"}, "a762b2be-fdb6-4b84-8e31-9f124322eba1": {"doc_hash": "59305c69b4b71df7a1be40a90901a5de1a4c419f7952738ad17068f9b44c7764", "ref_doc_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456"}, "940ccb52-a281-4aac-ba84-1b0a61298ca5": {"doc_hash": "c85676fdf5c93cb1685327dafcec2b6ea5823e3ef3337dd72e7e78b91ec87510", "ref_doc_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456"}, "3142c0b3-763c-41ae-b26d-dee166dda5a6": {"doc_hash": "0984df329b217685db0fcf393073e8d18176e500ad28c98e5be8dafb12f9cb7f", "ref_doc_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456"}, "f6b17a47-ecea-4066-b28c-0e7e0bd73345": {"doc_hash": "8d3a25f68ba05c1de8b24ee48f8aa392e4fbb2828095a8115c768aeffacab56e", "ref_doc_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456"}, "669febb1-46c0-418c-8412-8367671158e3": {"doc_hash": "77eb9013d5e895dc2eca6fba470d3a61895d348eb040b9ef1f021a28e97af25f", "ref_doc_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456"}, "f7ad7d59-80f9-4ec7-9f75-34a54f26aad9": {"doc_hash": "d796c054865ae67c43dcdba928be4afb73ed4342a10fe6e05a4ec1a272a13d5a", "ref_doc_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456"}, "aa1d601e-ac29-4af8-a9d0-33abc1807b28": {"doc_hash": "48a2ff52986194ea0d3b20d6b8fa99f74384d0c3a62daf1fdf74ca5b71e415d1", "ref_doc_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456"}, "7a8b40d8-b136-4d46-9573-b96ccdaa5451": {"doc_hash": "ac47d1620eee7684c265f054aecc6de22b4058f0ebd2e04a2c46a9807e7d2f40", "ref_doc_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456"}, "dfdede8a-f320-4261-be4a-5e9f2e33b2ac": {"doc_hash": "c292be1ce6348202283d7e1636a304eefc405178b57811a1e3c3b3d3ee9c6a74", "ref_doc_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456"}, "5093e3af-ef58-4ffc-9219-78a57f05aec6": {"doc_hash": "28975e3f748545b5cbbc82a3163b40038dbbe5571f522ad71501bd839e07a785", "ref_doc_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456"}, "0d6aa344-03e0-49d6-a675-09e99968378c": {"doc_hash": "d5532a9dec1403013de0066b8ac48e7bde5c69c6a54170b3b823e1bbcfe70cff", "ref_doc_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456"}, "9986ff9b-ed8c-4db2-a408-4ebf18119bb6": {"doc_hash": "94a327df3ce5b4fe618d7b8c21a60f4ed6fcae7619050eb43abab1826c96853f", "ref_doc_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456"}, "d4bc6ee1-b9df-40c9-b01b-d412530d6206": {"doc_hash": "9a9d81e47c3d75a9b5c83024824fff0b4d9e495963aad5b5b810800f63618844", "ref_doc_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456"}, "c48105c3-ddf4-4f6a-85a5-7213455aa53d": {"doc_hash": "bf59787a4ed0cae6d82b76c78ad4c57818e152f56770d96d9ebd47ca35ba11e9", "ref_doc_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456"}, "a9a0fec9-eadc-42be-9a37-18a6c9569b96": {"doc_hash": "4ffb5b6035ea7466cefdfb1cc4bcd1b674c9fe4a9ffda1aee71767f98e61e996", "ref_doc_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456"}, "7b140341-94c3-490c-af68-f121e6b49453": {"doc_hash": "dc872ec78550333a212beaabea0ad7c39aca3f9bd03bd1e9e792859035ce4410", "ref_doc_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456"}, "b0c03de6-26aa-43f8-b3d1-234ab0e15fb7": {"doc_hash": "e4dd09a164c334ddd1f75695279c04e85847a783d875fd424d10346d6305632c", "ref_doc_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456"}, "98ba4198-ed24-4651-a995-bfb793f3113b": {"doc_hash": "d69fe7df126d30682fd7f30fb6f1d00ea1e3212903556146368f8a1be942fbb0", "ref_doc_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456"}, "79e125bc-0789-4e37-bbb2-4cd3279dad6c": {"doc_hash": "024ec84c698827c26eeb9e2113792d9e53aaf6256b8e223c9d192b2d42074c8a", "ref_doc_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456"}, "5cd654fa-82ff-4dc9-833c-2a7d8525e9a3": {"doc_hash": "dd850bd5a95cad688d4c730e8b71759a4ccc7aae34bae93e4d185ab4157de763", "ref_doc_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456"}, "1111dcb9-eb02-4036-9121-2564b8749144": {"doc_hash": "6e965528a5ae189e964817aed0a4bd9c04f68ec68770619e0495f53c72032afc", "ref_doc_id": "fd41685b-0b10-477f-bbdc-bb96b80a5456"}, "22f68303-f56e-45d6-8a16-1d413f32c411": {"doc_hash": "363da4d0b3e0f674b70b4b3e46fa261fcc8be28fbf11b4e4c66235b7a04e1ec2", "ref_doc_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d"}, "84f0009a-32da-4310-933a-9b374ed1ee03": {"doc_hash": "157b40003a27b052229ac7fd05217404e78ccaa4a29a15c5e9df7002894413c2", "ref_doc_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d"}, "2a9d9432-2457-4fd9-90c1-91daec7bd102": {"doc_hash": "837f9bd72e99b791b60e015b96761765d990b7b7dd7dbca82b3576e7336c2ba9", "ref_doc_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d"}, "241ec7cc-7a2d-4164-a237-1da948683f53": {"doc_hash": "fb75c7e22477369320b3e89cabb2c62413cd3a2f7f2a4e555308e884a67219a1", "ref_doc_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d"}, "3b960c37-abdd-443d-aea7-2844cf672772": {"doc_hash": "212bbdd62e8f1ed1cbbe20810550eefb8a078abf3cd364e146cb27fe7f6d503f", "ref_doc_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d"}, "7c7257f6-7f3a-4432-aa51-9a88aaf233a1": {"doc_hash": "6d5fe09e01ed4bb497230a203a908abbd08da7409e031eb4e9bacd9afb70ab9c", "ref_doc_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d"}, "f3db129c-a587-4f2b-b98d-bbdca7fa548b": {"doc_hash": "718413041f7d0deafa6d6280ac258a35a4a8397451ed991769d4cf05476bd6b7", "ref_doc_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d"}, "c0f35e06-0ef7-4621-bf89-273472543196": {"doc_hash": "b8c4873b0607cf51fc378955f9a7ea1e86755c16adf201afab9ca1d03b9bcac2", "ref_doc_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d"}, "8459964a-9aaf-4bc1-bc09-86eb329afb61": {"doc_hash": "26b012ead4a3b88bd951d4aa1d08918c5fe50cbb47f37d41a1f2766d6d361f89", "ref_doc_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d"}, "0b65daf4-681d-4187-aea6-276d16fddf06": {"doc_hash": "a6d0aa5f50daa0bf4168fb1f3fa390e1de87157656a291510120dd8378198c1c", "ref_doc_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d"}, "6a0a6a63-40b9-44c5-b0ba-c8665e4444b7": {"doc_hash": "81d374770d442d835c2d9024480117e1fe3e1179fb5152e7e0912198baa99c71", "ref_doc_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d"}, "1cf11a54-d1a9-42d3-9edd-e0014570d3e2": {"doc_hash": "167631b26964098cf7e364e023fda7702749498087f7a62cce2de146a4b40a75", "ref_doc_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d"}, "a4066ec7-682a-4a58-85e2-b372005aa400": {"doc_hash": "1fef3f4704bc7dd3f31a782485ec6e1dc59a73f1c1fa08338df91edbfd3961cb", "ref_doc_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d"}, "9b4ae9f7-fe85-46d3-8f34-6434f23a8e19": {"doc_hash": "cc4bc68d7946b208e28a53f22d685b692db155704977baf494160009f289b66e", "ref_doc_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d"}, "44fea027-94b9-4243-9ab9-297cbdcfe4fc": {"doc_hash": "76d19f94da71df45b24804e91203953771a2a8d5e4a8d02da7dcaccd199e0eca", "ref_doc_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d"}, "1be8b022-c6cd-48c2-922d-504cd520f4a7": {"doc_hash": "7df509fccbc6cdcfd362d0660a91b30ce9379195ca5a86c0274018090b3b9d5c", "ref_doc_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d"}, "1636556f-5a21-4e72-9818-2a390b9db52c": {"doc_hash": "7c18b4bef465d23d126a56869a1878a596adf6eefb05e5a7a746ec2fff203e11", "ref_doc_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d"}, "55cb9374-a7c5-4d9a-9d90-5c99ca4ffd15": {"doc_hash": "9eec656d3423da3cf61d11fd365d785c14732835575ba4c64a31a14c385d5f04", "ref_doc_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d"}, "c91f0dd0-553d-404a-a7b5-2433333989ce": {"doc_hash": "616c3cd4640a6cac3c75ee34d4d62f38bfce43e8a31dc55e0fd2d08a14552bb5", "ref_doc_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d"}, "e62b8516-b0e8-49bc-93bb-7119312d0c95": {"doc_hash": "1e7e826b4abe9c10a928d5131d2256e60a33d5e53dad65e95f148f4f55a0206a", "ref_doc_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d"}, "180aa042-b296-4d18-8307-52a6210a6494": {"doc_hash": "2f7bc619daa3a3c43fb9a81c251ffeba879e93396809b491080b92df9af252bc", "ref_doc_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d"}, "30f33b45-ce16-4558-ba34-81bead9d823e": {"doc_hash": "16a8e2e347de541dcfd076251220a725f97bdaa95cfd10d04c82e50be10845db", "ref_doc_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d"}, "1d81b22a-e393-4412-8e2e-8f36f32780c9": {"doc_hash": "d2ab796cfe33ed6b2342f2f1aa2f211b4b109dc389b8d5a5dc0873eb7828ca91", "ref_doc_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d"}, "27334829-188a-4488-a42d-30aed987dac8": {"doc_hash": "bc7d5c6545e891814d1ba3a4e1f598be3d5321c5c71e5327155f9335a858f845", "ref_doc_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d"}, "7c33c7c7-7370-4ca2-a8d2-3306e749c9d4": {"doc_hash": "567c76ee8a78715a0e5a5cbcae4d6cc7fd93569d9a409c6f9957739c0e2d1c83", "ref_doc_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d"}, "9b1a36d5-7f79-4385-905f-b6dfab1d1a8f": {"doc_hash": "bf4c7429d9ea2e5b2136b129516f49f6f7e60884ae1c4b748832adf4427c6e1f", "ref_doc_id": "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d"}, "114bcc6f-cfd1-4fc7-b75b-352e1bfd36c5": {"doc_hash": "c05ef340db95e88ec59bda37b7796ba7135ee13d9ccb0e987f14649090e3a51e", "ref_doc_id": "f86456f2-58cd-4b88-b5c4-8660acccd329"}, "180cd1bf-cf0b-4a54-b153-cd63ef799a68": {"doc_hash": "aceb199ce8dd5c0932dcf4874db45c2cab2785e144f9a9d7ffbd23baa5276998", "ref_doc_id": "f86456f2-58cd-4b88-b5c4-8660acccd329"}, "f0ad64e0-bd40-406a-b924-06b387e26519": {"doc_hash": "9ceb706fbc4a2497f67f1cc5f27331b34bcd17b692e6dfee03305fc2a9b63b93", "ref_doc_id": "f86456f2-58cd-4b88-b5c4-8660acccd329"}, "5c3008ef-30b7-4763-81ae-4d41622ea4eb": {"doc_hash": "b59214516c9f5f8e6bbb10d74435304af5c399ad5683344a2d116ce257f81aac", "ref_doc_id": "f86456f2-58cd-4b88-b5c4-8660acccd329"}, "0ad3680f-c4df-4ba4-a324-9ce544737211": {"doc_hash": "42c4389893e086a3312ad9c06a0b1e59486aa1c3b11c0b0923dd4c1cac6e621e", "ref_doc_id": "f86456f2-58cd-4b88-b5c4-8660acccd329"}, "e9ebf426-8dcb-487b-982d-ac1a23fa1031": {"doc_hash": "f545e8fb4c0593968c4a0e426c643f33d473c9e6306f1ce7015e42453e053e6e", "ref_doc_id": "f86456f2-58cd-4b88-b5c4-8660acccd329"}, "81b49e91-053b-4bd4-be5a-00a56e85cec4": {"doc_hash": "06ac0e0736095cda53fdbe7078df862ed57584d241e6f3038d1eb65d5c13254d", "ref_doc_id": "f86456f2-58cd-4b88-b5c4-8660acccd329"}, "d42dd6cd-5a47-4ee1-8b59-c70ac04325f7": {"doc_hash": "0bf4d27adcb7ef63f8329b54becbebdaa97363f96ba80c89684ad4029d0b521d", "ref_doc_id": "f86456f2-58cd-4b88-b5c4-8660acccd329"}, "6e225a95-9262-49ee-ad04-d1b26dab0c32": {"doc_hash": "5f6ba865d5b3cdd081b4e31819bf6a04fb9df4399dcf5e5a2603c1122dfd1d76", "ref_doc_id": "f86456f2-58cd-4b88-b5c4-8660acccd329"}, "e10c88dc-10a9-4955-8b9c-00fd95869850": {"doc_hash": "45fc0fce2b76398b648142235f7fb1d4d55097d195952d19e5d5e486c00a63cc", "ref_doc_id": "f86456f2-58cd-4b88-b5c4-8660acccd329"}, "ac42b52c-b9ba-4938-be5a-ff64b35f4ff3": {"doc_hash": "39fadbfeaf18334a8c7331408198ceb23cfa9b4c9711c794bbf089bf25e72b49", "ref_doc_id": "f86456f2-58cd-4b88-b5c4-8660acccd329"}, "44d2040a-b5ae-4887-b5f7-2937b8fd87d0": {"doc_hash": "7c9fbbfb1094a9df02cb4581722c3fbc1c401001b09ab2c82f9727fde4e1cac4", "ref_doc_id": "f86456f2-58cd-4b88-b5c4-8660acccd329"}, "44afde78-60a0-4773-a43a-8ec42f267753": {"doc_hash": "b51c155d0ef2676d7965e1c472fcfa20229edf6e099fe75b35fc1413f8bece2e", "ref_doc_id": "f86456f2-58cd-4b88-b5c4-8660acccd329"}, "eb790ee9-fac1-4505-83b9-6967ec08ec4a": {"doc_hash": "84b6c4cbc54c844f15d1dc504d50115ec87600f2c1b700fb0b3358d17d44e089", "ref_doc_id": "f86456f2-58cd-4b88-b5c4-8660acccd329"}, "4a6dc8e8-6d5b-4106-8b1a-267b082aeeea": {"doc_hash": "dcbe5963d55550d277d30fbc5f8d9db04ba99cc9fde207c94bcb9169e3e28ba2", "ref_doc_id": "f86456f2-58cd-4b88-b5c4-8660acccd329"}, "1fad07b0-aed6-4ae9-813f-d1bd09b11f23": {"doc_hash": "9b9ff011419b24184b16ae8987835b205b9e29e308fba7316eb825a4f48db9d6", "ref_doc_id": "f86456f2-58cd-4b88-b5c4-8660acccd329"}, "fdbb39fc-e1f5-47a2-a28d-519b3f43ac48": {"doc_hash": "6eb00f646d8446ea8103fe8e7d40458277152f9eb72399b86b1ffc1ddeba3a14", "ref_doc_id": "f86456f2-58cd-4b88-b5c4-8660acccd329"}, "26c74fc3-0482-4ce0-af0b-d49a56f13976": {"doc_hash": "6e1d7e1e1f7d14882a2484be5e61e557f522731a703d50bc341c3159397e8703", "ref_doc_id": "f86456f2-58cd-4b88-b5c4-8660acccd329"}, "0bd52393-2422-4632-b63c-74b791b2e0cf": {"doc_hash": "38969acc825e701d9fa073abf51db62df8fafd5e75528fdabc97ad04aea98f2e", "ref_doc_id": "f86456f2-58cd-4b88-b5c4-8660acccd329"}, "c53a4b3b-c1e3-4f51-93b2-bcdcd33b2be1": {"doc_hash": "53382e1b3d9167bbcb956e0922a0cad3d14ea0e066963ae05e40d6c9a6bd61fb", "ref_doc_id": "f86456f2-58cd-4b88-b5c4-8660acccd329"}, "149261ee-5760-49c3-808a-3f2fc03466ac": {"doc_hash": "b4f0ace7fd083c96f2bc8c6d26aba28e771288e8bf10d7b13640a50464fd008a", "ref_doc_id": "f86456f2-58cd-4b88-b5c4-8660acccd329"}, "3b8c7533-af81-4fcd-bddf-72578afa7352": {"doc_hash": "732d3539d4bfd0b2e3c1391c26284fb85dc6c30d78fe51169c0dfaa908923d61", "ref_doc_id": "f86456f2-58cd-4b88-b5c4-8660acccd329"}, "8f9df2d3-1f63-4743-9819-88d92349df77": {"doc_hash": "cfeab9127b9ce5e5b2c815ec7688e3bd6d02c7f629aa9702dde593884838fc74", "ref_doc_id": "f86456f2-58cd-4b88-b5c4-8660acccd329"}, "66eb747a-927b-4063-a30a-abd7e7a9f354": {"doc_hash": "907d4b9d8924733763786aea0b375c0fa1715d7649ba73bf0ba0da718b7ce935", "ref_doc_id": "f86456f2-58cd-4b88-b5c4-8660acccd329"}, "0ee2d259-bee5-4c9a-811e-7ada37c0235d": {"doc_hash": "38f0b8043de0d82d5cf11e63ff407de704169115d923748a2f1545f591a6c48b", "ref_doc_id": "f86456f2-58cd-4b88-b5c4-8660acccd329"}, "a9f6eaee-0444-4904-a2d6-5b62da2bc853": {"doc_hash": "a7310f12d673d1387d74b66d47cce5e2122f14accec2f595128a95166a8274bf", "ref_doc_id": "f86456f2-58cd-4b88-b5c4-8660acccd329"}, "f3b31664-00c6-4813-8c12-11e933441d59": {"doc_hash": "7fa9bf1c95bcd9c94e85d4248fea10a1603a1089ec54c07f3da26945db5142b1", "ref_doc_id": "f86456f2-58cd-4b88-b5c4-8660acccd329"}, "52a79582-7588-423b-a5a9-7b14f4ab2dea": {"doc_hash": "d48b837598b93ab772c1cfd2f4febebf540b3a2fa1c9b00f2ebc5d158d8d16de", "ref_doc_id": "f86456f2-58cd-4b88-b5c4-8660acccd329"}, "c2d15e45-5ae9-4812-b4ff-109428ab2588": {"doc_hash": "f0c1e643829587c6debe3c50e9313112f6d320d19e6de19277ba3898d8548b69", "ref_doc_id": "f86456f2-58cd-4b88-b5c4-8660acccd329"}, "4dbafc38-19f1-4d69-85fe-dab741a29902": {"doc_hash": "8f9a5b97dfcd32bbacfe55422417fec0e7835c456a8b633490f457c09b70f14c", "ref_doc_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a"}, "d4167f3c-e528-41c0-b206-ea407a8c280e": {"doc_hash": "22d8189c00c59a73a64b54ac0fc81128dd160dfc53bdb755992437fb6572dc08", "ref_doc_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a"}, "5058e852-00d5-4e2e-9e83-08c6e2ae541c": {"doc_hash": "a4432f08bd24121e0e9c0e464b1985e8d9a24782f5593b23b4e873807184678d", "ref_doc_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a"}, "cb5ac963-6388-40a8-9f94-8ec88686db39": {"doc_hash": "4a934641309b3a7117d8e9905395e14b5eb01f25eefaeee6ec7dc476856bed32", "ref_doc_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a"}, "e65c9a7a-733e-4fbd-b5db-564c9b7a9f74": {"doc_hash": "5d176ef202d4a613175dde444194e496c635ed87a9871621917491ae9c500ff6", "ref_doc_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a"}, "83c057ba-0c63-4475-b70c-769acfbbf52f": {"doc_hash": "e18daacf2f7a5e901735aba4156321843d883c32edd7b99507e1847f373de711", "ref_doc_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a"}, "a92cc9e3-177d-4a36-a174-9af134ae1528": {"doc_hash": "4400f8dcc290722b6495ea657a85050323c6cda383b5054b5fdbfa5f764396a8", "ref_doc_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a"}, "b4352891-aeec-44e6-bcca-7bb2d6ef741b": {"doc_hash": "e306c1ce47d2f9b7e05abef327f98809dc5b1148727f70f4cd0444cd5c4c8fab", "ref_doc_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a"}, "1a676e52-3c6b-43a4-bf9e-844a790a298c": {"doc_hash": "e17cd4e831c82f5869ff17a9cb65c64cf7d215ae51126247adab66bc27b6b51d", "ref_doc_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a"}, "a81aa7ad-adaf-4667-8d24-d3a8f7282ab7": {"doc_hash": "11846bc51e7fb2db5abb5bd4883c6c58c570f75c80f179bc9802a796e7524379", "ref_doc_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a"}, "b69bee02-98c2-48f6-8359-4f2899e39e22": {"doc_hash": "bd5d92e2fb997b1aabe7102028fb43f569eb9e54568fe61cf4c7fd7354d8e821", "ref_doc_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a"}, "158c88e5-2874-415b-bc82-0236a65defae": {"doc_hash": "90e5cc194bbcc974e4bb0e62f9e791837cccdf737e8a38c1600de3ba7c2e6a4f", "ref_doc_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a"}, "2fb7d86e-06b7-4766-82bd-d1ab0a4fc3d9": {"doc_hash": "0f068c3a19e85ab851cfe66cfadb9e9e231547a76008614d175a2afa743d9b40", "ref_doc_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a"}, "5ef0f535-4256-4ada-859c-bece9652cc00": {"doc_hash": "6a155a1df64c98ed45690bdbbb3c555c9348697be37cba4a9c10f09387b348b4", "ref_doc_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a"}, "5137c6d0-ed3c-4987-8b74-a096b96d63ca": {"doc_hash": "e3eaacbb8bed9498a102b416c599951002cb9961d867738b99f6681eb95c4b24", "ref_doc_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a"}, "79967c5a-3b95-45b6-96fc-66eb1fd801ce": {"doc_hash": "17014ea13cbd4f477e3dda2e3e8d7242e131988b62f94b60d649178cb97f86a8", "ref_doc_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a"}, "28f41f28-467a-41db-b24c-08869c1b7257": {"doc_hash": "6a792a4f5d68e6c2fd915e4c5f6bfebc563fa27e514d1d4d2460874344865383", "ref_doc_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a"}, "7db1caa4-f667-46a5-807e-a6beb3e0921d": {"doc_hash": "f8ed9b95e6fe441bbab1d9a0518835729b8a97518ec61f9a445fd40431fbd049", "ref_doc_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a"}, "41c9e96c-c68b-4914-9b23-6fda06d54692": {"doc_hash": "e067ce57aeeb6c3cbdae3014fb219cc27b0fa9bb15cff4fa84d8c51bf8e6490a", "ref_doc_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a"}, "f90bed04-4b4f-4f83-a683-a5460046fcbe": {"doc_hash": "f44f086f39b3e2f99b31bdc7140fe76bb3331a5fe0cb9bfc653b78e54cd5bcf4", "ref_doc_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a"}, "c93a0e06-27f2-4493-b29e-b7b76146aad7": {"doc_hash": "df6ee031ebf3408e615a43eccdc904177ed0bade6230cf4e781a3bb16f282dc3", "ref_doc_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a"}, "7fc4c663-7c94-4a4f-a9a3-fa05a461e7de": {"doc_hash": "05d0f63810cbde87bb38ca0516071b4d68ee9fe2c05019a19ef363c8e3e083c4", "ref_doc_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a"}, "1a663b49-63b8-4dac-9308-5bd61941692a": {"doc_hash": "0722dbdbe34131113594ecd4e804c4c7d5a4b53c396dd666bb063b9477c35525", "ref_doc_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a"}, "322403d3-50a7-4085-b20e-2de493502678": {"doc_hash": "2734419b70c3371e9940dd6f7a1c117ae4cb665bbb9e17546fb8edd04742444e", "ref_doc_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a"}, "934f0ebf-9fdd-4541-affb-0d1c1c2351f6": {"doc_hash": "549f77c99831765a59383751f2f7dc4339ceff400cf8a387958f6cfbceb3c902", "ref_doc_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a"}, "1d62dd0d-5458-492a-80c6-1415e4826657": {"doc_hash": "391e05232de18c144984a594aba642f9e605558879cace5b6e120a65b2be7659", "ref_doc_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a"}, "af2ce118-7cc2-4d44-adc3-cd0694282dbc": {"doc_hash": "98bf04b11ae293aa02230d83082afbc8db5c08284bcf6d5dd1401e932c5f6d78", "ref_doc_id": "a38e83bb-3636-41cb-b23d-45eaa6a2158a"}, "3bb05fac-d9ba-4ac0-9e39-68bd9cc7184d": {"doc_hash": "ed3c5a8250b81335f4d8c50df69fd27aa8b27203a18e9b2eca8f00b849d98817", "ref_doc_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6"}, "7b0f41af-ceb2-4c04-8abb-a46168f2cde8": {"doc_hash": "6396dd9396d858547b596747991c0e54bfcb643d310ee6bb59b52df274a4942f", "ref_doc_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6"}, "9dccbde3-4356-4ced-b5fa-3fea65e53640": {"doc_hash": "b8cce1ac5aada7ae47d4bfb86fc3b6ba29c60be228c7cf00db98931444629e93", "ref_doc_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6"}, "dc0e67ed-bc78-4ed0-8729-d60a430eef83": {"doc_hash": "4ff2aa32a2d4fe626fb43994a1f13fd5a3925f49628effc61ccb71102323290a", "ref_doc_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6"}, "790011c1-93bf-447e-8aa9-894ee270cae5": {"doc_hash": "2a9b8ad69159b37fab8f958bb0e551249bf4c9af869b599a4a20d71dff97d52e", "ref_doc_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6"}, "19e70fac-31ab-43c3-83de-268588771c92": {"doc_hash": "49a33fe31cf8a81eaee0c851b17d4d09cf606b6f862a05d2717190b00354d8f8", "ref_doc_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6"}, "5786cf50-b82a-404a-bdb2-3caefd7899b7": {"doc_hash": "25e107e93ffc7c7e989d09141e13276cf68983a860d1ab35ca58dbb2d4d163b3", "ref_doc_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6"}, "4dc82ef6-00aa-485c-b824-3ae2322c5db6": {"doc_hash": "a7891b47d027c9dc9e3c23300866a1e5d99248b6dac1a504cec831cb75592b3f", "ref_doc_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6"}, "c9e69df4-953d-46a8-8033-6545f4d478ec": {"doc_hash": "b11f850aca592bb325246355183ea2a446c43f267516122843c6140647a96f17", "ref_doc_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6"}, "77caddce-39bb-4c4c-b5fd-8a37e3b3dd26": {"doc_hash": "788e5082a44ca1143c0a8d284cbb3e4d0d269223550086605e2bf521fb7521c4", "ref_doc_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6"}, "e69bf5d2-ee14-4579-b9ce-a6d7a0bbe44c": {"doc_hash": "00f18e6b7830fd841631f00ecf13f18974597490a017a7252a6252775a3299a2", "ref_doc_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6"}, "606be6f0-6817-4272-94cc-6a73485bdf72": {"doc_hash": "86b08bb45daf5ddb650bb99ba3a046f906e7f1acc9d178a5e9b3214038cf97e1", "ref_doc_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6"}, "acf82775-cb72-4a4b-b87b-cb6d4dcaf039": {"doc_hash": "bd4318e79e008ec83ae25df7e259a2472cc7219465f63097f5af1234edccac31", "ref_doc_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6"}, "65e3ded5-5009-4bc5-9236-03ac7ac9bb97": {"doc_hash": "1ab7f67cb4e4f5722d02856eec632e6bc456e116be30d0b1fc699083d61a5520", "ref_doc_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6"}, "dfc01c07-c2ef-41c8-b7ba-df4d0912f8b2": {"doc_hash": "7491072ff0c48c46b6fcba542e138c93f98208be94f9f16f3e3af589a4342bb4", "ref_doc_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6"}, "d8ce4a57-ac29-40e3-ad4e-fe53a241213f": {"doc_hash": "ea92b14986e2b9e730e01acc5e986e35a78b34b84e828824a111000f89511f9e", "ref_doc_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6"}, "a4a52ec3-914d-49bd-b062-7e327f994c45": {"doc_hash": "19100baaac170ce035d8a97422ece1b3b29d8e62c09af3ee8463a27f544f3b7a", "ref_doc_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6"}, "65a70996-b583-47d5-b956-5bb90e32a35d": {"doc_hash": "8abf69df2ca7486c74ba0b41277522add2907845e7506ab542ed05bcd8bf4857", "ref_doc_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6"}, "7fce1580-c9dc-480e-a1ad-cf705f133ad3": {"doc_hash": "01ef8b66dd1452d7bcfcabbd9544b242ab436f139a6716a858eb4260c90706fd", "ref_doc_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6"}, "881dbf0a-db4b-4076-9fac-4be10a655695": {"doc_hash": "d179d3873b1331b2c04939bdcefc836d8d1229cb4f7b730b1523e8ffbcebbdac", "ref_doc_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6"}, "16ab6417-51ba-4e65-adf4-f9eec3d4f257": {"doc_hash": "63a646851d294de1b289d9056b1dbda9d00233654af27297325bc13a7f8b7925", "ref_doc_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6"}, "651fb490-b2b6-459b-ad2c-6beb207d2ffe": {"doc_hash": "2954853ac190f67fde45d8e88482127f88e5e82a8088f88e4a7e5bd80261bb65", "ref_doc_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6"}, "b2776000-4899-4c8f-8431-727679a356b6": {"doc_hash": "57928d1dbc51fadf3b4b9531c068eb69729091a28f9a1ce469447fdfbe51437e", "ref_doc_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6"}, "b12bb143-29fa-4775-bc55-e27dda00b60d": {"doc_hash": "3f86445f1aa5438316491acf4b4ba4cf219f571234adb72a65b485a57e24aff9", "ref_doc_id": "ab737e80-568d-4a37-a45f-a8d6f34ff9f6"}, "65dcfc06-2a95-4ce3-be9b-871fc4942819": {"doc_hash": "10de65301bf32fe9b03fe076116a4e19003a3b33b90211f68cf35c4cead0f01a", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "53b52341-4e79-4b05-9d19-5ae14c99317b": {"doc_hash": "d9c2e02ae1e2af12b8ad51d207933ec21cb8e4c866e163986c1eb037266868b4", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "1921d992-8d4f-40c8-9b2b-12d8fa76fbe5": {"doc_hash": "5e11c298693d2b5a61df2e1cf2761649e5187d3937b58b0d2839b1748a3402fd", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "f51b231f-9469-4d9e-b6ce-e5e659e1f798": {"doc_hash": "2050b821b1e6ffb834fd83394460dbd6a28f6e23795ca2f559dfcda6970f88c8", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "097c9896-d355-49b6-aad5-0dad2577047b": {"doc_hash": "4ac89cb9a092e4a69b3548dddaf5d5b81e582b8fb3f77f914363de6f027f4645", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "997c0e27-cad6-40fd-87bd-3e7f712beaf1": {"doc_hash": "700cf6b73b966dfd8da5b8c6b06eea13ba7dfa98ffdcbdd71f68a437e3833342", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "151cae69-7c00-4b42-9dd9-ae31aeeb1a31": {"doc_hash": "9fe08f109111d349d7a2901fc5308ba0c0846d795682fe2e9d91582fc2236e34", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "2ab24049-7e5c-4dd2-9a5e-a3c961f46751": {"doc_hash": "cc25771dede64e136dea177f55166f5366187c253905a45ef21e826ba2f9d25b", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "7b625f16-01db-4595-87d2-e859baf4ff89": {"doc_hash": "177511ae461b81795c897a920737c54114d5d7cba150b118313dd16c4c60c7a5", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "8c106903-50be-441c-b3cc-8e411b183928": {"doc_hash": "404cf7fcf2df7fee788bd540f2c61d26249653404396a2d6a8c5656653f630fe", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "a75d9e7c-7683-4191-937e-d40ad810eb32": {"doc_hash": "fe962e9bf7064aaa04a1f5cf8874a691324be736c2a971d718ed386f35c9caf0", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "59356e4a-76d5-45ff-b07f-525c6c5d7a32": {"doc_hash": "0aebe91620f1f9179ac05d1e493490cc0724b1d7a241d12da6ad4e1ca3ea4e13", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "730d8759-eb66-4a63-bba8-449b1755d6bc": {"doc_hash": "1d523c53976953c84658339c1fa7c8adc262c731f1eecd8281039247a163e6ce", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "e9b0d033-ff1c-4fd5-8eeb-29e18cd6865e": {"doc_hash": "9b20b1e2dee5f16376090a5c72059c77cca909c1bb2671865c2ac8fd8534d1ad", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "6b964a8a-0859-4c94-b8b7-8119bbd4245d": {"doc_hash": "c3f9058de5d6f1ab2e90bf4218a1af60daaf775ea47de81ba23f62e02a2cffb7", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "67f47496-4e66-414e-b9ad-9ef80a071fde": {"doc_hash": "e2e95800a49bcac4bbebf98527f2dad3b41badd99cd7cb5924b6d8990f6dd1c9", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "729bbe2f-a8a6-4467-aba3-b987c7601fc5": {"doc_hash": "61872d9f922e817a17ab0f7e321826fd4720e27e63bc3ec139a8bc4859088318", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "7fbfc3c1-3875-4381-9cfd-0e36c60e8832": {"doc_hash": "3c55071bd2e0e72978492574e025fd2f1bb1086d16212d0c9ac52dbdfbb8368d", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "29a809e6-8458-49c9-a90a-2297d488bf4e": {"doc_hash": "1bba10e15d517278cec0319c928b7134ca30fdcbbd8f0b733a0061781a069837", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "3e5a67aa-b88b-4dde-818f-83cdb684f450": {"doc_hash": "d489f12c0344d3fc2127b8c8fe4afd926c5852a5d218085c15c816f6229fa73c", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "cb5c6bc2-657b-412d-b0ff-9a03ade3fc17": {"doc_hash": "c3e88f3f3fd2e05bdf82768466dd389a34f16205ccfd546023044856311c1979", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "c0abb394-1e10-4184-8637-1a13f6ed881d": {"doc_hash": "b53520c2bb691c4849efaf0e8fb6c20392bfc0825d0e65502bbb76e3042d39ce", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "849555d4-487d-4543-802d-540ea3507588": {"doc_hash": "34eb4e990bb2ae0f8e3cdedac5d3ec842dfe318c5a8b9b463be12efeed91b141", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "f338aa94-b162-4719-9a72-2a3337866fda": {"doc_hash": "0cbd9bf254eeead5bda176eeeca25754e5dacb428f3c3950077e68ac0841a0b4", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "ceefd178-a24e-4634-bb71-c6e72a4141a4": {"doc_hash": "c31bc32d641a40055d377fcdbbdafae57a69f881e2832e529a596f38c9396c78", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "eb07e1e6-1edf-4f1f-9cb3-a241f08d6dc9": {"doc_hash": "14cdd05ac7ca6682d8428f3cc4b03c88fb5e7207501c150d4b5eb501fc50267c", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "dd8e5518-ca3d-45b2-8605-08f9c12d6bd3": {"doc_hash": "ee7a4f53fa6a7d41b0233258b609928c6b81946ffede91265587b30037c78453", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "07d7bcfb-280e-4fdc-a6bb-d1bc296debbc": {"doc_hash": "447f44e5490fb181513bf429d584cbe9dc72d87f9e88c5d4acf353169a1fd3f6", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "0e797675-320f-42d3-a96d-6e37f96b78ef": {"doc_hash": "5f77d3b885be011ddc08192c5bee13ade9ef1bed2ebbe510833141d9a6c22a68", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "300788c9-f838-43f4-bbba-c8925b8beacd": {"doc_hash": "2c0f0b5b3a9b8f6938705a1e3b828896afb64f2865524475dd6d04a7eec4d2c1", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "681f68fa-d616-4c37-9dec-b6fe9864fef1": {"doc_hash": "e4a02f7584e2ce42f1d504060b4918573be5f3c8c1af917060c984947e2e1351", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "b40c7059-5529-4fb3-aac2-d996a440c780": {"doc_hash": "a217dfdb3a3edd5fdd3060b520eac3332a84c2f0d540c045393d8f20d3b87c0b", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "7784ae6e-168c-46f8-8a8d-84135ff02788": {"doc_hash": "460e9d2801cc0768f0ba0b8e6e65298425c2b65fa708154ae189936f903be3c1", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "a8bd8898-9327-48e2-97d1-3e5e8045645d": {"doc_hash": "63de840e28602e86e3390ffe3e30b9eed6c3ab871b23a37b93f85ca7c48ad6a6", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "9fe49024-d372-4396-94bf-24e3e255f591": {"doc_hash": "a77171e218a21726d4a8431811be97c563fa362483188ef9fabe590660011ea0", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "a941cc02-98bc-40ad-8c5c-afe67046d690": {"doc_hash": "066fdac8832328c029342356b3f3ca41a96bea4ce10f00dc0a857063c6b49744", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "2fdcedf5-24e7-45d8-b78b-aab0c57fefb7": {"doc_hash": "f025f4c50f453a7d7478adecf8327589a6643fe3eb6db9d996790e21d6f6cb78", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "03dbf9ff-5ec7-430d-bdc8-2f235f21a7c1": {"doc_hash": "375774f85233f645b0f32ea7844617254cd041bc6ce5a468b28470f67e0964e0", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "09594367-112a-4fe4-b024-73bc5ca88650": {"doc_hash": "02d9b992e3b701e32f5a3593b97bc0d96151c3df08f007a71d35ab4673eed27f", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "a9270fce-21e6-4a76-863b-6abdd454a7f1": {"doc_hash": "7f8ba0c3d603f011474777abf3583cdcd92e283780b684ade496ecdc4131e42d", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "b28d0dc7-1690-47ab-a872-9ec72639343d": {"doc_hash": "b5054205cb5137f1fc6c9ed0f7eef790dffe3ce1b0880f27b20244909e954fdd", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "350a34a7-c5a1-4bd8-a5f3-c001b3a5c56a": {"doc_hash": "8d99920eb4c23ced85f15cf2ade389e5d6bd7dc1c782d4d3f5e03f02bce91b55", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "599f6c04-513d-4365-bb7f-978f9b70326e": {"doc_hash": "005c5f6795dc71d17d35bde6ddd093b5530661b9ac98498de31f75172bc6d1f8", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "c5397df4-5c65-4682-930f-62a4f67e7fc5": {"doc_hash": "0e8289161b0aef89d5960db1bffef33aa50bb4ca007fbee95f5123735bb08a3e", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "51ef9ba8-964b-40ca-8a1b-0a21b0c9cf0a": {"doc_hash": "2df91e744e3f04be379bca5fc6f683ac9412b58188cd0cb4a35d462527bfa0b5", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "46eeec39-f094-4d05-9afa-e92b23630238": {"doc_hash": "025729ecd47876dd75e96681c6ad99675de385e86ffc25e71bc5ab6af26d3f7b", "ref_doc_id": "2085630e-ddcb-47a1-b1bc-0b859656a877"}, "e7025d7b-d4d8-42d3-b538-a51010dfcc65": {"doc_hash": "571fb7f552acab7fff280df3a99be19d1c5273be8a8ac1de65ea2d829a4acc0c", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "369f66a5-b991-44ab-8847-30979ffb663c": {"doc_hash": "89a1626833ad066760bfbb6f48c12752e4cd78d29233a583cfded8ca68711a42", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "ca3781a3-fc7e-4e64-bf5f-cef323db783e": {"doc_hash": "dbb8028c11b70e9637c53622c45a6cf43bcf0184c44cb627dd4f6d614b1d49f8", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "a10f302c-2ca5-4093-a4bf-306c0f28c076": {"doc_hash": "43f5893d35e57070f14555cbe9b17c8a30ac9cefd265aa7d37e7a7c57ee639c3", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "36aec282-ec62-4ede-b7c5-8593b7a3cd65": {"doc_hash": "e7bc4c6be203b20aa128745f8bf5db46f6d33707891ce8af6079f57da2fe5b30", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "c7c28033-e520-4fb6-865a-90c2228b62cc": {"doc_hash": "33f88f4c35fe80739b17f3d76060f69a1570d9cc0f7299a2b068295ce3f88799", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "a8c0bbf7-4784-460e-8b2e-fea0828c9fe9": {"doc_hash": "7c76b81bc2fe308ac4a77f2f551a3e3d2aa37675e9fbc8e34a84df566fef1586", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "f00cc933-a4f1-4a48-b797-f589bf6da184": {"doc_hash": "7c6731eac39c822924df41f66e22c8485ab99d74c19c792d09dabd257ce13661", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "5a6ebd35-2e22-4d60-99b0-db416e2e7e12": {"doc_hash": "89c83edcb73490cf5680ec0b527bcdbc96cb3c1209a80166632d7c7401583460", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "de0457fc-5153-4c00-9f6c-f21da442df3a": {"doc_hash": "f90089e3315d3e65f903d5533087058105f56b937eb5e05ee248ece61aab89f2", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "7aba5d1f-f843-42d9-9915-7fde58ed1cf0": {"doc_hash": "3c17a692d6ca03aa1aac1afd296a0a52356b81cfc71c29403932f5128155b462", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "b3e0a852-120a-465e-96b2-eced63741ed3": {"doc_hash": "2289040301d239ce7058bfd6d6892e2268ce10904150745547738fa6bc712d2d", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "c531e3aa-ebaa-44ae-a1e1-31d8ae5dece2": {"doc_hash": "432e7ebb3d95849278e7798cc676cae9d76d1a17233675981f3e14e8d45740ab", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "22c2f9aa-c8e5-4854-ac1d-85468f2a87d5": {"doc_hash": "b24f65949f64c2242a1bf7b2e30ba5c31e3e3c01e524441146d43f95f2db6c44", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "165ae2ab-7754-4e5e-87cb-880009e129f2": {"doc_hash": "b9803080610df34c1ab6f34ae48aec4ddc489f12f1c92847e01070e9ccbc9800", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "74172b2e-f37f-4e1d-b8f1-89f3ce3bab23": {"doc_hash": "9383c342c952d3176b89e9d2396471a693bde8c8ee52a839874d245122c6bf6c", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "77e260e0-bbef-4d7c-a0aa-d300cba8fe3d": {"doc_hash": "bb6695ea7357c3446c8c18682a6d475074d2f56e1e4041954d782fa9e0215f0e", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "8c7c6448-9fa0-4308-8a66-42192560c70e": {"doc_hash": "2bc266c9c6b2c1ebe09ca7de90d7a444e9c3a1157983b1f9d65284d7ad073d82", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "be3e252d-fa08-4555-9b6a-16a98ed64afd": {"doc_hash": "267890bcad70aa46914d59db40dbecbf8d88dc83c4198402154ca146643c6366", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "6b2c292b-02b4-4247-90a5-0bde5292fda5": {"doc_hash": "bcc216bcfa467f8e3d3eb21abdc5a8e50ae69913d45350a9f3f743f8a1533d43", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "141cc841-a90d-4407-ae97-d2f55df05a38": {"doc_hash": "6690d93505dbdb0380791746eafad2e787713cca94739b2f188ee06775db662b", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "d19c4f66-da40-4fb8-95d4-6508237f6e2f": {"doc_hash": "532bdb9ebfd80ae55555ff73268be0b42d61204ee0a4e0abf6b635db81d78ac0", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "672857f9-882d-4ac1-a349-9fcc13f6e296": {"doc_hash": "4e8f3087c8ea221f6f02a55e4b63f2c2279c2c22a00087a2aa9d1dc4a95a73c4", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "2f4c7692-65e1-44ae-ab68-00a10bfb257a": {"doc_hash": "000c939de24b730152d16b89c2ca2ad09b0e5802c393c874e464bd31ce62d19a", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "288524dd-9ae5-4f6c-9544-32cc3698a00e": {"doc_hash": "372e84277d4fd032ac71ab182ff5ae8fdcb844b519e8545be1c8c4dced1c1800", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "932b306a-8a0d-4443-817e-e3929411e8cb": {"doc_hash": "10f6ae324ebea3c4209c6188c3f77fd0460fc07820287cbc84b4ef7366aea38b", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "cd342539-8ef6-42a5-a448-17b8e47c3945": {"doc_hash": "7fcc8e6b713446360f5266144ae74ce7510fd9087721cc4397cc8cb0f617fb4b", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "a2ee87be-1f69-451b-b7e8-f3158b1cc68f": {"doc_hash": "ebbe67b47d3e9d821fd631b4b9396e04bd6e67e2629d83e11a36daa4c5f39e2e", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "1459fbb8-3a3f-448e-9135-0af802e7dbc1": {"doc_hash": "aa22948383afab06739d0d059bf398eab363a2be91d8a9e7fae6c503522ec35b", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "90bbbf4b-3770-4a2f-9624-6a44703c8923": {"doc_hash": "f7c2da1b5b5b71a83a243253fa3a5b64d4d67647a32cc9cdf3ecb8bd4ec864af", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "6094c13a-ba2e-42b5-b3f5-7d1c78dec922": {"doc_hash": "a1e795b46fbb8e3d4daaccffa49f794bab8a9b1a580447c8ae4c3d6a3788fe19", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "8cadea9f-30ab-438e-8c2d-94283815088b": {"doc_hash": "200f7e0533030ca14491a6db6b1c96c7594c5892ce652be77769193c0b028592", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "932ec76e-cb47-4547-b9f1-a47f3da00d0c": {"doc_hash": "50a0130209883429f2fd65ef637d50ac11f67ab8d8ee40e3d76c5afa7e5b8849", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "4df76e31-1373-457a-9513-aafe795df3f0": {"doc_hash": "0b7fbb86d203adcb923076708d5e1939f5d891bbb93d1505d871b16297ac8ba5", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "f8f8f6ce-379f-4270-af3a-c8df66be45af": {"doc_hash": "fc0352026f9d7a0c4008eab7d85f9920321e2a171123f4d771671a34a52a4bf1", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "29e2f8db-4564-4703-a42b-3b17fc7a6ae1": {"doc_hash": "0999000c78f0babc3172f68b966404c6b2ad1dc5b13146daab75cf17fd0d0b2a", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "acdd6eb9-b69e-4be4-ad96-4ead0937b868": {"doc_hash": "a22025863fb842c35b560f17cd9ad146e9bc80d82d953659419159b68ce80f5a", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "be6b322b-5eac-4e01-a484-b77c37d2b11a": {"doc_hash": "bba4af63fbd12c9862c139e6e3ed0f2d6212f2b290f96ea26355e0773e6aba75", "ref_doc_id": "1c142558-d937-4cde-883b-b05268c55f66"}, "4c8cb61b-3c73-4614-b689-eacabe2c96da": {"doc_hash": "aa870397de2abd3bc20f562d473b8048c91dc039215054a8f516b2fc594819a7", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "b5a0a4c2-17e6-49ce-8e63-4f6786fc2ed8": {"doc_hash": "2d93fca8dee5e6ebec3fabdc773582cb89fb04ab0260235e1c904b90fdb51bd1", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "4046fb1b-a97e-452b-8748-85b4bc6f03d0": {"doc_hash": "76d42655f4463d416409efb00c13bfabe49373883c51dad94d36bde2ca40996f", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "0bd91752-423f-4720-8c7a-c4a4694c83c2": {"doc_hash": "b2a75c66aedc9015b423021739929123b3eb6b2b7756b56ee52e3ca893bf3bfe", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "32035201-ac6b-4533-a6af-9d95fd7ba73c": {"doc_hash": "bd853412367e60aeb03bd1aeb3b593c8cbf1dc5f3d2b45c6460efe4f28fbe681", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "5b593d46-f981-48bc-8a76-996210e8b3b0": {"doc_hash": "092f8ba30472137c36318a5293579e38533b8fddc001dd549989080a8dfccee1", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "9a4d086f-19f9-4db9-8d13-ba0105bc5b15": {"doc_hash": "2ce94aedfc3ef5db4c162782de2d4c3c70ff2f4099061578bedb43cf057d487e", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "e1f4d929-4edb-414e-b292-8cf2494e8d3b": {"doc_hash": "2f4e310d5b411d7f7102292ce7f02e1c932e8da77cb109aab673ee5ad642c60d", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "3a3a4e8f-a754-4894-a953-d5defcc5b3b5": {"doc_hash": "45affb9188f94139b7408da09caa9d90279bf68207f312d108a03327311ee069", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "ef360279-0b62-452d-9c2c-719e7d825e51": {"doc_hash": "7af6b3c3fbe628f23eb1189f9789741f88c27630f83766529828d698749d31fa", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "ac64550b-0b28-4da6-8068-ea7c8102f38d": {"doc_hash": "3b73759372af1d7796911afc48c4a517d16978b5dc2f21e481b5b2248ca10281", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "190ba9e3-0ca7-4f8e-9dea-4d3b1889c7a7": {"doc_hash": "e599a7345b745dca172dcd8d54fb195311fab24949f75575f1a10d0d0f656bfd", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "9c1668a8-38e7-4217-ae80-94d99891c87d": {"doc_hash": "40e89babbaef8187d0d73aebf346504b11fc6393703f349813b53da9cbf4719b", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "0298f8ac-7a35-4b7b-9c60-e8023b4a5761": {"doc_hash": "85d6b8de1f9cf30bdb8cf9d0a761b69d2aaa0a53e0a9f37927a496f5bdfc2720", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "28082d02-63c9-4ec8-a638-e105a56c68bc": {"doc_hash": "35dcb4e529b7c377ef8afa2930309855c7d22f7909a4a39e14bc7c1c306926f5", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "8038bff8-8994-4136-833b-b00045bedf23": {"doc_hash": "3914030848a3b6af4af28124e45793ffb2c790e21c22b1b507353564f6e9dd01", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "5a585891-2934-4cc7-b6d1-1d0eb3a439a7": {"doc_hash": "d49387d0cdca140b5af70eebe71e8ef450ccd461d3b92ebed0dde86b3404170d", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "57c3804f-28a9-4625-ad3a-6a33bfa0136c": {"doc_hash": "ec795f351fa95936fdf338c9d460223db45ab1412802b5023af56cce8a3cefed", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "650145ed-7cf6-468f-8091-0e450f6d5b87": {"doc_hash": "d67e26b99608e12d8454ac6c40a2739077b3ae646e5bcf10337cc54414961426", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "ad77fb84-f263-4028-b9a5-c3a591318165": {"doc_hash": "02cee3c1385f6e0fc430d4752f4bc5acef931812ed31358a71c0a14370d6efe4", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "20dbabd5-5a99-4a50-af3a-ebf6a6948285": {"doc_hash": "5053a6d982dba18e4f77ab90fbfc2e36ea18d2a59c12c61aa9a4deb27f209e4d", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "21379790-4405-4bd5-b8fa-0e091c26df15": {"doc_hash": "49624618e68d0c8c7ece002493d82bf77ffe29e4df5c63a13f676c0514e44302", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "ce3a8a59-2e71-473a-9cb1-f09edbf88a72": {"doc_hash": "01ae1ba70421dfaec82cd21f50de6293f07a7fa8286465f190d306e1364704b7", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "93faee8a-d64a-4815-8178-38510273f9d8": {"doc_hash": "9deb87dc577d5fb183d99cffefe192b99c8cd67c414804adada28440cf179e93", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "ce482aa2-d31f-49dc-8932-bedc038eb9f7": {"doc_hash": "54d590a67e421e11404caf2ec70f673a71f71c37a1b382e2faec8b1140bb30fb", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "a98d155d-a709-4ca9-927d-af4fcdb34486": {"doc_hash": "9b52546d5fb96b9feb31cd3e7d31725e737b236abd049c7e5064a9bc90f0dc72", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "0aaf1c1f-0592-485d-a941-2e8ee2401cc3": {"doc_hash": "7e434ff16faac47ce4443f4efb9aa3905921e5bab385261c135c83627d4dccea", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "ca7a92d4-d03a-4892-a870-6aa18286fd0e": {"doc_hash": "22877814e377912301df6989f079fb933b0ae692093d3070dbed3ba492d5a9d4", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "00c23de5-0ad6-4f1f-8102-30e7121b5ffd": {"doc_hash": "ee791932753e76f40b7c11acb5646f332459d9dfc17e200119bfdb84d4a895f3", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "0e401b9e-a17d-4b16-95e2-de110819d0b0": {"doc_hash": "ec1bc5603a3c687b383018f24f98094edfbe0acdf541201a26e1669060adbe10", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "7adb4104-5c53-4d44-b1bf-c255f6aa4e02": {"doc_hash": "cb22ca7eb1381ca85608fba7d73056efbc691d0b06e012e37f72cc400e5c6156", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "8f01571f-3220-4e44-b565-d1b9ca1ca625": {"doc_hash": "72d3af297d4db6f3dce0aaead7209e08adb0830f78a89a9c68dbb9186a18e4bf", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "cac4d553-587f-46dc-9037-83675490d454": {"doc_hash": "f00357b43f88279812e706178664abe905e0016a05f724833d03212e02d7de5c", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "7e057e82-30de-43f6-b214-890bb942fe45": {"doc_hash": "b1d79e1e700ad89c678af667abcfd6bccf679e6d7d6ea626eb5731d8fcf79510", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "f0eb526c-23f8-49ae-aec5-2b3665f31e77": {"doc_hash": "5371c73de22699b4c608320e65b5d28897f86a5f86da03c62417d3d4f8cb6cdc", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "b0352525-9cbf-45eb-b070-99720a29b9d6": {"doc_hash": "fb18173fc2edc1de2186e9c881d151584bc25cf3a389380ba2cf7c214ea956d1", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "c16a8aab-9004-48bd-8f7d-3d96326cf24c": {"doc_hash": "704d4bbafdb06678032c7e79a9f250d0362acd02ac30903ff1f716c8d9500e88", "ref_doc_id": "d77464f5-828f-4e39-9ae4-96ac6228bdc9"}, "00e0a688-6cc5-4096-b9bb-387afb1c3f82": {"doc_hash": "6ca5d8e6a50f74a470f5182a65e6d4dcca97847e31fc8cc0dfae3b6c8f9c8be2", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "c686f040-c7e6-4f73-984e-ee6d9057e717": {"doc_hash": "6e35b1f4afb1c0cbe7ec06bfc1b15ad3f948b64f70f1ee4e469a245e7ecf460f", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "bb8721ce-03c9-45a5-b08c-60d0abdb5d1e": {"doc_hash": "edf8fbb1ee9a76de7dc98ab810bbc48147c9742c781601a4b9082075b0237910", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "cf4e3a05-7138-4431-9b86-0b5014d3ef6f": {"doc_hash": "9ddd066f4ad46799256053bfa8057bbaa8d65d5805bc6ac9cc555e37ebb4730f", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "c04cfd1f-92f4-482c-b5c8-f0bbcddd9a69": {"doc_hash": "5c91a0f41317656f27053fcc1fa99e3623e390cb709f11af8279077d4dc3ab5c", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "0bb33e2b-d942-4676-8db9-57e7f57a1030": {"doc_hash": "c3dde60d7fcc89ae69e97a2804022082c1ba3070176c1b144754edf7cdad806e", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "72bd4890-3a06-4722-a9de-0ba0a4add025": {"doc_hash": "594f6c92256d07fe4dca8c4a8d92622096c3db92e83a54ca015797c337081693", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "f4f31c62-405e-4089-9485-01bf650cd158": {"doc_hash": "4f6fdcba6b8caa69b8a443321164397da37115263223c76b225da9fd37f24498", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "71e0336d-896d-4b27-9ee9-2cdbbaf2d00c": {"doc_hash": "b16201d28ac0403b039f7f549f3cbc43997cee3255af69e32a0b2be62d02a7ec", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "7bd655b9-5bc5-4067-a4f7-d8e2efa64df0": {"doc_hash": "bb4103089e868edc34cb8e59d559cf6247c82f0a3cf0fcfc290fa289849f333b", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "8c774587-de1a-4d23-872e-c59ba7dcefc2": {"doc_hash": "f1d7f3a9d4908e835ff76f094caf561229fb74e5dd8ec0ca3f80297beaae15b8", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "45ffffe3-9b46-4770-b53b-95c6e571b92d": {"doc_hash": "128736796fdf5f10e6bc9c2eb00175ec001c8e40e289a4b1155f0b164d36ba6f", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "5f98aa26-a7d1-42b7-a0b8-7a1bcb4fbbb1": {"doc_hash": "4cfd8e50e4d0a587e01351df518325826550ace15132ee464ab3c53720b38dac", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "978d4b28-6f15-45b1-9e0c-6b15d188e6d9": {"doc_hash": "bedef38c19439518289d61c7ab1be1c6d1ace6f584aae6de3e0c296f51fa8ac2", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "4b63d9a2-32ee-420c-aef1-f086ad8394e2": {"doc_hash": "93c654cf3931ee491b5e67eb3cf4bae71da56311f02dcc7b1bbf96dc2ccba106", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "fc9d5413-b1aa-4330-a42f-655ee56cde26": {"doc_hash": "aeb6740c2d396ea16bb2b1462141150963c1177e97f9c3f611ba320bbbd0b61c", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "4771c77f-d2af-45ac-b840-3fb94b84a574": {"doc_hash": "5321a21603a8e89fb8fe1ba3185ee9125c725b06e24973a0ab4e7f0379176474", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "369dd560-62ef-4687-b3fb-adbcb7ac48ae": {"doc_hash": "1c1f7d3046da27d0656439ced1879edf5a4c6fa7f7156f6b17213b3441f8432f", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "e0d51709-9ade-4496-8fdb-6ae3a4406917": {"doc_hash": "9d5146d74c19da11f3ab1a8532e3a4c1b2c5e24da76d9105a006283f301b3ef8", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "5f024ab4-a0fa-47f8-8fee-00065c7287ce": {"doc_hash": "3b4517359b937a27c0aa1d482d8bb9a861377a5d8c9d18b0ee50cb43f0458217", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "33fbd059-f491-4c04-8da1-cc8ed1166636": {"doc_hash": "c1e4907a4d7ad4cccde5d7487b7801fd299ea65997f0f8e3548ea3830e8b249a", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "744e3815-0b84-4c2c-a839-b497f2f934b7": {"doc_hash": "123fdfdde15493c9428128875b6fb36033661a9d6dcfca5de6c24f5858a668e4", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "426dbe8f-d944-4f6f-93f8-79ce6d0bfa0e": {"doc_hash": "85a17caa72c715589365b808358325680391bc60b71b2b270d2ae2b9daffefb0", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "1a5e0e16-f798-4e2e-a617-6a006532218c": {"doc_hash": "9a74682d3ad8d4933d32b3ecd2c72fa8684f7749d9e5068a71f55c3a78dcfdcd", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "ca81a4d5-7730-4d5b-a677-a1b18010263c": {"doc_hash": "99accc577628fc535e8ccaeecfe4a3d572efc77dcb25a68b86183af789e4874b", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "d67c4c6c-c072-4cb7-a4ee-79d4d1d50e3f": {"doc_hash": "4bb86e127016311eab814b120e2609c86898c14755654819a9577c4a93b3b0b9", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "e1bdc43c-124d-4e09-a9f8-94d763245b89": {"doc_hash": "33d1a160405bc2bc9e58da1baeedec69d26a29ca5f3679399a95935bec6ed9bc", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "327c78b2-015d-463a-ad62-6a8ac7554e8a": {"doc_hash": "ed9e49ca3b69fe7d8892b1080c3260a80e68961bfafafd38280febf298861570", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "23d812ed-2ca4-4e64-8ca1-3e0b1fd9f5e3": {"doc_hash": "c3574b0bd9da5db39d660bcf2be72cd0ba8024af5ff16db92e419d4fed31e428", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "54242132-4b72-49a2-be02-9c52d5ef81b3": {"doc_hash": "7b2d42910fae0ab4bc7cdce8ea56dd817665e9f03bac257866a5123676be0618", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "c3c3c690-ecc2-4145-a66d-3f93d9c1ce6f": {"doc_hash": "03023c4ce97cb914bf678f60ff51fc88ef68bdfdca3cb2f64731699ef6cdefbb", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "aed0427d-32fb-4776-82fe-9bab74c18d9f": {"doc_hash": "f68767c6ae9e7ccdf827c9028ef6af2b41e92449201025410cf94b83748b1807", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "5d19f3c7-91c7-4ef6-b345-2818b3fcb5b8": {"doc_hash": "272a2f6db844e0dc7fe72826532bf124a410766698b89a4e6f74aa97cbf84170", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "a3a4f2f0-90a4-4797-acc7-418bffeccf40": {"doc_hash": "649c935da3c4466126752c68f57b44a3cd5e27f47887f97f03b948654faeabf7", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "777a3fa9-8a65-4e4e-bd1a-1b15caf1863f": {"doc_hash": "e1449e6827bb7b0628005cf9789859decfa7ddfdc0c5afd04c7443b25822024f", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "8e0fee1a-4158-498a-96f7-b071d1dd7c1a": {"doc_hash": "322baa6eedcb934c0bba2fac706e493baba31f9b8b605f20741f1fc569765e6e", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "e50770bb-cd9b-405f-848e-917ac02de75e": {"doc_hash": "cab015969d804e73f5c2d427189d2cda1707c7a79ed3b29cbf3f3560f863b06c", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "7c7c2e3b-1751-4476-9e9f-6dd0c50a5df2": {"doc_hash": "3ea392814696bc4c8f3b9b4aef3ad8ca5078b33f4267b176164008aa902e09fc", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "3df16078-79a9-4975-a85a-97372b2d0582": {"doc_hash": "2418c2c7d63846a97c89d39451ed7ec843abe0d716bd54dd768537fe988fb313", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "b0c47b71-fe9f-483a-ab7e-c6c393419fcb": {"doc_hash": "7900e8b179dc3fcb015b762b7f9f43f53764b874b72eedd31515bb81b04e26f7", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "c2eb3a4f-bdfc-480c-8204-6586e624550a": {"doc_hash": "986b8324e9644c1da891ee24d7c2fb9799cfa69a5c2341cd40b70c9d0efbd11b", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "d17b3e28-4c13-4921-bcc6-769b1a01d5b2": {"doc_hash": "06d1cd825888206d0c8546e9bf5d85ff5aad2f4132ada6623f20120363732a9f", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "bbd694e8-591a-453e-8532-ad527cb369d3": {"doc_hash": "59c586a918f9b79200f154b83e9cc23a003301b8b7002d649c09ae1a6a8065b8", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "f040d98e-50fd-4554-80e6-c0fea90bda01": {"doc_hash": "58453df9795273e34c98ccd3c9e00c99e8fb31564264f2284156695d9065f920", "ref_doc_id": "93792125-cca4-4866-bd7c-c7add3dd62ca"}, "2a9be002-440f-4c84-84db-7fc60323df41": {"doc_hash": "3a2823dc982756f8f8fdbe9321e11d1b09e47c43dec433107f1a98f9e40b581c", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "d7f4096b-9ceb-4fde-9b3e-fb7e72d2317f": {"doc_hash": "7813f41ce404704a3e9adea9a35651620fb9369fd33f5405cd4c2baa07a5f81f", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "3b31fbb0-02dc-4b64-b0ff-91be9f7eb37b": {"doc_hash": "d9962c1bd77aaefa2812ce9d1d06869a9e784b71d52aa0e0c5ddc17187d8d28e", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "cf556962-4bb0-4a13-bdd6-e24c3a3d7212": {"doc_hash": "86d354f72d2eb05a3839381a0802c8ae705f6c34a0b75c9ec7c33ae3749da2a7", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "92a82a42-60c1-4c33-9448-4ecb1719a01f": {"doc_hash": "8eb8d39fb437fc989bf9f4662702c9952879f0a191e9a455452eacc23ece9136", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "97cd0062-0935-44b2-aa3c-6af9342e0ec4": {"doc_hash": "3af94fd7e5d406b4bc21d9d16b641b7384e8bc73b96fd168118c10b1560fd206", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "2f094787-572c-4777-af0a-a1b94c6f0886": {"doc_hash": "afabb6c443936bff0c8a13dc32c0383b2bed432c2fc20c05eb31280e13ec78b8", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "168a7d2d-0f47-4fba-ad8a-25e652fc9efb": {"doc_hash": "f9f4bdac34615b84fba1bff8d57641e66e7bbdc45f9786c45c7d41a71dcfbeef", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "c0b2903b-affe-4a96-8c61-a6d142a87b43": {"doc_hash": "b6a5d293460a8c58d3fd99b0b849026f902ab5fc7d56aa471f31387b21900468", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "2a51a973-221e-4e0f-9506-b146288889d7": {"doc_hash": "f790719cfe6ac55c01303a5268f444e807109fadb1489d03dee27e1bdf8d1256", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "b67db03c-915c-4af0-a072-6f86f78387df": {"doc_hash": "1c0877b4e900d10923d4b5ad370aa2aaa937de5551cc223a1e8c2a9db5d57e88", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "c6ba3b26-4f76-4f12-a4a5-95388067f8aa": {"doc_hash": "c4fa9ef490e96ae327775de3ab4144a301668a203a66f658e5d4a2a2d0ea287d", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "a9ee9cd2-7e05-4ccd-8a6e-bd9b7d6459f4": {"doc_hash": "a8acb70c533395183ad1e7d67970687ea608266f4409ac9a07ba3c01a7839a84", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "cf08f4a6-91d4-4c75-9105-4ede4f49aac7": {"doc_hash": "472bbaef397470abec173ed389635ba1fde34e162797b08b30ccf9e502c55cf1", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "7d1ecd0d-b7fd-4e0a-83ce-4ccc2f837d57": {"doc_hash": "bf529561e9f6ee91740a8d24e514a3f0df28d83204be197c47c7f9fd29976384", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "3c74742b-acb8-49db-8e70-f90b071b2030": {"doc_hash": "79930b4e3fc6e7fa78ecbbbfbd4bbcad5210d35a485a9767f49a10ea9035f8e8", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "6fdf144f-4c74-4435-8083-b6cde6aebda2": {"doc_hash": "50774765a75dae24728a1a1d3fce1b82b05d5ad398c40b56528eb0f741da7c89", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "1c4e1582-a9b3-4d02-8c1f-57b27a8b4f7c": {"doc_hash": "c131be0cd81509bec503093c80d7a8df317dd7ed323fcadd972c883aff3ae49e", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "eabd42df-8596-46cc-9b7f-77c05a737ba4": {"doc_hash": "3d3580a66fd6f4392a313c065b7b3138254062716d3ec672349bccee1528e3a3", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "b8d71549-94a6-407d-aa3c-ded26c639bc3": {"doc_hash": "e04b1b7b17539fdfd0370af97117345f51f00dc8d6c370c5a7900691012ed1ab", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "1f981d8b-8780-4273-9065-e74022052c0a": {"doc_hash": "a0e90c7616fe9022bf2d02cf09ead6a5513e7c23e6a8fd2fe75ea42ff70f1b2d", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "236e91fe-d288-4151-b243-f22c80ce465f": {"doc_hash": "847c4285cfbdd0701683f4f1de3639b8840800000194d66a9005d0bc885c6a66", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "a0e2ff4b-cc8e-4532-a381-a8a015ee632f": {"doc_hash": "de30d40a616bd74444c2f040037ac3c706ffbb7e1e5b89394b4301823547b626", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "ebe52e4c-ee80-4d86-b74d-07fbcd070a96": {"doc_hash": "7d3a6ef53aeefe0fa4d9dba6497ee7cc1579d8845f54d17bb5f45a3e9df8593d", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "c52e36d1-a77b-4d47-adea-534b9b2d4ff5": {"doc_hash": "fbb5740f614cf15f1aa122deb345f332b08f43c2abfdc80a36445e28d9b204ab", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "17230693-17b4-4952-9150-273bd41b4391": {"doc_hash": "e995ede85a8a53a8c23a452b1870e606f771ab87d7d23c295c1efd2f9aaa5507", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "a322f617-15ad-403f-bca0-20e0b4d52b68": {"doc_hash": "092f8503d2cfe93b03a2126d37795e5eb63890297e8879b88d28ae4ff744887a", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "4acc5b8d-0847-4fe5-8293-5389c28126ef": {"doc_hash": "aaab85c8fd4559727343e132a6623a9502a4b3a9c19f5d9030241ec7fdffd21b", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "50828a2a-4e2a-4509-80fc-9375ebaaa3f2": {"doc_hash": "090b9f3a108f896507f0ce5e990eab30ea27c9b4f18e48bc2d2b1e8fb3ccfe02", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "eb8bc770-58fb-4338-a24e-c69c956773e1": {"doc_hash": "421ffea24fe7c17da7e7ffc8326cc0f41ed9fb81821bcd6db44effe5b58c0bd3", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "6ed39b28-2f95-4c0b-ba29-7d63a096d546": {"doc_hash": "ce4976c439e9cbc0dccdadf747c13530320d284da3d66cf0e7e4a68319ddddc4", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "73b70eb9-d272-4c7a-84fd-b08e603b0215": {"doc_hash": "f2907046d3af2bd30fd426553bc018308b1f3d7e677af2e623e9606d7a4ea2f3", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "1f81f03c-d3c4-4e12-89c8-60ab3fbdb5da": {"doc_hash": "90ab0353bd6f4761a87d6036e2efbeb43ccf763f69296ccf3cfa10b7f3fddf72", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "9fb87b9c-7e74-4ff7-b3a6-bd898cfc6642": {"doc_hash": "8c71eb1468e1ab683579349b5ddc844930f3209a059bde9f4d3ad62baacb2bc3", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "fe97ce2a-af68-4da8-9126-f95e0a46022f": {"doc_hash": "ec4c3215c3af4b93580c967a91717e4fd7275614282fcaa5e582afd39999bc86", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "84cecdfa-55dc-47f7-ae99-aa8e93d09446": {"doc_hash": "a331c8e9dac10c142e17d1d265b7407a002c9618c0162256ffbfc6bf747ce5ca", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "128bbbbe-1df9-4c96-b501-17815c5ba5c0": {"doc_hash": "64dc8235959db8a8365b32ebb4d0015fe1890f40d5463391865aa564380301df", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "80a07412-0bb9-45f1-9264-3aab5d0b71b7": {"doc_hash": "c958bc1e46652b4a896d68b2caca135da5d60231e8175e2aed676a1056a801c2", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "76f4aefc-3c96-45ae-84bf-d83d448be46b": {"doc_hash": "ca142dedec90bea1cbaabe18604c8d4127e9048a0b73d46114a3d22a997eede7", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "2985e563-0903-44d7-9565-1315702e8f02": {"doc_hash": "cc91fc035ceac0516cbe6530f31b39b5b3b42bd4cbca4cd1b1cd8bb118642a38", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "ef37376a-a31b-4ff0-99ef-732953969620": {"doc_hash": "3dce07a80c9b40c3f868a2276e47e85e14c0486db932631f50fefe15cd2f65a3", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "b8973678-110f-4901-844f-395824426440": {"doc_hash": "b89abb9b78b50b8c211cee338e00315f7846e7969b31770cda24c01d33e11a9e", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "734b6e39-704a-4b4b-8cd7-477f916245a9": {"doc_hash": "b7dbd32a2da4755ea68059e18e2c0a90646de3b573bd128dbc3e580f4ee28626", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "44c31dd2-2008-4c29-be17-a497581a5d79": {"doc_hash": "4c7d96e31a5b575d0250d0647a905e0573c3e2d05b7ff83db805383724edaa30", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "87a4e057-47ea-4649-b6b3-1d4db1908b95": {"doc_hash": "615e53a0f4953e319548beecf5dc01b7db8621a66801bc7704edc84dfdb4a018", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "124cf7bb-1e57-4489-9624-9571f502973e": {"doc_hash": "c02ad3365f31db067b96a6b01e6c79aeff0e7efee8f890ef6731a5cf43302346", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "dadc6c31-8e96-4f3a-a4f6-22307b8574cb": {"doc_hash": "c8d30ee6b952f63dbc4316b2efd01d19835d0d285d8292e56a653135f4a069f4", "ref_doc_id": "496ce0d1-7c51-4c96-9335-401f24ef2563"}, "b4204a6e-92ed-40f0-88b7-34a6a5f7fd7b": {"doc_hash": "b70772f84f587c3f8cd7be450705ac539d993498e5d9fe1d4be54a0bf34eae08", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "d56d5304-60db-4bda-997a-6ab2f78f15b9": {"doc_hash": "2285f64114a24701941713569c8f063f5557708cf22d95960e90bb02e180f303", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "e31dcb8f-8b2a-40db-9ab2-8fd39f7d536a": {"doc_hash": "ac636f13d435b0de9b6dfba3ba4f06a903e3a57b37f5fe79c790a08a892f20da", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "5533079a-c095-4316-8368-3ee7eec07c7b": {"doc_hash": "7bf21fbe176eee16dfa24e8ea3767947b419acfa1130e2c7506f0d5bd6dacbc5", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "58cc9867-15e2-4b8b-b9e5-e8e9d028dd66": {"doc_hash": "2a89140abe805bfe8e698fa097a3ffb476e1ed754d0d4013a78cd671c2159864", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "ee1f618c-9e9d-4ec2-aec8-beb9c152ded2": {"doc_hash": "2a7046bfc6d12a49c183701f9fc55625f8e36ca034f6095b177e445306d6e30d", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "f3aee708-71b5-45da-92dd-736aae46e86a": {"doc_hash": "7562d1769e6ca774b21db37bc54e9e4e5cc92b07d07827cf30c730382dffaaea", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "8de0eeb5-c2cb-4c3d-b2d7-1de75823286a": {"doc_hash": "0b926f3e6d8428a9108df2ba9412ccd6d643d01964d5ef30936faf48eb737ccf", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "bae11217-3b65-446c-afc8-e148b4e035f6": {"doc_hash": "5a4ce0faf79baa537cc024ea5410ba42ba3294847ff41575903298b43166b32f", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "46baeb0a-6c58-492e-a731-c603984e09a9": {"doc_hash": "c150e08a34d99eb1068b19f4addd9d0f1081438738c9865dc5e40f6d74b26ab2", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "a36e7f5d-d6d5-4ece-824f-1a785f6dd417": {"doc_hash": "8598517a78dc68256d27b08b0c6991f985c92a511ff8cf0c21e0d0ef49cef0c1", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "4273a581-c405-4a22-b028-142825308571": {"doc_hash": "e3ed23531a7de0ab8fa43fa48bc2507e5ee281932109029215e49c0e5647caed", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "fb2c9e93-c23e-423d-9b9e-9fe0127167f0": {"doc_hash": "79b0c199c0e668cac9591fa2fad4b2e6fe5163ed5cb4e192efbf76b368da2605", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "593de646-e717-4d4e-bd1d-5b747ba09602": {"doc_hash": "97d34c82757dc4a3d7bcfbb8f526ccdc6e09c03a2f1e96a8bac4f3aa48cf41d8", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "f630778e-171c-4d2c-bab5-1e2b63cba821": {"doc_hash": "5fae0ede021f48b4bbdb6de78ebfefb0d26ce5019210b1dd39d2758c17d49b68", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "19f61c7a-5a14-4ef4-99fb-c28527ac8c94": {"doc_hash": "165e5c4e72df3f8aae6ad858b1f7f4721fce52b3db263c2b9322922fc5246644", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "5bfba8ec-5496-40ce-ab9c-e2c06582bc99": {"doc_hash": "5e5e3cd0ae7c318f30680e9658b481dda3630c051a63928b1b38f7f8f12e7c6f", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "9fe9255e-4685-4305-8484-a9bc76173b0d": {"doc_hash": "94f02adbd57b61ec45b69b95a65b9575960e2f21773768144bf495e3dd624691", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "079018c0-5f4d-4396-8524-d225a4fafca4": {"doc_hash": "470710398709085c905899382f7206266a082681ad9ae47ba2a61aad81b57ebd", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "41f6213d-16db-4f48-bfcd-413d0fcf71b4": {"doc_hash": "89e75bdca9321dff7a3935ee751a684897f36fc0994d494762b3d2acd4eb7e67", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "8d106dc4-6ae8-48e5-99ba-9f4bbd8323cd": {"doc_hash": "20673bf60a00b4ebede2527bae70d7bf835ea6220836dbafc8c98e7e89d37b08", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "b81db33e-abe4-4cd2-bdf6-a63efa946e16": {"doc_hash": "ed770ffee06f261df5e09802c60a5fa06fc9acb0bfa1304a7b97fbfe1311a42f", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "6f450fdd-8053-43c8-94cc-803a26353d83": {"doc_hash": "8bf523ac756dabf9562fdba883042a368f1e7ba4291ea7d3a799f06d284c3a36", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "84c1e973-68b3-4b1e-a69c-cce9298cc746": {"doc_hash": "d1811de8cbf5a98dbb754aaf9a3132ea0ca16ceebb1a8eb15f9c7a77d5ed619a", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "27343d8a-e15d-4dd6-ae2c-16ce97af2ac0": {"doc_hash": "fb841812201dcf8a467446996cae381ea2a4af1689f9c0996fff8417585f77a6", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "68a4ce23-c9b8-4a53-b0af-c45fdc14b3f5": {"doc_hash": "ea3d285767eb74f3bbfb75ca257e4eb6c2d078f14cc1c7ef9aa516fb080ddb69", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "2ef42afe-58c4-4e86-a798-dc3ce35c4644": {"doc_hash": "f02e37ac0127fd6fc334ebc27e0fd89cf8a7f0e9d2788f3320ffdf65edaa25b6", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "b4de5ba6-4b1c-4031-b88f-09af677a551c": {"doc_hash": "ba483ba5ec22f54fff707a9c3c011799dfadaf6ac123059ade9b9405e61eac1b", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "f6cc768d-f809-4de4-ab21-b7db3c1d5355": {"doc_hash": "9a6ef235aa0baa99ca1cff5c39c39d89057c7c56ff94c2e43bb19155edc4d442", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "8a99a24b-c139-4793-979f-cd692689fe50": {"doc_hash": "8f9ff89eac08157bc8b58d08ebfd010c1981f7bfaa6219e5ce7a6879311f7caf", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "642a7a29-65f9-418b-9a89-f172fe33caf3": {"doc_hash": "d02cb0ec1fb6c3501adb0acdd7ff2ef326a044e363967cba960aefd47dd69d58", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "184b3869-a5eb-4a3b-b2b7-22bcad9bf306": {"doc_hash": "535422880a322e502838b33239ce9bdf65d7a2a295a045e60dbf63316b7cbee3", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "ea6fb941-62ae-4bb3-afad-a0e472e44104": {"doc_hash": "a1d0edc7afabf07be458c29942c1f46d5e4ae9b64d3d97e233b0319ce64af798", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "d99ab600-d4e6-4682-b243-88e550fcfa6c": {"doc_hash": "636f46999867be43de7f83581c40f419d7950b3ed5026bedf3522e07c9b3305d", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "2683e485-48c1-4ff2-8a6b-2e7d59711964": {"doc_hash": "42dee96e6415b22c836d255cc5c42812c393684f06642d3a1b40698ff127d355", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "e38ddda0-bf89-4111-b637-4a28f550d461": {"doc_hash": "1e86ed0da8e27484302607465b47510125f7faad3a8b4994a8ca38a76c920b87", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "5907f793-b866-4199-924c-ffb969315bf4": {"doc_hash": "2cd7eec90e06c59eb30da424867eeaea0aac4bab4c17d5cf6df1783bceebaae5", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "65162f28-f7c4-4a8e-b264-ef9843ad4885": {"doc_hash": "aac549c7f980cebe63870dd706e173ce6d6258c77853d466e4d09fcdbfc078aa", "ref_doc_id": "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2"}, "8dde9cbc-516b-4c3e-b117-afa0e1d7dc09": {"doc_hash": "d1bb25313f1ca92fc6d3e37df25d397182d82a21e6c485c5aa4fb9c550715df1", "ref_doc_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4"}, "22c1c59d-a956-46b0-8755-1fb296b4d386": {"doc_hash": "75940422a6fcded436166469f4a479e84050c7da8dff4e2f36d725a98965ccf0", "ref_doc_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4"}, "b5ef75bb-3f84-43ab-84a5-41fe0a9afc12": {"doc_hash": "fc0a6670a23218a56118f8dcafcead1031ff1d9dec75c6f9d1beaa914558d125", "ref_doc_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4"}, "3800a2e3-994b-4aea-9bcd-33c78d67c8bc": {"doc_hash": "067ea7aa9845fcad2b818ed0ac5abdb86b56071cddfa47787612d7b5cd184d40", "ref_doc_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4"}, "d13c4a0b-4d76-4775-b418-2d19fbe2b4d4": {"doc_hash": "7b5973dcb3ebc86c7864b3942f85246142f36d89538007f014fa8d24812c2905", "ref_doc_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4"}, "bf47a742-1dcd-4306-b476-4a854f64669a": {"doc_hash": "51b3a5f5d1167a8ccae3c7784cd7ff76f4d66a7fbe619d051927974022088792", "ref_doc_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4"}, "1d933f17-f70c-4a92-9521-a9160c3bdf22": {"doc_hash": "e6dc2f2d7a0e8eea76f443a67469d89ff2747dfc3d687197f88edee4e6d22ef7", "ref_doc_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4"}, "09029745-b23d-4ab5-9dc3-a8b7a0634f0b": {"doc_hash": "645ceab8397d9d34b4799894a04fab487220a6622fcb62f21e5e8079b14fccb5", "ref_doc_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4"}, "7e855c02-55ec-41bc-94a6-c7ee1859cfb4": {"doc_hash": "df17a1d6a6182f73e1f0c28869bf47986ea051a71184983fdeaf939f822e2823", "ref_doc_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4"}, "f4914a5e-dcca-4526-8830-f90f72f6bd9d": {"doc_hash": "65bb487d0e5f45e0d734763abed56f04bc36c8126d7370f8c69e6ab128c5b212", "ref_doc_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4"}, "afa00742-dfca-4ef4-aa03-5b05d169c801": {"doc_hash": "053bb7b5739ec25e1c8b3efbf7af505d3cd3a215f155d7297366d899db66271f", "ref_doc_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4"}, "88adea1e-9728-4dc4-89ae-3bdce7a8235d": {"doc_hash": "e5de3524c188552213484a57d80694ddf2b2a1f958fa8730c20e94138213a824", "ref_doc_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4"}, "ab53d07a-c838-4b6a-88ec-bbcd3b987530": {"doc_hash": "b8041228e6b095fe136d0b40503bc7dd70174829a9ecdce6007b892eb7aacf3c", "ref_doc_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4"}, "6cc9a3d0-eadc-454c-a66f-7e6b72244309": {"doc_hash": "ed9898ca50262c66d19be660ffd4ffc5317803ed09a7bf8eb13b59f1c78e3746", "ref_doc_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4"}, "5bbd9a82-436f-432a-a033-e4be866c6af0": {"doc_hash": "7c4a6a39eeee28901ad8c958df8c8608c2f7333269399d94be1e4d2191f80c22", "ref_doc_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4"}, "82aa1c64-fab3-42ef-8035-baea2c6fd92f": {"doc_hash": "7bef5c7fa2b0c9e2b998e46312dec41ff27cb788c709e36e4a2dbc600183aed2", "ref_doc_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4"}, "9eb814d3-b4f7-447a-914f-ce6efefdafdc": {"doc_hash": "dc1f0db3979928a48256737428c944e577f12de532d482c9c593a935a41ba3f8", "ref_doc_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4"}, "d3b77f4a-8e69-46b7-bc81-8414ba2ed7cb": {"doc_hash": "28ba78bf1432650dd7377d693d7dad6747d1a072628aa2283ce8f70631529589", "ref_doc_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4"}, "197881cf-f331-4d4c-b1b9-727d0a3cc1fa": {"doc_hash": "5d04ddac2e688a47d9af4de1878bf7a54748ac77584a38dbb5c8b5af0512c828", "ref_doc_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4"}, "47636be0-dda0-4bca-95f5-9faf847b8c7b": {"doc_hash": "b5f913895d5091969425f935932e0e8fed3d61ad3b28e40fc8b9b5909a8daf33", "ref_doc_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4"}, "19206760-d2a6-4f7d-bd68-1f0281c7f171": {"doc_hash": "fdee1762ce17963c3a7bd968104628f96668d8a959b1d97c94dcae0a9db7fbec", "ref_doc_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4"}, "35a6e226-9c60-4599-aab8-bf54b47f6896": {"doc_hash": "5113993c0e17da74fa092d74b08d35a259eecbc1a7691966701cf09d45f4b173", "ref_doc_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4"}, "25a48da2-c76a-4a4a-8e97-731c1699260a": {"doc_hash": "166ef6f2bfd68d46d8b4a705566e45e2d5dce4c0cbd631e2d85212c6cf87030e", "ref_doc_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4"}, "f7252e85-6aff-4d87-b677-c7108d8aca00": {"doc_hash": "9b3b48362e55a0ee23195847a036053c439c97bd41129a12ef38e58a7d32e426", "ref_doc_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4"}, "ace2958c-1dee-40b4-87c4-76bab5f884b0": {"doc_hash": "3492bd472b25113066be8e7061779d699da2d59d20a44bc2fa211e9d29818adf", "ref_doc_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4"}, "7892e6cb-c0bc-4c39-90ec-fa7bc2b0c94f": {"doc_hash": "d13f7791a3866d26e20fc0c3931f02aaee24e4ea1d00d2fb1516769b19d64224", "ref_doc_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4"}, "4526b873-46b5-4085-a373-e2fb7f36bff5": {"doc_hash": "b7debc7f9c720ea00cc9769cbdae6821c19ac7327a0c7e5769e21f6e19af537c", "ref_doc_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4"}, "091c0a5a-27e4-421f-8865-15abc19c6f73": {"doc_hash": "02a40872935ab8b784e92463e06e3ec2863c4586ce3e81b1cdd66e6310f55088", "ref_doc_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4"}, "46aebbcd-6b35-49b3-aeab-606a899b1b86": {"doc_hash": "a5f0b09305add624aa1d9e0ca0ca3459569a8156a64bffdb3ef0d6ddb7748774", "ref_doc_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4"}, "062f9cdb-e08c-4810-abf9-9f13d4c3f195": {"doc_hash": "09b1bbca38405d58685c6d132425c0218a7ad0dd7834ef6917e761b291253d6a", "ref_doc_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4"}, "56315fca-6a5d-46e0-b292-0b40b887d6c0": {"doc_hash": "50ebfbd4bd69879086634b88e65aaea29e4786204331526030615fac926816a4", "ref_doc_id": "d4af8d08-d98f-4495-9d3d-a184e13c4db4"}, "770365a1-3f5a-4479-ac8c-d33c1ae2892b": {"doc_hash": "deb3dc959d3261863b509b44e092df097dc7e7871bdeabd76b688f17dd63c829", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "4a73ff41-44d1-4c3e-b7ef-eac21312c5fb": {"doc_hash": "1bf25914ed612462cccb7856af3cabff960d45ee4bf3d9629b4ff56f68aad11b", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "65f3f973-f28a-497e-995a-088aeb9adadb": {"doc_hash": "786698034b1223666a4a440205a0264e117753f03592fa8b00e1f9f65dafbdc5", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "5fa4d053-ef2f-4a39-9be2-028c95e4aed1": {"doc_hash": "f6696e5c1da193808ea13f266f27bb41bf752bb9788fff709cb69c3547696905", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "1d76db69-6cca-4508-8f2b-618fba7a474c": {"doc_hash": "0f8cdfaf14f412deb3ee5c0b0e91b38f4c79fb1c1f4bc960604ed8ec69a316f4", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "040b4728-d88f-4fec-8608-0469b2cd0701": {"doc_hash": "177c29df31078e9c38d2676474da583d78dd0fc21bc9282b83a42a2de1557ff5", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "bf93af5a-3cb1-479d-b706-3b20919a617d": {"doc_hash": "e40d69487fcd3baf8c727607e3cff2015b5d6505ed661e9caa43e962320240f2", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "32089699-1801-497b-a2d3-ff7679df6331": {"doc_hash": "dfab438818b6e3802121320fe7c09cdc047aa3dd80b6428b47c55915336e1953", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "0c85c724-65ea-4c7d-9b0d-f495e574407d": {"doc_hash": "a6919bfe5abc84585203337fa6e0fb0987432b8467e11b00575ff9780dabb858", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "9db9abdb-108b-47e0-bad5-638c90d680cc": {"doc_hash": "4a2a684fec1e7bda295ded4497816c6ef4281ad1e3f9bfbf089e2a771391733a", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "dab714cd-4972-4df5-a657-d5d2319e77ec": {"doc_hash": "f6790ee5acc0b5e6e412cddb1fb9e368ef45ade28ee7abff2bd843e1a3ff2599", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "f3d8d701-03aa-4853-949e-16d192d1730d": {"doc_hash": "2f1dcb9f75cac23f12f43c07f0381c9895319b3e931ae698dddc1999b7c1445e", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "be724035-8296-441a-9799-6d76e5943385": {"doc_hash": "c6b013675dcf0221d37492725af611f9bd9f7e8284b7d0b8108b7c2070c21b29", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "c61e8c4a-82c9-4837-9b03-fb14c268cc01": {"doc_hash": "84f3d6160920000996fc6dff4c9c16fb5327a173f435ce239c82634e6a85abe4", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "98cf9980-b7e6-4875-bc1c-b9b1a4617da0": {"doc_hash": "df74bd763a5f4a455c98325091104077ef722f029595760c7601a684e9cab5bb", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "407881ef-94ad-4f88-9917-9e3e711fc792": {"doc_hash": "927e6627351aa99d0f07ee7a47fdda86a082f69cbff8f09801db4192030b76f8", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "7aecef13-3210-4b82-9a89-86a633c9ab66": {"doc_hash": "ff191716e128eb30dbf777e1aec20dc9d82eb0086d96ac6e9466ccc902748c60", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "572db1e6-c772-4994-8af1-ef48b96d0dd7": {"doc_hash": "870f672dc904cdb6c77f279a8b80fc29f05da25140c0f39b7ea0374b7dc46390", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "f36d7ca8-d8c0-4678-b14a-e59ad9f2bfdd": {"doc_hash": "77d3e371a51fb422f63479b9ec3a487d043d466ec02e2441873bb76c0f6b282d", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "a8befbb6-ec59-4e25-bdc9-4636672ca3ac": {"doc_hash": "39f752b2d766b5150f72c3f8531505e57e1a1a59d957088ad25186432bb3374a", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "5ea25ae6-3c58-4966-8450-f3ca11ca105d": {"doc_hash": "18005ea1d30d9ccd30cb8469f5e77c4f7d735fac02b5ab805bbad0a7d432f3d6", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "b7246bd4-09e2-4eb9-adf6-2518bc4f13c8": {"doc_hash": "a477b3821be47e86910d2d91e503f2e5b8b4d6650394e0e342339dfe7fb76855", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "ccf5b2e8-0c53-48ee-8bae-cc1fa89f34a1": {"doc_hash": "c9a666fe63cc570b6a265bd057085854eac46356a0f364343bb16cb9ab3bc691", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "1f0ebd66-9796-4d59-a99d-6d339b5bc01a": {"doc_hash": "1c3ca0d318743c05228fc9cb8cdc38c38aa0aee1e9eec0967f06ba1bb30668c5", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "79598a5f-c938-4b55-9171-b39c9c992e79": {"doc_hash": "54d2d7f257305805c194e49467ebda37d67356f8f11e72ac26c3a27268eb7ab7", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "be3975d9-acab-44d5-8f84-4cc0879a21be": {"doc_hash": "3e5d730d657ccb8ea325e30622183e258e319618399b4fe554a184ba6762477a", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "d58b7259-d8f5-4f5a-8cb5-762ff264cf18": {"doc_hash": "91dc548a0a3a9eb41579a6e13c8cbaa25af32e970c6263d6e166c98540cd8266", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "bdb8b7a6-371e-4789-9c27-109b7eed7252": {"doc_hash": "cf7e0ca650e0e6225020a40bbdef6b630c8226d0a26261012f0a30369f0969ef", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "174d23b4-3890-4ca6-8d48-0c9cdf92a2f6": {"doc_hash": "b299e627669f8c764dde1e7c6c778b6f666804b405e2b279b913dc5b7119a1cd", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "c510c6c0-c56d-4a56-afb7-6945ccc00c9f": {"doc_hash": "53d52c189c68473177128fa43a13ac241d67112cd3790aff9f9f26cd1f122f03", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "4905637a-72f0-496f-9b61-b36b6e945970": {"doc_hash": "e5f13d67a1fe8cd3d282c4e79599c92bdde8172e696131f36c8638dd69d416e1", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "423d2421-a962-45c4-8a0c-c8d62212a5ec": {"doc_hash": "094ecf898bf642bc097ecc00fc3466430c6a6e3986eaee707a9c0232fbccdd1d", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "2c52b3fa-e0b8-49a4-820b-b9652c1f3edf": {"doc_hash": "164239a382d79b209420e7c1ed0648b5a34e141bd9f4835d9bc711c96355996c", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "3132dc3a-44bd-4cb9-81ea-a3719f433f82": {"doc_hash": "062209e62cf2713314b93c4c0ca2716bbe39c5a9f4392f1101c77467a566a239", "ref_doc_id": "4626bade-5d38-4ff7-8aca-d885252f9706"}, "cbcc49a2-bf53-4faf-bd97-9715bbf02610": {"doc_hash": "05de1dbd05862b8dd5d5f32713d7ebfc172181748a0edc1d6d97c00cbfce36f3", "ref_doc_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce"}, "23f16354-28f7-4e5e-b0b4-271f96ea5196": {"doc_hash": "3ea76b03fd9259701ee3ec1ccbe253dd8b2887d1131406a92a1888280de2cf42", "ref_doc_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce"}, "c0cf9abf-2a0d-49fb-9d72-f6ae39d413c9": {"doc_hash": "c78981cc11fbd4cb116644c21a79aaea71b8079368d31aafb31b0335f80afb1d", "ref_doc_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce"}, "72d3d22f-0332-4497-9121-ebaf55545488": {"doc_hash": "6a7f2b611775165563ad44fe27f4d989293f6a4f0e67782d8a5ba42059c4a67b", "ref_doc_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce"}, "23e1f468-48eb-49d5-98d4-0d0242787ab5": {"doc_hash": "088e5425ce506da8b7f8d7de2ec3892e91713a34f194adde3cd298ae5067bfaf", "ref_doc_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce"}, "35ef8034-0bdd-4be9-8be6-1a1d98d27fcd": {"doc_hash": "94841f45bd44b854a884744f5bb22e2fd52c98e5bb803e0820683853c8b7e15a", "ref_doc_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce"}, "f0624576-2a5f-4dbd-a14e-6e0bc48e031e": {"doc_hash": "9a4861f614bef6d4ee19fc93771d987ab944eb469a448d6236bcd43ef8395642", "ref_doc_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce"}, "a00abec0-2820-40e5-a297-667bb5048947": {"doc_hash": "f211582647e6bd534bc8e96b137ccfc54af9a079291ceb76c06ebbf0d176b9b4", "ref_doc_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce"}, "1644832d-437a-4169-bef7-d9980b93d4bf": {"doc_hash": "6b0b7e19409f2cbc549406466e7c3c39c00a4600c7f65d3cd02aaba4f30037d2", "ref_doc_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce"}, "33e240ff-f971-42ed-9128-8ffc09ac405b": {"doc_hash": "b9bc986bec6b85c674e87e830401f3da84270fd27b4667a35632725d8d09c078", "ref_doc_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce"}, "79895b5e-d630-45f6-b86e-dc6c4df143a2": {"doc_hash": "66458b81d90788d6bd89efb192ff201860c8ab47ed1dcee5efbb5ce380b0991f", "ref_doc_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce"}, "ce8452d8-f369-4157-bc13-09169ef4a196": {"doc_hash": "da11809e210328ddd7f74405eb936892d5cb44b2f979b61753003539c842e557", "ref_doc_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce"}, "e198f658-8e5a-43ab-9204-af0d8b624059": {"doc_hash": "930cef41dfade3bd0890b896aa24365232a4055792f00896fb3b89cce8b5983e", "ref_doc_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce"}, "f0a7ea59-520e-4560-83ff-3b17e6a0e7c8": {"doc_hash": "f5b86e8169d14daba06b520dd8bf977e83acb41f7e18d7973c445e842e6ead70", "ref_doc_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce"}, "1b032a67-446e-4f34-9c94-590aa42ee728": {"doc_hash": "261641fda7225346a8694dd2f4cf023ca8f1b6e18412f3787e1cbbb83994dc6b", "ref_doc_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce"}, "1e26efc7-9480-4dcb-924f-54fd25b1c190": {"doc_hash": "140c9e00d928a386758a71212d48a41bcfb4732c3a095d471a5ca4703a233f17", "ref_doc_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce"}, "357ba423-ac63-45e3-8fc9-48efa523b06b": {"doc_hash": "e266c0adf95226311e6c98831cd77361206b454a97ebb6d287c2bb110299cb16", "ref_doc_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce"}, "0386035a-d096-4d5f-bf30-5954fef3337d": {"doc_hash": "bb744b8d232dddc7aff30c795fc0b5b7ee08d147c67226f5ef163917e896e980", "ref_doc_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce"}, "b74dedfd-736c-4b6f-90ec-82b572afbca4": {"doc_hash": "618d1f06329e4d3b6ed11331e7a466b76ab523328c2372aad5101e560b5f733a", "ref_doc_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce"}, "1b25ddfb-9637-40a3-bc69-316cab4d9963": {"doc_hash": "3578d69217cf2ed93ac0105a65300efb846605cf867917e4366c960480ad802a", "ref_doc_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce"}, "c694b9f9-00f5-42b1-baba-ef887fa665a6": {"doc_hash": "9e57e7c8b5e4e4bcfc70fe0d246408a67ea2f43e4e64284872057d7b79774c4c", "ref_doc_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce"}, "9d9bf935-9433-49ba-a4a4-fcf4f926df03": {"doc_hash": "c6782d85e1b0ed4734d72f043179df2d663d3bfc9a7bb159fd5c06579b67651c", "ref_doc_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce"}, "85a04192-4410-4c48-a55c-2cf9d8c56c35": {"doc_hash": "c16472bf90677adfd040f394855dd18878608774ceefa44afad1f9d699085195", "ref_doc_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce"}, "5fa34bf0-2c5e-40db-b4c9-0a294c88af02": {"doc_hash": "56fbad70efc5de6653e4a048ee5e49048d335b12d4a24d52ac4ec367f4264007", "ref_doc_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce"}, "f23c31a4-da06-4e82-b662-0a4c3043ca22": {"doc_hash": "ab34ac85c9b8e357175c184736b53e3af56d310f21f2ae146d4842e90a3b51c6", "ref_doc_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce"}, "4b64f4b6-6184-4c2b-9c09-a20ccb30fad0": {"doc_hash": "15ab4736573f955b22a18b503a1ad25ec42a0f85140d77af76eba4c79bd2023a", "ref_doc_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce"}, "ed18e989-4840-4c98-ac3e-df621d8008b8": {"doc_hash": "2d52ea32050d6c74b520946b2baa536ae23609fab3337d1cfc267e96f7590db1", "ref_doc_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce"}, "f0735e7c-c2b1-42fd-a1fe-192cf98f3409": {"doc_hash": "73e12875a6b420b9ecd8d2dc819ebb94c38d7416406bf8d6b94306fbf971d36b", "ref_doc_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce"}, "4531cc07-445b-4503-8969-e4f08f7e397c": {"doc_hash": "e96476fb0fd470e3b6b68ebfa43dd00f76a116c77e93cf1d3ca0f90f66518bff", "ref_doc_id": "5933e26b-3a89-4c69-b0dc-0acf593ec0ce"}}, "docstore/ref_doc_info": {"70020eb5-2224-4543-aef8-9b1b4fe4eba0": {"node_ids": ["df68f982-117d-44fb-a91a-bcfb23d17447", "a5f7a822-4b25-43c8-925c-3fcc0f1286b9"], "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 22 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n06-May -2021  \nMcKesson Corp.   (MCK ) \nQ4 2021 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 22 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n06-May -2021  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "78cda6f2-9cf3-42b7-afb0-13841559d1cb": {"node_ids": ["bfb2ae1f-2076-4e7c-baee-61a8862bba9c", "2df6c36c-4f4a-460d-a679-b39cbc4bb868", "1ab4f5f4-5b10-40ae-bc79-af33632e1362", "1aa3b904-8c18-49bc-97de-f374134132db", "3ff117b0-5756-4ff3-ba1c-18b9d8d0d7c5", "252a33a3-581a-4ab5-b953-420d28e71cd3", "947bb482-9404-4616-8412-88bbea06c3da", "0d1d3c3b-02d8-4731-8392-5f3d7b54597e", "98666372-6af5-4092-bb4a-17551a9a62c2", "39a88a04-d677-4a52-8e24-06ea81bf3fee", "0742350f-efea-4952-9288-7335deefb584"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSVP, Investor Relations, Corporate FP&A, M&A Finance, McKesson \nCorp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "4568d7c2-ac61-4065-94af-1af8cf739d2f": {"node_ids": ["046d6f12-1632-429b-a3f7-0d64d8bb59a4", "b5750b52-ab4f-49fe-92ff-73db09976056", "886628b5-e9a3-4183-a9e5-80b14e8659b1", "47ea722d-01e4-438e-81b0-39daaffa86d5", "531eec11-982b-4b38-951d-21bc222149a6", "ae751d68-767b-460c-bfb2-10175e94e806", "bb1e1204-820d-43fa-8211-08284f889719", "b0ccf3ef-daf4-49d2-9701-e8a350c2d4b7", "742dce34-a795-4152-ba46-c7ef2aa2f9d7", "49093942-6be4-4761-a1f4-3150419318fc", "93f22f59-4782-4460-9bc4-6ddd2939cffb", "0a80ee28-ca18-4332-87e0-a25a56427d1f", "4fa1e4f9-e704-4798-b504-86c088fe22d0", "d3ccac06-64f7-4d68-aade-c86c93406b78", "1d42212e-b4c0-42bf-8acc-f54a1397b396", "62875154-38b4-42e6-80b3-c161e33c88a5", "4989ea59-e65d-40d3-8a21-ab07888bd2f3", "e98f00df-cc60-42b7-aec0-95e9be34d4a9", "f3c662b9-0b87-47cd-a36f-5588327d2de1", "f12fbbfc-69b2-4e15-98d2-50b84a8afd8f", "f3084537-2fbc-4772-9539-353de900b0c1", "5ec1542b-2115-4ca4-a07f-2452f3411988", "d8e1accc-0d3b-41a2-8a4d-13e1b4a05618", "ba6788d0-40c5-4519-b5c7-889d330f67a8", "ee3d6f15-c39a-47cf-b477-e9164e2ded9b", "d562bafa-64e8-449f-bdba-dab5c7202afd"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd \nlike to turn the conference over to Holly Weiss. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "0a7c6e97-6ab5-4d2e-ad00-44839db06cff": {"node_ids": ["f6ef3b9f-1a91-434c-9da0-84980b4c1057", "e211340f-2291-4035-88f4-ceff80156b0f", "04217e57-0f2b-4cd1-b64b-6a17d3ab291f", "74c5f79c-780d-456c-a5f0-afcb9e8963ca", "d5a56c69-47c5-4fe4-b1c9-5c9de4f06ab0", "080ab470-5333-4ed4-b066-b14bf63381a1", "5d619075-fd38-4266-8524-8f0f03c12ec9", "a22546f7-0d26-4631-81b9-6597b6285b9b", "96b206c6-d381-435a-a90a-06fcf679a4ad", "8b57444f-07dd-4b66-9d6f-30da16b17b0a", "70ec0f27-d712-41e3-9c05-6d9c6a132502", "81828f5f-2dd8-4a1d-bd00-2c525770ccd0", "7ff40c8f-07b7-468c-9251-dd8eff5211a3", "3eb3adf6-4b9b-4116-99a3-af479a13f7b4", "91163152-3365-43ed-be8d-6e4473e53344", "6d2dcd97-687b-4681-9c6a-eb07e81036ea", "ac5ca5d8-40b4-4397-abf9-dfee9e1f96f9", "6b893570-a290-4260-8e6f-b2769610c2fd", "ec1e6dcc-1a43-44cd-880c-bc957188b153", "ec7595fb-58d3-4459-8acd-e6dad1e19ed8", "c6e0ac30-a3b0-446d-8ab2-c4789536ddd9", "96dcb479-73fa-4d0a-ad87-1f1148a57c7f", "52a50802-ca5d-45e1-98f5-fa4fc6086bd4", "2d21fd5f-48f3-423b-8a62-8bb739d8f10e", "be4361aa-c9b3-49f2-93b7-0db31011fd19", "39a3d417-1a2a-413c-ac63-23c860778fab", "73020832-c1c3-40fa-bb90-9db428cd2b34"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOur role in the COVID -19 response was also highlighted by our partnership with the US government's COVID -19 \nvaccine distribution effort, having been selected as the centralized distributor of refrigerated and frozen COVID -19 \nvaccines and the ancillary kits used to administer those COVID -19 vaccines.  We distributed our first COVID -19 \nvaccine in December, shortly after Moderna's vaccine was granted Emergency Use Authorization by th e FDA.  On \nFebruary 27, Johnson & Johnson's COVID -19 became the third COVID -19 vaccine granted EUA by the FDA and \nthe second vaccine within the scope of our contract with the CDC.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "9f207edc-0ead-4320-8205-fc7e356f115c": {"node_ids": ["2a935b6f-ce92-468f-8902-e653dabedd3a", "5c3bd72f-0207-4e07-92e5-58c23035c2f2", "292bbde4-7c9c-4793-9d67-b81e151819ab", "934f0843-8d80-4b96-91eb-7085bde66fd4", "69adfdbd-315e-4c1a-8781-47eb3fd8edff", "f65c6fd4-820a-42fe-b922-6d2fd8a2805a", "9a29b869-9b77-459f-a4e1-f551ffbf7341", "d2148298-c93f-4575-81af-8b40668d478e", "e6af438a-f874-4ced-8c0c-957efc6054f1", "933db460-0c73-407a-87f4-ad7648a45493", "172b3c75-2222-48fa-a6c7-9a9d3c98c49e", "cb96956c-8e65-4301-8ca4-8e01814e53bf", "b0a1ddad-7e29-49c0-aeca-6775517f930a", "2c81575c-6bcc-4aef-9a0c-3650b26fcaa2", "23a3875d-f6bd-4349-b095-316595e63b22", "3b580200-92df-4022-8bec-5e6f710fb092", "8a015e5e-e0bf-4b58-a374-d85ca57bd404", "3e06b3e9-85cd-42ea-a3aa-1397f44d10a8", "30814fcf-6a7c-48c3-86fc-fe072d78b1af", "63c96bce-fc94-4ef1-a189-9660b642787e", "38f0282c-42f4-460f-bffd-25bc6befdfe7", "10999feb-9d28-4106-a8fc-1920b2a1fcdc", "28f4a599-b7ed-421d-9f7c-781848087bd7", "c778b4dd-0330-4e1c-a5d2-068586c7b46b", "e07df121-0bc7-4910-96e7-e92e557279c1", "68e5d07c-e347-4a11-8205-ed56e6e63b4d", "03b20d68-83ed-4cd7-b6ee-3b594bdd6331", "d99f87e5-b1a2-446c-81f4-4c819e8b126f", "4c2e5d57-1416-4f5e-b871-9ea3776f3715"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe we re pleased to add more practices and over 100 providers to the US Oncology Network in fiscal 2021. \n Today, through US Oncology and our nonaffiliated provider business, we're connected to over 10,000 specialty \nphysicians.  And our oncology technology platform  has supported millions of patient journeys, providing us access \nto real -world outcomes data and research.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "7c850470-3a0a-4880-b2ec-54135610be69": {"node_ids": ["294ef126-98f9-4fd2-aea9-8d8e00f9d2ca", "b036ca4d-04fe-47fd-8c76-ded7694a6369", "99d23d9d-3092-4061-90c9-d6a54ed1d8cd", "85477257-d1d7-4302-9128-66c55d24767e", "0b132a37-7c1f-4315-8729-4c1805fd44db", "698e8ca5-27e2-466d-9eb0-5f5349feb92a", "33888a5e-41ce-479e-88a6-30388cca3f01", "21ecf89d-34ae-435d-82b0-0a2836f422b8", "2e5a138f-817a-445e-b199-7cd5970f5412", "dd21e1c0-080f-42a3-b410-5160e3ed0737", "1c290c30-7af3-4aef-bdb1-7ab3cb518ad5", "8827647a-824b-4885-93ca-8c0b9a862436", "5043786b-e3df-469c-a062-4a2b2623d5d6", "1223f457-4806-4de3-8fd4-8db4ba421706", "a60703ab-809b-4a5f-b70d-cdaaba2d05eb", "ee860429-a866-4139-b0e4-42ef28e3d5bc", "a3d8ea7d-1b99-44ab-97a9-7a97cd4e1e7f", "f608bc54-dd54-4917-bb5c-d0f64b828672", "f7d706c2-4cb8-4007-8ec3-230eb4e5528b", "75912faf-6a99-46b6-b094-4245f946f1ed", "24e8a5e4-1006-456d-8026-612103700f86", "fe3be52b-f100-4a72-b79e-13c4b9e7b9ae", "d547419f-f3fd-4c1a-b23d-fc00376a368f", "fa7fdbbc-894c-4d5b-8c4f-64276172465c"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nI'm also pleased with the performance of our specialty business this past year.  Our US On cology business, \npatient visits were at pre -COVID baselines in March, with many returning for in -person visits to their providers.  In \nfiscal 2022, we'll look to grow both our US Oncology and non -affiliated businesses, which are just another part of \nour con nected oncology ecosystem at McKesson.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "4964b67a-25c4-4eda-8bed-ee9ceda78009": {"node_ids": ["6aa2ae21-7553-4e20-8b84-12ebb1086bfb", "90acc317-59cd-405c-8d11-05f0c7b5653b", "10c1df44-2a24-4b7e-adf2-f3781d7d7d32", "13587e9f-1974-478a-99e6-31fb1a69a4f0", "f32a90bd-c8fc-45a9-92fc-dbbca3971165", "d2b9d696-1430-43c4-b6e5-41bea3eb36ec", "8aa56fc8-72b2-471c-9f66-a79cc0418f15", "6102cbff-33e6-44e7-acb3-1c695ec722bc", "0d112ad8-8dcc-481c-b78c-16b5f3556c86", "4efb2e70-068d-4862-b19f-d22921298a77", "52d01260-eb13-4cc0-8693-fcf7fe3817fe", "a0b45abb-6c13-455a-9dcb-5da16eac4eab", "c7762bc6-059b-4735-b756-583a221c2f5b", "848ee1e1-d449-4af5-9509-e67cfe31c4d1", "a27413a3-ae5d-49e2-8c44-7f2831966ae2", "e1e10b08-14c7-44f1-bedc-f8a7a7b663b6", "7ac73ef0-1be2-492e-9a55-c2fc8c23dd9e", "5a9fe624-3cd8-4eff-8c41-bef0098ce9e2", "9c2c8f23-03fd-409b-a61a-9e3f9085ba1e", "3ef6b98a-a602-4bb6-a9d6-db46142f8b32", "c8034d77-1756-4446-b07b-882ce38f26d9", "2b808256-0eef-470c-bf66-d0920fe09855", "016d993c-a585-40bd-8e2e-51c1688fe330", "20cff1a1-d221-41c9-a568-a79c2aa7ea3d", "e9553870-80bf-46b5-8496-eb3bbaeddbda"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nyear, we expect the stable fundamentals underlying our core business to serve as the foundatio n for the outlook \nwe are providing you today.  \n \n Our fiscal 2022 outlook of $18.85 to $19.45 of adjusted earnings per diluted share includes a return to solid \ngrowth in our core businesses, a continuation of our role in the COVID -19 vaccine efforts, investme nts in growth \nand a balanced approach to capital deployment.  Britt will take you through additional detailed assumptions that \nmake up this outlook.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "47c99048-affb-49f7-9b53-d38a3f456c08": {"node_ids": ["0a2a79f6-7f6f-466c-9b28-74f8dcf3746f", "4cff1a33-ea5c-4dd1-b411-8cd806610eb5", "0261475d-0036-40e8-9fd6-b5d5880e3769", "4cbf4f4a-61a3-4ca0-8da7-5e1437e001f0", "9d52751f-bd69-4118-ac4a-59774b9fcc99", "dfeaeb82-42dd-4994-a600-416edaf1af23", "62db6f64-905e-497a-8e66-1b97e19b4422", "f24ddc5d-33bf-49cd-923a-5c1bee9cb8c6", "9988fed4-896c-451a-8ebc-da58bff685d9", "4bb69ca8-1cdc-458d-83e8-55babc933712", "13cddd67-a6bc-4bd5-91f5-52bb7450be41", "e6aed691-fa96-4afa-b86f-7330d3dfc193", "016817e4-f9ec-4c3a-b94f-728c0830d050", "026aef1e-bb88-4832-86c0-f63fc021df28", "143587a9-dcf9-433e-a58f-7752a54ece00", "2a1f3a6f-7d36-400e-85e2-4a161574f43c", "c8419f3f-4c67-4bec-9ca5-2e0cd21f6c84", "71001735-dc83-4864-a502-df1c3eef5288", "d49aefcc-2f24-4c7b-9ead-09ad2689d802", "bdc2b03e-7a09-4f51-9596-a5f4bf94b440", "35813a01-9550-4954-b3e7-1c50b4ae7b7e"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWe also recognized benefits from our leadership role distributing COVID -19 vaccines and ancillary supply kits in \nour US Pharmaceutical and Medical -Surgical segments, respectively.  And similar  to previous two quarters, in the \nfourth quarter, we recognized unplanned gains on equity investments within our McKesson Ventures' portfolio.  \n \n Let me move now to a discussion of our adjusted earnings results for the fourth quarter. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "fd41685b-0b10-477f-bbdc-bb96b80a5456": {"node_ids": ["94d72ad1-19b2-4ffb-bea7-ea9081d9505c", "e689fbf3-e647-4578-8588-44b4e154696f", "350ef8a8-b6dd-4234-8aa1-cea6f3332949", "6cfc4e5e-cec3-46cc-83a7-e4f3edfb1926", "f9b4917f-c11c-4126-82ba-9a375786dd13", "49c1d266-0e34-4e54-8f7d-aae7ce37e46f", "a762b2be-fdb6-4b84-8e31-9f124322eba1", "940ccb52-a281-4aac-ba84-1b0a61298ca5", "3142c0b3-763c-41ae-b26d-dee166dda5a6", "f6b17a47-ecea-4066-b28c-0e7e0bd73345", "669febb1-46c0-418c-8412-8367671158e3", "f7ad7d59-80f9-4ec7-9f75-34a54f26aad9", "aa1d601e-ac29-4af8-a9d0-33abc1807b28", "7a8b40d8-b136-4d46-9573-b96ccdaa5451", "dfdede8a-f320-4261-be4a-5e9f2e33b2ac", "5093e3af-ef58-4ffc-9219-78a57f05aec6", "0d6aa344-03e0-49d6-a675-09e99968378c", "9986ff9b-ed8c-4db2-a408-4ebf18119bb6", "d4bc6ee1-b9df-40c9-b01b-d412530d6206", "c48105c3-ddf4-4f6a-85a5-7213455aa53d", "a9a0fec9-eadc-42be-9a37-18a6c9569b96", "7b140341-94c3-490c-af68-f121e6b49453", "b0c03de6-26aa-43f8-b3d1-234ab0e15fb7", "98ba4198-ed24-4651-a995-bfb793f3113b", "79e125bc-0789-4e37-bbb2-4cd3279dad6c", "5cd654fa-82ff-4dc9-833c-2a7d8525e9a3", "1111dcb9-eb02-4036-9121-2564b8749144"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 7% to $813 million driven by the contribution fro m COVID -19 \nvaccine distribution, partially offset by the previously mentioned prior year COVID pandemic impact and higher \noperating costs in support of the company's oncology growth initiatives and the impact of a weak cold and flu \nseason.  \n \n Adjusted operat ing profit for the full year increased 3% to $2.7 billion driven by growth in specialty product \ndistribution and contribution from COVID -19 vaccine distribution, offset by the previously mentioned prior year \nincrease in demand driven by the onset of the pa ndemic and by higher operating costs in support of the \ncompany's oncology growth initiatives.  \n \n Next on to Prescription Technology Solutions. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "5db72ddb-2ddd-42bf-b444-0c5b6ff8798d": {"node_ids": ["22f68303-f56e-45d6-8a16-1d413f32c411", "84f0009a-32da-4310-933a-9b374ed1ee03", "2a9d9432-2457-4fd9-90c1-91daec7bd102", "241ec7cc-7a2d-4164-a237-1da948683f53", "3b960c37-abdd-443d-aea7-2844cf672772", "7c7257f6-7f3a-4432-aa51-9a88aaf233a1", "f3db129c-a587-4f2b-b98d-bbdca7fa548b", "c0f35e06-0ef7-4621-bf89-273472543196", "8459964a-9aaf-4bc1-bc09-86eb329afb61", "0b65daf4-681d-4187-aea6-276d16fddf06", "6a0a6a63-40b9-44c5-b0ba-c8665e4444b7", "1cf11a54-d1a9-42d3-9edd-e0014570d3e2", "a4066ec7-682a-4a58-85e2-b372005aa400", "9b4ae9f7-fe85-46d3-8f34-6434f23a8e19", "44fea027-94b9-4243-9ab9-297cbdcfe4fc", "1be8b022-c6cd-48c2-922d-504cd520f4a7", "1636556f-5a21-4e72-9818-2a390b9db52c", "55cb9374-a7c5-4d9a-9d90-5c99ca4ffd15", "c91f0dd0-553d-404a-a7b5-2433333989ce", "e62b8516-b0e8-49bc-93bb-7119312d0c95", "180aa042-b296-4d18-8307-52a6210a6494", "30f33b45-ce16-4558-ba34-81bead9d823e", "1d81b22a-e393-4412-8e2e-8f36f32780c9", "27334829-188a-4488-a42d-30aed987dac8", "7c33c7c7-7370-4ca2-a8d2-3306e749c9d4", "9b1a36d5-7f79-4385-905f-b6dfab1d1a8f"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted operating profit increased 1% year over year to $138 million, on an FX adjusted basis, \nadjusted operating profit decreased, 8% to $126 mill ion due to the previously mentioned fiscal 2020 volume \nincrease, again, driven by the onset of the COVID -19 pandemic.  Adjusted operating profit for the full year \nincreased 5% to $485 million, and on an FX adjusted basis, adjusted operating profit increased  1% to $466 \nmillion.  \n \n Moving on to Corporate, for the quarter, adjusted Corporate expenses were $125 million, a decrease of 42% year \nover year, driven by gains of approximately $44 million on equity investments within our McKesson Ventures' \nportfolio and p rior year one -time expenses. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "f86456f2-58cd-4b88-b5c4-8660acccd329": {"node_ids": ["114bcc6f-cfd1-4fc7-b75b-352e1bfd36c5", "180cd1bf-cf0b-4a54-b153-cd63ef799a68", "f0ad64e0-bd40-406a-b924-06b387e26519", "5c3008ef-30b7-4763-81ae-4d41622ea4eb", "0ad3680f-c4df-4ba4-a324-9ce544737211", "e9ebf426-8dcb-487b-982d-ac1a23fa1031", "81b49e91-053b-4bd4-be5a-00a56e85cec4", "d42dd6cd-5a47-4ee1-8b59-c70ac04325f7", "6e225a95-9262-49ee-ad04-d1b26dab0c32", "e10c88dc-10a9-4955-8b9c-00fd95869850", "ac42b52c-b9ba-4938-be5a-ff64b35f4ff3", "44d2040a-b5ae-4887-b5f7-2937b8fd87d0", "44afde78-60a0-4773-a43a-8ec42f267753", "eb790ee9-fac1-4505-83b9-6967ec08ec4a", "4a6dc8e8-6d5b-4106-8b1a-267b082aeeea", "1fad07b0-aed6-4ae9-813f-d1bd09b11f23", "fdbb39fc-e1f5-47a2-a28d-519b3f43ac48", "26c74fc3-0482-4ce0-af0b-d49a56f13976", "0bd52393-2422-4632-b63c-74b791b2e0cf", "c53a4b3b-c1e3-4f51-93b2-bcdcd33b2be1", "149261ee-5760-49c3-808a-3f2fc03466ac", "3b8c7533-af81-4fcd-bddf-72578afa7352", "8f9df2d3-1f63-4743-9819-88d92349df77", "66eb747a-927b-4063-a30a-abd7e7a9f354", "0ee2d259-bee5-4c9a-811e-7ada37c0235d", "a9f6eaee-0444-4904-a2d6-5b62da2bc853", "f3b31664-00c6-4813-8c12-11e933441d59", "52a79582-7588-423b-a5a9-7b14f4ab2dea", "c2d15e45-5ae9-4812-b4ff-109428ab2588"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nLet me now spend a few minutes on our fiscal 2022 outlook.  And, I'll start by framing a couple of key macro level \nassumptions that underpin our outlook for fiscal 2022.  We do not assume a return waive of the virus,  additional \nshelter in place or increased social distancing. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "a38e83bb-3636-41cb-b23d-45eaa6a2158a": {"node_ids": ["4dbafc38-19f1-4d69-85fe-dab741a29902", "d4167f3c-e528-41c0-b206-ea407a8c280e", "5058e852-00d5-4e2e-9e83-08c6e2ae541c", "cb5ac963-6388-40a8-9f94-8ec88686db39", "e65c9a7a-733e-4fbd-b5db-564c9b7a9f74", "83c057ba-0c63-4475-b70c-769acfbbf52f", "a92cc9e3-177d-4a36-a174-9af134ae1528", "b4352891-aeec-44e6-bcca-7bb2d6ef741b", "1a676e52-3c6b-43a4-bf9e-844a790a298c", "a81aa7ad-adaf-4667-8d24-d3a8f7282ab7", "b69bee02-98c2-48f6-8359-4f2899e39e22", "158c88e5-2874-415b-bc82-0236a65defae", "2fb7d86e-06b7-4766-82bd-d1ab0a4fc3d9", "5ef0f535-4256-4ada-859c-bece9652cc00", "5137c6d0-ed3c-4987-8b74-a096b96d63ca", "79967c5a-3b95-45b6-96fc-66eb1fd801ce", "28f41f28-467a-41db-b24c-08869c1b7257", "7db1caa4-f667-46a5-807e-a6beb3e0921d", "41c9e96c-c68b-4914-9b23-6fda06d54692", "f90bed04-4b4f-4f83-a683-a5460046fcbe", "c93a0e06-27f2-4493-b29e-b7b76146aad7", "7fc4c663-7c94-4a4f-a9a3-fa05a461e7de", "1a663b49-63b8-4dac-9308-5bd61941692a", "322403d3-50a7-4085-b20e-2de493502678", "934f0ebf-9fdd-4541-affb-0d1c1c2351f6", "1d62dd0d-5458-492a-80c6-1415e4826657", "af2ce118-7cc2-4d44-adc3-cd0694282dbc"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ngrowth, and we expect adjus ted operating profit to be flat to 6% growth over the prior year, as growth in our \nunderlying business is offset by a lower contribution from COVID test kits.  \n \n Included in this guidance is $0.10 to $0.20 of contribution related to the kitting and distribut ion of ancillary supplies \nfor COVID -19 vaccines.  Again, the majority will be realized in our first quarter. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "ab737e80-568d-4a37-a45f-a8d6f34ff9f6": {"node_ids": ["3bb05fac-d9ba-4ac0-9e39-68bd9cc7184d", "7b0f41af-ceb2-4c04-8abb-a46168f2cde8", "9dccbde3-4356-4ced-b5fa-3fea65e53640", "dc0e67ed-bc78-4ed0-8729-d60a430eef83", "790011c1-93bf-447e-8aa9-894ee270cae5", "19e70fac-31ab-43c3-83de-268588771c92", "5786cf50-b82a-404a-bdb2-3caefd7899b7", "4dc82ef6-00aa-485c-b824-3ae2322c5db6", "c9e69df4-953d-46a8-8033-6545f4d478ec", "77caddce-39bb-4c4c-b5fd-8a37e3b3dd26", "e69bf5d2-ee14-4579-b9ce-a6d7a0bbe44c", "606be6f0-6817-4272-94cc-6a73485bdf72", "acf82775-cb72-4a4b-b87b-cb6d4dcaf039", "65e3ded5-5009-4bc5-9236-03ac7ac9bb97", "dfc01c07-c2ef-41c8-b7ba-df4d0912f8b2", "d8ce4a57-ac29-40e3-ad4e-fe53a241213f", "a4a52ec3-914d-49bd-b062-7e327f994c45", "65a70996-b583-47d5-b956-5bb90e32a35d", "7fce1580-c9dc-480e-a1ad-cf705f133ad3", "881dbf0a-db4b-4076-9fac-4be10a655695", "16ab6417-51ba-4e65-adf4-f9eec3d4f257", "651fb490-b2b6-459b-ad2c-6beb207d2ffe", "b2776000-4899-4c8f-8431-727679a356b6", "b12bb143-29fa-4775-bc55-e27dda00b60d"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nWe continue to execute at a high level, and we have confidence in the business today and in the future.  And we \ncontinue to believe that there's great value in our stock.  As indicated on slide 16, o ur fiscal 2022 outlook \nincorporates plans to repurchase approximately $2 billion of stock, which we expect will be more heavily weighted \nto the first half of the fiscal year.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "2085630e-ddcb-47a1-b1bc-0b859656a877": {"node_ids": ["65dcfc06-2a95-4ce3-be9b-871fc4942819", "53b52341-4e79-4b05-9d19-5ae14c99317b", "1921d992-8d4f-40c8-9b2b-12d8fa76fbe5", "f51b231f-9469-4d9e-b6ce-e5e659e1f798", "097c9896-d355-49b6-aad5-0dad2577047b", "997c0e27-cad6-40fd-87bd-3e7f712beaf1", "151cae69-7c00-4b42-9dd9-ae31aeeb1a31", "2ab24049-7e5c-4dd2-9a5e-a3c961f46751", "7b625f16-01db-4595-87d2-e859baf4ff89", "8c106903-50be-441c-b3cc-8e411b183928", "a75d9e7c-7683-4191-937e-d40ad810eb32", "59356e4a-76d5-45ff-b07f-525c6c5d7a32", "730d8759-eb66-4a63-bba8-449b1755d6bc", "e9b0d033-ff1c-4fd5-8eeb-29e18cd6865e", "6b964a8a-0859-4c94-b8b7-8119bbd4245d", "67f47496-4e66-414e-b9ad-9ef80a071fde", "729bbe2f-a8a6-4467-aba3-b987c7601fc5", "7fbfc3c1-3875-4381-9cfd-0e36c60e8832", "29a809e6-8458-49c9-a90a-2297d488bf4e", "3e5a67aa-b88b-4dde-818f-83cdb684f450", "cb5c6bc2-657b-412d-b0ff-9a03ade3fc17", "c0abb394-1e10-4184-8637-1a13f6ed881d", "849555d4-487d-4543-802d-540ea3507588", "f338aa94-b162-4719-9a72-2a3337866fda", "ceefd178-a24e-4634-bb71-c6e72a4141a4", "eb07e1e6-1edf-4f1f-9cb3-a241f08d6dc9", "dd8e5518-ca3d-45b2-8605-08f9c12d6bd3", "07d7bcfb-280e-4fdc-a6bb-d1bc296debbc", "0e797675-320f-42d3-a96d-6e37f96b78ef", "300788c9-f838-43f4-bbba-c8925b8beacd", "681f68fa-d616-4c37-9dec-b6fe9864fef1", "b40c7059-5529-4fb3-aac2-d996a440c780", "7784ae6e-168c-46f8-8a8d-84135ff02788", "a8bd8898-9327-48e2-97d1-3e5e8045645d", "9fe49024-d372-4396-94bf-24e3e255f591", "a941cc02-98bc-40ad-8c5c-afe67046d690", "2fdcedf5-24e7-45d8-b78b-aab0c57fefb7", "03dbf9ff-5ec7-430d-bdc8-2f235f21a7c1", "09594367-112a-4fe4-b024-73bc5ca88650", "a9270fce-21e6-4a76-863b-6abdd454a7f1", "b28d0dc7-1690-47ab-a872-9ec72639343d", "350a34a7-c5a1-4bd8-a5f3-c001b3a5c56a", "599f6c04-513d-4365-bb7f-978f9b70326e", "c5397df4-5c65-4682-930f-62a4f67e7fc5", "51ef9ba8-964b-40ca-8a1b-0a21b0c9cf0a", "46eeec39-f094-4d05-9afa-e92b23630238"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question comes from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalys t, JPMorgan Securities LLC  Q \nThanks. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "1c142558-d937-4cde-883b-b05268c55f66": {"node_ids": ["e7025d7b-d4d8-42d3-b538-a51010dfcc65", "369f66a5-b991-44ab-8847-30979ffb663c", "ca3781a3-fc7e-4e64-bf5f-cef323db783e", "a10f302c-2ca5-4093-a4bf-306c0f28c076", "36aec282-ec62-4ede-b7c5-8593b7a3cd65", "c7c28033-e520-4fb6-865a-90c2228b62cc", "a8c0bbf7-4784-460e-8b2e-fea0828c9fe9", "f00cc933-a4f1-4a48-b797-f589bf6da184", "5a6ebd35-2e22-4d60-99b0-db416e2e7e12", "de0457fc-5153-4c00-9f6c-f21da442df3a", "7aba5d1f-f843-42d9-9915-7fde58ed1cf0", "b3e0a852-120a-465e-96b2-eced63741ed3", "c531e3aa-ebaa-44ae-a1e1-31d8ae5dece2", "22c2f9aa-c8e5-4854-ac1d-85468f2a87d5", "165ae2ab-7754-4e5e-87cb-880009e129f2", "74172b2e-f37f-4e1d-b8f1-89f3ce3bab23", "77e260e0-bbef-4d7c-a0aa-d300cba8fe3d", "8c7c6448-9fa0-4308-8a66-42192560c70e", "be3e252d-fa08-4555-9b6a-16a98ed64afd", "6b2c292b-02b4-4247-90a5-0bde5292fda5", "141cc841-a90d-4407-ae97-d2f55df05a38", "d19c4f66-da40-4fb8-95d4-6508237f6e2f", "672857f9-882d-4ac1-a349-9fcc13f6e296", "2f4c7692-65e1-44ae-ab68-00a10bfb257a", "288524dd-9ae5-4f6c-9544-32cc3698a00e", "932b306a-8a0d-4443-817e-e3929411e8cb", "cd342539-8ef6-42a5-a448-17b8e47c3945", "a2ee87be-1f69-451b-b7e8-f3158b1cc68f", "1459fbb8-3a3f-448e-9135-0af802e7dbc1", "90bbbf4b-3770-4a2f-9624-6a44703c8923", "6094c13a-ba2e-42b5-b3f5-7d1c78dec922", "8cadea9f-30ab-438e-8c2d-94283815088b", "932ec76e-cb47-4547-b9f1-a47f3da00d0c", "4df76e31-1373-457a-9513-aafe795df3f0", "f8f8f6ce-379f-4270-af3a-c8df66be45af", "29e2f8db-4564-4703-a42b-3b17fc7a6ae1", "acdd6eb9-b69e-4be4-ad96-4ead0937b868", "be6b322b-5eac-4e01-a484-b77c37d2b11a"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you.  Our next question comes from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "d77464f5-828f-4e39-9ae4-96ac6228bdc9": {"node_ids": ["4c8cb61b-3c73-4614-b689-eacabe2c96da", "b5a0a4c2-17e6-49ce-8e63-4f6786fc2ed8", "4046fb1b-a97e-452b-8748-85b4bc6f03d0", "0bd91752-423f-4720-8c7a-c4a4694c83c2", "32035201-ac6b-4533-a6af-9d95fd7ba73c", "5b593d46-f981-48bc-8a76-996210e8b3b0", "9a4d086f-19f9-4db9-8d13-ba0105bc5b15", "e1f4d929-4edb-414e-b292-8cf2494e8d3b", "3a3a4e8f-a754-4894-a953-d5defcc5b3b5", "ef360279-0b62-452d-9c2c-719e7d825e51", "ac64550b-0b28-4da6-8068-ea7c8102f38d", "190ba9e3-0ca7-4f8e-9dea-4d3b1889c7a7", "9c1668a8-38e7-4217-ae80-94d99891c87d", "0298f8ac-7a35-4b7b-9c60-e8023b4a5761", "28082d02-63c9-4ec8-a638-e105a56c68bc", "8038bff8-8994-4136-833b-b00045bedf23", "5a585891-2934-4cc7-b6d1-1d0eb3a439a7", "57c3804f-28a9-4625-ad3a-6a33bfa0136c", "650145ed-7cf6-468f-8091-0e450f6d5b87", "ad77fb84-f263-4028-b9a5-c3a591318165", "20dbabd5-5a99-4a50-af3a-ebf6a6948285", "21379790-4405-4bd5-b8fa-0e091c26df15", "ce3a8a59-2e71-473a-9cb1-f09edbf88a72", "93faee8a-d64a-4815-8178-38510273f9d8", "ce482aa2-d31f-49dc-8932-bedc038eb9f7", "a98d155d-a709-4ca9-927d-af4fcdb34486", "0aaf1c1f-0592-485d-a941-2e8ee2401cc3", "ca7a92d4-d03a-4892-a870-6aa18286fd0e", "00c23de5-0ad6-4f1f-8102-30e7121b5ffd", "0e401b9e-a17d-4b16-95e2-de110819d0b0", "7adb4104-5c53-4d44-b1bf-c255f6aa4e02", "8f01571f-3220-4e44-b565-d1b9ca1ca625", "cac4d553-587f-46dc-9037-83675490d454", "7e057e82-30de-43f6-b214-890bb942fe45", "f0eb526c-23f8-49ae-aec5-2b3665f31e77", "b0352525-9cbf-45eb-b070-99720a29b9d6", "c16a8aab-9004-48bd-8f7d-3d96326cf24c"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nshould we think about where the adoption levels are coming from your customers in terms of supporting that \nunderlying growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "93792125-cca4-4866-bd7c-c7add3dd62ca": {"node_ids": ["00e0a688-6cc5-4096-b9bb-387afb1c3f82", "c686f040-c7e6-4f73-984e-ee6d9057e717", "bb8721ce-03c9-45a5-b08c-60d0abdb5d1e", "cf4e3a05-7138-4431-9b86-0b5014d3ef6f", "c04cfd1f-92f4-482c-b5c8-f0bbcddd9a69", "0bb33e2b-d942-4676-8db9-57e7f57a1030", "72bd4890-3a06-4722-a9de-0ba0a4add025", "f4f31c62-405e-4089-9485-01bf650cd158", "71e0336d-896d-4b27-9ee9-2cdbbaf2d00c", "7bd655b9-5bc5-4067-a4f7-d8e2efa64df0", "8c774587-de1a-4d23-872e-c59ba7dcefc2", "45ffffe3-9b46-4770-b53b-95c6e571b92d", "5f98aa26-a7d1-42b7-a0b8-7a1bcb4fbbb1", "978d4b28-6f15-45b1-9e0c-6b15d188e6d9", "4b63d9a2-32ee-420c-aef1-f086ad8394e2", "fc9d5413-b1aa-4330-a42f-655ee56cde26", "4771c77f-d2af-45ac-b840-3fb94b84a574", "369dd560-62ef-4687-b3fb-adbcb7ac48ae", "e0d51709-9ade-4496-8fdb-6ae3a4406917", "5f024ab4-a0fa-47f8-8fee-00065c7287ce", "33fbd059-f491-4c04-8da1-cc8ed1166636", "744e3815-0b84-4c2c-a839-b497f2f934b7", "426dbe8f-d944-4f6f-93f8-79ce6d0bfa0e", "1a5e0e16-f798-4e2e-a617-6a006532218c", "ca81a4d5-7730-4d5b-a677-a1b18010263c", "d67c4c6c-c072-4cb7-a4ee-79d4d1d50e3f", "e1bdc43c-124d-4e09-a9f8-94d763245b89", "327c78b2-015d-463a-ad62-6a8ac7554e8a", "23d812ed-2ca4-4e64-8ca1-3e0b1fd9f5e3", "54242132-4b72-49a2-be02-9c52d5ef81b3", "c3c3c690-ecc2-4145-a66d-3f93d9c1ce6f", "aed0427d-32fb-4776-82fe-9bab74c18d9f", "5d19f3c7-91c7-4ef6-b345-2818b3fcb5b8", "a3a4f2f0-90a4-4797-acc7-418bffeccf40", "777a3fa9-8a65-4e4e-bd1a-1b15caf1863f", "8e0fee1a-4158-498a-96f7-b071d1dd7c1a", "e50770bb-cd9b-405f-848e-917ac02de75e", "7c7c2e3b-1751-4476-9e9f-6dd0c50a5df2", "3df16078-79a9-4975-a85a-97372b2d0582", "b0c47b71-fe9f-483a-ab7e-c6c393419fcb", "c2eb3a4f-bdfc-480c-8204-6586e624550a", "d17b3e28-4c13-4921-bcc6-769b1a01d5b2", "bbd694e8-591a-453e-8532-ad527cb369d3", "f040d98e-50fd-4554-80e6-c0fea90bda01"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd maybe, Eric, just to follow up on that, as Brian talked about the breadth of our, the markets that we serve and \nthe breadth of prod ucts and capabilities that we have, our leading capabilities go across Rx, private brand, lab, as \nBrian talked about.  And, if you go before the pandemic, FY 2020, we had growth \u2013 AOP growth of about 12%. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "496ce0d1-7c51-4c96-9335-401f24ef2563": {"node_ids": ["2a9be002-440f-4c84-84db-7fc60323df41", "d7f4096b-9ceb-4fde-9b3e-fb7e72d2317f", "3b31fbb0-02dc-4b64-b0ff-91be9f7eb37b", "cf556962-4bb0-4a13-bdd6-e24c3a3d7212", "92a82a42-60c1-4c33-9448-4ecb1719a01f", "97cd0062-0935-44b2-aa3c-6af9342e0ec4", "2f094787-572c-4777-af0a-a1b94c6f0886", "168a7d2d-0f47-4fba-ad8a-25e652fc9efb", "c0b2903b-affe-4a96-8c61-a6d142a87b43", "2a51a973-221e-4e0f-9506-b146288889d7", "b67db03c-915c-4af0-a072-6f86f78387df", "c6ba3b26-4f76-4f12-a4a5-95388067f8aa", "a9ee9cd2-7e05-4ccd-8a6e-bd9b7d6459f4", "cf08f4a6-91d4-4c75-9105-4ede4f49aac7", "7d1ecd0d-b7fd-4e0a-83ce-4ccc2f837d57", "3c74742b-acb8-49db-8e70-f90b071b2030", "6fdf144f-4c74-4435-8083-b6cde6aebda2", "1c4e1582-a9b3-4d02-8c1f-57b27a8b4f7c", "eabd42df-8596-46cc-9b7f-77c05a737ba4", "b8d71549-94a6-407d-aa3c-ded26c639bc3", "1f981d8b-8780-4273-9065-e74022052c0a", "236e91fe-d288-4151-b243-f22c80ce465f", "a0e2ff4b-cc8e-4532-a381-a8a015ee632f", "ebe52e4c-ee80-4d86-b74d-07fbcd070a96", "c52e36d1-a77b-4d47-adea-534b9b2d4ff5", "17230693-17b4-4952-9150-273bd41b4391", "a322f617-15ad-403f-bca0-20e0b4d52b68", "4acc5b8d-0847-4fe5-8293-5389c28126ef", "50828a2a-4e2a-4509-80fc-9375ebaaa3f2", "eb8bc770-58fb-4338-a24e-c69c956773e1", "6ed39b28-2f95-4c0b-ba29-7d63a096d546", "73b70eb9-d272-4c7a-84fd-b08e603b0215", "1f81f03c-d3c4-4e12-89c8-60ab3fbdb5da", "9fb87b9c-7e74-4ff7-b3a6-bd898cfc6642", "fe97ce2a-af68-4da8-9126-f95e0a46022f", "84cecdfa-55dc-47f7-ae99-aa8e93d09446", "128bbbbe-1df9-4c96-b501-17815c5ba5c0", "80a07412-0bb9-45f1-9264-3aab5d0b71b7", "76f4aefc-3c96-45ae-84bf-d83d448be46b", "2985e563-0903-44d7-9565-1315702e8f02", "ef37376a-a31b-4ff0-99ef-732953969620", "b8973678-110f-4901-844f-395824426440", "734b6e39-704a-4b4b-8cd7-477f916245a9", "44c31dd2-2008-4c29-be17-a497581a5d79", "87a4e057-47ea-4649-b6b3-1d4db1908b95", "124cf7bb-1e57-4489-9624-9571f502973e", "dadc6c31-8e96-4f3a-a4f6-22307b8574cb"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nguidance that they give us in terms of volumes and where those volumes need to be distributed.  And that's how \nwe put this guide together.  \n \n So, that's how we formed the basis of the $0.40 to $0.50 for the vaccine distribution and the $0.10 to $0.20 for the \nkit distribution. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "06f4ae6c-6a86-4845-a6aa-9561e1e0a6e2": {"node_ids": ["b4204a6e-92ed-40f0-88b7-34a6a5f7fd7b", "d56d5304-60db-4bda-997a-6ab2f78f15b9", "e31dcb8f-8b2a-40db-9ab2-8fd39f7d536a", "5533079a-c095-4316-8368-3ee7eec07c7b", "58cc9867-15e2-4b8b-b9e5-e8e9d028dd66", "ee1f618c-9e9d-4ec2-aec8-beb9c152ded2", "f3aee708-71b5-45da-92dd-736aae46e86a", "8de0eeb5-c2cb-4c3d-b2d7-1de75823286a", "bae11217-3b65-446c-afc8-e148b4e035f6", "46baeb0a-6c58-492e-a731-c603984e09a9", "a36e7f5d-d6d5-4ece-824f-1a785f6dd417", "4273a581-c405-4a22-b028-142825308571", "fb2c9e93-c23e-423d-9b9e-9fe0127167f0", "593de646-e717-4d4e-bd1d-5b747ba09602", "f630778e-171c-4d2c-bab5-1e2b63cba821", "19f61c7a-5a14-4ef4-99fb-c28527ac8c94", "5bfba8ec-5496-40ce-ab9c-e2c06582bc99", "9fe9255e-4685-4305-8484-a9bc76173b0d", "079018c0-5f4d-4396-8524-d225a4fafca4", "41f6213d-16db-4f48-bfcd-413d0fcf71b4", "8d106dc4-6ae8-48e5-99ba-9f4bbd8323cd", "b81db33e-abe4-4cd2-bdf6-a63efa946e16", "6f450fdd-8053-43c8-94cc-803a26353d83", "84c1e973-68b3-4b1e-a69c-cce9298cc746", "27343d8a-e15d-4dd6-ae2c-16ce97af2ac0", "68a4ce23-c9b8-4a53-b0af-c45fdc14b3f5", "2ef42afe-58c4-4e86-a798-dc3ce35c4644", "b4de5ba6-4b1c-4031-b88f-09af677a551c", "f6cc768d-f809-4de4-ab21-b7db3c1d5355", "8a99a24b-c139-4793-979f-cd692689fe50", "642a7a29-65f9-418b-9a89-f172fe33caf3", "184b3869-a5eb-4a3b-b2b7-22bcad9bf306", "ea6fb941-62ae-4bb3-afad-a0e472e44104", "d99ab600-d4e6-4682-b243-88e550fcfa6c", "2683e485-48c1-4ff2-8a6b-2e7d59711964", "e38ddda0-bf89-4111-b637-4a28f550d461", "5907f793-b866-4199-924c-ffb969315bf4", "65162f28-f7c4-4a8e-b264-ef9843ad4885"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution of $0.40 to $0.50 on the range of $18.85 to $19.45, inside of that, the core business  is still growing. \n And we would expect that as utilization continues to improve through the first half and gets back to pre -COVID in \nthe second half that those core earnings would reflect that.  \n \n So again, I think historically, we've had higher second half contribution than the first half. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "d4af8d08-d98f-4495-9d3d-a184e13c4db4": {"node_ids": ["8dde9cbc-516b-4c3e-b117-afa0e1d7dc09", "22c1c59d-a956-46b0-8755-1fb296b4d386", "b5ef75bb-3f84-43ab-84a5-41fe0a9afc12", "3800a2e3-994b-4aea-9bcd-33c78d67c8bc", "d13c4a0b-4d76-4775-b418-2d19fbe2b4d4", "bf47a742-1dcd-4306-b476-4a854f64669a", "1d933f17-f70c-4a92-9521-a9160c3bdf22", "09029745-b23d-4ab5-9dc3-a8b7a0634f0b", "7e855c02-55ec-41bc-94a6-c7ee1859cfb4", "f4914a5e-dcca-4526-8830-f90f72f6bd9d", "afa00742-dfca-4ef4-aa03-5b05d169c801", "88adea1e-9728-4dc4-89ae-3bdce7a8235d", "ab53d07a-c838-4b6a-88ec-bbcd3b987530", "6cc9a3d0-eadc-454c-a66f-7e6b72244309", "5bbd9a82-436f-432a-a033-e4be866c6af0", "82aa1c64-fab3-42ef-8035-baea2c6fd92f", "9eb814d3-b4f7-447a-914f-ce6efefdafdc", "d3b77f4a-8e69-46b7-bc81-8414ba2ed7cb", "197881cf-f331-4d4c-b1b9-727d0a3cc1fa", "47636be0-dda0-4bca-95f5-9faf847b8c7b", "19206760-d2a6-4f7d-bd68-1f0281c7f171", "35a6e226-9c60-4599-aab8-bf54b47f6896", "25a48da2-c76a-4a4a-8e97-731c1699260a", "f7252e85-6aff-4d87-b677-c7108d8aca00", "ace2958c-1dee-40b4-87c4-76bab5f884b0", "7892e6cb-c0bc-4c39-90ec-fa7bc2b0c94f", "4526b873-46b5-4085-a373-e2fb7f36bff5", "091c0a5a-27e4-421f-8865-15abc19c6f73", "46aebbcd-6b35-49b3-aeab-606a899b1b86", "062f9cdb-e08c-4810-abf9-9f13d4c3f195", "56315fca-6a5d-46e0-b292-0b40b887d6c0"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nseveral quarters.  I'm very encouraged.  We're hopeful we can reach resolution. ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "4626bade-5d38-4ff7-8aca-d885252f9706": {"node_ids": ["770365a1-3f5a-4479-ac8c-d33c1ae2892b", "4a73ff41-44d1-4c3e-b7ef-eac21312c5fb", "65f3f973-f28a-497e-995a-088aeb9adadb", "5fa4d053-ef2f-4a39-9be2-028c95e4aed1", "1d76db69-6cca-4508-8f2b-618fba7a474c", "040b4728-d88f-4fec-8608-0469b2cd0701", "bf93af5a-3cb1-479d-b706-3b20919a617d", "32089699-1801-497b-a2d3-ff7679df6331", "0c85c724-65ea-4c7d-9b0d-f495e574407d", "9db9abdb-108b-47e0-bad5-638c90d680cc", "dab714cd-4972-4df5-a657-d5d2319e77ec", "f3d8d701-03aa-4853-949e-16d192d1730d", "be724035-8296-441a-9799-6d76e5943385", "c61e8c4a-82c9-4837-9b03-fb14c268cc01", "98cf9980-b7e6-4875-bc1c-b9b1a4617da0", "407881ef-94ad-4f88-9917-9e3e711fc792", "7aecef13-3210-4b82-9a89-86a633c9ab66", "572db1e6-c772-4994-8af1-ef48b96d0dd7", "f36d7ca8-d8c0-4678-b14a-e59ad9f2bfdd", "a8befbb6-ec59-4e25-bdc9-4636672ca3ac", "5ea25ae6-3c58-4966-8450-f3ca11ca105d", "b7246bd4-09e2-4eb9-adf6-2518bc4f13c8", "ccf5b2e8-0c53-48ee-8bae-cc1fa89f34a1", "1f0ebd66-9796-4d59-a99d-6d339b5bc01a", "79598a5f-c938-4b55-9171-b39c9c992e79", "be3975d9-acab-44d5-8f84-4cc0879a21be", "d58b7259-d8f5-4f5a-8cb5-762ff264cf18", "bdb8b7a6-371e-4789-9c27-109b7eed7252", "174d23b4-3890-4ca6-8d48-0c9cdf92a2f6", "c510c6c0-c56d-4a56-afb7-6945ccc00c9f", "4905637a-72f0-496f-9b61-b36b6e945970", "423d2421-a962-45c4-8a0c-c8d62212a5ec", "2c52b3fa-e0b8-49a4-820b-b9652c1f3edf", "3132dc3a-44bd-4cb9-81ea-a3719f433f82"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBut we're very pleased with the performance that this business has had.  We have worked diligently over the last \nfew years to really think about, how we organize and streamline and make that business more efficient, capturing  \nsome of the scale across all of the countries.  \n \n We've been rigorous in looking at our retail footprints. ", "original_text": "McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "5933e26b-3a89-4c69-b0dc-0acf593ec0ce": {"node_ids": ["cbcc49a2-bf53-4faf-bd97-9715bbf02610", "23f16354-28f7-4e5e-b0b4-271f96ea5196", "c0cf9abf-2a0d-49fb-9d72-f6ae39d413c9", "72d3d22f-0332-4497-9121-ebaf55545488", "23e1f468-48eb-49d5-98d4-0d0242787ab5", "35ef8034-0bdd-4be9-8be6-1a1d98d27fcd", "f0624576-2a5f-4dbd-a14e-6e0bc48e031e", "a00abec0-2820-40e5-a297-667bb5048947", "1644832d-437a-4169-bef7-d9980b93d4bf", "33e240ff-f971-42ed-9128-8ffc09ac405b", "79895b5e-d630-45f6-b86e-dc6c4df143a2", "ce8452d8-f369-4157-bc13-09169ef4a196", "e198f658-8e5a-43ab-9204-af0d8b624059", "f0a7ea59-520e-4560-83ff-3b17e6a0e7c8", "1b032a67-446e-4f34-9c94-590aa42ee728", "1e26efc7-9480-4dcb-924f-54fd25b1c190", "357ba423-ac63-45e3-8fc9-48efa523b06b", "0386035a-d096-4d5f-bf30-5954fef3337d", "b74dedfd-736c-4b6f-90ec-82b572afbca4", "1b25ddfb-9637-40a3-bc69-316cab4d9963", "c694b9f9-00f5-42b1-baba-ef887fa665a6", "9d9bf935-9433-49ba-a4a4-fcf4f926df03", "85a04192-4410-4c48-a55c-2cf9d8c56c35", "5fa34bf0-2c5e-40db-b4c9-0a294c88af02", "f23c31a4-da06-4e82-b662-0a4c3043ca22", "4b64f4b6-6184-4c2b-9c09-a20ccb30fad0", "ed18e989-4840-4c98-ac3e-df621d8008b8", "f0735e7c-c2b1-42fd-a1fe-192cf98f3409", "4531cc07-445b-4503-8969-e4f08f7e397c"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2021 Earnings Call  Corrected Transcript  \n06-May-2021   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everybody. ", "original_text": "McKesson Corp.  ", "page_label": "22", "file_name": "MCK-Q4-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 394426, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}}}